IdiPAZ
Instituto de Investigación
Hospital Universitario La Paz



SCIENTIFIC REPORT

2024

Published by:
Instituto de Investigación Sanitaria del Hospital Universitario la Paz - IdiPAZ

Crafted by:
Raúl Román Cañizares
Paloma Gómez Campelo
Isabel Polo Campos

IdiPAZ Scientific Report 2024 has been approved by the Internal Scientific Committee of IdiPAZ during its meeting on September 15, 2025.

IdiPAZ
Instituto de Investigación
Hospital Universitario La Paz

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

SCIENTIFIC REPORT 2024

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

La Paz University Hospital has stood at the forefront of healthcare in Madrid, Spain, Europe, and beyond for more than six decades. Its consolidation as a leading institution in care, research, and quality is the result of continuous and collective effort. Preserving this standard of excellence year after year requires the commitment and dedication of thousands of professionals who perform their duties with rigor and dedication while remaining faithful to an essential principle that guides all our work: the humanization of care. At the heart of our mission is always our patient, the driving force and reason for being of our activity.

La Paz is a comprehensive institution that integrates healthcare, research, and teaching. As a university hospital, it trains more than 700 professionals each year, making it the most sought-after destination in Spain for future specialists to complete their residency. A fundamental pillar sustains this environment of educational and clinical excellence: research. We are convinced that it is not possible to lead the way in healthcare without a firm commitment to the generation of knowledge, which has established us as a reference research institution at both the national and international level.

Our research institute, IdiPAZ, with more than 15 years of experience, has consolidated its position as a benchmark in biomedical research in Spain. Its international scientific impact continues to grow, surpassing its own records year after year, reflecting its outstanding position in the field of clinical and translational research. In the last year, IdiPAZ has produced more than 1,500 scientific publications and participated in 433 clinical trials. We are particularly proud to have one of the most powerful research institution in the country, supported by a solid infrastructure and a support network that guarantee the advancement of their research work.

Looking to the future with enthusiasm, we reaffirm our commitment to remaining at the forefront of healthcare and research. Two fundamental pillars of the future of IdiPAZ are the incorporation of state-of-the-art medical technology and the consolidation of translational research.

In addition, the comprehensive renovation of the hospital complex is one of the most important strategic actions for the future. This ambitious project will elevate La Paz University Hospital to a new level of technological, healthcare, and scientific excellence. The **City of Health** initiative, currently in progress and supported by an investment of €1 billion, will create the most modern and innovative biomedical campus in Europe. This transformation will ensure that our hospital continues to be an international benchmark, thanks to its high degree of specialization, its capacity for innovation, and its commitment to research.

In this context, the new spaces dedicated to research will position IdiPAZ as one of the scientific institutions with the most advanced infrastructure. These facilities will foster synergies between professionals in the healthcare, scientific, and academic fields, thus promoting multidisciplinary collaboration that will enrich the generation of knowledge and the transfer of results to clinical practice.

Dr. Rafael Pérez-Santamarina Feijóo
Managing Director of HULP Chairman of the Board of FIBHULP



2024 has been a year of both **continuity and renewal** for the Instituto de Investigación Sanitaria del Hospital Universitario La Paz (IdiPAZ). Following the celebration of its 15th anniversary in 2023, the Institute enters a new stage marked by scientific maturity, organizational consolidation, and a renewed strategic leadership. In September 2024, **Prof. Javier de Castro** was appointed as the new **Scientific Director,** succeeding **Prof. José Luis López-Sendón**, with **Dr. Alberto Borobia** as Deputy Scientific Director. This transition ensures continuity in the pursuit of excellence, while incorporating a vision more firmly rooted in translational impact, internationalization, and innovation.

Scientific Output and Collaboration

During 2024, IdiPAZ researchers contributed to **1,556 publications**, of which **665** list IdiPAZ investigators as first, last, or corresponding author. The quality of our output remains robust, with **54%** of all JCR articles published in **Q1 journals** and almost **one in five (19%)** in the **top decile (D1)**. For original research articles, the pattern is consistent (**53% Q1; 18% D1**).

Collaboration remains a cornerstone of our research culture. In 2024, **86%** of publications were produced in collaboration, evenly distributed between **national (49%)** and **international (51%)** partners. Importantly, **intra-IdiPAZ collaboration** reached **31% of total publications (28% in originals)**, a growing indicator of internal cohesion and cross-disciplinary integration. This dynamic fosters knowledge transfer across clinical services and research groups, and strengthens our capacity to generate innovation with real-world impact.

Financial Sustainability and Research Capacity

The "Fundación para la Investigación Biomédica del H.U. La Paz (FIBHULP)", the legal entity supporting IdiPAZ, closed 2024 with **revenues close to €28 million** and a **positive result** of approximately **€127,600**. The **clinical research and collaboration portfolio** showed remarkable growth, increasing from **€11.0 million in 2023** to **€13.4 million in 2024**. This reflects IdiPAZ's consolidation as a leading ecosystem for **clinical trials** and high-value translational research.

In addition, **84 agreements** were formalized with public and private institutions, broadening strategic partnerships and creating new opportunities for knowledge transfer and innovation. The **nominative transfer from the Regional Health Ministry** continued to play a critical role in supporting talent attraction and retention programmes (I3, Miguel Servet, Río Hortega, Juan de la Cierva, MSCA, Juan Rodés), researcher intensification, scientific culture and outreach initiatives, accreditation processes, and the operation of technical platforms. These efforts are essential to maintain and strengthen the professional trajectory of our researchers and the institutional infrastructure of IdiPAZ.

Looking Forward

The strategic priorities of IdiPAZ remain clear:


- **Excellence and visibility**: increasing leadership in top-tier publications and reinforcing the correct affiliation to IdiPAZ in all scientific outputs, a critical factor for benchmarking and international recognition.
- **Collaborative innovation**: further developing intra-institutional cooperation and expanding international networks with tangible scientific and clinical returns.
- **Clinical research and translation**: capitalizing on our strong clinical trials portfolio to accelerate innovation to patients, with enhanced methodological, ethical, and management standards.
- **Sustainability and governance**: diversifying funding sources, professionalizing management processes, and strengthening agreements that reinforce transfer and responsible innovation.

In addition to all these excellent results and continuous growth, I would like to highlight a key strategic focus that society demands of us: the IMPACT on health that our R&D&I generates through the work of our Institute. Beyond publication metrics, projects awarded, or agreements signed, we must think about the value we bring to people, to the institution itself, and to society as a whole. Let›s work toward that goal, seeking to improve the lives of the people we care for every day.

1 Introduction
2 Executive summary
3 Research areas and groups
4 Associated clinicians

Looking ahead, the integration of healthcare, university teaching, and biomedical research within the ongoing **campus transformation** provides a unique opportunity. The removal of physical and functional barriers between the hospital and the university will allow for an even deeper alignment of patient care, research, and education in a single project of excellence.

On behalf of the new leadership, I would like to express my gratitude to the **clinical services and basic units**, the **research groups**, the **technical platforms and support units**, and the **management team** for their commitment and effort throughout this demanding year. The achievements of 2024 reflect the talent and determination of the IdiPAZ community and reaffirm our shared conviction: **research transforms healthcare and improves patients' lives**.



Dr. Javier de Castro
Scientific Director of IdiPAZ

Mission

To become a research institute that develops multidisciplinary biomedical research in the prioritized areas and with cutting-edge technology. Promoting collaboration with internationally renowned centers, and oriented to the translation of knowledge to clinical practice and the improvement of patients' health.

Vision

To become a benchmark in translational biomedical research of excellence both nationally and internationally, committed to the health of patients.

Values

- Public engagement
- Continuous improvement throug quality fostering
- Orientation towards excellence
- Sense of belonging to the organization
- International vocation
- Leadership in innovation and transfer
- Focus on sustainability
- Encouragement of cooperation and the establishment of alliances.
- Commitment to diversity and equal opportunities

IdiPAZ
Instituto de Investigación
Hospital Universitario La Paz

SCIENTIFIC
REPORT
2024

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians



2 Executive summary

2.1 Global Analysis
2.1.1. Scientific Analysis
2.1.2 Scientific Production
2.1.3. Annual Accounts

2.2 Research Structure

2.3 Training Report and Teaching
2.3.1. Doctoral Theses
2.3.2 Master Theses
2.3.3 Final Degree Theses
2.3.4 Scientific Training Plan
2.3.5 Science and Society-Scientific Outreach Initiatives

2.4 IdiPAZ quality committe

IdiPAZ
Instituto de Investigación
Hospital Universitario La Paz


SCIENTIFIC
REPORT
2024

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians



2 Executive summary

2.5 Platforms
2.5.1. ISCIII Strategic Platforms
2.5.2. IdiPAZ Platforms

2.6. Mentor and prementor program
2.6.1. Mentor Program
2.6.2. Prementor Program

2.7 CIBERs and RETICs

2.8 Communication and public engagement
2.8.1. Selected media appearances
2.8.2. Scientific Newsletter: IdiPAZ+ii News
2.8.3. Our new website
2.8.4. Formative Pills about Sustainable Development Goals and Responsible Research and Innovation

2.9. Responsible Research and Innovation in IdiPAZ

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

2.1 Global Analysis

2.1.1 Scientific analysis

In 2024, IdiPAZ's scientific output comprised more than 1,500 publications. Of these, nearly 42% (665) were authored by researchers affiliated with the institute, acting as first, last or corresponding authors. IdiPAZ researchers produced over 1,300 original research articles and review papers, more than 54% of which were published in journals positioned in the first quartile of their subject category, and over 18% in journals ranked within the top decile.

	Total	%Q1	%D1
Publications	1,556	51.09	17,74
Owned Publications	665	41.95	9,02
Un-owned Publications	891	57.91	24,13
Originals	1,238	52.75	18,17
Owned Originals	487	42.92	7,60
Un-owned Originals	751	59.12	24,90
JCR Indexed Articles and Reviews	1,336	54.04	18,64
Owned JCR Indexed Articles and Reviews	515	44.85	8,54
Un-owned JCR Indexed Articles and Reviews	821	59.81	24,97

IdiPAZ researchers demonstrated a strong presence in national and international scientific networks, with more than 86% of all publications (86.38%) produced in collaboration. Of these collaborative works, 49.33% involved national partners, while 50.67% were developed through international collaborations.


Collaboration within IdiPAZ itself was also noteworthy. Publications co-signed by different research groups of the institute represent 17.74% of the total output. Considering only original articles and reviews, intra-institute collaborations accounted for 31.47% of the publications.

	Total	% National Collaboration	% International Collaboration
Collaborative Publications	1,344	49.33	50,67
Owned Collaborative Publications	453	68.43	31,57
Un-owned Collaborative Publications	891	39.62	60,38
Collaborative Originals	1,098	49.00	51,00
Owned Collaborative Originals	347	68.30	31,70
Un-owned Collaborative Originals	751	40.08	59,92
Collaborative JCR Indexed Articles and Reviews	1,195	47.87	52,13
Owned Collaborative JCR Indexed Articles and Reviews	374	66.04	33,96
Un-owned Collaborative JCR Indexed Articles and Reviews	821	39.59	60,41


	Total	% Intra-Institute Documents
Intra-Institute Publications	423	31.47
Owned Intra-Institute Publications	296	69.98
Un-owned Intra-Institute Publications	127	30.02
Intra-Institute Originals	345	27.87
Owned Intra-Institute Original	230	66.67
Un-owned Intra-Institute Original	115	50.00
Intra-Institute JCR Indexed Articles and Reviews	365	27.32
Owned Intra-Institute JCR Indexed Articles and Reviews	244	66.85
Un-owned Intra-Institute JCR Indexed Articles and Reviews	121	49.59

In 2024, IdiPAZ maintained the positive trajectory of its scientific activity observed in recent years. The impact of the institute's research is reflected in the fact that 51.09% of its publications were published in leading journals within their respective subject categories.


Distribution of publications by quartile 2020-2024




Distribution of originals by quartile 2020-2024



Papers with international collaboration between 2020-2024



Owned originals between 2020-2024



2.1.2 Scientific Production

The following list show the journals that are rankedin the top decile of their subject category in which IdiPAZ researchers have published paper in 2024

Journal	ISSN	Impact Factor
Advanced Science	2198-3844	14.1
Age and Ageing	0002-0729	7.1
Alimentary Pharmacology & Therapeutics	0269-2813	6.7
Allergy	0105-4538	12.0
Alzheimer & Dementia-Translational Research & Clinical Interventions	2352-8737	6.8
Alzheimer Research & Therapy	1758-9193	7.6
American Journal of Clinical Dermatology	1175-0561	8.8
American Journal of Human Genetics	0002-9297	8.1
American Journal of Kidney Diseases	0272-6386	8.2
American Journal of Obstetrics and Gynecology	0002-9378	8.4
Anaesthesia	0003-2409	6.9
Annals of Internal Medicine	0003-4819	15.2
Annals of Oncology	0923-7534	65.4
Annals of Surgery	0003-4932	6.4
Annals of the Rheumatic Diseases	0003-4967	20.6
Archivos de Bronconeumología	0300-2896	9.2
Arthritis & Rheumatology	2326-5191	10.9
Basic Research in Cardiology	0300-8428	8.0
Biomedicine & Pharmacotherapy	0753-3322	7,5
BJS Open	2474-9842	4.5
BJS-British Journal of Surgery	0007-1323	8.7
Blood	0006-4971	23.1
BMC Medicine	1741-7015	8.3
Bone & Joint Journal	2049-4394	4.6
Brain	0006-8950	11.7
Breast	0960-9776	7.9
Briefings in Bioinformatics	1467-5463	7.7
British Journal of Surgery	0007-1323	8.7
Cardiovascular Diabetology	1475-2840	10.6
Circulation	0009-7322	38.6
Circulation-Arrhythmia and Electrophysiology	1941-3149	9.8
Clinical Cancer Research	1078-0432	10.2
Clinical Chemistry	0009-9147	6.3
Clinical Gastroenterology and Hepatology	1542-3565	12.0
Clinical Infectious Diseases	1058-4838	7.3
Clinical Microbiology and Infection	1198-743X	8.5
Clinical Nutrition	0261-5614	7.4
Clinical Pharmacology & Therapeutics	0009-9236	5.5
Communications Biology	2399-3642	5.1
Developmental Cell	1534-5807	8.7
Developmental Medicine and Child Neurology	0012-1622	4.3
Diabetes Research and Clinical Practice	0168-8227	7.4
Drugs	0012-6667	14.4
Ear and Hearing	0196-0202	2.8
Eclinicalmedicine	2589-5370	10.0
Emergencies	1137-6821	6.3
Emerging Infectious Diseases	1080-6040	6.6
Emerging Microbes & Infections	2222-1751	7.5
Eurointervention	1774-024X	9.5
European Heart Journal	0195-668X	35.6
European Journal of Anaesthesiology	0265-0215	6.8
European Journal of Cardiovascular Nursing	1474-5151	3.9
European Journal of Heart Failure	1388-9842	10.8
European Journal of Physical and Rehabilitation Medicine	1973-9087	3.4
European Journal of Preventive Cardiology	2047-4873	7.5
European Neuropsychopharmacology	0924-977X	6.7
European Psychiatry	0924-9338	6.7
European Respiratory Journal	0903-1936	21.0
European Urology	0302-2838	25.2
European Urology Oncology	2588-9311	9.3
Eurosurveillance	1025-496X	7.8
Alzheimer & Dementia	1552-5260	11.1
Free Radical Biology And Medicine	0891-5849	8.2
Future Foods	2666-8335	8.2
Genes & Diseases	2352-4820	9.4
Gut	0017-5749	25.8
Gynecologic Oncology	0090-8258	4.1


Journal	ISSN	Impact Factor
Hepatobiliary Surgery and Nutrition	2304-3881	7.8
Hypertension	0194-911X	8.2
Innovation in Aging	2399-5300	4.3
Intensive and Critical Care Nursing	0964-3397	4.7
Intensive Care Medicine	0342-4642	21.2
International Journal of Biological Macromolecules	0141-8130	8.5
International Journal of Nursing Sciences	2352-0132	3.1
International Journal of Nursing Studies	0020-7489	7.1
International Journal of Surgery	1743-9191	10.1
Investigative Ophthalmology & Visual Science	0146-0404	4.7
JACC - Cardiovascular imaging	1876-7591	15.2
JACC - Cardiooncology	2666-0873	12.8
JACC - Cardiovascular interventions	1936-8798	11.4
JACC - Clinical electrophysiology	2405-500X	7.7
JAMA Cardiology	2380-6583	14.1
JAMA Network Open	2574-3805	9.7
JAMA Ophthalmology	2168-6165	9.2
JAMA - Journal of the American Medical Association	0098-7484	55.0
Journal for Immunotherapy of Cancer	2051-1426	10.6
Journal of Allergy and Clinical Immunology	0091-6749	11.2
Journal of Biomedical Science	1021-7770	12.1
Journal of Bone and Joint Surgery-American Volume	0021-9355	4.3
Journal of Cachexia Sarcopenia and Muscle	2190-5991	9.1
Journal of Clinical Investigation	0021-9738	13.6
Journal of Clinical Oncology	0732-183X	41.9
Journal of Controlled Release	0168-3659	11.5
Journal of Experimental Medicine	0022-1007	10.6
Journal of Hepatology	0168-8278	33.0
Journal of Medical Internet Research	1438-8871	6.0
Journal of Nanobiotechnology	1477-3155	12.6
Journal of Neurointerventional Surgery	1759-8478	4.3
Journal of Neurology Neurosurgery and Psychiatry	0022-3050	7.5
Journal of Pathology	0022-3417	5.2
Journal of Pediatrics	0022-3476	3.5
Journal of Stroke	2287-6391	8.6
Journal of the American Academy of Dermatology	0190-9622	11.8
Journal of the European Academy of Dermatology and Venereology	0926-9959	8.0
Journal of Travel Medicine	1195-1982	6.4
Journal of the American College of Cardiology	0735-1097	22.3
Kidney International	0085-2538	12.6

Journal	ISSN	Impact Factor
Kidney International Reports	2468-0249	5.7
Lancet	0140-6736	88.5
Lancet Diabetes & Endocrinology	2213-8587	41.8
Lancet Digital Health	2589-7500	24.1
Lancet Global Health	2214-109X	18.0
Lancet Haematology	2352-3026	17.7
Lancet HIV	2352-3018	13.0
Lancet Infectious Diseases	1473-3099	31.0
Lancet Microbe	2666-5247	20.4
Lancet Neurology	1474-4422	45.5
Lancet Oncology	1470-2045	35.9
Lancet Psychiatry	2215-0374	24.8
Metabolism-Clinical and Experimental	0026-0495	11.9
Molecular Aspects of Medicine	0098-2997	10.3
Molecular Cell	1097-2765	16.6
Nature Communications	2041-1723	15.7
Nature Genetics	1061-4036	29.0
Nature Medicine	1078-8956	50
Nature Metabolism	2522-5812	20.8
Nature Reviews Rheumatology	1759-4790	32.7
Nephrology Dialysis Transplantation	0931-0509	5.6
Neurology	0028-3878	8.5
Neuro-Oncology	1522-8517	13.4
Neuroscience and Biobehavioral Reviews	0149-7634	7.9
Neurosurgery	0148-396X	3.9
New England Journal of Medicine	0028-4793	78.5
Ophthalmology Retina	2468-6530	5.7
Pediatrics	0031-4005	6.4
Pharmacological Research	1043-6618	10.5
Plos Medicine	1549-1277	9.9
Plos Neglected Tropical Diseases	1935-2735	3.4
Psychological Medicine	0033-2917	5.5
Radiology	0033-8419	15.2
Rhinology	0300-0729	6.8
Redox Biology	2213-2317	11.9
Science	0036-8075	45.8
Science Advances	2375-2548	12.5
Stroke	0039-2499	8.9
Supportive Care In Cancer	0941-4355	3
Ultrasound in Obstetrics & Gynecology	0960-7692	6.3


2.1.3 Annual Accounts

In compliance with Law 19/2013, of December 9th, of Transparency, Access to Public Information and Good Governance, the Foundation for Biomedical Research of La Paz University Hospital (FIBHULP) publishes its information with the objective of ensuring institutional transparency:
https://idipaz.es/Documentacion/Transparencia

Economic Income Overhead 2004



Economic Income 2004



	2023	2024
INCOME	27,735,115.89	27,986,542.72
Grants	11,126,922.81	9,788,148.18
Corporate collaboration agreements and sponsorships	3,237,114.69	436,517.52
Grants and other private research projects	942,750.64	1,924,237.66
Scientific research (clinical trials, collaborations...)	11,028,187.17	13,445,827.97
Financial Income	1,386,600.68	1,845,791.29
Positive exchange rate differences	1,014.87	78,115.74
Extraordinary income	12,525.03	467,904.36
COST	27.659.385,83	27,858,901.26
Monetary aid and other	352,817.22	202,748.84

	2023	2024
Operating consumption	1,726,050.44	1,885,424.86
Leases and royalties	14,674.50	10,429.71
Repair and maintenance	2,405.38	1,497.70
Professional Services	2,860,613.27	3,160,789.46
Other expenses	3,743,698.09	4,061,707.82
Other taxes	12,216.30	14,804.81
Wages and salaries	8,545,325.48	9,510,462.31
Social charges	2,639,470.67	2,921,056.13
Compensations	22,930.55	81,353.37
Amortization of fixed assets	3,295,334.88	1,557,517.80
Provisions (Provision - Excess)	4,187,988.01	4,086,347.54
Financial expenses	118,974.92	117,097.73
Negative exchange differences	45,368.89	2,190.93
Refund of grants, donations and legacies	91,517.23	245,472.25
R&D expenses	0.00	0,00
SURPLUS FOR THE FINALCIAL YEAR	75,730.06	127,641.46

In 2024, FIBHULP received a nominative transfer from the *Consejeria de Sanidad de la Comunidad de Madrid,* under program 312D "Biomedical Research Foundations", to support the following items:

- Researchers and support staff funded through the I3, I3SNS, Miguel Servet I, Miguel Servet II, Río Hortega, Sara Borrell, Juan de la Cierva, Marie Skłodowska-Curie, and Juan Rodés programs.
- Intensification programs for healthcare professionals.
- Activities for the promotion and dissemination of research and scientific culture.
- Accreditations of research activity.
- Support for Technical Units and Platforms for Research and Management of R+D+i

In addition, during 2024, IdiPAZ formalized 84 agreements with public and private entities, distributed as follows:

- Service contracts: 18
  - Sponsorship contracts: 55
  - Training contracts: 11

The main entities with which these agreements were established include:

Organization	Nº Agreements
Abbvie Spain S.L.U.	3
Advanced Accelerator Applications Iberica S.L.U	1
Advanz Pharma Spain S.L.U	1
AJL Ophthalmic S.A.	1
Alcon Healthcare S.A.	1
Alk-Abello S.A.	1
Almirall S.A.	1
Astellas Pharma S.A.	1
Astrazeneca Farmaceutica Spain S.A.	6
Ayuntamiento de Colmenar Viejo	1
Baxter S.L.	1
Becton Dickinson UK Limited	1
Biocryst España S.L.	2
Bridge to Life Ltd	2
Bristol-Myers Squibb Argentina S.R.L	1
Consorcio Centro de Investigacion Biomedica en Red	2
CSL Behring S.A.	1
Daiichi Sankyo España	1
Danone Nutricia SRL	1
Erbe España Soluciones Médicas S.L	1
European Spine Study Group Association	1
F.Hoffmann-La Roche Ltd	2
Fresenius Medical Care España, S.A	1
Fundación Grupo Español de Investigación en Cáncer de Mama	1
Fundacion Juegaterapia	2
Gilead sciences S.L.	4
Glaxosmithkline S.A	3

Organization	Nº Agreements
Grunenthal Pharma S.A	2
Hologic iberia S.L.	1
Hospital Universitario de Fuenlabrada	1
Incyte Biosciences Iberia S.L.	1
ITF Research Pharma S.L.U	1
Lapharcon Llc	1
LFB Bioterapias Hispania S.L.	1
Livanova España S.L.U	1
Lundbeck España S.A.	1
Medtronic Ibérica S.A.	1
Nikkiso Belgium BV	1
Novartis Farmaceutica S.A.	3
Novo Nordisk Pharma S.A.	4
Olympus Iberia S.A.U	1
Omni Prex S.L	2
Organon Salud S.L.	1
Pfizer S.L.U.	1
Publicidad Permanyer S.L.	1
Quantamatrix Europe	1
Roche Farma S.A.	3
Sanidad y Ediciones S.L.	1
Sanofi Aventis S.A	1
SH Medical Salud y Servicios Ibérica S.L	1
Sistemas Genómicos S.L.	1
Springer Healthcare Iberica S.L.U	1
Takeda Farmaceutica España S.A.	3
Teva Pharma S.L.U	1
Thermo Fisher Diagnostics S.L.U	2

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

2.2. Research Structure

SCIENTIFIC DIRECTOR
Javier de Castro Carpeño

SCIENTIFIC DEPUTY DIRECTOR
Alberto Borobia

TECHNICAL DEPUTY DIRECTOR
Paloma Gómez Campelo



GOVERNING COUNCIL

Chairperson:
Laura Gutiérrez Barreno. *Deputy Minister of Health of the Community of Madrid*

Vice President:
Amaya Mendikoetxea Pelayo. *Rector of the UAM*

Members:
Rafael Pérez-Santamarina Feijóo. *Chairperson of the Board of Trustees*
Francisco García Río. *FIBHULP Patron*
Rodolfo Álvarez-Sala Walther. *FIBHULP Patron*
Almudena Castro Conde. *FIBHULP Patron*
Alicia Portas Martínez. *FIBHULP Patron*
Antonio Pérez Martínez. *FIBHULP Patron*
Inmaculada Ibáñez de Cáceres. *FIBHULP Patron*
Alicia Hernández Gutiérrez. *FIBHULP Patron*
Víctor Jiménez Yuste. *FIBHULP Patron*
Exuperio Díez Tejedor. *HULP Representative*
Susana Noval Martín. *HULP Representative*
Paloma Gómez Campelo. *HULP Representative*
Pilar López García. *Representative of the UAM*
José Manuel González Sancho. *UAM Representative*
Daniel Jaque García. *Representative of the UAM*
Zita Quintela González. *HUG Manager*
Javier de Castro Carpeño. *Scientific Director. Trustee of FIBHULP*
David Sanz Rosa. *EU Representative*

Secretary:
Ana Coloma Zapatero. *Director of FIBHULP*

DELEGATE COMMISION

Chairperson:
Rafael Pérez-Santamarina Feijóo, *President of FIBHULP; permanent delegation to Rodolfo Álvarez-Sala Walther*

Board members:
Javier de Castro Carpeño, *Scientific Director of IdiPAZ*
Alberto Borobia Pérez, *Scientific Deputy Director of IdiPAZ*
Paloma Gómez Campelo, *Deputy Technical Director of IdiPAZ*
Pilar López García, *Dean of the UAM*
Eduardo López Collazo, *Stabilized research representative.*
Francisco García Río, *HULP Representative*
Exuperio Díez Tejedo, *HULP Representative*
Francisco Arnalich Fernández, *Representative of the UAM*
Zita Quintela González, *HUG Manager*
Susana de Juan García, *HUG Representative*
David Sanz Rosa, *EU Representative*

Secretary
Ana Coloma Zapatero, *Director of FIBHULP*

FIBHULP

Director
Ana Coloma Zapatero

Foundation's board
Rafael Pérez-Santamarina Feijóo. *Chairperson*
Francisco García Río. *Vice-Chair*
Rodolfo Álvarez-Sala Walther. *Board member*
Almudena Castro Conde. *Board member*
Alicia Portas Martínez. *Board member*
Víctor Jiménez Yuste. *Board member*
Antonio Pérez Martínez. *Board member*
Javier de Castro Carpeño. *Board member*
Inmaculada Ibáñez de Cáceres. *Board member*
Alicia Hernández Gutierrez. *Board member*
Ana Coloma Zapatero. *Secretary*

Delegated Commission of the FIBHULP
Francisco García Río. *Chairperson*
Rodolfo Álvarez-Sala Walther. *Board member*
Javier de Castro Carpeño. *Board member*
Víctor Jiménez Yuste. *Board member*
Ana Coloma Zapatero. *Secretary*

Human Resources
Responsible: María Quintanar Jaime

Management of Private Projects
Responsible: F. G. G.

Management of Clinical Trials
Responsible: Sara Moral Álamo

Management of Public Projects
Responsible: Silvia Arce Santamaría

Management of European Projects
Responsible: José Luis Narro Villanueva

Contracting and Legal Affairs
Responsible: Sara Fernández Morata

Accounting
Responsible: Laura López Revuelta

TECHNICAL SECRETARY
Mercedes Ruiz Balibrea

OWN PREVENTION SERVICE
Aitana López Redondo. *Head of Own Prevention Service*

HEALTH AND SAFETY COMMITTEE
Compostion
Gema Vallés Pérez. *Representative of FIBHULP / President*
Sara Fernández Morata. *Representative of FIBHULP*
Estela Sánchez Simón. *Representative of FIBHULP*
Laura Saldaña Quero. *Prevention Delegate / Secretary*
Berta Rodés Soldevilla. *Prevention Delegate*
FGG. *Prevention Delegate*
Aitana López Redondo. *Head of the In-House Prevention Service*
Sergio Palomero Lorente. *In-House Prevention Service Technician*
Sonsoles Bedia Olmeda. *In-House Prevention Service Technician*

Guest
External Prevention Service Technician

WORKS COMMITTEE
Chairperson
Ángel Campos Barros

Members
Nuria Vilaboa Díaz
Berta Rodés Soldevila
Rosa Rodríguez Pérez
Laura Saldaña Quero
Rocío López Vacas
Pilar Sánchez-Corral Gómez
F.G.G.
Sara García Bercenilla
Vega Mauleón Martínez
Laura Vitón Vara
Laura González Rodríguez
Marina Arranz Álvarez

Secretary
Juan Ángel Fresno Vara

EXTERNAL SCIENTIFIC COMMITTEE



Juan Tamargo Menéndez. Professor. Institute of Pharmacology and Toxicology, Spanish National Research Council (CSIC)- Complutense University of Madrid. Madrid.



Joaquín Arribas López. Director of Research at Parc de Salut Mar (PSMAR) and director of the Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), as well as ICREA research professor at the Vall d'Hebron Institut d'Oncologia (VHIO) Barcelona. Chairman of the Technical Committee on Cancer Screening Health Research Fund (FIS). Institute of Health Carlos III.



Jacinta Cecilia Bustamante. Associate Professor. Paris Descartes University, Laboratory of Human Genetics of Infectious diseases (INSERM U980), Imagine Institut. Center for the Study of Primary Immunodeficiencies, Necker Enfants-Malades Hospital. Paris.



Isabel Fabregat Romero. Research Group Coordinator. Centre d´Oncologia Molecular. L´Hospitalet, Barcelona IDIBELL- Bellvitge Biomedical Research Institute. Barcelona.



Juan Pedro Bolaños Hernández. Departament of Biochemistry and Molecular Biology. University of Salmanca. Institute of Functional Biology and Genomics. Salamanca.



Santiago Rodríguez de Córdoba. Professor. Cellular and Molecular Medicine Department. Center of Biological Research. CSIC. Madrid.



Pablo Pelegrin Vivancos. Scientific Assistant Director. Principal Investigator in Group: Digestive Surgery, Endocrine and Abdominal Organ Transplantation. Virgen de la Arrixaca Biosanitary Research Institute. Murcia.



Elisa Martí Gorostiza. Head researcher of Development of the Spinal Cord in health and disease. Instituto de Biología Molecular de Barcelona (CSIC). Barcelona. Stanley Thomas. Chair of the Department of Neurology at UCLA: Neurologist and neuroscientist in the Department of Neurology at the Geffen School of Medicine at UCLA.



Stanley Thomas Carmichael. Chair of the Department of Neurology at UCLA: Neurologist and neuroscientist in the Department of Neurology at the Geffen School of Medicine at UCLA.



Jean-Claude Tardif Cardiologist, Montreal Heart Institute, Canada. Director, Research Chair, Canada Research Chair in Translational and Personalized Medicine. Professor of Medicine Montreal Heart Institute, University of Montreal, Canada. Director, Montreal Heart Institute Research Centre, Montreal Heart Institute, Canada



Sonia Villapol Assistant Professor of Neurosurgery. Department of Neurosurgery, Institute of Academic Medicine, Houston Methodist Research Institute, Houston, TX.
Assistant Professor of Neuroscience. Department of Neuroscience in Neurological Surgery, Weill Cornell Medical College, NY.

INTERNAL SCIENTIFIC COMMITTEE

Chairperson
Javier de Castro Carpeño. Scientific Director

Secretary
Nora Butta Coll. HULP representative

Members
Alberto Borobia Pérez. *Scientific Deputy Director of IdiPAZ*
Paloma Gómez Campelo. *Deputy Technical Director of IdiPAZ and Coordinator of the Training Committee*
Javier de Castro Carpeño. *Coordinator of the Innovation Platform*
José Jonay Ojeda Feo. *Coordinator of the Quality Committee*

Member by Hospital Universitario La Paz
Fernando Martin Sánchez
María Fe Bravo Ortiz
José Ignacio Bernardino de la Serna
Alberto Borobia Pérez
Nora Butta Coll
María Fernández Velasco
Blanca Fuentes Gimeno
María Gutiérrez Fernández
Alicia Hernández Gutiérrez
Esther Pérez David
Ana Sastre Perona
Nuria Vilaboa Díaz
Jesús Mingorance Cruz

Pre-doctoral representatives
Enrique Alfaro García
Javier Pozo Novoa

Members by Universidad Autónoma de Madrid
Francisco Arnalich Fernández
Gemma Domínguez Muñoz
Concepción Peiró Vallejo
Belén Pérez González
María Carmen Sellán Soto

Members by Hospital Universitario de Getafe
Joaquín Alonso Martín
Raquel Herrero Hernández
Javier Sánchez-Rubio Fernández

Members by Universidad Europea de Madrid
David Sanz Rosa

ANIMAL WELFARE ORGAN

Carmen Fernández Criado. *Director of the Veterinary Clinic at the Faculty of Medicine of the Universidad Autónoma de Madrid (UAM). She specializes in Animal Health and Welfare as an external advisor.*
Fernando Carceller Benito. *Assistant Professor of Neurosurgery at HULP, as a physician and researcher in the "Neurology and Cerebrovascular Diseases" Group at IdiPAZ.*
Nuria Vilaboa Díaz. *IdiPAZ researcher. Internal Advisor*
Carlota Largo Aramburu. *Head of the Animal Facility of the Experimental Surgery Service at HULP, as the Center's Animal Health and Welfare Specialist.*

RESEARCH ETHICS COMMITTEE WITH MEDICAL PRODUCTS

Chairperson
Almudena Castro Conde. *Head of Section of Cardiology Department*

Vice-Chair
Rosa Villanueva Peña. *Assistant Physician-Psychiatry Department*

Members
Ainara Albadalejo Santamaría. *Nurse, Cardiac Rehabilitation Coordinator - IdiPAZ*
Nora Viviana Butta Coll. *Head of the Coagulopathies and Hemostasis Disorders Research Laboratory. Representative of the Research Commission.*
Fernando Cabañas González. *Head of the Pediatrics and Neonatology Department at Salud Quirón Hospital in Madrid. Researcher at IdiPAZ*
Antonio J. *Carcas Sansuán. Head of Clinical Pharmacology Service. HULP*
Mariana Díaz Almiron. *Data analyst. Biostatistics Platform. IdiPAZ*
Jorge Díaz-Garzón Marco. *Assistant Pharmacist. Clinical Analysis Service. HULP*
María Dolores Diestro Tejeda. *Assistant Physician, Gynecology and Obstetrics Department, HULP*
Rosa Feltes Ochoa. *Assistant Physician, Dermatology Service, HULP*
Jaime Fernández-Bujarrabal Villoslada. *Associate Physician, Pulmonology Department, HULP*
Angelo Gámez Pozo. *Researcher at INGEMM - IdiPAZ*
Irene García García. *Clinical Pharmacology Specialist. HULP*
María Justa García-Matres Cortés. *Associate Physician in the Urology Department. Representative of the Healthcare Ethics Committee. HULP*
Mercedes Gasior Kabat. *Associate Physician in the Hematology Department. HULP*
Natalia Hormaeche Abecassis. *Law graduate. Head of Legal Services. Data protection expert*
Carlos Lahoz Rallo. *Attending Physician, Internal Medicine Department, HULP*
Montserrat Aránzazu Rodríguez Aguirregabiria. *Deputy Physician of the Intensive Medicine Service. HULP*
Nuria Rodríguez Salas. *Associate Physician in the Oncology Department. HULP*
Jorge Rodríguez Pardo. *Associate Physician, Neurology Department, HULP*

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

Miriam Romero Portales. *Assistant Physician, Digestive System Service, HULP*
Alejandra Vilanova Sánchez. *Attending Physician in the Pediatric Surgery Department. HULP*
Elena Villamañán Bueno. *Assistant Pharmacist in the Pharmacy Department. HULP*
Yale Tung Chen. *Attending Physician, Internal Medicine Service, HULP*

Members from outside the institution
Juan Manuel Martín Baranda. *Patient representative*
Evaristo Moliné Jorques. *Patient representative*
Eva Prieto Utiel. *Assistant Clinical Pharmacist of Primary Care-Pharmacy Department*

Technical Secretary
Emma Fernández de Uzquiano.
Head of Technical Secretary. Pharmacist
Elena García Mendez. *Pharmacist*
Laura Díez Ricote. *Biologist*
Susana Martín López. *Pharmacologist*
Sol de Gracia García. *Administrative Assistant*
María Isabel Arribas Álvarez. *Administrative*

QUALITY COMITTEE

Coordinator
José Jonay Ojeda Feo. *HULP Representative*

Members:
Blanca Fuentes Gimeno. *HULP Representative*
María Luisa Díaz Martínez. *UAM Representative*
Gema Vallés Pérez. *FIBHULP Representative*
Paloma Gómez Campelo. *FIBHULP Representative*
Ana Coloma Zapatero. *FIBHULP Representative*
Aitana López Redondo. *FIBHULP Representative*
Estela Sánchez Simón. *FIBHULP Representative*
Cristina Lázaro- Carrasco Escarpizo-Lorenzana. *FIBHULP Representative*

TRAINING COMMITTEE

Chairperson
Paloma Gómez Campelo. *HULP Representative*

Secretary
Mercedes Ruiz Balibrea. *HULP Representative*

Members
María Teresa García Morales. *Biostatistics Platform*
Ana Martínez Virto. *HULP Representative*
Ana García Redondo. *R3 Researcher, UAM Representative*
María Gutiérrez Fernández. *R4 Researcher, Neurosciences Area, IdiPAZ*
María Fernández Velasco. *R4 Researcher, Cardiovascular Area, IdiPAZ*
Pilar Sánchez-Corral Gómez. *R4 Researcher, Infectious Diseases and Immunity Area, IdiPAZ, Representative of the Works Council*
Beatriz Castelo. *HULP Representative*
Ana Sastre Perona. *R4 Researcher, Surgery, Transplants and Health Technologies Area, IdiPAZ, FIBHULP Representative*
Ane Miren Andrés Moreno. *Representative HULP Maternal, Child and Adolescent Area*
FGG. *Management Representative Works Council*
Aitana López Redondo. *FIBHULP Occupational Health and Safety Service*
Ana Martín de la Flor. *Management Representative FIBHULP*

EQUALITY, DIVERSITY AND CONFLICT RESOLUTION COMMISSION (ID&RC)

Members
María Quintanar Jaime. *FIBHULP Representative*
Paloma Gómez Campelo. *FIBHULP Representative*
Aitana López Redondo. *FIBHULP Representative*
Nuria Vilaboa Díaz. *Employee's Representative of FIBHULP*
Juan Ángel Fresno Vara. *Employee's Representative of FIBHULP*
Sara García Barcenilla. *Employee's Representative of FIBHULP*

COMMISSION FOR CITIZEN PARTICIPATION

Chairperson
Paloma Gómez Campelo. *Deputy Director of IdiPAZ - CSR, SDGs and Agenda 2030 Coordinator of IdiPAZ/FBIHULP*

Vice-Chair
Manuel Arellano Armisen. *Second Vice-President of the Platform of Patients' Organizations, Vice-President of the ALCER National Federation and member of the Board of the European Patients' Forum*

Members
Ana Coloma Zapatero. *Director of FIBHULP*
María Quintanar Jaime. *Human Resources Department of FIBHULP - Head of CSR of IdiPAZ/FIBHULP*
Isabel Polo Campos. *Communication Department of FIBHULP*
Sergio Palomero Lorente. *In-House Prevention Service Technician*
Eva M. Ortiz Vivanco. *Nursing Representative HULP*
Shona Brown. *Representative of the British Embassy*
With the participation of REDS-SDSN. *Spanish Network for Sustainable Development*

Secretary
Aitana López Redondo. *Responsible for SDGs and Agenda 2030 at IdiPAZ/FIBHULP*

RESEARCH AREAS

Neurosciences Area

Coordinator: Exuperio Díez Tejedor

Psychiatry and Mental Health
Director: María Fe Bravo Ortiz
Neurology and Cerebrovascular Diseases
Director: Exuperio Díez Tejedor
María Gutiérrez Fernández
Neuroprotective Strategies in Neurodegenerative Diseases
Director: Ana Isabel Rojo Sanchís
Involvement of Glycinergic and Glutamatergic Systems in Central Nervous System Pathologies
Director: Francisco Zafra Gómez
Mechanisms and Biomarkers in Neurodegenerative Diseases
Director: Isabel Lastres Becker
Multiple Sclerosis Research
Director: Yolanda Aladró Benito



Cardiovascular Area

Coordinators: José Raúl Moreno Gómez; María Fernández Velasco

Research on Invasive Clinical and Translational Cardiology – ICCI-Paz
Director: José Raúl Moreno Gómez
María Fernández Velasco
Coagulopathies and Alterations of Haemostasis
Director: Víctor Jiménez Yuste
Vascular Physiology and Pharmacology
Director: Ana María Briones Alonso
Vascular Pharmacology and Metabolism (FARMAVSM)
Director: Carlos F. Sánchez Ferrer
Concepción Peiró Vallejo
Paediatric Cardiology Research
Director: Federico Gutiérrez-Larraya Aguado



Infectious Diseases and Immunity Area

Coordinator: Eduardo López-Collazo


AIDS and Infectious Diseases
Director: José Ramón Arribas López
Molecular Microbiology
Director: Jesús Mingorance Cruz
Immuno-Rheumatology
Director: María Eugenia Miranda Carús
Innate Immune Response
Director: Eduardo López-Collazo
Carlos del Fresno Sánchez
Alterations of the Complement System in Human Pathology
Director: Margarita López Trascasa
Pilar Sánchez-Corral Gómez
Lymphocyte Pathophysiology in Immunodeficiencies
Director: Eduardo López Granados
Drug Hypersensibility and Innate Immune Response
Director: Teresa Bellón Heredia
Immunomediate Gastrointestinal Diseases and other Digestive Pathologies
Director: María Dolores Martín Arranz
MicroRNA Regulation of Immune Tolerance, Autoimmunity and Cancer
Director: Alicia González Martín
***Systemic Immune-Mediated Diseases**
Director: Juan José Ríos Blanco
**Group recently created, December 2024*

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians





Large System Pathology Area

Coordinator: Francisco García Río

Internal Medicine and Systemic Diseases
Director: Francisco Arnalich Férnandez
Organic Dysfunction and Failure in the Aggression
Director: José Manuel Añón Elizalde
Respiratory Diseases
Director: Francisco García Río
Carolina Cubillos Zapata
Regulation of Gene Expression and by Hypoxia
Director: Luis del Peso Ovalle
Nephrology
Director: María Gemma Fernández Juárez
Diagnosis and Treatment of Allergic Diseases
Director: Santiago Quirce Gancedo
Management of the Bleeding Patient
Director: Manuel Quintana Díaz
Health Care Nurses Research
Director: Esther Rey Cuevas
Tamara Domingo Pérez
Emergency and Critical Pathology
Director: Alejandro Martín Quirós
Hospital Pharmacy
Director: Alicia Herrero Ambrosio
Translational Hepatology
Director: Francisco Javier García-Samaniego Rey
***NEURO-CURE**
Director: Javier Marco Martínez
**Group recently created, December 2024*



Cancer and Human Molecular Genetics Area

Coordinator: Javier de Castro Carpeño

INGEMM- Institute of Medical and Molecular Genetics
Director: Pablo Lapunzina Badía
Translational Oncology
Director: Jaime Feliú Battle
Experimental Therapies and Biomarkers in Cancer
Director: Olga Vera Puente
Javier de Castro Carpeño
Oto-Neurosurgery Research
Director: Luis Lassaletta Atienza
Molecular Pathology of Cancer And Therapeutic Targets
Director: David Hardisson Hernáez
Mechanisms of Tumour Progression
Director: José Manuel González Sancho
Research and Diagnosis of Inherited Metabolic Diseases
Director: María Belén Pérez González
Dyslipemias of Genetic Origin and Metabolic Diseases
Director: Sonia Rodríguez Novoa
Human Genetic Variability
Director: Ana Fernández Santander



Surgery, Transplant and Health Technologies Area

Coordinator: Nuria Vilaboa Díaz

Bone Pathophysiology and Biomaterials
Director: Nuria Vilaboa Díaz
Cellular Engineering
Director: María Paz de Miguel González
Clinical Pharmacology
Director: Antonio J. Carcas Sansuán
Osteoarticular Surgery Research – GICOA
Director: Enrique Gómez Barrena
Translational Research in Maxillofacial Surgery and Head and Neck Cancer
Director: José Luis Cebrián Carretero
Ana Sastre Perona
Research in Patient Safety and Quality
Director: Elena Ramírez García
Translational Research and Innovation in General and Digestive Surgery
Director: Constantino Fondevila Campo
Anesthesia-Resuscitation Maternity
Director: Isabel Valbuena Gómez
***AI Health**
Director: Juan José Beunza Nuin
***Advanced Medical Informatics Laboratory (LIMA)**
Director: Fernando Martín Sanchez
**Group recently created, December 2024*

Maternal Infant Child and Youth Research


Coordinators: Cristina Calvo Rey; Antonio Pérez Martínez

Neonatology
Director: Adelina Pellicer Martínez
Molecular Hepatology
Director: Paloma Jara Vega
Loreto Hierro Llanillo
Maternal-Fetal Medicine
Director: José Luis Bartha Rasero
Pediatric Respiratory, Systemic and Neurological Infections & Host Immune Response
Director: Cristina Calvo Rey
Pediatric Systemic Infections; HIV, tuberculosis, Imported and Emergent Diseases
Director: Talía Sainz Costa
Translational Research in Pediatric Oncology, Hematopoietic Transplantation and Cell Therapy
Director: Antonio Pérez Martínez
Congenital Malformations and Transplantation
Director: Francisco Hernández Oliveros
Research in Endometriosis
Director: Alicia Hernández Gutiérrez
Research on Comprehensive Care for Transplanted Children and Adolescents
Director: María Jesús Pascau González-Garzón
Luz Yadira Bravo Gallego
Food Oxidative Stress and Cardiovascular Health
Director: Silvia M. Arribas Rodríguez

Multidisciplinar Research In Healthy Aging

Coordinator: Rocio Menéndez Colino

Aging and Fragility In The Elderly
Director: Rocío Menéndez Colino
Frailty and Healthy Aging
Director: Leocadio Rodríguez Mañas
Frailty, Multimorbidity Patterns and Mortality in the Elderly Population Residing in the Community
Director: Miguel Ángel Salinero Fort



PUBLIC RESEARCH CONTRACTS

Ramón y Cajal Stabilisation Contracts (I3) - CM
Karen Elise Heath. *INGEMM - Institute of Medical and Molecular Genetics Group*
Jesús Mingorance Cruz. *Molecular Microbiology Group*
Rebeca Pérez de Diego. *Innate Immune Response Group*

Miguel Servet Stabilisation Contracts (I2) - ISCIII/ CM
Teresa Bellón Heredia. *Drug Hypersensibility and Innate Immune Response Group*
Juan Ángel Fresno Vara. *Translational Oncology Group*
Ángel Campos Barros. *INGEMM - Institute of Medical and Molecular Genetics Group*
María Paz de Miguel González. *Cellular Engineering Group*
Eduardo López-Collazo. *Innate Immune Response Group*
Berta Rodés Soldevila. *AIDS and Infectious Diseases Group*
Pilar Sánchez-Corral Gómez. *Diagnosis and Treatment of Diseases Associated with Abnormalities of the Complement System Group*
María Rosa Torres Jiménez. *Metabolic-Vascular Unit Group*
David Vicent López. *Molecular Hepatology Group*
Nuria Vilaboa Díaz. *Bone Pathophysiology and Biomaterials Group*
Nora Viviana Butta Coll. *Coagulopathies and Alterations of Haemostasis Group*
Rosa María Rodríguez Pérez. *Diagnosis and Treatment of Allergic Diseases Group*
Laura Saldaña Quero. *Bone Pathophysiology and Biomaterials Group*
María Fernández Velasco (CPII16/00047). *Innate Immune Response Group*
Carolina Cubillos Zapata (MS18/00208). *Respiratory Diseases Group*
María Dolores Gutiérrez Fernández. *Neurology and Cerebrovascular Diseases Group*
Ana Sastre Perona. *Translational Research in Maxillofacial Surgery and Head and Neck Cancer*

Miguel Servet Contracts Type I - ISCIII
Carlos del Fresno Sánchez (CP20/00106). *Innate Immune Response Group*
Laura Otero Ortega (CP20/00024). *Neurology and Cerebrovascular Diseases Group*
Elias Dahdouh (CP23/00036). *Molecular Microbiology Group*
Olga Vera Puente (CP24/00005). *Experimental Therapies and Biomarkers in Cancer Group*
Adriana Mañas Núñez (CP24/00030). *Translational Research in Childhood Cancer, Hematopoietic Transplantation and Cell Therapy*

Intensification Contracts – ISCIII
José Ramón Arribas (INT23/00003). *AIDS and Infectious Diseases Group*
Teresa Álvarez Román (INT23/00069). *Coagulopathies and Alterations of Haemostasis Group*
José Carlos Moreno Navarro (INT23/00092). *INGEMM - Institute of Medical and Molecular Genetics Group*
Talía Sainz Costa (INT24/00011). *Systemic Infections in Pediatrics: HIV, Tuberculosis, Imported Diseases, and Emerging Diseases Group*
María Alonso de Leciñana (INT24/00034). *Neurology and Cerebrovascular Diseases Group*
Enmanuela Spagnolo (INT24/00022). *Endometriosis Research*

Río Hortega Contracts - ISCIII
Laura Casado Fernández (CM23/00022)
Gonzalo Solís García (CM23/00054)
Blanca Bravo Queipo de Llano (CM23/00057)
Patricia Martínez Martín (CM23/00058)
Borja Rivero Santana (CM23/00121)
Claudia Millán Longo (CM23/00139)
Julian Villamayor Sánchez (CM23/00159)
Berta Sufrate Vergara (CM24/00016)
Carlos Hervás Testal (CM24/00153)
Alejandro de Gea Grela (CM24/00182)
María del Mar Arcos Rueda (CM24/00234)
Alfredo Maldonado Barrueco (CM24/00250)

Juan Rodés Contracts - ISCIII
Sara Ruiz Martínez (JR22/00019)
Carlos Daniel Grasa Lozano (JR22/00044)
Irene García García (JR22/00036)
Victor Galán Gómez (JR24/00003)
Elisa Alonso López (JR24//00004)
Paula Rodríguez Molino (JR24/00015)

Sara Borrell Contracts - ISCIII
Luna Rindan Cordeiro Minute (CD22/00042)
Almudena Val Blasco (CD22/00055)
Clara Correa Paz (CD23/00005)
Marta Mascaraque Checa (CD23/00167)
Alba Tamargo García (CD24/00190)
Roberto del Amparo Temporao (CD24/00191)
Alicia Villacampa Calvo (CD24/00217)

Predoctoral Fellowship - ISCIII
Rebeca Gallego Ruiz (FI21/00033)
Andrea Bueno Sen (FI21/00259)
Andrea Guzmán de Antonio (FI22/00182)
María Paz López Molina (FI22/00009)
Javier Pozo Novoa (FI22/00187)
Lucía Gutiérrez Garcia (FI23/00061)
Paula Pérez Moreno (FI23/00151)
Ángela Calzado González (FI24/00043)
Germán Vallejo Palma (FI24/00151)
Ana B. Griso Acevedo (FI24/00184)

Predoctoral Contract – MINECO
Elsa Lucas Castro (PRE2021-098PRE2021874)
Merdeces León López (PREP2023-001933)

Predoctoral Contract - CM
Jesus Gonzalez Bejarano (PIPF-2023/SAL-GL-29945)
Aida Vaquero (PIPF-2023/SAL-GL-30428)

Technical Support Stabilisation Contracts - CM
Francisco Gayá Moreno. *AIDS and Infectious Diseases Group*
María Teresa Vallejo Cremades. *Congenital Malformation Surgery Group*
Eva Jaraba Redondo. *Associated Clinician*

Youth Guarantee Contracts - CM

Graduate
Paula Almellones Araiz (PEJ-2023-AI/SAL-GL-27602)
Rocío Sánchez Siles (PEJ-2023-AI/SAL-GL-27700)
Isabel García Pérez (PEJ-2023-AI/SAL-GL-27678)
Cecilia Zapata García (PEJ-2023-AI/SAL-GL-28777)
Nerea Díez Gamero (PEJ-2023-AI/SAL-GL-27704)
Sara de Pablos Vinader (PEJ-2023-AI/SAL-GL-27751)
María Octavia Santiesteban (PEJ-2024-AI/SAL-GL-32563)
Daniel Brihuega Frontera (PEJ-2024-AI/SAL-GL-33116)
Adriana Cuevas Domínguez (PEJ-2024-AI/SAL-GL-31793)
Pamela Heredia (PEJ-2024-AI/SAL-GL-32542)

Technical Support
Inés Álvarez Alonso (PEJ-2023-TL/SAL-GL-28762)
Sara Rodríguez Díaz (PEJ-2024-TL/SAL-GL-33182)
Marina de Pablo (PEJ-2024-TL/SAL-GL-33168)
Beatriz Horcajo Morera (PEJ-2024-TL/SAL-GL-31713)
Alicia Román San Martín (PEJ-2024-TL/SAL-GL-32466)

Investigo SEPE Contracts
Álvaro Clemente Bernal
Jesús Fernández Felipe
Gulce Bicakcioglu
Beatriz Sanz Verdejo


DATA: HUMAN RESOURCES


PROGRAMME	ORGANISATION	TOTAL
Ramón y Cajal Stabilisation Contracts (I3)	CM	3
Miguel Servet Stabilisation Contracts (I2)	ISCIII/ CM	18
Technical Support Stabilisation Contracts	CM	3
TOTAL ESTABLISHED		**24**
Miguel Servet Contracts CP Type 1	ISCIII	5
Miguel Servet Contracts CP Type 1I	ISCIII	0
Intensification Contracts	ISCIII	6
Río Hortega Contracts	ISCIII	12
Juan Rodés Contracts	ISCIII	6
Bioinformatics Technician Contract	ISCIII	0
Sara Borrell Contract	ISCIII	7
Predoctoral Fellowship	ISCIII	10
Investigo Contract	SEPE	4
Predoctoral Contract	MINECO	2
Predoctoral Contract	CM	2
Youth Guarantee Contracts	CM	15
TOTAL PROGRAMMES		**69**
TOTAL ESTABLISHED + PROGRAMMES		**93**
UCICEC	CAIBER	8
FIS Projects	ISCIII	41
European Projects	EU	27
Research Network	ISCIII	7
Research Network	CM	2
SAF/MAT	MINECO	4
Biobank	ISCIII	8
Commercial clinical trials	ISCIII	2
Commercial clinical trials	EECC Promoters	51
Private projects	Pharmaceutical Industry	64
In-house Projects	FIBHULP	11
ITEMAS Network	ISCIII	2
TOTAL EMPLOYEES DEPENDET ON P.I.		**227**
TOTAL STAFF DEPENDENT ON P.I.		**320**
Technical Unit Staff	FIBHULP	31

Researcher profile

The following graphs show the classification of IdiPAZ researchers according to the EURAXES regulations proposed by the European Union. In addition, in the following image we can see the evolution of this classification that has occurred in the last year.

Euraxess researcher profile





1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

2.3. Training Report and Teaching

Some of the goals of IdiPAZ are to generate knowledge, to train specialists in the biomedical, to promote research and to transfer the knowledge not only to clinical practice but the society too.

2.3.1. Doctoral Theses

In 2024, 54 Doctoral Theses have been read and/or supervised by IdiPAZ researchers, and 6 of them was thesis with International Doctorate mention ★.

Doctoral Student	Title	Directors	FECHA LECTURA	University
Abascal Saiz A	Relación de la lipidómica placentaria con la clínica y patogénesis de la preeclampsia	Bartha Rasero JL, Antolín Alvarado ME	2/7/24	UAM
Alonso Espías M	Estudio de los factores asociados al manejo integral del cáncer de cuello uterino precoz y su influencia en los resultados oncológicos	Zapardiel Gutiérrez I, Hernández Gutiérrez A	10/11/24	UAM
Bartha de las Peñas I ★	The influence of respiratory allergy, obesity and environment on obstetrics and perinatal outcomes	Bartha Rasero JL	14/2/24	UAM
Bartolomé Cabrero R ★	MiR-148a shapes brain development and function through regulating neurite growth and polarization	González Martín A, Gascón Jiménez S	16/12/24	UAM
Blázquez Ramos N	Estudio de la influencia de la adherencia y los niveles plasmáticos de factor en las comorbilidades, complicaciones y consecuencias de la hemofilia	Romero Garrido JA, González del Valle L, Benedí González JM	15/7/24	UCM
Bruna García E	Obtención de un nuevo ingrediente funcional derivado de la grasa de jamón ibérico. Análisis y caracterización	Miguel Castro M, Isabel Redondo B	29/11/24	UAM
Cadenas Martín M	Generación de córnea biomimética con células madre mesenquimales de tejido adiposo	Miguel González MP, Arnalich Montiel F	15/2/24	UAM
Camblor Murube M	Variantes de Aurora Quinasa B: nuevos biomarcadores predictivos de desarrollo de carcinoma hepatocelular en pacientes infectados con VHC, tratados con antivirales de acción directa	Madejón Seiz A	31/10/24	UAM
Carracedo Sanchidrián D	Terapia Cognitiva Basada en Mindfulness frente a Intervención Psicoeducativa en pacientes con Trastorno Bipolar con síntomas subsindrómicos depresivos: Estudio controlado aleatorizado	Dios Perrino MC, Lahera Forteza G	14/10/24	UAM
Castillo Díez F	Abordaje endoscópico preperitoneal ascendente suprapúbico para la reparación de hernias anteriores y laterales de la pared abdominal	Pascual Migueláñez I	16/10/24	UAM
Cristóbal Quevedo I	Estudio comparativo de la tasa de bilateralidad en cuanto a la técnica del ganglio centinela en el cáncer de endometrio: verde de indocianina como trazador único versus verde de indocianina junto a radiotrazador	Zapardiel Gutiérrez I, Hernández Gutiérrez MA	5/4/24	UAM
Díaz Saéz MC	La lengua como órgano clave en el abordaje de los trastornos temporomandibulares	Gil Martínez A, Beltrán Alacreu H	23/5/24	UAM
Faedda N ★	Interacciones vasculares y hormonales en la corteza suprarrenal	Briones Alonso AM	4/12/24	Universitad Paris Cité; UAM

Doctoral Student	Title	Directors	FECHA LECTURA	University
Falces Romero I	Diagnóstico molecular de bacteriemias y candidemias en pacientes pediátricos críticos: Un nuevo enfoque	Cendejas Bueno JL, García Rodríguez J	12/12/24	UAM
Fudio Muñoz S	Revisión crítica sobre los aspectos relativos a farmacología clínica de las combinaciones aprobadas por la FDA en hemato-oncología desde el año 2011 para aplicar a un caso práctico	Carcas Sansuán AJ	25/4/24	UAM
Galán Gómez V	Caracterización genética de la leucemia linfoblástica aguda en pediatría para su optimización diagnóstica, pronóstica y terapéutica	Pérez Martínez A, Escudero López A	24/5/24	UAM
Gallego Martínez D	Genómica funcional aplicada a la identificación de dianas terapéuticas en enfermedades metabólicas hereditarias.	Pérez González MB	23/5/24	UAM
García Calvo L	Biopsia del ganglio centinela en pacientes con carcinoma de mama sin afectación axilar al diagnóstico (cn0) que reciben terapia sistémica primaria	Sánchez Méndez JI	13/12/24	UAM
García Pineda V	Implicaciones clínicas de la implementación de la biopsia selectiva del ganglio centinela en el manejo quirúrgico del cáncer de endometrio	Hernández Gutiérrez A, Zapardiel Gutiérrez I	13/6/24	UAM
Garrote Camara ME	Características clínicas del síndrome de agitación psicomotriz en pacientes con trastorno mental grave	Juárez Vela R	24/5/24	UdL
Gil Fernández M ★	Role of NOD1 in atrial myopathy associated with heart failure	Fernández Velasco M, Bosca Gomar L	12/7/24	UAM
Gómez-Morán Quintana M	Reducción de la mortalidad intrahospitalaria con el uso precoz de la ventilación no invasiva prehospitalaria en el edema agudo de pulmón y la enfermedad pulmonar obstructiva crónica agudizada. Estudio ventilamadrid	Gutiérrez Misis A, Horrillo García CL	12/1/24	UAM
González Molina MP	Deciphering the role of microRNAs in tumor immunology	González Martín A	2/12/24	UAM
Gutiérrez Sainz L	Citoquinas y adenocarcinoma de páncreas: estudio de su relación con los síntomas, el pronóstico y el subtipo molecular	Feliú Batlle J	8/10/24	UAM
Hormigo Sánchez AI	Aplicación terapéutica de un protocolo sistemático de valoración oncohematogeriátrica individualizada e integral en pacientes mayores con linfoma de reciente diagnóstico	González Montalvo JI, Córdoba Mascuñano R	27/11/24	UAM
Jericó Alba CS	Estudio Observacional Retrospectivo sobre la Implementación (Implantación, Desarrollo y Evaluación) de un Programa de Patient Blood Management en un Hospital general	Quintana Díaz M, García Erce JA	9/2/24	UAM
Jiménez Estrada JA	Caracterización de KDELR2 como un nuevo gen asociado a osteogénesis imperfecta y determinación de los mecanismos que lo relacionan con esta enfermedad	Ruiz Pérez VL, Flores Mauriz CL	25/1/24	UAM
Laorden Escudero D	Evaluación de los criterios de super-respondedor y la escala FEOS como herramientas eficaces en valorar la respuesta al tratamiento biológico en el asma grave no controlada	Álvarez-Sala Walther R, Quirce Gancedo SE	11/3/24	UAM
Lozano Rodríguez R	SARS-CoV-2: desde la etiología inmunitaria hasta la respuesta a las vacunas	López Collazo E, Guerra Garcia MS	16/2/24	UAM
Lucia Montoya O	Conciencia corporal como factor protector de las orientaciones suicidas en estudiantes universitarios	Juárez Vela R	11/7/24	USAL
Maestro Paramio L	Regulación de las interacciones entre células que participan en la regeneración ósea por la composición y rigidez de hidrogeles naturales	Saldaña Quero L	12/6/24	UAM
Marcos Lorenzo D	Salud de la columna en la descarga axial provocada durante los vuelos espaciales y la recarga mediante ejercicio	Gil Martínez A, Green DA	12/4/24	UAM
Maria Matilla A	Epidemiología e implicaciones del Síndrome de Burnout en profesionales de enfermería	Juárez Vela R	26/9/24	USAL

Doctoral Student	Title	Directors	FECHA LECTURA	University
Miguéns Blanco I	Identificación de problemas en relación con la brecha de género en los Servicios de Urgencias hospitalarios de España y propuesta de soluciones para su erradicación	Munayco Sánchez AJ, Quintana Díaz M	27/6/24	UAM
Monroy Tapiador MA	Estudio de la microbiota en niños diagnosticados de Síndrome de Phelan-Mcdermid	Sainz Costa T, Álvarez Calatayud G	21/6/24	UAM
Moreno Caballero B	Prevención cardiovascular en atención primaria durante la pandemia por Sars-Cov-2	Castell Alcalá MV, Gutiérrez Misis A	11/10/24	UAM
Navarro Zapata A	Evaluation of the Combined Treatment of NKG2D-CAR T Cells and Epigenetic Drugs for Neuroblastoma Therapy	Pérez Martínez A, Fernández Casanova L	2/12/24	UAM
Novella Navarro M	Caracterización e implicaciones clínicas de la artritis reumatoide difícil de tratar	Balsa Criado A, Plasencia Rodríguez C	22/4/24	UAM
Oviedo Briones MR	Instrumentos de detección de fragilidad en distintos medios asistenciales	Checa López M, Rodríguez Mañas L	2/10/24	UAM
Prim Martínez T	Valoración clínica de dos dispositivos supraglóticos de 1ª y 2ª generación con tres métodos de inflado del manguito	Gilsanz Rodríguez F, Brogly N	15/3/24	UAM
Ramírez Cervantes KL	COVID-19-associated thrombosis: studying its prevalence in the deprived population, its clinical prediction in critically ill individuals, and the antithrombotic use patterns at a country level	Quintana Díaz M, Huerta Álvarez C	17/12/24	UAM
Ramos Marques dos Santos J	Ganancia auditiva, biocompatibilidad y extrusión de prótesis de titanio en la reconstrucción quirúrgica del oído medio	Gavilán Bouzas J	8/3/24	UAM
Ramos Rubio D	Valor diagnóstico de los niveles séricos de marcadores inflamatorios agudos como indicadores precoces de fugas anastomóticas post-gastrectomía	García-Moreno F	7/5/24	UAH
Recarte Rico M	Marcadores inflamatorios y metabólicos en obesidad y cirugía bariátrica	Cos Blanco AI, Mata Juberías A, Díaz Domínguez J	4/4/24	UAM
Ríos Germán PP	Diferencias entre los pacientes que ingresan por una fractura de cadera, que viven en residencia o en domicilio y la evolución al mes y al año en ambas poblaciones. Estudios de una cohorte hospitalaria y una cohorte multicéntrica a nivel nacional	González Montalvo JI, Gutiérrez Misis A	29/10/24	UAM
Rodriguez Molino P ★	Limitaciones en el diagnóstico de la tuberculosis en niños y adolescentes en un contexto de baja endemia	Sainz Costa T	3/6/24	UAM
Ros Pardo D	Técnicas de modelado por homología y dinámica molecular en el estudio de la funcionalidad de GSDMB y el complejo de cohesina	Gómez-Puertas P	21/2/24	UAM
Ruvira Hernando SA	Vascular effects of cocoa shell extract supplementation in a rat model of fetal programming of hypertension	Arribas Rodríguez SM, Ramiro Cortijo D	21/11/24	UAM
Sánchez Lijarcio O	Estrategia multi-ómica y de genómica funcional para la mejora del diagnóstico de enfermedades neurometabólicas.	Pérez González MB	9/4/24	UAM
Sanjuán Riera L	Resultados funcionales del tratamiento con Bevacizumab Intravítreo en retinopatía del prematuro	Peralta Calvo J	7/11/24	UAM
Tornero Marín C	Caracterización e historia natural de la hipofosfatasia congénita en pacientes adultos con confirmación genética frente a pacientes con fosfatasa alcalina baja y test genético negativo	Aguado Acín MP, Navarro Compán V	31/1/24	UAM
Torres Arrese M	Ecografía clínica en la valoración de la congestión sistémica derecha en pacientes con insuficiencia cardíaca aguda	Cuervas-Mons Martínez V, Tung Chen Y	13/6/24	UAM
Vilchez Sánchez F	Relevancia y repercusión clínica de la sensibilización a Pru p 7 en nuestro medio	Rodríguez Pérez R, Quirce Gancedo SE	1/7/24	UAM
Zozaya Nieto C	Necrotizing enterocolitis in preterm infants: magnitude of the problem and potential novel therapies	Sáenz de Pipaón Marcos M	8/7/24	UAM

2.3.2. Master Theses

In 2024, 27 Master Theses have been read and/or supervised by IdiPAZ researchers

Student	Title	Director	University
Coronel C	Evaluación de potenciales fármacos contra la Esclerosis Lateral Amiotrófica	Palomo Ruiz MV	UE
Blanco de Miguel D	Development of a web application for the analysis of neuropsychological tests in MS patients. Master's in Biomedical Engineering.	Otero Ortega L	UPM
Míguez Rodríguez R	Preclinical evaluation of novel NRF2 activators in neurodegenerative diseases.	Cuadrado Pastor A; Fernández Ginés R	UAM
Kaminski Santamaría S	Analysis of the role of gasdermind d in tau-dependent frontotemporal dementia mouse model	Lastres-Becker I	UAM
Zambonino Rodríguez CM	The NOD1 receptor modulates the calcium handling in the sinus node in a murine model of heart failure.	Fernández Velasco M	UAM
Arrúa Baez W	Resolvind D2 protects the heart of obese hypertensive mice by decreasing hypertrophy and fibrosis without affecting endoplasmic reticulum stress	Briones Alonso AM, García Redondo AB	UAM
Romero González R	Alamandine, a new anti-senescence and vasodilator peptide of the renin-angiotensin system	Peiró Vallejo C	UAM
Ciudad Sañudo M	Algoritmos diagnóstico-terapéuticos en enfermedades infecciosas: Neurocisticercosis; eosinofilia importada asintomática; Detección molecular de parásitos protozoarios en heces.	Díaz Menéndez M	US
Aguilera García M	Algoritmos diagnóstico-terapéuticos en enfermedades infecciosas: Manejo de la enfermedad de Chagas crónica en consulta. Diagnóstico de la fiebre en el viajero; Manejo de la diarrea en el viajero	Díaz Menéndez M	US
Guzmán Bustos ML	Factores que influyen en el seguimiento del VIH en la población indígena atendida en el centro regional de vigilancia, información y referencia de las ITS/VIH/Sida. Llallagua-Bolivia	Díaz Menéndez M	URJC
Cristina Limia Vita	Utilidad y conveniencia de realizar screening para infecciones por criptococcus en los pacientes VIH. Revisión de la literatura	Díaz Menéndez M	URJC
Iveth Salguero D	Manejo de Infecciones oportunistas en adultos con el VIH	Díaz Menéndez M	URJC
González Gómez I	Análisis mediante secuenciación masiva de Enterobacterias productoras de NDM en el Hospital Universitario de La Paz y pruebas de transferencia horizontal de genes mediante Vesículas de Membrana Externa (OMVs).	Dahdouh E	UAM
Shustrova S	Análisis de la incidencia y factores de riesgo de Enterobacterias Productoras de Carbapenemasa en una Unidad de Cuidados Intensivos de adultos de un hospital terciario en España: estudio retrospectivo y medidas de control	Pérez Blanco V	ENS
Blanco Córdoba J	Interacción entre microbiota intestinal y Alzheimer: Caracterización y desarrollo de un pipeline para su aplicación	González Soltero MR	UE
Castro García AB	Microbiota y esquizofrenia: reuso de datos públicos según estándares FAIR	González Soltero MR	UE
López Gualdrón OJ	Evaluación de la Adherencia a los Principios FAIR en Bases de Datos de Proyectos de Secuenciación Metagenómica	González Soltero MR	UE
Arvelo del Rosario D	Modelos de organoides como una nueva plataforma para la quimioterapia personalizada frente al cáncer de colon	Córdoba García L, Fernández J	UCM
Arsic N	Identification of novel regulators of B cell tolerance	González Martín A	UAB, UB , Universidad Claude Bernard Lyon; Universidad Jean Monnet
Fernández Ferrer A	Evaluación del tratamiento de Terapia Celular Avanzada con células madre derivadas de tejido adiposo en el tratamiento del daño limbar corneal	de Miguel González MP	USP CEU
de Sancha Maluenda M	Diferenciación dirigida de células madre mesenquimales a células de la cresta neural y queratocitos corneales para su uso en oftalmología	de Miguel González MP	USP CEU
Bedoya P	Respuesta ala vacuna nonavelente frente a VPH en niños y adolescentes inmunodeprimidos	Méndez Echevarría A	UCM
Díaz Rodriguez KG	Seguimiento de pacientes adolescentes VIH de un hospital pediátrico al de adulto	Sainz Costa T	URJC
Vidal Prado T	Características clínicas y epidemiológicas en relación con el VIH en menores de 17 años	Sainz Costa T	URJC
Bedoya P	Inmunogenicidad de la vacuna contra VPH 9 Valente en niños y adolescentes inmunocomprometidos	Sainz Costa T	UCM
Egido Rodríguez I	Eficacia de una intervención de refuerzo de enfermería sobre la presión arterial y el control de lípidos, frente a una intervención convencional en pacientes dados de alta recientemente por un ictus	Salinero Fort MA	UAX
Muñoz Martínez M	Revisión sistemática. Presencia de los familiares en la reanimación cardiopulmonar en pacientes adultos, para una mejora de las complicaciones psicológicas y afrontamiento de la situación.	Salinero Fort MA	UAX

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

2.3.3. Final Degree Theses

In 2024, 47 Final Degree Theses have been read and/or supervised by IdiPAZ researchers

Student	Title	Director	University
Alneng García del Salto C	Revisión sistemática sobre la preservación de la fertilidad en mujeres con síndrome de ovario poliquístico y su impacto psicológico	López Pedraza L	Escuela Enfermería Cruz Roja - UAM
Baceiredo Macho P	Análisis de la implicación de proteínas de unión al RNA en a neurodegeneración asociada a la demencia frontotemporal TAU-dependiente	Lastres-Becker I	UAM
Bernárdez Piñuela V	Intervenciones de humanización hospitalaria en el paciente pediátrico: revisión sistemática	López Pedraza L	Escuela Enfermería Cruz Roja - UAM
Cabeza Arciniega C	Estudio de la regulación del citoesqueleto de miosina no muscular durante resistencia a terapias en melanoma cutáneo	Orgaz Bueno JL	UAM
Cantero García L	Evaluación sagital en la artroplastia de rodilla: técnica asistida por robot frente a convencional	Gómez Barrena E	UAM
Castro Sánchez KW	Perfil mutacional de pole y sus implicaciones en inmunoterapia	Novillo Villajos A	UCM
Cereza de Burgos A	Impacto y utilidad de la información parental sobre el recién nacido en el municipio de Rivas Vaciamadrid	López Pedraza L	HGM
Comanescu RT	Factores predictores de éxito reproductivo en pacientes diagnosticadas de endometriosis sometidas a ciclos de fecundacion en vitro o de preservación fertilidad	Zapardiel Gutiérrez I, Hernández Gutiérrez MA, Iniesta S	UAM
Díaz Alonso G	Análisis de calidad de vida y disfunción sexual en mujeres premenopáusicas tratadas de cáncer de ovario	Diestro Tejada MD, Spagnolo E	UAM
Ejido Fuentetaja B	EV as a biomarker of treatment response in MS patients	Otero Ortega L	ULE
Fernández Cañizares M	Alteraciones metabólicas inducidas por la exposición a hipoxia intermitente, mimetizando la apnea obstructiva del sueño, en adipocitos marrones	del Peso Ovalle L	UAM
Fernández Moya LC	Adherencia terapéutica farmacológica en adolescentes de 13 a 18 años trasplantados de órgano sólido	Pascau González-Garzón MJ	Nebrija
Gala D	Factores moleculares implicados en la transformación maligna de la endometriosis ovárica	Spagnolo E, Tenorio J	UAM
García Bustos S	Análisis computacional de respuesta transcripcional a la hipoxia sostenida e intermitente	del Peso Ovalle L	UAM
García Candau JB, Dueñas López, L	Evaluación de la experiencia del cuidador principal del paciente pediátrico con epidermolisis bullosa	de Villarreal Arracó J	UAM
García Rubio A	Vesículas extracelulares de pacientes de escreloris lateral	Palomo Ruiz MV	UPM
González Matesanz M	Papel de las vesículas extracelulares derivadas del sistema inmune en un modelo preclínico de hemorragia intracerebral	Gutiérrez Fernández M	UPM
Gonzalo Santana T	Functional analysis of microRNAs and its target genes in B cell tolerance	González Martín A	UAM
Gozálvez Gozálvez I	La terapia CAR-T en el tratamiento de la leucemia linfática aguda infantil: una revisión sistemática	López Pedraza L	Escuela Enfermería Cruz Roja - UAM
Grima J	Desarrollo psicomotor en niños con infección grave por virus respiratorio sincitial	Calvo Rey C	UAM
Hernanz Arjonilla C	Revisión sistemática sobre el manejo del dolor en el parto con métodos no farmacológicos	López Pedraza L	Escuela Enfermería Cruz Roja - UAM
Hernanz Rodríguez S	Vacuna del virus del papiloma humano en hombres: revisión sistemática	López Pedraza L	Escuela Enfermería Cruz Roja - UAM
Herrero Monje M	Impacto de la flexibilización del horario de visitas en la unidad de cuidados intensivos: UCI de puertas abiertas	de Villarreal Arracó J	UAM

Student	Title	Director	University
Iglesias Martín J	Incidencia de adenomiosis en pacientes histerectomizadas por patologia benigna en el Hospital Universitario La Paz. Correlación con hallazgos clinicos	Hernández Gutiérrez MA, Lopez A	UAM
Jiménez Cardeñoso A	Analysis of immune checkpoint expression as a biomarker of treatment response in MS patients	Otero Ortega L	UAH
López-Reina Platas A	Afrontamiento del paciente paliativo pediátrico oncológico y su familia ante un pronóstico terminal	Avilés Martínez M	UAM
Lorente Moro A	Revalidación dela escala Madrid-DIRECT en el triaje prehospitalario del ictus agudo	Rodríguez Pardo de Donlebún J	UAM
Mencía Moreno S	Eficacia de la toxina botulínica para el tratamiento de la espasticidad muscular en Pediatría. Revisión narrativa	de Villarreal Arracó J	UAM
Mora Benítez R	Flexibilidad metabólica y rendimiento deportivo durante el ayuno y dieta cetogénica	Blanco Rivero J	UAM
Núñez I	Relación de la microbiota intestinal con la diabetes tipo 2 y sus complicaciones	Menéndez Gómez C	UAM
Porras Rojano A	El abordaje del paciente portador de dispositivos de asistencia ventricular: una revisión sistemática	López Pedraza L	Escuela Enfermería Cruz Roja - UAM
Punjabi G	Adecuación del tratamiento de Fentanilo de liberación inmediata durante urgencias, hospitalización y al alta	Ramírez García E	UAM
Ramírez Cassagne MC	Valor predictivo del secuestro plaquetario y marcadores de superficie de respuesta terapéutica a esplenectomía en pacientes con trombocitopenia inmune	Jiménez Yuste V	UAM
Rodríguez M, García Álvarez M	Estudio PRE-POST sobre la captación en RCP básica en cuidadores principales de niños con patología crónica compleja	de Villarreal Arracó J	UAM
Rodríguez Sanz C	El embarazo produce cambios en la estrutura y función del cerebro materno: revisión sistemática	López Pedraza L	Escuela Enfermería Cruz Roja - UAM
Rojo García A	El gen supresor tumoral FBXW7 como posible mediador de la acción antiproliferativa del calcitriol en cáncer colorrectal	González Sancho JM, Fernández Barral A	UAM
Ruiz Buceta S	Caracterización de los genes diana de MAFG en la progresión del melanoma	Vera Puente O	UFV
Sánchez Blasco F	El abuso de fármacos por el personal sanitario. Un abordaje cualitativo	Beobide Conde M	UAM
Sánchez García L	Estudio de la regulación del citoesqueleto de miosina no muscular durante la progresión maligna del melanoma cutáneo	Orgaz Bueno JL	UAM
Sánchez Miranda P	La fatiga por compasión de la enfermería oncohematológica:un proyecto cuasiexperimental	Beobide Conde M	UAM
Sanz Ontiveros A	Escala predictora del tiempo de fallecimiento para donación en asistolia controlada en pediatría	Sibón Sancho GM	Universidad Nebrija
Simón Montero M	Pet ownership and mental health in pediatric transplant recipients	Méndez Echevarría A	UAM
Sobreviela Sánchez S	Efecto cardiovascular de la suplementación deportiva vasodilatadora	García Redondo AB	UAM
Velasco Pérez de Gracia S	Manejo multidisciplinar de la obesidad: un proyecto cuasiexperimental	Beobide Conde M	UAM
Vergara Ortega S	Microbiota y envejecimiento saludable: análisis de datos de encuestas sobre conocimiento de microbiota, suplementos alimenticios e interés en productos de salud intestinal	Carrillo de Santa Pau E	UCM
Villaverde L	Efecto de la nutrición en la microbiota y en el inmunodesarrollo durante los primeros 1000 días de vida	Menéndez Gómez C	UAM
Xuanlan Tinoco Francés V	Percepción actual de los hermanos sanos de pacientes oncológicos pediátricos sobre el impacto de la enfermedad en su vida	Martínez Campos P	Nebrija

2.3.4. Scientific Training Plan

The Training Committee established a Training Plan, which specifies the training strategy for the institute´s human resources and covers the research training needs of their members. Annually it´s developed the training offer with several proposals to make up the plan. Also, it's developed a residents training program have been started for residents doctors of the University Hospital La PAZ.

The own training offer is mainly based on a series of transversal courses in research methodology and courses related of the different lines of research.

The plan included several activities such as conferences, scientific seminars and other activities linked to these areas.

In addition, The Training Committee established a Residents training program for residents of the University Hospital La Paz

Members:

Chairperson
Paloma Gómez Campelo. *HULP Representative*

Secretary
Mercedes Ruiz Balibrea. *HULP Representative*

Members
María Teresa García Morales. *Biostatistics Platform*
Ana Martínez Virto. *HULP Representative*
Ana García Redondo. *R3 Researcher, UAM Representative*
María Gutiérrez Fernández. *R4 Researcher, Neurosciences Area, IdiPAZ*
María Fernández Velasco. *R4 Researcher, Cardiovascular Area, IdiPAZ*
Pilar Sánchez-Corral Gómez. *R4 Researcher, Infectious Diseases and Immunity Area, IdiPAZ, Representative of the Works Council*
Beatriz Castelo. *HULP Representative*
Ana Sastre Perona. *R4 Researcher, Surgery, Transplants and Health Technologies Area, IdiPAZ, FIBHULP Representative*
Ane Miren Andrés Moreno. *Representative HULP Maternal, Child and Adolescent Area*
FGG. *Management Representative Works Council*
Aitana López Redondo. *FIBHULP Occupational Health and Safety Service*
Ana Martín de la Flor. *Management Representative FIBHULP*



2.3.4.1. Training Program

Course	Coordinator	Date	Places	Registered	Participants	Satisfaction
Estadística Aplicada a la Investigación Clínica	Alberto Borobia Pérez	**12-15 February**	35	21	**21**	8,75
Introducción a la Estadística con R	Alberto Borobia Pérez	**8-11 April**	35	14	**14**	9,64
Habilidades de Escucha y Desescalada de Conflictos para el trabajo en equipo en el ámbito de la Investigación	Merche Ruiz Balibrea	**18-19 and 22-23 April**	25	17	**11**	9,55
Divulgación Científica	Aitana López Redondo	**8-9 May**	25	12	**11**	9,2
Técnica de Escritura en Inglés	María Fernández Velasco	**12-13 and 18-19 June**	25	20	**13**	9,1
Bioestadística Avanzada con R	Alberto Borobia Pérez	**24-27 June**	35	15	**14**	8,81
Ciencia abierta y uso responsable de recursos. Integración de ciencias sociales y humanidades en proyectos sanitarios, RRI	Paloma Gómez Campelo	**21 and 22 October**	20	10	**7**	9
Divulgación Científica en Biomedicina: Acercando la Ciencia al Público	Eduardo López Collazo	**11-18 November**	-	438	**155**	-
Gestión de datos en investigación clínica	Alberto Borobia Pérez	**25-28 November**	35	17	**15**	8,9
Igualdad en el entorno laboral	Paloma Gómez Campelo	**25 and 28 November**	40	16	**15**	-


2.3.4.2 Scientific Seminars

IdiPAZ Scientific Seminars program welcomes renowned researchers and clinical investigators to our Institute to share, discuss and debate latest insights, discovery and next directions in oncology with our students, postdocs and senior faculty from our research groups.

Scientific Moderators:

- Eduardo López Collazo
- Ana Sastre Perona
- Carlos del Fresno

Research Area	Date	Speaker	Seminar title
INFECTIOUS DISEASES AND IMMUNITY	12/01/2024	**Eduardo López Collazo** Investigador senior, jefe de Laboratorio, director del grupo de investigación "Respuesta Inmune Innata", coordinador del Área de Enfermedades Infecciosas y subdirector científico de IdiPAZ.	**SIGLEC5: Saltando del cáncer a la sepsis**
NEUROSCIENCES	19/01/2024	**Elisa Martí Gorostiza** Profesora de Investigación del CSIC, directora científica del Instituto de Biología Molecular de Barcelona (IBMB) y miembro del Comité Científico Externo del IdiPAZ.	**Desarrollo de organoides de médula espinal humana: Biomodelos para el estudio de defectos del tubo neural**
INFECTIOUS DISEASES AND IMMUNITY	26/01/2024	**Alfredo Corell Almuzara** Catedrático de Inmunología. Facultativo Inmunología Hospital Virgen del Rocío. Universidad de Sevilla	**Linfocitos intraepiteliales (IELs) conjuntivales en individuos sanos y patologías inflamatorias"**
CANCER AND HUMAN MOLECULAR GENETICS	02/02/2024	**María Muñoz Caffarel** Ikerbasque Research Associate. Group Leader Breast Cancer Group. Oncology Area. Biodonostia	**Targeting cytokine signalling to block cancer-prompting inflammation and tumour progression"**
CANCER AND HUMAN MOLECULAR GENETICS	09/02/2024	**Manuel Collado Rodríguez** Investigador líder del grupo E028 - Senescencia celular, cáncer y envejecimiento- Instituto Investigación Sanitaria Santiago de Compostela	**Cell senescence in cancer therapy**
SURGERY, TRANSPLANT AND HEALTH TECHNOLOGIES	16/02/2024	**Ana Sastre Perona** Investigador senior, Directora del Grupo Investigación trasnacional en Cirugía Maxilofacial y Cáncer de Cabeza y cuello. IdiPAZ	**Mechanisms of cutaneous squamous cell carcinoma progression**
CANCER AND HUMAN MOLECULAR GENETICS	23/02/2024	**Pilar Martín Duque** Investigadora Científica. Centro de Terapias Avanzadas del ISCIII	**En busca del caballo de Troya ideal para las terapias antitumorales**
SURGERY, TRANSPLANT AND HEALTH TECHNOLOGIES	01/03/2024	**Alberto Corredera** Director del Área de Inteligencia Artificial en ERIS Innovation. Doctor Ingeniero de Telecomunicación.	**IA en investigación ya! La ciencia de Datos al servicio de la medicina**

Research Area	Date	Speaker	Seminar title
 INFECTIOUS DISEASES AND IMMUNITY	08/03/2024	**María Alieva Krasheninnikova** Investigadora principal en el Instituto de Investigaciones Biomedicas Sols-Morreale CSIC-UAM	**Unravelling cancer immunotherapy response heterogeneity with Patient Derived Organoids**
 INFECTIOUS DISEASES AND IMMUNITY	15/03/2024	**Rebeca Pérez de Diego** Investigadora Laboratory of Inmunogenetics on Human Diseases. IdiPAZ	**Retos en el diagnóstico genético de los errores innatos de la inmunidad. La deficiencia humana en Ezrina.**
 CANCER AND HUMAN MOLECULAR GENETICS	22/03/2024	**Jesús Sánchez Ruiz** Responsable de Proyectos Científicos. Fundación CRIS contra el Cáncer	**5 Tips to improve your science communication**
 SURGERY, TRANSPLANT AND HEALTH TECHNOLOGIES	12/04/2024	**Juan García Arriaza** Científico Senior del Grupo de Poxvirus y Vacunas del Centro Nacional de Biotecnología del CSIC.	**Modified vaccinia virus Ankara as a potent vector for development of vaccine candidates against infectious diseases**
 INFECTIOUS DISEASES AND IMMUNITY	19/04/2024	**Paula Jauregui Onieva** Senior Editor at Nature Microbiology and Nature Immunology	**Publishing at Nature research journals**
 LARGE SYSTEMS PATHOLOGIES	26/04/2024	**Antonia Tomás Loba** Jefa del laboratorio de ritmo circadiano y cáncer Instituto Murciano de Investigación Biosanitaria Virgen de la Arrixaca Universidad de Murcia (IMIB-UMU-Arrixaca).	**The hepatic social jet lag adaptation**
 CANCER AND HUMAN MOLECULAR GENETICS	10/05/2024	**Paula Rio Galdo** Jefa de la Unidad de Aplasia de Médula Ósea. CIEMAT	**Gene Therapy in Fanconi anemia: "From lentiviral vestor to gene editing**

Research Area	Date	Speaker	Seminar title
 SURGERY, TRANSPLANT AND HEALTH TECHNOLOGIES	05/05/17	**Juan José Beunza Nuin** Profesor Universidad Europea	**Inteligencia Artificial en entornos Clínicos: Buscando colaboraciones**
 CARDIOVASCULAR	05/05/24	**Marta Gil Fernández** Investigadora Predoctoral. IIB "Sols-Morreale". Grupo Investigación en Cardiología Clínica y Traslacional de IdiPAZ	**Papel del receptor NOD1 en la cardiomiopatía auricular asociada a insuficiencia cardíaca**
 INFECTIOUS DISEASES AND IMMUNITY	06/14/2024	**Alicia González Martín** MicroRNAs en Tolerancia Inmunológica, Autoinmunidad y Cáncer / 2.1.IIBM	**Deciphering microRNA control of B cell tolerance**
 CARDIOVASCULAR	21/06/24	**Ana María Briones** Profesora Farmacología. UAM	**Resolvina D2 y otros mediadores proresolutivos. Una nueva estrategia de protección cardiovascular**
 CANCER AND HUMAN MOLECULAR GENETICS	28/06/24	**Ana Cuenda Méndez** Investigadora at the National Center of Biotechnology and Head of Department of Immunology and Oncology (CNB-CSIC)	**Stress Kinases that control de link between and colon cancer**
 CARDIOVASCULAR	27/09/24	**Ilaria Rivolta** Univesitá degli Studi di Milano	**Mechanism of Sodium Channel Dysfunction in Brugada Syndrome: Froma Molecular Insights to Clinical Implications**
 SURGERY, TRANSPLANT AND HEALTH TECHNOLOGIES	18/10/24	**Nuria Vilaboa** Investigadora Senior. Jefa de Laboratorio de Fisiopatología Ósea y Biomateriales de IdiPAZ	**Virus que replican condicionalmente. Aplicación como potenciales vacunas**

2.3.4.3. Scientific Clinical Sessions-Hospital Universitario La Paz

DATE	TITLE	SERVICE/SECTION
10/01/2024	Mujer de 42 años, con antecedentes de cesárea y quistectomia de ovario izquierdo, y tumoración ovarica invasiva	Servicios de Ginecología y Obstetricia y Anatomía Patológica
17/01/2024	Hacia una estrategia digital basada en necesidades reales de los profesionales	Subdirección Gerencia de Estrategia Digital
24/01/2024	Atención multidisciplinar al paciente con patología tumoral hipotálamo hipofisaria	Servicio de Endocrinología y Nutrición
31/01/2024	Manejo multidisciplinario del feocromocitoma	Servicio de Urología
07/02/2024	Niña de 14 años, con antecedentes de LLB y de trasplante alogénico no emparentado en 2018, y sepsis y fracaso multiorgánico	Servicios de Hemato-Oncología Infantil y Anatomía Patológica
14/02/2024	Toma de decisiones y asistencia compartida en pacientes muy mayores con cáncer colorrectal	Servicios de Cirugía General y Geriatría
21/02/2024	Estrategias y desafíos en la adecuación de la práctica clínica	Comité de Adecuación de la Práctica Clínica
28/02/2024	Varón de 45 años con fiebre prolongada y afectación hepática	Servicios de Medicina Interna y Anatomía patológica
06/03/2024	Beneficios oncológicos del ejercicio físico y la nutrición en el cáncer ginecológico	Servicio de Obstetricia y Ginecología
13/03/2024	Tendencias en Informática Biomédica y actualización sobre el espacio de datos sanitarios	Subdirección Gerencia de Estrategia Digital
20/03/2024	Enfermedad renal crónica avanzada en mayores de 75 años: tratamiento sustitutivo vs tratamiento conservador	Servicios de Cuidados Paliativos y Nefrología
03/04/2024	Aféresis, 45 años de tratamiento en el Hospital La Paz	Servicio de Hematología y Hemoterapia
10/04/2024	Mujer de 62 años con artritis reumatoide en tratamiento inmunosupresor y shock séptico: cuando no todo es lo que parece	Servicios de Reumatología, Medicina Interna y Anatomía Patológica
17/04/2024	Animales de compañía e inmunodeprimidos: ¿sobrepasan los beneficios a los riesgos?	Servicio de Pediatría Hospitalaria, Enfermedades Infecciosas y Tropicales
24/04/2024	Actualización del cuadro de mandos integral del hospital	Subdirección Médica de Procesos y Sistemas
08/05/2024	Mujer de 40 años, antecedentes de infección VIH estadio C, con diarrea crónica y desnutrición	Servicios de Medicina interna y Anatomía Patológica
22/05/2024	Ayer, hoy y mañana de la donación y trasplantes en nuestro hospital	Comisión Técnica Consultiva de Trasplantes
29/05/2024	Cefalea en racimos refractaria: estimulación del nervio occipital	Servicios de Neurología y Neurocirugía
05/06/2024	Melanoma coroideo, el gran desconocido	Servicio de Oftalmología
12/06/2024	Varón de 63 años, antecedentes de HTA, con hemiparesia izquierda y LOE hepatica	Servicios de Oncología Médica y Anatomía Patológica
19/06/2024	Manejo multidisciplinar del espectro de la placenta acreta	Servicio de Obstetricia y Ginecología

DATE	TITLE	SERVICE/SECTION
26/06/2024	Tratamiento con bombas de baclofeno intratecal para el tratamiento de la espasticidad generalizada	Servicio de Medicina Física y Rehabilitación
29/06/2022	Presentación del cuadro de mandos asistencial del hospital	Subdirección Médica de Organización y Sistemas
25/09/2024	La riqueza de la diversidad generacional en una organización sanitaria	Dirección Médica y Dirección de Recursos Humanos
02/10/2024	Mujer de 61 años con empeoramiento de afasia, y resección completa de glioblastoma multiforme en 2009	Servicios de Neurología y Anatomía Patológica
09/10/2024	Protección de datos y seguridad informática, nuevos retos para el profesional sanitario	Subdirección Gerencia de Estrategia Digital
16/10/2024	Ayer y hoy de una unidad de aislamiento de alto nivel	Unidad de Aislamiento de Alto Nivel
23/10/2024	Presente y futuro de la oncología radioterápica pediátrica: ¿qué nos diferencia?	Servicio de Oncología Radioterápica
30/10/2024	Implementando Programas de Gestión Eficiente de la Sangre del Paciente (PBM)	Comisión Técnica Consultiva de Transfusiones
06/11/2024	Oncología Integrativa	Servicio de Oncología Médica
13/11/2024	RM corporal en pediatría: luces y sombras	Servicio de Radiodiagnóstico
20/11/2024	Mujer de 65 años con antecedentes de enfermedad mitocondrial, con afasia y alteraciones conductuales	Servicios de Neurología y Anatomía Patológica
27/11/2024	Optimizando juntos. La evolución de los antimicrobianos en nuestro hospital	Programa de Optimización de Antimicrobianos
04/12/2024	Más de 40 años de cirugía tiroidea en el Servicio de ORL: manejo de la hipocalcemia postquirúrgica y manejo quirúrgico de los carcinomas invasivos	Servicio de Otorrinolaringología
18/12/2024	Angelita Santos. La más surrealista de las sinsombrero	Dirección Médica

EXTRAORDINARY SESSIONS

DATE	TITLE	SERVICE/SECTION
15/02/2024	20 años de la Unidad de Parálisis Facial del HULP. Homenaje a la Dra. Susana Moraleda	Servicio de Otorrinolaringología
07/03/2024	El laboratorio de gestión 3D: un nuevo entorno al servicio del HULP	Servicio de Cirugía Maxilofacial
11/04/2024	Prevalencia de infecciones relacionadas con la asistencia sanitaria en el HULP. Resultados del estudio EPINE año 2023	Servicio de Medicina Preventiva
30/05/2024	Asistencia ventricular en pediatría: experiencia nacional	Servicio de Cuidados Intensivos Pediátricos
17/10/2024	Plan de mejora de la docencia clínica en la Facultad de Medicina de la UAM. Unidad de Educación en Ciencias de la Salud	Decanato de Medicina. UAM

2.3.4.4. Another Scientific activities

6ª Jornada PhDay

26th December 2024: 6th PhDay IdiPAZ



Awards:

Best translational thesis (1-2 years): **Olivia Fernández Molina**
Best clinical thesis (1-2 years): **Mónica Beobide Conde**
Best translational thesis (3-4 years): **Pablo Mata Martínez**

18th Febrery2025: Presentation Scientific Report 2023





Awards:

First award: **Jiménez-Yuste V.** Scientific publication: The New England Journal of Medicine, un ensayo clínico fase 3 sobre el concizumab en hemofilia con inhibidores (IF: 96.2, D1).
Second award: **Fondevila Campo C.** Scientifc publication: Journal of Hepatology, que explora alternativas de revascularización de la vena porta en trasplantes hepáticos con trombosis compleja (IF: 26.8, D1).
Third award: **Zamarrón E. and García-Río F.** Scientifc publication: American Journal of Respiratory and Critical Care Medicine, sobre el impacto de la presión positiva continua en la progresión de la albuminuria en pacientes con apnea obstructiva del sueño y enfermedad renal diabética (IF: 19.3, D1).

2.3.5. Science and Society-Scientific Outreach Initiatives

The Unit of Scientific Culture and Innovation of IdiPAZ (UCC+i) has the aim of dissemination of science and innovation performed in our institution and as a key service to increase the scientific education and culture, to promote scientific vocations and innovative talent, to communicate researchers' findings, and to foster research among new generations, knowledge the population and patients.

IdiPAZ participate in the International Day of Women and Girls in Science, to promote full and equal access and participation in science for women and girls. Gender equality is a global priority for UNESCO, and the support of young girls, their education, and their full ability to make their ideas heard are levers for development and peace. This year was focused on the role of Women and Girls and Science as relates to the Sustainable Development Goals namely Sustainable Development Goals 5 (Achieve gender equality and empower all women and girls) and Sustainable Development Goals 10 (Reduce inequality within and among countries).



In 2024, IdiPAZ developed ***Ciencia por la Calle*** an initiative through which scientific dissemination activities were organized for society in general. All these activities are free of charge and allow attendees to learn first-hand about R&D&I and the institution's researchers through talks in schools, workshops, fast meetings, guided tours, etc.



Activity

Entre linfocitos y anticuerpos: ¿Qué hago yo aquí? 05-feb Organizado por distintos grupos de IdiPAZ
Aproximación a la investigación en biología molecular en cáncer 08-feb Grupo de Terapias Experimentales y Biomarcadores en Cáncer, laboratorio de Epigenética - INGEMM
Ciencias y científicas en la investigación del cáncer, un trabajo en equipo 12-feb Organizado por distintos grupos de IdiPAZ y personal de gestión
A grandes males, mucha ciencia 13-feb Grupo Infecciones sistémicas en pediatría; VIH, Tuberculosis, Patología importada y Enfermedades emergentes
Tres mujeres y un destino 13-feb Organizado por distintos grupos de IdiPAZ
Primer Encuentro de Participación Ciudadana en el IdiPAZ 15-feb Comisión de Humanización y RSC de IdiPAZ
semana de la ciencia y la innovación
¿Cómo es el día a día de un científico en un instituto de investigación sanitaria de un hospital? 04-nov Grupo de Investigación respuesta Inume Innata
The future needs the best …biobanqueros! 05-nov Plataforma de Biobanco
El papel de las Matemáticas en la Investigación Biomédica 05-nov Laboratorio de Oncología Molecular

Activity
Como descubrimos los alérgenos en los alimentos 06-nov Grupo de Diagnóstico y Tratamiento de las Enfermedades Alérgicas
Luz y color para seguir las huellas moleculares de las enfermedades en nuestras células. Visita-Taller a la Unidad de Imagen Molecular e Inmunohistoquímica 06-nov y 12-nov Unidad de Imagen Molecular e Inmunohistoquímica
IdiPAZ: investigación al servicio de la salud y la medicina 07-nov Unidad de Cultivos Celulares y Grupo de Investigación Traslacional de Cirugía Maxilofacial y Cáncer de Cabeza y Cuello
Fibrilación auricular: ¿Que debo saber de una arritmia que afectara a 1 de cada 3? 07-nov Cardiología.
Aproximación a la investigación en biología molecular en cáncer 08-nov Terapias Experimentales y Biomarcadores en Cáncer
Conferencia sobre las Infecciones relacionadas con la asistencia sanitaria. Ventriculitis y Meningitis asociadas a la asistencia sanitaria. Proyecto de Ventriculitis 12-nov Unidad de Infecciosas, Grupo de Investigación SIDA y Enfermedades Infecciosas
Infarto Agudo de Miocardio con Arterias Coronarias Normales: A Quién, Cuándo y Porqué. 12-nov Cardiología
Detectives científicos: Descubriendo el ADN de la fruta 12-nov Servicio de pediatría y enfermedades infecciosas
¿Puedo volver a tomar un medicamento si me he vuelto alérgico? 12-nov Servicio de alergología/grupo hipersensibilidad a medicamentos y respuesta inmune innata/grupo diagnóstico y tratamiento de las enfermedades alérgicas.
Buscando defectos en genes y en proteínas: tanto monta, monta tanto 12-nov y 15-nov Grupo de Diagnóstico y tratamiento de patologías asociadas con el Sistema del Complemento.
Novedades en anomalías vasculares y sobrecrecimiento 14-nov Grupo Malformaciones y Trasplante
Tratamiento cardiovascular y diagnóstico de meningitis en recién nacidos asistido con Inteligencia Artificial 15-nov Unidad de Neonatología
Entendiendo la genética en el cine y las series 15-nov Grupo de Variabilidad Genética Humana

2.4. IdiPAZ Quality Committee

The search for quality and excellence in research management has been one of the main goals of IdiPAZ since its origin in 2009. This is shown in the fact that external monitoring audits of its Integrated Management System that jointly respond to the most relevant standards like ISO 9001 and UNE 166002 were satisfactorily completed once again. After this last cycle, the System covers a total of 5 management units, 8 supporting platforms and 3 collegiate bodies of IdiPAZ, highlighting on this occasion as a novelty the incorporation in the quality certificate of the support and assistance to researchers in the fields of Statistics in all types of clinical research studies. Likewise, a significant effort has been made with the integration into the System of the Social Responsibility Management System and the Certification of the Sustainability Strategy aligned with the UN, which started in 2021 and 2022, respectively, with the support of the hospital background.

Although the first certification of the Quality Management System was given in 2013 and its development has been a strategic objective all these years, its growth and consolidation has been especially notable in the last years, currently being included in it for 4 different standards including in the scope the following units, platforms and bodies:

- Quality Commission: body.
- Project request support: unit.
- Innovation Support Unit: platform.
- UICEC: platform.
- Biostatistics: platform
- SANGER sequencing: platform.
- Biobank: platform.
- Management of scientific production and communication: platform.
- Training Commission: body.
- Common laboratories: platform.
- Project management: unit.
- Accounting: unit.
- Legal and Contracting: unit.
- HR: unit.
- Collegiate Government Bodies: body.



AENOR

Certificado del Sistema de Gestión de la Responsabilidad Social

AENOR RESPONSABILIDAD SOCIAL IQNet SR10

SR-0282-ES

AENOR certifica que la organización

INSTITUTO DE INVESTIGACIÓN SANITARIA DEL HOSPITAL UNIVERSITARIO LA PAZ

dispone de un sistema de gestión de la Responsabilidad Social conforme con la especificación IQNet SR10:2015

para las actividades: Las actividades de investigación biomédica multidisciplinar y gestión de la investigación.

que se realizan en: PASEO DE LA CASTELLANA, 261. 28046 - MADRID

Primera emisión:2025-01-21 Expiración:2028-01-21

Rafael GARCÍA MEIRO
CEO

Certificado transferido. Fecha de primera emisión del certificado: 2021-03-19

IQNET

AENOR CONFIA S.A.U.
Génova, 6. 28004 Madrid. España
Tel. 91 432 60 00.- www.aenor.com



AENOR

Certificado de Conformidad Estrategia Objetivos de Desarrollo Sostenible

AENOR ESTRATEGIA SOSTENIBLE (ODS)

ODS-2025/0001

AENOR certifica que la organización

INSTITUTO DE INVESTIGACIÓN SANITARIA DEL HOSPITAL UNIVERSITARIO LA PAZ

cumple el Reglamento Particular de AENOR EOS.02, para la certificación de estrategias y proyectos de sostenibilidad y su contribución a los Objetivos de Desarrollo Sostenible (ODS).

para las actividades Las actividades de investigación biomédica multidisciplinar y gestión de la investigación.

que se realizan en PASEO DE LA CASTELLANA, 261. 28046 - MADRID

Primera emisión:2025-01-21 Expiración:2028-01-21

Rafael GARCÍA MEIRO
CEO

Certificado transferido. Fecha de primera emisión del certificado: 2022-07-14

AENOR CONFIA S.A.U.
Génova, 6. 28004 Madrid. España
Tel. 91 432 60 00.- www.aenor.com

Quality certificates to all units, platforms and bodies involved were delivered during the presentation of the Scientific Report of IdiPAZ 2023, which took place February 18th 2025.

Moreover, for a fourth year in a row, specific training webinars were developed by the Committee in order to strengthen the competence of IdiPAZ members in quality management, thus ensuring the sharing of best practices among them. These webinars are accessible at IdiPAZ website: Organigrama - Sistema Integrado de Gestión | IdiPAZ

Considering that IdiPAZ is a continuously evolving organisation, the Quality activities of our institution have been enriched by the different achievements made by its member organizations.

Finally, the following attached table shows the clinical pathways reviewed in 2024, as well as the protocols developed or updated in the same period. In addition, the staff continuously collaborates in the improvement of the institution by participating in clinical committees and setting up improvement groups, as well as by implementing patient and professional satisfaction surveys. Also during 2024, the quality management of the hospital's departments has been consolidated into a comprehensive management system in accordance with the various national and international ISO standards. The hospital has also been recognised by the National Accreditation System for Reference Units and the European Reference Networks of the European Commission

2.4.1 Protocol/Clinical pathway

Protocol/Clinical pathway	Status
Antibioterapia empírica en niños atendidos en el servicio de urgencias y hospitalización: infecciones vías respiratorias	Review
Tratamiento infecciones de la piel y partes blandas	Review
Asistencia al parto vaginal normal de mínima intervención	Review
Antibioterapia empírica en niños atendidos en urgencias y planta: infecciones osteoarticulares	Review
Procesamiento material de autopsias	Review
Marcaje quirúrgico adultos	Review
Actuación en caso de identificación de microorganismos de especial relevancia clínica y/o epidemiológica detectados en muestras (no hemocultivos) procedentes de pacientes ambulatorios	Review
Protocolo asistencial para el diagnóstico y tratamiento del adenocarcinoma de páncreas	Review
Proceso transfusional	Review
Protocolo Asistencial de Conciliación de medicamentos al alta del área de urgencias del paciente mayor institucionalizado a su centro sociosanitario.	Review
Tratamiento de parasitosis más frecuente en pediatría	Review
Protocolo de manejo de complicaciones en procedimientos estéticos	Review
Procedimiento de tratamiento ambulatorio con REMDESIVIR en pacientes con COVID	Review

Protocol/Clinical pathway	Status
Protocolo de curas	Review
Manejo del cordón umbilical en la estabilización inicial del recién nacido	Review
Diarrea del viajero en pediatría	Review
Solicitud de estudio farmacogenético al hospital de pacientes procedentes de otros centros de la Comunidad de Madrid	Review
Solicitud de inclusión de nuevos antimicrobianos en la guía farmacoterapéutica del hospital	Review
Traslados de pacientes del hospital Cantoblanco /Carlos III al Hospital La Paz	Review
Derivación a camas de media estancia	Review
Protocolo para la prevención, detección e intervención del delirium en el paciente mayor en el servicio de urgencias	Review
Protocolo de prevención, detección e intervención del delirum en el paciente mayor hospitalizado	Review
Protocolo de presalida	Review
Interconsulta servicio de endocrinología y nutrición	Review
Actualización recomendaciones de manejo y circuito de pacientes con sospecha o confirmación de viruela de mono (Monkeypox)en hospital infantil	Review
Actualización recomendaciones de manejo y circuito de pacientes con sospecha o confirmación de viruela de mono (Monkeypox) en pacientes obstétricas y neonatos	Review

2.5. Platforms

2.5.1. ISCIII Strategic Platforms

itemas isciii
Plataforma de dinamización e innovación de las capacidades industriales del Sistema Nacional de Salud

2.5.1.1 Innovation Support Unit (UAI)

2.5.1.1.1. Innovation and Transfer Activities

The institute has two main units (the Innovation Support Unit and the Knowledge Transfer Office) that are key to carrying out the transfer of knowledge and the explotation and market transfer of technologies developed within IdiPAZ.

The Innovation Support Unit (or Innovation Unit), UAI, of FIBHULP was created in June 2010 within the framework of the ITEMAS Network –currently called ITEMAS Platform- of the Carlos III Institute of Health. Since its creation, the Innovation Support Unit has contributed to promoting and protecting innovative/ ground breaking research conducted by IdiPAZ. The Innovation Unit also intends to harness our institute's considerable innovative potential generated, as a step prior to its subsequent transfer to society.

Therefore, one of the main commitments of the Innovation Unit is that researchers and health personnel perceive it as a resource at their service, to provide support and advice in all that relates to the identification, management, protection, transfer, marketing and dissemination of their research results.

The OTC was registered in the Registry of Knowledge Transfer Offices on May 7, 2024, under number 76.

The IdiPAZ OTC is the main body for knowledge transfer that carries out the identification, development and promotion of innovative ideas among research and healthcare staff in the HULP IdiPAZ environment, as well as their subsequent valorisation for transfer to society. In addition, these two units, the UAI and the OTC, have the support of other structures such as the Scientific Production and Communication Management Unit and the Legal and Contracting Unit.

The OTC, together with the UAI, aims to ensure that all the knowledge and applied research developed for years at IdiPAZ is reflected and returned to society and provides a direct benefit in improving patient care.

ACTIVITIES

The main aim of the Innovation Support Unit is to identify the potential transferable research results generated within our institute and to accompany and support the researcher throughout the whole innovation process: from the birth of the idea to its placement on the market.

Since the Innovation Unit has been in operation, several projects sponsored by the institute itself have been managed and different collaboration agreements have been signed with important private institutions and organisations to promote innovation.

Our main objectives are:

- Promoting a culture of innovation and entrepreneurship within the institute by fostering the generation of innovative ideas and solutions that meet the needs of patients and society, in general, and supporting their development through various initiatives.
- Actively searching and identifying knowledge and research results emerged within the institute and transferable to the market.
- Fostering and managing the protection and transfer of knowledge and research results to society and promoting the current technology portfolio of the institute while getting an economic return which allows its reinvestment in

research and development.


- Promoting the participation of industry in the innovation process acting as a stakeholder actively involved in it.
- Formalising business alliances, including technology companies as well as industrial and financial partners, to develop collaborative projects and to transfer the results to the market.
- Generating resources that achieve the greatest impact on society, enabling a better quality health care and at the same time contributing to the sustainability of the National Health System.
- Boosting a fruitful collaboration among all entities that make up the ITEMAS Platform.
- Scientific and legal advice on the initiative's protection potential and scope. Advice and support for researchers on intellectual and industrial property issues, through meetings with them in which the various procedures and steps to follow for the protection of their idea and the application for a potential patent are explained.
- Search for trends in technology. In this sense, the search for new technology trends emerges as an eminently necessary activity for the generation of an anticipation and preparation factor that improves the approach by the OTC (to exercise an effective knowledge transfer.
- The search for funding. The search for funding is a fundamental element for organizations like IdiPAZ, as funding is another of the most pressing constraints on their natural activity, as research requires a large amount of resources, both financial and material.
- Exploitation of results. For an innovation to be considered successful, it must produce a return for the institution, either through the commercialization of the results or through internal process improvements. To introduce an innovation to the market, the institution must plan the actions to be carried out, considering aspects such as:

  - Identification of the intellectual and industrial property environment in the target markets.
  - Development of the marketing and sales plan.
  - Ensure the availability of necessary funds and resources.
  - Establish production, supply chain, customer service, and training of the agents involved as appropriate.


The technology transfer plan aims to strengthen the links between the public and private sectors in research, development and innovation I+D+i to increase the socioeconomic impact of public investment in research and boost the innovative capacity of research institutes.

In the last years the UAI has definitely consolidated its presence and visibility in the whole environment


UAI PORTFOLIO BREAKDOWN BY PROJECT DEVELOPMENT (2024)



UAI PORTFOLIO BREAKDOWN BY PROJECT TYPE (2024)



PRIORITY OF IDIPAZ'S PATENT FAMILIESIN FORCE DURING 2024



Hospital-Institute. Among the greatest achievements of the Innovation Support Unit are the following:


1. The UAI has become one of IdiPAZ's most in-demand and requested platforms as it is responsible for promoting, supporting and managing all innovation projects.

At December 31 2024 the UAI had 289 innovation projects or ideas in active state, 26 of which were in the capture phase, 76 in the evaluation phase, 59 in development, 84 in transfer and 44 in the market. According to these data, it follows that 15% of the projects have been successfully exploited and positioned in the market, a very positive percentage (although far lower than the aspired figure) given the precariousness of the times we go through and the resources (both human and financial) with which the UAI counts. The analysis of IdiPAZ's technology portfolio according to the type of project show how Health ICT, Bio and Medical Device, and Materials and Devices types stand out above the others, with practically the same number of projects for all three types.


2. The UAI has built a wide and diverse technology portfolio. Each year the number of innovation projects managed by the UAI increases with respect to the previous year, also increasing the number of Hospital services, research groups and professionals in general who join IdiPAZ's innovation community.

During 2024 the UAI filed 1 priority patents (European patent kind) and 1 PCT. UAI´s portfolio of patent families in active state during the period 2024 reached the figure of 22 patent families (8 of them with Spanish priority, 12 of them of European priority and 2 of them having US priority).

TOTAL OF IP LEGAL FIGURES IN FORCE DURING 2024



TECHNOLOGIES LICENSED OR IN COMERCIAL EXPLORATION (2024)



The period of 2024 has been remarkable in this aspect, protecting 42 new computer softwares.

Special mention should also be made to the UAI trademark portfolio. During the period 2024, 1 Spanish and 8 European trademark applications were filed and 4 European trademark was granted. The total number of trademark families active and in force during 2024 was 33.

As well, in this year the UAI has made the applications to a new legal figure, the industrial design. Into this category, 1 Spanish was counted.

The totally of Intellectual Property figures in force during 2024 is the following 22 patent families, 42 SW, 33 trademark families, 8 IP Works and 5 know-how, and 1 industrial model.

It is important to note that these trademarks, besides allowing IdiPAZ to distinguish its products or services from competitors' products or services, are associated with the know-how of the institution, know-how that has been transferred along with the distinctive sign in the case of the license agreements signed by the institution in respect of trademarks.

3. The UAI has prepared a catalogue of technology offers -based on specification sheets-, which includes the complete portfolio of exploitable IdiPAZ results. This catalogue aims to promote the transfer of IdiPAZ's technology portfolio to the industrial sector, generate collaborative projects for technological development and foster the exploitation of research results. Those validated specification sheets are published on IdiPAZ's website. The catalogue is updated as the Institute's technology portfolio grows.

4. The UAI has been, is, and will continue to be the principal architect for the transfer and exploitation of IdiPAZ's technology portfolio. During 2024, the UAI succeeded in signing 19 license agreements -17 of which related to intellectual property works and 2 know-how- and the portfolio of licensed or commercially exploited inventions reached the figure of 23 technologies, 14 patents, 1 utility model, 3 SW, 2 trademarks, 2 IP Works and 1 know-how.

5. It should be noted as a milestone in the year 2024, the first steps for the establishment of a new spin off that will aim to exploit a technology developed within IdiPAZ. The "Polifyl" project will give rise in 2025 to a new company that will have the participation of the institution, as a sign of its support for innovation, and in line with its strategic objectives.

Due to the potential of the project, funding has been obtained from private investors, which is an endorsement of the scientific-technical quality of the project, in addition to obtaining different awards from the pharmaceutical sector. This is so because the research will represent a major advance in the diagnosis of colon cancer, which will improve the quality of life of patients and save costs for the National Health System.

6. Through the promotion of a culture of innovation, the UAI has managed to create a large community of innovative professionals. Over the last year, its promotional activity has consisted in the celebration of several working days, workshops, seminars, etc. Among all the promotional activities organised, the following stand out:

- Tips on data protection. 09/01/2024
- Day of women and girls in science. Science and women scientists in cancer research a team effort.11/02/2024
- Dialogues in Innovation and Entrepreneurship: The Boston Experience 07/15/2024
- Safe use of computer and electronic communication media. 16/10/2024
- Training pill, how much do you know about the UNE 166002:2021 21/10/2024
- III Conference of the Advanced Therapies Network of the Community of Madrid. Role of the Innovation Units. 22/10/2024
- SPIN OFFs in the Community of Madrid: How are they managed? 10/12/2024

In addition, the UAI has collaborated with important institutions and private entities to promote innovation, in particular, it has participated in various forums and round tables organized by various stakeholders of the biomedical sector. Such as, Bioentreprise, Shipventure, Assabys, Biopartner and others business angels and family office. Actors from the health sector with the ability of pushing new ideas and scale them up. Linking private entities and making ideas grow is one of the main functions of UAI but funding is one our main stoppers, for that reason, investors, private entities and funding companies are one of the most important driving forces which take in the process of scaling ideas up.

7. The UAI has succeeded in creating a wide-ranging network of contacts. By virtue of its membership in the ITEMAS Platform, the Unit has continued to strengthen ties and creating synergies with the members of this Platform in order to achieve its established objectives.

Apart from the above results, it is important to highlight the increasing amount of innovation projects managed by the Innovation Unit that has been awarded with prestigious awards and aids. The following are some of the projects that won grants or awards during 2024:

A.

A. MITIGA. MITIGA is an innovative tool designed to complement the medical care of people in the different stages of Alzheimer's disease and other types of cognitive impairment, with a special focus on the integration of socio-health aspects and therapeutic monitoring. It is a structured platform that allows daily recording of the patient's symptoms and those socio-health and therapeutic aspects that could influence them. The objective of this tool is to provide the caregiver and the neurologist with a structured and realistic record of the patient's situation from the clinical point of view, identifying therapeutic compliance, the need for rescue medication and those elements that may be playing a positive or negative role in the evolution of the patient's disease. It also aims to provide the caregiver with accurate information about the patient's disease, symptoms and non-pharmacological strategies that can help control cognitive and behavioural symptoms.

It is an acronym derived from:

- M: Continuous monitoring of the patient's condition performed by both the family and the physician.
- I: Information with data provided by the family on the patient's evolution and information on the disease provided by the professional.
- T: Treatment (adjustment of treatment based on the information collected)
- I: Interpretation (evaluation of symptoms and changes observed in the patient)
- G: Management (appropriate symptom and medication management)

- A: Accompaniment (active participation of the family/caregiver in the patient's daily follow-up)

B. VerbalizApp. VerbalizApp is an application designed to be run on mobile devices that allows people affected by post-stoke aphasia to establish basic communication as well as to perform rehabilitation-oriented exercises from the acute phase of stroke.

With it, patients find an accessible way to put voice to what they feel, want or need; and relatives or medical staff, a quick, easy, reliable way to work with them. In addition, the use of artificial intelligence techniques can help these patients recover their communication skills.

The tool provides the following benefits:

- Facilitating basic communication from the acute phase of the disease. Improving communication means reducing barriers, sequelae and increasing the likelihood of social reintegration.
- Improving the capacity for comprehension and expression through the use of exercises that favour language rehabilitation within the tool itself. The digitalization of the exercises means greater efficiency and improved working conditions in the Speech Therapy service.
- Facilitate and adapt the use of these communication and treatment tools, adapting to the motor and cognitive difficulties that characterize this type of patient.
- Facing the current pandemic situation, in which contact precautions must be extreme, face-to-face treatment is limited and the physical tools most frequently used by speech therapy cannot be exchanged between patients, increasing the importance of having a digital support that also allows unlimited reuse of the exercises.
- Personalization of the tool to the patient, from enabling the uploading of images of common personal objects in their daily life or of their relatives in the communication tool, to the option of using artificial intelligence methods to promote language recovery by individualizing the exercises that best suits the needs of each patient, according to their performance and level of aphasia.

C. ExpertAsma. This is an educational aimed at patients with severe asthma (SA) for their training as expert patients (EP). Through it, they acquire in-depth knowledge about the disease, skills on its management and treatment. All this with the ultimate goal of improving their clinical situation, quality of life and adherence to treatment.

In addition, through this platform, patients accredited as Eps lead periodic meetings with other patients in similar circumstances, but less skilled or with fewer skills, in order not to leave them behind. In such meetings, Eps pass on their knowledge and strategies to maintain necessary motivation and persist in self-care.

They also make them aware of the long-term importance of compliance and proper administration of the complex treatments they receive. For healthcare professionals, Eps also provide a new source of information on concerns and questions that patients with GA have about the disease and its pharmacotherapy. This facilitates the detection of unmet needs in their health care.

The training platform consists of eight modules that provide patients with the most up-to-date information, in a simple and understandable way, through short video lectures by experts in each material.

8. On the other hand, it is important to mention a sudden event that had happened in the last year, 2024. Carlos del Fresno Sánchez, principal investigator of the Immunomodulation laboratory and co-leader of the Innate Immune Response Group at the Instituto de Investigación Sanitaria del Hospital la Paz (IdiPAZ), has won the Pfizer Foundation - ITEMAS Award for the best health innovation project arising from the Units and Associated Units of the ITEMAS-ISCIII Platform. The PolyFIL project consists of the development of a liquid blood biopsy for the differential identification of patients suffering from colon polyps or tumors. This test improves the diagnosis of these diseases by optimizing the performance of colonoscopies. With an accurate diagnosis such as that offered by PolyFIL, colonoscopy will be performed only on those patients who really need it, eliminating polyps that may eventually develop into tumors. Using patient samples in a real hospital setting, PolyFIL has identified and differentiated patients with polyps from patients with colon tumors with 100% sensitivity and 100% specificity.

9. The UAI helps projects based on different disruptive technologies to go ahead and leading health innovation. These technologies such as IA or machine learning, probes the great labour taking in action by

this unit, the UAI. As well, as part of the action taking inside of IdiPAZ there are some projects have been succeed in 2024. The Dulcinea project, which consists of the development of software based on dubbing techniques to improve the functional communication of people with post-stroke aphasia, has received the Award for Technological Innovation in Psychology, granted by the College of Psychologists of Madrid. The award ceremony took place on December 11, 2024. This project has a highly innovative component as it involves the implementation of a personalized therapy, in which each patient can choose the words they want to train, and is also an example of collaboration between patient associations and hospitals.

The Dulcinea project, led by Dr. Blanca Fuentes Gimeno, researcher of the IdiPAZ group of Neurology and Cerebrovascular Diseases and head of section of the Neurology Service of the Hospital La Paz, was funded by the La Caixa Foundation in the Health Research 2018 call, and had the collaboration of the University of Comillas, the patient association Afasia Activa and RTVE. Dulcinea already won the Innovactoras 2022 Award for the best innovative solution with a digital or technological component created by a woman under 35 years of age, awarded by the Association of Industrial Engineers of Navarra.

10. One of the most relevant milestones of the year 2024 has been the collaboration established between the company DEKIPLING and the Neurology Department of our hospital, with the aim of jointly developing an innovative technological tool. This strategic alliance has not only favoured the progress of the project, but has also had direct funding from the company, which has been key to its momentum. Likewise, the Innovation Support Unit (UAI) has played a fundamental role in coordinating and accompanying the process, facilitating the connection between the clinical, business and technological spheres.

11. The Hospital Universitario La Paz, which belongs to the public health network of the Community of Madrid, has two research projects and is participating in a third, from among the 23 selected by the Mutua Madrileña Foundation in the XXI Call for Health Research Grants awarded by this organization. The aim of these grants, worth 2.3 million euros, is to promote and develop research in the field of health throughout Spain.

The Hospital Universitario La Paz projects selected







focus on different areas of research. On the one hand, in the area of transplants, the team led by Dr. Francisco Hernández Oliveros, head of the Pediatric Surgery Department, will test a new strategy to avoid the need for immunosuppression after a transplant. In the area of traumatology and its sequelae, the project led by Dr. Gerardo Ruiz Ares, from the centre's neurology service, will seek to identify evolutionary biomarkers of concussion associated with sports. And finally, the 3D Management Laboratory is involved in a collaborative project on the creation of organ-on-chip models, in this case kidneys, which are miniaturized organs that provide a dynamic environment similar to the body.

The project led by Gerardo Ruiz Ares, with the support of the Innovation Support Unit (UAI) in the strategic accompaniment of the project, focused on the study of concussion associated with sports practice. This condition causes neurological alterations that, in many cases, do not present evident lesions in conventional radiological techniques. Although it has traditionally been considered a benign condition, there is increasing evidence of its possible long-term cognitive consequences.

In view of this reality, the project proposed the need to develop new tools for early diagnosis to guide both treatment and safe return to sporting activity. The general objective was to deepen our knowledge of this pathology and to identify prognostic or evolutionary markers that would allow us to prevent progressive neurological deterioration. The results obtained could have a significant impact not only on the health of athletes, but also on the modification of the rules of the game to improve their safety.

ORGANISATION

Since its implementation, the Innovation Support Unit has been integrated into the organisational structure of FIBHULP, as one of the Support Platforms for IdiPAZ research.

The Innovation Unit is directed by Dr. Javier de Castro Carpeño, M.D. and Ph.D. in Medicine and he's a member of the Medical Oncology Department of the La Paz University Hospital, Autonomous University of Madrid and of the Translational Oncology Unit of IdiPAZ.

The Innovation Unit also consists of a team of three experts in fostering innovation and protecting research results and technology transfer:

Estela Sánchez Simón, Law Graduate;
Marta Navas Romero, Biomedical Engineer.
Patricia Goyanes Rodrigo, Telecommunication Engineer.

CONTACT

Coordinator
Javier de Castro Carpeño
javier.decastro@salud.madrid.org
Phone: (+34) 912071234

Responsible
Estela Sánchez Simón
innovacion.legal@idipaz.es
Phone: (+34) 912071234

Members
Marta Navas Romero
innovacion@idipaz.es
Phone: (+34) 912072945

Patricia Goyanes Rodrigo
international.grants@idipaz.es
Phone: (+34) 912071232

2.5.1.1.2. Patents and trademarks

NEUROSCIENCES AREA

Psychiatry and Mental Health

Rodríguez Vega B, author; FIBHULP, assignee. Trademark name: En calma; ESM 3.695.071; 2017 December 12.



Rodríguez Vega B, Mediavilla Torres R, Bravo Ortiz MF, Muñoz San José A, Bayón Pérez C, Lahera Forteza G, Palao Tarrero A. authors; FIBHULP, assignee. Trademark name: SocialMind; ESM 3.748.550; 2018 December 17.



Neurology and Cerebrovascular Diseases Group

Valdivieso Amate F, Bullido Gómez-Heras MJ, Martínez García A, inventors; UAM, assignee. Method of identifying compounds that induce or inhibit endoplasmic reticulum stress or oxidative stress. P200702997, PCT/ES2008/000705, EP2221379, US20100304384; 2007 November 13.

Vergés Milano J, García García A, Ruhí Roura R, Montell Bonaventura E, García López M, Aláez Versón CR, Escaich Ferrer J, Egea Máiquez J, Lorrio González S, Negredo Madrigal P, inventors; BIOIBÉRICA S.A., UAM, assignees. Sulphated disaccharides for the treatment of neurodegenerative and/or neurovascular diseases. P200902399, PCT/EP2010/070613, US20120309707, CA20102785237; 2010 December 22.

Valdivieso Ámate F, Burgos Muñoz JS, Ramírez Moreno C, Sastre Merlín I, inventors; UAM, CSIC, assignees. Method of identifying therapeutic compounds which can be used for the treatment and/or prevention of infections and diseases caused by human herpes viruses. P200400965, PCT/ES2005/000209, EP1769677, US20070218004, AT447321, AU2005235319, CA2562787, JP2007533315; 2004 April 21.

Valdivieso Ámate F, Montoliú JL, Pozueta Larios J, inventors; UAM, CSIC, assignees. Alzheimer's disease animal model, method for obtaining same and uses thereof. P200503002, PCT/ES2006/000673, EP1956091, EP20060841725, US20090222932, CA2638983, JP2009517066; 2005 December 02.

Ballesteros García P, López Larrubia P, Domínguez Mateo L, Marco Contelles JL, Cerdán García-Esteller S, inventors; Universidad Nacional de Educación a Distancia, CSIC, assignees. Set of magnetic resonance imaging and spectroscopy cell acidity extrinsic indicators comprise polyol derivatives based on alditols. P200300936; 2003 April 23.

Gil Martínez A, author; FIBHULP, assignee. Trademark name: Specular Face; ESM 4.022.981; 2019 June 10.



Egea Máiquez FJ, Farré Alins V, Palomino Antolín A, Narros Fernández P, Martins Rosa J, Parada Pérez E, Hernández García BJ, Roda Frade JM, Yus Teruel S, Lagares Gómez-Abascal A, Sánchez Carabias C, Gandía Juan L, inventors; Fundación Hospital La Princesa, FIBHULP, Fundación Hospital 12 de Octubre, UAM, assignees. Method for determining the progression of acute brain damage and pharmaceutical composition for its treatment. P202031194, PCT/ES2021/070856; 2020 November 30.

Gil Martínez A, Gil Castillo J, inventors; FIBHULP, Centro Superior de Estudio Universitarios La Salle, Javier Gil Castillo, assignees. Dispositivo de medición y/o entrenamiento de la fuerza o presión de los músculos de la cavidad oral y su uso para rehabilitación. MU 1201U MU202230128. 2022 July, 26.

Alonso de Leciñana M, Díez Tejedor E, Fuentes Gimeno B, Rodríguez-Pardo de Donlebun J, Lopez Martín D, Gutierrez Martín A and Fernandez Martín F, authors; FIBHULP and Universidad Politécnica de Madrid, assignee. Trademark name: Neuro Data Tracker; ESM 018860324; 2023 April 11

Martín Montes A, Blanco de Miguel D, Rodríguez-Pardo de Donlebun J, Medina López A, Alonso de Leciñana Cases M, Frank García A, inventors; FIBHULP, assignee. Cognipaz. N°019095718; 2024 October 24.

Neuroprotective Strategies in Neurodegenerative Diseases Group

Cuadrado Pastor A, Innamorato NG, inventors: CSIC, UAM. Use of sulforaphane as supplementary therapy for early-stage neurodegenerative disease. P201231693; 2012 November 06.

León Martínez R, Egea Maíquez J, Buendía Abaitua I, Parada Pérez E, Navarro González de Mesa E, inventors; Fundación para la Investigación Biomédica del Hospital Universitario de La Princesa, UAM, CSIC, DNS NEUROSCIENCE S.A., assignees. Use of 3-(2-isothiocyanatoethyl)-5-methoxy-1H-indole for the treatment of neurodegenerative diseases. P201300667; 2013 July 17.

León Martínez R, Buendía Abaitua I, Navarro González de Mesa E, Michalska P, Gameiro Ros I, López Vivo A, Egea Maíquez J, García López M, García García A, inventors; Fundación para la Investigación Biomédica del Hospital Universitario de La Princesa, UAM, DNS NEUROSCIENCE S.A., assignees. Compounds derived from 3-alkylamine-1H-indolyl acrylate and its use for the treatment of neurodegenerative diseases. P201400810, PCT/ES2015/000139, CA2964309; 2014 October15.

Cuadrado Pastor A, Fernández-Ginés R, León Martínez R, Encinar JA, Rodríguez Franco MI, García López MG, Rojo Sanchís AI, inventors. UAM, CSIC, UMH y Fundación de Investigación Biomédica del Hospital Universitario de la Princesa, assigness. Treatment of NRF2-Related diseases. PCT/2022/382025.1.

Mechanisms and Biomarkers in Neurodegenerative Diseases

López-Rodríguez ML, Viso A, Ortega S, Lastres-Becker I, González S, Fernández-Ruiz JJ, Ramos JA, inventors; Universidad Complutense de Madrid, assignees; Nuevos derivads de ácido araquidónico con afinidad por el transportador de anandamide. P200001920. 2020 nov 5

Martínez A, Gil C, Madruga E, Garcia-Rubia A, Lastres-Becker I, inventors; CSIC, assignees; Compuestos inhibidores de SGK1 y su uso para el tratamiento de enfermedades neurodegenerativas y/o cardiovasculares. ESP202430463. 2024 jun 5

CARDIOVASCULAR AREA

Research on Invasive Clinical Cardiology- ICCI-PAZ Group

Riera del Moral LF, inventor; FIBHULP, assignee. Aortic endoprosthesis for the treatment of aneurysm. P201231638, PCT/ES2013/070712; 2012 October 24.

Filgueiras Rama D, López de Sá y Areses E, Millet Roig J, Calvo Saiz CJ, inventors; Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), FIBHULP, Universidad Politécnica de Valencia, assignees. Method of predicting or prognosticating neurological performance in patients who have suffered a cardiac arrest and optionally comatose status due to ventricular fibrillation. PCT/EP2015/076893, EP3020333; 2014 November 17.

Castro Conde A, author; FIBHULP, assignee. Trademark name: RECAR Programa de Rehabilitación Cardiaca; CM 18457042; 2021 April 20.

Coagulopathies and Alterations of Hemostasis

Nora Butta JY. Trademark name: WELCOME von willebrand active e-learnig course. CM M4190835; 2022 November 8.

Arias-Salgado, MT Álvarez Román, V Jiménez Yuste, N Butta Coll, García Rivera Francisco Julián, García Rivera Mª Carmen, Carballo García Mª Ángeles, inventors. FIBHULP, García Rivera Mª Carmen, Carballo García Mª Ángeles, asignees. Dispositivo de recogida de muestras biológicas. P202230651. 2022 July 22.

Vascular Physiology and Pharmacology Group

Pérez Girón JV, Ruiz-Castellanos MJ, de Luis Jiménez O, Pérez Boto V, Sanz González R, Hernández Vélez MC, Mas Gutiérrez JA, Alonso Gordo MJ, Salaíces Sánchez M, Ros Pérez M, Coloma Jerez A, Asenjo Barahona A, Sanz Montaña JL, Puente Prieto J, Jensen J, inventors; NANOATE, S.L., assignee. Method for producing biosensors. P201031224, PCT/ES2011/070536; 2010 August 05.

Miguel Castro M, López-Alonso Fandiño R, Recio Sánchez MI, Ramos González MM, Aleixandre de Artiñano A, inventors; CSIC, assignee. Bioactive peptides derived from the proteins of egg white by means of enzymatic hydrolysis. P200301829, PCT/ES2004/070059, EP1661913, US8227207, AT388166, DE602004012289, DK1661913, JP2007523045; 2003 July 31.

Miguel Castro M, López-Alonso Fandiño R, Ramos González MM, Aleixandre de Artiñano A, inventors; CSIC, assignee. Production of and antihypertensive properties of peptides derived from egg white proteins. P200501246 PCT/ES2006/070067; 2005 May 23.

Recio Sánchez MI; Quirós del Bosque A, Hernández Ledesma B, Gómez Ruiz JA, Miguel Castro M, Amigo Garrido L, López Expósito I, Ramos González MM, Aleixandre de Artiñano A, (Contreras Gómez M), inventors; CSIC, assignee. Bioactive peptides identified in enzymatic hydrolyzates of milk caseins and method of obtaining same. P200501373, PCT/ES2006/070079, EP1905779, EP2495250, US8354502, AU2006256720, BRPI0611729, CA2611416, CN101305017, CN103254278, JP2008545774, KR20080045108, MX2007015528, NO20080103; 2005 June 08.

Garcés Rimón M, Miguel Castro M, López-Alonso Fandiño R, López-Miranda González V, Uranga Ocio J, inventors; CSIC, Universidad Rey Juan Carlos, assignees; Use of multifunctional bioactive products derived from the enzymatic hydrolysis of egg white proteins for treating metabolic syndrome. P201331767, PCT/ES2014/070880; 2013 December 04.

Miguel Castro M, Garcés Rimón M, López-Alonso Fandiño R, Sandoval Huertas M, inventors; CSIC, Mario Sandoval Huertas, assignees. Healthy food compositions having gel or foam textures and comprising hydrolyzed egg products. P201331886, PCT/ES2014/070902, EP3106042, US9648897, AR098685, JP2015130856, MX2014015135; 2013 December 20.

González-Muñiz R, Pérez de Vega MJ, Miguel M, Balsera-Paredes B, Moreno S, inventors; CSIC, assignee. Triazolyl polyphenols with antioxidant activity and uses thereof; P201531450; 2015 November 08.

González-Muñiz R, Miguel Castro M, Pérez de Vega MJ, Balsera-Paredes B, S Moreno, inventors; CSIC, assignee. Compounds with antioxidant activity and uses thereof. P201630362; 2016 March 29.

León Martínez R, Abril Comesaña S, Duarte Flórez P, Crisman Vigil E, Michalska P, Salaices Sánchez M, Menéndez Ramos JC, inventors; Fundación para la Investigación Biomédica del Hospital Universitario de la Princesa, UAM, UCM, assignees. Compuestos agonistas nicotínicos y antioxidantes para el tratamiento de enfermedades neurodegenerativas. P201930908. 2019 October 14.

León Martínez R, Abril Comesaña S, Michalska P, Buendia Abaitua I, Salaices Sánchez M, Menéndez Ramos JC, García López M; inventors; Fundación para la Investigación Biomédica del Hospital Universitario de la Princesa, UAM, UCM, assignees. Compuestos derivados de 2-iodo-7-(((2-(5-metoxi-1H-indol-3-il) etil)amino)metil)-1-alquil/aril-6,7,7a,8-tetrahidro-3H-pirrolo[2,1-j]quinolina-3,9(5H)-diona como agentes antioxidantes, inductores de NRF2 y moduladores nicotínicos para el tratamiento de enfermedades neurodegenerativas. P201930190. 2019 March 01.

Miguel Castro M, Garcés Rimón M, authors; Miguel Castro M, Garcés Rimón M, assignee. Trademark name: leggie. ESM4044711; 2019 November 22.

Miguel M, Bruna E, Redondo BI, Gómez J, Gómez Sánchez J. inventors: : Cárnicas Joselito S.L: assigne. Extracto procedente de la grasa de cerdo, método de obtención, composición alimenticia que lo comprende y usos del mismo. P2021130236. 2021 March 17

Miguel M, Bruna E, Redondo BI, Gómez J, Gómez Sánchez J, Sabater-Muñoz B. inventors: Cárnicas Joselito S.L. assignee. Composición farmacéutica que comprende un extracto procedente de la grasa de jamón de cerdo como principio activo y su uso en medicina para la prevención cardiovascular e inflamación intestinal. P202131111. 2021 november 30

Alonso Gordo MJ, Hernanz Martín R, Martínez Casales M, González Carnicero Z, León Martínez R, Michalska Djzma P. inventors; Universidad Rey Juan Carlos, Consejo Superior de Investigaciones Científicas, Universidad Autónoma de Madrid, assinees; (E)-3-(4-hidroxi-3-metoxifenil)-acrilato de 3-(2-acetamidoetil)-1H-indol-5-ilo para uso en la prevenciaón y/o tratamiento de la hipertensión arterial y las alteraciones cardiovasculares asociadas. P202230523

INFECTIOUS DISEASES AND IMMUNITY AREA

AIDS and Infectious Diseases Group

Romero Gómez M, Solá Lamoglia R, González García JJ, inventors; Servicio Andaluz de Salud, Universidad de Sevilla, Fundació Institut Mar D'Investigacions Mèdiques, FIBHULP, assignees. Kit for decision making in patients with Hepatitis C genotypes 1 and 4. P201330731; 2013 May 21.

Molecular Microbiology Group

Vicente Muñoz M, Mingorance Cruz J, Rueda González MS,inventors; CSIC, assignee. Method for determining state of growth and viability of bacterial FTsZ population, whether natural or cultivated, is based on determining existence of FTsZ rings in actively growing individual cells. P200200370; 2002 February 15.

Mingorance Cruz J, Castán García P, Franco de Sarabia Rosado PM, inventors; BIOTOOLS BIOTECHNOLOGICAL & MEDICAL LABORATORIES S.A., assignee. Composition, method and kit for detecting bacteria by means of sequencing. PCT/ES2009/000507, EP2492352, US2013157265, CA2775273, MX2012004627; 2009 October 22.

Mingorance Cruz J, Castán García P, Franco de Sarabia Rosado PM, inventors; 2B BLACKBIO S.L., assignee. Composition, method and kit for detecting fungi and yeasts by means of sequencing. PCT/ES2010/000248; 2010 June 02.

Immuno-Rheumatology Group

Pascual-Salcedo Pascual MD, Balsa Criado A, Plasencia Rodríguez C, authors; FIBHULP, assignee. Trademark name: BioDrug Analysis BIDA. CM 13.808.531, 2015 March 10.

Fernández Luna JL, Martínez Taboada VM, López Hoyos M, Torices del Val S, Muñoz Cacho P,Varela Egocheaga I, Juliá Cano A, Marsal Barril S, Balsa Criado A, inventors; FIBHULP, Fundación Instituto de Investigación Marqués de Valdecilla, Servicio Cántabro de Salud, Universidad de Cantabria, FUNDACIÓ HOSPITAL UNIVERSITARI VALL D´HEBRON - INSTITUT DE RECERCA (VHIR), assignees. Method for predicting the clinical response to anti-inflammatory agent therapies. P201600636, PCT/ES2017/000089; 2016 July 26.

Plasencia C. Trademark name: MAM Modelo Asistencial Mixto; CM 18637540; 2022 January 13.

Innate Immune Response Group
Llamas Matías MA, López-Collazo E, inventors; FIBHULP, Llamas Matías MA, Empireo S.L., assignees. Method for determine the risk of developing an infectious disease. P201330768, PCT/ES2014/070434, EP3006570; 2013 May 27.

Vela Cuenca M, González Navarro P, Valentín Quiroga J, Escudero López A, Pérez Martínez A, Fernández Casanova L, inventors; FIBHULP, CNIO, assignees. Anti-CXCR4 antibody combined with activated and expanded natural killer cells for cancer immunotherapy. 62/642,313 US Provisional Application; 2018 March 13.

del Fresno Sánchez C, Cantero Cid R, López-Collazo EM, inventors; FIBHULP, assignee. In vitro method and uses thereof for the differential diagnosis of CRC (colorectal cancer) and/or colorectal adenomas. EP24382100, PCT/EP2025/052243; 2024 February 1.

Diagnosis and Treatment of Diseases Associated with Abnormalities of the Complement System Group
López Trascasa M, authors; FIBHULP, assignee. Trademark name: COMPLEMENTest; CM 009.658.791; 2011, January 14.

COMPLEMENTest ®

Lymphocyte Pathophysiology in Immunodeficiencies Group
Van Dongen JJM, Orfao de Matos Correia E Vale JA, Van Der Burg M, Pérez Andrés M, Van Zelm MC, Kalina T, Vlkova M, López Granados E, Blanco Álvarez E, Kienzler AK, inventors; Erasmus University Medical Center Rotterdam, assignee. Reagents, methods, and kits for diagnosing primary immunodeficiencies. PCT/NL2015/050762, US62/072,498; 2014 Oct 30.

Lopez Granados E, del Pino L, authors; FIBHULP, CIBERer, assigne. Brand name: IMMUNE SIGNAL ®. EU 01906321; 2024, August 02

IMMUNE SIGNAL

Drug Hypersensibility and Innate Immune Response Group
Selgas Gutiérrez R, Bellón Heredia T, Rodríguez Sanz AI, Álvarez Builla J, Vaquero López JJ, Sánchez Alonso P, Alajarín Fernández R, inventors; FIBHULP, Universidad de Alcalá, assignees. Use of compounds derived from salts of pyridazine[1',6':1,2]pyrido[3,4-b] indolinium as anti-inflammatory agents. P201331143, PCT/ES2014/070603; 2013 July 25.

Selgas Gutiérrez R, Bellón Heredia T, Rodríguez Sanz AI, Álvarez Builla J, Vaquero López JJ, Sánchez Alonso P, Alajarín Fernández R, inventors; FIBHULP, Universidad de Alcalá, assignees. Use of compounds derived from salts of piridazine[3,2-b]benzimidazolium as anti-inflammatory agents. P201430411, PCT/ES2014/070603; 2013 July 25.

MicroRNA Regulation of Immune Tolerance, Autoimmunity And Cancer
Voss J, Huang D, Gonzalez-Martin A, Andrabi R, Burton D, inventors; The Srcipps Research Institute, assignees. B Cell receptor modification in B cells. PCT/US/45255. 2018 August 3

Gonzalez-Martin A, Gonzalez-Molina MdP, inventors; MicroRNAs for use in the stimulation of T-cell anti-tumor response. PCT/EP2024/064900. 2024 September 20

LARGE SYSTEM PATHOLOGIES AREA

Organic Dysfunction and Failure in the Agression Group
Herrero Ambrosio A, Ramírez García E, Ojeda Feo JJ, Pérez Rodríguez J, Asensio Martín MJ, González Sánchez ML, Moro Agud M, Lorente Romeo M, López Nieto M, Gómez Rioja R, authors; FIBHULP, assignee. Trademark name: SINOIRES; CM 13.080.056; 2014 July 14.

SINOIRES

Respiratory Diseases Group

Díaz García E, Laxman Nanwani K, Quintana Díaz M, García Río F, Cubillos-Zapata C, inventors; FIHULP, CIBER, assignees. Biomarcadores para el pronóstico de pacientes que han sufrido una hemorragia subaracnoidea aneurismática (SAH). P202130180; 2021 March 3

Villamañán E, Contreras J, Romero D, Carpio C, Álvarez-Sala R, Herrero A, Quirce S, inventors; FIBHULP, assignee. Expertasma. Nº018981670; 2024 June 14.

expertasma

Nephrology Group

Selgas Gutiérrez R, Bellón Heredia T, Rodríguez Sanz AI, Álvarez Builla J, Vaquero López JJ, Sánchez Alonso P, Alajarín Fernández R, inventors; FIBHULP, Universidad de Alcalá, assignees. Use of compounds derived from salts of pyridazine[1',6':1,2]pyrido[3,4-b] indolinium as anti-inflammatory agents. P201331143, PCT/ES2014/070603; 2013 July 25.

Selgas Gutiérrez R, Bellón Heredia T, Rodríguez Sanz AI, Álvarez Builla J, Vaquero López JJ, Sánchez Alonso P, Alajarín Fernández R, inventors; FIBHULP, Universidad de Alcalá, assignees. Use of compounds derived from salts of piridazine[3,2-b]benzimidazolium as anti-inflammatory agents. P201430411, PCT/ES2014/070603; 2013 July 25.

Aguilera Peralta AI, López-Cabrera M, Selgas Gutiérrez R, Steppan S, Passlickdeetjen J, inventors; Fresenius Medical Care Deutschland GMBH, assignee. Pharmaceutical compositions containing steviosides. EP14191301.2, PCT/EP2015/074955, CN107073022, US10213452; 2014 October 31.

López-Cabrera M, Aguilera Peralta AI, Selgas Gutiérrez R, Passlickdeetjen J. Buechel J, Steppan S, inventors; Fresenius Medical Care AG & Co. KGaA, assignee. Method and kit for diagnosing epithelial to mesenchymal transition of the peritoneum (EMT-Chip). DE102015115158.8, PCT/EP2016/071149, CN108449998B, EP3347715B1, ES2833553T3, JP6869963B2, US2018246098A1; 2015 September 09.

Diagnosis and Treatment of Allergic Diseases Group

Valenta R, Constantin C, Quirce Gancedo, SE, inventors; Phadia AB, assignee. Novel wheat allergens. PCT/SE2008/051377, EP2225266, US2010305049, AU2008330230, CA2707190, CN101932597, JP2011505134, RU2010126590; 2007 November 30.

Caballero Molina MT, Prior Gómez N, Remor Bitencourt EA, authors, FIBHULP, assignee. Trademark name: HAE-QoL HEREDITARY ANGIOEDEMA QUALITY OF LIFE. CM 13.083.068; 2014 July 15.

HAE-QoL
HEREDITARY ANGIOEDEMA QUALITY OF LIFE

Sánchez Herreros R, Martínez Fernández J, Castro Morera A, Gasset Vega M, Rodríguez Pérez RM, Pedrosa Delgado M, Quirce Gancedo S, inventors; FIBHULP, CSIC, assignees. Food allergen extracts and methods of producing and using the same. EP16382413.9 (EP3290438); 2016 September 06.

del Pozo Abejón V, Sastre Dominguez J, Rodrigo-Muñoz JM, Sastre Turrión B, Quirce Gancedo S, Cañas Mañas JA, inventors; FIISFJD, Centro de Investigación Biomédica en Red (CIBER), FIBHULP, Fundación Conchita Rábago de Jiménez Díaz, assignees.*In vitro* method for identifying severity levels in bronchial asthma patients. P201730739, PCT/ES2018/070390, EP3633050; 2017 May 29.

Villamañán E, Contreras J, Romero D, Carpio C, Álvarez-Sala R, Herrero A, Quirce S, inventors; FIBHULP, assignee. Expertasma. Nº018981670; 2024 June 14.

expertasma

Patient Blood Management

Díaz García E, Laxman Nanwani K, Quintana Díaz M, García Río F, Cubillos-Zapata C, inventors; FIHULP, CIBER, assignees. Biomarcadores para el pronóstico de pacientes que han sufrido una hemorragia subaracnoidea aneurismática (SAH). P202130180; 2021 March 3

Hospital Pharmacy

Herrero Ambrosio A, Ramírez García E, Ojeda Feo JJ, Pérez Rodríguez J, Asensio Martín MJ, González Sánchez ML, Moro Agud M, Lorente Romeo M, López Nieto M, Gómez Rioja R, authors; FIBHULP, assignee. Trademark name: SINOIRES; CM 13.080.056; 2014 July 14.

Villamañán E, Contreras J, Romero D, Carpio C, Álvarez-Sala R, Herrero A, Quirce S, inventors; FIBHULP, assignee. Expertasma. Nº018981670; 2024 June 14.

Translational Hepatology

Castán P, Gil-García AI, Madejón A, Sainz-Martínez E, Montoya JJ, OUAHID YOUNESS, inventors; MIRNAX BIOSENS S.L., assignee. Bivalent reverse primers Aplication number (EPO): 20382336.4-1118. 2020 April 24.

Madejón A; inventor; Agile Life Sciences LTD, assignee. Kit and methods Aplication number: GB202010372.A. 2020 July 6.

Associated Clinician

De la Oliva Senovilla P, inventor; FIBHULP, Instituto de Salud Carlos III, assignees. Shut-off valve for the interruption technique used in the analysis of respiratory mechanics. PCT/ES2005/000271, EP1897578; 2005 May 16.

Carballo Cardona C; author; FIBHULP, assignee. Trademark name: Diagether. CM15869911, 2016 September 29.

CANCER AND HUMAN MOLECULAR GENETICS AREA

INGEMM- Institute of Medical and Molecular Genetics Group

Friedman S, Li D, Narla G, Martignetti J, Heath K, inventors; Mount Sinai School of Medicine, assignee; Kruppel-like factor 6 (klf6), a tumor suppressor protein, and diagnostics, therapeutics, and screening based on this protein. PCT/US2001/025046, EP1332362, CA2419064, AU8479001, US2005181374, US2011059899; 2000 August 09.

INGEMM, author; FIBHULP, assignee. Trademark name: INGEMM INSTITUTO DE GENÉTICA MÉDICA Y MOLECULAR DEL HOSPITAL UNIVERSITARIO LA PAZ; ESM 2.884.849, USM 77.891.143, CM 8.746.869; 2009 July 16, 2009 December 11, 2009 December 10.

INGEMM, author; FIBHULP, assignee. Trademark name: KaryoArray; USM 79.078.751, CM8.512.907; 2010 January 07, 2009 August 27.



INGEMM, author; FIBHULP, assignee. Trademark name: OverGrowthArray; ESM 2.958.709-3, USM 85.334.932, CM10.009.256; 2010 December 02, 2011 June 01, 2011 May 31.

INGEMM, author; FIBHULP, assignee. Trademark name: MetabolArray; ESM 2.958.711-5, USM 85.334.903, CM10.009.348; 2010 December 02, 2011 June 01, 2011 May 31.

Palomares M, Lapunzina P, Nevado J, Vallespin E, Vallcorba I, Melero J, authors; FIBHULP, Hospital

Infanta Cristina (Badajoz) Fundesalud, assignees. Trademark name: OncoHematoArray; ESM 2.958.703-4, USM 85.334.842, CM10.009.181; 2010 December 02, 2011 June 01, 2011 May 31.

Lapunzina P, Nevado J, Solera J, Vallespin E, Martínez P, Martínez-González V, authors; FIBHULP, assignee. Trademark name: ONCOSeq; USM 85.457.843, CM9.969.064; 2011 October 27, 2011 May 16.

INGEMM, author; FIBHULP, assignee. Trademark name: OncoArray; ESM 2.962.910, USM 85.363.107, CM10.091.882; 2011 January 05, 2011 July 05, 2011 July 01.

Moreno JC, Moya CM, Vallespin E, Lapunzina P, Nevado J, authors; FIBHULP, assignee. Trademark name: ThyroArray; USM 85.686.688, CM10.904.951; 2012 July 25, 2012 May 23.

Lapunzina Badía P, Borobia Pérez AM, Carcas Sanjuán AJ, Tenorio Castaño JA, Arias Lajara P, Lubomirov Jristov R, authors; FIBHULP, UAM, assignees. Trademark name: PharmArray; USM 86.004.412, CM11.608.403; 2013 July 08, 2013 February 27.

Lapunzina Badía PD, Borobia Pérez AM, Carcas Sansuán AJ, Tenorio Castaño JA, Arias Lajara P, Frías Iniesta J, Dapia García I, Muñoz M, authors; FIBHULP, UAM, assignees. Brand name: ClinPharmarray., CM15489511; 2016 May 31, 2016 September 07.

Palomares Bralo M, Vallespín García E, del Pozo Mate A, Santos Simarro F, authors; FIBHULP, assignee. Trademark name: RD-Seq Sequencing Rare Diseases; CM 17.911.029; 2018 May 31.

Translational Oncology Group

Cejas Guerrero P, Belda Iniesta C, Feliú Batlle J, González Barón M, de Castro Carpeño J, Casado Sáenz E, Sánchez Hernández JJ, inventors; FIBHULP, UAM, assignees. Genomic fingerprint for the prognosis of the evolution of colorectal adenocarcinoma. P200703229, PCT/ES2008/000756, EP2236626; 2007 December 04.

Cejas Guerrero P, González Barón M, Casado Sáenz E, Sánchez Hernández JJ, Perona Abellón R, inventors; FIBHULP, UAM, CSIC, assignees. Use of trefoil factor family 3 (TFF3) in the prognosis of patients diagnosed with colorectal cancer. P200703230, PCT/ES2008/000757, EP2236625; 2007 December 04.

Espinosa Arranz E, Fresno Vara JA, Gámez Pozo A, Sánchez Navarro I, inventors; FIBHULP, assignee. Method for tumor subclassification. P200803509, PCT/ES2009/070533; 2008 December 11.

Redondo Sánchez A, Hardisson Hernaéz D, Barriuso Feijoo J, Mendiola Sabio M, inventors; FIBHULP, assignee. Method to obtain useful data for the prediction of a patient's clinical response to an anticancer treatment. P200930400; 2009 July 01.

Cejas Guerrero P, Belda Iniesta C, Feliú Batlle J, de Castro Carpeño J, Moreno García V, Burgos Lizalde E, Casado Sáenz E, Sánchez Hernández JJ, inventors; FIBHULP, UAM, Empresa Pública Hospital del Norte, assignees. Genomic fingerprint for predicting the clinical response to an antitumor therapy in colorectal cancer. P201130863, PCT/ES2012/070379; 2011 May 26.

Moreno Rubio J, Cejas Guerrero P, Feliú Batlle J, Ramírez de Molina AI, Reglero Rada G, Vargas Alonso T, Molina Arranz S, González-Vallinas Garrachón M, inventors; FIBHULP, Fundación Imdea Alimentacion, assignees. Methods and kits for the prognosis of colorectal cancer. P201231918, PCT/ES2013/070864; 2012 December 10.

Espinosa Arranz E, Fresno Vara JA, Gámez Pozo A, López Vacas R, Berges Soria J, inventors; FIBHULP, assignee. Method for tumor subclassification. P201430887, 2014 June 09.

Miranda Utrera N, Castellano D, Villacampa Aubá F, Fresno Vara JA, Gámez Pozo A, inventors; FIBH12O, FIBHULP, assignees. Prognostic method for determining the risk of relapse in renal cancer patients with a clear cell type of renal carcinoma, stages I and II, and kit for the same. P201531360, PCT/EP2016/072723, EP3353322B1, US20180346990, CN108174608, DE3353322, FR3353322, GB3353322; 2015 September 23.

Feliú Battle, J, Fernández Martos C, Fresno Vara JA, Ghanem Cañete I, Gámez Pozo A, Trilla Fuertes L, inventors; Biomedica Molecular Medicine SL (BMM), Grupo Español Multidisciplinar en Cáncer Digestivo (GEMCAD), assignees. In vitro method for the prognosis of anal squamous cell carcinoma. EP19382982.7; 2019 November 11.

Redondo Sánchez A, Hardisson Hernaéz D, Barriuso Feijoo J, Mendiola Sabio M, inventors; FIBHULP, assignee. Method to obtain useful data for the prediction of a patient's pathological response to an anticancer treatment. P200930438; 2009 July 10.

Fernández Martos C, Trilla Fuertes L, Fresno Vara JA, Gámez Pozo A, Ghanem Cañete I, Feliú Battle J, inventors; Biomedica Molecular Medicine SL, Grupo Español Multidisciplinar en Cáncer Digestivo (GEMCAD), assigne. In vitro method for the prognosis of anal squamous cell carcinoma. EP19382982.7; 2019; 2019 November 11.

Experimental Therapies and Biomarkers in Cancer Group

Perona Abellón R, Sánchez Pérez I, Machado Pinilla R, Sastre Garzón L, Murguía Ibáñez JR, inventors; CSIC, UAM, Universidad Politécnica de Valencia, assignees. Sequence of nucleotides and peptides GSE 24.2 of dyskerin, which can induce telomerase activity, method for obtaining the same, therapeutic compositions and applications thereof. P200502511, PCT/ES2006/070152, EP1947175, US20090202503, US2015337022, AT469212, CA2625981, DK1947175, JP2009511036, JP5560398, PT1947175; 2005 October 14.

Perona Abellón R, Sastre Garzón L, Machado Pinilla R, Sánchez Pérez I, inventors; CSIC, UAM, assignees. Use of inductor agents GSE24.2 for producing pharmaceutical compositions for treating illnesses relating to cellular senescence. P200703106, PCT/ES2008/070212, EP2216043, US2011300115, JP2011504483, CA2706467; 2007 November 23.

Cejas Guerrero P, Belda Iniesta C, Feliú Batlle J, González Barón M, de Castro Carpeño J, Casado Sáenz E, Sánchez Hernández JJ, inventors; FIBHULP, UAM, assignees. Genomic fingerprint for the prognosis of the evolution of colorectal adenocarcinoma. P200703229, PCT/ES2008/000756, EP2236626; 2007 December 04.

Cejas Guerrero P, González Barón M, Casado Sáenz E, Sánchez Hernández JJ, Perona Abellón R, inventors; FIBHULP, UAM, CSIC, assignees. Use of trefoil factor family 3 (TFF3) in the prognosis of patients diagnosed with colorectal cancer. P200703230, PCT/ES2008/000757, EP2236625; 2007 December 04.

Cejas Guerrero P, Belda Iniesta C, Feliú Batlle J, de Castro Carpeño J, Moreno García V, Burgos Lizalde E, Casado Sáenz E, Sánchez Hernández JJ, inventors; FIBHULP, UAM, Empresa Pública Hospital del Norte, assignees. Genomic fingerprint for predicting the clinical response to an antitumor therapy in colorectal cáncer. P201130863, PCT/ES2012/070379; 2011 May 26.

Martínez Máñez R, Murguía Ibáñez JR, Perona Abellón R, Agostini A, Mondragón Martínez L, Moreno Torres M, Manguán García C, Marcos Martínez MD, Soto Camino J, Sancenón Galarza F, inventors; Universidad Politécnica de Valencia, CSIC, Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), assignees. Release

of substances into senescent cells. P201231370, PCT/ES2013/070581, EP2893923, JP2015529216, US2015306037; 2012 September 04.

Ibáñez de Cáceres I, Belda Iniesta C, Pernía Arias O, Perona Abellón R, Cortés Sempere M; inventors. FIBHULP, CSIC, UAM, Fundación Hospital de Madrid, assignees. Method for predicting the response to a treatment consisting of radiotherapy combined with cisplatin-based chemotherapy. P201330783, PCT/ES2014/070433, EP3006572, US20160122828, IT1660.13, ES1660.13, FR1660.13, DE1660.13, GB1660.13; 2013 May 29.

Perona Abellón R, Sastre Garzón L, Pintado Berninches L, Carrillo García J, Molina Pachón A, Irradiccio Silva L, Manguán García C, inventors; CSIC, UAM, Advanced Medical Projects, Centro de Investigación Biomédica en Red (CIBER), assignees. Peptides derived from GSE 24.2 for treating diseases caused by oxidative stress and damage to DNA. P201331573, AU2014338820, CA2931429, EP3061815 PCT/ES2014/070803; 2013 October 25.

Ibáñez de Cáceres I, Pernía Arias O, de Castro Carpeño J, Vera Puente O, Jiménez Hernández J, Perona Abellón R, Rojo Todo F, inventors; FIBHULP, CSIC, UAM, Instituto de Investigación Sanitaria FJD, assignees. Determination of methylation and miRNA levels in response to a platinum-based antitumor compound. P201530997, PCT/ES2016/070516; 2015 July 09.

Ibáñez de Cáceres I, de Castro Carpeño J, Vera Puente O, Pernía Arias O, Rodríguez Antolín C, González Muñoz VM, Martín Palma ME, Salgado Figueroa AM, inventors; FIBHULP, FIBIOHRC, assignees. MAFG as a potential therapeutic target to restore chemosensitivity in platinum-resistant cancer cells. EP17382610.8 (EP3681515), PCT/EP2018/068156, US16/647,368; 2017 September 15.

Ibáñez de Cáceres I, de Castro Carpeño J, Jiménez Hernández J, Rodríguez Antolín C, Rodríguez Jiménez C, Rosas Alonso R, Cruz Castellanos P, Burdiel Herencia M, Pernía Arias O, Diestro Tejada MD, Esteban Rodríguez MI, inventors; FIBHULP, assignee. miR-151A-3p as an universal endogenous control for exosome cargo normalization. EP19382252.5 (EP3719144), PCT/EP2020/059774 PCT Direct, EP20719957.1 (EP3947733), US17/601,657; 2019 April 05.

Ibáñez de Cáceres I, de Castro Carpeño J, Rosas Alonso R, Pernía Arias O, Martínez Marín V, Esteban Rodríguez MI, inventors; FIBHULP, assignee. Method for determining the percentage of methylation of the promoter of the gene O6-methylguanine-DNA methyltransferase (MGMT) in circulating exosomes. EP19382299.6 (EP3725899), PCT/EP2020/060753 PCT Direct, EP20723998.9 (EP3956475), US17/604,172; 2019 April 16.

Ibáñez de Cáceres I, de Castro Carpeño J, Jiménez Hernández J, Rodríguez Antolín C, Vera Puente O, Rosas Alonso R, Pernía Arias O, Losantos García I, inventors; FIBHULP, assignee. Method for determining the response to treatment of a patient affected by non-small cell lung carcinoma (NSCLC). EP19382614.6 (EP3999664), PCT/EP2020/069659; 2019 July 19.

Oto-Neurosurgery Research Group

Polak M, Roca-Ribas Serdá F, Gavilán Bouzas J, Lassaletta Atienza L, Miró Castillo N, Rodrigo Dacosta J, inventors; MED-EL Elektromedizinische Geraete GmbH, assignee. Hearing treatment in patients with questionable cochlear nerve functionality. US2011275953, PCT/US2011/035312; 2010 May 05.

Cobo Parra P, Varela Nieto I, Murillo-Cuesta S, Navares Zaera R, Martínez Vega R, Cediel Algovia R, inventors; CSIC, UCM, assignees. Anechoic acoustic chamber for evaluating the auditory function in laboratory animals. P201031720; 2010 November 23.

Cobo Parra P, Varela Nieto I, Murillo-Cuesta S, Cediel Algovia R, inventors; CSIC, UCM, assignees. Method for designing a reverberating acoustic chamber for hearing test with animals. Procedimiento para diseñar una cámara acústica reverberante para ensayos auditivos con animales. P200802895, PCT/ES2009/070433; 2008 October 14.

Marco Contelles JL, Varela Nieto I, Murillo Cuesta S, Rodríguez de la Rosa L, Alcázar Gonzalez A, inventors; CSIC, CIBERER, FIBIOHRC, assignees. Quinolylnitrone derivatives for use in the prevention and/or treatment of hearing loss. EP22382706.4; 2023 July 22

Cancer Molecular Pathology and Therapeutics Targets Group

Redondo Sánchez A, Hardisson Hernaéz D, Barriuso Feijoo J, Mendiola Sabio M, inventors; FIBHULP, assignee. Method to obtain useful data for the prediction of a patient's clinical response to an anticancer treatment. P200930400; 2009 July 01.

Redondo Sánchez A, Hardisson Hernaéz D, Barriuso Feijoo J, Mendiola Sabio M, inventors; FIBHULP, assignee. Method to obtain useful data for the

prediction of a patient's pathological response to an anticancer treatment. P200930438; 2009 July 10.

Zapardiel Gutiérrez I, de Santiago García J, inventors; FIBHULP, assignee. Laparoscopic surgical instrument. P201230950, PCT/ES2013/000139; 2012 June 18.

Zapardiel Gutiérrez I, de Santiago García J, inventors; FIBHULP, assignee. Surgical device. P201330532, PCT/ES2014/070277; 2013 April 15.

Mechanisms of Tumour Progression Group

Olmeda Casadomé D, Peinado Selgas H, Portillo Pérez F, Nieto Toledano MA, Cano García A, inventors; UAM, assignee. Materials and methods for the derepression of the E-cadherin promoter. US20060003956; 2004 March 03.

Olmeda Casadomé D, Moreno Bueno G, Portillo Pérez F, Cano García A, inventors; UAM, CSIC, assignees. Method for the diagnosis and/or prognosis of breast cancer. P200702342, PCT/ES2008/000563; 2007 August 28.

Research and Diagnosis of Inherited Metabolic Diseases Group

Pérez González B, Ruiz Desviat L, Jorge Finnigan A, Ugarte Pérez M, Martínez Ruiz A, Underhaug J, Barnejee R, inventors; UAM, Universidad de Bergen, Universidad de Michigan, assignees; Compounds useful for the treatment of methylmalonic aciduria. P201330171; 2013 February 11.

Pérez González B, Gámez Abascal MA, Yuste Checa P, Arduim Brasil S, Ugarte Pérez M, Martínez Ruiz A, Underhaug J, inventors; UAM, University of Bergen, assignees; Compounds for treating congenital disorders of glycosylation. EP16382373.5, PCT/EP2017/069147; 2016 July 29.

Ruiz-Desviat L, Martínez-Pizarro A, Picó S, Lucas JJ, Andresen BS, inventors; UAM, CSIC,University of Southern Denmark, assignes; Splice shifting oligonucleotides for use in the treatment of diseases characterized by altered inclusion of microexons. PCT/EP2022/077882, EP4163373A1 2023 April 12

Dyslipidemias of Genetic Origin and Metabolic Diseases

Rodríguez Novoa SM, del Monte Vergara A, Rosas Alonso R, Queiruga Parada J, Yuste González F, authors; FIBHULP, assignee. Trademark name: Pharma Genfinder; CM18332183; 2020 November 05.

PHARMA GENFINDER

Ibáñez de Cáceres I, de Castro Carpeño J, Jiménez Hernández J, Rodríguez Antolín C, Rodríguez Jiménez C, Rosas Alonso R, Cruz Castellanos P, Burdiel Herencia M, Pernía Arias O, Diestro Tejada MD, Esteban Rodríguez MI, inventors; FIBHULP, assignee. miR-151A-3p as an universal endogenous control for exosome cargo normalization. EP19382252.5 (EP3719144), PCT/EP2020/059774 PCT Direct, EP20719957.1 (EP3947733), US17/601,657; 2019 April 05.

Associated Clinician

Glaría Enríquez A, Mañas Rueda A, Velázquez Soto R, inventors; FIBHULP, assignee. Isolation and immobilization device for test animals. P201031519, PCT/ES2011/070709; 2010 October 14.

SURGERY, TRANSPLANT AND HEALTH TECHNOLOGIES AREA

Bone Pathophysiology and Biomaterials Group

González Carrasco JL, Benavente Castro R, Cifuentes Cuellar SC, Lieblich Rodríguez M, Olalde Graells B, Atorrasagasti Goyalde G, Argarate Madariaga N, Pacha Olivenza MA, Fernández Calderón MC, Saldaña Quero L, González Martín ML, Pérez Giraldo C, Gallardo Moreno AM, inventors; CSIC, Fundación Tecnalia Research & Innovation, FIBHULP, Universidad de Extremadura, Centro de Investigación Biomédica en Red (CIBER). Moldable, biodegradable, biocompatible and bioresorbable implant material, method for its preparation and uses thereof. P201530683; 2015 May 18.

Martín Saavedra FM, Vilaboa Díaz NE, Cebrián Hernando V, Arruebo Gordo M, Santamaría Ramiro J, Gómez Navascués L, inventors; FIBHULP, CIBER-BBN, Universidad de Zaragoza, assignees. Fibrin hydrogel with plasmonic nanoparticles; P201330894, PCT/ES2014/070484; 2013 June 14.

Vilaboa Díaz NE, Calzado Martín A, Crespo García L, Saldaña Quero L, Moreo Calvo P, Alastrué Vera V, inventors; FIBHULP, CIBER-BBN, assignees. Chamber device for dynamic cell culture on biomaterials;

P201330040, PCT/ES2013/070819; 2013 January 16.

Vilaboa Díaz NE, González Carrasco JL, Saldaña Quero L, Frutos Torres E. inventors; FIBHULP, CSIC, CIBER-BBN, assignees. Method to obtain a metallic-coated biomaterial; P201030949, PCT/ES2011/070400; 2010 June 21.

Vilaboa Díaz NE, Gónzalez Carrasco JL, Multigner Domínguez M, Lieblich Rodríguez M, Muñoz Hernández M, Frutos Torres E, Saldaña Quero L, inventors; FIBHULP, CSIC, CIBER-BBN, Universidad Alfonso X El Sabio, assignees. Magnesium/polymer composite biomaterial for biomedical applications; P201030950, PCT/ES2011/070440; 2010 June 21.

Voellmy R, Vilaboa Díaz NE, inventors; HSF Pharmaceuticals S.A., assignee. Inhibitors of heat shock factor I and uses thereof. US 16501272, 2023 March 7.

Cellular Engineering Group

de Miguel González MP, Arnalich Montiel F, Royuela MM, inventors; FIBHULP, Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal, Universidad de Alcalá, assignees. Corneal endothelium injector; P201131222, PCT/ES2012/070543; 2011 July 18.

De Miguel González MP., Arnalich-Montiel F, Cadenas Martín M, Moratilla Riofrío A.inventors; FIBHULP, FIBHRYC, assignees. Constructos artificiales para su uso en oftalmología, su procedimiento de obtención y utilización del mismo. Patente Europea EP22382119.0 2022 February 14 . PCT/EP2023/053668 2023 February 14.

Clinical Pharmacology Group

Carcas Sansuán AJ, author; Carcas Sansuán AJ, assignee. Trademark name: IBJ IberoAmerican Journals; ESM 3.063.048; 2013 February 12.

Carcas Sansuán AJ, author; Carcas Sansuán AJ, assignee Trademark name: IberoAmerican Journals Plus; ESM 3.063.052; 2013 February 12.

Carcas Sansuán AJ, author; Carcas Sansuán AJ, assignee Trademark name: IberoAmerican Journals Clinical Pharmacology; ESM 3.063.053; 2013 February 12.

Carcas Sansuán AJ, author; Carcas Sansuán AJ, assignee Trademark name: IberoAmerican Journals Medicine; ESM 3.063.049; 2013 February 12.

Lapunzina Badía P, Borobia Pérez AM, Carcas Sansuán AJ, Tenorio Castaño JA, Arias Lajara P, Lubomirov Jristov R, authors; FIBHULP, UAM, assignees. Trademark name: PharmArray; USM 86.004.412, CM11.608.403; 2013 July 08, 2013 February 27.

Carcas Sansuán AJ, Borobia Pérez AM, authors; FIBHULP, assignee. Trademark name: CRDataX; CM13.681.614; 2015 May 28.

Lapunzina Badía PD, Borobia Pérez AM, Carcas Sansuán AJ, Tenorio Castaño JA, Arias Lajara P, Frías Iniesta J, Dapia García I, Muñoz M, authors; FIBHULP, UAM, assignees. Trademark name: ClinPharmarray. USM87054978, CM15489511; 2016 May 31, 2016 September 07.

Osteoarticular Surgery Research- GICOA Group

Arenas Vara MA, Conde del Campo A, De Damborenea González JJ, Matykina E, Esteban Moreno J, Gómez Barrena E, Pérez-Jorge Peremarch C, Pérez Tanoira R, inventors; CSIC, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, assignees. Titanium materials anodised with fluorine. P201030720, PCT/ES2011/070342; 2010 May 14.

Gómez Barrena E, Cordero García-Galán E, Rico Nieto A, Pozo JJ, Esteban Moreno J, Sarnago H, Lucía Gil O, Acero Acero J, Burdío JM. Portable desinfection system based on induction heating; September 2022.

Translational research in maxillofacial surgery and head and neck cancer

Cuéllar Navarro C, Cebrián JL, Magaña Menéndez J, inventors; Hospital General Universitario Gregorio Marañón and Hospital Universitario La Paz, assignees. Dispositivo de determinación de avance mandibular para un usuario con apnea. P202430809; 2024 October 8.

Patients Safety and Quality Research

Herrero Ambrosio A, Ramírez García E, Ojeda Feo JJ, Pérez Rodríguez J, Asensio Martín MJ, González Sánchez ML, Moro Agud M, Lorente Romeo M, López Nieto M, Gómez Rioja R, authors; FIBHULP, assignee. Brand name: SINOIRES. CM 13.080.056; 2014 July 14.

Translational Research and Innovation in General and Digestive Surgery

Álvarez Gallego M, Castejón Sisamón C, García Prada JC, Meneses Alonso J, inventors; FIBHULP, UC3M, assignees. Rectoscope. P201630551, PCT/ES2017/070249, EP17788865.8, US20190200853; 2016 April 29.

Álvarez Gallego M, inventor; FIBHULP, assignee. Device for the extraction of surgical specimens by insufflation and suction. P201031490, PCT/ES2011/002357; 2010 October 07.

Salinas Gómez J, García Sanz M; inventors; FIBHULP and DISTRIBUCIONES CLINICAS S.A. (DICLISA), assignees. Two-way probe for flushing and/or draining. U202100070; 2021 February 19.

Associated Clinician

Castell Gómez JT, inventor; FIBHULP, assignee. System of "partial" or "total" openings and buttonholes for patient pyjama or nightgown. P200401758; 2004 July 16.

García Fernández J, inventor; FIBHULP, assignee. Anaesthesia machine simulator. P200702128, PCT/ES2008/070109, US20090044803; 2007 July 30.

de Miguel del Campo E, Posadas Mañanes SJ, Reglero Rada GJ, Largo Aramburu C, García Grande A, Merino Martín JJ, Caz Bonillo V, Fornari Reale T, Rodríguez García-Risco M, Señorans Rodríguez FJ, inventors; FIBHULP, UAM, assignees. Composition for the protection of tissues from the digestive tract and the nervous system of radiotherapy patients; P200931189; 2009 December 17.

Goldman Tarlovky L, inventor; FIBHULP, assignee. System and method to obtain data on a patient's breathing cycle. P201030927, PCT/ES2011/070242; 2010 June 16.

de Miguel del Campo E, Reglero Rada GJ, Largo Aramburu C, Fornari Reale T, Rodríguez García-Risco M, Jaime de Pablo L, Santoyo Díez S, Señorans Rodríguez FJ, García Grande A, Merino Martín J, Caz Bonillo JV, Posadas Mañanes SJ, inventors; FIBHULP, UAM, assignees. Composition for the reduction of symptoms associated with menopause; P201031225, PCT/ES2011/070586; 2010 August 05.

Castell Gómez JT, inventor; FIBHULP, assignee. Surgical device for interrupted suture. P201031491, PCT/ES2011/002352, EP2626014, US13/878035; 2010 October 07.

de Miguel del Campo E, Largo Aramburu C, Tabernero Urbieta M, Reglero Rada GJ, Marín Martín F, Fornari Reale T, Prodanov Prodanov M, Ruiz Rodríguez A, Ibáñez Ezequiel E, Jaime de Pablo L, Soler Rivas C, Rodríguez García-Risco M, Santoyo Díez S, González Lorente M, Arranz Gutiérrez E, Gil Ramírez A, inventors; FIBHULP, UAM, CSIC, assignees. Functional heart-healthy beverage containing wine and extracts of hops; P201131014, PCT/ES2012/070443; 2011 June 16.

Reglero Rada GJ, de Miguel del Campo E, Marín Martín F, Fornari Reale T, Prodanov Prodanov M, Ruiz Rodríguez A, Largo Aramburu C, Tabernero Urbieta M, Ibáñez Ezequiel E, Jaime de Pablo L, Soler Rivas C, Rodríguez García-Risco M, Santoyo Díez S, González Lorente M, Arranz Gutiérrez E, Gil Ramírez A, inventors; FIBHULP, UAM, CSIC, assignees. Method to obtain extract of hop and the extract obtained. P201230584, PCT/ES2012/070443; 2011 June 16.

Brian Gahan P, Stroun M, García del Olmo D, García Arranz M, Vega Clemente ML, inventors; Peter Brian Gahan, Maurice Stroun, FIBHULP, assignees. Method for blocking tumour growth. EP2808027; 2013 May 29.

Castell Gómez JT, Carrascal Morillo T, inventors; FIBHULP, UNED, assignees. Synthetic surgical mesh. P201331453, PCT/ES2014/000161; 2013 October 03.

Froilán Torres C, de María Pallarés P, Díaz Lantada A, Ortego García P, inventors; FIBHULP, UPM, assignees. Endoscopic accessory.P201730569; 2017 March 31.

Azabal Agudo A, Ruiz-Valdepeñas Martín de Almagro S; Julián García Rivera F, de la Quintana Jiménez P, inventors; UP DEVICES AND TECHNOLOGIES, S.L., FIBHULP, assignees. Dispositivo de corte automático de discos de ostomía. P201830718, PCT/ES2019/070492. 2018 July 16.

Ramírez de Molina A, Tabernero Urbieta M, Reglero Rada G, Torres Olivares CF, Largo Aramburu C, Santamaría Ramiro M, Polo Paredes G, Ruiz Pérez D, de Miguel del Campo E, Álvarez Gómez de Segura I, inventors; Fundación IMDEA Alimentación, UAM, FIBHULP, IGENFARMA, assignees. Composición para la reducción del declive metabólico asociado al envejecimiento y/o el tratamiento de trastornos relacionados al metabolismo lípidico. P201830740; 2018 July 20.

Martín Mateos P, Acedo Gallardo P, Jorcano Noval JL, Díaz Ojeda L, Bonastre Juliá J, Martínez Méndez JR, Largo Aramburu C, inventors; UC3M and FIBHULP, assignees. Device for monitoring the perfusion status of skin flaps. P202130486; 2021 May 31.

Muñoz Caro JM; Azabal Agudo A, Ruiz-Valdepeñas Martín de Almagro S, inventors; FIBHULP and Up Devices and Technologies S.L. assignees. Light diffusing device for photodynamic therapy treatment of anogenital region. U202131773; 2021 September 03.

Gómez Candela C, López Plaza B, Bermejo López L, authors; FIBHULP, assignee. Trademark name: NUTRinvest Grupo de investigación en Nutrición y Alimentos Funcionales; ESM3.649.812-2; 2017 February 02.

NUTRinvest
Grupo de investigación en Nutrición y Alimentos Funcionales

De la Quintana Jiménez P, authors; FIBHULP, assignee. Trademark name: #OdeOstomía; CM 016922734; 2017 September 21.

#OdeOstomía


De la Quintana Jiménez P, authors; FIBHULP, assignee. Trademark name: CM 016922858; 2017 September 21.



De la Quintana Jiménez P, authors; FIBHULP, assignee. Trademark name: Ostomía; CM 017131822; 2017 August 22.



Asensio L, inventor; FIBHULP, assignee. Invención. M4250256; 2024 January 26.



Inguiz

MATERNAL INFANT CHILD AND YOUTH RESEARCH

Neonatology Group

Segovia Iñigo C, Montes Bueno MT, inventors; Segovia Iñigo C, assignee. Positioning device for neonates (Utility model). U201330102; 2013 January 31.

Pediatric systemic infections; HIV, tuberculosis, imported and emergent diseases
Mellado MJ, Piñeiro R, authors; Asociación Española de Pediatria (AEPED), assignee. Trademark name: PEDIAMÉCUM; ESM 3079824; 2013 June13.

Translational research in pediatric oncology, hematopoietic transplantation and cell therapy
Vela Cuenca M, González Navarro P, Valentín Quiroga J, Escudero López A, Pérez Martínez A, Fernández Casanova L, inventors; FIBHULP, CNIO, assignees. Anti-CXCR4 antibody combined with activated and expanded natural killer cells for cancer immunotherapy. 62/642,313 US Provisional Application, IB2019/052042; 2018 March 13.

Pérez Martínez A, Ferreras Puente C,B, inventors; UAM, FIBHULP, Universidad Miguel Hernández de Elche (UMH), Fundación de la Comunitat Valenciana para la gestión del Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL), assignees. Memory T cells as adoptive cell therapy for viral infections. EP20382850.4 (EP3974029), PCT/EP2021/076516; 2020 September 25.

Mayán Santos M, Acea Nebril B, Varela Eirín M, Rodríguez-Candela Mateos M, Díaz Carballa CC, Fonseca Capdevila E, Barrio LC, Escudero López A, inventors; Fundación Profesor Novoa Santos-Instituto de Investigación Biomédica de A Coruña (INIBIC), assignees. Composición para el tratamiento de los efectos secundarios de la radioterapia y/o quimioterapia. PCT/ES2020/070269: 2020 April 27

Research in Endometriosis
Hernández A, López A, Spagnolo E, authors; FIBHULP, assignees; Brand name: EndoPaz: 018876162. 2023 May 17, 2023 September 27

Congenital Malformations and Transplantation
Hernández Oliveros F, Nana Gómez Mayoral N, Raya González L, Guijarro Fernández E, authors; FIBHULP, HePA, U-TAD, Guijarro Fernández E, assignees. Trademark name: VTR Virtual Transplant Reality; CM18.000.131;2018 December 14.

Associated Clinician
Martínez A, inventor; FIBHULP, assignee. Pedidosis. Nº019079682; 2024 September 16.

OTHER TRADEMARKS OF IdiPAZ

FIBHULP, author; FIBHULP, assignee. Trademark name: IdiPAZ Instituto de Investigación Hospital Universitario La Paz; USM 85.078.878, CM8.871.873; 2010 July 06, 2010 February 10.

FIBHULP, author; FIBHULP, assignee. Trademark name: CEASEC Centro Avanzado de Simulación y Entrenamiento Clínico; ESM 3.567.901-8; 2015 June 22.

FIBHULP, author; FIBHULP, assignee. Trademark name: InnoPAZ Plataforma de Innovación Hospital Universitario La Paz; ESM 3.572.575-3; 2015 July 27.

FIBHULP, author; FIBHULP, assignee. Trademark name: CEASEC Centro Avanzado de Simulación y Entrenamiento Clínico; ESM 3.567.901-8; 2015 June 22.

2.5.1.2. Biobank

The Hospital La Paz Institute for Health Research Biobank (IdiPAZ Biobank) is a platform of support service to the Institute's research, product of the integration of different pre-existing nodes with a long and fruitful research trajectory within the University Hospital La Paz. The IdiPAZ Biobank works to obtain, store, manage and distribute large collections of human biological samples of diseases of interest for researchers.

In 2020, the Biobank increased its capacity with the incorporation of new scientific-technical services, and as result the platform has been renamed as Biobanks and Biomodels platform.

This service is created with the collaboration of the University Hospital La Paz, the Foundation for Biomedical Research of the University Hospital La Paz (FIBHULP) and the Carlos III Health Institute, being integrated into the Network of Hospital Biobanks (RetBioH). The Biobank of the University Hospital La Paz - Institute of Health Research of the University Hospital La Paz –IdiPAZ is registered in the National Biobank Network of the Carlos III Health Institute with the code B.0000684.

The *Platform for Biobanks and Biomodels of IdiPAZ* (PT23/00028) belongs to the *ISCIII Biobanks and Biomodels platform (https://www.isciiibiobanksbiomodels.es/)* to support research in Biomedicine and Health Sciences from Strategic Health Action 2017-2023 of the Carlos III Health Institute.

PLATFORM ISCIII BIOBANKS AND BIOMODELS

GOBIERNO DE ESPAÑA MINISTERIO DE CIENCIA E INNOVACIÓN

Instituto de Salud Carlos III

The ISCIII Biobanks and Biomodels Platform has joined the European Biobanking Infrastructure (BBMRI-ERIC) as an observing member, acting as the national node in BBMRI-ERIC, one of the most relevant research platforms in the European Union.

Since 2018, the Biobank of IdiPAZ was certified according to the ISO 9001:2015 quality management system standard within the scope of IQNet Certificate IdiPAZ Number ES-0512/2018.

Objectives

The main objective of the IdiPAZ Biobank is to promote biomedical research, which will increase and improve the quality of scientific production in Spain. This is a specialized work in the management of human biological samples and their associated data for biomedical research in accordance with the legislation in force in Spain, Law 14/2007 on Biomedical Research and the RD of Biobanks 1716/2011. This guarantees the confidentiality of the samples and associated data.

The IdiPAZ Biobank provides researchers with an agile channel to access samples, their products and data associated with quality assurances and ethical-legal adaptation.


The obtaining, and if necessary the revocation, of the patient's informed consent is controlled. Special attention is given to guarantee the protection of privacy and the confidential treatment of personal data contained in the IdiPAZ Biobank, clinical data and research results.

Thanks to this, the development of a continuous dynamic of analysis and evaluation of the needs of the users of the Biobank is favored. In addition, the activity of the IdiPAZ Biobank is made known and valued to society and, especially, in the field of patient and affected associations.

The IdiPAZ Biobank will provide benefits at different levels, starting with donors, patients, society in general and the clinicians and researchers involved. It also aims to facilitate communication and cooperation of different groups with common interests both nationally and internationally.

All of this will result in a higher quality of research and an increase in scientific production, without forgetting the strict compliance with the regulations on Data Protection and the Rights to Privacy and Confidentiality of all patients (Organic Law 3/2018 and Regulation General Data Protection 2016/679).

Biobank and biomodels (BB)



Composition

Scientific Director:
Eduardo López Collazo (PhD)

Coordinator:
Marina Arranz Álvarez

Senior Experts in Pathology and Cytology:
Sandra Nieto Torrero
Yaiza Pedroche Just

HUB Organoids Manager
Laura Córdoba García (PhD)

Contact:
biobanco.hulp@salud.madrid.org
Phone: Biobank Laboratory (+34) 91 207 11 91

Scientific Committee
David Hardisson Hernáez (MD, PhD)
Enrique Espinosa Arranz (MD, PhD)
Olga Vera Puente (PhD)
Alicia Hernández Gutiérrez (MD, PhD)
Eduardo López Granados (MD, PhD)

Equipment

- Seven -80ºC deep freezers equipped with remote alarm temperature control and a CO2 backup system. Seven of these are equipped with an open door control software
- One tank of liquid nitrogen at its gas phase with an alarm temperature control and a lack of CO2 detector
- W-2D tube system with a data matrix codification for liquids, with a scanner to read col boxes and reader for the identification and the traceability of the tubes
- Combined refrigerator of 4° C y – 20° C
- Cryostat to cut frozen samples
- Microtome y bath/coating to cut paraffin samples
- Laser Microdissector
- Biological safety cabins IIA
- Centrifuge with capacity to process samples in tubes and Eppendorfs
- Automatic platform to manipulate and trace liquids
- One mini coolers to freeze inclined biological samples below 1°C
- Two containers to freeze and transport Isopentane
- One container for the transport of isopentame samples
- Vortex Mixer /agitator
- Spectrophotometer (Nanodrop®) – Located in AP service
- Fungibility: basically kits and the necessary products to process and preserve tissues, blood, and cells.
- Printer/photocopier/scanner
- 4 computers and a management computer system
- Label printing system and a bar code reader connected to the management software

Portfolio of services

HUB Biobank

Technical and scientific assessment:

- Collection and management of new collection
- Work Methodology/ Methods
- Quality control of DNA/ARN sample treatment
- Expert training to use Biobank management system
- Training and advice on the use of Biobank management software.
- Information to the investigator on the custody, deposit, availability and transfer of samples associated with the biobank.
- Training of trainees (FCTs) of training cycles.

Sample/collection management:

- Coordinating a collection of samples in multiple study/research centers
- Storage of pre-existing collections under LIB 14/2007.
- Storage of preexisting samples in accordance with Spain's Biobank laws LIB 14/2007 and 1716/2011 Royal Decree
- Management and control of Informed Consent (CI) and/or clinic's regarding samples
- Aliquot of blood/serum/plasma/other liquids
- Sample reception and codification

Histology techniques:

- Making paraffin block
- Making frozen tissue blocks
- Paraffin/frozen cuts
- Hematoxylin and eosin stain (H&E)
- Other kinds of stains
- Laser microdissection

Cell techniques:

- Purifying and freezing of mononuclear cells of peripheral blood (PMBCs)

Molecular Techniques:

- DNA and RNA quantification via spectrophotometer (NANODROP)

Researchers who wish to deposit their collections in IdiPAZ' Biobank will have to sign an agreement of sample deposit (in which the terms and conditions under which the Biobank will deposit the samples) and in agreement with the existing legislation on the subject. Also, researchers who wish to use our samples will have to sign a Transfer Agreement (Material Transfer Agreement) in which the terms and conditions under which the Biobank will grant the samples.

HUB Organoids

IdiPAZ´s Biobank is working on the establishment of a living biobank of organoid 3D models directly IdiPAZ´s Biobank is working on the establishment

of a living biobank of organoid 3D models directly generated from patient biopsies. Patient derived organoids (PDOs) are novel in vitro 3D cell models that preserve the molecular, structural and functional characteristics of their tissues of origin, representing a clinically-relevant alternative to traditional 2D cell lines and an effective tool to study the biology of human tissues in health and disease. Currently we have a comprehensive collection of over 70 highly characterized human intestinal organoids, including rectum and colon, derived from both healthy and colorectal cancer biopsy tissue. This organoid patient-derived collection includes a detailed description of associated patient clinical and pathological data of great value for translational research purposes, as well as histological and molecular characterization of both the tissue of origin and the resulting organoid cultures.

Areas of application

- Studies of tissue morphogenesis and organ development
- Modelling of infectious, genetic and inflammatory diseases
- Oncology and immuno-oncology
- Identification of diagnostic and prognostic biomarkers
- Drug screening for toxicity and efficacy
- Personalized and precision medicine

Portfolio of services

- Culture of human healthy intestine organoids derived from donor biopsies
- Culture of human tumoral intestine organoids derived from donor biopsies
- Paraffin/OCT embeding and sectioning
- Hematoxilin and eosin characterization
- Characterization by immunofluorescence and confocal microscopy of organoid sections and 3D organoids
- Cryopreservation and biobanking


Biobank's scientific indicators


I. Nº of samples

During the analysed period (January 2023 January 2024 – June 2025), the Biobank managed a total of **199,066** samples from various active nodes. This volume reflects strong sample collection and management activity, with a particular focus on strategic areas such as oncology, maternal and child health, infectious diseases, and autoimmunity.

Node	Place of origin	Preview-2023-Available	2023-Available	2024-Available	2025-Available	Total
Biobanco IdiPAZ	Banco de líquidos	2.107			2	2.109
Biobanco IdiPAZ	Banco de tumores	23.678	41	1.000	447	25.166
Biobanco IdiPAZ	Cardiología	1.050	9	287	121	1.467
Biobanco IdiPAZ	Dietética y nutrición	171				171
Biobanco IdiPAZ	Digestivo-Inflamatoria	5.049				5.049
Biobanco IdiPAZ	Hematología	170				170
Biobanco IdiPAZ	Inmunología	221				221
Biobanco IdiPAZ	Inmunología II	358				358
Biobanco IdiPAZ	Inmunología celular I	2.897				2.897
Biobanco IdiPAZ	Inve-Complemento	5.000	37	1.002	79	6.118
Biobanco IdiPAZ	Inve-Hepatología Molecular	2.388				2.388

Node	Place of origin	Preview-2023-Available	2023-Available	2024-Available	2025-Available	Total
Biobanco IdiPAZ	Inve-Ingeniería Celular	122				122
Biobanco IdiPAZ	Inve-Patología Oncológica	34.030	58	1.483	600	36.171
Biobanco IdiPAZ	Inve-Reumatología	50		12		62
Biobanco IdiPAZ	Medicina interna	496			45	541
Biobanco IdiPAZ	Microbiología	11.822		732	1.024	13.578
Biobanco IdiPAZ	Neonatología	1.143		84	15	1.242
Biobanco IdiPAZ	Neurología	2.183				2.183
Biobanco IdiPAZ	Nodo COVID	2.302		2.800		5.102
Biobanco IdiPAZ	Nodo central	3.270				3.270
Biobanco IdiPAZ	Obstetricia	31.160	2	17	4	31.183
Biobanco IdiPAZ	Organoides	444		25		469
Biobanco IdiPAZ	Psiquiatría	907				907
Biobanco IdiPAZ	SEIMC-GESIDA	10.945				10.945
Biobanco IdiPAZ	Tumor Inmunología	2				2
Biobanco IdiPAZ	Unidad de VIH	6.929				6.929
Biobanco IdiPAZ	Urología-Nefrología	19.032	253	4.866	3.195	27.346
INGEMM	INGEMM	358		12		370
Inve-hipersensibilidad	Inve-hipersensibilidad	7.807		50	29	7.886
Neonatología	Neonatología				2.951	2.951
Neurología	Neurología				416	416
Terapia Celular	Terapia Celular	958		282	24	1.264
Unidad de trasplantes digestivos	Digestivo-Inflamatoria				13	13
		177.049	400	12.652	8.965	199.066


Suma(Suma de muestras) vs Año Registro-Estado de la muestra por Nodo-Lugar de procedencia
Suma(Suma de muestras)
12k
10k
8k
6k
4k
2k
0
2024-Disponible
2025-Disponible
Biobanco IdiPAZ-Banco de líquidos
Biobanco IdiPAZ-Banco de tumores
Biobanco IdiPAZ-Cardiología
Biobanco IdiPAZ-Inve-Complemento
Biobanco IdiPAZ-Inve-Patología Oncológica
Biobanco IdiPAZ-Inve-Reumatología
Biobanco IdiPAZ-Medicina interna
Biobanco IdiPAZ-Microbiología
Biobanco IdiPAZ-Neonatología
Biobanco IdiPAZ-Nodo COVID
Biobanco IdiPAZ-Obstetricia
Biobanco IdiPAZ-Organoides
Biobanco IdiPAZ-Urología-Nefrología
INGEMM-INGEMM
Inve-hipersensibilidad-Inve-hipersensibilidad
Neonatología-Neonatología
Neurología-Neurología
Terapia Celular-Terapia Celular
Unidad de trasplantes digestivos-Digestivo-Inflamat


Suma(Suma de muestras) vs Lugar de procedencia por Estado de la muestra-Año Registro
Suma(Suma de muestras)
8000
7000
6000
5000
4000
3000
2000
1000
0
Disponible-2024
Disponible-2025
Banco de líquidos
Banco de tumores
Cardiología
Digestivo-Inflamatoria
INGEMM
Inve-Complemento
Inve-Patología Oncológica
Inve-Reumatología
Inve-hipersensibilidad
Medicina interna
Microbiología
Neonatología
Neurología
Nodo COVID
Obstetricia
Organoides
Terapia Celular
Urología-Nefrología

II. Number of Strategic Collections Created

At the Biobank, we consider strategic collections to be those that, in addition to complying with regulatory and quality requirements, are aligned with institutional, healthcare, or scientific priorities, and provide added value in the field of translational biomedical research. The criteria that define a strategic collection include:

- Public health relevance, such as highly prevalent, emerging, or closely monitored diseases (e.g., COVID-19, HIV, cancer).
- Integration into national or international research networks, consortia, or platforms, or involvement in competitively funded projects.
- Usefulness in personalized or precision medicine, through inclusion of detailed clinical data, biomarkers, or genetic/immunological profiles.
- Application of innovative technologies, such as organoids, cell therapies, advanced molecular biology, or tissue engineering.

As such, the strategic collections created during this period include:

- COVID Node
- HIV Unit / SEIMC-GESIDA
- Tumor Bank
- INGEMM
- Organoids
- UCICEC Node
- Inve-Molecular Hepatology
- Cell Therapy
- Inve-Cellular Engineering
- Psychiatry
- Neurology

These collections not only address current health needs, but also offer essential infrastructure for the advancement of high-impact biomedical research.

III. % of Collections with Standardized or Detailed Clinical Data

In accordance with Royal Decree 1716/2011 of November 18, which regulates the basic requirements for the authorization and operation of biobanks for biomedical research purposes—as well as the processing and transfer of human biological samples—all collections managed by a biobank must be associated with relevant clinical data, sufficiently standardized and coded to ensure their traceability and scientific utility in research.

In compliance with this regulation, and following the guidelines of Decree 9/2016 of the Community of Madrid, which governs the operation of biobanks at the regional level, it is guaranteed that 100% of the collections held by the Biobank include standardized or detailed clinical data, integrated into secure information systems and accessible for use in accordance with authorized scientific purposes.

IV. Compliance with ISO 9001:2015 and ISO 20387:2018

The Biobank was included in the Integrated Management System (SIG) of IdiPAZ/FIBHULP from January 20, 2020, until May 5, 2025, following the last external audit for ISO 9001:2015 conducted at the Institute. During this period, and in accordance with the Biobank's operational processes included in the system, the AENOR certificate ER-0512/2028 covered the following scope: "Reception, preparation, preservation, and distribution of human biological samples for biomedical research purposes under Biobank governance."

On May 20, 2025, the Quality Commission of IdiPAZ resumed meetings with Biobank representatives to initiate its reintegration into the SIG in preparation for the upcoming certification cycle scheduled for June 2026.

In parallel, the Biobank is actively preparing to meet the requirements of ISO 20387:2018, the specific accreditation standard for biobanks. Unlike ISO 9001:2015, this standard sets stricter requirements and must be accredited exclusively by ENAC, the national accreditation body. It is not a voluntary certification but a high-standard regulation aimed at ensuring technical competence and procedural quality. Although the Biobank's adaptation to ISO 20387:2018 is already well advanced, the formal application for accreditation has not yet been submitted. The defined strategy consists of first consolidating ISO 9001:2015 certification in the upcoming 2026 cycle and, once achieved, progressing toward ISO 20387:2018 accreditation as the next step.

V. Publications with the mention of IdiPAZ Biobank authorship attribution

FILE	CENTRE	DOCUMENT REFERENCE	MONTH	YEAR	RECOGNITION IN
PT23/00028	INSTITUTO DE INVESTIGACION HOSPITAL UNIVERSITARIO LA PAZ (IdiPAZ)	**Comprehensive analysis of relapsed-refractory mature B-cell non-Hodgkin lymphoma in children and adolescents** Mato S, Carità L , Colmenero A, Andrés M, Balagué O, Andión M, Astigarraga I, Celis V, Mendoza C, Guerra-García P, Valero L, Galera A, Tallón M, Pol M, Castrejón-de-Anta N, Frauenfeld L, Garcia N, Campo E, Salaverria I, Verdú-Amorós J **Br J Haematol**. 2025;00:1–7. DOI: 10.1111/bjh.20012	February	2025	Agradecimientos
PT23/00028	INSTITUTO DE INVESTIGACION HOSPITAL UNIVERSITARIO LA PAZ (IdiPAZ)	**Biomarker and clinical data–based predictor tool (MAUXI) for ultrafiltration failure and cardiovascular outcome in peritoneal dialysis patients:a retrospective and longitudinal study** Arriero-País E.M, Bajo-Rubio MA,Arrojo-García R, Sandoval P, González-Mateo T, Albar-Vizcaíno P, del Peso-Gilsanz G, Ossorio-González M, Majano P, López-Cabrera M , Redes de Investigación Cooperativa Orientadas a Resultados en Salud (RICORS 2040-Renal) **BMJ Health Care Inform** 2025;32:e101138. doi:10.1136/bmjhci-2024-101138	February	2025	Métodos
PT23/00028	INSTITUTO DE INVESTIGACION HOSPITAL UNIVERSITARIO LA PAZ (IdiPAZ)	**Fatty acid uptake activates an AXL–CAV1–β-catenin axis to drive melanoma progression** Chocarro-Calvo A, Jociles-Ortega M,García-Martinez J.M, Louphrasitthiphol P, Carvalho-Marques S, Vivas-García Y, Ramírez-Sánchez A, Chauhan J, Fiuza M.C, Druan M, Sánchez-Danés A, R. Goding C and García-Jiménez C **Cold Spring Harbor Laboratory Press**; ISSN 0890-9369/25 doi:10.1101/gad.351985.124	February	2025	Mat&Met Agradecimientos

FILE	CENTRE	DOCUMENT REFERENCE	MONTH	YEAR	RECOGNITION IN
PT23/00028	INSTITUTO DE INVESTIGACION HOSPITAL UNIVERSITARIO LA PAZ (IdiPAZ)	**A prognostic microRNA-based signature for localized clear cell renal cell carcinoma: the Bio-miR study** Pinto-Marín A, Trilla-Fuertes L, Miranda Poma J, S. Vasudev N, García-Fernández E, López-Vacas R, Miranda N, Wilson M, López-Camacho E, Pertejo A, Dittmann A, Kunz L, Brown J, Pedroche-Just Y, Zapater-Moros A, de Velasco G, Castellano D, González-Peramato P, Espinosa E, E. Banks R, Fresno Vara J.A and Gámez-Pozo A **British Journal of Cancer** https://doi.org/10.1038/s41416-025-03008-2	May	2025	Mat&Met Agradecimientos Co-autora (Yaiza)



2.5.1.3. UCICEC

The Central Unit for Clinical Research and Clinical Trials of La Paz Hospital (UCICEC-HULP) is one of IdiPAZ's research support platforms. The UCICEC-HULP was created with funding from the Ministries of Health and Consumer Affairs and Science and Innovation to establish research support structures. It is currently part of the Spanish Clinical Research Network (SCReN).

Objectives

The fundamental objective of the UCICEC La Paz is to establish a clinical research support infrastructure at La Paz University Hospital capable of promoting the health and well-being of its citizens. To this end, it has the human and material resources, as well as operational and functional procedures that enable it to achieve its objectives:

- Clinical research and its projection into healthcare development and innovation.
- Contribute to the resolution of healthcare problems.
- Promote participation in national clinical research activities, especially those included in the European Framework Programmes for R&D&I.
- Promote the transfer of the results of clinical research processes into clinical practice.

Its broad portfolio of services offers support to researchers in the design, implementation (submission to CEIC and regulatory agencies), as well as management, analysis, and report writing of clinical trials and research projects.

Clinical Trial Coordination tasks are also performed, assisting researchers in the preparation and evaluation of their feasibility, administrative tasks (i.e., research coordination, visit scheduling management, etc.), audit and inspection preparation, as well as data and adverse reaction management tasks.

Nursing tasks are also performed (sample collection, processing, and shipping). All activities are carried out in accordance with Good Clinical Practice (GCP) standards. The UCICEC-HULP also has a Phase I-II Clinical Trials Unit that allows for the conduct of early-phase clinical trials in both healthy volunteers and patients.

The UCICEC-HULP is located in the Traumatology-Outpatient Clinic Building on the Semi-Basement Floor (next to Rehabilitation) and is equipped with facilities to support clinical research, such as a monitoring room, a medical consultation room, a meeting room, a laboratory/centralized sample collection point, work offices, and a multipurpose room. The Phase I Unit has eight inpatient beds and four patient chairs.



Composition

Responsible
Dr. Antonio J. Carcas

Technical Coordinator
Dr. Alberto M. Borobia
alberto.borobia@salud.madrid.org
Phone: (+34) 912 071 466

Head of Pharmacovigilance
Dr. Irene García

Quality Manager
Blanca Duque

Researchers / Pharmacologists
Dr. Alicia Marín
Dr. Arturo Gómez
Dr. Javier Guijarro
Dr. Irene García
Dr. Mikel Urroz

International Projects
Paloma Moraga
Paula Valle
Belén Ortíz
Cristina Marián
Amelia Brieva
Julia Molla

National Projects
Rocío Mª Prieto
Suriñe Valdespina
Noa Baz
Paula Gómez
Celia Cano

Data Entry
Silvia Llorente
Beatriz Llorente
Sira Alonso

SCReN - Spanish Clinical Research Network
Victor Alelú
Victoria Hernandez
Maria Jose Rubira
Gema de Prado
Amparo Sanchez

Nursing Supervisor
Tamara Domingo

Nursing Team - Trial Coordination
Vega Mauleon
Cristina L.
Laura Viton
María A.
Ana O.

Internist
Carlos Oñoro

Pediatric Hemato-Oncology
Andrés Gómez
Zaza Ceballos
María García

Waste Management
Eduardo Royón

Laboratory Technician
Pilar Ayllón

Secretaries
Cristina Miragall
cristina.miragall@salud.madrid.org
Laura Lozano
Marta Alonso
Phone: (+34) 912 071 466



Operation

Any researcher at the hospital can request assistance related to the conduct of clinical trials involving medicines or medical devices, post-authorization studies, etc., and at any stage of these studies (before the start of the trial, during its implementation, or after the completion of the clinical phase); the researcher will be provided with the necessary support in accordance with the UCICEC's service portfolio. Furthermore, the UCICEC's facilities are available to the hospital's researchers so they can carry out various activities related to any study.

Finally, the clinical trials unit at UCICEC La Paz has the necessary infrastructure to conduct both independent and commercial intervention studies requested by hospital researchers or other external sponsors.

Facilities

- Administrative Zone:
  - Nursing Office and Trial Coordinators
  - Secretary's Office
  - Coordinator's Office
  - Two work offices
  - Monitors' office
  - Archive (Basement Floor, 34m2)
  - Staff restroom
- Laboratory Area
  - Medication storage and preparation area.
  - Laboratory for the collection, handling, and storage of biological samples with refrigerated centrifuges and -20 and -80°C freezers with recorded temperatures.
- Participants Area
  - Hospitalization area with 8 beds distributed in two boxes
  - Nursing control with area for managing medical waste and washing materials.
  - Two queries
  - Bathroom with shower for participants
  - Rest area for participants
  - Office

The UCICEC also has satellite offices in the Clinical Pharmacology Center of the UAM Faculty of Medicine (International Project Management), in the IdiPaz building (National Project Management), and in the library building (Biostatistics and Data Management) of La Paz University Hospital.

Services Portfolio

- Scientific advice and methodological support
  - Preparation of protocols
  - Preparation of the final report
  - Preparation of expert reports
  - Scientific advice
  - Publication of results
- Development of Clinical Trials
  - Coordination of clinical trials
  - Help recruit patients
  - Medical and nursing procedures
  - Management of shipment of biological samples
- Academic CRO Activities (ARO and SCReN)
  - Clinical trial management
  - Start-up activities of the studies
  - Development of monitoring plans
  - Monitoring of clinical trials
  - Preparation of statistical analysis plans
  - Development of data collection notebooks
  - Statistical analysis
  - Planning pharmacovigilance activities
  - Development of clinical trial pharmacovigilance
  - Data Entry Activities

2.5.2. IdiPAZ Platforms

2.5.2.1 Biostatistics and Bioinformatics

The Biostatistics and Bioinformatics Platform is a pioneer in the field of research support in hospitals and performs work that is recognised by the vast majority of professionals who, for several decades, have requested statistical advice for their research work or for other studies with immediate application to healthcare practice.

The Biostatistics and Bioinformatics Platform aims to provide high-quality support for research, providing statistical consulting services for research projects or other studies with immediate application in clinical practice.

It is structured into three areas:

- Observational studies
- Clinical trials
- Data management and development of case report forms (eCRFs)

Portfolio of services Biostatistics

- Consulting on the methodological design of research projects and clinical trials, drafting protocols and statistical analysis plans.
- Sample size determination for clinical trials and research projects.
- Data analysis of research projects and clinical trials, writing interim and final reports, and futility analysis.
- Data management of research projects and clinical trials, eCRD designs in Macro and REDCap, writing data management plan and data validation plan.
- Development of software solutions dedicated to the extraction and pre-processing of data in information systems.
- Support for the interpretation of scientific publications and their applicability in clinical practice.
- Evaluation and validation of diagnostic tests.
- Design of clinical scales and scores.

Composition

Director:
Alberto M. Borobia. MD, PhD
alberto.borobia@salud.madrid.org
Phone: (+34) 912 071 466

Clinical Biostatisticians:
María Jiménez González
maria.jimenez.gonzalez@salud.madrid.org

Vega Rey Mauleón
vega.rey@salud.madrid.org
María Martínez Balaguer
mmbalaguer@salud.madrid.org

Itsaso Losantos García
itsaso.losantos@salud.madrid.org

Odelaisy León Triana
odelaisy.leon@salud.madrid.org
Phone: 917 277 000 (ext: 442617)

Clinical epidemiologist:
Jesús Díez Sebastián. MD, PhD.
jdiezseb@salud.madrid.org
Phone: 917 277 000 (ext: 447570)

Data Managers:
María Teresa García Morales
mariateresa.garcia.morales@salud.madrid.org

Francisco Gayá Moreno
francisco.gaya@salud.madrid.org

Elisa Medrano Buendía
elisa.medrano@idipaz.es
Phone: 917 277 000 (ext: 442616)

Bioinformatics:
Carlos Rodríguez Antolín
crodrigueza@salud.madrid.org

Antonio Giráldez Trujillo
Claudia Sánchez Lara
Beatriz Ruz Caracuel
Lucía de Dios Blázquez
Pamela Karime Heredia G. Canton

Portfolio of services Bioinformatics

- Experimental design. Advice on sample size, study design and methodology planning.
- Data analysis. Bioinformatics processing of the data obtained is performed on various high-performance technological platforms used in the field of genomics. These analyses include normalization, statistical analysis, and representation of the results. The most common analyses are:
  - Differential expression of genes, miRNAs, or lncRNAs. The technology used for experiments can be microarrays (Affymetrix, Agilent) or RNA-seq (Illumina, Ion Torrent).
  - Protein-DNA interactions from immunoprecipitation experiments and microarrays (ChIP-chip) or sequencing (ChIP-seq).
  - It helps interpret results. Once the genes of interest have been selected, biological-functional assignment studies are performed, such as the functional enrichment study of gene/protein lists.
  - Design, implementation and administration of databases (e.g. patients, samples, etc.).
  - Individualized training activities: Training for users (scientists/technicians) on the main theoretical and practical foundations for managing results and their interpretation.

Biostatiscs Activity in 2024

In 2024, ISO 9001:2015 certification was achieved for the activities carried out by the Biostatistics Platform.

In 2024, there were 227 requests (almost 150% more than in 2023).

Services requested	Number of requests
Methodological design consulting	54
Sample size calculation	44
Data analysis	183
eCRD design	26

The response time to the request registered by the investigador through the Platform is 48-72 hours.

Within the IDIPAZ MENTOR program, the Biostatistics Platform provides support to investigators reviewing proposals, calculating sample sizes, and providing methodological advice. In 2024, 103 applications were received for the MENTOR program.

The Biostatistics Platform is fully integrated with ISCIII platforms such as SCReN (Spanish Clinical Research Network), providing support in methodological, data management and statistics tasks for national and international clinical studies.



2.5.2.2. Experimental surgery

The Experimental Surgery Section includes a microsurgery room, an operating room, an animal facility, and service areas (changing rooms, office, and staff room). The microsurgery room is used for performing microsurgical procedures on small species, mainly rodents. It is equipped with surgical microscopes, inhalation anesthesia systems, and cardiovascular monitoring. It also has mobile tables and fixed benches that allow for flexible arrangements, making it versatile for both microsurgery courses and laparoscopic simulation.

The operating room is fully equipped with complete surgical stations: surgical tables, anesthesia stations, and cardiovascular monitoring systems. It also has laparoscopic, ultrasound, and X-ray equipment. This room is used for all procedures involving large animals (rabbits, pigs, or sheep), as well as training courses in various specialties such as laparoscopic surgery, anesthesia, trauma care, and the development of surgical techniques.

The animal facility has 7 conventional housing rooms plus 2 SPF rooms, handling rooms for large species and rodents. It also has specific equipment for washing and disinfecting housing materials.

Animal facility

Research and teaching at IdiPAZ involving the use of laboratory animals are managed through the experimental surgery platform of IdiPAZ, supervised by Dr. Carlota Largo Aramburu. This department develops biomedical research projects, specialized training courses in various areas, as well as procedures to implement new diagnostic techniques or therapies involving the use of experimental animals. Additionally, it collaborates with the Ethics Committee for Animal Welfare, whose authorization is necessary for all procedures.

The animal facility is located in basement 2 of the IdiPAZ building within the hospital complex. It has a total of 9 rooms for housing animals, both in breeding and experimental phases, plus 2 rooms for handling animals and experimental procedures, and 2 rooms for washing materials, which include a cage washer, an autoclave, and a pressure washing system. To ensure its proper functioning, it is connected with the rest of the Experimental Surgery departments, which include a double operating room, a microsurgery room, and various additional rooms (changing rooms, offices, and storerooms).

The species typically used include rodents (rats, mice, and gerbils), rabbits, pigs, sheep, and goats, and occasionally dogs, cats, or guinea pigs. There is also a housing unit for fish (zebrafish). To avoid contamination and ensure an efficient workflow, the rooms for housing large animals are physically separated from those for rodents and the rest of the facilities (washing area, storerooms, or handling room). Additionally, all rooms are equipped with an external video camera system to monitor the interior and avoid unauthorized personnel entry.

The cages provide the minimum dimensions required for housing pigs and/or small ruminants. The structure





of each cage includes stainless steel anchored to the wall, with sliding separators that allow the expansion of space by joining two cages. The rooms have the necessary slope to encourage the elimination of solid residue through a drain located at the rear of the cage, equipped with protection systems to prevent the entry of rodents or insects. For cleaning the room and the animals, there are hot and cold water connections via hoses.

The rabbit room includes modular mobile racks of 3, 6, or 9 cages, in which the rabbits are housed in individual stainless steel cages with plastic grids, complemented by an internal box structure that allows the animals to hide or climb to a higher position. The stainless steel feeders and water drinkers are located in the cage door, with a removable stainless steel tray to collect feces and urine. This room has a central drain similar to the facilities for large animals.

The rodent area is separated from the rest of the facility by a system of doors without locks, where staff can dress appropriately before entering (boots, gown, gloves, cap, and mask). This area contains 3 rooms for housing rats and mice. There is also a storeroom for food and shavings, as well as a room for handling and performing procedures.

In addition to the two large animal areas, the facilities include: a washroom equipped with a cage washer (Matachana), a stainless steel pool, and an autoclave. It also has a pressure washing system for cleaning the cages and/or visitors who require it.

A recently incorporated SPF area for immunodeficient mice with capacity for 4 ventilated racks, a housing area for them, and an SPF laboratory. This room is located in an isolated area within the biocontainment facility, with restricted access and airlock systems to prevent the entry of pathogens. The door has controlled access and features a HEPA filtration and ventilation system for both incoming and outgoing air, ensuring the air circulates without introducing pathogens.

The animal facility complies with all current legislation and is registered under number ES-280790001941.

Composition

Section Head:
Carlota Largo Aramburu
Phone: (+34) 91 207 15 81

Veterinarian:
Carlota Largo Aramburu
carlota.largo@salud.madrid.org
Phone: (+34) 91 207 15 81

Secretary:
Irene Cuevas Gordo
irene.cuevas@salud.madrid.org
Phone: (+34) 91 727 71 54





Technicians and assistants:
Maria del Mar Varona García
Fernando Gil Villaverde
Rubén Ruiz Garzón
Paloma Guijarro Bachiller
María del Carmen Rius Copoví
Lourdes Hernanz del Álamo
Elena Martín de Castro

Portfolio of services

- Animals for experimentation (own breeding)
- Housing and maintenance of animals
- Leasing of spaces for conducting courses (microsurgery laboratories and operating room)
- Performance of surgical procedures on large animals (leasing space and anaesthesia, does not include surgery)

Animal experimentation projects approved by the competent authority in 2024.

- "CHARACTERIZATION OF THE IMMUNOSUPPRESSIVE FUNCTIONS OF MAFG IN MELANOMA AND THEIR POTENTIAL IMPLICATIONS FOR CANCER THERAPY". Dra. Olga Vera Puente.

Currently, there are 18 investigations with living experimental models.

Training activity

The experimental surgery platform has hosted 30 training activities in addition to the fine-tuning of new surgical techniques or medical device and the training of multidisciplinary teams and residents.



2.5.2.3. Internationalisation

The Internationalisation Platform of IdiPAZ is the office in charge of mobilising, promoting and managing the international projection of the research groups. Our continuous objective is to promote the different research groups that make up the institute at an international level, identifying possible synergies between groups and centres, new partners and sources of funding, as well as the formation of strategic alliances. To this end, we try to maintain open dialogues, not only with our researchers but also with the policy centres involved in the designing and planning the future of research in the European Union.

Throughout 2024, the Platform has relied on the efforts of:

José Luis Narro Villanueva, Mba
Santi Rello Varona, Phd
Marta Casales Santa

During 2024, the Internationalisation officers have navigated the increasing effort required to apply with success to Horizon Europe (HE), while managing the 30 internationally funded projects active during the year. We have attended 54 events, workshops and information days concerning the deployment of new rules, tips for proposal preparation, brokerage events and the deployment of new standards of international research and innovation.

In addition, we have organised and performed six training courses, workshops or research stages.

In 2024, we explored our involvement in 30 initiatives, which translated into 19 proposals for competitive international research public funding (HE, EU4HEALTH and Partnerships) of which, six new projects were granted. These results cement our consolidation in the European Research Area.

One of those granted projects, READI (starting on 2025), will be coordinated by the institute, through our Clinical Trials Unit. This project, with more than 68 million euro of budget and 73 partners across the world, will explore how to ensure the integration of underserved populations in clinical trials to enhance the gathering of medically relevant evidences.

Besides, the Platform's staff participates directly in the IdiPAZ involvement in the Experts' Group assessing the Spanish National Representative for EU Health Research and the Coalition on Advancement of Research Assessment (CoARA). Within CoARA, we have been preparing the IdiPAZ Action Plan for reforming our research assessment. In addition, in 2024 the Platform assumed the management of IdiPAZ participation in EIT-Health and EIC. Finally, the Internationalisation Platform takes an active role in those projects coordinated or of the strategic importance for the institute: RISEinFAMILY, the ERN TransplantChild and JARDIN.

Throughout 2024 we have managed the following financed and active international projects:

Project		Programme	Logo
ASSIST	AI-powered triage of acute myocardial infarction and chronic heart disease	EIT-HEALTH	ASSIST
CARE	Corona Accelerated R&D in Europe	IMI	CARE
CLARITY	Causative Link between respirAtory syncytial viRus and chronic lung diseases: Identifying Targets for therapY	HE	CLARITY
CORDIAL	Clinical validation of a continuous flow peritoneal dialysis system, with dialysate regeneration	H2020	CORDIAL
EHRA-PATHS	Addressing multimorbidity in elderly atrial fibrillation patients through interdisciplinary, tailored, patient-centred care pathways	H2020	EHRA-PATHS
ERA4HEALTH	Fostering a European Research Area for Health Research	HE	ERA4Health Partnership
ERA4TB	European Tuberculosis Regimen Accelerator	IMI	ERA4TB
ERICA	European Rare Disease Research Coordination and Support Action	H2020	ERICA
ERN BOND	European Reference Network on Rare BONe Diseases 2023-2027	EU4HEALTH	ERN BOND
EUnetCCC	The European Comprehensive Cancer Centre Network	EU4HEALTH	EUnetCCC

Project		Programme	Logo
EU-RESPONSE	European Research and Preparedness Network for Pandemics and Emerging Infectious Diseases	H2020	EU RESPONSE
FOSTREN	Fostering and Strengthening Approaches to Reducing Coercion in European Mental Health Services (CA19133)	COST	FOSTREN
HosmartAI	Hospital Smart development based on AI	H2020	HOSMARTAI
iroNKiller	Joining the forces of Natural Killer Cells and Ferroptosis to treat Refractory Neuroblastoma	HE-MSCA	IRONKILLER
ISIDORe	Integrated Services for Infectious Diseases Outbreak Research	HE	ISIDORe
JARDIN	Joint Action on ERN Integration	EU4HEALTH	JARDIN
LIVERATION	Unravelling the impact of Radiofrequency in liver surgery: the key to decrease local recurrence?	HE-MISSION CANCER	Liveration

Project		Programme	Logo
MPX-RESPONSE	A clinical research network to improve the management of Monkeypox virus disease.	HE	MPX-RESPONSE
ORTHO-ALLO-UNION	ORTHOpaedic treatment with ALLOgenic combined ATMP in long bone fracture delayed UNION and nonunion	HE	Ortho Allo Union
RELECOV 2.0	Consolidation of WGS and RT-PCR activities for SARS-CoV-2 in Spain towards sustainable use and integration of enhanced infrastructure and processes in the RELECOV network	EU4HEALTH	RELECOV
RESPIN-VAR	REstoring balance: Specialized Proresolvin mediators for resolution of INflammation and VAscular Repair in humans at high cardiovascular risk	PARTNERSHIP-ERA 4HEALTH	RESPIN-VAR
RESPOND	Improving the Preparedness of Health Systems to Reduce Mental Health and Psychosocial Concerns resulting from the COVID-19 Pandemic	H2020	RESPOND
RISEinFAMILY (Coordinated by IdiPAZ)	Alliance for Family Integrated Care (FICare) Implementation in Neonatal Intensive Care Units	H2020-MSCA	RISEinFAMILY

Project		Programme	Logo
SHIELD	Strategic Health Initiatives for Effective Disease Prevention	HE	SHIELD
SPIDeRR	Stratification of Patients using advanced Integrative modeling of Data Routinely acquired for diagnosing Rheumatic complaints	HE	SPIDERR
TransplantChild 2023-2027 (Coordinated by IDIPAZ)	ERN TransplantChild 2023-27	EU4HEALTH	European Reference Network TransplantChild
UNDINE	The human genetic and immunological determinants of the clinical manifestations of SARS-CoV-2 infection: Towards personalized medicine.	HE	UNDINE
VACCELERATE	European Corona Vaccine Trial Accelerator Platform	H2020	VACCELERATE
VERDI	SARS-coV2 variants Evaluation in pRegnancy and paeDIatrics cohorts	HE	VERDI

2.5.2.4. Documentalist

The documentalist platform is responsible for the analysis, maintenance and dissemination of the scientific production generated by the Institute. This production is collected both in the bibliometric reports that are published on the IdiPAZ website as well as in the Institute's Research Report which is published annually and in which all the research activity of our research groups is collected. Also key is the support of the unit to the scientific management when carrying out internal evaluations of researchers or research groups.

The platform provides support to all IdiPAZ researchers when performing bibliographic searches, managing ORCID, CVN or different researcher profiles, advising on scientific evaluation, advising on quality criteria for scientific publications and any training related to this service.

This platform has also played a key role in publicizing and promoting open access policies, as well as participating in the initiatives carried out by public institutions for the creation of institutional repositories.

Through the documentalist, IdiPAZ members can print the posters that will be used to disseminate the results of their research at the congresses of their specialties.

Since 2018, the Documentalist Platform of IdiPAZ was certified according to the ISO 9001:2015 quality management system standard ES-0512/2018.

Objetives

The main objectives of the platform are:

- To show society the relevance of scientific research conducted at IdiPAZ.
- Facilitate transparency and maximize the impact of the scientific production of the institute.
- Collaborate in the transmission of knowledge generated in the IdiPAZ environment.

Composition

Head:
Raúl Román Cañizares
documentalista@idipaz.es
Phone: (+34) 91 727 75 76

Portfolio of services

- Elaboration of Research Report: Design of forms to collect information, bibliographic searches and calculation of bibliometric indicators.
- Collaboration with researchers: Collaboration with research personnel in the search and location of documents useful for their research.
- Elaboration of bibliometric reports: Creation of control tools to keep a record of the Institute's publications.
- Evaluation of researchers: Calculation of bibliometric indicators for decision making in calls where there is a quota of researchers.
- Bibliometric evaluation of research groups: Calculation of bibliometric indicators to determine the scientific production of both established IdiPAZ groups and new groups for their subsequent inclusion in the Institute.
- Advice on bibliographic search tools: Help in the knowledge of the different valid tools for conducting bibliographic searches in specialized databases.
- Advice on the use of bibliometric techniques: Assistance in the knowledge and application of bibliometric indicators to scientific production.
- Poster printing for congresses

2.5.2.5. Flow Cytometry Laboratory

Flow Cytometry Laboratory

The Flow Cytometry Core is an integrated facility into the Hospital La Paz Institute for Health Research (IdiPAZ), that provides all its members and external groups access to affordable and high-quality flow cytometry services, along with decisively scientific expertise using this technology in research.

We highlight a wide variety of flow cytometry applications: phenotypic analysis of cellular subpopulations using extracellular and intracellular staining, preliminary studies for subsequent clinical application, complex multicolor flow cytometry analysis, etc. This technology is an indispensable biomedicine tool, promoting symbiosis between clinical and basic researchers, as well as cooperation with external institutions.

The services provided include:

- Theoretical seminars and hands-on workshops training.
- Scientific and technical support.
- Experimental design, data analysis and interpretation assistance.
- Development of novel multicolor flow cytometry techniques assistance.

EQUIPMENT

Currently, the unit has three analyzers:

- Two Becton Dickinson FACSCalibur™ cytometer analysers:

A system that supports a wide variety of research and clinical applications and is complemented by a broad suite of intuitive software solutions to streamline analysis for a wide range of applications including enumeration of lymphocyte subsets, stem cells, residual white blood cells, and reticulocytes.

Each analyser has two lasers: Blue argon laser (3 detectors), and Red solid state Diode (1 detector), with which FACSCalibur™ can analyse four colors simultaneously.

- One Becton Dickinson FACSCelesta™ cytometer analyser:

It is designed to make multicolored flow cytometry more accessible and allow researchers to benefit from new equipment and reagent technological innovations. These optical and reagent technology parallel advances allow multi-laser equipment to complement with new bright fluorochromes, providing a deeper and more powerful insight into cell analysis.

This analyser has three lasers: Blue solid state Diode (4 detectors), Violet solid state Diode (6 detectors), and Ultra Violet solid state Diode (2 detectors), with which FACSCelesta™ can analyse twelve colors simultaneously.

These support a wide range of flow cytometry applications, and the possibility of developing new ones responding to facility needs and/or upon users demand. In addition, during the current year, the Flow Cytometry Core endured quality levels required according to ISO 9001:2015 standard.

Composition

Head
Kilian Gutiérrez Viñas
kilian.gutierrez@idipaz.es
Phone: (+34) 91 727 00 00 (ext. 441021)

Secretary
Susana García Pérez
investigcion.hulp@salud.madrid.org
Phone: (+34) 912 071 512


1 Introduction


2 Executive summary


3 Research areas and groups

4 Associated clinicians

INDICATORS







2.5.2.6. Cell Cuture Unit

The Cell Culture Unit has been established as a core support division that is integrated into and supported by the Hospital La Paz Institute for Health Research (IdiPAZ) and La Paz University Hospital (HULP). This unit facilitates the establishment and management of in vitro model systems and the application of experimental techniques for various research purposes. These include the elucidation of molecular and cellular mechanisms involved in several biological processes, the prediction of cellular and tissue responses to specific microenvironments and the identification and development of potential therapeutic drugs, compounds, or cellular targets. Therefore, this platform provides a fundamental basis for the development of research initiatives in the fields of Health Sciences and Biomedical and Pharmacological Research.

Objetives

The Cell Culture Unit accomplishes its mission by providing users with assistance and support at the scientific, technical and instrumental levels through access to knowledge, equipment, materials, and human resources. According to IdiPAZ strategic plan and other institutional guidelines, this division contributes to the translation of biomedical research by fostering synergies and cooperation among traslational-oriented research groups belonging to IdiPAZ as well as with external institutions. It also provides a dynamic and shared operational environment that serves as a foundation for the exchange and dissemination of the scientific knowledge, innovation and creativity as well as fostering collaborations and alliances among researchers from various fields and disciplines. Moreover, the association and proximity to other IdiPAZ core facilities such as the Molecular Imaging and Immunohistochemistry Unit, the Flow Cytometry Unit, and the BSL2-Virology Unit, enable users to develop complementary techniques, explore and refine research hypotheses, and extend or improve their objectives.

Composition

Coordinator:
Gema Vallés Pérez (PhD)
e-mail: gema.valles@salud.madrid.org
Phone: (+34) 917277000 (ext. 441576)

Technician:
Eva Jaraba Redondo
Phone: (+34) 917277000 (ext. 442142)

Secretary:
Susana García Pérez
Phone: (+34) 91 207 15 12
investigacion.hulp@salud.madrid.org

Equipment and facilities

The Cell Culture Unit consists of an experimentation laboratory, a cryopreservation room and a warehouse. All facilities are located in the IdiPAZ building.

The experimentation laboratory was fitted in 2024 with the following equipment:

Cabinets:

4 Telstar Bio-II-A biological safety cabinets
2 Telstar Bio-II Advanced 3 biological safety cabinets
2 Nuaire NU-437-400E biological safety cabinets
1 Heraeus HS-12 biological safety cabinet
1 Faster BH-EN 2004 biological safety cabinet
1 Gelaire BSB 4A biological safety cabinet
1 Esco Class II BSC biological safety cabinet
1 Labogene Mars Pro 1200 biological safety cabinet
1 Faster BIO 48 vertical laminar flow cabinet
1 Telstar Bio II Advance Plus biological safety cabinet

Incubators:

3 Thermo Forma 311 incubators
2 HERAcell incubators
1 Biotech Galaxy S incubator
3 Nuaire Autoflow incubators
1 Sanyo O2/CO2 incubator
1 POL-EKO incubator
1 Binder CB-S 260 incubator

This equipment is complemented with a centralized and alarmed gas system, which guarantees a constant and controlled supply of CO2 and N2.

Microscopes:

1 Nikon DIAPHOT TMD inverted light microscope connected to a Nikon D80 digital camera.
1 Leica DMIL inverted light microscope connected to a Canon Powershot S70 digital camera.
1 Optika inverted light microscope

1 Motic AE2000 inverted light microscope connected to an automatic counter Celeromics
1 Lan Optics inverted light microscope

Centrifuges:

2 Eppendorf 5810R refrigerated centrifuges
2 Eppendorf 5804 centrifuges
1 Hettich Universal 32R refrigerated centrifuge
1 Kubota 2010 centrifuge
1Eppendorf 5415D centrifuge
1 Heraeus Megafuge 1.0 R centrifuge

Freezing and refrigerating systems:

5 Liebherr refrigerators (4 ° C and -20 ° C)

Other equipment:

1 Presoclave 75 P-Selecta autoclave
1 Heidolph Reax 2000 vortex
1 Raypa BAE-4 thermostatic waterbath
1 Memmert WNB thermostatic waterbath
2 P-Selecta Precisterm thermostatic waterbaths
1 Grant JB Aqua 12 Plus thermostatic waterbath
Vacuum pumps, pipettes, counters, automatic pipettors, freezing containers, cell counting cameras, etc ....

The cryopreservation room is equipped with:

2 Statebourne Biorack 3000 liquid nitrogen tank
1 Thermo Locator 6 Plus liquid nitrogen tank
1 10 K Taylor Wharton liquid nitrogen tank
1 MVE Cryosystem 4000 liquid nitrogen tank
1 Cryo Diffusion B2016 liquid nitrogen tank
1 Cryo diffusion B2048 liquid nitrogen tank
1 Cryo Diffusion B2011 liquid nitrogen tank
1 SEO GT40 liquid nitrogen tank
1 MVE XLC 511 liquid nitrogen tank
1 Cryo Plus 7405 liquid nitrogen tank
1 Worthington LS SERIES liquid nitrogen tank
1 VWR 1478-0274 liquid nitrogen tank
1 Arpege 110 liquid nitrogen tank
1 Arpege 70 liquid nitrogen tank
1 Arpege 140 liquid nitrogen tank

The infrastructure for cryopreservation is completed with a liquid nitrogen transfer device and an alarmed Oxygen O2 detector coupled to a mechanical ventilation system.

Portfolio of services

In general, this Division offers support for experimental approaches across an extensive range of areas including cell experimentation, consumables and reagents, equipment and laboratory, technical assistance, training and research.

The main aspects of this support include:


- Scientific and technical advice, personalized support and consultation: guidance on experimental setup and design, study planning, optimization of techniques and protocols, acquisition of reagents and materials, cell supply, troubleshooting, and analysis and interpretation of results.
- Basic training and hands-on experiments (encouraging the self-service) in accordance with biosafety, waste disposal and good laboratory practice guidelines.
- Access to facilities, including instrumentation, equipment, materials and reagents.
- Preparation and supply of specific materials, reagents and sterile solutions.
- Management and general supervision, including good laboratory practices and work habits, occupational health and safety, cleaning and waste disposal, and operation and maintenance of equipment.
- Performance of experimental procedures, incuding establishment, maintenance, and propagation of cell lines and primary cultures, cryopreservation and resuscitation, and assessment of cell viability and proliferation.
- Control and maintenance of cryopreserved stock cells.
- Elaboration and management of protocols and guidelines, standard operating procedures, reports and other required documentation.
- Detection, identification and treatment of contaminations in cell cultures.


The Cell Culture Unit was certified in accordance with the ISO 9001:2015 quality management system standard within the scope of the IQNet Certificate issued to the INSTITUTO DE INVESTIGACIÓN SANITARIA DEL HOSPITAL UNIVERSITARIO LA PAZ (Certificate No. ES-0512/2018).

The personnel associated with the Unit express their gratitude to the users and collaborating users and staff who have contributed directly or indirectly to this achievement.

Cell Culture Unit´s scientific indicators

USERS: Distribution according to academic profile and IdiPAZ research areas






PROJECTS: Distribution according to IdiPAZ research areas

139 PROJECTS

57 FUNDING INSTITUTIONS



1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

Collaborations: Cooperative Health Research Networks & CIBER



International Collaborations



2.5.2.7. Molecular Imaging and Immunohistochemistry Unit

The Molecular Imaging and Immunohistochemistry Unit is a core facility at IdiPaz dedicated to supporting basic, clinical, and translational research by providing state-of-the-art instrumentation and expert technical assistance in histology, immunohistochemistry, and bioimaging. The Unit's strategic mission aligns with IdiPaz's institutional objectives to optimize research infrastructure, promote continuous professional development, and drive innovation through the integration of advanced methodologies in biomedical research.

The Unit is composed of two specialized laboratories: the Immunohistochemistry Laboratory, located on the first floor of the IdiPaz building, and the Microscopy Laboratory, situated on floor -1. The Immunohistochemistry Laboratory is equipped to perform comprehensive sample processing workflows, including cytospin preparation, tissue fixation (formalin-fixed paraffin-embedded [FFPE] or cryopreserved), sectioning using rotary microtomes and cryostats, and immunostaining using both manual and automated platforms (e.g., Dako Autostainer). Protocols support chromogenic and fluorescent detection methods, tailored for a wide range of tissue types and research applications.

The Microscopy Laboratory offers high-resolution imaging capabilities through conventional brightfield, fluorescence, and laser scanning confocal microscopy. It also houses a Nanosight NS300 system with Nanoparticle Tracking Analysis (NTA) for the characterization of submicron particles in liquid suspension, including extracellular vesicles and nanoparticles. These systems enable both fixed and live-cell imaging for quantification of cellular dynamics such as proliferation, apoptosis, morphology, and viability. Image acquisition is supported by advanced analysis software suites, including NIS Elements AR, Nanosight 3.1, LAS AF, Image-Pro Plus, and ImageJ, allowing for quantitative and morphometric analyses tailored to experimental needs.

This integrated infrastructure ensures high reproducibility, traceability, and adaptability to diverse experimental designs in health sciences research.





IMAGE UNIT
Microscopy and Immunohistochemistry labs.
IdiPAZ.



Composition

Head
María Teresa Vallejo Cremades (PhD)
Email: tvallejo.hulp@salud.madrid.org
Phone: (+34) 917277526

Technician
Onys Camps Ortega
Phone: (+34) 917 270 000 (ext.442148)

Secretary:
Susana García Pérez
investigacion.hulp@salud.madrid.org
Phone: (+34) 91 207 15 12

Resources, equipment and management of the laboratory

Access to the services of the ImageM_IHQ Core Facility is provided under three operational modalities: collaborative research projects, Do-It-Yourself (DiY) access, and fee-for-service use. For fee-based access, prior approval from the facility head is required, as service provision is contingent upon personnel availability and resource allocation.

DiY users are granted independent access to instrumentation only after completing hands-on training and competency assessment conducted by authorized facility staff. Training sessions are scheduled on demand and are available year-round. External academic institutions and private-sector entities may also request services under a fee-for-service model, subject to the facility's operational capacity.

Access control to the Immunohistochemistry and Microscopy Laboratories requires an individual magnetic ID card. All new users must undergo an initial orientation, during which they are instructed on biosafety protocols, equipment handling, and facility regulations. No equipment may be operated until the user has been formally certified by staff as technically competent. All instrumentation must be reserved in advance through the official booking system; equipment usage without prior reservation is strictly prohibited.

Equipment of Molecular Image and Immunohisto-chemistry Unit

- Immunohistochemistry Laboratory:
  - Tissue processor providing efficient, reliable and timely processing of paraffin wax (Leica TP1020)
  - Embedding unit for high quality paraffin blocking (Leica Arcadia HC)
  - Selecta Wax dispenser, paraffin wax dispenser with adjustable temperature from ambient to 100 °C
  - 2 microtomes for specimen sectioning Leica RM2255
  - Leica EG 1150C Cold plate
  - 2 thermostatic water Leica HI 1210 baths
  - 1 thermostatic water Selecta Thermofn bath
  - 2 Cryostat for frozen sectioning (Leica CM 3050S and Leica CM1950)
  - 2 ChemFast 6 and 9 fume hoods
  - PTLink DAKO
  - Crison pH meter
  - Liebher combi (-20°C and 4°C)
  - Liebher economy freezer (-20°C)
  - Shandon Cytospin 2
  - Memmert BE 500 and UN30, Termaks and Selecta ovens.
  - Selecta Agimatic-E magnetic stirrer with heating
  - Olympus CH microscope, for practical laboratory applications
  - Gilson pipette sets
  - Selecta Agimatic-E magnetic stirrer with heating
  - Staining area with manual options for Do-It-Yourself staining and cover slipping.
  - Olympus BX41 (Bright feld) upright microscope with an attached Digital camera
  - Zeiss Axio Lab.Al microscope five objectives from 5x to100x. ERC5S Axocan camera.
  - Nanosight LM10 viewing unit measures nanoparticles, exosomes, vesicles's size based on the scattering of light, includes
    - a microscope, a LM10 viewing unit with an objective x20
    - a Marlin camera connected to an image analysis software.
    - Laser camera
    - injector

The laboratory is equipped with shared facilities from Translational Oncology and Anatomopathology Breast and Gynecological Cancer groups that use them for diagnostic and clinical research purpose (ESCO fume hood and Crison Microtome).

Permission to use must be asked to the head of these laboratories.

The Microscopy laboratory equipment includes:

- Stellaris 8 Leica confocal. Leica DMI8 inverted microscope;
  - Ilumination source, White and diode 405 Lasers
  - equipped with incubation chamber Oko Lab
    - » Oko Lab incubation system
    - » Oko-Lab Gas Controller Bold line
  - Microscope culture plates adapter
- NIKON microscope ECIPSE IT to conventional and fluorescence microscopy, in vivo imaging and High Content (equipped with incubation chamber)
  - Camera IMAGING SOURCE
  - Lauda Ecoline Star incubator edition 003
  - Hotplate (OKO LAB)
  - Oko-Lab DualGas Mixer (Okolab)
  - Microscope culture plates adapter
- Leica DMI6000B inverted microscope. Filter cubes: A4(UV), L5 (green), N3 (red) and Y5 (far red)
- Zeiss Axioplan 2 upright microscope with five objectives from 5x to 100x, phase contrast and fuorescent capabilities
- Digital microscopy (photography with a Leica DFC 350 FXR2 digital camera attached)
- Image ProPlus 5.0 image analysis software
- Leica LASX and LAS AF image analysis software
- NIS elements image analysis software
- Analysis work station with Huygens deconvolution software, Image J, LASAF Lite programme and related image analysis software.

The laboratory is equipped with shared facility from Neuroscience group, Leica TCS SPE inverted confocal. Leica DMI4000B inverted microscope; Ilumination source, Lasers diode 405, Lasers diode 488, Lasers diode 532 and Lasers diode 635; Dishes, Standard microscope slides.

Service Portfolio

- Collection and processing for fixing and decalcification of samples.
- Sample processing in paraffin by hand or automatic.
  - Complete paraffin embedding processing.
  - Serial cut in microtome and tissue assembly.
- Antibodies' validation.
- Buffer preparation and distribution of consumables.
- Sample processing frozen.
  - Preparation of freeze blocks.
  - Serial sections of blocks freeze and cuts collected on slides or floating.
- Staining.
  - Hematoxylin - eosin.
  - Masson trichrome.
  - PAS.
- Cytochemical and immunohistochemical techniques.
  - Decalcification of samples required.
  - Dewaxing cuts, performing staining.
  - Immunohistochemical staining automated system Autostainer.
  - Protocols for Immunofluorescence in frozen and paraffin tissue.
  - Dehydration and slide assembly.
- Image acquisition. Viewing and digital format acquisition.
  - Light microscopy.
  - Light microscopy with phase contrast.
  - Epifluorescence.
  - Confocal microscopy.
  - Advanced Microscopy in living cell.
  - measures nanoparticles, exosomes, vesicles's size based on the scattering of light
- Fluorescence colocalization by confocal microscopy.
- 3D reconstruction.
- Morphometry in biological samples.
- Large images acquisitions (scanning the entire slide) for bright field and fluorescence.
- Collaboration for sample processing protocols for microscopy (fastening, staining, marking, etc.) and advice for planning projects that could require the use of microscopy.


Research highlights

In 2024, Image unit collaborate with the groups belonging to the research areas of IdiPAZ; Neurosciences, Infectious disease and immunity, Cancer and human molecular genetics, Cardiovascular, Organ system pathologies and Surgery, transplant and health technologies. The collaboration is reflected in scientific dissemination as congress presentations and international publications.

Vallejo-Cremades M, Merino J, Carmona R, Córdoba L, Salvador B, Martínez L, Tovar JA, Llamas MÁ, Muñoz-Chápuli R, Fresno M. Toll-like receptors ligand immunomodulators for the treatment congenital diaphragmatic hernia. Orphanet J Rare Dis. 2024 Oct 18;19(1):386.

The time of use of the equipment in 2024 has maintained the ratio of usage by 30%, similar to previous years.


EQUIPMENT USAGE RATIO




During 2024 the users who have made the most use of the platform are those from FIBHULP, both basic and clinical (FIBHULP I+D and HULP) and the usage time of external research groups (UCM, CSIC, etc.) remains practically the same.

That some year, the unit increased the number of users. As observed in previous years, the most of inner users are interested in both Microscopy and Immunohistochemistry labs. This year, the Unit has had almost equal external users in the Microscopy and the Immunohistochemistry lab

TIME OF USE. EQUIPMENT METRICS (HOURS)





In addition, the unit belong to the Spanisht network of microscopy cores (REMOA) and in November of 2024, the staff of the platform attended with a communication to the SPAOM Spanish-Portuguese Meeting for Advanced Optical Microscopy organized by the Spanish Network of Advanced Optical Microscopy (REMOA) in Toledo.

Comparative study of different image analysis systems. Camps-Ortega Onys1, Vallejo-Cremades MT1. Congreso: 8th Spanish and Portuguese Advanced Optical microscopy Meeting (SPAOM24), en Toledo del. 20 al 22 de noviembre de 2024.

This allows us to implement the collaboration with other image core platforms and the knowledge of recent advances in the field of bioimaging techniques.

In 2024, the Unit maintained the certified scope of quality by AENOR referring to its processes according to the guidelines of the UNE-EN ISO 9001: 2015 Standard, and participation in the XXIV Science Week organized by the CAM with the workshop entitled *"Luz y color para encontrar las huellas moleculares de intrusos en nuestras células. Visita- taller a la Unidad de Imagen Molecular e Inmunohistoquímica"* that allows us to disseminate the scientific activity carried out in our platform.

2.5.2.8. Radioisotope Functional Unit

The radioisotope laboratory of IdiPAZ is a second category radioactive facility authorized by the Nuclear Safety Council for the use of non-encapsulated radioactive sources. The radioisotopes authorized at the facility are: ^{3}H, ^{33}P, ^{32}P, ^{125}I, ^{14}C, ^{51}Cr.

The laboratory has equipment and working space for the performance of molecular biology and biochemical procedures and experiments with cell cultures. Currently the most common procedures are cell proliferation tests with tritiated thymidine.

The use of the facility both by staff of the institution and by external users requires prior authorization by those responsible for the facility that approves both the technical suitability of the users to work with radioactivity, and the procedures to be employed. The HULP Radiation Protection Service is responsible for control of the facility and of the radioactive wastes generated.

Composition

Head:
Nuria Vilaboa Díaz
nuria.vilaboa@salud.madrid.org
Phone: (+34) 912 071 034

David Vicent López
david.vicent@salud.madrid.org
Phone: (+34) 91 207 10 30

Secretary:
Susana García Pérez
investigacion.hulp@salud.madrid.org
Phone: (+34) 91 207 15 12

2.5.2.9. BSL2 Virology Laboratory

The BSL2-Virology laboratory is an IdiPAZ platform created in September 2019 to support the Institute's research. Many are the research groups that have benefited from the platform to conduct their research safely, since working with samples infected with a certain type of pathogen requires facilities with an adequate level of biosafety. The BSL2-Virology laboratory was certified according to ISO 9001 quality management standard within the scope of IQNet.

Objectives

The BSL2-virology laboratory has been adapted to work with human samples infected with the HIV, HBV and HCV viruses; as well as GMOs of risk group 1 and 2. It also allows developing certain experimental processes with other viral pathogens that require a biosafety level 2. The laboratory provides researchers with the necessary equipment to perform their own experimental processing and analysis, as well as training and assistance.

Composition

Coordinator
Berta Rodés Soldevila
berta.rodes@salud.madrid.org
Phone: (+34) 912 071 022

Secretary
Susana García Pérez
Investigación.hulp@salud.madrid.org
Phone: (+34) 912 071 512

New facility

Since July 2023, the IdiPAZ building has a new BSL2-Virology laboratory. The new facility of 44.5 m2 represents an increase of more than half of the previously available space.

The new Laboratory consists of an anteroom equipped with SAS, autoclave and hand wash sink with hand free operations, followed by a changing room located before entering the experimental laboratory. The laboratory airflow has negative pressure system and passes through HEPA filters.

Permitted laboratory processes

- Processing of different types of blood cells from people living with HIV (PLWH)
- Preparation of samples from PLWH for cytometry. Studies of cellular polyfunctionality in the immune response against HIV.
- Handling and experimental processes of cell cultures.
- Measurement of the impact of antiretroviral drugs on mitochondrial function in PBMCs.
- Construction of viral protein expression vectors in eukaryotic expression vectors.
- Constructs of gene expression with viral vectors (lentiviruses and retroviruses)
- ELISA techniques of infectious samples.
- In May 2020 the laboratory was authorized for use of blood samples from patients with covid-19 and certain related processes.

Resources

The new BSL2-Virology Laboratory consists of an anteroom equipped with SAS, autoclave and hand wash sink with hand free operations, followed by a changing room located before entering the experimental laboratory. The laboratory airflow has negative pressure system and passes through HEPA filters. All facilities are located in the IdiPAZ building.

The experimental laboratory is equipped with the following equipment:

- Type II Biological Safety Cabinets (BSC):
  - 2 BSC Telstar BIO-II-A/P
  - 1 BSC Neuroaire CSB120
- CO2 incubators:
  - 2 HERAEUS BB-6220 incubators
- Centrifuges:
  - 1 HERAEUS Biofuge primor refrigerated centrifuge
  - 1 Hettich Universal 320 non-refrigerated centrifuge
  - 1 Hettich Universal 320 R
  - 1 Hettich Mikro 220 R
- Microscope:
  - 1 NIKON Eclipse TS100 Inverted Optical Microscope
  - 1 OPTIKA Microscopio XDS3
- Refrigeration systems:
  - 1 Liebherr upright freezer (-20°C)
  - 1 Liebherr profi line fridge (4°C)
- Other equipment:
  - 1 P-Selecta Precisterm thermostatic bath
  - 1 Inteliwasher 3D-IW8 BIOSAN
  - 1 Automatic cell counter LUNA II






2.5.2.10 3D Managment Laboratory

In recent years, there have been significant changes and advances in the field of 3D medicine, with the inclusion of technologies such as CAD/CAM (Computer Assisted Design/Computer Assisted Manufacturing), 3D printing, and navigation, which have paved the way in various medical and surgical fields, aiming to improve quality and offer more predictable and safe results.

In this regard, HULP-IDIPAZ believes it necessary to develop a 3D laboratory where the various services can access 3D imaging software, navigation software, and 3D printers, among others. It is important that this laboratory be organized and, above all, that the teams involved be trained in order to carry out the various activities efficiently and safely.

The Laboratory: Objectives and Services

The 3D Management Laboratory has a multidisciplinary focus, serving all the hospital's specialties, as an environment that can encompass the entire process, from design to manufacturing on our premises. This represents not only a radical change in the workflow of the departments involved, but also makes the departments self-sufficient for the design and generation of 3D models, whether for clinical, research, or educational purposes. The use of in-house technology for the development of surgical elements and tools, such as cutting guides or virtual planning, can be economically beneficial for the hospital. Furthermore, we must keep in mind that in-house production reduces lead times and encourages staff training and involvement in the design and creation of models, allowing the knowledge to remain within the institution.

Furthermore, the Fab-Lab has established a partnership with Rayo Seco Systems to launch a virtual platform, b-onic , used for traceability in the 3D development process of customized medical devices and for storing well-classified, high-quality normal and pathological models. These models will have multiple uses: printing, visualization, patient communication, research, patent creation, etc. They are a fundamental tool in the design of surgical plans and as a means of communication with the scientific community in the fields of research and training.

Composition

Coordinator:
José Luis Cebrián Carretero

Technical/Compliance:
Javier Cobas Gamallo

Substitute coach:
Sergio Rico Elvira

Quality:
Barbara Martinez de Miguel

Surveillance:
José Luis Cebrián Carretero

Manufacturing Technician:
Rubén Rubio Bolívar

Engineering:
José Tadeo Borjas
Celia del Peso Ley

Data management:
Celia Martín Cubillo

Shopping:
Javier Campaño

Medical image:
Montserrat Bret Zurita

Investigation
Ramón Cantero Cid

Sterilization
Ana Martínez Pérez

Contact:
Phone: 912 071 115
3d.hulp@salud.madrid.org

To achieve this, it is necessary to have the appropriate personnel for its management, operation and maintenance, as well as having quality accreditation in the ISO 13485 standard and obtaining a license as a manufacturer of personalized medical devices (custom-made medical devices) up to group 2A .

Regarding the physical location, the laboratory is located on the 7th floor of the General Hospital , with two adjoining rooms, one serving as an office dedicated to office tasks, computer design and project management where applicants are received and cases are studied and worked on, and the other exclusively for manufacturing using 3D printing.

Dotation:

The 3D laboratory has the following resources:

- Certified design and planning software (Mimics by Materialize)
- 3D printers: Quality standards require the use of bio-printers, which work with materials that can come into contact with the body.
  - FDM. Plastic printing using filament
  - SLA. Plastic printing of resins, some of which are biocompatible.
- We currently have 3 filament printers (Ultimaker 2 and 5, Bamboo) and three resin printers (Formlabs 2 and 2 plus, Formlabs 3

2.5.2.11. PAIN Platform

The Support Platform for Early-Stage Researchers (Plataforma de Apoyo al Investigador Novel) from IdiPAZ is a platform that aims to promote the design and development of research projects in health areas. Focused in our early-stage professional researchers, training and research development will be encouraged to achieve our clinicians a better performance in competitive calls.

Composition

Head:
Paloma Gómez Campelo

Technical Manager:
Daniel Quijada Alcón
mentor@idipaz.es
Phone: (+34) 91 207 17 40

Portfolio of services

- Methodological and epidemiological support to the study design of the professionals in early-stage research.
- Technical and methodological support in developing a research protocol for a study.
- Analysis of the grounds for refusal of rejected project proposals.
- Methodological support to write grant proposals to access all available funding programs.
- Technical support in writing other scientific documents.
- Management of the Mentor and Prementor Programmes.

Mentor program

In 2024, IdiPAZ, with the support of La Paz University Hospital, has implemented the 4th **Mentor Program** with the purpose of supporting our clinical early-stage researchers in the achievement of competitive projects, mainly from the main national call for health research projects: "Acción Estratégica en Salud (AES)", granted by *Instituto de Salud Carlos III*.

The Mentor Program plans a scientific and technical support in the preparation and tracking of research proposals. Furthermore, it takes into account the experience and scientific knowledge from our senior researchers to help our early-stage researchers from the beginning of their research career.

The objectives of the program are:

- Increasing the number of clinical research in IdiPAZ.
- Avoiding a generational leap of clinical researchers.
- Strengthening the research profile of our clinical staff.
- Positioning IdiPAZ as a model of clinical research, at the same level as it is in clinical trials.
- Performing an internal cultural change in clinical research.

Mentor Program includes different action plans have been implemented:

- To update the standardized curriculum for researchers.
- Enable synergies to create research groups.
- Support from the different platforms of IdiPAZ.
- Services of medical writing.
- Stand out the impact and the strategic priorities of the projects for the National Health System.

In the 4th **Mentor Program** 92 participants were included:

RESEARCHER	# PROPOSAL SUBMITTED
ALBERTO ALONSO BABARRO	PI25/01461
ALFONSO JUARDO ROMÁN	
ALMUDENA VAL BLASCO	PI25/00806
AMELIA JUDITH HESSHEIMER	PI25/00466
ANA BELÉN CUSTODIO CARRETERO	
ANA FERNÁNDEZ SANTANDER	PI25/00833
ANA ISABEL BOROBIA PÉREZ	PI25/01489
ANA LOURDES LUIS HUERTAS	PI25/00931
ÁNGEL MARTÍN MONTES	PI25/01343
ATILANO JOSÉ CARCAVILLA URQUI	PI25/01554
BEATRIZ BARQUIEL ALCALÁ	
BEATRIZ DÍAZ POLLÁN	PI25/00891
BLANCA TAPIA SALINAS	PI25/00273
CARLOS ANTONIO ÁLVAREZ ORTEGA	
CARLOS JAVIER CARPIO SEGURA	PI25/01310
CARLOS ZOZAYA NIETO	PI25/00523
CARMEN RODRÍGUEZ JIMÉNEZ	PI25/01002
CARMEN SOBRINO JIMÉNEZ	PI25/00857

RESEARCHER	# PROPOSAL SUBMITTED
CHAMAIDA PLASENCIA RODRÍGUEZ	PI25/00970
CRISTINA JULIA SUÁREZ FERRER	PI25/01141
DAVID RAMIRO CORTIJO	PI25/01062
DIEGO CARRACEDO SANCHIDRIÁN	
ELENA I. DIAGO SEMPERE	PI25/00946
ELENA VILLAMAÑÁN BUENO	PI25/00857
ELISA ALONSO LÓPEZ	PI25/00505
ELISABET GONZÁLEZ DEL PORTILLO	PI25/01544
ENRIQUE VILLAGRÁN MEDINILLA	PI25/01978
ESTER CARREÑO SALAS	PI25/00097
EUGENIA ANTOLÍN ALVARADO	PI25/01185
EVA MARÍN SERRANO	PI25/00493
FEDERICO DEL CASTILLO DÍEZ	PI25/01878
FEDERICO GUTIÉRREZ-LARRAYA AGUADO	PI25/01686
FERNANDO CORVILLO RODRÍGUEZ	PI25/00388
FRANCISCO HERNÁNDEZ OLIVEROS	PI25/00262
GUILLERMINA BEJARANO REDONDO	
GUILLERMO GARCÍA PEREZ DE SEVILLA	PI25/01307


RESEARCHER	# PROPOSAL SUBMITTED
INMACULADA PUERTAS MUÑOZ	PI25/00478
IRENE GARCÍA GARCÍA	PI25/01016
ISABEL VALBUENA GÓMEZ	PI25/00995
ISMAEL GHANEM CAÑETE	PI25/00530
JAVIER PIZONES ARCE	PI25/00330
JOSÉ LUIS DEL CASTILLO PARDO DE VERA	PI25/00858
JOSÉ MOSTAZA PRIETO	PI25/02038
JUAN CARO CODÓN	
JUAN JOSÉ BEUNZA NUIN	PI25/01389
JUAN JOSÉ MENÉNDEZ SUSO	PI25/00870
JUAN JOSÉ RÍOS BLANCO	PI25/01309
JUAN JOSÉ SEGURA SAMPEDRO	PI25/01392
LAURA GUTIÉRREZ SAINZ	PI25/00276
LAURA LACRUZ BALLESTER	PI25/00655
LUCÍA FERNÁNDEZ GASSÓ	PI25/00806
LUCÍA TRILLA FUERTES	PI25/00254
LUIS ALBERTO GLARIA ENRIQUEZ	PI25/01689
LUISA SISINNI	PI25/01391
LUNA RIDAN CORDEIRO MINUTE	
Mª ANGUSTIAS QUESADA SIMÓN	PI25/01431
Mª CARMEN BRAVO LAGUNA	PI25/01019
Mª JESÚS MORO ÁLVAREZ	PI25/01724
Mª MAR GIL MIRA	
MANUEL QUINTANA DÍAZ	PI25/00996
MARCOS JAVIER CUERVA GONZÁLEZ	PI25/00579
MARÍA CONCEPCIÓN PRADOS SÁNCHEZ	PI25/01708
MARÍA ISABEL ESTEBAN RODRÍGUEZ	PI25/01041
MARÍA NIEVES MORENO	

RESEARCHER	# PROPOSAL SUBMITTED
MARÍA OVIDIA LÓPEZ OLIVA	PI25/00274
MARÍA TERESA SANCHO BUESO	
MARIO ÁLVAREZ MAESTRO	
MARTA CADENAS MARTÍN	PI25/00290
MARTA DÍAZ MENÉNDEZ	PI25/00381
MARTA MOLERO LUIS	PI25/00489
MARTA NOVELLA NAVARRO	PI25/01020
MERCEDES GASIOR KABAT	PI25/00894
MIRIAM ALONSO MAZA	PI25/01636
ONICA M. ARMIJO SUÁREZ	
ÓSCAR PEÑUELAS RODRÍGUEZ	PI25/01032
PABLO BARREIRO GARCÍA	
PABLO MARISCAL AGUILAR	PI25/01310
PATRICIA CONDORHUAMAN ALVARADO	
PAULA RODRÍGUEZ MOLINO	PI25/00811
RAQUEL ARRANZ JIMÉNEZ	
ROCÍO MENÉNDEZ COLINO	PI25/01301
ROCÍO PRIETO PÉREZ	PI25/01379
ROCIO ROSAS ALONSO	PI25/00179
ROSA ALCOBENDAS RUEDA	PI25/00575
ROSARIO LÓPEZ LÓPEZ	
SAMUEL ANTUÑA ANTUÑA	PI25/00960
SARA RUIZ MARTÍNEZ	PI25/00567
SERGIO CASTREJÓN CASTREJÓN	PI25/00282
SUSANA NOVAL MARTÍN	PI25/01455
VÍCTOR GALÁN GÓMEZ	PI25/00382
YALE TUNG CHEN	PI25/01201
YOLANDA ALADRÓ BENITO	PI25/00548

Below is the family collage of the participants in the 4th Mentor Programme:



The number of researchers who have participated in the programme can be seen since the launch of the Mentor Programme at IdiPAZ in the following chart:



The program is supported by a network of senior mentors from different fields and professional expertise. The mentors provide mentees constructive feedback, putting at their disposal all their experience, dedication and motivation, supporting the process of preparing their research project proposals.

In the 4th **Mentor Program** 36 senior mentor have collaborated:

MENTOR	# MENTORED PROPOSAL
ADELINA PELLICER MARTÍNEZ, PhD	PI25/01019
ALBERTO MANUEL BOROBIA PÉREZ, PhD	PI25/00274 PI25/00282 PI25/00857 PI25/00858 PI25/00870 PI25/00995 PI25/01016 PI25/01032 PI25/01489 PI25/01978
ANA SASTRE PERONA, PhD	PI25/00833 PI25/00931 PI25/00996
ANTONIO PÉREZ MARTÍNEZ, PhD	PI25/00382
BERTA RODÉS SOLDEVILA, PhD	PI25/00493
BLANCA FUENTES GIMENO, PhD	PI25/00548
CARLOS DEL FRESNO SÁNCHEZ, PhD	PI25/00960 PI25/01689
CONSTANTINO FONDEVILA CAMPO, PhD	PI25/00273 PI25/01544
CRISTINA CALVO REY, PhD	PI25/00575 PI25/00811
EDUARDO LÓPEZ GRANADOS, PhD	PI25/01020
EDUARDO LÓPEZ-COLLAZO, PhD	PI25/00097
ESTHER PÉREZ DAVID, PhD	PI25/01201

MENTOR	# MENTORED PROPOSAL
EXUPERIO DIEZ-TEJEDOR, PhD	PI25/00655
FERNANDO MARTÍN SÁNCHEZ, PhD	PI25/00530
ISABEL LASTRES BECKER, PhD	PI25/00505
JAVIER DE CASTRO CARPEÑO, PhD	PI25/00179 PI25/00276 PI25/01041
JOSE LUIS BARTHA RASERO, PhD	PI25/00579 PI25/01185
JOSE LUIS MERINO LLORENS, PhD	PI25/00806 PI25/01301
JOSE RAMÓN ARRIBAS LÓPEZ, PhD	PI25/00891 PI25/01309
JUAN JOSÉ BEUNZA NUIN, PhD	PI25/00330 PI25/00970
KAREN ELISE HEATH, PhD	PI25/00254
LAURA OTERO ORTEGA, PhD	PI25/00478
MARÍA ALONSO DE LECIÑANA CASES, PhD	PI25/01343
MARIA FERNANDEZ VELASCO, PhD	PI25/00806
MARÍA GUTIÉRREZ FERNÁNDEZ, PhD	PI25/00262
MARÍA PAZ DE MIGUEL GONZÁLEZ, PhD	PI25/00290
MIGUEL ANGEL SALINERO FORT, PhD	PI25/01431 PI25/02038

MENTOR	# MENTORED PROPOSAL
MIGUEL SÁENZ DE PIPAÓN MARCOS, PhD	PI25/00523 PI25/00567
NORA VIVIANA BUTTA COLL, PhD	PI25/00894
NURIA VILABOA DÍAZ, PhD	PI25/01392
PILAR SÁNCHEZ-CORRAL GÓMEZ, PhD	PI25/00388 PI25/00489
REBECA PEREZ DE DIEGO, PhD	PI25/01141
RODOLFO ÁLVAREZ-SALA WALTHER, PhD	PI25/01310 PI25/01708
ROSA TORRES JIMÉNEZ, PhD	PI25/01002
SILVIA MAGDALENA ARRIBAS RODRÍGUEZ, PhD	PI25/01062
TALIA SAINZ COSTA, PhD	PI25/01455
SUPPORT PLATFORM FOR EARLY-STAGE RESEARCHERS	PI25/00381 PI25/00466 PI25/00946 PI25/01307 PI25/01379 PI25/01389 PI25/01391 PI25/01461 PI25/01554 PI25/01636 PI25/01686 PI25/01724 PI25/01878

1 Introduction

2 Executive summary

3 Research areas and groups


4 Associated clinicians

In order to ensure that the research project proposals submitted by our early-stage researchers have a high degree of excellence, the Mentor Programme has a training plan structured in webinars for each section of the application report.

In 2024, the following webinars were held as part of the Mentor Programme training plan:

TOPIC	DATE	SPEAKER
FIS PROJECT PREPARATION KEYS. PROJECT EVALUATION.	17/10/2024	DANIEL QUIJADA ALCÓN
METHODOLOGY: STRUCTURE, BIASES AND CONTINGENCY PLAN	24/10/2024	DANIEL QUIJADA ALCÓN
GENDER PERSPECTIVE AND DIMENSION IN RESEARCH	31/10/2024	DANIEL QUIJADA ALCÓN
PI PROFILE & DORA CRITERIA	14/11/2024	DANIEL QUIJADA ALCÓN
STORYTELLING FOR PROJECT WRITING	21/11/2024	JORGE DE JUAN FERNÁNDEZ
METHODOLOGICAL PLANNING FOR CLINICAL TRIALS	28/11/2024	ALBERTO M. BOROBIA PÉREZ
ORCID IDENTIFIER	05/12/2024	RAÚL ROMÁN CAÑIZARES
HOW TO PREPARE A GOOD BUDGET	12/12/2024	SILVIA ARCE SANTAMARÍA JÉSSICA GARCÍA MOSCATEL
EXPERIENCES OF PARTICIPATION IN THE MENTOR PROGRAMME	19/12/2024	DANIEL QUIJADA ALCÓN FCO JAVIER DÍAZ DE TERÁN VELASCO Mª DOLORES MARTÍN ARRANZ
STATISTICAL ANALYSIS	09/01/2025	MARÍA JIMÉNEZ GONZÁLEZ
CVA	16/01/2025	RAÚL ROMÁN CAÑIZARES
METHODOLOGICAL PLANNING FOR OBSERVATIONAL STUDIES	23/01/2025	IRENE GARCÍA GARCÍA
BIBLIOMETRIC INDICATORS	30/01/2025	RAÚL ROMÁN CAÑIZARES
DATA MANAGEMENT PLAN. DATA PROTECTION	06/02/2025	DANIEL QUIJADA ALCÓN ESTELA SÁNCHEZ SIMÓN
STRATEGIC INTEREST OF THE PROJECT, DISSEMINATION AND CITIZEN ENGAGEMENT PLAN	13/02/2025	DANIEL QUIJADA ALCÓN

In its fourth year, all the actions developed in the Mentor Programme have led to an increase in the number of proposals applied to Acción Estratégica en Salud (AES) call for health research projects by IdiPAZ researchers:



In 2024, once the proposal deadline was expired, the Mentor Program organized an event where all support offered by our mentors was recognized. The Mentor Program want to thanks all the time and selfless support and time that mentors provide to the Program and to the mentees. In this event, an experience conference of mentors and mentees were held, so the audience could know deeply how to prepare an AES proposal and how the Mentor Program works from different points of views.



PREMENTOR PROGRAM

IdiPAZ, with the support of La Paz University Hospital, has implemented the 1st **Prementor Program** with the purpose of supporting our predoctoral researchers in the achievement of their Doctorate.

The objectives of the program are:

- Increasing the number of researchers with a PhD in IdiPAZ.
- Promote high quality training of researchers.
- Performing an internal cultural change in translational research in biomedicine.

The Prementor Program planned a formative and technical support during the second and third tutorial courses of our predoctoral researchers' doctoral studies. The following webinars have been held as part of the Prementor Programme training plan:

DATE	TOPIC	SPEAKER
20/09/2024	HOW TO ESTABLISH A RESEARCH QUESTION/HYPOTHESIS	DANIEL QUIJADA ALCÓN
18/10/2024	ETHICS AND SCIENTIFIC FRAUD	NORA BUTTA COLL
15/11/2024	PREPARING AND CLEANING DATABASES	MARÍA TERESA GARÍA MORALES
20/12/2024	FIGURES, VISUALIZATION AND DATA ANALYSIS	MARÍA JIMÉNEZ GONZÁLEZ
17/01/2025	IDIPAZ SUPPORT PLATFORMS FOR EXPERIMENTAL WORK	GEMA VALLÉS PÉREZ
21/02/2025	ORAL COMMUNICATIONS AND POSTER DESIGN	EMANUELA SPAGNOLO
25/04/2025	PROTECTION OF RESULTS	ESTELA SÁNCHEZ SIMÓN
23/05/2025	TOOLS FOR THE EMOTIONAL MANAGEMENT DURING THE DEVELOPMENT OF THE THESIS	ÁNGELA PALAO TARRERO
13/06/2025	TIPS FOR PUBLICATION AND SCIENTIFIC DISSEMINATION	ANA Mª SASTRE PERONA
20/06/2025	THESIS DEFENSE	REBECA PÉREZ DE DIEGO

In the 1st **Prementor Program** 69 participants were included:

DOCTORAL STUDENT	UNIVERSITY
AARON ABDELKADER GUILLÉN	UNIVERSIDAD AUTÓNOMA DE MADRID
ALEJANDRO DE GEA GRELA	UNIVERSIDAD AUTÓNOMA DE MADRID
ALICIA MARÍN CANDÓN	UNIVERSIDAD AUTÓNOMA DE MADRID
ANDREA BUENO SEN	UNIVERSIDAD AUTÓNOMA DE MADRID
ANDREA GUZMÁN DE ANTONIO	UNIVERSIDAD AUTÓNOMA DE MADRID
ANDREA LOPEZ SUAREZ	UNIVERSIDAD COMPLUTENSE DE MADRID
ARIADNA WITTE CASTRO	UNIVERSIDAD COMPLUTENSE DE MADRID
BEATRIZ NIETO CARVALHAL	UNIVERSIDAD AUTÓNOMA DE MADRID
BLANCA FABRE ESTREMERA	UNIVERSIDAD AUTÓNOMA DE MADRID
CARLOS DELGADO MIGUEL	UNIVERSIDAD AUTÓNOMA DE MADRID
CARLOS RODRÍGUEZ ANTOLÍN	UNIVERSIDAD AUTÓNOMA DE MADRID
COLOMA GRAU VAN LAAK	UNIVERSIDAD AUTÓNOMA DE MADRID
CRISTINA DE MANUEL GÓMEZ	UNIVERSIDAD AUTÓNOMA DE MADRID
CRISTINA MARCELO CALVO	UNIVERSIDAD AUTÓNOMA DE MADRID
DARÍO SÁNCHEZ CABRERO	UNIVERSIDAD AUTÓNOMA DE MADRID
DIEGO MORANTE MARTÍNEZ	UNIVERSIDAD AUTÓNOMA DE MADRID
EDUARDO CAZALLA IBÁÑEZ	UNIVERSIDAD AUTÓNOMA DE MADRID
ELENA MARTÍNEZ ROBLES	UNIVERSIDAD AUTÓNOMA DE MADRID
ENRIQUE ALFARO GARCIA	UNIVERSIDAD AUTÓNOMA DE MADRID
FRANCISCO DE BORJA NAVA HURTADO DE SARACHO	UNIVERSIDAD AUTÓNOMA DE MADRID
GABRIEL TORRES IGLESIAS	UNIVERSIDAD AUTÓNOMA DE MADRID
GEMA YAGÜE DE ANTONIO	UNIVERSIDAD DE LEÓN
GONZALO SÁENZ DE SANTA MARÍA DIEZ	UNIVERSIDAD AUTÓNOMA DE MADRID
GUILLERMO MANUEL SIBÓN SANCHO	UNIVERSIDAD NACIONAL DE EDUCACIÓN A DISTANCIA
GUILLERMO MARTÍN ÁVILA	UNIVERSIDAD EUROPEA DE MADRID
IGNACIO SILVA LLANES	UNIVERSIDAD AUTÓNOMA DE MADRID
IRENE BARRIENTOS RUIZ	UNIVERSIDAD AUTÓNOMA DE MADRID

DOCTORAL STUDENT	UNIVERSITY
ISABEL DIAZ SUAREZ	UNIVERSIDAD DE NAVARRA
ISABEL GONZÁLEZ BERTOLÍN	UNIVERSIDAD AUTÓNOMA DE MADRID
ISABEL MELLADO SOLA	UNIVERSIDAD AUTÓNOMA DE MADRID
ISABEL MELLADO SOLA	UNIVERSIDAD AUTÓNOMA DE MADRID
ISABEL MORENO PARRO	UNIVERSIDAD AUTÓNOMA DE MADRID
JAVIER POZO NOVOA	UNIVERSIDAD AUTÓNOMA DE MADRID
JAVIER SERRADILLA RODRIGUEZ	UNIVERSIDAD AUTÓNOMA DE MADRID
JESÚS PEÑA LÓPEZ	UNIVERSIDAD AUTÓNOMA DE MADRID
JOSÉ MARÍA RODRÍGUEZ PIÑAS	UNIVERSIDAD EUROPEA DE MADRID
JULIA DEL PRADO MONTERO	UNIVERSIDAD AUTÓNOMA DE MADRID
LAURA BRAVO ROBLES	UNIVERSIDAD AUTÓNOMA DE MADRID
LAURA CLARES VILLA	UNIVERSIDAD AUTÓNOMA DE MADRID
LAURA GARCIA ESPINOSA	UNIVERSIDAD AUTÓNOMA DE MADRID
LUCIA GUTIÉRREZ GARCÍA	UNIVERSIDAD AUTÓNOMA DE MADRID
MARI PAZ LÓPEZ MOLINA	UNIVERSIDAD AUTÓNOMA DE MADRID
MARÍA DE CEANO-VIVAS LA CALLE	UNIVERSIDAD AUTÓNOMA DE MADRID
MARÍA DEL ROSARIO GARCÍA SÁNCHEZ	UNIVERSIDAD COMPLUTENSE DE MADRID
MARIA JESUS ESPINOSA PASCUAL	UNIVERSIDAD COMPLUTENSE DE MADRID
MARIA JOSE ROL GARCIA	UNIVERSIDAD AUTÓNOMA DE MADRID
MARÍA PÉREZ PASCUAL	UNIVERSIDAD AUTÓNOMA DE MADRID
MARÍA SÁNCHEZ MARTÍN	UNIVERSIDAD AUTÓNOMA DE MADRID

DOCTORAL STUDENT	UNIVERSITY
MARÍA SANZ DE PEDRO	UNIVERSIDAD AUTÓNOMA DE MADRID
MARIA VARELA CERDEIRA	UNIVERSIDAD AUTÓNOMA DE MADRID
MARTA LUISA MUNER HERNANDO	UNIVERSIDAD AUTÓNOMA DE MADRID
MIKEL FERNÁNDEZ ARTAZCOZ	UNIVERSIDAD AUTÓNOMA DE MADRID
MÓNICA BEOBIDE CONDE	UNIVERSIDAD REY JUAN CARLOS
NEILA RODRÍGUEZ ROCA	UNIVERSIDAD AUTÓNOMA DE MADRID
NURIA LOURDES PÉREZ CHULIÁ	UNIVERSIDAD AUTÓNOMA DE MADRID
PALOMA MARTÍNEZ CAMPOS	UNIVERSIDAD AUTÓNOMA DE MADRID
PAULA ARAGÓN RAMOS	UNIVERSIDAD AUTÓNOMA DE MADRID
PAULA CANTOLLA PABLO	UNIVERSIDAD AUTÓNOMA DE MADRID
PAULA PATRICIA BURGOS MORALES	UNIVERSIDAD AUTÓNOMA DE MADRID
PAULA PÉREZ MORENO	UNIVERSIDAD AUTÓNOMA DE MADRID
PELAYO FERNÁNDEZ CIDÓN	PENDIENTE
RAQUEL CASITAS MATEO	UNIVERSIDAD AUTÓNOMA DE MADRID
REBECA GALLEGO RUIZ	UNIVERSIDAD AUTÓNOMA DE MADRID
RICARDO JAIME RIGUAL BOBILLO	UNIVERSIDAD AUTÓNOMA DE MADRID
SONIA ALCOLEA	UNIVERSIDAD AUTÓNOMA DE MADRID
SONIA MILKOVA IVANOVA	UNIVERSIDAD AUTÓNOMA DE MADRID
TAMARA DOMINGO PÉREZ	UNIVERSIDAD DE NAVARRA
TERESA MATO PATINO	UNIVERSIDAD AUTÓNOMA DE MADRID
VICTORIA ARNALICH MONTIEL	UNIVERSIDAD AUTÓNOMA DE MADRID

OTHERS ACTIVITIES CARRIED IN 2024

Throughout 2024, the PAIN platform has participated in the Science and Innovation Week. In this dissemination activity, a conference entitled: 'Solving the mystery: the scientific method in biomedical research' was planned to secondary school students.

2.5.2.12. Sequencing Platform

Biomedical research is the main core of IdiPAZ institute and automatic sequencing facility is proud to participate in this working arear of the hospital. Our facility is a support for translational research in the hospital in terms of genomic analysis and supporting diagnosis units. The facility has helped to incorporate research results in the routine of the hospital.

Automatic sequencing facility has the necessary equipment and infrastructure to perform tasks such as conventional sequencing (Sanger method), marker DNA genotyping and other molecular biology techniques based on capillary electrophoresis. The equipment can use up to five simultaneous colours on the same sample when it migrates to the genetic analyzers. Therefore, we are able to detect more than 30 polymorphic markers per sample. The expertise of the staff allows us to offer design, protocol development, and data analysis support and task training in genomic techniques.

On the other hand, the Genomic Analysis core offers assistance services in Next Generation Sequencing to the institute's research lines, providing support in the analysis of WES and WGS data.

During the last year, collaborations with different research groups has resulted in the co-authorship of seven articles in international journals.

The Genomic Analysis core has managed to develop two lines of research in the area of immunology and the Conventional Sequencing core has joined in another line of research in the area of paediatric thanks to the granting of two research projects.

Both Sanger Sequencing and Genomic analysis cores are committed to quality work by maintaining ISO 9001:2015 certification. In addition, lab participates in international external quality controls annual evaluations (EMQN) and quality control evaluations with other laboratories.

Composition

Coordinator:
María del Rocío Mena de la Cruz
mariarocio.mena@salud.madrid.org
Phone: (+34) 912071214

Conventional sequencing
Head:
María del Rocío Mena de la Cruz
mariarocio.mena@salud.madrid.org
Phone: (+34) 912071214

Technical Staff
Eva María Báez Monforte
evamaria.baez@salud.madrid.org
Carolina Pilar Blanco Agudo
carolinapilar.blanco@salud.madrid.org

Genomic Analysis
Head:
Rebeca Pérez de Diego
rebeca.perez@idipaz.es
Phone: (+34) 91 207 10 32

Technical Staff
Ana María Van Den Rym Mayoral

Equipment

- Eppendrof 5415D Centrifuge.
- Veriti Termocycler(Applied Biosystems).
- Genetic Analyzer SeqStudio (Thermo Fisher Scientific).

Software:

- Sequencing Analysis v5.7
- Sequence Scanner v1.0
- GeneMapper v4.1

Portofolio Service

Conventional sequencing

- Nucleic Acid quantitation (Tecan, Nanodrop).
- PCR purification for Sanger sequencing (Exosap).
- Sanger Sequencing.
- Migration Sanger samples.
- Fragments Analysis:
  - STRs analysis
  - QF-PCR.
  - MLPAs (multiplex ligation-dependent probe amplification).
  - Microsatellite instability (MSI).
  - AZF.
  - SnapShot.
  - TP-PCR.
  - ARMS.
  - AFLPs

Genomic Analysis

- Genetic analysis from annotated variants of PID Sequencing Panel.
- Genetic analysis from annotated whole exome sequencing (WES) variants.
- Genetic analysis from annotated whole genome sequencing (WGS) variants.
- Genetic analysis from raw data in FASQ format from PID Sequencing Panel.
- Genetic analysis from raw data in whole exome sequencing (WES) FASQ format.

2024 Facility Activity:

Conventional sequencing


Research Area	Genotyping products	Sanger Sequencing products	Sanger Sequencing	Total samples
Infectious diseases and immunity	2398	299	20	2717
Cardiovascular	138	4567	0	4705
Organ system pathologies	1605	1146	16	2767
Cancer and human molecular genetics	3898	2926	434	7258
External synergy	0	265	100	365
Total	8039	9203	570	17812

Genomic Analysis

Research Area	Genetic analysis from annotated variants of PID Sequencing Panel	Genetic analysis from annotated whole exome sequencing (WES) variants	Genetic analysis from annotated whole genome sequencing (WGS) variants	Total samples
External researches	1	32	0	33

Figures

Distribution conventional sequencing core service



Projects:

1. UNDINE_The human genetic and immunological determinants of the clinical manifestations of SARS-CoV-2 infection: Towards personalised medicine." programa marco europeo Horizonte Europa con acuerdo de subvención 101057100
2. Identificación de nuevos errores innatos de la inmunidad hacia el diagnóstico de precisión y prevención de enfermedades inmunológicas. FIS PI22/00790
3. Paving the way for personalized medicine in neonatal and pediatric intensive care units. PI22/01743

Publications:

1. IgG4-related disease and B-cell malignancy due to an IKZF1 gain-of-function variant.
García-Solís B, Tapia-Torres M, García-Soidán A, Hernández-Brito E, Martínez-Saavedra MT, Lorenzo-Salazar JM, García-Hernández S, Van Den Rym A, Mayani K, Govantes-Rodríguez JV, Gervais A, Bastard P, Puel A, Casanova JL, Flores C, Pérez de Diego R, Rodríguez-Gallego C. J Allergy Clin Immunol. 2024 Apr 4:S0091-6749(24)00330-0. doi: 10.1016/j.jaci.2024.03.018. Online ahead of print. PMID: 38579942

2. Heterozygous BTNL8 variants in individuals with multisystem inflammatory syndrome in children (MIS-C).
Bellos E, Santillo D, Vantourout P, Jackson HR, Duret A, Hearn H, Seeleuthner Y, Talouarn E, Hodeib S, Patel H, Powell O, Yeoh S, Mustafa S, Habgood-Coote D, Nichols S, Estramiana Elorrieta L, D'Souza G, Wright VJ, Estrada-Rivadeneyra D, Tremoulet AH, Dummer KB, Netea SA, Condino-Neto A, Lau YL, Núñez Cuadros E, Toubiana J, Holanda Pena M, Rieux-Laucat F, Luyt CE, Haerynck F, Mège JL, Chakravorty S, Haddad E, Morin MP, Metin Akcan Ö, Keles S, Emiroglu M, Alkan G, Tüter Öz SK, Elmas Bozdemir S, Morelle G, Volokha A, Kendir-Demirkol Y, Sözeri B, Coskuner T, Yahsi A, Gulhan B, Kanik-Yuksek S, Bayhan GI, Ozkaya-Parlakay A, Yesilbas O, Hatipoglu N, Ozcelik T, Belot A, Chopin E, Barlogis V, Sevketoglu E, Menentoglu E, Gayretli Aydin ZG, Bloomfield M, AlKhater SA, Cyrus C, Stepanovskiy Y, Bondarenko A, Öz FN, Polat M, Fremuth J, Lebl J, Geraldo A, Jouanguy E; COVID-19 Human Genetic Effort; DIAMONDS; EUCLIDS; Carter MJ, Wellman P, Peters M, Pérez de Diego R, Edwards LA, Chiu C, Noursadeghi M, Bolze A, Shimizu C, Kaforou M, Hamilton MS, Herberg JA, Schmitt EG, Rodriguez-Palmero A, Pujol A, Kim J, Cobat A, Abel L, Zhang SY, Casanova JL, Kuijpers TW, Burns JC, Levin M, Hayday AC, Sanc… See abstract for full author list J Exp Med. 2024 Dec 2;221(12):e20240699. doi: 10.1084/jem.20240699. Epub 2024 Nov 22. PMID: 39576310 Free PMC article.

3. Lack of association between classical HLA genes and asymptomatic SARS-CoV-2 infection.
Marchal A, Cirulli ET, Neveux I, Bellos E, Thwaites RS, Schiabor Barrett KM, Zhang Y, Nemes-Bokun I, Kalinova M, Catchpole A, Tangye SG, Spaan AN, Lack JB, Ghosn J, Burdet C, Gorochov G, Tubach F, Hausfater P; COVID Human Genetic Effort; COVIDeF Study Group; French COVID Cohort Study Group; CoV-Contact Cohort; COVID-STORM Clinicians; COVID Clinicians; Orchestra Working Group; Amsterdam UMC COVID-19 Biobank; NIAID-USUHS COVID Study Group; Dalgard CL, Zhang SY, Zhang Q, Chiu C, Fellay J, Grzymski JJ, Sancho-Shimizu V, Abel L, Casanova JL, Cobat A, Bolze A. HGG Adv. 2024 Jul 18;5(3):100300. doi: 10.1016/j.xhgg.2024.100300. Epub 2024 Apr 26. PMID: 38678364 Free PMC article.

4. Higher COVID-19 pneumonia risk associated with anti-IFN-α than with anti-IFN-ω auto-Abs in children.
Bastard P, Gervais A, Taniguchi M, Saare L, Särekannu K, Le Voyer T, Philippot Q, Rosain J, Bizien L, Asano T, Garcia-Prat M, Parra-Martínez A, Migaud M, Tsumura M, Conti F, Belot A, Rivière JG, Morio T, Tanaka J, Javouhey E, Haerynck F, Duvlis S, Ozcelik T, Keles S, Tandjaoui-Lambiotte Y, Escoda S, Husain M, Pan-Hammarström Q, Hammarström L, Ahlijah G, Abi Haidar A, Soudee C, Arseguel V, Abolhassani H, Sahanic S, Tancevski I, Nukui Y, Hayakawa S, Chrousos GP, Michos A, Tatsi EB, Filippatos F, Rodriguez-Palmero A, Troya J, Tipu I, Meyts I, Roussel L, Ostrowski SR, Schidlowski L, Prando C, Condino-Neto A, Cheikh N, Bousfiha AA, El Bakkouri J; COVID Clinicians; GEN-COVID Study Group; COVID Human Genetic Effort; Peterson P, Pujol A, Lévy R, Quartier P, Vinh DC, Boisson B, Béziat V, Zhang SY, Borghesi A, Pession A, Andreakos E, Marr N, Mentis AA, Mogensen TH, Rodríguez-Gallego C, Soler-Palacin P, Colobran R, Tillmann V, Neven B, Trouillet-Assant S, Brodin

P, Abel L, Jouanguy E, Zhang Q, Martinón-Torres F, Salas A, Gómez-Carballa A, Gonzalez-Granado LI, Kisand K, Okada S, Puel A, Cobat A, Casanova JL. J Exp Med. 2024 Feb 5;221(2):e20231353. doi: 10.1084/jem.20231353. Epub 2024 Jan 4. PMID: 38175961 Free PMC article.

5. Influence of rheumatoid factor levels and TNF inhibitor structure on secondary nonresponse in rheumatoid arthritis patients.
Plasencia-Rodríguez C, Martínez-Feito A, Novella-Navarro M, Pérez De Diego R, Bonilla G, Gehin JE, Villalba-Yllán A, Nuño L, Pascual-Salcedo D, Nozal P, Almirón MD, Balsa A. Front Med (Lausanne). 2024 Sep 4;11:1461396. doi: 10.3389/fmed.2024.1461396. eCollection 2024. PMID: 39296891 Free PMC article.


6. The phase I RELEASE clinical trial to evaluate the safety of NK cells in COVID-19.
Hernández-Blanco C, Al-Akioui-Sanz K, Herrera L, Aguirre-Portolés C, Lozano-Ojalvo D, Pérez-Rodriguez L, Cano-Ochando J, Guerra-García P, Martín-Quirós A, Vicario JL, Santos S, Pérez-Vaquero MÁ, Vesga MÁ, Borobia AM, Carcas AJ, Balas A, Moreno MÁ, Pérez de Diego R, Gasior M, Soria B, Eguizabal C, Pérez-Martínez A. iScience. 2024 Dec 27;28(2):111698. doi: 10.1016/j.isci.2024.111698. eCollection 2025 Feb 21. PMID: 39877904 Free PMC article.

7. Lack of Specific Immune Response after Five Doses of mRNA SARS-CoV-2 Vaccine in a Patient with CD4+ T-Cell Lymphopenia but Preserved Responses to CMV.
Alba-Cano T, Fernández-Cruz E, Alonso R, Muñoz-Gómez S, Pérez de Diego R, García Martínez E, Sánchez-Mateos P, Navarro Caspistegui J, Martín López M, Gil-Herrera J. Vaccines (Basel). 2024 Apr 6;12(4):386. doi: 10.3390/vaccines12040386. PMID: 38675768 Free PMC article.


Figures

Fig. Conventional sequencing:

A



B




1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

Fig. Genomic Analysis core:





2.5.2.13 Simulation Platform CEASEC

OBJECTIVES

The SimuPaz_HULP, Advanced Center for Clinical Simulation and Training at La Paz University Hospital, plays a fundamental role in the training and improvement of healthcare professionals' skills, as well as in patient care safety and quality. Clinical simulation emerges as a powerful tool for this purpose, enabling professionals to practice and refine their skills in a controlled and safe environment.

The center is designed to cater to a wide range of healthcare professionals, including physicians, nurses, and medical and nursing students. It is particularly beneficial for those working in critical or emergency environments, where teamwork and quick, accurate decision-making are crucial. Areas such as ICU, anesthesia and resuscitation, surgery, and emergency medicine are especially emphasized, but it also includes professionals who use complex or invasive technology in their practice.

At SimuPaz_HULP, emphasis is placed not only on mastering technical skills but also on developing professional competencies such as effective communication, teamwork, and the ability to analyze and make decisions. This ensures that professionals are well-prepared to face critical situations and provide the highest level of patient care.

Furthermore, as part of the Institute of Health Research of La Paz University Hospital (IdiPAZ), SimuPaz is firmly committed to a clear research vocation. This dedication not only promotes the generation and advancement of knowledge across various disciplines but also addresses complex problems to find effective solutions. From technological and scientific development to improving healthcare, fostering business innovation, and promoting sustainable development, research conducted at SimuPaz has a significant impact on society and the well-being of people.

COMPOSITION

Governing Council
Javier Cobas Gamallo
Ana Coloma Zapatero
Manuel Quintana Díaz
Carlota Largo Aramburu
Irene Cuevas Gordo
Javier Rubio Bolívar
Elena Martín de Castro
Alicia Portas Martínez
Ramón Cantero Cid
Ana Mª Sánchez Torres
Estela Sánchez Simón
Esther Rey Cuevas
Marta Cortés León

Chairman Governing Council
Manuel Quintana Díaz

Secretary Governing Council:
Ana Coloma Zapatero
Estela Sánchez Simón

Contact:
Irene Cuevas Gordo
irene.cuevas@salud.madrid.org
Phone: (+34) 91 727 71 54

Innovation projects in new technologies

In 2024 SimuPaz promoted the collaboration with several universities to promote applied research and innovative technologies development in the clinical field. Students from different universities and with varied technological profiles have been selected to provide feedback and reach a collaborative learning ecosystem. Remarkable research projects include:

- Physiological and performance metrics during a cardiopulmonary real-time feedback simulation to estimate cognitive load. Blanca L.G, Verónica R.B, Xabier O, Javier R.B, Manuel Q.D, Álvaro G.

This study explores the relationship between multitasking, working memory, and the performance of chest compressions during cardiopulmonary resuscitation (CPR). Multitasking is crucial for First Responders (FRs) in emergency scenarios, enabling them to prioritize and treat victims efficiently. However, research on multitasking and its impact on rescue operations are limited.

In this experiment, eighteen first-year residents participated in a CPR manoeuvre using a real-time feedback simulator to learn chest compressions concurrently developing additional secondary tasks. Heart rate, respiration rate, galvanic skin response, body temperature, eye gaze movements and chest compression performance data were collected. The findings of this study indicated that multitasking impacted negatively in chest compression performance. Nevertheless, this change on vital signs was different depending

on the type of secondary task accomplished. Understanding cognitive load and its impact on vital signs can aid in training FRs to handle complex scenarios efficiently.

- Augmented Reality Application for Macular Degeneration. David Méndez Encinas (UTAD)

An augment reality application has been developed in this project to simulate the age-related macular degeneration (AMD) in different stages. AMD is characterized by the emergence of a central scotoma in patients' vision, which, upon progression to its most advanced stage, leads to vision loss that may result in complete loss of visual acuity. In Europe, AMD affects approximately 20% of the population aged 65 to 75. The current scale for assessing AMD severity primarily relies on ophthalmologists' evaluations of the ocular fundus; however, this method fails to account for patients' functional performance in daily activities.

To address this limitation, the tool makes data collection on ocular patterns and user performance during routine tasks easier. Results indicated that enlargement of the central scotoma adversely affects the execution of simple activities, such as color and shape recognition, by significantly increasing task completion times. This application has enhanced awareness among medical professionals and families of AMD patients, while demonstrating the potential of immersive technologies in patient interaction and ophthalmic practices.

- Optimization of Process Management in the SimuPaz. Alfonso Jurado (UPM)

A digital tool was designed to enhance the management of training processes at SimuPaz. This tool enables the collection, storage, and analysis of data, thereby facilitating decision-making and optimizing the logistics of training activities. The system incorporates a centralized repository, web-based access, multi-user management, real-time synchronization, and an intuitive interface to streamline training logistics. Diverse forms were implemented for data collection, including course requests, resource management, and student enrolment tracking.

The project underwent validation testing to ensure data accuracy and system functionality. The results indicate that the digitalization of SimuPaz's course management has been significantly optimized compared to traditional processes. Future developments include the integration of Power BI for advanced analytics, automatic report generation, predictive maintenance, and satisfaction surveys to further refine the effectiveness of the training programs.

- Design and development of 3D models for training in coronary intervention. Jaime Llinás (UAM)

The design and development of 3D models for training in coronary intervention and the management of associated complications emerged as a collaborative effort between the Department of Cardiology at La Paz University Hospital, the 3D Laboratory, and the Advanced Center for Clinical Simulation and Training (SimuPaz). The stent placement and pericardiocentesis simulators facilitate the integration of theoretical knowledge with practical skills, resulting in more realistic, safe, and effective clinical care. In a training course, 27 cardiologists highlighted the utility and realism of the pericardiocentesis simulator in practical instruction.

- Development of a simulator for the detection of Venous thromboembolic. Inés López Ramos (URJC).

The objective of this thesis is the development of a simulator for the detection and diagnosis of deep vein thrombosis (DVT) using ultrasound. Venous thromboembolic disease (VTE) is a serious and potentially life-threatening condition characterized by the formation of thrombi within the venous system. It presents primarily in two forms: deep vein thrombosis (DVT) and pulmonary embolism (PE). Compression ultrasonography (CUS) is employed as a diagnostic method, which requires specialized training. Many hospitals lack additional simulators for training in this technique.

This simulator, created using 3D printing and a simulated blood flow system, enables healthcare professionals to train in a realistic and cost-effective manner in the use of ultrasonography for DVT detection. It improves training for one of the most severe and common pathologies, while reducing the need for more invasive diagnostic tests and the costs associated with diagnostic errors.

- Research about adaptive leadership in in medical-surgical teams. Ramón Rico (UC3M) y Manuel Quintana (UAM–H. La Paz).

The research project is developed at IdiPaz, Hospital La Paz in Madrid, is part of a study funded by the Ministry of Science and Innovation (MCI), entitled "Adaptive Team Leadership: Training Leaders and Team Members to Adapt to Unexpected and Novel Conditions." Adaptive leadership is understood as the ability of leaders and followers to dynamically adjust their leadership style according to situational demands, thereby promoting team effectiveness and the well-being of its members.

The objective is to analyse the impact of adaptive leadership in teams alternating between routine and novel situations, as well as to develop a training program to strengthen this capability in medical-surgical teams. Three analysis groups are distinguished in this study: one receiving training for both leaders and followers, another with training exclusively for leaders, and a control group. With the support of the Official College of Nursing of Madrid (CODEM), the sample will include between 60 and 90 teams composed of physicians and nurses. The results will not only contribute to the understanding of this leadership and adaptation model but will also enable the development of a healthcare training program and position CODEM as a national leader in innovation for team management and organization.

Activity of SimuPaz

In 2024, the centre underwent a rebranding process: what was formerly known as CEASEC is now SimuPaz, the Clinical Simulation Centre of Hospital Universitario La Paz. This change reflects a renewed commitment to innovation, educational excellence, and international visibility in clinical simulation.



SimuPaz - Foto by Edu Godfrey

During 2024, research within the centre has been promoted, both in the technological domain and in the field of educational research in clinical simulation.

The aim is to foster students' critical thinking and decision-making skills through problem-based learning. The main idea is to expose participants to a series of scenarios that allow for assessment of their problem-solving abilities and their actual competence in managing patients with EB and all its specificities.

The intention is to evaluate, through simulation, clinical competencies during the learning process via formative assessment, as well as final performance through summative assessment. Similarly, the study seeks to determine the effect of clinical simulation on learners' (both students and professionals) confidence in facing real-life situations, and how simulation contributes to creating a safer and more realistic clinical environment.


1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

2.6. Mentor and prementor program



2.6.1. Mentor Program

In 2024, IdiPAZ, with the support of La Paz University Hospital, has implemented the **4th Mentor Program** with the purpose of supporting our clinical early-stage researchers in the achievement of competitive projects, mainly from the main national call for health research projects: "Acción Estratégica en Salud (AES)", granted by Instituto de Salud Carlos III.

The Mentor Program plans a scientific and technical support in the preparation and tracking of research proposals. Furthermore, it takes into account the experience and scientific knowledge from our senior researchers to help our early-stage researchers from the beginning of their research career.

The objectives of the program are:

- Increasing the number of clinical research in IdiPAZ.
- Avoiding a generational leap of clinical researchers.
- Strengthening the research profile of our clinical staff.
- Positioning IdiPAZ as a model of clinical research, at the same level as it is in clinical trials.
- Performing an internal cultural change in clinical research.

Mentor Program includes different action plans have been implemented:

- To update the standardized curriculum for researchers.
- Enable synergies to create research groups.
- Support from the different platforms of IdiPAZ.
- Services of medical writing.
- Stand out the impact and the strategic priorities of the projects for the National Health System.

In the 4th **Mentor Program** 92 participants were included:

RESEARCHER	# PROPOSAL SUBMITTED
ALBERTO ALONSO BABARRO	PI25/01461
ALFONSO JUARDO ROMÁN	
ALMUDENA VAL BLASCO	PI25/00806
AMELIA JUDITH HESSHEIMER	PI25/00466
ANA BELÉN CUSTODIO CARRETERO	
ANA FERNÁNDEZ SANTANDER	PI25/00833
ANA ISABEL BOROBIA PÉREZ	PI25/01489
ANA LOURDES LUIS HUERTAS	PI25/00931
ÁNGEL MARTÍN MONTES	PI25/01343
ATILANO JOSÉ CARCAVILLA URQUI	PI25/01554
BEATRIZ BARQUIEL ALCALÁ	
BEATRIZ DÍAZ POLLÁN	PI25/00891
BLANCA TAPIA SALINAS	PI25/00273
CARLOS ANTONIO ÁLVAREZ ORTEGA	
CARLOS JAVIER CARPIO SEGURA	PI25/01310
CARLOS ZOZAYA NIETO	PI25/00523
CARMEN RODRÍGUEZ JIMÉNEZ	PI25/01002
CARMEN SOBRINO JIMÉNEZ	PI25/00857
CHAMAIDA PLASENCIA RODRÍGUEZ	PI25/00970
CRISTINA JULIA SUÁREZ FERRER	PI25/01141
DAVID RAMIRO CORTIJO	PI25/01062
DIEGO CARRACEDO SANCHIDRIÁN	
ELENA I. DIAGO SEMPERE	PI25/00946
ELENA VILLAMAÑÁN BUENO	PI25/00857
ELISA ALONSO LÓPEZ	PI25/00505
ELISABET GONZÁLEZ DEL PORTILLO	PI25/01544
ENRIQUE VILLAGRÁN MEDINILLA	PI25/01978
ESTER CARREÑO SALAS	PI25/00097
EUGENIA ANTOLÍN ALVARADO	PI25/01185
EVA MARÍN SERRANO	PI25/00493
FEDERICO DEL CASTILLO DÍEZ	PI25/01878
FEDERICO GUTIÉRREZ-LARRAYA AGUADO	PI25/01686
FERNANDO CORVILLO RODRÍGUEZ	PI25/00388
FRANCISCO HERNÁNDEZ OLIVEROS	PI25/00262
GUILLERMINA BEJARANO REDONDO	
GUILLERMO GARCÍA PEREZ DE SEVILLA	PI25/01307
INMACULADA PUERTAS MUÑOZ	PI25/00478
IRENE GARCÍA GARCÍA	PI25/01016

RESEARCHER	# PROPOSAL SUBMITTED
ISABEL VALBUENA GÓMEZ	PI25/00995
ISMAEL GHANEM CAÑETE	PI25/00530
JAVIER PIZONES ARCE	PI25/00330
JOSÉ LUIS DEL CASTILLO PARDO DE VERA	PI25/00858
JOSÉ MOSTAZA PRIETO	PI25/02038
JUAN CARO CODÓN	
JUAN JOSÉ BEUNZA NUIN	PI25/01389
JUAN JOSÉ MENÉNDEZ SUSO	PI25/00870
JUAN JOSÉ RÍOS BLANCO	PI25/01309
JUAN JOSÉ SEGURA SAMPEDRO	PI25/01392
LAURA GUTIÉRREZ SAINZ	PI25/00276
LAURA LACRUZ BALLESTER	PI25/00655
LUCÍA FERNÁNDEZ GASSÓ	PI25/00806
LUCÍA TRILLA FUERTES	PI25/00254
LUIS ALBERTO GLARIA ENRIQUEZ	PI25/01689
LUISA SISINNI	PI25/01391
LUNA RIDAN CORDEIRO MINUTE	
Mª ANGUSTIAS QUESADA SIMÓN	PI25/01431
Mª CARMEN BRAVO LAGUNA	PI25/01019
Mª JESÚS MORO ÁLVAREZ	PI25/01724
Mª MAR GIL MIRA	
MANUEL QUINTANA DÍAZ	PI25/00996
MARCOS JAVIER CUERVA GONZÁLEZ	PI25/00579
MARÍA CONCEPCIÓN PRADOS SÁNCHEZ	PI25/01708
MARÍA ISABEL ESTEBAN RODRÍGUEZ	PI25/01041
MARÍA NIEVES MORENO	
MARÍA OVIDIA LÓPEZ OLIVA	PI25/00274
MARÍA TERESA SANCHO BUESO	
MARIO ÁLVAREZ MAESTRO	
MARTA CADENAS MARTÍN	PI25/00290
MARTA DÍAZ MENÉNDEZ	PI25/00381
MARTA MOLERO LUIS	PI25/00489
MARTA NOVELLA NAVARRO	PI25/01020
MERCEDES GASIOR KABAT	PI25/00894
MIRIAM ALONSO MAZA	PI25/01636
ONICA M. ARMIJO SUÁREZ	
ÓSCAR PEÑUELAS RODRÍGUEZ	PI25/01032
PABLO BARREIRO GARCÍA	


RESEARCHER	# PROPOSAL SUBMITTED
PABLO MARISCAL AGUILAR	PI25/01310
PATRICIA CONDORHUAMAN ALVARADO	
PAULA RODRÍGUEZ MOLINO	PI25/00811
RAQUEL ARRANZ JIMÉNEZ	
ROCÍO MENÉNDEZ COLINO	PI25/01301
ROCÍO PRIETO PÉREZ	PI25/01379
ROCIO ROSAS ALONSO	PI25/00179
ROSA ALCOBENDAS RUEDA	PI25/00575

RESEARCHER	# PROPOSAL SUBMITTED
ROSARIO LÓPEZ LÓPEZ	
SAMUEL ANTUÑA ANTUÑA	PI25/00960
SARA RUIZ MARTÍNEZ	PI25/00567
SERGIO CASTREJÓN CASTREJÓN	PI25/00282
SUSANA NOVAL MARTÍN	PI25/01455
VÍCTOR GALÁN GÓMEZ	PI25/00382
YALE TUNG CHEN	PI25/01201
YOLANDA ALADRÓ BENITO	PI25/00548



The number of researchers who have participated in the program can be seen since the launch of the Mentor Program at IdiPAZ in the following chart:

Number of mentorees per year



The program is supported by a network of **senior mentors** from different fields and professional expertise. The mentors provide mentees constructive feedback, putting at their disposal all their experience, dedication and motivation, supporting the process of preparing their research project proposals.


In the 4th **Mentor Program** 36 senior mentor have collaborated:

MENTOR	# MENTORED PROPOSAL
ADELINA PELLICER MARTÍNEZ, PhD	PI25/01019
ALBERTO MANUEL BOROBIA PÉREZ, PhD	PI25/00274 PI25/00282 PI25/00857 PI25/00858 PI25/00870 PI25/00995 PI25/01016 PI25/01032 PI25/01489 PI25/01978
ANA SASTRE PERONA, PhD	PI25/00833 PI25/00931 PI25/00996
ANTONIO PÉREZ MARTÍNEZ, PhD	PI25/00382
BERTA RODÉS SOLDEVILA, PhD	PI25/00493
BLANCA FUENTES GIMENO, PhD	PI25/00548
CARLOS DEL FRESNO SÁNCHEZ, PhD	PI25/00960 PI25/01689
CONSTANTINO FONDEVILA CAMPO, PhD	PI25/00273 PI25/01544
CRISTINA CALVO REY, PhD	PI25/00575 PI25/00811
EDUARDO LÓPEZ GRANADOS, PhD	PI25/01020
EDUARDO LÓPEZ-COLLAZO, PhD	PI25/00097
ESTHER PÉREZ DAVID, PhD	PI25/01201
EXUPERIO DIEZ-TEJEDOR, PhD	PI25/00655
FERNANDO MARTÍN SÁNCHEZ, PhD	PI25/00530
ISABEL LASTRES BECKER, PhD	PI25/00505
JAVIER DE CASTRO CARPEÑO, PhD	PI25/00179 PI25/00276 PI25/01041
JOSE LUIS BARTHA RASERO, PhD	PI25/00579 PI25/01185
JOSE LUIS MERINO LLORENS, PhD	PI25/00806 PI25/01301
JOSE RAMÓN ARRIBAS LÓPEZ, PhD	PI25/00891 PI25/01309
JUAN JOSÉ BEUNZA NUIN, PhD	PI25/00330 PI25/00970
KAREN ELISE HEATH, PhD	PI25/00254
LAURA OTERO ORTEGA, PhD	PI25/00478
MARÍA ALONSO DE LECIÑANA CASES, PhD	PI25/01343
MARIA FERNANDEZ VELASCO, PhD	PI25/00806
MARÍA GUTIÉRREZ FERNÁNDEZ, PhD	PI25/00262
MARÍA PAZ DE MIGUEL GONZÁLEZ, PhD	PI25/00290
MIGUEL ANGEL SALINERO FORT, PhD	PI25/01431 PI25/02038
MIGUEL SÁENZ DE PIPAÓN MARCOS, PhD	PI25/00523 PI25/00567
NORA VIVIANA BUTTA COLL, PhD	PI25/00894
NURIA VILABOA DÍAZ, PhD	PI25/01392
PILAR SÁNCHEZ-CORRAL GÓMEZ, PhD	PI25/00388 PI25/00489
REBECA PEREZ DE DIEGO, PhD	PI25/01141
RODOLFO ÁLVAREZ-SALA WALTHER, PhD	PI25/01310 PI25/01708
ROSA TORRES JIMÉNEZ, PhD	PI25/01002
SILVIA MAGDALENA ARRIBAS RODRÍGUEZ, PhD	PI25/01062
TALIA SAINZ COSTA, PhD	PI25/01455
SUPPORT PLATFORM FOR EARLY-STAGE RESEARCHERS	PI25/00381 PI25/00466 PI25/00946 PI25/01307 PI25/01379 PI25/01389 PI25/01391 PI25/01461 PI25/01554 PI25/01636 PI25/01686 PI25/01724 PI25/01878

In order to ensure that the research project proposals submitted by our early-stage researchers have a high degree of excellence, the Mentor Program has a training plan structured in webinars for each section of the application report.
In 2024, the following webinars were held as part of the Mentor Program training plan:

TOPIC	DATE	SPEAKER
FIS PROJECT PREPARATION KEYS. PROJECT EVALUATION.	17/10/2024	Daniel Quijada Alcón
METHODOLOGY: STRUCTURE, BIASES AND CONTINGENCY PLAN	24/10/2024	Daniel Quijada Alcón
GENDER PERSPECTIVE AND DIMENSION IN RESEARCH	31/10/2024	Daniel Quijada Alcón
PI PROFILE & DORA CRITERIA	14/11/2024	Daniel Quijada Alcón
STORYTELLING FOR PROJECT WRITING	21/11/2024	Jorge De Juan Fernández
METHODOLOGICAL PLANNING FOR CLINICAL TRIALS	28/11/2024	Alberto M. Borobia Pérez
ORCID IDENTIFIER	05/12/2024	Raúl Román Cañizares
HOW TO PREPARE A GOOD BUDGET	12/12/2024	Silvia Arce Santamaría Jéssica García Moscatel
EXPERIENCES OF PARTICIPATION IN THE MENTOR PROGRAM	19/12/2024	Daniel Quijada Alcón Fco Javier Díaz De Terán Velasco Mª Dolores Martín Arranz
STATISTICAL ANALYSIS	09/01/2025	María Jiménez González
CVA	16/01/2025	Raúl Román Cañizares
METHODOLOGICAL PLANNING FOR OBSERVATIONAL STUDIES	23/01/2025	Irene García García
BIBLIOMETRIC INDICATORS	30/01/2025	Raúl Román Cañizares
DATA MANAGEMENT PLAN. DATA PROTECTION	06/02/2025	Daniel Quijada Alcón Estela Sánchez Simón
STRATEGIC INTEREST OF THE PROJECT, DISSEMINATION AND CITIZEN ENGAGEMENT PLAN	13/02/2025	Daniel Quijada Alcón

In its fourth year, all the actions developed in the Mentor Program have led to an increase in the number of proposals applied to *Acción Estratégica en Salud* (AES) call for health research projects by IdiPAZ researchers:



In 2024, once the proposal deadline was expired, the Mentor Program organized an event where all support offered by our mentors was recognized. The Mentor Program want to thanks all the time and selfless support and time that mentors provide to the Program and to the mentees. In this event, an experience conference of mentors and mentees were held, so the audience could know deeply how to prepare an AES proposal and how the Mentor Program works from different points of views.



2.6.2. Prementor Program

IdiPAZ, with the support of La Paz University Hospital, has implemented the 1st Prementor Program with the purpose of supporting our predoctoral researchers in the achievement of their Doctorate.

The objectives of the program are:

- Increasing the number of researchers with a PhD in IdiPAZ.
- Promote high quality training of researchers.
- Performing an internal cultural change in translational research in biomedicine.

The Prementor Program planned a formative and technical support during the second and third tutorial courses of our predoctoral researchers' doctoral studies. The following webinars have been held as part of the Prementor Program training plan:

DATE	TOPIC	SPEAKER
20/09/2024	HOW TO ESTABLISH A RESEARCH QUESTION/HYPOTHESIS	DANIEL QUIJADA ALCÓN
18/10/2024	ETHICS AND SCIENTIFIC FRAUD	NORA BUTTA COLL
15/11/2024	PREPARING AND CLEANING DATABASES	MARÍA TERESA GARÍA MORALES
20/12/2024	FIGURES, VISUALIZATION AND DATA ANALYSIS	MARÍA JIMÉNEZ GONZÁLEZ
17/01/2025	IDIPAZ SUPPORT PLATFORMS FOR EXPERIMENTAL WORK	GEMA VALLÉS PÉREZ
21/02/2025	ORAL COMMUNICATIONS AND POSTER DESIGN	EMANUELA SPAGNOLO
25/04/2025	PROTECTION OF RESULTS	ESTELA SÁNCHEZ SIMÓN
23/05/2025	TOOLS FOR THE EMOTIONAL MANAGEMENT DURING THE DEVELOPMENT OF THE THESIS	ÁNGELA PALAO TARRERO
13/06/2025	TIPS FOR PUBLICATION AND SCIENTIFIC DISSEMINATION	ANA Mª SASTRE PERONA
20/06/2025	THESIS DEFENSE	REBECA PÉREZ DE DIEGO

In the 1st Prementor Program 69 participants were included:

DOCTORAL STUDENT	UNIVERSITY
AARON ABDELKADER GUILLÉN	UNIVERSIDAD AUTÓNOMA DE MADRID
ALEJANDRO DE GEA GRELA	UNIVERSIDAD AUTÓNOMA DE MADRID
ALICIA MARÍN CANDÓN	UNIVERSIDAD AUTÓNOMA DE MADRID
ANDREA BUENO SEN	UNIVERSIDAD AUTÓNOMA DE MADRID
ANDREA GUZMÁN DE ANTONIO	UNIVERSIDAD AUTÓNOMA DE MADRID
ANDREA LOPEZ SUAREZ	UNIVERSIDAD COMPLUTENSE DE MADRID
ARIADNA WITTE CASTRO	UNIVERSIDAD COMPLUTENSE DE MADRID
BEATRIZ NIETO CARVALHAL	UNIVERSIDAD AUTÓNOMA DE MADRID
BLANCA FABRE ESTREMERA	UNIVERSIDAD AUTÓNOMA DE MADRID
CARLOS DELGADO MIGUEL	UNIVERSIDAD AUTÓNOMA DE MADRID
CARLOS RODRÍGUEZ ANTOLÍN	UNIVERSIDAD AUTÓNOMA DE MADRID
COLOMA GRAU VAN LAAK	UNIVERSIDAD AUTÓNOMA DE MADRID
CRISTINA DE MANUEL GÓMEZ	UNIVERSIDAD AUTÓNOMA DE MADRID
CRISTINA MARCELO CALVO	UNIVERSIDAD AUTÓNOMA DE MADRID
DARÍO SÁNCHEZ CABRERO	UNIVERSIDAD AUTÓNOMA DE MADRID
DIEGO MORANTE MARTÍNEZ	UNIVERSIDAD AUTÓNOMA DE MADRID
EDUARDO CAZALLA IBÁÑEZ	UNIVERSIDAD AUTÓNOMA DE MADRID
ELENA MARTÍNEZ ROBLES	UNIVERSIDAD AUTÓNOMA DE MADRID
ENRIQUE ALFARO GARCIA	UNIVERSIDAD AUTÓNOMA DE MADRID
FRANCISCO DE BORJA NAVA HURTADO DE SARACHO	UNIVERSIDAD AUTÓNOMA DE MADRID
GABRIEL TORRES IGLESIAS	UNIVERSIDAD AUTÓNOMA DE MADRID
GEMA YAGÜE DE ANTONIO	UNIVERSIDAD DE LEÓN
GONZALO SÁENZ DE SANTA MARÍA DIEZ	UNIVERSIDAD AUTÓNOMA DE MADRID
GUILLERMO MANUEL SIBÓN SANCHO	UNIVERSIDAD NACIONAL DE EDUCACIÓN A DISTANCIA
GUILLERMO MARTÍN ÁVILA	UNIVERSIDAD EUROPEA DE MADRID

DOCTORAL STUDENT	UNIVERSITY
IGNACIO SILVA LLANES	UNIVERSIDAD AUTÓNOMA DE MADRID
IRENE BARRIENTOS RUIZ	UNIVERSIDAD AUTÓNOMA DE MADRID
ISABEL DIAZ SUAREZ	UNIVERSIDAD DE NAVARRA
ISABEL GONZÁLEZ BERTOLÍN	UNIVERSIDAD AUTÓNOMA DE MADRID
ISABEL MELLADO SOLA	UNIVERSIDAD AUTÓNOMA DE MADRID
ISABEL MELLADO SOLA	UNIVERSIDAD AUTÓNOMA DE MADRID
ISABEL MORENO PARRO	UNIVERSIDAD AUTÓNOMA DE MADRID
JAVIER POZO NOVOA	UNIVERSIDAD AUTÓNOMA DE MADRID
JAVIER SERRADILLA RODRIGUEZ	UNIVERSIDAD AUTÓNOMA DE MADRID
JESÚS PEÑA LÓPEZ	UNIVERSIDAD AUTÓNOMA DE MADRID
JOSÉ MARÍA RODRÍGUEZ PIÑAS	UNIVERSIDAD EUROPEA DE MADRID
JULIA DEL PRADO MONTERO	UNIVERSIDAD AUTÓNOMA DE MADRID
LAURA BRAVO ROBLES	UNIVERSIDAD AUTÓNOMA DE MADRID
LAURA CLARES VILLA	UNIVERSIDAD AUTÓNOMA DE MADRID
LAURA GARCIA ESPINOSA	UNIVERSIDAD AUTÓNOMA DE MADRID
LUCIA GUTIÉRREZ GARCÍA	UNIVERSIDAD AUTÓNOMA DE MADRID
MARI PAZ LÓPEZ MOLINA	UNIVERSIDAD AUTÓNOMA DE MADRID
MARÍA DE CEANO-VIVAS LA CALLE	UNIVERSIDAD AUTÓNOMA DE MADRID
MARÍA DEL ROSARIO GARCÍA SÁNCHEZ	UNIVERSIDAD COMPLUTENSE DE MADRID
MARIA JESUS ESPINOSA PASCUAL	UNIVERSIDAD COMPLUTENSE DE MADRID
MARIA JOSE ROL GARCIA	UNIVERSIDAD AUTÓNOMA DE MADRID
MARÍA PÉREZ PASCUAL	UNIVERSIDAD AUTÓNOMA DE MADRID

DOCTORAL STUDENT	UNIVERSITY
MARÍA SÁNCHEZ MARTÍN	UNIVERSIDAD AUTÓNOMA DE MADRID
MARÍA SANZ DE PEDRO	UNIVERSIDAD AUTÓNOMA DE MADRID
MARIA VARELA CERDEIRA	UNIVERSIDAD AUTÓNOMA DE MADRID
MARTA LUISA MUNER HERNANDO	UNIVERSIDAD AUTÓNOMA DE MADRID
MIKEL FERNÁNDEZ ARTAZCOZ	UNIVERSIDAD AUTÓNOMA DE MADRID
MÓNICA BEOBIDE CONDE	UNIVERSIDAD REY JUAN CARLOS
NEILA RODRÍGUEZ ROCA	UNIVERSIDAD AUTÓNOMA DE MADRID
NURIA LOURDES PÉREZ CHULIÁ	UNIVERSIDAD AUTÓNOMA DE MADRID
PALOMA MARTÍNEZ CAMPOS	UNIVERSIDAD AUTÓNOMA DE MADRID
PAULA ARAGÓN RAMOS	UNIVERSIDAD AUTÓNOMA DE MADRID
PAULA CANTOLLA PABLO	UNIVERSIDAD AUTÓNOMA DE MADRID
PAULA PATRICIA BURGOS MORALES	UNIVERSIDAD AUTÓNOMA DE MADRID
PAULA PÉREZ MORENO	UNIVERSIDAD AUTÓNOMA DE MADRID
PELAYO FERNÁNDEZ CIDÓN	PENDIENTE
RAQUEL CASITAS MATEO	UNIVERSIDAD AUTÓNOMA DE MADRID
REBECA GALLEGO RUIZ	UNIVERSIDAD AUTÓNOMA DE MADRID
RICARDO JAIME RIGUAL BOBILLO	UNIVERSIDAD AUTÓNOMA DE MADRID
SONIA ALCOLEA	UNIVERSIDAD AUTÓNOMA DE MADRID
SONIA MILKOVA IVANOVA	UNIVERSIDAD AUTÓNOMA DE MADRID
TAMARA DOMINGO PÉREZ	UNIVERSIDAD DE NAVARRA
TERESA MATO PATINO	UNIVERSIDAD AUTÓNOMA DE MADRID
VICTORIA ARNALICH MONTIEL	UNIVERSIDAD AUTÓNOMA DE MADRID

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

2.7. CIBERs and RETICs

In 2024, IdiPAZ engaged actively in various thematic networks and research consortiums officially acknowledged by the Carlos III Health Institute.

PROJECT	ACRONYM	IMAGE	CIBER	FUNDING ORGANISATIONS	PRINCIPAL RESEARCHER	IdiPAZ GROUP	INSTITUTION	END DATE
CB06/05/0007	CIBERNED	ciber | NED	Centro de Investigación en Red de Enfermedades neurodegenerativas	Carlos III Health Institute	Bullido Gómez-Heras MJ.	Neurology and Cerebrovascular Diseases	FIBHULP	31/12/2024
CB06/05/0010	CIBERNED	ciber | NED	Centro de Investigación Biomédica en Enfermedades Neurodegenerativas	Carlos III Health Institute	Cuadrado Pastor A.	Neuroprotective Strategies in Neurodegenerative Diseases	UAM	31/12/2024
CB07/08/0033	CIBERDEM	ciber | DEM	Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas	Carlos III Health Institute	Martínez Valverde A.	Neuroprotective Strategies in Neurodegenerative Diseases	CSIC	31/12/2024
CB16/11/00286	CIBERCV	ciber | CV	Centro de Investigación Biomédica en Red Enfermedades Cardiovaculares	Carlos III Health Institute	Briones Alonso AM.	Vascular Physiology and Pharmacology	UAM	31/12/2024
CB21/13/00039	CIBERInfect	ciber | INFEC	Centro de Investigación Biomédica en Red de Enfermedades Infecciosas	Carlos III Health Institute	Arribas López JR.	AIDS and Infectious Diseases	FIBHULP	31/12/2024
CB19/07/00042	CIBERer	ciber | ER	Centro de Investigación Biomédica en Red de Enfermedades Raras	Carlos III Health Institute	Lopez Granados E.	Lymphocytic Pathophysiology in Immunodeficiencies	FIBHULP	31/12/2024
CB15/00037	CIBERes	ciber | ES	CIBER de Enfermedades Respiratorias	Carlos III Health Institute	García Río F.	Respiratory diseases	FIBHULP	31/12/2025
CB06/07/1033	CIBERer	ciber | ER	Centro de Investigación en Red de Enfermedades Raras	Carlos III Health Institute	Caballero Molina MT.	Diagnosis and treatment of allergic diseases	FIBHULP	31/12/2024
CB06/07/1005	CIBERer	ciber | ER	CIBER Enfermedades Raras	Carlos III Health Institute	Lapunzina Badía P.	INGEMM - Institute of Medical and Molecular Genetics	FIBHULP	31/12/2025
CB16/12/00398	CIBERonc	ciber | ONC	Networked Biomedical Research Center for Cancer	Carlos III Health Institute	Feliú Batlle J.	Translational Oncology	FIBHULP	31/12/2024
CB06/07/1021	CIBERer	ciber | ER	Centro de Investigación en Red de Enfermedades Raras	Carlos III Health Institute	Varela Nieto I.	Research in Otoneurosurgery	CSIC	31/12/2024
CB16/12/00273	CIBERonc	ciber | ONC	Networked Biomedical Research Center for Cancer	Carlos III Health Institute	Muñoz Terol A.	Mechanisms of Tumor Progression	CSIC	31/12/2025
CB06/07/0004	CIBERer	ciber | ER	Centro de Investigación en Red de Enfermedades Raras	Carlos III Health Institute	Pérez González MB.	Research and Diagnosis of Hereditary Metabolic Diseases	UAM	31/12/2024
CB06/01/0008	CIBER-bbn	ciber | BBN	Networked Biomedical Research Center for Bio-engineering, Biomaterials and Nanomedicine	Carlos III Health Institute	Vilaboa Díaz NE.	Bone Pathophysiology and Biomaterials	FIBHULP	31/12/2025
CB06/04/0011	CIBERehd	ciber | EHD	CIBER de Enfermedades Hepáticas y Digestivas	Carlos III Health Institute	Fondevila Campo C.	Translational research and innovation in general and digestive surgery	FIBHULP	31/12/2025

PROJECT	ACRONYM	IMAGE	CIBER	FUNDING ORGANISATIONS	PRINCIPAL RESEARCHER	IdiPAZ GROUP	INSTITUTION	END DATE
CB21/13/00025	CIBERINFEC	ciber INFEC	Centro de Investigación Biomédica en Res en Enfermedades Infecciosas	Carlos III Health Institute	Calvo Rey C.	Respiratory, systemic and neurological infectious pathology in childhood, and host immune response	FIBHULP	31/12/2024
CB16/10/00464	CIBERFES	ciber FES	Centro de Investigación Biomédica en Red en Fragilidad y Envejecimiento Saludable	Carlos III Health Institute	Rodríguez Mañas L.	Frailty and Healthy Aging	FIBHUG	31/12/2024

Networks and Platforms

IdiPAZ is integrated into various Platforms and Networks for Cooperative Research in Health, which are collaborative frameworks aimed at executing interdisciplinary research initiatives.

PROJECT	ACRONYM	IMAGE	RETICS	FUNDING ORGANISATIONS	PRINCIPAL RESEARCHER	IdiPAZ GROUP	INSTITUTION	END DATE
RD21/0006/0012	RICORS	RICORS-ICTUS Instituto de Salud Carlos III	Enfermedades vasculares cerebrales	Carlos III Health Institute	Fuentes Gimeno B.	Neurology and Cerebrovascular Diseases	FIBHULP	31/12/2025
RD21/0002/ CRG11	RICORS	Red de Enfermedades Inflamatorias RICORS (RD21/0002)	Inflamación	Carlos III Health Institute	Otero Ortega L.	Neurology and Cerebrovascular Diseases	FIBHULP	31/12/2024
CA20121	BenBedPhar	BenBedPhar	Bench to bedside transition for pharmacological regulation of NRF2 in noncommunicable diseases	EU European COST Action	Cuadrado Pastor A, Rojo Sanchís AI.	Neuroprotective Strategies in Neurodegenerative Diseases	Victor Babes Research (Romania)	18/10/2025
	ECLip	European Consortium of Lipodystrophies	The European Consortium of Lipodystrophies	European Union	López Trascasa M.	Alterations of the Complement System in Human Pathology	FIBHULP	31/12/2024

PROJECT	ACRONYM	IMAGE	RETICS	FUNDING ORGANISATIONS	PRINCIPAL RESEARCHER	IdiPAZ GROUP	INSTITUTION	END DATE
RD21/0005/0030		RICORS2040	Inflamación e inmunopatología de órganos y sistemas	Carlos III Health Institute	Fernández Juárez GM.	Nephrology	FIBHULP	31/12/2024
PT20/00002	ITEMAS	itemas isciii	Dinamización e innovación de las capacidades industriales del SNS y su transferencia al sector productivo	Carlos III Health Institute	de Castro Carpeño J.	Experimental Therapies and Biomarkers in Cancer	FIBHULP	31/12/2024
PT20/00036		SCReN Spanish Clinical Research Network ISCIII	Unidad de Investigación clínica y ensayos clínicos del Hospital Universitario la Paz	Carlos III Health Institute	Carcas Sansuán A.	Clinical Pharmacology	FIBHULP	31/12/2024
	ECRIN	ecrin	European Clinical Research Infraestructures Network	European Union	Carcas Sansuán A.	Clinical Pharmacology	FIBHULP	31/12/2024
PTC20/00018		SCReN Spanish Clinical Research Network ISCIII	Plataforma ISCIII de soporte para la Investigación Clínica	Carlos III Health Institute	Carcas Sansuán A.	Clinical Pharmacology	FIBHULP	31/12/2024
PTC23/00006		ECRIN EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORK	Coordinación Plataforma de Apoyo a la Investigación Clínica	Carlos III Health Institute	Borobia Pérez A.	Clinical Pharmacology	FIBHULP	31/12/2026
RD21/0012/0014	SAMID	RED SAMID RICORS	Primary Care Interventions to Prevent Maternal and Child Chronic Diseases of Perinatal and Developmental Origin	Carlos III Health Institute	Cabañas González F.	Neonatology	FIBHULP	31/12/2025
	RARE-LIVER	European Reference Networks / ERN RARE-LIVER	ERN on Hepatological diseases	European Union	Hierro Llanillo L.	Molecular Hepatology	FIBHULP	31/12/2024
	TransplantChild	TransplantChild	ERN on Transplantation in children	European Union	Jara Vega P.	Molecular Hepatology	FIBHULP	31/12/2024

PROJECT	ACRONYM	IMAGE	RETICS	FUNDING ORGANISATIONS	PRINCIPAL RESEARCHER	IdiPAZ GROUP	INSTITUTION	END DATE
	RELECOV		Red de Laboratorios Españoles de secuenciación Genómica de SARS-CoV-2	European Union	Casas Flecha I.	Respiratory, systemic and neurological infectious pathology in childhood, and host immune response	FIBHULP	31/12/2024
RD21/0017/0025	RICORS		Terapias avanzadas	Carlos III Health Institute	Pérez Martínez A.	Translational research in childhood cancer, hematopoietic transplantation, and cell therapy	FIBHULP	01/01/2024
RD21/0016/0027	RICAPPS		Red de Investigación en Cronicidad, Atención Primaria y Promoción de la Salud	Carlos III Health Institute	Salinero-Fort MA.	Frailty, multimorbidity patterns and mortality in the community-dwelling elderly population	FIIBAP	31/12/2025
	RICAPPS		Red de Investigación en Cronicidad, Atención Primaria y Promoción de la Salud	Carlos III Health Institute	Castell Alcalá V.	Frailty, multimorbidity patterns and mortality in the community-dwelling elderly population	FIIBAP	31/12/2025
PT20/00004			Plataforma de biobanco y biomodelos (organoides) del Instituto de Investigación Sanitaria del Hospital Universitario La Paz	Carlos III Health Institute	Gómez Campelo P.	Frailty, multimorbidity patterns and mortality in the community-dwelling elderly population	FIBHULP	31/12/2024
PT23/00028			Plataforma de Biomodelos y Biobanco de IdiPAZ	Carlos III Health Institute	López Collazo E		FIBHULP	31/12/26
PT23/00035			Plataforma de Dinamización e Innovación de las Capacidades Industriales del SNS y su Transferencia Efectiva al Sector Productivo	Carlos III Health Institute	de Castro Carpeño J		FIBHULP	31/12/26
PT23/00064			Unidad del Hospital Universitario La Paz de la Plataforma ISCIII de Apoyo a la Investigación Clínica	Carlos III Health Institute	Borobia Pérez AM		FIBHULP	31/12/26

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

2.8. Communication and public engagement

The main goals of Scientific Communications are to publish the research conducted by the talented scientists at IdiPAZ and to strengthen our connections with other institutions and the public.

We have seen a boost in media coverage for our research and activities, with a noticeable rise in press appearances and social media engagement. This surge is largely due to the active participation of many of IdiPAZ's researchers.

Thanks to the collaborative efforts of our center's scientists, IdiPAZ has taken part in events like the European Researchers' Night, Science and Innovation Week, and the International Day of Women and Girls in Science. We have also organized guided tours for high school students, offering both virtual and in-person visits, along with talks and workshops tailored for kids and schools.

We want to extend our gratitude to the communication office at **La Paz University Hospital** for their support

2.8.1. Selected media appearances

In 2024, we have published 18 press releases highlighting IdiPAZ's scientific achievements. Below is a summary of the year's most significant headlines.



03/01/2024 – La sanidad madrileña, primera de España con un brazo robótico para operaciones de columna vertebral



06/01/2024 – El hospital público La Paz gana el VI Concurso de Belenes sanitarios de la Comunidad de Madrid con un récord de participación



11/02/2024 – La Comunidad de Madrid celebra el Día Mundial de la Mujer y la Niña en la Ciencia con su divulgación desde la sanidad pública regional



14/02/2024 – La sanidad pública madrileña lidera el primer ensayo clínico en el mundo con una terapia CAR-T alogénica para sarcomas pediátricos



15/02/2024 – La Comunidad de Madrid inaugura el nuevo Hospital de Día de Hemato-oncología pediátrica del Hospital público La Paz



19/02/2024 – La sanidad pública madrileña aplica una terapia avanzada en un bebé tras detectarse el primer caso de atrofia muscular espinal en la región



01/03/2024 – La Comunidad de Madrid, pionera en España al estrenar en el Hospital público La Paz la primera Unidad para tratar enfermedades raras en niños



26/03/2024 – La sanidad pública madrileña, pionera en España en la extracción parcial de hígado de donante vivo mediante cirugía robótica

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians



13/05/2024 – El Hospital público La Paz de la Comunidad de Madrid, a la vanguardia en innovación sanitaria con su programa de IA para vigilar la salud de los astronautas



18/06/2024 – Díaz Ayuso presenta la Ciudad de la Salud, el complejo sanitario público más grande de Europa: "Es el proyecto más importante de la Legislatura"



27/06/2024 – El Hospital Universitario La Paz atiende más de 300 pacientes al año de toda España en su Unidad Multidisciplinar de ELA



19/08/2024 – La Comunidad de Madrid, primera de Europa en tratar la hidrocefalia con un brazo robótico en su sanidad pública



11/09/2024 – Una línea roja recorre el Hospital público La Paz para concienciar a los pacientes que han sufrido un infarto de miocardio sobre la importancia de reducir su colesterol LDL



05/11/2024 – La Comunidad de Madrid instruye a más de 1.500 profesionales en el Centro Avanzado de Simulación Clínica del Hospital público La Paz



05/11/2024 – Los hospitales públicos Ramón y Cajal y La Paz apoyan la creación de una Unidad de Cirugía Máxilofacial en África



04/12/2024 – El Hospital público La Paz y el SUMMA 112, premiados por un desarrollo informático sobre el Código Infarto



23/11/2024 – El Hospital público La Paz de la Comunidad de Madrid implanta un dispositivo cardíaco intracorpóreo por primera vez en España a un paciente pediátrico



26/12/2024 – Díaz Ayuso anuncia que en enero se licitarán las obras para construir las dos primeras infraestructuras de la Ciudad de la Salud

2.8.2. Scientific Newsletter: IdiPAZ+ii News

In the year 2024, the scientific culture unit has published two newsletters, each concentrating on different subjects pertinent to researchers.


IdiPAZ+ii News

BOLETÍN DE INFORMACIÓN CIENTÍFICA DEL IDIPAZ

PRIMER ENCUENTRO DE PARTICIPACIÓN CIUDADANA EN IDIPAZ


IdiPAZ+ii News

BOLETÍN DE INFORMACIÓN CIENTÍFICA DEL IDIPAZ

I JORNADA "LA INVESTIGACIÓN DE ATENCIÓN PRIMARIA" EN IDIPAZ

Evidencias Epidemiológicas sobre Multimorbilidad y Mortalidad en la Población Anciana Residente en la Comunidad de Madrid

1 Introduction


2 Executive summary

3 Research areas and groups

4 Associated clinicians

2.8.3. Our new website

In 2024, we have started the creation of a new website that will bring together all the work we are carrying out and allow us to disseminate it to society. This project aims to be a meeting point between the scientific community and the public. We are pleased to announce the launch of the new website on May 22, 2025, which achieved 5,946 visits in that same month.



1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

2.8.4. Formative Pills about Sustainable Development Goals and Responsible Research and Innovation

We are dedicated to promoting good practices related to the Sustainable Development Goals (SDGs) through our bite-sized training sessions. In 2024, we rolled out 46 training sessions focused on the 2030 Agenda, SDGs, and Responsible Research and Innovation.

04-jan	Nº 01/2024: Campaña de vacunación
05-jan	Nº 02/2024: Formación en Prevención de Riesgos (FREMAP)
12-jan	Nº 03/2024: Día Mundial contra la Depresión
19-jan	Nº 04/2024: Propuestas de Actividades del Día de la Mujer y la Niña
26-jan	Nº 05/2024: Día Mundial de educación ambiental
29-jan	Nº 06/2024: Curso de RRI en Biomedicina
14-feb	Nº 07/2024: Política y compromiso con los Objetivos de Desarrollo Sostenible
14-feb	Nº 08/2024: Actualización del Plan de Prevención de Riesgos Laborales
14-feb	Nº 09/2024: Jornada Día Internacional de la Mujer y la Niña en la Ciencia
22-feb	Nº 10/2024: XV Aniversario de IdiPAZ: Día Internacional de la Mujer y la Niña en la Ciencia en IdiPAZ
28-feb	Nº 11/2024: Cuídate (Programas formativos FREMAP)
01-mar	Nº 12/2024: Día de la Cero Discriminación
08-mar	Nº 13/2024: Día Internacional de la Mujer.
25-mar	Nº 14/2024: Píldora IdiPAZ Sostenible: Cuídate Programas Formativos FREMAP. Convocatoria: Innovar para prevenir.
02-apr	Nº 15/2024: Cuídate Programas Formativos de FREMAP. Formación: "Habilidades de escucha y desescalada de conflictos para el trabajo en equipo en el ámbito de la investigación". Formación: "Principios en Investigación e Innovación Responsable".
09-apr	Nº 16/2024: Formación: "Habilidades de escucha y desescalada de conflictos para el trabajo en equipo en el ámbito de la investigación".
12-apr	Nº 17/2024: Día Mundial sin Tabaco.
23-apr	Nº 18/2024: IdiPAZ Sostenible: "Día Mundial de la Madre Tierra".
26-apr	Nº 19/2024: Formación: "Divulga tu ciencia".
30-apr	Nº 20/2024: Píldora IdiPAZ Sostenible: Cuídate. Programas Formativos FREMAP. Recordatorio curso: "Divulga tu Ciencia".
03-may	Nº 21/2024: Jornadas IdiPAZ: "Día Internacional de los EECC". Día Mundial del Cáncer de Vejiga. XVIII Maratón de Donación de Sangre. Recordatorio: "Divulga tu Ciencia".
06-may	Nº 22/2024: Recordatorio Jornadas IdiPAZ: "Día Internacional de los EECC". Alianza entre La Paz y La Cruz Roja en los servicios de geriatría. Recordatorio: "Maratón de sangre". Recordatorio: "Divulga tu Ciencia".
07-may	Nº 23/2024: Curso Divulga tu Ciencia.
08-may	Nº 24/2024: Recordatorio Jornadas IdiPAZ XV Aniversario. III Jornada Healthtech Observer.
13-may	Nº 25/2024: Recordatorio curso Agenda 2030.
14-may	Nº 26/2024: Formación: "Código de Conducta". Recordatorio: Día Internacional de los EECC.
29-may	Nº 27/2024: 33ª Píldora formativa REGIC: "Resolviendo conflictos mediante la comunicación".
03-jun	Nº 28/2024: Píldora formativa: Semana de la Ciencia.
07-jun	Nº 29/2024: XV Aniversario de IdiPAZ. Jornada de concienciación por el Día Mundial del Medio Ambiente.
27-jun	Nº 30/2024: Píldora IdiPAZ Sostenible: Cuídate (Programas Formativos FREMAP).
02-jul	Nº 31/2024: Día del Donante de Médula con la UME
18-jul	Nº 32/2024: Día Internacional del Donante de Médula Ósea: Pedalea con el equipo de La Paz.
04-sep	Nº 33/2024: IdiPAZ Sostenible: Programa de Formación FREMAP
11-sep	Nº 34/2024: Píldora formativa: Formación en Investigación e Innovación Responsable y ODS: ¿Qué nos aporta la divulgación científica?
16-sep	Nº 35/2024: Día Internacional del Donante de Médula Ósea. Canal Agenda 2030: Semana Europea de la Movilidad. La Paz acoge pruebas de drones para transporte sanitario en la Semana Europea de la Movilidad.
20-sep	Nº 36/2024: Recordatorio Día Internacional del Donante de Médula Ósea.

25-sep	Nº 37/2024: I Carrera Popular Día del Ictus 2024. Día Mundial de la Narcolepsia y del Síndrome de Piernas Inquietas o Enfermedad de Willis-Ekbom.
27-sep	Nº 38/2024: Píldora formativa: Carta de la Diversidad.
08-oct	Nº 39/2024: Formación "Taller Investigación e Innovación Responsable (RRI) en Biomedicina".
16-oct	Nº 40/2024: Talleres de RCP para ciudadanos y profesionales. Canal Agenda 2030: el Hospital fomenta el consumo de fruta por el Día Mundial de la Alimentación.
24-oct	Nº 41/2024: Recordatorio Programa Mentor: 2º Seminario Formativo. Día Internacional de la lucha contra el cáncer de pulmón: I Woman Lung Cancer. Jornada Día Mundial del Ictus. Sesión informativa: Prevención del maltrato en personas mayores.
25-oct	Nº 42/2024: Recordatorio Semana de la Ciencia y la Innovación.
05-nov	Nº 43/2024: Píldora formativa: Curso online de divulgación científica en biomedicina: acercando la ciencia al público.
07-nov	Nº 44/2024: Píldora Formativa. Curso online de divulgación científica en Biomedicina: Acercando la ciencia al público. XIX Maratón de donación de sangre.
08-nov	Nº 45/2024: Recordatorio Píldora Formativa. Curso online de divulgación científica en Biomedicina: Acercando la ciencia al público.
25-nov	Nº 46/2024: Semana de la ciencia y la Innovación 2024, XIX Maratón de donación de sangre



1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

2.9. Responsible Research and Innovation in IdiPAZ

Responsible Research and Innovation (RRI) serves as the framework for Science with and for Society, incorporating all essential actions intended to anticipate and evaluate potential consequences and societal expectations related to research and innovation. Its objective is to promote the development of inclusive and sustainable research and innovation. Guided by RRI principles, IdiPAZ is evolving to engage societal stakeholders in collaboration throughout the research process, ensuring that both the process and its results are in harmony with the values, needs, and expectations of society.

IdiPAZ has continued to develop several RRI actions:

Ethics and Research Integrity

HR EXCELLENCE IN RESEARCH

Human Resources Strategy for Researchers (HRS4R) encompasses the principles of the Charter and Code, a gap analysis, OTM-R, and the design of an action plan. In 2020, the European Commission awarded the institution the 'HR Excellence in Research Award'. Over the past few years, our efforts have been directed towards executing the second phase of the HRS4R strategy, which revolves around refining the Action Plan and its updated version following the mid-term evaluation, thus achieving the intermediate stage of this strategy. Currently, we are concentrating on enhancing all aspects of this implementation while maintaining our commitment to excellence.

Today, we continue to be dedicated to realizing the primary benefits provided by this strategy:

- Encouraging a supportive working atmosphere for research personnel.
- Promoting a transformation in the workplace culture.
- Becoming a member of the European network of research institutions.
- Enhancing human resources policies.
- Assisting in increasing the international visibility of the institute
- Own Ethics Committee: Research Ethics Committee for Medical Products and Animal Welfare Organization.

International Organization for Standardization (ISO) 9001 Certification for Committees and Platforms of IdiPAZ.

Open Access

At IdiPAZ, we promote and encourage our researchers to upload their papers and research data to institutional Open-Access Repositories.

Good Practice Recommendations Guidelines:

- Open Access: Review and update of our own Open Access Guideline of IdiPAZ (07/03/2025).
- Repisalud of Carlos III Health Institute
- Institutional Repository of the Regional Health System of the Community of Madrid
- Biblos-e Archivo of the Universidad Autónoma de Madrid
- Repositories allow researchers to collect, preserve, and make scientific production available to any interested person. This production is generated by professionals as a result of their assistance, research, and teaching activities, thus guaranteeing its conservation, open access, and promoting its visibility and dissemination.

Creation and promotion of the Scientific Seminars web archive, including online video recordings to connect with the scientific community and society.

IdiPAZ is a member of the European Open Science Cloud (EOSC) Association (https://eosc.eu) to:

- Accelerate the creation of open knowledge,
- Increase the re-use of research databases by the larger community,
- Inspire ways to share medical data that ensure respect for the privacy of personal information,
- Promote education in Open Science practices,
- Spur innovation and foster new jobs aimed at sustaining openness and the curation of research.

Implementation of Act 19/2013, of December 9, on transparency, access to public information, and good governance. FIBHULP has been registered in the Transparency Register of the Madrid AR since March 4, 2021, with registration number 202100170.

FIBHULP is currently listed in the European Union Transparency Register as of May 10, 2021, under registration number 86699642652-90.

The Institute informs all its members of IdiPAZ's commitments to current European policies regarding Open Science and RRI through its website.

Science Education

- Scientific dissemination activities: At IdiPAZ, we have a Communication Plan focused on planning the Institute's communication actions, both internal and external. In this way, the Citizen Participation Commission of IdiPAZ carries out activities and workshops with educational centers, associations, and the public, bringing science closer to society in a more humane way.
  - » Activities for International Day of Women and Girls in Science
  - » Activities for International Women's Day
  - » Activities for Science and Innovation Week
  - » Activities for European Researchers' Night
  - » 'Ciencia por la calle' program
- Scientific Culture and Innovation Unit of IdiPAZ

Public engagement

- Current information about clinical trials and research studies in different phases for patients.
- Society has the opportunity to collaborate with IdiPAZ via sponsorship and our Patronage Strategy - Pazito: colabora.
- IdiPAZ+ii News is an information bulletin focused on communicating to society that the hospital is not only a place to treat patients, but also a place where researchers strive to improve the health and well-being of our population through research and innovation projects.

Governance

IdiPAZ is a participating member of the Coalition for Advancing Research Assessment. The Coalition will help all kinds of research-performing organizations transition away from uninformative metrics (such as the Journal Impact Factor, h-index, and Shanghai rankings) towards a more comprehensive system of scientific quality evaluation, aligned with DORA and HRS4R.

Participative Governance: European Reference Network on pediatric transplantation (ERN TransplantChild), coordinated by our institution, TransplantChild Patients Committee.

Research Ethics Committee with Medical Products

Citizen Participation Commission of IdiPAZ: This commission aims to ensure compliance with the principles of Responsible Research and Innovation (RRI) and Open Science, following the recommendations of the European Commission. It is also committed to promoting the social and scientific responsibility of our researchers, aimed at advancing research and innovation for society. Through this committee, we have launched a process of integration of the Sustainable Development Goals and the 2030 Agenda, receiving certification in June 2022

for sustainable strategy by AENOR and recertifying in 2025 to maintain our commitment. The members of the commission include representatives of patients' associations, environmental associations, the hospital, and FIBHULP/IdiPAZ.

Complaint Channels: As part of the IdiPAZ social responsibility management system and attention to our stakeholders, we have enabled the following reporting channels:

- Code of Conduct
- Code of Ethics and Good Scientific Practices
- Protocol Against Harassment
- Action Against Fraud, Corruption, and Conflict of Interest
- Claims or Suggestions regarding Job Offers

Gender Equality

IdiPAZ's Commission for Equality and Diversity developed the Protocol for the Prevention and Response to Discriminatory Harassment, Moral Harassment, Sexual Harassment, and Harassment Based on Gender. This protocol aims to recognize, prevent, and, if necessary, eradicate all behaviours and organizational factors that reveal violent behaviour in the workplace. It promotes a healthy work environment and climate, both physically and psychologically.

We participate in the International Day of Women and Girls in Science, and follow these plans and protocols:

- II Equality and Diversity Plan, registered with REGCON (*Registro y Depósito de Convenios Colectivos, acuerdos colectivos de trabajo y Planes de Igualdad*) with code 28109182112021
- Preventing and addressing situations of internal conflict, violence, and harassment in Biomedical Research Foundations
- Human Resources Strategy for Researchers- HRS4R: endorsed the Charter and Code principles, gap analysis, OTM-R and action plan design.

Social Responsibility



The Institute has received accreditation from AENOR in Corporate Social Responsibility and Sustainable Strategy, marking a significant achievement as the first Health Research Institute in the Community of Madrid to earn this certification. This recognition highlights our dedication to responsibility across economic, environmental, and social domains, as well as in ethical management and transparency-core values that the institution upholds.

IQNet SR10:2015 Certification of the Social Responsibility Management System of IdiPAZ

This certification covers the multidisciplinary biomedical research activities and research management of IdiPAZ. The initial certification date was 19/03/2021, and it remains valid from 21/01/2025 to the present.

Certification of the Sustainability Strategy of IdiPAZ and its contribution to the SDGs

This involves the development of a sustainability management model aligned with the United Nations' proposals. The first certification date was 14/07/2022, and it is valid from 21/01/2025 to the present.

As a Health Research Institute, IdiPAZ holds a unique position within society, driving biomedical research and innovation while disseminating knowledge to the community and patients. IdiPAZ is committed to the Sustainable Development Goals (SDGs) set forth by the UN, and its integration into the 2030 Agenda represents a strategic and cross-cutting commitment that requires aligning its research and management activities with these goals.

In addition, we have continued our commitment to the Sustainable Development Goals and the 2030 Agenda, as well as our corporate social responsibility policy, which includes the activities and guidelines that are carried out to fulfil this commitment.

Goals to Transform Our World (SDGs)

In line with the Social Responsibility Strategy, IdiPAZ began working in 2021 on the Sustainable Development Goals proposed by the 2030 Agenda for Sustainable Development, which was adopted by all Member States of the United Nations. This agenda is a shared plan for peace and prosperity for people and the planet, now and in the future, and includes 17 Sustainable Development Goals (SDGs). After months of work, IdiPAZ achieved its first AENOR certification in sustainable strategy in June 2022, and it remains valid to the present.

A materiality study was conducted through a process of sending questionnaires to the institute's stakeholders, identifying and mapping all the institute's lines of research and projects. As a result of the analysis, IdiPAZ prioritized four Sustainable Development Goals, which were included in its Strategic Plan for research and innovation as follows:

Strategic SDG:

- 3. Good Health
- 4. Quality education
- 8. Decent work and Economic Growth
- 9. Innovation and Infrastructure

Relevant SDG:

- 5. Gender Equality
- 10. Reduced inequalities
- 17. Partnerships for the goals

Other SDG:

- 7. Affordable and clean energy
- 12. Responsible consumption and production
- 13. Climate action

The prioritized SDGs have been aligned and integrated with the objectives and axes of the Strategic Plan for Research and Innovation 2020-2024. Additionally, a first Sustainability Report was drawn up, which has been updated yearly and includes the entire process of implementing the SDGs in the institute and the actions to be developed since their implementation. The intention is for IdiPAZ to contribute to the implementation of the SDGs through its work on the seven strategic goals and targets. The objectives we are going to work on in the short and long term are as follows:

3.3 By 2030, end the epidemics of AIDS, tuberculosis, malaria and neglected tropical diseases and combat hepatitis, water-borne diseases and other communicable diseases.


3.4 By 2030, reduce by one third premature mortality from non-communicable diseases through prevention and treatment and promote mental health and well-being.

3.5 Strengthen the prevention and treatment of substance abuse, including narcotic drug abuse and harmful use of alcohol.

3.A Strengthen the implementation of the World Health Organisation Framework Convention on Tobacco Control in all countries, as appropriate.

3.B Support the research and development of vaccines and medicines for the communicable and no communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all.

3.C Substantially increase health financing and the recruitment, development, training and retention of the health workforce in developing countries, especially in least developed countries and small island developing States.





5.1 End all forms of discrimination against all women and girls everywhere

5.2 Eliminate all forms of violence against all women and girls in the public and private spheres, including trafficking, sexual, and other types of exploitation

5.4 Recognize and value unpaid care and domestic work through the provision of public services, infrastructure and social protection policies and the promotion of shared responsibility within the household and the family as nationally appropriate

5.5 Ensure women's full and effective participation and equal opportunities for leadership at all levels of decision making in political, economic and public life

5.B Enhance the use of enabling technology, in particular information and communications technology, to promote the empowerment of women

5.C Adopt and strengthen sound policies and enforceable legislation for the promotion of gender equality and the empowerment of all women and girls at all levels



8.3 Promote development-oriented policies that support productive activities, decent job creation, entrepreneurship, creativity and innovation, and encourage the formalisation and growth of micro-, small- and medium-sized enterprises, including through access to financial services

8.5 By 2030, achieve full and productive employment and decent work for all women and men, including for young people and persons with disabilities, and equal pay for work of equal value

8.6 By 2020, substantially reduce the proportion of youth not in employment, education or training

8.7 Take immediate and effective measures to eradicate forced labour, end modern slavery and human trafficking and secure the prohibition and elimination of the worst forms of child labour, including recruitment and use of child soldiers, and by 2025 end child labour in all its forms

8.8 Protect labour rights and promote safe and secure working environments for all workers, including migrant workers, in particular women migrants, and those in precarious employment



9.1 Develop quality, reliable, sustainable and resilient infrastructure, including regional and trans-border infrastructure, to support economic development and human well-being, with a focus on affordable and equitable access for all

9.2 Promote inclusive and sustainable industrialization and, by 2030, significantly increase the contribution of industry to employment and gross domestic product, in accordance with national circumstances, and double that contribution in the least developed countries.

9.3 Increase access of small industries and other enterprises, particularly in developing countries, to financial services, including affordable credit, and their integration into value chains and markets.


9.5 Enhance scientific research, upgrade the technological capabilities of industrial sectors in all countries, in particular developing countries, including, by 2030, encouraging innovation and substantially increasing the number of research and development workers per 1 million people and public and private research and development spending

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians



10 REDUCED INEQUALITIES

10.2 By 2030, empower and promote the social, economic and political inclusion of all, irrespective of age, sex, disability, race, ethnicity, origin, religion or economic or other status

10.3 Ensure equal opportunity and reduce inequalities of outcome, including by eliminating discriminatory laws, policies and practices and promoting appropriate legislation, policies and action in this regard

10.4 Adopt policies, especially fiscal, wage and social protection policies, and progressively achieve greater equality

12 RESPONSIBLE CONSUMPTION AND PRODUCTION

12.2 By 2030, achieve the sustainable management and efficient use of natural resources

12.4 By 2020, achieve the environmentally sound management of chemicals and all wastes throughout their life cycle, in accordance with agreed international frameworks, and significantly reduce their release to air, water and soil in order to minimise their adverse impacts on human health and the environment

12.5 By 2030, substantially reduce waste generation through prevention, reduction, recycling and reuse

12.8 By 2030, ensure that people everywhere have the relevant information and awareness for sustainable development and lifestyles in harmony with nature

17 PARTNERSHIPS FOR THE GOALS

17.6 Enhance North-South, South-South and triangular regional and international cooperation on and access to science, technology and innovation and enhance knowledge sharing on mutually agreed terms, including through improved coordination among existing mechanisms, in particular at the United Nations level, and through a global technology facilitation mechanism

17.17 Encourage and promote effective public, public-private and civil society partnerships, building on the experience and resourcing strategies of partnerships.

In our sustainability report, you can find information on our sustainability management and the implementation of the Sustainable Development Goals in our institute, as well as all the action plans that will be carried out in the coming years.


In relation to our commitment to the SDGs, throughout 2023, we have developed a series of campaigns that favor their achievement and support the environmental and social improvement of our surroundings.

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians



3 Research areas and groups



3.1. Neurosciences Area

Documents: 173 | Originals: 148 | D1: 39 | Q1:97



3.2.Cardiovascular Area

Documents: 215 | Originals: 155 | D1: 48 | Q1: 113



3.3. Infectious Diseases and Immunity Area

Documents: 270 | Originals: 223 | D1: 40 | Q1: 146



3.4. Large System Pathology Area

Documents: 308 | Originals: 218 | D1: 64 | Q1: 170



3.5. Cancer and Human Molecular Genetics Area

Documents: 171 | Originals: 150 | D1: 42 | Q1: 94



3.6. Surgery, Transplant and Health Technologies Area

Documents: 221 | Originals: 179 | D1: 28 | Q1: 103



3.7. Maternal Infant Child and Youth Research

Documents: 248 | Originals: 218 | D1: 32 | Q1: 114




3.8. Multidisciplinar Research In Healthy Aging

Documents: 61 | Originals: 47 | D1: 8 | Q1: 22

3.1. Neurosciences Area

Documents: 173 | **Originals:** 148 | **D1:** 39 | **Q1:**97

Area coordinator: Exuperio Díez Tejedor
coordinadorneurociencias@idipaz.es



RESEARCH GROUPS

3.1.1 Psychiatry and Mental Health
María Fe Bravo Ortíz

3.1.2 Neurology and Cerebrovascular Diseases
Exuperio Díez Tejedor/María Gutiérrez Fernández

3.1.3 Neuroprotective Strategies in Neurodegenerative Diseases
Ana Isabel Rojo Sanchís

3.1.4 Involvement of Glycinergic and Glutamatergic Systems in Central Nervous System Pathologies
Francisco Zafra Gómez

3.1.5 Mechanisms and Biomarkers in Neurodegenerative Diseases
Isabel Lastres Becker

3.1.6 Multiple Sclerosis Research
Yolanda Aladró Benito

Strategic Objectives	Development forecast for the coming years:	Actions
Neuroscience Area is composed of 5 research groups and has as general objectives the promotion of teaching, research and dissemination of knowledge in the field of neurosciences and neurological diseases, particularly in relation to clinical neurosciences.	Cohesion between different disciplines (biomedical research, engineering).	Performing annual workshops and seminars science
	Encourage and promote research among the healthcare staff who sometimes perceive research as something negative.	Training in research methodology in specialized health personnel and in training
	Innovation and technology transfer	Innovation promotion program that involves health organizations, research institutions and companies

HIGH IMPACT PUBLICATIONS

Fernández-Ginés R, Encinar JA, Escoll M, Carnicero-Senabre D, Jiménez-Villegas J, García-Yagüe AJ, González-Rodríguez A, García-Martínez I, Valverde AM, Rojo AI, **Cuadrado A**. Specific targeting of the NRF2/β-TrCP axis promotes beneficial effects in NASH. Redox Biol. 2024; 69: 103027. Article. IF: 11,9; D1

Cantero JL, Atienza M, Sastre I, **Bullido MJ**. Human in vivo evidence of associations between herpes simplex virus and cerebral amyloid-beta load in normal aging. Alzheimers Res Ther. 2024; 16(1): 68. Article. IF: 7,6; D1

Frutos MCGD, Laso-García F, García-Suárez I, Piniella D, Otero-Ortega L, Alonso-López E, Pozo-Novoa J, Gallego-Ruiz R, Díaz-Gamero N, Fuentes B, de Leciñana MA, Díez-Tejedor E, Ruiz-Ares G, **Gutiérrez-Fernández M**. The impact of experimental diabetes on intracerebral haemorrhage. A preclinical study. Biomed Pharmacother. 2024; 176: 116834. Article. IF: 7,5; D1

Silva-Llanes I, Martín-Baquero R, Berrojo-Armisen A, Rodríguez-Cueto C, Fernández-Ruiz J, De Lago E, **Lastres-Becker I.** Beneficial Effect of Dimethyl Fumarate Drug Repositioning in a Mouse Model of TDP-43-Dependent Frontotemporal Dementia. Antioxidants. 2024; 13(9): 1072. Article. IF: 6,6; Q1

Rada P, Carceller-López E, Hitos AB, Gómez-Santos B, Fernández-Hernández C, Rey E, Pose-Utrilla J, García-Monzón C, González-Rodríguez A, Sabio G, García A, Aspichueta P, Iglesias T, **Valverde AM**. Protein kinase D2 modulates hepatic insulin sensitivity in male mice. Mol Metab. 2024; 90: 102045. Article. IF: 6,6; Q1

Scientific Events by Neurosciences Area

- **19/01/2024.** Scientific Seminar: Desarrollo de organoides de médula espinal humana: Biomodelos para el estudio de defectos del tubo neural
- **30/01/2024.** Jornada de Innovación en el conocimiento y tratamiento de las cefaleas primarias
- **26/02/2024.** Escuela de Ciencias Neurológicas IdiPAZ: Seminar - Conocimiento de las Bases Genéticas de las Enfermedades Neurológicas
- **29/02/2024.** Conectividad metabólica longitudinal de todo el cerebro y remodelación en un modelo de rata tipo Takotsubo inducido por estrés agudo
- **24/04/2024.** Escuela de Ciencias Neurológicas IdiPAZ: Seminar - Investigación Traslacional e innovación en las enfermedades neurológicas. Salud Cerebral
- **27/05/2024.** Escuela de Ciencias Neurológicas IdiPAZ: Seminar - Nuevas perspectivas en el abordaje de los trastornos del movimiento
- **18/11/2024.** Escuela de Ciencias Neurológicas IdiPAZ: Seminar - I Curso de Ecografía Preclínica en Modelos Animales
- **09/12/2024.** Curso Neurosonología Avanzada

3.1.1 Psychiatry and Mental Health Group



Publications: 30 | **Q1:**20

COMPOSITION

María Fe Bravo Ortíz.
Jefa del servicio de Psiquiatría, Psicología Clinica y Salud Mental. Hospital Universitario La Paz. Profesora Asociada CCSS. Facultad de Medicina. Universidad Auntónoma de Madrid

- **Teresa Alonso Poza.** *Investigadora Predoctoral. FIBHULP*
- **Blanca Amador Sastre.** *Facultativo Especialista de Área en Psicología Clínica. Hospital Universitario La Paz*
- **Jorge Andreo Jover.** *Investigador Predoctoral. FIBHULP*
- **Carmen Bayón Pérez.** *Jefa de Sección de Psiquiatría. Hospital Universitario La Paz. Profesora Asociada. CCSS. Facultad de Medicina. Universidad Autónoma de Madrid*
- **Katya Barros March.** *Investigadora Predoctoral. FIBHULP*
- **Laura Caraballo Romero.** *Enfermera Especialista en Salud Mental. Hospital Universitario La Paz*
- **Diego Carracedo Sanchidrian.** *Facultativo Especialista en Psicología Clínica. Hospital Universitario La Paz*
- **Susana Cebolla Lorenzo.** *Facultativo Especialista de Área en Psiquiatría. Hospital Universitario La Paz*
- **Ana Pilar Collado Blanco.** *Investigadora Predoctoral. FIBHULP*
- **Javier Curto Ramos.** *Facultativo Especialista de Área en Psiquiatría. Hospital Universitario La Paz*
- **Consuelo de Dios Perrino.** *Jefa de sección de Psiquiatría. Hospital Universitario La Paz. Profesora Asociada. Facultad de Medicina. Universidad Autónoma de Madrid*
- **María Jesús de la Iglesia Mansilla.** *Enfermera Especialista en Salud Mental. Hospital Universitario La Paz*
- **Eduardo Fernández Jiménez.** *Facultativo Especialista de Área en Psicología Clínica. Hospital Universitario La Paz*
- **Omar Ariel Gaona Casas.** *Investigador Predoctoral. FIBHULP*
- **Ignacio García Cabeza.** *Jefe de Servicio de Psiquiatría. Hosputal Dr. Rodríguez Lafora*
- **Blanca García Vázquez.** *Psicóloga Interna Residente . Hospital Universitario La Paz*
- **Jessica Garrido Boltón.** *Psicóloga Interna Residente. Hospital Universitario La Paz*
- **Nieves González Suárez.** *Facultativo Especialista de Área en Psiquiatría. Hospital Universitario La Paz*
- **Ana Hospital Moreno.** *Facultativo Especialista de Área en Psicología Clínica. Hospital Universitario La Paz*
- **Eduardo Jiménez Sola .** *Facultativo Especialista de Área en Psiquiatría . Hospital Universitario La Paz*
- **Jesús Martí Esquitino.** *Facultativo Especialista de Área en Psicología Clínica. Hospital Universitario La Paz*
- **Gonzalo Martínez-Ales García.** *Investigador Postdoctoral. Universidad de Harvard*
- **Manuel Agustín Morillas Romerales.** *Facultativo Especialista en Psiquiatría. Hospital Universitario La Paz*
- **Ainoa Muñoz San José.** *Facultativo Especialista de Área en Psiquiatría. Hospital Universitario La Paz. Profesora Asociada CCSS. Facultad de Medicina. Universidad Autónoma de Madrid*
- **Patricia Nieva Tejado.** *Enfermera Especialista en Salud Mental. Hospital Universitario La Paz*
- **Luis Nocete Navarro.** *Facultativo Especialista de Área en Psiquiatría. Hospital Universitario La Paz*
- **Óscar Pajares González-Gallego.** *Enfermero Especialista en Salud Mental CSM Fuencarral. Hospital Universitario La Paz*
- **Ángela Palao Tarrero.** *Jefa de Sección de Psiquiatría. Hospital Universitario La Paz. Profesora Asociada CCSS Facultad de Medicina. Universidad Autónoma de Madrid*
- **Irene Pérez de Ciriza Galarza.** *Enfermera Especialista en Salud Mental. Hospital Universitario La Paz*
- **Pau Pérez Sales.** *Facultativo Especialista de Área en Psiquiatría. Hospital Universitario La Paz*
- **Cristina Rocamora González.** *Psicologa. Residencia Asistida San Camilo*
- **Beatriz Rodríguez Vega.** *Facultativo Especialista de Área en Psiquiatría. Hospital Universitario La Paz. Profesora Asociada. Facultad de Medicina. Universidad Autónoma de Madrid*
- **María Paz Vidal Villegas.** *Técnico de Apoyo. Hospital Universitario La Paz*
- **Rosa Villanueva Peña.** *Facultativo Especialista de Área en Psiquiatría. Profesora Asociada CCSS. Hospital Universitario La Paz. Facultad de Medicina. Universidad Autónoma de Madrid*

STRATEGIC OBJETIVES

- The group is devoted to assess the efficacy of psychotherapeutic techniques as adjunctive to other therapeutic measures in mental disorders and other medical diseases.
- Their main areas of investigation are: research in severe mental disorder, psychosis and bipolar disorder, suicide prevention and other medical disorders such as cancer and chronic pain. We participate in clinical trials on new treatments and specific therapies in order to improve the prognosis of these disorders.
- It also focuses on the investigation of the interaction of genetic and environmental factors in the etiology and evolution of mental disorders, especially psychosis.
- Moreover, the group is involved in the evaluation of new treatments or new indications in mental disorders through the participation in clinical trials.
- We are specially focused in the assessment of the efficacy and effectiveness of third generation psychotherapies, including mindfulness, and other low intensity psychological intervention.

RESEARCH LINES

- Psychotherapeutic interventions in mental disorders
- Suicide prevention
- Psychological and social impact of the COVID-19 pandemic
- e-Health interventions
- Mindfulness-based interventions
- Environment/gene interaction in First Episode Psychosis

RESEARCH ACTIVITY

Doctoral Theses

- **Carracedo Sanchidrián D.** Terapia Cognitiva Basada en Mindfulness frente a Intervención Psicoeducativa en Pacientes con Trastorno Bipolar con Síntomas Subsindrómicos Depresivos: Estudio Controlado Aleatorizado [dissertation]. Madrid: Universidad Autónoma de Madrid: 2024(14/10/2024). Director: Dios Perrino C, Lahera Forteza G

Publications

- **A** Andreo-Jover J, Fernández-Jiménez E, Bobes J, Cebria AI, Crespo-Facorro B, de la Torre-luque A, González-Pinto A, Jiménez-Treviño L, Díaz-Marsá M, García-Ramos A, Grande I, Roberto N, Ruiz-Veguilla M, Palao-Tarrero A, Pérez-Sola V. Suicidal Behavior and Social Cognition: The Role of Hypomentalizing and Fearlessness About Death. Psicothema. 2024; 36(4): 403-413. Article. IF: 3.5; Q1
- **Andreo-Jover J, Ramos JC, Bobes J, Bravo-Ortiz M, Cebria AI, Crespo-Facorro B, de la Torre-Luque A, Díaz-Marsan M, Fernández-Rodrigues V, Garrido-Torres N, Grande I, Peña MPL, Pemau A, Roberto N, Ruiz-Veguilla M, Saiz P, Rodríguez-Vega B, Pérez-Sola V.** The mediating role of reflective functioning in the association between childhood trauma and suicide attempt. J Psychiatr Res. 2024; 171: 30-7. Article. IF: 3.2; Q2
- **Andreo-Jover J, Wootton O, Fernández-Jiménez E, Muñoz-Sanjosé A, Mediavilla R, Bravo-Ortiz MF, Susser E, Gur RC, Stein DJ.** Adverse childhood experiences and cognition: A cross-sectional study in Xhosa people living with schizophrenia and matched medical controls. Compr Psychiat. 2024; 130: 152459. Article. IF: 4.2; Q1
- **Asaoka H, Watanabe K, Miyamoto Y, Restrepo-Henao A, van der Ven E, Moro MF, Alnasser LA, Ayinde O, Balalian AA, Basagoitia A, Durand-Arias S, Eskin M, Fernández-Jiménez E, Ines FFM, Giménez L, Hoek HW, Jaldo RE, Lindert J, Maldonado H, Martínez-Alés G, Mediavilla R, McCormack C, Narvaez J, Ouali U, Barrera-Pérez A, Calgua-Guerra E, Ramírez J, Rodríguez AM, Seblova D, da Silva ATC, Valeri L, Gureje O, Ballester D, Carta MG, Isahakyan A, Jamoussi A, Seblova J, Solis-Soto MT, Alvarado R, Susser E, Mascayano F, Nishi D.** Association of depressive symptoms with incidence and mortality rates of COVID-19 over 2 years among healthcare workers in 20 countries: multi-country serial cross-sectional study. Bmc Med. 2024; 22(1): 386. Article. IF: 8.3; Q1
- **Bolton JG, Moreno AH, Sanchidrián DC.** Interconsulta de Psicología Clínica en una Unidad de Hospitalización Breve: un estudio de caso. ClíN Contemp (Madr). 2024; 15(2): e12. Article. IF: 0.1; Q4
- **Carracedo-Sanchidrián D, de Dios-Perrino C, Bayón-Pérez C, Rodríguez-Vega B, Bravo-Ortiz MF, Ortega MA, González-Pinto AM, Lahera G.** Effect of mindfulness-based cognitive therapy vs. psychoeducational intervention on plasma brain-derived neurotrophic factor and cognitive function in bipolar patients: a randomized controlled trial. Front Psychiatry. 2024; 14: 1279342. Article. IF: 3.2; Q2
- **Czepiel D, McCormack C, da Silva ATC, Seblova D, Moro MF, Restrepo-Henao A, Martínez AM, Afolabi O, Alnasser L, Alvarado R, Asaoka H, Ayinde O, Balalian A, Ballester D, Barathie JAL, Basagoitia A, Basic D, Burrone MS, Carta MG, Durand-Arias S, Eskin M, Fernández-Jiménez E, Frey MIF, Gureje O, Isahakyan A, Jaldo R, Karam EG, Khattech D, Lindert J, Martínez-Alés G, Mascayano F, Mediavilla R, Gonzalez JAN, Nasser-Karam A, Nishi D, Olaopa O, Ouali U, Puac-Polanco V, Ramírez DE, Ramírez J, Rivera-Segarra E, Rutten BPF, Santaella-Tenorio J, Sapag JC, Seblová J, Soto MTS, Tavares-Cavalcanti M, Valeri L, Sijbrandij M, Susser ES, Hoek HW, van der Ven E.** Inequality on the frontline: A multi-country study on gender differences in mental health among healthcare workers during the COVID-19 pandemic. Glob Ment Health (Camb). 2024; 11: e34. Article. IF: 3.4; Q2
- **de la Torre JA, Ronaldson A, Vilagut G, Martínez-Alés G, Dregan A, Bakolis I, Valderas JM, Molina AJ, Martín V, Bellón JA, Alonso J.** Implementation of community screening strategies for depression. Nat Med. 2024; 30(4): 930-2. Editorial Material. IF: 50; D1
- **de la Torre-luque A, Pérez-Díez I, Pemau A, Martínez-Ales G, Borges G, Pérez-Sola V, Ayuso-Mateos JL.** Suicide mortality in Spain during the COVID-19 pandemic: Longitudinal analysis of sociodemographic factors. Eur Neuropsychopharm. 2024; 82: 29-34. Article. IF: 6.7; D1
- **del Pozo-Herce P, Baca-García E, Martínez-Sabater A, Chover-Sierra E, Gea-Caballero V, Curto-Ramos J, Czapla M, Karniej P, Martínez-Tofe J, Sánchez-Barba M, de Viñaspre RR, Juárez-Vela R.** Descriptive study on substance uses and risk of sexually transmitted infections in the practice of Chemsex in Spain. Front Public Health. 2024; 12: 1391390. Article. IF: 3.4; Q1
- **Del Pozo-Herce P, Tovar-Reinoso A, Martínez-Sabater A, Chover-Sierra E, Sufrate-Sorzano T, Saus-Ortega C, Curto-Ramos J, Padilla-Brito JM, González-Navajas C, Baca-García E, Juárez-Vela R, Blas EGC.** Exploration of Mental Health Elements in Chemsex Behavior: Interventions, Influencing Factors, and Attitudes towards Risk and Harm Reduction in Spain. Nurs Rep. 2024; 14(3): 2313-26. Article. IF: 2; Q2
- **Díaz-Carracedo P, Marín C, Díaz-Marsa M, Borges G, de la Torre-luque A, Elices M, Toll A, Grande I, Roberto N, Vázquez M, González-Pinto A, Ruiz-Veguilla M, Canal-Rivero M,**

Cebria AI, Palao D, Bobes-Bascaran T, Jimenez-Treviño L, Saiz P, Andreo-Jover J, March K, Palao-Tarrero A, Pérez V. Symptom profile in suicide attempters during the COVID-19 pandemic: Relationships with suicide outcomes. Eur Psychiat. 2024; 67(1): e73. Article. IF: 6.7; D1

- **Dykxhoorn J, Rich N, Martínez-Alés G, Pitman A.** Hiding in plain sight: ethnic and migrant variation in suicide. Lancet Psychiatry. 2024; 11(8): 577-8. Editorial Material. IF: 24.8; D1
- **Fares-Otero NE, Verdolini N, Melero H, Andrés-Camazón P, Vilajosana E, Cavone V, García-Bueno B, Rapado-Castro M, Izquierdo A, Martín-Hernández D, Cárdenes PM, Leal I, Dompablo M, Ortiz-Tallo A, Martínez-Gras I, Muñoz-Sanjose A, de Lapuerta CL, Rodríguez-Jimenez R, Marsá MD, Bravo-Ortiz MF, Ibáñez A, Baca-García E, Vieta E, Ayuso-Mateos JL, Malpica N, Arango C, Díaz-Caneja CM, Radua J.** Triangulating the associations of different types of childhood adversity and first-episode psychosis with cortical thickness across brain regions. Psychol Med. 2024; 54(16): 4561-74. Article. IF: 5.5; D1
- **Fernández-Fernández J, Jiménez-Treviño L, Andreo-Jover J, Ayad-Ahmed W, Bascarán TB, Canal-Rivero M, Cebria A, Crespo-Facorro B, de la Torre-luque A, Díaz-Marsa M, González-Pinto A, Gomez S, Grande I, Iglesias N, Ortin F, March K, Palao A, Pérez-Díez I, Pérez-Guerra C, Ruiz-Veguilla M, Vieta E, Pérez-Sola V, Saiz PA.** Network analysis of influential risk factors in adolescent suicide attempters. Child Adolesc Psychiatry Ment Health. 2024; 18(1): 152. Article. IF: 4.6; Q1
- **Fernández-Jiménez E, Maran DA.** Editorial: Break the mental health stigma: mental health in the workplace. Front Psychiatry. 2024; 15: 1427097. Editorial Material. IF: 3.2; Q2
- **García-Fernández A, Martínez-Cao C, Sánchez-Fernández-Quejo A, Bobes-Bascarán T, Andreo-Jover J, Ayad-Ahmed W, Cebriá AI, Díaz-Marsá M, Garrido-Torres N, Gómez S, González-Pinto A, Grande I, Iglesias N, March KB, Palao DJ, Pérez-Díez I, Roberto N, Ruiz-Veguilla M, de la Torre-luque A, Zorrilla I, Pérez V, Sáiz PA, García-Portilla MP.** Validation of the Spanish Childhood Trauma Questionnaire-Short Form in adolescents with suicide attempts. Front Psychol. 2024; 15: -1378486. Article. IF: 2.9; Q1
- **Garrido-Bolton J, Alcami-Pertejo M, de la Vega R, Hernández-Oliveros F, Pérez-Martínez A, Bravo-Ortiz MF, Fernández-Jiménez E.** Neuropsychological and biopsychosocial evolution, therapeutic adherence and unmet care needs during paediatric transplantation: study protocol of a mixed-methods design (observational cohort study and focus groups) - the TransplantKIDS mental health project. Front Psychol. 2024; 15: 1308418. Article. IF: 2.9; Q1
- **González-Romero MF, Martínez-Avila JM, Moloney E, García-Cabeza I.** Aversive agents: Think twice. A case report on disulfiram-induced mania. Bipolar Disord. 2024; 26(4): 395-7. Editorial Material. IF: 4.5; Q1
- **Gonzalo-de Miguel A, Abascal-Peiró S, Cegla-Schvartzman FB, Martínez-Alés G, Baca-García E.** Antipsychotic use in a large community sample of patients with delusional disorder. Schizophr Res. 2024; 271: 194-9. Article. IF: 3.5; Q1
- **Keyes KM, Kandula S, Martínez-Ales G, Gimbrone C, Joseph V, Monnat S, Rutherford C, Olfson M, Gould M, Shaman J.** Geographic Variation, Economic Activity, and Labor Market Characteristics in Trajectories of Suicide in the United States, 2008-2020. Am J Epidemiol. 2024; 193(2): 256-66. Article. IF: 4.8; Q1
- **López-Cuadrado T, Susser E, Martínez-Alés G.** Recent trends in hospital admission due to bipolar disorder in 10-19-year-olds in Spain: A nationwide population-based study. Bipolar Disord. 2024; 26(8): 801-9. Article. IF: 4.5; Q1
- **Martínez-Alés G, López-Castromán J, Barrigón ML, Baca-García E.** Editorial: Suicide and related behaviour, volume II. Front Psychiatry. 2024; 15: 1462051. Editorial Material. IF: 3.2; Q2
- **Mediavilla R, García-Vázquez B, McGreevy KR, Underhill J, Bayón C, Bravo-Ortiz MF, Muñoz-Sanjosé A, Haro JM, Monistrol-Mula A, Nicaise P, Petri-Romao P, McDaid D, Park AL, Melchior M, Vuillermoz C, Turrini G, Compri B, Purgato M, Roos R, Witteveen AB, Sijbrandij M, Bryant RA, Fuhr D, Ayuso-Mateos JL.** Beyond effectiveness in eHealth trials: Process evaluation of a stepped-care programme to support healthcare workers with psychological distress (RESPOND-HCWs). Digit Health. 2024; 10: 20552076241287700. Article. IF: 3.3; Q1
- **Oliva V, Roberto N, Andreo-Jover J, Bobes T, Rivero MC, Cebriá A, Crespo-Facorro B, de la Torre-luque A, Díaz-Marsá M, Elices M, Fernández-Rodrigues V, Gonzalez-Pinto A, Tarrero AP, Pérez-Díez I, Rodríguez-Vega B, Ruiz-Veguilla M, Saiz PA, Seijo-Zazo E, Toll-Privat A, McIntyre RS, Vieta E, Grande I, Pérez-Solà V, De Prisco M, Vazquez M, Bracco L, Gómez S, Díaz C, Bobes J, Jimenez-Treviño L, Fernández-Fernandez J, García-Fenández A, Palao D, Ruiz IM, Guinovart M, Comendador L, Justicia A, Salgado P, Alvarez P, Puigdemont D, Gil IG, Fernandez-Rodrigues V, Ayad-Ahmed W, Carrasco JL, Mellor-Marsá B, Lara E, Leal-Leturia I, Sánchez-Fernandez-Quejo A, Ayuso-Mateos JL, Díaz-Carracedo P, García-Ligero E, Martínez MJ, Giner L, López A, Batanero MS, Abejas D, Zorrilla I, Mar-Barrutia L, Bravo-Ortiz M, Ramos JC, Jimenez-Sola E, Mediavilla R, Aguirre P.** Anxious and depressive symptoms and health-related quality of life in a cohort of people who recently attempted suicide: A network analysis. J Affect Disorders. 2024; 355: 210-9. Article. IF: 4.9; Q1
- **Rodríguez-Molino P, Alarcón A, Martínez-Biarge M, Cabrera-Lafuente M, Aldecoa V, Fernández-Sánchez A, Fernández-Jiménez E, Baquero-Artigao F, García-Alix A.** Behavioral Problems and Family Impact in Congenital Cytomegalovirus Infection. Pediatr Infect Dis J. 2024; 43(6): 556-8. Article. IF: 2.2; Q2
- **Segado JC, Lacasa CC, Sanchidrián DC, Esquitino JM.** Referral Profile of Adult Patients Attended in the Neuropsychology Consultation at Hospital Universitario La Paz in Madrid from 2018 to 2023. Rev Neurologia. 2024; 79(11): 36419. Article. IF: 0.8; Q4
- **Szmulewicz AG, Martínez-Alés G, Logan R, Ferrara M, Kelly C, Fredrikson D, Gago J, Conderino S, Díaz-Caneja CM, Galvañ J, Thorpe L, Srihari V, Yatham L, Sarpal DK, Shinn AK, Arango C, Öngür D, Hernán MA.** Antipsychotic drugs in first-episode psychosis: a target trial emulation in the FEP-CAUSAL Collaboration. Am J Epidemiol. 2024; 193(8): 1081-7. Article. IF: 4.8; Q1
- **Vázquez-Giraldo P, Muñoz-Sanjosé A, López-Cuadrado T.** Hospital Admissions for Eating Disorders in Children and Adolescents in Spain: A Population-Based Study. Int J Eat Disorder. 2024; 57(11): 2299-305. Article. IF: 4.3; Q1
- **Zamorano S, González-Sanguino C, Fernández-Jiménez E, Muñoz M.** A Burnt-Out Health: Stigma towards Mental Health Problems as a Predictor of Burnout in a Sample of Community Social Healthcare Professionals. Behav Sci (Basel). 2024; 14(9): 812. Article. IF: 2.5; Q2

Research projects

- **Bravo Ortiz MF.** Ambiente y genes en esquizofrenia. (S2022/BMD-7216 AGES 3-CM). CM. 2023-2026. Managment centre: FIBHULP
- **Bravo Ortiz MF.** Contrato garantía juvenil ayudante de investigación. (PEJ-2021-AI/SAL-22352). CM. 2023-2024. Managment centre: FIBHULP
- **Bravo Ortiz MF.** Estudio longitudinal de una cohorte representativa: superando la heterogeneidad clínica y biológica en primeros episodios psicóticos. (PI20/01113). ISCIII. 2021-2025. Managment centre: FIBHULP
- **Bravo Ortiz MF.** Impacto de la pandemia de COVID-19 en la salud mental de trabajadores en dispositivos sanitarios. Estudio internacional multicéntrico: the COVID-19 Heroes Study. (PI-4099-BRAVO ORTIZ). Sociedad Española de Psiquiatría. 2020-Ongoing. Managment centre: FIBHULP
- **Bravo Ortiz MF.** Improving the Preparedness of Health Systems to Reduce Mental Health and Psychosocial Concerns resulting from the COVID-19 Pandemic. (RESPOND). UE. 2020-2024. Managment centre: FIBHULP
- **Bravo Ortiz MF.** Estudio De Coste Efectividad De Un Programa De Hospitalización Domiciliaria De Salud Mental En Infancia Y Adolescencia En Dos Áreas De Influencia De Dos Hospitales De Madrid (Hospital Universitario La Paz Y Hospital Universitario Príncipe De Asturias). (Comité De Ética: 6758. Código identificativo: 2024.437). Fundación Nemesio Diez. 2024-Ongoing. Managment centre: FIBHULP
- **Bravo Ortiz MF.** Programa de enlace de salud mental y educación (CELSO ARANGO-MMA 2024). Fundación Mutua Madrileña. 2024-Ongoing. Managment centre: FIBHULP

- **Bravo Ortiz MF.** Apoyo a investigadores que han participado como mentores. (Dr. Luis Alvarez 2023). Fundación para la Investigación Biomédica Hospital Universitario La Paz. 2024-2025. Managment centre: FIBHULP
- **Fernandez Jimenez E.** Marcadores neurocognitivos y perfil psicológico en población infantil, adolescente y en adultos jóvenes receptores de terapia con células CAR-T y trasplante hematopoyético: Estudio observacional comparativo. (Dr. Luis Alvarez 2023). FIBHULP. 2023-2024. Managment centre: FIBHULP
- **Fernandez Jimenez E.** PsyCARTkids: impacto bio-psicológico del entrenamiento cognitivo y mindfulness en menores tras terapia car-t, trasplante hematopoyético o quimioterapia: estudio de métodos mixtos y ensayo controlado-aleatorizado (PI23/00179). ISCIII. 2024-2026. Managment centre: FIBHULP
- **Fernández Jiménez E.** Identificación de necesidades pre- y post-quirúrgica y evolución neuropsicológica y biopsicosocial en población infantojuvenil sometida a cirugía de trasplante de órgano sólido y pectus excavatum. proyecto psycmajorsurgeries. (PI-5223/2022014). Fundación Alicia Koplowitz. 2022-Ongoing. Managment centre: FIBHULP
- **Fernández Jiménez E.** Marcadores neurocognitivos y perfil psicológico en población infantil, adolescente y en adultos jóvenes receptores de terapia con células car-t y trasplante hematopoyético: estudio observacional comparativo. (PI-5562/2023.063). Fundación para la Investigación Biomédica Hospital Universitario La Paz. 2022-Ongoing. Managment centre: FIBHULP
- **Muñoz San José A.** Hacia una intervención estratificada en psiquiatría: predicción de trayectorias de riesgo y resiliencia para la salud mental en una muestra transdiagnóstica de jóvenes (PI23/00380). ISCIII. 2024-2026. Managment centre: FIBHULP
- **Nocete Navarro L.** Fostering and Strengthening Approaches to Reducing Coercion in European Mental Health Services (CA19133). 2024-Ongoing. Managment centre: FIBHULP
- **Palao Tarrera A.** Intensificación de la actividad investigadora de investigadores participantes del programa mentor. FIBHULP. 2023-2024. Managment centre: FIBHULP
- **Palao Tarrera A.** SURVIVE 2: un estudio de cohorte extendida para investigar la conducta suicida en España y la eficacia de estrategias de prevención secundaria (PI23/01469). ISCIII. 2024-2026. Managment centre: FIBHULP
- **Rodríguez Vega B.** Prevención e intervención en suicidio (SURVIVE): estudio de cohorte y ensayos clínicos controlados anidados de programas de prevención secundaria para intentos de suicidio. (PI19/00941). ISCIII. 2020-2024. Managment centre: FIBHULP
- **Rodríguez Vega B.** Traducción y validación de los instrumentos reflective functioning questionnaire e inventary of personality onganization. Fundación Vasca de Innovacion e Investigación Sanitarias. 2018-Ongoing. Managment centre: FIBHULP
- **Villanueva Peña R.** A Randomnized, Double-blind, Multicenter, Parallel-group, Placebo-controlled. Study to evaluated the efficacy, safety, and tolerability of aticaprant 10 mg as adjunctive therapy in adult participants with major depressive disorder (MDD) with moderated-to-severe anhedonia and inadequate response to current antidepressant therapy protocol 67953964MDD3001 VENTURA-1;PAHASE 3. Janssen Pharmaceutica. 2023-2024. Managment centre: FIBHULP

Clinical Trials

- **Villanueva Peña R.** a randomized, double-blind, multicenter, placebo-controlled study to evaluate the efficacy, safety, and tolerability of aticaprant 10 mg as adjunctive therapy in adult participants with major depressive disorder (mdd) with moderate-to-severe anhedonia and inadequate response to current antidepressant therapy and an open-label long-term extension treatment with aticaprant.
  Type/Phase: III
  Sponsored by: Janssen Research & Development Llc
  Signature date: 14/11/2024
- **Villanueva Peña R.** a two-part multicenter, double-blind, randomized placebo-controlled study to evaluate efficacy and safety and the maintenance of effect of 20-mg seltorexant as adjunctive therapy to antidepressants in adult and elderly patients with major depressive disorder with insomnia symptoms.
  Type/Phase: III
  Sponsored by: Icon Clinical Research Limited;Janssen Research & Development Llc
  Signature date: 17/12/2024
- **Villanueva Peña R.** estudio multicéntrico, aleatorizado, doble ciego, controlado con placebo, de aticaprant como tratamiento adyuvante a un antidepresivo para la prevención de recaídas en pacientes con trastorno depresivo mayor (tdm) con anhedonia de moderada a grave.
  Type/Phase: III
  Sponsored by: Janssen Research & Development Llc
  Signature date: 19/11/2024
- **Villanueva Peña R.** un estudio abierto y a largo plazo para evaluar la seguridad y la eficacia de aticaprant como tratamiento complementario en participantes adultos y de edad avanzada con trastorno depresivo mayor (tdm).
  Type/Phase: III
  Sponsored by: Janssen Cilag International Nv
  Signature date: 27/08/2024
- **Villanueva Peña R.** un estudio aleatorizado, doble ciego, multicéntrico, de grupos paralelos y controlado con placebo para evaluar la eficacia, la seguridad y la tolerabilidad de aticaprant 10 mg como tratamiento complementario en participantes adultos con trastorno depresivo mayor (tdm) con anhedonia moderada o grave y una respuesta insuficiente al tratamiento antidepresivo actual.
  Type/Phase: III
  Sponsored by: Janssen Cilag International Nv
  Signature date: 13/07/2024
- **Villanueva PeñaR.** LY2216684 Comparado frente a placebo como tratamiento combinado con isrs en la prevención de la reaparición de los síntomas en el trastorno depresivo mayor.
  Signature date: 16/03/2012-On Going
  Sponsored by: Lilly, S.A.
- **Villanueva Peña R.** Estudio aleatorizado, multicéntrico, doble ciego, controlado con placebo, de la seguridad y la eficacia de los 4 regímenes de dosis de smo.ir, una formulación oral sólida de oxibato de sodio, en el mantenimiento de la abstinencia de alcohol en pacientes con abstinencia reciente.
  Signature date:
  Sponsored by:
- **Villanueva Peña R.** Comparación de dos estrategias de tratamiento diferentes en pacientes con trastorno depresivo mayor en tratamiento con escitalopram que no presentan mejoría: estrategia de intervención temprana versus estrategia de intervención tardía.
  Signature date: 26/10/2009.
  Sponsored by: Lilly, S.A.
- **Villanueva Peña R.** Estudio aleatorizado, doble ciego, controlado con placebo, de grupos paralelos de 26 semanas, en fase 3, de 2 dosis de un agonista del receptor nicotínico de acetilcolina alfa-7 (ecp-6124) o placebo como tratamiento adyuvante pro-cognitivo en sujetos con esquizofrenia en tratamiento crónico estable con antipsicóticos atípicos.
  Signature date: 14/02/2008.
  Sponsored by: Envivo Pharmaceuticals, Inc.
- **Villanueva Peña R.** estudio aleatorizado, doble ciego, controlado con placebo, de grupos paralelos de 26 semanas, en fase 3, de 2 dosis de un agonista del receptor nicotínico de acetilcolina alfa-7 (ecp-6124) o placebo como tratamiento adyuvante pro-cognitivo en sujetos con esquizofrenia en tratamiento crónico estable con antipsicóticos atípicos.
  Signature date: 05/05/2015
  Sponsored by: Envivo Pharmaceuticals, Inc.
- **Villanueva Peña R.** Estudio aleatorizado, doble ciego, controlado con placebo y tratamiento activo de DS-5565 en pacientes con dolor asociado a la fibromialgia.
  Signature date: 18/08/2015
  Sponsored by: Daiichi Sankyo Development Limited.
- **Villanueva Peña R.**Estudio aleatorizado, doble ciego, controlado con placebo y tratamiento activo de DS-5565 en pacientes con dolor asociado a la fibromialgia.
  Signature date: 18/08/2015
  Sponsored by: Daiichi Sankyo Development



Limited.

- **Villanueva Peña R.** Estudio de fase II, aleatorizado, doble ciego, controlado con placebo y de grupos paralelos para evaluar la eficacia y la seguridad de 4 dosis orales de BI 425809 una vez al día durante un periodo de tratamiento de 12 semanas en pacientes con esquizofrenia. Signature date: 11/05/2018. Sponsored by: Boehringer Ingelheim España, S.A.
- **Villanueva Peña R.** Cohorte de depresión resistente al tratamiento en Europa.
  Signature date: 04/10/2018
  Sponsored by: Janssen Pharmaceutica NV.
- **Villanueva Peña R.** Estudio de fase II, aleatorizado, doble ciego, controlado con placebo y de grupos paralelos para evaluar la eficacia y la seguridad de 4 dosis orales de BI 425809 una vez al día durante un periodo de tratamiento de 12 semanas en pacientes con esquizofrenia.
  Signature date: 23/10/2018
  Sponsored by: Boehringer Ingelheim España, S.A.
- **Villanueva Peña R.** Cohorte de depresión resistente al tratamiento en Europa.
  Signature date: 25/09/2019
  Sponsored by: Janssen Pharmaceutica NV.
- **Villanueva Peña R.** Estudio multicéntrico, doble ciego, aleatorizado, de grupos paralelos, controlado con placebo, para evaluar la eficacia y la seguridad de seltorexant 20 mg como tratamiento complementario a los antidepresivos en pacientes adultos y de edad avanzada con trastorno depresivo mayor con síntomas de insomnio que respondieron de manera inadecuada al tratamiento con antidepresivos y un tratamiento de extensión de seguridad abierto a largo plazo con seltorexant.
  Signature date: 05/10/2020
  Sponsored by: Janssen Pharmaceutica NV.
- **Villanueva Peña R.** A 12-month observational prospective cohort study to analyze cardiometabolic profile changes to switch to lurasidone in patients with schizophrenia. Siendo en castellano: estudio observacional, prospectivo, de cohorte, de 12 meses para analizar los cambios en el perfil cardiometabólico del cambio a lurasidona en pacientes con esquizofrenia.
  Signature date: 04/11/2020
  Sponsored by: Adknoma Health Research, S.L.; Angelini Farmaceutica.
- **Villanueva Peña R.** Un estudio aleatorizado, doble ciego, multicéntrico, de grupos paralelos y controlado con placebo para evaluar la eficacia, la seguridad y la tolerabilidad de aticaprant 10 mg como tratamiento complementario en participantes adultos con trastorno depresivo mayor (TDM) con anhedonia moderada o grave y una respuesta insuficiente al tratamiento antidepresivo actual.
  Signature date: 11/07/2023
  Sponsored by: Janssen Cilag International NV.
- **Villanueva Peña R.** A phase 2/3, multicenter, randomized, double-blind, placebo-controlled trial of the safety and efficacy of flexible doses of sep-363856 as adjunctive therapy in the treatment of adults with major depressive disorder.
  Signature date: 08/02/2023
  Sponsored by: Otsuka Pharmaceutical Development & Commercializacion, Inc.
- **Villanueva Peña R.** Un estudio abierto y a largo plazo para evaluar la seguridad y la eficacia de aticaprant como tratamiento complementario en participantes adultos y de edad avanzada con trastorno depresivo mayor (TDM).
  Signature date: 09/08/2023
  Sponsored by: Janssen Cilag International NV.
- **Villanueva Peña R.** Estudio multicéntrico, doble ciego, aleatorizado, de grupos paralelos, controlado con placebo, para evaluar la eficacia y la seguridad de seltorexant 20 mg como tratamiento complementario a los antidepresivos en pacientes adultos y de edad avanzada con trastorno depresivo mayor con síntomas de insomnio que respondieron de manera inadecuada al tratamiento con antidepresivos y un tratamiento de extensión de seguridad abierto a largo plazo con seltorexant.
  Signature date: 12/01/2023
  Sponsored by: Janssen Pharmaceutica NV.
- **Villanueva Peña R.** Estudio de las características de la enfermedad y la eficacia del tratamiento habitual en la vida real en pacientes con trastorno depresivo mayor (TDM) con anhedonia y respuesta inadecuada al tratamiento antidepresivo actual, incluido un ISRS o un IRSN.
  Signature date: 13/12/2023
  Sponsored by: Janssen Research & Development, LLC.
- **Fernández Jiménez E.** Fase de tipificación de la adaptación española del MACI-II.
  Signature date: 22/04/2022
  Sponsored by: Pearson Educación SA.

Patents and Trademarks

En Calma

Rodríguez Vega B, authors; FIBHULP, assignee. Brand name: En calma; ESM 3.695.071; 2017 December 12.

SocialMind

Rodríguez Vega B, Mediavilla Torres R, Bravo Ortiz MF, Muñoz San José A, Bayón Pérez C, Lahera Forteza G, Palao Tarrero A. authors; FIBHULP, assignee. Brand name: SocialMind; ESM 3.748.550; 2018 December 17.

3.1.2 Neurology and Cerebrovascular Diseases




Publications: 66 | **Q1:**41

COMPOSITION

Exuperio Díez Tejedor
Investigador Emerito Catedrático Neurología. FIBHULP. Departamento de Medicina. Universidad Autónoma de Madrid

María Gutiérrez Fernández.
Investigadora Titular Senior. Coordinadora Laboratorio Ciencias Neurológicas y Cerebrovascular. FIBHULP

- **María José Aguilar-Amat Prior.** *Facultativo Especialista de Área en Neurología. Hospital Universitario La Paz*
- **María Alonso de Leciñana Cases .** *Jefe de Sección en Neurología. Hospital Universitario La Paz. Profesora Asociada. Universidad Autónoma de Madrid*
- **Elisa Alonso López.** *Contrato Juan Rodés. Hospital Universitario La Paz*
- **Cristina Aramendia Zabaleta.** *Enfermera. FIBHULP*
- **Francisco Javier Arpa Gutiérrez.** *Profesor Honorario. Universidad Autónoma de Madrid*
- **María Jesús Bullido Gómez-Heras.** *Profesor Titular. Departamento de Biología Molecular. Facultad de Ciencias. CBM "Severo Ochoa"*
- **Ángela Calzado González.** *Investigadora Predoctoral. Laboratorio de Ciencias Neurológicas y Cerebrovascular. FIBHULP*
- **Fernando Carceller Benito.** *Investigador Emérito. Hospital Universitario La Paz*
- **Laura Casado Fernández.** *Contrato Río Hortega. FIBHULP*
- **Elena de Celis Ruiz.** *Contrato Río Hortega. Hospital Universitario La Paz*
- **Jorge Eduardo Collazos Castro.** *Jefe de Laboratorio de Reparación Neural y Biomateriales. Hospital Nacional de Parapléjicos de Toledo*
- **Clara Correa Paz.** *Investigadora Sara Borrell. Laboratorio de Ciencias Neurológicas y Cerebrovascular. FIBHULP*
- **Francisco Javier Díaz de Terán Velasco.** *Facultativo Especialista de Área en Neurología. Hospital Universitario La Paz*
- **Nerea Díaz Gamero.** *Ayudante de investigación. Laboratorio de Ciencias Neurológicas y Cerebrovascular. FIBHULP*
- **Josué Fernández Carnero.** *Profesor e Investigador Postdoctoral. Centro Superior de Estudios Universitarios La Salle*
- **Andrés Francisco Fernández Prieto.** *Facultativo Especialista de Área en Radiología . Hospital Universitario La Paz*
- **Mireya Fernández-Fournier Fernández.** *Facultativo Especialista de Área en Neurología. Hospital Universitario La Paz*
- **Ana Frank García.** *Jefe de Servicio de Neurología. Hospital Universitario La Paz. Profesora Titular de Neurología. Facultad de Medicina. Universidad Autónoma de Madrid*
- **Remedios Frutos Martínez.** *Facultativo Especialista de Área en Radiología. Hospital Universitario La Paz*
- **Blanca Fuentes Gimeno.** *Jefe de Sección en Neurología. Hospital Universitario La Paz. Profesora Titular. Universidad Autónoma de Madrid*
- **Rebeca Gallego Ruiz.** *Investigadora Predoctoral. Laboratorio de Ciencias Neurológicas y Cerebrovascular. FIBHULP*
- **María Luisa Gandía González.** *Facultativa Especialista de Área en Neurocirugía. Hospital Universitario La Paz*
- **Iván García Suárez.** *Facultativo Especialista de Área en Urgencias. Hospital Universitario San Agustín*
- **Alfonso Gil Martínez.** *Fisioterapeuta. Hospital Universitario La Paz*
- **Laura González Martín.** *Facultativo Especialista de Área en Neurología. Hospital Universitario La Paz*
- **Ana Cristina Guadaño Ferraz.** *Científico Titular. Departamento de Fisiopatología Endocrina y del Sistema Nervioso. Instituto de Investigaciones Biomédicas Sols-Morreal*
- **María Hernández Barral.** *Facultativo Especialista de Área en Neurología. Hospital Universitario La Paz*
- **David Hernández Herrero.** *Jefe de Servicio de Rehabilitación y Medicina Física. Hospital Universitario La Paz*
- **Laura Lacruz Ballester.** *Facultativo Especialista de Área en Neurología. Hospital Universitario La Paz*
- **María Pilar López Larrubia.** *Científica Titular. Instituto de Investigaciones Biomédicas Sols-Morreal*
- **María Paz López Molina.** *Investigador Predoctoral. Laboratorio de Ciencias Neurológicas y Cerebrovascular. FIBHULP*
- **Begoña Marín Aguilera.** *Facultativo Especialista de Área en Radiología. Hospital Universitario La Paz*
- **Eduardo Mariño Trillo.** *Facultativo Especialista de Área de Neurología. Hospital Universitario La Paz*
- **Juan Andrés Martín Gonzalo.** *Profesor Titular. Escuela Universitaria de Fisioterapia de la ONCE*
- **Ángel Martín Montes.** *Facultativo Especialista de Área en Neurología. Hospital Universitario La Paz*
- **Marta María Martínez Martínez.** *Facultativo Especialista de Área en Neurología. Hospital Infanta Sofía. Profesora Asociada. Universidad Europea de Madrid*
- **Javier Pedro Mascias Cadavid.** *Facultativo Especialista de Área de Neurología. Hospital Universitario La Paz*
- **Marta Naranjo Castresana.** *Facultativo Especialista de Área en Neurofisiología Clínica. Hospital Universitario La Paz*
- **Pedro Navía Álvarez.** *Facultativo Especialista de Área en Radiología. Hospital Universitario La Paz*
- **Pilar Negredo Madrigal.** *Profesor Interino. Departamento de Anatomía, Histología y Neurociencia. Universidad Autónoma de Madrid*
- **Jesús Oliván Palacios.** *Facultativo Especialista de Área en Neurofisiología Clínica. Hospital Universitario La Paz*
- **Laura Otero Ortega.** *Investigadora Postdoctoral. Contrato Miguel Servet Tipo I. Laboratorio de Ciencias Neurológicas y Cerebrovascular. FIBHULP*



- **María del Valle Palomo Ruiz.** *Coordinador del Laboratorio de Biosensores en Neurociencia. Fundación IMDEA Nanociencia*
- **Joaquín Pardo Montero.** *Profesor Titular. Centro Superior de Estudios Universitarios La Salle*
- **José Francisco Paz Solís.** *Facultativo Especialista de Área en Neurocirugía. Hospital Universitario La Paz*
- **Irene Peirotén Pascual.** *Enfermera. FIBHULP*
- **Javier Pozo Novoa.** *Investigador Predoctoral. Laboratorio de Ciencias Neurológicas y Cerebrovascular. FIBHULP*
- **Inmaculada Puertas Muñoz.** *Facultativo Especialista de Área en Neurología. Hospital Universitario La Paz*
- **Estrella Rausell Tamayo.** *Catedrática. Departamento de Anatomía, Histología y Neurociencias. Facultad de Medicina. Universidad Autónoma de Madrid*
- **Ricardo Jaime Rigual Bobillo.** *Facultativo Especialista de Area de Neurología. Hospital Universitario La Paz*
- **Ivón Yamileth Rivera Derás.** *Facultativo Especialista de Área en Geriatría. Hospital Universitario La Paz*
- **Irene Rodríguez Andonaegui.** *Profesor Ayudante. Escuela Universitaria de Fisioterapia de la ONCE*
- **Jorge Rodríguez de Pardo de Donlebún.** *Facultativa Especialista de Área en Neurología. Hospital Universitario La Paz*
- **Francisco Javier Rodríguez de Rivera Garrido.** *Facultativo Especialista de Área en Neurología. Hospital Universitario La Paz*
- **Ana Rodríguez Sanz.** *Facultativo Especialista de Área en Neurología. Hospital Universitario La Paz*
- **Alicia Román San Martín.** *Técnica Superior de Laboratorio Clínico y Biomédico. Laboratorio de Ciencias Neurológicas y Cerebrovascular. FIBHULP*
- **Aranzazu Royo Orejas.** *Jefe de Sección de Radiología. Hospital Universitario La Paz*
- **Gerardo Ruiz Ares.** *Facultativo Especialista de Área en Neurología. Hospital Universitario La Paz*
- **María Teresa Salas Campos.** *Técnico Superior Psicología. Servicio de Neurología. Hospital Universitario La Paz*
- **Susana Santiago Pérez.** *Facultativo Especialista de Área en Neurofisiología. Hospital Universitario La Paz*
- **Soledad Serrano López.** *Facultativa Especialista de Área en Neurología. Hospital Universitario La Paz*
- **Gabriel Torres Iglesias.** *Contrato Río Hortega. FIBHULP*
- **Gema Torrijos Barbero.** *Especialista en Neuropsicología. Unidad de Memoria y Demencias. Hospital de Cantoblanco-Hospital Universitario La Paz*
- **Arturo Ugalde Canitrot.** *Facultativo Especialista de Área en Neurofisiología Clínica. Hospital Universitario La Paz*

STRATEGIC OBJETIVES

CEREBROVASCULAR

- Development of translational research studies (both animal and clinical studies) in cerebrovascular diseases, with the objectives of increasing the understanding of the pathogenesis of both cerebral infarction and cerebral hemorrhage. To analyze the influence of hyperglycemia in the evolution of stroke.To identify prognostic biomarkers and therapeutic targets mainly aimed at the promotion of brain protection and repair (cell therapy, trophic factors, extracellular vesicles). To analyze the contribution of comorbidities in the mechanisms that occur after stroke.
- Clinical trials of cell therapy in acute cerebral infarction (clinical trial AMASCIS and European Consortium RESSTORE-H2020).
- To analyze the recovery of post-stroke aphasia through a dubbing tool for television series and the development of a communication app (VerbalizApp).
- To evaluate the use of virtual reality in the recovery of motor and cognitive sequelae post-stroke, as well as the computational analysis of movement.
- To evaluate the effectiveness of keeping oral or parenteral anticoagulation in the acute phase of cardioembolic ischemic stroke
- To discover factors anticipating the development of atrial fibrillation through EKG and echocardiographic abnormalities in criptogenic stroke.
- Analysis of Patient Reported Outcome Measures (PROM) and Patient Reported Experience Measures (PREM) in stroke
- To analyze the differences between general anesthesia and sedation with high flow nasal canula in the endovascular treatment of ischemic stroke.

HEADACHES AND NEUROPATHIC PAIN

- Analysis of the expression of the phenomenon central painful awareness in different primary and secondary headaches.
- Central Sensitization and pain perception in patients with cluster headache.
- Refractory migraine database.
- Short Term Prophylaxis of Cluster Headache: A Comparative Study.
- Study of neuropathic and chronic craniofacial pain
- CGRP-pathway drugs in patients with refractory migraine (including autoinmune diseases and elderly patients) and medication overuse headache
- CGRP-pathway drugs in patients with refractory migraine and
- Multicentric colaboration in post-COVID related headache investigation
- Features and outcome of chronic refractory cluster headache treated with greater occipital nerve stimulation
- Cronic cluster headache registry

STRATEGIC OBJETIVES

Alzheimer´s disease.

- Study of the lysosomal pathway involvement in a model of neurodegeneration and cholesterol dysregulation in Alzheimer's disease.
- Study of genetic polymorfism related with PSP in the context of a multicentre Genome Wide Association study (GWAS)
- Extracellular vesicles as biomarkers in Alzheimer's disease and vascular dementia
- Role of cerebrovascular disease in neurodegenerative dementia
- Parkinson´s disease.
- Tremor as a negative predictive factor in developing dementia associated with Parkinson's disease.
- Evaluation of the benefits and risks of continuous infusion of intraduodenal levodopa in idiopathic Parkinson's disease.

Hereditary ataxias.

- Assessment of therapeutic response to Frenkel training exercises enhanced by Wii game console in patients with cerebellar ataxia.
- Participation in the Registry of the European Consortium EFACTS (European Friedreich's Ataxia Consortium for Translational Studies) aimed at improve the knowledge of the epigenetic mechanisms related to silencing the expression of frataxin and the pathogenesis of the disease, identification of biomarkers and genes modifying the clinical expression of the disease, development of new therapies as well as cellular and animal models for the study of Friedrich's Ataxia.

NEUROIMMUNOLOGY/NEUROINFLAMMATION

Multiple sclerosis

- Analysis of extracellular vesicles as biomarkers in multiple sclerosis patients.
- Analysis of molecular and neuroimaging biomarkers of brain damage and repair in Multiple Sclerosis.
- Search for diagnostic biomarkers, disease monitoring and response to treatment in Multiple Sclerosis
- Development of parametric test in multiple sclerosis by fotometric strategies.

Autoinmune encephalitis and other autoinmune neurological diseases

- Neurological syndromes associated to antiGAD antibodies
- Paraneoplasic syndromes and other neurological diseases associated to antibodies.

AUTONOMIC NERVOUS SYSTEM

- Evaluation of the Autonomic Nervous System in movement disorders.
- Evaluation of the Autonomic Nervous System in focal autonomic neuropathies and in Fabry disease.
- COMPASS-31 Study (collaboration with the Mayo Clinic): Registry of patients and controls with central and peripheral dysautonomia.

NEUROMUSCULAR DISEASES

- Develop a hand thermography tool for the diagnosis of fine fiber neuropathy.
- Analysis of the different profiles of cognitive impairment in ALS patients.Adaptation and validation of cognitive ALS specific scales for Spanish patients
- Study of cognitive potentials for identification of possible specific EEG endophenotypes in ALS patients.
- Participation In Project MinE: International program analyzing the genoma of 15000 patients and controls by the same genotyping platform.
- Participation in the National Registry of Pompe disease.
- Development of ultrasonography techniques in neuromuscular diseases.

SLEEP

- Development and evaluation of intervention protocols in childhood insomnia treatment.
- Analysis of sleep microstructure in newborns with Prader Willi Syndrome.
- Study on the efficacy of child insomnia treatment with oral iron supplements against placeb.

EPILEPSY

- Analysis of factors influencing the recurrence of seizures, tolerance and adherences to drugs, during the first monotherapy in patients with epilepsia.
- Analysis of neuropsychological disorders in the primary generalized epilepsy.
- Impact of perampanel in patients with epileptic encephalopathies. A multicentric study.
- Approach to refractory status epilepticus. Analysis of the different anesthetic agents commonly used in an intensive care unit

DIGITAL TECHNOLOGIES APPLIED TO NEUROLOGICAL DISEASES.

- Objective assessment of motor or other functional deficits (stroke, movement disorders, multiple sclerosis)
- Environmental enrichment to promote early stroke recovery
- Virtual reality in promoting cognitive and motor recovery
- New applications of ultrasound for diagnosis and research in neurological diseases
- Artificial Intelligence applied to diagnosis and clinical management
- NEUROSTIMULATION
- Neurostimulation in brain and spinal cord injuries

BRAIN PLASTICITY AND REPAIR AFTER CEREBRAL DAMAGE. TRASLATIONAL RESEARCH

- Therapies with trophic factors, stem cells and extracellular vesicles
- Biomarkers of damage and repair in neurological diseases
- Ultrasound monitoring and visualization of the brain and peripheral organs in animal models

RESEARCH LINES

- Cerebrovascular diseases.
- Headache and neuropathic pain.
- Neurodegenerative diseases: cognitive disorders, movement disorders and spinocerebellar ataxias.
- Neuroimmunology. Multiple sclerosis.
- Neuromuscular diseases. Motor neuron diseases Amyotrophic lateral sclerosis.
- Digital Technologies applied to neurological diseases
- Neurostimulation in brain and spinal cord injuries
- Brain plasticity and repair after cerebral damage. Traslational research

RESEARCH ACTIVITY

Doctoral Theses

- **Marcos Lorenzo D.** Salud de la columna en la descarga axial provocada durante los vuelos espaciales y la recarga mediante ejercicio[dissertation]. : Universidad Autónoma de Madrid: 2024(12/04/2024). Director: Gil Martínez A, Green DA
- **Díaz Saéz MC.** La lengua como órgano clave en el abordaje de los trastornos temporomandibulares[dissertation]. : Universidad Autónoma de Madrid: 2024(23/05/2024). Director: Gil Martínez A, Beltrán Alacreu H

Master Theses

- **Coronel C.** Evaluación de potenciales fármacos contra la Esclerosis Lateral Amiotrófica[dissertation]. Madrid: Universidad Europea: 2024(19/01/2024). Director: Palomo Ruiz MV
- **Blanco de Miguel D.** Development of a web application for the analysis of neuropsychological tests in MS patients. Master's in Biomedical Engineering. [dissertation]. Madrid: Universidad Politécnica de Madrid: 2024(17/07/2024). Director: Otero Ortega L

Final Degree Theses

- **González Matesanz M.** Papel de las vesículas extracelulares derivadas del sistema inmune en un modelo preclínico de hemorragia intracerebral[dissertation]. Madrid: Universidad Politécnica de Madrid: 2024(10/07/2024). Director: Gutiérrez Fernández M
- **Lorente Moro A.** Revalidación dela escala Madrid-DIRECT en el triaje prehospitalario del ictus agudo[dissertation]. Madrid: Universidad Autónoma de Madrid: 2024(10/06/2024). Director: Rodríguez Pardo de Donlebún J.
- **García Rubio A.** Vesículas extracelulares de pacientes de escleroris lateral [dissertation]. : Universidad Politécnica de Madrid: 2024(26/06/2024). Director: Palomo Ruiz MV
- **Ejido Fuentetaja B.** EV as a biomarker of treatment response in MS patients. Faculty of Biotechnology[dissertation]. León: Universidad de León: 2024(09/06/2024). Director: Otero Ortega L
- **Jiménez Cardeñoso A.** Analysis of immune checkpoint expression as a biomarker of treatment response in MS patients[dissertation]. Madrid: Universidad de Alcalá de Henares: 2024(10/02/2024). Director: Otero Ortega L. ISCIII

Publications

- **Almallouhi E, Zandpazandi S, Anadani M, Cunningham C, Sowlat MM, Matsukawa H, Orscelik A, Elawady SS, Maier I, Al Kasab S, Jabbour P, Kim JT, Wolfe SQ, Rai A, Starke RM, Psychogios MN, Samaniego EA, Arthur AS, Yoshimura S, Cuellar H, Grossberg JA, Alawieh A, Romano DG, Tanweer O, Mascitelli J, Fragata I, Polifka AJ, Osbun JW, Crosa RJ, Matouk C, Park MS, Levitt MR, Brinjikji W, Moss M, Dumont TM, Williamson R, Navia P, Kan P, De Leacy R, Chowdhry SA, Ezzeldin M, Spiotta AM.** Outcomes of mechanical thrombectomy in stroke patients with extreme large infarction core. J Neurointerv Surg. 2024; 16(12): 1268-74. Article. IF: 4.3; D1
- **Aranda CPD, Tosat-Bitrián C, Porras G, Dafinca R, Muñoz-Torrero D, Talbot K, Martin-Requero A, Martínez A, Palomo V.** Proteome Aggregation in Cells Derived from Amyotrophic Lateral Sclerosis Patients for Personalized Drug Evaluation. ACS Chem Neurosci. 2024; 15(21): 3945-53. Article. IF: 3.9; Q2
- **Arias-Ramos N, Vieira C, Pérez-Carro R, López-Larrubia P.** Integrative Magnetic Resonance Imaging and Metabolomic Characterization of a Glioblastoma Rat Model. Brain Sci. 2024; 14(5): 409. Article. IF: 2.8; Q3
- **Arranz-Martín B, del-Castillo-Pardo-de-Vera JL, Cebrian-Carretero JL, Rouco-García D, Fernández-Oliva C, Gil-Martínez A.** Quality of life, craniomandibular function, and psychosocial factors related to pain and movement in patients with head and neck cancer. Support Care Cancer. 2024; 32(6): 334. Article. IF: 3; D1
- **Balaceanu A, Puertas I, de Leciñana MA, Tallón A, Gutiérrez-Tenorio A, Vargas P, Torres G, Gutiérrez A.** Automatic evaluation of the Nine-Hole Peg Test in multiple sclerosis patients using machine learning models. Biomed Signal Proces. 2024; 92: 106128. Article. IF: 4.9; Q2
- **Bautista-Abad A, García-Magro N, Pinto-Benito D, Cáceres-Pajuelo JE, Alises CV, Ganchala D, Lagunas N, Negredo P, García-Segura LM, Arevalo MA, Grassi D.** Aging is associated with sex-specific alteration in the expression of genes encoding for neuroestradiol synthesis and signaling proteins in the mouse trigeminal somatosensory input. Geroscience. 2024; 46(6): 6459-72. Article. IF: 5.4; Q1
- **Benítez-Fernández R, Josa-Prado F, Sánchez E, Lao Y, García-Rubia A, Cumella J, Martínez A, Palomo V, de Castro F.** Efficacy of a benzothiazole-based LRRK2 inhibitor in oligodendrocyte precursor cells and in a murine model of multiple sclerosis. Cns Neurosci Ther. 2024; 30(1): e14552. Article. IF: 5; Q1
- **Bertotti G, Elizagaray-García JI, Rodríguez-Vico J, Gil-Martínez A.** Hyperalgesia, Increased Temporal Summation and Impaired Inhibitory Mechanisms in Episodic and Chronic Cluster Headache: An Observational Study. Biomedicines. 2024; 12(2): 374. Article. IF: 3.9; Q2
- **Bertotti G, Gil-Martínez A, Matesanz-García L, Angulo-Díaz-Parreno S, Rodríguez-Vico J, Díaz-de-Teran J, Elizagaray-García JI.** Somatosensory Profiling of Patients With Cluster Headache: A Systematic Review and Meta-analysis. J Pain. 2024; 25(8): 104498. Review. IF: 4; Q1
- **Bielawski PB, Zhang I, Correa-Paz C, Campos F, Migliavacca M, Polo E, Del Pino P, Pelaz B, Vivien D, Maysinger D.** Modulation of Abundance and Location of High-Mobility Group Box 1 in Human Microglia and Macrophages under Oxygen-Glucose Deprivation. ACS Pharmacol Transl Sci. 2024; 7(3): 680-92. Article. IF: 3.7; Q2
- **Bueno-Guerra N, Provencio M, Tarifa-Rodríguez A, Navarro A, Sempere-Iborra C, Jordi P, de Celis-Ruiz E, de Leciñana MA, Martín-Alonso M, Rigual R, Ruiz-Ares G, Rodríguez-Pardo J, Virués-Ortega J, Fuentes B.** Impact of post-stroke aphasia on functional communication, quality of life, perception of health and depression: A case-control study. Eur J Neurol. 2024; 31(4): e16184. Article. IF: 3.9; Q1
- **Candamo-Lourido M, Dopico-López A, López-Arias E, López-Amoedo S, Correa-Paz C, Chantada-Vázquez MP, Bugallo-Casal A, del Pozo-Filíu L, Pérez-Gayol L, Palomar-Alonso N, Bravo SB, Campos F, Pérez-Mato M.** Comparative Brain Proteomic Analysis between Sham and Cerebral Ischemia Experimental Groups. Int J Mol Sci. 2024; 25(14): 7538. Article. IF: 4.9; Q1
- **Cantero JL, Atienza M, Sastre I, Bullido MJ.** Human in vivo evidence of associations between herpes simplex virus and cerebral amyloid-beta load in normal aging. Alzheimers Res Ther. 2024; 16(1): 68. Article. IF: 7.6; D1
- **Casado-Fernández L, Laso-García F, Piniella D, Gómez-de Frutos MC, Otero-Ortega L, Bravo SB, Fuentes-Gimeno B, Docando F, Alonso-López**

E, Ruiz-Ares G, Rodríguez-Pardo J, Rigual R, de Celis-Ruiz E, Hervás C, Díez-Tejedor E, Gutiérrez-Fernández M, de Leciñana MA. The proteomic signature of circulating extracellular vesicles following intracerebral hemorrhage: Novel insights into mechanisms underlying recovery. Neurobiol Dis. 2024; 201: 106665. Article. IF: 5.6; Q1

- **Correa-Paz C, Pérez-Mato M, Bellemain-Sagnard M, González-Domínguez M, Marie P, Pérez-Gayol L, López-Arias E, del Pozo-Filíu L, López-Amoedo S, Bugallo-Casal A, Alonso-Alonso ML, Candamo-Lourido M, Santamaría-Cadavid M, Arias-Rivas S, Rodríguez-Yáñez M, Iglesias-Rey R, Castillo J, Vivien D, Rubio M, Campos F.** Pharmacological preclinical comparison of tenecteplase and alteplase for the treatment of acute stroke. J Cerebr Blood F Met. 2024; 44(8): 1306-18. Article. IF: 4.5; Q1
- **Cuevas EP, González LM, Gordillo C, Tosat-Bitrian C, de la Lastra CP, Sáenz A, Gil C, Palomo V, Martín-Requero A, Martínez A.** Casein kinase 1 inhibitor avoids TDP-43 pathology propagation in a patient-derived cellular model of amyotrophic lateral sclerosis. Neurobiol Dis. 2024; 192: 106430. Article. IF: 5.6; Q1
- **Dabhi N, Kumar JS, Ironside N, Kellogg RT, Sowlat MM, Uchida K, Maier I, Al Kasab S, Jabbour P, Kim JT, Wolfe SQ, Rai A, Starke RM, Psychogios MN, Samaniego EA, Arthur AS, Yoshimura S, Cuellar H, Howard BM, Alawieh A, Romano DG, Tanweer O, Mascitelli J, Fragata I, Polifka AJ, Osbun JW, Crosa RJ, Matouk C, Levitt MR, Brinjikji W, Moss M, Dumont TM, Williamson R, Navia P, Kan P, De Leacy R, Chowdhry SA, Ezzeldin M, Spiotta AM, Park MS.** Mechanical thrombectomy for the treatment of primary and secondary anterior cerebral artery occlusions: insights from STAR. J Neurointerv Surg. 2024; 16(12): 1282-7. Article. IF: 4.3; D1
- **Di-Bonaventura S, Ferrer-Peña R, Pardo-Montero J, Férnandez-Carnero J, La Touche R.** Perceived benefits and limitations of a psychoeducation program for patients with fibromyalgia: an interpretative phenomenological analysis. Front Psychol. 2024; 15: 1422894. Article. IF: 2.9; Q1
- **Elawady SS, Cunningham C, Matsukawa H, Uchida K, Lin S, Maier I, Jabbour P, Kim JT, Wolfe SQ, Rai A, Starke RM, Psychogios MN, Samaniego EA, Arthur A, Yoshimura S, Cuellar H, Grossberg JA, Alawieh A, Romano DG, Tanweer O, Mascitelli J, Fragata I, Polifka A, Osbun J, Crosa R, Matouk C, Park MS, Levitt MR, Brinjikji W, Moss M, Dumont T, Williamson R, Navia P, Kan PT, De Leacy R, Chowdhry S, Ezzeldin M, Spiotta AM, Al Kasab S.** Outcomes of Mechanical Thrombectomy for Patients With Stroke Presenting With Low Alberta Stroke Program Early Computed Tomography Score in Early and Late Time Windows. Neurosurgery. 2024; 95(4): 877-885. Article. IF: 3.9; D1
- **Elawady SS, Saway BF, Matsukawa H, Uchida K, Lin SV, Maier I, Jabbour P, Kim JT, Wolfe SQ, Rai A, Starke RM, Psychogios MN, Samaniego EA, Arthur A, Yoshimura S, Cuellar H, Grossberg JA, Alawieh A, Romano DG, Tanweer O, Mascitelli J, Fragata I, Polifka A, Osbun J, Crosa R, Matouk C, Park MS, Levitt MR, Brinjikji W, Moss M, Dumont T, Williamson R Jr, Navia P, Kan PT, De Leacy R, Chowdhry S, Ezzeldin M, Spiotta AM, Al Kasab S.** Thrombectomy in Stroke Patients With Low Alberta Stroke Program Early Computed Tomography Score: Is Modified Thrombolysis in Cerebral Infarction (mTICI) 2c/3 Superior to mTICI 2b?. J Stroke. 2024; 26(1): 95-103. Article. IF: 8.6; D1
- **Fongang B.** A genome-wide association meta-analysis of all-cause and vascular dementia. Alzheimers Dement. 2024; 20(9): 5973-95. Article. IF: 11.1; D1
- **Frutos MCGD, Laso-García F, García-Suárez I, Piniella D, Otero-Ortega L, Alonso-López E, Pozo-Novoa J, Gallego-Ruiz R, Díaz-Gamero N, Fuentes B, de Leciñana MA, Díez-Tejedor E, Ruiz-Ares G, Gutiérrez-Fernández M.** The impact of experimental diabetes on intracerebral haemorrhage. A preclinical study. Biomed Pharmacother. 2024; 176: 116834. Article. IF: 7.5; D1
- **Fuentes B, Jordi-Perea P, Sempere-Iborra C, Tarifa-Rodríguez A, de Celis-Ruiz E, Alonso MM, Ruiz-Ares G, Rigual R, Rodríguez-Pardo J, Alonso-López E, de Leciñana MA, Virués-Ortega J, Borobia AM, Jiménez-González M, Martínez-Balaguer M, Blanco P, Bueno N.** Dubbing language-therapy CINEma-based in aphasia post-stroke (DULCINEA): A feasibility randomized crossover controlled trial. Digit Health. 2024; 10: 20552076241288300. Article. IF: 3.3; Q1
- **García-Alberca JM, de Rojas I, Sánchez-Mejias E, Garrido-Martín D, Gonzalez-Palma L, Jimenez S, Pino-Angeles A, Cruz-Gamero JM, Mendoza S, Alarcón-Martín E, Muñoz-Castro C, Real LM, Tenao JJ, Polvillo R, Govantes F, López A, Royo-Aguado JL, Navarro V, González I, Ruiz M, Reyes-Engel A, Gris E, Bravo MJ, López-Gutierrez L, Mejias-Ortega M, De la Guía P, de la Rica ML, Ocejo O, Torrecilla J, Zafra C, Nieto MD, Urbano C, Jiménez-Sánchez R, Pareja N, Luque M, García-Peralta M, Carrillejo R, Furniet MD, Rueda L, Sánchez-Fernández A, Mancilla T, Peña I, García-Casares N, Moreno-Grau S, Hernández I, Montrreal L, Quintela I, Gónzalez-Pérez A, Calero M, Franco-Macías E, Macías J, Menéndez-González M, Frank-García A, Vilas RH, Díez-Fairen M, Lage C, García-Madrona S, García-González P, Valero S, Sotolongo-Grau O, Pérez-Cordón A, Rabano A, Pastor AA, Pastor AB, Espinosa A, Corma-Gómez A, Montes AM, Sanabria A, Rodríguez CM, Buiza-Rueda D, Rodríguez-Rodríguez E, Ortega G, Alvarez I, Allende IR, Pineda JA, Rosende-Roca M, Sánchez-Arjona MB, Fernández-Fuertes M, Alegret M, Roberto N, del Ser T, García-Ribas G, Sánchez-Juan P, Pastor P, Piñol-Ripoll G, Bullido MJ, Alvarez V, Mir P, Medina M, Marquié M, Sáez ME, Carracedo A, Laplana M, Tomas-Gallardo L, Orellana A, Tarraga L, Boada M, Palazon JF, Vitorica J, Ruiz A, Guigo R, Gutierrez A, Royo JL.** An Insertion Within SIRPβ1 Shows a Dual Effect Over Alzheimer's Disease Cognitive Decline Altering the Microglial Response. J Alzheimers Dis. 2024; 98(2): 601-18. Article. IF: 3.1; Q2
- **Grob A, Rohr J, Stumpo V, Vieli M, Ciobanu-Caraus O, Ricciardi L, Maldaner N, Raco A, Miscusi M, Perna A, Proietti L, Lofrese G, Dughiero M, Cultrera F, D'Andrea M, An SB, Ha Y, Amelot A, Cadelo JB, Vinuela-Prieto JM, Gandía-Gonzalez ML, Girod PP, Lener S, Koegl N, Abramovic A, Laux CJ, Farshad M, O'Riordan D, Loibl M, Galbusera F, Mannion AF, Scerrati A, De Bonis P, Molliqaj G, Tessitore E, Schroeder ML, Stienen MN, Regli L, Serra C, Staartjes VE.** Multicenter external validation of prediction models for clinical outcomes after spinal fusion for lumbar degenerative disease. Eur Spine J. 2024; 33(9): 3534-44. Article. IF: 2.7; Q2
- **Herraiz A, Morales MP, Martínez-Parra L, Arias-Ramos N, López-Larrubia P, Gutiérrez L, Mejías J, Díaz-Ufano C, Ruiz-Cabello J, Herranz F.** Periodic table screening for enhanced positive contrast in MRI and in vivo uptake in glioblastoma. Chem Sci. 2024; 15(22): 8578-90. Article. IF: 7.4; Q1
- **Hervas C, Peirotén I, Gonzalez L, de Leciñana MA, Alonso-López E, Casado L, De Celis-Ruíz E, Prieto AFF, Frutos R, Gallego-Ruiz R, de Villar NGP, Gutiérrez-Fernández M, Navia P, Otero-Ortega L, Pozo-Novoa J, Rigual R, Rodríguez-Pardo J, Ruiz G, Fuentes B.** Glycaemia and ischaemia-reperfusion brain injury in patients with ischaemic stroke treated with mechanical thrombectomy (GLIAS-MT): an observational, unicentric, prospective study protocol. Bmj Open. 2024; 14(8): e086745. Article. IF: 2.3; Q2
- **Iglesias GT, López-Molina M, Botella L, Laso-García F, Chamorro B, Fernández-Fournier M, Puertas I, Bravo SB, Alonso-López E, Díez-Tejedor E, Gutiérrez-Fernández M, Otero-Ortega L.** Differential Protein Expression in Extracellular Vesicles Defines Treatment Responders and Non-Responders in Multiple Sclerosis. Int J Mol Sci. 2024; 25(19): 10761. Article. IF: 4.9; Q1
- **Jhooty S, Barkhaus P, Brown A, Cadavid JM, Carter GT, Crayle J, Heiman-Patterson T, Li XY, Mallon E, Mcdermott C, Mushannen T, Pattee G, Ratner D, Wicks P, Wiedau M, Bedlack R.** ALSUntangled #74: Withania Somnifera (Ashwagandha). Amyotroph Lat Scl Fr. 2024; 25(7-8): 805-8. Article. IF: 2.8; Q2
- **Koo AB, Reeves BC, Renedo D, Maier IL, Al Kasab S, Jabbour P, Kim JT, Wolfe SQ, Rai A, Starke RM, Psychogios MN, Shaban A, Arthur A, Yoshimura S, Cuellar H, Grossberg JA, Alawieh A, Romano DG, Tanweer O, Mascitelli J, Fragata I, Polifka A, Osbun J, Crosa R, Park MS, Levitt MR, Brinjikji W, Moss M, Dumont T, Williamson R, Navia P, Kan PT, Spiotta AM, Sheth KN, de Havenon A, Matouk CC.** Impact of Procedure Time on First Pass Effect in Mechanical Thrombectomy for Anterior Circulation Acute Ischemic Stroke. Neurosurgery. 2024; 95(1): 128-36. Article. IF: 3.9; D1
- **La Touche R, Paris-Alemany A, Pardo-Montero J, Miñambres-Martin D, Mercado-Romero F, de**

la Rosa-Díaz I, Sorrel MA, Grande-Alonso M. The biobehavioural pain and movement questionnaire (BioPMovQ): development and psychometric validation of a new questionnaire. Front Med (Lausanne). 2024; 11: 1358829. Article. IF: 3; Q1

- **Leira Y, Vivancos J, Diz P, Martín A, Carasol M, Frank A.** The association between periodontitis, cerebrovascular disease, and dementia. Scientific report of the Working Group of the Spanish Society of Periodontology and the Spanish Society of Neurology. Neurología. 2024; 39(3): 302-11. Article. IF: 3.1; Q2
- **Lluncor-Salazar M, Phillips-Anglés E, Pedrosa M, Lamacchia D, Hernanz A, Prior N, Cabanas R, Caballero T.** Determinants of Disease Activity in Adults With Hereditary Angioedema due to C1-Esterase Inhibitor Deficiency. J Invest Allerg Clin. 2024; 34(6): 406-9. Editorial Material. IF: 4.8; Q1
- **López JG, Armas CE, Diéguez ML, Muñoz IP, Ruiz ED, Rigual R, Fernández-Fournier M, Iglesias GT, Velasco SS, Barranco AT, Rogozina O, Ramírez E, González-Muñoz M, Ballester LL.** Neurological manifestations of immune origin after COVID-19 vaccination: retrospective case study. Front Pharmacol. 2024; 15: 1376474. Article. IF: 4.8; Q1
- **Manoso-Hernando D, Bailón-Cerezo J, Angulo-Díaz-Parreño S, Reina-Varona A, Elizagaray-García I, Gil-Martínez A.** Shoulder mobility and strength impairments in patients with rotator cuff related shoulder pain: a systematic review and meta analysis. PEERJ. 2024; 12: e17604. Article. IF: 2.4; Q2
- **Manoso-Hernando D, Bailón-Cerezo J, Elizagaray-García I, Achútegui-García-Matres P, Suárez-Díez G, Gil-Martínez A.** Cervical and Thoracic Spine Mobility in Rotator Cuff Related Shoulder Pain: A Comparative Analysis with Asymptomatic Controls. J Funct Morphol Kinesiol. 2024; 9(3): 128. Article. IF: 2.5; Q2
- **Matías-Guiu JA, Alvarez-Sabín J, Botia E, Casado-Naranjo I, Castellanos M, Frank A, Íñiguez C, Jiménez-Hernández MD, Jiménez-Jiménez FJ, Láinez JM, Moral E, Pérez-Martínez DA, Rodríguez-Antigüedad A, Ruiz-Lavilla N, Segura T, Serrano-Castro PJ, Matias-Guiu J.** Perceptions of key informant neurologists before implementing anti-amyloid drugs in the Spanish departments of neurology. J Alzheimers Dis. 2024; 102(1): 207-17. Article. IF: 3.1; Q2
- **Matsukawa H, Crosa R, Cunningham C, Maier I, Al Kasab S, Jabbour P, Kim JT, Wolfe SQ, Rai A, Starke RM, Psychogios MN, Shaban A, Goyal N, Yoshimura S, Cuellar H, Howard B, Alawieh A, Alaraj A, Ezzeldin M, Romano DG, Tanweer O, Mascitelli J, Fragata I, Polifka A, Siddiqui F, Osbun J, Matouk C, Park MS, Levitt MR, Brinjikji W, Moss M, Williamson R, Navia P, Kan PT, De Leacy R, Chowdhry S, Spiotta AM.** Earlier Endovascular Thrombectomy and Mortality in Patients with Anterior Circulation Large Vessel Occlusion: A Propensity-Matched Analysis of the Stroke Thrombectomy and Aneurysm Registry. World Neurosurg. 2024; 189: E435-41. Article. IF: 2.1; Q2
- **Matsukawa H, Uchida K, Cunningham C, Sowlat MM, Elawady SS, Maier I, Jabbour P, Kim JT, Wolfe SQ, Rai A, Starke RM, Psychogios MN, Shaban A, Arthur A, Cuellar H, Howard BM, Alawieh A, Romano DG, Tanweer O, Mascitelli J, Fragata I, Polifka A, Osbun J, Crosa R, Matouk C, Park MS, Brinjikji W, Moss M, Williamson R, Navia P, Kan PT, De Leacy R, Chowdhry S, Ezzeldin M, Spiotta AM, Levitt MR, Yoshimura S.** Outcomes and differences by occluded vessel after endovascular thrombectomy for isolated medium vessel occlusions. J Neurol Sci. 2024; 462: 123054. Article. IF: 3.2; Q2
- **Mediratta S, Lippa L, Venturini S, Demetriades AK, El-Ouahabi A, Gandía-González ML, Harkness W, Hutchinson P, Park KB, Rabiei K, Rosseau G, Schaller K, Servadei F, Lafuente J, Kolias AG.** Current state of global neurosurgery activity amongst European neurosurgeons. J Neurosurg Sci. 2024; 68(4): 371-8. Article. IF: 1.2; Q3
- **Meyer L, Stracke CP, Broocks G, Wallocha M, Elsharkawy M, Sporns PB, Piechowiak E, Kaesmacher J, Maegerlein C, Petzsche MRH, Naziri W, Zimmermann H, Abdullayev N, Kabbasch C, Behme D, Thormann M, Maus V, Fischer S, Möhlenbruch MA, Weyland CS, Langner S, Ernst M, Jamous A, Meila D, Miszczuk M, Siebert E, Lowens S, Krause LU, Yeo LLL, Tan BYQ, Gopinathan A, Gory B, Fernández JG, Arteaga MS, Navia P, Raz E, Shapiro M, Arnberg F, Zelenák K, Martínez-Galdámez M, Alexandrou M, Kastrup A, Papanagiotou P, Dorn F, Kemmling A, Psychogios MN, Andersson T, Chapot R, Fiehler J, Hanning U.** Effect of anesthetic strategies on distal stroke thrombectomy in the anterior and posterior cerebral artery. J Neurointerv Surg. 2024; 16(3): 230-6. Article. IF: 4.3; D1
- **Migliavacca M, Correa-Paz C, Pérez-Mato M, Bielawski PB, Zhang I, Marie P, Hervella P, Rubio M, Maysinger D, Vivien D, del Pino P, Pelaz B, Polo E, Campos F.** Thrombolytic therapy based on lyophilized platelet-derived nanocarriers for ischemic stroke. J Nanobiotechnol. 2024; 22(1): 10. Article. IF: 12.6; D1
- **Muhana M, Lund I, Bromberg M, Wicks P, Benatar M, Barnes B, Pierce K, Ratner D, Brown A, Bertorini T, Barkhaus P, Carter G, Cadavid JM, McDermott C, Glass JD, Pattee G, Armon C, Bedlack R, Li XY.** ALSUntangled #73: Lion's Mane. Amyotroph Lat Scl Fr. 2024; 25(3-4): 420-3. Article. IF: 2.8; Q2
- **Navarro-Fernández G, Bravo-Aparicio J, del Castillo JL, Beltran-Alacreu H, Gil-Martínez A.** Pre-Surgical Factors Influencing Post-Surgical Outcomes in Orthognathic Surgery Patients: A Longitudinal Study. J Clin Med. 2024; 13(15): 4445. Article. IF: 2.9; Q1
- **Navia P, de Rueda ME, Rodríguez-Benitez A, Marco FB, Pumar JM, Gallego-Leon JI, Díaz-Valino JL, Mendez JC, Fernández FH, Rodríguez-Paz CM, Hernández D, Maynar EJ, Vega-Villar J, García-Benassi JM, Martínez-Galdámez M, Larrea JA, Fernández-Prieto A.** Endovascular thrombectomy first-pass reperfusion and ancillary device placement. J Neurointerv Surg. 2024; 16(9): 902-7. Article. IF: 4.3; D1
- **Nozal V, Fernández-Gómez P, García-Rubia A, Martínez-González L, Cuevas EP, Carro E, Palomo V, Martínez A.** Designing multitarget ligands for neurodegenerative diseases with improved permeability trough PLGA nanoencapsulation. Biomed Pharmacother. 2024; 175: 116626. Article. IF: 7.5; D1
- **Officer L, Armon C, Barkhaus P, Beauchamp M, Benatar M, Bertorini T, Bowser R, Bromberg M, Brown A, Carbunar OM, Carter GT, Crayle J, Denson K, Feldman E, Fullam T, Heiman-Patterson T, Jackson C, Jhooty S, Levinson D, Li XY, Linares A, Mallon E, Cadavid JM, Mcdermott C, Mushannen T, Ostrow L, Patel R, Pattee G, Ratner D, Sun YY, Sladky J, Wicks P, Bedlack R.** ALSUntangled #75: Portable neuromodulation stimulator therapy. Amyotroph Lat Scl Fr. 2024; 25(5-6): 648-52. Article. IF: 2.8; Q2
- **Orscelik A, Kallmes DF, Bilgin C, Musmar B, Senol YC, Kobeissi H, Elawady SS, Cunningham C, Matsukawa H, Zandpazandi S, Sowlat MM, Maier I, Al Kasab S, Jabbour P, Kim JT, Wolfe SQ, Rai A, Starke RM, Psychogios MN, Samaniego EA, Arthur AS, Yoshimura S, Cuellar H, Howard BM, Alawieh A, Romano DG, Tanweer O, Mascitelli J, Fragata I, Polifka AJ, Osbun JW, Crosa RJ, Matouk C, Park MS, Levitt MR, Moss M, Dumont TM, Williamson R, Navia P, Kan PT, De Leacy R, Chowdhry SA, Ezzeldin M, Spiotta AM, Brinjikji W, STAR Collaborators.** Comparison of balloon guide catheter versus non-balloon guide catheter for mechanical thrombectomy in patients with distal medium vessel occlusion. J Neurointerv Surg. 2024; 16(6): 587-94. Article. IF: 4.3; D1
- **Orscelik A, Matsukawa H, Elawady SS, Sowlat MM, Cunningham C, Zandpazandi S, Kasem RA, Maier I, Jabbour P, Kim JT, Wolfe SQ, Rai A, Starke RM, Psychogios MN, Shaban A, Goyal N, Yoshimura S, Cuellar H, Howard B, Alawieh A, Romano DG, Tanweer O, Mascitelli J, Fragata I, Polifka A, Osbun J, Crosa R, Matouk C, Park MS, Levitt MR, Brinjikji W, Moss M, Dumont T, Williamson R , Navia P, Kan PT, De Leacy R, Chowdhry S, Ezzeldin M, Spiotta AM, Al Kasab S.** Comparative Outcomes of Mechanical Thrombectomy in Acute Ischemic Stroke Patients with ASPECTS 2-3 vs. 4-5. J Stroke Cerebrovasc. 2024; 33(2): 107528. Article. IF: 1.8; Q3
- **Pérez-Mato M, Dopico-López A, Akkoc Y, López-Amoedo S, Correa-Paz C, Candamo-Lourido M, Iglesias-Rey R, López-Arias E, da Silva-Candal A, Bravo SB, Chantada-Vázquez MD, Arias S, Santamaría-Cadavid M, Estany-Gestal A, Zaghmi A, Gauthier MA, Gutiérrez-Fernández M, Martin A, Llop J, Rodríguez C, Almeida A, Migliavacca M, Polo E, Pelaz B, Gozuacik D, El Yamani N, SenGupta T, Rundén-Pran E, Vivancos J, Castellanos M, Díez-Tejedor E, Sobrino T, Rabinkov A, Mirelman D, Castillo J, Campos F.** Preclinical validation of human recombinant glutamate-oxaloacetate transaminase for the

treatment of acute ischemic stroke. Iscience. 2024; 27(11): 111108. Article. IF: 4.1; Q1

- **Pérez-Mato M, López-Arias E, Bugallo-Casal A, Correa-Paz C, Arias S, Rodríguez-Yáñez M, Santamaría-Cadavid M, Campos F.** New Perspectives in Neuroprotection for Ischemic Stroke. Neuroscience. 2024; 550: 30-42. Article. IF: 2.8; Q3
- **Rigual R, Castrejón-Castrejón S, Fernández-Gassó L, García-Castro J, Rodríguez-Pardo J, Martínez-Cossiani M, de Celis-Ruiz E, Casado-Fernández L, Hervás C, Alonso-López E, de Leciñana MA, Díez-Tejedor E, Pérez-David E, Ruiz-Ares G, Merino JL, Fuentes B.** Atrial Imaging and Cardiac Rhythm in Cryptogenic Embolic Stroke: The ARIES Study. J Am Heart Assoc. 2024; 13(17): e036236. Article. IF: 5.3; Q1
- **Rigual R, Rodríguez-Pardo J, Lorenzo-Diéguez M, Fernández-Fernández S, Iglesias GT, Lastras C, Ruiz-Ares G, de Leciñana MA, de Celis E, Casado-Fernández L, Hervás C, Alonso E, Díez-Tejedor E, Fuentes B.** Keeping prior anticoagulation treatment in the acute phase of ischaemic stroke: the REKOALA study. J Neurol. 2024; 271(6): 3702-7. Article. IF: 4.6; Q1
- **Rodríguez A, Amaya-Pascasio L, Gutiérrez-Fernández M, García-Pinteño J, Moreno M, Martínez-Sánchez P.** Non-invasive brain stimulation for functional recovery in animal models of stroke: A systematic review. Neurosci Biobehav R. 2024; 156: 105485. Review. IF: 7.9; D1
- **Rosas-Alonso R, Colmenarejo-Fernández J, Pernía O, Burdiel M, Rodríguez-Antolín C, Losantos-García I, Rubio T, Moreno-Velasco R, Esteban-Rodríguez I, Martínez-Marín V, Yubero P, Costa-Fraga N, Díaz-Lagares A, López-López R, Díaz-Martin E, García JF, Sánchez CV, Gandía-González ML, Moreno-Bueno G, de Castro J, de Cáceres II.** Evaluation of the clinical use of MGMT methylation in extracellular vesicle-based liquid biopsy as a tool for glioblastoma patient management. Sci Rep-Uk. 2024; 14(1): 11398. Article. IF: 3.9; Q1
- **Ruiz-García C, Lassaletta L, López-Larrubia P, Varela-Nieto I, Murillo-Cuesta S.** Tumors of the nervous system and hearing loss: Beyond vestibular schwannomas. Hearing Res. 2024; 447: 109012. Article. IF: 2.5; Q1
- **Salgado B, Izquierdo B, Zapata A, Sastre I, Kristen H, Terreros J, Mejías V, Bullido MJ, Aldudo J.** Cholesterol Modulation Attenuates the AD-like Phenotype Induced by Herpes Simplex Virus Type 1 Infection. Biomolecules. 2024; 14(5): 603. Article. IF: 4.8; Q1
- **Santalla CC, López IV, Rivera BB, Olmeda MDG, Domínguez RD, Martín PF, Prieto MB, Jorge SG, Hernanz AM, Serrano AM, Aparicio EM, García PN, Robert MS, Morla EMS, Avila BSA, Luengo AV, Arias MRM, Fuentenebro FJS.** Patient satisfaction with hospital health care on acute psychiatric units: Development and validation of the PSYQUEST questionnaire. Span J Psychiatry Ment Health. 2024; 17(4): 195-202. Article. IF: 2.8; Q2
- **Sivera R, Pelayo-Negro AL, Jerico I, Domínguez-González C, Horga A, De Rivera FJR, Gallardo E, Tembl JI, Bermejo-Guerrero L, Lorz MIP, Azorin I, Cordoba M, Fenollar-Cortés MD, Millet E, Vilchez JJ, Espinós C, Apellániz-Ruiz M, Sevilla T.** Expanding the Clinical Spectrum of DRP2-Associated Charcot-Marie-Tooth Disease. Neurology. 2024; 102(7): e209174. Article. IF: 8.5; D1
- **Stengel FC, Stienen MN, Ivanov M, Gandía-Gonz ML, Raffa G, Ganau M, Whitfield P, Motov S.** Can AI pass the written European Board Examination in Neurological Surgery? Ethical and practical issues. Brain Spine. 2024; 4: 102765. Article. IF: 2.5; Q2
- **Strambo D, Marto JP, Ntaios G, Nguyen TN, Michel P (Díez-Tejedor E).** Effect of Asymptomatic and Symptomatic COVID-19 on Acute Ischemic Stroke Revascularization Outcomes. Stroke. 2024; 55(1): 78-88. Article. IF: 8.9; D1
- **Thomalla G, Fiehler J, Subtil F, Bonekamp S, Aamodt AH, Fuentes B, Gizewski ER, Hill MD, Krajina A, Pierot L, Simonsen CZ, Zelenák K, Blauenfeldt RA, Cheng B, Denis A, Deutschmann H, Dorn F, Flottmann F, Gellissen S, Gerber JC, Goyal M, Haring J, Herweh C, Hopf-Jensen S, Hua VT, Jensen M, Kastrup A, Keil CF, Klepanec A, Kurca E, Mikkelsen R, Möhlenbruch M, Müller-Hülsbeck S, Münnich N, Pagano P, Papanagiotou P, Petzold GC, Pham M, Puetz V, Raupach J, Reimann G, Ringleb PA, Schell M, Schlemm E, Schönenberger S, Tennoe B, Ulfert C, Valis K, Vitková E, Vollherbst DF, Wick W, Bendszus M.** Endovascular thrombectomy for acute ischaemic stroke with established large infarct (TENSION): 12-month outcomes of a multicentre, open-label, randomised trial. Lancet Neurol. 2024; 23(9): 883-92. Article. IF: 45.5; D1
- **Torregrossa F, Peris-Celda M, Spiriev T, Zoia C, Drosos E, Aldea C, Bartek J, Bauer M, Belo D, Stastna D, Kaprovoy S, Lepic M, Lippa L, Mohme M, Motov S, Schwake M, Stengel F, Iacopino G, Grasso G, Gandìa-Gonzàlez ML, Meling TR, Raffa G.** A spotlight on cadaveric dissection in neurosurgical training: The perspective of the EANS young neurosurgeons committee. Brain Spine. 2024; 4: 102839. Letter. IF: 2.5; Q2
- **Tosat-Bitrián C, de Barrio JAB, Stewart MH, Susumu K, Medintz IL, Díaz SA, Palomo V.** Membrane-Targeted Quantum Dot-Based BACE1 Activity Sensors for In Vitro and In Cellulo Assays. ACS Appl Mater Inter. 2024; 16(46): 63186-94. Article. IF: 8.2; Q1
- **Tung-Chen Y, Apellaniz JS, Roca RA, Viladot JRA, González IA, Romero LB, Cebrián AC, Linares RC, Gil KAF, Suárez IG, Delgado ADG, Martínez AH, Ratti MFM, Villén OM, Mercadal JM, Puras EM, Belloso MEM, Párraga PPR, Urteaga ER, Galán AR, Barrancos IMS, Rodríguez JLS, Sánchez JCS, Grau AS, Macho JT, Villegas TV, Vives M, Sánchez GGD.** Executive summary of the consensus document on point-of-care ultrasound implementation: recommendations from the Clinical Ultrasound Working Groups of SEMI, SEDAR, SEGG, SEMERGEN, SEMES, SEMFYC and SEMG. Rev Clin Esp. 2024; 224(10): 670-8. Article. IF: 1.7; Q2
- **Zoia C, Stienen MN, Zaed I, Menna G, Aldea CC, Bartek J, Bauer M, Belo D, Drosos E, Freyschlag CF, Kaprovoy S, Lepic M, Lippa L, Mohme M, Motov S, Schwake M, Spiriev T, Stengel FC, Torregrossa F, Raffa G, Gandía-Gonzalez ML.** The prevalence of imposter syndrome among neurosurgeons in Europe: An EANS YNC survey. Brain Spine. 2024; 4: 102816. Article. IF: 2.5; Q2

Research projects

- **Aguilar-Amat Prior MJ.** Registro de pacientes en una clinica de primera crisis epileptica. Laboratorios Bial S.A. 2016-Ongoing. Managment centre: FIBHULP
- **Alonso De Leciñana Cases M.** Utilidad de la telemedicina mediante dispositivos móviles en el código Ictus y la detección precoz de signos radiológicos de afectación pulmonar por Sars-Cov 2 en la Red de Ictus de Madrid. Ministerio de Asuntos Internos y Comunicaciones de Japón. 2021-Ongoing. Managment centre: FIBHULP
- **Alonso de Leciñana Cases M; Gutiérrez Fernández M.** Desarrollo de un tratamiento basado en administración de proteínas encapsuladas para mejorar la recuperación funcional tras una hemorragia cerebral. Una aproximación traslacional (PI23/00436). ISCIII. 2024-2026. Managment centre: FIBHULP
- **Alonso López E.** Beca Dr. Luis Álvarez 2024 Modalidad 2 Mentor. FIBHULP. 2025-2026. Managment centre: FIBHULP
- **Alonso López E.** Contrato Juan Rodés (JR24/00004). ISCIII. 2025-2028. Managment centre: FIBHULP
- **Alonso López E.** Contrato Rio Hortega (CM20/00047). ISCII-IMICINN. 2021-2023. Managment centre: FIBHULP
- **Díaz de Terán Velasco FJ.** Sensibilizacion central y percepcion del dolor en pacientes con cefalea en racimos. Allergan S.A. 2019-Ongoing. Managment centre: FIBHULP
- **Díez Tejedor E; Fuentes Gimeno B.** AMASCIS-02. Alogenic adipose tissue-derived mesenchymal stem cells in ischemic stroke. A phase IIB multicenter double blind placebo controllled clinical trial (PIC18/00016). ISCIII. 2019-2024. Managment centre: FIBHULP
- **Frank García A.** Investigación en calidad: mejora continua en la gestion y organización de procesos asistenciales y de investigación del servicio de neurologia y del grupo de investigación de neurología y enfermedades cerebrovasculares. Various funders. 2022-Ongoing. Managment centre: FIBHULP
- **Fuentes Gimeno B.** Ensayo clínico piloto dulcinea (dubbing language-therapy cinemabased in aphasia post-stroke. A feasibility cross-over pilot-trial. Fundación la Caixa. 2019-Ongoing. Managment centre: FIBHULP
- **Fuentes Gimeno B.** Glucemia y daño cerebral por isquemia reperfusión en pacientes con infarto cerebral agudo tratados con trombectomía

mecánica. Estudio GLIAS-TM (PI21/00962). ISCIII. 2022-2026. Managment centre: FIBHULP

- **Fuentes Gimeno B.** Novedades en Ictus y afasia. Daichii S.A. Nkyo Pharma Development. 2022-Ongoing. Managment centre: FIBHULP
- **Gandía González ML.** Estudio de factores químicos medioambientales mediante cromatografía líquida y espectrometría de masas y su influencia en el perfil epigenético mediante técnicas de análisis masivo en el glioblastoma multiforme, nueva aproximación a la identificación de factores de riesgo prevenibles. FIBHULP. 2022-Ongoing. Managment centre: FIBHULP
- **Gil Martínez A.** Efectividad de un programa de ejercicios en pacientes con enfermedad de covid-19 ingresados en planta del Hospital Universitario La Paz. Colegio Oficial de Fisioterapeutas de la Comunidad de Madrid. 2020-Ongoing. Managment centre: FIBHULP
- **Gil Martínez A.** Sistema de interaccion natural para analisis y rehabilitacion de los trastornos de la marcha en la enfermedad de parkinson (Mobeeze). Fundación I+D Del Software Libre. 2016-Ongoing. Managment centre: FIBHULP
- **Gutiérrez Fernández MD.** Contrato Miguel servet Tipo II (CPII20/00002). ISCIII. 2021-2024. Managment centre: FIBHULP
- **Gutierrez Fernández MD; Alonso de Leciñana Cases M.** Descifrando el papel de las vesículas extracelulares como moduladores de la respuesta inmunológica para promover la recuperación funcional tras la hemorragia cerebral. Estudio traslacional. (PI20/00243). ISCIII. 2021-2025. Managment centre: FIBHULP
- **Hernández Herrero, D.** Primer portofolio de dispositivos de uso doméstico destinado a la rehabilitación de pacientes afectados por trastornos de la marcha (PMPTA22/00212). ISCIII. 2023-2024. Managment centre: FIBHULP
- **Martínez Moreno M.** Puesta en marcha del estudio de título provisional: "estudio en pacientes con atrofia muscular espinal de inicio tardío (ml43472). Roche Farma S.A. 2021-Ongoing. Managment centre: FIBHULP
- **Otero Ortega L.** Contrato Miguel Servet (CP20/00024). ISCIII-MICINN. 2021-2025. Managment centre: FIBHULP
- **Otero Ortega L.** MicroARNs derivados de vesículas extracelulares sanguíneas como biomarcadores de respuesta al tratamiento en pacientes con esclerosis múltiple. FIBHULP. 2022-Ongoing. Managment centre: FIBHULP
- **Otero Ortega L.** Moléculas moduladores del sistema inmune como biomarcadores de respuesta al tratamiento en Esclerosis Múltiple: estudio traslacional. (PI21/00918). ISCIII. 2022-2026. Managment centre: FIBHULP
- **Otero Ortega L.** Treatment choice matters in multiple sclerosis: The role of extracellular vesicles in predicting treatment response (CP20/00024). ISCIII. 2021-2024. Managment centre: FIBHULP
- **Palomo Ruiz MV.** Development of tools to study extracellular vesicle modulation in models of neurodegenerative diseases: improving drug evaluation in neurodegeneration (CNS2022-135852). Agencia Estatal de Invetsigación. 2023-Ongoign. Managment centre: IMDEA Nanociencia
- **Palomo Ruiz MV.** Improved biosensors for better drug asessment in amyotrophic lateral sclerosis (PID2021-1283400A-I00). Agencia Estatal de Invetsigación. 2022-Ongoing. Managment centre: IMDEA Nanociencia
- **Palomo Ruiz MV.** Investigating Extracellular Vesicles in ALS: from mechanisms to biomarkers. Fundación Luzón. 2024-Ongoing. Managment centre: IMDEA Nanociencia
- **Palomo Ruiz MV.** Targeting circadian clock dysfunction in Alzheimer's disease (101072895-HORIZON-TMA-MSCA-DN-JD). European Union. 2022-Ongoing. Managment centre: IMDEA Nanociencia
- **Pascual Pascual SI.** Longitudinal data collection from patients with spinal muscular atrophy in spain a nationwide registry-cuidame. Fundacion Sant Joan De Deu. 2020-Ongoing. Managment centre: FIBHULP
- **Rigual Bobillo RJ.** Continuación del tratamiento anticoagulante en la fase aguda infarto cerebral carioembolico. Estudio Coala-IC. Daiichi Sankyo España. 2020-Ongoing. Managment centre: FIBHULP
- **Rodriguez de Rivera Garrido FJ.** Consorcio europeo de ataxia de Friedreich para la realización de estudios traslacionales. Various funders. 2015-Ongoing. Managment centre: FIBHULP

Cibers and Retics

- **Bullido Gómez-Heras MJ.** Centro de Investigación en Red de Enfermedades neurodegenerativas (CIBERNED). ISCIII. (31/12/2024). FIBHULP
- **Fuentes Gimeno B.** Enfermedades vasculares cerebrales (RICORS). ISCIII. (31/12/2024). FIBHULP
- **Otero Ortega L.** Inflamación (RICORS). ISCIII. (31/12/2024). FIBHULP

Clinical Trials

- **Aguilar-Amat Prior MJ.** Epidemiología de los síndromes de dravet y lennox-gastaut en españa. Type/Phase: OTROS.
  Sponsored by: Takeda Farmacéutica España S.A.U
  Signature date: 13/02/2024
- **Aguilar-Amat Prior MJ.** safety and therapeutic measures of transcranial cathodal direct current stimulation (tdcs) in patients with refractory focal epilepsy.
  Type/Phase:
  Sponsored by: Neuroelectrics Usa Corporation
  Signature date: 04/06/2024
- **Díaz De Terán Velasco FJ.** cornerstone: estudio prospectivo y observacional de la efectividad de atogepant en la práctica clínica habitual.
  Type/Phase: EOm prospectivo
  Sponsored by: Abbvie Spain S.L.U.
  Signature date: 29/11/2024
- **Díaz De Terán Velasco FJ.** estudio aleatorizado, doble ciego, controlado con placebo, de crisis múltiples con una extensión abierta para evaluar la eficacia, seguridad, tolerabilidad y consistencia del efecto de atogepant para el tratamiento agudo de la migraña (eclipse) randomized, double-blind, placebo-controlled, multiple-attack study with an open-label extension to evaluate the efficacy, safety, tolerability, and the consistency of effect of atogepant for the acute treatment of migraine (eclipse).
  Type/Phase: III
  Sponsored by: Abbvie Deutschland GMBH & Co. Kg
  Signature date: 08/02/2024
- **Díaz De Terán Velasco FJ.** estudio de fase ii, aleatorizado, multicéntrico, de tratamiento con grupos paralelos y con enmascaramiento doble para investigar la seguridad y eficacia de medi0618 subcutáneo en la reducción de los días de cefalea migrañosa en comparación con placebo en participantes adultos con migraña episódica.
  Type/Phase: II
  Sponsored by: Astrazeneca Ab
  Signature date: 09/10/2024
- **Díaz De Terán Velasco FJ.** estudio en fase iv, aleatorizado, doble ciego, controlado con placebo, para evaluar la eficacia y tolerabilidad de rimegepant para la prevención de la migraña en adultos con antecedentes de respuesta inadecuada a medicamentos preventivos orales.
  Type/Phase: IV
  Sponsored by: Biohaven Pharmaceuticals
  Signature date: 04/10/2024
- **Díez Tejedor E.** estudio de fase 1/3, doble ciego, aleatorizado, con control activo y de grupos paralelos para comparar la eficacia, la farmacocinética, la farmacodinámica y la seguridad de ct-p53 y ocrevus en pacientes con esclerosis múltiple remitente-recurrente.
  Type/Phase: I
  Sponsored by: Celltrion Inc.
  Signature date: 08/05/2024
- **Díez Tejedor E.** estudio de fase ii, doble ciego, aleatorizado y controlado con placebo para evaluar la seguridad y la eficacia de dosis múltiples del producto farmacéutico It3001 en sujetos con accidente cerebrovascular isquémico agudo (acia.
  Type/Phase: II
  Sponsored by: Lumosa Therapeutics Co. Ltd.
  Signature date: 01/04/2024
- **Frank García A.** estudio fase ii, de grupos paralelos, aleatorizado, doble ciego, controlado con placebo, de 3 brazos, multicéntrico con tratamiento para evaluar la eficacia y seguridad de la infusión intravenosa de gsk4527226 [al101] en comparación con placebo en pacientes con enfermedad de alzheimer temprana.
  Type/Phase: II
  Sponsored by: Glaxosmithkline Research And Development Limited
  Signature date: 26/02/2024
- **Fuentes Gimeno B.** a phase 2b, multinational, randomized, double-blind study to investigate the efficacy and safety of redasemtide (s-005151) compared with placebo in adult participants with acute ischemic stroke.
  Type/Phase: IIb

Sponsored by: Shionogi B.V
Signature date: 02/11/2024

- **Mascías Cadavid J.** estudio multicéntrico, aleatorizado, con enmascaramiento doble, controlado con placebo y de fase 2 en el que se evalúan la seguridad y la eficacia de cort113176 (dazucorilant) en pacientes con esclerosis lateral amiotrófica (dazals)".
  Type/Phase: II
  Sponsored by: Corcept Therapeutics Inc.orporated
  Signature date: 31/07/2024
- **Navía Álvarez P.** estudio del sistema de aspiración millipede para revascularización en ictus (marrs por sus siglas en inglés).
  Type/Phase: PRODUCTO SANITARIO
  Sponsored by: Perfuze Ltd.
  Signature date: 10/01/2024
- **Navía Álvarez P.** general anesthesia versus sedation with high-flow nasal cannula for the endovascular treatment of acute ischemic stroke. ghifts study (general anesthesia vs high flow nasal cannula for thrombectomy on stroke).
  Type/Phase: PRODUCTO SANITARIO
  Sponsored by: Navía Álvarez Pedro
  Signature date: 28/08/2024
- **Puertas Muñoz I.** elaboración de panel de biomarcadores moleculares, clínicos y radiológicos de esclerosis múltiple mediante análisis con inteligencia artificial.
  Type/Phase: EPA-SP
  Sponsored by: FIBHULP; Puertas Muñoz Inmaculada
  Signature date: 10/06/2024
- **Puertas Muñoz I.** estudio transversal para evaluar la eficacia y seguridad de ofatumumab (kesimpta®) en pacientes con esclerosis múltiple recurrente en la práctica clínica española: estudio cronos-ms.
  Type/Phase: EOm no prospectivo
  Sponsored by: Novartis Farmaceutica S.A.
  Signature date: 15/04/2024
- **Puertas Muñoz I.** observational, multicenter study to describe the persistence in relapsing remitting multiple sclerosis naive patients with low-moderate activity treated with ozanimod (zeposia ®) in clinical practice in spain (appreziate study) estudio observacional multicéntrico para describir la persistencia en pacientes con esclerosis múltiple recurrente-remitente con actividad baja a moderada sin tratamiento previo, que han iniciado tratamiento con ozanimod (zeposia®) en la práctica clínica en españa (estudio appreziate)..
  Type/Phase: EOm prospectivo
  Sponsored by: Bristol Myers Squibb S.A.U.
  Signature date: 29/07/2024
- **Rodríguez de Rivera Garrido FJ.** estudio de fase 2, multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de alxn2050 en participantes adultos con miastenia grave generalizada.
  Type/Phase: II
  Sponsored by: Alexion Pharmaceutical Inc.
  Signature date: 22/02/2024
- **Rodríguez de Rivera Garrido FJ.** estudio en fase iii multicéntrico, aleatorizado, cuádruple ciego y controlado con placebo para evaluar la eficacia y seguridad de batoclimab como tratamiento de inducción y mantenimiento en participantes adultos con miastenia grave generalizada (mgg).
  Type/Phase: III
  Sponsored by: Immunovant Sciences
  Signature date: 19/01/2024
- **Torres Iglesias G.** estudio multicéntrico retrospectivo sobre la neurotoxicidad asociada a la terapia con células cart.
  Type/Phase: EOm no prospectivo
  Sponsored by: Hospital Clinic Barcelona
  Signature date: 15/10/2024

Patents and Trademarks

- **Valdivieso Amate F, Bullido Gómez-Heras MJ, Martínez García A,** inventors; UAM, assignee. Method of identifying compounds that induce or inhibit endoplasmic reticulum stress or oxidative stress. P200702997, PCT/ES2008/000705, EP2221379, US20100304384; 2007 November 13.
- **Vergés Milano J, García García A, Ruhí Roura R, Montell Bonaventura E, García López M, Aláez Versón CR, Escaich Ferrer J, Egea Máiquez J, Lorrio González S, Negredo Madrigal P,** inventors; BIOIBÉRICA S.A., UAM, assignees. Sulphated disaccharides for the treatment of neurodegenerative and/or neurovascular diseases. P200902399, PCT/EP2010/070613, US20120309707, CA20102785237; 2010 December 22.
- **Valdivieso Ámate F, Burgos Muñoz JS, Ramírez Moreno C, Sastre Merlín I,** inventors; UAM, CSIC, assignees. Method of identifying therapeutic compounds which can be used for the treatment and/or prevention of infections and diseases caused by human herpes viruses. P200400965, PCT/ES2005/000209, EP1769677, US20070218004, AT447321, AU2005235319, CA2562787, JP2007533315; 2004 April 21.
- **Valdivieso Ámate F, Montoliú JL, Pozueta Larios J,** inventors; UAM, CSIC, assignees. Alzheimer's disease animal model, method for obtaining same and uses thereof. P200503002, PCT/ES2006/000673, EP1956091, EP20060841725, US20090222932, CA2638983, JP2009517066; 2005 December 02.
- **Ballesteros García P, López Larrubia P, Domínguez Mateo L, Marco Contelles JL, Cerdán García-Esteller S,** inventors; Universidad Nacional de Educación a Distancia, CSIC, assignees. Set of magnetic resonance imaging and spectroscopy cell acidity extrinsic indicators comprise polyol derivatives based on alditols. P200300936; 2003 April 23.
- **Gil-Martínez A,** inventors; FIBHULP, assignees. Specular Face. 4022981/5. 2019 December 10

- **Egea Máiquez FJ, Farré Alins V, Palomino Antolín A, Narros Fernández P, Martins Rosa J, Parada Pérez E, Hernández García BJ, Roda Frade JM, Yus Teruel S, Lagares Gómez-Abascal A, Sánchez Carabias C, Gandía Juan L,** inventors; Fundación Hospital La Princesa, FIBHULP, Fundación Hospital 12 de Octubre, UAM, assignees. Method for determining the progression of acute brain damage and pharmaceutical composition for its treatment. P202031194, PCT/ES2021/070856; 2020 November 30.
- **Gil Martínez A, Gil Castillo J,** inventors; FIBHULP, Centro Superior de Estudio Universitarios La Salle, Javier Gil Castillo, assignees. Dispositivo de medición y/o entrenamiento de la fuerza o presión de los músculos de la cavidad oral y su uso para rehabilitación. MU 1201U MU202230128. 2022 July, 26.
- **Alonso de Leciñana M, Díez Tejedor E, Fuentes Gimeno B, Rodríguez-Pardo de Donlebun J, Lopez Martín D, Gutierrez Martín A and Fernandez Martín F,** authors; FIBHULP and Universidad Politécnica de Madrid, assignee. Trademark name: Neuro Data Tracker; ESM 018860324; 2023 April 11
- **Martín Montes A, Blanco de Miguel D, Rodríguez-Pardo de Donlebun J, Medina López A, Alonso de Leciñana Cases M, Frank García A,** inventors; FIBHULP, assignee. Cognipaz. Nº019095718; 2024 October 24.

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

3.1.3 Neuroprotective Strategies in Neurodegenerative Diseases



Publications: 15 | **Q1:**14

COMPOSITION

Ana Isabel Rojo Sanchís.
Profesor Permanente (Profesora Titular). Departamento de Bioquímica. Facultad Medicina. Universidad Autónoma de Madrid

- **Daniel Carnicero Senabre.** *Investigadora Predoctoral. Universidad Autónoma de Madrid*
- **Eduardo Cazalla Ibáñez.** *Investigadora Predoctoral. Universidad Autónoma de Madrid*
- **Antonio Cuadrado Pastor.** *Catedrático. Departamento de Bioquímica. Facultad Medicina. Universidad Autónoma de Madrid*
- **María Isabel Escoll Guerrero.** *Investigadora Postdoctoral. CIBERNED*
- **Raquel Fernández Ginés.** *Investigadora Postdoctoral. Universidad Autónoma de Madrid*
- **Ángel Juan García Yagüe.** *Investigador Postdoctoral. Universidad Autónoma de Madrid*
- **José Jiménez Villegas.** *Investigador Predoctoral. Universidad Autónoma de Madrid*
- **Ángela Martínez Valverde.** *Cientifico titular CSIC. Instituto de Investigaciones Biomédicas Sols-Morreale*
- **Patricia Rada Llano.** *Investigadora Postdoctoral. CIBERNED*

STRATEGIC OBJETIVES

- Oxidative stress is a key element in the aetiopathogenesis of neurodegenerative diseases and their comorbidities. Our laboratory studies the antioxidant protection mechanisms activated by extracellular signals and how this response ould be regulated pharmacologically to provide a therapeutic benefit in these diseases.
- To meet these two objectives, we are studying signalling pathways that regulate antioxidant metabolism and provide a general protective response. An important finding of this group was the observation that the PI3K/AKT/GSK-3 survival pathway regulates the transcription factor NRF2, guardian of cellular redox homeostasis, that provides protection against oxidative, inflammatory and proteotoxic stress. For the past year we have been working on the validation this transcription factor as a new therapeutic target to modify progression of Parkinson's and Alzheimer's disease as well co-morbid retinopathy and type II diabetes

RESEARCH LINES

- Role of oxidative stress in neuronal death and neuroinflammation in neurodegenerative diseases.
- Validation of NRF2 as a new therapeutic target in neurodegenerative diseases.
- Use of NRF2 transcriptional signature as a biomarker of prognosis, progression and therapeutic efficacy.
- Identification of NRF2 activating compounds by inhibiting their interaction with β-TrCP.
- Relevance of NRF2 transcriptional signature in altered molecular processes in ALS models.
- Molecular basis of the role of Nrf2 in type 2 diabetes and its complications (diabetic retinopathy and nephropathy).

RESEARCH ACTIVITY

Doctoral Theses

- **Carracedo Sanchidrián D.** Terapia Cognitiva Basada en Mindfulness frente a Intervención Psicoeducativa en Pacientes con Trastorno Bipolar con Síntomas Subsindrómicos Depresivos: Estudio Controlado Aleatorizado [dissertation]. Madrid: Universidad Autónoma de Madrid: 2024(14/10/2024). Director: Dios Perrino C, Lahera Forteza G

Publications

- **Ardanaz CG, de la Cruz A, Minhas PS, Hernández-Martín N, Pozo MA, Valdecantos MP, Valverde AM, Villa-Valverde P, Elizalde-Horcada M, Puerta E, Ramírez MJ, Ortega JE, Urbiola A, Ederra C, Ariz M, Ortiz-de-Solórzano C, Fernández-Irigoyen J, Santamaria E, Karsenty G, Brüning JC, Solas M.** Astrocytic GLUT1 reduction paradoxically improves central and peripheral glucose homeostasis. Sci Adv. 2024; 10(42): eadp1115. Article. IF: 12.5; D1
- **Caparrós E, García-Martínez I, Zapater P, Madero L, Valverde AM, Gutiérrez A, Francés R.** An altered expression of miR-376a-3p and miR-20a-5p in peripheral blood exosomes regulates the autophagy and inflammatory systemic substrates, and relates to the smoking habit and age in Crohn's disease. Faseb J. 2024; 38(2): e23418.

Article. IF: 4.2; Q1

- **Cazalla E, Cuadrado A, García-Yagüe AJ.** Role of the transcription factor NRF2 in maintaining the integrity of the Blood-Brain Barrier. Fluids Barriers Cns. 2024; 21(1): 93. Review. IF: 6.2; Q1
- **Fernández-Ginés R, Encinar JA, Escoll M, Carnicero-Senabre D, Jiménez-Villegas J, García-Yagüe AJ, González-Rodríguez A, García-Martínez I, Valverde AM, Rojo AI, Cuadrado A.** Specific targeting of the NRF2/β-TrCP axis promotes beneficial effects in NASH. Redox Biol. 2024; 69: 103027. Article. IF: 11.9; D1
- **Ferreira V, Folgueira C, Lorenzo AMS, Rodríguez-López A, González-Iglesias E, Zubiaur P, Abad-Santos F, Sabio G, Rada P, Valverde AM.** Estrogens prevent the hypothalamus-periphery crosstalk induced by olanzapine intraperitoneal treatment in female mice: Effects on brown/ beige adipose tissues and liver. BBA-Mol Basis Dis. 2024; 1870(5): 167227. Article. IF: 4.2; Q1
- **Gallardo-Villanueva P, Fernández-Marcelo T, Villamayor L, Valverde AM, Ramos S, Fernández-Millán E, Martín MA.** Synergistic Effect of a Flavonoid-Rich Cocoa-Carob Blend and Metformin in Preserving Pancreatic Beta Cells in Zucker Diabetic Fatty Rats. Nutrients. 2024; 16(2): 273. Article. IF: 5; Q1
- **García-Sáez J, Figueroa-Fuentes M, González-Corralejo C, Roncero C, Lazcanoiturburu N, Gutiérrez-Uzquiza A, Vaquero J, González-Sánchez E, Bhutia K, Calero-Pérez S, Maina F, Traba J, Valverde AM, Fabregat I, Herrera B, Sánchez A.** Uncovering a Novel Functional Interaction Between Adult Hepatic Progenitor Cells, Inflammation and EGFR Signaling During Bile Acids-Induced Injury. Int J Biol Sci. 2024; 20(7): 2339-55. Article. IF: 10; Q1
- **González-Sánchez E, Vaquero J, Caballero-Díaz D, Grzelak J, Fusté NP, Bertran E, Amengual J, García-Saez J, Martín-Mur B, Gut M, Esteve-Codina A, Alay A, Coulouarn C, Calero-Pérez S, Valdecantos P, Valverde AM, Sánchez A, Herrera B, Fabregat I.** The hepatocyte epidermal growth factor receptor (EGFR) pathway regulates the cellular interactome within the liver fibrotic niche. J Pathol. 2024; 263(4-5): 482-95. Article. IF: 5.2; D1
- **Jurado-Aguilar J, Barroso E, Bernard M, Zhang MJ, Peyman M, Rada P, Valverde AM, Wahli W, Palomer X, Vázquez-Carrera M.** GDF15 activates AMPK and inhibits gluconeogenesis and fibrosis in the liver by attenuating the TGF-β1/SMAD3 pathway. Metabolism. 2024; 152: 155772. Article. IF: 11.9; D1
- **Marañón P, Rey E, Isaza SC, Wu HH, Rada P, Choya-Foces C, Martínez-Ruiz A, Martín MA, Ramos S, García-Monzón C, Cubero FJ, Valverde AM, González-Rodríguez A.** Inhibition of ALK3-mediated signalling pathway protects against acetaminophen-induced liver injury. Redox Biol. 2024; 71: 103088. Article. IF: 11.9; D1
- **Morgenstern C, Lastres-Becker I, Demirdogen BC, Costa VM, Daiber A, Foresti R, Motterlini R, Kalyoncu S, Arioz BI, Genc S, Jakubowska M, Trougakos IP, Piechota-Polanczyk A, Mickael M, Santos M, Kensler TW, Cuadrado A, Copple IM.** Biomarkers of NRF2 signalling: Current status and future challenges. Redox Biol. 2024; 72: 103134. Article. IF: 11.9; D1
- **Patibandla C, van Aalten L, Dinkova-Kostova AT, Honda T, Cuadrado A, Fernández-Ginés R, Mcneilly AD, Hayes JD, Cantley J, Sutherland C.** Inhibition of glycogen synthase kinase-3 enhances NRF2 protein stability, nuclear localisation and target gene transcription in pancreatic beta cells. Redox Biol. 2024; 71: 103117. Article. IF: 11.9; D1
- **Rada P, Carceller-López E, Hitos AB, Gómez-Santos B, Fernández-Hernández C, Rey E, Pose-Utrilla J, García-Monzón C, González-Rodríguez A, Sabio G, García A, Aspichueta P, Iglesias T, Valverde AM.** Protein kinase D2 modulates hepatic insulin sensitivity in male mice. Mol Metab. 2024; 90: 102045. Article. IF: 6.6; Q1
- **Uruno A, Kadoguchi-Igarashi S, Saito R, Koiso S, Saigusa D, Chu CT, Suzuki T, Saito T, Saido TC, Cuadrado A, Yamamoto M.** The NRF2 inducer CDDO-2P-Im provokes a reduction in amyloid β levels in Alzheimer's disease model mice. J Biochem. 2024; 176(5): 405-14. Article. Not Indexed
- **Valdecantos MP, Ruiz L, Folgueira C, Rada P, Gomez-Santos B, Solas M, Hitos AB, Field J, Francisco V, Escalona-Garrido C, Zagmutt S, Calderon-Dominguez M, Mera P, García-Martínez I, Maymó-Masip E, Grajales D, Alen R, Mora A, Sainz N, Vides-Urrestarazu I, Vilarrasa N, Arbones-Mainar JM, Zaragoza C, Moreno-Aliaga MJ, Aspichueta P, Fernández-Veledo S, Vendrell J, Serra D, Herrero L, Schreiber R, Zechner R, Sabio G, Hornigold D, Rondinone CM, Jermutus L, Grimsby J, Valverde AM.** The dual GLP-1/glucagon receptor agonist G49 mimics bariatric surgery effects by inducing metabolic rewiring and inter-organ crosstalk. Nat Commun. 2024; 15(1): 10342. Article. IF: 15.7; D1

Research projects

- **Cuadrado Pastor A, Seabra M .** NRF2 as a novel therapeutic target in age-related macular degeneratio (HR22-00569). Fundación La Caixa. 2022-2026. Managment centre: UAM
- **Cuadrado Pastor A.** Activation of NRF2 by 6-MISTC, role in AD (2021/0175). Kinjirushi Ltd. Co. 2021-2023. Managment centre: Fundación UAM
- **Cuadrado Pastor A.** Bench to bedside transition for pharmacological regulation of NRF2 in noncommunicable diseases (1004040104). European Union - Programa COST. 2021-2025. Managment centre: "Victor Babes" National Institute of Pathology
- **Cuadrado Pastor A.** Optimización y validación in vivo de fármacos innovadores para el tratamiento de taupatías (1004020195). CAM. 2023-2026. Managment centre: UAM
- **Cuadrado Pastos A, Rojo Sanchís AI.** Desarrollo de nuevos fármacos antiinflamatorios basados en la activación del factor de transcripción NRF2 (PDC2021-121421-I00). Agencia Estatal de Investigación. 2021-2023. Managment centre: UAM
- **Cuadrado Pastos A, Rojo Sanchís AI.** El factor de transcripción NRF2 en la patofisiología de la enfermedad de Alzheimer (1004020167). MICIN. 2020-2023. Managment centre: UAM
- **Cuadrado Pastos A, Rojo Sanchís AI.** Optimización de un nuevo activador del factor de transcripción NRF2 para frenar la progresión de NASH (1004020190). Agencia Estatal de Investigación. 2022-2024. Managment centre: UAM
- **Cuadrado Pastos A, Rojo Sanchís AI.** Papel del factor de transcripción NRF2 en protección sináptica en las Taupatías (1004020200). MICIN. 2023-2026. Managment centre: UAM
- **Martínez Valverde A.** Extracelular vesicles: new insights into their role in liver-pancreas interactome in T2D. European Association for the Study of Diabetes. 2021-2023. Managment centre: CIBER

Cibers and Retics

- **Cuadrado Pastor A.** Centro de Investigación Biomédica en Enfermedades Neurodegenerativas (CIBERned). ISCIII. (31/12/2024). UAM
- **Martínez Valverde A.** Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERdem). ISCIII. (31/12/2024). CSIC
- **Cuadrado Pastor A, Rojo Sanchís AI.** Bench to bedside transition for pharmacological regulation of NRF2 in noncommunicable diseases (BenBedPhar). EU European COST Action. (18/10/2025). Victor Babes Research Institute (Romania)

Patents and Trademarks

- **Cuadrado Pastor A, Innamorato NG,** inventors: CSIC, UAM. Use of sulforaphane as supplementary therapy for early-stage neurodegenerative disease. P201231693; 2012 November 06.
- **León Martínez R, Egea Maíquez J, Buendía Abaitua I, Parada Pérez E, Navarro González de Mesa E,** inventors; Fundación para la Investigación Biomédica del Hospital Universitario de La Princesa, UAM, CSIC, DNS NEUROSCIENCE S.A., assignees. Use of 3-(2-isothiocyanatoethyl)-5-methoxy-1H-indole for the treatment of neurodegenerative diseases. P201300667; 2013 July 17.
- **León Martínez R, Buendía Abaitua I, Navarro González de Mesa E, Michalska P, Gameiro Ros I, López Vivo A, Egea Maíquez J, García López M, García García A,** inventors; Fundación para la Investigación Biomédica del Hospital Universitario de La Princesa, UAM, DNS NEUROSCIENCE S.A., assignees. Compounds derived from 3-alkylamine-1H-indolyl acrylate and its use for the treatment of neurodegenerative diseases. P201400810, PCT/ES2015/000139, CA2964309; 2014 October15.
- **Cuadrado Pastor A, Fernández-Ginés R, León Martínez R, Encinar JA, Rodríguez Franco MI, García López MG, Rojo Sanchís AI,** inventors. UAM, CSIC, UMH y Fundación de Investigación Biomédica del Hospital Universitario de la Princesa, assigness. Treatment of NRF2-Related diseases. PCT/2022/382025.1.

3.1.4 Involvement of Glycinergic and Glutamatergic Systems in Central Nervous System Pathologies





Publications: 2 | **Q1:**1

COMPOSITION

Francisco Zafra Gómez.
Catedrático. Facultad de Ciencias. Universidad Autónoma de Madrid

- **Maria del Carmen Aragon Rueda.** *Profesora Titular. Facultad de Ciencias. Universidad Autónoma de Madrid*
- **Beatriz Fuensanta López Corcuera.** *Profesora Titular. Facultad de Ciencias. Universidad Autónoma de Madrid*
- **Enrique Núñez Balbuena.** *Investigador Postdoctoral. Universidad Autónoma de Madrid*
- **Eva María Porlan Alonso.** *Profesora Contratada Doctora. Universidad Autónoma de Madrid*

STRATEGIC OBJETIVES

- Role of glutamate and glycine transporters in physiological and pathological aspects of glutamatergic and glycinergic neurotransmission.
- Pathologies of glycinergic neurotransmission such as hyperekplexia and pain
- Role of the adult neurogenesis in neurorepair.

RESEARCH LINES

- Glycinergic neurotransmission. Identification and characterization of new GlyT2 mutations (SLC6A5 gene) associated to human hyperekplexia. Effects of the mutations on transporter structure, function, proteostasis and glycinergic neurotransmission. Role in presynaptic hyperekplexia of different genes related to GlyT2 trafficking, interactoma, posttranslational modifications. Rescue interventions.
- Study of plastic adaptations affecting glycine transporters in physiological and pathological nociception. Regulation of GlyTs by receptors modulating nociceptive signaling (P2XR, P2YR, mAch, nAch, a2 adrenergic, 5-HT). Signaling pathways.
- Physiological and pathological aspects of Neuronal reparation by adult neurogenesis:
  - Identification of novel regulatory mechanisms of adult neurogenesis by kinases.
  - Identification of novel regulatory mechanisms of adult neurogenesis by microRNAs and other non-coding RNAs.
- GABAergic neurotransmission. Identification and characterization of new mutations in SLC6A1 gene (GABA transporter GAT-1) associated to epilepsy. Effects of the mutations on transporter structure, function in GABAergic neurotransmission. Pharmacological treatments with pharmacochaperones.

RESEARCH ACTIVITY

Publications

- **Arribas-Carreira L, Castro M, García F, Navarrete R, Bravo-Alonso I, Zafra F, Ugarte M, Richard E, Pérez B, Rodríguez-Pombo P.** Metabolic Rewiring and Altered Glial Differentiation in an iPSC-Derived Astrocyte Model Derived from a Nonketotic Hyperglycinemia Patient. Int J Mol Sci. 2024; 25(5): 2814. Article. IF: 4.9; Q1
- **Felipe R, Sarmiento-Jiménez J, Camafeita E, Vázquez J, López-Corcuera B.** Role of palmitoylation on the neuronal glycine transporter GlyT2. J Neurochem. 2024; 168(9): 2056-72. Article. IF: 4; Q2

Research projects

- **López Corcuera B.** El transportador neuronal de glicina GLYT2 en dolor y en hiperplexia. Implicaciones patológicas en desarrollo (PID2020-119399RB-I00). Ministerio de Economía, Industria y Competitividad. 2021-2024. Managment centre: UAM
- **López Corcuera B.** El transportador neuronal de glicina GlYT2 en hiperplexia: una patología glicinérgica del desarrollo. Fundación Ramón Areces. 2021-2024. Managment centre: Fundación Severo Ochoa

3.1.5 Mechanisms and Biomarkers in Neurodegenerative Diseases



Publications: 3 | Q1:3

COMPOSITION

Isabel Lastres Becker.
Profesora Titular. Universidad Autónoma de Madrid

- **Marina Arribas Blázquez.** *Investigadora Postdoctoral. Universidad Autónoma de Madrid*
- **Pablo Beceiredo Macho.** *Investigador Predoctoral. Universidad Autónoma de Madrid*
- **Daniel Flores Téllez.** *Investigador Predoctoral. Universidad Autónoma de Madrid*
- **Ignacio Silva Llanes.** *Investigador Predoctoral. Universidad Autónoma de Madrid*
- **Virginia Solar Fernández.** *Investigadora Postdoctoral. Universidad Autónoma de Madrid*
- **Javier Suárez Fonseca.** *Investigador Predoctoral. Universidad Autónoma de Madrid*

STRATEGIC OBJETIVES

- The aging of the population poses a growing burden in society. This is associated with the increase in disability and diseases that have a high impact on health care, on patients and their families. Likewise, aging is associated with the appearance of different neurodegenerative diseases, among which include Alzheimer's disease (AD), Parkinson's disease (PD) and amyotrophic lateral sclerosis (ALS). Therefore, the development of advanced biological markers, new drugs and appropriate technology is the key to establishing a treatment for these diseases, which is currently an important social challenge. In our laboratory we study the molecular basis of neurodegeneration. The research projects we develop have a multidisciplinary approach that combines basic and translational research, using cell culture techniques, murine models and postmortem samples from patients with AD, PD and ALS.

Amyotrophic lateral sclerosis (ALS): Design and development of innovative drugs for the treatment of ALS

- Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that affects motor neurons in the spinal cord and cerebral cortex. Patients have a loss of muscle strength and coordination that progressively progresses, preventing the performance of daily activities. Until now there is no treatment that cures ALS, and for this reason in our laboratory we are developing several lines of research that aim to address this challenge by designing and developing new therapies for the treatment of ALS. In collaboration with several laboratories in a project funded by the Community of Madrid (ELA_Madrid S2017/BMD-3813) we have generated and functionally and biochemically characterized cell models (lymphoblasts) based on human samples. In addition, we are developing new compounds that modulate the TDP-43 and NRF2 signaling pathways, respectively, validating them in cellular and mouse models of ALS. In this context, in a project funded by the Ministry of Science, Innovation and Universities (PID2019-105600RB-I00) we are also investigating the modulation of aging and neurodegeneration by small molecule protein kinase inhibitors, in collaboration with Dr. Ana Martínez . On the other hand, one of the main characteristics of ALS is that there are alterations in mRNA metabolism and deregulated axonal transport. For this reason, in a project financed by FUNDELA, we are determining if the TDP-43 aggregates kidnap the RNA-binding proteins, and do not let them carry out their function, in such a way that the mRNAs do not reach the synaptic connections and cannot be translate, causing there to be no connection between the neuron and the muscle, which ultimately leads to loss of muscle function. So we are looking at RNA granule transport and protein translation in situ in ALS, determining the involvement of STAUFEN and TDP-43 proteins.

Tauopathies: new biomarkers and targets against neurodegeneration

- The TAU protein is the main component of the intracellular filamentous deposits that define a series of neurodegenerative diseases called tauopathies. In general, tauopathies are characterized by alterations in synaptic plasticity, cell death, proteinopathy, and neuroinflammation. Despite enormous efforts to find a cure for these diseases, there is still no effective treatment. That is why in my laboratory we face this challenge with two different approaches. In our laboratory we have shown in vitro and in vivo that neurons with accumulation of TAU induce the expression of the cannabinoid receptor CB2, which enhances neurodegeneration. Therefore, in a first approach we focus on the study of the pharmacological modulation of the CB2 receptor and its effects on TAU-induced neurodegeneration, with a project funded by the Fundación Tatiana Pérez de Guzmán el Bueno (2021-2024). There are currently no specific biomarkers for tauopathies that allow a prognosis/diagnosis of these diseases.

Implication of alterations at the mitochondrial level in Parkinson's disease

- We are interested in elucidating the molecular aspects that underlie Parkinson's Disease (PD). PD is the second most common multisystem neurodegenerative disorder associated with aging. Most cases of PD are sporadic and of unknown aetiology, but mutations in genes such as PARKIN and PINK1 have been associated with familial forms of the disease. Mitochondrial impairment is a well-established pathological hallmark of PD, but whether mitophagy is impaired in this disease remains a subject of intense debate. Therefore, in this research project we are determining the role of mitochondria and the differential alterations in mithocondria between neurons and astrocytes in a-synuclein associated- PD.

RESEARCH LINES

- Research on targeted therapies to modulate neurodegeneration-associated TDP-43 and TAU proteins
- Analysis of RNA transport and protein translation in situ: implication of STAUFEN 1/2?
- Modulation of cannabinoid CB2 receptor as a new therapeutic strategy to protect against TAU-induced neurodegeneration
- Differential function of mitochondria in neuron-astrocyte-dependent-synuclein protein in Parkinson's disease.

RESEARCH ACTIVITY

Master Theses

- **Kaminski Santamaría S.** Analysis of the role of gasdermind d in tau-dependent frontotemporal dementia mouse model[dissertation]. Madrid: Universidad Autónoma de Madrid: 2024(01/06/2024). Director: Lastres-Becker I.

Final Degree Theses

- **Baceiredo Macho P.** Análisis de la implicación de proteínas de unión al RNA en a neurodegeneración asociada a la demencia frontotemporal TAU-dependiente[dissertation]. Madrid: Universidad Autónoma de Madrid: 2024(20/05/2024). Director: Lastres-Becker I.

Publications

- **Burgaz S, Navarro E, Rodríguez-Carreiro S, Navarrete C, Garrido-Rodríguez M, Lastres-Becker I, Chocarro J, Lanciego JL, Muñoz E, Fernández-Ruiz J.** Investigation in the cannabigerol derivative VCE-003.2 as a disease-modifying agent in a mouse model of experimental synucleinopathy. Behav Brain Funct. 2024; 20(1): 28. Article. IF: 3.3; Q1
- **Morgenstern C, Lastres-Becker I, Demirdogen BC, Costa VM, Daiber A, Foresti R, Motterlini R, Kalyoncu S, Arioz BI, Genc S, Jakubowska M, Trougakos IP, Piechota-Polanczyk A, Mickael M, Santos M, Kensler TW, Cuadrado A, Copple IM.** Biomarkers of NRF2 signalling: Current status and future challenges. Redox Biol. 2024; 72: 103134. Article. IF: 11.9; D1
- **Silva-Llanes I, Martín-Baquero R, Berrojo-Armisen A, Rodríguez-Cueto C, Fernández-Ruiz J, De Lago E, Lastres-Becker I.** Beneficial Effect of Dimethyl Fumarate Drug Repositioning in a Mouse Model of TDP-43-Dependent Frontotemporal Dementia. Antioxidants. 2024; 13(9): 1072. Article. IF: 6.6; Q1



Research projects

- **Lastres-Becker I.** A-Synuclein-dependent neuron-astrocyte differential function of mitochondria in Parkinson's disease (PID2022-137065OB-I00). MICIN. 2023-2026. Managment centre: UAM
- **Lastres-Becker I.** Modulación del receptor cannabinoide CB2 como nueva estrategia terapéutica para proteger contra la neurodegeneración inducida por TAU (2021/00072/001). Fundación Tatiana Pérez de Guzmán el Bueno. 2021-2024. Managment centre: UAM
- **Lastres-Becker I.** Receptor cannabinoide CB2: Validación como Biomarcador en Demencias TAU-dependientes. Beca Dr. Luis Álvarez. 2024-2026. Managment centre: FIBHULP
- **Martínez A, Lastres-Becker I.** Aging and neurodegeneration targeting by protein kinase small molecules inhibitors (PID2019-105600RB-I00). MICIN. 2020-2024. Managment centre: CSIC
- **Martínez A, Lastres-Becker I.** Luchando contra la enfermedad de Parkinson con inhibidores de SGK1 (PDC2022-133774-I00). MICIN. 2022-2024. Managment centre: CSIC
- **Martínez A, Lastres-Becker I.** TTBK1 inhibitors as new therapeutic approach for FTD and other related disorders (ADDF-AFTD RA-202205-2023343). ADDF. 2022-2024. Managment centre: CSIC-UAM

Patents and Trademarks

- **López-Rodríguez ML, Viso A, Ortega S, Lastres-Becker I, González S, Fernández-Ruiz JJ, Ramos JA,** inventors; Universidad Complutense de Madrid, assignees; Nuevos derivads de ácido araquidónico con afinidad por el transportador de anandamide. P200001920. 2020 nov 5
- **Martínez A, Gil C, Madruga E, Garcia-Rubia A, Lastres-Becker I,** inventors; CSIC, assignees; Compuestos inhibidores de SGK1 y su uso para el tratamiento de enfermedades neurodegenerativas y/o cardiovasculares. ESP202430463. 2024 jun 5

3.1.6 Multiple Sclerosis Research

Publications: 5 | **Q1:**2

COMPOSITION

Yolanda Aladró Benito.
Médico Adjunto Neurología. Hospital Universitario de Getafe. Profesor Asociado. Universidad Europea de Madrid

- **Judith Díaz Díaz.** *Facultativo Especialista de Área en Neurología. Hospital Universitario de Getafe*
- **Laura Lillo Triguero.** *Facultativo Especialista de Área en Neurología. Hospital Universitario de Getafe*
- **Guillermo Martín Ávila.** *Facultativo Especialista de Área en Neurología. Hospital Universitario de Getafe*
- **Alejandro Méndez Burgos.** *Facultativo Especialista Adjunto Neurología. Hospital Universitario de Getafe*
- **Belén Pilo de la Fuente.** *Facultativo Especialista de Área en Neurología. Hospital Universitario de Getafe*

STRATEGIC OBJETIVES

- To assess the progression of multiple sclerosis using gait analysis with inertial sensors to find more objective, sensitive and reliable measures to detect and monitor the clinical progression of progressive Multiple Sclerosis. To validate selected measures provided by inertial sensors to monitor gait in a prospective cohort of patients with Multiple Sclerosis in early (primary and secondary) stages.
- We are specially focused in the assessment of the efficacy and effectiveness of techniques such as Mindfulness and we evaluate hypothetical mediators of response, such as neurotrophic factors or factors related to inflammatory response.
- Moreover, the group is involved in the evaluation of new treatments or new indications in mental disorders through the participation in clinical trials.

RESEARCH LINES

- Gait study with biosensors in multiple sclerosis patients.
- Covid-19 in multiple sclerosis
- Late-onset multiple sclerosis
- Use of motion sensors in essential tremor

RESEARCH ACTIVITY

Publications

- **Fernández O, Montalbán X, Agüera E, Aladró Y, Alonso A, Arroyo R, Brieva L, Calles C, Costa-Frossard L, Eichau S, García-Domínguez JM, Hernández MA, Landete L, Llaneza M, Llufriu S, Meca-Lallana JE, Meca-Lallana V, Moral E, Prieto JM, Ramió-Torrentà L, Téllez N, Romero-Pinel L, Vilaseca A, Rodríguez-Antigüedad A.** XVI Post-ECTRIMS Meeting: review of the new developments presented at the 2023 ECTRIMS Congress (I). Rev Neurologia. 2024; 79(1): 21-9. Review. IF: 0.8; Q4
- **Fernández O, Montalbán X, Agüera E, Aladró Y, Alonso A, Arroyo R, Brieva L, Calles C, Costa-Frossard L, Eichau S, García-Domínguez JM, Hernández MA, Landete L, Llaneza M, Llufriu S, Meca-Lallana JE, Meca-Lallana V, Moral E, Prieto JM, Ramió-Torrentà L, Téllez N, Romero-Pinel L, Vilaseca A, Rodríguez-Antigüedad A.** XVI Post-ECTRIMS Meeting: review of the new developments presented at the 2023 ECTRIMS Congress (II). Rev Neurologia. 2024; 79(2): 51-66. Review. IF: 0.8; Q4
- **Fernández OF, Costa-Frossard L, Ginés MLM, Escribano PM, González JMP, Ramió-Torrentà L, Aladro Y, Torres AA, Rodríguez EA, Labiano-Fontcuberta A, Pascual LL, Martínez AM, Torres EM, Oliva-Nacarino P.** Practical tool to identify Spasticity-Plus Syndrome amongst patients with multiple sclerosis. Algorithm development based on a conjoint analysis. Front Neurol. 2024; 15: 1371644. Article. IF: 2.8; Q2
- **Grijalvo M, Ordieres-Meré J, Villalba-Díez J, Aladro-Benito Y, Martín-Avila G, Simon-Hurtado A, Vivaracho-Pascual C.** Sufficiency for PSS tracking gait disorders in multiple sclerosis: A managerial perspective. Heliyon. 2024; 10(9): e30001. Article. IF: 3.6; Q1



- **Monreal E, Fernández-Velasco JI, alvarez-Lafuente R, de la Maza SS, García-Sánchez MI, Llufriu S, Casanova B, Comabella M, Martínez-Yélamos S, Galimberti D, Ramió-Torrentà L, Martínez-Ginés ML, Aladro Y, Ayuso L, Martínez-Rodríguez JE, Brieva L, Villarrubia N, Eichau S, Zamora J, Rodero-Romero A, Espino M, Blanco Y, Saiz A, Montalbán X, Tintoré M, Domínguez-Mozo MI, Cuello JP, Romero-Pinel L, Ghezzi L, de la Fuente BP, Pérez-Miralles F, Quiroga-Varela A, Rubio L, Rodríguez-Jorge F, Chico-García JL, Sainz-Amo R, Masjuan J, Costa-Frossard L, Villar LM.** Serum biomarkers at disease onset for personalized therapy in multiple sclerosis. Brain. 2024; 147(12): 4084-93. Article. IF: 11.7; D1


Research projects

- **Aladro Benito Y.** Monitoring of gait impairment progression using wearable sensors in patients with progressive multiple sclerosis. Roche. Merck-Serono. 2021-Ongoing. Managment centre: Hospital Universitario de Getafe

3.2.Cardiovascular Area

Documents: 215 | **Originals:** 155 | **D1:** 48 | **Q1:** 113

Area coordinator: José Raúl Moreno Gómez; María Fernández Velasco
coordinadorcardiovascular@idipaz.es



RESEARCH GROUPS

3.2.1 Research on Invasive Clinical and Translational Cardiology - ICCIT-PAZ
José Raúl Moreno Gómez/María Fernández Velasco

3.2.2 Coagulopathies and Alterations of Haemostasis
Víctor Jiménez Yuste

3.2.3 Vascular Physiology and Pharmacology
Ana María Briones Alonso

3.2.4 Vascular Pharmacology and Metabolism (FARMAVSM)
Carlos F. Sánchez Ferrer/Concepción Peiró Vallejo

3.2.5 Paediatric Cardiology Research
Federico Gutiérrez-Larraya Aguado

Strategic Objectives	Development forecast for the coming years:	Actions
Cardiovascular Area is composed of 6 groups that carry out basic, experimental and clinical research in the fields of cardiology and cardiovascular risk factors. The area has an important activity in the performance of international clinical trials of wide impact and applicability. The scientific production of the cardiovascular area is supported by a high impact factor. The groups also have extensive experience in training researchers.	To merge the groups by research lines in order to avoid the duplicities that make the group lose strength and competitiveness and to bet on being more competitive and to take better advantage of the resources.	Foster and support translational research lines.
	The area should be focused on consolidated and multidisciplinary research lines rather than structured by pathologies. The collaboration with research groups from other organizations should be the norm.	Establish relationships/ collaboration/alliances with other IdiPAZ research groups and with groups from other institutions and maintain those already started.
	Resources should be focused on priorities established by the researchers themselves, or directly by IdiPAZ after analyzing the scientific production of each group.	Analyze the scientific production of each group
	Clinical research through the resources it provides (clinical trials) should guide basic research projects in order to offer the ideal field for translational medicine. This type of research also provides a stronger link between international research groups.	Encourage participation in clinical trials of researchers.

HIGH IMPACT PUBLICATIONS

Rivero-Santana B, Saldaña-García J, Caro-Codón J, Zamora P, Moliner P, Monzonis AM, Zatarain E, Álvarez-Ortega C, Gómez-Prieto P, Pernas S, Rodríguez I, Soto AB, Cadenas R, Ozores PP, Ramírez SP, Salvador MM, Valbuena S, Gasso LF, Juárez V, Severo A, Terol B, Álvarez TD, Rodríguez O, Brion M, González-Costello J, Albendea MC, González-Juanatey JR, Moreno R, López-Sendón J, **López-Fernández T.** Anthracycline-induced cardiovascular toxicity: validation of the Heart Failure Association and International Cardio-Oncology Society risk score. Eur Heart J. 2024; 46(3): 273-84. Article. IF: 35,6; D1

Boveda S, Sarkozy A, Duncker D, **Merino JL**. European Heart Rhythm Association congress: a constantly reinvented meeting. Eur Heart J. 2024; 45(32): 2905-7. Article. IF: 35,6; D1

Villacampa A, Alfaro E, Morales C, Díaz-García E, López-Fernández C, Bartha JL, López-Sánchez F, Lorenzo O, Moncada S, Sánchez-Ferrer CF, García-Río F, Cubillos-Zapata C, **Peiró C**. SARS-CoV-2 S protein activates NLRP3 inflammasome and deregulates coagulation factors in endothelial and immune cells. Cell Commun Signal. 2024; 22(1): 38. Article. IF: 8,9; Q1

Rodrigues-Díez R, Ballesteros-Martínez C, Moreno-Carriles RM, Nistal F, del Campo LSD, Cachofeiro V, Dalli J, García-Redondo AB, Redondo JM, Salaices M, **Briones AM**. Resolvin D2 prevents vascular remodeling, hypercontractility and endothelial dysfunction in obese hypertensive mice through modulation of vascular and proinflammatory factors. Biomed Pharmacother. 2024; 174: 116564. Article. IF: 7,5; D1

Rivero-Santana B, Galán C, Pérez-Martínez C, Ibáñez B, de Prado AP, Fernández-Velasco M, Moreno R, **Jurado-Román A**. ELLIS Study: Comparative Analysis of Excimer Laser Coronary Angioplasty and Intravascular Lithotripsy on Drug-Eluting Stent as Assessed by Scanning Electron Microscopy. Circ-Cardiovasc Inte. 2024; 17(11): -e014505. Article. IF: 7,4; Q1

Scientific Events by Cardiovascular Area

- **24/05/2024.** Scientific Seminar: Papel del receptor NOD1 en la cardiomiopatía auricular asociada a insuficiencia cardíaca
- **21/06/2024.** Scientific Seminar: Resolvina D2 y otros mediadores proresolutivos. Una nueva estrategia de protección cardiovascular
- **20/11/2024.** III Curso de donación en asistolia controlada pediátrica y perfusión de órganos ex situ. Formación e Investigación

3.2.1 Research on Invasive Clinical and Translational Cardiology - ICCIT-PAZ



Publications: 109 | **Q1:**63

COMPOSITION

José Raúl Moreno Gómez.
Jefe de Servicio de Cardiología. Hospital Universitario La Paz

María Fernández Velasco.
Investigadora Senior (Contrato Miguel Servet-Tipo I). Jefa de Laboratorio. FIBHULP

- **Joaquín Jesús Alonso Martín.** *Jefe de Servicio de Cardiología. Hospital Universitario Getafe*
- **Isabel Antorrena Miranda.** *Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz*
- **Eduardo Armada Romero.** *Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz*
- **Paula Awamleh García.** *Facultativo Especialista de Área en Cardiología. Hospital Universitario Getafe*
- **Andrea Bueno Sen.** *Investigadora Predoctoral. FIBHULP*
- **Paula Cantolla Pablo .** *Investigadora Predoctoral. FIBHULP*
- **Juan Caro Codón.** *Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz*
- **Almudena Castro Conde.** *Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz*
- **Regina Dalmau González-Gallarza.** *Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz*
- **Francisco Javier Domínguez Melcón.** *Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz*
- **Carlos Escobar Cervantes.** *Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz*
- **María Jesús Espinosa Pascual.** *Facultativo Especialista de Área en Cardiología. Hospital Universitario Getafe*
- **Jaime Fernández de Bobadilla Osorio.** *Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz*
- **Lucía Fernández Gasso.** *Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz*
- **Alfonso Fraile Sanz.** *Facultativo Especialista de Área en Cardiología. Hospital Universitario Getafe*
- **Javier Fuertes Beneítez.** *Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz*
- **Guillermo Galeote García.** *Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz*
- **Marta Gil Fernández.** *Investigadora Predoctoral. Instituto de Investigaciones Biomédicas Sols-Morreale*
- **Elvira Ana González García.** *Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz*
- **Teresa González Gallego.** *Investigadora Senior (Contrato Ramón y Cajal). Instituto de Investigaciones Biomédicas Sols-Morreale*
- **Gabriela Guzmán Martínez.** *Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz*
- **Ángel Manuel Iniesta Manjavacas.** *Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz*
- **Bárbara Izquierdo Coronel.** *Facultativo Especialista de Área en Cardiología. Hospital Universitario de Getafe*
- **Santiago Jiménez Valero.** *Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz*
- **Alfonso Jurado Román.** *Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz*
- **Teresa López Fernández.** *Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz*
- **Esteban López de Sá y Areses.** *Jefe de Sección de Cuidados Intensivos Cardiológicos. Hospital Universitario La Paz*
- **José Luis López-Sendón Hentschel.** *Director Científico IdiPAZ. Hospital Universitario La Paz*
- **José Luis Merino Llorens.** *Facultativo Especialista de Área en Cardiología. Director Unidad Investigación en Arritmias/ Electrofisiología Robótica. Hospital Universitario La Paz*
- **Pablo Merás Colunga.** *Médico Adjunto Cardiología. Hospital Universitario La Paz*
- **María del Mar Moreno Yangüela.** *Jefe de Sección de Imagen Cardiaca. Hospital Universitario La Paz*
- **Rene Olsen Rodríguez.** *Médico Interno Residente. Hospital Universitario de Getafe*
- **Rafael Peinado Peinado.** *Jefe de Sección de Arritmias y Electrofisiología. Hospital Universitario La Paz*
- **Jesús Ángel Perea Egido.** *Facultativo Especialista de Área en Cardiología . Hospital Universitario de Getafe*
- **Esther Pérez David.** *Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz*
- **Inés Ponz de Antonio.** *Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz*
- **Patricia Prieto Chinchilla.** *Profesora Contratada Doctora. Universidad Complutense de Madrid*
- **Elsa Prieto Moriche.** *Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz*
- **Elena Refoyo Salicio.** *Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz*
- **Juan Ramón Rey Blas.** *Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz*
- **Luis Riera del Moral.** *Facultativo Especialista de Área en Angiología y Cirugía Vascular. Hospital Universitario La Paz. Profesor Asociado Departamento de Cirugía. Universidad Autónoma de Madrid*
- **Adriana Rodríguez Chaverri.** *Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz*
- **Inmaculada Roldán Rabadán.** *Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz*
- **Sandra Rosillo Rodríguez.** *Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz*
- **José Ruiz Cantador.** *Facultativo Especialista de Área en Cardiología. Hospital Universitario La Paz*
- **Almudena Val Blasco.** *Investigadora Postdoctoral. FIBHULP*
- **Silvia Cayetana Valbuena López.** *Médico Interno Residente en Cardiología. Hospital Universitario La Paz*

STRATEGIC OBJETIVES

- The group consists of various healthcare units of the Department of Cardiology at Hospital La Paz: Clinic/Coronary Unit, interventional cardiology, cardiac imaging, electrophysiology, rehabilitation and adult congenital heart disease.
- The main research lines focus on providing clinical responses, with local research protocols and direct participation in clinical trials and international multicentre registries.

RESEARCH LINES

- Myocardial ischaemia. Acute and chronic. Diagnosis, prognosis and treatment.
- Cardiac arrhythmias. Catheter navigation systems.
- Diagnosis and treatment. Post cardiac arrest hypothermia.
- Heart Failure. Diagnosis and treatment. Cardiotoxicity of antineoplastic agents.
- Cardiac diagnostic imaging.
- Aortic stenosis. Diagnosis and treatment.
- Adult congenital heart diseases.
- Endovascular therapy and new cellular therapies in peripheral vascular disease

RESEARCH ACTIVITY

Doctoral Theses

- **Gil Fernández M.** Role of NOD1 in atrial myopathy associated with heart failure[dissertation]. Madrid: UAM: 2024(12/07/2024). Director: Fernández Velasco M, Bosca Gomar L

Master Theses

- **Zambonino Rodríguez CM.** The NOD1 receptor modulates the calcium handling in the sinus node in a murine model of heart failure.[dissertation]. Madrid: UAM: 2024(01/07/2024). Director: Fernández Velasco M.

Publications

- **Amat-Santos IJ, Gómez-Herrero J, Pinon P, Nombela-Franco L, Moreno R, Munoz-García AJ, Redondo A, Gómez-Menchero A, Gómez-Salvador I, San Román JA.** Impact of commissural alignment on the hemodynamic performance of supra-annular self-expandable transcatheter aortic valves. Catheter Cardio Inte. 2024; 104(5): 1060-70. Article. IF: 1.9; Q3
- **Ariza AT, Colunga PM, Merino C, Cantador JR, Pinilla I, Moreno R.** Ductus arteriosus presenting as systemic and pulmonary embolism. Rec-Interv Cardiol. 2024; 6(3): 256-8. Editorial Material. IF: 1.1; Q4
- **Bermúdez-Jimenez FJ, Protonotarios A, García-Hernández S, Asensio AP, Rampazzo A, Zorio E, Brodehl A, Arias MA, Macías-Ruiz R, Fernández-Armenta J, Pérez PR, Muñoz-Esparza C, Pilichou K, Bauce B, Merino JL, Moliner-Abós C, Ochoa JP, Barriales-Villa R, Garcia-Pavia P, Lopes LR, Syrris P, Corrado D, Elliott PM, McKenna WJ, Jimenez-Jaimez J.** Phenotype and Clinical Outcomes in Desmin-Related Arrhythmogenic Cardiomyopathy. Jacc Clin Electrophysiol.. 2024; 10(6): 1178-90. Article. IF: 7.7; D1
- **Blasco-Turrión S, Briedis K, Estévez-Loureiro R, Sánchez-Recalde A, Cruz-González I, Pascual I, Mascherbauer J, Altisent OAJ, Nombela-Franco L, Pan MN, Trillo R, Moreno R, Delle Karth G, Sánchez-Luna JP, Gonzalez-Gutiérrez JC, Revilla-Orodoea A, Zamorano JL, Gómez-Salvador I, Puri R, Román JAS, Amat-Santos IJ.** Bicaval TricValve Implantation in Patients With Severe Symptomatic Tricuspid Regurgitation 1-Year Follow-Up Outcomes. Jacc-Cardiovasc Inte. 2024; 17(1): 60-72. Article. IF: 11.4; D1
- **Blasco-Turrión S, Crespo-Leiro MG, Trenado VD, Hion PL, Molina BD, Roura G, Alvarez-Osorio MP, Gómez-bueno M, Bautista CO, Diaz JF, Bravo IPG, Moreno R, Sarnago-Cebada F, González NS, Hernández JM, del Blanco BG, Farrero M, Nadal RO, Martin P, de la Fuente L, Sanz-Sánchez J, Pérez SM, Fernández VA, Hospital JAG, Granados AL, Couto-Mallon D, Espinosa M, Sousa DR, Zatarain-Nicolás E, Aizpurua DA, Vilella RL, Roman JAS, Amat-Santos IJ.** Structural heart transcatheter interventions in orthotopic cardiac transplant and left ventricular assist devices recipients: A nationwide study. Int J Cardiol. 2024; 413: 132340. Article. IF: 3.2; Q2
- **Boveda S, Sarkozy A, Duncker D, Merino JL.** European Heart Rhythm Association congress: a constantly reinvented meeting. Eur Heart J. 2024; 45(32): 2905-27. News Item. IF: 35.6; D1
- **Calderón AT, Chiarito M, Santos IA, Cao DVD, Montilla BV, Román AJ, Garrido PP, Tartaglia F, García-García HM, Díez-Gil JL, Sanz-Sánchez J.** Uninterrupted direct-acting oral anticoagulation in patients undergoing transradial percutaneous coronary procedures: The DOAC-NOSTOP study rationale and design. Cardiovasc Revasc Med. 2024; 63: 68-72. Article. IF: 1.9; Q3
- **Calderon-Parra J, Dominguez F, Gonzalez-Rico C, de las Revillas FA, Goenaga MA, Alvarez , Munoz P, Alonso D, Rodríguez-Garcia R, Miro JM, De Alarcon A, Antorrena I, Goikoetxea-Agirre J, Moral-Escudero E, Ojeda-Burgos G, Ramos-Martínez A, Sánchez FF, de Lomas JMG, Rosas G, Lima JD, Bereciartua E, Vidal MJB, Blanco R, Boado MV, Lazaro MC, Crespo A, Carrion LG, de Lagos MDM, Ugarte GE, Goikoetxea AJ, Hierro MI, Iruretagoyena JR, Zuazabal JI, López-Soria L, Montejo M, Nieto J, Rodrigo D, Rodríguez R, Vitoria Y, Voces R, López MVG, Georgieva RI, Ojeda G, Bailon IR, Morales JR, Rodríguez IA, Galparsoro HA, Boronat EB, Odriozola MJB, Martin CD, Echeverria T, Yarza AE, Fuentes A, Goenaga MA, del Rio MG, Bauza AG, Iribarren JA, Urkola XK, López JIPM, Jimenez AR, Reviejo K, Berbejillo AS, Haza ES, Alda RS, Ruiz IS, Ugartemendia IU, Anza DV, Benito IV, Arrieta MZ, Carrasco R, Climent V, Llamas P, Merino E, Plazas J, Reus S, Alonso A, Bouzas A, Castelo B, Cuenca J, Gutierrez L, Ramos L, Mayo MR, Serrano JM, Regueiro DS, Martínez FJ, Alonso MD, Castro B, Melian TD, Sarabia JF, Rosado DG, Gonzalez JG, Lacalzada J, de la Pena LL, Ramirez AP, Arrondo PP, Moreno FR, Ciezar AP, Iglesias JMR, Alvarez VA, Costas C, de la Hera J, Suarez JF, Fraile LI, Arguero VL, Menendez JL, Bajo PM, Morales C, Torrico AM, Palomo C, Martínez BP, Esteban AR, Garcia RR, Asensio MT, Almela M, Ambrosioni J, Azqueta M, Brunet M, Bodro M, Cartana R, Cuervo G, Falces C, Fernández-Pittol MJ, Fita G, Fuster D, de la Maria CG, Garcia-Pares D, Hernández-Meneses M, Pérez JL, Marco F, Miro JM, Moreno A, Nicolas D, Ninot S, Quintana E, Pare C, Pereda D, Pericas JM, Pomar JL, Ramirez J, Roque M, Rovira I, Sandoval E, Sitges M, Soy D, Tellez A, Tolosana JM, Vidal B, Vila J, Adan I, Alonso D, Alonso JC, alvarez-Uria A, Bermejo J, Bouza E, Caballero GC, Montero AD, Estevez A, Ribas RF, Gargallo E, Leoni MEG, Mansilla AG, Moraga FJG, Ramallo VG, Hernández MK, Hualde AM, Machado M, Marin M, Martínez-Selles M, Melero R, Munoz P, Monzon D, Olmedo M, Pedraz A, Pinilla B, Pinto A, Rincon C, Rodríguez-Abella H, Rodríguez-Creixems M, Sánchez-Pérez E, Segado A, Toledo N, Valerio**

M, Vazquez P, Moreno EV, de la Villa S, Antorrena I, Loeches B, Moreno M, Ramirez U, Baston VR, Romero M, Rosillo S, Balbin JA, Fernández CA, Castillo CA, de las Revillas FA, Belaustegui MC, Farinas MC, Farinas-alvarez C, Sampedro MF, Garcia I, Rico CG, Gutierrez-Fernández L, Gutierrez-Cuadra M, Diez JG, Pajaron M, Parra JA, Teira R, Zarauza J, Parra JC, Cobo M, Dominguez F, Pavia PG, Cruz AF, Ramos-Martínez A, Romero IS, Centella T, Hermida JM, Moya JL, Martin-Davila P, Navas E, Oliva E, del Rio A, Stuart JRR, Ruiz S, Tenorio CH, Sequera S, Delia MA, Araji O, Barquero JM, Jambrina RC, de Cueto M, Acebal JG, Mendez I, Morales I, López-Cortes LE, de Alarcon A, Gutierrez-Carretero E, Lepe JA, López-Haldon J, Luque-Marquez R, Marin G, Ortiz-Carrellan A, Sánchez-Dominguez E, Alonso LJ, Azcarate P, Gutierrez JMA, Blanco JR, Armas EC, Garcia-alvarez L, Oteo JA, Membrilla AB, Iglesias AG, Grillo S, Petracca RL, López-Contreras J, Martínez MAR, Alvarez M, Fernández AL, Martínez A, Prieto A, Regueiro B, Tijeira E, Vega M, Quinonero AA, Minambres AA, Arana JCG, Ortega SGD, Rodríguez MAM, Rodríguez AM, de Zarate ZO, Zapirain JJP, Arroniz ESD, Sánchez DCS, Antonio SP, Alejandro UI, Leal JMA, Vazquez EG, Torres AH, Blazquez A, Valenzuela GD, Alonso A, Aramburu J, Calvo FE, Rodríguez AM, Tarabini-Castellani P, Galvez EH, Bellido CM, Pau JL, Sepulveda MA, Sierra PT, Iqbal-Mirza SZ, Alcolea EC, Yanez IK, Martínez JN, Ballesta AP, Escobar EM, Monje AP, Cabrera VS, Garcia DV, Asenjo MA, Luna CC, Morcillo JN, Seco MCP, Gelabert AV, Guallar CA, Abad NF, Mangas PG, Adell MM, Ruiz MPP, Porres JC, Vidal BA, Espin MJD, Buendia F, Sánchez RJ, Marmol R, Martínez F, Meseguer A, Pérez B, Risco L, Saura Z, Silva V, Villmarin MB, Blanco MAR, Bordes ERD, Bonet LV, Borras MV, Munera MCB, Garaizabal EE, Martínez AT, Luque JCS, Badia C, Palop LB, Xercavins M, Bosch SIX, Nebreda EG, Herrera IH, Gallego IM, Pulido I, Santiago HM, Martínez ID, Alamo EP, Sánchez DS, Pérez JB, Blanco EMA, Gonzalez MC, Peiretti MAC, Esteve AE, Pérez LD, Tejido SD, Roman FG, Robles JAG, Medrano FL, Gude MJL, Miguel MAO, Pilkington P, Ostalaza YR, Morales JR, Solis SR, Collado AS, Fernández MS, Rallo JS, Escrihuela-Vidal JSMF, Carratala J, Grau I, Ardanuy C, Berbel D, Salado JCS, Alegre O, Majoral AR, Sbraga F, Blasco A, Sánchez LG, Aldamiz ISRG, Alvarez B, Palacios MB, Ubeda AC, Roblas RF, Hernández R, Martin VAH, Kallmeyer A, Kancev CL, Martin M, Ruiz MM, Lobato MAN, Pello AM, Prieto L, Mallebrera MT, Triguero LVMD, Ceron REF, Ble LRGM, Gallego JPH, Ginel AJ, López I, Mas A, Mestres A, Molina L, Serrat R, Ribas N, Sánchez F, Silverio A, Suarez M, Sorli L, Recasens L, Regueras MTMF, Vallejo MAM, Rivera JAP, Cano NSMAC, Olivares MF, Nunez MVM, Sanz AM. Epidemiology and Risk Factors of Mycotic Aneurysm in Patients With Infective Endocarditis and the Impact of its Rupture in Outcomes. Analysis of a National Prospective Cohort. Open Forum Infect Dis. 2024; 11(3): ofae121. Article. IF: 3.8; Q1

- **Campo G, Guiducci V, Escaned J, Moreno R, Casella G, Cavazza C, Cerrato E, Contarini M, Arena M, Romo AI, Ibañes EG, Scarsini R, Vadalà G, Andò G, Pilato G, d'Amore SM, Capecchi A, Nouche RT, Moscarella E, Gambino A, Pavani M, Zanetti A, Pesenti N, Dudek D, Barbato E, Tebaldi M, Biscaglia S.** Health-Status Outcomes in Older Patients With Myocardial Infarction: Physiology-Guided Complete Revascularization Versus Culprit-Only Strategy. Circ-Cardiovasc Qual. 2024; 17(7): e010490. Article. IF: 6.7; Q1
- **Cebrián A, Escobar C, Aranda U, Palacios B, Capel M, Sicras A, Sicras A, Hormigo A, Manito N, Botana M, Alcázar R.** Including KDIGO cardiovascular risk stratification into SCORE scale could improve the accuracy to better stratify cardiovascular risk. Nefrologia. 2024; 44(2): 292-4. Letter. IF: 2.6; Q2
- **Cervantes CE.** SGLT2 inhibitors and GLP-1 receptor agonists: the definitive combination? Lancet Diabetes Endocrinol. 2024; 12(8): 507-8. Editorial Material. IF: 41.8; D1
- **Cobarro L, Jiménez-Valero S, Gutiérrez-Larraya F, Merino C, Merás P, Ruiz-Cantador J, Balbacid E, Poveda ID, Rosillo SO, Caro-Codón J, Jurado-Román A, Moreno R.** Novel percutaneous aspiration thrombectomy in Fontan conduit obstruction with cardiogenic shock. Case report. Int J Cardiol Congenit Heart Dis. 2024; 17: 100518. Review. IF: 1.2; Q4
- **Cocco M, Campo G, Guiducci V, Casella G, Cavazza C, Cerrato E, Sacchetta G, Moreno R, Menozzi A, Santos IA, Gil JLD, Scarsini R, Picchi A, Vadala G, Pilato G, Colaiori I, Barbierato M, Arioti M, Pavasini R, Lanzilotti V, Menozzi M, Varbella F, Erriquez A, Biscaglia S.** Complete vs Culprit-Only Revascularization in Older Patients With Myocardial Infarction With or Without ST-Segment Elevation. J Am Coll Cardiol. 2024; 84(20): 2014-22. Article. IF: 22.3; D1
- **Colunga PM, Valero SJ.** Percutaneous pulmonary valve implantation in native outflow tracts: has the time come? Rec-Interv Cardiol. 2024; 6(2): 63-6. Editorial Material. IF: 1.1; Q4
- **Costa F, Jurado-Román A, Carciotto G, Becerra-Munoz V, Márquez DT, Götzinger F, Cerrato E, Misra S, Spissu M, Pavani M, Mennuni M, Chinchilla FC, Dominguez-Franco A, Muñoz-Garcia A, Navarrete RS, Varbella F, Salinas-Sanguino P, Secemsky EA, Mahfoud F, Micari A, Alonso-Briales JH, Navarro MJ.** Advanced Management of Patients Undergoing Transcatheter Treatment for Pulmonary Embolism: Evidence-Based Strategies for Optimized Patient Care. J Clin Med. 2024; 13(24): 7780. Review. IF: 2.9; Q1
- **Cuesta J, Pérez-Vizcayno MJ, del Blanco BG, Bosa F, de Prado AP, Rumoroso JR, Romaguera R, Gutiérrez H, Touchard AG, López-Minguez JR, Trillo R, Hernández JMD, Moreno R, Velázquez M, Moris C, Kockar MJ, Jiménez-Quevedo P, Bastante T, del Val D, Rivero F, Alfonso F.** Long-Term Results of Bioresorbable Vascular Scaffolds in Patients With In-Stent Restenosis The RIBS VI Study. JACC-Cardiovasc Inte. 2024; 17(15): 1825-36. Article. IF: 11.4; D1
- **Dalmau R, Alanazi AM, Arora M, Banerjee A, Bianco E, Gaalema DE, Goma FM, Hasegawa K, Komiyama M, Ríos MP, Willett J, Wang YS.** A Complex Interplay: Navigating the Crossroads of Tobacco Use, Cardiovascular Disease, and the COVID-19 Pandemic: A WHF Policy Brief. Glob Heart. 2024; 19(1): 55. Article. IF: 3.1; Q2
- **Dalmau R, Cordero A, Masana L, Ruiz E, Sicras-Mainar A, González-Juanatey JR.** The CNIC-polypill (acetylsalicylic acid, atorvastatin, and ramipril), an effective and cost-saving secondary prevention strategy compared with other therapeutic options in patients with ischaemic heart disease. Eur Heart J Open. 2024; 4(2): oeae027. Article. Not Indexed
- **de Prado AP, Conde AC, Ferreira-González I.** Ethics in clinical research: what you should know before starting a study. Rev Esp Cardiol (Engl Ed). 2024; 77(10): 805-8. Editorial Material. IF: 4.9; Q1
- **Deanfield J, Verma S, Scirica BM, Kahn SE, Emerson SS, Ryan D, Lingvay I, Colhoun HM, Plutzky J, Kosiborod MN, Hovingh GK, Hardt-Lindberg S, Frenkel O, Weeke PE, Rasmussen S, Goudev A, Lang CC, Urina-Triana M, Pietilae M, Lincoff AM, ELECT Trial Investigators.** Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial. Lancet. 2024; 404(10454): 773-86. Article. IF: 88.5; D1
- **Dekker WKD, Elscot JJ, Bennett J, Schotborgh CE, van der Schaaf R, Sabaté M, Ameloot K, van Bommel R, Forlani D, van Reet B, Esposito G, Dirksen MT, Moreno R, Ruifrok WPT, Everaert BRC, Van Mieghem C, Cummins P, Lenzen M, Brugaletta S, Boersma E, Mieghem NMV, Diletti R, BIOVASC Investigators.** Timing of Complete Multivessel Revascularization in Acute Coronary Syndrome 2-Year Results of the BIOVASC Study. JACC-Cardiovasc Inte. 2024; 17(24): 2866-74. Article. IF: 11.4; D1
- **d'Entremont MA, Lee SF, Mian R, Kedev S, Montalescot G, Cornel JH, Stankovic G,**

Moreno R, Storey RF, Henry TD, Skuriat E, Tyrwhitt J, Mehta SR, Devereaux PJ, Eikelboom J, Cairns JA, Pitt B, Jolly SS. Design and rationale of the CLEAR SYNERGY (OASIS 9) trial: A 2x2 factorial randomized controlled trial of colchicine versus placebo and spironolactone vs placebo in patients with myocardial infarction. Am Heart J. 2024; 275: 173-82. Article. IF: 3.5; Q2

- **Díez-Delhoyo F, Lluva MTL, Cepas-Guillén P, Jurado-Román A, Bazal-Chacón P, Negreira-Caamaño M, Olavarri-Miguel I, Elorriaga A, Fernández-Sánchez JA, Escribano D, Salinas P, Vaquero-Luna J, Prieto-Lobato A, Pérez-Cebey L, Carrasquer A, Llaóo I, Mezcúa FJT, Giralt-Borrell T, Abellas M, García-Blas S, Matute-Blanco L, Robles-Gamboa C, Martínez-Guisado A, Fernández-Cordón C, González-Maniega C, Díez-Villanuevax P.** Timing of coronary angiography and use of antiplatelet pretreatment in patients with NSTEACS in Spain. Rev Esp Cardiol (Engl Ed). 2024; 77(3): 234-42. Article. IF: 4.9; Q1
- **Doblas JJG, García-Moll X, Freire RB, Juanatey CG, Morillas M, Muñoz AV, Escobar C.** Delphi consensus on oral anticoagulation management in special clinical situations in the cardiology setting. Future Cardiol. 2024; 20(13): 695-708. Article. IF: 1.0; Q4
- **Domingo-Gardeta T, Montero-Cabezas JM, Jurado-Román A, Sabaté M, Aboal J, Baranchuk A, Carrillo X, García-Zamora S, Dores H, van der Valk V, Scherptong RWC, Andrés-Cordon JF, Vidal P, Moreno-Martínez D, Toribio-Fernández R, Lillo-Castellano JM, Cruz R, De Guio F, Marina-Breysse M, Martínez-Sellés M.** Rationale and design of the artificial intelligence scalable solution for acute myocardial infarction (ASSIST) study. J Electrocardiol. 2024; 86: 153768. Article. IF: 1.2; Q4
- **Dorotheo E Ulysses, Arora Monika, Banerjee Amitava, Bianco Eduardo, Cheah Nuan Ping, Dalmau Regina, Eissenberg Thomas, Hasegawa Koji, Naidoo Pamela, Nazir Noreen T, Newby L Kristin, Obeidat Nour, Skipalskyi Andrii, Stepinska Janina, Willett Jeffrey, Wang Yunshu.** Nicotine and Cardiovascular Health: When Poison is Addictive - a WHF Policy Brief. Glob Heart. 2024; 19(1): 14. Article. IF: 3.1; Q2
- **Elscot JJ, Kakar H, Scarparo P, Dekker WKD, Bennett J, Schotborgh CE, van der Schaaf R, Sabate M, Moreno R, Ameloot K, Bommel RJV, Forlani D, Van Reet B, Esposito G, Dirksen MT, Ruifrok WPT, Everaert BRC, Van Mieghem C, Pinar E, Alfonso F, Cummins P, Lenzen M, Brugaletta S, Daemen J, Boersma E, Mieghem NMV, Diletti R.** Timing of Complete Multivessel Revascularization in Patients Presenting With Non-ST-Segment Elevation Acute Coronary Syndrome. Jacc-Cardiovasc Inte. 2024; 17(6): 771-72. Article. IF: 11.4; D1
- **Erríquez A, Campo G, Guiducci V, Casella G, Menozzi M, Cerrato E, Sacchetta G, Moreno R, Arena M, Santos IA, Gil JLD, Scarsini R, Ruozzi M, Arioti M, Picchi A, Barbierato M, Moscarella E, D'Amore SM, Lanzilotti V, Cavazza C, Rezzaghi M, Cocco M, Marrone A, Verardi FM, Escaned J, Barbato E, Colaiori I, Pesenti N, Carrara G, Biscaglia S.** QFR for the Revascularization of Nonculprit Vessels in MI Patients Insights From the FIRE Trial. Jacc-Cardiovasc Inte. 2024; 17(12): 1425-36. Article. IF: 11.4; D1
- **Erríquez A, Campo G, Guiducci V, Escaned J, Moreno R, Casella G, Menozzi M, Cerrato E, Sacchetta G, Menozzi A, Santos IA, Ibanes EG, Scarsini R, Vadala G, Ando G, Diez-Gil JL, d'Amore SM, Capecchi A, Colaiori I, Gallo F, Pavasini R, Marrone A, Pompei G, Lanzilotti V, Dudek D, Barbato E, Tebaldi M, Biscaglia S.** Complete vs Culprit-Only Revascularization in Older Patients With Myocardial Infarction and High Bleeding Risk. Jama Cardiol. 2024; 9(6): 565-73. Article. IF: 14.1; D1
- **Escobar C Rivero B Castrejón S Martínez-Cossiani M Merino JL.** Ivabradine for the treatment of vasovagal syncope. Rec: Cardioclinics. 2024; 59(3): 249-51. Letter. Not Indexed
- **Escobar C, Lara JG, Escaned J, Ruiz AC, Ibañes EG, Friera LF, Raposeiras-Roubín S, Martín JA, Agüero J, Gámez JM, Jorge-Pérez P, Freixa-Pamias R, Barrios V, González IC, Monzonís AM, Tejedor AV.** Diagnosis and treatment of patients with ANOCA. Consensus document of the SEC-Clinical Cardiology Association/ SEC-Interventional Cardiology Association/ SEC-Ischemic Heart Disease and Acute Cardiac Care Association/SEC-Cardiovascular Imaging Association. REC-Interv Cardiol. 2024; 6(2): 106-16. Article. IF: 1.1; Q4
- **Escobar C, Mazón P, Rivadulla C, Chandrappa S.** The role of eprosartan in the management of essential hypertension: literature review and expert opinion. Expert Rev Cardiovasc Ther. 2024; 22(10): 575-87. Review. IF: 2.1; Q3
- **Escobar C, Palacios B, Villarreal M, Gutiérrez M, Capel M, Aranda U, Hernández I, García M, Lledó L, Arenillas JF.** Clinical and Economic Consequences of a First Major Bleeding Event in Patients Treated with Direct Factor Xa Inhibitors in Spain: A Long-Term Observational Study. J Clin Med. 2024; 13(14): 4253. Article. IF: 2.9; Q1
- **Escobar C, Palacios B, Villarreal M, Gutierrez M, Capel M, Hernández I, Garcia M, Lledo L, Arenillas JF.** Clinical Characteristics and Incidence of Hemorrhagic Complications in Patients Taking Factor Xa Inhibitors in Spain: A Long-Term Observational Study. J Clin Med. 2024; 13(6): 1677. Article. IF: 2.9; Q1
- **Figuero SB, Delmas MEM, Peinado RP.** Subcutaneous ICD in pediatric patients: safety matches necessity. Rev Esp Cardiol (Engl Ed). 2024; 77(5): 370-1. Editorial Material. IF: 4.9; Q1
- **García-Escobar A, Galeote G, Jurado-Román A, Jiménez-Valero S, Cabrera JA, Moreno R.** Successful Management of Myval Transcatheter Heart Valve Embolization Into Abdominal Aortic Aneurysm During Transcatheter Aortic Valve Replacement. Tex Heart I J. 2024; 51(2): e227997. Article. IF: 0.9; Q4
- **García-Escobar A, Jiménez-Valero S, Galeote G, Jurado-Román A, Cabrera JA, Moreno R.** Severe acute recoil following transcatheter aortic valve replacement with a self-expanding prosthesis in a heavily calcified bicuspid aortic valve. Future Cardiol. 2024; 20(15-16): 823-6. Article. IF: 1.0; Q4
- **García-Escobar A, Lázaro-Garcia R, Cabrera JA, Jurado-Román A, Moreno R.** High systemic inflammation as a novel cardiovascular risk factor and target for anti-cytokine therapy: comment regarding the triglyceride glucose index. Int J Cardiovas Imag. 2024; 40(6): 1193-200. Letter. IF: 1.5; Q3
- **García-Escobar A, Lázaro-García R, Goicolea-Ruigómez J, González-Casal D, Fontenla-Cerezuela A, Soto N, González-Panizo J, Datino T, Pizarro G, Moreno R, Cabrera JA.** Red Blood Cell Distribution Width is a Biomarker of Red Cell Dysfunction Associated with High Systemic Inflammation and a Prognostic Marker in Heart Failure and Cardiovascular Disease: A Potential Predictor of Atrial Fibrillation Recurrence. High Blood Press Cardiovasc Prev. 2024; 31(5): 437-49. Review. IF: 2.9; Q2
- **García-Escobar A, Lázaro-García R, Goicolea-Ruigómez J, Pizarro G, Jurado-Román A, Moreno R, Cabrera JA.** Red Blood Cell Distribution Width as a Biomarker of Red Cell Dysfunction Associated with Inflammation and Macrophage Iron Retention: A Prognostic Marker in Heart Failure and a Potential Predictor for Iron Replacement Responsiveness. Card Fail Rev. 2024; 10: e17. Letter. IF: 5.7; Q1
- **Gassó LF, Dalmau R, López SV, Salicio ER, Weiland GB, David EP.** Challenges in advancing transesophageal echocardiography probes: identifying causes and solutions. Rev Esp Cardiol (Engl Ed). 2024; 77(10): 870-2. Editorial Material. IF: 4.9; Q1
- **Gómez-Lara J, López-Palop R, Rúmiz E, Jurado-Román A, Gómez-Menchero A, Valencia J, Fernández E, Ramírez LRG, Brugaletta S, Millán R, Cortés C, Tejedor P, Gutiérrez-Barrios A, Flores X, Cid-Alvarez AB, García-Blas S, García-Camarero T, Vicente JAL, Vaquerizo B, Soriano JGC, Caballero J, Piris RMC, Sánchez-Elvira G, Oyarzabal L, Pernigotti A, Tramullas A, Antuña P, Rodríguez-Leor O, Ojeda S, Rossello X, Gómez-Hospital JA, Bermejo J, García-García HM, Prado APD, Gutiérrez-Ibañes E.** Treatment of functionally nonsignificant vulnerable

plaques in multivessel STEMI: design of the VULNERABLE trial. Rec-Interv Cardiol. 2024; (4): 278-86. Article. IF: 1.1; Q4

- **González-Juanatey JR, Cordero A, Masana L, Dalmau R.** Effectiveness of the CNIC polypill in secondary cardiovascular prevention in the subgroup of patients of the NEPTUNO study using atorvastatin doses of 20 mg. Arch Cardiol Mex. 2024; 94(4): 429-43. Article. IF: 0.7; Q4
- **González-Lafuente L, Mercado-García E, Vázquez-Sánchez S, González-Moreno D, Boscá L, Fernández-Velasco M, Segura J, Kuro-O M, Ruilope LM, Liaño F, Ruiz-Hurtado G.** Interleukin-6 as a prognostic marker in acute renal injury and its klotho-dependent regulation. Nefrologia. 2024; 44(6): 818-29. Article. IF: 2.6; Q2
- **Gonzálvez-García A, Jurado-Román A, Tébar-Márquez D, Jiménez-Valero S, Galeote G, Rivero-Santana B, Moreno R.** Role of Dynamic Roadmapping in Renal Denervation Procedures. J Invasive Cardiol. 2024; 36(8): 64. Editorial Material. IF: 1.4; Q3
- **Gorgojo-Martínez JJ, Górriz JL, Cebrián-Cuenca A, Conde AC, Arribas MV.** Clinical Recommendations for Managing Genitourinary Adverse Effects in Patients Treated with SGLT-2 Inhibitors: A Multidisciplinary Expert Consensus. J Clin Med. 2024; 13(21): 6509. Review. IF: 2.9; Q1
- **Hengstenberg C, Unverdorben M, Möllmann H, Van Mieghem NM, Thiele H, Nordbeck P, Rassaf T, Moreno R, Mehran R, Jin J, Lang I, Veltkamp R, Dangas GD.** Risk Factors of Ischemic Stroke in Patients With Atrial Fibrillation After Transcatheter Aortic Valve Implantation from the Randomized ENVISAGE-TAVI AF Trial. Am J Cardiol. 2024; 227: 98-104. Article. IF: 2.1; Q3
- **Ikemura N, Spertus JA, Nguyen D, Fu ZX, Jones PG, Reynolds HR, Bangalore S, Bhargava B, Senior R, Elghamaz A, Goodman SG, Lopes RD, Pracon R, López-Sendón J, Maggioni AP, Kohsaka S, Roth GA, White HD, Mavromatis K, Boden WE, Rodríguez F, Hochman JS, Maron DJ.** International Variation in Health Status Benefits in Patients Undergoing Initial Invasive Versus Conservative Management for Chronic Coronary Disease: Insights From the ISCHEMIA Trial. Circ-Cardiovasc Qual. 2024; 17(10): e010534. Article. IF: 6.7; Q1
- **Jolly SS, Lee SF, Mian R, Kedev S, Lavi S, Moreno R, Montalescot G, Hillani A, Henry TD, Asani V, Storey RF, Silvain J, Spratt JCS, d'Entremont MA, Stankovic G, Zafirovska B, Natarajan MK, Sabate M, Shreenivas S, Pinilla-Echeverri N, Sheth T, Altisent OAJ, Ribas N, Skuriat E, Tyrwhitt J, Mehta SR.** SYNERGY-Everolimus-Eluting Stent With a Bioabsorbable Polymer in ST-Elevation Myocardial Infarction: CLEAR SYNERGY OASIS-9 Registry. Am J Cardiol. 2024; 220: 111-117. Article. IF: 2.1; Q3
- **Jurado-Román A, Agudo-Quílez P.** Tailoring antithrombotic treatment in patients with acute myocardial infarction and cancer: virtue lies in balance. Eur Heart J. 2024; 45(34): 3149-51. Editorial Material. IF: 35.6; D1
- **Jurado-Román A, Tébar-Márquez D, Hernández-Enriquez M, Birkemeyer R, Rodríguez-Leor O, Spinu R, Belle L, Galeote G, Jiménez-Valero S, Moreno R.** Meta-long Papyrus: Meta-analysis of mid to long-term outcomes of PK Papyrus covered stent. Catheter Cardio Inte. 2024; 104(3): 492-8. Article. IF: 1.9; Q3
- **Jurado-Román A, Wacinski PJ, Egred M.** Letter by Jurado-Román et al Regarding Article, Laser Coronary Atherectomy and Polymeric Coronary Wires in Uncrossable Lesions: A Word of Caution. Circ-Cardiovasc Inte. 2024; 17(3): e013954. Letter. IF: 7.4; Q1
- **Jurado-Román A.** Debate. Ablation vs lithotripsy in calcified coronary lesions. The ablation perspective. Rec-Interv Cardiol. 2024; 6(2): 133-5. Editorial Material. IF: 1.1; Q4
- **Kirchhof P, Bakhai A, de Asmundis C, de Groot JR, Deharo JC, Kelly P, López-de-Sa E, Monteiro P, Fronk EM, Lamparter M, Laeis P, Smolnik R, Steffel J, Waltenberger J, Weiss TW, De Caterina R.** Long-term effectiveness and safety of edoxaban in patients with atrial fibrillation: 4-year data from the ETNA-AF-Europe study. Int J Cardiol. 2024; 408: 132118. Article. IF: 3.2; Q2
- **Kosiborod MN, Windsor SL, Vardeny O, Berger JS, Reynolds HR, Boumakis S, Althouse AD, Solomon SD, Bhatt AS, Peikert A, Luther JF, Leifer ES, Kindzelski AL, Cushman M, Gong MN, Kornblith LZ, Khatri P, Kim KS, Kreuziger LB, Javaheri A, Carpio C, Wahid L, Moreno JLS, Alonso A, Ho MQ, López-Sendon J, Lopes RD, Curtis JL, Kirwan BA, Geraci MW, Neal MD, Hochman JS.** Effect of sodium-glucose co-transporter-2 inhibitors on survival free of organ support in patients hospitalised for COVID-19 (ACTIV-4a): a pragmatic, multicentre, open-label, randomised, controlled, platform trial. Lancet Diabetes Endocrinol. 2024; 12(10): 725-34. Article. IF: 41.8; D1
- **La Rosa G, Morillo CA, Quintanilla JG, Doltra A, Mont L, Rodríguez-Mañero M, Sarkozy A, Merino JL, Vivas D, Datino T, Calvo D, Pérez-Castellano N, Pérez-Villacastín J, Fauchier L, Lip G, Hatem SN, Jalife J, Sanchis L, Marín F, Filgueiras-Rama D.** Practical approach for atrial cardiomyopathy characterization in patients with atrial fibrillation. Rev Esp Cardiol (Engl Ed). 2024; 77(8): 656-66. Article. IF: 4.9; Q1
- **Lenarczyk R, Zeppenfeld K, Tfelt-Hansen J, Heinzel FR, Deneke T, Ene E, Meyer C, Wilde A, Arbelo E, Jedrzejczyk-Patej E, Sabbag A, Stühlinger M, di Biase L, Vaseghi M, Ziv O, Bautista-Vargas WF, Kumar S, Namboodiri N, Henz BD, Montero-Cabezas J, Dagres N, Peichi P, Frontera A, Tzeis S, Merino JL, Soejima K, de Chillou C, Tung RDR, Eckardt L, Maury P, Hlivak P, Tereshchenko LG, Kojodjojo P, Atié J.** Management of patients with an electrical storm or clustered ventricular arrhythmias: a clinical consensus statement of the European Heart Rhythm Association of the ESC-endorsed by the Asia-Pacific Heart Rhythm Society, Heart Rhythm Society, and Latin-American Heart Rhythm Society. Europace. 2024; 26(4): euae049. Article. IF: 7.4; Q1
- **Linz D, Andrade JG, Arbelo E, Boriani G, Breithardt G, Camm AJ, Caso V, Nielsen JC, De Melis M, De Potter T, Dichtl W, Diederichsen SZ, Dobrev D, Doll N, Duncker D, Dworatzek E, Eckardt L, Eisert C, Fabritz L, Farkowski M, Filgueiras-Rama D, Goette A, Guasch E, Hack G, Hatem S, Haeusler KG, Healey JS, Heidbuechel H, Hijazi Z, Hofmeister LH, Hove-Madsen L, Huebner T, Kääb S, Kotecha D, Malaczynska-Rajpold K, Merino JL, Metzner A, Mont L, Ng GA, Oeff M, Parwani AS, Puererfellner H, Ravens U, Rienstra M, Sanders P, Scherr D, Schnabel R, Schotten U, Sohns C, Steinbeck G, Steven D, Toennis T, Tzeis S, van Gelder IC, van Leerdam RH, Vernooy K, Wadhwa M, Wakili R, Willems S, Witt H, Zeemering S, Kirchhof P.** Longer and better lives for patients with atrial fibrillation: the 9th AFNET/EHRA consensus conference. Europace. 2024; 26(4): euae070. Article. IF: 7.4; Q1
- **Llacer P, Marcos MC, de la Espriella R, Ordás JG, Zegri I, Fort A, Chavarri AR, Mendez A, Blázquez Z, Pérez PC, Gracia JR, Fernández C, Recio-Mayoral A, Pomares A, Pinilla JMG, López-Ibor JV, Castro A, Soler MJ, Górriz JL, Claret RB, Fluvià P, Manzano L, Núñez J.** Congestion as a crucial factor determining albuminuria in patients with cardiorenal disease. Clin Kidney J. 2024; 17(6): sfae140. Article. IF: 4.6; Q1
- **Márquez DT, Jiménez-Valero S, Galeote G, Jurado-Román A, Gonzálvez-García A, Moreno R.** Decoding Neointimal Hematoma Following Cutting-Balloon Angioplasty: Comprehensive Optical Coherence Tomography Analysis and Resolution Perspectives. Can J Cardiol. 2024; 40(11): 2075-76. Editorial Material. IF: 5.3; Q1
- **Martínez-Campelo L, Blanco-Verea A, López-Fernández T, Martínez-Monzonis A, Buño A, Mazón P, Zamora P, Norton N, Reddy JS, Velasco-Ruiz A, González-Neira A, Vulsteke C, Alonso-Gordoa T, Cruz R, Diz-de Almeida S, Carracedo A, González-Juanatey J, López-Sendón J, Brion M.** Meta-analysis of genome-wide association studies for cancer therapy-related cardiovascular dysfunction and functional mapping highlight an intergenic region close to TP63. Sci Rep-Uk. 2024; 14(1): 18413. Article. IF: 3.9; Q1
- **Martínez-Guisado A, Cepas-Guillén P, Díez-Villanueva P, Lluva MTL, Jurado-Román**

A, Bazal-Chacón P, Negreira-Caamaño M, Olavarri-Miguel I, Elorriaga A, Rivera-López R, Escribano D, Salinas P, Vaquero-Luna J, Prieto A, Pérez-Cebey L, Carrasquer A, Llaó I, Mezcúa FJT, Giralt-Borrell T, Matute-Blanco L, Fernández-Cordón C, González C, Arbas-Redondo E, Aritza-Conty D, Díez-Delhoyo F. Influence of sex on the timing of coronary angiography and the prescription of antiplatelet therapy in patients with nonST-segment elevation myocardial infarction. Emergencias. 2024; 36(2): 123-30. Article. IF: 6.3; D1

- **Marzà-Florensa A, Vaartjes I, Graham I, Klipstein-Grobusch K, Grobbee DE.** A Global Perspective on Cardiovascular Risk Factors by Educational Level in CHD Patients: SURF CHD II. Glob Heart. 2024; 19(1): 60. Article. IF: 3.1; Q2
- **McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C, Christodorescu RM, Daskalopoulou SS, Ferro CJ, Gerdts E, Hanssen H, Harris J, Lauder L, McManus RJ, Molloy GJ, Rahimi K, Regitz-Zagrosek V, Rossi GP, Sandset EC, Scheenaerts B, Staessen JA, Uchmanowicz I, Volterrani M, Touyz RM, Abreu A, Olsen MH, Ambrosetti M, Androulakis E, Bang LE, Bech JN, Borger MA, Boutouyrie P, Bronze L, Buccheri S, Dalmau R, Zarzosa MCD, Delles C, Fiuza MM, Gabulova R, Haugen BO, Heiss C, Ibanez B, James S, Kapil V, Kayikçcioglu M, Kober L, Koskinas KC, Locati ET, MacDonald S, Mihailidou AS, Mihaylova B, Mindham R, Mortensen MB, Nardai S, Neubeck L, Nielsen JC, Nilsson PM, Pasquet AA, Pedro MM, Prescott E, Rakisheva A, Rietzschel E, Rocca B, Rossello X, Schmid JP, Shantsila E, Sudano I, Timóteo AT, Tsivgoulis G, Ungar A, Vaartjes I, Visseren F, Voeller H, Vrints C, Witkowski A, Zennaro MC, Zeppenfeld K, Sirenko YM.** 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024; 45(38): 3912-4018. Article. IF: 35.6; D1
- **Moreno R, Baptista SB, Valencia J, Gómez-Menchero A, Bouisset F, Ruiz-Arroyo JR, Bento A, Besutti M, -Valero SJ, Rivero-Santana B, Olhmann P, Santos M, Vaquerizo B, Cuissetm T, Lemoine J, Pinar E, Fiarresga A, Urbano C, Marliere S, Braga C, Amat-Santos I, Morgado G, Sarnago F, Telleria M, Van Belle E, Díaz-Fernández J, Borrego JC, Amabile N, Meneveau N.** OPTImized coronary interventions eXplaIn the bEst cliNical outcomEs (OPTI-XIENCE) study. Rationale and study design. Cardiovasc Revasc Med. 2024; 59: 93-8. Article. IF: 1.9; Q3
- **Moreno R, Jolly SS.** Thrombus Aspiration in Primary Angioplasty Faith Cannot Replace Evidence. Jacc-Cardiovasc Inte. 2024; 17(19): 2226-7. Editorial Material. IF: 11.4; D1
- **Mostaza JM, Escobar C.** Rosuvastatin-Based Lipid-Lowering Therapy for the Control of LDL Cholesterol in Patients at High Vascular Risk. J Clin Med. 2024; 13(7): 1894. Review. IF: 2.9; Q1
- **Oliveri F, Van Oort MJH, Al Amri I, Bingen BO, van der Kley F, Jukema JW, Jurado-Roman A, Cabezas JM.** Coronary calcified nodules versus nonnodular coronary calcifications: a systematic review and meta-analysis. J Cardiovasc Med. 2024; 25(6): 438-49. Article. IF: 2.0; Q3
- **Oort MJHV, Al Amri I, Bingen BO, Soriano JGC, Karalis I, Sanz-Sánchez J, Oliveri F, van der Kley F, Jukema JW, Jurado-Roman A, Montero-Cabezas JM.** Procedural and clinical impact of intravascular lithotripsy for the treatment of peri-stent calcification. Cardiovasc Revasc Med. 2024; 61: 16-23. Article. IF: 1.9; Q3
- **Osoro L, Zylla MM, Braunschweig F, Leyva F, Figueras J, Pürerfellner H, Merino JL, Casado-Arroyo R, Boriani G.** Challenging the status quo: a scoping review of value-based care models in cardiology and electrophysiology. Europace. 2024; 26(9): euae210. Article. IF: 7.4; Q1
- **Pavasini R, Campo G, Serenelli M, Tonet E, Guiducci V, Escaned J, Moreno R, Casella G, Cavazza C, Varbella F, Sacchetta G, Arena M, Santos IA, Ibañes EG, Scarsini R, D'Amico G, Ruiz-Poveda FL, Gil JLD, Pignatelli G, Iannopollo G, Colaiori I, Santos RC, Marrone A, Fileti L, Rigattieri S, Barbato E, Ocaranza-Sánchez R, Biscaglia S.** Impact of pre-admission physical activity on benefits of physiology-guided complete revascularization in older patients with myocardial infarction: insights from the FIRE trial. Eur J Prev Cardiol. 2024; 31(12): 1451-9. Article. IF: 7.5; D1
- **Peek N, Hindricks G, Akbarov A, Tijssen JGP, Jenkins DA, Kapacee Z, Parkes L, van der Geest RJ, Longato E, Sprague D, Taleb Y, Ong M, Miller CA, Shamloo AS, Albert C, Barthel P, Boveda S, Braunschweig F, Johansen JB, Cook N, de Chillou C, Elders P, Faxén J, Friede T, Fusini L, Gale CP, Jarkovsky J, Jouven X, Junttila J, Kautzner J, Kiviniemi A, Kutyifa V, Leclercq C, Lee DC, Leigh J, Lenarczyk R, Leyva F, Maeng M, Manca A, Marijon E, Marschall U, Merino JL, Mont L, Nielsen JC, Olsen T, Pester J, Pontone G, Roca I, Schmidt G, Schwartz PJ, Sticherling C, Suleiman M, Taborsky M, Tan HL, Tfelt-Hansen J, Thiele H, Tomaselli GF, Verstraelen T, Vinayagamoorthy M, Olesen KKW, Wilde A, Willems R, Wu KC, Zabel M, Martin GP, Dagres N.** Sudden cardiac death after myocardial infarction: individual participant data from pooled cohorts. Eur Heart J. 2024; 45(43): 4616-26. Article. IF: 35.6; D1
- **Pracon R, Spertus JA, Broderick S, Bangalore S, Rockhold FW, Ruzyllo W, Demchenko E, Nageh T, Grossman GB, Mavromatis K, Manjunath CN, Smanio PEP, Stone GW, Mancini GBJ, Boden WE, Newman JD, Reynolds HR, Hochman JS, Maron DJ.** Factors Associated With Coronary Angiography Performed Within 6 Months of Randomization to the Conservative Strategy in the ISCHEMIA Trial. Circ-Cardiovasc Inte. 2024; 17(6): e013435. Article. IF: 7.4; Q1
- **Ramírez E, Ruipérez-Campillo S, Casado-Arroyo R, Merino JL, Vogt JE, Castells F, Millet J.** The art of selecting the ECG input in neural networks to classify heart diseases: a dual focus on maximizing information and reducing redundancy. Front Physiol. 2024; 15: 1452829. Article. IF: 3.4; Q1
- **Ramos-Prada A, Redondo-Rodríguez A, Roca-Luque I, Porta-Sánchez A, ter Bekke RMA, Quintanilla JG, Sánchez-González J, Peinado R, Merino JL, Cluitmans M, Holtackers RJ, Marina-Breysse M, Gálan-Arriola C, Enríquez-Vázquez D, Vázquez-Calvo S, Alfonso-Almazán JM, Pizarro G, Ibáñez B, González-Ferrer JJ, Salgado-Aranda R, Cañadas-Godoy V, Calvo D, Pérez-Villacastín J, Pérez-Castellano N, Filgueiras-Rama D.** Novel systematic processing of cardiac magnetic resonance imaging identifies target regions associated with infarct-related ventricular tachycardia. Europace. 2024; 26(10): euae244. Article. IF: 7.4; Q1
- **Reynolds HR, Page CB, Shaw LJ, Berman DS, Chaitman BR, Picard MH, Kwong RY, Min JK, Leipsic J, Mancini GBJ, Budoff MJ, Hague CJ, Senior R, Szwed H, Bhargava B, Celutkiene J, Gadkari M, Bainey KR, Doerr R, Ramos RB, Ong P, Naik SR, Steg PG, Goetschalckx K, Chow BJW, Scherrer-Crosbie M, Phillips L, Mark DB, Spertus JA, Alexander KP, O'Brien SM, Boden WE, Bangalore S, Stone GW, Maron DJ, Hochman JS, ISCHEMIA Res Grp.** Relationship Between Severity of Ischemia and Coronary Artery Disease for Different Stress Test Modalities in the ISCHEMIA Trial. Circ-Cardiovasc Inte. 2024; 17(12): e013743. Article. IF: 7.4; Q1
- **Rigual R, Castrejón-Castrejón S, Fernández-Gassó L, García-Castro J, Rodríguez-Pardo J, Martínez-Cossiani M, de Celis-Ruiz E, Casado-Fernández L, Hervás C, Alonso-López E, de Leciñana MA, Díez-Tejedor E, Pérez-David E, Ruiz-Ares G, Merino JL, Fuentes B.** Atrial Imaging and Cardiac Rhythm in Cryptogenic Embolic Stroke: The ARIES Study. J Am Heart Assoc. 2024; 13(17): e036236. Article. IF: 5.3; Q1
- **Rivero-Santana B, Galán C, Pérez-Martínez C, Ibañez B, de Prado AP, Fernández-Velasco M, Moreno R, Jurado-Roman A.** ELLIS Study: Comparative Analysis of Excimer Laser Coronary Angioplasty and Intravascular Lithotripsy on Drug-Eluting Stent as Assessed by Scanning Electron Microscopy. Circ-Cardiovasc Inte. 2024; 17(11): e014505. Article. IF: 7.4; Q1
- **Rivero-Santana B, Galeote G, Jurado-Román A, Jimenez-Valero S, Gonzalvez-Garcia A, Moreno-Gómez R.** Successful Valve-in-Valve Replacement Using Intravascular Lithotripsy

for Femoral Access in an Elderly Patient With Critical Aortic Stenosis and Extensive Vascular Calcification. J Invasive Cardiol. 2024; 36(10): 123. Editorial Material. IF: 1.4; Q3

- **Rivero-Santana B, Jiménez-Valero S, Jurado-Román A, Galeote G, Gonzálvez A, Fernández-Velasco M, Moreno R.** A Decade Later: Unveiling Long-Term Coronary Artery Healing with Optical Coherence Tomography Following Bioresorbable-Scaffold Implantation. Can J Cardiol. 2024; 40(12): 2635-6. Editorial Material. IF: 5.3; Q1
- **Rivero-Santana B, Jimenez-Valero S, Jurado-Roman A, Galeote G, López-Fernández T, Moreno R.** The BALTO Registry: Long-term results of percutaneous BALloon pericardioTomy in oncological patients. Catheter Cardio Inte. 2024; 103(3): 482-9. Article. IF: 1.9; Q3
- **Rivero-Santana B, Jurado-Román A, Galeote G, Jiménez-Valero S, Gonzálvez A, Tebar D, Moreno R.** Drug-Eluting Balloons in Calcified Coronary Lesions: A Meta-Analysis of Clinical and Angiographic Outcomes. J Clin Med. 2024; 13(10): 2779. Article. IF: 2.9; Q1
- **Rivero-Santana B, Jurado-Roman A, Pascual I, Li CH, Jimenez P, Estevez-Loureiro R, Cepas-Guillén P, Benito-González T, Serrador A, de la Torre-Hernández JM, Avanzas P, Fernández-Peregrina E, Nombela L, Caneiro-Queija B, Freixas X, Fernández-Vazquez F, Amat-Santos I, Lee DH, Leon V, Arzamendi D, Moreno R, Galeote G.** Combined Use of MITRACLIP and Ventricular ASSIST Devices in Cardiogenic Shock: MITRA-ASSIST Registry. J Clin Med. 2024; 13(15): 4408. Article. IF: 2.9; Q1
- **Rivero-Santana B, Saldaña-García J, Caro-Codón J, Zamora P, Moliner P, Monzonis AM, Zatarain E, Alvarez-Ortega C, Gómez-Prieto P, Pernas S, Rodríguez I, Soto AB, Cadenas R, Ozores PP, Ramírez SP, Salvador MM, Valbuena S, Gasso LF, Juárez V, Severo A, Terol B, Alvarez TD, Rodríguez O, Brion M, González-Costello J, Albendea MC, González-Juanatey JR, Moreno R, López-Sendón J, López-Fernández T.** Anthracycline-induced cardiovascular toxicity: validation of the Heart Failure Association and International Cardio-Oncology Society risk score. Eur Heart J. 2024; 46(3): 273-84. Article. IF: 35.6; D1
- **Rodrigo CU, Gassó LF, Valero SJ.** Cardiac Lymphoma as a Cause of Dyspnea in anImmunosuppressed Patient: The Importance ofthe Endomyocardial Biopsy. J Invasive Cardiol. 2024; 36(8): 71. Editorial Material. IF: 1.4; Q3
- **Rodríguez-Leor O, Cid-Alvarez AB, López-Benito M, Gonzalo N, Vilalta V, de Miguel JAD, López LF, Jurado-Roman A, Diego A, Oteo JF, Cuellas C, Trillo R, Travieso A, Alfonso F, Carrillo X, Vegas-Valle JM, Cortes-Villar C, Pascual I, Camacho JFM, Flores X, Vera-Vera S, Moreu J, de Sousa GB, Martí D, Jimenez-Mazuecos J, Fuertes M, Ocaranza R, Hernández JMD, Lozano F, Martínez SGS, Gómez-Lara J, de Prado AP.** A Prospective, Multicenter, Real-World Registry of Coronary Lithotripsy in Calcified fi ed Coronary Arteries The REPLICA-EPIC18 Study. Jacc-Cardiovasc Inte. 2024; 17(6): 756-67. Article. IF: 11.4; D1
- **Rosado E, Marín-Cortés S, Moreno R.** Sintering, mechanical properties and hydrothermal resistance of ZrO2/ ZrSiO4 slip cast composites. J Eur Ceram Soc. 2024; 44(11): 6576-85. Article. IF: 6.2; D1
- **Ruiz-García A, Serrano-Cumplido A, Arranz-Martínez E, Escobar-Cervantes C, Pallarés-Carratalá V.** Hyperuricaemia Prevalence Rates According to Their Physiochemical and Epidemiological Diagnostic Criteria and Their Associations with Cardio-Renal-Metabolic Factors: SIMETAP-HU Study. J Clin Med. 2024; 13(16): 4884. Article. IF: 2.9; Q1
- **Ruiz-García A, Serrano-Cumplido A, Escobar-Cervantes C, Arranz-Martínez E, Pallarés-Carratalá V.** Atrial Fibrillation Prevalence Rates and Its Association with Cardiovascular-Kidney-Metabolic Factors: SIMETAP-AF Study. Med Lith. 2024; 60(8): 1309. Article. IF: 2.4; Q1
- **Ruiz-García A, Serrano-Cumplido A, Escobar-Cervantes C, Arranz-Martínez E, Pallarés-Carratalá V.** Prevalence Rates of Abdominal Obesity, High Waist-to-Height Ratio and Excess Adiposity, and Their Associated Cardio-Kidney-Metabolic Factors: SIMETAP-AO Study. Nutrients. 2024; 16(22): 3948. Article. IF: 5; Q1
- **Saldaña-García J, Jurado-Román A, Jiménez-Valero S, López AT, Santana BR, Tébar-Márquez D, Gonzálvez-García A, Galeote G, Gil JMD, Moreno R.** Sailing Through the Femoral Artery: Optical Coherence Tomography Depiction of a MANTA Anchor-Induced Complication. Can J Cardiol. 2024; 40(12): 2411-3. Editorial Material. IF: 5.3; Q1
- **Salinas P, Vázquez-Alvarez ME, Salvatella N, Quevedo VR, Martín MV, Valero E, Rumiz E, Jurado-Román A, Lozano I, Gallardo F, Amat-Santos IJ, Lorenzo O, Portaz JJP, Huanca M, Nombela-Franco L, Vaquerizo B, Martínez RR, Melón NMM, Sanchis J, Berenguer A, Gallardo-López A, Gutiérrez-Ibañes E, Mejía-Rentería H, Córdoba-Soriano JG, Jiménez-Mazuecosn JM.** Catheter-directed therapy for acute pulmonary embolism: results of a multicenter national registry. Rev Esp Cardiol (Engl Ed). 2024; 77(2): 138-47. Article. IF: 4.9; Q1
- **Sharma R, Kouranos V, Cooper LT, Metra M, Ristic A, Heidecker B, Baksi J, Wicks E, Merino JL, Klingel K, Imazio M, de Chillou C, Tschöpe C, Kuchynka P, Petersen SE, McDonagh T, Lüscher T, Filippatos G.** Management of cardiac sarcoidosis. Eur Heart J. 2024; 45(30): 2697-2726. Review. IF: 35.6; D1
- **Tebar D, Carrillo X, del Blanco BG, Gómez-Hospital JA, Nombela L, Molina E, Galeote G, Vilalta V, Serra-Garcia V, Carol GM, Jimenez-Valero S, Fernández-Nofrerias E, Calabuig-Goena A, Jurado-Roman A, Sánchez-Recalde A, Velasco MF, Pérez-Solares L, Moreno R.** Experience with the ACURATE neo and neo2 transcatheter aortic valves in Spain. The PRECISA (PRospective Evaluation Complementing Investigation with ACURATE devices) registry. Catheter Cardio Inte. 2024; 103(6): 1015-22. Article. IF: 1.9; Q3
- **Tébar-Márquez D, Juárez V, Arbas E, Rosillo S, Jurado-Román A, Moreno R.** Practical concepts of catheter-directed aspiration thrombectomy in ECMO-supported patients. REC-Interv Cardiol. 2024; 6(4): 346-8. Letter. IF: 1.1; Q4
- **Tejerizo FB, Sánchez FC, Jurado-Román A, Cruz-González I, Alvarez-Fuente M, Amat-Santos IJ, Blasco PB, Mata RB, Carrasco JI, Bellón JMC, Fernández MF, Gómez-Jaume A, Gutiérrez-Barrios A, Albert BI, Montañés LJ, Aguado FGL, Lalaguna LA, Segovia RM, Pérez MJN, Pineda SO, Núñez FR, Gila JS, Sanz-Ruiz R, Vázquez-Alvarez ME, Argüelles JIZ.** Spanish cardiac catheterization in congenital heart diseases registry. Third official report from the ACI-SEC and the GTH-SECPCC (2022). REC-Interv Cardiol. 2024; 6(3): 182-190. Article. IF: 1.1; Q4
- **Terricabras M, Martins RP, Peinado R, Derejko P, Mont L, Ernst S, Herranz D, Bailleul C, Verma A.** Cardiac Pulsed Field Ablation Lesion Durability Assessed by Polarization-Sensitive Optical Coherence Reflectometry. Circ-Arrhythmia Elec. 2024; 17(3): e012255. Article. IF: 9.8; D1
- **Trines SA, Moore P, Burri H, Nunes SG, Massoullie G, Merino JL, Paton MF, Porta-Sánchez A, Sommer P, Steven D, Whittaker-Axon S, Yorgun H, Arribas F, Deharo JC, Steffel J, Wolpert C.** 2024 updated European Heart Rhythm Association core curriculum for physicians and allied professionals: a statement of the European Heart Rhythm Association of the European Society of Cardiology. Europace. 2024; 26(11): euae243. Article. IF: 7.4; Q1
- **Troncoso JA, Abánades CS, Robles-Marhuenda A, Batres SA, Peña MFV, Valero SJ, Torre RS, Rios-Blanco JJ.** Prevalence, risk factors and echocardiographic predictors of pulmonary hypertension in systemic lupus erythematosus: towards a screening protocol. RMD Open. 2024; 10(1): e003674. Article. IF: 4.7; Q1
- **Tzeis S, Gerstenfeld EP, Kalman J, Saad E, Shamloo AS, Andrade JG, Barbhaiya CR, Baykaner T, Boveda S, Calkins H, Chan NY, Chen ML, Chen SA, Dagres N, Damiano RJ, De Potter T, Deisenhofer I, Derval N, Di Biase L, Duytschaever M, Dyrda K, Hindricks G, Hocini M, Kim YH, la Meir M, Merino JL, Michaud GF, Natale A, Nault I, Nava S, Nitta T, O'Neill M, Pak HN, Piccini JP, Puererfellner H, Reichlin T, Saenz LC, Sanders P, Schilling R, Schmidt B, Supple GE, Thomas KL, Tondo C, Verma A, Wan EY.** 2024 European Heart

Rhythm Association/Heart Rhythm Society/Asia Pacific Heart Rhythm Society/Latin American Heart Rhythm Society expert consensus statement on catheter and surgical ablation of atrial fibrillation. J Interv Card Electr. 2024; 67(5): 921-1072. Review. IF: 2.6; Q2

- **Tzeis S, Gerstenfeld EP, Kalman J, Saad EB, Shamloo AS, Andrade JG, Barbhaiya CR, Baykaner T, Boveda S, Calkins H, Chan NY, Chen ML, Chen SA, Dagres N, Damiano RJ, De Potter T, Deisenhofer I, Derval N, Di Biase L, Duytschaever M, Dyrda K, Hindricks G, Hocini M, Kim YH, la Meir M, Merino JL, Michaud GF, Natale A, Nault I, Nava S, Nitta T, O'Neill M, Pak HN, Piccini JP, Pürerfellner H, Reichlin T, Saenz LC, Sanders P, Schilling R, Schmidt B, Supple GE, Thomas KL, Tondo C, Verma A, Wan EY.** 2024 European Heart Rhythm Association/Heart Rhythm Society/Asia Pacific Heart Rhythm Society/Latin American Heart Rhythm Society expert consensus statement on catheter and surgical ablation of atrial fibrillation. Europace. 2024; 26(4): euae043. Article. IF: 7.4; Q1
- **Tzeis S, Gerstenfeld EP, Kalman J, Saad EB, Shamloo AS, Andrade JG, Barbhaiya CR, Baykaner T, Boveda S, Calkins H, Chan NY, Chen ML, Chen SA, Dagres N, Damiano RJ, De Potter T, Deisenhofer I, Derval N, Di Biase L, Duytschaever M, Dyrda K, Hindricks G, Hocini M, Kim YH, la Meir M, Merino JL, Michaud GF, Natale A, Nault I, Nava S, Nitta T, O'Neill M, Pak HN, Piccini JP, Pürerfellner H, Reichlin T, Saenz LC, Sanders P, Schilling R, Schmidt B, Supple GE, Thomas KL, Tondo C, Verma A, Wan EY.** 2024 European Heart Rhythm Association/Heart Rhythm Society/Asia Pacific Heart Rhythm Society/Latin American Heart Rhythm Society expert consensus statement on catheter and surgical ablation of atrial fibrillation. Heart Rhythm. 2024; 21(9): E31-E149. Article. IF: 5.7; Q1
- **Tzeis S, Gerstenfeld EP, Kalman J, Saad EB, Shamloo AS, Andrade JG, Barbhaiya CR, Baykaner T, Boveda S, Calkins H, Chan NY, Chen ML, Chen SA, Dagres N, Damiano RJ, De Potter T, Deisenhofer I, Derval N, Di Biase L, Duytschaever M, Dyrda K, Hindricks G, Hocini M, Kim YH, la Meir M, Merino JL, Michaud GF, Natale A, Nault I, Nava S, Nitta T, O'Neill M, Pak HN, Piccini JP, Pürerfellner H, Reichlin T, Saenz LC, Sanders P, Schilling R, Schmidt B, Supple GE, Thomas KL, Tondo C, Verma A, Wan EY.** 2024 European Heart Rhythm Association/Heart Rhythm Society/Asia Pacific Heart Rhythm Society/Latin American Heart Rhythm Society expert consensus statement on catheter and surgical ablation of atrial fibrillation. J Arrhythm. 2024; 40(6): 1217-354. Article. IF: 1.7; Q3
- **Valencia J, Torres-Mezcua F, Pineda J, Bordes P, Jurado-Román A, Ruiz-Nodar JM.** Possible delayed effectiveness of intracoronary laser atherectomy. Rec-Interv Cardiol. 2024; 6(2): 136-8. Letter. IF: 1.1; Q4
- **van Oort MJH, Al Amri I, Bingen BO, Oliveri F, Vilalta V, Jurado-Román A, Pereira AR, Cordoba-Soriano JG, González ER, Fernández-Peregrina E, van der Kley F, Jukema JW, Montero-Cabezas JM.** Current applications, procedural and 1-year outcomes of Rotatripsy for the treatment of calcified coronary lesions. Catheter Cardio Inte. 2024; 104(2): 203-12. Article. IF: 1.9; Q3
- **Viera E, Meras P, Merino C, Pérez E, Ruiz J, Balbacid E, Abelleira C, Aroca A, Moreno R.** Diagnosis of Congenital Heart Disease in Adulthood: How Often, How Relevant? Am J Cardiol. 2024; 231(): 72-4. Article. IF: 2.1; Q3
- **Vila-García J, Clement IM, Pinedo IDP, Yagüe BL, Menéndez AC, Moreno R.** First Evidence of a HeartMate 3 Driveline Infection by Rhizopus Arrhizus: A Case Report. Can J Cardiol. 2024; 40(12): 2637-9. Article. IF: 5.3; Q1
- **Vivas D Escobar C Cordero A Fernández-Olmo R Oterino A Blanco-Echevarría A Botana M Escribano D Freijo M Martínez-Losas P Pascual V Quiroga B Sánchez-Peinador C Torres-Fonseca M Freixa-Pamias R Barrios V Barón-Esquivias G.** Practical use of new therapies for the management of dyslipidaemias. Consensus SEC/SEA/SEEN/SEMFYC/SEMERGEN/SEMG/SEN/SEACV/S.E.N. REC: Cardioclinics. 2024; 59(4): 310-1. Article. Not Indexed
- **Wang B, Yang XL, Wei B, Ren TT, Huang NW, Escobar C, Pang PYK, Liu XD, Zhou HY.** Associations between waist circumference, central obesity, and the presence of non-valvular atrial fibrillation patients with heart failure. J Thorac Dis. 2024; 16(3): 2049-59. Article. IF: 1.9; Q3
- **Zylla MM, Imberti JF, Leyva F, Casado-Arroyo R, Braunschweig F, Pürerfellner H, Merino JL, Boriani G.** Same-day discharge vs. overnight stay following catheter ablation for atrial fibrillation: a comprehensive review and meta-analysis by the European Heart Rhythm Association Health Economics Committee. Europace. 2024; 26(8): euae200. Review. IF: 7.4; Q1

Research projects

- **Antorrena Miranda MI.** International study of comparative health effectiveness with medical and invasive approaches - Estudio internacional comparativo de la eficacia sanitaria con enfoques médicos e invasivos. New York University School Of Medicine. 2013-Ongoing. Managment centre: FIBHULP
- **Fernández Velasco M.** Determinación de nuevos mediadores del sistema inmune innato como biomarcadores de daño cardiaco en el infarto agudo de miocardio. Sociedad Española de Cardiología. 2019-Ongoing. Managment centre: FIBHULP
- **Fernández Velasco M.** New inflammatory targets for atrial myopathy associated with heart failure (PI20/01482). ISCIII. 2021-2025. Managment centre: FIBHULP
- **Fernández Velasco M.** NODI, una nueva diana terapeutica en el tratamiento del infarto agudo de miocardio. FIBHULP. 2022-Ongoing. Managment centre: FIBHULP
- **Fernández Velasco M.** Nuevos mecanismos nanomoleculares implicados en la fisiopatología de la insuficiencia cardíaca (CNS2023-145161). Mninisterio de Ciencia e Innovación. 2024-2026. Managment centre: FIBHULP
- **Fernández Velasco M.** Papel de los receptores NOD1 en la cardiotoxicidad inducida por inmunoterapia en pacientes oncológicos (PI23/01014). ISCIII. 2024-2026. Managment centre: FIBHULP
- **Guzmán Martínez G.** Inmunidad en Sars-Cov-2 y riego cardiovascular. Cohorte prospectiva. Fundacion Para La Investigacion Biomedica Hospital Universitario La Paz. 2020-Ongoning. Managment centre: FIBHULP
- **Guzmán Martínez G.** Marcadores precoces de disfunción ventricular derecha y alteraciones de la circulación pulmonar en pacientes afectos de hipertensión pulmonar. Siemens Heatlhcare S.L. 2018-Ongoning. Managment centre: FIBHULP
- **Jiménez Valero S.** Análisis de correlación entre los marcadores de inflamación y morfología de placas coronarias mediante tomografía de coherencia óptica y tec multicorte: Estudio IVI. Abbott Laboratories S.A. 2009-Ongoning. Managment centre: FIBHULP
- **Jiménez Valero S.** Estudio en modelo porcino para evaluar la utilidad de la tomografía de coherencia óptica en el análisis de las lesiones endocárdicas producidas por radiofrecuencia. Medlumics S.L. 2015-Ongoning. Managment centre: FIBHULP
- **Jurado Román A.** ASSIST_AI scalable solution for st myocardial infarction (2023_391). EIT-HEALTH. 2023-2025. Managment centre: FIBHULP
- **López-Sendón Hentschel JL.** Biomarcadores en la cardiotoxicidad por agentes antineoplás: rendimiento dianóstico. Boehringer Ingelheim España S.A. 2015-Ongoning. Managment centre: FIBHULP
- **López-Sendón Hentschel JL.** Colchicine cardiovascular outcome trial_COLCOT. Varios Financiadores. 2017-Ongoning. Managment centre: FIBHULP
- **López-Sendón Hentschel JL.** Colchicine coronavirus Sars-Cov2 trial (Colcorona-Covid-19). 2020-Ongoning. Managment centre: FIBHULP
- **López-Sendón Hentschel JL.** Dinamización de ciencia disruptiva en predictores de enfermedades tumorales, infecciosas y hereditarias como base de la medicina personalizada (FORT23/00006_GRUPO II). ISCIII. 2024-2027. Managment centre: FIBHULP
- **López-Sendón Hentschel JL.** Predicción de riesgo de cardiotoxicidad en las unidades

de cardiooncología. Valor de la genética y diferentes biomarcadores. El registro cardiotox (PMP22/00098). ISCIII. 2023-2025. Managment centre: FIBHULP

- **Merino Llorens JL.** Ablación mediante aislamiento de venas pulmonares solo o combinado con ablación lineal para eliminar recurrencias de fa persistente: un ensayo clínico multicéntrico aleatorizado (SUPAFER) (PI22/00278). ISCIII. 2023-2025. Managment centre: FIBHULP
- **Merino Llorens JL.** Addressing multimorbidity in elderly atrial fibrillation patients through interdisciplinary, tailored, patient-centred care pathways. UE. 2020-2026. Managment centre: FIBHULP
- **Merino Llorens JL.** Comparative safety evaluation of atrial fibrillation by catheter with tissue temperature control mode (POWER FAST V). Medtronic. 2023-Ongoing. Managment centre: FIHULP
- **Merino Llorens JL.** EHRA-PATHS Addressing multimorbidity in elderly atrial fibrillation patients through interdisciplinary, tailored, patient-centered care pathways (GA 945260). UE. 2021-Ongoing. Managment centre: FIHULP
- **Merino Llorens JL.** El vectorcaidiograma como herramienta de caracterización no invasiva de iá dinámtca de activación y de i-a presencia y locauzación de zonas de conducción lenta en los circuitos de flijter auricutár atípico tzquierdo mediante vectorcardiograma. Arrhythmia Network Technology S.L. 2018-Ongoning. Managment centre: FIBHULP
- **Merino Llorens JL.** High radiofrequency power for fast and safe pulmonary veins ablastion-a pilot observational study (POWERFAST III) (PI18/01522). ISCIII. 2018-Ongoning. Managment centre: FIBHULP
- **Merino Llorens JL.** HosmartAI Hospital Smart development based on AI (GA 101016834). UE. 2021-2024. Managment centre: FIHULP
- **Merino Llorens JL.** Hospital Smart development based on AI. UE. 2020-2024. Managment centre: FIBHULP
- **Merino Llorens JL.** Implementation of personalised risk prediction and prevention of sudden cardiac death after myocardial infarction (PROFID EHRA) (GA 847999 (H2020-SC1-BHC-2018-2020)). UE. 2023-Ongoing. Managment centre: FIHULP
- **Merino Llorens JL.** Left atrial FLUTter: a comparison of ablation guided by high-density MApping and empirical LINEar ablation – the FLUTMALINE Trial. Biosense Webster. 2021-Ongoing. Managment centre: FIHULP
- **Merino Llorens JL.** Registro retrospectivo de identificación de factores cardiovasculares de mal pronóstico en pacientes covid-19 (Card-Covid). Medtronic Iberica Sa. 2020-Ongoning. Managment centre: FIBHULP
- **Moreno Gómez JR.** Evaluacion clínica y seguimiento de los pacientes con cardiopatía estructural sometidos a procedimientos de tratamiento percutáneo. Abbott Laboratories S.A. 2011-Ongoning. Managment centre: FIBHULP
- **Peinado Peinado R.** Comparación de un cateter multielectrodo frente a un catéter de ablación de punta irrigada para crear mapas de voltaje y activacion en pacientes con taquicardias auriculares macroreentrantes. Medtronic Iberica S.A. 2019-Ongoning. Managment centre: FIBHULP
- **Peinado Peinado R.** Influencia del remodelado eléctrico del miocardio auricular en la recurrencia de fibrilación auricular tras el aislamiento eléctrico de las venas pulmonares por fibrilación auricular paroxística. Abbott Medical España S.A. 2009-Ongoning. Managment centre: FIBHULP
- **Peinado Peinado R.** Papel de los receptores del sistema inmune innato en el desarrollo y evoluación de la fibrilación auricular. Medtronic Iberica S.A. 2021-Ongoning. Managment centre: FIBHULP
- **Peinado Peinado R.** Síndrome de apneas-hipopneas obstructivas del sueño y arritmias ventriculares en pacientes con disfunción ventricular sistólica portadores de DAI. Fundación Casa del Corazón. 2008-Ongoning. Managment centre: FIBHULP
- **Peinado Peinado R.** Registro de pacientes con cardipatía congénita del adulto portadores de un sistema de terapia de resincronización cardiaca (Retracca). Abbott Medical España S.A. 2017-Ongoning. Managment centre: FIBHULP
- **Peinado Peinado R.** Utilidad de los algoritmos de diagnostico diferencial electrocardiografico de las taquicardias regulares de qrs ancho en pacientes con cardiopatias congenitas de adulto. Medtronic Ibérica S.A. 2019-Ongoning. Managment centre: FIBHULP
- **Pérez David E.** Caracterización de la fibrosis miocárdica en transposición de grandes vasos y ventrículo derecho sistémico mediante técnicas de imagen y biomarcadores moleculares y asociación con eventos adversos (PI22/00707). ISCIII. 2023-2025. Managment centre: FIBHULP
- **Pérez David E.** Fibrosis micocárdica en transposición de grandes vasos y ventrículo derecho sitémico: valoración mediante técnicas de imagen y asociación con clase funcional, biomarcadores de isuficiencia cardiaca y evento adversos. FIBHULP. 2022-Ongoning. Managment centre: FIBHULP
- **Riera del Moral LF.** Tratamiento celular de los aneurismas de aorta abdominal en un modelo murino. Jotec Cardiovascular S.L. 2017-Ongoning. Managment centre: FIBHULP

Clinical Trials

- **Antorrena Miranda MI.** easi-hf: ensayo de fase iii de superioridad, doble ciego, aleatorizado y con grupos paralelos para evaluar la eficacia y la seguridad del uso combinado de bi 690517 por vía oral y empagliflozina en comparación con placebo y empagliflozina en participantes con insuficiencia cardíaca sintomática (ic: clases ii-iv de la nyha) y fracción de eyección ventricular izquierda (fevi) ≥40 %".
  Type/Phase: III
  Sponsored by: Boehringer Ingelheim International GMBH
  Signature date: 17/09/2024
- **Antorrena Miranda MI.** estudio de fase iii, aleatorizado, doble ciego, con doble simulación, con grupos paralelos y comparativo con tratamiento activo para evaluar la eficacia y la seguridad de milvexian, un inhibidor oral del factor xia, en comparación con apixabán en participantes con fibrilación auricular.
  Type/Phase: III
  Sponsored by: Janssen Research & Development Llc
  Signature date: 26/11/2024
- **Antorrena Miranda MI.** estudio no intervencionista sobre el tratamiento con ácido bempedoico y/o su combinación de dosis fija con ezetimiba en la práctica clínica habitual en pacientes con hipercolesterolemia primaria o dislipidemia mixta.
  Type/Phase: EOm prospectivo
  Sponsored by: Daiichi-Sankyo Europe GMBH
  Signature date: 01/10/2024
- **Escobar Cervantes C.** riesgo cardiovascular de la población atendida por cardiólog.
  Type/Phase: EOm prospectivo
  Sponsored by: Fundación Casa Del Corazón;Sociedad Española De Cardiología (Sec)
  Signature date: 06/03/2024
- **Escobar Cervantes C.** tratamiento de pacientes dislipémicos con alto riesgo y muy alto riesgo para la prevención de eventos cardiovasculares en europa- estudio multinacional observacional (santorini).
  Type/Phase: EPA-SP
  Sponsored by: Daiichi-Sankyo Europe GMBH
  Signature date: 30/07/2024
- **Iniesta Manjavacas AM.** validación prospectiva de un modelo de predicción y score para el diagnóstico de amiloidosis cardiaca por transtiretina (t-amylo) - estudio provalta.
  Type/Phase: OTROS
  Sponsored by: Pfizer S.L.U.
  Signature date: 06/11/2024
- **Jiménez Valero S.** utilidad de los betabloqueantes en el syndrome de takotsubo: ensayo clínico aleatoriozado.
  Type/Phase: IV
  Sponsored by: Fundación Casa Del Corazón;Sociedad Española De Cardiología (Sec)
  Signature date: 19/11/2024
- **Jurado Román A.** balón liberador de fármaco o stent liberador de fármaco para el tratamiento de nódulos calcificados tras la aplicación de litotricia intravascular.
  Type/Phase: PRODUCTO SANITARIO
  Sponsored by: FIBHULP;Jurado Román Alfonso
  Signature date: 29/11/2024
- **Jurado Román A.** comparación entre tomografía de coherencia óptica y ecografía intravascular para lesiones intermedias de tronco coronario izquierdo estudio emperatriz epic36.

Type/Phase: PRODUCTO SANITARIO
Sponsored by: Fundación Epic
Signature date: 29/05/2024

- **Merino Llorens JL.** marcapasos para la bradicardia con modulación del intervalo av para el tratamiento de la tensión arterial.
  Type/Phase: PRODUCTO SANITARIO
  Sponsored by: Orchestra Biomed Inc.
  Signature date: 14/05/2024
- **Merino Llorens JL.** profid- prevention of sudden cardiac death after myocardial infarction by defibrillator im-plantation.
  Type/Phase: OTROS
  Sponsored by: Charite-Universitatsmedizin Berlin
  Signature date: 16/04/2024
- **Moreno Gómez JR.** a placebo-controlled, double-blind, randomized, phase 3 study to evaluate the effect of obicetrapib/ezetimibe fixed dose combinationdaily on coronary plaque characteristics in participants with atherosclerotic cardiovascular disease on coronary ctangiography (rembrandt trial).
  Type/Phase: III
  Sponsored by: Newamsterdam Pharma B.V.
  Signature date: 15/04/2024
- **Moreno Gómez JR.** efectos de ziltivekimab versus placebo en los resultados cardiovasculares en pacientes con infarto agudo de miocardio y evidencia angiográfica de enfermedad arterial coronaria.
  Type/Phase: IIIa
  Sponsored by: Novo Nordisk Pharma S.A.
  Signature date: 11/03/2024
- **Moreno Gómez JR.** efectos de ziltivekimab versus placebo en los resultados cardiovasculares en pacientes con infarto agudo de miocardio y evidencia angiográfica de enfermedad arterial coronaria.
  Type/Phase: IIIa
  Sponsored by: Novo Nordisk Pharma S.A.
  Signature date: 25/09/2024
- **Moreno Gómez JR.** ensayo aleatorizado de estrategias de revascularización completa de lesiones no culpables guiadas por fisiología frente a estrategias de revascularización completa de lesiones no culpables guiadas por angiografía en pacientes con infarto agudo de miocardio y enfermedad coronaria multivaso.
  Type/Phase: PRODUCTO SANITARIO
  Sponsored by: Hamilton Health Sciencies Corporation
  Signature date: 18/03/2024
- **Moreno Gómez JR.** ensayo clínico abierto, de fase 2b, para evaluar la tolerabilidad y seguridad de una dosis inicial de 5 mg de vericiguat en participantes con insuficiencia cardíaca crónica con fracción de eyección reducida.
  Type/Phase: IIb
  Sponsored by: Bayer Ag
  Signature date: 27/02/2024
- **Moreno Gómez JR.** ensayo de fase 2, adaptativo, doble ciego, controlado con placebo, aleatorizado y multicéntrico para evaluar la eficacia, seguridad y tolerabilidad de la infusión intracoronaria de ab-1002 en sujetos adultos con insuficiencia cardíaca de clase funcional III de la nyha (new york heart association) y miocardiopatía no isquémica (genephit).
  Type/Phase: II
  Sponsored by: Asklepios Biopharmaceutical (Askbio)
  Signature date: 22/11/2024
- **Moreno Gómez JR.** estudio clínico fundamental de fase 3, aleatorizado y controlado con placebo para evaluar la eficacia y la seguridad del estimulador de la gcs vericiguat/mk-1242 en adultos con insuficiencia cardíaca crónica con fracción de eyección reducida.
  Type/Phase: III
  Sponsored by: Merck Sharp And Dohme De España S.A.;Merck Sharp And Dohme De España S.A.
  Signature date: 15/11/2024
- **Moreno Gómez JR.** estudio de fase 2, doble ciego, aleatorizado, controlado con placebo, de 4 grupos para estudiar los síntomas, la funcionalidad, la calidad de vida relacionada con la salud y la seguridad de la administración subcutánea repetida de ponsegromab comparado con placebo en participantes adultos con insuficiencia cardíaca.
  Type/Phase: II
  Sponsored by: Pfizer Inc.
  Signature date: 22/05/2024
- **Moreno Gómez JR.** estudio de fase 3, aleatorizado y controlado con placebo para evaluar la eficacia y la seguridad de mk-0616 para reducir las complicaciones cardiovasculares graves en participantes con riesgo cardiovascular elevado.
  Type/Phase: III
  Sponsored by: Merck Sharp & Dohme Llc
  Signature date: 01/10/2024
- **Moreno Gómez JR.** estudio persevere. rct of high risk pulmonary embolism comparing flowtriever system vs standard of care.
  Type/Phase: PRODUCTO SANITARIO
  Sponsored by: Inari Medical Europe GMBH
  Signature date: 12/11/2024
- **Moreno Gómez JR.** hermes: efectos de ziltivekimab frente a placebo sobre la morbimortalidad en pacientes con insuficiencia cardíaca con fracción de eyección levemente reducida o preservada e inflamación sistémica.
  Type/Phase: III
  Sponsored by: Novo Nordisk A/S
  Signature date: 09/12/2024
- **Moreno Gómez JR.** investigación de la seguridad y el funcionamiento del sistema nvt allegra plus thv en pacientes con estenosis aórtica grave o bioprótesis aórtica quirúrgica fallida (empire ii).
  Type/Phase: PRODUCTO SANITARIO
  Sponsored by: Nvt GMBH
  Signature date: 25/03/2024
- **Moreno Gómez JR.** registro de dispositivos médicos vasculares de abbott (abbott vascular medical device registry av-mdr.
  Type/Phase: PRODUCTO SANITARIO
  Sponsored by: Sjm Coordination Center Bvba
  Signature date: 06/05/2024
- **Moreno Gómez JR.** tricus registry- seguimiento clínico retrospectivo, prospectivo y multicéntrico de pacientes con regurgitación tricúspidea severa tras tratamiento con el sistema de válvulas bicavales transcatéter tricvalve®.
  Type/Phase: PRODUCTO SANITARIO
  Sponsored by: P+F Products + Features GMBH
  Signature date: 13/05/2024
- **Ponz de Antonio I.** registro fine: utilidad clínica y seguridad de finerenona (antagonista de los receptores de mineralocoides) en pacientes con insuficiencia cardiaca.
  Type/Phase: EOm prospectivo
  Sponsored by: Sociedad Española De Cardiología (Sec)
  Signature date: 15/10/2024
- **Rey Blas JR.** ensayo aleatorizado para determinar la eficacia y seguridad de la finerenona en la morbimortalidad en pacientes con insuficiencia cardíaca con fracción de eyección ventricular izquierda superior o igual al 40 % hospitalizados debido a un episodio de insuficiencia cardíaca aguda descompensada (redefine-hf).
  Type/Phase: III
  Sponsored by: Cpc Clinical Research
  Signature date: 18/10/2024
- **Riera de Cubas L.** abdominal aortic aneurysm stabilization with truncal cells: controlled clinical trial with historical cohorts.
  Type/Phase: IIa
  Sponsored by: Grupo Dermatologico Y Estetico Pedro Jaen S.A.
  Signature date: 27/05/2024
- **Rosillo Rodríguez S.** estudio de supervivencia y eficacia del enfriamiento intranasal en la resucitación prehospitalaria 2.
  Type/Phase: PRODUCTO ALIMENTICIO
  Sponsored by: Karolinska Universitetssjukhuset
  Signature date: 04/11/2024

Patents and trademarks

- **Riera del Moral LF, inventor; FIBHULP, assignee.** Aortic endoprosthesis for the treatment of aneurysm. P201231638, PCT/ES2013/070712; 2012 October 24.
- **Filgueiras Rama D, López de Sá y Areses E, Millet Roig J, Calvo Saiz CJ, inventors; Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), FIBHULP, Universidad Politécnica de Valencia, assignees.** Method of predicting or prognosticating neurological performance in patients who have suffered a cardiac arrest and optionally comatose status due to ventricular fibrillation. PCT/EP2015/076893, EP3020333; 2014 November 17.
- **Castro Conde A, author; FIBHULP, assignee.** Trademark name: RECAR Programa de Rehabilitación Cardiaca; CM 18457042; 2021 April 20.

3.2.2 Coagulopathies and Alterations of Haemostasis Group

Publications: 30 | **Q1:**5

COMPOSITION

Víctor Manuel Jiménez Yuste.
Jefe de Servicio de Hematología. Hospital Universitario La Paz. Profesor Asociado. Universidad Autónoma de Madrid

- **María Teresa Álvarez Román.** *Jefa de Sección de Coagulopatías. Hospital Universitario La Paz Universidad Autónoma de Madrid*
- **Nora Viviana Butta Coll.** *Investigadora Senior Miguel Servet estabilizada. Jefe de Laboratorio. Hospital Universitario La Paz-IdiPAZ*
- **Hortensia de la Corte Rodríguez.** *Facultativo Especialista de Área en Hematología y Hemoterapia. Hospital Universitario La Paz*
- **Raquel Fernández Morata.** *Técnico de Laboratorio. Hospital Universitario La Paz-IdiPAZ*
- **Elena García Arias-Salgado.** *Investigadora. Hospital Universitario La Paz-IdiPAZ*
- **Sara García Barcenilla.** *Coordinadora de Estudios. Hospital Universitario La Paz-IdiPAZ*
- **Mercedes Gassior Kabat.** *Facultativo Especialista de Área en Hematología y Hemoterapia. Hospital Universitario La Paz*
- **Mónica Martín Salces.** *Facultativo Especialista de Área en Hematología y Hemoterapia. Hospital Universitario La Paz*
- **Elena Monzón Manzano.** *Investigadora Postdoctoral. Hospital Universitario La Paz-IdiPAZ*
- **Isabel Rivas Pollmar.** *Médico Adjunto en Hematología. Hospital Universitario La Paz*

STRATEGIC OBJETIVES

- This group's research activities address various relevant questions in the area of haematology and focus on the characterisation of the genetic and molecular basis of coagulation and haemostatic function. Our group investigates physiological processes such as coagulation, haemostasis, innate immunity, inflammation, cell adhesion and migration, and cell signalling, with special emphasis on their relevance to pathological processes.
- In addition, we perform epidemiological studies to facilitate patient data analysis and therapeutic treatment.

RESEARCH LINES

- Haemophilia A and B: Individualisation of treatment according to the characteristics of the patient
- Coagulopathies: New haemostatic treatments for bleeding disorders
- Disorders of haemostasia: thrombocytopenias, thrombocytosis, bleeding disorders, proinflammatory diseases
- Stem cell transplantation


RESEARCH ACTIVITY

Final Degree Theses

- **Ramírez Cassagne MC.** Valor predictivo del secuestro plaquetario y marcadores de superficie de respuesta terapéutica a esplenectomía en pacientes con trombocitopenia inmune[dissertation]. Madrid: Universidad Autónoma de Madrid: 2024(26/06/2024). Director: Jiménez Yuste V

Publications

- **Alvarez-Román MT, Jiménez-Yuste V, Martín-Salces M, De la Corte-Rodríguez H, Bonanad S, Núñez R, Fernández-Mosteirín N, García-Frade LJ, Martinoli C, Kim HK.** A post hoc comparative real-world analysis of HEAD-US score for joint health assessment of patients with severe haemophilia A and B in Spain. Haemophilia. 2024; 30(2): 513-22. Article. IF: 3.0; Q2
- **Álvarez-Román MT, Vazquez RJN, Hidalgo OB, París LQ, Urena LE, Jaime FJL, la De Corte-Rodríguez H, Dasi MG, Bosch P, Castellano MEM, Garaeta IG, Soto-Ortega I.** Humanistic burden of haemophilia A without inhibitors: A cross-sectional analysis of the HemoLIFE study. Haemophilia. 2024; 30(4): 950-8. Article. IF: 3.0; Q2
- **Blatny J, Astermark J, Catarino C, Dolan G, Fijnvandraat K, Hermans C, Holstein K, Jiménez-Yuste V, Klamroth R, Lavin M, Lenting PJ, Lobet S, Mancuso ME, Motwani J, O'Donnell JS, Königs C.** Future needs for continuing innovation in hemophilia: improving outcomes for individuals of all severities, including women and those in resource-constrained regions. Ther Adv Hematol. 2024; 15: 20406207241285100. Review. IF: 3.1; Q2
- **Calvo-Villas JM, Núñez-Vázquez R, Benítez-Hidalgo O, García-Díaz C, Galmés B, Carvalho M, Serrano-Torres P, Aznar-Salatti J, Álvarez-Román MT.** Switching hemophilia A patients to rVIII-SingleChain: The Iberian experience.



Medicine. 2024; 103(36): e39255. Article. IF: 1.4; Q2

- **Castaman G, Jiménez-Yuste V, Gouw S, D'Oiron R.** Outcomes and outcome measures. Haemophilia. 2024; 30: 112-9. Article. IF: 3.0; Q2
- **Castaman G, Peyvandi F, Hovinga JAK, Schutgens REG, Robson S, Moreno K, Jiménez-Yuste V.** Surgical Experience from the STASEY Study of Emicizumab Prophylaxis in People with Hemophilia A with Factor VIII Inhibitors. Th Open. 2024; 8(1): e42-4. Article. IF: 1.8; Q3
- **Chowdary P, Angchaisuksiri P, Apte S, Astermark J, Benson G, Chan AKC, Yuste VJ, Matsushita T, Nielsen ARH, Sathar J, Sutton C, Trakymiene SS, Tran H, Martínez LV, Wheeler AP, Windyga J, Young G, Zaw JJT, Eichler H, Haematol L.** Concizumab prophylaxis in people with haemophilia A or haemophilia B without inhibitors (explorer8): a prospective, multicentre, open-label, randomised, phase 3a trial. Lancet Haematol. 2024; 11(12): e891-e904. Article. IF: 17.7; D1
- **de la Corte-Rodríguez H, Rodríguez-Merchan EC, Álvarez-Román MT, Gómez-Cardero P, Jiménez-Yuste V.** Ultrasound-guided joint procedures in hemophilia: technique, indications and tips. Expert Rev Hematol. 2024; 17(8): 419-30. Article. IF: 2.1; Q3
- **Hurtado FNY, Manzano EM, Viana-Huete V, Junco PT, Álvarez-Román MT, Arias-Salgado EG, Butta N, Gutierrez JCL.** Assessing coagulopathy and endothelial dysfunction in pediatric venous malformation: A thromboelastometry and syndecan-1 study. Pediatr Blood Cancer. 2024; 71(5): e30915. Article. IF: 2.3; Q2
- **Jiménez-Yuste V, Álvarez-Román MA, Berrueco R, Bonanad S, Calvo-Villas JM, González-González R, Porras JRG, Núñez-Vázquez RJ, Rodríguez-López M.** Management of Urgent Bleeding in Patients with Hemophilia A: Focus on the Use of Emicizumab. Th Open. 2024; 8(2): e194-e201. Review. IF: 1.8; Q3
- **Jiménez-Yuste V, Oldenburg J, Tzeng E, Lim E, Sanabria F, Mahlangu J.** Emicizumab is efficacious in people with hemophilia A with comorbidities aged ≥50 years: analysis of 4 phase III trials. Res Pract Thromb Haemost. 2024; 8(3): e102405. Article. IF: 3.4; Q2
- **Kabat MG, Li Y, Galán V, Mozo Y, Sisinni L, Bueno-Sánchez D, Corral D, Naik S, Echecopar C, Aguirre-Portolés C, Al-Akioui-Sanz K, De Paz R, Marcos A, Romero AB, Talleur A, Yuste VJ, Triplett B, Pérez-Martínez A.** Safety and Efficacy of High-Dose Memory CD45RO+Donor Lymphocyte Infusion in Pediatric Recipients after Hematopoietic Stem Cell Transplantation. Cytotherapy. 2024; 26(12): 1458-64. Article. IF: 3.2; Q2
- **Kiialainen A, Adamkewicz JI, Petry C, Oldenburg J, Pipe SW, Young G, Mahlangu J, Lehle M, Niggli M, Castaman G, Jiménez-Yuste V, Shima M, Négrier C, Schmitt C.** Pharmacokinetics and coagulation biomarkers in children and adults with hemophilia A receiving emicizumab prophylaxis every 1, 2, or 4 weeks. Res Pract Thromb Haemost. 2024; 8(1): e102306. Article. IF: 3.4; Q2
- **Klukowska A, Sidonio RF, Young G, Mancuso ME, alvarez-Román MT, Bhatnagar N, Jansen M, Knaub S.** Simoctocog alfa (Nuwiq®) in children: early steps in life's journey for people with severe hemophilia A. Ther Adv Hematol. 2024; 15: 20406207241245500. Review. IF: 3.1; Q2
- **Königs C, Motwani J, Jiménez-Yuste V, Blatny J.** Teenagers and Adolescents with Hemophilia-Need for a Specific Approach. J Clin Med. 2024; 13(17): 5121. Review. IF: 2.9; Q1
- **Mahlangu J, Jiménez-Yuste V, Ventriglia G, Niggli M, Barlera S, Hermans C, Lehle M, Chowdary P, Jew L, Windyga J, Frenzel L, Schmitt C, Castaman G, Pipe SW.** Long-term outcomes with emicizumab in hemophilia A without inhibitors: results from the HAVEN 3 and 4 studies. Res Pract Thromb Haemost. 2024; 8(2): e102364. Article. IF: 3.4; Q2
- **Manuel JMCV, López MR, Tovar JC, Boix SB, Calatayud JCR, Alvarez-Román MT.** Suitability and readiness assessment of organizational resources for the implementation of gene therapy in hemophilia in Spain and Portugal: A survey-based study. Thromb Res. 2024; 244: 109180. Letter. IF: 3.4; Q2
- **Martínez-López J, de la Cruz J, Gil-Manso R, Yuste VJ, Aspa-Cilleruelo JM, Escobar CE, López-Jiménez J, Duarte R, Yerovi CJ, Hernández-Rivas JA, Herraez R, Quiroz-Cervantes K, Bustelos-Rodríguez R, Benavente C, Barranco PM, Oteiro MB, Alegre A, Pérez-Oteyza J, Ruiz E, Marcheco-Pupo EA, Cedillo A, Alvarez TD, Ramirez PG, Trillo RA, Herrera P, Casado MLB, Barea AA, De Bustamante JMM, Ortiz J, Robles MC, Garcia-Suarez J, Picardi M.** COVID-19 Outcomes in Patients with Hematologic Malignancies in the Era of COVID-19 Vaccination and the Omicron Variant. Cancers (Basel). 2024; 16(2): 379. Article. IF: 4.4; Q2
- **Meijón-Ortigueira MD, Álvarez-Román MT, de la Corte H, Butta N, Jiménez-Yuste V.** Predicting joint involvement through tailored prophylaxis in severe haemophilia A, is it possible?. Haemophilia. 2024; 30(3): 678-84. Article. IF: 3.0; Q2
- **Miesbach W, Boban A, Chowdary P, Coppens M, Crato M, Jiménez-Yuste V, Klamroth R, Makris M, Mulders G, Peyvandi F.** Administration of gene therapy for haemophilia - The hub and spoke model and its regional differences and challenges. Haemophilia. 2024; 30(3): 855-7. Letter. IF: 3.0; Q2
- **Miesbach W, Boban A, Chowdary P, Coppens M, Crato M, Jiménez-Yuste V, Klamroth R, Makris M, Mulders G, Peyvandi F.** EAHAD haemophilia gene therapy clinical outcome database (EAHAD-GTD). Haemophilia. 2024; 30(3): 852-4. Letter. IF: 3.0; Q2
- **Miesbach W, Carcao M, Mahlangu J, Dargaud Y, Jiménez-Yuste V, Hermans C.** Eptacog beta for the management of patients with haemophilia A and B with inhibitors: A European perspective. Haemophilia. 2024; 30(2): 257-66. Review. IF: 3.0; Q2
- **Pascual-Izquierdo C, Sánchez-González B, Canaro-Hirnyk MI, García-Donas G, Menor-Gómez M, Gil-Fernández JJ, Monsalvo-Saornil S, de-Laiglesia A, Álvarez-Román MT, Jarque-Ramos I, Llácer MJ, Pedrote-Amador B, Zafra-Torres D, Caparrós-Miranda I, Ortúzar-Pasalodos A, Revilla-Calvo N, Bastida-Bermejo JM, Chica-Gullón E, Alvarellos M, Jiménez-Bárcenas R, Bernat S, Martínez-Carballeira D, Lakhwani S, López-Ansoar E, Moreno-Beltrán ME, Lorenzo-Vizcaya A, Aguirre MA, Lasa-Eguialde M, Canet M, González-Gascón-y-Marín IT, Caballero-Navarro G, Cuesta A, Díaz-López M, Arquero T, Moreno-Carbonell M, Mingot-Castellano ME.** Avatrombopag in immune thrombocytopenia: A real-world study of the Spanish ITP Group (GEPTI). Am J Hematol. 2024; 99(12): 2328-9. Article. IF: 9.9; Q1
- **Pipe SW, Collins P, Dhalluin C, Kenet G, Schmitt C, Buri M, Jiménez-Yuste V, Peyvandi F, Young G, Oldenburg J, Mancuso ME, Kavakli K, Kiialainen A, Deb S, Niggli M, Chang T, Lehle M, Fijnvandraat K.** Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial. Blood. 2024; 143(14): 1355-64. Article. IF: 23.1; D1
- **Quintana-Castanedo L, Sánchez-Ramon S, Maseda R, Illera N, Pérez-Conde I, Molero-Luis M, Butta N, Arias-Salgado EG, Monzón-Manzano E, Zuluaga P, Martínez-Santamaría L, Fernández-Arquero M, Llames SG, Meana A, de Lucas R, del Río M, Vicente A, Escámez MJ, Sacedón R.** Unveiling the value of C-reactive protein as a severity biomarker and the IL4/IL13 pathway as a therapeutic target in recessive dystrophic epidermolysis bullosa: A multiparametric cross-sectional study. Exp Dermatol. 2024; 33(8): e15146. Article. IF: 3.1; Q2
- **Raventós A, Arias-Salgado EG, Pérez A, Alvarez-Román MT, Butta NV, Manzano EM, Acuña P, Jiménez-Yuste V, Costa M, Bravo MI.** Ex vivo evaluation of the effect of plasma-derived factor VIII/von Willebrand factor in patients with severe hemophilia A on emicizumab prophylaxis. Clin Exp Med. 2024; 25(1): 14. Article. IF: 3.5; Q2
- **Rodríguez-Merchan EC, de la Corte-Rodríguez H, Gómez-Cardero P, Alvarez-Román MT, Jiménez-Yuste V.** Arthroscopic ankle surgery in people with haemophilia. Haemophilia. 2024; 30(2): 286-94. Review. IF: 3.0; Q2
- **Román MTA, Pollmar MIR, de la Corte-Rodríguez H, Gómez-Cardero P, Rodríguez-Merchán EC, Gutierrez-Alvariño M, Garcia-**



Pérez E, Martín-Salces M, Zagrean D, Butta-Coll NV, Jiménez-Yuste V. Knee replacement surgery in a patient with acquired von Willebrand disease: a case study with recommendations for patient management. Ann Med Surg (Lond). 2024; 86(3): 1681-6. Article. IF: 1.6; Q2

- **Tyrrell PN, Álvarez-Román MT, Bakeer N, Brand-Staufer B, Jiménez-Yuste V, Kras S, Martinoli C, Méndez M, Nagao A, Ozelo M, Ricciardi JBS, Zak M, Roth J.** Utilizing artificial intelligence for the detection of hemarthrosis in hemophilia using point-of-care ultrasonography. Res Pract Thromb Haemost. 2024; 8(8): e102602. Article. IF: 3.4; Q2
- **Vandewalle B, Castaman G, Álvarez-Román MT, Ettingshausen CE, Nemes L, Tomic R, Martins P, Rodrigues JF, Pinachyan K.** Pharmacokinetic model-based assessment of factor IX prophylaxis treatment regimens in severe hemophilia B. Sci Rep-Uk. 2024; 14(1): 20534. Article. IF: 3.9; Q1

Research projects

- **Álvarez Román MT.** Análisis descriptivo de los resultados del tratamiento en el mundo real con damoctocog alfa pegol en comparación con el tratamiento anterior (Dacopri). Bayer Consumer Care A.G. 2021-Ongoing. Managment centre: FIBHULP
- **Álvarez Román MT.** Experiencias reales en la práctica clínica con elocta. Swedish Orphan Biovitrum A.B. 2019-Ongoing. Managment centre: FIBHULP
- **Álvarez Román MT; Butta Coll NV.** Fenotipo clínico y respuesta a agonistas de receptores de trombopoyetina en pacientes ancianos con trombocitopenia inmune (PI22/01489). ISCIII. 2023-2025. Managment centre: FIBHULP
- **Álvarez Román MT.** Hemolution: Estudio observacional ambisprectivo para evaluar la efectividad y seguridad del tratamiento con emicizumab de pacientes con hemofilia a en condiciones de practica clinica habitual ML41684. Olga Roche Losada . 2019-Ongoing. Managment centre: FIBHULP
- **Álvarez Román MT.** Monitorización del efecto hemostático de concentrados de derivados plasmáticos de FVW/FVIII para la enfermedad de von willebrand utilizando un sistema de cámara de flujo de microfluidos. Grifols S.A. 2022-Ongoing. Managment centre: FIBHULP
- **Álvarez Román MT.** Programa del tratamiento multidisciplinario del paciente con hemofilia. Omnix Pharma S.L. 2017-Ongoing. Managment centre: FIBHULP
- **Álvarez Román MT.** Puesta en marcha y realización del estudio clínico ML40944 Hemolife: un estudio observacional de calidad de vida en personas con hemofilia a y cuidadores (no definitivo) y el estudio: Hemolution: estudio observacional ambispectivo para evaluar la eficacia y seguridad del tratamiento en emicizumab de pacientes con hemofilia a en condiciones práctica clinica habitual (no definitivo). Roche Farma S.A. 2018-Ongoing. Managment centre: FIBHULP
- **Butta Coll NV.** Desarrollo de nanosistemas para eliminar la respuesta inmune contra el factor VIII en ratones con hemofilia grave e inhibidores:un estudio de prueba de concepto para el diseño de nuevos protocolos de tolerancia inmune en pacientes con hemofilia. Real Fundación Victoria Eugenia. 2018-Ongoing. Managment centre: FIBHULP
- **Butta Coll NV.** Determinación de los niveles y actividad de TFPI en el plasma de pacientes con alteración hemostática no filiada. Novo Nordisk Pharma S.A. 2020-Ongoing. Managment centre: FIBHULP
- **Butta Coll NV.** Estudio de la hemostasia en la enfermedad de Behçet. Baxter S.L. 2011-Ongoing. Managment centre: FIBHULP
- **Butta Coll NV.** Evaluación del efecto procoagulante in vitro de concentrados de factor IX en pacientes en profilaxis con emicizumab. CSL Behring S.A. 2021-Ongoing. Managment centre: FIBHULP
- **Butta Coll NV.** Fenotipo clínico y respuesta ancianos con trombocitopenia inmune. FIBHULP. 2022-Ongoing. Managment centre: FIBHULP
- **Butta Coll NV.** Role of platelet glycosylation on platelet function and immune response in immune thrombocytopenia patients (PI19/00772). ISCIII. 2020-2024. Managment centre: FIBHULP
- **García Barcenilla S.** Puesta en marcha del estudio clinico con codigo:ML42270: estudio observacional para evaluar las estrategias de afrontamiento del dolor crónico en pacientes con hemofilia a desde el punto de vista de enfermería (no definitivo). Roche Farma S.A. 2020-Ongoing. Managment centre: FIBHULP
- **Jiménez Yuste VM.** Aplicación de inteligencia artificial para detectar de hemorragias articulares en pacientes con hemofilia. Novo Nordisk Health Care A. G. 2022-Ongoing. Managment centre: FIBHULP
- **Jiménez Yuste VM.** Asesoramiento para la puesta en marcha del estudio de fase 3 sin enmascaramiento y de un solo grupo para evaluar la eficacia y la seguridad de pf-07055480 (terapia génica con el vaa2/6 recombinante/ factor VIII humano) en varones adultos con hemofilia a entre moderadamente grave y grave (FVIII: c<1%". Parexel International Limited. 2022-Ongoing. Managment centre: FIBHULP

- **Jiménez Yuste VM; García Arias-Salgado E.** Desarrollo de nuevas estrategias para mejorar el manejo terapeútico de los pacientes con hemofilia a en presencia de inhibidor (PI22/01461). ISCIII. 2023-2025. Managment centre: FIBHULP
- **Jiménez Yuste VM.** Desarrollo de un nuevo método de laboratorio de alta sensibilidad para la detección cuantitativa de anticuerpos contra el factor VIII. Pfizer S.L.U. 2012-Ongoing. Managment centre: FIBHULP
- **Jiménez Yuste VM.** Estudio del papel de los biomarcadores de daño endotelial, hepatocelular y fibrosis hepatica y la elastografia de transición en el diagnostico del sindrome de obstrucción sinusoidal. Jazz Pharmaceuticals Iberia S.L. 2015-Ongoing. Managment centre: FIBHULP
- **Jiménez Yuste VM.** Estudio in vitro del efecto procoagulante de factor VII recombinante activado y vatreptacog alfa en sangre de pacientes con hemofilia grave mediante tromboelastografía y test de generación de tromina. Novo Nordisk A/S. 2012-Ongoing. Managment centre: FIBHULP
- **Jiménez Yuste VM.** Estudio in vitro del efecto procoagulante de feibar en pacientes en profilaxis con emicizumab. Takeda Pharmaceutical International A. G. 2020-Ongoing. Managment centre: FIBHULP
- **Jiménez Yuste VM.** Field study to evaluate the activity a site specific of b-domain deleted pegylated recombinant FVIII protein (BAY 94-9024) in plasma samples measured with both chromogenic and one stage assays used in clinical laboratories Bayer Hispania S.L.. 2015-Ongoing. Managment centre: FIBHULP
- **Jiménez Yuste VM.** Individualización de la profilaxis: estudio de los niveles valles mediante técnicas globales e impacto de la actividad fisica. World Federation of Hemophilia. 2015-Ongoing. Managment centre: FIBHULP
- **Jiménez Yuste VM.** Iniciativas confihe: profilaxis personalizada: estudios prospectivos de la influencia de los parámetros farmacocinéticos individuales, test globales de la coagulación y actividad deportiva en la eficacia de la profilaxis. Mk Media S.L. 2017-Ongoing. Managment centre: FIBHULP
- **Jiménez Yuste VM.** Monitorización del tratamiento con agentes bypass, en pacientes con hemofilia e inhibidor mediante tres métodos de evaluación global de la hemostasia. Sanofi Aventis S.A. 2007-Ongoing. Managment centre: FIBHULP
- **Jiménez Yuste VM.** Sinovitis post-hemartros. Estudio clínico, biológico y ecográfico. Post-hemarthrosis sinovitis markers on patients with haemophilia on prophilaxis. clinical, biological and ultrasonographic stuyd. Pfizer S.L.U. 2012-Ongoing. Managment centre: FIBHULP
- **Rivas Pollmar MI.** Evaluación de la carga asistencial de enfermería durante el uso de bombas de infusión intravenosa programables para la administración frecuente de bolos de RFVIIA. Novo Nordisk Pharma S.A. 2020-Ongoing. Managment centre: FIBHULP
- **Rivas Pollmar MI.** Individualización de la profilaxis en pacientes pediátricos con hemofilia a grave mediante estudio farmacocinético y farmacodinámico en tratamiento con productos de vida media estándar y vida media extendida. Swedish Orphan Biovitrum S.L. 2020-Ongoing. Managment centre: FIBHULP
- **Jiménez Yuste VM.** Head-Us Mobile App: Desingn and implementation. Pfizer S.L.U. 2017-Ongoing. Managment centre: FIBHULP

Clinical Trials

- **Álvarez Román MT.** nuwiq for perioperative management of patients with haemophilia a on emicizumab regular prophylaxis study (nupower).
  Type/Phase:
  Sponsored by: Octapharma Ag
  Signature date: 30/05/2024
- **Álvarez Román MT.** nuwiq dosing and outcomes in the management of women/girls with haemophilia a needing fviii treatment for surgery – an international, open-label, non-controlled study (nudimension).
  Type/Phase: IV
  Sponsored by: Octapharma Ag
  Signature date: 30/05/2024
- **Álvarez Román MT.** estudio transversal para evaluar la percepción de la actividad física en pacientes con hemofilia a tratados con emicizumab. estudio hemo-act.. Type/Phase: EOm prospectivo; Sponsored by: Roche Farma S.A. ;Signature date: 05/03/2024
- **Jiménez Yuste VM.** estudio en fase iii, aleatorizado, doble ciego, controlado con placebo de acalabrutinib en combinación con rituximab, ciclofosfamida, doxorrubicina, vincristina y prednisona (r-chop) en pacientes ≤65 años con linfoma difuso de células b grandes sin centro germinal no tratado previamente.
  Type/Phase: III
  Sponsored by: Acerta Pharma B.V
  Signature date: 12/01/2024
- **Jiménez Yuste VM.** estudio abierto de extensión para evaluar la seguridad a largo plazo, la tolerabilidad y la eficacia de marstacimab en profilaxis en pacientes con hemofilia a grave (actividad del factor de coagulación <1 %) con o sin inhibidores o en pacientes con hemofi.
  Type/Phase: III
  Sponsored by: Pfizer S.L.U.
  Signature date: 23/02/2024
- **Álvarez Román MT.** estudio abierto, multinacional de profilaxis con fitusiran en pacientes pediátricos varones de 1 a menos de 12 años de edad con hemofilia a o b.
  Type/Phase: II
  Sponsored by: Sanofi Aventis S.A
  Signature date: 22/04/2024
- **Jiménez Yuste VM; López de la Guia A.** estudio de fase 3, de dos etapas, aleatorizado, multicéntrico, abierto, para comparar cc-92480 (bms-986348), carfilzomib y dexametasona (480kd) frente a carfilzomib y dexametasona (kd) en participantes con mieloma múltiple en recidiva o refractario (mmrr).
  Type/Phase: III
  Sponsored by: Celgene Corporation
  Signature date: 23/05/2024
- **Gasior Kabat M.** estudio de fase ii abierto para evaluar la seguridad, tolerabilidad, farmacocinética y eficacia de ker-050 en monoterapia o en combinación con ruxolitinib en participantes con mielofibrosis.
  Type/Phase: II
  Sponsored by: Keros Therapeutics Inc.
  Signature date: 09/04/2024
- **Álvarez Román MT.** estudio de fase 4, intervencionista, sin enmascaramiento, de 12 meses de duración, en europa (shine), para investigar la evolución de la hipertrofia sinovial identificada mediante ecografía articular y resonancia magnética en pacientes con hemofilia a en tratamiento profiláctico con efanesoctocog alfa.
  Type/Phase: IV
  Sponsored by: Swedish Orphan Biovitrum Ab
  Signature date: 26/11/2024
- **Álvarez Román MT.** analisis integral del tratamiento de la hemofilia en españa y portugal.
  Type/Phase: EPA-OD
  Sponsored by: Álvarez Román María Teresa;Novo Nordisk A/S
  Signature date: 29/08/2024
- **Jiménez Yuste VM.** estudio abierto en participantes pediátricos (<18 años de edad) con hemofilia a severa (actividad del factor de coagulación <1 %) con o sin inhibidores, o con hemofilia b de moderadamente severa a severa (actividad del factor de coagulación ≤2 %) con o sin inhibidores, que compara 12 meses de tratamiento estándar histórico con la profilaxis con marstacimab.
  Type/Phase: III
  Sponsored by: Pfizer Inc.
  Signature date: 02/07/2024
- **Gasior Kabat M.** estudio de fase ii abierto para evaluar la seguridad, tolerabilidad, farmacocinética y eficacia de ker-050 en monoterapia o en combinación con ruxolitinib en participantes con mielofibrosis.
  Type/Phase: II
  Sponsored by: Keros Therapeutics Inc.
  Signature date: 14/10/2024

Patents and trademarks

- **Nora Butta JY.** Trademark name: WELCOME von willebrand active e-learnig course. CM M4190835; 2022 November 8.
- **Arias-Salgado, MT Álvarez Román, V Jiménez Yuste, N Butta Coll, García Rivera Francisco Julián, García Rivera Mª Carmen, Carballo García Mª Ángeles, inventors.** FIBHULP, García Rivera Mª Carmen, Carballo García Mª Ángeles, asignees. Dispositivo de recogida de muestras biológicas. P202230651. 2022 July 22.

3.2.3 Vascular Physiology and Pharmacology Group

Publications: 7 | **Q1:**6

COMPOSITION

Ana María Briones Alonso.
Profesora Titular. Dpto. Farmacología, Facultad de Medicina. Universidad Autónoma de Madrid

- **María Jesús Alonso Gordo.** *Catedrática. Departamento de Ciencias Básicas de la Salud. Facultad de Ciencias de la Salud. Universidad Rey Juan Carlos*
- **Constanza Ballesteros Martínez.** *Investigadora Predoctoral. Universidad Autónoma de Madrid*
- **María Teresa Barrús Ortiz.** *Profesora Contratada doctor. Departamento de Ciencias de la Salud. Facultad de Ciencias de la Salud. Universidad Rey Juan Carlos*
- **Javier Blanco Rivero.** *Profesor Titular. Departamento de Fisiología. Facultad de Medicina. Universidad Autónoma de Madrid*
- **Naoual Boukich El Houari.** *Investigadora Predoctoral. Universidad Autónoma de Madrid*
- **Ana Belén García Redondo.** *Profesora Permanente Laboral. Departamento de Fisiología. Facultad de Medicina. Universidad Autónoma de Madrid*
- **Raquel González Blázquez.** *Investigadora Postdoctoral. Universidad San Pablo CEU*
- **Zoe González Carnicero.** *Profesora Ayudante Doctor Departamento de Ciencias de la Salud. Facultad de Ciencias de la Salud. Universidad Rey Juan Carlos*
- **Raquel Hernanz Martín.** *Profesora Titular. Departamento de Ciencias Básicas de la Salud. Facultad de Ciencias de la Salud. Universidad Rey Juan Carlos*
- **Ángela Martín Cortes.** *Profesora Contratada Doctor. Departamento de Ciencias de la Salud. Facultad de ciencias de la Salud. Universidad Rey Juan Carlos*
- **Marta Martínez Casales.** *Profesora Ayudante Doctor Departamento de Ciencias de la Salud. Facultad de Ciencias de la Salud. Universidad Rey Juan Carlos*
- **Abraham Merino López.** *Ayudante de Investigación. Universidad Autónoma de Madrid*
- **Marta Miguel Castro.** *Científico Titular. Instituto de Investigación en Ciencias de la Alimentación Consejo Superior de Investigaciones Científicas*
- **Roberto Palacios Ramírez.** *Investigador Postdoctoral. Universidad de Valladolid*
- **Raquel Rodrígues Díez.** *Profesora Ayudante Doctor. Departamento de Fisiologíaa. Facultad de Medicina. Universidad Complutense*
- **Mercedes Salaices Sánchez.** *Catedrática. Departamento de Farmacología. Facultad de Medicina. Universidad Autónoma de Madrid*
- **Lucía Serrano Díaz del Campo.** *Investigadora predoctoral. Universidad Autónoma de Madrid*



STRATEGIC OBJETIVES

- Our group is a well-established research group with more than 30 years of experience in the study of the mechanisms involved in the functional, structural and mechanical alterations of the vasculature in various cardiovascular pathologies such as ageing, diabetes and, in particular, hypertension.
- The group is located at the Faculty of Medicine (UAM) and maintains research collaborations with investigators at various universities in Spain and in other countries. Our main objective is to gain further insight into the physiological and molecular mechanisms involved in alterations of resistance and conductance arteries in cardiovascular pathologies. To conduct our research, we generally use various experimental approaches including in vivo animal models, ex vivo experiments and in vitro cellbased studies combined with physiological, pharmacological and molecular biology techniques. In addition, we have begun to translate this knowledge into human studies. In terms of the mediators involved, we have a particular interest in proinflammatory prostanoids, reactive oxygen species (and their interaction among each other or with other mediators such as nitric oxide) and proresolvin lipid mediators. This research is important given the essential role these mediators play in the control of vascular smooth muscle tone and vascular structure.

RESEARCH LINES

- Inflammation and vascular function and remodelling. Changes with hypertension and other cardiovascular pathologies.
- Adipose tissue and vascular alterations in cardiovascular pathologies.
- Neural control of vascular tone.
- Cardiovascular effects of heavy metals.
- Antioxidant and antihypertensive properties of food bioactive compounds.
- Resolution of inflammation as a therapeutic approach for cardiovascular diseases
- Effect of gut microbiota modulation in different physiopathological sitiuations
- Cardiovascular effects of antineoplasic drugs on menopause
- GLP-1 and ACE2 as new targets for the treatment of hypertension in menopause

RESEARCH ACTIVITY

Doctoral Theses

- **Faedda N.** Interacciones vasculares y hormonales en la corteza suprarrenal[dissertation]. Paris; Madrid: Universitad Paris Cité; Universidad Autónoma de Madrid: 2024(04/12/2024. Director: Briones Alonso AM
- **Bruna García E.** Obtención de un nuevo ingrediente funcional derivado de la grasa de jamón ibérico. Análisis y caracterización [dissertation]. Madrid: Universidad Autónoma de Madrid: 2024 (29/11/2024). Director: Miguel Castro M, Isabel Redondo B.

Master Theses

- **Arrúa Baez W.** Resolvind D2 protects the heart of obese hypertensive mice by decreasing hypertrophy and fibrosis without affecting endoplasmic reticulum stress[dissertation]. Madrid: Universidad Autónoma de Madrid: 2024(26/06/2024). Director: Briones Alonso AM, García Redondo AB.

Final Degree Theses


- **Sobreviela Sánchez S.** Efecto cardiovascular de la suplementación deportiva vasodilatadora [dissertation]. Madrid: Universidad Autónoma de Madrid: 2024(26/06/2024). Director: García Redondo AB.
- **Mora Benítez R.** Flexibilidad metabólica y rendimiento deportivo durante el ayuno y dieta cetogénica [dissertation]. Madrid: Universidad Autónoma de Madrid: 2024(26/06/2024). Director: Blanco Rivero J.

Publications

- **Avendaño MS, Perdices-López C, Guerrero-Ruiz Y, Ruiz-Pino F, Rodríguez-Sánchez AB, Sánchez-Tapia MJ, Sobrino V, Pineda R, Barroso A, Correa-Saez A, Lara-Chica M, Fernández-Garcia JC, García-Redondo AB, Hernanz R, Ruiz-Cruz M, García-Galiano D, Pitteloud N, Calzado MA, Briones AM, Vázquez MJ, Tena-Sempere M.** The evolutionary conserved miR-137/325 tandem mediates obesity-induced hypogonadism and metabolic comorbidities by repressing hypothalamic kisspeptin. Metabolism. 2024; 157: 155932. Article. IF: 11.9; D1
- **Ballester-Servera C, Alonso J, Cañes L, Vázquez-Sufuentes P, García-Redondo AB, Rodríguez C, Martínez-González J.** Lysyl Oxidase in Ectopic Cardiovascular Calcification: Role of Oxidative Stress. Antioxidants. 2024; 13(5): 523. Article. IF: 6.6; Q1
- **Díaz-Pérez A, Lope-Piedrafita S, Pérez B, Vázquez-Sufuentes P, Rodríguez-Garcia M, Briones AM, Navarro X, Penas C, Jiménez-Altayó F.** Transient cerebral ischaemia alters mesenteric arteries in hypertensive rats: Limited reversal despite suberoylanilide hydroxamic acid cerebroprotection. Life Sci. 2024; 359: 123247. Article. IF: 5.1; Q1
- **dos Passos RR, Santos CV, Priviero F, Briones AM, Tostes RC, Webb RC, Bomfim GF.** Immunomodulatory Activity of Cytokines in Hypertension: A Vascular Perspective. Hypertension. 2024; 81(7): 1411-23. Review. IF: 8.2; D1
- **Martínez-Casales M, Hernanz R, González-Carnicero Z, Barrús MT, Martín A, Briones AM, Michalska P, León R, Pinilla E, Simonsen U, Alonso MJ.** The Melatonin Derivative ITH13001 Prevents Hypertension and Cardiovascular Alterations in Angiotensin II-Infused MiceS. J Pharmacol Exp Ther. 2024; 388(2): 670-87. Article. IF: 3.8; Q2
- **Mohaissen T, Kij A, Bar A, Marczyk B, Wojnar-Lason K, Buczek E, Karas A, García-Redondo AB, Briones AM, Chlopicki S.** Chymase-independent vascular Ang-(1-12)/Ang II pathway and TXA2 generation are involved in endothelial dysfunction in the murine model of heart failure. Eur J Pharmacol. 2024; 966: 176296. Article. IF: 4.7; Q1
- **Rodrigues-Díez R, Ballesteros-Martínez C, Moreno-Carriles RM, Nistal F, del Campo LSD, Cachofeiro V, Dalli J, García-Redondo AB, Redondo JM, Salaices M, Briones AM.** Resolvin D2 prevents vascular remodeling, hypercontractility and endothelial dysfunction in obese hypertensive mice through modulation of vascular and proinflammatory factors. Biomed Pharmacother. 2024; 174: 116564. Article. IF: 7.5; D1

Research projects

- **Alonso Gordo MJ.** GLP-1 y ECA2 como nuevas dianas para el tratamiento de la hipertensión en la menopausia. Programa Propio URJC. 2025-2025. Managment centre: URJC
- **Blanco Rivero J.** Efecto bivalente de la suplementación con un concentrado de kiwi en la digestión-absorción proteica y microbiota intestinal. Pharmactive Biotech Products. 2024-2026. Managment centre: Fundación UAM
- **Blanco Rivero J.** Efecto de la suplementación con un extracto de kiwi sobre la digestibilidad y absorción de proteínas de origen vegetal. Programa de Fomento de Trasferencia del Conocimiento UAM. 2024-2026. Managment centre: Fundación UAM
- **Briones Alonso AM, UngerT (University of Maastricht).** Mechanistic Integration of vascular aND endocrine pathways for Subtyping Hypertension: an Innovative network approach for Future generation research Training-MINDSHIFT (Grant agreement 954798). Marie Sklodowska-Curie actions. Innovative Training Networks (ITN)-European Joint Doctorates . 2021-2025. Managment centre: UAM
- **Briones Alonso AM.** Deciphering the role of novel inflammatory mediators derived from interferon and the inefficient resolution of inflammation in the cardiovascular damage associated to hypertension (PID2020-116498RB-I00). AEI. 2021-2025. Managment centre: UAM
- **Briones Alonso AM.** Papel del gen 15 estimulado por interferon (ISG15) en el remodelado vascular patológico. Sociedad Española de Aterosclerosis. 2022-2024. Managment centre: UAM
- **Briones Alonso AM.** Restaurando el balance: mediadores proresolutivos especializados para la resolución de la inflamación y la reparación vascular en humanos con alto riesgo cardiovascular (AC23_2/00044). ERA4Health EU / ISCIII. 2024-2026. Managment centre: FIBHULP
- **Briones Alonso AM.** Targeting SGK1: Bridging therapies for Parkirson and Cardiovascular diseases (SGK1-4PDCAR). CiberCV. 2024-2026. Managment centre: CiberCV
- **López-Miranda V.** Menopausia: ¿un factor de riesgo para el desarrollo de hipertensión secundaria al tratamiento antitumoral? Instituto de las Mujeres. 2024-2025. Managment centre: URJC
- **Miguel Castro, M.** Envejecimiento saludable. Hidrolizados de proteínas alimentarias multifuncionales como abordaje terapéutico en el síndrome de sarcopenia. SARCOPEP (PID2022-138610OB-I00). Ministerio de Ciencia e Innovacion. 2023-2026. Managment centre: CIAL (CSIC-UAM)
- **Rodrigues Díez R.** Extracellular microvesicles from mesenchimal stem cells enriched with Omega-3 polyunsaturated fatty acids as



therapeutic tool for renal disease. CiberCV. 2024-2026. Managment centre: CiberCV

Ciber y Retics

- **Briones Alonso AM.** Centro de Investigación Biomédica en Red Enfermedades Cardiovaculares (CIBERCV)(CB16/11/00286). IISCIII. (31/12/2024). UAM


Patents and Trademarks

- **Pérez Girón JV, Ruiz-Castellanos MJ, de Luis Jiménez O, Pérez Boto V, Sanz González R, Hernández Vélez MC, Mas Gutiérrez JA, Alonso Gordo MJ, Salaíces Sánchez M, Ros Pérez M, Coloma Jerez A, Asenjo Barahona A, Sanz Montaña JL, Puente Prieto J, Jensen J, inventors; NANOATE, S.**L., assignee. Method for producing biosensors. P201031224, PCT/ES2011/070536; 2010 August 05.
- **Miguel Castro M, López-Alonso Fandiño R, Recio Sánchez MI, Ramos González MM, Aleixandre de Artiñano A, inventors; CSIC, assignee.** Bioactive peptides derived from the proteins of egg white by means of enzymatic hydrolysis. P200301829, PCT/ES2004/070059, EP1661913, US8227207, AT388166, DE602004012289, DK1661913, JP2007523045; 2003 July 31.
- **Miguel Castro M, López-Alonso Fandiño R, Ramos González MM, Aleixandre de Artiñano A, inventors; CSIC, assignee.** Production of and antihypertensive properties of peptides derived from egg white proteins. P200501246 PCT/ES2006/070067; 2005 May 23.
- **Recio Sánchez MI; Quirós del Bosque A, Hernández Ledesma B, Gómez Ruiz JA, Miguel Castro M, Amigo Garrido L, López Expósito I, Ramos González MM, Aleixandre de Artiñano A, (Contreras Gómez M), inventors; CSIC, assignee.** Bioactive peptides identified in enzymatic hydrolyzates of milk caseins and method of obtaining same. P200501373, PCT/ES2006/070079, EP1905779, EP2495250, US8354502, AU2006256720, BRPI0611729, CA2611416, CN101305017, CN103254278, JP2008545774, KR20080045108, MX2007015528, NO20080103; 2005 June 08.
- **Garcés Rimón M, Miguel Castro M, López-Alonso Fandiño R, López-Miranda González V, Uranga Ocio J, inventors; CSIC, Universidad Rey Juan Carlos, assignees; Use of multifunctional bioactive products derived from the enzymatic hydrolysis of egg white proteins for treating metabolic syndrome.** P201331767, PCT/ES2014/070880; 2013 December 04.
- **Miguel Castro M, Garcés Rimón M, López-Alonso Fandiño R, Sandoval Huertas M, inventors; CSIC, Mario Sandoval Huertas, assignees.** Healthy food compositions having gel or foam textures and comprising hydrolyzed egg products. P201331886, PCT/ES2014/070902, EP3106042, US9648897, AR098685, JP2015130856, MX2014015135; 2013 December 20.
- **González-Muñiz R, Pérez de Vega MJ, Miguel M, Balsera-Paredes B, Moreno S, inventors; CSIC, assignee.** Triazolyl polyphenols with antioxidant activity and uses thereof; P201531450; 2015 November 08 .
- **González-Muñiz R, Miguel Castro M, Pérez de Vega MJ, Balsera-Paredes B, S Moreno, inventors; CSIC, assignee.** Compounds with antioxidant activity and uses thereof. P201630362; 2016 March 29.
- **León Martínez R, Abril Comesaña S, Duarte Flórez P, Crisman Vigil E, Michalska P, Salaices Sánchez M, Menéndez Ramos JC, inventors; Fundación para la Investigación Biomédica del Hospital Universitario de la Princesa, UAM, UCM, assignees.** Compuestos agonistas nicotínicos y antioxidantes para el tratamiento de enfermedades neurodegenerativas. P201930908. 2019 October 14 .
- **León Martínez R, Abril Comesaña S, Michalska P, Buendia Abaitua I, Salaices Sánchez M, Menéndez Ramos JC, García López M; inventors; Fundación para la Investigación Biomédica del Hospital Universitario de la Princesa, UAM, UCM, assignees.** Compuestos derivados de 2-iodo-7-(((2-(5-metoxi-1H-indol-3-il)etil)amino) metil)-1-alquil/aril-6,7,7a,8-tetrahidro-3H-pirrolo[2,1-j]quinolina-3,9(5H)-diona como agentes antioxidantes, inductores de NRF2 y moduladores nicotínicos para el tratamiento de enfermedades neurodegenerativas. P201930190. 2019 March 01 .
- **Miguel Castro M, Garcés Rimón M, authors; Miguel Castro M, Garcés Rimón M, assignees.** Brand name: leggie. ESM4044711; 2019 November 22. Concesión 8 Junio 2020

leggie

- **Miguel M, Bruna E, Redondo BI, Gómez J, Gómez Sánchez J.** inventors: : Cárnicas Joselito S.L: assigne. Extracto procedente de la grasa de cerdo, método de obtención, composición alimenticia que lo comprende y usos del mismo. P2021130236. 2021 March 17
- **Miguel M, Bruna E, Redondo BI, Gómez J, Gómez Sánchez J, Sabater-Muñoz B.** inventors: Cárnicas Joselito S.L. assignee. Composición farmacéutica que comprende un extracto procedente de la grasa de jamón de cerdo como principio activo y su uso en medicina para la prevención cardiovascular e inflamación intestinal. P202131111. 2021 november 30
- **Alonso Gordo MJ, Hernanz Martín R, Martínez Casales M, González Carnicero Z, León Martínez R, Michalska Djzma P.** inventors; Universidad Rey Juan Carlos, Consejo Superior de Investigaciones Científicas, Universidad Autónoma de Madrid, assinees; (E)-3-(4-hidroxi-3-metoxifenil)-acrilato de 3-(2-acetamidoetil)-1H-indol-5-ilo para uso en la prevenciaón y/o tratamiento de la hipertensión arterial y las alteraciones cardiovasculares asociadas. P202230523

3.2.4 Vascular Pharmacology and Metabolism (FARMAVSM) Group



Publications: 2 | **Q1:**2

COMPOSITION

Carlos Félix Sánchez Ferrer.
Catedrático de Farmacología. Universidad Autónoma de Madrid
Concepción Peiró Vallejo.
Catedrática de Farmacología. Universidad Autónoma de Madrid

- **Diego Berlanas Vicente.** *Ayudante de Investigación. Universidad Autónoma de Madrid*
- **Ana Cuadrado Gómez.** *Investigadora Predoctoral. Universidad Autónoma de Madrid*
- **Fernando de la Cuesta Marina.** *Investigador Postdoctoral. Universidad Autónoma de Madrid*
- **Jorge Francisco Gómez Cerezo.** *Jefe de Servicio de Medicina Interna. Hospital Universitario Infanta Sofía*
- **Fátima Ainara González Moro.** *Investigadora Predoctoral. Universidad Autónoma de Madrid*
- **Estela Herranz Martín.** *Técnico de Grado Superior. Universidad Autónoma de Madrid*
- **Miriam Morales Rodríguez de Lope.** *Ayudante de investigación. Universidad Autónoma de Madrid*
- **Angel Moreno Luque.** *Ayudante de Investigación. Universidad Autónoma de Madrid*
- **Carmen María Parra Moreno.** *Investigadora Predoctoral. Universidad Autónoma de Madrid*
- **Alan Andrés Rivera Tenorio.** *Investigadora Predoctoral . Universidad Autónoma de Madrid*
- **Ibone Rubio Sánchez-Pajares.** *Investigadora Postdoctoral. Universidad Autónoma de Madrid*
- **Alicia Villacampa Calvo.** *Investigadora Postdoctoral. Universidad Autónoma de Madrid*

STRATEGIC OBJETIVES

- Understanding vascular ageing, both in healthy and pathological conditions, like obesity ant diebetes mellitus

RESEARCH LINES

- Mechanisms of human vascular ageing
- Mechanisms for vascular damage in diabetes mellitus
- Obesity, adipokines, insulin resistance, and vascular dysfunction
- Role for the angiotensin-(1-7)/Mas receptor axis on vascular function and inflammation.
- Development of novel extracellular vesicle-based therapies for cardiovascular diseases

RESEARCH ACTIVITY

Master Theses

- **Romero González R.** Alamandine, a new anti-senescence and vasodilator peptide of the renin-angiotensin system [dissertation]. Madrid: Universidad Autónoma de Madrid: 2024(17/09/2024). Director: Peiró Vallejo C

Publications

- **Valencia I, Lumpuy-Castillo J, Magalhaes G, Sánchez-Ferrer CF, Lorenzo O, Peiró C.** Mechanisms of endothelial activation, hypercoagulation and thrombosis in COVID-19: a link with diabetes mellitus. Cardiovasc Diabetol. 2024; 23(1): 75. Review. IF: 10.6; D1
- **Villacampa A, Alfaro E, Morales C, Díaz-García E, López-Fernández C, Bartha JL, López-Sánchez F, Lorenzo O, Moncada S, Sánchez-Ferrer CF, García-Río F, Cubillos-Zapata C, Peiró C.** SARS-CoV-2 S protein activates NLRP3 inflammasome and deregulates coagulation factors in endothelial and immune cells. Cell Commun Signal. 2024; 22(1): 38. Article. IF: 8.9; Q1

Research projects

- **de la Cuesta Marina F.** Developing novel nanotherapies for atherosclerosis by delivering senolytics to the plaque using mesenchymal stem cell-derived extracellular vesicles (2019-T1/IND-13794 y 2023-5A/IND-28938). CM. 2020-2025. Managment centre: UAM
- **de la Cuesta Marina F.** Nueva terapia senolítica para enfermedad vascular asociada al envejecimiento mediante bioingeniería de vesículas extracelulares de células madre para administración dirigida (PID2021-126274OB-I00). AEI. 2022-2025. Managment centre: UAM
- **de la Cuesta Marina F.** Terapias senoliticas avanzadas basadas en nanoparticulas biologicas para tratar el envejecimiento vascular (CNS2022-135368). AEI. 2023-2025. Managment centre: UAM
- **de la Cuesta Marina F.** Escalado y fabricación GMP de vesículas extracelulares de células madre mesenquimales para terapias avanzadas (IND2023/BMD-27323). CM. 2024-2027. Managment centre: UAM
- **Peiro Vallejo C, Sánchez Ferrer CF.** Identifying pharmacological targets for the prevention of cardiometabolic vascular inflammageing (PID2020-115590RB-I00). Plan Nacional de I+D+i. 2021-2024. Managment centre: UAM
- **Peiro Vallejo C, Sánchez Ferrer CF.** NLRP3 inflamasome at the crossroad of vascular inflammageing: a novel target for senomorphic drugs (PID2023-147378OB-I00). Plan Nacional de I+D+i. 2024-2027. Managment centre: UAM
- **Peiro Vallejo C.** Vesículas extracelulares (EVs) y envejecimiento vascular: nuevas dianas farmacológicas (). Embajada de Francia en España . 2024-2024. Managment centre: UAM

3.2.5 Paediatric Cardiology Research



Publications: 3 | **Q1:**1

COMPOSITION

Federico Gutiérrez-Larraya Aguado.
Jefe de Servicio de Cardiología Pediátrica. Hospital Universitario La Paz. Profesor Titular. Universidad Francisco de Vitoria.

- **César Abelleiro Pardeiro.** *Facultativo Especialista de Área en Cardiología Pediátrica. Hospital Universitario La Paz*
- **Viviana Arreo del Val.** *Facultativo Especialista de Área en Cardiología Pediátrica. Hospital Universitario La Paz*
- **Antonio Javier Cartón Sánchez.** *Facultativo Especialista de Área en Pediatría. Hospital Universitario La Paz*
- **Lucía Deiros Bronte.** *Facultativo Especialista de Área en Pediatría. Hospital Universitario La Paz*
- **Marta Gambra Arzoz.** *Facultativo Especialista de Área en Pediatría. Hospital Universitario La Paz*
- **Luis García-Guereta Silva.** *Jefe de Sección de Cardiología Pediátrica. Hospital Universitario La Paz*
- **Carlos Labrandero de Lera.** *Facultativo Especialista de Área en Cardiología Pediátrica. Hospital Universitario La Paz*
- **Álvaro Lafuente Romero.** *Facultativo Especialista de Área en Pediatría. Hospital Universitario La Paz*
- **Diana Salas Mera.** *Médico Adjunto Cardiología Pediátrica. Hospital Universitario La Paz*

STRATEGIC OBJETIVES

- Establishment of Cardiopathy Registers: Creation of comprehensive databases that comply with all legal regulations regarding security, confidentiality, and data protection.
- Advances in Imaging Diagnosis: Innovation and refinement of imaging techniques for precise characterization of pediatric heart diseases.
- Minimally Invasive Diagnostic and Therapeutic Techniques: Development and application of procedures that minimize impact and improve patient recovery.
- Research on Vascular Risk and Environmental Factors: Dedicated studies to understand how environmental factors and lifestyle influence pediatric heart diseases and their prevention.
- Role of Exercise in Pediatric Cardiology: Research on the importance of physical exercise in the detection and treatment of cardiac alterations in children.
- Telemedicine and Cardiac Monitoring: Implementation of telemedicine solutions and the use of IoT devices for efficient and real-time cardiac monitoring.
- Blockchain in Medical Record Management: Application of blockchain technology to ensure the integrity and privacy of medical records.
- Omics Research for Pediatric Cardiology: Search for biomarkers and therapeutic targets through genomic, proteomic, and metabolomic studies.
- Scientific Dissemination and Industrial Collaboration: Publication of research in high-impact journals and collaboration with the pharmaceutical sector for the development of new therapies.
- Creation of Specialized Care Units: Formation of multidisciplinary teams based on the latest research to provide the best care.
- Continuous Training and Public Awareness: Development of educational programs for professionals and families, and collaboration with media to increase the visibility of pediatric heart diseases.

RESEARCH LINES

- Application of Artificial Intelligence and New Technologies: Exploration and adoption of technological advances to enhance the diagnosis, treatment, and monitoring of pediatric heart diseases.
- Innovation in Medical Devices and Pharmacology: Development and assessment of advanced medical devices and new pharmacological compounds tailored to the specific needs of the pediatric population.
- Management of Vascular Risk in Pediatrics: Study and management of vascular risk from the earliest stages of life, focusing on the prevention and early detection of cardiovascular diseases.

RESEARCH ACTIVITY

Publications

- **Cobarro L, Jiménez-Valero S, Gutiérrez-Larraya F, Merino C, Merás P, Ruiz-Cantador J, Balbacid E, Poveda ID, Rosillo SO, Caro-Codón J, Jurado-Román A, Moreno R.** Novel percutaneous aspiration thrombectomy in Fontan conduit obstruction with cardiogenic shock. Case report. Int J Cardiol Congenit Heart Dis. 2024; 17: 100518. Letter. IF: 1.2; Q4
- **González-Costello J, Pérez-Blanco A, Delgado-Jiménez J, González-Vílchez F, Mirbet S, Sandeval E, Cuenca-Castillo J, Camino M, Segovia-Cubero J, Sánchez-Salado JC, de la Sota EP, Almenar-Bonet L, Farrero M, Zataraín E, García-Cosío MD, Garrido I, Caballero EB, Gómez-Bueno M, Bagudá JD, Manito-Lorite N, López-Granados A, García-Guereta L, Blasco-Peiró T, Sarralde-Aguayo JA, Sobrino-Márquez M, de la Fuente-Galán L, Crespo-Leiro MG, Coll E, Gran-Ipiña F, Díaz-Molina B, Doñate L, Arribas-Leal JM, Sánchez-Vicario F, Atienza F, Juan-Aracil GR, García-Quintana A, Martínez-Alpuente I, Riesgo-Gil F, Hernández-Montfort J, Oliver-Juan E, Sánchez-Rivas J, Padilla-Martínez M, Pérez-Villares JM, Miñambres E, Domínguez-Gil B.** Review of the allocation criteria for heart transplant in Spain in 2023 . SEC-Heart Failure Association/ONT/SECCE consensus document. Rev Esp Cardiol (Engl Ed). 2024; 77(1): 69-78. Review. IF: 4.9; Q1
- **Labrandero C, Deiros L, Abelleira C, Arreo V, Balbacid EJ, Gutiérrez-Larraya F.** Hemodynamic Monitoring of Pediatric Patients With Heart Failure and Pulmonary Hypertension Using CardioMEMS. J Soc Cardiovasc Angiogr Interv. 2024; 3(6): 101933. Article. Not Indexed

Clinical Trial

- **Gambra Arzoz M.** estudio clínico aleatorizado, controlado con placebo y con doble enmascaramiento para evaluar mavacamten en adolescentes (de 12 a <18 años de edad) con miocardiopatía hipertrófica obstructiva sintomática.
  Type/Phase: III
  Sponsored by: Bristol-Myers Squibb Services Unlimited Company
  Signature date: 03/04/2024
- **Labrandero de Lera C.** estudio clínico de fase 2/3, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia, la seguridad y la farmacocinética del vericiguat en pacientes pediátricos con insuficiencia cardíaca debido a disfunción sistólica sistémica del ventrículo izquierdo (valor).
  Type/Phase: III
  Sponsored by: Merck Sharp & Dohme Llc
  Signature date: 09/09/2024
- **Gutiérrez-Larraya Aguado F.** abbott structural heart device registry (abbott sh registry).
  Type/Phase: PRODUCTO SANITARIO
  Sponsored by: Abbott Medical España S.A.
  Signature date: 05/08/2024
- **Gambra Arzoz M.** estudio clínico aleatorizado, controlado con placebo y con doble enmascaramiento para evaluar mavacamten en adolescentes (de 12 a <18 años de edad) con miocardiopatía hipertrófica obstructiva sintomática.
  Type/Phase: III
  Sponsored by: Bristol-Myers Squibb Services Unlimited Company
  Signature date: 12/06/2024
- **García-Guereta Silva L.** estudio retrospectivo, multicéntrico e internacional para describir la evolución natural de la enfermedad de danon.
  Type/Phase: No EPA
  Sponsored by: Oracle France S.A.S.
  Signature date: 12/07/2024
- **Gambra Arzoz M.** estudio clínico aleatorizado, controlado con placebo y con doble enmascaramiento para evaluar mavacamten en adolescentes (de 12 a <18 años de edad) con miocardiopatía hipertrófica obstructiva sintomática.
  Type/Phase: III
  Sponsored by: Bristol-Myers Squibb Services Unlimited Company
  Signature date: 19/12/2024




1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians



3.3.Infectious Diseases and Immunity Area

Documents: 270 | **Originals:** 223 | **D1:** 40 | **Q1:** 146

Area coordinator: Eduardo López-Collazo
coordinadorinfecciosas@idipaz.es

RESEARCH GROUPS

3.3.1 AIDS and Infectious Diseases
José Ramón Arribas López

3.3.2 Molecular Microbiology
Jesús Mingorance Cruz

3.3.3 Immuno-Rheumatology
María Eugenia Miranda Carús

3.3.4 Innate Immune Response
Eduardo López-Collazo/Carlos del Fresno Sánchez

3.3.5 Alterations of the Complement System in Human Pathology
Margarita López Trascasa/Pilar Sánchez-Corral Gómez

3.3.6 Lymphocyte Pathophysiology in Immunodeficiencies
Eduardo López Granados

3.3.7 Drug Hypersensitivity and Innate Immune Response
Teresa Bellón Heredia

3.3.8 Immunomediate Gastrointestinal Diseases and Other Digestive Pathologies
María Dolores Martín Arranz

3.3.9 MicroRNA Regulation of Immune Tolerance, Autoimmunity and Cancer
Alicia González Martín

3.3.10 Systemic Immune-Mediated Diseases
Juan José Ríos Blanco

Strategic Objectives	Development forecast for the coming years:	Actions
Infectious Diseases and Immunity Area is composed of 11 groups focused on the study of diseases related to the immune system such as HIV, autoimmune diseases, cancer, etc., as well as the molecular mechanisms that explain the phenomena associated with these pathologies.	To identify priority research topics in our area and if necessary expand some of them.	Promote the priority research line identified
	To generate and develop scientific research projects that allow the production of knowledge in the biomedical area.	Obtain national and international scientific research projects in biomedical area
	To generate a significant number of research products/results, such as publications in nationally and internationally indexed journals, journals that contribute to the social appropriation of knowledge.	Improve the annual number of publications in the first quartile and decile, and total impact factor of the area
	To socialize the research resultsby presenting papers at national and international events	Increase the presence of area researchers in national and international events
	To establish agreements and strategic alliances with other communities of knowledge that allow academic discussion and project development.	Search for synergies with other groups with similar and complement research lines.
	To promote the training of young researchers and undergraduate and graduate students.	Training in research methodology undergraduate, predoctoral and postdoctoral personal.
	To develop a good system of applied research so that everything studied in the laboratory has repercussions on both our patients and our entities.	Promote the synergies of translational researchers and clinical researchers, and their incorporation into groups

HIGH IMPACT PUBLICATIONS

Gessl I, Sakellariou G, Wildner B, Filippou G, Mandl P, D'Agostino MA, **Navarro-Compán V**. Systematic literature review to inform the EULAR recommendations for the use of imaging in crystal-induced arthropathies in clinical practice. Ann Rheum Dis. 2024; 83(9): 1208-24. Article. IF: 20,6; D1

García-Solís B, Tapia-Torres M, García-Soidán A, Hernández-Brito E, Martínez-Saavedra MT, Lorenzo-Salazar JM, García-Hernández S, Van Den Rym A, Mayani K, Govantes-Rodríguez JV, Gervais A, Bastard P, Puel A, Casanova JL, Flores C, de Diego RP, Rodríguez-Gallego C. IgG4-related disease and B-cell malignancy due to an IKZF1 gain-of-function variant. J Allergy Clin Immun. 2024; 154(3): 819-26. Article. IF: 11,2; D1

González-Sánchez L, Agudo AM, van den Rym A, Begiristain MI, Saizar A, de Diego RP, Nozal P, López-Lera A, López-Trascasa M, **Corvillo F**. Properdin deficiency associated with systemic meningococcal disease due to a novel p.Cys337Arg pathogenic variant. Genes Dis. 2024; 11(6): 101134. Article. IF: 9,4; D1

Montejano R, Soler-Carracedo A, Borobia AM, Martín-Quirós A, Grandioso D, Canada C, Roman A, **Arribas JR**. The Current Mismatch Between Coronavirus Disease 2019 Clinical Trial Design and the Evolving Profile of Hospitalized Patients: A Retrospective Cohort Analysis. Clin Infect Dis. 2024; 78(4): 918-21. Article. IF: 7,3; D1

Martínez-Sánchez N, Alvarez-Troncoso J, Robles-Marhuenda A, Fernández-Miranda MD, Hernando MLM, Bartha JL. Safety of biologic immunosuppressants in pregnant women with immune-mediated inflammatory diseases. J Autoimmun. 2024; 148: 103301. Article. IF: 7; Q1

Scientific Events by Infectious Diseases and Immunity Area

- **11/01/2024.** PROA Session: "Estancia en el MSKCC de NY
- **12/01/2024.** Scientific Seminar: SIGLEC5: Saltando del cáncer a la sepsis
- **18/01/2024.** PROA Session: La membrana celular de Streptococcus pneumoniae como diana para el reposicionamiento de fármacos
- **24/01/2024.** PROA Session: Revisión de fiebre de Katayama
- **26/01/2024.** Scientific Seminar: Linfocitos intraepiteliales (IELs) conjuntivales en individuos sanos y patologías inflamatorias
- **08/02/2024.** PROA Session: Actualización en fiebre Q: a propósito de dos casos
- **28/02/2024.** PROA Session: Enfermedades Infecciosas: VRS, lo que viene
- **06/03/2024.** PROA Session enfermedades infecciosas: Un brote inesperado
- **08/03/2024.** Scientific Seminar: Unravelling cancer immunotherapy response heterogeneity with Patient-Derived Organoids
- **13/03/2024.** PROA Session: Heterorresistencia a colistina en aislados clínicos
- **15/03/2024.** Scientific Seminar: Retos en el diagnóstico genético de los errores innatos de la inmunidad. La deficiencia humana en Ezrina.
- **20/03/2024.** PROA Session: Enfermedades Infecciosas: Actualización en ventriculitis. Revisión de los últimos 5 años
- **17/04/2024.** PROA Session: La colonización intestinal como factor de riesgo de infecciones por enterobacterias resistentes a carbapenémicos y la prevalencia de KPC y sus impactos clínicos en Brasil
- **29/04/2024.** Scientific Seminar: Nuevo SIL, nuevas posibilidades
- **22/05/2024.** PROA Session: Actualización en hidatidosis
- **29/05/2024.** PROA Session: Actualización en ventriculitis y situación en Hospital La Paz
- **05/06/2024.** PROA Session: HTLV
- **12/06/2024.** PROA Session: Biofilms, microbioma intestinal y Clostridioides difficile
- **13/06/2024.** PROA Session. Curso de infección en inmunocomprometidos
- **19/06/2024.** PROA Session: Lo mejor de la SEIMC
- **26/06/2024.** PROA Session. El tracto gastrointestinal como reservorio de especies de cándida
- **27/09/2024.** Seminario Científico: Mechanism of Sodium Channel Dysfunction in Brugada Syndrome: Froma Molecular Insights to Clinical Implications
- **02/10/2024.** PROA Session. Actualización en ventriculitis. Revisión de los últimos 5 años
- **16/10/2024.** PROA Session: Análisis computacional de la interacción de susbtratos con OXA 48. Un primer paso para el diseño de nuevos inhibidores
- **18/10/2024.** Seminario científico. Virus que replican condicionalmente. APlicación como potenciales vacunas
- **23/10/2024.** PROA Session. Actualización en Monkeypox
- **30/10/2024.** PROA Session: Crimea Congo: novedades
- **06/11/2024.** PROA Session: Diagnóstico molecular de ITS

3.3.1 AIDS and Infectious Diseases Group



Publications: 66 | **Q1:** 36

COMPOSITION

José Ramón Arribas López.
Jefe de Sección del Servicio de Medicina Interna (Unidad de Infecciosas). Hospital Universitario La Paz. Profesor Titular. Universidad Autónoma de Madrid

- **María del Mar Arcos Rueda.** *Facultativo Especialista de Área en Medicina Interna. Hospital Universitario La Paz*
- **Marta Arsuaga Vicente.** *Médico Adjunto en Medicina Interna. Hospital Carlos III - Hospital Universitario La Paz*
- **José Ignacio Bernardino de la Serna.** *Facultativo Especialista de Área en Medicina Interna. Unidad VIH. Hospital Universitario La Paz*
- **Carmen Busca Arenzana.** *Contrato Río Hortega. Hospital Universitario La Paz*
- **Julen Cadiñanos Loidi.** *Contrato Río Hortega. Hospital Universitario La Paz*
- **Irene Casado Juárez.** *Técnico de Grado Superior. FIBHULP*
- **Fernando de la Calle Prieto.** *Médico adjunto en Medicina Interna. Unidad de Medicina Tropical. Hospital Carlos III - Hospital Universitario La Paz. Profesor Colaborador. Universidad Autónoma de Madrid*
- **Rosa de Miguel Buckley.** *Facultativo Especialista Adjunto en Medicina Interna. Hospital Universitarios La Paz*
- **Marta Díaz Menéndez.** *Médico adjunto en Medicina Interna. Unidad de Medicina Tropical. Hospital Universitario La Paz*
- **Beatriz Díaz Pollán.** *Facultativo Especialista de Área en Medicina Interna. Unidad de Enfermedades Infecciosas y Microbiología Clínica. Hospital Universitario La Paz*
- **Alejandro Díez Vidal.** *Facultativo Especialista de Área en Medicina Interna. Hospital Universitario La Paz*
- **Sara Rodríguez Díez.** *Técnico de Grado Superior. FIBHULP*
- **Andrés Esteban Cantos.** *Investigador postdoctoral (R2A). Hospital Universitario La Paz*
- **Marta Gálvez Charro.** *Enfermera. Unidad de VIH. Hospital Universitario La Paz*
- **Nicolás García-Arenzana Les.** *Facultativo Especialista de Área en Medicina Preventiva. Hospital Universitario La Paz*
- **Francisco Gayá Moreno.** *Investigador Predoctoral (Contrato de Estabilización de Técnicos de Apoyo). Hospital Universitario La Paz*
- **Juan Julián González García.** *Facultativo Especialista de Área en Medicina Interna. Unidad de VIH. Hospital Universitario La Paz*
- **Juan Carlos González Rodríguez.** *Técnico de Grado Superior. FIBHULP*
- **Lucía Gutierrez García.** *Investigadora Predoctoral. FIBHULP*
- **Pedro Herranz Pinto.** *Facultativo Especialista de Área en Dermatología. Jefe de Sección. Hospital Universitario La Paz*
- **Víctor Hontañón Antoñana.** *Investigador predoctoral . Hospital Universitario La Paz*
- **María Jiménez González.** *Bioestadística. FIBHULP*
- **María del Mar Lago Núñez.** *Facultativo Especialista de Área en Medicina Interna. Unidad de Medicina Tropical. Hospital Carlos III - Hospital Universitario La Paz*
- **Jara Llenas García.** *Facultativo Especialista de Área en Medicina Interna. Hospital Universitario La Paz*
- **Cristina Marcelo Calvo.** *Contrato Rio Hortega. Hospital Universitario La Paz*
- **Luz Martín Carbonero.** *Facultativo Especialista de Área. Hospital Universitario La Paz*
- **Patricia Martínez Martín.** *Médico Adjunto en Medicina Interna. Hospital Universitario La Paz*
- **Mario Mayoral Muñoz.** *Enfermero. Hospital Universitario La Paz*
- **Juan José Miguel Castro.** *Enfermero. Hospital Universitario La Paz*
- **Rocío Montejano Sánchez.** *Investigadora Postdoctoral. Hospital Universitario La Paz*
- **María Luisa Montes Ramírez.** *Facultativo Especialista de Área de Medicina Interna. Unidad de VIH. Hospital Universitario La Paz*
- **Marta Mora Rillo.** *Facultativo Especialista de Área de Medicina Interna. Unidad de Enfermedades Infecciosas y Microbiología Clínica. Hospital Universitario La Paz*
- **Francisco Moreno Ramos.** *Farmacéutico. Hospital Universitario La Paz*
- **Carlos Manuel Oñoro López.** *Médico Interno Residente. FIBHULP*
- **Juan Carlos Ramos Ramos.** *Facultativo Especialista de Área en Medicina Interna. Hospital Universitario La Paz*
- **Luis Ramos Ruperez.** *Investigación Rio Hortega. Hospital Universitario La Paz*
- **Berta Rodés Soldevila.** *Investigadora Titular. Responsable laboratorio BSL2-virología.FIBHULP*
- **Javier Rodríguez Centeno.** *Investigador postdoctoral. Hospital Universitario La Paz*
- **Elena Sendagorta Cudós.** *Facultativo Especialista de Área de Dermatología. Hospital Universitario La Paz*
- **Lucía Serrano Morago.** *Investigadora predoctoral. Hospital Universitario La Paz*
- **Eulalia Valencia Ortega.** *Facultativo Especialista de Área en Medicina Interna. Hospital Univeristario La Paz*

STRATEGIC OBJETIVES

- Although great progress has been made, HIV infection remains an incurable disease. Even under the best circumstances, HIV-infected patients who receive current antiretroviral therapy have a survival disadvantage compared with the general non-infected population, which is estimated to be a life expectancy of 15 years less than the general population.
- HIV infection is highly prevalent in Spain. Among western European countries, Spain has the second highest prevalence. An important local characteristic of the HIV-infected population in Spain is the high prevalence of hepatitis C coinfection.
- This research line covers four main topics of research in HIV infection: antiretroviral treatment, HIV-HCV coinfection, metabolic complications and HIV-resistance to antiretroviral drugs. In addition, we are planning to start another research project on infections other than HIV.
- The group has started a new research line regarding the aging and HIV Infection.
- Tropical diseases are increasing as a consequence of global travel. These diseases continue to be relatively rare however, and therefore, often sub-optimal treated if managed by non-speciaslists. Furthermore, every year an increasing amount of special travelers (pregnants, comorbidities, immunossupressed) travel abroad, adding complexity in terms of a timely and effective diagnosis and management. The Tropical and Travel Medicine Unit provide both pre and postravel assistance in imported infectious diseases. The aim of this Unit is to provide efficient and effecrive specialist care with proven or suspected tropical disease and a specific preventative travel advice, togheter with international vaccines recommended for the trip.

RESEARCH LINES

- Antiretroviral therapy & resistance.
- Metabolic complications of antiretroviral therapy.
- Liver disease.
- Neurocognitive impairment.
- Paediatric HIV infection and MTCT.
- Epigenetic and cellular factors related to HIV progression
- Optimisation of antibiotic therapy (ID no HIV)
- Tropical diseases
- Emerging and re-emerging virus
- Molecular and cellular biomarkers of aging

RESEARCH ACTIVITY

Master Theses

- **Ciudad Sañudo M.** Algoritmos diagnóstico-terapéuticos en enfermedades infecciosas: Neurocisticercosis; eosinofilia importada asintomática; Detección molecular de parásitos protozoarios en heces. [dissertation]. Sevilla: Universidad de Sevilla: 2024(18/05/2024). Director: Díaz Menéndez M.
- **Aguilera García M.** Algoritmos diagnóstico-terapéuticos en enfermedades infecciosas: Manejo de la enfermedad de Chagas crónica en consulta. Diagnóstico de la fiebre en el viajero; Manejo de la diarrea en el viajero [dissertation]. Sevilla: Universidad de Sevilla: 2024(18/05/2024). Director: Díaz Menéndez M.
- **Guzmán Bustos ML.** Factores que influyen en el seguimiento del VIH en la población indígena atendida en el centro regional de vigilancia, información y referencia de las ITS/VIH/Sida. Llallagua-Bolivia[dissertation]. Madrid: Universidad Rey Juan Carlos: 2024(25/06/2024). Director: Díaz Menéndez M.
- **Guzmán Bustos ML.** población indígena atendida en el centro regional de[dissertation]. Madrid: Universidad Rey Juan Carlos: 2024(25/06/2024). Director: Díaz Menéndez M.
- **Iveth Salguero D.** Vigilancia, información y referencia de las ITS/VIH/SIDA[dissertation]. Madrid: Universidad Rey Juan Carlos: 2024(25/06/2024). Director: Díaz Menéndez M.

Publications

- **Aggarwal NR, Nordwall J, Braun DL, Chung LCY, Coslet J, Der T, Eriobu N, Ginde AA, Hayanga AJ, Highbarger H, Holodniy M, Horcajada JP, Jain MK, Kim K, Laverdure S, Lundgren J, Natarajan V, Nguyen HH, Pett SL, Phillips A, Poulakou G, Price DA, Robinson P, Rogers AJ, Sandkovsky U, Shaw-Saliba K, Sturek JM, Trautner BW, Waters M, Reilly C.** Viral and Host Factors Are Associated With Mortality in Hospitalized Patients With COVID-19. Clin Infect Dis. 2024; 78(6): 1490-503. Article. IF: 7.3; D1
- **Arca-Lafuente S, Yépez-Notario C, Cea-Callejo P, Lara-Aguilar V, Crespo-Bermejo C, Martín-Carbonero L, de los Santos I, Briz V, Madrid R.** Development and validation of a new and rapid molecular diagnostic tool based on RT-LAMP for Hepatitis C virus detection at point-of-care. Methods. 2024; 232(): 43-51. Article. IF: 4.3; Q1
- **Arenzana CB, González-García J, Blas-García A, Esplugues JV, Martín AO, Ramírez MLM.** Benefits of rilpivirine for liver stiffness in HIV/HCV-coinfected patients. Enferm Infec Micr Cl. 2024; 42(2): 74-9. Article. IF: 2.5; Q2
- **Armario-Hita JC, Pereyra-Rodríguez JJ, González-Quesada A, Herranz P, Suárez R, Galán-Gutiérrez M, Rodríguez-Serna M, de Frutos JO, Carrascosa JM, Serra-Baldrich E, Ara-Martín M, Figueras-Nart I, Silvestre JF, Zaragoza-Ninet V, Ruiz-Villaverde R.** Treatment of atopic dermatitis with abrocitinib in real practice in Spain: efficacy and safety results from a 24-week multicenter study. Int J Dermatol. 2024; 63(11): e289-95. Article. IF: 3.2; Q1
- **Arsuaga M, Buckley RD, de la Calle-prieto F, Diaz-Menéndez M.** Imported infectious diseases in migrants from Latin America: A retrospective study from a referral centre for tropical diseases in Spain, 2017-2022. Travel Med Infect Di. 2024; 59: 102708. Article. IF: 4.7; Q1
- **Arsuaga M, Buckley RD, Díaz-Menéndez M.** Rabies: Epidemiological update and pre- and post-exposure management. Med Clin-Barcelona. 2024; 162(11): 542-8. Article. IF: 2.1; Q2
- **Arsuaga M, Coloma R, Guerra S, Díaz-Menéndez M.** Sequencing the evolution of vaccinia skin lesions in a laboratory worker: Insights from image analysis. Enferm Infec Micr Cl. 2024; 42(8): 459-60. Editorial Material. IF: 2.5; Q2
- **Berenguer J, Calvo-Alcántara MJ, Alvaro-Meca A, Estévez JC, Basanta M, Ruiz S, Matáix**

AL, Bienzóbas C, Cosano L, Silva AP, Salas P, Gullón P, Franco M, Arribas JR, Molero JM, Hernán MA. Three Years of the Coronavirus Disease 2019 Pandemic in a European Region: A Population-Based Longitudinal Assessment in Madrid Between 2020 and 2022. Open Forum Infect Dis. 2024; 11(1): ofad635. Article. IF: 3.8; Q1

- **Berenguer J, Jarrín I, Bellón JM, Díez C, Jiménez-Sousa MA, López JC, Pinto-Martínez A, Moreno S, Montes ML, Iribarren JA, Orviz E, Portilla J, Villarroya F, Domingo P, Resino S.** Mitochondrial Haplogroups and Weight Gain After Initiating ART in Patients With HIV. J Infect Dis. 2024; 230(2): 421-5. Article. IF: 4.5; Q1
- **Berzosa A, Guillen S, Epalza C, Escosa L, Navarro ML, Prieto LM, Sainz T, de Ory SJ, Montes M, Abad R, Vázquez JA, García IS, Ramos-Amador JT.** Immunogenicity of the Conjugate Meningococcal ACWY-TT Vaccine in Children and Adolescents Living with HIV. Microorganisms. 2024; 12(1): 30. Article. IF: 4.2; Q2
- **Brochado-Kith O, Rava M, Berenguer J, González-García J, Rojo D, Díez C, Hontañon V, Virseda-Berdices A, Ibañez-Samaniego L, Llop-Herrera E, Olveira A, Pérez-Latorre L, Barbas C, Fernández-Rodríguez A, Resino S, Jiménez-Sousa MA.** Altered blood microbiome in patients with HCV-related Child-Pugh class B cirrhosis. J Infect Public Health. 2024; 17(10): 102524. Article. IF: 4.0; Q1
- **Busca-Arenzana C, Ortega-González D, Díaz-Almirón M, Montes ML, Martin-Carbonero L, Mican R, Montejano R, Ramos-Ruperto L, Valencia E, Delgado-Hierro A, Bernardino JI.** Metabolic effects of switching to Biktarvy (B/F/TAF) in patients with HIV-1 treated with antiretroviral regimens that do not include tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF): The Metabic study. Hiv Med. 2024; 25(9): 1030-9. Article. IF: 3.2; Q2
- **Cadiñanos J, Rodríguez-Centeno J, Montejano R, Esteban-Cantos A, Mena-Garay B, Jiménez-González M, Saiz-Medrano G, de Miguel R, Rodríguez-Artalejo F, Bernardino J, Marcelo-Calvo C, Gutierrez-García L, Martínez-Martin P, Vidal AD, Grela AD, Ortolá R, Rodés B, Arribas JR.** Partial Recovery of Telomere Length After Long-term Virologic Suppression in Persons With HIV-1. Open Forum Infect Dis. 2024; 11(10): ofae550. Article. IF: 3.8; Q1
- **Calle-Prieto FD, Barriga JJ, Arsuaga M, de Miguel R, Díaz-Menéndez M.** Clinical profile and management of a Spanish single-center retrospective cohort of patients with post-chikungunya associated complications. Travel Med Infect Di. 2024; 60: 102726. Article. IF: 4.7; Q1
- **Camprubíi-Ferrer D, Menéndez MD, Crespillo-Andújar C, Galparsoro HA, Belhassen-García M, González JC, Rubio JM, García JL, Oteo JA, Martín SG, Larrégola LS, Salvador F, Rojo-Marcos G, Balerdi-Sarasola L, Urkola XK, Pérez MJS, Onieva-García MA, Coll IA, Arranz J, de Novales JM.** Executive Summary of the Spanish Guidelines for the Diagnosis and Management of Imported Febrile Illnesses from the Spanish Society of Tropical Medicine and International Health (SEMTSI), the Imported Pathology Group of the Spanish Society of Infectious Diseases and Clinical Microbiology (GEPI-SEIMC), the Spanish Society of Family and Community Medicine (SEMFYC), the Spanish Society of Primary Care Physicians (SEMERGEN) and the Spanish Society of Emergency Medicine (SEMES). Enferm Infec Micr Cl. 2024; 42(7): 380-5. Article. IF: 2.5; Q2
- **Casares-Jiménez M, Rivero-Juárez A, López-López P, Montes ML, Navarro-Soler R, Peraire J, Espinosa N, Alemán-Valls MR, García-García T, Caballero-Gomez J, Corona-Mata D, Pérez-Valero I, Ulrich RG, Rivero A.** Rat hepatitis E virus (Rocahepevirus ratti) in people living with HIV. Emerg Microbes Infect. 2024; 13(1): 2295389. Article. IF: 7.5; D1
- **De Gea-Grela A, Maldonado-Barrueco A, Cabañuz C, Díaz-Almiron M, Rico A, Ruíz-Carrascoso G, Palacios ME, Martín-Arranz E, Escudero-Nieto R, Bernardino J.** Human intestinal spirochetosis: an entity associated with sexual transmitted infections. Enferm Infec Micr Cl. 2024; 42(5): 231-5. Article. IF: 2.5; Q2
- **de la Calle-Prieto F, Arsuaga M, Rodríguez-Sevilla G, Paiz NS, Díaz-Menéndez M.** The current status of arboviruses with major epidemiological significance in Europe. Enferm Infec Micr Cl. 2024; 42(9): 516-26. Article. IF: 2.5; Q2
- **de Moraes-Souza R, Chater RC, Calvi IP, Mesquita Y, Sarto R, Lapenda I, Pereira LF, Moury L, Herranz-Pinto P.** Efficacy and Safety of Topical Roflumilast for the Treatment of Psoriasis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Clin Drug Invest. 2024; 44(9): 655-65. Review. IF: 2.7; Q2
- **Delgado-Wicke P, Fernández de Córdoba-Oñate S, Roy-Vallejo E, Alegría-Carrasco E, Rodríguez-Serrano DA, Lamana A, Montes N, Nicolao-Gómez A, Carracedo-Rodríguez R, Marcos-Jiménez A, Díaz-Fernández P, Galván-Román JM, Rabes-Rodríguez L, Sanz-Alba M, Ivarez-Rodríguez J, Villa-Martí A, Rodríguez-Franco C, Villapalos-García G, Zubiaur P, Abad-Santos F, de los Santos I, Gomariz RP, García-Vicuña R, Muñoz-Calleja C, González-Ivaro I, Fernández-Ruiz E.** Genetic variants regulating the immune response improve the prediction of COVID-19 severity provided by clinical variables. Sci Rep-Uk. 2024; 14(1): 20728. Article. IF: 3.9; Q1
- **Duvignaud A, Stoney RJ, Angelo KM, Chen LH, Cattaneo P, Motta L, Gobbi FG, Bottieau E, Bourque DL, Popescu CP, Glans H, Asgeirsson H, Oliveira-Souto I, Vaughan SD, Amatya B, Norman FF, Waggoner J, Diaz-Menéndez M, Beadsworth M, Odolini S, Camprubí-Ferrer D, Epelboin L, Connor BA, Eperon G, Schwartz E, Libman M, Malvy D, Hamer DH, Huits R.** Epidemiology of travel-associated dengue from 2007 to 2022: A GeoSentinel analysis. J Travel Med. 2024; 31(7): taae089. Article. IF: 6.4; D1
- **Escudero-Sánchez R, Ramos-Martínez A, Caballero-Bermejo AF, Diaz-Pollán B, Ruiz-Carrascoso G, Samperio MO, García PM, Amador PM, Romo FG, Segarra OM, Jiménez GN, Albendea LD, García AM, Cobo J.** Bezlotoxumab during the first episode of Clostridioides difficile infection in patients at high risk of recurrence. Eur J Clin Microbiol. 2024; 43(3): 533-40. Article. IF: 3.0; Q2
- **Esteban-Cantos A, Montejano R, Pinto-Martínez A, Rodríguez-Centeno J, Pulido F, Arribas JR.** Non-suppressible viraemia during HIV-1 therapy: a challenge for clinicians. Lancet Hiv. 2024; 11(5): e333-40. Review. IF: 13.0; D1
- **Falces-Romero I, García-Pérez I, Martín-Carbonero L, García-Rodríguez J, Mingorance J.** Quantification of human immunodeficiency virus type 2 (HIV-2) viral load in plasma: Comparison of three commercial assays. J Clin Virol. 2024; 175: 105745. Article. IF: 3.4; Q2
- **Ferrer AL, Romero IB, Díaz RR, Pinto PH.** Four-Year Maintenance of Complete Skin Clearance With Bimekizumab in 10 Spanish Patients from the Be Radiant Trial. Actas Dermosifiliogr. 2024; 115(10): T1024-6. Letter. IF: 2.8; Q2
- **Frutos JOD, Baldrich ES, Boixareu MJT, Hita JCA, Carrillo JMC, Nart IF, Flórez A, Pinto PH, Silvestre JF.** Consensus on the Diagnostic Algorithm for Chronic Nodular Prurigo. Actas Dermosifiliogr. 2024; 115(10): T967-73. Article. IF: 2.8; Q2
- **García JCLA, Marco I, Martin JG, López-Medrano F, Eixeres-Esteve A, Pérez PC, Baguda JD, López-Jimenez EA, Arribas F, Delgado-Jimenez JF, Carmena MDGC.** Evolution of the impact of the COVID-19 pandemic on heart transplant recipients: Decreasing risk, improving perspective. Transpl Infect Dis. 2024; 26(2): e14250. Article. IF: 2.6; Q2
- **García L, Gutiérrez-Arroyo A, Miguel-Buckley R, Ucero A, Cantizani J, Boto-de-los-Bueis A.** Persistent and Severe Mpox Keratitis Despite Systemic and Topical Treatment. Cornea. 2024; 43(6): 777-83. Article. IF: 2.1; Q2
- **García-Bujalance S, Rubio-Mora E, Maldonado-Barrueco A, Montejano R, Rodríguez JG.** Chronic bacterial prostatitis with microbiological diagnosis: about two cases. Rev Esp Quim. 2024; 37(1): 118-20. Letter. IF: 2.2; Q3
- **García-Pérez J, Borobia AM, Pérez-Olmeda M, Portolés A, Castaño L, Campins-Arti M, Bertran MJ, Bermejo M, Arribas JR, López A, Ascaso-del-Rio A, Arana-Arri E, Camps IF, Vilella A, Cascajero A, García-Morales MT,**

de la Osa MC, Ingidua CP, Lora D, Jiménez-Santana P, Pino-Rosa S, de la Cámara AG, de la Torre-tarazona E, Calonge E, Cruces R, Belda-Iniesta CB, Alcami J, Frias J, Carcas AJ, Díez-Fuertes F. Immunogenicity of a third dose with mRNA-vaccines in the ChAdOx1-S/BNT162b2 vaccination SARS-CoV-2 variants. Iscience. 2024; 27(9): 110728. Article. IF: 4.1; Q1

- **González-Fernández MA, Herranz-Pinto P, Alonso-Pacheco ML, Mateo-Salillas C, Hoyo-Muñoz A, Jiménez-Nácher I, Moreno-Ramos F, Herrero-Ambrosio A.** Incorporation of patient-reported outcomes into pharmacy and dermatology departments, in psoriasis and atopic dermatitis patients, as a tool to improve the healthcare quality and health outcomes. J Healthc Qual Res. 2024; 39(1): 13-22. Article. IF: 1.0; Q4
- **Guagliardo SAJ, Smith T, Hamer DH, Huits R, Kozarsky P, Libman M, Mccollum AM, Angelo KM.** Analysis of Monkeypox Virus Exposures and Lesions by Anatomic Site. Emerg Infect Dis. 2024; 30(11): 2381-4. Article. IF: 6.6; D1
- **Jensen T, Murray TA, Grandits GA, Jain MK, Grund B, Shaw-Saliba K, Matthay MA, Abassi M, Ardelt M, Baker J, Chen PT, Dewar RL, Goodman AL, Hatlen TJ, Highbarger HC, Holodniy M, Lallemand P, Laverdure S, Leshnower BG, Looney D, Moschopoulos C, Mugerwa H, Murray D, Mylonakis E, Nagy-Agren S, Rehman MT, Rupert A, Stevens R, Turville S, Weintrob A, Wick K, Lundgren J, Ko ER.** Early trajectories of virological and immunological biomarkers and clinical outcomes in patients admitted to hospital for COVID-19: an international, prospective cohort study. Lancet Microbe. 2024; 5(6): e559-69. Article. IF: 20.4; D1
- **Jiménez RMR, Pinto PH, Domínguez MC, Mata SA, Bellmunt A, Prades M, Arumi D, Hernández-Martín I, Herrera-Lasso V, Llevat N, Juste AD, Laserna FJR.** Cost-Effectiveness Analysis of Abrocitinib Compared with Other Systemic Treatments for Severe Atopic Dermatitis in Spain. Pharmacoecon Open. 2024; 8(2): 291-302. Article; Early Access. IF: 2.1; Q2
- **Lara-Aguilar V, Llamas-Adán M, Brochado-Kith O, Crespo-Bermejo C, Grande-García S, Arca-Lafuente S, de los Santos I, Prado C, Alía M, Sainz-Pinós C, Fernández-Rodríguez A, Martín-Carbonero L, Madrid R, Briz V.** Low-level HIV-1 viremia affects T-cell activation and senescence in long-term treated adults in the INSTI era. J Biomed Sci. 2024; 31(1): 80. Article. IF: 12.1; D1
- **Maldonado-Barrueco A, Moreno-Ramos F, Díaz-Pollán B, Loeches-Yagüe B, Rico-Nieto A, García-Rodríguez J, Ruiz-Carrascoso G.** Increase of healthcare-onset Clostridioides difficile infection in adult population since SARS-CoV-2 pandemic: A retrospective cohort study in a tertiary care hospital from 2019 to 2022. Anaerobe. 2024; 86: 102836. Article. IF: 2.6; Q3
- **Maldonado-Barrueco A, San José-Villar SM, García-Rodríguez J, Alguacil-Guillén M, López-Janeiro A, Trigo-Esteban E, Díaz-Menéndez M, Ruiz-Carrascoso G.** Answer to April 2024 Photo Quiz. J Clin Microbiol. 2024; 62(4): e0125923. Editorial Material. IF: 5.4; Q1
- **Maldonado-Barrueco A, San José-Villar SM, García-Rodríguez J, Alguacil-Guillén M, López-Janeiro A, Trigo-Esteban E, Díaz-Menéndez M, Ruiz-Carrascoso G.** Photo Quiz: Mmm … delicious ceviche from Ecuador!. J Clin Microbiol. 2024; 62(4): e0125823. Editorial Material. IF: 5.4; Q1
- **Maldonado-Barrueco A, Utrilla C, Hernández-González A, Perteguer MJ, Díaz-Pollán B, Untoria-Tabares Y, Díaz-Menéndez M, Falces-Romero I, Gutiérrez-Arroyo A, García-Rodríguez J, Montero-Vega D.** Intraventricular neurocysticercosis in a migrant from Honduras. J Travel Med. 2024; 31(3): taad090. Article. IF: 6.4; D1
- **Manau JV, Calvo CM, Grela AD, Ruperto LR, Serrano L, Arenzana CB, Micán R, Buckley RD, Sánchez RM, Bernardino I, Valenciab ME, Moreno V, Montes ML, Arribas JR, González J, Martín-Carbonero L.** Epidemiological characteristic and prognosis changes in chronic hepatitis B in people living with HIV. Enferm Infec Micr Cl. 2024; 42(3): 130-4. Article. IF: 2.5; Q2
- **Mangas-Moro A, Zamarrón E, Carpio C, Alvarez-Sala R, Arribas-López JR, Prados C.** Influenza vaccination mitigates severe complications in hospitalized patients: A ten-year observational study, Spain, 2009-2019. Am J Infect Control. 2024; 52(5): 563-9. Article. IF: 2.4; Q2
- **Mariscal-Aguilar P, Gómez-Carrera L, Bonilla G, Carpio C, Zamarrón E, Fernández-Velilla M, Díaz-Almirón M, Gayá F, Villamañán E, Prados C, alvarez-Sala R.** Impact of Air Pollution on the Long-Term Decline of Non-Idiopathic Pulmonary Fibrosis Interstitial Lung Disease. Atmosphere-Basel. 2024; 15(12): 1405. Article. IF: 2.3; Q3
- **Mariscal-Aguilar P, Gómez-Carrera L, Bonilla G, Díaz-Almirón M, Gayá F, Carpio C, Zamarrón E, Fernández-Velilla M, Torres I, Esteban I, Regojo R, Villamañán E, Prados C, Alvarez-Sala R.** Air pollution exposure and its effects on idiopathic pulmonary fibrosis: clinical worsening, lung function decline, and radiological deterioration. Front Public Health. 2024; 11: 1331134. Article. IF: 3.4; Q1
- **Martín-Carbonero L, Gutierrez A, Bisbal O, Vergas J, González-Baeza A, Martín CR, Vivancos MJ, Sanz J, Alvarez B, Palomar M, de los Santos I, Sepúlveda-Crespo D, Resino S, Berenguer J, Cano-Smith J, González-García J, Ryan P.** Recently acquired hepatitis C: Epidemiological characteristics and treatment response in a large cohort of MSM living with HIV in Madrid. Enferm Infec Micr Cl. 2024; 42(8): 414-9. Article. IF: 2.5; Q2
- **Martín-Escolano R, Virseda-Berdices A, Berenguer J, González-García J, Brochado-Kith O, Fernández-Rodríguez A, Díez C, Hontañon V, Resino S, Jiménez-Sousa MA, Marathon Study Grp.** Immune checkpoint proteins are associated with persistently high liver stiffness after successful HCV treatment in people with HIV: a retrospective study. Front Immunol. 2024; 15: 1505864. Article. IF: 5.9; Q1
- **Martín-Escolano R, Virseda-Berdices A, Berenguer J, González-García J, Brochado-Kith O, Fernández-Rodríguez A, Díez C, Hontañon V, Resino S, Jiménez-Sousa MA.** Low plasma levels of BTLA and LAG-3 before HCV therapy are associated with metabolic disorders after HCV eradication in persons with HIV/HCV coinfection: a retrospective study. Front Pharmacol. 2024; 15: 1341612. Article. IF: 4.8; Q1
- **Masenga SK, Bernardino JI.** Binge eating correlates with weight excess in people with HIV. Aids. 2024; 38(14): 1978-9. Editorial Material. IF: 3.1; Q2
- **Montejano R, Arribas JR.** COVID-19 Clinical Trials: Are Adaptive Methodologies the Solution?. Clin Infect Dis. 2024; 79(5): 1323. Letter. IF: 7.3; D1
- **Montejano R, Soler-Carracedo A, Borobia AM, Martin-Quiros A, Grandioso D, Canada C, Román A, Arribas JR.** The Current Mismatch Between Coronavirus Disease 2019 Clinical Trial Design and the Evolving Profile of Hospitalized Patients: A Retrospective Cohort Analysis. Clin Infect Dis. 2024; 78(4): 918-21. Article. IF: 7.3; D1
- **Montes ML, Busca C, Espinosa N, Bernardino JI, Ibarra-Ugarte S, Martin-Carbonero L, Moreno C, Macias J, Rivero A, Cervero-Jimenez M, González-García J.** Incidence of Diabetes Mellitus and Associated Factors in the Era of Antiretroviral Drugs With a Low Metabolic Toxicity Profile. Open Forum Infect Dis. 2024; 11(4): ofae112. Article. IF: 3.8; Q1
- **Montes ML, Busca C, Rava M, Bernardino JI, Rivero A, Martin-Carbonero L, Cañas-Ruano E, Ugarte SI, Galindo MJ, Cabello A, González-García J.** Hepatic steatosis-insulin resistance and type 2 diabetes in people with HIV at diagnosis: effect of initial antiretroviral therapy. Aids. 2024; 38(14): 1982-7. Letter. IF: 3.1; Q2
- **Moragrega AB, Busca C, Apostolova N, Olveira A, Martin-Carbonero L, Valencia E, Moreno V, Bernardino JI, Abadia M, González-García J, Esplugues JV, Montes ML, Blas-García A.** Rilpivirine Activates STAT1 in Non-Parenchymal Cells to Regulate Liver Injury in People Living with HIV and MASLD. Biomedicines. 2024; 12(7): 1454. Article. IF: 3.9; Q2
- **Ramírez-Olivencia G, Arribas MV, García MMV, Casabona J, Martínez MJ, De**

Novales FJM. Clinical and Epidemiological Characteristics of the 2022 Mpox Outbreak in Spain (CEME-22 Study). Open Forum Infect Dis. 2024; 11(3): ofae105. Article. IF: 3.8; Q1

- **Ramos-Ruperto L, Arcos-Rueda MD, de Miguel-Buckley R, Busca-Arenzana C, Mican R, Montejano R, Delgado-Hierro A, Montes ML, Valencia ME, Serrano L, Arribas JR, González J, Bernardino JI, Martín-Carbonero L.** Sex differences in the effectiveness and tolerability of dolutegravir plus rilpivirine as a switch strategy in people living with HIV. Hiv Med. 2024; 25(6): 684-91. Article. IF: 3.2; Q2
- **Rodríguez-Aguirregabiria M, Lázaro-Perona F, Cacho-Calvo JB, Arellano-Serrano MS, Ramos-Ramos JC, Rubio-Mora E, Díaz-Almirón M, Asensio-Martín MJ.** Challenges Facing Two Outbreaks of Carbapenem-Resistant Acinetobacter baumannii: From Cefiderocol Susceptibility Testing to the Emergence of Cefiderocol-Resistant Mutants. Antibiotics (Basel). 2024; 13(8): 784. Article. IF: 4.6; Q1
- **Rodríguez-Molino P, Martínez SG, Amador JB, Mellado-Sola I, Martín LM, Falces-Romero I, López-Hortelano MG, Hurtado-Gallego J, Mellado MJ, Grasa C, Sainz T.** Schistosomiasis in migrant children and adolescents in a paediatric tropical referral unit in Spain: diagnosis and long-term management challenges. Eur J Pediatr. 2024; 183(10): 4457-65. Article. IF: 2.6; Q1
- **Sáez-Llorens X, Norero X, Mussi-Pinhata MM, Luciani K, de la Cueva IS, Díez-Domingo J, López-Medina E, Epalza C, Brzostek J, Szymanski H, Boucher FD, Cetin BS, De Leon T, Dinleyici EC, Gabriel MAM, Ince T, Macias-Parra M, Langley JM, Martinón-Torres F, Rämet M, Kuchar E, Pinto J, Puthanakit T, Baquero-Artigao F, Gattinara GC, Arribas JMM, Amador JTR, Szenborn L, Tapiero B, Anderson EJ, Campbell JD, Faust SN, Nikic V, Zhou YJ, Pu WJ, Friel D, Dieussaert I, López AG, McPhee R, Stoszek SK, Vanhoutte N.** Safety and Immunogenicity of a ChAd155-Vectored Respiratory Syncytial Virus Vaccine in Infants 6-7 Months of age: A Phase 1/2 Randomized Trial. J Infect Dis. 2024; 229(1): 95-107. Article. IF: 4.5; Q1
- **Salgado M, Gálvez C, Nijhuis M, Kwon M, Cardozo-Ojeda EF, Badiola J, Gorman MJ, Huyveneers LEP, Urrea V, Bandera A, Jensen BEO, Vandekerckhove L, Jurado M, Raj K, Wiesch JSZ, Bailen R, Eberhard JM, Nabergoj M, Hütter G, Saldaña-Moreno R, Oldford S, Barrett L, Ramirez MLM, Garba S, Gupta RK, Revollo B, Ferra-Coll C, Kuball J, Alter G, Sáez-Cirión A, Diez-Martin JL, Duke ER, Schiffer JT, Wensing A, Martínez-Picado J.** Dynamics of virological and immunological markers of HIV persistence after allogeneic haematopoietic stem-cell transplantation in the IciStem cohort: a prospective observational cohort study. Lancet Hiv. 2024; 11(6): e389-e405. Article. IF: 13.0; D1
- **Sendagorta E, Herranz P.** Optimising anal cancer screening through risk stratification. Lancet Hiv. 2024; 11(9): e570-2. Editorial Material. IF: 13.0; D1
- **Sepúlveda-Crespo D, Volpi C, Amigot-Sánchez R, Yélamos MB, Díez C, Gómez J, Hontañón V, Berenguer J, González-García J, Martín-Escolano R, Resino S, Martínez I.** Sustained Long-Term Decline in Anti-HCV Neutralizing Antibodies in HIV/HCV-Coinfected Patients Five Years after HCV Therapy: A Retrospective Study. Pharmaceuticals (Basel). 2024; 17(9): 1152. Article. IF: 4.8; Q1
- **Shafat T, Grupel D, Porges T, Abuhasira R, Belkin A, Deri O, Oster Y, Zahran S, Horwitz E, Horowitz NA, Khatib H, Batista MV, Cortez AC, Brosh-Nissimov T, Segman Y, Ishay L, Cohen R, Atamna A, Spallone A, Chemaly RF, Ramos-Ramos JC, Chowers M, Rogozin E, Oren NC, Keske S, Barchad OW, Nesher L.** An international multicenter study comparing COVID-19 omicron outcomes in patients with hematological malignancies treated with obinutuzumab versus rituximab. Cancer Med. 2024; 13(3): e6997. Article. IF: 3.1; Q2
- **Tamarozzi F, Mazzi C, Antinori S, Arsuaga M, Becker SL, Bottieau E, Camprubi-Ferrer D, Caumes E, Duvignaud A, Grobusch MP,**



Jaureguiberry S, Jordan S, Mueller A, Neumayr A, Pérez-Molina JA, Salas-Coronas J, Salvador F, Tomasoni LR, van Hellemond JJ, Vaughan S, Wammes LJ, Zammarchi L, Buonfrate D, Huits R, van Lieshout L, Gobbi F. Consensus definitions in imported human schistosomiasis:a GeoSentinel and TropNet Delphi study. Lancet Infect Dis. 2024; 24(10): e627-37. Review. IF: 31.0; D1

- **Vidas MM, Rubio EM, Quiroga B, Montejano R, Morales E, Candel FJ.** Strategies for prevention and treatment of SARS-COV-2 infection in patients with chronic kidney disease: Literature review. Nefrologia. 2024; 44(2): 150-8. Review. IF: 2.6; Q2
- **Virseda-Berdices A, Martín-Escolano R, Berenguer J, González-García J, Brochado-Kith O, Rojo D, Fernández-Rodríguez A, Pérez-Latorre L, Hontañón V, Barbas C, Resino S, Jiménez-Sousa MA.** Plasma metabolomic profile is near-normal in people with HIV on long-term suppressive antiretroviral therapy. Front Cell Infect Mi. 2024; 14: 1340610. Article. IF: 4.8; Q1
- **Vliegenthart-Jongbloed KJ, Vasylyev M, Jordans CCE, Bernardino JI, Nozza S, Psomas CK, Voit F, Barber TJ, Skrzat-Klapaczynska A, Sandulescu O, Rokx C.** Systematic Review: Strategies for Improving HIV Testing and Detection Rates in European Hospitals. Microorganisms. 2024; 12(2): 254. Review. IF: 4.2; Q2
- **Weitzel T, Brown A, Libman M, Perret C, Huits R, Chen L, Leung DT, Leder K, Connor BA, Menendez MD, Asgeirsson H, Schwartz E, Salvador F, Malvy D, Saio M, Norman FF, Amatya B, Duvignaud A, Vaughan S, Glynn M, Angelo KM.** Intestinal protozoa in returning travellers: a GeoSentinel analysis from 2007 to 2019. J Travel Med. 2024; 31(4): taae010. Article. IF: 6.4; D1

Research projects

- **Arribas López JR.** Biomarcadores epigenéticos de envejecimiento como predictores de eventos SIDA no-SIDA y enfermedades propias del envejecimiento (PI22/00285). ISCIII. 2023-2025. Managment centre: FIBHULP
- **Arribas López JR.** European Research and Preparedness Network for Pandemics and Emerging Infectious Diseases (EU-RESPONSE). EU. 2020-2025. Managment centre: FIBHULP
- **Arribas López JR.** Impacto de abacavir y tenofovir en la recuperación a largo plazo del estado de inmunosenescencia en una cohorte

prospectiva de adultos de avirímicos infrectador por el VIH (PI19/00294). ISCIII. 2020-2024. Managment centre: FIBHULP

- **Arribas López JR.** Metformina vs placebo para la reversión de la aceleración de la edad biológica en personas de 50 años o mayores que viven con el VIH y con replicación viral suprimida (ICI20/00043). ISCIII. 2021-2024. Managment centre: FIBHULP
- **Arribas López JR.** MPX-RESPONSE_A clinical research network to improve the management of Monkeypox virus disease. (2022.565). EU. 2022-2026. Managment centre: FIBHULP
- **Arribas López JR.** Puesta en marcha del ensayo clinico MK-7110-009-estudio clinico de fase 3 aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y al seguridad de MK-7110 en participantes hospitalizados con convid-19 moderada o grave. Merck Sharp and Dohme de España S.A. 2021-Ongoing. Managment centre: FIBHULP
- **Arribas López JR.** Dinamización de ciencia disruptiva en predictores de enfermedades tumorales, infecciosas y hereditarias como base de la medicina personalizada (FORT23/00006_GRUPO IV). ISCIII. 2024-2027. Managment centre: FIBHULP
- **Arsuaga Vicente M.** Filling key research gaps with clinical implications in mansonellosis and schistosomiasis. a network approach. IRCCS Sacro Cuore Don Calabria Hospital. 2021-Ongoing. Managment centre: FIBHULP
- **Bernardino de la Serna JI.** Biological age and cardiovascular ischemic events or diabtes in HIV-infected patients. Gilead Sciences S. L. 2017-Ongoing. Managment centre: FIBHULP
- **Bernardino de la Serna JI.** Programa de actualización sobre investigación en pacientes infectados por el VIH ¿qué hay de nuevo? nuevos pacientes, nuevos retos, nuevos investigadores. Gilead Sciences S. L. 2018-Ongoing. Managment centre: FIBHULP
- **de Miguel Buckely R.** Proof of concept, pilot, open, single center randomized study of a group intervention vs. robotic companion pets to reduce loneliness in elderly persons living with HIV (GLD23/00017). Gilead Sciences S. L. 2024-Ongoing. Managment centre: FIBHULP
- **Díaz Menéndez M.** Caracterización de los cuadros de fiebre tras la vuelta de un viaje internacional sin diagnóstico por métodos convencionales y evaluación de técnicas basadas en secuenciación masiva para el diagnóstico microbiológico: estudio Meta-Pyrexis" meta-pyrexis (PI-5690). Becas Luis Álvarez/FIBHULP. 2023-Ongoing. Managment centre: FIBHULP
- **Díaz Menéndez M.** Evaluación de la patología adquirida por viajeros de riesgo durante un viaje internacional: estudio prospectivo en un centro de referencia. International Society of Travel Medicine. 2017-Ongoing. Managment centre: FIBHULP
- **Díaz Menéndez M.** Impact of international travel on the prevalence of intestinal carriage of resistant enterobacteriae and its interaction with the gut microbiota. FIBHULP. 2022-Ongoing. Managment centre: FIBHULP
- **Gayá Moreno F.** Contrato técnico de apoyo a estabilizado (ECA07/013). CM. 2008-2025. Managment centre: FIBHULP
- **Gonzalez García JJ.** Infecciones Agudas/ Recientes y Reinfecciones por VHC en Hombres que tienen Sexo con Hombres con y sin VIH (PI20/00507). ISCIII. 2021-2025. Managment centre: FIBHULP
- **Herranz Pinto P.** Dermatitis atopica y patologia alergica en dermatologia: actualización y perspectivas futuras para medicos y pacientes: de la investigación a la práctica clínica. Sanofi Aventis S.A. 2020-Ongoing. Managment centre: FIBHULP
- **Montejano Sánchez R.** Aceleración de la edad epigenética en personas que viven con VIH: Impacto de factores biológicos y de comportamiento (PI21/01349). ISCIII. 2022-2024. Managment centre: FIBHULP
- **Montes Ramírez ML.** Estudio de hepatopatías en pacientes infectados por VIH sin hepatitis víricas que reciben tratamiento antirretroviral. Abbvie Spain S. L. U. 2016-Ongoing. Managment centre: FIBHULP
- **Rodés Soldevila B.** Contrato Miguel Servet Categoria A (CES11/021). ISCIII. 2007-2025. Managment centre: FIBHULP
- **Rodés Soldevila B.** Efecto de la Metformina sobre el Reservorio Viral en Personas con (2023.64). FIBHULP. 2023-2024. Managment centre: FIBHULP
- **Rodés Soldevila B.** Impacto de la regulación epigenética de la proteina p21 y su asociación a la progresión a sida en la infección por VIH (PI25-11). Genoma España. 2011-Ongoing. Managment centre: FIBHULP
- **Rodés Soldevila B.** Perfiles de metilación del ADN y transcripción génica como marcadores del agotamiento de las células T en individuos VIH+ no tratados y crónicos avirémicos (PI21/00177). ISCIII. 2022-2026. Managment centre: FIBHULP
- **Rodés Soldevila B.** Efecto de la metformina sobre el reservorio viral en personascon VIH: caracterización virológica, genética y epigenética. (PI24/00927). ISCIII. 2025-2027. Managment centre: FIBHULP
- **Rodríguez Centeno J.** Marcadores de respuesta post-vacunal en población inmunocomprometida (MARVIC): oportunidades para el desarrollo de nuevas inmunoterapias para la prevención de la covid 19 (2024.128). Fundacio de la Lluita contra el SIDA. 2023-Ongoing. Managment centre: FIBHULP
- **Sendagorta Cudós E.** ClearPap: dispositivo de terapia fotodinámica para el tratamiento de lesiones anales asociadas a VPH (DTS22/00181). ISCIII. 2023-2025. Managment centre: FIBHULP

Ciber and Retics

- **Arribas López JR.** Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERInfect) (CB21/13/00039). ISCIII. (31/12/2024). FIBHULP

Clinical Trial

- **Arcos Rueda MM.** estudio de seroconvertores frente al vih en el contexto de uso de prep: estudio scope\.
  Type/Phase: EPA-SP
  Sponsored by: Arcos Rueda Maria Del Mar
  Signature date: 10/10/2024
- **Arribas López JR.** brand-specific respiratory syncytial virus vaccine effectiveness in europe\.
  Type/Phase: EPA-SP
  Sponsored by: P95 Bv
  Signature date: 08/08/2024
- **Arribas López JR.** estudio de fase 2, multicéntrico, aleatorizado, doble ciego, controlado con placebo para evaluar la eficacia, la seguridad, la tolerabilidad y la farmacocinética de abbv 382 y/o budigalimab en personas que viven con vih con tratamiento antirretroviral estable sometidas a una interrupción analítica del tratamiento\.
  Type/Phase: II
  Sponsored by: Abbvie Deutschland GMBH & Co. Kg
  Signature date: 29/02/2024
- **Arribas López JR.** estudio de fase 2, multicéntrico, aleatorizado, doble ciego, controlado con placebo para evaluar la eficacia, la seguridad, la tolerabilidad y la farmacocinética de abbv 382 y/o budigalimab en personas que viven con vih con tratamiento antirretroviral estable sometidas a una interrupción analítica del tratamiento\.
  Type/Phase: II
  Sponsored by: Abbvie Deutschland GMBH & Co. Kg
  Signature date: 03/12/2024
- **Arribas López JR.** estudio internacional observacional para la caraterización de adultos hospitalizados por las complicaciones de la gripe a pandémica h1n1\.
  Type/Phase: No EPA
  Sponsored by: Copenhagen Hiv Programme
  Signature date: 13/03/2024
- **Arribas López JR.** surveillance study of respiratory pathogens in adults hospitalised for sari across europe\.
  Type/Phase: OTROS
  Sponsored by: P95 Bv
  Signature date: 08/08/2024
- **Arsuaga Vicente M.** ensayo clínico aleatorizado de no inferioridad para evaluar la eficacia de una dosis única y fija de 18 mg de ivermectina para el tratamiento de la estrongiloidiasis no complicada\.
  Type/Phase: IIb
  Sponsored by: Fundacio Hospital Vall D'Hebron
  Signature date: 05/01/2024
- **Bernardino de la Serna JI.** european randomised clinical trial on monkeypox infection (epoxi)\.
  Type/Phase: IV
  Sponsored by: UMC Utrecht
  Signature date: 30/09/2024

- **Bernardino de la Serna JI.** morbilidad, mortalidad y factores de riesgo de mpox en asistentes a clínicas de salud sexual de alto riesgo y vih negativos y personas que viven con el vih – estudio mash-1\.
  Type/Phase: OTROS
  Sponsored by: Neat Id Foundation
  Signature date: 29/10/2024
- **Bernardino de la Serna JI.** un ensayo clínico fase iv adaptativo, multicéntrico, controlado, aleatorizado y simple ciego para evaluar la eficacia, seguridad y coste eficacia de una estrategia de genotipado anticipado en una población en riesgo de enfermedad cardiovascular y susceptible de recibir de estatinas de alta o moderada\.
  Type/Phase: IV
  Sponsored by: FIBHULP
  Signature date: 27/05/2024
- **Bonilla Hernán MG**
- **Herranz Pinto P.** sjögren syndrome and atopic dermatitis cohorts' generation and multi-omics characterization (ssad project) / generación de cohortes y caracterización multiómica del síndrome de sjögren y la dermatitis atópica (proyecto ssad)\.
  Type/Phase: No EPA
  Sponsored by: Fundacio Hospital Vall D'Hebron ;Signature date: 15/02/2024
- **de Miguel Buckley R.** estudio aleatorizado de prueba de concepto, piloto, abierto, unicéntrico, de una intervención grupal vs. mascotas de compañía robóticas para reducir la soledad en personas mayores que viven con vih\.
  Type/Phase: I
  Sponsored by: De Miguel Buckley Rosa
  Signature date: 30/04/2024
- **Díaz Pollán B.** estudio en fase iii, aleatorizado, doble ciego, controlado con placebo y multicéntrico para evaluar la eficacia, la seguridad y la inmunogenicidad de la vacunación con expec9v en la prevención de la enfermedad por escherichia coli patógena extraintestinal invasiva en adultos de 60 años de edad en adelante con antecedentes de infección urinaria en los últimos 2 años\.
  Type/Phase: III
  Sponsored by: Janssen Research & Development Llc
  Signature date: 28/03/2024
- **Díaz Pollán B.** estudio pseudonova2. diseño de pautas optimizadas de tratamiento antimicrobiano de infecciones respiratorias por pseudomonas aeruginosa. estudio clínico observacional, microbiológico y farmacodinámico mediante el modelo in vitro hollow fiber\.
  Type/Phase: EOm no prospectivo
  Sponsored by: Fundación Imim
  Signature date: 29/11/2024
- **Díaz Pollán B.** randomized, double-blind, placebo-controlled phase 3 study of ve303 for prevention of recurrent cdi (restorative303 study)\.
  Type/Phase: III
  Sponsored by: Vedanta Biosciences Inc.
  Signature date: 02/09/2024
- **González García JJ.** estudio de fase 3, aleatorizado, controlado con tratamiento activo y abierto para evaluar el cambio a una pauta semanal de islatravir/lenacapavir por vía oral en personas con vih1 con supresión virológica bajo el tratamiento habitual\.
  Type/Phase: III
  Sponsored by: Gilead Sciences Inc.
  Signature date: 17/12/2024
- **González García JJ.** estudio de fase 3, doble ciego, multicéntrico, aleatorizado y con control activo para evaluar la seguridad y la eficacia de la combinación de bictegravir/lenacapavir frente a biktarvy® (bictegravir/emtricitabina/tenofovir alafenamida) en personas con vih-1 con supresión virológica (artistry-2)\.
  Type/Phase: III
  Sponsored by: Gilead Sciences Inc.
  Signature date: 05/06/2024
- **González García JJ.** survey on the experience and satisfaction of patients with their participation in a clinical trial in spain and portugal\.
  Type/Phase: OTROS
  Sponsored by: Merck Sharp And Dohme De España S.A.
  Signature date: 15/10/2024
- **Herranz Pinto P.** a phase 3, 2-part, open-label and double-blind, randomised study to evaluate the effectiveness and safety of lebrikizumab treatment in adults and adolescents with moderate-to-severe atopic dermatitis\.
  Type/Phase: IIIb
  Sponsored by: Almirall S.A.
  Signature date: 20/05/2024
- **Herranz Pinto P.** a phase 3, 52-week, multicenter, randomized, placebo-controlled, double-blind study to assess the efficacy, safety, and tolerability of rocatinlimab in adult subjects with prurigo nodularis who are inadequately controlled on topical therapies or not eligible for topical therapies\.
  Type/Phase: III
  Sponsored by: Amgen Inc.
  Signature date: 01/11/2024
- **Herranz Pinto P.** ensayo fase 2b, aleatorizado, doble ciego, controlado con placebo, multicéntrico, de grupos paralelos y de búsqueda de dosis para evaluar la eficacia y la seguridad de diferentes dosis de leo 138559 administrado por vía subcutánea en sujetos adultos con dermatitis atópica (da) de moderada a grave\.
  Type/Phase: IIb
  Sponsored by: Leo Pharma A/S
  Signature date: 12/06/2024
- **Herranz Pinto P.** estudio de extensión a largo plazo para evaluar la seguridad, tolerabilidad y eficacia a largo plazo de amlitelimab administrado por vía subcutánea en participantes adultos con dermatitis atópica de moderada a grave que participaron en el estudio ky1005-ct05 (dri17366)\.
  Type/Phase: II
  Sponsored by: Sanofi-Aventis Recherche & Developpement
  Signature date: 06/11/2024
- **Herranz Pinto P.** estudio de extensión de fase iii, multinacional, multicéntrico, aleatorizado, doble ciego, controlado con placebo y de grupos paralelos de 48 semanas para evaluar la respuesta al tratamiento y la seguridad de dos pautas posológicas de amlitelimab administradas en monoterapia mediante inyección subcutánea en participantes de 12 años de edad y mayores con dermatitis atópica de moderada a severa\.
  Type/Phase: III
  Sponsored by: Sanofi-Aventis Recherche Et Developp
  Signature date: 07/06/2024
- **Herranz Pinto P.** estudio de fase iii, abierto, multicentrico, a largo plazo, para investigar la seguridad y la eficacia de pf 06651600 en participantes adultos y adolescentes con alopecia areata\.
  Type/Phase: III
  Sponsored by: Pfizer S.L.U.
  Signature date: 03/12/2024
- **Herranz Pinto P.** estudio de fase iii, aleatorizado, multicéntrico, doble ciego, controlado con placebo y con un fármaco comparativo, con un período aleatorizado de reposo farmacológico y repetición del tratamiento para evaluar la eficacia, la seguridad y la tolerabilidad de tak-279 en sujetos con psoriasis en placas de moderada a grave\.
  Type/Phase: III
  Sponsored by: Takeda Pharmaceuticals International Ag
  Signature date: 09/01/2024
- **Herranz Pinto P.** estudio de fase iiib, doble ciego, multicéntrico, aleatorizado y comparado con un excipiente para evaluar la eficacia y la seguridad de ruxolitinib en crema en adultos con dermatitis atópica moderada\.
  Type/Phase: IIIb
  Sponsored by: Incyte Corporation
  Signature date: 07/10/2024
- **Herranz Pinto P.** estudio de prueba de concepto en fase ii, aleatorizado, doble ciego, controlado con placebo y con grupos paralelos para evaluar la eficacia y la seguridad de amlitelimab en participantes adultos con hidradenitis supurativa de moderada a severa\.
  Type/Phase: II
  Sponsored by: Sanofi-Aventis Recherche Et Developp
  Signature date: 21/03/2024
- **Herranz Pinto P.** estudio de vida real sobre las características, manejo clínico y comorbilidades de los pacientes con psoriasis en españa (psolve)\.
  Type/Phase: EPA-OD
  Sponsored by: Bristol Myers Squibb S.L
  Signature date: 05/07/2024
- **Herranz Pinto P.** estudio en fase 3, aleatorizado, doble ciego, controlado con placebo, de grupos paralelos, con 3 ramas de tratamiento, multinacional y multicéntrico para evaluar la eficacia y la seguridad de amlitelimab mediante inyección subcutánea en participantes de 12 años de edad y mayores con dermatitis atópica de moderada a severa en tratamiento con corticosteroides tópicos de base y que han tenido una respuesta inadecuada a la terapia biológica



previa o al tratamiento oral con inhibidores de janus kinase (jak)\.
Type/Phase: III
Sponsored by: Sanofi-Aventis Recherche Et Developp
Signature date: 24/04/2024

- **Herranz Pinto P.** estudio en fase 3, aleatorizado, doble ciego, controlado con placebo, y de grupos paralelos para evaluar la eficacia y la seguridad de dupilumab en el tratamiento del prurito del liquen simple crónico (lsc) en adultos\.
  Type/Phase: III
  Sponsored by: Sanofi Aventis S.A
  Signature date: 29/11/2024
- **Herranz Pinto P.** estudio en fase iii de retirada aleatorizada, doble ciego, controlado con placebo y multicéntrico para investigar la eficacia y la seguridad de pf-04965842 en pacientes de 12 o más años de edad con dermatitis atópica moderada o grave con la opción de un tratamiento de rescate para aquellos pacientes que presenten un empeoramiento de la enfermedad\.
  Type/Phase: III
  Sponsored by: Pfizer Inc.
  Signature date: 27/09/2024
- **Herranz Pinto P.** estudio en fase iii, aleatorizado, con enmascaramiento doble, comparativo con placebo, sobre la eficacia y la seguridad de povorcitinib en participantes con prurigo nodular\.
  Type/Phase: III
  Sponsored by: Incyte Corporation
  Signature date: 27/12/2024
- **Herranz Pinto P.** estudio en fase iii, aleatorizado, con enmascaramiento doble, controlado con placebo y multicéntrico para evaluar la eficacia y la seguridad de sonelokimab subcutáneo en participantes adultos con hidradenitis supurativa de moderada a grave\.
  Type/Phase: III
  Sponsored by: Moonlake Immunotherapeutics Ag
  Signature date: 15/10/2024
- **Herranz Pinto P.** estudio en fase iii, aleatorizado, doble ciego, controlado con placebo, de grupos paralelos, con 3 ramas de tratamiento, multinacional y multicéntrico para evaluar la eficacia y la seguridad de amlitelimab en monoterapia mediante inyección subcutánea en participantes de 12 años de edad y mayores con dermatitis atópica de moderada a severa\.
  Type/Phase: III
  Sponsored by: Sanofi-Aventis Recherche Et Developp
  Signature date: 09/04/2024
- **Herranz Pinto P.** estudio en fase iii, multicéntrico, aleatorizado, doble ciego, controlado con placebo y controlado con el comparador activo deucravacitinib para evaluar la eficacia y la seguridad de jnj-77242113 para el tratamiento de pacientes con psoriasis en placas de moderada a grave\.
  Type/Phase: III
  Sponsored by: Janssen Research & Development Llc
  Signature date: 18/01/2024
- **Herranz Pinto P.** estudio prospectivo, multicéntrico y a largo plazo para evaluar la seguridad y la eficacia de nemolizumab (cd14152) en sujetos con dermatitis atópica de moderada a grave\.
  Type/Phase: III
  Sponsored by: Galderma S.A.
  Signature date: 12/06/2024
- **Herranz Pinto P.** programa de fase 3, aleatorizado, doble ciego y comparativo con placebo para evaluar la eficacia y la seguridad de upadacitinib en adultos y adolescentes con alopecia areata grave\.
  Type/Phase: III
  Sponsored by: Abbvie Deutschland GMBH & Co. Kg
  Signature date: 25/01/2024
- **Herranz Pinto P.** programa de fase 3, aleatorizado, doble ciego y comparativo con placebo para evaluar la eficacia y la seguridad de upadacitinib en adultos y adolescentes con alopecia areata grave\.
  Type/Phase: III
  Sponsored by: Abbvie Deutschland GMBH & Co. Kg
  Signature date: 20/05/2024
- **Herranz Pinto P.** programa de fase 3, aleatorizado, doble ciego y comparativo con placebo para evaluar la eficacia y la seguridad de upadacitinib en adultos y adolescentes con alopecia areata grave\.
  Type/Phase: III
  Sponsored by: Abbvie Deutschland GMBH & Co. Kg
  Signature date: 04/11/2024
- **Herranz Pinto P.** sjögren syndrome and atopic dermatitis cohorts' generation and multi-omics characterization (ssad project) / generación de cohortes y caracterización multiómica del síndrome de sjögren y la dermatitis atópica (proyecto ssad)\.
  Type/Phase: No EPA
  Sponsored by: Fundacio Hospital Vall D'Hebron
  Signature date: 05/02/2024
- **Marcelo Calvo C.** a phase 4 study using a test-negative design to evaluate the effectiveness of a 20-valent pneumococcal conjugate vaccine against vaccine-type radiologically-confirmed community-acquired pneumonia in adults ≥ 65 years of age\.
  Type/Phase: IV
  Sponsored by: Pfizer Inc.
  Signature date: 17/01/2024
- **Marcelo Calvo C.** a phase 4 study using a test-negative design to evaluate the effectiveness of a 20-valent pneumococcal conjugate vaccine against vaccine-type radiologically-confirmed community-acquired pneumonia in adults ≥ 65 years of age\.
  Type/Phase: IV
  Sponsored by: Pfizer Inc.
  Signature date: 30/07/2024
- **Martín Carbonero L.** estudio multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y seguridad del tratamiento con bepirovirsen en participantes portadores crónicos del virus de la inmunodeficiencia humana y del virus de la hepatitis b, que reciben tratamiento antirretroviral\.
  Type/Phase: IIb
  Sponsored by: Glaxosmithkline Research And Development Limited
  Signature date: 14/10/2024
- **Martín Carbonero L.** prevalence of hdv among hiv/hbv coinfected patients in spain\.
  Type/Phase: OTROS
  Sponsored by: Fundación SEIMC-GESIDA
  Signature date: 12/06/2024
- **Montes Ramírez ML.** estudio de fase 3b, abierto, aleatorizado, controlado con tratamiento estándar, multicéntrico, de superioridad para evaluar la eficacia, la seguridad y la tolerabilidad de cab ap + rpv ap inyectable en participantes virémicos que viven con vih-1. (crown)\.
  Type/Phase: IIIb
  Sponsored by: Viiv Healthcare Uk Limited
  Signature date: 18/11/2024
- **Ramos Ramos JC.** estudio en fase iii, aleatorizado y ciego para el adjudicador para evaluar la eficacia y la seguridad del tratamiento con olorofim en comparación con ambisome® seguido de la práctica clínica habitual en pacientes con micosis invasiva (mi) causada por el género aspergillus\.
  Type/Phase: III
  Sponsored by: F2G Ltd.
  Signature date: 07/05/2024

Patents and Trademarks

- **Romero Gómez M, Solá Lamoglia R, González García JJ, inventors; Servicio Andaluz de Salud, Universidad de Sevilla, Fundació Institut Mar D'Investigacións Mèdiques, FIBHULP, assignees.** Kit for decision making in patients with Hepatitis C genotypes 1 and 4. P201330731; 2013 May 21.

3.3.2 Molecular Microbiology Group

Publications: 66 | **Q1:** 23

COMPOSITION

Jesús Mingorance Cruz.
Investigador Titular. FIBHULP

- **Iván Bloise Sánchez.** *Facultativo Especialista en Microbiología y Parasitología Clínica. Hospital Universitario La Paz*
- **Emilio Cendejas Bueno.** *Facultativo Especialista de Área en Microbiología. Hospital Universitario La Paz*
- **Fernando José Corrales Izquierdo.** *Profesor de Investigación CSIC. CSIC*
- **Elias Dahdouh.** *Investigador Postdoctoral Miguel Servet. FIBHULP*
- **Iker Falces Romero.** *Facultativo Especialista de Área en Microbiología. Hospital Universitario La Paz*
- **Silvia García Bujalance.** *Facultativo Especialista de Área en Microbiología. Hospital Universitario La Paz*
- **María Jesús García García.** *Profesora Emérita. Departamento de Medicina Preventiva y Salud Pública y Microbiología. Facultad de Medicina. Universidad Autónoma de Madrid*
- **Isabel García Pérez.** *Ayudante de Investigación. FIBHULP*
- **Julio García Rodríguez.** *Jefe de Servicio de Microbiología. Hospital Universitario La Paz*
- **Paulino Gómez Puertas.** *Científico Titular CSIC. CBM Severo Ochoa*
- **Rocío González Soltero.** *Catedrática de Genética Molecular. Universidad Europea*
- **David Grandioso Vas.** *Facultativo Especialista de Área en Microbiología. Hospital Universitario La Paz*
- **Almudena Gutiérrez Arroyo.** *Facultativo Especialista de Área en Microbiología. Hospital Universitario La Paz*
- **Fernando Lázaro Perona.** *Facultativo Especialista de Área en Microbiología. Hospital Universitario La Paz*
- **María Fátima López Fabal.** *Facultativo Especialista en Microbiología y Parasitología Clínica. Hospital Universitario La Paz*
- **María Belén Loeches Yagüe.** *Médico Adjunto. Unidad de Enfermedades Infecciosas. Hospital Universitario La Paz*
- **Carmen Menéndez Gómez.** *Profesor contratado Doctor, Departamento de Medicina Preventiva y Salud Pública y Microbiología. Facultad de Medicina. Universidad Autónoma de Madrid*
- **Dolores Montero Vega.** *Facultativo Especialista de Área en Microbiología. Hospital Universitario La Paz*
- **Alberto Paradela Elizalde.** *Investigador Científico. CSIC*
- **Verónica Pérez Blanco.** *Facultativo Especialista de Área en Medicina Preventiva. Hospital Universitario La Paz*
- **Rafael Carlos Prados Rosales.** *Profesor Titular de Universidad . Universidad Autónoma de Madrid*
- **María Inmaculada Quiles Melero.** *Facultativo Especialista de Área en Microbiología. Hospital Universitario La Paz*
- **Alicia Rico Nieto.** *Facultativo Especialista de Área en Microbiología. Hospital Universitario La Paz*
- **Graciela Rodríguez Sevilla.** *Facultativo Especialista de Área en Microbiología. Hospital Universitario La Paz*
- **Mario David Ruiz Bastián.** *Facultativo Especialista en Microbiología y Parasitología Clínica. Hospital Universitario La Paz*
- **Guillermo Ruiz Carrascoso.** *Facultativo Especialista de Área en Microbiología. Hospital Universitario La Paz*
- **Carlos Toro Rueda.** *Facultativo Especialista de Área en Microbiología. Hospital Universitario La Paz*

STRATEGIC OBJETIVES

- The Molecular Microbiology research group originated in the Microbiology Service of Hospital La Paz, and a significant portion of its members are staff physicians from the Service with clinical activity. This shapes the group's strategic approach, which is why the various research lines focus on different aspects of clinical microbiology and infectious pathology.
- A core line, Clinical Microbiology, stems directly from the Service's clinical activity. However, our work in this area goes beyond, delving into the methodological and epidemiological challenges that arise in daily routine.
- In this context, another line focuses on developing molecular methods for the typing and characterization of pathogenic microorganisms. These methods have applications in microbiological diagnosis, epidemiological analysis, and the detection and characterization of antibiotic-resistant bacteria. We have extensive experience in techniques such as PCR, Sanger sequencing, massive sequencing (NGS), bioinformatics analysis, and proteomics.
- Since the emergence of the first carbapenemases between 2008 and 2010, an important line has concentrated on studying the epidemiology, hospital ecology, and evolution of carbapenemase-producing Enterobacteriaceae, especially Klebsiella pneumoniae.
- Related to this line and the difficulties in developing new antibiotics, we utilize molecular dynamics methods to search for novel carbapenemase inhibitors.
- Additionally, several group members, who belong to the UAM Faculty of Medicine, have a long research history in the Molecular Biology and Pathogenesis of Mycobacterium tuberculosis and other mycobacteria.
- Finally, we are exploring the gut microbiome and its alterations in relation to various pathologies and clinical conditions.

RESEARCH LINES

- Molecular epidemiology and evolution of pathogens
- Molecular methods for diagnostics of infectious diseases
- Genomics of hospital microbial pathogens
- Design of new metallo-beta-lactamase inhibitors using computational molecular dynamics simulations of protein-ligand interactions.
- Molecular Biology and Pathogenesis of *Mycobacterium tuberculosis*

RESEARCH ACTIVITY

Doctoral Theses

- **Falces Romero I.** Diagnóstico molecular de bacteriemias y candidemias en pacientes pediátricos críticos: Un nuevo enfoque. [dissertation]. Madrid: UAM: 2024 (19/01/2024). Director: Cendejas Bueno E.
- **Ros Pardo D.** Técnicas de modelado por homología y dinámica molecular en el estudio de la funcionalidad de GSDMB y el complejo de cohesina [dissertation]. Madrid: UAM: 2024(21/02/2024). Director: Gómez-Puertas P.

Master Theses

- **González Gómez I.** Análisis mediante secuenciación masiva de Enterobacterias productoras de NDM en el Hospital Universitario de La Paz y pruebas de transferencia horizontal de genes mediante Vesículas de Membrana Externa (OMVs). [dissertation]. Madrid: UAM: 2024 (18/09/2024). Director: Dahdouh E.
- **Shustrova S.** Análisis de la incidencia y factores de riesgo de Enterobacterias Productoras de Carbapenemasa en una Unidad de Cuidados Intensivos de adultos de un hospital terciario en España: estudio retrospectivo y medidas de control [dissertation]. Madrid: Escuela Nacional de Sanidad: 2024(25/09/2024). Director: Pérez Blanco V.
- **Blanco Córdoba J.** Interacción entre microbiota intestinal y Alzheimer: Caracterización y desarrollo de un pipeline para su aplicación [dissertation]. Madrid: Universidad Europea de Madrid: 2024 (26/11/2024). Director: González Soltero MR.
- **Castro García AB.** Microbiota y esquizofrenia: reuso de datos públicos según estándares FAIR [dissertation]. Madrid: Universidad Europea de Madrid: 2024 (26/11/2024). Director: González Soltero MR.
- **López Gualdrón OJ.** Evaluación de la Adherencia a los Principios FAIR en Bases de Datos de Proyectos de Secuenciación Metagenómica [dissertation]. Madrid: Universidad Europea de Madrid: 2024 (20/10/2024). Director: González Soltero MR.

Final Degree Theses


- **Villaverde L.** Efecto de la nutrición en la microbiota y en el inmunodesarrollo durante los primeros 1000 días de vida [dissertation]. Madrid: UAM: 2024 (17/05/2024). Director: Menéndez Gómez C.
- **Núñez I.** Relación de la microbiota intestinal con la diabetes tipo 2 y sus complicaciones [dissertation]. Madrid: UAM: 2024(17/05/2024). Director: Menéndez Gómez C.

Publications

- **Allende JMB, Antón EF, Gómez-Junyent J, Redó LS, Rodríguez-Pardo D, Rubio OM, Sampedro MF, Escudero-Sánchez R, Gutiérrez MG, Portillo ME, Sancho I, Nieto AR, Carrión LG, Viladomiu AS, Ruiz LM, Iglesias FJD.** Impact of antibiotic prophylaxis in second-stage surgery in joint prosthesis infection treated with two-stage exchange. A multicenter case-control study. Eur J Clin Microbiol. 2024; 43(7): 1319-28. Article. IF: 3.0; Q2
- **Allende JMB, Gómez-Junyent J, Redó LS, Rodríguez-Pardo D, Rubio OM, Sampedro MF, Escudero-Sánchez R, Gutiérrez MG, Portillo ME, Sancho I, Nieto AR, Carrión LG, Soriano A, Ruiz LM.** Description of reinfection of joint prosthesis after 2-stage replacement (infection of the 2nd stage prosthesis): A multicenter study. Enferm Infec Micr Cl. 2024; 42(7): 354-60. Article. IF: 2.5; Q2
- **Arévalo-Romero JA, López-Cantillo G, Moreno-Jiménez S, Marcos-Alcalde I, Ros-Pardo D, Camacho BA, Gomez-Puertas P, Ramírez-Segura CA.** In Silico Design of miniACE2 Decoys with In Vitro Enhanced Neutralization Activity against SARS-CoV-2, Encompassing Omicron Subvariants. Int J Mol Sci. 2024; 25(19): 10802. Article. IF: 4.9; Q1
- **Ascunce M, Coccolo A, Mozo Y, Baquero-Artigao F, Rodríguez-Molino P, Toro-Rueda C, García-Clemente P, Sánchez-Zapardiel E, López-Granados E, Corral-Sánchez D, Bueno D, Sisinni L, Pérez-Martínez A, Calvo C, del Rosal T.** Severe Impairment of T-cell Immunity and Pulmonary GvHD Are Major Risk Factors for Nontuberculous Mycobacterial Infection After Pediatric Allogeneic Hematopoietic Stem Cell Transplantation. Pediatr Infect Dis J. 2024; 43(9): 885-8. Article. IF: 2.2; Q2
- **Auñón A, Salar-Vidal L, Mahillo-Farnández I, Almeida F, Pereira P, Lora-Tamayo J, Ferry T, Souèges S, Dinh A, Escudero R, Fernández-Miranda CM, Rico A, Rossi N, Esteban J.** Prosthetic Joint Infections Caused by Mycobacterium tuberculosis Complex-An ESGIAI-ESGMYC Multicenter, Retrospective Study and Literature Review. Microorganisms. 2024; 12(5): 849. Article. IF: 4.2; Q2
- **Aya JV, Vega LC, Muñoz E, Munoz M, López DF, Guzmán MP, Martínez DF, Cruz-Saavedra LB, Castillo AK, Quintero KJ, Soltero RRG, Cala MP, Ramirez JD.** Divergent Gut Microbiota: Archaeal and Bacterial Signatures Unveil Unique Patterns in Colombian Cyclists Compared to Weightlifters and Non-Athletes. Adv Biol (Weinh). 2024; 8(6): e2400069. Article. IF: 2.6; Q3
- **Bloise-Sánchez I, Alonso-Acero L.** Considerations on the implementation of the Clinical Microbiology and Parasitology training program in Spanish hospitals: A national survey. Enferm Infec Micr Cl. 2024; 42(7): 361-6. Article. IF: 2.5; Q2
- **Buenestado-Serrano S, Martínez-Lirola M, Herranz-Martín M, Esteban J, Broncano-Lavado A, Molero-Salinas A, Sanz-Pérez A, Blázquez J, Ruedas-López A, Toro C, López-Roa P, Domingo D, Zamarrón E, Serrano MJR, Muñoz P, Pérez-Lago L, de Viedma DG.** Microevolution, reinfection and highly complex genomic diversity in patients with sequential isolates of Mycobacterium abscessus. Nat Commun. 2024; 15(1): 2717. Article. IF: 15.7; D1
- **Calderon-Parra J, Domínguez F, González-Rico C, de las Revillas FA, Goenaga MA, Alvarez , Munoz P, Alonso D, Rodríguez-García R, Miro JM, De Alarcon A, Antorrena I, Goikoetxea-Agirre J, Moral-Escudero E, Ojeda-Burgos G, Ramos-Martínez A, Sánchez FF, de Lomas JMG, Rosas G, Lima JD, Bereciartua E, Vidal MJB, Blanco R, Boado MV, Lazaro MC, Crespo A, Carrion LG, de Lagos MDM, Ugarte GE, Goikoetxea AJ, Hierro MI, Iruretagoyena JR, Zuazabal JI, López-Soria L, Montejo M, Nieto J, Rodrigo D, Rodríguez R, Vitoria Y, Voces R, López MVG, Georgieva RI, Ojeda G, Bailon IR, Morales JR, Rodríguez IA, Galparsoro HA, Boronat EB, Odriozola MJB, Martin CD, Echeverria T, Yarza AE, Fuentes A, Goenaga MA, del Rio MG, Bauza AG, Iribarren JA, Urkola XK, López JIPM, Jimenez AR, Reviejo K, Berbejillo AS, Haza ES, Alda RS, Ruiz IS, Ugartemendia IU, Anza DV, Benito IV, Arrieta MZ, Carrasco R, Climent V, Llamas P, Merino E, Plazas J, Reus S, Alonso A, Bouzas A, Castelo B, Cuenca J, Gutierrez L, Ramos L, Mayo MR, Serrano JM, Regueiro DS, Martínez FJ, Alonso MD, Castro B, Melian TD, Sarabia JF, Rosado DG, González JG, Lacalzada J, de la Pena LL, Ramirez AP, Arrondo PP, Moreno FR, Ciezar AP, Iglesias JMR, Alvarez VA, Costas C, de la Hera J, Suárez JF, Fraile LI, Arguero VL, Menendez JL, Bajo PM, Morales C, Torrico AM, Palomo C, Martínez BP, Esteban AR, García RR, Asensio MT, Almela M, Ambrosioni J, Azqueta M, Brunet M, Bodro M, Cartana R, Cuervo G, Falces C, Farnández-Pittol MJ, Fita G, Fuster D, de la Maria CG, García-Pares D, Hernandez-Meneses M, Pérez JL, Marco F, Miro JM, Moreno A, Nicolas D, Ninot S, Quintana E, Pare C, Pereda D, Pericas JM, Pomar JL, Ramirez J, Roque M, Rovira I, Sandoval E, Sitges M, Soy D, Tellez A, Tolosana JM, Vidal B, Vila J, Adan I, Alonso D, Alonso JC, alvarez-Uria A, Bermejo J, Bouza E, Caballero GC, Montero AD, Estevez A, Ribas RF, Gargallo E, Leoni MEG, Mansilla AG, Moraga FJG, Ramallo VG, Hernandez MK, Hualde AM, Machado M, Marin M, Martínez-Selles M,**

Melero R, Munoz P, Monzon D, Olmedo M, Pedraz A, Pinilla B, Pinto A, Rincon C, Rodríguez-Abella H, Rodríguez-Creixems M, Sánchez-Pérez E, Segado A, Toledo N, Valerio M, Vazquez P, Moreno EV, de la Villa S, Antorrena I, Loeches B, Moreno M, Ramirez U, Baston VR, Romero M, Rosillo S, Balbin JA, Farnández CA, Castillo CA, de las Revillas FA, Belaustegui MC, Farinas MC, Farinas-alvarez C, Sampedro MF, García I, Rico CG, Gutierrez-Farnández L, Gutierrez-Cuadra M, Diez JG, Pajaron M, Parra JA, Teira R, Zarauza J, Parra JC, Cobo M, Domínguez F, Pavia PG, Cruz AF, Ramos-Martínez A, Romero IS, Centella T, Hermida JM, Moya JL, Martin-Davila P, Navas E, Oliva E, del Rio A, Stuart JRR, Ruiz S, Tenorio CH, Sequera S, Delia MA, Araji O, Barquero JM, Jambrina RC, de Cueto M, Acebal JG, Mendez I, Morales I, López-Cortes LE, de Alarcon A, Gutierrez-Carretero E, Lepe JA, López-Haldon J, Luque-Marquez R, Marin G, Ortiz-Carrellan A, Sánchez-Domínguez E, Alonso LJ, Azcarate P, Gutierrez JMA, Blanco JR, Armas EC, García-alvarez L, Oteo JA, Membrilla AB, Iglesias AG, Grillo S, Petracca RL, López-Contreras J, Martínez MAR, Alvarez M, Farnández AL, Martínez A, Prieto A, Regueiro B, Tijeira E, Vega M, Quinonero AA, Minambres AA, Arana JCG, Ortega SGD, Rodríguez MAM, Rodríguez AM, de Zarate ZO, Zapirain JJP, Arroniz ESD, Sánchez DCS, Antonio SP, Alejandro UI, Leal JMA, Vazquez EG, Torres AH, Blazquez A, Valenzuela GD, Alonso A, Aramburu J, Calvo FE, Rodríguez AM, Tarabini-Castellani P, Galvez EH, Bellido CM, Pau JL, Sepulveda MA, Sierra PT, Iqbal-Mirza SZ, Alcolea EC, Yanez IK, Martínez JN, Ballesta AP, Escobar EM, Monje AP, Cabrera VS, García DV, Asenjo MA, Luna CC, Morcillo JN, Seco MCP, Gelabert AV, Guallar CA, Abad NF, Mangas PG, Adell MM, Ruiz MPP, Porres JC, Vidal BA, Espin MJD, Buendia F, Sánchez RJ, Marmol R, Martínez F, Meseguer A, Pérez B, Risco L, Saura Z, Silva V, Villmarin MB, Blanco MAR, Bordes ERD, Bonet LV, Borras MV, Munera MCB, Garaizabal EE, Martínez AT, Luque JCS, Badia C, Palop LB, Xercavins M, Bosch SIX, Nebreda EG, Herrera IH, Gallego IM, Pulido I, Santiago HM, Martínez ID, Alamo EP, Sánchez DS, Pérez JB, Blanco EMA, González MC, Peiretti MAC, Esteve AE, Pérez LD, Tejido SD, Roman FG, Robles JAG, Medrano FL, Gude MJL, Miguel MAO, Pilkington P, Ostalaza YR, Morales JR, Solis SR, Collado AS, Farnández MS, Rallo JS, Escrihuela-Vidal JSMF, Carratala J, Grau I, Ardanuy C, Berbel D, Salado JCS, Alegre O, Majoral AR, Sbraga F, Blasco A, Sánchez LG, Aldamiz ISRG, Alvarez B, Palacios MB, Ubeda AC, Roblas RF, Hernandez R, Martin VAH, Kallmeyer A, Kancev CL, Martin M, Ruiz MM, Lobato MAN, Pello AM, Prieto L, Mallebrera MT, Triguero LVMD, Ceron REF, Ble LRGM, Gallego JPH, Ginel AJ, López I, Mas A, Mestres A, Molina L, Serrat R, Ribas N, Sánchez F, Silverio A, Suárez M, Sorli L, Recasens L, Regueras MTMF, Vallejo MAM, Rivera JAP, Cano NSMAC, Olivares MF, Nunez MVM, Sanz AM. Epidemiology and Risk Factors of Mycotic Aneurysm in Patients With Infective Endocarditis and the Impact of its Rupture in Outcomes. Analysis of a National Prospective Cohort. Open Forum Infect Dis. 2024; 11(3): ofae121. Article. IF: 3.8; Q1

- **Cepeda JG, Perona FL, Sánchez IB, Calvo JC, Rico A, Loeches B.** Case report: Prosthetic aortic valve endocarditis due to Staphylococcus epidermidis with acquired resistance in the walK gene. Diagn Micr Infec Dis. 2024; 108(2): 116132. Article. IF: 1.8; Q2
- **Cordero García-Galan E, Medel-Plaza M, Pozo-Kreilinger JJ, Sarnago H, Lucia O, Rico-Nieto A, Esteban J, Gómez-Barrena E.** In vivo reduction of biofilm seeded on orthopaedic implants.. Bone Joint Res. 2024; 13(12): 695-702-. Journal Article. IF: 5.1; Q1
- **Dahdouh E, Gómez-Marcos L, Cañada-García JE, de Arellano ER, Sánchez-García A, Sánchez-Romero I, López-Urrutia L, de la Iglesia P, González-Praetorius A, Sotelo J, Valle-Millares D, Alonso-González I, Bautista V, Lara N, García-Cobos S, Cercenado E, Aracil B, Oteo-Iglesias J, Pérez-Vázquez M.** Characterizing carbapenemase-producing Escherichia coli isolates from Spain: high genetic heterogeneity and wide geographical spread. Front Cell Infect Mi. 2024; 14: 1390966. Article. IF: 4.8; Q1
- **De Gea-Grela A, Maldonado-Barrueco A, Cabañuz C, Díaz-Almiron M, Rico A, Ruíz-Carrascoso G, Palacios ME, Martín-Arranz E, Escudero-Nieto R, Bernardino J.** Human intestinal spirochetosis: an entity associated with sexual transmitted infections. Enferm Infec Micr Cl. 2024; 42(5): 231-5. Article. IF: 2.5; Q2
- **de la Calle-prieto F, Arsuaga M, Rodríguez-Sevilla G, Paiz NS, Díaz-Menéndez M.** The current status of arboviruses with major epidemiological significance in Europe. Enferm Infec Micr Cl. 2024; 42(9): 516-26. Article. IF: 2.5; Q2
- **Díez-Vidal A, Arroyo-Acosta C, Elvira-Lafuente C, Díaz-Pollán B, Grandioso-Vas D, Loeches B, Azores-Moreno J, Marcelo-Calvo C, Martínez-Martín P, González-García ME.** Epstein-Barr Virus Infection Presenting With Acute Gastrointestinal Involvement. Report of Two Cases of Epstein-Barr Virus Colitis in Kidney-Transplant Recipients and Scoping Review of the Literature. J Med Virol. 2024; 96(12): e70121. Article. IF: 4.6; Q1
- **Díez-Vidal A, González-García ME, Marco-Clement I, Azores-Moreno J, Roces-Alvarez P, Marcelo-Calvo C, Martínez-Martín P, González-Muñoz B, Fernández-Hinojal F, Loeches B.** Recurrent bacteremia and endocarditis due to Staphylococcus capitis in a patient with Bowen's disease: a case report. Eur J Clin Microbiol. 2024; 43(5): 999-1002. Article. IF: 3.0; Q2
- **Escrig J, Marcos-Alcalde I, Domínguez-Zotes S, Abia D, Gómez-Puertas P, Valbuena A, Mateu MG.** Structural Basis for Alternative Self-Assembly Pathways Leading to Different Human Immunodeficiency Virus Capsid-Like Nanoparticles. Acs Nano. 2024; 18(40): 27465-78. Article. IF: 16.0; Q1




- **Escudero-Sánchez R, Ramos-Martínez A, Caballero-Bermejo AF, Díaz-Pollán B, Ruiz-Carrascoso G, Samperio MO, García PM, Amador PM, Romo FG, Segarra OM, Jiménez GN, Albendea LD, García AM, Cobo J.** Bezlotoxumab during the first episode of Clostridioides difficile infection in patients at high risk of recurrence. Eur J Clin Microbiol. 2024; 43(3): 533-40. Article. IF: 3.0; Q2
- **Falces-Romero I, García-Pérez I, Martín-Carbonero L, García-Rodríguez J, Mingorance J.** Quantification of human immunodeficiency virus type 2 (HIV-2) viral load in plasma: Comparison of three commercial assays. J Clin Virol. 2024; 175: 105745. Article. IF: 3.4; Q2
- **Feltes-Ochoa RA, Quiles-Melero I, Martin-Gorgojo A.** AEDV Expert Consensus Document on the Organization of a Multidisciplinary Unit for Patients With or at Risk of Venereal Infections. Actas Dermosifiliogr. 2024; 115(6): T583-91. Article. IF: 2.8; Q2
- **Furia F, Levy AM, Theunis M, Bamshad MJ, Bartos MN, Bijlsma EK, Brancati F, Cejudo L, Chong JX, De Luca C, Dean SJ, Egense A, Goel H, Guenzel AJ, Hüffmeier U, Legius E, Mancini GMS, Marcos-Alcalde I, Niclass T, Planes M, Redon S, Ros-Pardo D, Rouault K, Schot R, Schuhmann S, Shen JJ, Tao AM, Thiffault I, Van Esch H, Wentzensen IM, Barakat TS, Moller RS, Gomez-Puertas P, Chung WK, Gardella E, Tümer Z.** The phenotypic and genotypic spectrum of individuals with mono- or biallelic ANK3 variants. Clin Genet. 2024; 106(5): 574-84. Article. IF: 2.3; Q3
- **García-Boyano M, Alcala FJC, Alonso AR, de Villalta MGF, Alonso OZ, Retolaza IR, Melero IQ, Calvo C, García LE.** Pneumonia in Children With Complex Chronic Conditions With Tracheostomy: An Emerging Challenge. Pediatr Infect Dis J. 2024; 43(10): 919-23. Article. IF: 2.2; Q2
- **García-Boyano M, Díez MA, Tomé LF, Escosa-García L, Ramos FM, Schuffelmann-Gutiérrez C, Bueno EC, Calvo C, Baquero-Artigao F, Remacha EF.** Ceftazidime-Avibactam Use in a Case Series of Difficult-to-Treat or Recurrent Infections in Pediatric Patients with Complex Chronic Conditions: Effectiveness and Absence of Resistance Development. Antibiotics (Basel). 2024; 13(7): 598. Article. IF: 4.6; Q1
- **García-Bujalance S, Rubio-Mora E, Maldonado-Barrueco A, Montejano R, Rodríguez JG.** Chronic bacterial prostatitis with microbiological diagnosis: about two cases. Rev Esp Quim. 2024; 37(1): 118-20. Letter. IF: 2.2; Q3
- **García-Sánchez C, García-Rodríguez J, Ruiz-Carrascoso G.** Clinical and microbiological findings of recurrent Campylobacter spp. gastroenteritis in a tertiary care hospital. Enferm Infec Micr Cl. 2024; 42(5): 257-62. Article. IF: 2.5; Q2
- **García-Sánchez P, Romero-Trancón D, Falces-Romero I, Carrera PN, Ruiz-Carrascoso G, Carmena D, Jiménez MC, Rivero-Juárez A, Moya L, Rodón J, Esperón F, Pérez-Hernando B, Sánchez-León R, Hurtado-Gallego J, Alcolea S, Sainz T, Calvo C, Méndez-Echevarría A.** Zoonosis screening in Spanish immunocompromised children and their pets. Front Vet Sci. 2024; 11: 1425870. Article. IF: 2.9; Q1
- **Giammarino F, de Salazar A, Malet I, Viñuela L, Fuentes A, Saladini F, Bartolini N, Charpentier C, Lambert-Niclot S, Sterrantino G, Colao MG, Micheli V, Bertoli A, Fabeni L, Teyssou E, Delgado R, Falces-Romero I, Aguilera A, Gomes P, Paraskevis D, Santoro MM, Ceccherini-Silberstein F, Marcelin AG, Moreno C, Zazzi M, García F.** Prevalence and Phenotypic Susceptibility to Doravirine of the HIV-1 Reverse Transcriptase V106I Polymorphism in B and Non-B Subtypes. J Infect Dis. 2024; 229(6): 1796-802. Article. IF: 4.5; Q1
- **González-Soltero R, Tabone M, Larrosa M, Bailen M, Bressa C.** VDR gene TaqI (rs731236) polymorphism affects gut microbiota diversity and composition in a Caucasian population. Front Nutr. 2024; 11: 1423472. Article. IF: 5.1; Q1
- **Guinea J, Alcoceba E, Padilla E, Ramírez A, De Carolis E, Sanguinetti M, Muñoz-Algarra M, Durán-Valle T, Quiles-Melero I, Merino P, González-Romo F, Sánchez-García A, Gómez-García-de-la-Pedrosa E, Pérez-Ayala A, Mantecon-Vallejo MA, Pemán J, Cuétara MS, Zurita ND, García-Esteban C, Martínez-Jiménez MD, Castellano MAS, Reigadas E, Muñoz P, Escribano P.** Fluconazole-resistant Candida parapsilosis: fast detection of the Y132F ERG11p substitution, and a proposed microsatellite genotyping scheme. Clin Microbiol Infec. 2024; 30(11): 1447-52. Article. IF: 8.5; Q1
- **Ligero-López J, Escosa-García L, Schüffelmann-Gutiérrez C, Laplaza-González M, Quiles-Melero MI, Moreno-Ramos F, Baquero-Artigao F, Cacho-Calvo J, Cendejas-Bueno E.** Is it in their eyes? Correlation between microorganisms isolated from bronchial aspirates and conjunctival swabs in a Pediatric Intensive Care Unit. Rev Esp Quim. 2024; 37(2): 176-9. Article. IF: 2.2; Q3
- **Ligero-López J, Falces-Romero I, Aranda-Díaz A, García-Ballesteros D, García-Rodríguez J, Cendejas-Bueno E.** Rapid AST: Possibility of inferring resistance mechanisms with complex phenotypes. Rev Esp Quim. 2024; 37(1): 88-92. Article. IF: 2.2; Q3
- **López-Cortés LE, Delgado-Valverde M, Moreno-Mellado E, Aguirre JG, Carrión LG, Vidal MJB, Soria LML, Pérez-Rodríguez MT, Lamas LM, de las Revillas FA, Arminanzas C, de Alegría-Puig CR, Aguilar PJ, Martínez-Rubio MD, Sáez-Bejar C, de las Cuevas C, Martín-Aspas A, Galán F, Yuste JR, Leiva-León J, Bou G, González PC, Boix-Palop L, Xercavins-Valls M, Goenaga-Sánchez MA, Anza DV, Castón JJ, Rufián MR, Merino E, Rodríguez JC, Loeches B, Cuervo G, Laso JMG, Plata A, Cortés SP, Mato PL, Monzón JLS, Rosso-Fernández C, Bravo-Ferrer J, Retamar-Gentil P, Rodríguez-Baño J.** Efficacy and safety of a structured de-escalation from antipseudomonal β-lactams in bloodstream infections due to Enterobacterales (SIMPLIFY): an open-label, multicentre, randomised trial. Lancet Infect Dis. 2024; 24(4): 375-85. Article. IF: 31.0; D1
- **Maldonado-Barrueco A, Almazán-Garate E, Armijo-Suárez O, Iniesta-Pérez S, Sanz-González C, Falces-Romero I, Alvarez-López C, Cacho-Calvo J, Quiles-Melero I.** Utility of culture and molecular methods using Allplex™ Bacterial Vaginosis Plus Assay (Seegene®) as a tool for endometriosis, infertility and recurrent pregnancy loss diagnosis. Diagn Micr Infec Dis. 2024; 110(3): 116437. Article. IF: 1.8; Q2
- **Maldonado-Barrueco A, Bloise I, Cendejas-Bueno E, López-Rodrigo F, García-Rodríguez J, Lázaro-Perona F.** Epidemiological changes in invasive Streptococcus pyogenes infection during the UK alert period: A molecular comparative analysis from a tertiary Spanish hospital in 2023. Enferm Infec Micr Cl. 2024; 42(1): 34-7. Article. IF: 2.5; Q2
- **Maldonado-Barrueco A, García-Rodríguez J, Ruiz-Carrascoso G.** Impact of the SARS-CoV-2 Pandemic on Prevalence and Incidence of Bacterial Gastroenteritis in Spain, 2019-2022. Foodborne Pathog Dis. 2024; 21(5): 279-87. Article. IF: 1.9; Q3
- **Maldonado-Barrueco A, Grandioso-Vas D, Ruiz-Bastián M, Cacho-Calvo J, Toro C, Quiles-Melero I.** Mycobacterium abscessus subsp. massilliense causing bartholinitis infection: A case report. Rev Esp Quim. 2024; 37(5): 422-4. Letter. IF: 2.2; Q3
- **Maldonado-Barrueco A, Gutiérrez-Arroyo A, Bloise I, de Ceano-Vivas M, Rivera-Nuñez A, Santos-Olmos RT, Vega DM, García-Rodríguez J.** Evaluation of CLINITEST® Rapid Covid-19+Influenza antigen test in a cohort of symptomatic patients in an emergency department. Eur J Clin Microbiol. 2024; 43(5): 853-61. Article. IF: 3.0; Q2
- **Maldonado-Barrueco A, Moreno-Ramos F, Díaz-Pollán B, Loeches-Yagüe B, Rico-Nieto A, García-Rodríguez J, Ruiz-Carrascoso G.** Increase of healthcare-onset Clostridioides difficile infection in adult population since SARS-CoV-2 pandemic: A retrospective cohort study in a tertiary care hospital from 2019 to 2022. Anaerobe. 2024; 86: 102836. Article. IF: 2.6; Q3
- **Maldonado-Barrueco A, San José-Villar SM, García-Rodríguez J, Alguacil-Guillén M, López-Janeiro A, Trigo-Esteban E, Díaz-Menéndez M, Ruiz-Carrascoso G.** Answer to



April 2024 Photo Quiz. J Clin Microbiol. 2024; 62(4): e0125923. Editorial Material. IF: 5.4; Q1

- **Maldonado-Barrueco A, San José-Villar SM, García-Rodríguez J, Alguacil-Guillén M, López-Janeiro A, Trigo-Esteban E, Díaz-Menéndez M, Ruiz-Carrascoso G.** Photo Quiz: Mmm … delicious ceviche from Ecuador!. J Clin Microbiol. 2024; 62(4): e0125823. Editorial Material. IF: 5.4; Q1
- **Maldonado-Barrueco A, Sanz-González C, Falces-Romero I, García-Clemente P, Cacho-Calvo J, Quiles-Melero I.** Comparison of gradient diffusion and molecular methods using Allplex™ NG&DR assay (Seegene®) for macrolide and fluoroquinolone screening resistance in Neisseria gonorrhoeae. Eur J Clin Microbiol. 2024; 43(5): 1009-12. Article. IF: 3.0; Q2
- **Maldonado-Barrueco A, Sanz-González C, Falces-Romero I, Gutiérrez-Arroyo A, Montero-Vega D, Quiles-Melero I.** Increase in congenital syphilis in a tertiary-care centre from Madrid, Spain: Back to the classics. Int J Std Aids. 2024; 35(11): 916-8. Article. IF: 1.3; Q4
- **Maldonado-Barrueco A, Sanz-González C, Grandioso-Vas D, Falces-Romero I, García-Rodríguez J, Quiles-Melero I.** Allplex™ NG&DR (Seegene) utility for switching oral regimens with fluoroquinolones in gonococcal arthritis. Rev Esp Quim. 2024; 37(5): 425-6. Letter. IF: 2.2; Q3
- **Maldonado-Barrueco A, Sanz-González C, Rico-Nieto A, Grandioso-Vas D, Ruiz-Bastián M, Falces-Romero I, Cacho-Calvo J, Quiles-Melero I.** Increase in gonococcal arthritis in Madrid, Spain, 2022-2023. Int J Std Aids. 2024; 35(10): 831-5. Article. IF: 1.3; Q4
- **Maldonado-Barrueco A, Utrilla C, Hernández-González A, Perteguer MJ, Díaz-Pollán B, Untoria-Tabares Y, Díaz-Menéndez M, Falces-Romero I, Gutiérrez-Arroyo A, García-Rodríguez J, Montero-Vega D.** Intraventricular neurocysticercosis in a migrant from Honduras. J Travel Med. 2024; 31(3): taad090. Article. IF: 6.4; D1
- **Martín-Delgado MC, Ramos PD, García-Botella A, Cantón R, García-Lledó A, Hernández-Sampelayo T, Gómez-Pavon J, del Castillo JG, Sánchez FJM, Martínez-Sellés M, García JMM, Guillén SM, Rodríguez-Artalejo F, Ruiz-Galiana J, Burillo A, Muñoz P, Rey CC, Catalán-González M, Cendejas-Bueno E, Halperin-Benito AV, Recio R, Vinuela-Benitez C, Bouza E.** Invasive group A Streptococcus infection (Streptococcus pyogenes): Current situation in Spain. Rev Esp Quim. 2024; 37(6): 454-71. Article. IF: 2.2; Q3
- **Martínez-López S, Tabone M, Clemente-Velasco S, González-Soltero MD, Bailén M, de Lucas B, Bressa C, Domínguez-Balmaseda D, Marín-Muñoz J, Antúnez C, Gálvez BG, Larrosa M.** A systematic review of lifestyle-based interventions for managing Alzheimer's disease: Insights from randomized controlled trials. J Alzheimers Dis. 2024; 102(4): 943-66. Review. IF: 3.1; Q2
- **Mesquida A, Alcoceba E, Padilla E, Ramírez A, Merino P, González-Romo F, De Carolis E, Sanguinetti M, Mantecón-Vallejo MD, Muñoz-Algarra M, Durán-Valle T, Pérez-Ayala A, Gomez-García-de-la-Pedrosa E, Martínez-Jiménez MD, Sánchez-Castellano MA, Quiles-Melero I, Cuetara MS, Sánchez-García A, Muñoz P, Escribano P, Guinea J.** Fluconazole-resistant Candida parapsilosis genotypes from hospitals located in five Spanish cities and one in Italy: Description of azole-resistance profiles associated with the Y132F ERG11p substitution. Mycoses. 2024; 67(3): e13706. Article. IF: 3.1; Q2
- **Monzó-Gallo P, Lopera C, Badía-Tejero AM, Machado M, García-Rodríguez J, Vidal-Cortés P, Merino E, Calderón J, Fortún J, Palacios-Baena ZR, Pemán J, Sanchis JR, Aguilar-Guisado M, Gudiol C, Ramos JC, Sánchez-Romero I, Martin-Davila P, López-Cortés LE, Salavert M, Ruiz-Camps I, Chumbita M, Aiello TF, Peyrony O, Puerta-Alcalde P, Soriano A, Marco F, García-Vidal C.** Safety and effectiveness of isavuconazole in real-life non-neu tropenic patients. Int J Infect Dis. 2024; 144: 107070. Article. IF: 4.3; Q1
- **Moreno-Sanz B, Lázaro-Perona F, Escribano E, Lafuente MC, Montes MT, Amoros R, Arboleya S, Gueimonde M, Mingorance J, de Pipaon MS.** Assessment trial of the effect of enteral insulin on the preterm infant intestinal microbiota. Pediatr Res. 2024; 95(4): 1117-23. Article. IF: 3.1; Q1
- **Rico Nieto A, Loeches Yague B, Quiles Melero I, Talavera Buedo G, Pizones J, Farnández-Baillo Sacristana N.** Descriptive study of spinal instrumentation-related infections in a tertiary hospital.. Rev Esp Cir Ortop Traumatol. 2024; 68(3): T201-8-. Journal Article. Not Indexed
- **Rodríguez-Aguirregabiria M, Lázaro-Perona F, Cacho-Calvo JB, Arellano-Serrano MS, Ramos-Ramos JC, Rubio-Mora E, Díaz-Almirón M, Asensio-Martín MJ.** Challenges Facing Two Outbreaks of Carbapenem-Resistant Acinetobacter baumannii: From Cefiderocol Susceptibility Testing to the Emergence of Cefiderocol-Resistant Mutants. Antibiotics (Basel). 2024; 13(8): 784. Article. IF: 4.6; Q1
- **Ros-Pardo D, Gómez-Puertas P, Marcos-Alcalde I.** STAG2: Computational Analysis of Missense Variants Involved in Disease. Int J Mol Sci. 2024; 25(2): 1280. Article. IF: 4.9; Q1
- **Ros-Pardo D, Gómez-Puertas P, Marcos-Alcalde I.** STAG2-RAD21 complex: A unidirectional DNA ratchet mechanism in loop extrusion. Int J Biol Macromol. 2024; 276: 133822. Article. IF: 8.5; D1
- **Rubio-Mora E, Cacho-Calvo J, Melero IQ.** An unexpected pathogen in the amniotic fluid of a patient with chorioamnionitis. Rev Esp Quim. 2024; 37(2): 191-2. Letter. IF: 2.2; Q3
- **Rubio-Mora E, Carrascoso GR, Rodríguez JG.** Sapovirus infection as another cause of persistent viral diarrhea: case series and review of the literature. Eur J Clin Microbiol. 2024; 43(1): 55-9. Review. IF: 3.0; Q2
- **Rubio-Mora E, Rodríguez JG, Carrascoso GR.** Persistent diarrhea in immunocompromised patients: Have you ever thought about an astrovirus infection?. Transpl Infect Dis. 2024; 26(3): e14276. Letter. IF: 2.6; Q2
- **Ruiz-Bastián M, Díaz-Pollán B, Falces-Romero I, Toro-Rueda C, García-Rodríguez J.** Impact on tuberculosis diagnostic during COVID-19 pandemic in a tertiary care hospital. Enferm Infec Micr Cl. 2024; 42(3): 135-9. Article.



IF: 2.5; Q2

- **Salamanca-Rivera E, Palacios-Baena ZR, Cañada JE, Moure Z, Pérez-Vázquez M, Calvo-Montes J, Martínez-Martínez L, Cantón R, Carrascoso GR, Pitart C, Navarro F, Bou G, Mulet X, González-López JJ, Sivianes F, Delgado-Valverde M, Pascual A, Oteo-Iglesias J, Rodríguez-Baño J.** Epidemiological and clinical characterization of community, healthcare-associated and nosocomial colonization and infection due to carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in Spain. Infection. 2024; 5(6): 2231-40. Article. IF: 3.6; Q2
- **Salgueiro VC, Passemar C, Vázquez-Iniesta L, Lerma L, Floto A, Prados-Rosales R.** Extracellular vesicles in mycobacteria: new findings in biogenesis, host-pathogen interactions, and diagnostics. Mbio. 2024; 15(5): e0255223. Review. IF: 4.7; Q1
- **Shephard JLV, Pérez EM, Bujalance SG, Aguilar IM, Martínez BG, Martínez AP, Granados EL, Feito AM, Zapardiel ES.** The challenge of standardizing CAR-T cell monitoring: A comparison of two flow-cytometry methods and correlation with qPCR technique. Cytom Part A. 2024; 105(5): 368-75. Article. IF: 2.1; Q3
- **Sobral-Costas TG, López-Alcázar S, Escudero-Tornero R, Servera-Negre G, Pascual DMM, Quiles-Melero I, Cudós ES.** Single case of lymphogranuloma venereum on the tongue. Sex Transm Infect. 2024; 100(2): 108-9. Article. IF: 2.9; Q2
- **Soltero RG, García DP, Bellido A, Ryan P, Rodríguez-Learte AI.** FAIR data management: a framework for fostering data literacy in biomedical sciences education. BMC Med Res Methodol. 2024; 24(1): 284. Article. IF: 3.4; Q1
- **Soriano-Martín A, Muñoz P, García-Rodríguez J, Cantón R, Vena A, Bassetti M, Bouza E.** Unresolved issues in the diagnosis of catheter related candidemia: A position paper. Rev Esp Quim. 2024; 37(1): 1-16. Review. IF: 2.2; Q3
- **Udaondo C, Rueda RMA, Diaz-Delgado B, Remesal A, Quiles-Melero I, Calvo C.** Clinical Utility of a Multiplex PCR Panel (BioFire Joint Infection®) in the Adjustment of Empiric Antimicrobial Therapy: Experience in Pediatric Osteoarticular Infections. Children (Basel). 2024; 11(10): 1236. Article. IF: 2.1; Q2
- **Villar-Hernández R, Latorre I, Noguera-Julián A, Martínez-Planas A, Minguell L, Vallmanya T, Méndez M, Soriano-Arandes A, Baquero-Artigao F, Rodríguez-Molino P, Guillén-Martín S, Toro-Rueda C, De Souza-Galvao ML, Jiménez-Fuentes MA, Stojanovic Z, Sabriá J, Santos JR, Puig J, Domínguez-Álvarez M, Millet JP, Altet N, Galea Y, Muriel-Moreno B, García-García E, Bach-Griera M, Prat-Aymerich C, Julián E, Torrelles JB, Rodrigo C, Domínguez J.** Development and Evaluation of an NTM-IGRA to Guide Pediatric Lymphadenitis Diagnosis. Pediatr Infect Dis J. 2024; 43(3): 278-85. Article. IF: 2.2; Q2

Research projects

- **Dahdouh E.** Miguel Servet (CP23/00036). ISCIII. 2024-2029. Managment centre: FIBHULP
- **García Bujalance S.** Evaluación del rendimiento del ensayo aptima hiv-1 quant para la detección y cuantificación del hiv-1 en muestras de plasma. Hologic Deuschland GMBH. 2016-Ongoing. Managment centre: FIBHULP
- **García Rodríguez J.** Evaluación infectious diseases panel en cobas e801. Roche diagnostics S.L. 2017-Ongoing. Managment centre: FIBHULP
- **García Rodríguez J.** Validación de un nuevo kit para detección de virus respiratorios por pcr a tiempo real. Genómica S.A.U. 2018-Ongoing. Managment centre: FIBHULP
- **García Rodríguez J.** Consolidation of WGS and RT-PCR activities for SARS-CoV-2 in Spain towards sustainable use and integration of enhanced infrastructure and processes in the RELECOV network. (RELECOV 2.0). UE. 2023-2026. Managment centre: FIBHULP
- **García Rodríguez J.** EURL-IVD-1_ Harmonization process of European Reference Laboratories for in vitro diagnosis. (EURL-IVD-1_ GARCÍA). UE. 2024-2025. Managment centre: FIBHULP
- **Mingorance Cruz J.** Aplicación de los métodos de tipado genómico y molecular a la elaboración del mapa microbiológico del Hospital Universitario La Paz. Genómica S.A.U. 2012-Ongoing. Managment centre: FIBHULP
- **Mingorance Cruz J.** Aplicaciones de la pcr digital (quantstudio) en microbiología clínica. Proquinorte S.A. 2022-Ongoing. Managment centre: FIBHULP
- **Mingorance Cruz J.** Contrato I3 Estabilizado (CESI311). CM. 2011-2025. Managment centre: FIBHULP
- **Mingorance Cruz J.** Desarrollo y fabricación de hisopos por impresión 3D para la elaboración de kits de extracción de muestras covid19: validación hospitalaria de su uso. Agencia Estatal Consejo Superior de Investigaciones Científicas. 2020-Ongoing. Managment centre: FIBHULP
- **Mingorance Cruz J, Lázaro Perona F.** Identificación de los factores que modifican la carga intestinal de EPCS y desarrollo de modelos predictivos del riesgo de infección mediante algoritmos de inteligencia artificial (PI22/01523). ISCIII. 2023-2025. Managment centre: FIBHULP
- **Prados-Rosales R.** Role of mycobacterial dynamin-like proteins in the biogenesis of membrane vesicles, and host-pathogen interactions (1R01AI161821-01). National Institutes of Health . 2021-2024. Managment centre: FUAM

Clinical trials

- **Loeches Yagüe MB.** eficacia y seguridad de la perfusión continua vs. perfusión intermitente de ampicilina y ceftriaxona para el tratamiento de endocarditis infecciosa por enterococcus faecalis (doβlei).
  Type/Phase: IV
  Sponsored by: Fundación Publica Andaluza Para La Gestion De La Investigacion En Salud De Sevilla
  Signature date: 24/09/2024

Patents and trademarks

- **Vicente Muñoz M, Mingorance Cruz J, Rueda González MS, inventors; CSIC, assignee.** Method for determining state of growth and viability of bacterial FTsZ population, whether natural or cultivated, is based on determining existence of FTsZ rings in actively growing individual cells. P200200370; 2002 February 15.
- **Mingorance Cruz J, Castán García P, Franco de Sarabia Rosado PM, inventors; Biotools Biotechnological & Medical Laboratories S.**A., assignee. Composition, method and kit for detecting bacteria by means of sequencing. PCT/ES2009/000507, EP2492352, US2013157265, CA2775273, MX2012004627; 2009 October 22.
- **Mingorance Cruz J, Castán García P, Franco de Sarabia Rosado PM, inventors; 2B Blackbio S.**L., assignee. Composition, method and kit for detecting fungi and yeasts by means of sequencing. PCT/ES2010/000248; 2010 June 02.

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

3.3.3 Immuno-Rheumatology Group

Publications: 34 | **Q1:** 24

COMPOSITION

María Eugenia Miranda Carús.
Facultativo Especialista de Área en Reumatología. Hospital Universitario La Paz

- **Pilar Aguado Acín.** *Facultativo Especialista de Área en Reumatología. Hospital Universitario La Paz*
- **Alejandro Balsa Criado.** *Jefe de Sección de Reumatología. Hospital Universitario La Paz. Profesor Asociado. Facultad de Medicina. Universidad Autónoma de Madrid*
- **María Gema Bonilla Hernán.** *Facultativo Especialista de Área en Reumatología. Hospital Universitario La Paz*
- **Ana Castilla Plaza.** *Facultativo Especialista de Área en Reumatología. Hospital Universitario La Paz*
- **Eugenio de Miguel Mendieta.** *Facultativo Especialista de Área en Reumatología. Hospital Universitario La Paz*
- **Francisco de Borja Hernández de Breijo.** *Investigador Postdoctoral. Hospital Universitario La Paz*
- **Paula Fortea Gordo.** *Investigadora Predoctoral. Hospital Universitario La Paz*
- **Sara García Carazo.** *Facultativo Especialista de Área en Reumatología. Hospital Universitario La Paz*
- **Emilio Martín Mola.** *Jefe de Servicio de Reumatología. Hospital Universitario La Paz. Profesor Asociado. Facultad de Medicina. Universidad Autónoma de Madrid*
- **Ana Martínez Feito.** *Investigadora Predoctoral. Hospital Universitario La Paz*
- **Irene Monjo Henry.** *Facultativo Especialista de Área en Reumatología. Hospital Universitario La Paz*
- **María Victoria Navarro Compán.** *Facultativo Especialista de Área en Reumatología. Hospital Universitario La Paz*
- **Laura Nuño Nuño.** *Médico Adjunto Interino en Reumatología. Hospital Universitario La Paz*
- **María Dora Pascual-Salcedo Pascual.** *Químico Adjunto en Inmunología. Hospital Universitario La Paz*
- **Chamaida Plasencia Rodríguez.** *Facultativo Especialista de Área en Reumatología. Hospital Universitario La Paz*
- **Diana Peiteado López.** *Facultativo Especialista de Área en Reumatología. Hospital Universitario La Paz*
- **Alejandro Villalba Yllán.** *Facultativo Especialista de Área en Reumatología. Hospital Universitario La Paz*



STRATEGIC OBJETIVES

- Our objective is to investigate the pathogenesis and evolution of rheumatic diseases, specifically focusing on imaging, genetics, metabolic pathways and immunopathogenesis.
- Finally, we are exploring the gut microbiome and its alterations in relation to various pathologies and clinical conditions.

RESEARCH LINES

- Immunopathogenesis, genetic, evolution, prognosis and biomarkers of inflammatory and autoimmune arthritis
- Imaging of inflammatory and autoimmune arthritis
- Immunopathogenesis and genetics of osteoporosis
- Immunogenicity of biological therapies with monoclonal antibodies
- Immunopathogenesis, evolution, prognosis and biomarkers of ocular inflammatory pathology
- Classification and Clinical outcomes of patients with inflammatory and autoimmune arthritis

RESEARCH ACTIVITY

Doctoral Theses

- **Novella Navarro M.** Caracterización e implicaciones clínicas de la artritis reumatoide difícil de tratar [dissertation]. Madrid: Universidad Autónoma de Madrid: 2024(22/04/2024). Director: Balsa Criado A, Plasencia Rodríguez C
- **Tornero Marín C.** Caracterización e historia natural de la hipofosfatasia congénita en pacientes adultos con confirmación genética frente a pacientes con fosfatasa alcalina baja y test genético negativo [dissertation]. Madrid: Universidad Autónoma de Madrid: 2024(31/01/2024). Director: Aguado Acín MP, Navarro Compán V

Publications

- **Álvaro JMAG, Fontecha PDD, Sánchez JLA, Criado AB, Cáliz RC, Fernández IC, Corominas H, Puerta JAG, Arija SM, Vázquez NM, García AO, Rodríguez CP, Fernández LS, Molina JT.** Update of the Consensus Statement of the Spanish Society of Rheumatology on the use of biological and synthetic targeted therapies in rheumatoid arthritis. Reumatol Clin. 2024; 20(8): 423-39. Article. IF: 1.3; Q4
- **Baraliakos X, Ostergaard M, Poddubnyy D, van der Heijde D, Deodhar A, Machado PM, Navarro-Compán V, Hermann KGA, Kishimoto M, Lee EY, Gensler LS, Kiltz U, Eigenmann MF, Pertel P, Readie A, Richards HB, Porter B, Braun J.** Effect of Secukinumab Versus Adalimumab Biosimilar on Radiographic Progression in Patients With Radiographic Axial Spondyloarthritis: Results From a Head-to-Head Randomized Phase IIIb Study. Arthritis Rheumatol. 2024; 76(8): 1278-87. Article. IF: 10.9; D1
- **Benavent D, Benavent-Núñez M, Marin-Corral J, Arias-Manjón J, Navarro-Compán V, Taberna M, Salcedo I, Peiteado D, Carmona L, de Miguel E.** Natural language processing to identify and characterize spondyloarthritis in clinical practice. RMD Open. 2024; 10(2): e004302. Article. IF: 4.7; Q1
- **Benavent D, Navarro-Compán V.** Exploring the latest advances in axial spondyloarthritis management. Nat Rev Rheumatol. 2024; 20(2): 79-80. Editorial Material. IF: 32.7; D1
- **Calvo-Aranda E, Barrio-Nogal L, Blanco-Caceres BA, Peiteado D, Novella-Navarro M, De Miguel E, Palomo JA, Arroyo RA, Navarro JAM, Lucas MF, Domínguez MED, Gallardo MAV, Estevez EB, Oliveira LL.** Preclinical gout is common in the patient with stages 3-5 chronic kidney disease: Relevance of musculoskeletal ultrasound. Nefrologia. 2024; 44(6): 877-84. Article. IF: 2.6; Q2
- **Cella D, de la Loge C, Fofana F, Guo S, Ellis A, Fleurinck C, Massow U, Dougados M, Navarro-Compán V, Walsh JA.** The Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) scale in patients with axial spondyloarthritis: psychometric properties and clinically meaningful thresholds for interpretation. J Patient Rep Outcomes. 2024; 8(1): 92. Article. IF: 2.9; Q1
- **Cuesta-López L, Escudero-Contreras A, Hanaee Y, Pérez-Sánchez C, Ruiz-Ponce M, Martínez-Moreno JM, Pérez-Pampin E, González A, Plasencia-Rodríguez C, Martínez-Feito A, Balsa A, López-Medina C, Ladehesa-Pineda L, Rojas-Giménez M, Ortega-Castro R, Calvo-Gutiérrez J, López-Pedrera C, Collantes-Estévez E, de la Rosa I, Barbarroja N.** Exploring candidate biomarkers for rheumatoid arthritis through cardiovascular and cardiometabolic serum proteome profiling. Front Immunol. 2024; 15: 1333995. Article. IF: 5.9; Q1
- **Díaz IG, Riart MG, Martin-Arranz MD, Rodríguez CP, Ferrer CS.** Incidence and Course of Joint Inflammation Associated with Inflammatory Bowel Disease in Patients Undergoing Treatment with Vedolizumab/Ustekinumab: The VEDUSTAR Study. J Clin Med. 2024; 13(4): 1076. Article. IF: 2.9; Q1
- **Diekhoff T, Eshed I, Giraudo C, Haibel H, Hermann KGA, de Hooge M, Jans L, Jurik AG, Lambert RG, Machado P, Mallinson M, Maksymowych WP, Marzo-Ortega H, Navarro-Compán V, Ostergaard M, Pedersen SJ, Rudwaleit M, Sommerfleck F, Weber U, Baraliakos X, Poddubnyy D.** Reporting Sacroiliac Joint Imaging Performed for Known or Suspected Axial Spondyloarthritis: Assessment of SpondyloArthritis International Society Recommendations. Radiology. 2024; 311(3): e231786. Review. IF: 15.2; D1
- **Dubreuil M, Navarro-Compán V, Boonen A, Gaffney K, Gensler LS, de la Loge C, Vaux T, Fleurinck C, Massow U, Taieb V, Morup MF, Deodhar A, Rudwaleit M.** Improved physical functioning, sleep, work productivity and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: results from two phase 3 studies. RMD Open. 2024; 10(2): e004202. Article. IF: 4.7; Q1
- **Fernández-Fernández E, Brugarolas E, Monjo-Henry I, Novella-Navarro M, Balsa A, De Miguel E.** The influence of the cardiac cycle on the halo sign and its impact on the ultrasound diagnosis of giant cell arteritis. Rheumatology. 2024; 64(3): 1459-63. Article. IF: 4.4; Q1
- **Ferraz-Amaro I, Genre F, Blanco R, Calvo-Rio V, Corrales-Selaya C, Portilla V, Aurrecoechea E, Batanero R, Hernández- Hernández V, Quevedo-Abeledo JC, Rodríguez-Lozano C, López-Medina C, Ladehesa-Pineda L, Castañeda S, Vicente-Rabaneda EF, Fernández-Carballido C, Vidal MPM, Corredor DC, Fernández JA, Peiteado D, Plasencia-Rodríguez C, Expósito R, Vivar MLG, Galíndez-Agirregoikoa E, Vegas N, Urionagüena I, Montes-Pérez E, González-Gay MA, Rueda-Gotor J.** Sex-specific impact of inflammation on traditional cardiovascular risk factors and atherosclerosis in axial spondyloarthritis. A multicentre study of 913 patients. Rmd Open. 2024; 10(2): e004187. Article. IF: 4.7; Q1
- **Garrido-Cumbrera M, Navarro-Compán V, Poddubnyy D, Sommerfleck F, Makri S, Correa-Fernández J, Akerkar S, Lowe J, Karam E, Bundy C.** Factors Associated with Poor Mental Health in Patients with Axial Spondyloarthritis: Results from the International Map of Axial Spondyloarthritis (IMAS). RMD Open. 2024; 10(2): e004218. Article. IF: 4.7; Q1
- **Garrido-Cumbrera M, Poddubnyy D, Sommerfleck F, Bundy C, Makri S, Correa-Fernández J, Akerkar S, Lowe J, Karam E, Christen L, Navarro-Compán V.** International Map of Axial Spondyloarthritis (IMAS): results from the perspective of 5557 patients from 27 countries around the globe. RMD Open. 2024; 10(2): e003504. Article. IF: 4.7; Q1
- **Garrido-Cumbrera M, Poddubnyy D, Sommerfleck F, Bundy C, Makri S, Correa-Fernández J, Akerkar S, Lowe J, Karam E, Navarro-Compán V.** Do patients with axial spondyloarthritis with active disease suffer from greater disease burden and work impairment? Results from the International Map of Axial Spondyloarthritis (IMAS). Reumatol Clin. 2024; 20(10): 547-54. Article. IF: 1.3; Q4
- **Garrido-Cumbrera M, Poddubnyy D, Sommerfleck F, Bundy C, Makri S, Correa-Fernández J, Akerkar S, Lowe J, Karam E, Navarro-Compán V.** Regional Differences in Diagnosis Journey and Healthcare Utilization: Results from the International Map of Axial Spondyloarthritis (IMAS). Rheumatol Ther. 2024; 11(4): 927-95. Article. IF: 2.9; Q2
- **Gessl I, Sakellariou G, Wildner B, Filippou G, Mandl P, D'Agostino MA, Navarro-Compán V.** Systematic literature review to inform the EULAR recommendations for the use of imaging in crystal-induced arthropathies in clinical practice. Ann Rheum Dis. 2024; 83(9): 1208-24. Article. IF: 20.6; D1
- **López-Medina C, Calvo-Gutiérrez J, Abalos-Aguilera MC, Cepas F, Plasencia-Rodríguez C, Martínez-Feito A, Balsa A, Faré-García R, Juan-Mas A, Ruiz-Esquide V, Sainz L, Díaz-Torné C, Godoy-Navarrete EJ, Añón-Oñate I, Mena-Vázquez N, Manrique-Arija S, Moreno-García MS, Ortega-Castro R, Escudero-Contreras A.** Exploring the influence of baseline rheumatoid factor levels on TNF inhibitor retention rate in patients with rheumatoid arthritis: a multicentre and retrospective study. RMD Open. 2024; 10(1): e003975. Article. IF: 4.7; Q1
- **Mandl P, D'Agostino MA, Navarro-Compán V, Gessl I, Sakellariou G, Abhishek A, Becce F, Dalbeth N, Ea HK, Filippucci E, Hammer HB, Iagnocco A, de Thurah A, Naredo E, Ottaviani**

S, Pascart T, Pérez-Ruiz F, Pitsillidou IA, Proft F, Rech J, Schmidt WA, Sconfienza LM, Terslev L, Wildner B, Zufferey P, Filippou G. 2023 EULAR recommendations on imaging in diagnosis and management of crystal-induced arthropathies in clinical practice. Ann Rheum Dis. 2024; 83(6): 752-9. Article. IF: 20.6; D1

- **Martínez-Feito A, Novella-Navarro M, Hernández-Breijo B, Nozal P, Peiteado D, Villalba A, Nuño L, Monjo I, Pascual-Salcedo D, Balsa A, Plasencia-Rodríguez C.** Early monitoring of anti-infliximab antibodies by drug-tolerant assay predicts later immunogenicity and drug survival in rheumatic diseases. Rheumatology. 2024; 64(1): 344-51. Article. IF: 4.4; Q1
- **Molto A, López-Medina C, Sepriano A, Ramiro S, de Hooge M, van Lunteren M, Navarro-Compán V, Wendling D, Dougados M.** Sacroiliac radiographic progression over 10 years in axSpA: data from the DESIR inception cohort. Ann Rheum Dis. 2024; 83(7): 858-64. Article. IF: 20.6; D1
- **Monjo-Henry I, Uyaguari M, Nuño L, Nieto-Carvalhal B, Fernández-Fernández E, Peiteado D, Villalba A, García-Carazo S, Balsa A, Miranda-Carús ME.** Circulating Tfh cells are differentially modified by abatacept or TNF blockers and predict treatment response in rheumatoid arthritis. Rheumatology. 2024; 64(2): 517-25. Article. IF: 4.4; Q1
- **Navarro-Compán V, Deodhar A, Bahiri R, Bushmakin AG, Cappelleri JC, Rammaoui J.** Time to improvement of pain, morning stiffness, fatigue, and disease activity in patients with ankylosing spondylitis treated with tofacitinib: a post hoc analysis. Arthritis Res Ther. 2024; 26(1): 105. Article. IF: 4.6; Q1
- **Navarro-Compán V, Garrido-Cumbrera M, Poddubnyy D, Bundy C, Makri S, Correa-Fernández J, Akerkar S, Lowe J, Karam E, Sommerfleck F.** Females With Axial Spondyloarthritis Have Longer Diagnostic Delay and Higher Burden of the Disease. Results From the International Map of Axial Spondyloarthritis (IMAS). Int J Rheum Dis. 2024; 27(12): e15433. Article. IF: 2.0; Q3
- **Navarro-Compán V, Ramiro S, Deodhar A, Mease PJ, Rudwaleit M, de la Loge C, Fleurinck C, Taieb V, Morup MF, Massow U, Kay J, Magrey M.** Association of clinical response criteria and disease activity levels with axial spondyloarthritis core domains: results from two phase 3 randomised studies, BE MOBILE 1 and 2. RMD Open. 2024; 10(2): e004040. Article. IF: 4.7; Q1
- **Novella-Navarro M, Iniesta-Chamorro JM, Benavent D, Bachiller-Corral J, Calvo-Aranda E, Borrell H, Berbel-Arcobé L, Navarro-Compán V, Michelena X, Lojo-Oliveira L, Arroyo-Palomo J, Díaz-Almirón M, García VG, Monjo-Henry I, González CMG, Gomez EJ, Balsa A, Plasencia-Rodríguez C.** Toward Telemonitoring in Immune-Mediated Inflammatory Diseases: Protocol for a Mixed Attention Model Study. Jmir Res Protoc. 2024; 13: e55829. Article. IF: 1.5; Q3
- **Novella-Navarro M, Ruiz-Esquide V, López-Juanes N, Chacur CA, Monjo-Henry I, Nuño L, Peiteado D, Villalba A, Fernández-Farnández E, Sanz-Jardón M, Kafati M, Sanmartí R, Plasencia-Rodríguez C, Balsa A.** Subsequent biologic and targeted synthetic disease modifying anti rheumatic drugs after fulfilling difficult-to-treat rheumatoid arthritis criteria: a survival analysis. Clin Rheumatol. 2024; 43(9): 2817-23. Article. IF: 2.8; Q2
- **Plasencia-Rodríguez C, Martínez-Feito A, Novella-Navarro M, De Diego RP, Bonilla G, Gehin JE, Villalba-Yllán A, Nuño L, Pascual-Salcedo D, Nozal P, Almirón MD, Balsa A.** Influence of rheumatoid factor levels and TNF inhibitor structure on secondary nonresponse in rheumatoid arthritis patients. Front Med (Lausanne). 2024; 11: 1461396. Article. IF: 3; Q1
- **Rudwaleit M, Marzo-Ortega H, Navarro-Compán V, Tham R, Kumke T, Bauer L, de Peyrecave N, Kim M, van den Bosch F.** Exploratory analysis of the potential disconnect between objective inflammatory response and clinical response following certolizumab pegol treatment in patients with active axial spondyloarthritis. Rmd Open. 2024; 10(3): 1-10. Article. IF: 4.7; Q1
- **Smolen JS, Taylor PC, Tanaka Y, Takeuchi T, Hashimoto M, Cara C, Lauwerys B, Tilt N, Ufuktepe B, Xavier RM, Balsa A, Curtis JR, Mikuls TR, Weinblatt M.** Impact of high rheumatoid factor levels on treatment outcomes with certolizumab pegol and adalimumab in patients with rheumatoid arthritis. Rheumatology. 2024; 63(11): 3015-24. Article. IF: 4.4; Q1
- **Soriano ER, Navarro-Compán V, Bautista-Molano W, Baraliakos X.** Comparing Treatment Guidelines for Axial Spondyloarthritis Insights From PANLAR and ASAS-EULAR. Jcr-J Clin Rheumatol. 2024; 30(8): 340-4. Editorial Material. IF: 1.8; Q3
- **Taylor PC, Balsa A, Mongey AB, Filková M, Chebbah M, Le Clanche S, Verhagen LAW, Witte T, Opris-Belinski D, Marotte H, Avouac J.** Does Concomitant Use of Methotrexate with JAK Inhibition Confer Benefit for Cardiovascular Outcomes? A Commentary. Rheumatol Ther. 2024; 11(6): 1425-35. Article. IF: 2.9; Q2
- **Taylor PC, Feist E, Pope JE, Nash P, Sibilia J, Caporali R, Balsa A.** What have we learnt from the inhibition of IL-6 in RA and what are the clinical opportunities for patient outcomes? Ther Adv Musculoskelet Dis. 2024; 16: 1759720X241283340. Review. IF: 4.1; Q1
- **Tornero C, de Miguel E, Navarro-Compán V, Balsa A, Aguado P.** Prevalence of chondrocalcinosis and calcium pyrophosphate deposition disease in a cohort of adult patients with low alkaline phosphatase levels and a positive versus negative genetic ALPL study. JBMR Plus. 2024; 8(11): ziae124. Article. IF: 2.4; Q3

Research projects

- **Aguado Acín P.** Caracterización e historia natural de la hipofosfatasia en pacientes adultos con confirmacion genetica frente a pacientes con fosfatasa alcalina baja y test genético negativo. Hipofosfatasia del adulto. Alexion Pharmaceutical Inc. 2017-Ongoing. Managment centre: FIBHULP
- **Balsa Criado A, Plasencia Rodríguez C.** Actualización y renovación de la actividad investigadora en el servicio de reumatología del Hospital Universitario La Paz. Roches Farma S.A. 2016-Ongoing. Managment centre: FIBHULP
- **Balsa Criado A.** Desarrollo de biochips para monitorización de infliximab y la presencia de anticuerpos frente a infliximab en sangre. IMG Pharma Biotech. 2017-Ongoing. Managment centre: FIBHULP
- **Balsa Criado A.** Hacia la Telemonitorización en Enfermedades Inflamatorias Inmunomediadas: Implementación de un Modelo Asistencial Mixto (MAM) en una Unidad de Terapias Complejas (PI22/00777). ISCIII. 2022-Ongoing. Managment centre: FIBHULP
- **Balsa Criado A.** Mejora de herramientas y procedimientos para facilitar la consulta virtual en pacientes con enfermedad inflamatoria. Abbvie Spain S.L.U. 2021-Ongoing. Managment centre: FIBHULP
- **Balsa Criado A.** Puerta digital a la unidad de terapias complejas de reumatologia. Abbvie Spain S.L.U. 2022-Ongoing. Managment centre: FIBHULP
- **de Miguel Mendieta E.** Análisis de imagenes ecograficas para el diagnostico de arteritis de celulas gigantes mediante tecnicas de deep learning. Roche Farma S.A. 2021-Ongoing. Managment centre: FIBHULP
- **Martínez Feito A.** Relevancia de la presencia y titulo de autoanticuerpos (factor reumatoide y antipéptido citrulinado ciclico) en los niveles de farmacos anti-tnf en pacientes con artritis reumatoide. UCB Pharma S.A. 2021-Ongoing. Managment centre: FIBHULP
- **Miranda Carús ME.** Células T helper foliculares (Tfh), T foliculares reguladoras (Tfr) y T helper periféricas (Tph) en Artritis Reumatoide preclínica, temprana y establecida: herramientas para la medicina personalizada (PI20/00141). ISCIII. 2021-2024. Managment centre: FIBHULP
- **Miranda Carús ME.** Efecto del metotrexato en la frecuencia y función de las células T helper foliculares; implicaciones patogénicas y pronósticas. Laboratorios Gebro Pharma S. A. 2020-Ongoing. Managment centre: FIBHULP
- **Miranda Carús ME.** Frecuencia y función de las células T helper foliculares circulantes y plasmablastos en pacientes con artritis reumatoide, y su relación con los niveles de autoanticuerpos: odificaciones asociadas con el bloqueo de la coestimulación por Abatacept. Bristol Myers Squibb S. A. U. 2016-Ongoing. Managment centre: FIBHULP
- **Navarro Compán MV.** Resonancia magnética de sacroilíacas y desarrollo de un cuestionario para identificar espondiloartritis axial precoz en pacientes con dolor lumbar crónico remitidos

a otros especialistas distintos al reumatólogo. Novartis Farmaceutica S.A. 2021-Ongoing. Managment centre: FIBHULP

- **Pascual-Salcedo Pascual MD, Herranz Pinto P.** Identificación precoz de buenos respondedores primarios a las terapias biológicas en la psoriasis moderada a grave. Laboratorios Leo Pharma S. A. 2014-Ongoing. Managment centre: FIBHULP
- **Miranda Carús ME.** Stratification of Patients using advanced Integrative modeling of Data Routinely acquired for diagnosing Rheumatic complaints (SPIDeRR). EU. 2023-2028. Managment centre: FIBHULP
- **Balsa Criado A.** Hacia la telemonitorización en enf. inflamatorias inmunomediadas: implementación de un modelo asistencial mixto (MAM) en una unidad de terapias complejas (PI22/00777). ISCIII. 2023-2025. Managment centre: FIBHULP
- **Plasencia Rodríguez C.** Identificación de biomarcadores farmacogenéticos asociados a eficacia y toxicidad a ratamientos en pacientes con artritis reumatoide: estudio biofar (2022.26). Fundación José Luis Castaño para al Desarrollo del Laboratorio Clínico. 2023-2024. Managment centre: FIBHULP

Clinical trials

- **Aguado Acín P.** estudio de fase 3, aleatorizado, doble ciego, controlado con placebo, multicéntrico para evaluar la eficacia y la seguridad de alxn1850 (fosfatasa alcalina recombinante) administrada por vía subcutánea en participantes adolescentes (de 12 a < 18 años de edad) y adultos con hipofosfatasia que no hayan sido tratados anteriormente con asfotasa alfa.
  Type/Phase: III
  Sponsored by: Alexion Pharmaceutical Inc.
  Signature date: 26/02/2024
- **Aguado Acín P.** estudio de fase 3, aleatorizado, doble ciego, controlado con placebo, multicéntrico para evaluar la eficacia y la seguridad de alxn1850 (fosfatasa alcalina recombinante) administrada por vía subcutánea en participantes adolescentes (de 12 a < 18 años de edad) y adultos con hipofosfatasia que no hayan sido tratados anteriormente con asfotasa alfa.
  Type/Phase: III
  Sponsored by: Alexion Pharmaceutical Inc.
  Signature date: 01/10/2024
- **Balsa Criado A.** estudio de fase iii, aleatorizado, doble ciego, controlado con placebo para demostrar la eficacia y la seguridad de tildrakizumab en sujetos con artritis psoriásica activa i que habían recibido tratamiento previo con anti-tnf (inspire 1.
  Type/Phase: III
  Sponsored by: Sun Pharmaceutical Industries Ltd.
  Signature date: 30/01/2024
- **Balsa Criado A.** programa en fase iii aleatorizado, comparativo con placebo, doble ciego y con grupos paralelos para evaluar la eficacia y la seguridad de filgotinib en participantes adultos con espondiloartritis axial activa.
  Type/Phase: III
  Sponsored by: Galapagos Nv
  Signature date: 19/06/2024
- **Bonilla Hernán MG.** a phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of dazodalibep in participants with sjögren's syndrome with moderate-to-severe systemic disease activity.
  Type/Phase: III
  Sponsored by: Horizon Therapeutics Ireland Dac
  Signature date: 21/05/2024
- **Bonilla Hernán MG.** estudio de fase 3, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y seguridad de dazodalibep en participantes con síndrome de sjögren con sintomatología de moderada a grave.
  Type/Phase: III
  Sponsored by: Horizon Therapeutics Ireland Dac
  Signature date: 28/06/2024
- **Bonilla Hernán MG.** estudio de fase 3, aleatorizado, doble ciego, controlado con placebo y de grupos paralelos para evaluar la eficacia y la seguridad de belimumab administrado por vía subcutánea en adultos con enfermedad pulmonar intersticial (epi) asociada a enfermedad del tejido conectivo (etc).
  Type/Phase: III
  Sponsored by: Glaxosmithkline Research And Development Limited
  Signature date: 10/09/2024
- **Bonilla Hernán MG.** estudio en fase ii/iii aleatorizado, con enmascaramiento doble, comparativo con placebo y con grupos paralelos para evaluar la eficacia, la seguridad, la tolerabilidad, la farmacodinámica, la farmacocinética y la inmunogenia del efgartigimod ph20 sc en participantes adultos con miopatía inflamatoria idiopática activa.
  Type/Phase: II
  Sponsored by: Argenx Bv (Argenx Bvba)
  Signature date: 27/12/2024
- **Bonilla Hernán MG, Herranz Pinto P.** sjögren syndrome and atopic dermatitis cohorts' generation and multi-omics characterization (ssad project) / generación de cohortes y caracterización multiómica del síndrome de sjögren y la dermatitis atópica (proyecto ssad).
  Type/Phase: No EPA
  Sponsored by: Fundacio Hospital Vall D'Hebron
  Signature date: 15/02/2024
- **de Miguel Mendieta E.** estudio abierto y multicéntrico para pacientes que hayan completado un estudio previo con secukinumab patrocinado por novartis y que, a criterio del investigador, se estén beneficiando del tratamiento continuado con secukinumab.
  Type/Phase: IV
  Sponsored by: Novartis Farmaceutica S.A.
  Signature date: 14/05/2024
- **de Miguel Mendieta E.** estudio aleatorizado y controlado para evaluar lnp023 (iptacopan) en pacientes con vasculitis asociada a anca activa.
  Type/Phase: IIa
  Sponsored by: Novartis Pharma Services Ag
  Signature date: 22/07/2024
- **de Miguel Mendieta E.** estudio de extensión multicéntrico y abierto que evalúa la seguridad y la tolerabilidad a largo plazo de secukinumab subcutáneo en polimialgia reumática.
  Type/Phase: III
  Sponsored by: Novartis Farmaceutica S.A.
  Signature date: 25/03/2024
- **de Miguel Mendieta E.** estudio multicéntrico y abierto en el que se evalúan la farmacocinética, la seguridad y la tolerabilidad de la infusión intravenosa de secukinumab en adultos con arteritis de células gigantes o polimialgia reumátic.
  Type/Phase: I
  Sponsored by: Novartis Pharma Services Ag
  Signature date: 17/01/2024
- **de Miguel Mendieta E.** estudio multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la seguridad y la eficacia de upadacitinib en sujetos con arteritis de células gigantes.
  Type/Phase: III
  Sponsored by: Abbvie Deutschland GMBH
  Signature date: 14/11/2024
- **Robles Marhuenda AJ**
- **Bonilla Hernán MG.** observational retrospective study to describe characteristics and clinical outcomes of patients withsystemic lupus erythematosus initiating saphnelo (anifrolumab) in a real-world setting. estudio azahar.
  Type/Phase: EOm no prospectivo
  Sponsored by: Astrazeneca Farmaceutica Spain S.A.
  Signature date: 10/12/2024

Patents and trademarks

- **Pascual-Salcedo Pascual MD, Balsa Criado A, Plasencia Rodríguez C, authors; FIBHULP, assignee.** Brand name: BioDrug Analysis BIDA. CM 13.808.531, 2015 March 10.

BioDrug Analysis BIDA

- **Fernández Luna JL, Martínez Taboada VM, López Hoyos M, Torices del Val S, Muñoz Cacho P, Varela Egocheaga I, Juliá Cano A, Marsal Barril S, Balsa Criado A, inventors; FIBHULP, Fundación Instituto de Investigación Marqués de Valdecilla, Servicio Cántabro de Salud, Universidad de Cantabria, Fundació Hospital Universitari Vall D´Hebron - Institut de Recerca (VHIR), assignees.** Method for predicting the clinical response to anti-inflammatory agent therapies. P201600636, PCT/ES2017/000089; 2016 July 26.
- **Plasencia C.** Trademark name: MAM Modelo Asistencial Mixto; CM 18637540; 2022 January 13.

+ MAM MODELO ASISTENCIAL MIXTO

3.3.4 Innate Immune Response Group



Publications: 30 | **Q1:** 18

COMPOSITION

Eduardo Manuel López-Collazo.
Investigador Senior (Contrato Miguel Servet - I2). Jefe de Laboratorio. FIBHULP
Carlos del Fresno Sánchez.
Investigador Postdoctoral (Contrato Miguel Servet - Tipo I). FIBHULP

- **Susana Alemany de la Peña.** *Investigadora Senior. Jefe de Laboratorio. IIB "Alberto Sols"*
- **Daniel Arvelo del Rosario.** *Investigador Predoctoral. FIBHULP*
- **Gülce Bicakcioglu.** *Técnico Grado Superior. FIBHULP*
- **Gloria Cristina Bonel Pérez.** *Research Assistant. FIBHULP*
- **Lisardo Boscá Gomar.** *Investigador Senior. Jefe de Laboratorio. IIB "Alberto Sols"*
- **Antonio Castrillo Viguera.** *Investigador Senior. Jefe de Laboratorio. IIB "Alberto Sols"*
- **Luna Ridan Cordeiro Minute.** *Investigadora Sara Borrel. FIBHULP*
- **Laura Córdoba García.** *Resposable HUB - Organoides. FIBHULP*
- **Francisco Javier Cueto Rodríguez.** *Investigador Senior. FIBHULP*
- **Julia del Prado Montero.** *Investigadora Predoctoral. FIBHULP*
- **Jesús Fernández Felipe.** *Investigador Postdoctoral. FIBHULP*
- **Olivia Fernández Molina.** *Ayudante de Investigación . FIBHULP*
- **Jaime Fernández Pascual.** *Técnico Antomía Patológica. FIBHULP*
- **Laura Gómez Lage.** *Enfermera. Hospital Universitario La Paz*
- **Santiago Gómez Ruiz.** *Profesor Titular. Universidad Rey Juan Carlos*
- **María Susana Guerra García.** *Investigadora Postdoctoral. Universidad Autónoma de Madrid*
- **Kilián Jesús Gutiérrez Viñas.** *Responsable de laboratorio de Citometría de Flujo. FIBHULP*
- **Laura Hurtado Navarro.** *Investigadora Postdoctoral. FIBHULP*
- **Roberto Lozano Rodríguez.** *Investigadora Postdoctoral. FIBHULP*
- **Cristina de Manuel Gómez.** *Facultativo Especialista de Área en Pediatría. Hospital Universitario La Paz*
- **Charbel Antonio Maroun Eid.** *Facultativo Especialista de Área en Urgencias. Hospital del Norte*
- **Pablo Mata Martínez.** *Investigador Predoctoral. FIBHULP*
- **Elena Muñoz del Val.** *Facultativo especialista de área en Medicina Familiar y Comunitaria. Hospital Universitario La Paz*
- **Alejandro Pascual Iglesias.** *Bioinformatician. FIBHULP*
- **Rebeca Pérez de Diego.** *Investigadora Senior (Contrato Ramón y Cajal). FIBHULP*
- **Sanjiv Prashar.** *Profesor Titular. Universidad Rey Juan Carlos*
- **Marta Roche Molina.** *Postdoctoral Researcher. FIBHULP*
- **Gonzalo Saénz de Santamaría Díez.** *Investigador Predoctoral. FIBHULP*
- **Verónica Terrón Arcos.** *Técnico de Laboratorio. FIBHULP*
- **Jaime Valentín Quiroga.** *Predoctoral Researcher. FIBHULP*

STRATEGIC OBJETIVES

- This group focuses on the study of the reprogramming of the immune response in the context of inflammatory diseases (e.g., sepsis, cystic fibrosis, lung and colon cancer) using the description of the various molecular mechanisms that underlie the reprogramming of monocytes/macrophages.

RESEARCH LINES

- Molecular and cellular mechanisms of sepsis.
- Evolution markers and molecular/cellular basis of Long COVID19.
- Evolution and prognostic markers in infectious (sepsis and COVID-19) and tumour (lung, breast, colorectal) diseases.
- Molecular and cellular mechanisms of metastasis (lung, breast and colorectal).
- Immunomodulation in various clinical contexts (infectious diseases, tumours, cystic fibrosis, etc.).
- Immunophenotyping and immune response to vaccines (HIV, tumours, etc.).
- 3D tumor organoids models in immuno-oncology

RESEARCH ACTIVITY

Doctoral Theses

- **Lozano Rodríguez R.** SARS-CoV-2: desde la etiología inmunitaria hasta la respuesta a las vacunas [dissertation]. Madrid: Universidad Autónoma de Madrid: 2024(16/02/2024). Director: López-Collazo E

Final Degree Theses

- **Arvelo del Rosario D.** Modelos de organoides como una nueva plataforma para la quimioterapia personalizada frente al cáncer de colon[dissertation]. Madrid: Universidad Complutense de Madrid: 2024(28/06/2024). Director: Córdoba García L, Fernández J.

Publications

- **Alba-Cano T, Fernández-Cruz E, Alonso R, Múñoz-Gómez S, de Diego RP, Martínez EG, Sánchez-Mateos P, Caspistegui JN, López M, Gil-Herrera J.** Lack of Specific Immune Response after Five Doses of mRNA SARS-CoV-2 Vaccine in a Patient with CD4+ T-Cell Lymphopenia but Preserved Responses to CMV. Vaccines (Basel). 2024; 12(4): 386. Article. IF: 3.4; Q2
- **Alsaidalani AA, García-Solis B, Bukhari E, Van Den Rym A, López-Collazo E, Sánchez-Ramón S, Corvillo F, López-Lera A, de Andrés A, Martínez-Barricarte R, de Diego RP.** Inherited Human BCL10 Deficiencies. J Clin Immunol. 2024; 44(1): 13. Review. IF: 5.7; Q1
- **Álvarez E, Falqui M, Sin L, Mcgrail JP, Perdiguero B, Coloma R, Marcos-Villar L, Tarrega C, Esteban M, Gomez CE, Guerra S.** Unveiling the Multifaceted Roles of ISG15: From Immunomodulation to Therapeutic Frontiers. Vaccines (Basel). 2024; 12(2): 153. Review. IF: 3.4; Q2
- **Apaza CJ, Días M, Tejedor AG, Boscá L, Llopis JML.** Contribution of Nucleotide-Binding Oligomerization Domain-like (NOD) Receptors to the Immune and Metabolic Health. Biomedicines. 2024; 12(2): 341. Review. IF: 3.9; Q2
- **Arsuaga M, Coloma R, Guerra S, Díaz-Menéndez M.** Sequencing the evolution of vaccinia skin lesions in a laboratory worker: Insights from image analysis. Enferm Infec Micr Cl. 2024; 42(8): 459-60. Editorial Material. IF: 2.5; Q2
- **Bellos E, Santillo D, Vantourout P, Jackson HR, Duret A, Hearn H, Seeleuthner Y, Talouarn E, Hodeib S, Patel H, Powell O, Yeoh S, Mustafa S, Habgood-Coote D, Nichols S, Elorrieta LE, D'Souza G, Wright VJ, Estrada-Rivadeneyra D, Tremoulet AH, Dummer KB, Netea SA, Condino-Neto A, Lau YL, Cuadros EN, Toubiana J, Pena MH, Rieux-Laucat F, Luyt CE, Haerynck F, Mège JL, Chakravorty S, Haddad E, Morin MP, Akcan ÖM, Keles S, Emiroglu M, Alkan G, Öz SKT, Bozdemir SE, Morelle G, Volokha A, Kendir-Demirkol Y, Sözeri B, Coskuner T, Yahsi A, Gulhan B, Kanik-Yuksek S, Bayhan GI, Ozkaya-Parlakay A, Yesilbas O, Hatipoglu N, Ozcelik T, Belot A, Chopin E, Barlogis V, Sevketoglu E, Menentoglu E, Aydin ZGG, Bloomfield M, AlKhater SA, Cyrus C, Stepanovskiy Y, Bondarenko A, Öz FN, Polat M, Fremuth J, Lebl J, Geraldo A, Jouanguy E, Carter MJ, Wellman P, Peters M, de Diego RP, Edwards LA, Chiu C, Noursadeghi M, Bolze A, Shimizu C, Kaforou M, Hamilton MS, Herberg JA, Schmitt EG, Rodríguez-Palmero A, Pujol A, Kim J, Cobat A, Abel L, Zhang SY, Casanova JL, Kuijpers TW, Burns JC, Levin M, Hayday AC, Sancho-Shimizu V.** Heterozygous BTNL8 variants in individuals with multisystem inflammatory syndrome in children (MIS-C). J Exp Med. 2024; 221(12): e920240699. Article. IF: 10.6; D1
- **Benito JM, Jiménez-Carretero D, Restrepo C, Ligos JM, Valentín-Quiroga J, Mahillo I, Cabello A, López-Collazo E, Sánchez-Cabo F, Górgolas M, Estrada V, Rallón N.** T Cell Homeostasis Disturbances in a Cohort of Long-Term Elite Controllers of HIV Infection. Int J Mol Sci. 2024; 25(11): 5937. Article. IF: 4.9; Q1
- **Brea R, Casanova N, Alvarez-Lucena C, Fuertes-Agudo M, Luque-Tevar M, Cucarella C, Capitani MC, Marinochi MV, Fusini ME, Lahoz A, Nogueroles ML, Fraile J, Ronco MT, Boscá L, González-Rodríguez A, García-Monzón C, Martín-Sanz P, Casado M, Francés DE.** Beneficial effects of hepatic cyclooxygenase-2 expression against cholestatic injury after common bile duct ligation in mice. Liver Int. 2024; 44(9): 2409-23. Article. IF: 5.2; Q1
- **Chakraborty A, Sreenivasmurthy SG, Miller W, Huai WH, Biswas T, Mandal SM, Boscá L, Krishnan B, Ghosh G, Hazra T.** Fructose-2,6-bisphosphate restores DNA repair activity of PNKP and ameliorates neurodegenerative symptoms in Huntington's disease. P Natl Acad Sci Usa. 2024; 121(39): e2406308121. Article. IF: 9.1; Q1
- **de la Rosa JV, Tabraue C, Huang ZQ, Orizaola MC, Martin-Rodríguez P, Steffensen KR, Zapata JM, Boscá L, Tontonoz P, Alemany S, Treuter E, Castrillo A.** Reprogramming of the LXRα Transcriptome Sustains Macrophage Secondary Inflammatory Responses. Adv Sci (Weinh). 2024; 11(20): e2307201. Article. IF: 14.1; D1
- **Domínguez-Luis MJ, Castro-Hernández J, Santos-Concepción S, Díaz-Martín A, Arce-Franco M, Pérez-González N, Díaz M, Castrillo A, Salido E, Machado JD, Guma M, Corr M, Díaz-González F.** Modulation of the K/BxN arthritis mouse model and the effector functions of human fibroblast-like synoviocytes by liver X receptors. Eur J Immunol. 2024; 54(11): e2451136. Article. IF: 3.7; Q2
- **Ferreras C, Hernández-Blanco C, Martín-Quirós A, Al-Akioui-Sanz K, Mora-Rillo M, Ibáñez F, Díaz-Almirón M, Cano-Ochando J, Lozano-Ojalvo D, Jiménez-González M, Goterris R, Sánchez-Zapardiel E, de Paz R, Guerra-García P, Queiruga-Parada J, Molina P, Briones ML, Ruz-Caracuel B, Borobia AM, Carcas AJ, Planelles D, Vicario JL, Moreno MA, Balas A, Llano M, Llorente A, del Balzo A, Cañada C, García MA, Calvin ME, Arenas I, de Diego RP, Eguizábal C, Soria B, Solano C, Pérez-Martínez A.** Results of phase 2 randomized multi-center study to evaluate the safety and efficacy of infusion of memory T cells as adoptive therapy in severe. Cytotherapy. 2024; 26(1): 25-35. Article. IF: 3.2; Q2
- **García-Solís B, Tapia-Torres M, García-Soidán A, Hernández-Brito E, Martínez-Saavedra MT, Lorenzo-Salazar JM, García-Hernández S, Van Den Rym A, Mayani K, Govantes-Rodríguez JV, Gervais A, Bastard P, Puel A, Casanova JL, Flores C, de Diego RP, Rodríguez-Gallego C.** IgG4-related disease and B-cell malignancy due to an IKZF1 gain-of-function variant. J Allergy Clin Immun. 2024; 154(3): 819-26. Article. IF: 11.2; D1
- **González-Lafuente L, Mercado-García E, Vázquez-Sánchez S, González-Moreno D, Boscá L, Fernández-Velasco M, Segura J, Kuro-O M, Ruilope LM, Liaño F, Ruiz-Hurtado G.** Interleukin-6 as a prognostic marker in acute renal injury and its klotho-dependent regulation. Nefrologia. 2024; 44(6): 818-29. Article. IF: 2.6; Q2
- **González-Nicolás MA, González-Guerrero C, Goicoechea M, Boscá L, Valiño-Rivas L, Lázaro A.** Biomarkers in Contrast-Induced Acute Kidney Injury: Towards A New Perspective. Int J Mol Sci. 2024; 25(6): 3438. Review. IF: 4.9; Q1
- **González-Sánchez L, Agudo AM, van den Rym A, Begiristain MI, Saizar A, de Diego RP, Nozal P, López-Lera A, López-Trascasa M, Corvillo F.** Properdin deficiency associated with systemic meningococcal disease due to a novel p.Cys337Arg pathogenic variant. Genes Dis. 2024; 11(6): 101134. Article. IF: 9.4; D1
- **Hernández-García M, Barbero-Herranz R, Bastón-Paz N, Díez-Aguilar M, López-Collazo E, Márquez-Garrido EJ, Hernández-Pérez JM, Baquero F, Ekkelenkamp MB, Fluit AC, Fuentes-Valverde V, Moscoso M, Bou G, del Campo R, Cantón R, Avendaño-Ortiz J.** Unravelling the mechanisms causing murepavadin resistance in Pseudomonas aeruginosa: lipopolysaccharide alterations and its consequences. Front Cell Infect Mi. 2024; 14: 1446626. Article. IF: 4.8; Q1
- **Hernández-Hernández I, De La Rosa JV, Martín-Rodríguez P, Díaz-Sarmiento M, Recio C, Guerra B, Fernández-Pérez L, León TE, Torres**

R, Font-Díaz J, Roig A, de Mora F, Boscá L, Díaz M, Valledor AF, Castrillo A, Tabraue C. Endogenous LXR signaling controls pulmonary surfactant homeostasis and prevents lung inflammation. Cell Mol Life Sci. 2024; 81(1): 287. Article. IF: 6.2; Q1

- **López-Collazo E, del Fresno C.** Endotoxin tolerance and trained immunity: breaking down immunological memory barriers. Front Immunol. 2024; 15: 1393283. Review. IF: 5.9; Q1
- **Mcgrail JP, Mondolfi AP, Ramírez JD, Vidal S, García-Sastre A, Palacios G, Sánchez-Seco MP, Guerra S.** Comparative Analysis of 2022 Outbreak MPXV and Previous Clade II MPXV. J Med Virol. 2024; 96(11): e70023. Article. IF: 4.6; Q1
- **Minute L, Bergón-Gutiérrez M, Mata-Martínez P, Fernández-Pascual J, Terrón V, Bravo-Robles L, Biçakcioglu G, Zapata-Fernández G, Aguiló N, López-Collazo E, del Fresno C.** Heat-killed Mycobacterium tuberculosis induces trained immunity in vitro and in vivo administered systemically or intranasally. Iscience. 2024; 27(2): 108869. Article. IF: 4.1; Q1
- **Monzón S, Varona S, Negredo A, Vidal-Freire S, Patino-Galindo JA, Ferressini-Gerpe N, Zaballos A, Orviz E, Ayerdi O, Muñoz-Gómez A, Delgado-Iribarren A, Estrada V, García C, Molero F, Sánchez-Mora P, Torres M, Vazquez A, Galán JC, Torres I, del Rio MC, Merino-Díaz L, López M, Galar A, Cardenoso L, Gutiérrez A, Loras C, Escribano I, Alvarez-Argueelles ME, del Rio L, Simón M, Meléndez MA, Camacho J, Herrero L, Jiménez P, Navarro-Rico ML, Jado I, Giannetti E, Kuhn JH, Sánchez-Lockhart M, Di Paola N, Kugelman JR, Guerra S, García-Sastre A, Cuesta I, Sánchez-Seco MP, Palacios G.** Monkeypox virus genomic accordion strategies. Nat Commun. 2024; 15(1): 3059. Article. IF: 15.7; D1
- **Perdiguero B, Álvarez E, Marcos-Villar L, Sin L, López-Bravo M, Valverde JR, Sorzano COS, Falqui M, Coloma R, Esteban M, Guerra S, Gómez CE.** B and T Cell Bi-Cistronic Multiepitopic Vaccine Induces Broad Immunogenicity and Provides Protection Against SARS-CoV-2. Vaccines (Basel). 2024; 12(11): 1213. Article. IF: 3.4; Q2
- **Plasencia-Rodríguez C, Martínez-Feito A, Novella-Navarro M, De Diego RP, Bonilla G, Gehin JE, Villalba-Yllán A, Nuño L, Pascual-Salcedo D, Nozal P, Almirón MD, Balsa A.** Influence of rheumatoid factor levels and TNF inhibitor structure on secondary nonresponse in rheumatoid arthritis patients. Front Med (Lausanne). 2024; 11: 1461396. Article. IF: 3; Q1
- **Povo-Retana A, Landauro-Vera R, Álvarez-Lucena C, Cascante M, Boscá L.** Trabectedin and Lurbinectedin Modulate the Interplay between Cells in the Tumour Microenvironment-Progresses in Their Use in Combined Cancer Therapy. Molecules. 2024; 29(2): 331. Review. IF: 4.6; Q2
- **Rallón N, Jiménez-Carretero D, Restrepo C, Ligos JM, Valentin-Quiroga J, Mahillo I, Cabello A, López-Collazo E, Sánchez-Cabo F, Gorgolas M, Estrada V, Benito JM.** A specific natural killer cells phenotypic signature associated to long term elite control of HIV infection. J Med Virol. 2024; 96(5): e29646. Article. IF: 4.6; Q1
- **Sánchez-García S, Castrillo A, Boscá L, Prieto P.** Potential Beneficial Role of Nitric Oxide in SARS-CoV-2 Infection: Beyond Spike-Binding Inhibition. Antioxidants. 2024; 13(11): 1301. Article. IF: 6.6; Q1
- **Sánchez-Ramón S, Fuentes-Antrás J, Rider NL, Pérez-Segura P, de la Fuente-Muñoz E, Fernández-Arquero M, Neves E, de Diego RP, Ocaña A, Guevara-Hoyer K.** Exploring gastric cancer genetics: A turning point in common variable immunodeficiency. J Allergy Clin Immunol Glob. 2024; 3(2): 100203. Article. Not Indexed
- **Tebar D, Carrillo X, del Blanco BG, Gomez-Hospital JA, Nombela L, Molina E, Galeote G, Vilalta V, Serra-García V, Carol GM, Jimenez-Valero S, Fernández-Nofrerias E, Calabuig-Goena A, Jurado-Roman A, Sánchez-Recalde A, Velasco MF, Perez-Solares L, Moreno R.** Experience with the ACURATE neo and neo2 transcatheter aortic valves in Spain. The PRECISA (PRospective Evaluation Complementing Investigation with ACURATE devices) registry. Catheter Cardio Inte. 2024; 103(6): 1015-22. Article. IF: 1.9; Q3
- **Vallejo-Cremades M, Merino J, Carmona R, Córdoba L, Salvador B, Martínez L, Tovar JA, Llamas MA, Muñoz-Chápuli R, Fresno M.** Toll-like receptors ligand immunomodulators for the treatment congenital diaphragmatic hernia. Orphanet J Rare Dis. 2024; 19(1): 386. Article. IF: 3.5; Q2

Research projects

- **del Fresno Sánchez C.** Biopsia Líquida Inmune Polifuncional (PolyFIL) para el diagnóstico diferencial de adenomas y cáncer de colon (Luís Álvarez 2024). FIBHULP. 2024-Ongoing. Managment centre: FIBHULP
- **del Fresno Sánchez C.** Biopsia líquida Inmune Polifuncional para el diagnóstico diferencial de adenomas y cáncer de colon (PremioPfizer-CarlosdelFresno). Fundación Pfizer. 2024-Ongoing. Managment centre: FIBHULP
- **del Fresno Sánchez C.** Biopsia Poli-Funcional Inmunitaria líquida (PoliFIL): una nueva plataforma para predecir y mejorar respuestas a inmunoterapia del cáncer usando moduladores inmunes innatos (PI21/01178). ISCIII. 2022-2024. Managment centre: FIBHULP
- **del Fresno Sánchez C.** Cancer immunotherapy trough mucosae based on innate ummune memory (Luís Álvarez 2021). FIBHULP. 2022-Ongoing. Managment centre: FIBHULP
- **del Fresno Sánchez C.** Development of a new treatment against colorectal cancer based on the combination of trained immunity and immune checkpoint inhibitors (CP20/00106). ISCIII. 2021-2023. Managment centre: FIBHULP
- **del Fresno Sánchez C.** Identificación de los mecanismos efectores de una vacuna antineoplásica basada en CA10 y su potencial aplicación clínica (IND2022/BMD-23669). CM. 2022-2025. Managment centre: FIBHULP
- **del Fresno Sánchez C.** Identifying the effector mechanisms of the antineoplastic ca10-based vaccine and its potential clinical application/ niveles de ca10 como parametro pronostico y de evolución en cancer colorrectal y su correlación con el sistema inmunitario circulante" (PI-4925). Inmunotek. 2021-Ongoing. Managment centre: FIBHULP
- **del Fresno Sánchez C.** Inmunoterapia bacteriana frente a infecciones recurrentes en pacientes pediátricos con fibrosis quística (2023.56). Fundación Familia Alonso. 2022-2024. Managment centre: FIBHULP
- **del Fresno Sánchez C.** Prueba en concepto para nuevas inmunoterapias contra el cáncer dirigidas a la memoria inmunitaria innata (Semilla AECC). Fundación Cientifica de la Asociación Española Contra el Cáncer. 2022-Ongoing. Managment centre: FIBHULP
- **López Collazo EM.** Abordaje multiómico y estructural al estudio de los mecanismos de respuesta del hepatocito al daño inflamatorio (S2022/BMD-7232). CM. 2023-2026. Managment centre: FIBHULP
- **López Collazo EM.** Análisis de muestras del proyecto "ensayo clínico para la realización de la investigación clínica sobre una nueva tecnica diagnostica basada en pcr a tiempo real, para determinar la predisposición a infecciones en pacientes con infarto de miocardio, necesario para su aprobación regulatoria". Crazy Science & Business S.L. 2021-Ongoing. Managment centre: FIBHULP
- **López Collazo EM.** Caracterización de la inmunidad innata en niños nacidos de madres portadoras de VIH. Fundación Familia Alonso. 2019-Ongoing. Managment centre: FIBHULP
- **López Collazo EM.** Contrato Miguel Servet Categoria A (CES08/002). CM. 2009-2025. Managment centre: FIBHULP
- **López Collazo EM.** Contribución de las células híbridas tumorales a la metástasis del cáncer de pulmón: estudio exhastivo en modelos animales y pacientes con metástasis avanzada. FIBHULP. 2018-Ongoing. Managment centre: FIBHULP
- **López Collazo EM.** Detection of pro-metastatic hybrids in primari tumour, peripheral blood and



metastasis from patients with cáncer: a strategy for its deactivation. Siemens Gamesa Renewable Energy S. A. 2020-Ongoing. Managment centre: FIBHULP

- **López Collazo EM.** Dinamización de ciencia disruptiva en predictores de enfermedades tumorales, infecciosas y hereditarias como base de la medicina personalizada (FORT23/00006_ GRUPO II). ISCIII. 2024-2028. Managment centre: FIBHULP
- **López Collazo EM.** El desarrollo de biomodelos partiendo de animales genéticamente transformados, biopsias, piezas de cirugía, células madres y vesículas extracelulares contribuirá al estudio e implantación de nuevas terapias y de una medicina personalizada (). FIBHULP. 2020-Ongoing. Managment centre: FIBHULP
- **López Collazo EM.** El estudio de los agentes patógenos que provocan las enfermedades infecciosas, así como la interacción del sistema inmunológico con ellos establecerá marcadores de tempranos de evolución y potenciales dianas farmacéuticas, así como repercutirá en la modernización y agilización de la toma de decisiones terapéuticas. FIBHULP. 2020-Ongoing. Managment centre: FIBHULP
- **López Collazo EM.** Estudio de la interacción entre celulas troncales de cancer colorrectal y el sistema inmune innato. Study of the interaction between colerectal cancer stem cells and the innate immune system. FIBHULP. 2022-Ongoing. Managment centre: FIBHULP
- **López Collazo EM.** Estudio del sistema inmune infiltrado en el cáncer de pulmón y búsqueda de marcadores pronósticos en células circulantes de pacientes que sufren esta enfermedad. Immunostep S. L. 2014-Ongoing. Managment centre: FIBHULP
- **López Collazo EM.** Estudio inmunológico comparativo de la alopecia areata en pacientes pediátricos. Fundación Familia Alonso. 2023-2026. Managment centre: FIBHULP
- **López Collazo EM.** Fallo en trasplante renal infantil: un abordaje inmunológico para los efectos secundarios y el rechazo. Fundación Familia Alonso. 2020-Ongoing. Managment centre: FIBHULP
- **López Collazo EM.** Inmune checkpoint en pacientes con COVID-19: una propuesta para la estratificación y la terapia dirigida al huésped. Encinar Rodriguez, Jesus. 2020-Ongoing. Managment centre: FIBHULP
- **López Collazo EM.** La metástasis del cáncer de ovario en la niñez y la adolescencia: un abordaje inmunológico para su erradicación. Fundación Familia Alonso. 2020-Ongoing. Managment centre: FIBHULP
- **López Collazo EM.** La metástasis tumoral infantil: una propuesta para eliminarla. Fundación Familia Alonso. 2018-Ongoing. Managment centre: FIBHULP
- **López Collazo EM.** Los inmune-checkpoints en la sepsis: un abordaje para el diagnóstico y la terapia (PI18/00148). ISCIII. 2019-2024. Managment centre: FIBHULP
- **López Collazo EM.** Plataforma de caracterización celular de alta dimensionalidad (CellDA) (IFCS21/00009). ISCIII. 2022-2026. Managment centre: FIBHULP
- **López Collazo EM.** Sepsis: un estudio longitudinal exhaustivo de la respuesta inmune para la estratificación de los pacientes y una medicina personalizada (PI21/00869). ISCIII. 2022-2024. Managment centre: FIBHULP
- **López Collazo EM.** Transplantation (SOT & HSCT) in children transchild. Comunidad de Madrid. 2016-Ongoing. Managment centre: FIBHULP
- **López Collazo EM.** UCIPREDICT. UE. 2022-2026. Managment centre: CIEMAT
- **López Collazo EM.** Viral intestinal reservoir and microbiota dysbiosis as pathological base for long COVID (MERCK). MERCK. 2023-2026. Managment centre: FIBHULP
- **Lozano Rodríguez R.** Contrato predoctoral (FI19/00334). ISCIII. 2020-2023. Managment centre: FIBHULP
- **Mallonas Masferrer J, López-collazo E.** A phase 1 Clinincal Trial to evaluate safety and immunogenecity of HIV-1 Evelope-based vaccine (ICI23/00025). ISCIII. 2023-2026. Managment centre: IdiBAS
- **Pérez De Diego R.** Identificación de nuevos errores innatos de la inmunidad hacia el diagnóstico de precisión y prevención de enfermedades inmunológicas (PI22/00790). ISCIII. 2023-2025. Managment centre: FIBHULP
- **Pérez De Diego R.** Medicina de precisión en inmunodeficiencias primarias: desentrañando nuevas etiologías genéticas mediante aproximaciones "ómicas" . Opesa Centro de Formación. 2022-Ongoing. Managment centre: FIBHULP
- **Pérez De Diego R.** The human genetic and immunological determinants of the clinical manifestations of SARS-CoV-2 infection: Towards personalized medicine (UNDINE). UE. 2022-2026. Managment centre: FIBHULP

Ciber and Retics

- **López Collazo E.** Plataforma de Biomodelos y Biobanco de IdiPAZ (PT23/00028). ISCIII. (31/12/2026). FIBHULP

Patents and trademarks

- **Llamas Matías MA, López-Collazo E, inventors; FIBHULP, Llamas Matías MA, Empireo S.**L., assignees. Method for determine the risk of developing an infectious disease. P201330768, PCT/ES2014/070434, EP3006570; 2013 May 27.
- **Vela Cuenca M, González Navarro P, Valentín Quiroga J, Escudero López A, Pérez Martínez A, Fernández Casanova L, inventors; FIBHULP, CNIO, assignees.** Anti-CXCR4 antibody combined with activated and expanded natural killer cells for cancer immunotherapy. 62/642,313 US Provisional Application; 2018 March 13.
- **del Fresno C, Cantero Cid R, Lopez Collazo, inventors; FIBHULP, assignes.** Poly Functional Immune Liquid Biopsy (PolyFIL Biopsy) for the differential diagnosis of colon adenoma and carcinoma differential diagnosis of colon adenoma and carcinoma. EP24382100.6. 2024 January 31

3.3.5 Alterations of the Complement System in Human Pathology



Publications: 8 | **Q1:** 6

COMPOSITION

Margarita López Trascasa.
Investigadora "Ad honorem". IdiPAZ. Profesora de la Facultad de Medicina. Universidad Autónoma de Madrid
Pilar Sánchez Corral Gómez.
Investigadora Senior (Contrato Miguel Servet - I2). Jefe de Laboratorio. Hospital Universitario La Paz

- **Fernando Corvillo Rodríguez.** *Investigador postdoctoral. Hospital Universitario La Paz*
- **Laura Espinosa Román.** *Jefa de Servicio Nefrología Pediátrica. Hospital Universitario La Paz*
- **María del Rosario García Sánchez.** *Investigadora predoctoral. FIBHULP*
- **Laura González Sánchez.** *Investigadora postdoctoral. Hospital Universitario La Paz*
- **Alberto López Lera.** *Investigador Postdoctoral. Contratado CIBERER. Hospital Universitario La Paz*
- **Marta Melgosa Hijosa.** *Facultativo Especialista de Área en Nefrología Infantil. Hospital Universitario La Paz*
- **Pilar Nozal Aranda.** *Facultativo Especialista de Área en Inmunología. Investigadora Postdoctoral. Hospital Universitario La Paz*

STRATEGIC OBJETIVES

- This is a national reference group for the study of primary or acquired defects in the complement system.
- The main aim is to gain an understanding of the molecular mechanisms underlying in complement deficiency or dysregulation in several human diseases, the majority of which are classified as rare diseases.
- In this context, the group implements and applies various methodological strategies (immunological, biochemical, proteomic and genetic) to detect clinically relevant deficiencies or functional defects in complement components. By following a clearly translational approach, the group also develops new diagnostic tests which are implemented in the clinical practice, especially for treatment adjustment and patient follow-up.
- The research lines could be classified as: screening and characterization of genetic or acquired complement defects that cause renal pathology (I), functional and molecular diagnosis of deficiencies affecting individual components of the complement system (II), diagnosis and molecular studies in Hereditary Angioedema and screening for disease modifying genes (III), study of pathogenic mechanisms in acquired lipodystrophies (IV).

RESEARCH LINES

- Screening and characterization of genetic and acquired Complement defects in renal disease.
- Biochemical and molecular diagnosis of isolated Complement deficiencies.
- Biochemical and molecular diagnosis of Hereditary and Acquired forms of bradykinin-mediated Angioedema.
- Pathogenic mechanisms of adquired lipodistrhphies: Barraquer-Simons syndrome, and Lawrence syndrome.
- Complement defects in Age Related Macular Degeneration

RESEARCH ACTIVITY

Publications

- **Alsaidalani AA, García-Solis B, Bukhari E, Van Den Rym A, López-Collazo E, Sánchez-Ramón S, Corvillo F, López-Lera A, de Andrés A, Martínez-Barricarte R, de Diego RP.** Inherited Human BCL10 Deficiencies. J Clin Immunol. 2024; 44(1): 13. Review. IF: 5.7; Q1
- **Espinosa LG, Santoveña AZ, Feito JB, Hijosa MM, Camblor CF, Melgar AA, Roman LE.** 40 Years experience in Bartter's syndrome. Nefrologia. 2024; 44(5): 766-8. Editorial Material. IF: 2.6; Q2
- **Gallego MAM, Sánchez MGC, Olmedo MGS, Soto AB, Casasempere SA, Nozal P, Martínez-Ojinaga E, Arias MM, Losantos-García I, Molero-Luis M.** Trends in Faecal Zonulin Concentrations in Paediatric Patients with Celiac Disease at Baseline and on a Gluten-Free



Diet: Exploring Correlations with Other Faecal Biomarkers. Nutrients. 2024; 16(5): 684. Article. IF: 5; Q1

- **González-Sánchez L, Agudo AM, van den Rym A, Begiristain MI, Saizar A, de Diego RP, Nozal P, López-Lera A, López-Trascasa M, Corvillo F.** Properdin deficiency associated with systemic meningococcal disease due to a novel p.Cys337Arg pathogenic variant. Genes Dis. 2024; 11(6): 101134. Article. IF: 9.4; D1
- **Magno S, Ceccarini G, Corvillo F, Pelosini C, Gilio D, Paoli M, Fornaciari S, Pandolfo G, Sánchez-Iglesias S, Nozal P, Curcio M, Sessa MR, López-Trascasa M, Araújo-Vilar D, Santini F.** Clinical Characteristics of Patients With Acquired Partial Lipodystrophy: A Multicenter Retrospective Study. J Clin Endocr Metab. 2024; 109(3): e932-44. Article. IF: 5.1; Q1
- **Martínez-Feito A, Novella-Navarro M, Hernández-Breijo B, Nozal P, Peiteado D, Villalba A, Nuño L, Monjo I, Pascual-Salcedo D, Balsa A, Plasencia-Rodríguez C.** Early monitoring of anti-infliximab antibodies by drug-tolerant assay predicts later immunogenicity and drug survival in rheumatic diseases. Rheumatology. 2024; 64(1): 344-51. Article. IF: 4.4; Q1
- **Martínez-Feito A, Plasencia-Rodríguez C, Novella-Navarro M, Gehin JE, Hernández-Breijo B, Brenis CM, Villalba-Yllán A, Fernández E, Monjo-Henry I, Pascual-Salcedo D, Nozal P, Balsa A.** Influence of rheumatoid factor on serum drug levels of TNF inhibitors with different structures in rheumatoid arthritis. Clin Exp Rheumatol. 2024; 42(5): 999-1005. Article. IF: 3.3; Q2
- **Plasencia-Rodríguez C, Martínez-Feito A, Novella-Navarro M, De Diego RP, Bonilla G, Gehin JE, Villalba-Yllán A, Nuño L, Pascual-Salcedo D, Nozal P, Almirón MD, Balsa A.** Influence of rheumatoid factor levels and TNF inhibitor structure on secondary nonresponse in rheumatoid arthritis patients. Front Med (Lausanne). 2024; 11: 1461396. Article. IF: 3; Q1

Research projects

- **López Lera A.** Identification and Functional Characterization of Genetic Variants Associated with Specific Clinical Phenotypes in Hereditary Angioedema due to C1 Inhibitor Deficiency: An Unbiased Approach. Takeda Pharmaceuticals. 2024-Ongoing. Managment centre: Hospital Universitari Vall d'Hebron
- **López Trascasa M.** Estudio de las bases moleculares del Síndrome Hemolítico Urémico Atípico y creación de un registro español de SHU-Atípico (PI-1106). Secugen S.L. 2011-Ongoing. Managment centre: FIBHULP
- **Nozal Aranda P.** Detección y caracterización de autoanticuerpos frente a perilipina 1 en pacientes con lipodistrofia generalizada adquirida (síndrome de Lawrence). AELIP (Asociación Internacional de Familiares y Afectados de Lipodistrofias). 2024-Ongoing. Managment centre: FIBHULP
- **Sánchez-Corral Gómez P.** Perfiles cuantitativos de las proteínas FH/FHRS del complemento como biomarcadores de predisposición y pronóstico en el síndrome hemolítico-urémico primario y secundario (PI19/00970). ISCIII. 2020-2024. Managment centre: FIBHULP
- **Sánchez-Corral Gómez P.** Caracterización funcional de la deglicosilación y proteolisis del FH del Complemento y relevancia en la patologia del Síndrome Hemolítico-Urémico Atípico. Fundación SENEFRO. 2022-Ongoing. Managment centre: FIBHULP
- **Sánchez-Corral Gómez P.** Caracterización de patrones de expresión del FH y proteínas FHRS del complemento mediante western-blot e inteligencia artificial. Correlación genotipo-fenotipo en patología renal y ocular (PI22/00211). ISCIII. 2023-2025. Managment centre: FIBHULP
- **Sánchez-Corral Gómez P.** El sistema del complemento en salud y enfermedad (Complemento III-CM) (P2022/BMD-7278). CM. 2023-Ongoing. Managment centre: FIBHULP
- **Sánchez-Corral Gómez P.** Contrato Miguel Servet Categoria A (CES07/030). CM. 2008-2025. Managment centre: FIBHULP

Cibers and Retics

- **López Trascasa M.** The European Consortium of Lipodystrophies. (ECLip). EU. (31/12/2024). FIBHULP

Clinical trials

- **Melgosa Hijosa M.** ensayo de 6 meses multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia, seguridad, farmacocinética y farmacodinámica de un régimen de finerenona oral, ajustado por edad y peso corporal, añadido a un ieca o ara ii para el tratamiento de pacientes pediátricos de 6 meses a <18 años con enfermedad renal crónica y proteinuria.
  Type/Phase: III
  Sponsored by: Bayer Ag
  Signature date: 07/11/2024
- **Melgosa Hijosa M.** estudio de cohortes de fase 2, con un solo grupo, abierto para evaluar la seguridad, la eficacia y la farmacocinética del tratamiento con esparsentán en pacientes pediátricos con determinadas enfermedades glomerulares proteinúricas (eppik.
  Type/Phase: II
  Sponsored by: Travere therapeutics Inc.
  Signature date: 11/09/2024

Patents and trademarks

- **López Trascasa M, authors; FIBHULP, assignee.** Brand name: COMPLEMENTest; CM 009.658.791; 2011, January 14.

COMPLEMENTest ®

3.3.6 Lymphocyte Pathophysiology in Immunodeficiencies



Publications: 24 | **Q1:** 15

COMPOSITION

Eduardo López Granados.
Coordinador de Inmunología. Hospital Universitario La Paz

- **María Bravo García-Morato.** *Facultativo Especialista de Área en Inmunología. Hospital Universitario La Paz*
- **Carmen Cámara Hijón.** *Facultativo Especialista de Área en Inmunología. Hospital Universitario La Paz*
- **Álvaro Clemente Bernal.** *Técnico de Grado Superior. FIBHULP*
- **Ricardo Cuesta Martín de la Cámara.** *Biólogo Interno Residente en la especialidad de Inmunología. Hospital Universitario La Paz*
- **Andrea González Torbay.** *Médico Interno Residente en Inmunología. Hospital Universitario La Paz*
- **Carla Cecilia Gianelli.** *Facultativo Especialista de Área en Inmunología. Hospital Universitario La Paz*
- **Diego Plaza López de Sabando.** *Facultativo Especialista de Área en Hemato-Oncología Pediátrica. Hospital Universitario La Paz*
- **Keren Reche Yebra.** *Técnico de Laboratorio. FIBHULP*
- **Ángel Julián Robles Marhuenda.** *Facultativo Especialista de Área en Medicina Interna. Hospital Universitario La Paz*
- **Rebeca Rodríguez Pena.** *Facultativo Especialista de Área en Inmunología. Hospital Universitario La Paz*
- **María Carmen Salcedo Moreno.** *Técnico de Laboratorio. Hospital Universitario La Paz*
- **Elena Sánchez Zapardiel.** *Facultativo Especialista de Área en Inmunología. Hospital Universitario La Paz*
- **Ana Sastre Urguelles.** *Facultativo Especialista de Área en Hemato-Oncología Pediátrica. Hospital Universitario La Paz*
- **Juan Manuel Torres Canizales.** *Médico Inmunólogo. Hospital Universitario La Paz*

STRATEGIC OBJETIVES

- Our group attempts to unravel the molecular bases of primary immunodeficiencies (PIDs), a large group of rare conditions (more that 400 types described so far) that virtually affect any cell type of the immune system and increase the risk of infections, autoimmunity and cancer in patients. We take a multidisciplinary clinical, anatomic, genetic, epigenetic and functional approach. By correlating clinical and experimental data, we aim to achieve a better understanding of these rare diseases and lay the grounds for, repurposed or new, more effective treatments.
- Taking advantage of the knowledge and resources developed to dissect the immune system in PIDs, we are developing new schemes for immune monitoring of transplanted patients, to better estimate immunosupresion and tolerance, and early detection of severe complications as infections and rejection. Finally, we explore novel approaches for monitoring, and fine tuning of immunotherapies

RESEARCH LINES

- To define the anatomical, cellular, molecular and (epi)genetic bases of immunological dysfunction in patients diagnosed with primary immunodeficiency in our clinic.
- The maturation and functional specialization of human B lymphocytes, and its pathophysiology in primary and secondary antibody immunodeficiencies.
- The analysis of the immunological reconstitution after haemopoietic stem cell transplantation, and the discovery and clinical validation of immunological biomarkers for immunosuppression and tolerance in solid organ transplantation.
- The development and clinical implementation of patient-tailored monitoring schemes of immunotherapies in wide clinical use.

RESEARCH ACTIVITY

Publications

- **Abad MR, Alerany C, Alsina L, Granados EL, Neth O, Poveda JL, Rivière JG, Rodríguez-Gallego C, Nolthenius JBT, Figueiredo R, Labazuy SS, Gil A.** Determining value in the treatment of activated PI3Kδ syndrome in Spain: a multicriteria decision analysis from the perspective of key stakeholders. Glob Reg Health Technol Assess. 2024; 11(): 124-30. Article. IF: 0.5; Q1
- **Alsaidalani AA, García-Solis B, Bukhari E, Van Den Rym A, López-Collazo E, Sánchez-Ramón S, Corvillo F, López-Lera A, de Andrés A, Martínez-Barricarte R, de Diego RP.** Inherited Human BCL10 Deficiencies. J Clin Immunol. 2024; 44(1): 13. Review. IF: 5.7; Q1
- **Antón J, Mosquera JM, Calzada J, Iglesias E, Zacarías A, Olivé A, Bittermann V, Lorenzo TR, Remesal A, Quintana-Ortega C, Nuño-Nuño L, Robles-Marhuenda A, de Inocencio J, Martín-López M, Carreira PE, Brandy-García AM, Holgado S, Camacho-Lovillo M, Ruiz-Román A, Clemente D, Narváez J, Campos J, Sánchez-Manubens J, Bernabéu P, Graña J, Vargas C, Ortiz-Santamaria V, Castañeda S, de Yébenes MJG, Carmona L.**

Similarities and differences between systemic juvenile idiopathic arthritis and adult-onset Still's disease: a multicenter Spanish study. Rheumatol Int. 2024; 44(12): 2911-20. Article. IF: 2.9; Q2

- **Ascunce M, Coccolo A, Mozo Y, Baquero-Artigao F, Rodríguez-Molino P, Toro-Rueda C, García-Clemente P, Sánchez-Zapardiel E, López-Granados E, Corral-Sánchez D, Bueno D, Sisinni L, Perez-Martínez A, Calvo C, del Rosal T.** Severe Impairment of T-cell Immunity and Pulmonary GvHD Are Major Risk Factors for Nontuberculous Mycobacterial Infection After Pediatric Allogeneic Hematopoietic Stem Cell Transplantation. Pediatr Infect Dis J. 2024; 43(9): 885-8. Article. IF: 2.2; Q2
- **Cabañero-Navalón MD, García-Bustos V, Balastegui-Martin H, Bracke C, Mateu L, Solanich X, Carrillo-Linares JL, Robles-Marhuenda A, Puchades F, Ballesta AP, López-Osle N, Torralba-Cabeza MA, Masdeu AMB, Niño JG, Gaya NT, Castellanos GP, Sánchez-Martínez R, Barragán-Casas JM, González-García A, de la Peña JLP, López-Wolf D, Rufete AM, Mora AC, Moral PM.** The impact of immune dysregulation on the risk of malignancy in common variable immunodeficiency: insights from a multicenter study. Front Immunol. 2024; 15: 1465159. Article. IF: 5.9; Q1
- **Calvo-Apalategi A, Nevado ML, Bravo-Gallego LY, González-Granado LI, Allende LM, Pena RR, López-Granados E, Reyburn HT.** The lack of either IRF9, or STAT2, has surprisingly little effect on human natural killer cell development and function. Immunology. 2024; 172(3): 440-50. Article. IF: 5.0; Q1
- **de la Cámara RCM, Morato MBG, Cámara-Hijón C, Magallares L, Martínez-Ojinaga E, González-Torbay A, Miguel-Berenguel L, del Rosal T, Sarría-Osés J, Rodríguez-Pena R.** Novel hypomorphic CYBB variant causing chronic granulomatous disease with incomplete penetrance. Pediat Allerg Imm-Uk. 2024; 35(10): e14259. Article. IF: 4.5; Q2
- **de la Cámara RCM, Torices-Pajares A, Miguel-Berenguel L, Reche-Yebra K, Frauca-Remacha E, Hierro-Llanillo L, Muñoz-Bartolo G, Lledín-Barbacho MD, Gutiérrez-Arroyo A, Martínez-Feito A, López-Granados E, Sánchez-Zapardiel E.** Epstein-Barr virus-specific T-cell response in pediatric liver transplant recipients: a cross-sectional study by multiparametric flow cytometry. Front Immunol. 2024; 15: 1479472. Article. IF: 5.9; Q1
- **Espinosa LG, Santoveña AZ, Feito JB, Hijosa MM, Camblor CF, Melgar AA, Román LE.** 40 Years experience in Bartter's syndrome. Nefrologia. 2024; 44(5): 766-8. Editorial Material. IF: 2.6; Q2
- **Ferreras C, Hernández-Blanco C, Martín-Quirós A, Al-Akioui-Sanz K, Mora-Rillo M, Ibáñez F, Díaz-Almirón M, Cano-Ochando J, Lozano-Ojalvo D, Jiménez-González M, Goterris R, Sánchez-Zapardiel E, de Paz R, Guerra-García P, Queiruga-Parada J, Molina P, Briones ML, Ruz-Caracuel B, Borobia AM, Carcas AJ, Planelles D, Vicario JL, Moreno MA, Balas A, Llano M, Llorente A, del Balzo A, Cañada C, García MA, Calvin ME, Arenas I, de Diego RP, Eguizábal C, Soria B, Solano C, Pérez-Martínez A.** Results of phase 2 randomized multi-center study to evaluate the safety and efficacy of infusion of memory T cells as adoptive therapy in severe. Cytotherapy. 2024; 26(1): 25-35. Article. IF: 3.2; Q2
- **Gallego MAM, Sánchez MGC, Olmedo MGS, Soto AB, Casasempere SA, Nozal P, Martínez-Ojinaga E, Arias MM, Losantos-García I, Molero-Luis M.** Trends in Faecal Zonulin Concentrations in Paediatric Patients with Celiac Disease at Baseline and on a Gluten-Free Diet: Exploring Correlations with Other Faecal Biomarkers. Nutrients. 2024; 16(5): 684. Article. IF: 5; Q1
- **González-García A, Fabregate M, Serralta G, Campo BD, Mozo AN, Robles-Marhuenda A.** The utility of 18 F-FDG-PET/TC in detecting extracranial large vessel vasculitis in rheumatic polymyalgia or giant cell arteritis: a systematic review and meta-analysis. Rev Clin Esp. 2024; 224(7): 445-456. Review. IF: 1.7; Q2
- **González-Sánchez L, Agudo AM, van den Rym A, Begiristain MI, Saizar A, de Diego RP, Nozal P, López-Lera A, López-Trascasa M, Corvillo F.** Properdin deficiency associated with systemic meningococcal disease due to a novel p.Cys337Arg pathogenic variant. Genes Dis. 2024; 11(6): 101134. Article. IF: 9.4; D1
- **Lacombe D, Bloch-Zupan A, Bredrup C, Cooper EB, Houge SD, García-Miñaúr S, Kayserili H, Larizza L, González VL, Menke LA, Milani D, Saettini F, Stevens CA, Tooke L, van der Zee JA, Van Genderen MM, Van-Gils J, Waite J, Adrien JL, Bartsch O, Bitoun P, Bouts AHM, Cueto-González AM, Dominguez-Garrido E, Duijkers FA, Fergelot P, Halstead E, Huisman SA, Meossi C, Mullins J, Nikkel SM, Oliver C, Prada E, Rei A, Riddle I, Rodríguez-Fonseca C, Pena RR, Russell J, Saba A, Santos-Simarro F, Simpson BN, Smith DF, Stevens MF, Szakszon K, Taupiac E, Totaro N, Palafoll IV, van der Kaay DCM, Van Wijk MP, Vyshka K, Wiley S, Hennekam RC.** Diagnosis and management in Rubinstein-Taybi syndrome: first international consensus statement. J Med Genet. 2024; 61(6): 503-19. Review. IF: 3.7; Q2
- **Martínez-Feito A, Novella-Navarro M, Hernández-Breijo B, Nozal P, Peiteado D, Villalba A, Nuño L, Monjo I, Pascual-Salcedo D, Balsa A, Plasencia-Rodríguez C.** Early monitoring of anti-infliximab antibodies by drug-tolerant assay predicts later immunogenicity and drug survival in rheumatic diseases. Rheumatology. 2024; 64(1): 344-51. Article. IF: 4.4; Q1
- **Martínez-Feito A, Plasencia-Rodríguez C, Novella-Navarro M, Gehin JE, Hernández-Breijo B, Brenis CM, Villalba-Yllán A, Fernández E, Monjo-Henry I, Pascual-Salcedo D, Nozal P, Balsa A.** Influence of rheumatoid factor on serum drug levels of TNF inhibitors with different structures in rheumatoid arthritis. Clin Exp Rheumatol. 2024; 42(5): 999-1005. Article. IF: 3.3; Q2
- **Martínez-Sánchez N, Alvarez-Troncoso J, Robles-Marhuenda A, Fernández-Miranda MD, Hernando MLM, Bartha JL.** Safety of biologic immunosuppressants in pregnant women with immune-mediated inflammatory diseases. J Autoimmun. 2024; 148: 103301. Article. IF: 7.0; Q1
- **Molina LD, Yebra KR, Serrano YS, Bernal AC, Avendaño-Monje CL, Ocejo-Vinyals JG, Pena RR, Granados EL.** Technical challenges of intracellular flow cytometry-based assays as a functional complement to diagnosis of signaling defects of inborn errors of immunity: PI3K pathway as a case of study. Front Immunol. 2024; 15: 1476218. Article. IF: 5.9; Q1
- **Pérez EM, Torbay AG, López MS, de la Cámara RCM, Jiménez CR, Alvarez MAM, Blanco JN, Gianelli C, Hijón CC, Granados EL, Pena RR, Mate AD, García-Morato MB.** Genetics of inborn errors of immunity: Diagnostic strategies and new approaches to CNV detection. Eur J Clin Invest. 2024; 54(6): e14191. Article. IF: 3.6; Q1
- **Pérez-Jurado LA, Cáceres A, Balagué-Dobón L, Esko T, de Heredia ML, Quintela I, Cruz R, Lapunzina P, Carracedo A, Abellán J, Acosta-Isaac R, Aguado JM, Aguilar C, Aguilera-Albesa S, Sabbagh AA, Alba J, Albu S, Alcalá-Gallardo KAM, Alcoba-Florez J, Batres SA, Algarin-Lara HR, Almadana V, Medeiros KA, Almeida J, Almoguera B, Alonso MR, Alvarez N, Walther RAS, Alvarez-Benítez Y, Alvarez-Navia F, dos Santos KA, Andreu-Bernabeu A, Antonijoan MR, Martínez-Aquino E, Arana-Arri E, Aranda C, Arango C, Araque C, Araujo NK, Arcanjo AC, Arnaiz A, Fernández FA, Arranz MJ, López JRA, Artiga MJ, Avello-Malaver Y, Ayuso C, Martín BB, Baptista-Rosas RC, Baldion AM, Barranco-Díaz A, Barreda-Sánchez M, Barrera-Penagos V, Belhassen-García M, Bernal-Bello D, Bernal E, Bezerra JF, Bezerra MAC, Blanca-López N, Blancas R, Boix-Palop L, Borobia A, Bravo E, Brion M, Brochado-Kith O, Brugada R, Bustos M, Cabello A, Cáceres A, Cáceres-Agra JJ, Calbo E, Calderón EJ, Camacho S, Ceballos FC, Cañadas Y, Carbonell C, Cardona-Huerta S, Abad MSC, Segura CC, Carrillo-Avila JA, Campos MC, Casasnovas C, Castaño L, Castaño CF, Castelao JE, Candalija AC, Castillo MA, Chaves-Santiago WG, Chiquillo-Gómez S, Cid-López MA, Cienfuegos-Jiménez O, Conde-Vicente R, Cunha GCR, Cordero-Lorenzana ML, Corella D, Corrales A, Cortés-Sánchez JL, Corton M, Souza KSC, Silva FTC,**

Cruz R, Cuesta L, Tavares NAC, Carvalho MCC, Dalmau D, Dantas-Komatsu RCS, Darnaude MT, de Andrés R, de Juan C, Troca JJD, de la Horra C, de la Hoz AB, De Martino-Rodríguez A, Cruz MS, Neri JLDA, del Campo-Pérez V, Delgado-Cuesta J, de Bustamante AD, Díaz-Pérez A, Dietl B, Diz-de Almeida S, Alves MD, Domínguez-Garrido E, Rosa LS, Luchessi AD, Echave-Sustaeta J, Eiros R, Enciso-Olivera CO, Escudero G, España PP, Sanabria GE, Fariñas MC, Fernández R, Fernández-Caballero L, Fernández-Cruz A, Fernández-Ferrero S, Martínez YF, Fernández-Nestosa MJ, Fernández-Robelo U, Fernández-Rodríguez A, Fernández-Sampedro M, Fernández R, Fernández-Villa T, Fernández-Capitán C, Carioca AAF, Flores-Pérez P, Fuenmayor-Hernández L, Fuertes-Núñez M, Fumadó V, Gadea I, Gagliardi L, Gago-Domínguez M, Gallego N, Galoppo C, García-Soidán A, García-Cerrada C, García-de-Vicuña A, García-García J, García-García I, García-Ibarbia C, García-Montero AC, García L, García M, Torrejón MCG, García I, García-Vázquez E, Garza-Frias E, Gentile A, Gil-Fournier B, de Araújo JNG, Gómez-Duque M, Gómez-Arrue J, Carrera LG, García MG, Sacristán AG, González JR, González-Neira A, Alvarez BG, de Quirós FGB, González-Montelongo R, González-Peñas J, González-Sagrado M, Gonzalo-Benito H, Gorgojo-Galindo O, Górgolas M, Guaragna F, Chaux JG, Guillén-Navarro E, Guillén-Guío B, Guisado-Vasco P, Gutiérrez-Castañeda LD, Gutiérrez-Bautista JF, Heili-Frades S, Jacomo RH, Hernández E, Hernández-Moro C, Hernández-Ortega LD, Hernández-Pérez G, Hernández-Vaquero R, Herráez B, Herranz MT, Herrera M, Herrero MJ, Herrero-González A, Horcajada JP, Imaz-Ayo N, Intxausti-Urrutibeaskoa M, Iñigo-Campos A, Iñiguez M, Jara R, Jiménez A, Jiménez-Alfaro I, Jiménez P, Jiménez-Sousa MA, Jordan I, Laguna-Goya R, Laorden D, Lasa-Lázaro M, Lattig MC, Lauriente A, Borja AL, Llanos L, López-Bernus A, de Heredia ML, López-García E, López-Granados E, López-Rodríguez R, López-Ruz MA, Lorente L, Lorenzo-Salazar J, Lozano JE, Lozano-Espinosa M, Mahillo I, Mancebo E, Mar C, Calvo CM, Marcos-Delgado A, Marcos M, Marín-Candón A, Mariscal-Aguilar P, Martin-Pedraza L, Martin-Fernández M, Martín-López C, Martín-Oterino JA, Martín MD, Martín V, Martín MM, Martín-Vicente M, Martínez A, Martínez-González O, Martínez R, Martínez-Paz P, Díaz-Caneja CM, Martínez-Nieto O, Martínez-López I, Martínez-Reséndez MF, Martínez S, Martínez JJ, Martínez-Pérez A, Martínez-Ramas A, Martínez-Robles V, Marzal L, Mazzeu JF, Medrano FJ, Meijome XM, Mejuto-Montero N, Mendes I, Duarte AL, Méndez-Echevarría A, Charris HM, Macías EM, Mercadillo F, Mercado-Sesma AR, Mínguez P, Molina-Roldán E, Molina AJ, Montoya JJ, Pinho SMT, Moreira-Escriche P, Morelos-Arnedo X, Moreno R, Cuerda VM, Moreno-Docón A, Moreno-Escalante J, Fernández AM, García PM, Neira P, Nevado J, Nieto-Gañán I, Silbiger VN, Nuñez-Torres R, Obrador-Hevia A, Ocejo-Vinyals JG, Virginia O, Oliveira SF, Ondo L, Orfao A, Ortega-Paino E, Ortega L, Ortiz-López R, Ortiz-Flores F, Oteo JA, Pacheco M, Pacheco-Miranda FJ, Padilla-Conejo I, Panadero-Fajardo S, Parellada M, Pariente-Rodríguez R, Friaza V, Paz-Artal E, Peces-Barba G, Kus MSP, Perales C, Santos NPC, Guegel GP, Pérez MJ, Pérez A, Pérez-Matute P, Pérez C, Pérez-de-Nanclares G, Pérez-García F, Pérez P, Pérez-Jurado LA, Pérez-Tomás ME, Perucho T, Pichardo LA, Ribeiro AP, Pinsach-Abuin ML, Pinzón LA, Medeiros JFP, Pita G, Pla-Juncà F, Planas-Serra L, Pompa-Mera EN, Porras-Hurtado GL, Pujol A, Quevedo-Chávez ME, Quijada MA, Quintela I, Ramiro-León S, Sedes PR, Nunes JFR, Recalde D, Recio-Fernández E, Resino S, Sousa RR, Rivadeneira-Chamorro CS, Roa-Agudelo D, Pardo MR, Fernandes MR, Rodríguez-Hernández MA, Rodríguez-Palmero A, Rodríguez-Ruiz E, Rodríguez MJ, Rodríguez-Artalejo F, Rodríguez-Ferrer M, Rodríguez-Gallego C, Rodríguez-García JA, Maya BR, Rodríguez-Nicolas A, Rodríguez-Novoa GE, Rodríguez-Urrego PA, Rojo F, Romero-Coronado A, Morilla R, Rondón-García F, Rosales-Castillo A, Rubio C, Olivera MR, Ruiz-Cabello F, Ruiz-Casares E, Ruiz-Cubillan JJ, Ruiz-Hornillos J, Ruiz M, Ryan P, Salamanca HD, Salazar-García L, Salgueiro-Origlia GG, Sangil A, Sánchez-Pernaute O, Sánchez PL, López AJS, Sánchez-Pablo C, Sánchez-Prados MC, Sánchez-Real J, Sánchez-Redondo J, Sancho-Sainz C, Sande E, Santos A, Schlüter A, Segovia S, Serra-Llovich A, Sevil-Puras F, Sevilla-Porras M, Sicolo MA, Silván-Fuentes C, Moraes VMS, Souza VS, Solé-Violán J, Soria JM, Sorlí JV, Silva NS, Souto JC, Sprockel JJ, Suárez-Rama JJ, Suárez-Zamora DA, Taboada-Fraga X, Tamayo E, Tamayo-Velasco A, Taracido-Fernández JC, Vasconcelos RHT, Tellería C, Carratto TMT, Tenorio-Castano JA, Teper A, Araujo IMT, Torres-Macho J, Torres-Tobar L, Torres-Gutiérrez RP, Troya J, Urioste M, Valencia-Ramos J, Valido A, Vargas-Gallo JP, Varón B, Vega T, Velasco-Quirce S, Vélez-Santamaría V, Víctor V, Vidán-Estévez J, Silva GV, Vieitez-Santiago M, Vilches C, Villalobos L, Villar F, Villar-García J, Villaverde C, Villoslada-Blanco P, Virseda-Berdices A, Costa TX, Yáñez Z, Zapatero-Gaviria A, Zarate R, Zazo S, Flores C, Riancho JA, Rojas-Martínez A, Lapunzina P, Carracedo A, González JR. Clonal chromosomal mosaicism and loss of chromosome Y in elderly men increase vulnerability for SARS-CoV-2. Commun Biol. 2024; 7(1): 202. Article. IF: 5.1; D1

- **Plasencia-Rodríguez C, Martínez-Feito A, Novella-Navarro M, De Diego RP, Bonilla G, Gehin JE, Villalba-Yllán A, Nuño L, Pascual-Salcedo D, Nozal P, Almirón MD, Balsa A.** Influence of rheumatoid factor levels and TNF inhibitor structure on secondary nonresponse in rheumatoid arthritis patients. Front Med (Lausanne). 2024; 11: 1461396. Article. IF: 3; Q1
- **Shephard JLV, Perez EM, Bujalance SG, Aguilar IM, Martínez BG, Martínez AP, Granados EL, Feito AM, Zapardiel ES.** The challenge of standardizing CAR-T cell monitoring: A comparison of two flow-cytometry methods and correlation with qPCR technique. Cytom Part A. 2024; 105(5): 368-75. Article. IF: 2.1; Q3
- **Shephard JLV, Robles EJA, Hijón CC, Breijo BH, Novella-Navarro M, Schay PB, de la Cámara RC, Criado AB, Granados EL, Rodríguez CP.** Predicting anti-TNF treatment response in rheumatoid arthritis: An artificial intelligence-driven model using cytokine profile and routine clinical practice parameters. Heliyon. 2024; 10(1): e22925. Article. IF: 3.6; Q1
- **Troncoso JA, Abánades CS, Robles-Marhuenda A, Batres SA, Peña MFV, Valero SJ, Torre RS, Rios-Blanco JJ.** Prevalence, risk factors and echocardiographic predictors of pulmonary hypertension in systemic lupus erythematosus: towards a screening protocol. RMD Open. 2024; 10(1): e003674. Article. IF: 4.7; Q1

Research projects

- **López Granados E.** Actualización y renovación de la actividad en el servicio de inmunología del hospital universitario la paz. Octapharma S.A. 2012-Ongoing. Managment centre: FIBHULP
- **López Granados E.** Desarrollo de ensayos de validación funcional como complemento del diagnóstico molecular de errores congénitos de la respuesta inmunológica. Fundación Mutua Madrileña. 2022-Ongoing. Managment centre: FIBHULP
- **López Granados E.** Estudio exploratorio sistemático de la competencia en la respuesta linfocitaria al Sars-Cov-2, en diversas situaciones del huésped y según severidad de la COVID-19 (InmunoCOVID). Cytognos. 2021-Ongoing. Managment centre: FIBHULP
- **López Granados E.** European Rare Disease Coordination and support action (ERICA). UE. 2020-2024. Managment centre: FIBHULP
- **López Granados E.** Síndrome inflamatorio multisistémico asociado a covid-19 en niños (mis-c): bases genéticas, epigenéticas e inmunopatogenéticas. Fundació Marató Tv3. 2021-Ongoing. Managment centre: FIBHULP
- **López Granados E.** Un esfuerzo integral para intentar descifrar las bases (epi) genéticas,



fenotípicas y funcionales de la desregulación del linfocito B en deficiencias de anticuerpos, para un mejor pronóstico y tratamiento de los pacientes. (PI20/01371). ISCIII. 2021-2024. Managment centre: FIBHULP

- **López Granados E, del Pino Molina L.** Ensayos basados en citometría de flujo para la evaluación patogénica de la vía PI3K-Akt-Mtor. Pharming. 2023-2025. Managment centre: FIBHULP
- **Sánchez Zapardiel E.** Validación de nuevas técnicas de estimación de la inmunosupresión y detección del rechazo en trasplante hepático pediátrico (PI19/01311). ISCIII. 2020-2024. Managment centre: FIBHULP

Cibers and Retics

- **Lopez Granados E.** Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER). ISCIII. (31/12/2024). FIBHULP

Clinical trials

- **"López Granados E.** estudio multicéntrico, prospectivo, abierto, aleatorizado y con grupos cruzados para evaluar la farmacocinética (fc), la seguridad y la tolerabilidad de tak-881 en inmunodeficiencias primarias (idp) multicenter, prospective, open-label, randomized, crossover study to evaluate pharmacokinetics (pk), safety, and tolerability of tak-881 in primary immunodeficiency diseases (pidd).
  Type/Phase: II
  Sponsored by: Takeda Development Center Americas
  Signature date: 26/05/2024"
- **López Granados E.** seguridad y tolerabilidad a largo plazo de tak-881 en pacientes con inmunodeficiencias primarias (idp).
  Type/Phase: III
  Sponsored by: Takeda Development Center Americas
  Signature date: 05/06/2024
- **Plaza López de Sabando D.** estudio en fase ii, aleatorizado y abierto para evaluar abemaciclib en combinación con temozolomida comparado con la temozolomida en monoterapia en niños y adultos jóvenes con glioma de alto grado recién diagnosticado después de la radioterapia.
  Type/Phase: II
  Sponsored by: Eli Lilly Co Uk Ltd.
  Signature date: 19/07/2024
- **Plaza López de Sabando D.** loggic/firefly-2: ensayo en fase iii, aleatorizado, internacional y multicéntrico de day101 en monoterapia frente a la quimioterapia estándar en pacientes con glioma pediátrico de bajo grado que presentan una alteración de raf activadora que requiere tratamiento sistémico de primera línea.
  Type/Phase: III
  Sponsored by: Day One Biopharmaceuticals Inc.
  Signature date: 05/12/2024
- **Plaza López de Sabando D.** un ensayo global prospectivo internacional para niños con tumores teratoides / rabdoides atípicos (atrt) incluyendo un estudio de fase iii aleatorizado que evalúa la no inferioridad de tres ciclos de quimioterapia a dosis altas (hdct).
  Type/Phase: III
  Sponsored by: Fundación De La Sociedad Española De Hemetologia Y Oncologia Pediatricas
  Signature date: 10/06/2024
- **Robles Marhuenda AJ.** estudio de fase ii, multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad del obexelimab en pacientes con lupus eritematoso sistémico.
  Type/Phase: II
  Sponsored by: Zenas Biopharma (Usa) Llc
  Signature date: 14/10/2024
- **Robles Marhuenda AJ.** estudio de fase ii, multicéntrico, aleatorizado, doble ciego, controlado con placebo y de grupos paralelos para evaluar la eficacia y la seguridad de nipocalimab en participantes con miopatías inflamatorias idiopáticas activas.
  Type/Phase: II
  Sponsored by: Janssen Cilag International Nv
  Signature date: 29/03/2024
- **Robles Marhuenda AJ.** estudio fase 1b, abierto, de escalado de dosis para evaluar la seguridad, tolerabilidad, farmacocinética y efecto farmacológico de una única infusión intravenosa de belantamab en pacientes con enfermedad autoinmune.
  Type/Phase: I
  Sponsored by: Glaxosmithkline Research And Development Limited
  Signature date: 09/12/2024
- **Robles Marhuenda AJ.** estudio vitales. estudio longitudinal observacional para evaluar la utilidad clínica de la iniciativa de salud vitales en pacientes con lupus eritematoso sistémico (les).
  Type/Phase: OTROS
  Sponsored by: Astrazeneca Farmaceutica Spain S.A.
  Signature date: 17/12/2024
- **Robles Marhuenda AJ, Bonilla Hernán MG.** observational retrospective study to describe characteristics and clinical outcomes of patients withsystemic lupus erythematosus initiating saphnelo (anifrolumab) in a real-world setting. estudio azahar.
  Type/Phase: EOm no prospectivo
  Sponsored by: Astrazeneca Farmaceutica Spain S.A.
  Signature date: 10/12/2024


Patents and trademarks


- **Van Dongen JJM, Orfao de Matos Correia E Vale JA, Van Der Burg M, Pérez Andrés M, Van Zelm MC, Kalina T, Vlkova M, López Granados E, Blanco Álvarez E, Kienzler AK, inventors; Erasmus University Medical Center Rotterdam, assignee.** Reagents, methods, and kits for diagnosing primary immunodeficiencies. PCT/NL2015/050762, US62/072,498; 2014 Oct 30.
- **Lopez Granados E, del Pino L, authors; FIBHULP, CIBERer, assigne.** Brand name: IMMUNE SIGNAL ®. EU 01906321; 2024, August 02

IMMUNE SIGNAL

3.3.7 Drug Hypersensitivity and Innate Immune Response





Publications: 7 | **Q1:** 5

COMPOSITION

Teresa Bellón Heredia.
Investigadora Senior (Contrato Miguel Servet -I2). Jefe de laboratorio. FIBHULP

- **María del Rosario Cabañas Moreno.** *Facultativo Especialista de Área en Alergología. Hospital Universitario La Paz*
- **Sofía Caiqin Linares Reyes.** *Investigadora Predoctoral. FIBHULP*
- **Guillermo Servera Negre.** *Facultativo Especialista en Dermatología Médico-Quirúrgica y Venereología. Hospital Universitario La Paz*

STRATEGIC OBJETIVES

- Cutaneous adverse drug reactions are unpredictable and represent a plethora of skin diseases with various degrees of severity. The spectrum ranges from mild to potentially fatal multisystem maladies. Those of most concern are usually referred to as severe cutaneous adverse reactions (SCARs), and include acute generalized exanthematous pustulosis (AGEP), drug reaction with eosinophilia and systemic symptoms (DRESS), also known as drug induced hypersensitivity syndrome or hypersensitivity síndrome (DIHS/HSS), Stevens-Johnson's syndrome (SJS), and toxic epidermal necrolysis (TEN). Among them, SJS and TEN are the most severe clinical entities and are nowadays considered as variants of the same disease characterized by keratinocyte necrosis and epidermal detachment with the formation of subepidermal bullae. From the immunopatohogenic point of view, SCARs are T-cell mediated type IV hypersensitivity reactions. However, T cells can orchestrate different types of immune responses and this functional heterogeneity has led to a further sub-classification into type IVa-IVd hypersensitivity that considers the distinct cytokine production pattern by T cell subpopulations, and emphasizes the participation of different effector cells causing inflammation and tissue damage. Current knowledge supports the active participation of cytotoxic lymphocytes in different clinical entities.
- Our project aims to a better understanding of the immune mechanisms underlying the etiopathogenesis of these diseases. The study is performed in the framework of the consortium PIELenRed (Plataforma interdisciplinar para el estudio de reacciones cutáneas graves en red) integrated by researchers belonging to different hospitals in Madrid. A Biobank of biological samples has been created linked to the epidemiological registry
- Reactivation of latent herpesvirus has been described during the development of some of the previously mentioned clinical entities. In order to improve our understanding of the behavior of the immune system during viral replication, a collaboration was established with the Kidney Transplant Unit (Nephrology Service, HULP). Kidney transplant recipients were followed immediately before and after transplant in order to identify patients with active CMV replication. Samples from the patients have been stored in the Biobank for immunological studies.
- Desensitization procedures have allowed the treatment of patients with drug allergies with their first line medications or when there are no alternatives available. A new project has been initiated to understand mechanism of tolerance in patients undergoing drug desensitization procedures
- General objectives for the next 5 years
- The main objectives are:
  - I) Biobanking of samples of severe cutaneous adverse reactions to medications (DRESS, AGEP and SJS/TEN) associated to the registry PIELenRed, and integrated in the international registry RegiSCAR.
  - II) To investigate in vitro test for drug causality assessement.
  - III) To explore the involvement of the innate immune response (in particular natural cytotoxic activity) during the development of SCARs.
  - IV) Identification of biomarkers of susceptibility.
  - V) Analysis mechanisms leading to tolerance in patients undergoing drug desensitization

RESEARCH LINES

- Biobanking of biological samples from patients with severe cutaneous adverse reactions to medications (DRESS, AGEP and SJS/TEN).
- Development and evaluation of in vtro tests for drug causality assessment.
- Identification of biomarkers of susceptibility.
- Involvement of NK receptors in the etiopathogenesis of Stevens-Johnson syndrome /Toxic epidermal necrolysis (SJS/TEN).
- Differential analysis of the cytokine pattern involved in different SCARs (AGEP, DRESS and SJS/TEN).
- Identification of biomarkers of tolerance to drug desensitization procedures

RESEARCH ACTIVITY

Publications

- **Entrala A, Loli-Ausejo D, Pérez T, Losantos , Cabañas R, Caballero T.** Real-life Experience of Subcutaneous Plasma Derived C1-Inhibitor as Long-term Prophylaxis in HAE-C1INH. J Invest Allerg Clin. 2024; 34(4): 261-3. Editorial Material. IF: 4.8; Q1
- **Fernández-Concha I, Pose K, de las Vecillas L, Lluch-Bernal M, Tomás-Pérez M, Soto T, de la Guía AL, Cabañas R.** Successful Desensitization to Lenalidomide in Leukocytoclastic Vasculitis. J Invest Allerg Clin. 2024; 34(5): 352-3. Editorial Material. IF: 4.8; Q1
- **Lluncor-Salazar M, Phillips-Anglés E, Pedrosa M, Lamacchia D, Hernanz A, Prior N, Cabañas R, Caballero T.** Determinants of Disease Activity in Adults With Hereditary Angioedema due to C1-Esterase Inhibitor Deficiency. J Invest Allerg Clin. 2024; 34(6): 406-9. Editorial Material. IF: 4.8; Q1
- **Mir-Ihara P, Vecillas LD, Heredia R, Fiandor A, González-Muñoz M, Zamarrón E, Prados C, Cabañas R.** Protocol for Successful Desensitization to Ivacaftor and Elexacaftor/Tezacaftor/Ivacaftor in a Delayed Hypersensitivity Reaction Confirmed by the Lymphocyte Transformation Test. J Invest Allerg Clin. 2024; 34(3): 211-3. Article. IF: 4.8; Q1
- **Nitola-Mendoza L, Sánchez-Cardenas M, Rodríguez-Chitiva N, Mora Gutiérrez JM, Rodríguez-Pena R, Romero-González G, Bleda Perez M, Cuenca Casbas P, Calsina-Berna A, Alvaro-Pardo M, Granados Casas V, Garrido Ballart P, Beroiz Groh P, Bover J, Miralles Basseda R, Leiva-Santos JP, Alonso-Babarro A, Julia-Torras J.** Nomenclature in Palliative and Kidney Supportive Care: Not Just at the End-of-Life. Nefrologia. 2024; 44(4): 475-45-. Review. Not Indexed
- **Pose K, Narváez-Fernández E, de la Guía AL, De Las Vecillas L, Domínguez-Ortega J, Lluch-Bernal M, Fiando A, Cabañas R.** A Tailored 7-to 10-Day Lenalidomide Desensitization Protocol. J Invest Allerg Clin. 2024; 34(1): 49-50. Editorial Material. IF: 4.8; Q1
- **Souza RD, Bellón T, Benito EF, Cudós ES.** Flow Cytometric Analysis of Skin Blister Fluid Cells: A Promising Tool in the Differential Diagnosis of Acute Cutaneous Graft-versus-host Disease and Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. Actas Dermosifiliogr. 2024; 115(10): 1042-4. Editorial Material. IF: 2.8; Q2

Research projects

- **Bellón Heredia T.** Contrato Miguel Servet Categoria B (CES06/016). ISCIII. 2007-2025. Managment centre: FIBHULP



- **Bellón Heredia T.** Creación de un centro de referencia para el estudio de los mecanismos implicados en las reacciones de hipersensibilidad a las membranas de hemodiálisis basadas en polysulfona (PI-3009). Nipro Euope NV. 2017-Ongoing. Managment centre: FIBHULP
- **Bellón Heredia T.** ELISpot como método diagnóstico para identificación del fármaco causal en pacientes con reacciones graves de hipersensibilidad cutánea a medicamentos: comparación con TTL. FIBHULP. 2023-2025. Managment centre: FIBHULP
- **de las Vecillas Sánchez L.** Estudio de la inmunomodulación celular inducida en las desensibilizaciones a quimioterápicos tras reacciones inmediatas y tardías. Sociedad Española de Alergología e Inmunología Clínica. 2022-2024. Managment centre: Fundación SEAIC

Patents and trademarks

- **Selgas Gutiérrez R, Bellón Heredia T, Rodríguez Sanz AI, Álvarez Builla J, Vaquero López JJ, Sánchez Alonso P, Alajarín Fernández R, inventors; FIBHULP, Universidad de Alcalá, assignees.** Use of compounds derived from salts of pyridazine[1′,6′:1,2]pyrido[3,4-b]indolinium as anti-inflammatory agents. P201331143, PCT/ES2014/070603; 2013 July 25.
- **Selgas Gutiérrez R, Bellón Heredia T, Rodríguez Sanz AI, Álvarez Builla J, Vaquero López JJ, Sánchez Alonso P, Alajarín Fernández R, inventors; FIBHULP, Universidad de Alcalá, assignees.** Use of compounds derived from salts of piridazine[3,2-b]benzimidazolium as anti-inflammatory agents. P201430411, PCT/ES2014/070603; 2013 July 25.


3.3.8 Immunomediate Gastrointestinal Diseases and Other Digestive Pathologies

Publications: 21 | **Q1:** 10

COMPOSITION

María Dolores Martín Arranz.
Jefa de Sección de Aparato Digestivo (Jefa de Servicio en funciones). Hospital Universitario La Paz. Profesora Asociada. Unidad Autónoma de Madrid

- **Laura García Ramírez.** *Investigadora Predoctoral. FIBHULP*
- **Eduardo Martin Arranz.** *Facultativo Especialista de Área en Aparato Digestivo. Hospital Universitario La Paz*
- **Jesús Noci Belda.** *Enfermero. Hospital Universitario La Paz*
- **Joaquín Poza Cordón.** *Facultativo Especialista de Área en Aparato Digestivo. Hospital Universitario La Paz*
- **José Luis Rueda García.** *Facultativo Especialista de Área en Aparato Digestivo. Hospital Universitario La Paz*
- **María Sánchez Azofra.** *Facultativo Especialista de Área en Aparato Digestivo. Hospital Universitario La Paz*
- **Cristina Julia Suárez Ferrer.** *Facultativo Especialista de Área en Aparato Digestivo. Hospital Universitario La Paz*
- **Tamara Verges Martínez-Meco.** *Investigadora Predoctoral. FIBHULP*



STRATEGIC OBJETIVES

- Our work focuses on diseases of the Digestive System with special dedication to Inflammatory Bowel Disease (IBD) and other immune-mediated diseases.
- The group is formed by gastroenterologists, biologists, pharmacists and nurses; all of them are part of a multidisciplinary working group.
- In addition to promoting our own research projects in our area, we participate in numerous clinical trials of molecules in development.
- Our objectives are to optimize existing treatments, promote measures to improve the quality of life and translational research in search of precision medicine, incorporating new technologies to the management of our patients.

RESEARCH LINES

- Correlation of drug levels with therapeutic response
- Intestinal ultrasound
- Dysplasia detection techniques in IBD
- Hypercoagulability studies in IBD
- Immunological basis of inflammatory bowel disease: changes in cellular and inflammatory mediator expression with different therapies.

RESEARCH ACTIVITY

Publications

- **Aguas M, Del Hoyo J, Vicente R, Barreiro-de Acosta M, Melcarne L, Hernandez-Camba A, Madero L, Arroyo MT, Sicilia B, Chaparro M, Martin-Arranz MD, Pajares R, Mesonero F, Mañosa M, Martínez P, Chacón S, Tosca J, Marín S, Sanroman L, Calvo M, Monfort D, Saiz E, Zabana Y, Guerra I, Varela P, Baydal V, Faubel R, Corsino P, Porto-Silva S, Brunet E, González M, Gutiérrez A, Nos P.** Telemonitoring of Active Inflammatory Bowel Disease Using theApp TECCU:Short-Term Results of a Multicenter Trial of GETECCU. J Med Internet Res. 2024; 26(): -e60966. Article. IF: 6.0; D1
- **Bastón-Rey I, Rodríguez-Lago I, Luque AM, Caballol B, Soutullo-Castiñeiras C, Bravo A, Castaño A, Gros B, Bernal L, Diz-Lois MT, Alonso-Galán H, Canete F, Castro B, Pérez-Galindo P, González-Munoza C, El Hajra I, Martínez-Montiel P, Alonso-Abreu I, Mesonero F, González-Vivo M, Peries L, Martín-Arranz E, Abril C, Marin-Jiménez I, Baltar R, Vicuña M, Moreno N, Brunet E, de Célix CR, Fajardo I, Cruz N, Calvino-Suárez C, Rojas-Feria M, Fernández-Clotet A, Gimeno-Torres M, Nieto-García L, de la Iglesia D, Zabana Y, Suarez-Ferrer C, de Acosta MB.** The Natural History of Patients With Pre-Existing and De Novo Inflammatory Bowel Disease After Solid Organ Transplantation: EITOS Study of GETECCU. Inflamm Bowel Dis. 2024; 31(1): 1-10. Article. IF: 4.3; Q1
- **Chaparro M, Hermida S, Acosta D, Fernández-Clotet A, Acosta MBD, Martínez AH, Arroyo M, Bosca-Watts MM, Palomares MTDL, Menchen L, Cadilla JM, Leo-Carnerero E, Villafranca CM, Sierra-Ausin M, González-Lama Y, Riestra S, Rumbeu PS, Tapia MJC, de la Filia IG, Vicente R, Ceballos D, Villarroya RP, de la Piscina PR, Martin-Arranz MD, Ramos L, Ruiz-Cerulla A, Martínez-Perez TD, Amelivia ES, Calvet X, Huguet JM, Keco-Huerga A, Poyatos RHL, Munoz JF, Ponferrada-Diaz A, Sicilia B, Delgado-Guillena P, Delgado EG, Rancel-Medina FJ, Alonso-Galan H, Herreros B, Rivero M, Varela P, Bermejo F, Sepulcre MG, Gimeno-Pitarch L, Kolle-Casso L, Marquez-Mosquera L, Tirado PM, Ramírez C, Abizanda ES, Sadornil CD, Rosaenz**

HF, Casbas AG, Dominguez REM, Castillejo ON, Nieto YB, Mateu BB, Larramona SF, Serrano PL, Mateos JMR, Alsina ST, Iyo E, Forcelledo JLF, Hernandez L, Rodríguez-Grau MC, Miquel DM, Van Domselaar M, Ramos CL, Barcia MJR, Gisbert JP. Long-term benefit of ustekinumab in ulcerative colitis in clinical practice: ULISES study. Aliment Pharm Ther. 2024; 60(10): 1325-38. Article. IF: 6.7; D1

- **De Gea-Grela A, Maldonado-Barrueco A, Cabañuz C, Díaz-Almirón M, Rico A, Ruíz-Carrascoso G, Palacios ME, Martín-Arranz E, Escudero-Nieto R, Bernardino J.** Human intestinal spirochetosis: an entity associated with sexual transmitted infections. Enferm Infec Micr Cl. 2024; 42(5): 231-5. Article. IF: 2.5; Q2
- **Díaz IG, Riart MG, Martín-Arranz MD, Rodríguez CP, Ferrer CS.** Incidence and Course of Joint Inflammation Associated with Inflammatory Bowel Disease in Patients Undergoing Treatment with Vedolizumab/Ustekinumab: The VEDUSTAR Study. J Clin Med. 2024; 13(4): 1076. Article. IF: 2.9; Q1
- **Ferrer CS, Argüelles JA, García JLR, Ramírez LG, Arranz EM, Azofra MS, Cordón JP, Belda JN, Martín-Arranz MD.** Intensification with Intravenous Ustekinumab in Refractory Crohn's Disease. J Clin Med. 2024; 13(3): 669. Article. IF: 2.9; Q1
- **Ferrer CS, Gismero FM, Caballol B, Ballester MP, Rey IB, García AC, Bautista JM, Chumillas RS, Benítez JM, Sánchez-Delgado L, López-García A, de Celix CR, Abreu IA, Melcarne L, Santos RP, Marques-Camí M, Mateos AC, Díez CG, Calafat M, Galan HA, Vilaamil PV, Senosiain BC, Moya AG, Díaz CYR, Spicakova K, Marcos NM, Molina G, Parga LD, Angulo AR, del Campo LC, Grau MDR, Ramírez F, Pastrana BG, Partida IG, Mateu BB, González EP, Iyo E, González AE, Arnau ES, Villalba LH, Galindo PP, Medina LT, Alonso SM, Perez JAO, Sadornil CD, Ramírez LG, Martín-Arranz MD, Sanroman AL, Fernández A, Murgui VM, Suarez CC, Flórez-Diez P, Matilla MEL, Sicilia B, Escribano PS, Martin CM, Manosa M, Acosta MBD.** Efficacy and safety of biological treatment for inflammatory bowel disease in elderly patients: Results from a GETECCU cohort. Gastroent Hepat-Barc. 2024; 47(10): 502197. Article. IF: 1.9; Q3
- **Ferrer CS, Martín-Arranz E, Martin-Arranz MD.** Selective granulocyte-monocyte apheresis during induction with vedolizumab in moderate-severe ulcerative colitis: Experience in a tertiary hospital. Gastroent Hepat-Barc. 2024; 47(7): 721-6. Article. IF: 1.9; Q3
- **Fraga-Blanco P, Boullón-Batalla N, Benítez JM, Suárez-Ferrer C, Bastón-Rey I, Calafat M.** What strategies do we employ in the prevention andmonitoring of human papillomavirus inpatients with inflammatory bowel disease?. Gastroent Hepat-Barc. 2024; 47(7): 771-3. Editorial Material. IF: 1.9; Q3
- **Gargallo-Puyuelo CJ, Ricart E, Iglesias E, de Francisco R, Gisbert JP, Taxonera C, Mañosa M, Peris MA, Navarrete-Muñoz EM, Sanahuja A, Guardiola J, Mesonero F, Tirado MR, Barrio J, Mendoza IV, Parga LD, García-Planella E, Calvet X, Arranz MDM, García S, Sicilia B, Carpio D, Domenech E, Gomollón F.** Sex-Related Differences in the Phenotype and Course of Inflammatory Bowel Disease: SEXEII Study of ENEIDA. Clin Gastroenterol H. 2024; 22(11): 2280-90. Article. IF: 12.0; D1
- **Gisbert JP, Donday MG, Riestra S, Lucendo AJ, Benítez JM, Navarro-Llavat M, Barrio J, Morales-Alvarado VJ, Rivero M, Busquets D, Carnerero EL, Merino O, Castillejo ON, Navarro P, Van Domselaar M, Gutiérrez A, Alonso-Abreu I, Mejuto R, Fernández-Salazar L, Iborra M, Martin-Arranz MD, Pineda JR, Sampedro MJ, Nilsson KS, Bouhmidi A, Batista L, Villafranca CM, Rodríguez-Lago I, Ceballos D, Guerra I, Manosa M, Jimenez IM, Torrella E, Mendoza MV, Casanova MJ, de Francisco R, Arias-González L, Pedrosa SM, García-Bosch O, García-Alonso FJ, Delgado-Guillena P, García MJ, Torrealba L, Nunez-Ortiz A, Arregui MV, Bosca-Watts MM, Blazquez I, Acosta D, Garre A, Baldan M, Martínez C, Acosta MBD, Domenech E, Esteve M, García-Sánchez V, Nos P, Panes J, Chaparro M.** Withdrawal of antitumour necrosis factor in inflammatory bowel disease patients in remission: a randomised placebo-controlled clinical trial of GETECCU. Gut. 2024; 74(3): 387-96. Article. IF: 25.8; D1
- **Gómez-Labrador C, Ricart E, Iborra M, Iglesias E, Martín-Arranz MD, de Castro L, De Francisco R, García-Alonso FJ, Sanahuja A, Gargallo-Puyuelo CJ, Mesonero F, Casanova MJ, Mañosa M, Rivero M, Calvo M, Sierra-Ausin M, González-Muñoza C, Calvet X, García-López S, Guardiola J, García LA, Márquez-Mosquera L, Gutiérrez A, Zabana Y, Navarro-Llavat M, Poyatos RL, Piqueras M, Torrealba L, Bermejo F, Ponferrada-Díaz A, Pérez-Calle JL, Barreiro-de Acosta M, Tejido C, Cabriada JL, Marín-Jiménez I, Roncero O, Ber Y, Fernández-Salazar L, Aler BC, Lucendo AJ, Llaó J, Bujanda L, Villafranca CM, Domènech E, Chaparro M, Gisbert JP.** Trends in Targeted Therapy Usage in Inflammatory Bowel Disease: TRENDY Study of ENEIDA. Pharmaceutics. 2024; 16(5): 629. Article. IF: 5.5; Q1
- **González-Muñoza C, Calafat M, Gisbert JP, Iglesias E, Minguez M, Sicilia B, Aceituno M, Gomollón F, Calvet X, Ricart E, De Castro L, Rivero M, Mesonero F, Márquez L, Nos P, Rodríguez-Pescador A, Guardiola J, García-Sepulcre M, García-López S, Lorente-Poyatos RH, Alba C, Sánchez-Ocaña R, Vera I, Madero L, Riestra S, Navarro-Llavat M, Pérez-Calle JL, Camps B, Van Domselaar M, Lucendo AJ, Martin-Arranz MD, Montoro-Huguet MA, Sierra-Ausin M, Llao J, Carpio D, Varela P, Merino O, Fernández-Salazar L, Piqueras M, Sese E, Busquets D, Tardillo C, Maroto N, Riera J, Martínez-Flores C, Munoz F, Gordillo-abalos J, Bertoletti F, García-Planella E, Domènech E.** Influence of familial forms of inflammatory bowel disease on the use of immunosuppressants, biological agents, and surgery in the era of biological therapies. Results from the ENEIDA project. Postgrad Med J. 2024; 100(1189): 836-44. Article. IF: 2.7; Q1
- **Guerra I, Barros F, Chaparro M, Benítez JM, Martín-Arranz MD, de Francisco R, Piqueras M, de Castro L, Carbajo AY, Bermejo F, Mínguez M, Gutiérrez A, Mesonero F, Cañete F, González-Muñoza C, Calvo M, Sicilia B, Alfambra E, Rivero M, Lucendo AJ, Tardillo CA, Almela P, Bujanda L, van Domselaar M, Ramos L, Sánchez MF, Hinojosa E, Verdejo C, Gimenez A, Rodríguez-Lago I, Manceñido N, Calle JLP, Moreno MD, Delgado-Guillena PG, Antolin B, de la Piscina PR, Casanova MJ, Escribano PS, Arranz EM, Perez-Martínez I, Mena R, Morales NG, Granja A, Watts MMB, Francés R, Fernández C, Calafat M, Roig-Ramos C, Vera MI, Carracedo A, Domènech E, Gisbert JP.** Evaluation of Genetic Variants Associated with the Risk of Thiopurine-Related Pancreatitis: A Case Control Study from ENEIDA Registry. Digest Dis. 2024; 42(3): 257-64. Article. IF: 2.1; Q3
- **Marín-Serrano E, Cano AB, Martos RF, Barno MA, Martín AO, Arranz MDM.** Protocol for acquisition of images and measurement of transabdominal ultrasound pancreatic two-dimensional shear wave elastography (2D-SWE). Gastroent Hepat-Barc. 2024; 47(9): 502198. Article. IF: 1.9; Q3
- **Martín-Cardona A, Horta D, Florez-Diez P, Vela M, Mesonero F, Belinchón CR, García MJ, Masnou H, Peña-Negro LD, Ferrer CS, Casanova MJ, Duran MO, Peña E, Calvet X, Fernández-Prada SJ, González-Muñoza C, Piqueras M, Rodríguez-Lago I, Sainzs E, Bas-Cutrina F, Marcos NM, Ojeda A, Orts B, Sicilia B, García AC, Domènech E, Esteve M.** Safety and effectiveness of direct-acting antiviral drugs in the treatment of hepatitis C in patients with inflammatory bowel disease. Digest Liver Dis. 2024; 56(3): 468-76. Article. IF: 3.8; Q2
- **Moya MC, Gismero FM, Ferrer CS, Hernández-Camba A, Carlón DV, Benasach FG, Peris MA, Oliva FJD, González-Lama Y, Scheiding MM, Sebastián IA, Martel LC, Arriero VG, Piudo AE, Castillo PB, Sanz NC, Mendoza MIV, Labajos RS, Martínez AV, Restoy LP, Abdo YZ, Ciria MM, Rodríguez-Moranta F, Barreiro-de Acosta M, Casbas AG.** Position statement of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis on sexuality and inflammatory bowel disease. Gastroent Hepat-Barc. 2024; 47(7): 774-92. Article. IF: 1.9; Q3
- **Navarro-Gerrard C, Calafat M, Benítez JM, Suárez-Ferrer C, Bastón-Rey I.** Are biological drugs effective and safe in patients with IBD and solid organ transplant? Are biological agents effective and safe in patients with IBD and solid organ transplantation? Gastroent Hepat-Barc. 2024; 47(3): 289-92. Editorial Material. IF: 1.9; Q3
- **Rodríguez-Moranta F, Argüelles-Arias F, del Val JH, Colomino MI, Martín-Arranz MD, Viso LM, Núñez FM, Gómez ER, Sánchez-Hernández JG, Valdés-Delgado T, Capón JG, Barreiro-de Acosta M, Ciria MM, Abdo YZ, Casbas AG.** Therapeutic drug monitoring in inflammatory bowel diseases. Position statement of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis. Gastroent Hepat-Barc. 2024; 47(5): 522-52. Article. IF: 1.9; Q3
- **Salazar J, García-Planella E, Fernández-Clotet A, Esteve M, Gisbert JP, Busquets D, Lucendo**

A, Márquez L, Guardiola J, Martín-Arranz MD, Iglesias E, Monfort D, Villoria A, Cañete F, Bell O, Ricart E, Zabana Y, Chaparro M, Domènech E, Gordillo J. Genetic biomarkers of methotrexate response and safety in Crohn's disease: Data from the Spanish ENEIDA registry. Brit J Clin Pharmaco. 2024; 90(5): 1301-11. Article. IF: 3.0; Q2

- **Spigarelli IM, Pillado B, Vincent D, Poza J, Abadia M, Ruiz-Fernández G, Marin E, Castillo P, Polo B, Olveira A.** Low phospholipid-associated cholelithiasis syndrome, a not uncommon cause of biliary problems and hospital admissions. Rev Esp Enferm Dig. 2024; 116(10): 532-38. Article. IF: 4.0; Q1

Research projects

- **Martín Arranz MD.** Efecto terapeutico de la administración colonoscópica de células madre mesenquimales derivadoas de tejido adiposo humano de diferentes donantes en un modelo de colitis de rata por enema de TNBS. Abbvie Spain S.L.U. 2010-Ongoing. Managment centre: FIBHULP
- **Martín Arranz MD.** Protocolo de abordaje temprano de pacientes con enfermedad inflamatoria intestinal. Abbvie Spain S.L.U. 2021-Ongoing. Managment centre: FIBHULP
- **Martín Arranz MD.** Dynamics of A4B7+ dendritic dells in inflammatory bowel disease. personalised medicine with biological therapies. Dinámica de las celulas dendríticas A4B7+ en la enfermedad inflamatoria intestinal. avances hacia una medicina personalizada. FIBHULP. 2022-Ongoing. Managment centre: FIBHULP
- **Martín Arranz MD.** Programa de actualización en el conocimiento de la enfermedad inflamatoria intestinal. Abbvie Spain S.L.U. 2020-Ongoing. Managment centre: FIBHULP

Clinical trials

- **Martín Arranz MD.** estudio aleatorizado multicéntrico para evaluar la seguridad y la eficacia del lutikizumab como tratamiento de inducción y mantenimiento en sujetos con colitis ulcerosa activa de moderada a grave.
  Type/Phase: IIa
  Sponsored by: Abbvie Deutschland GMBH & Co. Kg
  Signature date: 01/07/2024
- **Martín Arranz MD.** estudio aleatorizado multicéntrico para evaluar la seguridad y la eficacia del lutikizumab como tratamiento de inducción y mantenimiento en sujetos con colitis ulcerosa activa de moderada a grave.
  Type/Phase: IIa
  Sponsored by: Abbvie Deutschland GMBH & Co. Kg
  Signature date: 06/08/2024
- **Martín Arranz MD.** estudio de fase 2, aleatorizado, con doble enmascaramiento y controlado con placebo para evaluar la seguridad y la eficacia de 2 tratamientos con dosis activa de morf-057 en adultos con enfermedad de crohn activa de moderada a grave (garnet).
  Type/Phase: II
  Sponsored by: Morphic Therapeutic Inc.
  Signature date: 12/06/2024
- **Martín Arranz MD.** estudio de fase iii, multicéntrico, doble ciego, controlado con placebo, para evaluar la eficacia y la seguridad del tratamiento continuo de inducción y mantenimiento con ro7790121 en pacientes con colitis ulcerosa activa de moderada a grave.
  Type/Phase: III
  Sponsored by: F.Hoffmann-La Roche Ltd.
  Signature date: 20/08/2024
- **Martín Arranz MD.** estudio de fase iii, multicéntrico, doble ciego, controlado con placebo, para evaluar la eficacia y la seguridad del tratamiento continuo de inducción y mantenimiento con ro7790121 en pacientes con enfermedad de crohn activa de moderada a grave.
  Type/Phase: III
  Sponsored by: F.Hoffmann-La Roche Ltd.
  Signature date: 18/12/2024
- **Martín Arranz MD.** estudio de plataforma en fase iia, multicéntrico, aleatorizado, de terapias dirigidas para el tratamiento de pacientes adultos con enfermedad de crohn de moderada a grave.
  Type/Phase: IIa
  Sponsored by: Abbvie Deutschland GMBH
  Signature date: 19/09/2024
- **Martín Arranz MD.** estudio de utilización de fármaco para evaluar medidas adicionales de minimización del riesgo para upadacitinib en el tratamiento de la colitis ulcerosa en europa.
  Type/Phase: EOm no prospectivo
  Sponsored by: Abbvie Deutschland GMBH & Co. Kg
  Signature date: 27/12/2024
- **Martín Arranz MD.** estudio en fase 3b, de un solo grupo, abierto y multicéntrico para evaluar la curacióntransmural y el efecto modificador de la enfermedad por guselkumab en pacientes conenfermedad de crohn.
  Type/Phase: III
  Sponsored by: Janssen Research & Development Llc
  Signature date: 07/02/2024
- **Martín Arranz MD.** estudio en fase 3b, de un solo grupo, abierto y multicéntrico para evaluar la curacióntransmural y el efecto modificador de la enfermedad por guselkumab en pacientes conenfermedad de crohn.
  Type/Phase: III
  Sponsored by: Janssen Research & Development Llc
  Signature date: 12/12/2024
- **Martín Arranz MD.** estudio en fase iiib, aleatorizado, con enmascaramiento doble para evaluar la eficacia y la seguridad a corto y a largo plazo del tratamiento dirigido doble con vedolizumab intravenoso y upadacitinib oral en comparación con vedolizumab intravenoso y placebo oral para la inducción, seguido de monoterapia con vedolizumab intravenoso para el tratamiento de mantenimiento de adultos con enfermedad de crohn activa de moderada a grave.
  Type/Phase: IIIb
  Sponsored by: Takeda Development Center Americas
  Signature date: 20/11/2024
- **Martín Arranz MD.** estudio multicéntrico aleatorizado, doble ciego y controlado con placebo, con tratamiento de mantenimiento durante 52 semanas y una extensión abierta para evaluar la eficacia y la seguridad de risankizumab en sujetos con colitis ulcerosa que respondan al tratamiento de inducción en los estudios m16-067 o m16-065.
  Type/Phase: III
  Sponsored by: Abbvie Deutschland GMBH
  Signature date: 24/04/2024
- **Martín Arranz MD.** estudio multicéntrico, aleatorizado, doble ciego y de grupos paralelos para evaluar la eficacia y seguridad del etrasimod por vía oral como tratamiento de inducción y mantenimiento para la enfermedad de crohn activa de moderada a grave.
  Type/Phase: III
  Sponsored by: Arena Pharmaceuticals Inc.
  Signature date: 09/10/2024
- **Martín Arranz MD.** estudio prospectivo en vida real de upadacitinib en colitis ulcerosa (profundus).
  Type/Phase: EOm prospectivo
  Sponsored by: Abbvie Spain S.L.U.
  Signature date: 23/05/2024
- **Martín Arranz MD.** estudio prospectivo, multicéntrico, para evaluar la seguridad y efectividad de sulky® gel lubricante hidrosoluble en instrumentaciones y exploraciones ginecológicas, urológicas y gastroenterológicas.
  Type/Phase: OTROS
  Sponsored by: Laboratorios Bohm S.A.
  Signature date: 08/07/2024
- **Martín Arranz MD.** programa de fase 3, aleatorizado, con doble enmascaramiento y comparativo con placebo para evaluar la eficacia y la seguridad de tulisokibart en participantes con enfermedad de crohn activa moderada o grave.
  Type/Phase: III
  Sponsored by: Merck Sharp & Dohme Llc
  Signature date: 20/09/2024
- **Martín Arranz MD.** programa de fase 3, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de mk-7240 en participantes con colitis ulcerosa activa moderada o grave.
  Type/Phase: III
  Sponsored by: Merck Sharp & Dohme Llc
  Signature date: 21/05/2024
- **"Martín Arranz MD.** seguridad de los tratamientos para la enfermedad inflamatoria intestinal durante el embarazo y la lactancia y a largo plazo: registro dumbo 2. Safety of ibd drugs during pregnancy and breasfeeding: mothers and babies' outcomes (dumbo 2 registry).
  Type/Phase: EOm prospectivo
  Sponsored by: Martín Arranz María Dolores
  Signature date: 17/06/2024"
- **Martín Arranz MD.** seguridad de los tratamientos para la enfermedad inflamatoria intestinal durante el embarazo y la lactancia: impacto en las madres y en los niños (registro dumbo.
  Type/Phase: EPA-AS
  Sponsored by: Fundación Hospital Universitario La Princesa
  Signature date: 24/04/2024
- **Suárez Ferrer CJ.** estudio prospectivo de la historia natural y las características inmunológicas y genéticas de la enfermedad inflamatoria intestinal preclínica.
  Type/Phase: OTROS
  Sponsored by: Grupo Español De Trabajo En Enfermedad De Crhon Y Colitis Ulcerosa
  Signature date: 30/01/2024

3.3.9 MicroRNA Regulation of Immune Tolerance, Autoimmunity and Cancer

COMPOSITION

Alicia González Martín.
Investigadora Ramón y Cajal. Universidad Autónoma de Madrid

- **Rocío Bartolomé Cabrero.** *Investigadora Predoctoral. Universidad Autónoma de Madrid*
- **María del Pilar González Molina.** *Investigadora Predoctoral. Universidad Autónoma de Madrid*
- **Laura Gámez Reche.** *Investigador Predoctoral. Universidad Autónoma de Madrid*
- **Laura Mañas Cordero.** *Técnico de Investigación. Universidad Autónoma de Madrid*
- **Eleftheria Papaioannou.** *Investigadora Juan de la Cierva. Universidad Autónoma de Madrid*
- **Ana María Prieto Muñoz.** *Técnico de Investigación. Universidad Autónoma de Madrid*
- **Javier Sanz Gallardo.** *Técnico de Investigación. Universidad Autónoma de Madrid*

STRATEGIC OBJETIVES

- Our laboratory investigates the role of microRNAs (miRNAs) in immune regulation, with a particular focus on immune tolerance, autoimmune diseases, and cancer. We previously identified miR-148a and the miR-17~92 cluster as essential regulators of B cell tolerance, demonstrated a causal role of miR-148a in the development of lethal autoimmunity, and elucidated the molecular mechanisms through which these miRNAs exert their effects. Overall, our findings have established miRNAs as critical regulators of B cell tolerance and autoimmunity.
- Current research in the lab continues to identify and study the roles of miRNAs and their target genes in immune tolerance, autoimmunity and tumor immunology by combining genetic, genomic, biochemical, and functional screening approaches to understand the functions and molecular mechanisms of miRNA control at molecular, cellular, and system levels. This research may lead to the identification of new therapeutic targets for the treatment of autoimmune diseases and for cancer immunotherapy.

RESEARCH LINES

- 1. Identify novel regulators of B cell tolerance and T cell responses in autoimmunity and cancer.
- 2. Establish the cellular and molecular mechanisms underlying their regulatory function.
- 3. Determine the contribution of these regulators to the development and progression of autoimmune diseases and cancer.

RESEARCH ACTIVITY

Doctoral Theses

- **González Molina MP.** Deciphering the role of microRNAs in tumor immunology[dissertation]. Madrid: Universidad Autónoma de Madrid: 2024(02/12/2024). Director: González Martín A.
- **Bartolomé Cabrero R.** MiR-148a shapes brain development and function through regulating neurite growth and polarization [dissertation]. Madrid: Universidad Autónoma de Madrid: 2024(16/12/2024). Director: González Martín A, Gascón Jiménez S

Master Theses

- **Arsic N.** Identification of novel regulators of B cell tolerance[dissertation]. Madrid: Universidad Autónoma de Madrid, Universidad de Barcelona, Universidad de Amberes , Universidad Claude Bernard Lyon; Universidad Jean Monnet: 2024(19/07/2024). Director: González Martín A

Final Degree Theses

- **Gonzalo Santana T.** Functional analysis of microRNAs and its target genes in B cell tolerance[dissertation]. Madrid: Universidad Autónoma de Madrid: 2024(05/06/2024). Director: González Martín A

Research projects

- **González Martín A.** Systematic analysis of tumor-specific B cell immunity (CNS2022-136069). Agencia Estatal de Investigación. 2023-2025. Managment centre: UAM
- **González Martín A.** Harnessing microRNAs for improved lung cancer immunotherapies. Fundación Ramón Areces. 2023-2026. Managment centre: UAM
- **González Martín A.** MicroRNA regulatory networks in B cell tolerance and autoimmunity (PID2021-128244OB-I00). Agencia Estatal de Investigación. 2022-2026. Managment centre: UAM
- **González Martín A.** Harnessing microRNAs for improved lung cancer immunotherapies. Fundación FERO. 2023-2026. Managment centre: UAM
- **González Martín A.** B cell engineering in murine and human primary B cells (OPP11839562019). Bill and Melinda Gates Foundation. 2019-2025. Managment centre: UAM
- **González Martín A.** Identifying novel targets for cancer immunotherapy (LABAE20001GONZ). Asociación Española Contra el Cáncer. 2020-2024. Managment centre: UAM

Patents and trademarks

- **Voss J, Huang D, Gonzalez-Martin A, Andrabi R, Burton D, inventors; The Srcipps Research Institute, assignees.** B Cell receptor modification in B cells. WO2019028417A1-PCT/US/45255. 2018 August 3
- **Gonzalez-Martin A, Gonzalez-Molina MdP.** MicroRNAs for use in the stimulation of T-cell anti- tumor response. PCT/EP2024/064900. 2024 September 20

3.3.10 Systemic Immune-Mediated Diseases*

COMPOSITION

Juan José Ríos Blanco.
Investigador Titular. Hospital Universitario La Paz

- **Sergio Carrasco Molina.** *Facultativo Especialista de Área Medicina Interna. FIBHULP*
- **Belén del Pilar Gutiérrez Sancerni.** *Facultativo Especialista de Área Medicina Interna. Hospital Universitario La Paz*
- **Ana María Noblejas Mozo.** *Facultativo Especialista de Área Medicina Interna. Hospital Universitario La Paz*

STRATEGIC OBJETIVES

1. Establishment and consolidation of the group
- To create an efficient organizational structure for clinical research in systemic immune-mediated diseases.
- Develop standardized clinical data collection protocols
- Implement a unified database of patients with immune-mediated diseases.

2. Development of excellent clinical research
- Design and execute clinical trials in systemic immune-mediated diseases.
- Establish collaborations with other national and international research groups.
- To create prospective patient registries for observational studies.

3. Implementation of translational research
- Establish a specific biobank of samples from patients with immune-mediated diseases.
- Develop projects that connect clinical findings with basic research.
- Identifying biomarkers with potential clinical application

4. Development of innovative cell therapies
- Establish a cell therapy unit for immune-mediated diseases.
- Develop personalized cell therapy protocols
- Implement clinical trials with advanced cell therapies

5. Education and training
- To train new researchers in the field of immune-mediated diseases.
- Establish specific doctoral and master's degree programs.
- Organize specialized seminars and workshops

RESEARCH LINES

1. Clinical and epidemiological characterization of systemic immune-mediated diseases.
- Natural history studies and prognostic factors
- Recording and follow-up of rare clinical manifestations
- Analysis of comorbidities and their therapeutic implications

2. Therapeutic optimization in immune-mediated diseases
- Effectiveness and safety studies of conventional and biologic therapies
- Development of personalized treatment algorithms
- Monitoring of adverse events and complications

3. Cell therapy in immune-mediated diseases.
- Development of mesenchymal stem cell protocols.
- CAR-T cells research for autoimmune diseases
- Studies of immune modulation by cell therapy

4. Biomarkers and personalized medicine
- Identification of prognostic and predictive biomarkers
- Development of specific activity and damage scores
- Implementation of precision medicine in clinical practice.

5. Pathogenic mechanisms and new therapeutic targets.
- Study of altered immunological pathways
- Identification of new therapeutic targets
- Clinical validation of basic findings

6. Research on patient-reported outcomes (PROs)
- Development and validation of specific questionnaires
- Quality of life and satisfaction studies
- Implementation of PROs in routine clinical practice

**Group recently created, december 2024*

3.4.Large System Pathologies Area

Documents: 308 | **Originals:** 218 | **D1:** 64 | **Q1:** 170

Area coordinator: Francisco García Río
coordinadorsistemas@idipaz.es

RESEARCH GROUPS

3.4.1 Internal Medicine and Systemic Diseases
Francisco Arnalich Férnandez

3.4.2 Organic Dysfunction and Failure in the Aggression
José Manuel Añón Elizalde

3.4.3 Respiratory Diseases
Francisco García Río/Carolina Cubillos Zapata

3.4.4 Regulation of Gene Expression and by Hypoxia
Luis del Peso Ovalle

3.4.5 Nephrology
María Gemma Fernández Juárez

3.4.6 Diagnosis and Treatment of Allergic Diseases
Santiago Quirce Gancedo

3.4.7 Patient Blood Management
Manuel Quintana Díaz


3.4.8 Health Care Nurses Research
Esther Rey Cuevas

3.4.9 Emergency and Critical Pathology
Alejandro Martín Quirós

3.4.10 Hospital Pharmacy
Alicia Herrero Ambrosio

3.4.11 Translational Hepatology
Francisco Javier García-Samaniego Rey

3.4.12 Neuro-Cure
Javier Marco Martínez



Strategic Objectives	Development forecast for the coming years:	Actions
Large System Pathologies Area includes 16 research groups that focus their interest on the study of pathogenic mechanisms and therapeutic options in some of the most prevalent diseases in our environment: respiratory, allergological, renal, digestive, gynaecological, and ophthalmological and paediatric, both in stable phase and at different levels of severity. In addition, we maintain interest in their involvement in the different phases of development, analyzing both the neonatal phase and old age.	Redefinition of the area with a more transversal character. Although this proposal requires a greater elaboration and consensus of all the groups in the area, the reformulation of the area is proposed as a new one focused, for example, on inflammation and hypoxia.	Conduct seminars and coordination meetings among groups of different areas
	Incorporation of related groups from other areas (immunorheumatology, hepatology, among others) and consolidation of some emerging groups.	Promote work and synergies with other research groups of the institute with a deeper trajectory
	To ensure that 50% of the publications are in the first quartile of each thematic area.	Improve the annual number of publications in the first quartile
	To promote intramural collaborations between groups.	Promote work and synergies with other research groups of the institute with a deeper trajectory.

HIGH IMPACT PUBLICATIONS

Díaz-García E, García-Sánchez A, Álfaro E, López-Fernández C, Mañas E, Casitas R, Vega S, Cano-Pumarega I, **García-Río F, Cubillos-Zapata C.** Dysregulation in CD39/CD73 Axis May Trigger the Upsurge of the Immune Suppressive Agent Adenosine in OSA Patients. Arch Bronconeumol. 2024; 60(4): 207-14. Article. IF: 9,2; D1

Casitas R, Galera R, Torres-Vargas M, García-Tovar S, Alfaro E, Díaz-García E, Martínez-Cerón E, García-García M, Torres I, Núñez-Fernández M, Fernández-Villar A, Fernández-Velilla M, Anón JM, Cubillos-Zapata C, **García-Rio F.** Medium-Term Disability and Long-Term Functional Impairment Persistence in Survivors of Severe COVID-19 ARDS: Clinical and Physiological Insights. Arch Bronconeumol. 2024; 60(10): 619-26. Article. IF: 9,2; D1

Alfaro E, Díaz-García E, García-Tovar S, Galera R, Casitas R, Torres-Vargas M, López-Fernández C, Añón JM, **García-Río F, Cubillos-Zapata C**. Endothelial dysfunction and persistent inflammation in severe post-COVID-19 patients: implications for gas exchange. BMC Med. 2024; 22(1): 242. Article. IF: 8,3; D1


Poole JA, Zamora-Sifuentes JL, de las Vecillas L**, Quirce S.** Respiratory Diseases Associated With Organic Dust Exposure. J Allergy Clin Immunol Pract. 2024; 12(8): 1960-71. Article. IF: 6,6; Q1

Moreno-Parro I, Diaz-Garzon J, Aarsand AK, Sandberg S, Aikin R, Equey T, Ríos-Blanco JJ, Soto AB, **Fernández-Calle P.** Biological Variation Data in Triathletes for Metabolism and Growth-Related Biomarkers Included in the Athlete Biological Passport. Clin Chem. 2024; 70(7): 987-96. Article. IF: 6,3; D1

Scientific Events by Large System Pathologies

- **05/03/2024.** Curso avanzado de simulación en ecografía: E.Pi.Ca: Ecografía a Pie de Cama
- **05/04/2024.** Primer Curso de Atención al Paciente Quemado Crítico
- **26/04/2024.** Scientific Seminar: The hepatic social jet lag adaptation
- **20/09/2024.** Scientific Seminar: Explorando nuevas estrategias en el estudio de la proteinosis alveolar pulmona: Modelo preclínico

3.4.1 Internal Medicine and Systemic Diseases










Publications: 31 | **Q1:** 16

COMPOSITION

Francisco Arnalich Fernández.
Investigador "Ad Honorem". IdiPAZ. Catedrático. Facultad de Medicina UAM. Universidad Autónoma de Madrid

- **María del Carmen Fernández Capitán.** *Jefa de Servicio de Medicina Interna. Hospital Universitario La Paz. Profesora asociada ciencias de la Salud. Facultad Medicina UAM.*
- **Clara Hernández Blanco.** *Facultativo Especialista de Área en Medicina Interna. Hospital Universitario La Paz*
- **Alicia Lorenzo Hernández.** *Facultativo Especialista de Área en Medicina Interna. Hospital Universitario La Paz*
- **Raquel Marín Baselga.** *Facultativo Especialista de Área en Medicina Interna. Hospital Universitario La Paz*
- **Carmen Montiel López.** *Catedrática de Farmacologia y Terapeútica. Facultad de Medicina, UAM. Universidad Autónoma de Madrid*
- **Alberto Moreno Fernández.** *Facultativo Especialista de Área en Medicina Interna. Hospital Universitario La Paz*
- **María Angustias Quesada Simón.** *Facultativo Especialista de Área en Medicina Interna. Hospital Universitario La Paz. Profesora asociada ciencias de la Salud. Facultad Medicina UAM. Universidad Autónoma de Madrid*
- **Giorgina Gabriela Salgueiro Origlia.** *Facultativo Especialista de Área en Medicina Interna. Hospital Universitario La Paz*
- **Teresa Sancho Bueso.** *Facultativo Especialista de Área en Medicina Interna. Hospital Universitario La Paz*
- **Yale Tung Chen.** *Facultativo Especialista de Área en Medicina Interna. Hospital Universitario La Paz*

STRATEGIC OBJETIVES

- The current lines of research in the Group are multiple and are in constant change and evolution. Some of the most relevant are indicated below, regarding the lines of research

RESEARCH LINES

SARS-COV-2 INFECTION: DIFFERENTIAL MANIFESTATIONS AND UPDATED TREATMENT

- Main objective: To study the clinical and microbiological evolution of COVID-19 in the different waves of the pandemic and compare the clinical characteristics between patients who require hospital admission due to their severity with those of those that can be treated on an outpatient basis. – To precise characterization of the behavior of COVID-19 currently, and provide clues about the most appropriate measures to take once social distancing measures can be relaxed without putting the population at risk. most vulnerable population

THROMBOEMBOLIC DISEASE. PREVENTION, DIAGNOSIS AND TREATMENT

- Main objectives:
- Improve the diagnosis, treatment, prognosis and monitoring of patients with VTE.
- Improve VTE prevention (Thromboprophylaxis).
- Transmit our knowledge to Hospital and Primary Care professionals.
- Spread knowledge of VTE to patients themselves and to society in general.

HEART FAILURE. MECHANISMS, DIAGNOSIS, AND TREATMENT UPDATE:

VASCULAR RISK AND INFLAMMATION: PREVENTION, DIAGNOSIS AND TREATMENT:

- In atherosclerosis, there is a hardening of the arteries and an accumulation of fat and cholesterol that prevents good blood flow. Despite these characteristics, during the first years of the disease, atherosclerosis may not show symptoms in the patient and, therefore, it is vitally important to identify new risk factors capable of predicting the evolution of the disease in people who do not yet manifest. clinical sequelae

CLINICAL ULTRASOUND IN INTERNAL MEDICINE: clinical ultrasound as another complementary tool for the internist (which helps him solve the specific problem for which the patient consults, what they call second level ultrasound, more exhaustive and usually performed by radiologists.

- Main objectives: Improve the clinical history and physical examination from this global and comprehensive approach.
- Promote the targeted use of clinical ultrasound in the consultation (point of care) to document the clinical diagnosis, making it more decisive and more effective

DIGITAL MEDICINE

- Digital Health Research is to investigate, develop and innovate in the use of Information and Communications Technologies (ICT) in Health, with the aim of improving the health and well-being of people.
- o carry out this activity, the Unit is currently organized into 4 areas: Interoperability and Information Systems, Platforms and Devices, Clinical Validation and Evaluation

Lines of study framed in basic research projects:

- Study of the pathophysiological role of nicotinica7 and dup-a7 receptors expressed in human macrophages, neurons and lung carcinoma cells.
- Identification of signalling pathways connecting nicotinic alpha7 receptors and negative regulators of TLRmediated inflammation in human macrophages.


RESEARCH ACTIVITY

Doctoral Theses

- **Torres Arrese M.** Ecografía clínica en la valoración de la congestión sistémica derecha en pacientes con insuficiencia cardíaca aguda[dissertation]. Madrid: Universidad Autónoma de Madrid: 2024(13/06/2024). Director: Cuervas-Mons Martínez V, Tung Chen Y.

Publications

- **Andrade ERP, Tung-Chen Y, Dueñas LP.** Ultrasound in the diagnosis and monitoring of chylothorax; a case report and literature review. Galicia Clin. 2024; 85(2): 30-1. Article. IF: 0.1; Q4
- **Belmonte AP, Madrazo M, Piles L, Rubio-Rivas M, Huerta LD, Antúnez MG, Caleya JFL, Fernández FA, Gericó-Aseguinolaza M, Fontan PMP, Rhyman N, Dehesa MP, Cabrera JLR, García GMG, García-Casasola G, Ruiz ALI, Carrasco-Sánchez EJ, Hernández SM, Pérez MDP, Castro JL, Albornoz JLSCD, Varona JF, Gomez-Huelgas R, Antón-Santos JM, Lumbreras-Bermejo C.** Assessing the impact of long-term inhaled corticosteroid therapy on patients with COVID-19 and coexisting chronic lung disease: A multicenter retrospective cohort study. Can J Respir Ther. 2024; 60(1): 86-94. Article. IF: 1.1; Q4
- **Cohen O, Kenet G, Levy-Mendelovich S, Tzoran I, Brenner B, De Ancos C, López-Miguel P, Varona JF, Catella J, Monreal M.** Outcomes of venous thromboembolism in patients with inherited thrombophilia treated with direct oral anticoagulants: insights from the RIETE registry. J Thromb Thrombolys. 2024; 57(4): 710-20. Article. IF: 2.2; Q2
- **Del Giorno R, Mazzolai L, Keller S, Siniscalchi C, López-Jimenez L, Ballaz A, Montenegro AC, Otero R, Rashidi F, Monreal M.** Assessment of bleeding events in patients receiving DOACs with or without statins to treat venous thromboembolism: insights from the RIETE registry. Bmj Open. 2024; 14(10): e085401. Article. IF: 2.3; Q2
- **Díez-Vidal A, López JG, Fuertes PR, Jurado FT, Espinosa PB, Ballester JFM, Roca SR, Núñez MAR, Virto AMM, Tung-Chen Y.** Superficial vein thrombosis and its relationship with malignancies: a prospective observational study. J Thromb Thrombolys. 2024; 57(4): 650-7. Article. IF: 2.2; Q2
- **Díez-Vidal A, Martínez-Martín P, González-Muñoz B, Tung-Chen Y.** Point-of-care Ultrasound in Infectious Diseases: Current Insights and Future Perspectives. Clin Infect Dis. 2024; 79(2): 420-9. Review. IF: 7.3; D1
- **Gabara C, Aibar J, Nishimoto Y, Yamashita Y, Prandoni P, Barnes GD, Bikdeli B, Enez DJ, Demelo-Rodriguez P, Peris ML, Nguyen ST, Monreal M.** Clinical outcomes after discontinuing anticoagulant therapy in patients with fi rst unprovoked venous thromboembolism. J Thromb Haemost. 2024; 22(8): 2234-46. Article. IF: 5.0; Q1
- **Giangregorio F, Mosconi E, Debellis MG, Provini S, Esposito C, Garolfi M, Oraka S, Kaloudi O, Mustafazade G, Marín-Baselga R, Tung-Chen Y.** A Systematic Review of Metabolic Syndrome: Key Correlated Pathologies and Non-Invasive Diagnostic Approaches. J Clin Med. 2024; 13(19): 5880. Review. IF: 2.9; Q1
- **González-Muñoz B, Oñoro-López C, Díez-Vidal A, Sorriguieta-Torre R, Quesada-Simón MA, Martínez-Prieto M, Marín-Baselga R, Moreno-Fernández A, Hontañón-Antoñana V, Tung-Chen Y.** Multi-organ clinical ultrasound as a complement to the diagnostic process in an internal medicine consultation. J Clin Ultrasound. 2024; 52(7): 837-45. Article. IF: 1.4; Q3
- **González-Muñoza B, Oñoro-López C, Díez-Vidal A, Quesada-Simón MA, Tung-Chen Y.** Usefulness of multi-organ point-of-care ultrasound as a complement to the diagnostic process in an Internal Medicine outpatient clinic. Eur J Intern Med. 2024; 120: 125-7. Letter. IF: 6.1; Q1
- **Hueso RR, Bautista PS, Simón MAQ, Yun S, Martel AC, Rull JLM, Mera IF, Pérez DA, Rubio IP, Bodas OA.** Cardiac amyloidosis worsens prognosis in patients with heart failure: findings from the PREVAMIC study. Rev Clin Esp. 2024; 224(8): 494-502. Article. IF: 1.7; Q2
- **Jara-Palomares L, Bikdeli B, Jiménez D, Muriel A, Demelo-Rodríguez P, Mahé I, López-Núñez JJ, Megido JA, Jiménez BF, Monreal M.** Rate of recurrence after discontinuing anticoagulation in patients with venous thromboembolism within 30 days after COVID-19 vaccine. Eur J Clin Invest. 2024; 54(12): e14310. Letter. IF: 3.6; Q1
- **Lafaie L, Poenou G, Hanon O, López-Jiménez L, Nieto JA, Lorenzo A, Porras JA, Lumbierres M, Bertoletti L, Monreal M, RIETE investigators.** Anticoagulation and venous thromboembolism in patients aged 90 years and older: Data from the RIETE registry. J Am Geriatr Soc. 2024; 72(1): 113-25. Article. IF: 4.5; Q1
- **Lyhne MD, Bikdeli B, Jiménez D, Kabrhel C, Dudzinski DM, Moisés J, Lobo JL, Armestar F, Guirado L, Ballaz A, Monreal M, RIETE Investigators.** Right ventricular-pulmonary artery coupling for prognostication in acute pulmonary embolism. Eur Heart J Acute Cardiovasc Care. 2024; 13(12): 817-25. Article. IF: 4.6; Q1
- **Martín-Escolano R, Virseda-Berdices A, Berenguer J, González-García J, Brochado-Kith O, Fernández-Rodríguez A, Díez C, Hontañon V, Resino S, Jiménez-Sousa MA.** Low plasma levels of BTLA and LAG-3 before HCV therapy are associated with metabolic disorders after HCV eradication in persons with HIV/HCV coinfection: a retrospective study. Front Pharmacol. 2024; 15: 1341612. Article. IF: 4.8; Q1
- **Moratilla A, Martín D, Cadenas-Martín M, Stokking M, Quesada MA, Arnalich F, De Miguel MP.** Hypoxia Increases the Efficiencies of Cellular Reprogramming and Oncogenic Transformation in Human Blood Cell Subpopulations In Vitro and In Vivo. Cells. 2024; 13(11): 971. Article. IF: 5.2; Q2
- **Ortega AG, Jiménez D, Pedro-Tudela A, Pérez-Ductor C, Fernández-Capitán C, Falgá C, Skride A, Siniscalchi C, Weinberg I, Monreal M.** Age-Related Differences in the Presentation, Management, and Clinical Outcomes of 100,000 Patients With Venous Thromboembolism in the RIETE Registry. Arch Bronconeumol. 2024; 60(3): 143-52. Article. IF: 9.2; D1
- **Pérez-Jurado LA, Cáceres A, Balagué-Dobón L, Esko T, de Heredia ML, Quintela I, Cruz R, Lapunzina P, Carracedo A, Abellán J, Acosta-Isaac R, Aguado JM, Aguilar C, Aguilera-Albesa S, Sabbagh AA, Alba J, Albu S, Alcalá-Gallardo KAM, Alcoba-Florez J, Batres SA, Algarin-Lara HR, Almadana V, Medeiros KA, Almeida J, Almoguera B, Alonso MR, Alvarez N, Walther RAS, Alvarez-Benítez Y, Alvarez-Navia F, dos Santos KA, Andreu-Bernabeu A, Antonijoan MR, Martínez-Aquino E, Arana-Arri E, Aranda C, Arango C, Araque C, Araujo NK, Arcanjo AC, Arnaiz A, Fernández FA, Arranz MJ, López JRA, Artiga MJ, Avello-Malaver Y, Ayuso C, Martín BB, Baptista-Rosas RC, Baldion AM, Barranco-Díaz A, Barreda-Sánchez M, Barrera-Penagos V, Belhassen-García M, Bernal-Bello D, Bernal E, Bezerra JF, Bezerra MAC, Blanca-López N, Blancas R, Boix-Palop L, Borobia A, Bravo E, Brion M, Brochado-Kith O, Brugada R, Bustos M, Cabello A, Cáceres A, Cáceres-Agra JJ, Calbo E, Calderón EJ, Camacho S, Ceballos FC, Cañadas Y, Carbonell C, Cardona-Huerta S, Abad MSC, Segura CC, Carrillo-Avila JA, Campos MC, Casasnovas C, Castaño L, Castaño CF, Castelao JE, Candalija AC, Castillo MA, Chaves-Santiago WG, Chiquillo-Gómez S, Cid-López MA, Cienfuegos-Jiménez O, Conde-Vicente R, Cunha GCR, Cordero-Lorenzana ML, Corella D, Corrales A, Cortés-Sánchez JL,**



Corton M, Souza KSC, Silva FTC, Cruz R, Cuesta L, Tavares NAC, Carvalho MCC, Dalmau D, Dantas-Komatsu RCS, Darnaude MT, de Andrés R, de Juan C, Troca JJD, de la Horra C, de la Hoz AB, De Martino-Rodríguez A, Cruz MS, Neri JLDA, del Campo-Pérez V, Delgado-Cuesta J, de Bustamante AD, Díaz-Pérez A, Dietl B, Diz-de Almeida S, Alves MD, Domínguez-Garrido E, Rosa LS, Luchessi AD, Echave-Sustaeta J, Eiros R, Enciso-Olivera CO, Escudero G, España PP, Sanabria GE, Fariñas MC, Fernández R, Fernández-Caballero L, Fernández-Cruz A, Fernández-Ferrero S, Martínez YF, Fernández-Nestosa MJ, Fernández-Robelo U, Fernández-Rodríguez A, Fernández-Sampedro M, Fernández R, Fernández-Villa T, Fernández-Capitán C, Carioca AAF, Flores-Pérez P, Fuenmayor-Hernández L, Fuertes-Núñez M, Fumadó V, Gadea I, Gagliardi L, Gago-Domínguez M, Gallego N, Galoppo C, García-Soidán A, García-Cerrada C, García-de-Vicuña A, García-García J, García-García I, García-Ibarbia C, García-Montero AC, García L, García M, Torrejón MCG, García I, García-Vázquez E, Garza-Frias E, Gentile A, Gil-Fournier B, de Araújo JNG, Gómez-Duque M, Gómez-Arrue J, Carrera LG, García MG, Sacristán AG, González JR, González-Neira A, Alvarez BG, de Quirós FGB, González-Montelongo R, González-Peñas J, Gonzalez-Sagrado M, Gonzalo-Benito H, Gorgojo-Galindo O, Górgolas M, Guaragna F, Chaux JG, Guillén-Navarro E, Guillén-Guío B, Guisado-Vasco P, Gutiérrez-Castañeda LD, Gutiérrez-Bautista JF, Heili-Frades S, Jacomo RH, Hernández E, Hernández-Moro C, Hernández-Ortega LD, Hernández-Pérez G, Hernández-Vaquero R, Herráez B, Herranz MT, Herrera M, Herrero MJ, Herrero-González A, Horcajada JP, Imaz-Ayo N, Intxausti-Urrutibeaskoa M, Iñigo-Campos A, Iñiguez M, Jara R, Jiménez A, Jiménez-Alfaro I, Jiménez P, Jiménez-Sousa MA, Jordan I, Laguna-Goya R, Laorden D, Lasa-Lázaro M, Lattig MC, Lauriente A, Borja AL, Llanos L, López-Bernus A, de Heredia ML, López-García E, López-Granados E, López-Rodriguez R, López-Ruz MA, Lorente L, Lorenzo-Salazar J, Lozano JE, Lozano-Espinosa M, Mahillo I, Mancebo E, Mar C, Calvo CM, Marcos-Delgado A, Marcos M, Marín-Candón A, Mariscal-Aguilar P, Martin-Pedraza L, Martin-Fernández M, Martín-López C, Martín-Oterino JA, Martín MD, Martín V, Martín MM, Martín-Vicente M, Martínez A, Martínez-González O, Martínez R, Martínez-Paz P, Díaz-Caneja CM, Martínez-Nieto O, Martínez-López I, Martínez-Reséndez MF, Martínez S, Martínez JJ, Martínez-Pérez A, Martínez-Ramas A, Martínez-Robles V, Marzal L, Mazzeu JF, Medrano FJ, Meijome XM, Mejuto-Montero N, Mendes I, Duarte AL, Méndez-Echevarría A, Charris HM, Macías EM, Mercadillo F, Mercado-Sesma AR, Mínguez P, Molina-Roldán E, Molina AJ, Montoya JJ, Pinho SMT, Moreira-Escriche P, Morelos-Arnedo X, Moreno R, Cuerda VM, Moreno-Docón A, Moreno-Escalante J, Fernández AM, García PM, Neira P, Nevado J, Nieto-Gañán I, Silbiger VN, Nuñez-Torres R, Obrador-Hevia A, Ocejo-Vinyals JG, Virginia O, Oliveira SF, Ondo L, Orfao A, Ortega-Paino E, Ortega L, Ortiz-López R, Ortiz-Flores F, Oteo JA, Pacheco M, Pacheco-Miranda FJ, Padilla-Conejo I, Panadero-Fajardo S, Parellada M, Pariente-Rodríguez R, Friaza V, Paz-Artal E, Peces-Barba G, Kus MSP, Perales C, Santos NPC, Guegel GP, Pérez MJ, Pérez A, Pérez-Matute P, Pérez C, Pérez-de-Nanclares G, Pérez-García F, Pérez P, Pérez-Jurado LA, Pérez-Tomás ME, Perucho T, Pichardo LA, Ribeiro AP, Pinsach-Abuin ML, Pinzón LA, Medeiros JFP, Pita G, Pla-Juncà F, Planas-Serra L, Pompa-Mera EN, Porras-Hurtado GL, Pujol A, Quevedo-Chávez ME, Quijada MA, Quintela I, Ramiro-León S, Sedes PR, Nunes JFR, Recalde D, Recio-Fernández E, Resino S, Sousa RR, Rivadeneira-Chamorro CS, Roa-Agudelo D, Pardo MR, Fernandes

MR, Rodríguez-Hernández MA, Rodriguez-Palmero A, Rodríguez-Ruiz E, Rodriguez MJ, Rodríguez-Artalejo F, Rodríguez-Ferrer M, Rodríguez-Gallego C, Rodríguez-García JA, Maya BR, Rodriguez-Nicolas A, Rodríguez-Novoa GE, Rodriguez-Urrego PA, Rojo F, Romero-Coronado A, Morilla R, Rondón-García F, Rosales-Castillo A, Rubio C, Olivera MR, Ruiz-Cabello F, Ruiz-Casares E, Ruiz-Cubillan JJ, Ruiz-Hornillos J, Ruiz M, Ryan P, Salamanca HD, Salazar-García L, Salgueiro-Origlia GG, Sangil A, Sánchez-Pernaute O, Sánchez PL, López AJS, Sánchez-Pablo C, Sánchez-Prados MC, Sánchez-Real J, Sánchez-Redondo J, Sancho-Sainz C, Sande E, Santos A, Schlüter A, Segovia S, Serra-Llovich A, Sevil-Puras F, Sevilla-Porras M, Sicolo MA, Silván-Fuentes C, Moraes VMS, Souza VS, Solé-Violán J, Soria JM, Sorlí JV, Silva NS, Souto JC, Sprockel JJ, Suárez-Rama JJ, Suárez-Zamora DA, Taboada-Fraga X, Tamayo E, Tamayo-Velasco A, Taracido-Fernández JC, Vasconcelos RHT, Tellería C, Carratto TMT, Tenorio-Castano JA, Teper A, Araujo IMT, Torres-Macho J, Torres-Tobar L, Torres-Gutiérrez RP, Troya J, Urioste M, Valencia-Ramos J, Valido A, Vargas-Gallo JP, Varón B, Vega T, Velasco-Quirce S, Vélez-Santamaría V, Víctor V, Vidán-Estévez J, Silva GV, Vieitez-Santiago M, Vilches C, Villalobos L, Villar F, Villar-García J, Villaverde C, Villoslada-Blanco P, Virseda-Berdices A, Costa TX, Yáñez Z, Zapatero-Gaviria A, Zarate R, Zazo S, Flores C, Riancho JA, Rojas-Martínez A, Lapunzina P, Carracedo A, González JR. Clonal chromosomal mosaicism and loss of chromosome Y in elderly men increase vulnerability for SARS-CoV-2. Commun Biol. 2024; 7(1): 202. Article. IF: 5.1; D1

- **Puchades R, Said-Criado I.** Telemedicine in clinical practice: Barriers and risks. Med Clin-Barcelona. 2024; 162(3): 123-5. Editorial Material. IF: 2.1; Q2
- **Puchades R, Tung-Chen Y, Salgueiro G, Lorenzo A, Sancho T, Capitan CF.** Artificial intelligence for predicting pulmonary embolism: A review of machine learning approaches and performance evaluation. Thromb Res. 2024; 234: 9-11. Letter. IF: 3.4; Q2
- **Reinoso-Párraga PP, González-Montalvo JI, Menéndez-Colino R, Perkisas S, Rivera-Deras I, Garmendia-Prieto B, Arain SJ, Tung-Chen Y, Vilches-Moraga A.** Usefulness of point of care ultrasound in older adults: a multicentre study across different geriatric care settings in Spain and the United Kingdom. Age Ageing. 2024; 53(7): afae165. Article. IF: 7.1; Q1
- **Siddiqui F, Tafur A, Hussain M, García-Ortega A, Darki A, Fareed J, Jiménez D, Bikdeli B, Galeano-Valle F, Fernández-Reyes JL, Pérez-Pinar M, Monreal M.** The prognostic value of blood cellular indices in pulmonary embolism. Am J Hematol. 2024; 99(9): 1704-11. Article. IF: 9.9; Q1
- **Torres Arrese M, Barbera Rausell P, Lago Gancedo H, Mata Martínez A, Tung Chen Y, García de Casasola Sánchez G.** Usefulness of the pulsed wave doppler flow pattern in the common femoral vein to detect high probability of pulmonary hypertension in patients attended in the emergency department. Emergencias. 2024; 13(3): 234. Letter. IF: 6.3; D1
- **Torres-Arrese M, Barberá-Rausell P, Li-Zhu JWO, Salas-Dueñas R, Real-Martín AE, Mata-Martínez A, Gonzalo-Moreno B, Núñez JH, Luordo D, Cano JGS, Villegas TV, Caurcel-Díaz L, de Casasola-Sánchez GG, Tung-Chen Y.** The Cardiac Pulsed Wave Doppler Pattern of the Common Femoral Vein in Diagnosing the Likelihood of Severe Pulmonary Hypertension: Results from a Prospective Multicentric Study. J Clin Med. 2024; 13(13): 3860. Article. IF: 2.9; Q1
- **Tung-Chen Y, Apellaniz JS, Roca RA, Viladot JRA, González IA, Romero LB, Cebrián AC, Linares RC, Gil KAF, Suárez IG, Delgado ADG, Martínez AH, Ratti MFM, Villén OM, Mercadal JM, Puras EM, Belloso MEM, Párraga PPR, Urteaga ER, Galán AR, Barrancos IMS, Rodríguez JLS, Sánchez JCS, Grau AS, Macho JT, Villegas TV, Vives M, Sánchez GGD.** Executive summary of the consensus document on point-of-care ultrasound implementation: recommendations from the Clinical Ultrasound Working Groups of SEMI, SEDAR, SEGG, SEMERGEN, SEMES, SEMFYC and SEMG. Rev Clin Esp. 2024; 224(10): 670-8. Article. IF: 1.7; Q2
- **Tung-Chen Y, da Silva BML, Dueñas-López FC.** A rare case of venous thromboembolic disease detected with pocus augmented clinical exam. Galicia Clin. 2024; 85(2): 42-3. Letter. IF: 0.1; Q4
- **Tung-Chen Y, Martí-de Gracia M.** Physical exam with ultrasound, lights and shadows of an unstoppable multidisciplinary advance. Rev Clin Esp. 2024; 224(3): 187-8. Editorial Material. IF: 1.7; Q2
- **Tung-Chen Y, Platero-Dueñas L, Otero-González J.** The rapid access to sonographic diagnosis of fecal impaction: Description of a case with fatal outcome. Semergen. 2024; 50(6): 102194. Letter. IF: 0.9; Q4
- **Tung-Chen Y, Sánchez GGD, Rubio SG, Romero LB, Wittel MB, Figuero LSB, Lebrato JC, Gil DG, Palmero SL, Tedesco DL, Rico PM, González MM, Bailón MM, Porcel JM, Serralta G, Arrese MT, Olaso JO, García PV, Macho JT.** Executive summary of the consensus document for the training and development of clinical ultrasound in internal medicine: Recommendations from the Clinical Ultrasound Working Group of the Spanish Society of Internal Medicine (GTECO-SEMI). Rev Clin Esp. 2024; 224(1): 57-63. Article. IF: 1.7; Q2
- **Vidal AD, López JG, Núñez MAR, Virto AMM, Chen YT.** Risk factors and complications associated with superficial venous thrombosis. Eur J Intern Med. 2024; 121: 146-8. Letter. IF: 6.1; Q1
- **Villén T, Tung YL, Llamas R, Neria F, Carballo C, Vázquez JL, Monge D.** Results of the implementation of a double-check protocol with point-of-care ultrasound for acute heart failure in the emergency department. Crit Ultrasound J. 2024; 16(1): 25. Article. Not Indexed

Research projects

- **Arnalich Fernández F.** Estudio de disfunción ventricular precoz en pacientes con esclerodermia. Glaxosmithkline S.A. 2011-Ongoing. Managment centre: FIBHULP
- **Montiel Lopez C, Soria Chacartegui P, Zubiaur Precioso P.** Utilidad de la farmacogenéticapara mejorar la prescripción de estatinas en atencion primaria y especializada: percepciones y formación de medicos prescriptores (PI22/01655). ISCIII. 2023-2025. Managment centre: UAM

Clinical trials

- **Lorenzo Hernandez A.** ensayo multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y seguridad de bay 3018250 en pacientes con trombosis venosa profunda proximal sintomática.
  Type/Phase: IIa
  Sponsored by: Bayer Ag
  Signature date: 09/10/2024
- **Puchades Rincón de Arellano R.** ensayo clínico basado en registro para determinar el papel del oxígeno para la tromboembolia de pulmón aguda sintomática.
  Type/Phase: III
  Sponsored by: Fundación Hospital Ramon Y Cajal
  Signature date: 14/05/2024
- **Quesada Simón MA.** registro attracking.
  Type/Phase:
  Sponsored by: Fundación Centro Nacional Investigaciones Cardiovasculares
  Signature date: 04/06/2024

3.4.2 Organic Dysfunction and Failure in the Aggression

Publications: 27 | **Q1:** 17

COMPOSITION

José Manuel Añón Elizalde.
Jefe de Servicio en Medicina Intensiva. Hospital Universitario La Paz

- **Alejandro Agrifoglio Rotaeche.** *Facultativo Especialista de Área en Medicina Intensiva. Hospital Universitario La Paz*
- **Maria Soledad Arellano Serrano.** *Facultativo Especialista de Área en Medicina Intensiva. Hospital Universitario La Paz*
- **María José Asensio Martín.** *Jefa de Sección en Medicina Intensiva. Hospital Universitario La Paz*
- **Lucía Cachafeiro Fuciños.** *Facultativo Especialista de Área en Medicina Intensiva. Hospital Universitario La Paz*
- **Belén Civantos Martín.** *Facultativo Especialista de Área en Medicina Intensiva. Hospital Universitario La Paz*
- **Claudia Díaz Alvariño.** *Facultativo Especialista de Área en Medicina Intensiva. Hospital Universitario La Paz*
- **María Belén Estebánez Montiel.** *Facultativo Especialista de Área en Medicina Intensiva. Coordinador de Trasplante. Hospital Universitario La Paz*
- **Juan Carlos Figueira Iglesias.** *Jefe de Sección en Medicina Intensiva. Hospital Universitario La Paz*
- **Eva Mercedes Flores Cabeza.** *Facultativo Especialista de Área en Medicina Intensiva. Hospital Universitario La Paz*
- **Andoni García Muñoz.** *Facultativo Especialista de Área en Medicina Intensiva. Hospital Universitario La Paz*
- **Mónica Hernández Bernal.** *Médico Adjunto Especialista en Unidad de Cuidados Intensivos. Hospital Universitario La Paz*
- **Gonzalo Hernandez Martinez.** *Facultativo Especialista de Área en Medicina Intensiva. Hospital Universitario de Toledo*
- **Alba López Fernández.** *Facultativo Especialista de Área en Medicina Intensiva. Hospital Universitario La Paz*
- **Jesús Javier Manzanares Gómez.** *Facultativo Especialista de Área en Medicina Intensiva. Hospital Universitario La Paz*
- **Pablo Millán Estañ.** *Facultativo Especialista de Área en Medicina Intensiva. Hospital Universitario La Paz*
- **Kapil Laxman Nanwani Nanwani.** *Facultativo Especialista de Área en Medicina Intensiva. Hospital Universitario La Paz*
- **Óscar Peñuelas Rodríguez.** *Jefe de sección en Medicina Intensiva. Hospital Universitario de Getafe*
- **Eva Perales Ferrera.** *Facultativo Especialista de Área en Medicina Intensiva. Hospital Universitario La Paz*
- **Montserrat Aránzazu Rodríguez Aguirregabiria.** *Facultativo Especialista de Área en Medicina en Intensiva. Hospital Universitario La Paz*
- **Jorge Rodríguez Peláez.** *Facultativo Especialista de Área en Medicina Intensiva. Hospital Universitario La Paz*
- **Santos Manuel Sánchez Sánchez.** *Jefe de Sección de Medicina Intensiva. Hospital Universitario La Paz*
- **Santiago Yus Teruel.** *Facultativo Especialista de Área en Medicina Intensiva. Hospital Universitario La Paz*



STRATEGIC OBJETIVES

- The global objective of the investigation team on DYSFUNCTION AND ORGAN FAILURE IN AGGRESSION is the optimization of the patient management in the really critical ill patients who can develop Organ Dysfunction or Organ Failure. Multiorgan Dysfuntion & Multiorgan Failure Syndrome (MOF-MOD Syndrome) are correlated with bad prognostic and high mortality rates
- D-FMO Syndrome is correlated both with the disease severity and the therapeutic efforts. The therapeutic management of the patient must be early and directed to specific objectives
- Otherwise, the support measures must be directed to the specific situations (like sepsis, trauma …) and to the Organs or Systems in Dysfunction or Failure (coagulation, haemodynamic, respiratory or renal ..) Finally, the detection or D-FMO Syndrome employing not only single markers (clinic) but early and organ specific biomarkers (basic or advanced biochemical markers, molecular markers …) can bring a higher efficacy and better results
- Finally, the detection or D-FMO Syndrome employing not only single markers (clinic) but early and organ specific biomarkers (basic or advanced biochemical markers, molecular markers …) can bring a higher efficacy and better results

RESEARCH LINES

- Biomarkers
- Resuscitation income
- Therapeutic support
- Mechanical ventilation
- Artificial airway
- Post-Intensive Care Syndrome
- Sedation

RESEARCH ACTIVITY

Publications

- **Alfaro E, Casitas R, Díaz-García E, García-Tovar S, Galera R, Torres-Vargas M, Fernández-Velilla M, López-Fernández C, Añón JM, Quintana-Díaz M, García-Río F, Cubillos-Zapata C.** TGF-β1 overexpression in severe COVID-19 survivors and its implications for early-phase fibrotic abnormalities and long-term functional impairment. Front Immunol. 2024; 15: 1401015. Article. IF: 5.9; Q1
- **Alfaro E, Díaz-García E, García-Tovar S, Galera R, Casitas R, Torres-Vargas M, López-Fernández C, Añón JM, García-Río F, Cubillos-Zapata C.** Endothelial dysfunction and persistent inflammation in severe post-COVID-19 patients: implications for gas exchange. Bmc Med. 2024; 22(1): -242. Article. IF: 8.3; D1
- **Añón JM, Giménez-Esparza C, Nanwani-Nanwani K, Urbez MR, Bonan MV.** Are post-intensive care unit consultations actually harmful?. Intens Care Med. 2024; 50(8): 1400-1. Letter. IF: 21.2; D1
- **Añón JM, Nanwani KLN, Bonan MV.** Mental disorders in ICU survivors: A critical thinking approach. Med Intensiva. 2024; 48(6): 360-4. Editorial Material. IF: 3.1; Q2
- **Añón JM, Suárez-Sipmann F, Escuela MP, Pérez-Lucendo A, García-Muñoz A.** Volatile anaesthetics for ICU sedation: beyond hypnosis?. Crit Care. 2024; 28(1): 369. Letter. IF: 9.3; Q1
- **BalandÍn B, Pintado V, Pérez-Pedrero MJ, Martínez-Sagasti F, Sancho-González M, Soriano-Cuesta C, Gesso CMD, Chicot M, de Luna RR, Asensio-Martin MJ, Catalán M, Díaz-Díaz JJ, Carbonell N, Iranzo R, Royuela A, Ballesteros D.** Multicentre study of cefiderocol for treatment of Gram-negative bacteria infections in critically ill patients. Int J Antimicrob Ag. 2024; 63(5): 107121. Letter. IF: 4.6; Q1
- **Benbenishty J, Ganz FD, Lautrette A, Jaschinski U, Aggarwal A, Soreide E, Weiss M, Dybwik K, Çizmeci EA, Ackerman RCM, Estebanez-Montiel B, Ricou B, Robertsen A, Sprung CL, Avidan A.** Variations in reporting of nurse involvement in end-of-life practices in intensive care units worldwide (ETHICUS-2): A prospective observational study. Int J Nurs Stud. 2024; 155: 104764. Article. IF: 7.1; D1
- **Candel FJ, Salavert M, Cantón R, del Pozo JL, Galán-Sánchez F, Navarro D, Rodríguez A, Rodríguez JC, Rodríguez-Aguirregabiria M, Suberviola B, Zaragoza R.** The role of rapid multiplex molecular syndromic panels in the clinical management of infections in critically ill patients: an experts-opinion document. Crit Care. 2024; 28(1): 440. Review. IF: 9.3; Q1
- **Casitas R, Galera R, Torres-Vargas M, García-Tovar S, Alfaro E, Díaz-García E, Martínez-Cerón E, García-García M, Torres I, Núñez-Fernández M, Fernández-Villar A, Fernández-Velilla M, Anón JM, Cubillos-Zapata C, García-Rio F.** Medium-Term Disability and Long-Term Functional Impairment Persistence in Survivors of Severe COVID-19 ARDS: Clinical and Physiological Insights. Arch Bronconeumol. 2024; 60(10): 619-26. Article. IF: 9.2; D1
- **Ceccato A, Forne C, Bos LD, Camprubi-Rimblas M, Areny-Balaguero A, Campana-Duel E, Quero S, Diaz E, Roca O, De Gonzalo-Calvo D, Fernández-Barat L, Motos A, Ferrer R, Riera J, Lorente JA, Penuelas O, Menendez R, Amaya-Villar R, Anon JM, Balan-Marino A, Barbera C, Barberan J, Blandino-Ortiz A, Boado MV, Bustamante-Munguira E, Caballero J, Carbajales C, Carbonell N, Catalan-Gonzalez M, Franco N, Galban C, Gumucio-Sanguino VD, de la Torre MD, Estella A, Gallego E, García-Garmendia JL, Garnacho-Montero J, Gomez JM, Huerta A, Jorge-García RN, Loza-Vazquez A, Marin-Corral J, de la Gandara AM, Martin-Delgado MC, Martínez-Varela I, Messa JL, Muniz-Albaiceta G, Nieto MT, Novo MA, Penasco Y, Pozo-Laderas JC, Pérez-García F, Ricart P, Roche-Campo F, Rodriguez A, Sagredo V, Sánchez-Miralles A, Sancho-Chinesta S, Socias L, Sole-Violan J, Suárez-Sipmann F, Tamayo-Lomas L, Trenado J, Ubeda A, Valdivia LJ, Vidal P, Bermejo J, Gonzalez J, Barbe F, Calfee CS, Artigas A, Torres A, Adell-Serrano B, Cabello MA, Aguilera L, Alcaraz-Serrano V, Aldecoa C, Alegre C, Almansa R, Alvarez S, Ruiz AA, Villar RA, Andrea R, Novo MA, Angel J, Anon JM, Arrieta M, Ayestaran J, Badia JR, Badia M, Pravia OB, Marino AB, Balsera B, Barbera C, Barberan J, Barbena L, Barbeta E, Bardi T, Segade PB, Barroso M, García JAB, Bermejo-Martin JF, Betere B, Bigas J, Ortiz AB, Blancas R, Cortes MLB, Boado M, Saera MB, Bofill N, Vieiro MTB, Bueno L, Bustamante-Munguira E, Bustamante-Munguira J, Martínez CD, Caballero J, Hermoso DC, Fernández SC, Carbajales C, Cano I, Canton-Bulnes ML, Carbonell N, Fernández PC, García LC, Carvalho S, Casacuberta-Barbera N, Castella M, Castellvi A, Castro P, Catalan-Gonzalez M, Avila RC, Cilloniz C, Clar L, Climent C, Codina J, Conde P, Contreras S, Martin MC, Sánchez RD, De Mendoza D, Diaz E, Diaz Y, Vilas MDR, Moreno CD, Dot I, Giraudo PE, Arijon IE, Estella A, Monjo TF, Fernández J, Ferrando C, Figueras A, Forcadell-Ferreres E, Espina LF, Franco N, Franquesa E, Furro A, Gabarrus A, Galban C, Gallego E, García F, García B, Garmendia JLG, García-Gasulla D, Prieto EG, Redruello CG, Sagastume AG, Garnacho-Montero J, Castillo MLG, Goma G, Gomez JM, Casal VG, Gomez S, Gonzalez CG, de Gonzalo-Calvo D, Gonzalez J, Gordo F, Gracia MP, Gumucio-Sanguino VD, Herraiz A, Herran-Monge R, Huerta A, Ibarz M, Iglesias S, Janer MT, Jimenez G, García RNJ, Diaz MJ, Kiarostami K, Alvarez JI, Leon M, López-Gavin A, Lago AL, Messa JL, López-Ramos E, Loza-Vazquez A, Guerrero DM, Herrera NM, Mendiluce RM, Mantellini CL, Naya GM, Marcos P, Marin-Corral J, Peis EM, Vicente PM, Martínez M, Fernández CEM, de la Gandara AM, Juan MDM, Palacios BM, Varela IM, Jimenez JFM, Masclans JR, Maseda E, Fernández EMM, Miralbes M, Monclou J, Montejo-Gonzalez JC, Montserrat N, Aznar MM, Morales D, Cano SGM, Rodriguez DM, Munoz-Bermudez R, Albaiceta GM, Nicolas JM, Nieto MT, Bou RN, Salinas RN, Ocon M, Ortega A, Ossa S, Pagliarani P, Parrilla F, Pedregosa-Diaz J, Penasco Y, Penuelas O, Bastida LP, Pérez P, Pérez-García F, Planelles GP, Rubio EP, Laguna DP, Pinol-Tena A, Prados J, Pujol A, Pozo JC, Coll NR, Sánchez-Giron GR, Riera J, Ricart P, Roche-Campo F, Rodriguez A, Rodriguez L, de Castro FR, Rodriguez S, Ruiz CR, Rubio J, López AR, Ruiz-García AL, Miralles MR, Murua PR, Paz ES, Sagredo V, Degracia AS, Salvador-Adell I, Sánchez M, Sánchez A, Sánchez-Miralles A, Chinesta SS, Santacoloma B, Sánchez M, Sarinena MT, Pensado MS, Serra L, Serra-Fortuny M, Lazaro AS, Servia L, Socias L, Soliva L, Sole-Violan J, Sipmann FS, Speziale C, Lomas LT, Tormos A, de la Torre MD, Torres G, Torres M, Trefler S, Trenado J, Trujillano J, Ubeda A, Urrelo-Cerron L, Val E, Valledor M, Ruiz LV, Vallverdu M, Martin-montalvo MV, Adrio SV, Vazquez N, Vengoechea J, Vidal P, Vila-Vilardel C, Vilanova J, Warrington TV, Yang H, Yang ML, Zapatero A.** Clustering COVID-19 ARDS patients through the first days of ICU admission. An analysis of the CIBERESUCICOVID Cohort. Crit

Care. 2024; 28(1): 91. Article. IF: 9.3; Q1

- **Estella A, Lagares C, Furones MJ, López PM, Martín NL, Estebánez B, García JMG, Rubio O, Tejedor BV, Galarza L, Navarro MP, Camps VL, Martín MC, Montejo JC, Avidan A, Sprung C.** Limitation of life support treatments in Spanish Intensive Care Units: Analysis of the ETHICUS II study. Med Intensiva. 2024; 48(5): 247-53. Article. IF: 3.1; Q2
- **Flores E, Estébanez B, Quintana M, Fernández-Puntero B, Nanwani K, Cachafeiro L, Martínez JR, Agrifoglio A, Sánchez-Sánchez M.** Usefulness of mid-regional proadrenomedullin levels in the resuscitation phase of severely burned patients and its utility in early sepsis detection. Burns. 2024; 50(6): 1519-27. Article. IF: 2.9; Q2
- **Frat JP, Coudroy R, Quenot JP, Guitton C, Badie J, Gacouin A, Ehrmann S, Demoule A, Jarousseau F, Carteaux G, Rigaud JP, Reignier J, Sedillot N, Contou D, Beloncle F, Daubin C, Dureau AF, Fatah A, Besse MC, Ferre A, Turbil E, Merdji H, Galerneau LM, Lacombe B, Richard JC, Romen A, Delbove A, Prat G, Lautrette A, Colin G, Soum E, Bourdin G, Hernández G, Ragot S, Thille AW.** Effect of high-flow nasal cannula oxygen versus standard oxygen on mortality in patients with acute hypoxaemic respiratory failure: protocol for a multicentre, randomised controlled trial (SOHO). BMJ Open. 2024; 14(10): e083232. Article. IF: 2.3; Q2
- **García-de-Acilu M, Sellas A, Hernández G, Roca O.** Optimal Postextubation Support in Critically Ill Patients: One Size Does Not Fit All. Resp Care. 2024; 69(12): 1564-72. Article. IF: 2.1; Q3
- **Hernández G, Rodriguez P.** Weaning strategy in patients at low-to-medium risk of extubation failure. Author's reply. Intens Care Med. 2024; 50(6): 999-1000. Letter. IF: 21.2; D1
- **Hessheimer AJ, Flores E, Fondevila C.** No Evidence of Progressive Proinflammatory Cytokine Storm in Brain Dead Organ Donors: Should We Avoid the Rush to Flush?. Transplantation. 2024; 108(4): 839-40. Editorial Material. IF: 5.0; Q1
- **Hessheimer AJ, Flores E, Vengohechea J, Fondevila C.** Better liver transplant outcomes by donor interventions?. Curr Opin Organ Tran. 2024; 29(4): 219-27. Review. IF: 1.9; Q3
- **Hidalgo-Tenorio C, Bou G, Oliver A, Rodríguez-Aguirregabiria M, Salavert M, Martínez-Martínez L.** The Challenge of Treating Infections Caused by Metallo-β-Lactamase-Producing Gram-Negative Bacteria: A Narrative Review. Drugs. 2024; 84(12): 1519-39. Review. IF: 14.4; D1
- **Laterre PF, García MS, van der Poll T, Wittebole X, Martínez-Sagasti F, Hernández G, Ferrer R, Caballero J, Cadogan KA, Sullivan A, Zhang BRR, de la Rosa O, Lombardo E, François B.** The safety and efficacy of stem cells for the treatment of severe community-acquired bacterial pneumonia: A randomized clinical trial. J Crit Care. 2024; 79: 154446. Article. IF: 2.9; Q2
- **Luján M, Gómez CC, Peñuelas O, Ferrando C, Heili-Frades SB, Perales JMC, Mas A, Catalán JS, Mediano O, Roca O, Fernández JG, Varela AG, Montes GS, Cervera GR, Hernández G, Millán T, Monreal MF, Santaolalla CE.** Multidisciplinary Consensus on the Management of Non-Invasive Respiratory Support in the COVID-19 Patient. Arch Bronconeumol. 2024; 60(5): 285-95. Article. IF: 9.2; D1
- **Martínez GH, Rodríguez P, Soto J, Caritg O, Castellvi-Font A, Mariblanca B, García AM, Colinas L, Anon JM, Parrilla-Gomez FJ, Silva-Obregón JA, Masclans JR, Propin A, Cuadra A, Dalorzo MG, Rialp G, Suárez-Sipmann F, Roca O.** Effect of aggressive vs conservative screening and confirmatory test on time to extubation among patients at low or intermediate risk: a randomized clinical trial. Intens Care Med. 2024; 50(2): 258-67. Article. IF: 21.2; D1
- **Nanwani KLN, Victoria M.** Use of mirrors in the critically ill patient admitted to the Intensive Care Unit, do they have a place? Med Intensiva. 2024; 48(3): 183-4. Editorial Material. IF: 3.1; Q2
- **Pérez-Blanco A, Acevedo M, Padilla M, Gomez A, Zapata L, Barber M, Martínez A, Calleja V, Rivero MC, Fernández E, Velasco J, Flores EM, Quindos B, Rodriguez ST, Virgos B, Nebra AC, Robles JC, Moya J, Trenado J, García N, Vallejo A, Herrero E, García A, Rodriguez ML, García F, Lara R, Lage L, Gil FJ, Guerrero FJ, Meilan A, Del Prado N, Fernández C, Coll E, Dominguez-Gil B.** Assessing Outcomes of Patients Subject to Intensive Care to Facilitate Organ Donation: A Spanish Multicenter Prospective Study. Transpl Int. 2024; 37: 12791. Article. IF: 3.0; Q1
- **Rodríguez P, Hernández G.** Weaning from mechanical ventilation: Speed it up and make it safe. Med Intensiva. 2024; 48(6): 356-9. Editorial Material. IF: 3.1; Q2
- **Rodríguez-Aguirregabiria M, Lázaro-Perona F, Cacho-Calvo JB, Arellano-Serrano MS, Ramos-Ramos JC, Rubio-Mora E, Díaz-Almirón M, Asensio-Martín MJ.** Challenges Facing Two Outbreaks of Carbapenem-Resistant Acinetobacter baumannii: From Cefiderocol Susceptibility Testing to the Emergence of Cefiderocol-Resistant Mutants. Antibiotics (Basel). 2024; 13(8): 784. Article. IF: 4.6; Q1
- **Rucci Justin M, Law Anica C, Bolesta Scott, Quinn Emily K, García Michael A, Gajic Ognjen, Boman Karen, Yus Santiago, Goodspeed Valerie M, Kumar Vishakha, Kashyap Rahul, Walkey Allan J.** Variation in Sedative and Analgesic Use During the COVID-19 Pandemic and Associated Outcomes. Chest Crit Care. 2024; 2(1): 100047. Article. Not Indexed
- **Villar J, González-Martín JM, Fernández C, Soler JA, Ambrós A, Pita-García L, Fernández L, Ferrando C, Arocas B, González-Vaquero M, Añón JM, González-Higueras E, Parrilla D, Vidal A, Fernández MM, Rodríguez-Suárez P, Fernández RL, Gómez-Bentolila E, Burns KEA, Szakmany T, Steyerberg EW.** Predicting the Length of Mechanical Ventilation in Acute Respiratory Disease Syndrome Using Machine Learning: The PIONEER Study. J Clin Med. 2024; 13(6): 1811. Article. IF: 2.9; Q1

Clinical trials

- **Añón Elizalde JM.** ensayo clínico aleatorizado controlado frente a placebo, doble ciego, para evaluar la eficacia de metoprolol intravenoso en pacientes con síndrome de distrés respiratorio agudo (sdra).
  Type/Phase: III
  Sponsored by: Consorcio Centro De Investigacion Biomedica En Red Instituto De Salud Carlos III
  Signature date: 30/04/2024
- **"Asensio Martín MJ.** estudio basado en la revisión retrospectiva de los resultados y la seguridad en la vida real de cefiderocol en el tratamiento de pacientes con infecciones bacterianas gramnegativas (ibgn) en ee. uu. y europa.
- **A retrospective chart review study of cefiderocol real world outcomes and safety in the treatment of patients with gram-negative bacterial infections (gnbi) in the usa and europe.** prove (retrospective cefiderocol chart review study).
  Type/Phase: EPA-SP
  Sponsored by: Shionogi B.V
  Signature date: 06/03/2024"

Patents and trademarks

- **Herrero Ambrosio A, Ramírez García E, Ojeda Feo JJ, Pérez Rodríguez J, Asensio Martín MJ, González Sánchez ML, Moro Agud M, Lorente Romeo M, López Nieto M, Gómez Rioja R, authors; FIBHULP, assignee.** Trademark name: SINOIRES; CM 13.080.056; 2014 July 14.

3.4.3 Respiratory Diseases

Publications: 38 | **Q1:** 27

COMPOSITION

Francisco José García Río.
Jefe de Sección de Neumología. Hospital Universitario La Paz. Catedrático de Universidad. Facultad de Medicina. Universidad Autónoma de Madrid
Carolina Cubillos Zapata.
Investigadora Postdoctoral. Contrtato Miguel Servet tipo I. Hospital Universitario La Paz

- **Sergio Alcolea Batres.** *Facultativo Especialista de Área en Neumología. Hospital Universitario La Paz*
- **Enrique Alfaro García.** *Investigador Predoctoral. FIBHULP*
- **Rodolfo Álvarez-Sala Walther.** *Jefe de Servicio de Neumología. Hospital Universitario La Paz. Catedrático. Facultad de Medicina. Universidad Autónoma de Madrid*
- **Victoria Arnalich Montiel.** *Facultativo Especialista de Área en Neumología. Hospital Universitario La Paz*
- **Juan José Cabanillas Martín.** *Facultativo Especialista de Área en Neumología. Hospital Universitario La Paz*
- **Carlos Javier Carpio Segura.** *Facultativo Especialista de Área en Neumología. Hospital Universitario La Paz*
- **Raquel Casitas Mateo.** *Facultativo Especialista de Área en Neumología. Hospital Universitario La Paz*
- **Elena Díaz García.** *Investigador Posdoctoral. CIBERER*
- **Raúl Galera Martínez.** *Facultativo Especialista de Área en Neumología. Hospital Universitario La Paz*
- **Luis Gómez Carrera.** *Jefe de Sección de Neumología. Hospital Universitario La Paz*
- **María Antonia Gómez Mendieta.** *Facultativo Especialista de Área en Neumología. Hospital Universitario La Paz*
- **Ana Jaureguizar Oriol.** *Facultativo Especialista de Área en Neumología. Hospital Universitario La Paz*
- **Cristina López Fernández.** *Técnico de Laboratorio. FIBHULP*
- **Elisabet Martínez Cerón.** *Facultativo Especialista de Área en Neumología. Hospital Universitario La Paz*
- **Paula Pérez Moreno.** *Investigadora Predoctoral. Hospital Universitario La Paz*
- **Concepción Prados Sánchez.** *Jefe de Sección de Neumología. Hospital Universitario La Paz*
- **David Romero Ribate.** *Facultativo Especialista de Área en Neumología. Hospital Universitario La Paz*
- **Ana Santiago Recuerda.** *Facultativo Especialista de Área en Neumología. Hospital Universitario La Paz*
- **Carlos Villasante Fernández-Montes.** *Jefe de Sección de Neumología. Hospital Universitario La Paz*
- **Ester Zamarrón de Lucas.** *Facultativo Especialista de Área en Neumología. Hospital Universitario La Paz*



STRATEGIC OBJETIVES

- Our group studies the molecular mechanisms of cardiovascular morbidity associated with sleep breathing disorders, in particular, the sleep apnoeahypopnea syndrome(SAHS).
- We also provide evidence for making clinical decisions on patients with these disorders. We conduct studies to evaluate the mechanisms involved in the development of arterial hypertension, arrhythmias, heart failure, ischaemic heart disease, pulmonary hypertension, pulmonary embolism, and carbohydrate metabolism disorders.
- In terms of the pathogenesis of airflow limitations, several of our projects have focused on small airway function, bronchial hyperresponsiveness and exercise adaptation in a number of obstructive diseases, particularly COPD, asthma and cystic fibrosis. We also evaluate the objective measurement of daily physical activity in these patients and contribute to the best definition of its determinants and its clinical and prognostic usefulness. We collaborate with other research groups to study the contribution of the innate immune system to the evolution of these diseases and the relationship between the response to hypoxia and the clinical expression of COPD and SAHS.
- Finally, in the field of the systematisation of lung function testing, we create reference values for various population groups and define the methodological aspects of the measurement of exhaled breath condensate and nitric oxide.

RESEARCH LINES

- Morbidity of sleep-disordered breathing
- Pathogenesis of airflow limitation
- Systematization of lung function testing

RESEARCH ACTIVITY

Doctoral Theses

- **Laorden Escudero D.** Evaluación de los criterios de super-respondedor y la escala FEOS como herramientas eficaces en valorar la respuesta al tratamiento biológico en el asma grave no controlada[dissertation]. Madrid: Universidad Autónoma de Madrid: 2024(11/03/2024). Director: Álvarez-Sala Walther R, Quirce Gancedo SE.

Publications

- **Alfaro E, Casitas R, Díaz-García E, García-Tovar S, Galera R, Torres-Vargas M, Fernández-Velilla M, López-Fernández C, Añón JM, Quintana-Díaz M, García-Río F, Cubillos-Zapata C.** TGF-β1 overexpression in severe COVID-19 survivors and its implications for early-phase fibrotic abnormalities and long-term functional impairment. Front Immunol. 2024; 15: 1401015. Article. IF: 5.9; Q1
- **Alfaro E, Díaz-García E, García-Tovar S, Galera R, Casitas R, Martínez-Cerón E, Torres-Vargas M, Padilla JM, López-Fernández C, Pérez-Moreno P, García-Río F, Cubillos-Zapata C.** Effect of physical activity in lymphocytes senescence burden in patients with COPD. Am J Physiol-Lung C. 2024; 327(4): L464-72. Article. IF: 3.5; Q1
- **Alfaro E, Díaz-García E, García-Tovar S, Galera R, Casitas R, Torres-Vargas M, López-Fernández C, Añón JM, García-Río F, Cubillos-Zapata C.** Endothelial dysfunction and persistent inflammation in severe post-COVID-19 patients: implications for gas exchange. Bmc Med. 2024; 22(1): 242. Article. IF: 8.3; D1
- **Aliberti S, Blasi F, Burgel PR, Calcagno A, Floe A, Grogono D, Papavasileiou A, Polverino E, Prados C, Rohde G, Salzer HJF, Sánchez-Montalvá A, Shteinberg M, Van Braeckel E, van Ingen J, Veziris N, Wagner D, Loebinger MR.** Mycobacterium avium complex pulmonary disease patients with limited treatment options. ERJ Open Res. 2024; 10(1): 610. Letter. IF: 4.0; Q1
- **Aljama C, Granados G, Ramon M, Barrecheguren M, Loeb E, Núñez A, Pleguezuelos E, García-Río F, Miravitlles M.** Motivation and Confidence about Physical Activity in Chronic Obstructive Pulmonary Disease Patients: Health Benefits Matter to Patients. Respiration. 2024; 103(7): 378-87. Article. IF: 3.8; Q1
- **Barbado AC, de Lucas EZ, Walther RAS, Sánchez MCP.** Self-care capacity of adult cystic fibrosis patients during transition/transfer between services. An Sist Sanit Navar. 2024; 47(2): e1084. Article. IF: 0.6; Q4
- **Buenestado-Serrano S, Martínez-Lirola M, Herranz-Martín M, Esteban J, Broncano-Lavado A, Molero-Salinas A, Sanz-Pérez A, Blázquez J, Ruedas-López A, Toro C, López-Roa P, Domingo D, Zamarrón E, Serrano MJR, Muñoz P, Pérez-Lago L, de Viedma DG.** Microevolution, reinfection and highly complex genomic diversity in patients with sequential isolates of Mycobacterium abscessus. Nat Commun. 2024; 15(1): 2717. Article. IF: 15.7; D1
- **Casitas R, Galera R, Torres-Vargas M, García-Tovar S, Alfaro E, Díaz-García E, Martínez-Cerón E, García-García M, Torres I, Núñez-Fernández M, Fernández-Villar A, Fernández-Velilla M, Anón JM, Cubillos-Zapata C, García-Río F.** Medium-Term Disability and Long-Term Functional Impairment Persistence in Survivors of Severe COVID-19 ARDS: Clinical and Physiological Insights. Arch Bronconeumol. 2024; 60(10): 619-26. Article. IF: 9.2; D1
- **Cubillos-Zapata C, Troncoso-Acevedo F, Díaz-García E, Alfaro E, Gotera-Rivera C, Pérez-Warnisher T, Peces-Barba G, Seijo LM, García-Río F.** Sleep apnoea increases biomarkers of immune evasion, lymphangiogenesis and tumour cell aggressiveness in high-risk patients and those with established lung cancer. ERJ Open Res. 2024; 10(1): 00777. Article. IF: 4.0; Q1
- **Díaz-García E, García-Sánchez A, Alfaro E, López-Fernández C, Mañas E, Casitas R, Vega S, Cano-Pumarega I, García-Río F, Cubillos-Zapata C.** Dysregulation in CD39/CD73 Axis May Trigger the Upsurge of the Immune Suppressive Agent Adenosine in OSA Patients. Arch Bronconeumol. 2024; 60(4): 207-14. Article. IF: 9.2; D1
- **Esteban-Gorgojo I, Gorgojo MP, Sastre J, García-Río F, Quirce S.** The Influence of BMI in Asthma: Which Traits Are due to Obesity and Which to the Asthma and Obesity Phenotype? J Invest Allerg Clin. 2024; 34(1): 30-7. Article. IF: 4.8; Q1
- **García IA, Moreno RMG, Plaza BL, Alcalá BB, Pérez PV, Bonis ACB, de Lucas EZ, Milla SP, Sánchez MCP, de Villar NGP.** Impact of triple transmembrane regulator therapy on glucose metabolism in cystic fibrosis related diabetes during clinical practice. Diabetes Res Clin Pr. 2024; 216: 111839. Article. IF: 7.4; Q1
- **García-Sánchez A, Villalaín-Rodes I, Jaureguizar A, Zamarrón E, Martínez-Cerón E, Casitas R, Galera R, Cubillos-Zapata C, García J, Asencio M, García-Río F.** Continuous Positive Airway Pressure Effect on Progression of Retinal Disease in Patients with Sleep Apnea and Nonproliferative Diabetic Retinopathy A Randomized Clinical Trial. Ann Am Thorac Soc. 2024; 21(1): 102-13. Article. IF: 5.4; Q1
- **Germán-Díaz M, Alcolea A, Cabello V, Blasco-Alonso J, Rodríguez A, Galera R, García-Romero R, Romero C, González-Sacristán R, Redecillas-Ferreiro S, Moreno-Villares JM, Ramos-Boluda E.** Early use of teduglutide in paediatric patients with intestinal failure is associated with a greater response rate: a multicenter study. Eur J Pediatr. 2024; 183(8): 3173-82. Article. IF: 2.6; Q1
- **Granda P, Villamañán E, Carpio C, Laorden D, Quirce S, Álvarez-Sala R.** Anti-IL-5 and anti-IL-5R biologics for severe asthma. Are there any differences in their effects? J Asthma. 2024; 61(8): 857-66. Article. IF: 1.3; Q3
- **Granda P, Villamañán E, Heinz S, Laorden D, Romero D, Añón JM, Carpio C, Sobrino C, Collada , Domínguez-Ortega J, Herrero A, Quirce S, Álvarez-Sala R.** Compassionate Use of Reslizumab in a Life-threatening Asthma Exacerbation. J Invest Allerg Clin. 2024; 34(1): 60-1. Editorial Material. IF: 4.8; Q1
- **Granda P, Villamañán E, Laorden D, Carpio C, Collada V, Domínguez-Ortega J, de las Vecillas L, Romero-Ribate D, Chaparro-Díaz OF, Miguel-Sin TL, Alloca-Alvarez DJ, Correa-Borit JM, Losantos I, Mir-Ihara P, Narváez-Fernández EJ, Quirce S, Álvarez-Sala R.** Cardiovascular Events in Patients with Severe Asthma-A Retrospective Study of Two Cohorts: Asthma Type T2 Treated with Biologics and Non-Type T2. J Clin Med. 2024; 13(15): 4299. Article. IF: 2.9; Q1
- **Kosiborod MN, Windsor SL, Vardeny O, Berger JS, Reynolds HR, Boumakis S, Althouse AD, Solomon SD, Bhatt AS, Peikert A, Luther JF, Leifer ES, Kindzelski AL, Cushman M, Gong MN, Kornblith LZ, Khatri P, Kim KS, Kreuziger LB, Javaheri A, Carpio C, Wahid L, Moreno JLS, Alonso A, Ho MQ, López-Sendón J, Lopes RD, Curtis JL, Kirwan BA, Geraci MW, Neal MD, Hochman JS.** Effect of sodium-glucose co-transporter-2 inhibitors on survival free of organ support in patients hospitalised for COVID-19 (ACTIV-4a): a pragmatic, multicentre, open-label, randomised, controlled, platform trial. Lancet Diabetes Endocrinol. 2024; 12(10): 725-34. Article. IF: 41.8; D1
- **Laorden D, Hernández I, Domínguez-Ortega J, Romero D, Álvarez-Sala R, Quirce S.** A real-life cohort of mepolizumab treatment in severe eosinophilic asthma. Eur Ann Allergy Clin Immunol. 2024; 56(4): 169-75. Article. IF: 2.3; Q3
- **Loeb E, Zock JP, Miravitlles M, Rodríguez E, Kromhout H, Vermeulen R, Soler-Cataluña JJ,**

Soriano JB, García-Río F, de Lucas P, Alfageme I, Casanova C, González-Moro JR, Ancochea J, Cosío BG, Sancho JF. Occupational Exposures, Chronic Obstructive Pulmonary Disease and Tomographic Findings in the Spanish Population. Toxics. 2024; 12(10): 689. Article. IF: 4.1; Q1

- **Loeb E, Zock JP, Miravitlles M, Rodríguez E, Soler-Cataluña JJ, Soriano JB, García-Río F, de Lucas P, Alfageme I, Casanova C, González-Moro JMR, Ancochea J, Cosío BG, Sancho JF.** Association between occupational exposure and chronic obstructive pulmonary disease and respiratory symptoms in the Spanish population. Arch Bronconeumol. 2024; 60(1): 16-22. Article. IF: 9.2; D1
- **López-Campos JL, Presas FM, Manzano JR, Tordera MP, Clara PC, García-Río F, Barreiro E, García MAM.** Bronconeumology Archives: 60 Years and Going on. Arch Bronconeumol. 2024; 60(12): 735-6. Editorial Material. IF: 9.2; D1
- **Lorenzana I, Galera R, Casitas R, Martínez-Cerón E, Castillo MA, Alfaro E, Cubillos-Zapata C, García-Río F.** Dynamic hyperinflation is a risk factor for mortality and severe exacerbations in COPD patients. Resp Med. 2024; 225: 107597. Article. IF: 3.1; Q2
- **Mangas-Moro A, Casitas R, Sánchez-Sánchez B, Fernández-Navarro I, Fernández-Lahera J, Galera R, Martínez-Cerón E, Zamarrón E, García-Río F.** Characteristics of obstructive sleep apnea related to insulin resistance. Sleep Breath. 2024; 28(4): 1625-34. Article. IF: 2.0; Q3
- **Mangas-Moro A, Zamarrón E, Carpio C, Alvarez-Sala R, Arribas-López JR, Prados C.** Influenza vaccination mitigates severe complications in hospitalized patients: A ten-year observational study, Spain, 2009-2019. Am J Infect Control. 2024; 52(5): 563-9. Article. IF: 2.4; Q2
- **Mariscal-Aguilar P, Gomez-Carrera L, Bonilla G, Carpio C, Zamarrón E, Fernández-Velilla M, Díaz-Almirón M, Gayá F, Villamañán E, Prados C, alvarez-Sala R.** Impact of Air Pollution on the Long-Term Decline of Non-Idiopathic Pulmonary Fibrosis Interstitial Lung Disease. Atmosphere-Basel. 2024; 15(12): 1405. Article. IF: 2.3; Q3
- **Mariscal-Aguilar P, Gómez-Carrera L, Bonilla G, Díaz-Almirón M, Gayá F, Carpio C, Zamarrón E, Fernández-Velilla M, Torres I, Esteban I, Regojo R, Villamañán E, Prados C, Alvarez-Sala R.** Air pollution exposure and its effects on idiopathic pulmonary fibrosis: clinical worsening, lung function decline, and radiological deterioration. Front Public Health. 2024; 11: 1331134. Article. IF: 3.4; Q1
- **Mir-Ihara P, Vecillas LD, Heredia R, Fiandor A, González-Muñoz M, Zamarrón E, Prados C, Cabañas R.** Protocol for Successful Desensitization to Ivacaftor and Elexacaftor/Tezacaftor/Ivacaftor in a Delayed Hypersensitivity Reaction Confirmed by the Lymphocyte Transformation Test. J Invest Allerg Clin. 2024; 34(3): 211-3. Article. IF: 4.8; Q1
- **Pérez-Jurado LA, Cáceres A, Balagué-Dobón L, Esko T, de Heredia ML, Quintela I, Cruz R, Lapunzina P, Carracedo A, Abellán J, Acosta-Isaac R, Aguado JM, Aguilar C, Aguilera-Albesa S, Sabbagh AA, Alba J, Albu S, Alcalá-Gallardo KAM, Alcoba-Florez J, Batres SA, Algarin-Lara HR, Almadana V, Medeiros KA, Almeida J, Almoguera B, Alonso MR, Alvarez N, Walther RAS, Alvarez-Benítez Y, Alvarez-Navia F, dos Santos KA, Andreu-Bernabeu A, Antonijoan MR, Martínez-Aquino E, Arana-Arri E, Aranda C, Arango C, Araque C, Araujo NK, Arcanjo AC, Arnaiz A, Fernández FA, Arranz MJ, López JRA, Artiga MJ, Avello-Malaver Y, Ayuso C, Martín BB, Baptista-Rosas RC, Baldion AM, Barranco-Díaz A, Barreda-Sánchez M, Barrera-Penagos V, Belhassen-García M, Bernal-Bello D, Bernal E, Bezerra JF, Bezerra MAC, Blanca-López N, Blancas R, Boix-Palop L, Borobia A, Bravo E, Brion M, Brochado-Kith O, Brugada R, Bustos M, Cabello A, Cáceres A, Cáceres-Agra JJ, Calbo E, Calderón EJ, Camacho S, Ceballos FC, Cañadas Y, Carbonell C, Cardona-Huerta S, Abad MSC, Segura CC, Carrillo-Avila JA, Campos MC, Casasnovas C, Castaño L, Castaño CF, Castelao JE, Candalija AC, Castillo MA, Chaves-Santiago WG, Chiquillo-Gómez S, Cid-López MA, Cienfuegos-Jiménez O, Conde-Vicente R, Cunha GCR, Cordero-Lorenzana ML, Corella D, Corrales A, Cortés-Sánchez JL, Corton M, Souza KSC, Silva FTC, Cruz R, Cuesta L, Tavares NAC, Carvalho MCC, Dalmau D, Dantas-Komatsu RCS, Darnaude MT, de Andrés R, de Juan C, Troca JJD, de la Horra C, de la Hoz AB, De Martino-Rodríguez A, Cruz MS, Neri JLDA, del Campo-Pérez V, Delgado-Cuesta J, de Bustamante AD, Díaz-Pérez A, Dietl B, Diz-de Almeida S, Alves MD, Domínguez-Garrido E, Rosa LS, Luchessi AD, Echave-Sustaeta J, Eiros R, Enciso-Olivera CO, Escudero G, España PP, Sanabria GE, Fariñas MC, Fernández R, Fernández-Caballero L, Fernández-Cruz A, Fernández-Ferrero S, Martínez YF, Fernández-Nestosa MJ, Fernández-Robelo U, Fernández-Rodríguez A, Fernández-Sampedro M, Fernández R, Fernández-Villa T, Fernández-Capitán C, Carioca AAF, Flores-Pérez P, Fuenmayor-Hernández L, Fuertes-Núñez M, Fumadó V, Gadea I, Gagliardi L, Gago-Domínguez M, Gallego N, Galoppo C, García-Soidán A, García-Cerrada C, García-de-Vicuña A, García-García J, García-García I, García-Ibarbia C, García-Montero AC, García L, García M, Torrejón MCG, García I, García-Vázquez E, Garza-Frias E, Gentile A, Gil-Fournier B, de Araújo JNG, Gómez-Duque M, Gómez-Arrue J, Carrera LG, García MG, Sacristán AG, González JR, González-Neira A, Alvarez BG, de Quirós FGB, González-Montelongo R, González-Peñas J, Gonzalez-Sagrado M, Gonzalo-Benito H, Gorgojo-Galindo O, Górgolas M, Guaragna F, Chaux JG, Guillén-Navarro E, Guillén-Guío B, Guisado-Vasco P, Gutiérrez-Castañeda LD, Gutiérrez-Bautista JF, Heili-Frades S, Jacomo RH, Hernández E, Hernández-Moro C, Hernández-Ortega LD, Hernández-Pérez G, Hernández-Vaquero R, Herráez B, Herranz MT, Herrera M, Herrero MJ, Herrero-González A, Horcajada JP, Imaz-Ayo N, Intxausti-Urrutibeaskoa M, Iñigo-Campos A, Iñiguez M, Jara R, Jiménez A, Jiménez-Alfaro I, Jiménez P, Jiménez-Sousa MA, Jordan I, Laguna-Goya R, Laorden D, Lasa-Lázaro M, Lattig MC, Lauriente A, Borja AL, Llanos L, López-Bernus A, de Heredia ML, López-García E, López-Granados E, López-Rodriguez R, López-Ruz MA, Lorente L, Lorenzo-Salazar J, Lozano JE, Lozano-Espinosa M, Mahillo I, Mancebo E, Mar C, Calvo CM, Marcos-Delgado A, Marcos M, Marín-Candón A, Mariscal-Aguilar P, Martin-Pedraza L, Martin-Fernández M, Martín-López C, Martín-Oterino JA, Martín MD, Martín V, Martín MM, Martín-Vicente M, Martínez A, Martínez-González O, Martínez R, Martínez-Paz P, Díaz-Caneja CM, Martínez-Nieto O, Martínez-López I, Martínez-Reséndez MF, Martínez S, Martínez JJ, Martínez-Pérez A, Martínez-Ramas A, Martínez-Robles V, Marzal L, Mazzeu JF, Medrano FJ, Meijome XM, Mejuto-Montero N, Mendes I, Duarte AL, Méndez-Echevarría A, Charris HM, Macías EM, Mercadillo F, Mercado-Sesma AR, Mínguez P, Molina-Roldán E, Molina AJ, Montoya JJ, Pinho SMT, Moreira-Escriche P, Morelos-Arnedo X, Moreno R, Cuerda VM, Moreno-Docón A, Moreno-Escalante J, Fernández AM, García PM, Neira P, Nevado J, Nieto-Gañán I, Silbiger VN, Nuñez-Torres R, Obrador-Hevia A, Ocejo-Vinyals JG, Virginia O, Oliveira SF, Ondo L, Orfao A, Ortega-Paino E, Ortega L, Ortiz-López R, Ortiz-Flores F, Oteo JA, Pacheco M, Pacheco-Miranda FJ, Padilla-Conejo I, Panadero-Fajardo S, Parellada M, Pariente-Rodríguez R, Friaza V, Paz-Artal E, Peces-Barba G, Kus MSP, Perales C, Santos NPC, Guegel GP, Pérez MJ, Pérez A, Pérez-Matute P, Pérez C, Pérez-de-Nanclares G, Pérez-García F, Pérez P, Pérez-Jurado LA, Pérez-Tomás ME, Perucho T, Pichardo LA, Ribeiro AP, Pinsach-Abuin ML, Pinzón LA, Medeiros JFP, Pita G, Pla-Juncà F, Planas-Serra L, Pompa-Mera EN, Porras-Hurtado GL, Pujol A, Quevedo-Chávez ME, Quijada MA, Quintela I, Ramiro-León S, Sedes PR, Nunes JFR, Recalde D, Recio-Fernández E, Resino S, Sousa RR, Rivadeneira-Chamorro CS, Roa-Agudelo D, Pardo MR, Fernandes MR, Rodríguez-Hernández MA, Rodriguez-Palmero A, Rodríguez-Ruiz E, Rodriguez MJ, Rodríguez-Artalejo F, Rodríguez-Ferrer M, Rodríguez-Gallego C, Rodríguez-García JA, Maya BR, Rodriguez-Nicolas A, Rodríguez-Novoa GE, Rodriguez-Urrego PA, Rojo F,

Romero-Coronado A, Morilla R, Rondón-García F, Rosales-Castillo A, Rubio C, Olivera MR, Ruiz-Cabello F, Ruiz-Casares E, Ruiz-Cubillan JJ, Ruiz-Hornillos J, Ruiz M, Ryan P, Salamanca HD, Salazar-García L, Salgueiro-Origlia GG, Sangil A, Sánchez-Pernaute O, Sánchez PL, López AJS, Sánchez-Pablo C, Sánchez-Prados MC, Sánchez-Real J, Sánchez-Redondo J, Sancho-Sainz C, Sande E, Santos A, Schlüter A, Segovia S, Serra-Llovich A, Sevil-Puras F, Sevilla-Porras M, Sicolo MA, Silván-Fuentes C, Moraes VMS, Souza VS, Solé-Violán J, Soria JM, Sorlí JV, Silva NS, Souto JC, Sprockel JJ, Suárez-Rama JJ, Suárez-Zamora DA, Taboada-Fraga X, Tamayo E, Tamayo-Velasco A, Taracido-Fernández JC, Vasconcelos RHT, Tellería C, Carratto TMT, Tenorio-Castano JA, Teper A, Araujo IMT, Torres-Macho J, Torres-Tobar L, Torres-Gutiérrez RP, Troya J, Urioste M, Valencia-Ramos J, Valido A, Vargas-Gallo JP, Varón B, Vega T, Velasco-Quirce S, Vélez-Santamaría V, Víctor V, Vidán-Estévez J, Silva GV, Vieitez-Santiago M, Vilches C, Villalobos L, Villar F, Villar-García J, Villaverde C, Villoslada-Blanco P, Virseda-Berdices A, Costa TX, Yáñez Z, Zapatero-Gaviria A, Zarate R, Zazo S, Flores C, Riancho JA, Rojas-Martínez A, Lapunzina P, Carracedo A, González JR. Clonal chromosomal mosaicism and loss of chromosome Y in elderly men increase vulnerability for SARS-CoV-2. Commun Biol. 2024; 7(1): 202. Article. IF: 5.1; D1

- **Prior-de Castro C, Gallego MAM, Gómez-González C, Martín RD, Rodriguez-Antolín C, Rodríguez-Jiménez C, Mate AD, de Lucas EZ, Maiz MRD, Gómez CD, Batres SA, Sánchez MCP, Torres RJ.** Molecular diagnosis of cystic fibrosis by RNA obtained from nasal epithelial cells. J Cyst Fibros. 2024; 23(4): 788-95. Article. IF: 6.0; Q1
- **Raboso B, Pou C, Abril R, Erro M, Sánchez C, Manzano C, Zamarrón E, Suárez-Cuartin G, González J.** Bronchiectasis.. Open Respir Arch. 2024; 6(3): 100339. Review. Not Indexed
- **Redondo MM, Segura CC, De Lucas EZ, Walther RAS, Sánchez CP.** Should atelectasis be considered a pulmonary complication and indicator of poor prognosis in cystic fibrosis?. J Int Med Res. 2024; 52(3): 3000605241233520. Article. IF: 1.5; Q3
- **Torres G, Sánchez-de-la-Torre M, Gracia-Lavedan E, Benitez ID, Martínez D, Dalmases M, Pinilla L, Minguez O, Vaca R, Pascual L, Aguilá M, Cortijo A, Gort C, Martínez-García MA, Mediano O, Peralta SR, Fortuna-Gutierrez AM, Marquez PP, Drager LF, Cabrini M, de Barros S, Masa JF, Peñafiel JC, Felez M, Vázquez S, Abad J, García-Río F, Casitas R, Lee CH, Barbé F.** Long-term effect of obstructive sleep apnoea management on blood pressure in patients with resistant hypertension: the SARAH study. Eur Respir J. 2024; 64(2): 2400269. Article. IF: 21.0; D1
- **Troncoso JA, Abánades CS, Robles-Marhuenda A, Batres SA, Peña MFV, Valero SJ, Torre RS, Ríos-Blanco JJ.** Prevalence, risk factors and echocardiographic predictors of pulmonary hypertension in systemic lupus erythematosus: towards a screening protocol. RMD Open. 2024; 10(1): e003674. Article. IF: 4.7; Q1
- **Troncoso JA, Fuentes OP, Velilla MF, Carrera LG, Abánades CS, Robles EM, Torre RS, Blanco JJR.** Evaluating the diagnostic and prognostic utility of serial KL-6 measurements in connective tissue disease patients at risk for interstitial lung disease: correlations with pulmonary function tests and high-resolution computed tomography. Bmc Pulm Med. 2024; 24(1): 603. Article. IF: 2.8; Q2
- **Villacampa A, Alfaro E, Morales C, Díaz-García E, López-Fernández C, Bartha JL, López-Sánchez F, Lorenzo O, Moncada S, Sánchez-Ferrer CF, García-Río F, Cubillos-Zapata C, Peiró C.** SARS-CoV-2 S protein activates NLRP3 inflammasome and deregulates coagulation factors in endothelial and immune cells. Cell Commun Signal. 2024; 22(1): 38. Article. IF: 8.9; Q1
- **Villamañán E, Laorden D, Granda P, Sobrino C, De Andrés S, Carpio C, Domínguez-Ortega J, Romero D, Mariscal P, de las Vecillas L, Quirce S, alvarez-Sala R, AsmaGrave HULP Study Grp.** Current Biologic Therapies for Severe Asthma and Real-World Data: Are Expectations Being Met?. J Clin Med. 2024; 13(23): 7152. Review. IF: 2.9; Q1
- **Zamarrón E, Diab L, Pavón J, Carpio C, Alvarez-Sala R, Prados MC.** Renal involvement in adults with cystic fibrosis: study of 89 patients. Med Clin-Barcelona. 2024; 163(5): 238-241. Article. IF: 2.1; Q2



Research projects

- **Álvarez-Sala Walther R.** Actualización y renovación de la actividad investigadora en el servicio de neumología del Hospital Universitario La Paz. Chiesi España S.A. 2015-Ongoing. Managment centre: FIBHULP
- **Cubillos Zapata C.** Contratos predoctorales de formación en investigación de salud (FI23/00151). ISCIII. 2024-Ongoing. Managment centre: FIBHULP
- **Cubillos Zapata C.** Identificación del riesgo de cáncer en pacientes con apnea obstructiva del sueño con la detección de inmunocheckpoints (PI19/01363). ISCIII. 2020-2024. Managment centre: FIBHULP
- **Cubillos Zapata C.** Investigo Técnico. CM. 2022-2024. Managment centre: FIBHULP
- **Cubillos Zapata C.** Mecanismos de la activación y control del inflamasoma en la generación de comorbilidades en la apnea obstructiva del sueño (PI22/01257). ISCIII. 2022-2025. Managment centre: FIBHULP
- **Galera Martínez R.** Evaluación del perfil de hipermetilación de microRNAs para la estimación de riesgo de cáncer de pulmón en pacientes con EPOC (PI22/01764). ISCIII. 2023-2025. Managment centre: FIBHULP
- **García Río F.** Análisis de la actividad del sistema inmune innato en pacientes con síndrome de apneas-hipopneas del sueño grave. Roche Farma S. A. 2014-Ongoing. Managment centre: FIBHULP
- **García Río F.** Análisis de la actividad física cotidiana en pacientes con síndrome de apneas-hipopneas del sueño. Aia Product t Sud Europa S.L. 2007-Ongoing. Managment centre: FIBHULP
- **García Río F.** Contribución de las alteraciones de la percepción de la disnea al diagnóstico de asma ficticio en obesos . Astrazeneca Farmacéutica Spain S. A. 2009-Ongoing. Managment centre: FIBHULP
- **García Río F.** Evaluación de las vías patogénicas de la asociación apnea del sueño y cáncer para una medicina de precisión (PI22/01262). ISCIII. 2022-2025. Managment centre: FIBHULP
- **García Río F.** Identificación de mecanismos, biomarcadores e intervenciones en comorbilidad en enfermedades respiratorias hipoxémicas

mediante abordajes preclínicos, clínicos y computacionales (S2022/BMD-7224). CM. 2023-2026. Managment centre: FIBHULP

- **García Río F.** Impacto de la actividad física en la senescencia de linfocitos T e inmunidad en EPOC: hacia nuevas estrategias terapéuticas personalizadas. SEPAR. 2024-Ongoing. Managment centre: SEPAR
- **Gómez Carrera L.** Auditoría clínica sobre manejo de fibrosis pulmonar idiopática en el area sanitaria del Hospital La Paz. Boehringer Ingelheim España S. A. 2016-Ongoing. Managment centre: FIBHULP
- **Martínez Ceron E, Zamarrón de Lucas E.** Análisis del impacto de las características del sueño y del microbioma intestinal y respiratorio en la asociación apnea del sueño y diabetes para caracterizar potenciales biomarcadores de riesgo (PI23/00695). ISCIII. 2024-2026. Managment centre: FIBHULP

Cibers and Retics

- **García Río F.** CIBER de Enfermedades Respiratorias (CIBERes). ISCIII. (31/12/2025). FIBHULP

Clinical trials

- **Alcolea Batres S.** estudio de extensión abierto para evaluar la seguridad, tolerabilidad y eficacia del uso a largo plazo de treprostinil palmitilo en polvo para inhalación en pacientes con hipertensión arterial pulmonar.
  Type/Phase: II
  Sponsored by: Insmed Inc.orporated
  Signature date: 14/05/2024
- **Alcolea Batres S.** estudio de fase 2b, aleatorizado, doble ciego, multicéntrico y controlado con placebo para evaluar la eficacia, la seguridad y la farmacocinética de treprostinil palmitilo en polvo para inhalación en pacientes con hipertensión arterial pulmonar.
  Type/Phase: IIb
  Sponsored by: Insmed Inc.orporated
  Signature date: 08/02/2024
- **"Alcolea Batres S.** estudio de fase iii, aleatorizado, doble ciego y controlado con placebo para evaluar sotatercept añadido al tratamiento de base de la hipertensión arterial pulmonar (hap) en pacientes con hap de riesgo intermedio y alto recién diagnosticada.
  Type/Phase: III
  Sponsored by: Acceleron Pharma Inc.
  Signature date: 04/09/2024"
- **Álvarez-Sala Walther R.** a randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety, and tolerability of dexpramipexole administered orally for 52 weeks in participants with severe eosinophilic asthma (exhale-3).
  Type/Phase: III
  Sponsored by: Areteia Therapeutics
  Signature date: 26/01/2024
- **Álvarez-Sala Walther R.** the antes b+ study: an open-label, pragmatic, randomized, controlled trial of triple therapy versus laba-lama combination to improve clinical control in high-risk gold b patients (b+).
  Type/Phase: IV
  Sponsored by: Fundació Món Clínic Barcelona
  Signature date: 11/06/2024
- **Casitas Mateo R.** estudio observacional retrospectivo para describir las características y evaluar los resultados en condiciones de vida real en pacientes que inician tratamiento con trixeo aerosphere (budesonida/bromuro de glicopirronio/fumarato de formoterol) en españa (observational retrospective study to describe characteristics and evaluate real-world outcomes in patients initiating trixeo aerosphere (budesonide/glycopyrronium bromide/formoterol fumarate) in spain.
  Type/Phase: EPA-OD
  Sponsored by: Astrazeneca Farmaceutica Spain S.A.
  Signature date: 05/06/2024
- **García Río FJ.** a phase iii, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of astegolimab in patients with chronic obstructive pulmonary disease.
  Type/Phase: III
  Sponsored by: F.Hoffmann-La Roche Ltd.
  Signature date: 06/05/2024
- **García Río FJ.** ensayo de fase iii, multicéntrico, aleatorizado, doble ciego, de administración crónica, con grupos paralelos y controlado con placebo para evaluar la eficacia y la seguridad de benralizumab 100 mg en pacientes con enfermedad pulmonar obstructiva crónica (epoc) de moderada a muy grave y con antecedentes de exacerbaciones frecuentes de la epoc y eosinófilos elevados en sangre periférica (resolute).
  Type/Phase: III
  Sponsored by: Astrazeneca Farmaceutica Spain S.A.
  Signature date: 30/01/2024
- **García Río FJ.** estudio de extensión abierto de fase iii para evaluar la seguridad a largo plazo de astegolimab en pacientes con enfermedad pulmonar obstructiva crónica.
  Type/Phase: III
  Sponsored by: F.Hoffmann-La Roche Ltd.
  Signature date: 19/09/2024
- **García Río FJ.** estudio de obtención de pruebas para la detección de cáncer de roche.
  Type/Phase: OTROS
  Sponsored by: F.Hoffmann-La Roche Ltd.
  Signature date: 04/04/2024
- **García Río FJ.** evaluación de las vías patogénicas de la asociación apnea del sueño y cáncer para una medicina de precisión.
  Type/Phase: IV
  Sponsored by: FIBHULP
  Signature date: 25/04/2024
- **Gómez Carrera L.** a multicenter, randomized, double-blind, placebo-controlled, phase 3 study to evaluate the efficacy, safety, and tolerability of bms-986278 in participants with idiopathic pulmonary fibrosis (ipf).
  Type/Phase: III
  Sponsored by: Bristol Myers Squibb S.A.U.;Bristol-Myers Squibb Services Unlimited Company
  Signature date: 27/02/2024
- **"Gómez Carrera L.** a multicenter, randomized, double-blind, placebo-controlled, phase 3 study to evaluate the efficacy, safety, and tolerability of bms-986278 in participants with progressive pulmonary fibrosis (ppf). Estudio en fase iii, multicéntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia, la seguridad y la tolerabilidad de bms-986278 en participantes con fibrosis pulmonar progresiva.
  Type/Phase: III
  Sponsored by: Bristol-Myers Squibb International Corporation (Bmsic)
  Signature date: 16/05/2024"
- **Gómez Carrera L.** estudio aleatorizado, doble ciego, controlado con placebo y multicéntrico de 26 semanas de duración para evaluar la eficacia, seguridad y tolerabilidad de axatilimab en pacientes con fibrosis pulmonar idiopática (fpi).
  Type/Phase: IIb
  Sponsored by: Syndax Pharmaceuticals Inc.
  Signature date: 21/06/2024
- **Romero Ribate D.** estudio de cohortes retrospectivo para evaluar el impacto de un programa de apoyo al paciente en pacientes con asma grave tratados con benralizumab en vida real en españa. estudio galerna.
  Type/Phase: EPA-OD
  Sponsored by: Astrazeneca Farmaceutica Spain S.A.
  Signature date: 18/04/2024
- **Romero Ribate D.** estudio en fase i/iia para evaluar los efectos de la solución para inhalación aro-rage en sujetos sanos y pacientes con enfermedad pulmonar inflamatoria.
  Type/Phase: IIa
  Sponsored by: Arrowhead Pharmaceuticals Inc.
  Signature date: 26/04/2024
- **Santiago Recuerda A.** evaluación de la monitorizacion al alta de pacientes atendidos en una unidad de cuidados respiratorios intermedios.
  Type/Phase:
  Sponsored by: Electricidad Viala S.L.
  Signature date: 18/06/2024

Patents and trademarks

- **Díaz García E, Laxman Nanwani K, Quintana Díaz M, García Río F, Cubillos-Zapata C, inventors; FIHULP, CIBER, assignees.** Biomarcadores para el pronóstico de pacientes que han sufrido una hemorragia subaracnoidea aneurismática (SAH). P202130180; 2021 March 3.
- **Villamañán E, Contreras J, Romero D, Carpio C, Álvarez-Sala R, Herrero A, Quirce S, inventors; FIBHULP, assignee.** Expertasma. Nº018981670; 2024 June 14.

expertasma

3.4.4 Regulation of Gene Expression and by Hypoxia

Publications: 2 | **Q1:** 1

COMPOSITION

Luis del Peso Ovalle.
Profesor Titular. Departamento de Bioquímica. Facultad de Medicina. Universidad Autónoma de Madrid

- **Benilde Jiménez Cuenca.** *Profesor Titular. Departamento de Bioquímica Facultad de Medicina. Universidad Autónoma de Madrid*



STRATEGIC OBJETIVES

- La homeostasis del oxígeno, central en fisiología, se encuentra alterada en patologías de alta incidencia tales como las enfermedades cardiovasculares y el cáncer. Por ello, la elucidación de las respuestas adaptativas celulares y moleculares a la hipoxia constituye un importante tema de investigación biomédica. Los factores de transcripción inducibles por hipoxia (HIF) desempeñan un papel fundamental en esta respuesta al controlar la expresión de la mayoría de los genes implicados en la adaptación a la hipoxia. El objetivo de nuestro grupo es contribuir a la comprensión de la respuesta transcripcional a la hipoxia y los mecanismos celulares y moleculares que subyacen a las respuestas de adaptación tales como la inducción de angiogénesis. Nuestro objetivo a largo plazo es explotar este conocimiento para mejorar el manejo clínico de patologías en las que el desarrollo de hipoxia tisular es una característica común.

RESEARCH LINES

- Caracterización de los mecanismos moleculares responsables de la respuesta transcripcional a la hipoxia
- Identificación de polimorfismos que afectan los sitios de unión de HIF y caracterización de su efecto funcional
- Mecanismo celular y molecular de regulación de la angiogénesis por hipoxia
- Regulación del metabolismo por hipoxia y papel del HIF en enfermedades metabólicas

RESEARCH ACTIVITY

Master Theses

- **Abanades Salmerón M.** Papel de la Bhlhe40 en la diferenciación y función de adipocitos marrones[dissertation]. Madrid: Universidad Complutense de Madrid: 2024(26/06/2024). Director: del Peso Ovalle L

Final Degree Theses

- **Fernández Cañizares M.** Alteraciones metabólicas inducidas por la exposición a hipoxia intermitente, mimetizando la apnea obstructiva del sueño, en adipocitos marrones[dissertation]. Madrid: Universidad Autónoma de Madrid: 2024(26/06/2024). Director: del Peso Ovalle L
- **García Bustos S.** Análisis computacional de respuesta transcripcional a la hipoxia sostenida e intermitente[dissertation]. Madrid: Universidad Autónoma de Madrid: 2024(26/06/2024). Director: del Peso Ovalle L


Publications

- **Acosta-Iborra B, Gil-Acero AI, Sanz-Gómez M, Berrouayel Y, Puente-Santamaría L, Alieva M, del Peso L, Jiménez B.** Bhlhe40 Regulates Proliferation and Angiogenesis in Mouse Embryoid Bodies under Hypoxia. Int J Mol Sci. 2024; 25(14): 7669. Article. IF: 4.9; Q1
- **Puente-Santamaría L, del Peso L.** SinglePointRNA, an user-friendly application implementing single cell RNA-seq analysis software. Plos One. 2024; 19(6): e0300567. Article. IF: 2.6; Q2

Research projects

- **del Peso Ovalle L.** Contribución de BHLHE40 a la respuesta transcripcional a la hipoxia y su implicación en patologías metabólicas y respiratorias (PID2020-118821RB-I00). MICIN. 2021-2025. Managment centre: UAM
- **del Peso Ovalle L.** Identificación de Mecanismos, Biomarcadores e Intervenciones en comorbilidad en Enfermedades Respiratorias Hipoxémicas mediante abordajes preclínicos, clínicos y computacionales. (P2022/ BMD-7224). CAM. 2023-2027. Managment centre: UAM

3.4.5 Nephrology



Publications: 11 | **Q1:** 6

COMPOSITION

Gemma María Fernández Juárez.
Jefa de Servicio en Nefrología. Hospital Universitario La Paz

- **María José Castro Notario.** *Enfermera. Hospital Universitario La Paz*
- **Olga Costero Fernández.** *Facultativo Especialista de Área en Nefrología. Hospital Universitario La Paz*
- **Gloria del Peso Gilsanz.** *Facultativo Especialista de Área en Nefrología. Hospital Universitario La Paz*
- **María Elena González García.** *Facultativo Especialista de Área en Nefrología. Hospital Universitario La Paz*
- **Yanieli Hernández Perdomo.** *Facultativo Especialista de Área en Nefrología. Hospital Universitario La Paz*
- **Carlos Jiménez Martín.** *Jefe de Sección de Nefrología. Hospital Universitario La Paz*
- **María Ovidia López Oliva.** *Facultativo Especialista de Área en Nefrología. Hospital Universitario La Paz*
- **Marta Ossorio González.** *Facultativo Especialista de Área en Nefrología. Hospital Universitario La Paz*
- **Almudena Pérez Torres.** *Dietista-Nutricionista. Hospital Universitario Santa Cristina*
- **Begoña Rivas Becerra.** *Facultativo Especialista de Área en Nefrología. Hospital Universitario La Paz*
- **Amir Shabaka Fernández .** *Facultativo Especialista de Área en Nefrología. Hospital Universitario La Paz*
- **Rafael Jesús Sánchez Villanueva.** *Facultativo Especialista de Área en Nefrología. Hospital Universitario La Paz*
- **Maria Cristina Vega Cabrera.** *Facultativo Especialista de Área en Nefrología. Hospital Universitario La Paz*

STRATEGIC OBJETIVES

- The strategic objective of this care-research group is to enable, by developing a deep understanding of the various components that make up nephrology (kidney diseases in initial stages, progression of kidney disease, particular and general complications of dialysis and kidney transplantation), access by affected patients to the best diagnostic and therapeutic interventions available at any time. Each of the areas must ensure a minimum level of research and development activity representing the innovation in these areas. The lines of research are at times cross-sectional to the four components indicated for overall nephrology

RESEARCH LINES

A) Glomerular nephropathies:
- Role of PLA2r levels in membranous nephropathy.
- Study of the alternative pathway of complement in glomerular pathologies: vasculitis, membranous nephropathy, IgA glomerulonephritis...
- Morbidity, mortality and progression of diabetic nephropathy and other glomerular nephropathies.
- Adult polycystic kidney disease. Family studies and therapeutic approaches.
- Association between cardiovascular disease and progression of nephropathies (NEFRONA multicenter studies).

B) Renal replacement therapy:
- Evolution of peritoneal function in peritoneal dialysis. Implications for patient and technique survival. New peritoneal dialysis devices and solutions. Aquaporin 1 and its genetic polymorphisms. Involvement of alternatively activated macrophages and CC
- Cardiovascular risk in dialysis patients. Study of endocrine alterations in dialysis patients. Role of FGF 21 in uremic insulin resistance.
- Mouse model for peritoneal dialysis: exploration of the effects of dialysis fluids, pharmacological interventions and genetic manipulation (KO, transgenic).

C) Complications of renal transplantation.
- Infection and CMV disease in renal transplantation. Personalized treatment.
- Graft tolerance.
- Quality of life of the transplanted patient. Patient-reported transplant outcome.
- Individualization of immunosuppression.
- Knowledge of graft cortical microcirculation.
- Continuous active collaboration with the Spanish renal transplant group (SENTRA), some led by the La Paz group: Covid disease, renal prevention (iSGLT-2), pregnancy in renal transplantation, bacterial infections, thrombotic microangiopathy, asystole donation, relapses of different renal diseases after transplantation...

RESEARCH ACTIVITY

Publications

- **Bada-Bosch T, Sevillano AM, Sánchez-Calvín MT, Palma-Milla C, de Cáceres IA, Díaz-Crespo F, Trujillo H, Alonso M, Cases-Corona C, Shabaka A, Quesada-Espinosa JF, Lezana-Rosales JM, Gutiérrez E, Fernández-Juárez G, Caravaca-Fontán F, Praga M.** Cystic phenotype and chronic kidney disease in autosomal dominant Alport syndrome. Nephrol Dial Transpl. 2024; 39(8): 1288-98. Article. IF: 5.6; D1
- **Blasco M, Quiroga B, García-Aznar JM, Castro-Alonso C, Fernández-Granados SJ, Luna E, Fresnedo GF, Ossorio M, Izquierdo MJ, Sanchez-Ospina D, Castañeda-Infante L, Mouzo R, Cao M, Besada-Cerecedo ML, Pan-Lizcano R, Torra R, Ortiz A, de Sequera P, GENSEN Study Investigators.** Genetic Characterization of Kidney Failure of Unknown Etiology in Spain: Findings From the GENSEN Study. Am J Kidney Dis. 2024; 84(6): 719-30. Article. IF: 8.2; D1
- **Lucientes-Continente L, Fernández-Juárez G, Márquez-Tirado B, Jiménez-Villegas L, Acevedo M, Cavero T, Cámara LS, Draibe J, Anton-Pampols P, Caravaca-Fontán F, Praga M, Villacorta J, de Jorge EG.** Complement alternative pathway determines disease susceptibility and severity in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Kidney Int. 2024; 105(1): 177-88. Article. IF: 12.6; D1
- **Mirioglu S, Bruchfeld A, Caravaca-Fontán F, Fernandez-Juárez GM, Floege J, Frangou E, Goumenos D, Griffith M, Moran SM, Stevens K, Teng YKO, Turkmen K, Kronbichler A, Steiger S.** Immunoengineering for autoimmune-kidney disease. Nephrol Dial Transpl. 2024; 39(12): 1934-7. Editorial Material. IF: 5.6; D1
- **Mirioglu S, Daniel-Fischer L, Berke I, Ahmad SH, Bajema IM, Bruchfeld A, Fernandez-Juárez GM, Floege J, Frangou E, Goumenos D, Griffith M, Moran SM, van Kooten C, Steiger S, Stevens K, Turkmen K, Willcocks LC, Kronbichler A.** Management of adult patients with podocytopathies: an update from the ERA Immunonephrology Working Group. Nephrol Dial Transpl. 2024; 39(4): 569-80. Article. IF: 5.6; D1
- **Molina P, Quilis A, Durbá A, Barril G, Pérez-Torres A, Sánchez-Villanueva R, Huarte E, Gonzalez-Oliva JC, Cigarrán S, Prieto-Velasco M, García-Falcón T, Salgueira M, Gaínza FJ, Carrero JJ.** A roadmap for implementing a successful clinical experience with intradialytic parenteral nutrition. Clin Nutr Espen. 2024; 63: 322-31. Review. IF: 2.6; Q3
- **Perez-Bernat ME, Vinas A, Vera M, González-Rico M, Montomoli M, Astudillo-Cortes E, Quevedo-Reina JC, García-Méndez I, Martinez-Losa A, Rama-Arias I, Maldonado-Martín MM, Munar MA, Ortega-Cerrato A, Beltrán-Catalán S, del Peso G, Cases A, Corriz JL.** Non-valvular atrial fibrillation in patients on peritoneal dialysis: prevalence, treatment and professionals involved. Nefrologia. 2024; 44(2): 268-75. Article. IF: 2.6; Q2
- **Ramírez IL, del Moral LR, Villanueva RS, Kiuri SS, García LA, Carrillo RE, Villalobos AG, Heredero AF.** Effect of a multidisciplinary team in the management of vascular access for hemodialysis. Nefrologia. 2024; 44(3): 450-2. Letter. IF: 2.6; Q2
- **Rojas-Rivera JE, Hasegawa T, Fernández-Juárez G, Praga M, Saruta Y, Fernández-Fernández B, Ortiz A.** Prognostic and therapeutic monitoring value of plasma and urinary cytokine profile in primary membranous nephropathy: the STARMEN trial cohort. Clin Kidney J. 2024; 17(8): sfae239. Article. IF: 4.6; Q1
- **Ruiz-Arabi E, Torre-Cisneros J, Aguilera V, Alonso R, Berenguer M, Bestard O, Bodro M, Cantisan S, Carratalà J, Castón JJ, Cordero E, Facundo C, Fariñas MC, Fernández-Alonso M, Fernández-Ruiz M, Fortún J, García-Cosío MD, Herrera S, Iturbe-Fernández D, Len O, López-Medrano F, López-Oliva MO, Los-Arcos I, Marcos MA, Martín-Dávila P, Monforte V, Muñoz P, Navarro D, Páez-Vega A, Pérez AB, Redondo N, Álvarez RR, Rodríguez-Benot A, Rodríguez-Goncer I, San-Juan R, Sánchez-Céspedes J, Valerio M, Vaquero JM, Viasus D, Vidal E, Aguado JM.** Management of cytomegalovirus in adult solid organ transplant patients: GESITRA-IC-SEIMC, CIBERINFEC, and SET recommendations update. Transplant Rev-Orlan. 2024; 38(4): 100875. Review. IF: 2.5; Q2
- **Sans MB, Clemente EP, Carmona AR, Rivera MV, Fontán MP, Rodríguez-Navarro CQ, Rubio MAB, Piña VD, Plaza MM, Contreras JP, Gilsanz GDP, Velasco MP, Ganga PQ, Rodríguez CR, Alvarez ES, Rodríguez NV, Fosalba NA, Benito Y, Reyes MJF, Martínez IG, Pesquera JIM, Gorrín MR, Nuño AU.** Clinical guideline on adequacy and prescription of peritoneal dialysis. Nefrologia. 2024; 44: 1-29. Article. IF: 2.6; Q2

Research projects


- **del Peso Gilsanz G.** Clinical validation of a continuous flow peritoneal dialysis system, with dialysate regeneration (CORDIAL). UE. 2020-2024. Managment centre: FIBHULP
- **del Peso Gilsanz G.** Relación de la funcionalidad de la membrana peritoneal y la patología cardiovascular en pacientes en diálisis peritoneal tratados con soluciones biocompatibles. Repercusión sistémica de un problema local (PI22/00574). ISCIII. 2023-2025. Managment centre: FIBHULP
- **del Peso Gilsanz G.** Las células mesoteliales del efluente crecidas ex vivo reflejan las alteraciones peritoneales encontradas en la biopsia peritoneal. Oportunidades adicionales para biomarcadores en el efluente. Fundación SENEFRO. 2016-Ongoing. Managment centre: FIBHULP
- **Fernández Juárez GM.** Aproximación diagnóstica y terapéutica de las microangiopatías trombóticas. Alexion Pharma Spain S.L. 2022-Ongoing. Managment centre: FIBHULP
- **Fernández Juárez GM.** Descifrando el papel de factor h-related proteins en las enfermedades renales relacionadas con complemento (PI19/01695). ISCIII. 2020-2024. Managment centre: FIBHULP
- **Fernández Juárez GM.** Nefropatías asociadas con desregulación del complemento: estudio genético y de proteínas para determinar factores de riesgo y de progresión de daño renal (PI-2749). SEN. 2023-Ongoing. Managment centre: FIBHULP
- **Jiménez Martín C.** Desarrollo y aplicacion de un programa grupal de atencion psicologica basada en las preferencias y valores con el objetivo de mejora de resultados en salud en el paciente con trasplante renal. Astellas Pharma S.A. 2018-Ongoing. Managment centre: FIBHULP
- **Jiménez Martín C.** Evaluación de la microciculación cortical del trasplante renal a largo plazo medida por ecografía con contraste y su correlación histopatológica por biopsia renal. Sociedad Madrileña De Trasplantes. 2019-Ongoing. Managment centre: FIBHULP
- **Sánchez Villanueva R.** Abordaje nutricional en pacientes con enfermedad renal. Fresenius Kabi España S.A.U. 2021-Ongoing. Managment centre: FIBHULP
- **Sánchez Villanueva R.** Creación de un centro de referencia para el estudio de los mecanismos implicados en las reacciones de hipersensibilidad a las membranas de hemodialisis basadas en polysulfona. Nipro Europe Nv. 2017-Ongoing. Managment centre: FIBHULP

Cibers and Retics

- **Fernández Juárez GM.** Inflamación e inmunopatología de órganos y sistemas (RD21/0005/0030). ISCIII. (31/12/2024). FIBHULP

Clinical trials

- **del Peso Gilsanz G.** validación clínica de un sistema de diálisis peritoneal de flujo continuo con regeneración del dializado-cordial.
  Type/Phase: PRODUCTO SANITARIO
  Sponsored by: Del Peso Gilsanz Gloria;Umc Utrecht
  Signature date: 11/09/2024



- **Jiménez Martín C.** estudio observacional longitudinal para determinar la aso ciación entre la respuesta farmacodinámica del paciente al tratamiento inmunosupresor medida in vitro con nmunobiograma y la presencia de signos de rechazo inmunológico en biopsias del injerto en pacientes con trasplante renal. Estudio biotraim.
  Type/Phase: EPA-OD
  Sponsored by: Biohope Scientific Solutions For Human Healt .
  Signature date: 27/06/2024"
- **Rivas Becerra B.** estudio de fase iii, multicéntrico, aleatorizado, doble ciego, controlado con placebo para evaluar la eficacia y la seguridad de ro7434656, un inhibidor antisentido del factor b del complemento, en pacientes con nefropatía por iga primaria con alto riesgo de progresión.
  Type/Phase: III
  Sponsored by: F.Hoffmann-La Roche Ltd.
  Signature date: 14/10/2024
- **Sánchez Villanueva RJ.** estudio multicéntrico, doble ciego, aleatorizado y controlado con placebo para evaluar la eficacia y la seguridad de nemolizumab en sujetos con enfermedad renal crónica con prurito moderado o intenso asociado.
  Type/Phase: II
  Sponsored by: Galderma S.A.
  Signature date: 25/04/2024
- **Sánchez Villanueva RJ.** relief census: estudio transversal para evaluar la prevalencia y la carga del prurito urémico en pacientes que se someten a hemodiálisis.
  Type/Phase: No EPA
  Sponsored by: Vifor Pharma- Vifor International Inc.
  Signature date: 12/07/2024
- **Vega Cabrera MC.** estudio de fase 3, aleatorizado, doble ciego, controlado con placebo para evaluar la eficacia y seguridad de ravulizumab en participantes adultos con nefropatía por inmunoglobulina a (igan)".
  Type/Phase: III
  Sponsored by: Alexion Pharmaceutical Inc.
  Signature date: 12/07/2024

Patents and trademarks

- **Selgas Gutiérrez R, Bellón Heredia T, Rodríguez Sanz AI, Álvarez Builla J, Vaquero López JJ, Sánchez Alonso P, Alajarín Fernández R, inventors; FIBHULP, Universidad de Alcalá, assignees.** Use of compounds derived from salts of piridazine[3,2-b]benzimidazolium as anti-inflammatory agents. P201430411, PCT/ES2014/070603; 2013 July 25.
- **Selgas Gutiérrez R, Bellón Heredia T, Rodríguez Sanz AI, Álvarez Builla J, Vaquero López JJ, Sánchez Alonso P, Alajarín Fernández R, inventors; FIBHULP, Universidad de Alcalá, assignees.** Use of compounds derived from salts of pyridazine[1',6':1,2]pyrido[3,4-b]indolinium as anti-inflammatory agents. P201331143, PCT/ES2014/070603; 2013 July 25.
- **López-Cabrera M, Aguilera Peralta AI, Selgas Gutiérrez R, Passlickdeetjen J.** Buechel J, Steppan S, inventors; Fresenius Medical Care AG & Co. KGaA, assignee. Method and kit for diagnosing epitelial to mesenchymal transition of the peritoneum (EMT-Chip). WO2017042253, DE102015115158; 2015 September 09.
- **Aguilera Peralta AI, López-Cabrera M, Selgas Gutiérrez R, Steppan S, Passlickdeetjen J, inventors; Fresenius Medical Care Deutschland GMBH, assignee.** Pharmaceutical compositions containing steviosides. PCT/EP2015/074955, EP3212199, US2017304335, CN107073022; 2014 October 31.

3.4.6 Diagnosis and Treatment of Allergic Diseases



Publications: 67 | **Q1:** 47

COMPOSITION

Santiago Eugenio Quirce Gancedo.
Jefe de Servicio de Alergología. Hospital Universitario La Paz

- **María Teresa Caballero Molina.** *Facultativo Especialista de Área en Alergología. Hospital Universitario La Paz*
- **María Luisa Caballero Soto.** *Facultativo Especialista de Área en Farmacia hospitalaria. Hospital Universitario La Paz*
- **Francisco Javier Contreras Porta.** *Facultativo Especialista de Área en Alergología. Hospital Universitario La Paz*
- **Leticia de las Vecillas Sánchez.** *Facultativo Especialista en Alergología. Hospital Universitario La Paz*
- **Francisco Javier Domínguez Ortega.** *Jefe de Sección de Alergología. Hospital Universitario La Paz*
- **Ana Fiandor Román.** *Jefe de Sección de Alergología. Hospital Universitario La Paz*
- **María del Mar Gandolfo Cano.** *Jefe de Sección de Alergologia Infantil. Hospital Universitario La Paz*
- **Carmen Gómez Traseira.** *Facultativo Especialista de Área en Alergología. Hospital Universitario La Paz*
- **Juan Alberto Luna Porta .** *Facultativo Especialista de Área en Alergología. Hospital Universitario La Paz*
- **María Magdalena Lluch Bernal.** *Facultativo Especialista de Área en Alergología . Hospital Universitario La Paz*
- **María Pedrosa Delgado.** *Facultativo Especialista de Área en Alergología. Hospital Universitario La Paz*
- **Elsa Phillips Angles.** *Facultativo Especialista de Área en Alergología Pediátrica. Hospital Universitario La Paz*
- **Mónica Rodríguez Álvarez.** *Facultativo Especialista de Área en Alergología. Hospital Universitario La Paz*
- **María Rosa Rodríguez Pérez.** *Investigadora titular, jefe de laboratorio. Hospital Universitario La Paz*
- **Margarita Tomás Pérez.** *Facultativo Especialista de Área en Alergología. Hospital Universitario La Paz*
- **Inés Torrado Español.** *Facultativo Especialista de Área en Alergología . Hospital Universitario La Paz*

STRATEGIC OBJETIVES

- These group members are specialists in various areas of allergic diseases, which enable them to perform clinical studies and basic research on the main allergic diseases (food allergies, asthma and rhinitis, urticaria/ angiooedema and drug allergies). The group's strategic research objectives include:
- The development of new techniques to improve the diagnosis of food allergies by determining the molecular sensitisation profile
- The study of hyperresponsiveness and airway inflammation in asthma, as well as the role of allergen exposure and comorbidities in this disease
- The study of the pathogenesis and treatment of eosinophilic diseases of the airways (asthma, eosinophilic bronchitis) and the gastrointestinal tract (eosinophilic oesophagitis)
- The characterisation of various types of angiooedema caused by Bradykinin (hereditary and acquired) and improvements in their diagnosis and treatment
- Research on the epidemiology and pathomechanisms of severe adverse reactions caused by immune hypersensitivity reactions to drugs

RESEARCH LINES

- Food allergy (milk, egg, fruit, cereals): molecular diagnosis (by allergenic components) and treatment with oral desensitisation
- Epidemiology, physiopathology, diagnosis and treatment of angioedema and urticaria
- Studies on bronchial hyperresponsiveness to direct and indirect agents and airway inflammation
- Eosinophilic diseases of the respiratory tract (eosinophilic bronchitis) and digestive system (eosinophilic esophagitis)
- Persistent and difficult to control asthma: study on the influence of common and occupational allergens, comorbidities and new therapies
- Aspirin-exacerbated respiratory disease (AERD): inflammatory markers and desensitisation protocol
- Adverse immunologic reactions to drugs: study on the cellular and molecular mechanisms involved.
- Molecular basis of allergy: characterization of allergens and modulating factors of allergenicity. Novel allergy biomarkers: microRNAs and mRNAs. Seeking the differences of specific IgE between allergic patients and asymptomatic individuals.
- Identification and characterization of new environmental allergens and modulating factors of allergenicity.

RESEARCH ACTIVITY

Doctoral Theses

- **Laorden Escudero D.** Evaluación de los criterios de super-respondedor y la escala FEOS como herramientas eficaces en valorar la respuesta al tratamiento biológico en el asma grave no controlada[dissertation]. Madrid: Universidad Autónoma de Madrid UAM: 2024(11/03/2024). Director: Álvarez-Sala Walther R, Quirce Gancedo SE
- **Vilchez Sánchez F.** Relevancia y repercusión clínica de la sensibilización a Pru p 7 en nuestro medio[dissertation]. Madrid: Universidad Autónoma de Madrid UAM: 2024(01/07/2024). Director: Rodríguez Pérez R, Quirce Gancedo SE

Publications

- **Agache I, Annesi-Maesano I, Cecchi L, Biagioni B, Chung KF, Clot B, D'Amato G, Damialis A, del Giacco S, Domínguez-Ortega J, Galán C, Gilles S, Holgate S, Jeebhay M, Kazadzis S, Nadeau K, Papadopoulos N, Quirce S, Sastre J, Tummon F, Traidl-Hoffmann C, Walusiak-Skorupa J, Jutel M, Akdis CA.** EAACI guidelines on environmental science for allergy and asthma: The impact of short-term exposure to outdoor air pollutants on asthma-related outcomes and recommendations for mitigation measures. Allergy. 2024; 79(7): 1656-86. Article. IF: 12.0; D1
- **Agache I, Canelo-Aybar C, Annesi-Maesano I, Cecchi L, Biagioni B, Chung F, D'Amato G, Damialis A, Del Giacco S, De las Vecillas L, Domínguez-Ortega J, Galàn C, Gilles S, Giovannini M, Holgate S, Jeebhay M, Nadeau K, Papadopoulos N, Quirce S, Sastre J, Traidl-Hoffmann C, Walusiak-Skorupa J, Sousa-Pinto B, Salazar J, Rodríguez-Tanta LY, Cantero Y, Montesinos-Guevara C, Song Y, Alvarado-Gamarra G, Sola I, Alonso-Coello P, Nieto-Gutiérrez W, Jutel M, Akdis CA.** The impact of indoor pollution on asthma-related outcomes: A systematic review for the EAACI guidelines on environmental science for allergic diseases and asthma. Allergy. 2024; 79(7): 1761-88. Review. IF: 12.0; D1
- **Agache I, Canelo-Aybar C, Annesi-Maesano I, Cecchi L, Rigau D, Rodríguez-Tanta LY, Nieto-Gutiérrez W, Song Y, Cantero-Fortiz Y, Roqué M, Vasquez JC, Sola I, Biagioni B, Chung F, D'Amato G, Damialis A, del Giacco S, Vecillas LD, Domínguez-Ortega J, Galàn C, Gilles S, Giovannini M, Holgate S, Jeebhay M, Nadeau K, Papadopoulos N, Quirce S, Sastre J, Traidl-Hoffmann C, Walusiak-Skorupa J, Sousa-Pinto B, Alonso-Coello P, Salazar J, Jutel M, Akdis C.** The impact of outdoor pollution and extreme temperatures on asthma-related outcomes: A systematic review for the EAACI guidelines on environmental science for allergic diseases and asthma. Allergy. 2024; 79(7): 1725-60. Review. IF: 12.0; D1
- **Agache I, Ricci-Cabello I, Canelo-Aybar C, Annesi-Maesano I, Cecchi L, Biagioni B, Chung KF, D'Amato G, Damialis A, del Giacco S, de las Vecillas L, Domínguez-Ortega J, Galán C, Gilles S, Giovannini M, Holgate S, Jeebhay M, Nadeau K, Papadopoulos N, Quirce S, Sastre J, Traidl-Hoffmann C, Walusiak-Skorupa J, Salazar J, Sousa-Pinto B, Colom M, Fiol-deRoque MA, López LG, Malih N, Moro L, Pardo MG, Pazo PG, Campos RZ, Saletti-Cuesta L, Akdis M, Alonso-Coello P, Jutel M, Akdis CA.** The impact of exposure to tobacco smoke and e-cigarettes on asthma-related outcomes: Systematic review informing the EAACI guidelines on environmental science for allergic diseases and asthma. Allergy. 2024; 79(9): 2346-65. Article. IF: 12.0; D1
- **Almonacid C, Ausín P, Villacampa JM, Dávila I, Pinilla M, Domínguez-Ortega J.** Evaluation Checklist for the Multidisciplinary Approach to Patients with Asthma or Suspected Asthma in United Airway Disease. J Asthma Allergy. 2024; 17: 1325-32. Article. IF: 3.0; Q2
- **Álvarez-Gutiérrez FJ, Casas-Maldonado F, Soto-Campos G, Blanco-Aparicio M, Delgado J, Galo AP, Quirce S, Plaza V.** Spanish Consensus on Remission in Asthma (REMAS). Arch Bronconeumol. 2024; 60(8): 503-9. Article. IF: 9.2; D1
- **Arismendi E, Puente-Maestu L, Domingo C, Dávila I, Quirce S, González-Barcala FJ, Crespo-Lessmann A, Sánchez-Jareño M, Rivas-Pardinas C, Cea-Calvo L.** Diagnosed and undiagnosed cough-related stress urinary incontinence in women with refractory or unexplained chronic cough: Its impact on general health status and quality of life. Chron Resp Dis. 2024; 21: 14799731241273800. Article. IF: 2.3; Q2
- **Betancor D, Barroso B, Valverde-Monge M, Gómez-López A, Sastre J.** The discrepancy in bronchodilator response between ATS/ERS 2021 and 1991 criteria. Resp Med. 2024; 226: 107609. Editorial Material. IF: 3.1; Q2
- **Betancor D, Otal M, Olaguibel JM, Rodrigo-Muñoz JM, Puebla MJA, Arismendi E, Barranco P, Barroso B, Bobolea , Cárdaba B, Cruz MJ, Curto E, Del Pozo , Domínguez-Ortega J, González-Barcala FJ, Luna-Porta JA, Martínez-Rivera C, Mullol J, Muñoz X, Picado C, Plaza , Quirce S, Rial MJ, Roibás-Veiga , Soto-Retes L, Valero A, Valverde-Monge M, Sastre J.** Global Lung Initiative as Diagnostic Criteria in Asthma-COPD Overlap Syndrome: Prevalence and Disease Characterization in a Real-Life Asthma Cohort. J Invest Allerg Clin. 2024; 34(3): 192-5. Article. IF: 4.8; Q1
- **Betschel SD, Caballero T, Jones DH, Longhurst HJ, Manning M, van Kooten S, Heckmann M, Danese S, Goga L, Burnette AF.** The complexities of decision-making associated with on-demand treatment of hereditary angioedema (HAE) attacks. Allergy Asthma Clin Immunol. 2024; 20(1): 43. Article. IF: 2.4; Q2
- **Bourdin A, Brusselle G, Couillard S, Fajt ML, Heaney LG, Israel E, Mcdowell J, Menzies-Gow A, Martin N, Mitchell PD, Petousi N, Quirce S, Schleich F, Pavord ID.** Phenotyping of Severe Asthma in the Era of Broad-Acting Anti-Asthma Biologics. J Allergy Clin Immunol Pract. 2024; 12(4): 809-23. Review. IF: 6.6; Q1
- **Bousquet J, Schünemann HJ, Sousa-Pinto B, Zuberbier T, Togias A, Samolinski B, Bedbrook A, Czarlewski W, Hofmann-Apitius M, Litynska J, Vieira RJ, Anto JM, Fonseca JA, Brozek J, Bognanni A, Brussino L, Canonica GW, Cherrez-Ojeda I, Cruz AA, de las Vecillas L, Dykewicz M, Gemicioglu B, Giovannini M, Haahtela T, Jacobs M, Jacomelli C, Klimek L, Kvedariene V, Larenas-Linnemann DE, Louis G, Lourenço O, Leemann L, Morais-Almeida M, Neves AL, Nadeau KC, Nowak A, Palamarchuk Y, Palkonen S, Papadopoulos NG, Parmelli E, Pereira AM, Pfaar O, Regateiro FS, Savouré M, Taborda-Barata L, Toppila-Salmi SK, Torres MJ, Valiulis A, Ventura MT, Williams S, Yepes-Nunez JJ, Yorgancioglu A, Zhang L, Zuberbier J, Latiff AHA, Abdullah B, Agache I, Al-Ahmad M, Al-Nesf MA, Al Shaikh NA, Amaral R, Ansotegui IJ, Asllani J, Balotro-Torres MC, Bergman KC, Bernstein JA, Bindslev-Jensen C, Blaiss MS, Bonaglia C, Bonini M, Bossé I, Braido F, Caballero-Fonseca F, Camargos P, Carreiro-Martins P, Casale T, Castillo-Vizuete JA, Cecchi L, Teixeira MD, Chang YS, Loureiro CC, Christoff G, Ciprandi G, Cirule I, Correia-de-Sousa J, Costa EM, Cvetkovski B, de Vries G, Del Giacco S, Devillier P, Dokic D, Douagui H, Durham SR, Enecilla ML, Fiocchi A, Fokkens WJ, Fontaine JF, Gawlik R, Gereda JE, Gil-Mata S, Giuliano AFM, Gotua M, Gradauskiene B, Guzman MA, Hossny E, Hrubisko M, Iinuma T, Irani C, Ispayeva Z, Ivancevich JC, Jartti T, Jesenák MS, Julge K, Jutel M, Kaidashev I, Bennoor KS, Khaltaev N, Kirenga B, Kraxner H, Kull I, Kulus M, Kuna P, Kupczyk M, Kurchenko**



A, La Grutta S, Lane S, Miculinic N, Lee SM, Tuyet LLT, Lkhagvaa B, Louis R, Mahboub B, Makela M, Makris M, Maurer M, Melén E, Milenkovic B, Mohammad Y, Moniuszko M, Montefort S, Moreira A, Moreno P, Mullol J, Nadif R, Nakonechna A, Navarro-Locsin CG, Neffen HE, Nekam K, Niedoszytko M, Nunes E, Nyembue D, O'Hehir R, Ollert M, Ohta K, Okamoto Y, Okubo K, Olze H, Padukudru MA, Palomares O, Pali-Scholl I, Panzner P, Palosuo K, Park HS, Passalacqua G, Patella V, Pawankar R, Pétré B, Pitsios C, Plavec D, Popov TA, Puggioni F, Quirce S, Raciborski F, Ramonaité A, Recto M, Repka-Ramírez S, Roberts G, Robles-Velasco K, Roche N, Rodriguez-Gonzalez M, Romualdez JA, Rottem M, Rouadi PW, Salapatas M, Sastre J, Serpa FS, Sayah Z, Scichilone N, Senna G, Sisul JC, Solé D, Soto-Martínez ME, Sova M, Sozinova O, Stevanovic K, Ulrik CS, Szylling A, Tan FM, Tantilipikorn P, Todo-Bom A, Tomic-Spiric V, Tsaryk V, Tsiligianni I, Urrutia-Pereira M, Rostan MV, Sofiev M, Valovirta E, Van Eerd M, Van Ganse E, Vasankari T, Vichyanond P, Viegi G, Wallace D, Wang DY, Waserman S, Wong G, Worm M, Yusuf OM, Zaitoun F, Zidarn M.** Concepts for the Development of Person-Centered, Digitally Enabled, Artificial Intelligence-Assisted ARIA Care Pathways (ARIA 2024). J Allergy Clin Immunol Pract. 2024; 12(10): 2648-68. Article. IF: 6.6; Q1

- **Bousquet J, Sousa-Pinto B, Anto JM, Bedbrook A, Czarlewski W, Ansotegui IJ, Bergmann KC, Braido F, Brussino L, Cecchi L, Loureiro CC, Cruz AA, Devillier P, Fiocchi A, Gemicioglu B, Haahtela T, Ivancevich JC, Klimek L, Kulus M, Kuna P, Kupczyk M, Kvedariene V, Larenas-Linnemann DE, Louis G, Louis R, Makris M, Morais-Almeida M, Niedoszytko M, Ohta K, Ollert M, Papadopoulos N, Patella V, Pétré B, Pfaar O, Puggioni F, Quirce S, Regateiro FS, Roche N, Rouadi PW, Samolinski B, Sastre J, Schleich F, Scichilone N, Taborda-Barata L, Toppila-Salmi S, Valiulis A, Koyuncu IV, Ventura MT, Yorgancioglu A, Fonseca JA, Zuberbier T.** Concurrent validity, cut-offs and ability to change of patient-reported outcome measures for rhinitis and asthma in MASK-air®. Clin Transl Allergy. 2024; 14(9): e12390. Article. IF: 4.0; Q2
- **Bousquet J, Sousa-Pinto B, Anto JM, Bedbrook A, Fonseca JA, Zuberbier T.** MASK-air: An OECD (Organisation for Economic Co-operation and Development) Best Practice for Public Health on Integrated Care for Chronic Diseases. J Allergy Clin Immunol Pract. 2024; 12(8): 2010-6. Article. IF: 6.6; Q1
- **Buttgereit T, Aulenbacher F, Gutsche A, Kolkhir P, Weller K, Ayala CV, Magerl M, Farkas H, Grumach AS, Aygoeren-Puersuen E, Bara N, Ben-Shoshan M, Bernstein J, Betschel S, Bouillet L, Caballero T, Cancian M, Castaldo AJ, Cimbollek S, Cohn DM, Craig T, Fomina D, Gelincik A, Grivcheva-Panovska V, Jindal A, Katelaris C, Kessel A, Kinaciyan T, Longhurst HJ, Martínez-Saguer I, Riedl M, Schoeffl C, Staubach P, Zanichelli A, Zhi Y, Boysen HB, Fok JS, Li PH, Hakl R, Hide M, Peter J, Maurer M.** The Chronic Angioedema Registry (CARE): Rationale, Methods and Implementation. Clin Exp Allergy. 2024; 54(9): 712-6. Article. IF: 5.2; Q1
- **Caballero M, Quirce S.** Highlighting the Need for Each Excipient to Appear Under a Single Name in All Products That Contain it to Guarantee Identification. J Invest Allerg Clin. 2024; 34(4): 280-1. Letter. IF: 4.8; Q1
- **Caballero ML, Quirce S.** Allergological reappraisal of the Annex to the European Commission guideline on excipients (SANTE-2017-11,668). Allergy. 2024; 79(3): 735-9. Letter. IF: 12.0; D1
- **Caballero T, Alonso C, Baeza ML, Baynova K, Cabeza J, Cortés I, Oblitas DE, Guilarte M, Joral A, Palomo JJ, Jiménez MAL, Virto AM, Medrano L, Boquet EM, Navarro M, Pérez D, Martí MJP, Foltz SLS, Suero C, Zamora C.** Hereditary angioedema in Spain: medical care and patient journey. Orphanet J Rare Dis. 2024; 19(1): 210. Article. IF: 3.5; Q2
- **Camino-Mera A, Pardo-Seco J, Bello X, Argiz L, Boyle RJ, Custovic A, Herberg J, Kaforou M, Arasi S, Fiocchi A, Pecora V, Barni S, Mori F, Bracamonte T, Echeverria L, O'Valle-Aisa V, Hernández-Martínez NL, Carballeira I, García E, García-Magan C, Moure-Gonzalez JD, Gonzalez-Delgado P, Garriga-Baraut T, Infante S, Zambrano-Ibarra G, Tomas-Pérez M, Machinena A, Pascal M, Prieto A, Vazquez-Cortes S, Fernández-Rivas M, Vila L, Alsina L, Torres MJ, Mangone G, Quirce S, Martinon-Torres F, Vazquez-Ortiz M, Gomez-Carballa A, Salas A.** Whole Exome Sequencing Identifies Epithelial and Immune Dysfunction-Related Biomarkers in Food Protein-Induced Enterocolitis Syndrome. Clin Exp Allergy. 2024; 54(11): 919-29. Article. IF: 5.2; Q1
- **Cerecedo I, López-Picado A, Hernández-Núñez MG, Rubio-Herrera MA, de la Hoz B, Infante S, Vázquez-Cortés S, Ruano FJ, Gómez-Traseira C, Freundt-Serpa NP, Martínez-Botas J, Fernández-Rivas M.** Milk Ladder for Reintroduction of Cow's Milk in Infants With IgE-Mediated Cow's Milk Allergy: Version Adapted to the Spanish Population. J Invest Allerg Clin. 2024; 34(1): 51-3. Editorial Material. IF: 4.8; Q1
- **Colque-Bayona M, Hernández-Cano N, Tomás-Pérez M, Caballero T, Quirce S, Domínguez-Ortega J.** Global influence of dupilumab on Quality of Life in a severe asthma patient with T2 multimorbidities: a case report on atopic dermatitis, chronic rhinosinusitis with nasal polyposis, and eosinophilic esophagitis. J Asthma. 2024; 61(7): 762-5. Article. IF: 1.3; Q3
- **De Agrela-Mendes I, Pedrosa M, Gómez-Traseira C, Phillips-Anglés E, Rodríguez-Alvarez M, Quirce S.** Tolerance of peanuts and tree nuts in Spanish children with exclusive sensitization to lipid transfer proteins. Pediat

Allerg Imm-Uk. 2024; 35(7): e14204. Article. IF: 4.5; Q2

- **de las Vecillas L, Quirce S.** The Multiple Trajectories of the Allergic March. J Invest Allerg Clin. 2024; 34(2): 75-84. Review. IF: 4.8; Q1
- **de Llano LP, Urrutia I, Cosío BG, Gullón-Blanco JA, Mena AH, Cisneros C, Martínez-Moragón E, Malanda NM, Esquerre MM, Quirce S, Rivas DD.** Impact of comorbidities on the achievement of specific therapeutic goals in biologic-treated asthma patients. Allergy. 2024; 79(8): 2235-40. Article. IF: 12.0; D1
- **Domingo C, Quirce S, Dávila I, Crespo-Lessman A, Arismendi E, De Diego A, González-Barcala FJ, de Llano LP, Cea-Calvo L, Sánchez-Jareño M, López-Cotarelo P, Puente-Maestu L.** Cough severity visual analog scale scores and quality of life in patients with refractory or unexplained chronic cough. Respir Investig. 2024; 62(6): 987-94. Article. IF: 2.0; Q3
- **Domínguez-Ortega J, Colás C, Romero JD, Mena AH, Ferrer AM, Sanz PB, Montaño PP, Lázaro JF, Bonilla PG, Melcón MG, Bernal MML, Pérez RG, Antolin-Amérigo D, Lacomba JM, Santiago ALV, Sánchez-García S, Del Cuvillo A.** Baseline Clinical Characteristics and Phenoendotypes of Patients With Severe Asthma in Alergodata: The Spanish Allergy Society Registry. J Invest Allerg Clin. 2024; 34(2): 135-8. Editorial Material. IF: 4.8; Q1
- **Domínguez-Ortega J, Laorden D, Vilchez-Sánchez F, Bañas-Conejero D, Quirce S.** Cost-effectiveness and resource use analysis of patients with asthma before and after treatment with mepolizumab in a real-life setting. J Asthma. 2024; 61(1): 39-47. Article. IF: 1.3; Q3
- **Domínguez-Ortega J, Muñoz-Gall X, Delgado-Romero J, Casas-Maldonado F, Blanco-Aparicio M.** Challenges in the Implementation of the Spanish Consensus on the Reduction of Oral Corticosteroids: Insights From the Medical Community. Open Respir Arch. 2024; 6(3): 100331. Article. Not Indexed
- **Doyen V, Migueres N, Frère A, Walusiak-Skorupa J, Wiszniewska M, Suojalehto H, Munoz X, Romero-Mesones C, van Kampen V, Sastre J, Quirce S, Barranco P, Rifflart C, de Blay F, Vandenplas O.** Diagnostic Accuracy of Specific IgE Against Wheat and Rye in Flour-Induced Occupational Asthma. J Allergy Clin Immunol Pract. 2024; 12(8): 2017-25. Article. IF: 6.6; Q1
- **Entrala A, Loli-Ausejo D, Pérez T, Losantos , Cabañas R, Caballero T.** Real-life Experience of Subcutaneous Plasma Derived C1-Inhibitor as Long-term Prophylaxis in HAE-C1INH. J Invest Allerg Clin. 2024; 34(4): 261-3. Editorial Material. IF: 4.8; Q1
- **Esteban-Gorgojo I, Gorgojo MP, Sastre J, García-Río F, Quirce S.** The Influence of BMI in Asthma: Which Traits Are due to Obesity and Which to the Asthma and Obesity Phenotype? J Invest Allerg Clin. 2024; 34(1): 30-7. Article. IF: 4.8; Q1
- **Fernández-Concha I, Pose K, de las Vecillas L, Lluch-Bernal M, Tomás-Pérez M, Soto T, de la Guía AL, Cabañas R.** Successful Desensitization to Lenalidomide in Leukocytoclastic Vasculitis. J Invest Allerg Clin. 2024; 34(5): 352-3. Editorial Material. IF: 4.8; Q1
- **Gil-Mata S, Teixeira T, Bedbrook A, Bousquet J, Sousa-Pinto B, Vieira RJ.** Perceptions of the impact of individual allergic rhinitis symptoms: A survey of ARIA clinical experts. World Allergy Organ J. 2024; 17(12): 100999. Article. IF: 4.3; Q2
- **Giovannini M, Beken B, Agache I, Akdis CA, Carvalho D, Chivato T, Comberiati P, de las Vecillas L, Eguiluz-Gracia I, Heffler E, Jutel M, Karabacak DE, Kolkhir P, Moya B, Ollert M, O'Neil S, Santos AF, Schwarze J, Skevaki C, Sokolowska M, Tsilochristou O, van Wijk RG, del Giacco S, Riggioni C.** Mentoring as the cornerstone of continued education in Allergy and Clinical Immunology: 10th anniversary of the EAACI mentorship program. Allergy. 2024; 79(1): 7-11. Editorial Material. IF: 12.0; D1
- **Granda P, Villamañán E, Carpio C, Laorden D, Quirce S, alvarez-Sala R.** Anti-IL-5 and anti-IL-5R biologics for severe asthma. Are there any differences in their effects? J Asthma. 2024; 61(8): 857-66. Article. IF: 1.3; Q3
- **Granda P, Villamañán E, Heinz S, Laorden D, Romero D, Añón JM, Carpio C, Sobrino C, Collada , Domínguez-Ortega J, Herrero A, Quirce S, Álvarez-Sala R.** Compassionate Use of Reslizumab in a Life-threatening Asthma Exacerbation. J Invest Allerg Clin. 2024; 34(1): 60-1. Editorial Material. IF: 4.8; Q1
- **Granda P, Villamañán E, Laorden D, Carpio C, Collada V, Domínguez-Ortega J, de las Vecillas L, Romero-Ribate D, Chaparro-Díaz OF, Miguel-Sin TL, Alloca-Alvarez DJ, Correa-Borit JM, Losantos I, Mir-Ihara P, Narváez-Fernández EJ, Quirce S, Álvarez-Sala R.** Cardiovascular Events in Patients with Severe Asthma-A Retrospective Study of Two Cohorts: Asthma Type T2 Treated with Biologics and Non-Type T2. J Clin Med. 2024; 13(15): 4299. Article. IF: 2.9; Q1
- **Jiménez-Rodríguez TW, de las Vecillas L, Labella M, Lynch DM, Besz KM, Marquis K, Burgos A, Gomis VS, Lozano I, Antón RAM, de la Calle FM, Delgado MPG, Gutiérrez A, Montenegro E, Rodríguez F, Sánchez FJF, Castells M.** Differential presentation of hypersensitivity reactions to carboplatin and oxaliplatin: Phenotypes, endotypes, and management with desensitization. Allergy. 2024; 79(3): 679-89. Article. IF: 12.0; D1
- **Kiani-Alikhan S, Gower R, Craig T, Wedner J, Kinaciyan T, Aygören-Pürsün E, Banerji A, Bernstein JA, Anderson J, Collis P, Johnston DT, Desai B, Tomita D, Gagnon R, Tachdjian R, Soteres DF, Farkas H, Caballero T, Mcneil D, Jacobs J, Lumry WR.** Once-Daily Oral Berotralstat for Long-Term Prophylaxis of Hereditary Angioedema: The Open-Label Extension of the APeX-2 Randomized Trial. J Allergy Clin Immunol Pract. 2024; 12(3): 733-43. Article. IF: 6.6; Q1
- **Klimek L, Chaker A, Hox V, Del Giacco S, Gevaert P, Shamji M, Salmi ST, Bonadonna P, Walusiak-Skorupa J, Morreira A, Palomares O, Pfaar O, Gracia IE, Arasi S, Solano JM, Reitsma S, Mösges R, Gane S, Hagemann J, van Gerven L, Schiappoli M, Lundberg M, Doan S, Karavelia A, Santamaria RF, de las Vecillas L, Giovannini M, Riggioni C, Combierati P, Correia M, Hannachi F, Carvalho D, Trikamjee T, Perea AA, Castagnoli R, Khaleva E, Barni S, Tsilochristou O, Quecchia C, Vijverberg S, Kolkhir P, Bussolino C, Arcolaci A, Sava F, Boccabela C, Moya B, Karabacak DE, Beken B, Graessel A, Akdis CA, Torres MJ.** Professor Peter Valentin Tomazic, Graz, Austria. Allergy. 2024; 79(8): 2311-2. Article. IF: 12.0; D1
- **Laorden D, Hernández I, Domínguez-Ortega J, Romero D, Álvarez-Sala R, Quirce S.** A real-life cohort of mepolizumab treatment in severe eosinophilic asthma. Eur Ann Allergy Clin Immunol. 2024; 56(4): 169-75. Article. IF: 2.3; Q3
- **Lluch-Bernal M, Pedrosa M, Domínguez-Ortega J, Colque-Bayona M, Correa-Borit J, Phillips-Anglés E, Gómez-Traseira C, Quirce S, Rodríguez-Pérez R.** Sensitization to Quercus ilex Pollen Is Clinically Relevant in Patients With Seasonal Pollen Allergy. J Invest Allerg Clin. 2024; 34(5): 338-40. Article. IF: 4.8; Q1
- **Lluncor-Salazar M, Phillips-Anglés E, Pedrosa M, Lamacchia D, Hernanz A, Prior N, Cabanas R, Caballero T.** Determinants of Disease Activity in Adults With Hereditary Angioedema due to C1-Esterase Inhibitor Deficiency. J Invest Allerg Clin. 2024; 34(6): 406-9. Editorial Material. IF: 4.8; Q1
- **Migueres N, Vandenplas O, Walusiak-Skorupa J, Wiszniewska M, Munoz X, Romero-Mesones C, Suojalehto H, Lindström , van Kampen , Merget R, Mason P, Maestrelli P, Sastre J, Quirce S, Rifflart C, Godet J, de Blay F.** Sputum Inflammatory Patterns Are Associated With Distinct Clinical Characteristics in Patients with Occupational Asthma Independently of the Causal Agent. J Invest Allerg Clin. 2024; 34(2): 85-96. Article. IF: 4.8; Q1
- **Miralles-López JC, Álvarez-Gutiérrez F, Delgado-Romero J, Quirce S, Soto-Campos JG, Andújar-Espinosa R, Cabrejos-Perotti S, Castilla-Martínez M, Flores-Martín I, Pajarón-Fernández MJ, Valverde-Molina J.** Disease Modification in Asthma: Are We on the Right Way? A Multidisciplinary Expert Delphi Consensus (MODIASTHMA Consensus). J Asthma Allergy. 2024; 17: 1163-71. Article. IF: 3.0; Q2
- **Miralles-López JC, Antolín-Amérigo D, García-Moguel , Domínguez-Ortega J, Delgado-Romero J, Quirce S.** Positioning of Tezepelumab in Severe Asthma. J Invest Allerg Clin. 2024; 34(1): 1-11. Review. IF: 4.8; Q1

- **Mir-Ihara P, Vecillas LD, Heredia R, Fiandor A, González-Muñoz M, Zamarrón E, Prados C, Cabañas R.** Protocol for Successful Desensitization to Ivacaftor and Elexacaftor/Tezacaftor/Ivacaftor in a Delayed Hypersensitivity Reaction Confirmed by the Lymphocyte Transformation Test. J Invest Allerg Clin. 2024; 34(3): 211-3. Article. IF: 4.8; Q1
- **Mullol J, Sastre J, Domínguez-Ortega J, Blanco-Aparicio M, Vizuete JAC, Alobid I, García-Vitoria M, Palomo-Jiménez PI.** Prevalence of chronic rhinosinusitis without/with nasal polyps according to severity in Spain. Rhinology. 2024; 62(4): 421-31. Article. IF: 6.8; D1
- **Narváez-Fernández E, Pose K, Caballero ML, Rodríguez-Pérez R, Quirce S.** Occupational Asthma and Food Allergy due to Soybean in a Bakery Worker. J Invest Allerg Clin. 2024; 34(3): 207-9. Article. IF: 4.8; Q1
- **Pascal M, Bax HJ, Bergmann C, Bianchini R, Castells M, Chauhan J, de las Vecillas L, Hartmann K, Alvarez EI, Jappe U, Jimenez-Rodriguez TW, Knol E, Levi-Schaffer F, Mayorga C, Poli A, Redegeld F, Santos AF, Jensen-Jarolim E, Karagiannis SN.** Granulocytes and mast cells in AllergoOncology-Bridging allergy to cancer: An EAACI position paper. Allergy. 2024; 79(9): 2319-45. Article. IF: 12.0; D1
- **Plaza V, Trigueros JA, Carretero JA, Arranz IO, Chicote JMV, Sánchez CA, Tomás JB, Serrano CC, Juncal LD, Domínguez-Ortega J, Rivero JF, Campos JGS, Fernández EM, Martínez S, Lacomba JM, Quirce S.** Use of Triple Therapy in Asthma: The GEMAFORUM V Task Force. J Invest Allerg Clin. 2024; 34(4): 257-60. Editorial Material. IF: 4.8; Q1
- **Plaza V, Blanco M, Ferreira J, García G, Morete A, Quirce S, Soto-Campos G, Almonacid C.** Highlights of the Spanish Asthma Guidelines (GEMA), Version 5.4. Open Respir Arch. 2024; 6(4): 100356. Editorial Material. Not Indexed
- **Podder I, Salman A, Asero R, Caballero MT, Caffarelli C, De las Vecillas L, Gimenez-Arnau AM, Giovannini M, Kocatürk E, Kolkhir P, Manti S, Cascales TN, Maurer M.** Biological drugs for the treatment of children with chronic spontaneous urticaria. Expert Rev Clin Immu. 2024; 20(12): 1427-35. Review. IF: 3.7; Q2
- **Poole JA, Zamora-Sifuentes JL, de las Vecillas L, Quirce S.** Respiratory Diseases Associated With Organic Dust Exposure. J Allergy Clin Immunol Pract. 2024; 12(8): 1960-71. Article. IF: 6.6; Q1
- **Pose K, Narváez-Fernández E, de la Guía AL, De Las Vecillas L, Domínguez-Ortega J, Lluch-Bernal M, Fiando A, Cabañas R.** A Tailored 7-to 10-Day Lenalidomide Desensitization Protocol. J Invest Allerg Clin. 2024; 34(1): 49-50. Editorial Material. IF: 4.8; Q1
- **Presa IJ, Sala-Cunill A, Martí-Garrido J, Cid MN, Vargas SIC, Mendizábal SL, Sánchez MTA, González PR, Quirce S, Hernández MCS, Badas AJ, Vidal C, Antolin-Amérigo D, Veleiro B, Sastre ML.** Profile of Patients With Moderate-to-Severe Atopic Dermatitis and Chronic Urticaria Undergoing Biological Treatment in Hospital Allergy Units in Spain: First Report of the Alergodata Registry. J Invest Allerg Clin. 2024; 34(2): 131-3. Editorial Material. IF: 4.8; Q1
- **Reshef A, Buttgereit T, Betschel SD, Caballero T, Farkas H, Grumach AS, Hide M, Jindal AK, Longhurst H, Peter J, Riedl MA, Zhi YX, Aberer W, Abuzakouk M, Al Farsi T, Al Sukaiti N, Al-Ahmad M, Altrichter S, Aygören-Pürsüm E, Baeza ML, Bara NA, Bauer A, Bernstein JA, Boccon-Gibod I, Bonnekoh H, Bouillet L, Brzoza Z, Bygum A, Calderon O, Campos RD, Romero FHC, Cancian M, Chong-Neto HJ, Christoff G, Cimbollek S, Cohn DM, Craig T, Danilycheva I, Darlenski R, Du-Thanh A, Ensina LF, Fomina D, Fonacier L, Fukunaga A, Gelincik A, Giavina-Bianchi P, Godse K, Gompels M, Goncalo M, Gotua M, Guidos-Fogelbach G, Guilarte M, Kasperska-Zajac A, Katelaris CH, Kinaciyan T, Kolkhir P, Kulthanan K, Kurowski M, Latysheva E, Lauerma A, Launay D, Lleonart R, Lumry W, Malbran A, Ali RM, Nasr I, Nieto-Martínez S, Parisi C, Pawankar R, Piñero-Saavedra M, Popov TA, Porebski G, García AP, Pyatilova P, Rudenko M, Sekerel BE, Serpa FS, Sheikh F, Siebenhaar F, Soria A, Staevska M, Staubach P, Stobiecki M, Thomsen SF, Triggiani M, Valerieva A, Valle S, Van Dinh N, Ayala CEV, Zalewska-Janowska A, Zanichelli A, Magerl M, Maurer M.** Definition, acronyms, nomenclature, and classification of angioedema (DANCE): AAAAI, ACAAI, ACARE, and APAAACI DANCE consensus. J Allergy Clin Immun. 2024; 154(2): 398-411. Article. IF: 11.2; D1
- **Rodríguez-Pérez R, Del Pozuelo S, Pulido E, Brigido C, Carretero P, Caballero ML.** Chemiluminescence-Based IgE Dot-Blot Assay in the Diagnosis of Anaphylaxis Caused by Prontosan. J Invest Allerg Clin. 2024; 34(2): 141-2. Editorial Material. IF: 4.8; Q1
- **Scadding GK, Gray C, Conti DM, McDonald M, Backer V, Scadding G, Bernal-Sprekelsen M, De Corso E, Diamant Z, Hopkins C, Jesenak M, Johansen P, Kappen J, Mullol J, Price D, Quirce S, Reitsma S, Toppila-Salmi S, Senior B, Thyssen JP, Wahn U, Hellings PW.** Pre-asthma: a useful concept? A EUFOREA paper. Part 2-late onset eosinophilic asthma. Front Allergy. 2024; 5: 1404735. Review. IF: 3.1; Q2
- **Scadding GK, McDonald M, Backer V, Scadding G, Bernal-Sprekelsen M, Conti DM, De Corso E, Diamant Z, Gray C, Hopkins C, Jesenak M, Johansen P, Kappen J, Mullol J, Price D, Quirce S, Reitsma S, Salmi S, Senior B, Thyssen JP, Wahn U, Hellings PW.** Pre-asthma: a useful concept for prevention and disease-modification? A EUFOREA paper. Part 1-allergic asthma. Front Allergy. 2024; 4: 1291185. Review. IF: 3.1; Q2
- **Sousa-Pinto B, Vieira RJ, Marques-Cruz M, Bognanni A, Gil-Mata S, Jankin S, Amaro J, Pinheiro L, Mota M, Giovannini M, de las Vecillas L, Pereira AM, Litynska J, Samolinski B, Bernstein J, Dykewicz M, Hofmann-Apitius M, Jacobs M, Papadopoulos N, Williams S, Zuberbier T, Fonseca JA, Cruz-Correia R, Bousquet J, Schünemann HJ.** Artificial Intelligence-Supported Development of Health Guideline Questions. Ann Intern Med. 2024; 177(11): 1518-29. Article. IF: 15.2; D1
- **Suhaimi AH, Rajendram A, Khaidizar FD, Mir P, Pulido-Lucas E, Quirce S, Pedrosa M, Rodriguez-Pérez R, Al-Idrus A.** Occurrences of allergenicity to banana pathogenesis-related-10 (PR10) protein variants. Food Funct. 2024; 15(23): 11715-25. Article. IF: 5.4; Q1
- **Tómas-Pérez M, Alonso AT, Montoro-Ferrer A, Domínguez-Ortega J, Galindo-Bonilla PA, Castelló MC, Naves JE, Ausín P.** Concomitant Efficacy of Dupilumab in Treating Eosinophilic Esophagitis and Type 2 Asthma. J Invest Allerg Clin. 2024; 34(6): 412-4. Editorial Material. IF: 4.8; Q1
- **Valerieva A, Caballero T, Magerl M, Frade JP, Audhya PK, Craig T.** Advent of oral medications for the treatment of hereditary angioedema. Clin Transl Allergy. 2024; 14(9): e12391. Review. IF: 4.0; Q2
- **Valverde-Monge M, Sánchez-Carrasco P, Betancor D, Barroso B, Rodrigo-Muñoz JM, Mahillo-Fernández I, Arismendi E, Bobolea I, Cárdaba B, Cruz MJ, Del Pozo V, Domínguez-Ortega J, González-Barcala FJ, Olaguibel JM, Luna-Porta JA, Martínez-Rivera C, Mullol J, Muñoz X, Peleteiro-Pedraza L, Valles CP, Plaza V, Quirce S, Rial MJ, Soto-Retes L, Valero A, Sastre J.** Comparison of Long-term Response and Remission to Omalizumab and Anti-IL-5/IL-5R Using Different Criteria in a Real-life Cohort of Severe Asthma Patients. Arch Bronconeumol. 2024; 60(1): 23-32. Article. IF: 9.2; D1
- **Vieira RJ, Azevedo LF, Pereira AM, Nogueira-Leite D, Gonçalves FNR, Larenas-Linnemann DE, Cruz AA, Gemicioglu B, Samolinski B, de las Vecillas L, Giovannini M, Cunha MJ, Rodrigues J, Kvedariene V, Klimek L, Pfaar O, Zuberbier T, Fonseca JA, Bousquet J, Sousa-Pinto B.** Impact of Allergic Rhinitis Control on Work Productivity and Costs: A Real-World Data MASK-air Study. J Allergy Clin Immunol Pract. 2024; 12(11): 3107-15. Article. IF: 6.6; Q1
- **Villamañán E, Laorden D, Granda P, Sobrino C, De Andrés S, Carpio C, Domínguez-Ortega J, Romero D, Mariscal P, de las Vecillas L, Quirce**

S, alvarez-Sala R, AsmaGrave HULP Study Grp. Current Biologic Therapies for Severe Asthma and Real-World Data: Are Expectations Being Met? J Clin Med. 2024; 13(23): 7152. Review. IF: 2.9; Q1

Research projects

- **Caballero Molina MT.** Desarrollar las tareas necesarias para poner en marcha el proyecto angiocare 2021. Ediciones Mayo S.A. 2022-Ongoing. Managment centre: FIBHULP
- **Caballero Molina MT.** Development and trans-cultural validation of an international specific questionnaire (IHAE-QOL) for assessment of health related quality of life in adult patients with hereditary angioedema due to c1 inhibitor deficiency (HAE) and quality of life study (DTV-IHAE-QOL). Hereditary Angio-Edema In. 2009-Ongoing. Managment centre: FIBHULP
- **Caballero Molina MT.** Estudio de las características clínicas y fisiopatológicas del angioedema sin habones (PI19/01434). ISCIII. 2020-2024. Managment centre: FIBHULP
- **Caballero Molina MT.** Impacto humanístico y económico del angioedema hereditario en España. Estudio Impactaeh. Shire International Gmbh. 2021-Ongoing. Managment centre: FIBHULP
- **de las Vecillas Sánchez L.** Estudio de la inmunomodulación celular inducida en las desensibilizaciones a quimioterápicos tras reacciones inmediatas y tardías. Fundación de la Sociedad Española de Alergologia e Inmunología Clínica. 2022-Ongoing. Managment centre: FIBHULP
- **Domínguez Ortega FJ.** Asesoramiento para el diseño del estudio clínico Ensayo clínico prospectivo multicéntrico aleatorizado de doble simulación controlado con placebo de búsqueda de la dosis más eficaz para el tratamiento de rinitis/rinoconjuntivitis por alergia frente al polen gramíneas. Inmunotek. 2015-Ongoing. Managment centre: FIBHULP
- **Domínguez Ortega FJ.** Estudio de coste-efectividad de mepolizumab en pacientes con asma grave no controlada en condiciones de vida-real. Glaxosmithkline S. A. 2021-Ongoing. Managment centre: FIBHULP
- **Quirce Gancedo SE.** Integra: utilidad de los ratios en el diagnóstico alergológico: de la investigación a la práctica clínica. Thermo Fisher Diagnostics S.L.U. 2022-Ongoing. Managment centre: FIBHULP
- **Quirce Gancedo SE.** Relación entre asma y obesidad en la población española mayor o igual a 18 años. Novartis Farmaceutica S.A. 2009-Ongoing. Managment centre: FIBHULP
- **Quirce Gancedo SE.** Sesiones en investigación del diagnostico molecular como herramienta de identificación de perfiles de respuesta en pacientes con enfermedad respiratoria alergica y alergia a alimentos. Thermo Fisher Diagnostics S.L.U. 2017-Ongoing. Managment centre: FIBHULP
- **Rodríguez Pérez MR.** Caracterización alergénica y determinación de la relevancia clínica del polen de encina como alérgeno de interés en pacientes policlínicos y su relación con el desarrollo de síndrome de alergia oral con alimentos (PI22/00221). ISCIII. 2023-2025. Managment centre: FIBHULP
- **Rodríguez Pérez MR.** Evaluación de la capacidad alergénica de productos alimentarios mediante test de activación de basófilos y sensibilización cutánea con alimentos. Angulas Aguinaga S. A. U. 2018-Ongoing. Managment centre: FIBHULP
- **Tomás Pérez M.** Efectividad de la inmunoterapia sublingual de ltp (slit melocoton) en pacientes con alergia a melocoton y otros vegetales por sensibilización a ltp en condiciones de práctica clinica habitual. Alk-Abello S.A. 2020-Ongoing. Managment centre: FIBHULP

Cibers and Retics

- **Caballero Molina MT.** Centro de Investigación en Red de Enfermedades Raras. (CIBERer). ISCIII. (31/12/2024). FIBHULP

Clinical trials

- **Caballero Molina MT.** estudio de fase iiib, global, multicéntrico, aleatorizado, doble ciego, con doble enmascaramiento y de grupos paralelos para evaluar la eficacia, seguridad y tolerabilidad de remibrutinib 25 mg b.i.d., en comparación con placebo, con omalizumab 300 mg cada 4 semanas como control activo, a lo largo de 52 semanas en pacientes adultos con urticaria crónica espontánea inadecuadamente controlada con antihistamínicos h1 de segunda generación.
  Type/Phase: III
  Sponsored by: Novartis Pharma Services Ag
  Signature date: 15/02/2024
- **Domínguez Ortega FJ.** tyrex: estudio observacional retrospectivo para evaluar el impacto del tratamiento con mepolizumab a los 5 años en pacientes con asma grave en vida real en españa.
  Type/Phase: EPA-OD
  Sponsored by: Glaxosmithkline S.A.
  Signature date: 26/06/2024
- **Phillips Anglés E.** estudio en fase iii para evaluar la seguridad y farmacocinética de la profilaxis con berotralstat en niños de 2 a <12 años con angioedema hereditario.
  Type/Phase: III
  Sponsored by: Biocryst Pharmaceuticals Inc.
  Signature date: 08/07/2024
- **Tomás Pérez M.** estudio observacional, multicéntrico, prospectivo, para evaluar la efectividad yseguridad en vida real de depigoid® perro (100 dpp/ml) en pacientes con rinitis/ rinoconjuntivitispersistente moderada-grave con o sin asma alérgica controlada en españa.
  Type/Phase: EOm prospectivo
  Sponsored by: Leti Pharma S.L.U.
  Signature date: 25/01/2024

Patents and trademarks


- **Valenta R, Constantin C, Quirce Gancedo, SE, inventors; Phadia AB, assignee.** Novel wheat allergens. PCT/SE2008/051377, EP2225266, US2010305049, AU2008330230, CA2707190, CN101932597, JP2011505134, RU2010126590; 2007 November 30.
- **Caballero Molina MT, Prior Gómez N, Remor Bitencourt EA, authors, FIBHULP, assignee.** Brand name: HAE-QoL HEREDITARY ANGIOEDEMA QUALITY OF LIFE. CM 13.083.068; 2014 July 15.

HAE-QoL
HEREDITARY ANGIOEDEMA QUALITY OF LIFE

- **Sánchez Herreros R, Martínez Fernández J, Castro Morera A, Gasset Vega M, Rodríguez Pérez RM, Pedrosa Delgado M, Quirce Gancedo S, inventors; FIBHULP, CSIC, assignees.** Food allergen extracts and methods of producing and using the same. EP16382413.9 (Publication Number pending); 2016 September 06.
- **del Pozo Abejón V, Sastre Dominguez J, Rodrigo-Muñoz JM, Sastre Turrión B, Quirce Gancedo S, Cañas Mañas JA, inventors; FIISFJD, Centro de Investigación Biomédica en Red (CIBER), FIBHULP, Fundación Conchita Rábago de Jiménez Díaz, assignees.** In vitro method for identifying severity levels in bronchial asthma patients. P201730739; 2017 May 29.
- **Villamañán E, Contreras J, Romero D, Carpio C, Álvarez-Sala R, Herrero A, Quirce S, inventors; FIBHULP, assignee.** Expertasma. Nº018981670; 2024 June 14.

expertasma

3.4.7 Patient Blood Management



Publications: 52 | **Q1:** 23

COMPOSITION

Manuel Quintana Díaz. Facultativo
Especialista de Área en Medicina Intensiva. Hospital Universitario La Paz. Profesor Asociado Facultad de Medicina. Universidad Autónoma de Madrid

- **María José Alcaide Martín.** *Facultativo Especialista de Área en Análisis Clínicos. Tutora de residentes de Análisis Clínicos. Hospital Universitario La Paz*
- **Aúrea Díez Tascón.** *Facultativo Especialista de Radiodiagnóstico. Hospital Universitario La Paz*
- **Sara Fabra Cadenas.** *Facultativo Especialista de Área en Medicina Familiar y Comunitaria. Hospital Universitario La Paz*
- **Pilar Fernández Calle.** *Facultativo Especialista de Área en Análisis Clínicos. Coordinadora de Calidad de Análisis Clínicos. Hospital Universitario La Paz*
- **José Antonio García Erce.** *Facultativo Especialista de Área en Hematología. Hospital San Jorge de Huesca*
- **Raúl Juárez Vela.** *Profesor Titular de Universidad. Universidad de La Rioja*
- **Milagros Martí de Gracia.** *Jefe de Sección de Radiología de Urgencias. Hospital Universitario La Paz*
- **Ana María Martínez Virto.** *Facultativo Especialista de Área en Medicina Familiar y Comunitaria. Coordinadora Adjunta de Urgencias. Hospital Universitario La Paz*
- **Paloma Oliver Sáez.** *Facultativo Especialista de Área en Análisis Clínicos. Tutora de residentes de Análisis Clínicos. Hospital Universitario La Paz*
- **María Inmaculada Pinilla Fernández.** *Facultativo Especialista de Área en Radiodiagnóstico. Hospital Universitario La Paz*
- **María Angélica Rivera Núñez.** *Facultativo Especialista de Área en Medicina Interna. Hospital Universitario La Paz*
- **Marcelino Sánchez Casado.** *Facultativo Especialista de Área en Medicina Intensiva. Hospital Virgen de la Salud*

STRATEGIC OBJETIVES

- Stratifying risk in the critically ill patient
- Stratify pulmonary thromboembolis risk
- Try to diagnose the potentially ill politraumatized patient at the emergency room Enhance the use of blood products
- Critically ill patient coagulopathy
- Early diagnose of anemia at the emergency room
- Intravenous iron usage
- Anticoagulation Reserval
- Patient Blood Mangement Implementation

RESEARCH LINES

- Critical Bleeding
- Anticoagulation reversal
- Fraility
- COVID19
- Interrelation in Cardiovascular Diseases and Cares

RESEARCH ACTIVITY

Doctoral Theses

- **Ramirez Cervantes KL.** COVID-19-associated thrombosis: studying its prevalence in the deprived population, its clinical prediction in critically ill individuals, and the antithrombotic use patterns at a country level[dissertation]. Madrid: Universidad Autónoma de Madrid: 2024(17/12/2024). Director: Quintana Díaz M, Huerta Álvarez C
- **Miguéns Blanco I.** Identificación de problemas en relación con la brecha de género en los Servicios de Urgencias hospitalarios de España y propuesta de soluciones para su erradicación[dissertation]. Madrid: Universidad Autónoma de Madrid: 2024(27/06/2024). Director: Quintana Díaz M, Munayco Sánchez AJ
- **Jericó Alba C.** Estudio Observacional Retrospectivo sobre la Implementación (Implantación, Desarrollo y Evaluación) de un Programa de Patient Blood Management en un Hospital general[dissertation]. Madrid: Universidad Autónoma de Madrid: 2024(09/02/2024). Director: Quintana Díaz M, García Erce JA
- **Lucia Montoya O.** Conciencia corporal como factor protector de las orientaciones suicidas en estudiantes universitarios[dissertation]. Salamanca: Universidad de salamanca: 2024(11/07/2024). Director: Juárez Vela R
- **Maria Matilla A.** Epidemiología e implicaciones del Síndrome de Burnout en profesionales de enfermería[dissertation]. Salamanca: Universidad de salamanca: 2024(26/09/2024). Director: Juárez Vela R
- **Garrote Camara ME.** Características clínicas del síndrome de agitación psicomotriz en pacientes con trastorno mental grave[dissertation]. Lérida: Universitat de Lleida: 2024(24/05/2024). Director: Juárez Vela R

Publications

- **Alfaro E, Casitas R, Díaz-García E, García-Tovar S, Galera R, Torres-Vargas M, Fernández-Velilla M, López-Fernández C, Añón JM, Quintana-Díaz M, García-Río F, Cubillos-Zapata C.** TGF-β1 overexpression in severe COVID-19 survivors and its implications for early-phase fibrotic abnormalities and long-term functional impairment. Front Immunol. 2024; 15: 1401015. Article. IF: 5.9; Q1
- **Barrio-Ruiz C, de Vinaspre-Hernández RR, Colaceci S, Juárez-Vela R, Santolalla-Arnedo I, Durante A, Di Nitto M.** Language and Cultural Barriers and Facilitators of Sexual and Reproductive Health Care for Migrant Women in High-Income European Countries: An Integrative Review. J Midwifery Wom Heal. 2024; 69(1): 71-90. Review. IF: 2.3; Q1
- **Briz VD, Gea-Caballero V, Chover-Sierra E, Czapla M, Fehler P, Rodríguez-Calvo A, Ballestar-Tarin ML, Marin-Maicas P, Cabellos-García AC, Pardo-Bosch M, Juarez-Vela R, Martínez-Sabater A.** Knowledge Level of ICU Nurses Regarding Nutritional Assessment of Critically Ill Patients: A Systematic Review. Nurs Rep. 2024; 14(1): 586-602. Review. IF: 2; Q2
- **Burgos-Esteban A, Quintana-Díaz M, Cordón-Hurtado V, Giménez-Luzuriaga M, Santolalla-Arnedo I, de Viñaspre-Hernández RR, Gea-Caballero V, Santos-Sánchez JA, Navas-Echazarreta N, Rodríguez-Calvo A, Sánchez-Conde P, Juárez-Vela R.** Epidemiology, use, and practice of the intraosseous route in an out-of-hospital emergency department: a retrospective cross-sectional study. Front Public Health. 2024; 12: 1375431. Article. IF: 3.4; Q1
- **Caballero T, Alonso C, Baeza ML, Baynova K, Cabeza J, Cortés I, Oblitas DE, Guilarte M, Joral A, Palomo JJ, Jiménez MAL, Virto AM, Medrano L, Boquet EM, Navarro M, Pérez D, Martí MJP, Foltz SLS, Suero C, Zamora C.** Hereditary angioedema in Spain: medical care and patient journey. Orphanet J Rare Dis. 2024; 19(1): 210. Article. IF: 3.5; Q2
- **Calderón-Moreno J, Delgado-Rodríguez MJ, Juárez-Vela R, Tejada-Garrido CI, de Viñaspre-Hernández RR, Burgos-Esteban A, Sánchez-Conde P, Andreu-Fernández V, Gea-Caballero V, Santos-Sánchez JA, Quintana-Diaz M, Andrés-Esteban EM.** Approximation to the economic cost of healthcare for hypertensive patients diagnosed with COVID-19. Front Public Health. 2024; 12: 1333081. Article. IF: 3.4; Q1
- **de Viñaspre-Hernández RR, Garrido-Santamaría R, Urra-Martínez R, Sáenz-Cabredo P, Garrido-Rivas AE, Juárez-Vela R, Sánchez-González JL, Lafuente-Jimenez A, Ramón-Arbués E, Navas-Echazarreta N, Santolalla-Arnedo I.** Early removal of the etonogestrel contraceptive implant in Spanish women: a prospective cohort study. Front Med (Lausanne). 2024; 11: 1172793. Article. IF: 3; Q1
- **del Pozo-Herce P, Baca-García E, Martínez-Sabater A, Chover-Sierra E, Gea-Caballero V, Curto-Ramos J, Czapla M, Karniej P, Martínez-Tofe J, Sánchez-Barba M, de Viñaspre RR, Juárez-Vela R.** Descriptive study on substance uses and risk of sexually transmitted infections in the practice of Chemsex in Spain. Front Public Health. 2024; 12: 1391390. Article. IF: 3.4; Q1
- **Del Pozo-Herce P, Baca-García E, Martínez-Sabater A, Pérez-Elvira R, Gea-Caballero V, Chover-Sierra E, Satústegui-Dordá PJ, Tovar-Reinoso A, Rodríguez-Velasco FJ, Sánchez-Barba M, Pérez J, Juárez-Vela R.** The Chem-Sex Inventory Scale (CSI): A Tool to Assess the Mental Health Risk of Chemsex Behaviors in Men Who Have Sex with Men. Nurs Rep. 2024; 14(3): 2226-45. Article. IF: 2; Q2
- **Del Pozo-Herce P, Martínez-Sabater A, Sánchez-Palomares P, García-Boaventura PC, Chover-Sierra E, Martínez-Pascual R, Gea-Caballero V, Saus-Ortega C, Ballestar-Tarín ML, Karniej P, Baca-García E, Juárez-Vela R.** Effectiveness of Harm Reduction Interventions in Chemsex: A Systematic Review. Healthcare (Basel). 2024; 12(14): 1411. Review. IF: 2.7; Q2
- **Del Pozo-Herce P, Tovar-Reinoso A, Martínez-Sabater A, Chover-Sierra E, Pacheco-Tabuenca T, Carrasco-Yubero J, Sánchez-González JL, González-Fernández S, Santolalla-Arnedo I, Sufrate-Sorzano T, Juárez-Vela R, Blas EGC.** Mental Health Nursing Student's Perception of Clinical Simulation about Patients at Risk of Suicide: A Qualitative Study. Nurs Rep. 2024; 14(1): 641-54. Article. IF: 2; Q2
- **Del Pozo-Herce P, Tovar-Reinoso A, Martínez-Sabater A, Chover-Sierra E, Sufrate-Sorzano T, Saus-Ortega C, Curto-Ramos J, Padilla-Brito JM, González-Navajas C, Baca-García E, Juárez-Vela R, Blas EGC.** Exploration of Mental Health Elements in Chemsex Behavior: Interventions, Influencing Factors, and Attitudes towards Risk and Harm Reduction in Spain. Nurs Rep. 2024; 14(3): 2313-26. Article. IF: 2; Q2
- **Díez-Vidal A, López JG, Fuertes PR, Jurado FT, Espinosa PB, Ballester JFM, Roca SR, Núñez MAR, Virto AMM, Tung-Chen Y.** Superficial vein thrombosis and its relationship with malignancies: a prospective observational study. J Thromb Thrombolys. 2024; 57(4): 650-7. Article. IF: 2.2; Q2
- **Durante A, Vellone E, Younas A, Juarez-Vela R, Boyne J, Piredda M, De Maria M.** Psychometric testing of the Care Dependency Scale in patients with heart failure and their caregivers. Eur J Cardiovasc Nur. 2024; 23(5): 540-8. Article. IF: 3.9; D1
- **Estrella-Alonso A, Silva-Obregón JA, Fernández-Tobar R, Marián-Crespo C, de Santaquiteria-Torres VR, Jiménez-Puente G, Arroyo-Espliguero R, Viana-Llamas MC, Ramírez-Cervantes KL, Quintana-Díaz M.** Extended Prone Position and 90-Day Mortality in Mechanically Ventilated Patients With COVID-19. Resp Care. 2024; 69(10): 1255-65. Article. IF: 2.1; Q3
- **Fabre-Estremera B, Martínez-Chavez E, Manzano Ocana M, Carcavilla Urqui A, Morales**



Sánchez MA, Pinilla Tejado I, González-Casado I, Losantos García I, Fernández-Calle P, Soto AB, Oliver P. Uso de glucometros durante la prueba de tolerancia oral a la glucosa en ninos para el diagnostico de prediabetes y diabetes. Estudio comparativo. Adv Lab Med. 2024; 5(2): 197-204. Article. IF: 0.9; Q4

- **Fernández-Pedruelo D, Juárez-Vela R, de Viñaspre-Hernández RR, Alonso-Alonso J, Criado-Gutiérrez JM, Sancho-Sánchez C.** Influence of smoking and obesity on post-COVID-19 sequelae and risk of hospitalization. Front Med (Lausanne). 2024; 11: 1499239. Article. IF: 3; Q1
- **Flores E, Estébanez B, Quintana M, Fernández-Puntero B, Nanwani K, Cachafeiro L, Martínez JR, Agrifoglio A, Sánchez-Sánchez M.** Usefulness of mid-regional proadrenomedullin levels in the resuscitation phase of severely burned patients and its utility in early sepsis detection. Burns. 2024; 50(6): 1519-27. Article. IF: 2.9; Q2
- **Freire-Moreira I, Sánchez-Conde MP, Sousa GBD, Garrido-Gallego MI, Rodriguez-López JM, Juárez-Vela R, Bragado JA, Carretero-Hernández M, Vargas-Chiarella CR, Calderón-Moreno J, Lorenzo-Gómez MF, Vaquero-Roncero LM.** Systematic preoperative approach for bariatric surgery, perioperative results, and economic impact. Front Public Health. 2024; 12: 1439948. Article. IF: 3.4; Q1
- **Gea-Caballero V, Pellin-Carcelén A, Piera-Gomar JL, Mármol-López MI, Santolalla-Arnedo I, Garrido CIT, Burgos-Esteban A, Sánchez MR, Sánchez AR, Carboneres-Tafaner MI, Juárez-Vela R.** Evaluation of the impact of speak out and human libraries educational methodologies on nursing students' attitudes toward immigration. Front Public Health. 2024; 12: 1308973. Article. IF: 3.4; Q1
- **Guiote JMC, Contreras CU, Raya PG, Vélez SO, de Gracia MM, Moll GG.** Checklist: Neck computed tomography in non-traumatic emergencies. Radiologia. 2024; 66(2): 155-65. Article. IF: 1.1; Q4
- **Gurdiel-Álvarez F, Navarro-López V, Varela-Rodríguez S, Juárez-Vela R, Cobos-Rincón A, Sánchez-González JL.** Transcranial magnetic stimulation therapy for central post-stroke pain: systematic review and meta-analysis. Front Neurosci. 2024; 18: 1345128. Article. IF: 3.2; Q2
- **Itkonen O, Jonker N, Aarsand AK, Sandberg S, Diaz-Garzon J, Calle PF, Coskun A, Bartlett WA, Locatelli M, Carobene A.** The European biological variation study (EuBIVAS): Biological variation data for testosterone, follicle stimulating hormone, prolactin, luteinizing hormone and dehydroepiandrosterone sulfate in men. Clin Chim Acta. 2024; 555: 117806. Article. IF: 2.9; Q2
- **Jones GRD, Aarsand AK, Carobene A, Coskun A, Fernández-Calle P, Bartlett B, Diaz-Garzon J, Sandberg S.** A New Concept for Reference Change Values-Regression to the Population Mean. Clin Chem. 2024; 70(8): 1076-84. Article. IF: 6.3; D1
- **Karniej P, Dissen A, Juárez-Vela R, Sabater AM, del Pozo-Herce P, Gea-Caballero V, Echaniz-Serrano E, Czapla M.** Cultural Adaptation and Psychometric Properties of the Spanish Version of the Gay Affirmative Practice Scale (GAP-ES). Healthcare (Basel). 2024; 12(22): 2258. Article. IF: 2.7; Q2
- **Karniej P, Dissen A, Juárez-Vela R, Santolalla-Arnedo I, Sufrate-Sorzano T, Garrote-Camara ME, Czapla M.** Psychometric properties and cultural adaptation of the Polish Version of the Gay Affirmative Practice Scale. Front Public Health. 2024; 12: 1384429. Article. IF: 3.4; Q1
- **Kopiczko A, Czapla M, Juárez-Vela R, Ross C, Uchmanowicz B.** Dairy product consumption, eating habits, sedentary behaviour and physical activity association with bone mineral density among adolescent boys: a cross-sectional observational study. BMC Pediatr. 2024; 24(1): 53. Article. IF: 2.0; Q2
- **Larraga-García B, Bejerano VR, Oregui X, Rubio-Bolívar J, Quintana-Díaz M, Gutiérrez A.** Physiological and performance metrics during a cardiopulmonary real-time feedback simulation to estimate cognitive load. Displays. 2024; 84: 102780. Article. IF: 3.4; Q2
- **Larraga-García B, López LC, Escobar FM, Míguez RQ, Quintana-Díaz M, Gutiérrez A.** Improvement and Evaluation of Emergency Trauma Management Using Interactive Simulation. Ifmbe Proc. 2024; 109: 412-20. Proceedings Paper. Not Indexed
- **Lassaletta L, Sánchez-Cuadrado I, Mato-Patino T, Peñarrocha J, Rivera-Núñez MA, Santos-Olmo RMT, Gavilán J, Morales-Puebla JM.** Has Coranavirus Disease 2019 Changed the Incidence and Outcome of Bell's Palsy? J Int Adv Otol. 2024; 20(1): 19-25. Article. IF: 1.2; Q3
- **Lewandowski L, Czapla M, Uchmanowicz I, Kubielas G, Zielinski S, Krzystek-Korpacka M, Ross C, Juárez-Vela R, Zielinska M.** Machine Learning and Clinical Predictors of Mortality in Cardiac Arrest Patients: A Comprehensive Analysis. Med Sci Monitor. 2024; 30: e944408. Article. IF: 2.1; Q3
- **Maldonado-Barrueco A, Gutiérrez-Arroyo A, Bloise I, de Ceano-Vivas M, Rivera-Nuñez A, Santos-Olmos RT, Vega DM, García-Rodríguez J.** Evaluation of CLINITEST® Rapid Covid-19+Influenza antigen test in a cohort of symptomatic patients in an emergency department. Eur J Clin Microbiol. 2024; 43(5): 853-61. Article. IF: 3.0; Q2
- **Martínez-Tofé J, Ausili D, Soto-Ruiz N, Santolalla-Arnedo I, Durante A, di Nitto M, Lysanets Y, de Viñaspre-Hernández RR, Tejada-Garrido CI, Barba MS, Gea-Caballero V, Juárez-Vela R.** Transcultural adaptation and theoretical models validation of the Spanish version of the Self-Care of Diabetes Inventory. Front Med (Lausanne). 2024; 11: 1423948. Article. IF: 3; Q1
- **Montoya-Hurtado OL, Sobral-Monteiro-Junior R, Meneses-Castaño CY, Sancho-Sánchez C, Martínez-Sabater A, Andrés-Olivera P, Sánchez-Conde P, Sánchez-Toledo JP, Criado-Gutiérrez JM, Criado-Pérez L, Sánchez-González JL, Juárez-Vela R.** Body Awareness as a Protective Factor against Suicidal Orientations in College Students. Behav Sci (Basel). 2024; 14(5): 358. Article. IF: 2.5; Q2
- **Moreno-Parro I, Diaz-Garzon J, Aarsand AK, Sandberg S, Aikin R, Equey T, Ríos-Blanco JJ, Soto AB, Fernández-Calle P.** Biological Variation Data in Triathletes for Metabolism and Growth-Related Biomarkers Included in the Athlete Biological Passport. Clin Chem. 2024; 70(7): 987-96. Article. IF: 6.3; D1
- **Navas-Echazarreta N, Juárez-Vela R, Martínez-Sabater A, Echániz-Serrano E, Fernández-Rodrigo MT, Navarro-Martínez O, Sancho-Sánchez C, Cobos-Rincón A, Rodríguez-Calvo A, González-Fernández S, Chover-Sierra E,**

Satústegui-Dordá PJ. Measuring Instruments for Media Health Literacy: A Systematic Review of Psychometric Properties. Nurs Rep. 2024; 14(4): 2795-818. Review. IF: 2; Q2

- **Navas-Echazarreta N, Juárez-Vela R, Martínez-Sabater A, Gea-Caballero V, Chover-Sierra E, Echaniz-Serrano E, de Viñaspre-Hernández RR, Jodrá-Esteban B, Sánchez-Conde P, Fernández-Rodrigo MT, Rodríguez-Calvo A, Satústegui-Dordá PJ.** Psychometric properties of the Spanish version of the media health literacy questionnaire (MeHLit-SV). Front Public Health. 2024; 12: 1440386. Article. IF: 3.4; Q1
- **Navas-Echazarreta N, Satústegui-Dordá PJ, Rodríguez-Velasco FJ, García-Perea ME, Martínez-Sabater A, Chover-Sierra E, Ballestar-Tarín ML, Del Pozo-Herce P, González-Fernández S, de Vinaspre-Hernández RR, Czapla M, Juárez-Vela R.** Media Health Literacy in Spanish Nursing Students: A Multicenter Cross-Sectional Study. Nurs Rep. 2024; 14(3): 2565-79. Article. IF: 2; Q2
- **Ocaña-Ortiz A, Gea-Caballero V, Juárez-Vela R, Peiró R, Pérez-Sanz E, Santolalla-Arnedo I, Sufrate-Sorzano T, Garrote-Cámara ME, Paredes-Carbonell JJ.** Health equity in urban and rural settings: implementation of the place standard tool in Spain. Front Public Health. 2024; 12: 1292032. Article. IF: 3.4; Q1
- **Ramírez-Cervantes KL, Campillo-Morales S, García-Poza P, Quintana-Díaz M, Huerta-Álvarez C.** Antithrombotic Use Patterns in COVID-19 Patients from Spain: A Real-World Data Study. J Clin Med. 2024; 13(8): 2403. Article. IF: 2.9; Q1
- **Rodríguez-Alcázar FJ, Juárez-Vela R, Sánchez-González JL, Martín-Vallejo J.** Interventions Effective in Decreasing Burden in Caregivers of Persons with Dementia: A Meta-Analysis. Nurs Rep. 2024; 14(2): 931-45. Review. IF: 2; Q2
- **Ros Gómez B Gómez-López J Quintana-Díaz M Calvo Sevilla SV Rodríguez-Fuertes P Tejeda-Jurado F Berrocal-Espinosa P Martínez-Ballester JF Rodríguez-Roca S Rivera Núñez MA Martínez Virto AM Martín-Vega A Fernández-Capitán C Salgueiro-Origlia G Marín-Baselga R Lorenzo Hernández A Sancho Bueso T Puchades Rincón de Arellano R Gutiérrez-Sancerni B Díez-Vidal A Carrasco-Molina S Tung-Chen Y.** Factors Associated with the Evolution of Superficial Vein Thrombosis and Its Impact on the Quality of Life: Results from a Prospective, Unicentric Study. J Vasc Dis. 2024; 3(1): 1-10. Article. Not Indexed
- **Sánchez-González JL, Juárez-Vela R, de la Torre VDM, Andrés-Olivera MD, Martín-Vallejo J, Morán-Bayón A, Gonçalves-Cerejeira JI, Gestoso-Uzal N, González-Sarmiento R, Pérez J.** Effect of strength-based physical exercise on telomere length as a marker of premature ageing in patients with schizophrenia: study protocol for a pilot randomised controlled trial. Bjpsych Open. 2024; 10(5): e162. Article. IF: 3.5; Q1
- **Sánchez-Gonzalez JL, Sánchez-Rodriguez JL, Varela-Rodriguez S, Gonzalez-Sarmiento R, Rivera-Picon C, Juárez-Vela R, Tejada-Garrido CI, Martin-Vallejo J, Navarro-López V.** Effects of Physical Exercise on Telomere Length in Healthy Adults: Systematic Review, Meta-Analysis, and Meta-Regression. JMIR Public Health Surveill. 2024; 10: e46019. Review. IF: 3.9; Q1
- **Sandberg S, Coskun A, Carobene A, Fernández-Calle P, Díaz-Garzón J, Bartlett WA, Jonker N, Galior K, Gonzales-Lao E, Moreno-Parro I, Sufrate-Vergara B, Webster C, Aarsand AK.** Analytical performance specifications based on biological variation data - considerations, strengths and limitations. Clin Chem Lab Med. 2024; 62(8): 1483-89. Article. IF: 3.7; Q1
- **Sufrate-Sorzano T, Corton-Carrasco O, Garrote-Cámara ME, Navas-Echazarreta N, Pozo-Herce PD, Di Nitto M, Juárez-Vela R, Santolalla-Arnedo I.** Social Networks as a Tool for Evidence-Based Health Education: Umbrella Review. Nurs Rep. 2024; 14(3): 2266-82. Review. IF: 2; Q2
- **Taccone FS, Bittencourt CR, Moller K, Lormans P, Quintana-Díaz M, Caricato A, Ferreira MAC, Badenes R, Kurtz P, Sondergaard CB, Colpaert K, Petterson L, Quintard H, Cinotti R, Bogossian EG, Righy C, Silva S, Roman-Pognuz E, Vandewaeter C, Lemke D, Huet O, Mahmoodpoor A, Ortiz AB, van der Jagt M, Chabanne R, Videtta W, Bouzat P, Vincent JL, TRAIN Study Grp.** Restrictive vs Liberal Transfusion Strategy in Patients With Acute Brain Injury The TRAIN Randomized Clinical Trial. JAMA-J Am Med Assoc. 2024; 332(19): 1623-33. Article. IF: 55.0; D1
- **Tintu AN, Soto AB, Van Hoof V, Bench S, Malpass A, Schilling UM, Rooney K, Sáez PO, Relker L, Luppa P.** The influence of undetected hemolysis on POCT potassium results in the emergency department. Clin Chem Lab Med. 2024; 62(11): 2169-76. Article. IF: 3.7; Q1
- **Tung-Chen Y, Martí-de Gracia M.** Physical exam with ultrasound, lights and shadows of an unstoppable multidisciplinary advance. Rev Clin Esp. 2024; 224(3): 187-8. Editorial Material. IF: 1.7; Q2
- **Vidal AD, López JG, Núñez MAR, Virto AMM, Chen YT.** Risk factors and complications associated with superficial venous thrombosis. Eur J Intern Med. 2024; 121: 146-8. Letter. IF: 6.1; Q1
- **Wojciechowki J, Czapla M, Konop M, Juárez-Vela R, Rosinczuk J.** Evaluation of Accidental and Intentional Pediatric Poisonings: Retrospective Analysis of Emergency Medical Service Interventions in Wroclaw, Poland. Nurs Rep. 2024; 14(3): 2523-34. Article. IF: 2; Q2
- **Zaher-Sánchez S, Satústegui-Dordá PJ, Ramón-Arbués E, Santos-Sánchez JA, Aguilón-Leiva JJ, Pérez-Calahorra S, Juárez-Vela R, Sufrate-Sorzano T, Angulo-Nalda B, Garrote-Cámara ME, Santolalla-Arnedo I, Echániz-Serrano E.** The Management and Prevention of Delirium in Elderly Patients Hospitalised in Intensive Care Units: A Systematic Review. Nurs Rep. 2024; 14(4): 3007-22. Review. IF: 2; Q2

Research projects

- **Martínez Virto AM.** Epidemiología del angioedema en los servicios de urgencias. Shire International GMBH. 2020-Ongoing. Managment centre: FIBHULP
- **Oliver Sáez P.** Estudio de gasometría en el lugar de asistencia. Beneficio para el paciente. Asociación Española de Farmacéuticos Analistas. 2012-Ongoing. Managment centre: FIBHULP
- **Quintana Díaz M.** Estudio de la coagulopatía y de los perfiles de inflamación sistémica asociados a la hemorragia subaracnoidea aneurismática. FIBHULP. 2020-Ongoing. Managment centre: FIBHULP
- **Quintana Díaz M.** Estudio de monitorización de heparinas de bajo peso molecular como profilaxis en un Servicio de Urgencias. Bayer Hispania S. L. 2011-Ongoing. Managment centre: FIBHULP
- **Quintana Díaz M.** Identificaión de factores de gravedad en el paciente con traumatismo potencialmente grave. FIBHULP. 2013-Ongoing. Managment centre: FIBHULP
- **Quintana Díaz M.** Manejo inicial del paciente con hemorragia critica traumatica en urgencias y emergencias. Varios. 2021-Ongoing. Managment centre: FIBHULP
- **Quintana Díaz M.** Tratamientos de depuración extracorporea en pacientes criticos. de la investigación a la practica clinica. Nikkiso America Inc. 2016-Ongoing. Managment centre: FIBHULP
- **Quintana Díaz M.** Traumatismo y transfusión ¿una asociación necesaria? Fundación Mutua Madrileña. 2019-2024. Managment centre: FIBHULP
- **Quintana Díaz M.** Trombosis en el paciente crítico por COVID-19. Estudio Tromcco. Laboratorios Farmaceúticos Rovi S.A. 2022-Ongoing. Managment centre: FIBHULP

Patents and trademarks

- **Díaz García E, Laxman Nanwani K, Quintana Díaz M, García Río F, Cubillos-Zapata C, inventors; FIHULP, CIBER, assignees.** Biomarcadores para el pronóstico de pacientes que han sufrido una hemorragia subaracnoidea aneurismática (SAH). P202130180; 2021 March 3

3.4.8 Health Care Nurses Research

Publications: 3

COMPOSITION

Esther Rey Cuevas.
Directora de Enfermería. Hospital Universitario La Paz
Tamara Domingo Pérez.
Supervisora Investigación I+D+i. Hospital Universitario La Paz

- **María Avilés Martínez.** *Profesora Ayudante Doctora Universidad Autónoma de Madrid*
- **Laura Alonso Recio.** *Profesora Contratada. Universidad de Educación a Distancia*
- **Mónica Beobide Conde.** *Enfermera Especialista en Enfermería del Trabajo. Hospital Universitario La Paz*
- **Jesús Castro Toro.** *Supervisor de Área Funcional. Hospital Universitario La Paz*
- **Víctor Manuel Cornejo del Río.** *Supervisor de Unidad Quirúrgica. Hospital Carlos III- Hospital Universitario La Paz*
- **María Ricardina Delgado Sandoval.** *Enfermera en Servicio de Consultas Externas. Hospital Universitario La Paz*
- **Julia de Villarreal de Arracó.** *Enfermera especialista en Pediatría. Hospital Universitario La Paz*
- **María Luisa Díaz Martínez.** *Profesora Contratada. Universidad Autónoma de Madrid*
- **Isabel Díaz Suárez.** *Supervisora de Enfermería. Hospital Universitario La Paz*
- **María Durán Agüi.** *Enfermera en Servicio de Medicina Interna. Hospital Universitario La Paz*
- **Salomé Herrero Cereceda.** *Enfermera Unidad Quirúrgica. Hospital Cantoblanco-Hospital Universitario La Paz*
- **Judith Hernández Alonso.** *Enfermera - Hospital Universitario La Paz*
- **Leticia López Pedraza.** *Profesora Titular. Escuela Cruz Roja adscrita a la UAM*
- **Ginés Mateo Martínez.** *Profesor Asociado en Enfermería. Universidad Autónoma de Madrid*
- **Yolanda Morán Benito.** *Enfermera especialista en Neurología. Hospital Universitario La Paz*
- **María Begoña Ortiz Ortega.** *Supervisora de Enfermería. Hospital Universitario La Paz*
- **Pedro Piqueras Rodríguez.** *Supervisor de Enfermería en Unidad de Neonatología. Hospital Universitario La Paz*
- **Ana Ramos Cruz.** *Supervisor de Enfermería en Reanimación Maternidad. Hospital Universitario La Paz. Profesora Asociada de Grado de Enfermería. Centro Universitario de Ciencias de la Salud San Rafael-Nebrija*
- **Maria José Rol García.** *Supervisora de Enfermería de Unidades de Puerperio del Hospital Maternal. Hospital Universitario La Paz*
- **María del Carmen Sellán Soto.** *Profesora Contratada. Universidad Autónoma de Madrid*
- **Gema Tapia Serrano.** *Enfermera de Cuidados Intensivos Pediátricos. Hospital Universitario La Paz*
- **Raquel Torres Luna.** *Enfermera Especialista en Pediatría. Hospital Universitario La Paz*
- **Antonio Vázquez Sellánz.** *Profesor Ayudante Doctor. Universidad Autónoma de Madrid*



STRATEGIC OBJETIVES

- Care is an indispensable activity for survival, since humanity exists. Care has been relevant as a primary function to promote and develop all those activities that make people live.
- This research group aims to collaborate on growing clinical evidence on health care. The real gap between what generates scientific knowledge and the decisions that are made in the day to day is ethically unacceptable. Between 30 and 40% of patients do not receive care consistent with the results of the research and around 20-25% of care may be unnecessary or potentially harmful. Evidence-Based Practice (PBE) or Evidence is based on the fact that greater knowledge and use of research results in clinical practice will contribute to improving the health of the population. Today, it is well known that the implementation of the best scientific evidence available in the clinical practice improves quality of care and clinical outcomes.
- In addition, decision-makers based on available evidence tend to be more satisfied with their role and focus on improving the quality of care given to patients.
- Finally, it should be noted that using evidence in daily practice can achieve health goals at a minimum cost.
- Cost-effectiveness studies have been conducted in which evidence-based care is linked to a reduction in health costs compared to traditional care.
- At the same time, society is facing new economic, political, demographic, social and cultural challenges that require health services capable of meeting the growing health needs of the population.
- It is necessary to investigate in clinical practice the most advanced care in order to achieve the full development of care and ensure the achievement of the best results in terms of overall health and quality of life of patients, Effectiveness of interventions, greater cohesion of health care teams, and of course, all contribute to the sustainability of the health system and user satisfaction.

RESEARCH LINES

- Advanced Practice Nursing (APN) Care and Patient Experience: Patient-reported outcomes and experience measures (PROM and PREM).
- Vital Processes of Care and Complex Care. Attention to Frailty and Vulnerability. Pediatric care. Women's care. Transitional care and complex chronic care.
- Technological innovation and AI and its application in health care: evaluation of programs and validation of tools and questionnaires
- Professional Identity and Professional Development in Nursing: Historical and Contemporary Perspectives: Identity, profession, professional development, history of nursing.

RESEARCH ACTIVITY

Master Theses

- **Moran Benito Y.** Factores determinantes de la calidad de vida del paciente con ELA: de la evidencia a la experiencia[dissertation]. Avila: Universidad Catolica de Avila: 2025(10/02/2024). Director: Moreno Casillas L.
- **Muñoz González A.** Intervenciones para el mantenimiento de los catéteres centrales de inserción periférica en las unidades de cuidados intensivos[dissertation]. Madrid: UAM-UB: 2024(2024). Director: Sellán Soto MC.
- **Vallejo Gómez B.** Métodos no farmacológicos para el manejo del delirium en el paciente intubado en la unidad de cuidados intensivos: aplicación del ABCDEF Bundle[dissertation]. Madrid: UAM-UB: 2024(19/06/2024). Director: Sellán Soto MC.
- **Azcuénaga Lara A.** Relevancia del papel de enfermería en los cuidados de los potenciales donantes de órganos en las unidades de cuidados intensivos en la muerte encefálica[dissertation]. Madrid: UAM-UB: 2024(19/06/2024). Director: Sellán Soto MC.
- **Cantueso Muñoz M.** Errores adversos en la asisitencia pediátirca: revisión sistemática exploratoria[dissertation]. Madrid: UAM-UB: 2024(19/06/2024). Director: Díaz Martínez ML.
- **López Fernández-Sordo MC.** Diagnóstico enfermero: Trastorno del patrón del sueño en una Unidad de Cuidados Intensivos[dissertation]. Madrid: UAM-UB: 2024(19/06/2024). Director: Díaz Martínez ML.

Final Degree Theses

- **Sanchez Blasco F.** El abuso de fármacos por el personal sanitario. Un abordaje cualitativo. [dissertation]. Madrid: Universidad Autónoma de Madrid: 2024(26/06/2024). Director: Beobide Conde M.
- **Sanchez Miranda P.** La fatiga por compasión de la enfermería oncohematológica:un proyecto cuasiexperimental[dissertation]. Madrid: Universidad Autónoma de Madrid: 2024(26/06/2024). Director: Beobide Conde M.
- **Velasco Perez de Gracia S.** Manejo multidisciplinar de la obesidad: un proyecto cuasiexperimental.[dissertation]. Madrid: Universidad Autónoma de Madrid: 2024(26/06/2024). Director: Beobide Conde M.
- **Herrero Monje M.** Impacto de la Flexibilización del horario de visitas en la unidad de cuidados intensivos: UCI de puertas abiertas[dissertation]. Madrid: Universidad Autónoma de Madrid: 2024(26/06/2024). Director: de Villarreal Arracó J.
- **Mencía Moreno S.** Eficacia de la toxina botulínica para el tratamiento de la espasticidad muscular en Pediatría. Revisión narrativa. [dissertation]. Madrid: Universidad Autónoma de Madrid: 2024(26/06/2024). Director: de Villarreal Arracó J.
- **Rodríguez M, García Álvarez M.** Estudio PRE-POST sobre la captación en RCP básica en cuidadores principales de niños con patología crónica compleja.[dissertation]. Madrid: Universidad Autónoma de Madrid: 2024(26/06/2024). Director: de Villarreal Arracó J.
- **García Candau JB, Dueñas López, L.** Evaluación de la experiencia del cuidador principal del paciente pediátrico con epidermolisis bullosa[dissertation]. Madrid: Universidad Autónoma de Madrid: 2024(26/06/2024). Director: de Villarreal Arracó J.
- **Hernanz Arjonilla C.** Revisión sistemática sobre el manejo del dolor en el parto con métodos no farmacológicos[dissertation]. Madrid: Escuela Enfermería Cruz Roja - UAM: 2024(26/06/2024). Director: López Pedraza L.
- **Bernárdez Piñuela V.** Intervenciones de humanización hospitalaria en el paciente pediátrico: revisión sistemática[dissertation]. Madrid: Escuela Enfermería Cruz Roja - UAM: 2024(26/06/2024). Director: López Pedraza L.
- **Alneng García del Salto C.** Revisión sistemática sobre la preservación de la fertilidad en mujeres con síndrome de ovario poliquístico y su impacto psicológico[dissertation]. Madrid: Escuela Enfermería Cruz Roja - UAM: 2024(26/06/2024). Director: López Pedraza L.
- **Hernanz Rodríguez S.** Vacuna del virus del papiloma humano en hombres: revisión sistemática[dissertation]. Madrid: Escuela Enfermería Cruz Roja - UAM: 2024(26/06/2024). Director: López Pedraza L.
- **Rodríguez Sanz C.** El embarazo produce cambios en la estrutura y función del cerebro materno: revisión sistemática[dissertation]. Madrid: Escuela Enfermería Cruz Roja - UAM: 2024(26/06/2024). Director: López Pedraza L.
- **Gozálvez Gozálvez I.** La terapia CAR-T en el tratamiento de la leucemia linfática aguda infantil: una revisión sistemática[dissertation]. Madrid: Escuela Enfermería Cruz Roja - UAM: 2024(26/06/2024). Director: López Pedraza L.
- **Porras Rojano A.** El abordaje del paciente portador de dispositivos de asistencia ventricular: una revisión sistemática[dissertation]. Madrid: Escuela Enfermería Cruz Roja - UAM: 2024(26/06/2024). Director: López Pedraza L.
- **Cereza de Burgos A.** Impacto y utilidad de la información parental sobre el recién nacido en el municipio de Rivas Vaciamadrid[dissertation]. Madrid: Hospital Gregorio Marañón Madrid: 2024(26/06/2024). Director: López Pedraza L.
- **López-Reina Platas A.** Afrontamiento del paciente paliativo pediátrico oncológico y su familia ante un pronóstico terminal[dissertation]. Madrid: Universidad Autónoma de Madrid: 2024(26/06/2024). Director: Avilés Martínez M.

Publications

- **Lacerda A, Bravo-Carretero IM, Ehrlich BS, Job G, Martínez MA, Leiss U, Kokkinou G, Scheinemann K, Craig F, Krottendorfer K, Devidas M, Baker JN, Agulnik A, McNeil MJ.** Perceptions of physicians caring for pediatric patients with cancer in Europe: insights into the use of palliative care, its timing, and barriers to early integration. Front Oncol. 2024; 14: 1461668. Article. IF: 3.3; Q2
- **Peláez A, del Arbol NR, Sellán AV, Castellano JM, Soriano JB, Ancochea J, Peñalvo JL.** Clinical characteristics and outcomes among hospitalised COVID-19 patients across epidemic waves in Spain: An unCoVer analysis. Med Clin-Barcelona. 2024; 162(11): 523-31. Article. IF: 2.1; Q2
- **Rol MJ, Cuerva MJ, Palomares MD, Vallecillo C, Franke S, Bartha JL.** Impact of Peripartum Depression and Anxiety Symptoms on Unplanned Cesarean or Operative Vaginal Births: A Prospective Observational Study. Clin Exp Obstet Gyn. 2024; 51(1): 26. Article. IF: 0.6; Q4

Research projects

- **Piqueras Rodríguez P.** Catéter permanente versus iyecciones en el confort del paciente pediátrico durante la administracion de heparina de bajo peso molecular: ensayo clinico cruzado. Piqueras Rodríguez P. 2021-Ongoing. Managment centre: FIBHULP
- **Sellán Soto MC.** Eficacia del masaje terapeutico para aliviar el malestar de niños y niñas con bronquiolitis. CODEM. 2022-Ongoing. Managment centre: FIBHULP

3.4.9 Emergency and Critical Pathology



Publications: 4 | **Q1:** 2

COMPOSITION

Alejandro Martín Quiros.
Unidad de Aislamientode Alto Nivel. Hospital Universitario La Paz

- **Gillermina Bejarano Redondo.** *Médico Adjunto en Urgencias. Hospital Universitario La Paz*
- **María Elena Calvín García.** *Facultativo Especialista de Área en Urgencias. Hospital Universitario La Paz*
- **Julio Cobo Mora.** *Jefe de la Unidad de Urgencias. Hospital Universitario La Paz*
- **María de los Ángeles García Martín.** *Facultativo Especialista de Área especialista en Farmacia Hospitalaria. Hospital Universitario La Paz*
- **Olga González Peña.** *Facultativo Especialista de Área en Medicina Familiar y Comunitaria. Hospital Universitario La Paz*
- **Manuel Jesús González Viñolis.** *Facultativo Especialista de Área en Urgencias. Hospital Universitario La Paz*
- **Macarena Lerín Baratas.** *Facultativo Especialista de Área en Urgencias. Hospital Universitario La Paz*
- **Maria Lorena López Corcuera.** *Facultativo Especialista de Área en Medicina Interna. Hospital Universitario La Paz*
- **Mikel Rico Briñas.** *Facultativo Especialista de Área en Urgencias. Hospital Universitario La Paz*
- **Paloma Isabel Romero Gallego-Acho.** *Facultativo Especialista de Área en Medicina Interna. Hospital Universitario La Paz*
- **María José Simón Merlo.** *Facultativo Especialista de Área en Radiología. Hospital Universitario La Paz*

STRATEGIC OBJETIVES

- Our group will investigate new strategies to address very different pathologies that are presented in our emergency department, national referent in different fields of diagnosis and treatment. This heterogeneous group of specialists, will approach 6 main lines of research, which aim to contribute to the better definition of clinical, diagnostic and treatment strategies.
- We collaborate with other research groups, to study clinical and prognostic usefulness tests in cardiology, to develop new strategies for the treatment and diagnosis of infectious diseases, and to investigate new antibiotics with the pneumology group.
- We develop a new and pioneering line of imagingdiagnostic, with the line of emergency ultrasound, being national referents in research in this field, in which we have the active support of private enterprise.
- We will investigate the possibility of supporting us in new technologies that help the clinician in the decisión making in the field of the treatment of the diabetes, impelling global initiatives both at the hospital and the population level.
- Finally, we will develop a line of toxicological research, focusing both on the early recognition of the intoxicated patient, as well as their adequate treatment, in collaboration with the clinical toxicology unit (CTU), with the aim of becoming a national reference center in the Management of the intoxicated patient, as well as in the development of protocols of attention to multiple victims of biological attack.

RESEARCH LINES

- Integral management of the treatment and follow-up of the diabetic patient.
- Emergency ultrasound.
- Sepsis
- SARS-CoV-2 and COVID19 acute management
- Care of infectious diseases in the emergency room.
- Optimization of the management of the acute intoxicated patient and use of chemical substances for terrorist purposes.
- Attention to cardiovascular pathology of emergencies.
- Attention to respiratory pathology.



RESEARCH ACTIVITY

Publications

- **Álvarez N, Martín A, Dorado S, Colmenares R, Rufián L, Rodriguez M, Gimenez A, Carneros L, Sánchez R, Carreño G, Rapado I, Heredia Y, Martínez-López J, Barrio S, Ayala R.** Detection of minimal residual disease in acute myeloid leukemia: evaluating utility and challenges. Front Immunol. 2024; 15: 1252258. Article. IF: 5.9; Q1
- **Ferreras C, Hernández-Blanco C, Martín-Quirós A, Al-Akioui-Sanz K, Mora-Rillo M, Ibáñez F, Díaz-Almirón M, Cano-Ochando J, Lozano-Ojalvo D, Jiménez-González M, Goterris R, Sánchez-Zapardiel E, de Paz R, Guerra-García P, Queiruga-Parada J, Molina P, Briones ML, Ruz-Caracuel B, Borobia AM, Carcas AJ, Planelles D, Vicario JL, Moreno MA, Balas A, Llano M, Llorente A, del Balzo A, Cañada C, García MA, Calvin ME, Arenas I, de Diego RP, Eguizábal C, Soria B, Solano C, Pérez-Martínez A.** Results of phase 2 randomized multi-center study to evaluate the safety and efficacy of infusion of memory T cells as adoptive therapy in severe. Cytotherapy. 2024; 26(1): 25-35. Article. IF: 3.2; Q2
- **Ramos JR, Perrín MRS, del Castillo JG, Candel FJ, Quirós AM, González JLC, Jiménez AJ, Grande ASL.** Design of a panel of indicators for antibiotic stewardship programs in the Emergency Department. Farm Hosp. 2024; 48(2): 57-63. Article. IF: 1.3; Q4
- **Schoffelen T, Papan C, Carrara E, Eljaaly K, Paul M, Keuleyan E, Quirós AM, Peiffer-Smadja N, Palos C, May L, Pulia M, Beovic B, Batard E, Resman F, Hulscher M, Schouten J.** European society of clinical microbiology and infectious diseases guidelines for antimicrobial stewardship in emergency departments (endorsed by European association of hospital pharmacists). Clin Microbiol Infec. 2024; 30(11): 1384-407. Article. IF: 8.5; D1

Research projects

- **Martín Quirós A.** Impacto del retraso en el inicio de la antibioterapia e identificación de biomarcadores pronósticos en la evolución de pacientes con sepsis a shock séptico (PI20/01589). ISCIII. 2021-2023. Managment centre: FIBHULP

3.4.10 Hospital Pharmacy

Publications: 9 | **Q1:** 4

COMPOSITION

Alicia Herrero Ambrosio.
Jefa de Servicio de Farmacia Hospitalaría. Hospital Universitario La Paz. Profesora Asociada. Universidad Complutense De Madrid

- **Susana Andrés Morera.** *Facultativo Especialista de Área en Farmacia Hospitalaria. Hospital Universitario La Paz*
- **Cristina Bilbao Gómez-Martino.** *Facultativo Especialista de Área en Farmacia Hospitalaria. Hospital Universitario La Paz*
- **Cristina Cárdenas Serralde.** *Farmacéutico. FIBHULP*
- **María Gema Casado Abad.** *Facultativo Especialista de Área en Farmacia Hospitalaria. Hospital Universitario La Paz*
- **María del Río Durango.** *Farmacéutico . FIBHULP*
- **Macarena García-Trevijano Cabetas.** *Facultativo Especialista de Área en Farmacia Hospitalaria. Hospital universitario La Paz*
- **Luis González del Valle.** *Jefe de Sección de Farmacia Hsopitalaria. Hospital Universitario La Paz*
- **María Ángeles González Fernández.** *Facultativo Especialista de Área en Farmacia Hospitalaria. Hospital Universitario La Paz*
- **Catalina Lara Cátedra.** *Facultativo Especialista de Área en Farmacia Hospitalaria. Hospital Universitario La Paz*
- **Marta Moro Agud.** *Subdirectora Médico de Servicios Centrales. Hospital Universitario La Paz*
- **Tamara Pérez Robles.** *Facultativo Especialista de Área en Farmacia Hospitalaria. Hospital Universitario La Paz*
- **Elena María Rodríguez Martín.** *Facultativo Especialista de Área en Farmacia Hospitalaria. Hospital Universitario La Paz*
- **José Antonio Romero Garrido.** *Facultativo Especialista de Área en Farmacia Hospitalaría. Hospital Universitario La Paz. Personal Docente e Investigador. Universidad Complutense De Madrid*
- **Rosario Fátima Ros Catellar.** *Facultativo Especialista de Área en Farmacia Hospitalaria. Hospital Universitario La Paz*
- **Margarita Ruano Encinar.** *Facultativo Especialista de Área en Farmacia Hospitalaria. Hospital Universitario La Paz*
- **Luis Sánchez-Rubio Fernández.** *Facultativo Especialista de Área en Farmacia Hospitalaria. Hospital Universitario La Paz*
- **Carmen Sobrino Jiménez.** *Facultativo Especialista de Área en Farmacia Hospitalaria. Hospital Universitario La Paz*
- **María Luisa Testillano Tarrero.** *Facultativo Especialista de Área en Farmacia Hospitalaria. Hospital Universitario La Paz*
- **Elena Villamañán Bueno.** *Facultativo Especialista de Área en Farmacia Hospitalaria. Hospital Universitario La Paz*

STRATEGIC OBJETIVES

- The Hospital Pharmacy group aims to investigate on pharmacotherapy focused on both, researches on treatments and innovation technology related to the medication use process, in order to optimize clinical practice.

RESEARCH LINES

1. Development of new drugs: Advanced therapies

2. Evaluation of Drugs - Real World Outcomes, especially those associated with high economic impact or with limited clinical evidence. In this regard, our target is to investigate on the following fields:
   - Coagulopathies
   - Oncology
   - Biologic therapies
   - Infectious diseases
   - Rare diseases
   - Gene therapy
   - Molecular biology of the innate immune system

3. Investigation on strategies for early detection and prevention of medication errors

4. Analysis of the impact on medication adherence and health outcomes of innovation in new technologies applied to the medication use process:
   - Telepharmacy programs. Evaluation of their impact on medication adherence and health outcomes in different pathologies such as migraine, multiple sclerosis and asthma.
   - Development and evaluation of digital health tools applied to congenital coagulopathies and its impact in terms of adherence and treatment cost-effectiveness improvement

5. Green Pharmacy. Investigation on strategies to reduce the environmental impact of drug use

6. Development of humanization projects, with the aim of improving the patient experience and quality of care



RESEARCH ACTIVITY

Doctoral Theses

- **Blázquez Ramos N.** Estudio de la influencia de la adherencia y los niveles plasmáticos de factor en las comorbilidades, complicaciones y consecuencias de la hemofilia[dissertation]. Madrid: Universidad Complutense de Madrid: 2024(15/07/2024). Director: Romero Garrido JA, González del Valle L, Benedí González JM

Publications

- **Castellar FR, Encinar MR, Robles TP, Vázquez NG, Abad GC, Rubio LS, Sánchez MYR, Ambrosio AH.** Training program in compounding for pharmacy technicians through a digital platform and simulation techniques. Farm Hosp. 2024; 48(3): 93-100. Article. IF: 1.3; Q4
- **Castellar FR, Encinar MR, Robles TP, Vázquez NG, Abad GC, Rubio LS, Sánchez MYR, Ambrosio AH.** Compounding training programme for pharmacy

technicians using a digital platform and simulation techniques. Farm Hosp. 2024; 48(3): T93-100. Article. IF: 1.3; Q4

- **González-Fernández MA, Herranz-Pinto P, Alonso-Pacheco ML, Mateo-Salillas C, Hoyo-Muñoz A, Jiménez-Nácher I, Moreno-Ramos F, Herrero-Ambrosio A.** Incorporation of patient-reported outcomes into pharmacy and dermatology departments, in psoriasis and atopic dermatitis patients, as a tool to improve the healthcare quality and health outcomes. J Healthc Qual Res. 2024; 39(1): 13-22. Article. IF: 1.0; Q4
- **Granda P, Villamañán E, Carpio C, Laorden D, Quirce S, Álvarez-Sala R.** Anti-IL-5 and anti-IL-5R biologics for severe asthma. Are there any differences in their effects? J Asthma. 2024; 61(8): 857-66. Article. IF: 1.3; Q3
- **Granda P, Villamañán E, Heinz S, Laorden D, Romero D, Añón JM, Carpio C, Sobrino C, Collada , Domínguez-Ortega J, Herrero A, Quirce S, Álvarez-Sala R.** Compassionate Use of Reslizumab in a Life-threatening Asthma Exacerbation. J Invest Allerg Clin. 2024; 34(1): 60-1. Editorial Material. IF: 4.8; Q1
- **Granda P, Villamañán E, Laorden D, Carpio C, Collada V, Domínguez-Ortega J, de las Vecillas L, Romero-Ribate D, Chaparro-Díaz OF, Miguel-Sin TL, Alloca-Alvarez DJ, Correa-Borit JM, Losantos I, Mir-Ihara P, Narváez-Fernández EJ, Quirce S, Álvarez-Sala R.** Cardiovascular Events in Patients with Severe Asthma-A Retrospective Study of Two Cohorts: Asthma Type T2 Treated with Biologics and Non-Type T2. J Clin Med. 2024; 13(15): 4299. Article. IF: 2.9; Q1
- **Mariscal-Aguilar P, Gómez-Carrera L, Bonilla G, Carpio C, Zamarrón E, Fernández-Velilla M, Díaz-Almirón M, Gayá F, Villamañán E, Prados C, Álvarez-Sala R.** Impact of Air Pollution on the Long-Term Decline of Non-Idiopathic Pulmonary Fibrosis Interstitial Lung Disease. Atmosphere-Basel. 2024; 15(12): 1405. Article. IF: 2.3; Q3
- **Mariscal-Aguilar P, Gómez-Carrera L, Bonilla G, Díaz-Almirón M, Gayá F, Carpio C, Zamarrón E, Fernández-Velilla M, Torres I, Esteban I, Regojo R, Villamañán E, Prados C, Alvarez-Sala R.** Air pollution exposure and its effects on idiopathic pulmonary fibrosis: clinical worsening, lung function decline, and radiological deterioration. Front Public Health. 2024; 11: 1331134. Article. IF: 3.4; Q1
- **Villamañán E, Laorden D, Granda P, Sobrino C, De Andrés S, Carpio C, Domínguez-Ortega J, Romero D, Mariscal P, de las Vecillas L, Quirce S, alvarez-Sala R, AsmaGrave HULP Study Grp.** Current Biologic Therapies for Severe Asthma and Real-World Data: Are Expectations Being Met?. J Clin Med. 2024; 13(23): 7152. Review. IF: 2.9; Q1

Research projects

- **González Fernández MA.** CNTO1959PSO4024 Adherence: Estudio observacional para evaluar la adherencia a TREMFYA® (Guselkumab) en la práctica clínica en pacientes con psoriasis moderada grave. Fundación Española de Farmacia Hospitalaria (FEFH). 2023-Ongoing. Managment centre: FIBHULP
- **Herrero Ambrosio A.** Actualización y promoción de la actividad investigadora en el Servicio de Farmacia del Hospital Universitario La Paz. Vifor Pharma España S.L. 2016-Ongoing. Managment centre: FIBHULP
- **Herrero Ambrosio A.** Desarrollo de un sistema de gestión de medicamentos en investigación. Sanofi Aventis S.A. 2008-Ongoing. Managment centre: FIBHULP
- **Herrero Ambrosio A.** Estudio de evaluación del servicio de telefarmacia y entrega no presencial de medicación desde la farmacia hospitalaria a partir de la pandemia covid-19. Amgen S.A. 2020-Ongoing. Managment centre: FIBHULP
- **Herrero Ambrosio A.** Evaluación de la notificación de alergias a fármacos en pacientes hospitalizados. Utilidad de la prescripción electrónica en la prevención de errores de medicación. Amgen S.A. 2012-Ongoing. Managment centre: FIBHULP
- **Herrero Ambrosio A.** Implantación del módulo epase en la elaboración de antineoplásicos (PI-1609). Amgen S.A. 2013-Ongoing. Managment centre: FIBHULP
- **Herrero Ambrosio A.** Informatización y optimización de procesos en la unidad de ensayos clínicos del Servicio de Farmacia. Vifor Pharma España S.L. 2015-Ongoing. Managment centre: FIBHULP
- **Lara Cátedra C.** Proyecto MEDSPAIN: Revisión sistemática de la estabilidad físico-química de las mezclas analgésicas vía parenteral más utilizadas. Fundación Española de Farmacia Hospitalaria (FEFH). 2023-Ongoing. Managment centre: FIBHULP
- **Moro Agud M.** Evaluación de la implantación de una plataforma de gestión del conocimiento para la comunicación, formación y docencia en el Hospital Universitario La Paz. Pfizer S.L.U. 2020-Ongoing. Managment centre: FIBHULP
- **Pérez Robles T.** Farmacovigilancia de terapia génica in vivo en España: onasemnogén abeparvovec y voretigén neparvovec. Fundación Española de Farmacia Hospitalaria (FEFH). 2023-Ongoing. Managment centre: FIBHULP
- **Romero Garrido JA.** Estudio de adherencia al tratamiento de los pacientes en profilaxis con factores de la coagulación y su relación con los episodios de sangrado (PI-2356). Amgen S.A. 2014-Ongoing. Managment centre: FIBHULP
- **Romero Garrido JA.** Estudio de adherencia al tratamiento sustitutivo con factores de la coagulación en pacientes diagnosticados de hemofilia grave en regimen de demanda y profilaxis y su relación con episodios de sangrado. Pfizer S.L.U. 2016-Ongoing. Managment centre: FIBHULP
- **Romero Garrido JA.** Fármacos que marcan un antes y un después: Resultados e implicaciones económicas de la incorporación de emcizumab al tratamiento de la hemofilia. Fundación Española de Farmacia Hospitalaria (FEFH). 2021-Ongoing. Managment centre: FIBHULP
- **Sobrino Jiménez C.** Proyecto Less Chron Validation. Fundación Española de Farmacia Hospitalaria (FEFH). 2023-Ongoing. Managment centre: FIBHULP
- **Sobrino Jiménez C.** Reto medicación sin daño. Bayer Hispania S.L. 2023-Ongoing. Managment centre: FIBHULP
- **Testillano Tarrero, ML.** Guía de conciliación farmacoterapéutica en pacientes ingresados en unidades de cuidados críticos Fundación Española de Farmacia Hospitalaria (FEFH). 2023-Ongoing. Managment centre: FIBHULP
- **Villamañan Bueno E.** Análisis de resultados en salud y de la satisfacción de los pacientes del programa "paciente experto en enfermedades pulmonares intersticiales difusas y su tratamiento expertepid (PI-6033). Fundación Universidad Autónoma de Madrid (FUAM). 2023-Ongoing. Managment centre: FIBHULP
- **Villamañan Bueno E.** Aplicación móvil (App) PulmoTox para la mejora de la seguridad de la farmacoterapia de pacientes respiratorios. Fundación Universidad Autónoma de Madrid (FUAM). 2023-Ongoing. Managment centre: FIBHULP
- **Villamañan Bueno E.** Búsqueda de marcadores genéticos en el tratamiento de la fibrosis pulmonar idiopática con pirfenidona y nintedanib. Fundación Española de Farmacia Hospitalaria (FEFH). 2020-Ongoing. Managment centre: FIBHULP
- **Villamañan Bueno E.** Evaluación de las objeciones alegadas por un comité ético de investigación clínica a los consentimientos informados de los estudios clínicos. Amgen S.A. 2016-Ongoing. Managment centre: FIBHULP
- **Villamañan Bueno E.** Gestión del impacto medioambiental de los inhaladores desde la farmacia hospitalaria (Proyecto GIMAFH) (PI-5744). Fundación Española de Farmacia Hospitalaria (FEFH). 2023-Ongoing. Managment centre: FIBHULP

Patents and trademarks

- **Herrero Ambrosio A, Ramírez García E, Ojeda Feo JJ, Pérez Rodríguez J, Asensio Martín MJ, González Sánchez ML, Moro Agud M, Lorente Romeo M, López Nieto M, Gómez Rioja R, authors; FIBHULP, assignee.** Trademark name: SINOIRES; CM 13.080.056; 2014 July 14.

- **Villamañán E, Contreras J, Romero D, Carpio C, Álvarez-Sala R, Herrero A, Quirce S, inventors; FIBHULP, assignee.** Expertasma. Nº018981670; 2024 June 14.

3.4.11 Translational Hepatology



Publications: 15 | **Q1:** 12

COMPOSITION

Francisco Javier García-Samaniego Rey. Jefe de Seeción en Hepatología. Hospital Universitario La Paz. Profesor Titular. Universidad Autónoma de Madrid

- **Marina Camblor Murube.** *Investigadora Predoctoral. Universidad Autónoma de Madrid*
- **Antonio Madejón Seiz.** *Investigador Postdoctoral. CIBERehd*
- **Antonio Olveira Martín.** *Facultativo Especialista de Área en Hepatología. Hospital Universitario La Paz*
- **Miriam Romero Portales.** *Facultativo Especialista de Área en Gastroenterología. Hospital Universitario La Pazz*

STRATEGIC OBJETIVES

- The research group conducted by Dr. García-Samaniego has extensive experience in the study of liver diseases, focusing its research activity, in both, clinical and basic aspects. In recent years the group has developed its activity preferentially in the study of viral hepatitis. The expertise areas of the research group are the study of infections caused by the hepatitis viruses [hepatitis viruses B (HBV), C (HCV) and delta (HDV)] and the chronic liver disease related to HBV, HCV and HDV at a time in which highly efficient antiviral systems against HBV, and especially against HCV has been developed.
- In addition to complete the research lines, the global strategy of the group will be focused in maintaining the high level of collaboration, both with CIBERehd research groups and with external groups, as well as to increase of the cooperation ways with private enterprise.

RESEARCH LINES

Main research lines:

- Study of the epidemiological situation and optimization of the cascade of care for patients with infection by the hepatitis delta virus (HDV). Project in collaboration with the Hospital Clinic of Barcelona and Infanta Leonor of Madrid, and funded by the HDV DESCRIBE program sponsored by Gilead Scientific, S.A.
- Development of HCV micro-elimination strategies through the optimization and implementation of HCV detection and quantification systems at diagnostic points.
- Analysis of the role of epigenetic modifications induced by infection by hepatotropic viruses in the evolution of liver disease and the development of liver cancer, before and after antiviral treatment. Project performed in collaboration with the Department of Biochemistry of the Faculty of Medicine of the UAM and the Virology laboratory of the Molecular Biology Center "Severo Ochoa".
- Study of liver fibrosis progression factors in patients with metabolic hepatic steatosis.

Alternative lines of work:

- Study of the role of the intestinal microbiota as a prognostic factor for adverse effects in biological cancer therapy. Project developed in collaboration with the Department of Biochemistry of the Faculty of Medicine of the UAM.
- Study of the influence of pre-existing liver disease on the evolution of COVID.

RESEARCH ACTIVITY

Doctoral Theses

- **Camblor Murube M.** Variantes de aurora quinasa B: nuevos biomarcadores predictivos de desarrollo de carcinoma hepatocelular en pacientes infectados con VHC, tratados con antivirales de acción directa[dissertation]. Madrid: Universidad Autónoma de Madrid: 2024(31/10/2024). Director: Madejón Seiz A

Publications

- **Ampuero J, Aller R, Gallego-Durán R, Crespo J, Calleja JL, García-Monzón C, Gómez-Camarero J, Caballería J, Lo Iacono O, Ibañez L, García-Samaniego J, Albillos A, Francés R, Fernández-Rodríguez C, Maya-Miles D, Diago M, Poca M, Andrade RJ, Latorre R, Jorquera F, Morillas RM, Escudero D, Hernández-Guerra M, Pareja-Megia MJ, Banales JM, Aspichueta P, Benlloch S, Rosales JM, Turnes J, Romero-Gómez M.** The biochemical pattern defines MASLD phenotypes linked to distinct histology and prognosis. J Gastroenterol. 2024; 59(7): 586-597. Article. IF: 5.5; Q1
- **Ampuero J, Lucena A, Berenguer M, Hernández-Guerra M, Molina E, Gómez-Camarero J, Valdivia C, Gómez E, Casado M, Álvarez-Navascuez C, Jorquera F, García-Buey L, Díaz-González A, Morillas R, García-Retortillo M, Sousa JM, Pérez-Medrano I, Simón MA, Martínez J, Arenas J, Londoño MC, Olveira A, Fernández-Rodríguez C.** Predictive factors for decompensating events in cirrhotic patients with primary biliary cholangitis under different lines of therapy. Hepatology. 2024; 80(4): 887-900. Article. IF: 15.8; D1
- **Brochado-Kith O, Rava M, Berenguer J, González-García J, Rojo D, Díez C, Hontañón V, Virseda-Berdices A, Ibáñez-Samaniego L, Llop-Herrera E, Olveira A, Pérez-Latorre L, Barbas C, Fernández-Rodríguez A, Resino S, Jiménez-Sousa MA.** Altered blood microbiome in patients with HCV-related Child-Pugh class B cirrhosis. J Infect Public Health. 2024; 17(10): 102524. Article. IF: 4.0; Q1
- **Colom J, Torrens M, Rodríguez-Cejas A, Aguilar I, Álvarez-Crespo R, Armenteros L, Ayala V, Cantero H, Casado MA, Crespo J, Estévez J, García-Samaniego J, Hernández-Guerra M, Mur C, Pérez-Bech E, Ricote M, Pineda JA.** Certification program of Addiction Centres for hepatitis C virus elimination in Spain. HepCelentes Project. Adicciones. 2024; 36(2): 129-44. Article. IF: 1.8; Q3
- **De Vincentis A, Ampuero J, Terracciani F, D'Amato D, Gerussi A, Cristoferi L, Cazzagon N, Bonaiuto E, Floreani A, Calvaruso V, Cadamuro L, Degasperi E, Morgando A, Vanni E, Lleo A, Colapietro F, Alvaro D, Castellaneta A, Labanca S, Viganò M, Distefano M, Palitti VP, Ricci C, De Matthaeis N, Marzioni M, Gómez-Domínguez E, Montero JL, Molina E, García-Buey L, Casado M, Berenguer M, Conde I, Simón MA, Fuentes J, Costa-Moreira P, Macedo G, Jorquera F, Morillas RM, Presa J, Sousa JM, Gomes D, Santos L, Olveira A, Hernández-Guerra M, Aburruza L, Santos A, Carvalho A, Uriz J, Gutierrez ML, Pérez E, Chessa L, Pellicelli A, Marignani M, Muratori L, Niro GA, Brunetto M, Ponziani FR, Pompili M, Marra F, Galli A, Mussetto A, Alagna G, Simone L, Bertino G, Rosina F, Cozzolongo R, Russello M, Baiocchi L, Saitta C, Terreni N, Zolfino T, Rigamonti C, Vigano R, Cuccorese G, Pozzoni P, Pedone C, Grasso S, Picardi A, Invernizzi P, Sacco R, Izzi A, Fernández-Rodriguez C, Vespasiani-Gentilucci U, Carbone M.** Development and Validation of a Scoring System to Predict Response to Obeticholic Acid in Primary Biliary Cholangitis. Clin Gastroenterol H. 2024; 22(10): 2062-74. Article. IF: 12.0; D1
- **Fernández C, Olveira A.** Letter: Metabolic Dysfunction-Associated Steatotic Liver Disease in Primary Biliary Cholangitis-Friend, Foe or Red Herring? Authors' Reply. Aliment Pharm Ther. 2024; 60(11-12): 1643-44. Letter. IF: 6.7; D1
- **Fernández-Rodríguez CM, Gutiérrez ML, Olveira A.** Editorial: Unravelling real-world impact of second-line therapies in primary biliary cholangitis-Time to change our targets? Authors' reply. Aliment Pharm Ther. 2024; 60(1): 91-2. Editorial Material. IF: 6.7; D1
- **Gómez E, Montero JL, Molina E, García-Buey L, Casado M, Fuentes J, Simón MA, Díaz-González A, Jorquera F, Morillas RM, Presa J, Berenguer M, Conde MI, Olveira A, Macedo G, Garrido I, Hernández-Guerra M, Olivas I, Rodríguez-Taje S, Londoño M, Sousa JM, Ampuero J, Romero-González E, González-Padilla S, Escudero-García D, Carvalho A, Santos A, Gutiérrez ML, Pérez-Fernández E, Aburruza L, Uriz J, Gomes D, Santos L, Martínez-González J, Albillos A, Fernández-Rodríguez CM.** Longitudinal outcomes of obeticholic acid therapy in ursodiol-nonresponsive primary biliary cholangitis: Stratifying the impact of add-on fibrates in real-world practice. Aliment Pharm Ther. 2024; 59(12): 1604-15. Article. IF: 6.7; D1
- **Hernández-Pérez M, Riado D, Pena E, Méndez C, Pinedo F, Ramos P, Castillo P, Romero M, Fernández-Rodríguez C, Olveira A.** The overlap with metabolic dysfunction-associated steatotic liver disease negatively affects outcomes of primary biliary cholangitis. Aliment Pharm Ther. 2024; 60(5): 613-9. Article. IF: 6.7; D1
- **Moragrega AB, Busca C, Apostolova N, Olveira A, Martin-Carbonero L, Valencia E, Moreno V, Bernardino JI, Abadia M, Gonzalez-García J, Esplugues JV, Montes ML, Blas-García A.** Rilpivirine Activates STAT1 in Non-Parenchymal Cells to Regulate Liver Injury in People Living with HIV and MASLD. Biomedicines. 2024; 12(7): 1454. Article. IF: 3.9; Q2
- **Olveira A, Jimenez V.** Hemophilia and hepatology, back to the future. Rev Esp Enferm Dig. 2024; 116(4): 179-81. Editorial Material. IF: 4.0; Q1
- **Razavi-Shearer DM, Buti M, Tacke F, Terrault NA, Zeuzem S, Abbas Z, Aghemo A, Akarca US, Al Masri NM, Alalwan AM, Blomé MA, Aleman S, Alghamdi AS, Alghamdi M, Alghamdi S, Al-Hamoudi WK, Ali E, Aljumah AA, Altraif IH, Amarsanaa J, Asselah T, Baatarkhuu O, Babameto A, Ben-Ari Z, Berg T, Biondi MJ, Braga WSM, Brandao-Mello CE, Brown RS , Brunetto MR, Cabezas J, Cardoso M, Chan HLY, Cheinquer H, Chen CJ, Chen PJ, Chien CH, Child H, Chuang WL, Garza LEC, Coco B, Coffin CS, Coppola N, Cornberg M, Craxi A, Crespo J, Cuko L, De Ledinghen V, Duberg AS, Etzion O, Ferraz MLG, Ferreira PRA, Forns X, Foster GR, Fung J, Gaeta GB, García-Samaniego J, Genov J, Gheorghe LS, Gholam PM, Gish RG, Glenn J, Goldis A, Hamid SS, Hercun J, Hsu YC, Hu CC, Huang JF, Idilman R, Jafri WSM, Janjua N, Jelev D, Jerkeman A, Jia JD, Kåberg M, Kaita KDE, Kao JH, Khan AG, Kim DY, Kondili LA, Lagging M, Lampertico P, Lázaro P, Lazarus J, Lee MH, Lim YS, Lobato CMO, Macedo G, Marinho RT, Marotta PJ, Martins A, Mendes-Correa MC, Méndez-Sánchez N, Navas MC, Ning Q, Örmeci N, Orrego M, Osiowy C, Pan CQ, Pessoa MG, Piracha ZZ, Pop C, Ramos JAP, Qureshi H, Raimondo G, Ramji A, Razavi-Shearer K, Ribeiro S, Ríos-Hincapié CY, Rodríguez M, Rosenberg WMC, Roulot D, Ryder SD, Saeed U, Safadi R, Sanai FM, Sánchez-Avila JF, Santantonio TA, Sarrazin C, Seto WK, Shouval D, Simonova MY, Tanaka J, Tergast TL, Tsendsuren O, Valente C, Villalobos-Salcedo JM, Voeller AS, Waheed Y, Wong GLH, Wong VWS, Wu JC, Yang H, Yip TCF, Yu ML, Yuen MF, Yurdaydin C, Zuckerman E, Razavi HA.** Adjusted estimate of the prevalence of hepatitis delta virus in 25 countries and territories. J Hepatol. 2024; 80(2): 232-42. Article. IF: 33.0; D1
- **Romero-Gutiérrez M, Alonso P, Berenguer M,**

Olveira A, González-Diéguez ML, Iruzubieta P, Masnou H, Delgado M, Hernández-Guerra M, Lorente S, Lázaro M, Moreno-Planas JM, Gonzalez C, Fernández-Alvarez P, Cuenca F, Gómez J, García-Villareal L, Rodríguez O, Mariño Z. Reproductive and pregnancy control in Wilson disease patients in Spain. Eur J Gastroen Hepat. 2024; 36(11): 1340-5. Article. IF: 1.8; Q3

- **Ruiz-Cobo JC, Llaneras J, Forns X, Moya AG, Amiel IC, Arencibia A, Diago M, García-Samaniego J, Castellote J, Llerena S, Rodriguez-Seguel E, Mateos B, Rodriguez M, Zabal JMR, Fernández I, Calleja JL, Morillas RM, Montoliu S, Andrade RJ, Aranda EB, Hernández-Guerra M, Mate CJ, Gonzalez-Santiago JM, de Cuenca B, Bernal-Monterde V, Delgado M, Turnes J, Lens S, Buti M.** Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir. Aliment Pharm Ther. 2024; 60(2): 201-11. Article. IF: 6.7; D1
- **Spigarelli IM, Pillado B, Vincent D, Poza J, Abadia M, Ruiz-Fernández G, Marin E, Castillo P, Polo B, Olveira A.** Low phospholipid-associated cholelithiasis syndrome, a not uncommon cause of biliary problems and hospital admissions. Rev Esp Enferm Dig. 2024; 116(10): 532-8. Article. IF: 4.0; Q1

Research projects

- **García-Samaniego Rey J.** Búsqueda activa de pacientes con hepatitis crónica viral (VHC Y VHD) no diagnosticada, en población general, desde los Centros de salud de la Comunidad de Madrid (2023.263). Gilead Sciences. 2022-2024. Managment centre: FIBHULP
- **García-Samaniego Rey J.** Estudio epidemiológico y molecular de la infección por vhd en una gran área urbana de España. Optimización de la cascada de atención (PI22/00849). ISCIII. 2023-2025. Managment centre: ISCIII
- **García-Samaniego Rey J.** Study of the epidemiological situation and optimization of the cascade of care for patients with infection by the hepatitis delta virus (HDV). HDV Describe (EHD22PE02). Gilead Sciences. 2023-2025. Managment centre: CIBER

Clinical trials

- **"García-Samaniego Rey J.** estudio fase ii, simple ciego, aleatorizado, controlado e internacional para evaluar la seguridad, reactogenicidad, eficacia y respuesta inmune tras el tratamiento secuencial con un oligonucleótido antisentido (aso) para la hepatitis b crónica (hbc) seguido de inmunoterapia dirigida contra la hepatitis b crónica (hbcit) en pacientes con hbc en tratamiento con análogos de nucleós(t)idos (an).
  Type/Phase: II
  Sponsored by: Glaxosmithkline S.A.
  Signature date: 13/06/2024"
- **"García-Samaniego Rey J.** multicentre, observational study in patients with liver cirrhosis who have been hospitalised for the first time for hepatic decompensation. Estudio multicéntrico y observacional en pacientes con cirrosis hepática que hayan sido hospitalizados por primera vez debido a descompensación hepática. rtx001-01s.
  Type/Phase: OTROS
  Sponsored by: Resolution Therapeutics Ltd.
  Signature date: 18/07/2024"
- **Olveira Martín A.** a phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated nonalcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (nash/mash) cirrhosis.
  Type/Phase: III
  Sponsored by: Boehringer Ingelheim International GMBH
  Signature date: 21/11/2024
- **Olveira Martín A.** a phase iiib randomised, parallel-group, double-blind, placebo-controlled, two-arm study to evaluate the effect of elafibranor 80 mg on normalisation of alkaline phosphatase in adult participants with primary biliary cholangitis (pbc) and inadequate response or intolerance to ursodeoxycholic acid.
  Type/Phase: IIIb
  Sponsored by: Ipsen Bioscience Inc.
  Signature date: 24/05/2024
- **Olveira Martín A.** a randomised, double-blind, placebo-controlled, multicentre, phase iii trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (nash/mash) and (f2) - (f3) stage of liver fibrosis.
  Type/Phase: IIIa
  Sponsored by: Boehringer Ingelheim International GMBH
  Signature date: 21/11/2024
- **Olveira Martín A.** ensayo de fase iii multicéntrico, aleatorizado, doble ciego, comparativo con placebo, de 48 semanas de duración, para evaluar la eficacia y la seguridad de survodutide administrada por vía subcutánea en participantes con sobrepeso u obesidad y esteatohepatitis no alcohólica (ehna) presunta o confirmada.
  Type/Phase: III
  Sponsored by: Boehringer Ingelheim International GMBH
  Signature date: 30/04/2024
- **Olveira Martín A.** estudio de fase 2a, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de efinopegdutida (mk-6024) en adultos con cirrosis compensada secundaria a esteatohepatitis asociada a disfunción metabólica.
  Type/Phase: IIa
  Sponsored by: Merck Sharp & Dohme Llc
  Signature date: 17/08/2024
- **Olveira Martín A.** estudio en fase ii, multicéntrico, con doble enmascaramiento, aleatorizado, comparado con placebo y de extensión a largo plazo sin enmascaramiento para evaluar la seguridad y la eficacia de elafibranor en participantes adultos con colangitis esclerosante primaria (cep).
  Type/Phase: II
  Sponsored by: Ipsen Bioscience Inc.
  Signature date: 13/03/2024
- **Olveira Martín A.** registro observacional de enfermedad y resultados clínicos de pacientes con deficiencia de lipasa ácida lisosomal (lal) (enfermedad de wolman y enfermedad por almacenamiento de ésteres de colesterol) y portadores del trastorno.
  Type/Phase: No EPA
  Sponsored by: Pharmaceuticals Inc.
  Signature date: 12/01/2024
- **Romero Portales M.** optimización de las exploraciones mediante vcte en el bazo con fibroscan.
  Type/Phase: PRODUCTO SANITARIO
  Sponsored by: Echosens S.A.
  Signature date: 02/05/2024

Patents and trademarks

- **Castán P, Gil-García AI, Madejón A, Sainz-Martínez E, Montoya JJ, Ouahid Younes, inventors; MIRNAX BIOSENS S.**L., assignee. Bivalent reverse primers Aplication number (EPO): 20382336.4-1118. 2020 April 24.
- **Madejón A; inventor; Agile Life Sciences LTD, assignee.** Kit and methods Aplication number: GB202010372.A. 2020 July 6.

3.4.12 Neuro-Cure*

Publications: 3 | **Q1:** 0

COMPOSITION

Javier Marco Martínez.
Gerente. Hospital de Emergencias Enfermera Isabel Zendal


- **Marina Arce Maurin.** *Enfermera. Hospital de Emergencias Enfermera Isabel Zendal*
- **Stefano Cabras.** *Catedrático de Universidad. Universidad Carlos III de Madrid*
- **Nazaret Casillas Ramos.** *Facultativo Especialista de Área en Medicina Interna. Hospital de Emergencias Enfermera Isabel Zendal*
- **María Eugenia Castellanos Nueda.** *Catedrática en el Deparamento de Informática y Estadística. Universidad Rey Juan Carlos*
- **Ana Elisabeth García Sipolis.** *Profesora Titular. Universidad Rey Juan Carlos*
- **Guillermo García Pérez de Sevilla.** *Fisioterapeuta. Universidad Europea de Madrid*
- **María García Sánchez.** *Enfermera. Hospital de Emergencias Enfermera Isabel Zendal*
- **Óscar Generoso Gutiérrez.** *Director de Tecnologías de la Información y Excelencia en Ventas. Universidad Rey Juan Carlos*
- **Antonio Martín Alonso.** *Facultativo Especialista de Área en Farmacia Hospitalaria. Hospital de Emergencias Enfermera Isabel Zendal*
- **María del Carmen Marcos Sastre.** *Directora Técnica Centro Especializado de Atención Diurna para pacientes ELA. Hospital de Emergencias Enfermera Isabel Zendal*
- **Enrique Muñoz de Maya.** *Enfermero. Hospital de Emergencias Enfermera Isabel Zendal*
- **Victoria Ruiz Parrado.** *Profesora Contratada Doctor Interino. Universidad Rey Juan Carlos*
- **Clara Simón de Blas.** *Profesora Titular. Universidad Rey Juan Carlos*
- **María Teresa Santos Martín.** *Profesora Titular. Universidad de Salamanca*
- **Natacha María Soto Vargas.** *Enfermera. Hospital de Emergencias Enfermera Isabel Zendal*
- **Ángela Trueba Vicente.** *Facultativo Especialista de Área en Medicina Interna. Hospital de Emergencias Enfermera Isabel Zendal*

STRATEGIC OBJETIVES


- To investigate issues related to the care and rehabilitation of neurological patients.
- Different lines of work will be generated seeking to encompass an interdisciplinary approach that includes technological advances as well as human and holistic strategies to improve the quality of life of neurological patients.

RESEARCH LINES

- Innovation in neurofunctional rehabilitation techniques: Design, implementation and evaluation of advanced therapies based on neuroplasticity; use of technology such as robotics, exoskeletons and virtual reality to enhance rehabilitation; development of personalized protocols for the recovery of motor and cognitive functions
- Comprehensive care for neurological patients: research on patient- and family-centered care models; study of the psychosocial impact of neurological care on patients and caregivers; development of tools to improve the quality of life of patients with neurodegenerative diseases
- Evaluation of assisted technologies and telemedicine: validation of assisted devices for home rehabilitation; implementation and evaluation of tele-rehabilitation and remote monitoring programs; study of the results of artificial intelligence in the prediction of clinical outcomes
- Palliative care in advanced neurological diseases: research on pain and non-motor symptom management strategies; design of interdisciplinary protocols for end-of-life care; analysis of the emotional and psychological impact on patients and their families
- Prevention and management of associated complications: study of strategies to prevent complications such as pressure ulcers, infections and thrombosis in neurological patients; development of programs for early detection of functional deterioration
- Personalized nutrition. design of individualized nutritional plans based on metabolic status and specific needs; study of the impact of specific supplementation on the recovery of cognitive and motor functions. research on dietary strategies to prevent dysphagia-related complications in patients with neurological damage; development of adapted food textures and formulas to optimize intake in patients with dysphagia; evaluation of diets in neurological recovery processes; study of the role of the intestinal microbiota in neurological function and its modulation through nutrition



*Group recently created, december 2024



3.5.Cancer and Human Molecular Genetics Area

Documents: 171 | **Originals:** 150 | **D1:** 42 | **Q1:** 94

Javier de Castro Carpeño
coordinadorcancer@idipaz.es

RESEARCH GROUPS

3.5.1 INGEMM - Instituto de Genética Médica y Molecular (Institute of Medical and Molecular Genetics)
Pablo Lapunzina Badía

3.5.2 Translational Oncology
Jaime Feliú Battle

3.5.3 Experimental Therapies and Biomarkers in Cancer
Javier de Castro Carpeño / Olga Vera Puente

3.5.4 Oto-Neurosurgery Research
Luis Lassaletta Atienza

3.5.5 Molecular Pathology of Cancer and Therapeutic Targets
David Hardisson Hernáez

3.5.6 Mechanisms of Tumour Progression
José Manuel González Sancho

3.5.7 Research and Diagnosis of Inherited Metabolic Diseases
María Belén Pérez González

3.5.8 Dyslipidemias of Genetic Origin and Metabolic Diseases
Sonia Rodríguez Novoa

3.5.9 Human Genetic Variability
Ana Fernández Santander

Strategic Objectives	Development forecast for the coming years:	Actions
Cancer and Medical Genetics area is made up of 10 groups and its objective is to deepen its knowledge in all aspects related to neoplastic disease, including the biology of the tumour, identification of therapeutic targets, development of new treatments, analysis of the efficacy of available treatments, identification of biomarkers and carrying out studies aimed at prevention and early diagnosis. In relation to human and molecular genetics, the aim is to identify genetic alterations related to human diseases in order to make an early diagnosis and prevent the development of pathologies.	Research in the area of cancer and genetics is expanding, both in terms of basic and translational research and in terms of clinical research. It is foreseeable that collaboration between groups in the area will continue to increase but also the collaboration with external organisations.	Facilitate the application request for European projects through the IdiPAZ Internalization Platform
	In order to facilitate its development, it will be necessary for the Institution to provide sufficient space and adequate common infrastructures	Support researchers to continue being a reference in the international area.
	It is foreseeable that this expansion will lead to the possibility of applying for European projects and leading consortiums, where once again the support of the Foundation will be essential for their application and management	Promote at international level the different research groups of the area, identifying possible synergies between groups and centers, new partners and funding sources, as well as to forge strategic alliances.

HIGH IMPACT PUBLICATIONS

Bustamante-Madrid P, Barbáchano A, Albandea-Rodríguez D, Rodríguez-Cobos J, Rodríguez-Salas N, Prieto I, Burgos A, de Villarreal JM, Real FX, González-Sancho JM, Larriba MJ, Lafarga M, Muñoz A, **Fernández-Barral A**. Vitamin D opposes multilineage cell differentiation induced by Notch inhibition and BMP4 pathway activation in human colon organoids. Cell Death Dis. 2024; 15(4): 301. Article. IF: 9,6; Q1

Mendiola M, Saarela J, Escudero FJ, Heredia-Soto V, Potdar S, Rodríguez-Marrero S, Miguel M, Pozo-Kreilinger JJ, Berjon A, Ortiz-Cruz E, Feliu J, **Redondo A**. Characterisation of new in vitro models and identification of potentially active drugs in angiosarcoma. Biomed Pharmacother. 2024; 173: 116397. Article. IF: 7,5; D1

Feliú J, Gámez-Pozo A, Martínez-Pérez D, Pérez-Wert P, Matamala-Luengo D, Viñal D, Kunz L, López-Vacas R, Dittmann A, Rodríguez-Salas N, Custodio A, Vara JAF, **Trilla-Fuertes L**. Functional proteomics of colon cancer Consensus Molecular Subtypes. Brit J Cancer. 2024; 130(10): 1670-8. Article. IF: 6,8; Q1

Villafuerte B, Carrasco-López C, Herranz A, Garzón L, Simón R, Natera-de-Benito D, Alikhani P, Tenorio J, Garcia-Santiago F, Solis M, del-Pozo A, Lapunzina P, Ortigoza-Escobar JD, Santisteban P, **Moreno JC**. A Novel Missense Variant in the NKX2-1 Homeodomain Prevents Transcriptional Rescue by TAZ. Thyroid. 2024; 34(7): 942-8. Article. IF: 6,7; Q1

Prior-de Castro C, Gallego MAM, Gómez-González C, Martín RD, Rodríguez-Antolín C, Rodríguez-Jiménez C, Mate AD, de Lucas EZ, Maiz MRD, Gómez CD, Batres SA, Sánchez MCP, **Torres RJ**. Molecular diagnosis of cystic fibrosis by RNA obtained from nasal epithelial cells. J Cyst Fibros. 2024; 23(4): 788-95. Article. IF: 6; Q1

Scientific Events by Cancer and Human Molecular Genetics

- **16/01/2024.** Cancer Next Generation: Hot topics, pending questions
- **25/01/2024.** INGEMM Session. Habilidades No Técnicas en el entorno sanitario
- **02/02/2024.** Scientific Seminar: Targeting cytokine signalling to block cancer-prompting inflammation and tumour progression
- **08/02/2024.** INGEMM Session: Single cell sequencing y su aplicación en el estudio de la diversidad celular en organismos no modelo
- **15/02/2024.** INGEMM Session: AFG is a novel oncogene in melanoma with therapeutic potential
- **22/02/2024.** INGEMM Session: Heterogeneidad clínica y diferentes fenotipos en pacientes con variantes en SETD2: 18 nuevos pacientes y revisión de la literatura
- **23/02/2024.** Scientific Seminar: En busca del caballo de Troya ideal para las terapias antitumorales
- **27/02/2024.** Curso de simulación en ecografía: E.B.O: Ecografía Básica para Oncólogos
- **29/02/2024.** INGEMM Session: Estrategias colaborativas en genética humana
- **07/03/2024.** NGEMM Session: Patología mitocondrial: dónde estamos
- **14/03/2024.** INGEMM Session: RNA-seq para diagnóstico de ER
- **21/03/2024.** INGEMM Session: Actualización síndrome Phelan-Mcdermid
- **04/04/2024.** INGEMM Session: Secuenciación de lecturas largas basada en nanoporos para mejorar caracterización genética de enfermedades raras
- **11/04/2024.** INGEMM Session: Genética de las malformaciones vasculares y mecanismos patogénico
- **18/04/2024.** INGEMM Session: Genética Clínica a propósito de un caso
- **09/05/2024.** INGEMM Sesión: Genética y genómica del feocromocitoma: pilares de la medicina personalizada
- **10/05/2024.** Scientific Seminar: Gene Therapy in Fanconi anemia: From lentiviral vestor to gene editing
- **16/05/2024.** INGEMM Session: Diagnóstico Prenatal No Invasivo de Aneuploidías (TPNI) en el Hospital 12 de Octubre
- **23/05/2024.** INGEMM Session: Manejo y utilidades del MinIon
- **30/05/2024.** INGEMM Session: Subtipos proteómicos del cáncer de vejiga músculo invasivo y su impacto en el tratamiento
- **06/06/2024.** INGEMM Session:
- **13/06/2024.** INGEMM Session: Integrando moléculas y semántica en el descubrimiento de estructuras funcionales en cáncer
- **14/06/2024.** Scientific Seminar: Deciphering microRNA control of B cell tolerance
- **20/06/2024.** INGEMM Session: Qué es y cómo funciona una unidad multidisciplinar: La UMDE
- **27/06/2024.** INGEMM Session: Caracterización del metiloma para el diagnóstico de tumores del sistema nervioso central
- **28/06/2024.** Scientific Seminar: Stress Kinases that control de link between and colon cancer

3.5.1 INGEMM - Instituto de Genética Médica y Molecular (Institute of Medical and Molecular Genetics)



Publications: 27 | **Q1:** 11

COMPOSITION

Pablo Daniel Lapunzina Badía.
Facultativo Especialista de Área en Genética. Hospital Universitario La Paz

- **Pedro Arias Lajara.** *Técnico de Laboratorio. Hospital Universitario La Paz*
- **Ángel Campos Barros.** *Investigador Senior (Contrato Miguel Servet- I2). Jefe de Laboratorio. FIBHULP*
- **Luis Fernández García-Moya.** *Biólogo. Hospital Universitario La Paz*
- **María Victoria Fernández Montaña.** *Técnico de Laboratorio. Hospital Universitario La Paz*
- **Fe Amalia García Santiago.** *Bióloga. Hospital Universitario La Paz*
- **Isabel Gómez Nieto.** *Técnico de Laboratorio. Hospital Universitario La Paz*
- **Karen Elise Heath.** *Investigadora Senior (Contrato Ramón y Cajal- I3). Jefe de Laboratorio. FIBHULP*
- **Juan Andrés Jiménez Estrada.** *Investigador Postdoctoral. FIBHULP*
- **Teresa López Timénez.** *Técnico de Laboratorio. Hospital Universitario La Paz*
- **Alicia Llorente Alonso.** *Técnico de Laboratorio. Hospital Universitario La Paz*
- **María Elena Mansilla Aparicio.** *Genetista. Hospital Universitario La Paz*
- **Pilar Martínez González.** *Bióloga. Hospital Universitario La Paz*
- **José Carlos Moreno Navarro.** *Facultativo Especialista de Área en Genética. Hospital Universitario La Paz*
- **Julián Nevado Blanco.** *Biólogo. Hospital Universitario La Paz*
- **María Palomares Bralo.** *Bióloga. Hospital Universitario La Paz*
- **Víctor Luis Ruiz Pérez.** *Investigador Cientifico de OPIs. Jefe de laboratorio. Instituto de Investigaciones Biomédicas Sols-Morreale*
- **Elena Vallespín García.** *Jefa de Grupo de la Sección de Ofalmogenética Molecular. Hospital Universitario La Paz*

STRATEGIC OBJETIVES

- This is a clinical and basic research team that conducts several lines of research into early diagnosis, disease mechanisms and new therapeutic strategies for genetic diseases, developmental disorders and congenital defects.
- It is a heterogeneous group consisting of physicians, pharmacists, molecular biologists, bioinformaticians, technicians and administrative officers.

RESEARCH LINES

- Subtelomeric rearrangements in patients with idiopathic mental retardation.
- Genetic and functional analysis of the SHOX and SHOX2 genes in human growth.
- Overgrowth syndromes. Clinical and molecular analysis.
- Genetic determinants of syndromic and non-syndromic proportional short stature
- Genetic detrerminants of disglycaemia: hypoglycaemia, diabetes mellitus and hyperinsulinism
- Genetic determinants of congenital hypopitutarism
- SNPs arrays in pharmacogenetics, HIV patients and genetic associations.
- CGHarrays and genomic rearrangements in patients with congenital malformations, intelectual disability and tumores.
- Molecular genetics of hypertrophic myocardiopathy.
- Functional analysis of CLCN1 mutations in congenital myotonia.
- Molecular study of endothelial dysfunction in diabetes and ageing.
- Molecular characterization of the 22q11.2 región by MLPA, microsatélites and FISH.
- Pharmacogenetics and pharcogenomics.
- Autosomal recessive osteogénesis imperfecta.
- Genomic tools for diagnosis: oligos and SNP arrays.
- Macrocephaly-capillary malformations and syndromes with macrocephaly.
- Next generation sequencing as a new tool in the diagnosis of genetic diseases.
- Classification and Ontolgies of Diseases
- Primary Pulmonary hypertension
- Análisis genómico global en el Síndrome de invdup(15) [idic(15) syndrome]
- Molecular characterization of inv dup del (8p) by Karyotype, SNP arrays and FISH

RESEARCH ACTIVITY

Doctoral Theses

- **Jiménez Estrada JA.** Caracterización de KDELR2 como un nuevo gen asociado a osteogénesis imperfecta y determinación de los mecanismos que lo relacionan con esta enfermedad[dissertation]. Madrid: Universidad Autónoma de Madrid: 2024(25/01/2024). Director: Ruiz Pérez VL, Flores Mauriz CL

Publications


- **Altunoglu U, Palencia-Campos A, Günes N, Turgut GT, Nevado J, Lapunzina P, Valencia M, Iturrate A, Otaify G, Elhossini R, Ashour A, Amin AK, Elnahas RF, Fernández-Nuñez E, Flores CL, Arias P, Tenorio J, Fernández CIC, Güven Y, Özsu E, Eklioglu BS, Ibarra-Ramírez M, Diness BR, Burnyte B, Ajmi H, Yüksel Z, Yildirim R, Ünal E, Abdalla E, Aglan M, Kayserili H, Tuysuz B, Ruiz-Pérez V.** Variant characterisation and clinical profile in a large cohort of patients with Ellis-van Creveld syndrome and a family with Weyers acrofacial dysostosis. J Med Genet. 2024; 61(7): 633-44. Article. IF: 3.7; Q2
- **Arroyuelo MC, Tenorio-Castaño J, García-Moya LF, Parra A, Cazalla M, Gallego N, Miranda L, Mori MA, García-Gueretta L, Labrandero C, Mansilla E, Rikeros E, García-Santiago F, Vallcorba I, Arias P, Silván C, Bronte LD, Nevado J, Lapunzina P.** Mortality in Patients with 22q11.2 Rearrangements. Genes (Basel). 2024; 15(9): 1146. Article. IF: 2.8; Q2
- **Baca MDP, Jacobs EZ, Vantomme L, Leblanc P, Bogaert E, Dheedene A, De Cock L, Haghshenas S, Foroutan A, Levy MA, Kerkhof J, Mcconkey H, Chen CA, Batzir NA, Wang X, Palomares M, Carels M, Dermaut B, Sadikovic B, Menten B, Yuan B, Vergult S, Callewaert B.** Haploinsufficiency of ZFHX3, encoding a key player in neuronal development, causes syndromic intellectual disability. Am J Hum Genet. 2024; 111(3): 509-28. Article. IF: 8.1; D1
- **Boonsawat P, Asadollahi R, Niedrist D, Steindl K, Begemann A, Joset P, Bhoj EJ, Li D, Zackai E, Vetro A, Barba C, Guerrini R, Whalen S, Keren B, Khan A, Jing D, Bralo MP, Orozco ER, Hao Q, Kristiansen BS, Zheng BX, Donnelly D, Clowes V, Zweier M, Papik M, Siegel G, Sabatino V, Mocera M, Horn AHC, Sticht H, Rauch A.** Deleterious ZNRF3 germline variants cause neurodevelopmental disorders with mirror brain phenotypes via domain-specific effects on Wnt/(3-catenin signaling. Am J Hum Genet. 2024; 111(9): 1994-2011. Article. IF: 8.1; D1
- **Candelo E, Giraldo-Ocampo S, Nevado J, Lapunzina P, Pachajoa H.** 2q31 microdeletion syndrome with the velocardiofacial phenotype and review of the literature: a case report. BMC Pediatr. 2024; 24(1): 641. Article. IF: 2.0; Q2
- **Carmona-Hidalgo B, Herrera-Ramos E, Rodríguez-López R, Nou-Fontanet L, Moreno JC, Blasco-Amaro JA, Léger J, Ortigoza-Escobar JD.** Systematic review of thyroid function in NKX2-1-related disorders: Treatment and follow-up. Plos One. 2024; 19(10): e0309064. Article. IF: 2.6; Q2
- **Carmona-Hidalgo B, Martín-Gómez C, Herrera-Ramos E, Rodríguez-López R, Fontanet LN, Moreno JC, Blasco-Amaro JA, Léger J, Dario-Ortigoza-Escobar J.** Systematic review of thyroid function in NKX2-1-related disorders: Screening and diagnosis. Plos One. 2024; 19(7): e0303880. Article. IF: 2.6; Q2
- **Casareto L, Appelman-Dijkstra NM, Brandi ML, Chapurlat R, Cormier-Daire V, Hamdy NAT, Heath KE, Horn J, Mantovani G, Mohnike K, Sousa SB, Travessa A, Wekre LL, Zillikens MC, Sangiorgi L.** ERN BOND: The key European network leveraging diagnosis, research, and treatment for rare bone conditions. Eur J Med Genet. 2024; 68: 104916. Article. IF: 1.7; Q3
- **Díaz-González F, Sentchordi-Montané L, Lucas-Castro E, Modamio-Hoybjor S, Heath KE.** Variants in both the N- or C-terminal domains of IHH lead to defective secretion causing short stature and skeletal defects. Eur J Endocrinol. 2024; 191(1): 38-46. Article. IF: 5.2; Q1
- **Diz-de Almeida S, Cruz R, Luchessi AD, Lorenzo-Salazar JM, de Heredia ML, Quintela I, González-Montelongo R, Nogueira Silbiger V, Porras MS, Tenorio Castaño JA, Nevado J, Aguado JM, Aguilar C, Aguilera-Albesa S, Almadana V, Almoguera B, Alvarez N, Andreu-Bernabeu Á, Arana-Arri E, Arango C, Arranz MJ, Artiga MJ, Baptista-Rosas RC, Barreda-Sánchez M, Belhassen-Garcia M, Bezerra JF, Bezerra MAC, Boix-Palop L, Brion M, Brugada R, Bustos M, Calderón EJ, Carbonell C, Castano L, Castelao JE, Conde-Vicente R, Cordero-Lorenzana ML, Cortes-Sanchez JL, Corton M, Darnaude MT, De Martino-Rodríguez A, Del Campo-Pérez V, de Bustamante AD, Domínguez-Garrido E, Eirós R, Fariñas MC, Fernandez-Nestosa MJ, Fernández-Robelo U, Fernández-Rodríguez A, Fernández-Villa T, Gago-Dominguez M, Gil-Fournier B, Gómez-Arrue J, Álvarez BG, Bernaldo de Quirós FG, González-Neira A, González-Peñas J, Gutiérrez-Bautista JF, Herrero MJ, Herrero-Gonzalez A, Jimenez-Sousa MA, Lattig MC, Borja AL, Lopez-Rodriguez R, Mancebo E, Martín-López C, Martín V, Martinez-Nieto O, Martinez-Lopez I, Martinez-Resendez MF, Martinez-Perez A, Mazzeu JF, Macías EM, Minguez P, Cuerda VM, Oliveira SF, Ortega-Paino E, Parellada M, Paz-Artal E, Santos NPC, Pérez-Matute P, Perez P, Pérez-Tomás ME, Perucho T,**

Pinsach-Abuin M, Pita G, Pompa-Mera EN, Porras-Hurtado GL, Pujol A, León SR, Resino S, Fernandes MR, Rodríguez-Ruiz E, Rodriguez-Artalejo F, Rodriguez-Garcia JA, Ruiz-Cabello F, Ruiz-Hornillos J, Ryan P, Soria JM, Souto JC, Tamayo E, Tamayo-Velasco A, Taracido-Fernandez JC, Teper A, Torres-Tobar L, Urioste M, Valencia-Ramos J, Yáñez Z, Zarate R, de Rojas I, Ruiz A, Sánchez P, Real LM; SCOURGE Cohort Group; Guillen-Navarro E, Ayuso C, Parra E, Riancho JA, Rojas-Martinez A, Flores C, Lapunzina P, Carracedo Á. Novel risk loci for COVID-19 hospitalization among admixed American populations. Elife. 2024; 13: RP93666. Article. Not Indexed

- **Doncel SS, Peláez RG, Lapunzina P, Corrales-Medina FF, Mosquera GAD, Bonanad S, Cortes JM, Cazalla M, Gallego N, Querol-Giner F, Tenorio J, Guerrero JAL.** Comprehensive Screening of Genetic Variants in the Coding Region of F8 in Severe Hemophilia A Reveals a Relationship with Disease Severity in a Colombian Cohort. Life (Basel). 2024; 14(8): 1041. Article. IF: 3.4; Q1
- **Esteban ME, Pino D, Romero-Lorca A, Novillo A, Gaibar M, Riancho JA, Rojas-Martínez A, Flores C, Lapunzina P, Carracedo A, Athanasiadis G, Fernández-Santander A.** Worldwide distribution of genetic factors related to severity of COVID-19 infection. Ann Hum Biol. 2024; 51(1): 2366248. Article. IF: 1.3; Q4
- **Freud LR, Galloway S, Crowley B, Moldenhauer J, Swillen A, Breckpot J, Borrell A, Vora NL, Cuneo B, Hoffman H, Gilbert L, Nowakowska B, Geremek M, Kutkowska-Kazmierczak A, Vermeesch JR, Devriendt K, Busa T, Sigaudy S, Vigneswaran T, Simpson JM, Dungan J, Gotteiner N, Gloning KP, Digilio MC, Unolt M, Putotto C, Marino B, Repetto G, Fadic M, Garcia-Minaur S, Buil AA, Thomas MA, Fruitman D, Beecroft T, Hui PW, Oskarsdottir S, Bradshaw R, Criebaum A, Norton ME, Lee TFY, Geiger M, Dunnington L, Isaac J, -Haug LW, Hunter L, Izzi C, Toscano M, Ghi T, Mcglynn J, Grati FR, Emanuel BS, Gaiser K, Gaynor W, Goldmuntz E, Mcginn DE, Schindewolf E, Tran O, Zackai EH, Yan Q, Bassett AS, Wapner R, McDonald-McGinn DM.** Prenatal vs postnatal diagnosis of 22q11.2 deletion syndrome: cardiac and noncardiac outcomes through 1 year of age. Am J Obstet Gynecol. 2024; 230(3): 368.e1-12. Article. IF: 8.4; D1
- **Ji CX, Zonias D, Djumaeva N, Cheng RC, Salim K, Alikhani P, Oyelade T, Moore KP, Moreno JC, Mani AR.** Identification and determination of the urinary metabolite of iodotyrosine in vivo. Biochem Bioph Res Co. 2024; 735: 150854. Article. IF: 2.2; Q3
- **Lacombe D, Bloch-Zupan A, Bredrup C, Cooper EB, Houge SD, García-Miñaúr S, Kayserili H, Larizza L, Gonzalez VL, Menke LA, Milani D, Saettini F, Stevens CA, Tooke L, van der Zee JA, Van Genderen MM, Van-Gils J, Waite J, Adrien JL, Bartsch O, Bitoun P, Bouts AHM, Cueto-González AM, Dominguez-Garrido E, Duijkers FA, Fergelot P, Halstead E, Huisman SA, Meossi C, Mullins J, Nikkel SM, Oliver C, Prada E, Rei A, Riddle I, Rodríguez-Fonseca C, Pena RR, Russell J, Saba A, Santos-Simarro F, Simpson BN, Smith DF, Stevens MF, Szakszon K, Taupiac E, Totaro N, Palafoll IV, van der Kaay DCM, Van Wijk MP, Vyshka K, Wiley S, Hennekam RC.** Diagnosis and management in Rubinstein-Taybi syndrome: first international consensus statement. J Med Genet. 2024; 61(6): 503-19. Review. IF: 3.7; Q2
- **Li D, Wang Q, Bayat A, Battig MR, Zhou YJ, Bosch DGM, van Haaften G, Granger L, Petersen AK, Pérez-Jurado LA, Aznar-Laín G, Aneja A, Hancarova M, Bendova S, Schwarz M, Pourova RK, Sedlacek Z, Keena BA, March ME, Hou CP, O'Connor N, Bhoj EJ, Harr MH, Lemire G, Boycott KM, Towne M, Li M, Tarnopolsky M, Brady L, Parker MJ, Faghfoury H, Parsley LK, Agolini E, Dentici ML, Novelli A, Wright M, Palmquist R, Lai K, Scala M, Striano P, Iacomino M, Zara F, Cooper A, Maarup TJ, Byler M, Lebel RR, Balci TB, Louie R, Lyons M, Douglas J, Nowak C, Afenjar A, Hoyer J, Keren B, Maas SM, Motazacker MM, Martínez-Agosto JA, Rabani AM, McCormick EM, Falk MJ, Ruggiero SM, Helbig I, Moller RS, Tessarollo L, Ardori FT, Palko ME, Hsieh TC, Krawitz PM, Ganapathi M, Gelb BD, Jobanputra V, Wilson A, Greally J, Jacquemont S, Jizi K, Bruel AL, Quelin C, Misra VK, Chick E, Romano C, Greco D, Arena A, Morleo M, Nigro V, Seyama R, Uchiyama Y, Matsumoto N, Taira R, Tashiro K, Sakai Y, Yigit G, Wollnik B, Wagner M, Kutsche B, Hurst ACE, Thompson ML, Schmidt R, Randolph L, Spillmann RC, Shashi V, Higginbotham EJ, Cordeiro D, Carnevale A, Costain G, Khan T, Funalot B, Mau-Them FT, Moya LFG, García-Miñaúr S, Osmond M, Chad L, Quercia N, Carrasco D, Li CM, Sánchez-Valle A, Kelley M, Nizon M, Jensson BO, Sulem P, Stefansson K, Gorokhova S, Busa T, Rio M, Habdallah HH, Lesieur-Sebellin M, Amiel J, Pingault V, Mercier S, Vincent M, Philippe C, Fatus-Fauconnier C, Friend K, Halligan RK, Biswas S, Rosser J, Shoubridge C, Corbett M, Barnett C, Gecz J, Leppig K, Slavotinek A, Marcelis C, Pfundt R, de Vries BBA, van Slegtenhorst MA, Brooks AS, Cogne B, Rambaud T, Tümer Z, Zackai EH, Akizu N, Song YQ, Hakonarson H.** Spliceosome malfunction causes neurodevelopmental disorders with overlapping features. J Clin Invest. 2024; 134(1): e171235. Article. IF: 13.6; D1
- **Lucia-Campos C, Parenti I, Latorre-Pellicer A, Gil-Salvador M, Bestetti I, Finelli P, Larizza L, Arnedo M, Ayerza-Casas A, Del Rincón J, Trujillano L, Morte B, Pérez-Jurado LA, Lapunzina P, Leitao E, Beygo J, Lich C, Kilpert F, Kaya S, Depienne C, Kaiser FJ, Ramos FJ, Puisac B, Pié J.** An intragenic duplication in the AFF2 gene associated with Cornelia de Lange syndrome phenotype. Front Genet . 2024; 15: 1472543. Article. IF: 2.8; Q2
- **Mackay DJG, Gazdagh G, Monk D, Brioude F, Giabicani E, Krzyzewska IM, Kalish JM, Maas SM, Kagami M, Beygo J, Kahre T, Tenorio-Castano J, Ambrozaityte L, Burnyte B, Cerrato F, Davies JH, Ferrero GB, Fjodorova O, Manero-Azua A, Pereda A, Russo S, Tannorella P, Temple KI, Ounap K, Riccio A, de Nanclares GP, Maher ER, Lapunzina P, Netchine I, Eggermann T, Bliek J, Tümer Z.** Multi-locus imprinting disturbance (MLID): interim joint statement for clinical and molecular diagnosis. Clin Epigenetics. 2024; 16(1): 99. Review. IF: 4.4; Q1
- **Nisbet AF, Viswanathan A, George AM, Arias P, Klein SD, Nevado J, Parra A, Pascual P, Romeo DJ, Tenorio-Castaño J, Taylor JA, Zackai EH, Lapunzina P, Kalish JM.** Phenotypic spectrum and tumor risk in Simpson-Golabi-Behmel syndrome: Case series and comprehensive literature review. Am J Med Genet A. 2024; 194(12): e63840. Article. IF: 1.7; Q3
- **Palma-Milla C, Prat-Planas A, Soengas-Gonda E, Centeno-Pla M, Sánchez-Pozo J, Lazaro-Rodríguez I, Quesada-Espinosa JF, Arteche-López A, Olival J, Pacio-Miguez M, Palomares-Bralo M, Santos-Simarro F, Cancho-Candela R, Vázquez-López M, Seidel V, Martínez-Monseny AF, Casas-Alba D, Grinberg D, Balcells S, Serrano M, Rabionet R, Martin MA, Urreizti R.** Expanding the Phenotypic Spectrum of TRAF7-Related Cardiac, Facial, and Digital Anomalies With Developmental Delay: Report of 11 New Cases and Literature Review. Pediatr Neurol. 2024; 155: 8-17. Review. IF: 2.1; Q1
- **Parra A, Tenorio-Castano J, Nevado J, Cazalla M, Miranda-Alcaraz L, Gallego-Zazo N, Silván C, Arias P, Pozo-Román J, Ballesta-Martínez MJ, Guillén-Navarro E, Arroyo I, Lotersztein V, Cosentino V, González-Meneses A, Galán E, Rosell J, Ramos F, Lapunzina P.** Identification of copy-number variants in patients with overgrowth disorders. Clin Genet. 2024; 106(5): 614-24. Article. IF: 2.3; Q3
- **Pérez-Jurado LA, Cáceres A, Balagué-Dobón L, Esko T, de Heredia ML, Quintela I, Cruz R, Lapunzina P, Carracedo A, Abellán J, Acosta-Isaac R, Aguado JM, Aguilar C, Aguilera-Albesa S, Sabbagh AA, Alba J, Albu S, Alcalá-Gallardo KAM, Alcoba-Florez J, Batres SA, Algarin-Lara HR, Almadana V, Medeiros KA, Almeida J, Almoguera B, Alonso MR, Alvarez N, Walther RAS, Alvarez-Benítez Y, Alvarez-Navia F, dos Santos KA, Andreu-Bernabeu A, Antonijoan MR, Martínez-Aquino E, Arana-Arri E, Aranda C, Arango C, Araque C, Araujo NK,**

Arcanjo AC, Arnaiz A, Fernández FA, Arranz MJ, López JRA, Artiga MJ, Avello-Malaver Y, Ayuso C, Martín BB, Baptista-Rosas RC, Baldion AM, Barranco-Díaz A, Barreda-Sánchez M, Barrera-Penagos V, Belhassen-Garcia M, Bernal-Bello D, Bernal E, Bezerra JF, Bezerra MAC, Blanca-López N, Blancas R, Boix-Palop L, Borobia A, Bravo E, Brion M, Brochado-Kith O, Brugada R, Bustos M, Cabello A, Cáceres A, Cáceres-Agra JJ, Calbo E, Calderón EJ, Camacho S, Ceballos FC, Cañadas Y, Carbonell C, Cardona-Huerta S, Abad MSC, Segura CC, Carrillo-Avila JA, Campos MC, Casasnovas C, Castaño L, Castaño CF, Castelao JE, Candalija AC, Castillo MA, Chaves-Santiago WG, Chiquillo-Gómez S, Cid-López MA, Cienfuegos-Jiménez O, Conde-Vicente R, Cunha GCR, Cordero-Lorenzana ML, Corella D, Corrales A, Cortés-Sánchez JL, Corton M, Souza KSC, Silva FTC, Cruz R, Cuesta L, Tavares NAC, Carvalho MCC, Dalmau D, Dantas-Komatsu RCS, Darnaude MT, de Andrés R, de Juan C, Troca JJD, de la Horra C, de la Hoz AB, De Martino-Rodríguez A, Cruz MS, Neri JLDA, del Campo-Pérez V, Delgado-Cuesta J, de Bustamante AD, Díaz-Pérez A, Dietl B, Diz-de Almeida S, Alves MD, Domínguez-Garrido E, Rosa LS, Luchessi AD, Echave-Sustaeta J, Eiros R, Enciso-Olivera CO, Escudero G, España PP, Sanabria GE, Fariñas MC, Fernández R, Fernández-Caballero L, Fernández-Cruz A, Fernández-Ferrero S, Martínez YF, Fernández-Nestosa MJ, Fernández-Robelo U, Fernández-Rodríguez A, Fernández-Sampedro M, Fernández R, Fernández-Villa T, Fernández-Capitán C, Carioca AAF, Flores-Pérez P, Fuenmayor-Hernández L, Fuertes-Núñez M, Fumadó V, Gadea I, Gagliardi L, Gago-Domínguez M, Gallego N, Galoppo C, García-Soidán A, García-Cerrada C, García-de-Vicuña A, Garcia-García J, García-García I, García-Ibarbia C, García-Montero AC, García L, García M, Torrejón MCG, García I, García-Vázquez E, Garza-Frias E, Gentile A, Gil-Fournier B, de Araújo JNG, Gómez-Duque M, Gómez-Arrue J, Carrera LG, García MG, Sacristán AG, González JR, González-Neira A, Alvarez BG, de Quirós FGB, González-Montelongo R, González-Peñas J, Gonzalez-Sagrado M, Gonzalo-Benito H, Gorgojo-Galindo O, Górgolas M, Guaragna F, Chaux JG, Guillén-Navarro E, Guillén-Guío B, Guisado-Vasco P, Gutiérrez-Castañeda LD, Gutiérrez-Bautista JF, Heili-Frades S, Jacomo RH, Hernández E, Hernández-Moro C, Hernández-Ortega LD, Hernández-Pérez G, Hernández-Vaquero R, Herráez B, Herranz MT, Herrera M, Herrero MJ, Herrero-González A, Horcajada JP, Imaz-Ayo N, Intxausti-Urrutibeaskoa M, Iñigo-Campos A, Iñiguez M, Jara R, Jiménez A, Jiménez-Alfaro I, Jiménez P, Jiménez-Sousa MA, Jordan I, Laguna-Goya R, Laorden D, Lasa-Lázaro M, Lattig MC, Lauriente A, Borja AL, Llanos L, López-Bernus A, de Heredia ML, López-Garcia E, López-Granados E, López-Rodríguez R, López-Ruz MA, Lorente L, Lorenzo-Salazar J, Lozano JE, Lozano-Espinosa M, Mahillo I, Mancebo E, Mar C, Calvo CM, Marcos-Delgado A, Marcos M, Marín-Candón A, Mariscal-Aguilar P, Martin-Pedraza L, Martin-Fernández M, Martín-López C, Martín-Oterino JA, Martín MD, Martín V, Martín MM, Martín-Vicente M, Martínez A, Martínez-González O, Martínez R, Martínez-Paz P, Díaz-Caneja CM, Martínez-Nieto O, Martínez-López I, Martínez-Reséndez MF, Martínez S, Martínez JJ, Martínez-Pérez A, Martínez-Ramas A, Martínez-Robles V, Marzal L, Mazzeu JF, Medrano FJ, Meijome XM, Mejuto-Montero N, Mendes I, Duarte AL, Méndez-Echevarría A, Charris HM, Macías EM, Mercadillo F, Mercado-Sesma AR, Mínguez P, Molina-Roldán E, Molina AJ, Montoya JJ, Pinho SMT, Moreira-Escriche P, Morelos-Arnedo X, Moreno R, Cuerda VM, Moreno-Docón A, Moreno-Escalante J, Fernández AM, Garcia PM, Neira P, Nevado J, Nieto-Gañán I, Silbiger VN, Nuñez-Torres R, Obrador-Hevia A, Ocejo-Vinyals JG, Virginia O, Oliveira SF, Ondo L, Orfao A, Ortega-Paino E, Ortega L, Ortiz-López R, Ortiz-Flores F, Oteo JA, Pacheco M, Pacheco-Miranda FJ, Padilla-Conejo I, Panadero-Fajardo S, Parellada M, Pariente-Rodríguez R, Friaza V, Paz-Artal E, Peces-Barba G, Kus MSP, Perales C, Santos NPC, Guegel GP, Pérez MJ, Pérez A, Pérez-Matute P, Pérez C, Pérez-de-Nanclares G, Pérez-García F, Pérez P, Pérez-Jurado LA, Pérez-Tomás ME, Perucho T, Pichardo LA, Ribeiro AP, Pinsach-Abuin ML, Pinzón LA, Medeiros JFP, Pita G, Pla-Juncà F, Planas-Serra L, Pompa-Mera EN, Porras-Hurtado GL, Pujol A, Quevedo-Chávez ME, Quijada MA, Quintela I, Ramiro-León S, Sedes PR, Nunes JFR, Recalde D, Recio-Fernández E, Resino S, Sousa RR, Rivadeneira-Chamorro CS, Roa-Agudelo D, Pardo MR, Fernandes MR, Rodríguez-Hernández MA, Rodríguez-Palmero A, Rodríguez-Ruiz E, Rodríguez MJ, Rodríguez-Artalejo F, Rodríguez-Ferrer M, Rodríguez-Gallego C, Rodríguez-García JA, Maya BR, Rodríguez-Nicolas A, Rodríguez-Novoa GE, Rodríguez-Urrego PA, Rojo F, Romero-Coronado A, Morilla R, Rondón-García F, Rosales-Castillo A, Rubio C, Olivera MR, Ruiz-Cabello F, Ruiz-Casares E, Ruiz-Cubillan JJ, Ruiz-Hornillos J, Ruiz M, Ryan P, Salamanca HD, Salazar-García L, Salgueiro-Origlia GG, Sangil A, Sánchez-Pernaute O, Sánchez PL, López AJS, Sánchez-Pablo C, Sánchez-Prados MC, Sánchez-Real J, Sánchez-Redondo J, Sancho-Sainz C, Sande E, Santos A, Schlüter A, Segovia S, Serra-Llovich A, Sevil-Puras F, Sevilla-Porras M, Sicolo MA, Silván-Fuentes C, Moraes VMS, Souza VS, Solé-Violán J, Soria JM, Sorlí JV, Silva NS, Souto JC, Sprockel JJ, Suárez-Rama JJ, Suárez-Zamora DA, Taboada-Fraga X, Tamayo E, Tamayo-Velasco A, Taracido-Fernández JC, Vasconcelos RHT, Tellería C, Carratto TMT, Tenorio-Castano JA, Teper A, Araujo IMT, Torres-Macho J, Torres-Tobar L, Torres-Gutiérrez RP, Troya J, Urioste M, Valencia-Ramos J, Valido A, Vargas-Gallo JP, Varón B, Vega T, Velasco-Quirce S, Vélez-Santamaría V, Víctor V, Vidán-Estévez J, Silva GV, Vieitez-Santiago M, Vilches C, Villalobos L, Villar F, Villar-Garcia J, Villaverde C, Villoslada-Blanco P, Virseda-Berdices A, Costa TX, Yáñez Z, Zapatero-Gaviria A, Zarate R, Zazo S, Flores C, Riancho JA, Rojas-Martínez A, Lapunzina P, Carracedo A, González JR. Clonal chromosomal mosaicism and loss of chromosome Y in elderly men increase vulnerability for SARS-CoV-2. Commun Biol. 2024; 7(1): 202. Article. IF: 5.1; D1

- **Rybak-Krzyszkowska M, Madetko-Talowska A, Szewczyk K, Bik-Multanowski M, Sakowicz A, Stejskal D, Trková M, Smetanová D, Serafim S, Correia H, Nevado J, Mori MA, Mansilla E, Rutkowska L, Kucinska A, Gach A, Huras H, Kolak M, Srebniak MI.** Is Nuchal Translucency of 3.0-3.4 mm an Indication for cfDNA Testing or Microarray? - A Multicenter Retrospective Clinical Cohort Study. Fetal Diagn Ther. 2024; 51(5): 453-62. Article. IF: 1.6; Q3
- **Tenorio-Castano J, Aparicio EM, Santiago FAG, Klotz CM, Regojo RM, Anguita E, Ryan E, Juusola J, Herrero B, Arias P, Parra A, Pascual P, Gallego N, Cazalla M, Rodríguez-González R, Antolín E, Nevado J, Ruiz-Perez VL, Lapunzina P.** Non-immune hydrops fetalis is associated with bi-allelic pathogenic variants in the MYB Binding Protein 1a (MYBBP1A) gene. Clin Genet. 2024; 106(6): 713-20. Article. IF: 2.3; Q3
- **van der Laan L, Lauffer P, Rooney K, Silva A, Haghshenas S, Relator R, Levy MA, Trajkova S, Huisman SA, Bijlsma EK, Kleefstra T, van Bon BW, BaysalÖ, Zweier C, Palomares-Bralo M, Fischer J, Szakszon K, Faivre L, Piton A, Mesman S, Hochstenbach R, Elting MW, van Hagen JM, Plomp AS, Mannens MMAM, Alders M, van Haelst MM, Ferrero GB, Brusco A, Henneman P, Sweetser DA, Sadikovic B, Vitobello A, Menke LA.** DNA methylation episignature and comparative epigenomic profiling for Pitt-Hopkins syndrome caused by TCF4 variants. 0. 2024; 5(3): 100289. Article. IF: 3.6; Q2
- **Villafuerte B, Carrasco-López C, Herranz A, Garzón L, Simón R, Natera-de-Benito D, Alikhani P, Tenorio J, Garcia-Santiago F, Solis M, del-Pozo A, Lapunzina P, Ortigoza-Escobar JD, Santisteban P, Moreno JC.** A Novel Missense Variant in the NKX2-1 Homeodomain



Prevents Transcriptional Rescue by TAZ. Thyroid. 2024; 34(7): 942-8. Article. IF: 6.7; Q1

- **Vong KI, Lee S, Au KS, Crowley TB, Capra V, Martino J, Haller M, Araújo C, Machado HR, George R, Gerding B, James KN, Stanley V, Jiang N, Alu K, Meave N, Nidhiry AS, Jiwani F, Tang IS, Nisal A, Jhamb I, Patel A, Patel A, McEvoy-Venneri J, Barrows C, Shen CLA, Ha YJ, Howarth R, Strain M, Ashley-Koch AE, Azam M, Mumtaz S, Bot GM, Finnell RH, Kibar Z, Marwan AI, Melikishvili G, Meltzer HS, Mutchinick OM, Stevenson DA, Mroczkowski HJ, Ostrander B, Schindewolf E, Moldenhauer J, Zackai EH, Emanuel BS, Garcia-Minaur S, Nowakowska BA, Stevenson RE, Zaki MS, Northrup H, McNamara HK, Aldinger KA, Phelps IG, Deng M, Glass IA, Koch AEA, Le J, Lupo PJ, Magana T, Marwan A, Yurrita A, Zaki MS, Medina-Bereciartu JR, Kolvenbach CM, Shril S, Hildebrandt F, Noureldeen MM, Salem AM, Takahashi Y, Salimi-Dafsari H, Phillips HW, Hanak B, Kara B, Günes AS, Gonda DD, Kirmani S, Tkemaladze T, Morrow B, McDonald-McGinn DM, Sanna-Cherchi S, Lamb DJ, Gleeson JG.** Risk of meningomyelocele mediated by the common 22q11.2 deletion. Science. 2024; 384(6695): 584-90. Article. IF: 45.8; D1

Research projects

- **Heath KE.** Análisis genético y funcional de las displasias esqueléticas (PID2020-116263RB-100). Ministerio de Ciencia e Innovación. 2021-2025. Managment centre: FIBHULP
- **Heath KE.** Estudio comprensivo de la genetica de las displasias esqueleticas: 1) caracterización de la regulación de shox en la placa de crecimiento humano, y 2) analisis genetico de las displasias esqueleticas mediante acgh y ngs. Biomarin International Limited. 2012-Ongoing. Managment centre: FIBHULP
- **Heath KE.** Estudio comprensivo de la genetica de las displasias esqueleticas: 1) caracterización de la regulación de shox en la placa de crecimiento humano, y 2) analisis genetico de las displasias esqueleticas mediante acgh y ngs. EU. 2023-2027. Managment centre: FIBHULP
- **Lapunzina Badía PD.** ONTOPREC. Implementación de Ontologías, taxonomías y estandarización de las enfermedades crónicas en Medicina de Precisión. Uso de los escores de riesgo poligénicos (PRS) como casos de uso. (PMP21/00063). ISCIII. 2021-2025. Managment centre: FIBHULP
- **Lapunzina Badía PD.** An omnigenic view of genetic susceptibility to severe covid19. Fundació Marató TV3. 2021-Ongoing. Managment centre: FIBHULP
- **Lapunzina Badía PD.** Análisis genético y genómico en pacientes afectados por la enfermedad de gorham-stout y por anomalías generales. Lymphatic Malformation Institute. 2012-Ongoing. Managment centre: FIBHULP
- **Lapunzina Badía PD.** Análisis genómico global en el síndrome de invdup 15 syndrome: evaluación de la dosis genómica mediante microarrays personalizados de snps y estudio de genes candidatos del fenotipo. Fundación Inversión Duplicación del Cromosoma 15. 2017-Ongoing. Managment centre: FIBHULP
- **Lapunzina Badía PD.** Análisis genómico global en el síndrome de invdupdel 8p: evaluación de la dosis genómica mediante microarrays personalizados de snps y estudio de genes candidatos del fenotipo. Asociación Síndrome Duplicidada, Inversión, Deleción del Brazo Corto del Cromosoma 8. 2015-Ongoing. Managment centre: FIBHULP
- **Lapunzina Badía PD.** Analisis genomico y funcional de una variante patogenica en el gen klhl11 en 6 miembros de una familia sin diagnostico. Fundación Feder. 2022-Ongoing. Managment centre: FIBHULP
- **Lapunzina Badía PD.** Aplicación de técnicas genómicas (genoma completo y 4C-Seq para TDA) en pacientes con síndromes de sobrecrecimiento (PI20/01053). ISCIII. 2021-2024. Managment centre: FIBHULP
- **Lapunzina Badía PD.** Busqueda de mutaciones en el gen cripak y otros modificadores en pacientes con hipertension arterial pulmonar. Fundación Contra la Hipertension Pulmonar. 2018-Ongoing. Managment centre: FIBHULP
- **Lapunzina Badía PD.** Craniofacial microsomia> genetic causes and pathway discovery. Seattle Children-S Hospital Research Foundation. 2017-Ongoing. Managment centre: FIBHULP
- **Lapunzina Badía PD.** Dinamización de ciencia disruptiva en predictores de enfermedades tumorales, infecciosas y hereditarias como base de la medicina personalizada (FORT23/00006_GRUPO I). ISCIII. 2024-2028. Managment centre: FIBHULP
- **Lapunzina Badía PD.** Estudio clínico molecular en pacientes con síndrome de sobrecrecimiento. Estudio de los genes nsd1, nizp1, hras, cdkn1c, glp3, y de las regiones cromosómicas 5q35, xq26 y 11p en pacientes con ssc. Effice Servicios Para La Investigacion S.L. 2005-Ongoing. Managment centre: FIBHULP
- **Lapunzina Badía PD.** Estudio genético-molecular de genes candidatos en pacientes con hipertensión pulmonar idiopática. Actelion Pharmaceuticals España. 2011-Ongoing. Managment centre: FIBHULP
- **Lapunzina Badía PD.** Evaluación genomica en el sindrome de wolf-hirschhorn [sindrome 4p]: microarrays personalizados de snps y estudio de genes candidatos. Asociación Española del Síndrome de Wolf Hirschhom. 2017-Ongoing. Managment centre: FIBHULP
- **Lapunzina Badía PD.** Evaluación psicomética en pacientes con síndrome de phelan-m dermid síndrome de microdelección 22q13. Oryzon Genomics S.A. 2020-Ongoing. Managment centre: FIBHULP
- **Lapunzina Badía PD.** Inteligencia artificial y machine learning en enfermedades humanas. Fundación Ramón Areces. 2019-Ongoing. Managment centre: FIBHULP
- **Lapunzina Badía PD.** PRivacy-prOTecting Environment for Child Transplants health-related and genomic data integration in the European Reference Network. EU. 2024-2028. Managment centre: FIBHULP
- **Lapunzina Badía PD.** Screening of high-risk pediatric population using an epilepsy gene panel for early diagnosis of neuronal ceroid lipofuscinosis type 2 (cln2) disease. Biomarin International Limited. 2017-Ongoing. Managment centre: FIBHULP
- **Martínez González VM.** En busqueda del diagnostico genetico en pacientes con espectro pros. Fundación La Caixa. 2019-Ongoing. Managment centre: FIBHULP
- **Moreno Navarro JC.** Biomarcadores de disrupción tiroidea gestacional y daño cerebral fetal en el ratón KO para DEHAL1 y en mujeres embarazadas y sus hijos (PI22/01375). ISCIII. 2023-2025. Managment centre: FIBHULP
- **Moreno Navarro JC.** Disección genética de

la narcolepsia y otras hipersomnias centrales. Francisco Jose Garcia Sanpedro. 2019-Ongoing. Managment centre: FIBHULP

- **Moreno Navarro JC.** Síndrome de restistencia a las hormonas tiroideas. estudio genético-molecular en población española. José Carlos Moreno Navarro. 2013-Ongoing. Managment centre: FIBHULP
- **Nevado Blanco J.** Aproximación genómica en el síndrome de phelan mcdermid [sindrome de microdeleción 22q13]: microarrays personalizados de snps y evaluación de los genes candidatos. Asociación Síndrome Phelan-Mcdermid. 2017-Ongoing. Managment centre: FIBHULP
- **Nevado Blanco J.** ÚNICAS. Implementación de una red pediátrica para la medicina personalizada en enfermedades raras pediátricas. Un proyecto piloto (PMP22/00008). ISCIII. 2023-2025. Managment centre: FIBHULP
- **Palomares Bralo M.** Implementación y evaluación de un protocolo de secuenciación rápida del exoma en pacientes pediátricos ingresados en unidades de críticos o de alta complejidad (PI19/01681). ISCIII. 2020-2024. Managment centre: FIBHULP
- **Palomares Bralo M.** Paving the way for personalized medicine in neonatal and pediatric intensive care units (PI22/01743). ISCIII. 2023-2025. Managment centre: FIBHULP
- **Pedrosa Delgado M.** caracterización alergénica y determinación de la relevancia clínica del polen de encina como alérgeno de interés en pacientes policlínicos y su relación con el desarrollo de síndrome de alergia oral con alimentos (PI22/00221). ISCIII. 2023-2026. Managment centre: FIBHULP
- **Solera García J.** Estudio de micrornas en pacientes con glucogenosis tipo II (enfermedad de Pompe) como marcadores de diagnóstico, progresión de la enfermedad y respuesta al tratamiento. Fundación Genzyme. 2013-Ongoing. Managment centre: FIBHULP
- **Tenorio Castaño JA.** Moving toward to a -omic classification for pulmonary arterial hypertension (PI21/01593). ISCIII. 2022-2024. Managment centre: FIBHULP
- **Tenorio Castaño JA.** Pasión hp-genetica de la hipertensión pulmonar. Fundación Contra La Hipertension Pulmonar. 2020-Ongoing. Managment centre: FIBHULP
- **Vallespín García E.** Desarrollo e implementación de un protocolo integral combinado con la búsqueda de nuevos genes de cataratas congénitas bilaterales (cc) no sindrómicas. Grupo Social Once. 2020-Ongoing. Managment centre: FIBHULP

Cibers and Retics

- **Lapunzina Badía P.** CIBER Enfermedades Raras. (CIBERer). ISCIII. (31/12/2025). FIBHULP

Patents and trademarks

- **Friedman S, Li D, Narla G, Martignetti J, Heath K, inventors; Mount Sinai School of Medicine, assignee; Kruppel-like factor 6 (klf6), a tumor suppressor protein, and diagnostics, therapeutics, and screening based on this protein.** PCT/US2001/025046, EP1332362, US2005181374, US2011059899, AU8479001, CA2419064; 2000 August 09.
- **INGEMM, author; FIBHULP, assignee.** Brand name: INGEMM INSTITUTO DE GENÉTICA MÉDICA Y MOLECULAR DEL HOSPITAL UNIVERSITARIO LA PAZ; ESM 2.884.849, USM 77.891.143, CM 8.746.869; 2009 July 16, 2009 December 11, 2009 December 10.

INGEMM

- **INGEMM, author; FIBHULP, assignee.** Brand name: KaryoArray; USM 79.078.751, CM 8.512.907; 2010 January 07, 2009 August 27.



- **INGEMM, author; FIBHULP, assignee.** Brand name: OverGrowthArray; ESM 2.958.709-3, USM 85.334.932, CM 10.009.256; 2010 December 02, 2011 June 01, 2011 May 31.

Over Growth Array

- **INGEMM, author; FIBHULP, assignee.** Brand name: MetabolArray; ESM 2.958.711-5, USM 85.334.903, CM 10.009.348; 2010 December 02, 2011 June 01, 2011 May 31.

Metabol Array

- **Palomares M, Lapunzina P, Nevado J, Vallespin E, Vallcorba I, Melero J, authors; FIBHULP, Hospital Infanta Cristina (Badajoz) Fundesalud, assignees.** Brand name: OncoHematoArray; ESM 2.958.703-4, USM 85.334.842, CM 10.009.181; 2010 December 02, 2011 June 01, 2011 May 31.

OncoHematoArray

- **INGEMM, author; FIBHULP, assignee.** Brand name: OncoArray; ESM 2.962.910, USM 85.363.107, CM 10.091.882; 2011 January 05, 2011 July 05, 2011 July 01.

OncoArray

- **Lapunzina P, Nevado J, Solera J, Vallespin E, Martínez P, Martínez-González V, authors; FIBHULP, assignee.** Brand name: ONCOSeq; USM 85.457.843, CM 9.969.064; 2011 October 27, 2011 May 16.

ONCOSeq

- **Moreno JC, Moya CM, Vallespin E, Lapunzina P, Nevado J, authors; FIBHULP, assignee.** Brand name: ThyroArray; USM 85.686.688, CM 10.904.951; 2012 July 25, 2012 May 23.

ThyroArray

- **Lapunzina Badía P, Borobia Pérez AM, Carcas Sansuán AJ, Tenorio Castaño JA, Arias Lajara P, Lubomirov Jristov R, authors; FIBHULP, UAM, assignees.** Brand name: PharmArray; USM 86.004.412, CM 11.608.403; 2013 July 08, 2013 February 27.

PharmArray


- **Lapunzina Badía PD, Borobia Pérez AM, Carcas Sansuán AJ, Tenorio Castaño JA, Arias Lajara P, Frías Iniesta J, Dapia García I, Muñoz M, authors; FIBHULP, UAM, assignees.** Brand name: ClinPharmarray., CM15489511; 2016 May 31, 2016 September 07.

ClinPharmarray

- **Palomares Bralo M, Vallespín García E, del Pozo Mate A, Santos Simarro F, authors; FIBHULP, assignee.** Brand name: RD-Seq Sequencing Rare Diseases; CM 17.911.029; 2018 May 31.

RD-Seq
Sequencing Rare Diseases

3.5.2 Translational Oncology



Publications: 43 | **Q1:** 28

COMPOSITION

Jaime Feliú Batlle.
Jefe de Servicio de Oncología Médica. Hospital Universitario La Paz. Catedrático de Oncología. Universidad Autónoma de Madrid

- **Borja Belandía Gómez.** *Científico Titular. Instituto de Investigaciones Biomédicas Sols-Morreale*
- **Beatriz Castelo Fernández.** *Facultativo Especialista de Área en Oncología. Hospital Universitario La Paz*
- **Paloma Cejas Guerrero.** *Investigadora Postdoctoral. Hospital Universitario La Paz*
- **Ana Belén Custodio Carretero.** *Facultativo Especialista de Área en Oncología. Hospital Universitario La Paz*
- **Enrique Espinosa Arranz.** *Jefe de Sección de Oncología Médica. Hospital Universitario La Paz. Profesor Titular de Oncología. Universidad Autónoma de Madrid*
- **Juan Ángel Fresno Vara.** *Investigador Senior (Contrato Miguel Servet - I2). Jefe de Laboratorio. FIBHULP*
- **Ángelo Gámez Pozo.** *Investigador Postdoctoral (Contrato Técnico de Apoyo). FIBHULP*
- **Laura García Acebedo.** *Médico Interno Residente. Coordinadora del Registro de Tumores. Hospital Universitario La Paz*
- **Ismael Ghanem Cañete.** *Facultativo Especialista de Area en Oncología. Hospital Universitario La Paz*
- **Juan Carlos Lacal Sanjuán.** *Profesor de Investigación. Instituto de Investigaciones Biomédicas Sols-Morreale*
- **Victoria María Heredia Soto.** *Investigadora Postdoctoral. Hospital Universitario La Paz*
- **Rocío López Vacas.** *Técnico de Laboratorio (Contrato Técnico de Apoyo). FIBHULP*
- **Virginia Martínez Marín.** *Facultativo Especialista de Área en Oncología. Hospital Universitario La Paz*
- **Ignacio Palmero Rodríguez.** *Científico Titular. Instituto de Investigaciones Biomédicas Sols-Morreale*
- **Jesús Peña López.** *Facultativo Especialista en Oncología Médica. Hospital Universitario La Paz*
- **Juan PabloPérez Wert.** *Facultativo Especialista en Oncología Médica. Hospital Universitario La Paz*
- **Ana Pertejo Fernández.** *Facultativo Especialista de Oncología Médica. Hospital Universitario La Paz*
- **Álvaro Pinto Marín.** *Facultativo Especialista de Área en Oncología. Hospital Universitario La Paz*
- **Andrés Redondo Sánchez.** *Jefe de Sección de Oncología Médica. Hospital Universitario La Paz. Profesor Asociado. Universidad Autónoma de Madrid*
- **Nuria Rodríguez Salas.** *Facultativo Especialista de Área en Oncología. Hospital Universitario La Paz*
- **Lucía Trilla Fuertes.** *Investigadora Postdoctoral. FIBHULP*
- **Pilar Zamora Auñón.** *Facultativo Especialista de Área en Oncología. Hospital Universitario La Paz. Profesor Asociado. Universidad Autónoma de Madrid*

STRATEGIC OBJETIVES

- The aim of cancer research is to improve understanding of all aspects of the disease, including deepening our understanding of the biology of the tumour, developing new treatments, analysing the efficacy of diagnostic tests and performing studies aimed at prevention and early diagnosis.
- The Translational Oncology group's objective is to conduct highly scientific applied research in such a way that basic research can be rapidly translated to clinical practice. In other words, cancer patients at La Paz University Hospital benefit almost immediately from the results of research conducted by their own physicians.
- Although important advances have been made in recent years in our understanding of the origin and evolution of cancer, their implementation in healthcare takes too much time. The Translational Oncology Unit (TOU) was established with the objective of facilitating the incorporation into clinical practice of new advances in molecular biology and the technology developed in this field.
- The main lines of study are based on digestive tumors, gynecologic tumors, urologic tumors, breast cancer and sarcomas. A series of fundamental objectives have been established for these neoplasms that can be summarised as early diagnosis, molecular classification for therapeutic goals and the search for individualised treatments. The majority of TOU projects have as their primary objective the search for predictors of susceptibility or resistance to anticancer agents and the search for prognostic factors related to the evolution of the tumour

RESEARCH LINES

- Identification of mechanisms of drug resistance in cancer.
- Identification of cancer biomarkers in tissues and liquid biopsy through. genomic, proteomic and metabolomic approaches.
- Study of the mechanisms involved in carcinogenesis.
- Identification of new therapeutic targets in cancer.
- Efficacy and toxicity of antineoplastic therapies.
- Palliative care and supportive treatments in oncology.
- The main tumors on which we carry out our research are:
  - Breast cancer
  - Digestive tract cancers
  - Gynecological tumors
  - Sarcomas
  - Melanoma
  - Genitourinary tumors
  - Head and neck tumors

RESEARCH ACTIVITY

Doctoral Theses

- **Gutiérrez Sainz L.** Citoquinas y adenocarcinoma de páncreas: Estudio de su relación con los síntomas, el pronóstico y el subtipo molecular[dissertation]. Madrid: Universidad Autónoma de Madrid: 2024(08/10/2024). Director: Feliu Batlle J.

Master Theses

- **Becerril Gómez F.** Tumor microbiota related to response to neoadjuvant chemotherapy in muscle-invasive bladder cancer[dissertation]. Madrid: Univiversidad Francisco de Vitoria: 2024(01/07/2024). Director: Gámez Pozo A, Bressa C
- **Wisultschew A.** Factores predictivos perioperatvos en carcinoma de vejiga músculo-invasivo[dissertation]. Madrid: Universitat Oberta Catalunya: 2024(01/07/2024). Director: Trilla Fuertes L.

Publications

- **Acero-Riaguas L, Griso-Acevedo AB, SanLorenzo-Vaquero A, Ibáñez-Herrera B, Fernández-Díaz SM, Mascaraque M, Sánchez-Siles R, López-García I, Benitez-Buelga C, Bravo-Burguillos ER, Castelo B, Cebrián-Carretero JL, Perona R, Sastre L, Sastre-Perona A.** DUSP1 and SOX2 expression determine squamous cell carcinoma of the salivary gland progression. Sci Rep-Uk. 2024; 14(1): 15007. Article. IF: 3.9; Q1
- **Alcalá S, Villarino L, Ruiz-Cañas L, Couceiro JR, Martínez-Calvo M, Palencia-Campos A, Navarro D, Cabezas-Sainz P, Rodríguez-Arabaolaza I, Cordero-Barreal A, Trilla-Fuertes L, Rubiolo JA, Batres-Ramos S, Vallespinos M, González-Páramos C, Rodríguez J, Gámez-Pozo A, Vara JAF, Fernández SF, Berlinches AB, Moreno-Mata N, Redondo AMT, Carrato A, Hermann PC, Sánchez L, Torrente S, Fernández-Moreno MA, Mascareñas JL, Sainz B Jr.** Targeting cancer stem cell OXPHOS with tailored ruthenium complexes as a new anti-cancer strategy. J Exp Clin Canc Res. 2024; 43(1): 33. Article. IF: 12.8; Q1
- **Alés-Martínez JE, Balmaña J, Sánchez-Rovira P, Bofill FJS, Sáenz JAG, Pimentel I, Morales S, Fernández-Abad M, Martínez AL, Ferrer N, Zamora P, Bermejo B, Díaz-Redondo T, López-Ceballos MH, Galán M, Pérez-Escuredo J, Calabuig L, Sampayo M, Pérez-Garcia JM, Cortés J, Llombart-Cussac A.** Olaparib plus trastuzumab in HER2-positive advanced breast cancer patients with germline BRCA1/2 mutations: The OPHELIA phase 2 study. Breast. 2024; 77: 103780. Article. IF: 7.9; D1
- **Bustamante-Madrid P, Barbáchano A, Albandea-Rodríguez D, Rodríguez-Cobos J, Rodríguez-Salas N, Prieto I, Burgos A, de Villarreal JM, Real FX, González-Sancho JM, Larriba MJ, Lafarga M, Muñoz A, Fernández-Barral A.** Vitamin D opposes multilineage cell differentiation induced by Notch inhibition and BMP4 pathway activation in human colon organoids. Cell Death Dis. 2024; 15(4): 301. Article. IF: 9.6; Q1
- **Carrillo-García J, Hindi N, Conceicao M, Sala MA, Ugalde A, López-Pousa A, Bagué S, Sevilla I, Vicioso L, Ramos R, Martínez-Trufero J, Mateo MCG, Cruz J, Hernández-León CN, Redondo A, Mendiola M, García JM, Hernández JE, Alvarez R, Agra C, de Juan-Ferré A, Valverde C, Cano JM, de Sande LM, Pérez-Fidalgo JA, Lavernia J, Marcilla D, Gutiérrez A, Moura DS, Martín-Broto J.** Prognostic impact of tumor location and gene expression profile in sporadic desmoid tumor. Eur J Cancer. 2024; 209: 114270. Article. IF: 7.1; Q1
- **Cervantes A, Tabernero J, García-Carbonero R, Sastre J, Feliú J, Guillén-Ponceg C, Paredes BG, Carral A, Munoz J.** Regorafenib in patients with metastatic colorectal cancer in Spain: from clinical trials to real-world evidence. Future Oncol. 2024; 20(20): 1401-13. Article. IF: 2.6; Q3
- **Di Cosimo S, Pérez-García JM, Bellet M, Dalenc F, Gil MJG, Ruiz-Borrego M, Gavilá J, Aguirre E, Schmid P, Marmé F, Gligorov J, Schneeweiss A, Albanell J, Zamora P, Wheatley D, de Dueñas EM, Amillano K, Shimizu E, Sampayo-Cordero M, Cortés J, Llombart-Cussac A.** Impact of coadministration of proton-pump inhibitors and palbociclib in hormone receptor-positive/HER2-negative advanced breast cancer. Breast. 2024; 76: 103761. Article. IF: 7.9; D1
- **Feliú J, Gámez-Pozo A, Martínez-Pérez D, Pérez-Wert P, Matamala-Luengo D, Viñal D, Kunz L, López-Vacas R, Dittmann A, Rodríguez-Salas N, Custodio A, Vara JAF, Trilla-Fuertes L.** Functional proteomics of colon cancer Consensus Molecular Subtypes. Brit J Cancer. 2024; 130(10): 1670-8. Article. IF: 6.8; Q1
- **Fiala O, Buti S, Bamias A, Massari F, Pichler R, Maruzzo M, Grande E, De Giorgi U, Molina-Cerrillo J, Seront E, Calabrò F, Myint ZW, Facchini G, Kopp RM, Berardi R, Kucharz J, Vitale MG, Pinto A, Formisano L, Büttner T, Messina C, Monteiro FSM, Battelli N, Kanesvaran R, Büchler T, Kopecky J, Santini D, Giudice GC, Porta C, Santoni M.** Real-World Impact of Upfront Cytoreductive Nephrectomy in Metastatic Non-Clear Cell Renal Cell Carcinoma Treated with First-Line Immunotherapy Combinations or Tyrosine Kinase Inhibitors (A Sub-Analysis from the ARON-1 Retrospective Study). Target Oncol. 2024; 19(4): 587-99. Article. IF: 4.0; Q2
- **Fiala O, Massari F, Basso U, Giannatempo P, Grande E, Buti S, Myint ZW, De Giorgi U, Pichler R, Grillone F, Ürün Y, Calabrò F, Bourlon MT, Galli L, Kanesvaran R, Roviello G, Kucharz J, Rizzo M, Park SH, Cerbone L, Seront E, Messina C, Molina-Cerrillo J, Santini D, Yano A, Incorvaia L, Catalano M, Pinto A, Formisano L, Soares A, Facchini G, Fornarini G, Poprach A, Rebuzzi SE, Nasso C, Spinelli GP, Angel M, Stellato M, Tural D, Aurilio G, Epstein I, Carrozza F, Monteiro FSM, Benedetti G, Büchler T, Ortega C, Zakopoulou R, Battelli N, Porta C, Bellmunt J, Gupta S, Santoni M.** Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma:

A Retrospective Data from the ARON-2EV Study. Target Oncol. 2024; 19(6): 905-15. Article. IF: 4.0; Q2

- **García-Donas J, Redondo A, Santaballa A, Garrigos L, Rubio MJ, Lainez N, González MI, Cueva JF, Barquin A, Grazioso TP, Hurtado A, Sevillano E, Grande E, Rodríguez-Moreno JF, Navarro P.** Phase II clinical trial assessing the efficacy of enzalutamide in advanced non-resectable granulosa cell ovarian tumors: The GREKO III study (GETHI2016-01). Gynecol Oncol. 2024; 191: 233-9. Article. IF: 4.1; D1
- **González-Cao M, Puertolas T, Manzano JL, Maldonado C, Yelamos O, Berciano-Guerrero MA, Cerezuela P, Martin-Liberal J, Muñoz-Couselo E, Espinosa E, Drozdowskyj A, Berrocal A, Soria A, Marquez-Rodas I, Martin-Algarra S, Quindos M, Puig S.** Access to melanoma drugs in Spain: a cross-sectional survey. Clin Transl Oncol. 2024; 26(10): 2572-83. Article. IF: 2.5; Q3
- **Gutiérrez-Sainz L, Heredia-Soto V, Rodríguez-García AM, Sánchez MGC, Serrano-Olmedo MG, Molero-Luis M, Losantos-García I, Ghanem I, Pérez-Wert P, Custodio A, Mendiola M, Feliu J.** Cytokines and Pancreatic Ductal Adenocarcinoma: Exploring Their Relationship with Molecular Subtypes and Prognosis. Int J Mol Sci. 2024; 25(17): 9368. Article. IF: 4.9; Q1
- **Harter P, Bogner G, Chiva L, Cibula D, Concin N, Fotopoulou C, Gonzalez-Martin A, Guyon F, Heinzelmann-Schwarz V, Kridelka F, Mahner S, Marmé F, Marth C, Morice P, Novák Z, Papadia A, Ray-Coquard I, Redecha M, Redondo A, Schwameis R, Sehouli J, Undurraga M, Van Gorp T, Vergote I.** Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria, Swiss AGO, BGOG, CEEGOG, GEICO, and SFOG regarding the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in epithelial ovarian cancer. B Cancer. 2024; 111(3): 277-84. Review. IF: 0.8; Q4
- **Lee CH, Shah AY, Rao A, Taylor MH, Di Simone C, Hsieh JJ, Pinto A, Sarrió RG, Cohn AL, Bilen MA, Ribe SG, Tennoe OK, Richards D, Sweis RF, Courtright J, Heinrich D, Perini R, Kubiak P, Bock D, Okpara CE, Motzer RJ.** Lenvatinib plus Pembrolizumab Following Immune Checkpoint Inhibitor Treatment in Patients with Metastatic Clear Cell Renal Cell Carcinoma: Results from Study 111/KEYNOTE-146. Eur Urol. 2024; 86(5): 470-3. Article. IF: 25.2; D1
- **López CL, Calvo M, Cámara JC, García-Paredes B, Gómez-Martin C, López AM, Pazo-Cid R, Sastre J, Yaya R, Feliu J.** SEOM-GEMCAD-TTD clinical guidelines for the management of hepatocarcinoma patients (2023). Clin Transl Oncol. 2024; 26(11): 2800-11. Article. IF: 2.5; Q3
- **López-Plaza B, Alvarez-Mercado AI, Arcos-Castellanos L, Plaza-Díaz J, Ruiz-Ojeda FJ, Brandimonte-Hernández M, Feliú-Batlle J, Hummel T, Gil A, Palma-Milla S.** Efficacy and Safety of Habitual Consumption of a Food Supplement Containing Miraculin in Malnourished Cancer Patients: The CLINMIR Pilot Study. Nutrients. 2024; 16(12): 1905. Article. IF: 5; Q1
- **Lorenzo-Sanz L, López-Cerda M, da Silva-Diz V, Artés MH, Llop S, Penin RM, Bermejo JO, Gonzalez-Suárez E, Esteller M, Viñals F, Espinosa E, Oliva M, Piulats JM, Martin-Liberal J, Muñoz P.** Cancer cell plasticity defines response to immunotherapy in cutaneous squamous cell carcinoma. Nat Commun. 2024; 15(1): 5352. Article. IF: 15.7; D1
- **Márquez-Rodas I, Couselo EM, Moreno JFR, Fernández AMA, Guerrero MAB, Balea BC, Merino LD, Arranz EE, Castaño AG, Jaime AB.** SEOM-GEM clinical guidelines for cutaneous melanoma (2023). Clin Transl Oncol. 2024; 26(11): 2841-55. Article. IF: 2.5; Q3
- **Martínez-Campelo L, Blanco-Verea A, López-Fernández T, Martínez-Monzonis A, Buño A, Mazón P, Zamora P, Norton N, Reddy JS, Velasco-Ruiz A, González-Neira A, Vulsteke C, Alonso-Gordoa T, Cruz R, Diz-de Almeida S, Carracedo A, González-Juanatey J, López-Sendón J, Brion M.** Meta-analysis of genome-wide association studies for cancer therapy-related cardiovascular dysfunction and functional mapping highlight an intergenic region close to TP63. Sci Rep-Uk. 2024; 14(1): 18413. Article. IF: 3.9; Q1
- **Massari F, Santoni M, Takeshita H, Okada Y, Tapia JC, Basso U, Maruzzo M, Scagliarini S, Buettner T, Fornarini G, Myint ZW, Galli L, Souza VC, Pichler R, De Giorgi U, Gandur N, Lam ET, Gilbert D, Popovic L, Grande E, Mammone G, Berardi R, Crabb SJ, Kemp R, Molina-Cerrillo J, Freitas M, Luz M, Iacovelli R, Calabro F, Tural D, Atzori F, Kueronya Z, Chiari R, Campos S, Caffo O, Fay AP, Kucharz J, Zucali PA, Rinck JA, Zeppellini A, Bastos DA, Aurilio G, Mota A, Trindade K, Ortega C, Sade JP, Rizzo M, Fiala O, Vau N, Giannatempo P, Barillas A, Monteiro FSM, Dauster B, Mennitto A, Nogueira L, Fernandes RD, Seront E, Aceituno LG, Grillone F, Cutuli HJ, Fernández M, Bassanelli M, Kopp RM, Roviello G, Abahssain H, Procopio G, Milella M, Kopecky J, Martignetti A, Messina C, Caitano M, Inman E, Kanesvaran R, Herchhorn D, Santini D, Bamias A, Bisonni R, Mosca A, Morelli F, Maluf F, Soares A, Nunes F, Pinto A, Zgura A, Incorvaia L, Ansari J, Zabalza IO, Landmesser J, Rizzo A, Mollica V, Marchetti A, Rosellini M, Sorgentoni G, Battelli N, Buti S, Porta C, Bellmunt J.** Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study. Cancer Immunol Immun. 2024; 73(6): 106. Article. IF: 5.1; Q1
- **Mendiola M, Heredia-Soto V, Ruz-Caracuel I, Baillo A, Ramon-Patino JL, Berjon A, Escudero FJ, Pelaez-Garcia A, Hernández A, Feliu J, Hardisson D, Redondo A.** Performance of the Idylla microsatellite instability test in endometrial cancer. Mol Cell Probe. 2024; 77: 101976. Article. IF: 3.0; Q2
- **Mendiola M, Saarela J, Escudero FJ, Heredia-Soto V, Potdar S, Rodríguez-Marrero S, Miguel M, Pozo-Kreilinger JJ, Berjon A, Ortiz-Cruz E, Feliu J, Redondo A.** Characterisation of new in vitro models and identification of potentially active drugs in angiosarcoma. Biomed Pharmacother. 2024; 173: 116397. Article. IF: 7.5; D1
- **Morales MG, Visa L, Vázquez EB, Batlle JF, Shahi PK, Sáez BL, Hernández BLD, Macarulla T, Sarrió RG.** Update on the management of older patients with pancreatic adenocarcinoma: a perspective from medical oncology. Clin Transl Oncol. 2024; 26(7): 1570-83. Review. IF: 2.5; Q3
- **Mortier L, Villabona L, Lawrence B, Arance A, Butler MO, Beylot-Barry M, Saiag P, Samimi M, Ascierto PA, Spada F, De Pontville M, Maio M, Berrocal A, Espinosa E, Capdevila J, Levin M, Das D, Krepler C, Grebennik D, Chiarion-Sileni V.** Pembrolizumab for the First-Line Treatment of Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma: Results from the Single-Arm, Open-Label, Phase III KEYNOTE-913 Study. Am J Clin Dermatol. 2024; 25(6): 987-96. Article. IF: 8.8; D1
- **Moura DS, López-Marti JM, Benesova I, de Andrea C, di Lernia D, Lacerenza S, Mondaza-Hernández JL, Martin-Ruiz M, Ramirez-Calvo M, Grignani G, Martínez-Trufero J, Redondo A, Valverde C, Stacchiotti S, López-Pousa A, López-Guerrero JA, Gutierrez A, Encinas-Tobajas V, Hindi N, Sangiolo D, López-Martin JA, Strizova ZO, Martin-Broto J.** Predictive and Dynamic Signature for Antiangiogenics in Combination with a PD1 Inhibitor in Soft-Tissue Sarcoma: Correlative Studies Linked to the IMMUNOSARC Trial. Clin Cancer Res. 2024; 30(22): 5192-206. Article. IF: 10.2; D1
- **Ostios-García L, Pérez DM, Castelo B, Herradón NH, Zamora P, Feliu J, Espinosa E.** Classification of anticancer drugs: an update with FDA- and EMA-approved drugs. Cancer Metast Rev. 2024; 43(4): 1561-71. Review. IF: 8.7; Q1
- **Peña-López J, Jiménez-Bou D, Ruíz-Gutiérrez I, Martín-Montalvo G, Alameda-Guijarro M, Rueda-Lara A, Ruíz-Giménez L, Higuera-Gómez O, Gallego A, Pertejo-Fernández A, Sánchez-Cabrero D, Feliu J, Rodríguez-Salas N.** Prevalence and Distribution of MUTYH Pathogenic Variants, Is There a Relation with an Increased Risk of Breast Cancer? Cancers (Basel). 2024; 16(2): 315. Article. IF: 4.4; Q2
- **Peña-López J, Gutiérrez-Sainz L, Jiménez-Bou D, Ruíz-Gutiérrez I, Navas-Jiménez C, Alonso-Eiras JI, García-Zamarriego A, Sánchez-Cabrero D, Ruíz-Giménez L, Pertejo-Fernández A, Villamayor-Sánchez J, Cruz-Castellanos P, Higuera-Gómez O, de Castro J.** Assessing Prognosis: Factors Influencing Outcomes in Hospitalized Lung Cancer. Onco (Basel). 2024; 4(4): 458-70. Article. Not Indexed

- **Pérez-Wert P, Fernández-Hernández S, Gamez-Pozo A, Arranz-Álvarez M, Ghanem I, López-Vacas R, Díaz-Almirón M, Méndez C, Vara JAF, Feliu J, Trilla-Fuertes L, Custodio A.** Layer Analysis Based on RNA-Seq Reveals Molecular Complexity of Gastric Cancer. Int J Mol Sci. 2024; 25(21): 11371. Article. IF: 4.9; Q1
- **Pinto A, Ocanto A, Couñago F.** Potential role of transmembrane 9 superfamily member 1 as a biomarker in urothelial cancer. World J Clin Oncol. 2024; 15(8): 965-7. Editorial Material. IF: 3.2; Q2
- **Piulats JM, Watkins C, Costa-García M, del Carpio L, Piperno-Neumann S, Rutkowski P, Hassel JC, Espinosa E, de la Cruz-merino L, Ochsenreither S, Shoushtari AN, Orloff M, Salama AKS, Goodall HM, Baurain JF, Nathan P.** Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: a propensity score-weighted analysis. Ann Oncol. 2024; 35(3): 317-26. Article. IF: 65.4; D1
- **Plaza-Díaz J, Ruiz-Ojeda FJ, López-Plaza B, Brandimonte-Hernández M, Alvarez-Mercado AI, Arcos-Castellanos L, Feliú-Batlle J, Hummel T, Palma-Milla S, Gil A.** Effect of a Novel Food Rich in Miraculin on the Oral Microbiome of Malnourished Oncologic Patients with Dysgeusia. Cancers (Basel). 2024; 16(19): 3414. Article. IF: 4.4; Q2
- **Rio-Vilariño A, Cenigaonandia-Campillo A, García-Bautista A, Mateos-Gómez PA, Schlaepfer MI, del Puerto-Nevado L, Aguilera O, García-García L, Galeano C, de Miguel I, Serrano-López J, Baños N, Fernández-Aceñero MJ, Lacal JC, Medico E, García-Foncillas J, Cebrián A.** Inhibition of the AURKA/YAP1 axis is a promising therapeutic option for overcoming cetuximab resistance in colorectal cancer stem cells. Brit J Cancer. 2024; 130(8): 1402-13. Article. IF: 6.8; Q1
- **Rivero-Santana B, Saldaña-García J, Caro-Codón J, Zamora P, Moliner P, Monzonis AM, Zatarain E, Alvarez-Ortega C, Gómez-Prieto P, Pernas S, Rodríguez I, Soto AB, Cadenas R, Ozores PP, Ramírez SP, Salvador MM, Valbuena S, Gasso LF, Juárez V, Severo A, Terol B, Alvarez TD, Rodríguez O, Brion M, González-Costello J, Albendea MC, González-Juanatey JR, Moreno R, López-Sendón J, López-Fernández T.** Anthracycline-induced cardiovascular toxicity: validation of the Heart Failure Association and International Cardio-Oncology Society risk score. Eur Heart J. 2024; 46(3): 273-84. Article. IF: 35.6; D1
- **Rizzo M, Soares A, Grande E, Bamias A, Kopp RM, Lenci E, Buttner T, Salah S, Grillone F, de Carvalho IT, Tapia JC, Gucciardino C, Pinto A, Mennitto A, Abahssain H, Rescigno P, Myint Z, Takeshita H, Spinelli GP, Popovic L, Vitale MG, Fiala O, Giannatempo P, Zakopoulou R, Carrozza F, Massari F, Monteiro FSM, Pace MP, Giannini M, Roviello G, Porta C, Battelli N, Kanesvaran R, Santoni M.** Radiotherapy plus pembrolizumab for advanced urothelial carcinoma: results from the ARON-2 real-world study. Sci Rep-Uk. 2024; 14(1): 19802. Article. IF: 3.9; Q1
- **Rodríguez-Vida A, Valderrama BP, Castellano D, Pinto A, Mellado B, Puente J, Climent MA, Domenech M, Vazquez F, Perez-Gracia JL, Bonfill T, Morales-Barrera R, Gonzalez-Billalabeitia E, Garcia-del-Muro X, Maroto P, Navarro-Gorro N, Juanpere N, Juan O, Bellmunt J.** Induction avelumab followed by chemoimmunotherapy and maintenance versus chemotherapy alone as first-line therapy in cis-ineligible metastatic urothelial carcinoma (INDUCOMAIN): a randomized phase II study. ESMO Open. 2024; 9(9): 103690. Article. IF: 8.3; Q1
- **Sacco JJ, Carvajal RD, Butler MO, Shoushtari AN, Hassel JC, Ikeguchi A, Hernández-Aya L, Nathan P, Hamid O, Piulats JM, Rioth M, Johnson DB, Luke JJ, Espinosa E, Leyvraz S, Collins L, Holland C, Sato T.** Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanoma. J Immunother Cancer. 2024; 12(6): e009028. Article. IF: 10.6; D1
- **Santoni M, Buti S, Myint ZW, Maruzzo M, Iacovelli R, Pichler M, Kopecky J, Kucharz J, Rizzo M, Galli L, Büttner T, De Giorgi U, Kanesvaran R, Fiala O, Grande E, Zucali PA, Kopp RM, Fornarini G, Bourlon MT, Scagliarini S, Molina-Cerrillo J, Aurilio G, Matrana MR, Pichler R, Cattrini C, Büchler T, Massari F, Seront E, Calabrò F, Pinto A, Berardi R, Zgura A, Mammone G, Ansari J, Atzori F, Chiari R, Bamias A, Caffo O, Procopio G, Sunela K, Bassanelli M, Ortega C, Grillone F, Landmesser J, Milella M, Messina C, Küronya Z, Mosca A, Bhuva D, Santini D, Vau N, Morelli F, Incorvaia L, Rebuzzi SE, Roviello G, Soares A, Bisonni R, Bimbatti D, Zabalza IO, Rizzo A, Mollica V, Sorgentoni G, Monteiro FSM, Battelli N, Bracarda S, Porta C.** Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group? Eur Urol Oncol. 2024; 7(1): 102-11. Article. IF: 9.3; D1
- **Schmid P, Turner NC, Barrios CH, Isakoff SJ, Kim SB, Sablin MP, Saji S, Savas P, Vidal GA, Oliveira M, O'Shaughnessy J, Italiano A, Espinosa E, Boni V, White S, Rojas B, Freitas-Junior R, Chae Y, Bondarenko I, Lee J, Mattos CT, Rodríguez JLM, Lam LH, Jones S, Reilly SJ, Huang XY, Shah K, Dent R.** First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results. Clin Cancer Res. 2024; 30(4): 767-78. Article. IF: 10.2; D1
- **Valladares-Ayerbes M, Safont MJ, Flores EG, García-Alfonso P, Aranda E, Muñoz AML, Ferrer EF, Nogueras LC, Rodríguez-Salas N, Aparicio J, Muñoz ML, Cáceres PPP, Trujillo OAC, Tocino RV, Fernández MS, Salud-Salvia A, Sureda BM, Garcia-Carbonero R, Conesa MAV, Vila AL.** Sequential RAS mutations evaluation in cell-free DNA of patients with tissue RAS wild-type metastatic colorectal cancer: the PERSEIDA (Cohort 2) study. Clin Transl Oncol. 2024; 26(10): 2640-51. Article. IF: 2.5; Q3
- **Van Laethem JL, Borbath I, Prenen H, Geboes KP, Lambert A, Mitry E, Cassier PA, Blanc JF, Pilla L, Batlle JF, Garrote MR, Pazo-Cid RA, Gallego I, Smith KE, Ellmark P, de Coana YP, Ambarkhane SV, Macarulla T.** Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre, phase 1b/2 study. Lancet Oncol. 2024; 25(7): 853-64. Article. IF: 35.9; D1
- **Weichenthal M, Mangana J, Gavrilova I, Lugowska I, Shalamanova GK, Kandolf L, Chiarion-Sileni V, Mohr P, Karanikolova TS, Teterycz P, Espinosa E, Schnecko P, Cheng P, Bender M, Jiang S, Burke T, Ascierto PA, Gogas H, Rodas IM, Rutkowski P, Schadendorf D, Dummer R.** Adjuvant Use of Pembrolizumab for Stage III Melanoma in a Real-World Setting in Europe. Cancers (Basel). 2024; 16(21): 3558. Article. IF: 4.4; Q2

Research projects

- **Castelo Fernández B.** Construyendo desde la vulnearibilidad en el cancer: de la investigación a la practica clinica. EISAI Farmaceutica S.A. 2022-Ongoing. Managment centre: FIBHULP
- **Castelo Fernández B.** Identification of new biomarkers to predict patient progression in ductal salivary cancer. Gilead Sciences S.L. 2023-Ongoing. Managment centre: FIBHULP
- **Castelo Fernández B.** Characterization of cancer-cell plasticity in head and neck cancers: discovery of new therapeutic targets and biomarkers for disease progression and treatment response(PI23/00192). ISCIII. 2024-2026. Managment centre: FIBHULP
- **Cejas Guerrero P.** Estudio de los cambios estructurales de la cromatina implicados en la resistencia a la quimioterapia en el adenocarcinoma de páncreas y de la posible utilidad de los inhibidores de ezh2 para revertirlos. (PI23/01533). ISCIII. 2024-2026. Managment centre: FIBHULP
- **Custodio Carretero A.** Perfiles transcriptómicos implicados en el pronóstico y las resistencias terapéuticas a quimioterapia perioperatoria en adenocarcinoma gástrico localmente avanzado. FIBHULP. 2022-Ongoing. Managment centre: FIBHULP
- **Custodio Carretero A.** Perfiles transcriptómicos implicados en el pronóstico y las resistencias terapéuticas a quimioterapia perioperatoria en adenocarcinoma gástrico localmente avanzado. SEOM. 2023-Ongoing. Managment centre: FIBHULP
- **Espinosa Arranz E.** Antitumor effects o anti PD-LI



immunotherapy atezolizumab plus metformin and chemotherapy in triple negative breast cáncer. Roche Farma S. A. 2021-Ongoing. Managment centre: FIBHULP

- **Espinosa Arranz E.** Búsqueda de biomarcadores predictivos de respuesta a inmunoterapia en melanoma avanzado (2022455). Grupo Español Multidisciplinar de Melanoma. 2022-Ongoing. Managment centre: FIBHULP
- **Feliú Batlle J.** Clinical implications of microbiome analysis in colorectal cancer usin paraffin samples. EASI Genomics European Consortium. 2022-Ongoing. Managment centre: EASI Genomics European Consortium
- **Feliú Batlle J.** Estudio de biomarcadores pronósticos y predictivos en adenocarcinoma de páncreas. Varios. 2015-Ongoing. Managment centre: FIBHULP
- **Feliú Batlle J.** Estudio de factores predictivos de toxicidad grave (grado 3-4) en anciano. Fundación Pfizer. 2012-Ongoing. Managment centre: FIBHULP
- **Feliú Batlle J.** Foro iberoamericano de investigación oncologica. Lapharcon LLC. 2017-Ongoing. Managment centre: FIBHULP
- **Feliú Batlle J.** Identificación de una huella genética para el pronóstico en pacientes con cáncer de colon en estado II operados con intención curativa Varios. 2013-Ongoing. Managment centre: FIBHULP
- **Feliú Batlle J.** Optimización del tratamiento adyuvante del cáncer de páncreas en función del subtipo molecular determinado por biomarcadores inmunohistoquímicos. Fundación SEOM. 2022-Ongoing. Managment centre: FIBHULP
- **Feliú Batlle J.** Promover la actividad investigadora en el servicio de oncología. Amgen S.A. 2010-Ongoing. Managment centre: FIBHULP
- **Feliú Batlle J.** Proyecto desarrollo de consulta de psicooncología en el Hospital Universitario La Paz. Merck S. L. 2012-Ongoing. Managment centre: FIBHULP
- **Feliú Batlle J.** Utilidad de la determinación del DNA circulante para monitorizar la respuesta al tratamiento neoadyuvante en los pacientes con cáncer de recto localmente avanzado. Fundación SEOM. 2014-Ongoing. Managment centre: FIBHULP
- **Feliú Batlle J.** Validation of biomakers to predict response to anti-egfr therapy identified by shotgun proteomics. FIBHULP. 2018-Ongoing. Managment centre: FIBHULP
- **Feliú Batlle J.** Estudio de los cambios estructurales de la cromatina implicados en la resistencia a la quimioterapia en el adenocarcinoma de páncreas y de la posible utilidad de los inhibidores de ezh2 para revertirlos (PI23/01533). ISCIII. 2024-2026. Managment centre: FIBHULP
- **Feliú Batlle J.** Predicción de riesgo de cardiotoxicidad en la unidades de cardio-oncología. Valor de la genética y diferentes biomarcadores. El registro CARDIOTOX (PMP22/00098). ISCIII. 2022-ongoing. Managment centre: FIBHULP
- **Fresno Vara JA.** Caracterización molecular del cáncer de mama mediante TaqMan Low Density Arrays: Aplicación al diagnósitico. FIBHULP. 2014-Ongoing. Managment centre: FIBHULP
- **Fresno Vara JA.** Contrato Miguel Servet Categoria A (CES11/020). ISCIII. 2012-2025. Managment centre: FIBHULP
- **Ghanem Cañete I.** Alteraciones genómicas en carcinoma escamoso de ano. Secuenciación del exoma completo. Roche Farma S.A. 2019-Ongoing. Managment centre: FIBHULP
- **Ghanem Cañete I.** Análisis integral del perfil de metilación en el cáncer colorrectal juvenil: Un enfoque traslacional. Grupo Español de Tumores Huérfanos e Infrecuentes. 2024-2026. Managment centre: FIBHULP
- **Martinez Marín V.** Estudio perfil mutacional e inmunohistoquímico en GIST: búsqueda de factores pronósticos y predictivos. Pfizer S. L. U. 2013-Ongoing. Managment centre: FIBHULP
- **Pinto Marín A.** Evaluación del metaboloma sanguineo como fuente de biomarcadores para el manejo del paciente con cáncer: el caso del cáncer de prostata metastásico. Varios. 2015-Ongoing. Managment centre: FIBHULP
- **Pinto Marín A.** Predictive factors for perioperative treatments in bladder carcinoma (EPIC-XS-000310). EPIC-XS Proteomics Consotirum. 2021-Ongoing. Managment centre: EPIC-XS Proteomics Consortium
- **Pinto Marín A.** Validación del test con valor pronóstico BIO-MIRCC. Biomédica Molecular Medicine S. L. 2020-Ongoing. Managment centre: FIBHULP
- **Redondo Sánchez A.** Análisis de expresión de miRNAs relacionados con el proceso angiogénico en cáncer mama. Roche Farma S. A. 2014-Ongoing. Managment centre: FIBHULP
- **Redondo Sánchez A.** Cáncer de mama y angiogénesis: estudio de perfiles de expresión génica en muestras parafinadas. Roche Farma S. A. 2009-Ongoing. Managment centre: FIBHULP
- **Redondo Sánchez A.** Caracterización de la acción de trabectedina y análogos, lurbinectedina y análogos y PM60184 en modelos celulares en dos y tres dimensiones de carcinoma de ovario. Pharmamar S. A. 2016-Ongoing. Managment centre: FIBHULP
- **Redondo Sánchez A.** Caracterización in vitro del efecto antitumoral de eribulina (en monoterapia y en combinación con otros fármacos) en líneas celulares de liposarcoma y leiomiosarcoma. EISAI Farmacéutica S. A. 2018-Ongoing. Managment centre: FIBHULP
- **Redondo Sánchez A.** Caracterización molecular y estudio de biomarcadores de inmunomodulación en el cáncer de endometrio. Subestudio: Estudio in vitro de modelos de cocultivo entre células tumorales de cáncer de ovario y fibroblastos. Grupo Español de Investigación Cáncer de Ovario. 2019-Ongoing. Managment centre: FIBHULP
- **Redondo Sánchez A.** Estudio in vitro de modelos en tres dimensiones de cáncer de ovario: interaccion entre las celulas tumorales y celulas del microambiente tumoral. Roche Farma S. A. 2017-Ongoing. Managment centre: FIBHULP
- **Redondo Sánchez A.** Identificación de marcadores de HRD y predicción de la respuesta a inhibidores de parp en líneas celulares establecidas y organoides derivados de pacientes con cancer de ovario. Grupo Español de Investigación Cáncer de Ovario. 2021-Ongoing. Managment centre: FIBHULP
- **Redondo Sánchez A.** Sesiones clinicas en investigación y actualización en oncologia medica del Hospital Universitario La Paz. Astrazeneca Farmaceutica Spain S.A. 2021-Ongoing. Managment centre: FIBHULP

- **Rodríguez Salas N.** Cáncer colorrectal en población joven. Estudio farmacogenómico en organoides y efectos del microambiente tumoral (ICI20/00057). ISCIII. 2021-2024. Managment centre: FIBHULP
- **Zamora Auñón P.** Metabolómica y modelización del matebolismo celular del cáncer para la deteccion de enfermedad mínima residual en pacientes con cáncer de mama. Roche Farma S. A. 2018-Ongoing. Managment centre: FIBHULP
- **Zamora Auñón P.** Sesiones clinicas en investigación y actualización en oncologia medica del Hospital Universitario La Paz. Astrazeneca Farmaceutica Spain S.A. 2010-Ongoing. Managment centre: FIBHULP

Cibers and Retics

- **Feliú Batlle J.** Networked Biomedical Research Center for Cancer (CIBERonc). ISCII. (31/12/2024). FIBHULP

Clinical trials

- **Castelo Fernandez B.** a multicenter, randomized, double-blind, placebo-controlled, phase 3 study of ficlatuzumab in combination with cetuximab in participants with recurrent or metastatic (r/m) hpv-negative head and neck squamous cell carcinoma (fierce-hn).
  Type/Phase: III
  Sponsored by: Aveo Pharmaceuticals Inc.
  Signature date: 15/04/2024
- **Castelo Fernandez B.** ensayo aleatorizado de fase i/ii en pacientes con carcinoma de células escamosas de cabeza y cuello (scchn) locorregionalmente avanzado, negativo para vph, de diagnóstico reciente, en el que se evalúa una inmunoterapia dirigida al mutanoma iniciada al finalizar el tratamiento primario o en el momento de la recidiva.
  Type/Phase: I
  Sponsored by: Transgene
  Signature date: 07/08/2024
- **Castelo Fernandez B.** ensayo de fase 1b, abierto, con escalado de dosis, para determinar la seguridad y las respuestas inmunitarias dirigidas contra antígenos específicos provocadas por vb.10 neo en combinación con atezolizumab en sujetos con tumores localmente avanzados y metastásicos.
  Type/Phase: I
  Sponsored by: Vaccibody As
  Signature date: 15/07/2024
- **Castelo Fernandez B.** estudio de fase ii, multicéntrico, abierto, de dos cohortes, de un solo brazo, para evaluar la eficacia y la seguridad del anticuerpo-fármaco conjugado anti-trop2 sacituzumab govitecan en pacientes con neoplasias tiroideas anaplásicas y diferenciadas avanzadas.
  Type/Phase: II
  Sponsored by: Grupo Español De Tumores Neuroendocrinos Y Endocrinos
  Signature date: 07/02/2024
- **Castelo Fernandez B.** estudio de fase ii/III, aleatorizado, doble ciego y comparativo de zanzalintinib (xl092) en combinación con pembrolizumab frente a pembrolizumab en el tratamiento de primera línea de participantes con carcinoma epidermoide de cabeza y cuello recurrente o metastásico positivo en pd-l1.
  Type/Phase: III
  Sponsored by: Exelisis Inc.
  Signature date: 10/05/2024
- **Castelo Fernandez B.** estudio de fase iii, aleatorizado y abierto para evaluar pembrolizumab como tratamiento neoadyuvante y en combinación con la asistencia habitual como tratamiento adyuvante en el carcinoma epidermoide de cabeza y cuello locorregionalmente avanzado (cecc la), extirpable, en estadio III-iva.
  Type/Phase: III
  Sponsored by: Merck Sharp & Dohme Llc
  Signature date: 08/09/2024
- **Castelo Fernandez B.** estudio fase 3 aleatorizado, doble ciego y controlado con placebo para evaluar dostarlimab como terapia secuencial después de quimioradioterapia en pacientes con carcinoma de células escamosas de cabeza y cuello localmente avanzado no resecable.
  Type/Phase: III
  Sponsored by: Glaxosmithkline Research And Development Limited
  Signature date: 01/02/2024
- **Castelo Fernandez B.** primer ensayo en humanos, abierto, de aumento escalonado de la dosis con cohortes de ampliación para evaluar la seguridad y la actividad antineoplásica de gen1042 en sujetos con tumores sólidos malignos.
  Type/Phase: I
  Sponsored by: Genmab A/S
  Signature date: 08/05/2024
- **Custodio Carretero AB.** beamion bcgc-1: ensayo de fase ib de aumento de la dosis y de fase ii de optimización de la dosis, aleatorizado, en abierto y multicéntrico para evaluar el zongertinib (bi 1810631) por vía oral en combinación con el trastuzumab deruxtecán (t-dxd) por vía intravenosa o en combinación con el trastuzumab emtansina (t-dm1) por vía intravenosa para el tratamiento de pacientes con cáncer de mama metastásico (cmm) her2+ avanzado y adenocarcinoma gástrico, de la unión gastroesofágica o esofágico metastásico (acgem).
  Type/Phase: II
  Sponsored by: Boehringer Ingelheim International GMBH
  Signature date: 27/11/2024
- **Custodio Carretero AB.** dareon™-7: a phase i, open-label, dose escalation and expansion trial to investigate safety and tolerability of bi 764532 intravenous infusions in combination with standard of care (platinum and etoposide) in first-line treatment of patients with neuroendocrine carcinomas (nec).
  Type/Phase: I
  Sponsored by: Boehringer Ingelheim España S.A.
  Signature date: 15/01/2024
- **Custodio Carretero AB.** ensayo de fase 1b/3, global, aleatorizado, controlado y abierto, para comparar el tratamiento con ryz101 frente al tratamiento habitual en sujetos con tumores neuroendocrinos gastroenteropancreáticos bien diferenciados que expresen receptores de somatostatina (sstr+), avanzados e inoperables, que hayan progresado tras un tratamiento anterior con un análogo de la somatostatina marcado con 177lu (action-1).
  Type/Phase: I
  Sponsored by: Rayzebio Inc.
  Signature date: 19/12/2024
- **Custodio Carretero AB.** ensayo en fase 3 aleatorizado, multicéntrico, abierto, comparativo con tratamiento activo para evaluar la eficacia y seguridad de octreotida (cam2029) subcutánea de liberación; prolongada frente a octreotida lp o lanreotida atg en pacientes con; Tumores neuroendocrinos gastroenteropancreáticos.
  Type/Phase: III
  Sponsored by: Fortrea Spain S.A.
  Signature date: 01/07/2024"
- **Espinosa Arranz E.** a phase 3 randomized, controlled study of imc-f106c plus nivolumab versus nivolumab regimens in hla-a*02:01-positive participants with previously untreated advanced melanoma (prism-mel-301)".
  Type/Phase: III
  Sponsored by: Immunocore Ltd.
  Signature date: 25/06/2024
- **Espinosa Arranz E.** ensayo de extensión de fase III, abierto y multicéntrico para estudiar la seguridad y eficacia a largo plazo en participantes con tumores avanzados que actualmente están en tratamiento o en seguimiento en un ensayo de pembrolizumab.
  Type/Phase: III
  Sponsored by: Merck Sharp And Dohme De España S.A.
  Signature date: 05/08/2024
- **Espinosa Arranz E.** ensayo en fase iii de fianlimab (anti-lag-3) y cemiplimab en comparación con pembrolizumab como terapia adyuvante en pacientes con melanoma de alto riesgo completamente extirpado.
  Type/Phase: III
  Sponsored by: Regeneron Pharmaceuticals Inc.;Signature date: 08/07/2024
- **Espinosa Arranz E.** ide196 (darovasertib) en combinación con crizotinib frente a la elección del investigador como tratamiento de primera línea en el melanoma maligno uveal metastásico con hla-a2 negativo.
  Type/Phase: IIb
  Sponsored by: Ideaya Biosciences Inc.
  Signature date: 24/10/2024
- **Espinosa Arranz E.** resultados de la investigación de una plataforma de registro europea sobre datos de vida-real de tratamiento en pacientes con cáncer de piel no melanoma (nmsc) avanzado.
  Type/Phase: EPA-SP
  Sponsored by: European Melanoma Registry
  Signature date: 03/07/2024
- **Feliú Batlle J.** a phase 1/2, safety confirmation and double-blind, placebo-controlled, randomized study of relatlimab in combination with nivolumab and bevacizumab in treatment-naïve

advanced/metastatic hepatocellular carcinoma (relativity-106).
Type/Phase: I
Sponsored by: Bristol-Myers Squibb International Corporation (Bmsic)
Signature date: 14/03/2024

- **Feliú Batlle J.** a phase iii, multicenter, randomized, open-label trial to evaluate the safety and efficacy of systemic therapy with regorafenib and pembrolizumab, versus locoregional therapy with transarterial chemoembolization (tace) or transarterial radioembolization (tare), for the first-line treatment of intermediate-stage hepatocellular carcinoma with beyond up-to-7 criteria (replace).
  Type/Phase: III
  Sponsored by: Translational Research Oncology (Trio)
  Signature date: 29/02/2024
- **Feliú Batlle J.** análisis de la supervivencia excepcional a largo plazo en pacientes con tumores sólidos de mal pronóstico.
  Type/Phase: OTROS
  Sponsored by: Cure 51;Feliú Batlle Jaime
  Signature date: 26/09/2024
- **Feliú Batlle J.** estudio de fase 2, abierto, multicéntrico, aleatorizado y de 3 grupos para evaluar la eficacia y la seguridad del ttx-030 en combinación con quimioterapia con o sin budigalimab, en comparación con la quimioterapia sola, para tratar a pacientes que no han recibido tratamiento previo para el adenocarcinoma de páncreas metastásico.
  Type/Phase: II
  Sponsored by: Trishula Therapeutics Inc.
  Signature date: 21/05/2024
- **Feliú Batlle J.** estudio de fase 2, abierto, multicéntrico, aleatorizado y de 3 grupos para evaluar la eficacia y la seguridad del ttx-030 en combinación con quimioterapia con o sin budigalimab, en comparación con la quimioterapia sola, para tratar a pacientes que no han recibido tratamiento previo para el adenocarcinoma de páncreas metastásico.
  Type/Phase: II
  Sponsored by: Trishula Therapeutics Inc.
  Signature date: 23/10/2024
- **Feliú Batlle J.** estudio de fase ib/ ii, pantumoral y en abierto para evaluar la eficacia y la seguridad de ifinatamab deruxtecán (i-dxd) en participantes con tumores sólidos recurrentes o metastásicos (ideate-pantumor02).
  Type/Phase: II
  Sponsored by: Daiichi Sankyo Inc.
  Signature date: 11/11/2024
- **Feliú Batlle J.** estudio en fase i, aleatorizado, sin enmascaramiento, de una sola dosis, de dos etapas, con biterapia y con grupos cruzados bidireccional para evaluar la bioequivalencia de onivyde (inyección liposomal de irinotecán) fabricado en dos centros diferentes y.
  Type/Phase: I
  Sponsored by: Ipsen Pharma S.P.S.
  Signature date: 17/04/2024
- **Ghanem Cañete I.** ensayo aleatorizado abierto sobre la eficacia y la seguridad del zanidatamab en combinación con el tratamiento habitual frente a solo tratamiento habitual para el cáncer de vías biliares avanzado positivo para her2.
  Type/Phase: III
  Sponsored by: Jazz Pharmaceuticals Ireland Limited
  Signature date: 11/06/2024
- **Ghanem Cañete I.** estudio de factores pronósticos y de respuesta a tratamiento quimioterápico en pacientes diagnosticados de cáncer de páncreas.
  Type/Phase: EOm prospectivo
  Sponsored by: Fundación Seom
  Signature date: 23/02/2024
- **Ghanem Cañete I.** revisión retrospectiva y longitudinal de historias clínicas de pacientes con colangiocarcinoma.
  Type/Phase: EOm prospectivo
  Sponsored by: Cerner Enviza France Sas
  Signature date: 12/07/2024
- **Pertejo Fernández A.** duration of treatment with parp inhibitors in patients with platinumsensitive recurrent ovarian cancer: how long is long enough?.
  Type/Phase: EOm prospectivo
  Sponsored by: Grupo Español De Investigacion En Cancer Ginecologico
  Signature date: 04/12/2024
- **Pinto Marín A.** a phase 1/2 study of epi-7386 in combination with enzalutamide compared with enzalutamide alone in subjects with metastatic castration-resistant prostate cancer.
  Type/Phase: II
  Sponsored by: Essa Pharma Inc.
  Signature date: 18/06/2024
- **Pinto Marín A.** estudio de fase i/ii para determinar la seguridad, farmacocinética y actividad clínica preliminar de bt8009 en pacientes con neoplasias malignas avanzadas que expresan nectina-4.
  Type/Phase: I
  Sponsored by: Bicycletx Ltd.
  Signature date: 19/03/2024
- **Pinto Marín A.** estudio de fase ib/ii abierto para evaluar tazemetostat en combinación con enzalutamida o; abiraterona/prednisona en pacientes con cáncer de próstata resistente a la castración metastásico, que no han recibido quimioterapia previa.
  Type/Phase: II
  Sponsored by: Epizyme Inc.
  Signature date: 05/03/2024"
- **Pinto Marín A.** estudio multicéntrico aleatorizado fase ii, doble ciego, para evaluar la eficacia y seguridad de autogene cevumeran más nivolumab frente a nivolumab como tratamiento adyuvante en pacientes con carcinoma urotelial músculo invasivo de alto riesgo.
  Type/Phase: II
  Sponsored by: F.Hoffmann-La Roche Ltd. Roche Farma S.A.
  Signature date: 14/05/2024
- **Pinto Marín A.** estudio multicéntrico aleatorizado fase ii, doble ciego, para evaluar la eficacia y seguridad de autogene cevumeran más nivolumab frente a nivolumab como tratamiento adyuvante en pacientes con carcinoma urotelial músculo invasivo de alto riesgo.
  Type/Phase: II
  Sponsored by: F.Hoffmann-La Roche Ltd. **Roche Farma S.A.**
  Signature date: 13/06/2024
- **Pinto Marín A.** estudio profit: manejo de radio-223 en pacientes con cáncer de próstata resistente a la castración metastásico (cprcm) en la práctica clínica habitual en españa; profit study: management of radium-223 in patients with metastatic castration-resistant prostate cancer (mcrpc) in real world clinical practice in spain..
  Type/Phase: EOm prospectivo
  Sponsored by: Bayer Hispania S.L.
  Signature date: 30/09/2024"
- **Pinto Marín A.** psmaddition: estudio de fase iii, prospectivo, aleatorizado, abierto e internacional en el que se compara 177lu-psma-;617 en combinación con el tratamiento de referencia con el tratamiento de referencia en monoterapia en pacientes varones adultos con cáncer de próstata metastásico sensible a hormonas.
  Type/Phase: III
  Sponsored by: Novartis Farmaceutica S.A.
  Signature date: 31/10/2024"
- **Pinto Marín A.** un estudio de fase iii abierto, aleatorizado y controlado de disitamab vedotin en combinación con pembrolizumab, en comparación con quimioterapia, en sujetos con carcinoma urotelial localmente avanzado o metastásico no tratado previamente que expresa her2 (ihc 1+ y superior).
  Type/Phase: III
  Sponsored by: Seagen Inc.
  Signature date: 10/06/2024
- **Redondo Sánchez A.** a phase 2/3, multicenter, randomized study of raludotatug deruxtecan (r-dxd), a cdh6-directed antibody-drug conjugate, in subjects with platinum-resistant, high-grade ovarian, primary peritoneal, or fallopian tube cancer.
  Type/Phase: II
  Sponsored by: Daiichi Sankyo Inc.
  Signature date: 28/02/2024
- **Redondo Sánchez A.** a phase 2/3, multicenter, randomized study of raludotatug deruxtecan (r-dxd), a cdh6-directed antibody-drug conjugate, in subjects with platinum-resistant, high-grade ovarian, primary peritoneal, or fallopian tube cancer.
  Type/Phase: II
  Sponsored by: Daiichi Sankyo Inc.
  Signature date: 18/06/2024
- **Redondo Sánchez A.** duoende a phase iiib study to evaluate the use of durvalumab in combination with platinum-based chemotherapy followed by durvalumab with olaparib as first-line treatment in patients with newly diagnosed pmmr advanced or recurrent endometrial cancer in spain.
  Type/Phase: IIIb
  Sponsored by: Astrazeneca Farmaceutica Spain S.A.
  Signature date: 18/11/2024
- **Redondo Sánchez A.** estudio aleatorizado,

abierto, fase 3 de tisotumab vedotina frente a la quimioterapia elegida por el investigador en segunda o tercera línea en el cáncer de cuello uterino recidivante o metastásico.
Type/Phase: III
Sponsored by: Seagen Inc.
Signature date: 10/06/2024"

- **Redondo Sánchez A.** estudio de fase 3, aleatorizado, comparativo con tratamiento activo, abierto y multicéntrico para comparar la eficacia y la seguridad de mk-2870 en monoterapia frente al tratamiento elegido por el médico en participantes con cáncer de endometrio que han recibido previamente quimioterapia con un derivado del platino e inmunoterapia (engot-en23/gog3095).
  Type/Phase: III
  Sponsored by: Merck Sharp & Dohme Llc
  Signature date: 01/07/2024
- **Redondo Sánchez A.** estudio de fase 3, aleatorizado, comparativo con tratamiento activo, sin enmascaramiento y multicéntrico para comparar la eficacia y la seguridad de mk-2870 en monoterapia frente al tratamiento elegido por el médico como tratamiento de segunda línea en participantes con cáncer de cuello uterino recurrente o metastásico (trofuse-020/gog-3101/engot-cx20).
  Type/Phase: III
  Sponsored by: Merck Sharp & Dohme Llc
  Signature date: 28/05/2024
- **Redondo Sánchez A.** estudio de fase i para evaluar la seguridad, tolerabilidad, farmacocinética y actividad clínica de gsk5733584 en participantes con tumores sólidos avanzados.
  Type/Phase: I
  Sponsored by: Glaxosmithkline Research And Development Limited
  Signature date: 18/12/2024
- **Redondo Sánchez A.** estudio en fase ii aleatorizado de la evaluación y la mitigación de la toxicidad ocular durante el tratamiento con mirvetuximab soravtansina en pacientes con cáncer de ovario recurrente con una alta expresión del receptor de folato α.
  Type/Phase: II
  Sponsored by: Immunogen Inc.
  Signature date: 03/12/2024
- **Redondo Sánchez A.** phase ii multicohort trial of trabectedin and low-dose radiation therapy in advanced/metastatic sarcomas.
  Type/Phase: II
  Sponsored by: Grupo Español De Investigacion En Sarcomas
  Signature date: 10/01/2024
- **Redondo Sánchez A.** phase ii study to assess the efficacy of niraparib rechallenge treatment after surgery in ovarian cancer patients with oligometastatic progression (anallisa).
  Type/Phase: II
  Sponsored by: Medica Scientia Innovation Research S.L
  Signature date: 10/07/2024
- **Redondo Sánchez A.** realze: real-word evidence retrospective study on the characteristics, treatment patterns, and outcomes of patients newly diagnosed with advanced epithelial high-grade serous ovarian cancer.
  Type/Phase: EOm no prospectivo
  Sponsored by: Glaxosmithkline Research And Development Limited
  Signature date: 24/01/2024
- **Rodríguez Salas N.** a randomized, multicentre, open-label controlled phase ii trial of foxy-5 as neo-adjuvant therapy in subjects with wnt-5a low colon cancer.
  Type/Phase: II
  Sponsored by: Wnt Research Ab Peter Morsing
  Signature date: 04/06/2024
- **Rodríguez Salas N.** estudio de fase 3 abierto, aleatorizado, perioperatorio de dostarlimab en monoterapia frente al tratamiento estándar en pacientes con cáncer de colon resecable con pérdida del mecanismo de reparación de apareamiento de bases (dmmr)/inestabilidad de microsatélites alta (msi-h), t4n0 o estadio iii, no tratado.
  Type/Phase: III
  Sponsored by: Glaxosmithkline Research And Development Limited
  Signature date: 16/05/2024
- **Rodríguez Salas N.** estudio de fase i/iia, abierto y multicéntrico, para evaluar la seguridad, tolerabilidad, farmacocinética y, de manera preliminar, la eficacia de art0380, un inhibidor de la quinasa atr, administrado por vía oral en monoterapia y en combinación a pacientes con tumores sólidos avanzados o metastásicos.
  Type/Phase: IIa
  Sponsored by: Artios Pharma Ltd.
  Signature date: 14/11/2024
- **Rodríguez Salas N.** estudio en fase iii, abierto y aleatorizado de tucatinib en combinación con trastuzumab y mfolfox6 frente a mfolfox6 administrado con o sin cetuximab o bevacizumab como tratamiento de primera línea para pacientes con cáncer colorrectal metastásico her2+.
  Type/Phase: III
  Sponsored by: Seagen Inc.
  Signature date: 25/09/2024
- **Rodríguez Salas N.** phase 3 multicenter, randomized, open-label, active-controlled study of sotorasib, panitumumab and folfiri versus folfiri with or without bevacizumab-awwb for treatment-naïve subjects with metastatic colorectal cancer with kras p.g12c mutation(codebreak 301).
  Type/Phase: III
  Sponsored by: Amgen Inc.
  Signature date: 06/06/2024
- **Virginia Martinez Marin.** a phase 3, randomized, open-label, multicenter trial of arv-471 (pf-07850327) vs fulvestrant in participants with estrogen receptor-positive, her2-negative advanced breast cancer whose disease progressed after prior endocrine based treatment for advanced disease (veritac-2).
  Type/Phase: III
  Sponsored by: Pfizer Inc.
  Signature date: 25/06/2024
- **Virginia Martinez Marin.** an open-label, multicenter, phase 2 dose optimization and expansion study to evaluate the safety and efficacy of bb-1701, an anti-human epidermal growth factor receptor 2 (anti-her2) antibody-drug conjugate (adc), in previously treated subjects with her2-positive or her2-low unresectable or metastatic breast cancer.
  Type/Phase: II
  Sponsored by: Eisai Inc.
  Signature date: 10/06/2024
- **Virginia Martinez Marin.** demether: a multicenter, open-label, single-arm, phase ii trial exploring the maintenance of trastuzumab and pertuzumab following trastuzumab deruxtecan as induction treatment for her2-positive unresectable locally recurrent or metastatic breast cancer patients.
  Type/Phase: II
  Sponsored by: Medica Scientia Innovation Research S.L
  Signature date: 16/07/2024
- **Virginia Martinez Marin.** estudio retrospectivo, observacional y multicéntrico del tratamiento con sacituzumab govitecan en pacientes con cáncer de mama triple negativo localmente avanzado y/o metastásico en la práctica clínica habitual en españa (tropspain.
  Type/Phase: EOm no prospectivo
  Sponsored by: Gilead Sciences S.L.
  Signature date: 09/02/2024
- **Virginia Martinez Marin.** preoperative window of opportunity study with giredestrant (gdc-9545) or tamoxifen in premenopausal women with er[+]/her2[-] & ki67≥10% early breast cancer.
  Type/Phase: II
  Sponsored by: Medica Scientia Innovation Research S.L
  Signature date: 16/07/2024
- **Zamora Auñon P.** a phase 1b/2, open-label umbrella study to evaluate safety and efficacy of elacestrant in various combinations in patients with metastatic breast cancer (elevate).
  Type/Phase: I
  Sponsored by: Stemline Therapeutics Inc.
  Signature date: 15/01/2024
- **Zamora Auñon P.** a proof of concept study to evaluate treatments' efficacy by monitoring minimal residual disease using ctdna in hr-positive/her2-negative early breast cancer population. the mirador study.
  Type/Phase: II
  Sponsored by: Medica Scientia Innovation Research S.L
  Signature date: 29/05/2024
- **Zamora Auñon P.** ensayo fase iii de trastuzumab

deruxtecan (t-dxd) con osin pertuzumab versus taxanos, trastuzumab y pertuzumab en primera línea de cáncer de mama metastásico her2 positivo (destiny-breast09.
Type/Phase: III
Sponsored by: Astrazeneca Ab
Signature date: 17/09/2024

- **Zamora Auñon P.** estudio observacional, prospectivo, multicéntrico e internacional, de pacientes que comiencen con t-dxd en su primera o segunda línea de tratamiento por cáncer de mama her2+ o her2-low no resecable y/o metastásico.
Type/Phase: EOm prospectivo
Sponsored by: Astrazeneca Ab
Signature date: 19/03/2024

Patents and trademarks

- **Cejas Guerrero P, Belda Iniesta C, Feliú Batlle J, González Barón M, de Castro Carpeño J, Casado Sáenz E, Sánchez Hernández JJ, inventors; FIBHULP, UAM, assignees.** Genomic fingerprint for the prognosis of the evolution of colorectal adenocarcinoma. P200703229, PCT/ES2008/000756, EP2236626; 2007 December 04.
- **Cejas Guerrero P, Belda Iniesta C, Feliú Batlle J, de Castro Carpeño J, Moreno García V, Burgos Lizalde E, Casado Sáenz E, Sánchez Hernández JJ, inventors; FIBHULP, UAM, Empresa Pública Hospital del Norte, assignees.** Genomic fingerprint for predicting the clinical response to an antitumor therapy in colorectal cancer. P201130863, PCT/ES2012/070379; 2011 May 26.
- **Espinosa Arranz E, Fresno Vara JA, Gámez Pozo A, Sánchez Navarro I, inventors; FIBHULP, assignee.** Method for tumor subclassification. P200803509, PCT/ES2009/070533; 2008 December 11.
- **Redondo Sánchez A, Hardisson Hernaéz D, Barriuso Feijoo J, Mendiola Sabio M, inventors; FIBHULP, assignee.** Method to obtain useful data for the prediction of a patient's clinical response to an anticancer treatment. P200930400; 2009 July 01.



- **Cejas Guerrero P, González Barón M, Casado Sáenz E, Sánchez Hernández JJ, Perona Abellón R, inventors; FIBHULP, UAM, CSIC, assignees.** Use of trefoil factor family 3 (TFF3) in the prognosis of patients diagnosed with colorectal cancer. P200703230, PCT/ES2008/000757, EP2236625; 2007 December 04.
- **Moreno Rubio J, Cejas Guerrero P, Feliú Batlle J, Ramírez de Molina AI, Reglero Rada G, Vargas Alonso T, Molina Arranz S, González-Vallinas Garrachón M, inventors; FIBHULP, Fundación Imdea Alimentacion, assignees.** Methods and kits for the prognosis of colorectal cancer. P201231918, PCT/ES2013/070864; 2012 December 10.
- **Espinosa Arranz E, Fresno Vara JA, Gámez Pozo A, López Vacas R, Berges Soria J, inventors; FIBHULP, assignee.** Method for tumor subclassification. P201430887, 2014 June 09.
- **Miranda Utrera N, Castellano D, Villacampa Aubá F, Fresno Vara JA, Gámez Pozo A, inventors; FIBH120, FIBHULP, assignees.** Prognostic method for determining the risk of relapse in renal cancer patients with a clear cell type of renal carcinoma, stages I and II, and kit for same. P201531360, PCT/EP2016/072723, EP16774644.5, US20180346990, CN108174608; 2015 September 23.
- **Feliú Battle, J, Fernández Martos C, Fresno Vara JA, Ghanem Cañete I, Gámez Pozo A, Trilla Fuertes L, inventors; Biomedica Molecular Medicine SL (BMM), Grupo Español Multidisciplinar en Cáncer Digestivo (GEMCAD), assignees.** In vitro method for the prognosis of anal squamous cell carcinoma. EP19382982.7; 2019 November 11.
- **Redondo Sánchez A, Hardisson Hernaéz D, Barriuso Feijoo J, Mendiola Sabio M, inventors; FIBHULP, assignee.** Method to obtain useful data for the prediction of a patient's pathological response to an anticancer treatment. P200930438; 2009 July 10.
- **Fernández Martos C, Trilla Fuertes L, Fresno Vara JA, Gámez Pozo A, Ghanem Cañete I, Feliú Battle J, inventors; Biomedica Molecular Medicine SL, Grupo Español Multidisciplinar en Cáncer Digestivo (GEMCAD), assigne.** In vitro method for the prognosis of anal squamous cell carcinoma. EP19382982.7; 2019; 2019 November 11.

3.5.3 Experimental Therapies and Biomarkers in Cancer



Publications: 9 | **Q1:** 7

COMPOSITION

Javier de Castro Carpeño.
Director Científico de IdiPAZ. Jefe de Sección de Oncología. Hospital Universitario La Paz. Profesor Asociado. Universidad Autónoma de Madrid
Olga Vera Puente.
Investigadora Principal, Miguel Servet. FIBHULP

- **Ana Arauzo Cabrera.** *Investigadora Predoctoral. FIBHULP*
- **María José Beato Merino.** *Facultativo Especialista de Área en Anatomía Patológica Hospital Universitario La Paz*
- **Miranda Burdiel Herencia.** *Investigadora Predoctoral. Universidad Autónoma de Madrid*
- **César Casado Sánchez.** *Profesor Asociado Universidad Autónoma de Madrid*
- **Patricia Cruz Castellanos.** *Facultativo Especialista de Área en Oncología Médica. Hospital Universitario La Paz*
- **Lucía de Dios Blázquez.** *Bioinformática. FIBHULP*
- **María Dolores Diestro Tejada.** *Facultativo Especialista de Área en Ginecología y Obstetricia. Unidad de Ginecología Oncológica. Hospital Universitario La Paz*
- **María Isabel Esteban Rodríguez.** *Facultativo Especialista de Área en Anatomía Patológica. Hospital Universitario La Paz*
- **Álvaro García Guede.** *Investigador Predoctoral. FIBHULP*
- **Laura Gutiérrez Sainz.** *Facultativo Especialista de Área en Oncología Médica. Hospital Universitario La Paz*
- **Cristina Manguán García.** *Técnico de Laboratorio. Instituto de Investigaciones Biomédicas Sols-Morreale*
- **Ander Paulo Mayor Ibarguren.** *Facultativo Especialista de Área en Dermatología. Hospital Universitario La Paz*
- **Rocío Moreno Velasco.** *Técnico de Laboratorio. FIBHULP*
- **Olga Pernía Arias.** *Investigadora Predoctoral. Universidad Autónoma de Madrid*
- **Carlos Rodríguez Antolín.** *Bioinformático. FIBHULP*
- **Rocío Rosas Alonso .** *Facultativo Especialista de Área en Bioquímica Clínica. Hospital Universitario La Paz*
- **Sara Ruiz Buceta.** *Investigadora Predoctoral FIBHULP*
- **Paloma Nerea Yubero Delgado.** *Técnico Auxiliar en Enfermería. FIBHULP*

STRATEGIC OBJETIVES

- Genetic and epigenetic mechanisms play significant roles in tumor progression and the development of resistance to treatment. The dynamic nature of tumors and their ability to adapt and resist therapies pose critical challenges in clinical practice. In our research, we have employed diverse strategies to address these challenges. Firstly, we have focused on the identification of novel markers throughout the course of lung cancer, aiming to uncover crucial indicators of disease progression. Additionally, we have pursued various approaches to identify specific targets involved in drug response, striving to enhance treatment efficacy. Our investigations have transcended the realm of theory, extending into the realm of clinical practice through the meticulous analysis of human samples. It is through this granular examination that we have unraveled the alterations occurring at the individual patient level. Moreover, we have successfully pinpointed epigenetic changes in tumor suppressor genes that are strongly associated with drug resistance. Furthermore, we have made significant strides in understanding the role of epigenetic regulators in lung and melanoma, particularly in the context of oxidative stress. These findings shed light on novel avenues for therapeutic interventions and provide valuable insights into the complex interplay between genetic, epigenetic, and environmental factors in cancer progression and treatment resistance.
- Through the application of genomic, transcriptomic, and expression reactivation techniques, we have made significant strides in identifying a diverse array of biomarkers, including genes and microRNAs. These biomarkers hold immense potential for non-invasive cancer diagnosis, particularly in the context of non-small cell lung cancer (NSCLC). Our pioneering research has demonstrated the efficacy of liquid biopsy as a reliable method for detecting these biomarkers, providing a promising avenue for early detection and diagnosis of lung cancer. In addition, we have focused our attention on assessing chronic obstructive pulmonary disease (COPD) patients to establish the presence of early-stage lung cancer. By leveraging these advanced techniques, we have successfully unraveled the intricate transcriptomic alterations at miRNA level, occurring during the establishment of lung cancer in COPD patients. These groundbreaking findings not only hold great promise for improving the accuracy and efficiency of cancer diagnosis but also pave the way for personalized treatment approaches that can potentially enhance patient outcomes.



RESEARCH LINES

- Identification of predictive epigenetic biomarkers in the appearance of resistance to treatment in solid tumors. Within the oncological markers, those for predictive use are the most necessary to help direct therapies since the vast majority of patients are diagnosed when the tumor needs to be treated. Platinum-derived compounds are the standard treatment for high-incidence tumors such as those of the lung, ovary, and rectum, so the fact of finding markers of response to their use would allow the selection of patients, optimizing treatment and associated healthcare costs.
  - Lung cancer: In this line we have identified the methylation of the IGFBP3 gene promoter, whose epigenetic silencing is related to platinum resistance, extending its validation to cohorts of lung cancer patients likely to benefit from its use. In addition, the effectiveness of this biomarker is being tested in liquid biopsy as a non-invasive test. This line of research has given rise to three concatenated publications (Oncogene 2010 PMID: 20023704, Oncogene 2013 PMID: 22543588, Epigenetics 2014 PMID: 25482372) and a patent in the joint exploitation phase with a Spanish biotechnology company that has licensed said patent. This patent has passed a Pre-commercial Public Purchase in SERGAS and its validation in national phases has had the support of two concatenated RETOS projects.
  - Brain Tumors: Regarding our line with brain tumors, we assess the methylation status of the MGMT gene in glioblastomas, as a care and research task since 2014 in our laboratory, developing advanced high-sensitivity technology for its detection in liquid biopsy. The data obtained to date in more than 200 patients in a prospective trial has given rise to a recent publication (Clinical epigenetics 2021 PMID: 33750464) and a second article in process, in addition to a European patent that has just passed PCT extension, and the award of two competitive public projects, one of them a DTS20 technological project for diagnosis and blood monitoring of patients with glioblastomas, and a PLEC project (RETOS) in collaboration with Val`deHebron for fine-tuning diagnostic technologies and monitoring with tracers PET. In addition, these results have allowed the defense in 2021 of the doctoral thesis of Rocío Rosas, a member of our team, who has just started her independent line in January 2022 as a "Juan Rodés" researcher.
  - Ovarian Cancer: We also have an open line in ovarian cancer, in which we have published a recent article (Clinical Epigenetics 2021 PMID: 34454589) and has allowed us to participate as work package leaders in a Transcan European project led by Italy, which has just successfully passed the first round of evaluation.
  - Melanoma. In this emerging line, we are focusing on the characterization of the oncogenic role of MAFG in the response to immunotherapy in melanoma. Dr. Olga Vera, recently has incorporated to the group as a Sara Borrell postdoctoral researcher to lead this line. Previous studies of Olga have identified MAFG as a potential oncogene in melanoma and with potential therapeutic applications. The successful completion of our study will significantly advance our understanding of the role of MAFG in melanoma, determine new therapeutic targets and open new lines of research focused on dissecting the oncogenic role of MAFG.
- Study of the molecular mechanisms underlying simultaneous resistance to platinum in cancer, through the epigenetic regulation of regulatory non-coding RNAs. In this line, changes in the expression of microRNAs and lncRNAs in platinum-sensitive and -resistant human NSCLC and ovarian cancer cell lines established in our research group are studied. We have identified 7 microRNAs whose expression appears to be under epigenetic regulation. One of them under the epigenetic regulation of its regulatory region (miRNA-7) as a potential predictive biomarker of response to platinum in ovarian cancer in terms of overall survival and time to progression. Product of the development of this line has been the publication of an article in the journal (Theranostics 2017 PMID: 29158814), as well as a patent that is in the PCT phase. Based on these findings, in 2016 we began a collaboration with the MOFFITT cancer center in Tampa (USA) to study Long Non-Coding RNAs (lnc-RNAs) and their possible regulation through DNA methylation in these cell lines. With this project we assess the changes in the expression of lncRNAs and their epigenetic regulation at the level of DNA methylation, characterizing two groups of lncRNAs differentially regulated in the development of resistance to cisplatin, and thus opening the way for the identification of new ones. As a result of the activity of this collaboration, highly innovative results were obtained in this field (Epigenetics PMID: 29436261 and Translational Research 2018, PMID: 30053382), and the research activity focused on the characterization of these novel biomarkers is maintained thanks to the funding supported for the PI21/00145 and Caixa Impulse projects.
- Identification of new therapeutic targets. In recent years we have also identified the direct regulation of the MAFG gene through miR-7 in our experimental models. The function of MAFG is associated with detoxification in a situation of oxidative stress and our in vitro studies have shown its involvement in the appearance of cisplatin-resistant phenotypes. Our translational approach indicates that MAFG could be a diagnostic marker in patients with lung and ovarian cancer treated with platinum-based chemotherapy. To date, this line has provided four articles (Translational Research 2018, PMID: 30053382; Cell Biosci. 2019 PMID: 31406565; Arch Bronconeumol (Engl Ed). 2020.PMID: 31780284; Antioxidants (Basel).PMID: 32492865) and one European patent that has just been extended to national phases in the USA and Europe, which describes the clinical use of MAFG in patients with lung and ovarian cancer. We have currently addressed the study and use of MAFG as a therapeutic target through in vitro and in vivo assays after editing the MAFG gene using CRISPR/Cas9 technology, a project funded by the ISCIII (PI18/00050, P21/000145) in addition to extending and validating its use with the potential development of a kit for clinical use thanks to obtaining a RETOS project (RTC2019-007229-1) from the 2019 call and which is ongoing with the collaboration of H. Ramón y Cajal and the companies Aptus and Atrys.
- Identification of biomarkers in exosomes such as liquid biopsy in patients with lung and ovarian cancer. With this line we intend, through a first basic approach, to characterize and compare the protein and microRNA content of exosomes from the secretome of paired sensitive and resistant lung cancer cell lines. In the translational study of the project, the candidates identified in the cell lines in circulating exosomes from samples of lung and ovarian cancer patients are being validated, which have given rise to different results. On the one hand, two candidate miRNAs with prognostic significance in this pathology, and on the other hand, a miRNA with possible universal value has been identified as endogenous capable of normalizing the value of the content of the exosomal miRNoma, both in healthy individuals and in individuals with different tumor types. These results have given rise to a European patent that is in national phases and the obtaining of a Caixa Impulse Validate project for the constitution of a Spin-off, in our institution focused on the development of a first RUO product for the normalization of exosomal content. in human blood samples, in addition to two manuscripts in preparation, as well as the defense of Julia Jiménez's thesis in July 2019.
- Identification of pharmacogenetic biomarkers associated with efficacy and toxicity of cancer treatments. Led by Dr R Rosas. Pharmacogenetics is the field of knowledge that seeks to identify genetic variants to provide information that will allow a better understanding of drug response in terms of efficacy and toxicity, thus contributing to personalised precision medicine. Despite progress in the research and development of new cancer treatments, the efficacy and safety of

these drugs vary widely between patients. In this context, this line of research aims to understand how genetic variations in individuals may influence the efficacy and toxicity of cancer treatments. The use of pharmacogenetic biomarkers is a reality in routine clinical practice and has been shown to improve the efficacy and reduce the side effects of treatments, resulting in a better quality of life for patients and reduced costs for the national healthcare system. Our ultimate goal is to identify new pharmacogenetic biomarkers that will allow better selection of cancer treatments for each patient, thus promoting the medicine of the future with a personalised and individualised approach. This line currently has two projects awarded in public (PI22/00128) and private (Jose Luis Castaño-SEQC Foundation) competitive calls, led by Dr Rocío Rosas."

- Identification of microRNA hypermethylation patterns associated with an increased risk of developing non-small cell lung cancer in patients with mild COPD and moderate to high tobacco consumption. In recent years, the potential role of epigenetic alterations in the development of lung cancer in COPD patients, mediated by changes in the activity of various microRNAs, small non-coding RNA molecules (19-25 nucleotides) with a regulatory function of gene expression, which induce the degradation of messenger RNA or inhibit its translation, has gained particular importance. It is therefore interesting to consider whether there may be hypermethylation profiles of different microRNAs that are associated with an increased risk of lung cancer in COPD patients, which would facilitate appropriate risk selection for screening programmes.This line currently has one project, which was awarded in a competitive public call (PI22/001764), under the co-direction of Olga Pernía Arias.
- Fine-tuning of high performance techniques available to the National Health System (NHS). (NGS and Characterization of DNA methylation status). Implicit in the group's cross-cutting lines and in our commitment to support the implementation in the NHS of the technological advances derived from our research activity, we have fine-tuned the characterization of the methylation status at the PAZ genetics facilities of DNA through the use of these new aspects of NGS applied to the field of epigenetics, both from a global approach and limited to certain regions, to implement its possible care applicability in cancer patients through personalized panels in solid tumors including glioblastomas, through the use of Methylseq technology and the 850K EPIC-arrays. Likewise, in these years we have fine-tuned the use of commercial NGS panels in strict compliance with quality regulations to address the characterization of the genetic profile of tumors in patients with lung cancer. Thanks to the addition to our team such as Dra Rocío Rosas, Juan Rodés from 2022, we are starting the hospital implementation phase, in which we have already tested careers with various platforms from different commercial houses. Its fine-tuning would allow its use both for research activities and its future healthcare applicability, especially in the classification of brain tumors. This activity is financed by the Spanish Group of Transversal Oncology and Rare Orphan Tumors (Getthi), which has just financed the group with a competitive project for this purpose. Given the experience acquired by the group in the use of massive data, we have been able to participate in the EU ISIDORE project and have begun the study of predictive bioinformatic matrices of response to platinum treatment. We intend to combine the information available in public domain databases with relevant clinical information associated with our own experimental results (methylation and gene expression microarrays and microRNAs, bisulfite sequencing, RNAseq and miRNAseq) to generate a predictive matrix of response to treatment. With these analytical models, we intend to identify "global markers" that define a predictive profile for treatment with platinum in lung and ovarian cancer based on the transcriptome, microRNome, and/or methylome. **This research line is led by Carlos Rodriguez Antolín, Bioinformatic of the group. Breast cancer**

RESEARCH ACTIVITY

Master Theses

- **Arauzo Cabrera A.** Estudio del perfil de expresión diferencial de miARNs en la detección temprana del cáncer de pulmón no microcítico[dissertation]. Madrid: Univerisad Autónoma de Madrid: 2024(26/06/2024). Director: Ibáñez de Cáceres I

Final Degree Theses

- **Ruiz Buceta S.** Caracterización de los genes diana de MAFG en la progresión del melanoma[dissertation]. Madrid: Universidad Francisco de Vitoria: 2024(01/07/2024). Director: Vera Puente O

Publications

- **Arriola E, de Castro J, García-Campelo R, Bernárdez B, Bernabé R, Bruna J, Dómine M, Isla D, Juan-Vidal O, López-Fernández T, Nadal E, Rodríguez-Abreu D, Vares M, Asensio U, Garcia LF, Felip E.** Expert Consensus on the Management of Adverse Events of Lorlatinib in the Treatment of ALK plus Advanced Non-small Cell Lung Cancer. Clin Drug Invest. 2024; 44(8): 553-76. Review. IF: 2.7; Q2
- **Conde E, Hernández S, Carrillo JLR, Martínez R, Alonso M, Curto D, Jimenez B, Caminoa A, Benito A, Garrido P, Clave S, Arriola E, Esteban-Rodríguez I, De Castro J, Sansano I, Felip E, Rojo F, Dómine M, Abdulkader I, Garcia-Gonzalez J, Teixido C, Reguart N, Compañ D, Insa A, Mancheño N, Palanca S, Juan-Vidal O, Baixeras N, Nadal E, Cebollero M, Calles A, Martin P, Salas C, Provencio M, Aranda I, Massuti B, López-Vilaro L, Majem M, Paz-Ares L, López-Rios F.** RET Fusion Testing in Patients With NSCLC: The RETING Study. JTO Clin Res Rep. 2024; 5(4): 100653. Article. IF: 3.5; Q1
- **Molina-Alejandre M, Perea F, Calvo V, Martínez-Toledo C, Nadal E, Sierra-Rodero B, Casarrubios M, Casal-Rubio J, Martínez-Martí A, Insa A, Massuti B, Viteri S, Aranda IB, Rodríguez-Abreu D, de Castro J, Martínez JM, Cobo M, Wistuba II, Parra ER, Martín-López J, Megías D, Muñoz-Viana R, Garrido F, Aptsiauri N, Ruiz-Cabello F, Provencio M, Cruz-Bermúdez A.** Perioperative chemoimmunotherapy induces strong immune responses and long-term survival in patients with HLA class I-deficient non-small cell lung cancer. J Immunother Cancer. 2024; 12(10): e009762. Article. IF: 10.6; D1
- **Peña-López J, Gutiérrez-Sainz L, Jiménez-Bou D, Ruíz-Gutiérrez I, Navas-Jiménez C, Alonso-Eiras JI, García-Zamarriego A, Sánchez-Cabrero D, Ruíz-Giménez L, Pertejo-Fernández A, Villamayor-Sánchez J, Cruz-Castellanos P, Higuera-Gómez O, de Castro J.** Assessing Prognosis: Factors Influencing Outcomes in Hospitalized Lung Cancer. Onco (Basel). 2024; 4(4): 458-70. Article. Not Indexed
- **Peressini M, Garcia-Campelo R, Massuti B, Marti C, Cobo M, Gutiérrez V, Dómine M, Fuentes J, Majem M, de Castro J, Córdoba JF, Diz MP, Isla D, Esteban E, Carcereny E, Vila L, Moreno-Vega A, Ros S, Moreno A, García FJ, Huidobro G, Aguado C, Cebey-López V, Valdivia J, Palmero R, Lianes P, López-Brea M, Vidal OJ, Provencio M, Arriola E, Baena J, Herrera M, Bote H, Molero M, Adradas V, Ponce-Aix S, Núñez-Buiza A, Ucero A, Hernández S, López-Rios F, Conde E, Paz-Ares L, Zugazagoitia J.** Spatially Preserved Multi-Region Transcriptomic Subtyping and Biomarkers of Chemoimmunotherapy Outcome in Extensive-Stage Small Cell Lung Cancer. Clin Cancer Res. 2024; 30(14): 3036-49. Article. IF: 10.2; D1
- **Provencio M, de Lope LR, Serna-Blasco R, Nadal E, Tain PD, Massuti B, González-Larriba JL, Insa A, Sánchez-Hernández A, Casal-Rubio J, Garcia-Campelo R, López SS, Rogado J, Martínez-Martí A, Bosch-Barrera J, Bernabé R, Estévez SV, Ponce S, de Castro J, Sarto JC, Reguart N, Dómine M, Aguilar A, Majem M, Estival A, Cabia SP, Martín AL, González MAS, Cobo M, Camps C, Barneto I, Calvo V,**



Collazo-Lorduy A, Cruz-Bermúdez A, Romero A. BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC. Lung Cancer. 2024; 194: 107865. Article. IF: 4.4; Q1

- **Provencio M, Nadal E, Insa A, Campelo RG, Casal J, Dómine M, Massuti B, Majem M, Rodríguez-Abreu D, Martínez-Marti A, de Castro J, de Antonio DG, Macia I, Figueroa S, Vago LF, Calvo V, Palmero R, Sierra-Rodero B, Martínez-Toledo C, Molina-Alejandre M, Serna-Blasco R, Romero A, Cruz-Bermúdez A.** Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2024; 25(11): 1453-64. Article. IF: 35.9; D1
- **Rosas-Alonso R, Colmenarejo-Fernández J, Pernía O, Burdiel M, Rodríguez-Antolín C, Losantos-García I, Rubio T, Moreno-Velasco R, Esteban-Rodríguez I, Martínez-Marín V, Yubero P, Costa-Fraga N, Díaz-Lagares A, López-López R, Díaz-Martin E, García JF, Sánchez CV, Gandía-González ML, Moreno-Bueno G, de Castro J, de Cáceres II.** Evaluation of the clinical use of MGMT methylation in extracellular vesicle-based liquid biopsy as a tool for glioblastoma patient management. Sci Rep-Uk. 2024; 14(1): 11398. Article. IF: 3.9; Q1
- **Soo RA, Dafni U, Han JY, Cho BC, Nadal E, Yeo CM, Carcereny E, de Castro J, Sala MA, Coate L, Provencio M, Britschgi C, Vagenknecht P, Dimopoulou G, Kammler R, Finn SP, Peters S, Stahel RA.** ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial. Clin Cancer Res. 2024; 30(22): 5180-91. Article. IF: 10.2; D1

Research projects

- **Cruz Castellanos p.** App respira. Boehringer Ingelheim España S.A. 2019-Ongoing. Managment centre: FIBHULP
- **de Castro Carpeño J.** Avanzando en el tratamiento del cáncer de pulmón con terapia dirigida. un paso más: de la investigación a la práctica clínica. Pfizer S.L.U.. 2022-Ongoing. Managment centre: FIBHULP
- **de Castro Carpeño J.** Desarrollo de las tareas necesarias para la puesta en marcha del estudio clínico ml40221 título: estudio de práctica clínica en condiciones reales para evaluarla toma de decisiones en el tratamiento de segunda línea conforme a las normas asistenciales y basado en los perfiles de foundation medicine en pacientes con cáncer de pulmón no microcítico (CPNM) localmente avanzado o metastásico con histologia de adenocarcinoma en españa. Roche Farma S. A. 2018-Ongoing. Managment centre: FIBHULP
- **de Castro Carpeño J.** Determinación mediante inmunohistoquímica de la expresion de PDL-1 en carcinoma de célula no pequeña de pulmón. Fundación ECO. 2016-Ongoing. Managment centre: FIBHULP
- **de Castro Carpeño J.** Eluxa 2: estudio de fase III, abierto, aleatorizado y controlado con producto activo, multicéntrico e internacional, para evaluar la eficacia de BI1482694 frente a un doblete de quimioterapia estandar que incluye platino en pacientes con cáncer de pulmón no microcítico localmente avanzado o metastásico, con la mutación T790 M, cuya enfermedad ha progresado con el tratamiento previo con un inhibidor de la tirosina cinasa del receptor del factor de crecimiento epidérmico (EGFR-TKI). Parexel International (Irl) Limited. 2016-Ongoing. Managment centre: FIBHULP
- **de Castro Carpeño J.** Estudio de la Plasticidad Tumoral Epigenética a través de la carcinogénesis y progresión del CPNM en biopsia líquida. SETuP (PI21/00145). ISCIII. 2022-2024. Managment centre: FIBHULP
- **de Castro Carpeño J.** Evaluación del perfil de hipermetilación de microRNAs para la estimación de riesgo de cáncer de pulmón en pacientes con EPOC (PI22/01764). ISCIII. 2023-2025. Managment centre: FIBHULP
- **de Castro Carpeño J.** Identificación de nuevos mecanismos genéticos y epigenéticos de resistencia a la inmunoterapia de primera linea en pacientes con cáncer de pulmón no microcítico metastásico (CPNMM) con alta expresión PD-l1. Estudio keypredict. Fundación Mutua Madrilena. 2022-Ongoing. Managment centre: FIBHULP
- **de Castro Carpeño J.** Plataforma del grupo de investigación de terapias experimentales y biomarcadores en cáncer. Helicon Medical S.L. 2021-Ongoing. Managment centre: FIBHULP
- **de Castro Carpeño J.** Prestación de servicios para el desarrollo de las tareas necesarias en el estudio Estudio observacional de alectinib en pacientes con CPNM ALK+ en el programa de acceso precoz en España. Roche Farma S. A. 2018-Ongoing. Managment centre: FIBHULP
- **de Castro Carpeño J.** SurvAI: Plataforma web para la automatización de la anotación, clasificación e interpretación de variantes genéticas en cáncer a través de algoritmos basados en deep learning. Predicción de supervivencia y efecto de variantes de significado incierto (DTS22/00145). ISCIII. 2023-Ongoing. Managment centre: FIBHULP
- **de Castro Carpeño J.** Título: INtegrative GENomic, digital Imaging and clinical information towars Precision Oncology Optimization (PMP21/00107). ISCIII-MICIIN. 2022-2025. Managment centre: FIBHULP
- **Esteban Rodríguez MI.** Proyecto para la evaluación retrospectiva de muestras pareadas de biopsia y citología para la detección de reordenamientos de alk y expresión de pd-l1 en cpcnp. Roche Farma S.A. 2017-Ongoing. Managment centre: FIBHULP
- **Galera Martínez R, Pernía Arias O.** Evaluación del perfil de hipermetilación de micrornas para la estimación de riesgo de cáncer de pulmón en pacientes con EPOC (PI22/01764). ISCIII. 2023-2025. Managment centre: FIBHULP
- **de Castro Carpeño J.** Resistencia a la inmunoterapia de primera línea en pacientes con cáncer de pulmón no microcítico metastásico con expresión de PD-L1 mayor o igual al 50%. Mutua Madrileña. 2022-ongoing. Managment centre: FIBHULP
- **Rodríguez Antolín C.** Aplicación del metiloma en el diagnóstico de tumores del sistema nervioso central de difícil clasificación a través de algoritmos de aprendizaje automático. Fundación de la Comunidad Valenciana Hospital Provincial de Castelló. 2022-Ongoing. Managment centre: FIBHULP

- **Rodríguez Antolín C.** aplicacion del metiloma en el diagnostico del sistema nervioso central de dificil clasificaición a través de algoritmos de aprendizaje automatico. Ghetti. 2022-Ongoing. Managment centre: FIBHULP
- **Rodríguez Antolín C.** Implementación diagnóstica del análisis de metilación dirigida en plataformas de secuenciación masiva de cáncer. Roche Farma S. A. 2019-Ongoing. Managment centre: FIBHULP
- **Rodríguez Antolín C.** Personal técnico bioinformático de apoyo a investigación (CA22/00002). ISCIII. 2023-Ongoing. Managment centre: FIBHULP
- **Rosas Alonso R.** Estudio de nuevas variantes asociadas a toxicidad por fluoropirimidinas. Fundación Jose Luis Castaño para el Desarrollo del Laboratorio Clínico. 2022-Ongoing. Managment centre: FIBHULP
- **Rosas Alonso R.** Farmacogenética de inhibidores tirosina-quinasa en cáncer de pulmón: medicina de precisión más allá de un solo gen (PI22/00128). ISCIII. 2023-2025. Managment centre: FIBHULP
- **Rosas Alonso R.** Identificación de biomarcadores farmacogenéticos asociados a eficacia y toxicidad a tratamientos en pacientes con artritis reumatoide: estudio BIOFAR (2022.26). Fundación Jose Luis Castaño para el Desarrollo del Laboratorio Clínico. 2023-Ongoing. Managment centre: FIBHULP
- **Vera Puente O.** Caracterización de las funciones inmunosupresoras de MAFG en melanoma y sus potenciales implicaciones para la terapia del cáncer (PI 5815). FIBHULP. 2024-Ongoing. Managment centre: FIBHULP
- **Vera Puente O.** Early molecular nanoDIAGnostics of brain tumors using Immune-PET (DIAGBI) (PLEC2021-008034). MICIIN. 2021-2024. Managment centre: FIBHULP
- **Vera Puente O.** Evalución y puesta a punto del biomarcardor epigenético MGMT en biopsia líquida como prueba no invasiva de seguimiento, en pacientes con gliomas. Cuesta Barrio, Juan. 2017-Ongoing. Managment centre: FIBHULP
- **Vera Puente O.** Validación clínica en biopsia líquida de una firma genética y epigenética como herramienta pronóstica frente a quimioinmunoterapia en pacientes con cáncer de pulmón (CPP2022-009545). MICIIN. 2023-2026. Managment centre: FIBHULP
- **Vera Puente O.** Caracterización de las funciones inmunosupresoras de mafg en melanoma y sus potenciales implicaciones para la terapia del cáncer (GEM2023_OVP). Grupo Español Multidisciplinar de Melanoma. 2024-2026. Managment centre: FIBHULP
- **Vera Puente O.** Dinamización de ciencia disruptiva en predictores de enfermedades tumorales, infecciosas y hereditarias como base de la medicina personalizada (FORT23/00006_ GRUPO III). ISCIII. 2024-2028. Managment centre: FIBHULP

Cibers and Retics

- **de Castro Carpeño J.** Plataforma de Dinamización e Innovación de las Capacidades Industriales del SNS y su Transferencia Efectiva al Sector Productivo (PT23/00035). ISCIII. (31/12/2026). FIBHULP
- **de Castro Carpeño J.** Dinamización e innovación de las capacidades industriales del SNS y su transferencia al sector productivo (PT20/00002). ISCIII. (31/12/2024). FIBHULP

Clinical trials

- **de Castro Carpeño J.** a first-in-human (fih) phase i/II open-label, multicentre, dose escalation and expansion trial of vert-002 in patients with locally advanced or metastatic solid tumors including non-small cell lung cancer (nsclc) harboring met alterations.
  Type/Phase: I
  Sponsored by: Pierre Fabre Medicament S.A.S.
  Signature date: 26/09/2024
- **de Castro Carpeño J.** a multicentre, phase II, single-arm, interventional study of neoadjuvant durvalumab and platinum-based chemotherapy (ct), followed by either surgery and adjuvant durvalumab or chemoradiotherapy (crt) and consolidation durvalumab, in participants with resectable or borderline resectable stage IIb-IIIb non-small cell lung cancer (nsclc).
  Type/Phase: II
  Sponsored by: Astrazeneca Ab
  Signature date: 18/01/2024
- **de Castro Carpeño J.** a phase 1/2, dose escalation, dose expansion, and dose optimization study of the safety, tolerability, and anti-tumor activity of sar444881 administered alone and in combination with pembrolizumab, cetuximab, and/or chemotherapy in participants with advanced solid tumors.
  Type/Phase: I
  Sponsored by: Sanofi-Aventis Recherche Et Developp
  Signature date: 02/07/2024
- **de Castro Carpeño J.** a phase 2, open-label, parallel cohort study of subcutaneous amivantamab in multiple regimens in patients with advanced or metastatic solid tumors including epidermal growth factor receptor mutated non-small cell lung cancer (paloma-2).
  Type/Phase: II
  Sponsored by: Janssen Cilag International Nv
  Signature date: 12/01/2024
- **de Castro Carpeño J.** a phase 3, open-label, randomized study of lazertinib with subcutaneous amivantamab administered via manual injection compared with intravenous amivantamab or subcutaneous amivantamab administered via on body delivery system in patients with egfr-mutated advanced or metastatic non-small cell lung cancer after progression on osimertinib and chemotherapy (paloma-3).
  Type/Phase: III
  Sponsored by: Janssen Cilag International Nv
  Signature date: 28/11/2024
- **de Castro Carpeño J.** a phase 3, open-label, randomized, multi-center study of dzd9008 versus platinum-based doublet chemotherapy as first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer harboring epidermal growth factor receptor exon 20 insertion mutation.
  Type/Phase: III
  Sponsored by: Dizel Pharmaceuticals Inc.
  Signature date: 05/02/2024
- **de Castro Carpeño J.** a randomized phase 2 platform study to evaluate cemiplimab plus chemotherapy versus cemiplimab plus chemotherapy plus other cancer treatments for the perioperative treatment of patients with resectable non-small cell lung cancer.
  Type/Phase: II
  Sponsored by: Regeneron Pharmaceuticals Inc.
  Signature date: 30/10/2024
- **de Castro Carpeño J.** a randomized, double-blind, placebo-controlled, multi-regional phase III clinical study of toripalimab alone or in combination with tifcemalimab (js004/tab004) as consolidation therapy in patients with limited-stage small cell lung cancer without disease progression following chemoradiotherapy.
  Type/Phase: III
  Sponsored by: Shanghai Junshi Biosciences Co Ltd.
  Signature date: 09/07/2024
- **de Castro Carpeño J.** an open-label, randomized phase 3, global multi-center trial to assess the efficacy and safety of zipalertinib (tas6417) plus pemetrexed and cisplatin or carboplatin, versus pemetrexed and cisplatin or carboplatin, in patients with previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer (nsclc) with epidermal growth factor receptor (egfr) exon 20 insertion (ex20ins) mutations.
  Type/Phase: III
  Sponsored by: Taiho Oncology Inc.
  Signature date: 24/01/2024
- **de Castro Carpeño J.** an open-label, randomized phase 3, global multi-center trial to assess the efficacy and safety of zipalertinib (tas6417) plus pemetrexed and cisplatin or carboplatin, versus pemetrexed and cisplatin or carboplatin, in patients with previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer (nsclc) with epidermal growth factor receptor (egfr) exon 20 insertion (ex20ins) mutations.
  Type/Phase: III
  Sponsored by: Taiho Oncology Inc.
  Signature date: 07/11/2024
- **de Castro Carpeño J.** beamion lung-2: a phase III, open-label, randomized, active-controlled, multi-centre trial evaluating orally administered bi 1810631 compared with standard of care as first-line treatment in patients with unresectable,

locally advanced or metastatic nonsquamous non-small cell lung cancer harbouring her2 tyrosine kinase domain mutations.
Type/Phase: III
Sponsored by: Boehringer Ingelheim International GMBH
Signature date: 05/03/2024

- **de Castro Carpeño J.** comparación de la eficacia entre cobolimab + dostarlimab + docetaxel y dostarlimab + docetaxel y docetaxel en monoterapia en participantes con cáncer de pulmón no microcítico avanzado que hayan progresado al tratamiento previo con anti-pd (l)1 y quimioterapia (costar lung.
  Type/Phase: II
  Sponsored by: Glaxosmithkline Research And Development Limited;Glaxosmithkline Research And Development Limited
  Signature date: 20/03/2024
- **de Castro Carpeño J.** ensayo clínico fase III de tratamiento adyuvante con sacituzumab y zimberelimab para pacientes con cáncer de pulmón no microcítico (cpnm) en estadio ib-IIIa-IIIb (n2) previamente operados (r0) que no alcanzaron una respuesta patológica completa tras el tratamiento neoadyuvante.
  Type/Phase: III
  Sponsored by: Fundación Gecp
  Signature date: 01/10/2024
- **de Castro Carpeño J.** ensayo en fase III, aleatorizado, con el anticuerpo monoclonal anti-pd-1 pembrolizumab (mk-3475), en comparación con placebo para pacientes con cpnm en fase temprana después de resección y finalización del tratamiento complementario de referencia (pearls.
  Type/Phase: III
  Sponsored by: Merck & Co. Inc.
  Signature date: 13/12/2024
- **de Castro Carpeño J.** ensayo en fase III, aleatorizado, sin enmascaramiento para comparar la eficacia y la seguridad de ose2101 frente a docetaxel en pacientes positivos para hla-a2 con cáncer de pulmón no microcítico (cpnm) metastásico y con resistencia secundaria a los inhibidores de puntos de control inmunitario (inhibidores del pci) - estudio artemia.
  Type/Phase: III
  Sponsored by: Ose Immunotherapeutics
  Signature date: 03/09/2024
- **de Castro Carpeño J.** estudio aleatorizado, doble ciego, multicéntrico internacional, de fase III para evaluar la eficacia antitumoral y la seguridad de hlx10 (inyección de anticuerpos monoclonales humanizados anti-pd-1 recombinantes) o placebo, en combinación con quimioterapia (carboplatino/cisplatino-etopósido) y radioterapia concomitante en pacientes con cáncer de pulmón de células pequeñas en estadio limitado (cpcp-el).
  Type/Phase: III
  Sponsored by: Shanghai Henlius Biotech
  Signature date: 15/04/2024
- **de Castro Carpeño J.** estudio de diseño abierto de 2 partes, multicentro y de fase 1b de datopotamab deruxtecan (dato-dxd) en combinación con inmunoterapia con o sin carboplatino en participantes con cáncer de pulmón de células no pequeñas metastásico o avanzado.
  Type/Phase: I
  Sponsored by: Astrazeneca Ab
  Signature date: 08/04/2024
- **de Castro Carpeño J.** estudio de fase i, con aumento escalonado de la dosis y ampliación de cohortes de tsr-022, un anticuerpo monoclonal anti-tim-3, en pacientes con tumores sólidos avanzados (amber).
  Type/Phase: I
  Sponsored by: Tesaro Inc.
  Signature date: 05/08/2024
- **de Castro Carpeño J.** estudio de fase ib/II, abierto y aleatorizado de vudalimab en combinación con quimioterapia o pembrolizumab en combinación con quimioterapia como tratamiento de primera línea en pacientes con cáncer de pulmón no microcítico avanzado.
  Type/Phase: II
  Sponsored by: Xencor Inc.
  Signature date: 21/06/2024
- **de Castro Carpeño J.** estudio de fase III aleatorizado, controlado y multirregional de ivonescimab en combinación con quimioterapia frente a pembrolizumab en combinación con quimioterapia para el tratamiento de primera línea del cáncer de pulmón no microcítico escamoso metastásico (harmoni-3).
  Type/Phase: III
  Sponsored by: Summit Therapeutics Inc.
  Signature date: 09/09/2024
- **de Castro Carpeño J.** estudio de fase III aleatorizado, doble ciego de tiragolumab más atezolizumab comparado con placebo más atezolizumab, en participantes con cáncer de pulmón no microcítico completamente resecado, en estadio IIb, IIIa o IIIb selectivo, pd-l1 positivo, que hayan recibido quimioterapia adyuvante basada en platino.
  Type/Phase: III
  Sponsored by: F.Hoffmann-La Roche Ltd.
  Signature date: 23/04/2024
- **de Castro Carpeño J.** estudio de fase III, multicéntrico, aleatorizado, en doble ciego y controlado con placebo, para evaluar la eficacia y la seguridad de azd9291 frente a placebo en pacientes con carcinoma de pulmón no microcítico con mutación del receptor del factor de crecimiento epidérmico, en estadio ib-IIIa, tras la resección completa del tumor, con o sin quimioterapia adyuvante (adaura.
  Type/Phase: III
  Sponsored by: Astrazeneca Farmaceutica Spain S.A.
  Signature date: 08/04/2024
- **de Castro Carpeño J.** estudio de la respuesta inmune antitumoral generada tras quimio-radioterapia concurrente (qrtc) y tratamiento con io en pacientes con estadio IIIa/b y IIIc nsclc no resecables tratados en el mundo real. sienna.
  Type/Phase: EOm prospectivo
  Sponsored by: Fundación Gecp
  Signature date: 17/09/2024
- **de Castro Carpeño J.** estudio en fase i, abierto, de escalada y ampliación de la dosis para evaluar la seguridad, la tolerabilidad, la farmacocinética, la farmacodinámica y la eficacia preliminar de d3s-001 en monoterapia en sujetos con tumores sólidos avanzados con mutación p.g12c en kras.
  Type/Phase: I
  Sponsored by: D3 Bio
  Signature date: 07/11/2024
- **de Castro Carpeño J.** estudio en fase II abierto, de un solo grupo y multicéntrico para evaluar la eficacia y la seguridad de taletrectinib en pacientes con cpnm ros1 positivo avanzado o metastásico y otros tumores sólidos.
  Type/Phase: II
  Sponsored by: Anheart Therapeutics Inc.
  Signature date: 28/07/2024
- **de Castro Carpeño J.** estudio en fase II de tratamiento combinado con adagrasib en pacientes con carcinoma pulmonar no microcítico avanzado con mutación del gen kras g12c.
  Type/Phase: II
  Sponsored by: Mirati Therapeutics Inc.
  Signature date: 27/11/2024
- **de Castro Carpeño J.** estudio en fase II, aleatorizado, doble ciego de relatlimab más nivolumab en combinación con quimioterapia frente a nivolumab en combinación con quimioterapia como tratamiento de primera línea para los participantes con cáncer de pulmón de células no pequeñas (cpcnp) en estadio iv o recurrente.
  Type/Phase: II
  Sponsored by: Bristol-Myers Squibb International Corporation (Bmsic)
  Signature date: 28/06/2024"
- **de Castro Carpeño J.** estudio en fase III abierto y aleatorizado del tratamiento combinado de amivantamab y lazertinib con quimioterapia basada en platino en comparación con quimioterapia basada en platino en pacientes con cáncer de pulmón no microcítico con mutación del egfr localmente avanzado o metastásico tras el fracaso de osimertinib.
  Type/Phase: III
  Sponsored by: Janssen Cilag International Nv
  Signature date: 25/10/2024"
- **de Castro Carpeño J.** estudio en fase III multicéntrico, abierto, randomizado para evaluar la eficacia y la seguridad de divarasib comparado con sotorasib o adagrasib en pacientes con cáncer de pulmón no microcítico kras g12c positivo avanzado o metastásico, tratados previamente.
  Type/Phase: III
  Sponsored by: F.Hoffmann-La Roche Ltd.
  Signature date: 20/06/2024
- **de Castro Carpeño J.** estudio en fase

III, multicéntrico, aleatorizado y sin enmascaramiento de ifinatamab deruxtecán (i-dxd), un conjugado anticuerpo-fármaco (caf) b7-h3 frente al tratamiento elegido por el médico (tpc) en participantes con carcinoma pulmonar de células pequeñas (cpcp) recidivante (ideate-lung02)".
Type/Phase: III
Sponsored by: Dallchi Sankyo Inc.
Signature date: 19/06/2024

- **de Castro Carpeño J.** estudio fase 3 abierto y aleatorizado de la combinación de la terapia amivantamab y carboplatino-pemetrexed, frente a carboplatino-pemetrexed, en pacientes con cáncer de pulmón no microcítico localmente avanzado o metastásico con egfr mutado por inserciones en el exon 20.
  Type/Phase: III
  Sponsored by: Janssen Cilag International Nv;Janssen-Cilag España S.A.
  Signature date: 23/04/2024
- **de Castro Carpeño J.** estudio fase 3 aleatorizado de la combinación de amivantamab y lazertinib frente a osimertinib como tratamiento de primera línea en pacientes con cáncer de pulmón no microcítico ocalmente avanzado o metastásico con mutación del egfr. mariposa.
  Type/Phase: III
  Sponsored by: Janssen Cilag International Nv
  Signature date: 20/12/2024"
- **de Castro Carpeño J.** estudio multicéntrico de fase 3, aleatorizado, doble ciego, controlado con placebo, para comparar niraparib añadido a pembrolizumab versus placebo añadido a pembrolizumab como terapia de mantenimiento en participantes cuya enfermedad se haya mantenido estable o haya respondido a una primera línea de quimioterapia basada en platino y pembrolizumab en cáncer de pulmón no microcítico estadío IIIb o iv.
  Type/Phase: III
  Sponsored by: Glaxosmithkline S.A.
  Signature date: 22/02/2024
- **de Castro Carpeño J.** phase i/II first-in-human open-label trial to assess safety and efficacy of stx-241 in participants with locally advanced or metastatic non-small cell lung cancer (nsclc) resistant to egfr tyrosine kinase inhibitors (tkis).
  Type/Phase: I
  Sponsored by: Sas Pierre Fabre Medicament
  Signature date: 18/07/2024
- **Vera Puente O.** estudio farmacogenómico en la quimioterapia con platinos.
  Type/Phase: EPA-OD
  Sponsored by: Duponte Investigación Y Desarrollo S.L
  Signature date: 18/06/2024

Patents and trademarks

- **Perona Abellón R, Sánchez Pérez I, Machado Pinilla R, Sastre Garzón L, Murguía Ibáñez JR, inventors; CSIC, UAM, Universidad Politécnica de Valencia, assignees.** Sequence of nucleotides and peptides GSE 24.2 of dyskerin, which can induce telomerase activity, method for obtaining same, therapeutic compositions and applications thereof. P200502511, PCT/ES2006/070152, EP1947175, US20090202503, US2015337022, AT469212, CA2625981, DK1947175, JP2009511036, JP5560398, PT1947175; 2005 October 14.
- **Perona Abellón R, Sastre Garzón L, Machado Pinilla R, Sánchez Pérez I, inventors; CSIC, UAM, assignees.** Use of inductor agents GSE24.2 for producing pharmaceutical compositions for treating illnesses relating to cellular senescence. P200703106, PCT/ES2008/070212, EP2216043, US2011300115, JP2011504483, CA2706467; 2007 November 23.
- **Cejas Guerrero P, González Barón M, Casado Sáenz E, Sánchez Hernández JJ, Perona Abellón R, inventors; FIBHULP, UAM, CSIC, assignees.** Use of trefoil factor family 3 (TFF3) in the prognosis of patients diagnosed with colorectal cancer. P200703230, PCT/ES2008/000757, EP2236625; 2007 December 04.
- **Cejas Guerrero P, Belda Iniesta C, Feliú Batlle J, González Barón M, de Castro Carpeño J, Casado Sáenz E, Sánchez Hernández JJ, inventors; FIBHULP, UAM, assignees.** Genomic fingerprint for the prognosis of the evolution of colorectal adenocarcinoma. P200703229, PCT/ES2008/000756, EP2236626; 2007 December 04.
- **Cejas Guerrero P, Belda Iniesta C, Feliú Batlle J, de Castro Carpeño J, Moreno García V, Burgos Lizalde E, Casado Sáenz E, Sánchez Hernández JJ, inventors; FIBHULP, UAM, Empresa Pública Hospital del Norte, assignees.** Genomic fingerprint for predicting the clinical response to an antitumor therapy in colorectal cáncer. P201130863, PCT/ES2012/070379; 2011 May 26.
- **Martínez Máñez R, Murguía Ibáñez JR, Perona Abellón R, Agostini A, Mondragón Martínez L, Moreno Torres M, Manguán García C, Marcos Martínez MD, Soto Camino J, Sancenón Galarza F, inventors; Universidad Politécnica de Valencia, CSIC, Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), assignees.** Release of substances into senescent cells. P201231370, PCT/ES2013/070581, EP2893923, JP2015529216, US2015306037; 2012 September 04.
- **Ibáñez de Cáceres I, Belda Iniesta C, Pernía Arias O, Perona Abellón R, Cortés Sempere M; inventors.** FIBHULP, CSIC, UAM, Fundación Hospital de Madrid, assignees. Method for predicting the response to a treatment consisting of radiotherapy combined with cisplatin-based chemotherapy. P201330783, PCT/ES2014/070433, EP3006572, US20160122828; 2013 May 29.
- **Perona Abellón R, Sastre Garzón L, Pintado Berninches L, Carrillo García J, Molina Pachón A, Irradiccio Silva L, Manguán García C, inventors; CSIC, UAM, Advanced Medical Projects, Centro de Investigación Biomédica en Red (CIBER), assignees.** Peptides derived from GSE 24.2 for treating diseases caused by oxidative stress and damage to DNA. P201331573, AU2014338820, CA2931429, EP3061815 PCT/ES2014/070803; 2013 October 25.
- **Ibáñez de Cáceres I, Pernía Arias O, de Castro Carpeño J, Vera Puente O, Jiménez Hernández J, Perona Abellón R, Rojo Todo F, inventors; FIBHULP, CSIC, UAM, Instituto de Investigación Sanitaria FJD, assignees.** Determination of methylation and miRNA levels in response to a platinum-based antitumor compound. P201530997, PCT/ES2016/070516; 2015 July 09.
- **Ibáñez de Cáceres I, de Castro Carpeño J, Vera Puente O, Pernía Arias O, Rodríguez Antolín C, González Muñoz VM, Martín Palma ME, Salgado Figueroa AM, inventors; FIBHULP, FIBIOHRC, assignees.** MAFG as a potential therapeutic target to restore chemosensitivity in platinum-resistant cancer cells. EP17382610.8 (Publication Number pending), PCT/EP2018/068156; 2017 September 15.
- **Ibáñez de Cáceres I, de Castro Carpeño J, Jiménez Hernández J, Rodríguez Antolín C, Rodríguez Jiménez C, Rosas Alonso R, Cruz Castellanos P, Burdiel Herencia M, Pernía Arias O, Diestro Tejada MD, Esteban Rodríguez MI, inventors; FIBHULP, assignee.** miR-151A-3p as an universal endogenous control for exosome cargo normalization. EP19382252.5 (Publication Number pending); 2019 April 05.
- **Ibáñez de Cáceres I, de Castro Carpeño J, Rosas Alonso R, Pernía Arias O, Martínez Marín V, Esteban Rodríguez MI, inventors; FIBHULP, assignee.** Method for determining the percentage of methylation of the promoter of the gene O6-methylguanine-DNA methyltransferase (MGMT) in circulating exosomes. EP19382299.6 (Publication Number pending); 2019 April 16.
- **Ibáñez de Cáceres I, de Castro Carpeño J, Jiménez Hernández J, Rodríguez Antolín C, Vera Puente O, Rosas Alonso R, Pernía Arias O, Losantos García I, inventors; FIBHULP, assignee.** Method for determining the response to treatment of a patient affected by non-small cell lung carcinoma (NSCLC). EP19382614.6 (Publication Number pending); 2019 July 19.

3.5.4 Oto-Neurosurgery Research

Publications: 14 | **Q1:** 6

COMPOSITION

Luis Lassaletta Atienza.
Jefe de Sección de Otorrinolaringología. Hospital Universitario La Paz

- **Carolina Alfonso Carrillo.** *Facultativo Especialista de Área en Otorrinolaringología. Hospital Universitario La Paz*
- **Miryam Calvino Fernández.** *Investigador Adjunto Senior. FIBHULP*
- **Alejandro Castro Calvo.** *Jefe de Sección de Otorrinolaringología. Hospital Universitario La Paz*
- **Sandra Franco Caspueñas.** *Investigadora Predoctoral. Instituto de Investigaciones Biomédicas Sols-Morreale*
- **Isabel García López.** *Facultativo Especialista de Área en Otorrinolaringología. Hospital Universitario La Paz*
- **Javier Gavilán Bouzas.** *Jefe de Servicio de Otorrinolaringología. Hospital Universitario La Paz. Catedrático. Departamento de Cirugía. Facultad de Medicina. Universidad Autónoma de Madrid*
- **Teresa González Otero.** *Facultativo Especialista de Área en Cirugía Maxilofacial. Hospital Universitario La Paz*
- **Coloma Grau Van Laak.** *Facultativo Especialista de Área en Otorrinolaringología. Hospital Universitario La Paz*
- **Ana María Jiménez Lara.** *Investigador Titular. Instituto de Investigaciones Biomédicas Sols-Morreale*
- **Marta Mancheño Losa.** *Facultativo Especialista de Área en Otorrinolaringología. Hospital Universitario La Paz*
- **José Manuel Morales Puebla.** *Facultativo Especialista de Área en Otorrinolaringología. Hospital Universitario La Paz*
- **Silvia Murillo Cuesta.** *Investigadora Postdoctoral. Instituto de Investigaciones Biomédicas Sols-Morreale*
- **María Fernanda Pedrero Escalas.** *Facultativo Especialista de Área en Otorrinolaringología. Hospital Universitario La Paz*
- **Carmen Ruiz García.** *Facultativo Especialista de Área en Otorrinolaringología. Hospital Universitario La Paz*
- **Isabel Pilar Sánchez Cuadrado.** *Facultativo Especialista de Área en Otorrinolaringología. Hospital Universitario La Paz*
- **María Isabel Varela Nieto.** *Profesor de Investigación. Instituto de Investigaciones Biomédicas Sols-Morreale*
- **Antonio Villalobo Polo.** *Profesor de Investigación. Instituto de Investigaciones Biomédicas Sols-Morreale*



STRATEGIC OBJETIVES

- The systematic use of magnetic resonance imaging (MRI) has dramatically increased the diagnosis of patients with vestibular schwannoma (VS). The majority of patients with VS complain of hypoacusis or tinnitus, and very few present more debilitating symptoms. Therefore, the approach with a patient with VS is complex because the treatment of the tumour is directed towards avoiding complications arising from its growth and not necessarily towards improving the patient's quality of life. Currently, there are no factors that allow us to predict the growth of vestibular schwannoma.
- Recent advances in the field of oncogenetics have allowed us to better understand the development of VS.
- The study of the correlation between clinical variables related to the biological behaviour of VS and its genetic and epigenetic disorders aims to find the factors that predict the behaviour of VS. This will help us identify patients who need active treatment of the tumour and avoid the morbidity associated with the treatment in those who do not need it.
- The cochlear implant (CI) is currently the only solution for relieving the condition in patients with severe or profound hypoacusis who do not benefit from a prosthetic adaptation with a conventional hearing aid. It is estimated that there are currently 120,000 adults in Spain with profound sensorineural hypoacusis. In recent years, new hearing implants have been developed including osseointegrated implants and active middle ear implants. It´s excellent and often spectacular results and its low rate of complications have transformed CI from an innovative technology in the experimental phase to a routine, safe and effective procedure, capable of returning deaf individuals to the hearing world and ending their isolation, increasing their quality of life. Over the past decade the relationship between hearing loss and cognitive decline in the

older population has become the subject of research. We also explore the relationships between the cognitive function and the audiometric performances in patients wearing a CI.

- Moderate to severe hypoacusis is one of the most prevalent medical problems. Ciliated sensory cells and neurons do not regenerate in mammals, which is the main cause of sensorineural hearing loss (SNHL). Mutations altering the levels of Insulin like growth factor type 1 (IGF-1) cause SNHL in humans and mice. IGF-1 is an essential factor in the postnatal development of mammals, and its level decreases with ageing. We are studying the participation of IGF-1 in the pathophysiology of SNHL, as well as the molecular signalling networks conferring specificity in the otic cellular response to IGF-1. We are studying the signals that regulate otic damage with the objective of identifying the key factors implicated in functional repair and regeneration of inner ear cells. In short, our work contributes to the study of auditory pathophysiology, with the ultimate objective of investigating the potential clinical usefulness of IGF-1 and downstream signalling in human sensorineural deafness.
- Bell´s palsy is the most common diagnosis associated with facial nerve weakness or paralysis. However, not all patients with facial paresis / paralysis have Bell's palsy. Other common causes include treatment of
- vestibular schwannoma, head and neck tumors, iatrogenic injuries, Herpes zoster, or trauma. The approach to each of these conditions varies widely, The addition of adjunctive major or minor facial procedures in
- the context of a multidisciplinary Facial Paralysis Unit improves the final facial outcome.

RESEARCH LINES

- Tumors of the CNS: vestibular schwannoma, meningiomas, gliomas, and other: surgery, oncogenetics, quality of life, etc.
- Auditory implants: cochlear implants, middle ear implants, bone-conduction implants: surgical aspects, telephone use, quality of life, perception of music, cognitive declive, anatomy based fitting, etc.
- Hereditary hearing loss, including rare syndromic (IGF-I deficiency) and non syndromic human deafness.
- Neurobiology of hearing: molecular and cellular basis of hearing loss of different aetiology (genetic, noise exposure, malnutrition, and ototoxic drugs). Identification of transcriptional networks, possible therapeutic targets and potential markers for diagnosis.
- Development of experimental models of deafness (genetic, noise exposure, malnutrition, ototoxic drugs and surgery associated trauma) for pre-clinical studies and validation of potential therapeutic molecules.
- Head and Neck tumors and voice pathology.
- The role of cellular senescence in the development of the inner ear and the auditory pathology.
- Studies on three systems implicated in the development of tumor metastasis: the tyrosine kinase receptors EGFR/ErbB2; the non-receptor tyrosine kinase c-Src; and the adaptor protein Grb7.
- Facial paralysis: evaluation, diagnosis and surgery
- Thyroid cancer
- Vocal fold paresis and paralysis: evaluation, diagnosis and treatment options

RESEARCH ACTIVITY

Doctoral Theses

- **Ramos Marques dos Santos J.** Ganancia auditiva, biocompatibilidad y extrusión de prótesis de titanio en la reconstrucción quirúrgica del oído medio[dissertation]. Madrid: Universidad Autónoma de Madrid: 2024(08/03/2024). Director: Gavilán Bouzas J.

Master Theses

- **Pérez Troncoso JL.** Estudio del papel de la NADPH oxidasa 4 (NOX4) en la función auditiva y su evolución con la edad[dissertation]. Madrid: Universidad Autónoma de Madrid: 2024(01/06/2024). Director: Murillo Cuesta S. PID2020-THEARPY

Publications

- **Alzhrani F, Aljazeeri I, Abdelsamad Y, Alsanosi A, Kim AH, Ramos-Macías A, Ramos-de-Miguel A, Kurz A, Lorens A, Gantz B, Buchman CA, Tavora-Vieira D, Sprinzl G, Mertens G, Saunders JE, Kosaner J, Telmesani LM, Lassaletta L, Bance M, Yousef M, Holcomb MA, Adunka O, Thomasen PC, Skarzynski PH, Rajeswaran R, Briggs RJ, Oh SH, Plontke S, O'Leary SJ, Agrawal S, Yamasoba T, Lenarz T, Wesarg T, Kutz W, Connolly P, Anderson I, Hagr A.** International Consensus Statements on Intraoperative Testing for Cochlear Implantation Surgery. Ear Hearing. 2024; 45(6): 1418-26. Article. IF: 2.8; D1
- **Andries E, Lorens A, Skarzynski PH, Skarzynski H, Calvino M, Gavilán J, Lassaletta L, Tavora-Vieira D, Acharya A, Kurz A, Hagen R, Anderson I, Koinig K, Abdelsamad Y, van de Heyning P, Van Rompaey V, Mertens G.** Holistic assessment of cochlear implant outcomes using the international classification of functioning disability and health model: data analysis of a longitudinal prospective multicenter study. Eur Arch Oto-Rhino-L. 2024; 281(8): 4161-73. Article. IF: 2.2; Q1
- **Calvino M, Zuazua-González A, Gavilán J, Lassaletta L.** Objective and Subjective Assessment of Music Perception and Musical Experiences in Young Cochlear Implant Users. Audiol Res. 2024; 14(1): 86-95. Article. IF: 1.8; Q2
- **Domínguez-Ruiz M, Murillo-Cuesta S, Contreras J, Cantero M, Garrido G, Martín-Bernardo B, Gómez-Rosas E, Fernández A, del Castillo FJ, Montoliu L, Varela-Nieto I, del Castillo I.** A murine model for the del(GJB6-D13S1830) deletion recapitulating the phenotype of human DFNB1 hearing impairment: generation and functional and histopathological study. Bmc Genomics. 2024; 25(1): 359. Article. IF: 3.7; Q2
- **Grau-van Laak C, Ruiz-García C, Lassaletta L, Morales-Puebla JM.** Chronic otorrhea and osteomyelitis of the external auditory canal by Achromobacter xylosoxidans: an uncommon diagnosis. Eur Arch Oto-Rhino-L. 2024; 281(4): 2031-5. Article. IF: 2.2; Q1
- **Lassaletta L, Calvino M, Díaz M, Morales-Puebla JM, Sánchez-Cuadrado I, Varela-Nieto I, Gavilán J.** Intraoperative assessment of cochlear nerve functionality in various vestibular schwannoma scenarios: Lessons learned. Hearing Res. 2024; 446: 108997. Article. IF: 2.5; Q1
- **Lassaletta L, Cervera LA, Altuna X, Cabeza EA, Ruiz MA, Caletrio AB, Rosario JBD, Farpon RC, Marcos MC, Escada P, Espinosa-Sánchez JM, Leal RG, Gavilán J, Martínez JG, González-Aguado R, Martínez-González V, Jiménez GG, Antoli-Candela AH, García BJH, Dotu CO, López RP, Manrique M, Sanz EM, Álvarez RM, Martínez H, Martínez-Martínez M, Rey-Martínez J, Romero FR, Ruiz SS, Vallejo LA, Varela AS, Varela-Nieto I, Puebla JMM.** Clinical practice guideline on the management of vestibular schwannoma. Acta Otorrinolaringol Esp. 2024; 75(2): 108-28. Article. IF: 1.1; Q3
- **Lassaletta L, Sánchez-Cuadrado I, Mato-Patino T, Peñarrocha J, Rivera-Núñez MA, Santos-Olmo RMT, Gavilán J, Morales-Puebla JM.** Has Coranavirus Disease 2019 Changed the Incidence and Outcome of Bell's Palsy? J Int Adv Otol. 2024; 20(1): 19-25. Article. IF: 1.2; Q3

- **Morales-Puebla JM, Fernández-Fournier M, Plana-Blanco A, Lassaletta L.** Variations in the treatment of acute peripheral facial paralysis. A nationwide survey. Acta Otorrinolaringol Esp. 2024; 75(1): 31-9. Article. IF: 1.1; Q3
- **Ruiz-García C, Lassaletta L, López-Larrubia P, Varela-Nieto I, Murillo-Cuesta S.** Tumors of the nervous system and hearing loss: Beyond vestibular schwannomas. Hearing Res. 2024; 447: 109012. Article. IF: 2.5; Q1
- **Ruiz-García C, Riesco LR, Mateos-Serrano B, Millán RB, Muñoz AJD, Gavilán J, Ramírez PP, Marcos PMR, Catalán AL, Lecumberri B, Álvarez-Escolá C, Castro A.** Disease-free survival and response to therapy of clinically node- negative papillary thyroid cancer treated without central neck dissection: Retrospective study of 321 patients. Acta Otorrinolaringol Esp. 2024; 75(4): 224-30. Article. IF: 1.1; Q3
- **Usami S, Nishio S, Gavilán J, van de Heyning P, Mertens G, Karltorp E, Skarzynski H, Hagr A, Manoj M, Staecker H, Zernotti ME, Rajan GP, Müller J, Simón F, Anderson I.** HEARRING group genetic marker study: genetic background of CI patients. Acta Oto-Laryngol. 2024; 144(10): 542-51. Article. IF: 1.0; Q3
- **Usami SI, Nishio S, Gavilán J, Acharya A, Hagr A, Lassaletta L, Li YX, Maheshwari SS, Kameswaran M, Parzefall T, Raine C, Rak K, Selleck AM, Staecker H, Stöver T, Sugarova S, Topsakal V, Van Rompaey V, Mertens G, Volkenstein S, Völter C, Shehata-Dieler W, Zernotti ME, Van de Heyning P.** Testing for genetic and viral etiologies in congenital hearing loss based on a survey of cochlear implant centers: proposed HEARRING group consensus and future directions. Acta Oto-Laryngol. 2024; 144(11-12): 602-9. Article. IF: 1.0; Q3
- **Zuazua-Gonzalez A, Calvino M, Postigo A, Domingo C, Gavilán J, Lassaletta L.** Spanish translation and validation of the Music-Related Quality of Life Questionnaire (MuRQoL) in postlingually deaf cochlear implant users. Eur Arch Oto-Rhino-L. 2024; 281(9): 4575-84. Article. IF: 2.2; Q1

Research projects

- **Castro Calvo A.** Caracterización multiómica del carcinoma escamoso de cabeza y cuello mediante biopsia gaseosa y líquida: aplicación diagnóstica, pronóstica y de seguimiento. HN-OMICS. (PI-5761). ISCIII. 2023-2025. Managment centre: IDIBAPS
- **Castro Calvo A.** Estudio sobre la utilidad del tubo de derivación salivar ("by-pass") en la prevención de la fístula faringo-cutánea tras laringectomía total. (PI-5952). SEORL - CCC. 2022-2024. Managment centre: IDIBAPS
- **Castro Calvo A.** Towards A better paradigm for head and neck Cancer Treatment applying artificial Intelligence: an international Cohort study of electronic health records. HNC-TACTIC. (PI-5150). Head and Neck Cancer International Group y Savana. 2022-Ongoing. Managment centre: FIBHULP
- **García-López I.** Parálisis bilateral de las cuerdas vocales: epidemiología y posibilidades terapéuticas aplicadas (PI-3780). Med-El Elektromedizinische Geräte Gesellschaft M. B. H. 2019-Ongoing. Managment centre: FIBHULP
- **Isabel Varela Nieto.** CAM Investigo (09-PIN1-00004.3/2022). CAM. 2022-2023. Managment centre: CSIC
- **Isabel Varela Nieto; Silvia Murillo Cuesta.** Ayudas extraordinarias a realizar en el marco del plan estatal de I+D+I (2024AEP115). CSIC. 2024-2024. Managment centre: CSIC
- **Lassaletta Atienza L.** Análisis de las habilidades musicales y de la voz en niñoz y adultos con IC (PI21/0147). ISCIII. 2022-2024. Managment centre: FIBHULP
- **Lassaletta Atienza L.** Leespq en niños con implante coclear en español (PI-4725). Med-El Elektromedizinische Gerate GMBH. 2021-Ongoing. Managment centre: FIBHULP
- **Lassaletta Atienza L.** Implantes cocleares y función cognitiva en mayores de 55 años . Confederación Española de Familias de Personas Sordas. 2021-Ongoing. Managment centre: FIBHULP
- **Marco-Contelles JL.** MINA-CM Madrid Innovative Neurotech Alliance (P2022/BMD-7236). CAM. 2023-2026. Managment centre: UPM
- **Murillo Cuesta S.** Ayudas para a la adquisición de equipamiento científico-técnico de los laboratorios de la red de laboratorios e infraestructuras científico-técnicas de la Comunidad de Madrid (REDLAB) (2024 REDLAB/SAL 33887). CAM. 2024-Ongoing. Managment centre: CSIC
- **Murillo Cuesta S.** Nuevas estrategias terapéuticas para el tratamiento de enfermedades raras neurosensoriales (SensoRare) (ER24P5AC761-ACCI2023-19-761). CIBERER. 2024-2026. Managment centre: CIBERER
- **Murillo Cuesta S.** Grupo de Trabajo CIBERER Modelos murinos para el estudio de enfermedades raras (ERP1PDI761). CIBERER. 2024-2026. Managment centre: CIBERER
- **Murillo Cuesta S; Varela Nieto I.** Hipoacusia neurosensorial y protección auditiva: explorando las bases genéticas y moleculares para desarrollar nuevas estrategias terapéuticas (PROHEAR) (PID2023-147347OB-I00). MICINN. 2024-Ongoing. Managment centre: CIBERER
- **Sánchez Cuadrado I.** Validación al español de la escala de valoración clínica eFACE y del sunnybrook facial grading system (PI20/01032). ISCIII. 2021-2024. Managment centre: FIBHULP
- **Varela Nieto I.** A sound proteome for a sound body: targeting proteolysis for proteome remodeling (ProteoCure). (CA20113). EU Framework Programme Horizon 2020. COST. 2021-2025. Managment centre: Centro de Investigación Príncipe Felipe
- **Varela Nieto I.** Conexion Nanomedicina del CSIC (NANOMED-CSIC). Agencia Estatal CSIC. 2021-2024. Managment centre: Instituto de Química Médica CSIC
- **Varela Nieto I.** Desarrollo e implementación de métodos alternativos en investigación auditiva (202320E217). CSIC. 2023-2024. Managment centre: CSIC
- **Varela Nieto I.** SENESCENCE2030: Targeting Cell Senescence to Prevent Age-Related Diseases (CA23119). EU Framework Programme Horizon 2020. COST. 2024-2028. Managment centre: CSIC
- **Varela Nieto I .** Bench to bedside transition for pharmacological regulation of NRF2 in noncommunicable diseases (BenBedPhar) (CA20121). EU Framework Programme Horizon 2020. COST.. 2021-2025. Managment centre: Department of Biochemistry and Institute of Biomedical Research.
- **Varela Nieto I, Murillo Cuesta S.** Addendum to the contract by and between Consorcio Centro de Investigación Biomédica en Red, M.P. (CIBER) and Spiral Therapeutics Inc (SPIRAL) on April 26 2017 for scientific research and development services in the field of hearing loss. (ER17PE12). Spiral Therapeutics. 2017-2025. Managment centre: CIBERER
- **Varela Nieto I, Murillo Cuesta S.** Bases genéticas y moleculares de la sordera neurosensorial y del daño auditivo: exploración de nuevas dianas y estrategias terapéuticas (T-HEARPY) (PID2020-115274RB-I00). MCIN/AEI/10.13039/501100011033. 2021-2024. Managment centre: CSIC
- **Varela Nieto I, Murillo Cuesta S.** Contract by and between Consorcio Centro de Investigación Biomédica en Red, M.P. (CIBER) and Spiral Therapeutics Inc (SPIRAL) on April 26 2017 for scientific research and development services in the field of hearing loss and addedums (CIBERER-SPIRAL THERAPEUTICS ERP17PE12). Spiral Therapeutics. 2017-2024. Managment centre: CIBERER

Cibers and Retics

- **Varela Nieto I.** Centro de Investigación en Red de Enfermedades Raras. (CIBERer). ISCIII. (31/12/2024). CSIC

Patents and trademarks

- **Polak M, Roca-Ribas Serdá F, Gavilán Bouzas J, Lassaletta Atienza L, Miró Castillo N, Rodrigo Dacosta J, inventors; MED-EL Elektromedizinische Geraete GmbH, assignee.** Hearing treatment in patients with questionable cochlear nerve functionality. US2011275953, PCT/US2011/035312; 2010 May 05.
- **Cobo Parra P, Varela Nieto I, Murillo-Cuesta S, Navares Zaera R, Martínez Vega R, Cediel Algovia R, inventors; CSIC, UCM, assignees.** Anechoic acoustic chamber for evaluating the auditory function in laboratory animals. P201031720; 2010 November 23.
- **Cobo Parra P, Varela Nieto I, Murillo-Cuesta S, Cediel Algovia R, inventors; CSIC, UCM, assignees.** Method for designing a reverberating acoustic chamber for hearing test with animals. Procedimiento para diseñar una cámara acústica reverberante para ensayos auditivos con animales. P200802895, PCT/ES2009/070433; 2008 October 14.
- **Marco Contelles JL, Varela Nieto I, Murillo Cuesta S, Rodríguez de la Rosa L, Alcázar Gonzalez A, inventors; CSIC, CIBERER, FIBIOHRC, assignees.** Quinolylnitrone derivatives for use in the prevention and/or treatment of hearing loss. EP22382706.4; 2023 July 22

3.5.5 Molecular Pathology of Cancer and Therapeutic Targets

Publications: 15 | **Q1:** 7

COMPOSITION

David Hardisson Hernáez.
Jefe de Servicio de Anatomía Patológica. Hospital Universitario La Paz. Catedrático. Facultad de Medicina. Universidad Autónoma de Madrid

- **Alberto Berjón García.** *Médico Adjunto Especialista de Área en Anatomía Patológica. Hospital Universitario La Paz*
- **Javier de Santiago García.** *Jefe de Servicio de Ginecológica Oncológica. Hospital Universitario La Paz. Profesor Asociado. Facultad de Medicina. Universidad Autónoma de Madrid*
- **Marta Mendiola Sabio.** *Investigadora Postdoctoral. Hospital Universitario La Paz*
- **María Miguel Martín.** *Técnico de Laboratorio. Hospital Universitario La Paz*
- **José Juan Pozo Kreilinger.** *Facultativo Especialista de Área en Anatomía Patológica. Hospital Universitario La Paz*
- **José Ignacio Sánchez Méndez.** *Jefe de Sección en Ginecología y Obstetricia. Hospital Universitario La Paz. Profesor Asociado. Facultad de Medicina. Universidad Autónoma de Madrid*
- **Laura Yébenes Gregorio.** *Médico Adjunto Especialista de Área en Anatomía Patológica. Hospital Universitario La Paz*

STRATEGIC OBJETIVES

- The fundamental interest of our research group is centered in the study of molecular biomarkers that have a direct implication in the handling of the cancer patients with the last aim to identify and to validate therapeutic targets.

Ovarian cancer Research Line

- The ovarian carcinoma is the main cause of gynecological cancer mortality in the western societies. Nevertheless, the classic parameters are imperfect predictors for patients outcome, partly due to the complexity of the molecular genetic events that sublie these tumors and to the fact that they are not totally known. Research on this field could identify more precise markers to correctly stratify the patients according to their probability to recur and response to treatments.
- Angiogenesis, epithelial to mesenchymal transition and hypoxia are processes demonstrated to have an important role in the development of these tumors. The main objective of this line of investigation, therefore, is to identify discrete markers or gene expression profiles related to these events, with predictive and prognostic value for ovarian cáncer patients.

Endometrial cancer Research Line

- Endometrial carcinoma is the fourth most common cancer in women in the developed world. Histomorphologic criteria are not strongly enouygh tools to distinguish more aggressive tumors. Based on molecular characterization, risk stratification systems could be useful for decision making.
- The main objective of this line of investigation, therefore, is to identify molecular markers with predictive and prognostic value for endometrial cancer patients.

Breast cancer Research Line


- Angiogenesis and breast cancer. Angiogenesis is a key process in tumor development. Our group has been working for years on the search of biomarkers related to this process. Specifically on breast cancer, it is important to identify patients that will benefit of evacizumab containing regimes.

Sarcomas Research Line

- Bone and Soft tissue sarcomas includes a group of heterogeneous pathologies that were traditionally treated in the same way. The clinical investigation has allowed the identification of sub-groups with different response to treatments. The objective of this line of work is to find biomarkers for the best stratification of the patients, as well as to get a better knowledge of the molecular mechanisms for the development of these tumors.

In vitro 2- and 3D cell culture models for functional studies.


- The identification of potential markers in different pathologies might be complemented by functional studies, focused on the characterization of cancer and estromal cell features, important for tumor development that it improves the rates of survival.



RESEARCH LINES

- Ovarian and endometrial cancer
- Breast cancer
- Sarcomas
- New in vitro models of disease

RESEARCH ACTIVITY



Doctoral Theses

- **García Calvo L.** Biopsia del ganglio centinela en pacientes con carcinoma de mama sin afectación axilar al diagnóstico (CN0) que reciben terapia sistémica primaria[dissertation]. Madrid: Universidad Autónoma de Madrid: (13/12/2024). Director: Sánchez Méndez JI.
- **Pérez González S.** Estudio de las mutaciones del promotor del gen TERT, de POLE y clasificación molecular mediante análisis de la expresión de marcadores inmunohistoquímicos en el carcinoma urotelial de vejiga de pacientes adultos jóvenes (40 años o menores)[dissertation]. Madrid: Universidad Autónoma de Madrid: 2024(24/07/2024). Director: González-Peramato Gutiérrez MP, Mendiola Sabio M.

Publications

- **Cameán MM, Marin IJ, Méndez JIS, Álvarez CM, Alegre FB, Boado EM, Spagnolo E, Zapardiel I, Gutiérrez AH.** Survival in pregnancy-associated breast cancer patients compared to non-pregnant controls. Reprod Biol Endocrin. 2024; 22(1): 34. Article. IF: 4.7; Q1
- **Carrillo-García J, Hindi N, Conceicao M, Sala MA, Ugalde A, López-Pousa A, Bagué S, Sevilla I, Vicioso L, Ramos R, Martínez-Trufero J, Mateo MCG, Cruz J, Hernández-León CN, Redondo A, Mendiola M, García JM, Hernández JE, Alvarez R, Agra C, de Juan-Ferré A, Valverde C, Cano JM, de Sande LM, Pérez-Fidalgo JA, Lavernia J, Marcilla D, Gutiérrez A, Moura DS, Martín-Broto J.** Prognostic impact of tumor location and gene expression profile in sporadic desmoid tumor. Eur J Cancer. 2024; 209: 114270. Article. IF: 7.1; Q1
- **García-Galán EC, Medel-Plaza M, Pozo-Kreilinger JJ, Sarnago H, Lucía O, Rico-Nieto A, Esteban J, Gómez-Barrena E.** In vivo reduction of biofilm seeded on orthopaedic implants safety and efficacy of portable electromagnetic induction heating. Bone Joint Res. 2024; 13(12): 695-702. Article. IF: 5.1; Q1
- **Gutiérrez-Sainz L, Heredia-Soto V, Rodríguez-García AM, Sánchez MGC, Serrano-Olmedo MG, Molero-Luis M, Losantos-García I, Ghanem I, Pérez-Wert P, Custodio A, Mendiola M, Feliu J.** Cytokines and Pancreatic Ductal Adenocarcinoma: Exploring Their Relationship with Molecular Subtypes and Prognosis. Int J Mol Sci. 2024; 25(17): 9368. Article. IF: 4.9; Q1
- **Matías-Guiu X, Lax S, Raspollini MR, Palacios J, Zheng WX, Liu CR, de Brot L, Lordello L, Hardisson D, Gaffney D, Mutch D, Scambia G, Creutzberg CL, Fotopoulou C, Berek JS, Concin N.** FIGO 2023 staging for endometrial cancer, when, if it is not now?. Eur J Cancer. 2024; 213: 115115. Review. IF: 7.1; Q1
- **Mendiola M, Heredia-Soto V, Ruz-Caracuel I, Baillo A, Ramón-Patiño JL, Berjon A, Escudero FJ, Peláez-García A, Hernández A, Feliu J, Hardisson D, Redondo A.** Performance of the Idylla microsatellite instability test in endometrial cancer. Mol Cell Probe. 2024; 77:-101976. Article. IF: 3.0; Q2
- **Mendiola M, Saarela J, Escudero FJ, Heredia-Soto V, Potdar S, Rodríguez-Marrero S, Miguel M, Pozo-Kreilinger JJ, Berjon A, Ortiz-Cruz E, Feliú J, Redondo A.** Characterisation of new in vitro models and identification of potentially active drugs in angiosarcoma. Biomed Pharmacother. 2024; 173: 116397. Article. IF: 7.5; D1
- **Moreno-Palacios E, Martí C, Frías L, Meléndez M, Loayza A, Roca MJ, Córdoba V, Oliver JM, Hernández A, Sánchez-Méndez JI.** Breast-Conserving Surgery Guided with Magnetic Seeds vs. Wires: A Single-Institution Experience. Cancers (Basel). 2024; 16(3): 566. Article. IF: 4.4; Q2
- **Navarro MJR, Goldaracena JMO, Alonso DG, Monforte YN, Durbán TDD, Chicote MVC, Martínez FG, Álvarez CM, Gregorio LY, Botella JLM, Hervás CM, Méndez JIS.** Pre-surgical cryoablation in ≤ 2 cm ER + /HER2-tumors. Prognostic factors for the presence of residual invasive carcinoma. Breast Cancer Res Tr. 2024; 206(3): 561-73. Article. IF: 3.0; Q2
- **Peña-Burgos EM, D'Angelo C, Díez-Corral MC, Villanueva ES, Tapia-Viñe M, Pozo-Kreilinger JJ, Velázquez DV.** Giant thigh hemosiderotic/ aneurysmal dermatofibroma: Case report with radiologic-pathologic correlation. Rev Esp Patol. 2024; 57(3): 217-24. Article. IF: 0.5; Q4
- **Peña-Burgos EM, Díez-Corral MC, Ortiz-Cruz EJ, Bernabéu D, Tapia-Viñe M, Redondo A, Pérez-Martínez A, Peláez A, Mascaró CV, López AE, Pozo-Kreilinger JJ.** Periosteal Ewing Sarcoma with Distant Metastases: Report of Two Patients and Review of the Literature. Int J Surg Pathol. 2025; 33(1): 178-88. Article. IF: 1.0; Q3
- **Pena-Burgos EM, Duyos-Mateo I, Pozo-Kreilinger JJ, Regojo-Zapata RM, Quirós-González V, de la Calle M.** Comparison of maternal, fetal, obstetric and neonatal outcomes for 234 triplet pregnancies conceived in vivo versus IVF and ICSI conceptions. Reprod Biomed Online.



2024; 48(2): 103419. Article. IF: 3.5; Q1

- **Peña-Burgos EM, Lerchundi NT, Fuentes-Sánchez J, Tapia-Viñe M, Fernández-Baíllo N, Pozo-Kreilinger JJ.** Notochordal cell derived lesions: a 55-year casuistic analysis of 50 cases with radiologic-pathologic correlation in a tertiary referral hospital, and literature review. Eur Spine J. 2024; 33(9): 3315-23. Review. IF: 2.7; Q2
- **Pozo-Kreilinger JJ, Pena-Burgos EM, Ortiz-Cruz EJ, Cordero-García JM, Ruiz IB, Tapia-Viñe M, Peleteiro-Pensado M, Bernabeu-Taboada D.** Primary intraosseous papillary intralymphatic angioendothelioma of the distal femoral epiphysis: a case report with literature review. Skeletal Radiol. 2026; 54(1): 125-30. Article. IF: 2.2; Q2
- **Rodríguez-Molinero J, Pozo-Kreilinger JJ, Ruiz-Roca JA, López-Sánchez AF, Cebrian-Carretero JL.** Clinical and Pathological Features of Osteosarcomas of the Jaws: A Retrospective Study. Clin Pract. 2024; 14(3): 965-79. Article. IF: 2.2; Q2

Research projects

- **Guerra Pastrián L.** Desarrollo de tareas de revisión patológica nacional del ensayo clínico Paediatric Hepatic International Tumour Trial (PHITT). Fundación para la Investigación Biomédica de Córdoba Fibico. 2019-Ongoing. Managment centre: FIBHULP
- **Hardisson Hernáez D.** Identificación de biomarcadores de recaída en carcinomas de endometrio de riesgo clínico intermedio mediante análisis multi-ómico y de microambiente inmune (PI21/00920). ISCIII. 2022-2024. Managment centre: FIBHULP
- **Hardisson Hernáez D.** Identificación de biomarcadores en cáncer de pulmón no microcítico. Astrazeneca Farmaceutica Spain S.A. 2020-Ongoing. Managment centre: FIBHULP
- **Hardisson Hernáez D.** Puesta en marcha del ensayo clínico "idyllatm"genefusion panel 1.x clinical performance study. Biocartis NV. 2022-Ongoing. Managment centre: FIBHULP
- **Hardisson Hernáez D.** Realización de las tareas necesarias para el desarrollo del ensayo clínico a phase ib/iia, radomized, double blind, placebo controlled, multicenter clinical trial to evaluate the safety, pharmacokinetics and efficacy of oral treatment with ost-122 in patients with moderate to severe ulcerative colitis (ct-ost-122-02). Oncostellae S.L. 2020-Ongoing. Managment centre: FIBHULP
- **Hardisson Hernáez D.** Riesgo de recaída en pacientes con carcinoma de mama primario HER2 negativo y receptores estrogénicos positivos: estudio comparativo de dos perfiles de expresión génica (Mammaprint® y Endopredict®). Fundación Sociedad Española de Anatomía Patológica. 2019-Ongoing. Managment centre: FIBHULP
- **Mendiola Sabio M.** Establecimiento y caracterización de modelos in vitro de sarcoma. FIBHULP. 2022-Ongoing. Managment centre: FIBHULP
- **Mendiola Sabio M.** Exploration of 2 and 3d models of angiosarcoma and their farcological sdreening. Grupo Español de Investigación en Sarcomas. 2019-Ongoing. Managment centre: FIBHULP
- **Mendiola Sabio M.** Identificación de marcadores de HRD y predicción de la respuesta a inhibidores de PARP en líneas celulares establecidas y organoides derivados de pacientes con cancer de ovario. Grupo Español de Investigación en Cáncer de Ovario. 2021-Ongoing. Managment centre: FIBHULP
- **Mendiola Sabio M.** Identificación de perfiles de expresión génica diferencial relacionados con la angiogénesis entre el carcinoma de ovario primario y sus metástasis. Ortomedimatec. 2012-Ongoing. Managment centre: FIBHULP
- **Mendiola Sabio M.** Papel de RANKL en el sarcoma de Ewing: un estudio in vitro para la confirmación de una nueva diana terapéutica. Grupo Español de Investigación en Sarcomas. 2012-Ongoing. Managment centre: FIBHULP
- **Mendiola Sabio M.** Realización de técnicas de detección de expresión proteica el IGTP. Construcción de matrices tisularees y tinciones con anticuerpos específicos . Fundacio Institut Dínvestigació en Ciéncies de la Salut Germans Trias I Pujol. 2015-Ongoing. Managment centre: FIBHULP

Clinical trials

- **Mendiola Sabio M.** Estudio retrospectivo, observacional, multicéntrico en vida real de dostarlimab en pacientes con cáncer de endometrio recurrente o metastásico con deficiencia del sistema mismatch repair (mmr) o inestabilidad alta de microsatélites.

Type/Phase: EPA-OD
Sponsored by: Grupo Español De Investigacion En Cancer Ginecologico
Signature date: 13/06/2024

Patents and trademarks

- **Redondo Sánchez A, Hardisson Hernaéz D, Barriuso Feijoo J, Mendiola Sabio M, inventors; FIBHULP, assignee.** Method to obtain useful data for the prediction of a patient's clinical response to an anticancer treatment. P200930400; 2009 July 01.
- **Redondo Sánchez A, Hardisson Hernaéz D, Barriuso Feijoo J, Mendiola Sabio M, inventors; FIBHULP, assignee.** Method to obtain useful data for the prediction of a patient's pathological response to an anticancer treatment. P200930438; 2009 July 10.
- **Zapardiel Gutiérrez I, de Santiago García J, inventors; FIBHULP, assignee.** Laparoscopic surgical instrument. P201230950, PCT/ES2013/000139; 2012 June 18.
- **Zapardiel Gutiérrez I, de Santiago García J, inventors; FIBHULP, assignee.** Surgical device. P201330532, PCT/ES2014/070277; 2013 April 15.

3.5.6 Mechanisms of Tumour Progression

Publications: 6 | **Q1:** 5

COMPOSITION

José Manuel González Sancho.
Profesor Titular. Universidad Autónoma de Madrid

- **David Albandea Rodríguez.** *Instituto de Investigaciones Biomédicas Sols-Morreale*
- **Antonio Barbachano Becerril.** *Investigador Postdoctoral. Instituto de Investigaciones Biomédicas Sols-Morreale*
- **Aurora Burgos García.** *Jefe de Sección Unidad de Endoscopias. Hospital Universitario La Paz*
- **Gemma Domínguez Muñoz.** *Profesora Titular. Universidad Autónoma de Madrid*
- **Asunción Fernández Barral.** *Profesora Ayudante Doctor. Universidad Autónoma de Madrid*
- **Arturo González de la Aleja Molina.** *Investigador Postdoctoral. Universidad Autónoma de Madrid*
- **María Jesús Larriba Muñoz.** *Científica Titular. Instituto de Investigaciones Biomédicas Sols-Morreale*
- **Ester Martín Villar.** *Investigadora Postdoctoral. Instituto de Investigaciones Biomédicas Sols-Morreale*
- **Alberto Muñoz Terol.** *Profesor de Investigación. Instituto de Investigaciones Biomédicas Sols-Morreale*
- **José Luis Orgaz Bueno.** *Jefe de Laboratorio de Citoesqueleto y Metástasis. Instituto de Investigaciones Biomédicas Sols-Morreale*
- **Silvia Rodríguez Marrero .** *Investigadora Predoctoral . Instituto de Investigaciones Biomédicas Sols-Morreale*
- **Johana Alexandra Troya Balseca.** *Lab Manager. FIBHULP*



STRATEGIC OBJETIVES

- Characterize vitamin D action in stem cells and tumor microenvironment in colorectal cancer.
- Comparative study of early onset colorectal cancer (EOCRC) vs. late onset colorectal cancer (LOCRC).
- Analysis of tumor invasion, metastasis and therapy resistance mechanisms in solid tumors.

RESEARCH LINES

- Estudio de los efectos de la vitamina D en fibroblastos y organoides colónicos obtenidos de tejido normal y tumoral de pacientes con cáncer colorrectal / Study of vitamin D effects on patient-derived colon normal and cancer-associated fibroblasts and organoids.
- Estudio comparativo del cáncer colorrectal de aparición temprana frente al de aparición tardía: Efectos de la vitamina D / Comparative study of early onset colorectal cancer (EOCRC) vs. late onset colorectal cancer: Effects of vitamin D (LOCRC).
- Identificación de marcadores de diagnóstico precoz en biopsia líquida en cáncer colorrectal / Identification of early diagnostic biomarkers in liquid biopsy in colorectal cancer.
- Plasticidad celular y metástasis tumoral. / Cell plasticity and tumor metastasis.
- Mecanismos responsables de la resistencia tumoral / Mechanisms of tumor resistance

RESEARCH ACTIVITY

Master Theses


- **Pérez de Gracia Velázquez N.** The susceptibility of distinct cutaneous melanoma phenotypes to inhibition of Non-Muscle Myosin II cytoskeleton. [dissertation]. Madrid: Univerisdad Autónoma de Madrid: 2024(26/06/2024). Director: Orgaz Bueno JL
- **Novo Acedo S.** Studying the Regulation of non-muscle Myosin II Cytoskeleton During Adaptation and Resistance to MAPK-targeted Therapy in Cutaneous Melanoma.[dissertation]. Madrid: Univerisdad Autónoma de Madrid: 2024(27/06/2024). Director: Orgaz Bueno JL. si

Final Degree Theses

- **Rojo García A.** El gen supresor tumoral FBXW7 como posible mediador de la acción antiproliferativa del calcitriol en cáncer colorrectal[dissertation]. Madrid: Univerisdad Autónoma de Madrid: 2024(27/05/2024). Director: González Sancho JM, Fernández Barral A
- **Sánchez García L.** Estudio de la regulación del citoesqueleto de miosina no muscular durante la progresión maligna del melanoma cutáneo[dissertation]. Madrid: Univerisdad Autónoma de Madrid: 2024(28/06/2024). Director: Orgaz Bueno JL
- **Cabeza Arciniega C.** Estudio de la regulación del citoesqueleto de miosina no muscular durante resistencia a terapias en melanoma cutáneo[dissertation]. Madrid: Univerisdad Autónoma de Madrid: 2024(28/06/2024). Director: Orgaz Bueno JL

Publications

- **Bustamante-Madrid P, Barbáchano A, Albandea-Rodríguez D, Rodríguez-Cobos J, Rodríguez-Salas N, Prieto I, Burgos A, de Villarreal JM, Real FX, González-Sancho JM,**



Larriba MJ, Lafarga M, Muñoz A, Fernández-Barral A. Vitamin D opposes multilineage cell differentiation induced by Notch inhibition and BMP4 pathway activation in human colon organoids. Cell Death Dis. 2024; 15(4): 301. Article. IF: 9.6; Q1

- **Fisac J, Burgos A, Mendez MC.** Adenoma-like adenocarcinoma. Gastrointest Endosc. 2024; 100(2): 341-3. Editorial Material. IF: 7.5; Q1
- **García-Martínez JM, Chocarro-Calvo A, Martínez-Useros J, Regueira-Acebedo N, Fernández-Aceñero MJ, Muñoz A, Larriba MJ, García-Jiménez C.** SIRT1 Mediates the Antagonism of Wnt/(3-Catenin Pathway by Vitamin D in Colon Carcinoma Cells. Int J Biol Sci. 2024; 20(13): 5495-509. Article. IF: 10; Q1
- **Orgaz JL.** Creating a path during melanoma amoeboid migration: When too crowded, start worrying. Dev Cell. 2024; 59(18): 2395-97. Editorial Material. IF: 8.7; D1
- **Pastor-Morate D, Amigo-Morán L, Garranzo-Asensio M, Rejas-González R, Carnicero P, Rodríguez N, Pérez-Robledo JP, Barderas R, Prieto-Nieto I, Domínguez G.** ΔNp73 and its effector targets promote colorectal peritoneal carcinosis and predict survival. J Pathol. 2024; 263(3): 328-37. Article. IF: 5.2; D1.
- **Pereira F, Fernández-Barral A, Larriba MJ, Barbáchano A, González-Sancho JM.** From molecular basis to clinical insights: a challenging future for the vitamin D endocrine system in colorectal cancer. FEBS J. 2024; 291(12): 2485-518. Review. IF: 4.2; Q2

Research projects

- **Domínguez Muñoz G.** Combinación de técnicas ómicas y de imagen para la identificación de marcadores asociados a la respuesta al tratamiento neoadyuvante en pacientes con cáncer de recto: Implicaciones pronósticas y terapéuticas (PI21/01047). ISCIII. 2022-2024. Managment centre: FIBHULP
- **González Sancho JM.** PRECICOLON-CM Hacia la medicina de precisión en cáncer de colon: Biomarcadores, microambiente tumoral y microbiota (P2022/BMD-7212). Comunidad de Madrid. 2023-2026. Managment centre: UAM
- **Martín Villar E.** Podoplanin-mediated crosstalk between cancer cells and the microenvironment controls epithelial carcinogenesis and malignant progression. Opening new therapeutic avenues (PID2021-126816OB-I00). Ministerio de Ciencia e Innovación, Proyectos de generación del conocimiento 2021. 2022-2025. Managment centre: UFV
- **Muñoz Terol A, Larriba Muñoz MJ.** Efectos de la vitamina D sobre las células troncales y el microambiente tumoral en cáncer de colon: diferenciación, metabolismo y comunicación intercelular (PID2022-136729OB-I00). Ministerio de Ciencia e Innovación, Proyectos de Generación de Conocimiento. 2023-2026. Managment centre: CSIC
- **Orgaz JL.** Estudio de la regulación de miosina no muscular de clase II en la progresión del melanoma (MYOMEL) (PID2021-122306OB-I00). Ministerio de Ciencia e Innovación, Proyectos del Programa Estatal de I+D+i orientada a los Retos de la Sociedad. 2022-2025. Managment centre: CSIC
- **Orgaz JL.** Investigando la regulación del citoesqueleto de miosina durante la adaptación a terapias dirigidas en melanoma e intervenciones terapéuticas ootenciales para retrasar la resistencia (2019-T1/BMD-13642). Comunidad de Madrid, Programa de Atracción de Talento Investigador. 2020-2024. Managment centre: CSIC
- **Rodríguez Salas N, Muñoz Terol A.** Cáncer colorrectal en población joven. Estudio farmacogenómico en organoides y efectos del microambiente tumoral (ICI20/00057). ISCIII. 2021-2026. Managment centre: FIBHULP
- **Orgaz JL.** Identifying strategies after targeting the cytoskeleton to eradicate cutaneous melanomas. (CNS2023-143636). Ministerio de Ciencia e Innovación, Ayudas Consolidación Investigadora 2023. 2024-2026. Managment centre: CSIC

Cibers and Retics

- **Muñoz Terol A.** Networked Biomedical Research Center for Cancer (CIBERonc). ISCIII. (31/12/2025). Managment Centre: CSIC

Patents and trademarks

- **Olmeda Casadomé D, Moreno Bueno G, Portillo Pérez F, Cano García A, inventors; UAM, CSIC, assignees.** Method for the diagnosis and/or prognosis of breast cancer. P200702342, PCT/ES2008/000563; 2007 August 28.
- **Olmeda Casadomé D, Peinado Selgas H, Portillo Pérez F, Nieto Toledano MA, Cano García A, inventors; UAM, assignee.** Materials and methods for the derepression of the Ecadherin promoter. US20060003956; 2004 March 03.

3.5.7 Research and Diagnosis of Inherited Metabolic Diseases

Publications: 15 | **Q1:** 11

COMPOSITION

María Belén Pérez González.
Catedrática Bioquimica y Biología Molecular. Universidad Autónoma de Madrid. CBM "Severo Ochoa"

- **Patricia Alcaide Alonso.** *Investigadora Senior. CEDEM*
- **Margarita Castro Reguera.** *Tecnico Titulado Superior. CEDEM*
- **Magdalena de Ugarte Pérez.** *Directora del CEDEM. CEDEM*
- **Isaac Ferrer López.** *Técnico de Laboratorio. CEDEM*
- **María Alejandra Gámez Abascal.** *Profesora Titular. Universidad Autónoma de Madrid. CBM "Severo Ochoa"*
- **Fernando García Muñoz.** *Técnico de Laboratorio. CEDEM*
- **Fátima Leal Pérez.** *Técnico de Laboratorio. CIBERER*
- **Rosa María Navarrete López de Soria.** *Técnico de Laboratorio. CIBERER*
- **Eva María Richard Rodríguez.** *Profesora Titular. Universidad Autónoma de Madrid. CBM "Severo Ochoa"*
- **María Pilar Rodríguez Pombo.** *Profesora Titular. Universidad Autónoma de Madrid. CBM "Severo Ochoa"*
- **María Lourdes Ruiz Desviat.** *Catedrática Bioquimica y Biología Molecular. Universidad Autónoma de Madrid. CBM "Severo Ochoa"*
- **Pedro Ruiz Sala.** *Investigadora Senior. CEDEM*



STRATEGIC OBJETIVES

- Diagnóstico integral y de alta precisión de enfermedades metabólicas hereditarias
- Validación funcional y generación de conocimiento en relacion a patologia
- Innovación terapéutica y medicina personalizada
- Trasnferencia de conocimiento a la sociedad
- Comprehensive and high-precision diagnosis of inherited metabolic diseases
- Functional Validation and Knowledge disease generation
- Therapeutic Innovation and Personalized Medicine
- Knowledge transfer to society.

RESEARCH LINES

- Optimización del diagnóstico de enfermedades metabólicas hereditarias mediante tecnologías genómicas, transcriptómicas, metabolómicas, proteómicas y epigenómicas.
- Validación funcional del efecto de variantes genéticas mediante genómica funcional.
- Identificación y caracterización de nuevas asociaciones gen-enfermedad.
- Generación de modelos celulares mediante diferenciación de iPSC hacia distintos linajes celulares.
- Identificación de biomarcadores predictivos de severidad y como herramientas para evaluar la eficacia terapéutica.
- Compromiso con la colaboración activa con asociaciones de pacientes para facilitar la transferencia del conocimiento científico a la sociedad.
- Optimization of the diagnosis of inherited metabolic diseases through genomic, transcriptomic, metabolomic, proteomic, and epigenomic technologies.
- Functional validation of the effect of genetic variants through functional genomics.
- Identification and characterization of novel gene-disease associations.
- Development of cellular and animal models using gene editing for functional and therapeutic studies.
- Development of targeted therapeutic strategies: small molecules, RNA therapies, and gene editing.
- Generation of cellular models by differentiating iPSCs into various cell lineages.
- Identification of predictive biomarkers of disease severity and as tools to evaluate therapeutic efficacy.
- Commitment to active collaboration with patient associations to facilitate the transfer of scientific knowledge to society.

RESEARCH ACTIVITY

Doctoral Theses

- **Gallego Martínez D.** Genómica funcional aplicada a la identificación de dianas terapéuticas en enfermedades metabólicas hereditarias [dissertation]. Madrid: UAM: 2024(23/05/2024). Director: Pérez González MB
- **Sánchez Lijarcio O.** Estrategia multi-ómica y de genómica funcional para la mejora del diagnóstico de enfermedades neurometabólicas.[dissertation]. Madrid: UAM: 2024 (09/04/2024). Director: Pérez González MB

Publications

- **Arribas-Carreira L, Castro M, García F, Navarrete R, Bravo-Alonso I, Zafra F, Ugarte M, Richard E, Pérez B, Rodríguez-Pombo P.** Metabolic Rewiring and Altered Glial Differentiation in an iPSC-Derived Astrocyte Model Derived from a Nonketotic Hyperglycinemia Patient. Int J Mol Sci. 2024; 25(5): 2814. Article. IF: 4.9; Q1
- **Barbero-Herranz R, Garriga-Garcia M, Moreno-Blanco A, Palacios E, Ruiz-Sala P, Vicente-Santamaría S, Stanescu S, Belanger-Quintana A, Pintos-Morell G, Arconada B, del Campo R, Avendano-Ortiz J.** The Role of the Gut Microbiota in Sanfilippo Syndrome's Physiopathology: An Approach in Two Affected Siblings. Int J Mol Sci. 2024; 25(16): 8856. Article. IF: 4.9; Q1
- **Cordoba-Caballero J, Perkins JR, García-Criado F, Gallego D, Navarro-Sánchez A, Moreno-Estellés M, Garcés C, Bonet F, Romá-Mateo C, Toro R, Perez B, Sanz P, Kohl M, Rojano E, Seoane P, Ranea JAG.** Exploring miRNA-target gene pair detection in disease with coRmiT. Brief Bioinform. 2024; 25(2): bbae060. Article. IF: 7.7; D1
- **Gallego D, Serrano M, Cordoba-Caballero J, Gámez A, Seoane P, Perkins JR, Ranea JAG, Pérez B.** Transcriptomic analysis identifies dysregulated pathways and therapeutic targets in PMM2-CDG. Bba-Mol Basis Dis. 2024; 1870(5): 167163. Article. IF: 4.2; Q1
- **Himmelreich N, Ramón-Maiques S, Navarrete R, Castejon-Fernández N, Garbade SF, Martínez A, Desviat LR, Pérez B, Blau N.** Significance of utilizing in silico structural analysis and phenotypic data to characterize phenylalanine hydroxylase variants: A PAH landscape. Mol Genet Metab. 2024; 142(3): 108514. Article. IF: 3.5; Q2
- **Houge G, Bratland E, Aukrust I, Tveten K, Zukauskaite G, Sansovic I, Brea-Fernández AJ, Mayer K, Paakkola T, McKenna C, Wright W, Markovic MK, Lildballe DL, Konecny M, Smol T, Alhopuro P, Gouttenoire EA, Obeid K, Todorova A, Jankovic M, Lubieniecka JM, Stojiljkovic M, Buisine MP, Haukanes BI, Lorans M, Roomere H, Petit FM, Haanpää MK, Beneteau C, Perez B, Plaseska-Karanfilska D, Rath M, Fuhrmann N, Ferreira BI, Stephanou C, Sjursen W, Maver A, Rouzier C, Chirita-Emandi A, Gonçalves J, Kuek WCD, Broly M, Haer-Wigman L, Thong MK, Tae SK, Hyblova M, den Dunnen JT, Laner A.** Comparison of the ABC and ACMG systems for variant classification. Eur J Hum Genet. 2024; 32(7): 858-63. Article. IF: 4.6; Q1
- **Martín JCH, Ansa BS, Álvarez-Rivera G, Domínguez-Zorita S, Rodríguez-Pombo P, Pérez B, Calvo E, Paradela A, Miguez DG, Cifuentes A, Cuezva JM, Formentini L.** An ETFDH-driven metabolon supports OXPHOS efficiency in skeletal muscle by regulating coenzyme Q homeostasis. Nat Metab. 2024; 6(2): 209-25. Article. IF: 20.8; D1
- **Martínez-Pizarro A, Álvarez M, Dembic M, Lindegaard CA, Castro M, Richard E, Andresen BS, Desviat LR.** Splice-Switching Antisense Oligonucleotides Correct Phenylalanine Hydroxylase Exon 11 Skipping Defects and Rescue Enzyme Activity in Phenylketonuria. Nucleic Acid Ther. 2024; 34(3): 134-42. Article. IF: 4.7; Q1
- **Martínez-Pizarro A, Picó S, López-Márquez A, Rodríguez-López C, Montalvo E, Álvarez M, Castro M, Ramón-Maiques S, Pérez B, Lucas JJ, Richard E, Desviat LR.** PAH deficient pathology in humanized c.1066-11G>A phenylketonuria mice. Hum Mol Genet. 2024; 33(12): 1074-89. Article. IF: 3.2; Q2
- **Oliva C, Arias A, Ruiz-Sala P, Garcia-Villoria J, Carling R, Bierau J, Ruijter GJG, Casado M, Ormazabal A, Artuch R.** Targeted ultra performance liquid chromatography tandem mass spectrometry procedures for the diagnosis of inborn errors of metabolism: validation through ERNDIM external quality assessment schemes. Clin Chem Lab Med. 2024; 62(10): 1991-2000. Article. IF: 3.7; Q1
- **Petersen USS, Dembic M, Martínez-Pizarro A, Richard E, Holm LL, Havelund JF, Doktor TK, Larsen MR, Faergeman NJ, Desviat LR, Andresen BS.** Regulating PCCA gene expression by modulation of pseudoexon splicing patterns to rescue enzyme activity in propionic acidemia. Mol Ther Nucleic Acids. 2024; 35(1): 102101. Article. IF: 6.1; Q1
- **Richard E, Martínez-Pizarro A, Desviat LR.** Exploring RNA therapeutics for urea cycle disorders. J Inherit Metab Dis. 2024; 47(6): 1269-77. Review. IF: 3.8; Q2
- **Schumann A, Martínez-Pizarro A, Richard E, Schell C, Kössinger AL, Zeyer KA, Tholen S, Schilling O, Barry M, Neubauer B, Köttgen M, Hannibal L, Desviat LR, Spiekerkötter U.** Renal phenotyping in a hypomorphic murine model of propionic aciduria reveals common pathomechanisms in organic acidurias. Sci Rep-Uk. 2024; 14(1): 30478. Article. IF: 3.9; Q1
- **Vilas A, Briso-Montiano A, Segovia-Falquina C, Martín-Martínez A, Soriano-Sexto A, Gallego D, Ruiz-Montés V, Gámez A, Pérez B.** HepG2 PMM2-CDG knockout model: A versatile platform for variant and therapeutic evaluation. Mol Genet Metab. 2024; 143(1-2): 108538. Article. IF: 3.5; Q2
- **Wang Y, Zhu SH, He WT, Marchuk H, Richard E, Desviat LR, Young SP, Koeberl D, Kasumov T, Chen XX, Zhang GF.** The attenuated hepatic clearance of propionate increases cardiac oxidative stress in propionic acidemia. Basic Res Cardiol. 2024; 119(6): 1045-62. Article. IF: 8.0; D1

Research projects

- **Carracedo A, Pérez González MB.** IMPACT Genomica 2: Avanzando hacia la medicina de precisión en enfermedades raras y tumores de baja frecuencia (PMPER24/00002). ISCIII. 2024-2026. Managment centre: CIBER
- **Pérez González MB.** Enfoque cross-ómico para el descubrimiento de la base genética de errores innatos del metabolismo y para una intervención terapéutica personalizada (PI19/01155). ISCIII. 2020-2024. Managment centre: UAM
- **Pérez González MB.** Mejora del diagnóstico y desarrollo de terapias para errores congénitos del metabolismo a través del análisis genómico, transcriptómico, epigenómico y funcional de pacientes y modelos (PI22/00699). ISCIII. 2023-2025. Managment centre: FIBHULP
- **Richard Rodríguez EM.** Acidemia propiónica: impacto en el epigenoma y el proteoma en relación con el fenotipo cardiaco y neurológico. Fundación Ramón Areces. 2021-2024. Managment centre: UAM
- **Ruiz Desviat LM.** Rare neurometabolic diseases: from research in novel disease models to targeted therapies- (PID2022-137238OB-I00 MCINN). MCINN. 2023-2026. Managment centre: UAM
- **Stojiljkovic M, Pérez González MB.** BRIDGing the research and INnovation Gap for Rare Diseases in Europe by upgrading the excellence of IMGGE (BRIDGING-RD). (Number 101160079). EU. 2024-2027. Managment centre: UAM

Cibers and Retics

- **Pérez González MB.** Centro de Investigación en Red de Enfermedades Raras. (CIBERer). ISCIII. (31/12/2024). UAM

Patents and trademarks

- **Pérez González B, Ruiz Desviat L, Jorge Finnigan A, Ugarte Pérez M, Martínez Ruiz A, Underhaug J, Barnejee R, inventors; UAM, Universidad de Bergen, Universidad de Michigan, assignees; Compounds useful for the treatment of methylmalonic aciduria.** P201330171; 2013 February 11.
- **Pérez González B, Gámez Abascal A, Yuste Checa P, Arduim Brasil S, Ugarte Pérez M, Martínez Ruiz A, Underhaug J, inventors; UAM, Universidad de Bergen, assignees; Compounds for treating congenital disorders of glycosylation.** EP16382373.5; 2016.
- **Ruiz-Desviat L, Martínez-Pizarro A, Picó S, Lucas JJ, Andresen BS, inventors; UAM, CSIC, University of Southern Denmark, assignes; Splice shifting oligonucleotides for use in the treatment of diseases characterized by altered inclusion of microexons.** PCT/EP2022/077882, EP4163373A1 2023 April 12

3.5.8 Dyslipidemias of Genetic Origin and Metabolic Diseases



Publications: 5 | **Q1:** 4

COMPOSITION

Sonia María Rodriguez Novoa.
Facultativo Especialista-área Genética. Responsable del Laboratorio de Genética de Enfermedades Metabólicas. Hospital Universitario La Paz

- **Ana Carazo Álvarez.** *Técnico Superior Especialista en Laboratorio de Diagnóstico Clínico. Hospital Universitario La Paz*
- **Amanda Herranz Cecilia.** *Facultativo Especialista Área Genética. Hospital Universitario La Paz*
- **Irene Hidalgo Mayoral.** *Facultativo Especialista-área Genética. Hospital Universitario La Paz*
- **Carmen Prior de Castro.** *Facultativo Especialista-área Genética. Hospital Universitario La Paz*
- **Carmen Rodríguez Jiménez.** *Facultativo Especialista-área Genética. Hospital Universitario La Paz*
- **Rosa Torres Jiménez.** *Investigadora Senior (Contrato Miguel Servet - I2) Jefe de Laboratorio. FIBHULP*

STRATEGIC OBJETIVES

- Improve early diagnosis of genetic dyslipidemias, especially Familial Hypercholesterolemia (FH), through the use of advanced genomic technologies such as next-generation sequencing (NGS).
- Optimize the identification of affected family members through cascade genetic screening programs, promoting a cost-effective strategy for cardiovascular prevention.
- Develop and apply in vitro functional studies to characterize genetic variants in genes involved in FH (LDLR, APOB, PCSK9), enhancing their clinical classification and understanding their biological impact.
- Promote personalized medicine in patients with genetic dyslipidemias by integrating genetic and functional data to predict treatment response and guide individualized therapeutic decisions.
- Explore new genetic and epigenetic mechanisms involved in non-monogenic or unexplained dyslipidemias, expanding the understanding of the molecular basis of lipid metabolism.
- Promote training, scientific dissemination, and multidisciplinary collaboration, both nationally and internationally, in the field of hereditary cardiovascular diseases.

RESEARCH LINES

1. Molecular Diagnosis of Genetic Dyslipidemias
- Implementation and optimization of NGS sequencing protocols for the study of FH and other genetic dyslipidemias.
- Family screening strategies in different healthcare settings.

2. Functional Studies of Genetic Variants
- Validation of cell-based assays to determine the pathogenicity of variants in LDLR, APOB, and PCSK9.
- Genotype-phenotype correlation based on the variant and its functional impact.

3. Discovery of New Genetic and Epigenetic Causes
- Identification of new candidate genes through genomic studies in patients without known pathogenic variants.
- Investigation of the role of microRNAs in the regulation of LDLR, PCSK9, and other genes involved in lipid metabolism.
- Study of potential epigenetic mechanisms underlying complex forms of dyslipidemia.
- Definition and implementation of a workflow for systematic analysis of variants in the LDLR 3'UTR region in patients with suspected Familial Hypercholesterolemia.

4. Personalized Medicine and Treatment Response
- Evaluation of the influence of variant type on the response to lipid-lowering therapies.
- Pharmacogenetic analysis and study of molecular predictors of therapeutic response or resistance.

5. Rare and Underdiagnosed Dyslipidemias
- Genetic and clinical characterization of rare dyslipidemias (e.g., familial chylomicronemia, dysbetalipoproteinemia).
- Development of diagnostic algorithms integrating genomics, biochemistry, and clinical phenotype.

6. Metabolic Myopathy
- Identification of the genetic-molecular cause in patients with suspected metabolic etiology myopathy.

RESEARCH ACTIVITY

Publications

- **Escudero-Ferruz P, Ontiveros N, Cano-Estrada C, Sutcliffe DJ, Jinnah HA, Torres RJ, López JM.** A new physiological medium uncovers biochemical and cellular alterations in Lesch-Nyhan disease fibroblasts. Mol Med. 2024; 30(1): 3. Article. IF: 6.4; Q1
- **Major TJ, Takei R, Matsuo H, Leask MP, Sumpter NA, Topless RK, Shirai Y, Wang W, Cadzow MJ, Phipps-Green AJ, Li ZQ, Ji AC, Merriman ME, Morice E, Kelley EE, Wei WH, McCormick SPA, Bixley MJ, Reynolds RJ, Saag KG, Fadason T, Golovina E, O'Sullivan JM, Stamp LK, Dalbeth N, Abhishek A, Doherty M, Roddy E, Jacobsson LTH, Kapetanovic MC, Melander O, Andrés M, Pérez-Ruiz F, Torres RJ, Radstake T, Jansen TL, Janssen M, Joosten LAB, Liu RQ, Gaal OI, Crisan TO, Rednic S, Kurreeman F, Huizinga TWJ, Toes R, Lioté F, Richette P, Bardin T, Ea HK, Pascart T, McCarthy GM, Helbert L, Stiburková B, Tausche AK, Uhlig T, Vitart V, Boutin TS, Hayward C, Riches PL, Ralston SH, Campbell A, MacDonald TM, Nakayama A, Takada T, Nakatochi M, Shimizu S, Kawamura Y, Toyoda Y, Nakaoka H, Yamamoto K, Matsuo K, Shinomiya N, Ichida K, Lee C, Bradbury LA, Brown MA, Robinson PC, Buchanan RRC, Hill CL, Lester S, Smith MD, Rischmueller M, Choi HK, Stahl EA, Miner JN, Solomon DH, Cui J, Giacomini KM, Brackman DJ, Jorgenson EM, Liu HB, Susztak K, Shringarpure S, So A, Okada Y, Li CG, Shi YY, Merriman TR.** A genome-wide association analysis reveals new pathogenic pathways in gout. Nat Genet. 2024; 56(11): 2392-406. Article. IF: 29; D1
- **Otero JS, Rodríguez-Jiménez C, Prieto JM, Rodríguez-Antolín C, Álvarez AC, Blanco FA, Rodríguez-Nóvoa S.** Functional Analysis of 3′UTR Variants at the LDLR and PCSK9 Genes in Patients with Familial Hypercholesterolemia. Hum Mutat. 2024; 2024: 9964734. Article. IF: 3.7; Q2
- **Prior-de Castro C, Gallego MAM, Gómez-González C, Martín RD, Rodríguez-Antolín C, Rodríguez-Jiménez C, Mate AD, de Lucas EZ, Maiz MRD, Gómez CD, Batres SA, Sánchez MCP, Torres RJ.** Molecular diagnosis of cystic fibrosis by RNA obtained from nasal epithelial cells. J Cyst Fibros. 2024; 23(4): 788-95. Article. IF: 6.0; Q1
- **Villafuerte B, Carrasco-López C, Herranz A, Garzón L, Simón R, Natera-de-Benito D, Alikhani P, Tenorio J, Garcia-Santiago F, Solis M, del-Pozo A, Lapunzina P, Ortigoza-Escobar JD, Santisteban P, Moreno JC.** A Novel Missense Variant in the NKX2-1 Homeodomain Prevents Transcriptional Rescue by TAZ. Thyroid. 2024; 34(7): 942-8. Article. IF: 6.7; Q1



Research projects

- **Rodríguez Novoa SM.** Impacto de las variantes genéticas en región 3´UTR de los genes causantes de la Hipercolesterolemia Familiar: regulación del metabolismo de lípidos mediante miRNAs. (PI21/01239). ISCIII. 2022-2024. Managment centre: FIBHULP
- **Rodríguez Novoa SM.** Plataforma: dislipemias de origen genético y enfermedades metabólicas. Varios Financiadores. 2021-Ongoing. Managment centre: FIBHULP
- **Rodríguez Novoa SM.** Renal tubular and markers of bone turnover in hbv monoinfected patients during long term tretament with entecavir or tenofovir (P11/30). Bristol-Myers Squibb International Corporation. 2011-Ongoing. Managment centre: FIBHULP
- **Torres Jiménez R.** Alteracion del desarrollo neuronal en la enfermedad de Lesch Nyhan: papel de ZMP, hipoxantina y estres energetico. Fundació Marató TV3. 2021-Ongoing. Managment centre: FIBHULP
- **Torres Jiménez R.** Alteraciones del desarrollo neuronal en células pluripotentes humana HPRT deficientes (PID2020-113124RB-C22). MICIIN. 2021-2025. Managment centre: FIBHULP

Patents and trademarks

- **Rodríguez Novoa SM, del Monte Vergara A, Rosas Alonso R, Queiruga Parada J, Yuste González F, authors; FIBHULP, assignee.** Trademark name: Pharma Genfinder; CM18332183; 2020 November 05.

PHARMA GENFINDER

- **Ibáñez de Cáceres I, de Castro Carpeño J, Jiménez Hernández J, Rodríguez Antolín C, Rodríguez Jiménez C, Rosas Alonso R, Cruz Castellanos P, Burdiel Herencia M, Pernía Arias O, Diestro Tejada MD, Esteban Rodríguez MI, inventors; FIBHULP, assignee.** miR-151A-3p as an universal endogenous control for exosome cargo normalization. EP19382252.5 (EP3719144), PCT/EP2020/059774 PCT Direct, EP20719957.1 (EP3947733), US17/601,657; 2019 April 05.

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians


3.5.9 Human Genetic Variability

Publications: 5 | **Q1:** 2

COMPOSITION

Ana Fernández Santander.
Catedrática de Genética del Departamento de Medicina. Universidad Europea de Madrid

- **Beatriz Antón Pascual.** *Médico Adjunto en Oncología Médica. Hospital Universitario Doce de Octubre*
- **Alberto Carretero González.** *Facultativo especialista de área en Oncología Médica. Hospital Universitario de Getafe*
- **María Gaibar Alonso.** *Profesora titular. Universidad Camilo José Cela*
- **Diego Malón Jiménez.** *Médico Adjunto en Oncología Médica. Hospital Universitario de Fuenlabrada*
- **Apolonia Novillo Villajos.** *Profesora ayudante doctor. Universidad Complutense de Madrid*
- **José María Rodríguez Piñas.** *Profesor Adjunto. Universidad Europea de Madrid*
- **Alicia Romero Lorca.** *Catedrática de Bioquímica y Biología Molecular. Universidad Europea de Madrid*
- **David Sanz Rosa.** *Director de Investigación. Universidad Europea de Madrid*



STRATEGIC OBJETIVES

- The final objective of our group is to contribute to pharmacogenetics and precision medicine. We try to identify genetic biomarkers that could be used to predict who patients will have better response, benefit and outcome and lesser toxicity to specific drugs.

Planned Research Projects
- Genetic biomarkers of toxicity in oncological immunotherapy
- Genetic biomarkers of efficacy in oncological immunotherapy
- Worldwide genetic variability in polymorphisms associated with COVID severity

Transfer of Results
- Contributions in national and international congresses
- Publications in JCR journals

Training and education programme
- Students of medicine, nursery, etc, will be able to join to the group as PhD students

Dissemination
- Publications in JCR journals and national and international congresses
- Guides for physicians

Internationalization
- The team will call for European programs when specific programs related to our research will be opened. Gender Equality Quality Program: Gender equality is achieved in our group because women and men have the same conditions and opportunities to belong and to work with us.

RESEARCH LINES

- **Pharmacogenetics and cancer**
- Pharmacogenetics in breast cancer
- Pharmacogenetics in colorectal cancer
- Pharmacogenetics and immunotherapy
- **Genetic variability of human populations**

RESEARCH ACTIVITY

Final Degree Theses

- **Castro Sánchez KW.** Perfil mutacional de pole y sus implicaciones en inmunoterapia[dissertation]. Madrid: Universidad Complutense de Madrid: 2024(24/07/2024). Director: Novillo Villajos A

Publications

- **Esteban ME, Pino D, Romero-Lorca A, Novillo A, Gaibar M, Riancho JA, Rojas-Martínez A, Flores C, Lapunzina P, Carracedo A, Athanasiadis G, Fernández-Santander A.** Worldwide distribution of genetic factors related to severity of COVID-19 infection. Ann Hum Biol. 2024; 51(1): 2366248. Article. IF: 1.3; Q4
- **Fernández-Tocino M, Pun-Garcia A, Gómez M, Clemente-Moragón A, Oliver E, Villena-Gutierrez R, Trigo-Anca S, Díaz-Guerra A, Sanz-Rosa D, Prados B, del Campo L, Andrés V, Fuster V, de la Pompa JL, Cádiz L, Ibañez B.** β3-Adrenergic receptor overexpression in cardiomyocytes preconditions mitochondria to withstand ischemia-reperfusion injury. Basic Res Cardiol. 2024; 119(5): 773-94. Article. IF: 8.0; D1
- **Valdes-Devesa V, Sanz-Rosa D, Thuissard-Vasallo IJ, Andreu-Vázquez C, de la Cuesta RS.** Xenoestrogen concentration in women with endometriosis or leiomyomas: A case-control study. Plos One. 2024; 19(6): e0304766. Article. IF: 2.6; Q2
- **Díaz-Gavela AA, Peñalver ED, Sánchez-Garcia S, Pardo-Pérez E, Thuissard-Vasallo IJ, Andreu-Vázquez C, López MYM, Huertas MP, Guerrero-Gómez LL, Sanz-Rosa D, Lorenzo FC.** Hypofractionated whole breast IMRT with HDR brachytherapy boost in early-stage breast cancer: Long-term results from a single-center. Brachytherapy. 2024; 23(3): 342-54. Article. IF: 1.8; Q3
- **McLaughlin AM, Helland T, Klima F, Koolen SLW, van Schaik RHN, Mathijssen RHJ, Neven P, Swen JJ, Guchelaar HJ, Dalenc F, White-Koning M, Michelet R, Mikus G, Schroth W, Müdter T, Brauch H, Schwab M, Soiland H, Mellgren G, Thomas F, Kloft C, Hertz DL.** Nonlinear Mixed-Effects Model of Z-Endoxifen Concentrations in Tamoxifen-Treated Patients from the CEPAM Cohort. Clin Pharmacol Ther. 2024; 116(3): 690-702. Article. IF: 5.5; D1

Research projects

- **Antón Pascual B.** Evaluación del impacto de la práctica ejercicio físico en salud osteomuscular, emocional y tumoral en pacientes con tumores neuroendocrinos gastroenteropancreáticas u origen desconocido avanzados: FIT-NETs. NET España. 2023-2025. Managment centre: Hospital 12 de Octubre
- **Gaibar Alonso M.** Análisis de la expresión de microRNAs como posibles biomarcadores de toxicidad en inmunoterapia en cáncer genitourinario. Universidad Camilo Jose cela. 2024-2025. Managment centre: Universidad Camilo Jose Cela
- **Fernández-Santander A.** Estudio de polimorfimos de tipo SNP y CNV como posibles marcadores de toxicidad en inmunoterapia aplicada a tumores genitourinarios. FIBHULP. 2024-2025. Managment centre: IdiPAZ

3.6.Surgery, Transplant and Health Technologies Area

Documents: 221 | **Originals:** 179 | **D1:** 28 | **Q1:** 103

Nuria Vilaboa Díaz
coordinadorcirugia@idipaz.es



RESEARCH GROUPS

3.6.1 Bone Pathophysiology and Biomaterials
Nuria Vilaboa Díaz

3.6.2 Cellular Engineering
María Paz de Miguel González

3.6.3 Clinical Pharmacology
Antonio J. Carcas Sansuán

3.6.4 Osteoarticular Surgery Research – GICOA
Enrique Gómez Barrena

3.6.5 Translational Research in Maxillofacial Surgery and Head and Neck Cancer
José Luis Cebrián Carretero/Ana Sastre Perona

3.6.6 Patients Safety and Quality Research
Elena Ramírez García

3.6.7 Translational Research and Innovation in General and Digestive Surgery
Constantino Fondevila Campo

3.6.8 Anesthesia-Resuscitation Maternity
Isabel Valbuena Gómez

3.6.9 Advanced Medical Informatics Laboratory (LIMA)
Fernando Martín Sanchez

3.6.10 AI Health
Juan José Beunza Nuin

Strategic Objectives	Development forecast for the coming years:	Actions
Surgery, Transplant and Health Technologies Area is composed of 10 very heterogeneous groups and the absence of common activities between them make the general objectives equivalent to the sum of the research lines of each of the groups. The main objective of the area is to locate points where synergies between groups can be established.	Cellular and organ engineering, underdeveloped.	Support researchers to continue being a reference in the national area.
	Stem and precursor cells. This is one of the most successful lines and the one that has motivated more collaborations between them. It is certainly one of the possibilities for the future	Identify and promote at international level the new research lines identifying as innovative and competitive.
	Animal models. Cellular models. They require personnel trained in cell culture techniques and who masters animal models of human disease	
	Minimally invasive surgery: one of the most important translational fields in recent years, a permanent demand from the population and an indicator of the quality of healthcare systems	

HIGH IMPACT PUBLICATIONS

Elizalde MU, Eguinoa EJG, de las Huertas AGL, Jiménez-González M, **Ramírez E**. Myocarditis and pericarditis risk with mRNA COVID-19 vaccination compared to unvaccinated individuals: A retrospective cohort study in a Spanish Tertiary Hospital. Biomed Pharmacother. 2024; 171: 116181. Article. IF: 7,5; D1

Delclós LO, Rich RS, Loureda RA, García AM, **Barrena EG**. Efficacy and safety of autologous or allogeneic mesenchymal stromal cells from adult adipose tissue expanded and combined with tricalcium phosphate biomaterial for the surgical treatment of atrophic nonunion of long bones: a phase II clinical trial. J Transl Med. 2024; 22(1): 493. Article. IF: 7,5; Q1

Moratilla A, Martín D, Cadenas-Martín M, Stokking M, Quesada MA, Arnalich F, **De Miguel MP**. Hypoxia Increases the Efficiencies of Cellular Reprogramming and Oncogenic Transformation in Human Blood Cell Subpopulations In Vitro and In Vivo. Cells. 2024; 13(11): 971. Article. IF: 5,2; Q2

Pastor-Morate D, Amigo-Morán L, Garranzo-Asensio M, Rejas-González R, Carnicero P, Rodríguez N, Pérez-Robledo JP, Barderas R, **Prieto-Nieto I (CA),** Domínguez G. ΔNp73 and its effector targets promote colorectal peritoneal carcinosis and predict survival. J Pathol. 2024; 263(3): 328-37. Article. IF: 5,2; D1

García-Galán EC, Medel-Plaza M, Pozo-Kreilinger JJ, Sarnago H, Lucía O, Rico-Nieto A, Esteban J, **Gomez-Barrena E**. In vivo reduction of biofilm seeded on orthopaedic implants safety and efficacy of portable electromagnetic induction heating. Bone Joint Res. 2024; 13(12): 695-702. Article. IF: 5,1; Q1

Scientific Events by Surgery, Transplant and Health Technologies

- **19/01/2024.** II Curso de soporte vital avanzado Hospital Universitario La Paz
- **16/02/2024.** Scientific Seminar: Mechanisms of cutaneous squamous cell carcinoma progression
- **01/03/2024.** IA en investigación ya! La ciencia de Datos al servicio de la medicina
- **09/05/2024.** VIII Curso de simulación clínica en el manejo seguro de la vía aérea
- **27/09/2024.** Curso de Simulación Avanzada en Patología Aguda Traumática (SAVA-TRAUMA)
- **14/10/2024.** Curso de Soporte Vital avanzado
- **25/10/2024.** (TAT) Anestesia
- **25/11/2024.** Curso avanzado para instructores en simulación clínica

3.6.1 Bone Pathophysiology and Biomaterials

Publications: 9 | **Q1:** 2

COMPOSITION

Nuria Elda Vilaboa Díaz.
Investigadora Senior (Miguel Servet contract - I2). Jefe de Laboratorio. FIBHULP

- **Marcos de Mesa Cáceres.** *Ténico de Laboratorio. FIBHULP*
- **Eduardo García Cimbrelo.** *Médico Emérito de la Comunidad de Madrid. Hospital Universitario La Paz. Profesor Asociado. Departamento de Cirugía. Facultad de Medicina. Universidad Autónoma de Madrid*
- **Beatriz García Brihuega.** *Técnico de Laboratorio. FIBHULP*
- **Rebeca Garrido Punzano.** *Técnico de Laboratorio. FIBHULP*
- **Carmen Martin Hervás.** *Facultativo Especialista de Área en Radiodiagnóstico. Hospital Universitario La Paz. Profesora Asociada. Facultad de Medicina. Universidad Autónoma de Madrid*
- **Alonso Carlos Moreno García.** *Facultativo Especialista de Área en Cirugía Orotopédica y Traumatología. Hospital Universitario La Paz*
- **Laura Saldaña Quero.** *Investigadora Senior (Contrato Miguel Servet-Tipo II). Jefe de Laboratorio. FIBHULP*
- **María Recuero Vicente.** *Investigadora Postdoctoral. CIBER*
- **Rodrigo Fernando Serrano Yamba.** *Investigador Predoctoral. FIBHULP*
- **Gema Vallés Pérez.** *Investigadora Senior. Responsables de Cultivos Celulares y de los Laboratorios Comunes de IdiPAZ. FIBHULP*

STRATEGIC OBJETIVES

- The Bone Physiopathology and Biomaterials group includes basic and clinical researchers from IdiPAZ. The group has broad experience in clinical and basic research on biomaterials for orthopaedic implants and bone tissue engineering. The main goal of the group is to improve the clinical outcome of orthopaedic surgery through research on implants and biomaterials used for manufacturing prosthetic devices.
- The group is interested in the study of mechanisms underlying joint diseases, in developing tissue engineering-based therapies as well as in evaluating biomaterials manufactured by collaborative partners. Specific areas of clinical research on implants include follow-up studies on various devices in use for osteoarticular surgery.
- The team is also involved in the manipulation of the heat shock response to generate transcriptional targeting strategies that provide tight control of the expression of therapeutic proteins. Their potential application in bone and wound healing therapies as well as in the generation of influenza vaccines with anti-herpetic activity are being explored. This strategic objective also includes the identification and characterization of the heat shock transcription factor 1 (HSF1) inhibitors as potential antitumoral agents.



RESEARCH LINES

- Clinical research in implants for bone repair
- Study of the pathophysiology of joint diseases and mechanisms involved in bone regeneration.
- Evaluation of new biomaterials, including scaffolds and nanoparticles, for their potential use in wound healing and bone tissue engineering application.
- Development of gene therapy switches to control the expression of transgenes to a) enhance bone regeneration and wound healing or b) generate influenza vaccines. Application of non-invasive near-infrared energy combined with photothermal nanoparticles.
- Identification and characterization of HSF1 inhibitors as antitumoral drugs.

RESEARCH ACTIVITY

Doctoral Theses

- **Maestro Paramio L.** Regulación de las interacciones entre células que participan en la regeneración ósea por la composición y rigidez de hidrogeles naturales[dissertation]. Madrid: Universidad Autónoma de Madrid: 2024(12/06/2024). Director: Saldaña Quero L.

Publications

- **Bloom DC, Lilly C, Canty W, Vilaboa N, Voellmy R.** Very Broadly Effective Hemagglutinin-Directed Influenza Vaccines with Anti-Herpetic Activity. Vaccines (Basel). 2024; 12(5): 537. Article. IF: 3.4; Q2
- **Delclós LO, Rich RS, Loureda RA, García AM, Barrena EG.** Efficacy and safety of autologous or allogeneic mesenchymal stromal cells from adult adipose tissue expanded and combined with tricalcium phosphate biomaterial for the surgical treatment of atrophic nonunion of long bones: a phase II clinical trial. J Transl Med. 2024; 22(1): 493. Article. IF: 7.5; Q1
- **García-Rey E, Saldaña L.** Long-term results of total hip arthroplasty in severe congenital hip disease: A ten- to 20-year follow-up study. Orthop Traumatol-Sur. 2024; 110(6): 103850. Article. IF: 2.2; Q2
- **García-Rey E, Saldaña L.** Spinopelvic interactions in total hip arthroplasty: 295 patients followed for a minimum follow-up of 10 years. Hip Int. 2024; 34(4): 487-97. Article. IF: 1.1; Q3
- **Llobet EL, Poggio MC, Hernández CL, Hervás CM, Morales DT, Araujo DM, Marina SR, Gadea LD.** Controversy in the initial nodal staging of rectal cancer (MRI or PET/CT?). Rev Esp Med Nucl Ima. 2024; 43(3): 500004. Article. IF: 1.0; Q4
- **Navarro MJR, Goldaracena JMO, Alonso DG, Monforte YN, Durbán TDD, Chicote MVC, Martínez FG, Álvarez CM, Gregorio LY, Botella JLM, Hervás CM, Méndez JIS.** Pre-surgical cryoablation in ≤ 2 cm ER + /HER2-tumors. Prognostic factors for the presence of residual invasive carcinoma. Breast Cancer Res Tr. 2024; 206(3): 561-73. Article. IF: 3.0; Q2
- **Sánchez-Fernández D, Eguibar A, López C, Cuesta AM, Albiñana V, Rogers-Ezewuike S, Gómez-Rivas JA, Saldaña L, Botella LM, Ferrer M.** Effect of 5β-dihydrotestosterone on vasodilator function and on cell proliferation. Plos One. 2024; 19(10): e0312080. Article. IF: 2.6; Q2
- **Vilaboa N, Bloom DC, Canty W, Voellmy R.** A Broad Influenza Vaccine Based on a Heat-Activated, Tissue-Restricted Replication-Competent Herpesvirus. Vaccines (Basel). 2024; 12(7): 703. Article. IF: 3.4; Q2
- **Vilaboa N, Voellmy R.** Withaferin A and Celastrol Overwhelm Proteostasis. Int J Mol Sci. 2024; 25(1): 367. Review. IF: 4.9; Q1

Research projects

- **Escudero-Duch C.** Films de PLA con patrón microestructurado para promover la cicatrización de heridas. CIBER-BBN. 2023-2024. Managment centre: CIBER-BBN
- **García Brihuega B.** Contrato garantía juvenil (PEJ-2021-TL/BMD-22184). CM. 2022-2024. Managment centre: FIBHULP
- **Lerma Juarez MA.** Contrato predoctoral (PRE2019-090430). MICIU. 2020-2024. Managment centre: FIBHULP
- **Saldaña Quero L.** Contrato Miguel Servet (CPII16/00038). CM. 2016-2025. Managment centre: FIBHULP
- **Saldaña Quero L.** Osteonecrosis de cabeza femoral: identificación de alteraciones en el hueso trabecular, correlación clínica y factores de riesgo en la fijación de la prótesis total de cadera (PI22/00939). ISCIII. 2023-2025. Managment centre: FIBHULP
- **Vilaboa Díaz NE, Saldaña Quero L.** Desarrollo de fluidos que potencien o favorezcan la osteointegración de los implantes ante distintas situaciones. Mozo-Grau S. A. 2017-Ongoing. Managment centre: FIBHULP
- **Vilaboa Díaz NE.** Contrato Miguel Servet Categoria A (CES07/031). CM. 2007-2025. Managment centre: FIBHULP
- **Vilaboa Díaz NE.** Detección de activación de HSF partes XVII y XVIII. HSF Pharmaceuticals S.A. 2004-Ongoing. Managment centre: FIBHULP
- **Vilaboa Díaz NE.** Nuevas soluciones terapéuticas para el tratamiento de la piel radiada (RADIOPROTECT-CM) (P2022/BMD-7406). CM. 2023-2026. Managment centre: FIBHULP
- **Vilaboa Díaz NE.** Potencial traslacional de inhibidores del factor de transcripción HSF1 como drogas anticancerigenas (PID2021-126325OB-I00). Ministerio de Ciencia e Innovación. 2022-2026. Managment centre: FIBHULP

Cibers and Retics

- **Vilaboa Díaz NE.** Networked Biomedical Research Center for Bio-engineering, Biomaterials and Nanomedicine. (CIBER-bbn). Carlos III Health Institute. (31/12/2025). FIBHULP

Patents and trademarks

- **González Carrasco JL, Benavente Castro R, Cifuentes Cuellar SC, Lieblich Rodríguez M, Olalde Graells B, Atorrasagasti Goyalde G, Argarate Madariaga N, Pacha Olivenza MA, Fernández Calderón MC, Saldaña Quero L, González Martín ML, Pérez Giraldo C, Gallardo Moreno AM, inventors; CSIC, Fundación Tecnalia Research & Innovation, FIBHULP, Universidad de Extremadura, Centro de Investigación Biomédica en Red (CIBER).** Moldable, biodegradable, biocompatible and bioresorbable implant material, method for its preparation and uses thereof. P201530683; 2015 May 18.
- **Martín Saavedra FM, Vilaboa Díaz NE, Cebrián Hernando V, Arruebo Gordo M, Santamaría Ramiro J, Gómez Navascués L, inventors; FIBHULP, CIBER-BBN, Universidad de Zaragoza, assignees.** Fibrin hydrogel with plasmonic nanoparticles; P201330894, PCT/ES2014/070484; 2013 June 14.
- **Vilaboa Díaz NE, Calzado Martín A, Crespo García L, Saldaña Quero L, Moreo Calvo P, Alastrué Vera V, inventors; FIBHULP, CIBER-BBN, assignees.** Chamber device for dynamic cell culture on biomaterials; P201330040, PCT/ES2013/070819; 2013 January 16.
- **Vilaboa Díaz NE, Gónzalez Carrasco JL, Multigner Domínguez M, Lieblich Rodríguez M, Muñoz Hernández M, Frutos Torres E, Saldaña Quero L, inventors; FIBHULP, CSIC, CIBER-BBN, Universidad Alfonso X El Sabio, assignees.** Magnesium/polymer composite biomaterial for biomedical applications; P201030950, PCT/ES2011/070440; 2010 June 21.
- **Vilaboa Díaz NE, González Carrasco JL, Saldaña Quero L, Frutos Torres E.** inventors; FIBHULP, CSIC, CIBER-BBN, assignees. Method to obtain a metallic-coated biomaterial; P201030949, PCT/ES2011/070400; 2010 June 21.
- **Voellmy R, Vilaboa Díaz NE, inventors; HSF Pharmaceuticals S.A., assignee.** Inhibitors



3.6.2 Cellular Engineering

Publications: 5 | **Q1:** 1

COMPOSITION

María Paz de Miguel González.
Investigadora Senior (Contrato Miguel Servet - I2). Jefe de Laboratorio. FIBHULP

- **Marta Cadenas Martín.** *Investigador Predoctoral. FIBHULP*
- **María Pilar González-Peramato Gutiérrez.** *Facultativo Especialista de Área en Anatomía Patológica. Hospital Universitario La Paz*
- **Anna Marc Malgorzata.** *Investigadora Postdoctoral. FIBHULP*
- **Ana Isabel Martín González.** *Investigadora Predoctoral. FIBHULP*
- **Manuel Nistal Martín de Serrano.** *Catedrático Departamento de Histología y Neurociencia. Facultativo de Medicina. Universidad Autónoma de Madrid*
- **Elsa Umiri Condo.** *Técnico de Laboratorio. FIBHULP*



STRATEGIC OBJETIVES

- To ascertain the mechanisms responsible for converting a differentiated cell into a pluripotent cell and at the same time how these establish a relationship between cellular reprogramming and oncogenic transformation, in order to use divergent pathways governing these processes as clinical early diagnostic tools and therapeutic targetsfor clinical intervention.
- To develop new cell therapy approaches in diverse organs transplants.

RESEARCH LINES

- Molecular mechanisms of cellular reprogramming in normal and neoplastic environments.
- New techniques and therapies in transplants.

RESEARCH ACTIVITY

Doctoral Theses


- **Cadenas Martín M.** Generación de córnea biomimética con células madre mesenquimales de tejido adiposo[dissertation]. Madrid: Universidad Autónoma de Madrid: 2024(15/02/2024). Director: de Miguel González MP
- **Pérez González S.** Estudio de las mutaciones del promotor del gen TERT, de POLE y clasificación molecular mediante análisis de la expresión de marcadores inmunohistoquímicos en el carcinoma urotelial de vejiga de pacientes adultos jóvenes (40 años o menores) [dissertation]. Madrid: Universidad Autónoma de Madrid: 2024(24/07/2024). Director: González-Peramato Gutiérrez MP, Mendiola Sabio M.

Master Theses

- **Fernández Ferrer A.** Evaluación del tratamiento de Terapia Celular Avanzada con células madre derivadas de tejido adiposo en el tratamiento del daño limbar corneal[dissertation]. Madrid: Universidad CEU San Pablo: 2024(01/06/2024). Director: de Miguel González MP. StemVision
- **de Sancha Maluenda M.** Diferenciación dirigida de células madre mesenquimales a células de la cresta neural y queratocitos corneales para su uso en oftalmología[dissertation]. Madrid: Universidad CEU San Pablo: 2024(01/06/2024). Director: de Miguel González MP. ISCIII

Publications

- **Cuadras M, Semidey ME, Planas J, de Torres IM, Regis L, Celma A, Trilla E, Cajal SRY, Medina RA, Congregado B, Marcilla D, Japón MA, Ramírez M, Calatrava-Fons A, Leivar A, Alonso MB, García E, González-Peramato P, Vázquez-Martul D, Concha-López A, Chantada V, Queipo FJ, Gago JL, Carrato C, Luque RJ, Moreno-Jiménez J, Catalina-Fernández I, León C, Morote J.** Molecular Detection of Lymph Node Metastases with One-Step Nucleic Acid Amplification (OSNA) Pooling in Prostate



Cancer: The POPCORN Study. Int J Mol Sci. 2024; 25(24): 13489. Article. IF: 4.9; Q1

- **El Zarif M, Jawad KA, Alió JL, Makdissy N, De Miguel MP.** In vivo confocal microscopy evaluation of infiltrated immune cells in corneal stroma treated with cell therapy in advanced keratoconus. J Ophthalmic Inflamm Infect. 2024; 14(1): 5. Article. IF: 2.3; Q2
- **González SP, Heredia-Soto V, de Francisco MG, Pérez-Fernandez E, Casans-Francés R, Rodríguez VD, Sabio MM, González-Peramato P.** Clinical, Pathological Characteristics and Progression of Urothelial Bladder Cancer in Young Adult Patients. Our Experience and Literature Review. Arch Esp Urol. 2024; 77(5): 463-70. Review. IF: 0.9; Q4
- **González SP, Heredia-Soto V, de Francisco MG, Pérez-Fernández E, Casans-Francés R, Sabio MM, González-Peramato P.** Telomerase Reverse Transcriptase-Promoter Mutation in Young Patients with Bladder Tumors. Curr Issues Mol Biol. 2024; 46(4): 2845-55. Article. IF: 3.0; Q3
- **Moratilla A, Martín D, Cadenas-Martín M, Stokking M, Quesada MA, Arnalich F, De Miguel MP.** Hypoxia Increases the Efficiencies of Cellular Reprogramming and Oncogenic Transformation in Human Blood Cell Subpopulations In Vitro and In Vivo. Cells. 2024; 13(11): 971. Article. IF: 5.2; Q2

Research projects

- **de Miguel González MP.** Bio-Ingeniería de tejido corneal para trasplante endotelial: desarrollo de láminas ultrafinas de cornea decelularizada colonizadas por endoletio corneal humano expandido en cultivo. Roche Farma S.A. 2016-Ongoing. Managment centre: FIBHULP
- **de Miguel González MP.** Contrato Miguel Servet Categoria A (CP03/0007). CM. 2010-2025. Managment centre: FIBHULP
- **de Miguel González MP.** Contribución de la modificación metabólica a la reprogramación celular y la transformación oncogénica. Fundación Domingo Martínez. 2017-Ongoing. Managment centre: FIBHULP
- **de Miguel González MP.** Generación de estroma corneal bio-mimético por impresión 3D de colageno y celulas madre mesenquimales. Stem Vision S. L. 2021-Ongoing. Managment centre: FIBHULP
- **de Miguel González MP.** Contratos de Ayudante de Investigación financiados por el Fondo Social Europeo. Fondo Social Europeo. 2023-2025. Managment centre: FIBHULP
- **de Miguel González MP.** Explorando las células madre pluripotentes inducidas como fuente para regenerar el estroma corneal (PI23/00207). ISCIII. 2024-2026. Managment centre: FIBHULP
- **de Miguel González MP.** Córnea artificial biomimética: síntesis mediante impresión 3D de arquitecturas poliméricas basadas en colágeno entrecruzado como soporte celular para regeneración corneal. Zeiss AG. 2024-2026. Managment centre: FIBHULP
- **de Miguel González MP.** Puesta en marcha del ensayo clínico de biocompatibilidad y estabilidad. AJL Ophthalmic S. A. 2023-2024. Managment centre: FIBHULP

Clinical trials

- **González-Peramato Gutiérrez MP.** concordance of pd-l1 expression between matched transurethral resections of the bladder and radical cystectomy samples in muscle invasive urothelial carcinoma: a retrospective, observational, multicenter, real-world study (accord study) concordancia en la expresión de pd-l1 entre muestras pareadas de resección transuretral de vejiga y de cistectomía radical en carcinoma urotelial músculo invasivo: estudio retrospectivo, observacional, multicéntrico y en vida real (estudio accord).
  Type/Phase: OTROS
  Sponsored by: Bristol-Myers Squibb Services Unlimited Company
  Signature date: 06/11/2024

Patents and trademarks

- **de Miguel González MP, Arnalich Montiel F, Royuela MM, inventors; FIBHULP, Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal, Universidad de Alcalá, assignees.** Corneal endothelium injector; P201131222, PCT/ES2012/070543; 2011 July 18.
- **De Miguel González MP.**, Arnalich-Montiel F, Cadenas Martín M, Moratilla Riofrío A.inventors; FIBHULP, FIBHRYC, assignees. Constructos artificiales para su uso en oftalmología, su procedimiento de obtención y utilización del mismo. Patente Europea EP22382119.0 2022 February 14 . PCT/EP2023/053668 2023 February 14.

3.6.3 Clinical Pharmacology

Publications: 9 | **Q1:** 6

COMPOSITION

Antonio Javier Carcas Sansuán.
Facultativo Especialista de Área en Farmacología Clínica. Hospital Universitario La Paz. Profesor Titular. Facultad de Medicina. Universidad Autónoma de Madrid

- **Pilar Ayllón García.** *Técnico de laboratorio. Universidad Autónoma de Madrid*
- **Alberto Borobia Pérez.** *Facultativo Especialista de Área en Farmacología Clínica. Hospital Universitario La Paz*
- **Raquel de Madariaga Castell.** *Enfermera. Coordinadora de Ensayos Clínicos. FIBHULP*
- **Laura Díaz García.** *Facultativo Especialista en Farmacología Clínica. Hospital Universitario La Paz*
- **Blanca Duque Bascuñana.** *Responsable de calidad. Universidad Autónoma de Madrid*
- **Jesús Frías Iniesta.** *Jefe de Servicio de Farmacología Clínica.Hospital Universitario La Paz. Catedrático. Facultad de Medicina. Universidad Autónoma de Madrid*
- **Alberto García Bartolomé.** *Investigador Postdoctoral . Hospital Universitario La Paz*
- **Irene García García.** *Facultativo Especialista en Farmacología Clínica. Hospital Universitario La Paz*
- **Andrea Guzmán de Antonio.** *Predoctoral Researcher. FIBHULP*
- **Cristina López Crespo.** *Enfermera. Coordinadora de Ensayos Clínicos. FIBHULP*
- **Alicia Marín Candón.** *Medico Especialista en Farmacología Clínica. FIBHULP*
- **José Carlos Martínez Ávila.** *Investigador Postdoctoral . Hospital Universitario La Paz*
- **Lucía Martínez de Soto.** *Coordinadora de Ensayos Clínicos. FIBHULP*
- **Vega Mauleón Martínez.** *Enfermera. Coordinadora de Ensayos Clínicos. FIBHULP*
- **Pablo Molina Benítez.** *Investigador Predoctoral . FIBHULP*
- **Paloma Moraga Alapont.** *Gestora de proyectos SCReN (Spanish Clinical Research Network). FIBHULP*
- **María Cristina Murano Murano.** *Investigador Postdoctoral. FIBHULP*
- **Paula Prieto Correa.** *Monitora de Ensayos Clínicos. FIBHULP*
- **Rocío Prieto Pérez.** *Gestora de proyectos SCReN (Spanish Clinical Research Network). FIBHULP*
- **Laura Vitón Vara.** *Enfermera. Coordinadora de Ensayos Clínicos. FIBHULP*
- **Hoi Yan Tong.** *Responsable de Farmacovigilancia. Hospital Universitario La Paz*



STRATEGIC OBJETIVES

- Clinical pharmacology, as a scientific and professional discipline, has the objective of achieving an effective, efficacious and efficient use of drugs, at both the individual and group level. This means that Clinical Pharmacology is a cross-sectional discipline that must establish collaborations with numerous other disciplines and health professionals.
- In this context and in the field of clinical research, the interests of our group are focused on two fundamental aspects:
- 1. Customisation of drug treatments: research and development of techniques and methods that individualise the use of drugs, improve their efficacy and reduce their risks.
- 2. The improvement of treatment by obtaining high quality evidence on the efficacy of clinical trials, strategies of identification, evaluation and prevention of adverse reactions to medication (pharmacovigilance programmes) and evaluation of the suitability of their use and effectiveness (studies on the use of medication).

RESEARCH LINES

- Therapeutic drug monitoring (TDM) – Development of individualised therapeutic drug monitoring programmes and pharmacogenetics.
- Getting quality evidences for the stablishment of drug efficacy, safety and adecuate use of medicines in humans

RESEARCH ACTIVITY

Doctoral Theses

- **Fudio Muñoz S.** Revisión crítica sobre los aspectos relativos a farmacología clínica de las combinaciones aprobadas por la FDA en hemato-oncología desde el año 2011 para aplicar a un caso práctico[dissertation]. Madrid: Universidad Autónoma de Madrid: 2024(25/04/2024). Director: Carcas Sansuán AJ.

Publications

- **Abad-Santos F, Alino SF, Borobia AM, García-Martín E, Gassó P, Maroñas O, Agúndez JAG.** Developments in pharmacogenetics, pharmacogenomics, and personalized medicine. Pharmacol Res. 2024; 200: 107061. Article. IF: 10.5; D1
- **Cardenas V, Le Gars M, Truyers C, Ruiz-Guiñazú J, Struyf F, Colfer A, Bonten M, Borobia A, Reisinger EC, Kamerling IMC, Douoguih M, Sadoff J.** Safety and immunogenicity of Ad26.COV2.S in adults: A randomised, double-blind, placebo-controlled Phase 2a dose-finding study. Vaccine. 2024; 42(16): 3536-46. Article. IF: 3.5; Q2
- **Ferreras C, Hernández-Blanco C, Martín-Quirós A, Al-Akioui-Sanz K, Mora-Rillo M, Ibáñez F, Díaz-Almirón M, Cano-Ochando J, Lozano-Ojalvo D, Jiménez-González M, Goterris R, Sánchez-Zapardiel E, de Paz R, Guerra-García P, Queiruga-Parada J, Molina P, Briones ML, Ruz-Caracuel B, Borobia AM, Carcas AJ, Planelles D, Vicario JL, Moreno MA, Balas A, Llano M, Llorente A, del Balzo A, Cañada C, García MA, Calvin ME, Arenas I, de Diego RP, Eguizábal C, Soria B, Solano C, Pérez-Martínez A.** Results of phase 2 randomized multi-center study to evaluate the safety and efficacy of infusion of memory T cells as adoptive therapy in severe. Cytotherapy. 2024; 26(1): 25-35. Article. IF: 3.2; Q2
- **Fuentes B, Jordi-Perea P, Sempere-Iborra C, Tarifa-Rodríguez A, de Celis-Ruiz E, Alonso MM, Ruiz-Ares G, Rigual R, Rodríguez-Pardo J, Alonso-López E, de Leciñana MA, Viués-Ortega J, Borobia AM, Jiménez-González M, Martínez-Balaguer M, Blanco P, Bueno N.** Dubbing language-therapy CINEma-based in aphasia post-stroke (DULCINEA): A feasibility randomized crossover controlled trial. Digit Health. 2024; 10: 20552076241288300. Article. IF: 3.3; Q1
- **García-Pérez J, Borobia AM, Pérez-Olmeda M, Portolés A, Castaño L, Campins-Arti M, Bertran MJ, Bermejo M, Arribas JR, López A, Ascaso-del-Rio A, Arana-Arri E, Camps IF, Vilella A, Cascajero A, García-Morales MT, de la Osa MC, Ingidua CP, Lora D, Jiménez-Santana P, Pino-Rosa S, de la Cámara AG, de la Torre-tarazona E, Calonge E, Cruces R, Belda-Iniesta CB, Alcami J, Frias J, Carcas AJ, Díez-Fuertes F.** Immunogenicity of a third dose with mRNA-vaccines in the ChAdOx1-S/BNT162b2 vaccination SARS-CoV-2 variants. Iscience. 2024; 27(9): -110728. Article. IF: 4.1; Q1
- **Pérez-Jurado LA, Cáceres A, Balagué-Dobón L, Esko T, de Heredia ML, Quintela I, Cruz R, Lapunzina P, Carracedo A, Abellán J, Acosta-Isaac R, Aguado JM, Aguilar C, Aguilera-Albesa S, Sabbagh AA, Alba J, Albu S, Alcalá-Gallardo KAM, Alcoba-Florez J, Batres SA, Algarin-Lara HR, Almadana V, Medeiros KA, Almeida J, Almoguera B, Alonso MR, Alvarez N, Walther RAS, Alvarez-Benítez Y, Alvarez-Navia F, dos Santos KA, Andreu-Bernabeu A, Antonijoan MR, Martínez-Aquino E, Arana-Arri E, Aranda C, Arango C, Araque C, Araujo NK, Arcanjo AC, Arnaiz A, Fernández FA, Arranz MJ, López JRA, Artiga MJ, Avello-Malaver Y, Ayuso C, Martín BB, Baptista-Rosas RC, Baldion AM, Barranco-Díaz A, Barreda-Sánchez M, Barrera-Penagos V, Belhassen-Garcia M, Bernal-Bello D, Bernal E, Bezerra JF, Bezerra MAC, Blanca-López N, Blancas R, Boix-Palop L, Borobia A, Bravo E, Brion M, Brochado-Kith O, Brugada R, Bustos M, Cabello A, Cáceres A, Cáceres-Agra JJ, Calbo E, Calderón EJ, Camacho S, Ceballos FC, Cañadas Y, Carbonell C, Cardona-Huerta S, Abad MSC, Segura CC, Carrillo-Avila JA, Campos MC, Casasnovas C, Castaño L, Castaño CF, Castelao JE, Candalija AC, Castillo MA, Chaves-Santiago WG, Chiquillo-Gómez S, Cid-López MA, Cienfuegos-Jiménez O, Conde-Vicente R, Cunha GCR, Cordero-Lorenzana ML, Corella D, Corrales A, Cortés-Sánchez JL, Corton M, Souza KSC, Silva FTC, Cruz R, Cuesta L, Tavares NAC, Carvalho MCC, Dalmau D, Dantas-Komatsu RCS, Darnaude MT, de Andrés R, de Juan C, Troca JJD, de la Horra C, de la Hoz AB, De Martino-Rodríguez A, Cruz MS, Neri JLDA, del Campo-Pérez V, Delgado-Cuesta J, de Bustamante AD, Díaz-Pérez A, Dietl B, Diz-de Almeida S, Alves MD, Domínguez-Garrido E, Rosa LS, Luchessi AD, Echave-Sustaeta J, Eiros R, Enciso-Olivera CO, Escudero G, España PP, Sanabria GE, Fariñas MC, Fernández R, Fernández-Caballero L, Fernández-Cruz A, Fernández-Ferrero S, Martínez YF, Fernandez-Nestosa MJ, Fernández-Robelo U, Fernández-Rodríguez A, Fernández-Sampedro M, Fernández R, Fernández-Villa T, Fernández-Capitán C, Carioca AAF, Flores-Pérez P, Fuenmayor-Hernández L, Fuertes-Núñez M, Fumadó V, Gadea I, Gagliardi L, Gago-Domínguez M, Gallego N, Galoppo C, García-Soidán A, García-Cerrada C, García-de-Vicuña A, Garcia-García J, García-García I, García-Ibarbia C, García-Montero AC, García L, García M, Torrejón MCG, García I, García-Vázquez E, Garza-Frias E, Gentile A, Gil-Fournier B, de Araújo JNG, Gómez-Duque M, Gómez-Arrue J, Carrera LG, García MG, Sacristán AG, González JR, González-Neira A, Alvarez BG, de Quirós FGB, González-Montelongo R, González-Peñas J, Gonzalez-Sagrado M, Gonzalo-Benito H, Gorgojo-Galindo O, Górgolas M, Guaragna F, Chaux JG, Guillén-Navarro E, Guillén-Guío B, Guisado-Vasco P, Gutiérrez-Castañeda LD, Gutiérrez-Bautista JF, Heili-Frades S, Jacomo RH, Hernández E, Hernández-Moro C, Hernández-Ortega LD, Hernández-Pérez G, Hernández-Vaquero R, Herráez B, Herranz MT, Herrera M, Herrero MJ, Herrero-González A, Horcajada JP, Imaz-Ayo N, Intxausti-Urrutibeaskoa M, Iñigo-Campos A, Iñiguez M, Jara R, Jiménez A, Jiménez-Alfaro I, Jiménez P, Jiménez-Sousa MA, Jordan I, Laguna-Goya R, Laorden D, Lasa-Lázaro M, Lattig MC, Lauriente A, Borja AL, Llanos L, López-Bernus A, de Heredia ML, Lopez-Garcia E, López-Granados E, Lopez-Rodriguez R, López-Ruz MA, Lorente L, Lorenzo-Salazar J, Lozano JE, Lozano-Espinosa M, Mahillo I, Mancebo E, Mar C, Calvo CM, Marcos-Delgado A, Marcos M, Marín-Candón A, Mariscal-Aguilar P, Martin-Pedraza L, Martin-Fernandez M, Martín-López C, Martín-Oterino JA, Martín MD, Martín V, Martín MM, Martín-Vicente M, Martinez A, Martínez-González O, Martínez R, Martinez-Paz P, Díaz-Caneja CM, Martínez-Nieto O, Martínez-López I, Martínez-Reséndez MF, Martínez S, Martínez JJ, Martínez-Pérez A, Martínez-Ramas A, Martínez-Robles V, Marzal L, Mazzeu JF, Medrano EJ, Meijome XM, Mejuto-Montero N, Mendes I, Duarte AL, Méndez-Echevarría A, Charris HM, Macías EM, Mercadillo F, Mercado-Sesma AR, Mínguez P, Molina-Roldán E, Molina AJ, Montoya JJ, Pinho SMT, Moreira-Escriche P, Morelos-Arnedo X, Moreno R, Cuerda VM, Moreno-Docón A, Moreno-Escalante J, Fernández AM, Garcia PM, Neira P, Nevado J, Nieto-Gañán I, Silbiger VN, Nuñez-Torres R, Obrador-Hevia A, Ocejo-Vinyals JG, Virginia O, Oliveira SF, Ondo L, Orfao A, Ortega-Paino E, Ortega L, Ortiz-López R, Ortiz-Flores F, Oteo JA, Pacheco M, Pacheco-Miranda FJ, Padilla-Conejo I, Panadero-Fajardo S, Parellada M, Pariente-Rodríguez R, Friaza V, Paz-Artal E, Peces-Barba G, Kus MSP, Perales C, Santos NPC, Guegel GP, Pérez MJ, Pérez A, Pérez-Matute P, Pérez C, Pérez-de-Nanclares G, Pérez-García F, Pérez P, Pérez-Jurado LA, Pérez-Tomás ME, Perucho T, Pichardo LA, Ribeiro AP, Pinsach-Abuin ML, Pinzón LA, Medeiros JFP, Pita G, Pla-Juncà F, Planas-Serra L, Pompa-Mera EN, Porras-Hurtado GL, Pujol A, Quevedo-Chávez ME, Quijada MA, Quintela I, Ramiro-León S, Sedes PR, Nunes JFR, Recalde D, Recio-Fernández E, Resino S, Sousa RR, Rivadeneira-Chamorro CS, Roa-Agudelo D, Pardo MR, Fernandes MR, Rodríguez-Hernández MA, Rodriguez-Palmero A, Rodríguez-Ruiz E, Rodriguez MJ, Rodríguez-Artalejo F, Rodríguez-Ferrer M, Rodríguez-Gallego C, Rodríguez-García JA, Maya BR,**

Rodriguez-Nicolas A, Rodríguez-Novoa GE, Rodriguez-Urrego PA, Rojo F, Romero-Coronado A, Morilla R, Rondón-García F, Rosales-Castillo A, Rubio C, Olivera MR, Ruiz-Cabello F, Ruiz-Casares E, Ruiz-Cubillan JJ, Ruiz-Hornillos J, Ruiz M, Ryan P, Salamanca HD, Salazar-García L, Salgueiro-Origlia GG, Sangil A, Sánchez-Pernaute O, Sánchez PL, López AJS, Sánchez-Pablo C, Sanchez-Prados MC, Sanchez-Real J, Sanchez-Redondo J, Sancho-Sainz C, Sande E, Santos A, Schlüter A, Segovia S, Serra-Llovich A, Sevil-Puras F, Sevilla-Porras M, Sicolo MA, Silván-Fuentes C, Moraes VMS, Souza VS, Solé-Violán J, Soria JM, Sorlí JV, Silva NS, Souto JC, Sprockel JJ, Suárez-Rama JJ, Suárez-Zamora DA, Taboada-Fraga X, Tamayo E, Tamayo-Velasco A, Taracido-Fernández JC, Vasconcelos RHT, Tellería C, Carratto TMT, Tenorio-Castano JA, Teper A, Araujo IMT, Torres-Macho J, Torres-Tobar L, Torres-Gutiérrez RP, Troya J, Urioste M, Valencia-Ramos J, Valido A, Vargas-Gallo JP, Varón B, Vega T, Velasco-Quirce S, Vélez-Santamaría V, Víctor V, Vidán-Estévez J, Silva GV, Vieitez-Santiago M, Vilches C, Villalobos L, Villar F, Villar-Garcia J, Villaverde C, Villoslada-Blanco P, Virseda-Berdices A, Costa TX, Yáñez Z, Zapatero-Gaviria A, Zarate R, Zazo S, Flores C, Riancho JA, Rojas-Martinez A, Lapunzina P, Carracedo A, González JR. Clonal chromosomal mosaicism and loss of chromosome Y in elderly men increase vulnerability for SARS-CoV-2. Commun Biol. 2024; 7(1): 202. Article. IF: 5.1; D1

- **Stemler J, Yeghiazaryan L, Stephan C, Mohn KGI, Carcas-Sansuan AJ, Rodriguez ER, Moltó J, Mitxeltorena IV, Welte T, Zablockiene B, Akova M, Bethe U, Heringer S, Salmanton-García J, Jeck J, Tischmann L, Zarrouk M, Cüppers A, Biehl LM, Grothe J, Mellinghoff SC, Nacov JA, Neuhann JM, Sprute R, Frías-Iniesta J, Negi R, Gaillard C, Saini G, León AG, Mallon PWG, Lammens C, Hotterbeekx A, Loens K, Malhotra-Kumar S, Goossens H, Kumar-Singh S, Koenig F, Posch M, Köhler P, Cornely OA.** Immunogenicity, reactogenicity, and safety of a second booster with BNT162b2 or full-dose mRNA-1273: A randomized VACCELERATE trial in adults aged ≥75 years (EU-COVAT-1-AGED Part B). Int J Infect Dis. 2024; 146: 107161. Article. IF: 4.3; Q1
- **Stewart S, de las Huertas AGL, Jiménez-González M, Carcas AJ, Borobia AM, Ramírez E.** ALDRESS: A Retrospective Pilot Study to Develop a Pharmacological Causality Algorithm for Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). J Clin Med. 2024; 13(9): 2622. Article. IF: 2.9; Q1
- **Stewart S, Seco-Meseguer E, Diago-Sempere E, Marín-Candón A, Carmona M, Estébanez M, López-Fernández LA, Imaz-Iglesia I, Saiz MDG, Laserna-Mendieta EJ, Peiró AM, Farré M, Rodriguez-Jiménez C, Saiz-Rodríguez M, Sanabria-Cabrera J, Rosas-Alonso R, Abad-Santos F, Pedrosa L, Carcas AJ, García IG, Borobia AM.** Phase IV adaptive randomised clinical trials evaluating efficacy and cost-efficacy of pre-emptive pharmacogenetic genotyping strategies in the Spanish National Health System: iPHARMGx Master Protocol and PREVESTATGx nested clinical trial. BMJ Open. 2024; 14(11): e089823. Article. IF: 2.3; Q2

Research projects

- **Borobia Pérez A.** AMASCIS-02. Alogenic adipose tissue-derived mesenchymal stem cells in ischemic stroke. A phase IIB multicenter double blind placebo controllled clinical trial (PIC18/00016). ISCIII. 2019-2024. Managment centre: FIBHULP
- **Borobia Pérez A.** Coordinación del ensayo clínico Ensayo multicéntrico, adaptativo, aleatorizado y controlado sobre la seguridad y eficacia de las estrategias antitrombóticas en adultos hospitalizados con COVID-19. New York University School of Medicine. 2020-Ongoing. Managment centre: FIBHULP
- **Borobia Pérez A.** Corona Accelerated R&D in Europe (H2020-JTI-IMI2-2020-21). UE. 2020-2025. Managment centre: FIBHULP
- **Borobia Pérez A.** Ensayo clínico de fase II, comparativo, aleatorizado, adaptativo para evaluar la seguridad e immunogenicidad de una dosis de cominarty® en sujetos que hayan recibido una dosis de vaxzeria (5859 CombiVacS). ISCIII. 2021-Ongoing. Managment centre: FIBHULP
- **Borobia Pérez A.** ERA4HEALTH_Fostering a European Research Area for Health Research. UE. 2023-2029. Managment centre: FIBHULP
- **Borobia Pérez A.** European Regimen Accelerator for Tuberculosis - ERA4TB. UE. 2020-2026. Managment centre: FIBHULP
- **Borobia Pérez A.** LIVERATION_Unravelling the impact of radiofrequency in liver surgery: the key to decrease the local recurrence? (2023.417). UE. 2023-2028. Managment centre: FIBHULP
- **Borobia Pérez A.** Care in clinical trials involving youth. exploring vulnerability through empirical philosophy in a clinical trials unit. (CareInTrials). UE. 2019-2023. Managment centre: FIBHULP
- **Borobia Pérez A.** Optimización del tratamiento de la dermatitis atópica con ciclosporina mediante el desarrollo de modelos multiómicos de predicción de respuesta (Proyecto DermAtOmics) (PI21/01219). ISCIII. 2022-2024. Managment centre: FIBHULP
- **Borobia Pérez A.** Proyecto ipharmgx: estudio colaborativo nacional para evaluaar la efectividad y eficiencia de la implementación de biomarcadores farmacogenéticos mediante una estrategia de genotipado anticipado en el sns (PMP22/00055). ISCIII. 2023-2025. Managment centre: FIBHULP
- **Borobia Pérez A.** Puesta en marcha del ensayo clínico: efficacy and safety of thrombectomy in stroke with extended lesion and extended time window: a randomized controlled trial. ECRIN European Clinical Research Inf. 2021-Ongoing. Managment centre: FIBHULP
- **Borobia Pérez A.** Puesta en marcha del ensayo clínico: test de gaxilosa en orina en niños de 5 a 11 años de edad: confirmación de la tolerabilidad de la dosis y del limite de normalidad de la cantidad de xilosa excretada en orina. Venter Pharma S.L. 2022-Ongoing. Managment centre: FIBHULP
- **Borobia Pérez A.** Puesta en marcha del estudio: a randomized, double-blind, placebo-controlled, parallel-group, multicentre study of the efficacy and safety of nicotinamide in patients with friedreich`s ataxia. ECRIN European Clinical Research Inf. 2020-Ongoing. Managment centre: FIBHULP
- **Borobia Pérez A.** Puesta en marcha del estudio:multi-centre, adaptive, randomized trial of the safety and efficacy of treatments of COVID-19 in hospitalized adults - discovery. ECRIN European Clinical Research Inf. 2022-Ongoing. Managment centre: FIBHULP
- **Borobia Pérez A.** Puesta en marcha y realización del EE.CC.: ensayo clinico aleatorizado controlado y simple ciego en mujeres con cancer de mama y linfadenectomia axilar, para evaluar la efectividad de hemopathcr en la reducción del drenaje seroso postquirúrgico. Asociación de Cirujanos de Mama de Toledo. 2021-Ongoing. Managment centre: FIBHULP
- **Borobia Pérez A.** Puesta en marcha y realización del ensao clínico: european discovery for solidarity: an adaptative pandemic and emerging infection platform trial. ECRIN European Clinical Research Inf. 2022-Ongoing. Managment centre: FIBHULP
- **Borobia Pérez A.** Puesta en marcha y realización del ensayo clinico-proyecto acanto y proyecto facet. Fundación para ia Investigación Biomédica Hospital Universitario de Getafe. 2018-Ongoing. Managment centre: FIBHULP
- **Borobia Pérez A.** Puesta en marcha y realización del ensayo consistentes principalmente en las que se describen a continiación: apoyo metodológico, monitorización, farmacovigilancia y estadística y manejo de datos. ensayo clínico para la realización de la investigación clínica sobre una nueva tecnica diagnostica basada en pcr a tiempo real, para determinar la predisposición a infecciones en pacientes con infarto de miocardio, necesario para su aprobación regulatoria. Crazy Science & Business S.L. 2021-Ongoing. Managment centre: FIBHULP
- **Borobia Pérez A.** Registro de pacientes atendidos en la unidad de farmacogenética del Hospital La Paz y análisis de la actividad realizada desde su creación. Varios. 2017-Ongoing. Managment centre: FIBHULP
- **Borobia Pérez A.** Tareas necesarias para la puesta en marcha y realización del ensayo clínico Treatment of high grade non-muscle invasive urothelial carcinoma of the bladder by standard number and dose of intravesical BCG instillations versus reduced number of intravesical instillations with standard dose of BCG, a european association of urology research foundation randomised phase iii clínical trial- nimbus. Fundación para la Investigación de la Asociación Europea de Urologia. 2017-Ongoing. Managment centre: FIBHULP
- **Borobia Pérez A.** Tareas necesarias para la puesta en marcha y realización del estudio observacional Estudio de evaluación y manejo del dolor agudo en Servicios de Urgencias hospitalarias e intervención educativa: estudio Edurg17. Laboratorio Menarini S. A. 2018-Ongoing. Managment centre: FIBHULP
- **Borobia Pérez A.** ZODIAC Coordinación. Imperial College of Science, Technology and Medicine. 2023-2029. Managment centre: FIBHULP
- **Carcas Sansuán AJ.** Dosificación individualizada

de tacrolimus en trasplante renal pediátrico: desarrollo de modelos predictivos, simulaciones y aplicaciones basados en PBPK (PI21/01507). ISCIII. 2022-2024. Managment centre: FIBHULP

- **Carcas Sansuán AJ.** Eficacia a cuatro años de las vacunas COVID-19 frente a enfermedad graves e infecciones asintomáticas: estudio COVIDVAC @ España (ICI21/00065). ISCIII. 2022-2024. Managment centre: FIBHULP
- **Carcas Sansuán AJ.** Four-year effectiveness of covid-19 vaccines against severe disease and asymptomatic infection: the covidvac@spain study. FIBHULP. 2021-Ongoing. Managment centre: FIBHULP
- **Carcas Sansuán AJ.** Unidad clínica de Investigación y Control de Ensayos Clínicos. CM. 2011-Ongoing. Managment centre: FIBHULP
- **Frias Iniesta J.** Población en riesgo de hipertermia maligna: cohorte ambispectiva (PI20/01444). ISCIII. 2021-2024. Managment centre: FIBHULP
- **Frias Iniesta J.** VACCELERATE_European Corona Vaccine Trial Accelerator Platform. UE. 2021-2025. Managment centre: FIBHULP

Cibers and Retics

- **Carcas Sansuán A.** Unidad de Investigación clínica y ensayos clínicos del Hospital Universitario la Paz (PT20/00036). ISCIII. (31/12/2024). FIBHULP
- **Carcas Sansuán A.** European Clinical Research Infraestructures Network (ECRIN). EU. (31/12/2024). FIBHULP
- **Carcas Sansuán A.** Plataforma ISCIII de soporte para la Investigación Clínica (PTC20/00018). ISCIII. (31/12/2024). FIBHULP
- **Borobia Pérez A.** Coordinación Plataforma de Apoyo a la Investigación Clínica (PTC23/00006). ISCIII. (31/12/2026). FIBHULP
- **Borobia Pérez AM.** Unidad del Hospital Universitario La Paz de la Plataforma ISCIII de Apoyo a la Investigación Clínica (PT23/00064). ISCIII. (31/12/2026). FIBHULP

Clinical trials

- **Borobia Pérez A.** estudio fase I, abierto, de secuencia fija e interacción farmacológica unidireccional para investigar la farmacocinética de gsk3036656 y un anticonceptivo oral que contiene etinilestradiol y levonorgestrel, cuando el anticonceptivo oral se administra solo y en combinación con gsk3036656 en mujeres sanas de entre 18 y 65 años sin capacidad reproductiva.
  Type/Phase: I
  Sponsored by: Glaxosmithkline Research And Development Limited
  Signature date: 31/01/2024
- **Borobia Pérez A.** A phase 1, single dose, open-label, parallel group study to investigate the pharmacokinetics and safety of rupatadine (10 mg) and its active metabolites in participants with hepatic impairment compared to matched control participants with normal hepatic function.
  Type/Phase: I
  Sponsored by: Biohorm S.L.
  Signature date: 03/04/2024
- **Borobia Pérez A.** Estudio fase IIIb, aleatorizado, abierto, multinacional, multicéntrico, de extensión y vacunación cruzada para evaluar la inmunogenicidad y seguridad de diferentes pautas de revacunación, así como la persistencia de una dosis única de la vacuna rsvpref3 oa en adultos de 60 años o más de edad que participaron en el estudio rsv oa=adj-006.
  Type/Phase: IIIb
  Sponsored by: Glaxosmithkline Biologicals S.A
  Signature date: 27/05/2024
- **Borobia Pérez A.** estudio de fase iii, multinacional, observador ciego, aleatorizado, controlado con placebo para demostrar la eficacia de una dosis única, así como de dosis anuales de revacunación, de la vacuna en investigación rsvpref3 oa de gsk en adultos de 60 años o más de edad", con el número de protocolo 212494 (rsv oa=adj-006.
  Type/Phase: III
  Sponsored by: Glaxosmithkline S.A.
  Signature date: 28/02/2024
- **Borobia Pérez A.** estudio de fase 2/3, aleatorizado, con observador ciego y controlado con placebo para evaluar la seguridad y la eficacia de mrna-1345, una vacuna de arnm contra el virus respiratorio sincitial (vrs), en adultos a partir de 60 años de edad.
  Type/Phase: II
  Sponsored by: Modernatx Inc.
  Signature date: 31/01/2024
- **Borobia Pérez A.** estudio de fase 1, aleatorizado, doble ciego, controlado con placebo para evaluar la seguridad y la farmacocinética de dosis únicas ascendentes y múltiples dosis ascendentes de cs6253 en voluntarios sanos y en portadores de apoe4.
  Type/Phase: I
  Sponsored by: Artery Therapeutics Inc.
  Signature date: 04/04/2024
- **Borobia Pérez A.** estudio fase i, primera vez en humanos, observador-ciego, aleatorizado y controlado para evaluar la seguridad, reactogenicidad y respuesta inmune de varias dosis de una vacuna en investigación basada en arnm frente al virus respiratorio sincitial (vrs) en participantes sanos de 18 a 45 años de edad.
  Type/Phase: I
  Sponsored by: Glaxosmithkline Biologicals S.A
  Signature date: 01/07/2024
- **"Borobia Pérez A.** estudio de fase 3, aleatorizado, con observador ciego, controlado con placebo para evaluar la eficacia, la seguridad y la inmunogenicidad de la vacuna mrna-1647 para el citomegalovirus (cmv) en participantes sanos de 16 a 40 años de edad.
  Type/Phase: III
  Sponsored by: Modernatx Inc.
  Signature date: 21/10/2024"
- **"Borobia Pérez A.** estudio de fase 3, aleatorizado, con observador ciego, controlado con placebo para evaluar la eficacia, la seguridad y la inmunogenicidad de la vacuna mrna-1647 para el citomegalovirus (cmv) en participantes sanos de 16 a 40 años de edad.
  Type/Phase: III
  Sponsored by: Modernatx Inc.
  Signature date: 08/11/2024"

Patents and trademarks

- **Carcas Sansuán AJ, author; Carcas Sansuán AJ, assignee.** Brand name: IBJ IberoAmerican Journals. ESM 3.063.048; 2013 February 12.
- **Carcas Sansuán AJ, author; Carcas Sansuán AJ, assignee Brand name: IberoAmerican Journals Plus.** ESM 3.063.052; 2013 February 12.
- **Carcas Sansuán AJ, author; Carcas Sansuán AJ, assignee Brand name: IberoAmerican Journals Clinical Pharmacology.** ESM 3.063.053; 2013 February 12.
- **Carcas Sansuán AJ, author; Carcas Sansuán AJ, assignee Brand name: IberoAmerican Journals Medicine.** ESM 3.063.049; 2013 February 12.
- **Lapunzina Badía P, Borobia Pérez AM, Carcas Sansuán AJ, Tenorio Castaño JA, Arias Lajara P, Lubomirov Jristov R, authors; FIBHULP, UAM, assignees.** Brand name: PharmArray. USM 86.004.412, CM 11.608.403; 2013 July 08, 2013 February 27.
- **Carcas Sansuán AJ, Borobia Pérez AM, authors; FIBHULP, assignee.** Brand name: CRDataX. CM 13.681.614; 2015 May 28.
- **Lapunzina Badía PD, Borobia Pérez AM, Carcas Sansuán AJ, Tenorio Castaño JA, Arias Lajara P, Frías Iniesta J, Dapia García I, Muñoz M, authors; FIBHULP, UAM, assignees.** Brand name: ClinPharmarray., CM15489511; 2016 May 31, 2016 September 07.

3.6.4 Osteoarticular Surgery Research – GICOA

Publications: 34 | **Q1:** 9

COMPOSITION

Enrique Gómez Barrena.
Jefe de Sección de Cirugía Ortopédica y Traumatología. Hospital Universitario La Paz. Catedrático de Cirugía Ortopédica y Traumatología. Facultad de Medicina. Universidad Autónoma de Madrid

- **Samuel Antuña Antuña.** *Jefe de Sección en Cirugía Ortopédica y Traumatología. Hospital Universitario La Paz. Profesor Asociado en Cirugía Ortopédica y Traumatología. Facultad de Medicina. Universidad Autónoma de Madrid*
- **Raúl Barco Laakso.** *Facultativo Especialista de Área en Cirugía Ortopédica y Traumatología. Hospital Universitario La Paz*
- **Ana Cruz Pardos.** *Jefe de Sección en Cirugía Ortopédica y Traumatología. Hospital Universitario La Paz*
- **Ana de Andrés Torán.** *Médico Interno Residente en Cirugía Ortopédica y Traumatología. Hospital Universitario La Paz*
- **Marta Domínguez García-Simón.** *Enfermera Coordinadora de Ensayos Clínicos. Universidad Autónoma de Madrid*
- **Eduardo García Rey.** *Facultativo Especialista de Área en Cirugía Ortopédica y Traumatología. Hospital Universitario La Paz. Profesor Asociado en Cirugía Ortopédica y Traumatología. Facultad de Medicina. Universidad Autónoma de Madrid*
- **Pablo Hernández Esteban.** *Facultativo Especialista de Área en Cirugía Ortopédica y Traumatología. Hospital Universitario La Paz*
- **Luis Rodrigo Merino Rueda.** *Facultativo Especialista de Área en Cirugía Ortopédica y Traumatología. Hospital Universitario La Paz*
- **Norma Griset Padilla Eguiluz.** *Investigadora Predoctoral. Universidad Autónoma de Madrid*
- **Carlos Emérito Rodríguez Merchán.** *Jefe de Sección de Cirugía Ortopédica y Traumatología. Hospital Universitario La Paz*
- **Juan Carlos Rubio Suárez.** *Jefe de Sección en Cirugía Ortopédica y Traumatología. Hospital Universitario La Paz*

STRATEGIC OBJETIVES

- Orthopaedic implant studies are required to assess the results of implants, detect the causes of failure, and deepen our understanding of the prevention and solution of these failures. The medical, social, and economic relevance of orthopaedic implants, and their influence on quality of life, place this technology in the centre of translational research in orthopaedic surgery. Reconstruction based on biological strategies and biomaterials is rapidly evolving, and cutting edge research on these topics may offer an advantage in clinical translational research. The group has also developed studies on sports medicine and ligament reconstruction, with various outcome approaches and devices that may enhance surgical results. In this context, a multidisciplinary clinical and basic research group on orthopaedic surgery deepens our understanding of a wide variety of current research topics in the field and provides further progress towards clinical translation.
- In order to contribute to new advances in the field, our main clinical and experimental objectives are addressed by a joint research line that covers issues related to bone and joint reconstruction. These issues include the following:
  - Failed hip and knee prostheses, including the material, biological, and clinical mechanisms of failure. This research may lead to proposals for materials and design modifications in orthopaedic implants and reconstructive devices and techniques. Functional recovery of the patient is the ultimate goal, considering various scenarios from an experimental and clinical point of view.
  - Regenerative medicine approaches to bone and joint reconstruction, to generate preclinical and clinical proposals for bone and joint regeneration and repair, both in traumatic and non-traumatic bone and soft-tissue injuries.



RESEARCH LINES

- Clinical and basic research in Orthopaedics implants, and in bone and joint reconstruction

RESEARCH ACTIVITY

Final Degree Theses

- **Cantero García L.** Evaluación sagital en la artroplastia de rodilla: técnica asistida por robot frente a convencional[dissertation]. Madrid: Universidad Autónoma de Madrid: 2024(26/06/2024). Director: Gómez Barrena E .

Publications

- **Álvarez-Gariburoa I, García-Galán EC, Plaza MM, Barrena EG, Esteban J, Sarnago H, Acero J, Burdío JM, Lucia O.** A portable induction heating system for implanted prosthesis disinfection. Int J Appl Electrom. 2024; 75(2): 131-43. Article. IF: 0.7; Q4
- **Arenas-Miquélez A, Barco R, Cabo FJC, Hachem A.** Management of bone loss in anterior shoulder instability: Current satate of the art and future directions. Bone Joint J. 2024; 106B(10): 1100-10. Article. IF: 4.6; D1
- **Bellostas L, Rubio I, Mills S, Rubio JC, García-Rey E.** Clinical and radiological factors related to dislocation in patients undergoing hip hemiarthroplasty for femoral neck fractures: A case-control study. Injury. 2024; 55: 111737. Article. IF: 2.0; Q2
- **de la Corte-Rodríguez H, Rodríguez-Merchán EC, Álvarez-Román MT, Gomez-Cardero P, Jimenez-Yuste V.** Ultrasound-guided joint procedures in hemophilia: technique, indications and tips. Expert Rev Hematol. 2024; 17(8): 419-30. Article. IF: 2.1; Q3
- **de la Corte-Rodríguez H, Román-Belmonte JM, Resino-Luis C, Madrid-González J, Rodríguez-Merchán EC.** The Role of Physical Exercise in Chronic Musculoskeletal Pain: Best Medicine-A Narrative Review. Healthcare (Basel). 2024; 12(2): 242. Review. IF: 2.7; Q2
- **Delclós LO, Rich RS, Loureda RA, García AM, Barrena EG.** Efficacy and safety of autologous or allogeneic mesenchymal stromal cells from adult adipose tissue expanded and combined with tricalcium phosphate biomaterial for the surgical treatment of atrophic nonunion of long bones: a phase II clinical trial. J Transl Med. 2024; 22(1): 493. Article. IF: 7.5; Q1
- **Enrique CGG, Medel-Plaza M, Correa JJA, Sarnago H, Acero J, Burdio JM, Lucía O, Esteban J, Gómez-Barrena E.** Biofilm on total joint replacement materials can be reduced through electromagnetic induction heating using a portable device. J Orthop Surg Res. 2024; 19(1): 304. Article. IF: 2.8; Q1
- **Fernández-Fernández R, Fuentes-Sánchez J, Gómez-Luque J, Cruz-Pardos A.** Indications and clinical results of Non-Operative management of periprosthetic hip fractures in elderly patients. Injury. 2024; 55: 111738. Article. IF: 2.0; Q2
- **Gallego JA, Sánchez BD, Vaquero-Picado A, Antuña S, Barco R.** Failed radial head arthroplasty treated by removal of the implant. Bone Joint J. 2024; 106B(11): 1327-32. Article. IF: 4.6; D1
- **García-Galán EC, Medel-Plaza M, Pozo-Kreilinger JJ, Sarnago H, Lucía O, Rico-Nieto A, Esteban J, Gomez-Barrena E.** In vivo reduction of biofilm seeded on orthopaedic implants safety and efficacy of portable electromagnetic induction heating. Bone Joint Res. 2024; 13(12): 695-702. Article. IF: 5.1; Q1
- **García-Rey E, Saldaña L.** Spinopelvic interactions in total hip arthroplasty: 295 patients followed for a minimum follow-up of 10 years. Hip Int. 2024; 34(4): 487-97. Article. IF: 1.1; Q3
- **García-Rey E, Saldaña L.** Long-term results of total hip arthroplasty in severe congenital hip disease: A ten- to 20-year follow-up study. Orthop Traumatol-Sur. 2024; 110(6): 103850. Article. IF: 2.2; Q2
- **Gómez-Barrena E, Ehrnthaller C.** Long bone uninfected non-union: grafting techniques. Efort Open Rev. 2024; 9(5): 329-38. Article. IF: 4.0; Q1
- **Larose G, Aibinder WR, Greene AT, Roche CP, Grey S, Faber KJ, Routman H, Antuna S, Wright T, Flurin PH, Zuckerman JD, Virk MS.** Two-year minimum survivorship and radiographic analysis of a pressfit short humeral stem for total shoulder arthroplasty. JSVES Int. 2024; 8(1): 191-6. Article. Not Indexed
- **Palacios-Díaz L, González A, Urgellés PS, Antuña S, Barco R.** Biomechanical outcomes of pharmacological therapies for post-traumatic arthrofibrosis in preclinical animal models: a systematic review and meta-analysis. Connect Tissue Res. 2024; 65(4): 265-78. Review. IF: 2.1; Q2
- **Pasta G, Annunziata S, Ruggieri R, Abruzzi D, Arrigoni P, Jannelli E, Benazzo F, Pedrotti L, Viola EM, Rodríguez-Merchán EC, Mosconi M.** Managing Surgical Risks in Hemophilic Elbow Arthropathy: An In-Depth Case Study and Literature Review. Healthcare (Basel). 2024; 12(17): 1776. Article. IF: 2.7; Q2
- **Perut F, Roncuzzi L, Gómez-Barrena E, Baldini N.** Association between Bone Turnover Markers and Fracture Healing in Long Bone Non-Union: A Systematic Review. J Clin Med. 2024; 13(8): 2333. Review. IF: 2.9; Q1
- **Raganato R, Mills S, Crespo-Lastras P, González-Ruíz N, Rubio-Saez I, Pallares-Sanmartín J, Martínez-Díez JM, Ibarzábal-Gil A, Rubio-Suárez JC, Rodríguez-Merchan EC.** Locking Attachment Plate for the Surgical Treatment of Periprosthetic and Periimplant Fractures: Long-Term Follow-Up. Arch Bone Jt Surg. 2024; 12(4): 256-63. Article. IF: 1.8; Q2
- **Rodríguez-Merchán C.** Primary Total Knee Arthroplasty in Hemophilia and Allied Disorders: Revision Rates and Their Causes. Arch Bone Jt Surg. 2024; 12(5): 428-32. Article. IF: 1.8; Q2
- **Rodríguez-Merchán C, Kalbakdij-Sánchez C, Encinas-Ullán CA, Labib-Zarad A.** Simultaneous High Tibial Osteotomy and Anterior Cruciate Ligament Reconstruction in knees with Bony Frontal and/or Sagittal Deformities: Review of the Current Literature. Arch Bone Jt Surg. 2024; 12(8): 603-7. Article. IF: 1.8; Q2
- **Rodríguez-Merchán E.** Biofilm Related Total Knee Arthroplasty Infection: Prevention, Diagnosis and Treatment. Arch Bone Jt Surg. 2024; 12(7): 531-4. Article. IF: 1.8; Q2
- **Rodríguez-Merchán EC.** Can Isolated Tibial Component Revision Be an Alternative to Isolated Aseptic Loosening of the Tibial Component in Total Knee Arthroplasty? Arch Bone Jt Surg. 2024; 12(2): 136-8. Article. IF: 1.8; Q2
- **Rodríguez-Merchán EC.** Discoid LaterL Meniscus: A Concise Literature Update. Arch Bone Jt Surg. 2024; 12(4): 289-95. Article. IF: 1.8; Q2
- **Rodríguez-Merchán EC.** Re-revision Total Knee Arthroplasty: Causes, Risk Factors and Results. Arch Bone Jt Surg. 2024; 12(5): 328-32. Review. IF: 1.8; Q2
- **Rodríguez-Merchán EC.** Total Hip Arthroplasty in Hemophilic Patients: are their Results Similar to those of Nonhemophilic Patients? Arch Bone Jt Surg. 2024; 12(5): 357-60. Article. IF: 1.8; Q2
- **Rodríguez-Merchán EC.** Foot and ankle surgery: Tourniquet placement site to cause as little postoperative pain as possible. World J Orthop. 2024; 15(6): 498-500. Editorial Material. IF: 2.3; Q2
- **Rodríguez-Merchan EC.** Mortality rate after total knee arthroplasty or total hip arthroplasty in patients with a history of liver transplant. World J Orthop. 2024; 15(4): 310-311. Editorial Material. IF: 2.3; Q2
- **Rodríguez-Merchán EC, de la Corte-Rodríguez H, Gómez-Cardero P, Álvarez-Román MT, Jimenez-Yuste V.** Arthroscopic ankle surgery in people with haemophilia. Haemophilia. 2024; 30(2): 286-94. Review. IF: 3.0; Q2
- **Rodríguez-Merchán EC, Encinas-Ullán CA.** Intraosseous Regional Administration



of Vancomycin Prophylaxis for Primary and Revision Total Knee Arthroplasty. Arch Bone Jt Surg. 2024; 12(3): 219-22. Article. IF: 1.8; Q2

- **Rodríguez-Merchán EC, Encinas-Ullán CA, Ruiz-Pérez JS, Gómez-Cardero P.** Complications of ankle arthroscopy: frequency, prevention, and treatment. Efort Open Rev. 2024; 9(1): 3-15. Article. IF: 4.0; Q1
- **Rodríguez-Merchán EC, Moracia-Ochagavia I.** Results of Total Ankle Arthroplasty Versus Ankle Arthrodesis. Foot Ankle Clin. 2024; 29(1): 27-52. Article. IF: 1.6; Q3
- **Rodríguez-Merchán EC, Mosconi M, De la Corte-Rodríguez H, Jannelli E, Pasta G.** Total Knee Arthroplasty in People with Hemophilia: Higher Incidence of Periprosthetic Joint Infection and 1-Year Revision/Re-Operation than the General Population and Lower Prosthetic Survival When Early Postoperative Bleeding Complications Occurred: Current Literature Review. J Clin Med. 2024; 13(8): 2447. Review. IF: 2.9; Q1
- **Román MTA, Pollmar MIR, de la Corte-Rodríguez H, Gómez-Cardero P, Rodríguez-Merchán EC, Gutierrez-Alvariño M, García-Pérez E, Martín-Salces M, Zagrean D, Butta-Coll NV, Jiménez-Yuste V.** Knee replacement surgery in a patient with acquired von Willebrand disease: a case study with recommendations for patient management. Ann Med Surg (Lond). 2024; 86(3): 1681-6. Article. IF: 1.6; Q2
- **Vallet-Regi M, De Alarcón A, Barrena EG, Planell JA, Silva J, Bouza E.** New materials and complications of prostheses in humans: situation in Spain. Rev Esp Quim. 2024; 37(5): 369-86. Review. IF: 2.2; Q3

Research projects

- **Barco Laakso R.** Artoplastía de cabeza radial anatómica versus espaciador de metal de vástago liso para traumatismo de codo. Médical Simulator S. L. 2018-Ongoing. Managment centre: FIBHULP
- **Barco Laakso R.** Morfología radiocapitelar, un estudio anatómico. Acumed LLC. 2018-Ongoing. Managment centre: FIBHULP
- **Barco Laakso R.** Terapia celular con células troncales derivadas del tejido adiposo (ASC) para mejorar el proceso de reparación en suturas tendinosas. Unión tendón-hueso (roturas del manguito rotador); unión tendón-músculo (roturas del tendón de aquiles). Sociedad Española de Cirugia Ortopedica y Traumatologia. 2009-Ongoing. Managment centre: FIBHULP
- **García Rey E.** Identificación de factores moleculares implicados en la Osteonecrosis Idiopática: análisis del transcriptoma del tejido óseo (PI18/00643). ISCIII. 2018-2023. Managment centre: FIBHULP
- **Gómez Barrena E.** Desinfección in vivo de implantes ortopédicos metálicos mediante calor generado por inducción electromagnética. Fundación Mutua Madrileña. 2020-2024. Managment centre: FIBHULP
- **García Rey E.** Osteonecrosis de cabeza femoral: identificación de alteraciones en el hueso trabecular, correlación clínica y factores de riesgo en la fijación de la prótesis total de cadera (PI22/00939). ISCIII. 2023-2025. Managment centre: FIBHULP
- **Barco Laakso R.** Traumatic and neurogenic joint contracture in an experimental model in the Rat: preventive role of Celecoxib and Ketotifen. European Society for Surgery of the Shoulder and the Elbow. 2023-Ongoing. Managment centre: FIBHULP
- **Antuña Antuña S.** Rigidez articular postraumática en un modelo en la rata: eficacia del celecoxib y el ketotifeno en su prevención (FSECOT2024_SAA). Fundación SECOT. 2024-Ongoing. Managment centre: FIBHULP
- **Gómez Barrena E (Scientific Coordinator and WP3 leder) .** ORTHOALLOUNION: ORTHOpaedic treatment with ALLOgenic combined Advanced Therapy Medicinal Products (ATMPs) in long bone delayed UNION and non-union fractures (HORIZON-GA No: 101137464). European Health and Digital Executive Agency. Dec-2023-Ongoing. Managment centre: SERMAS

Patents and trademarks

- **Arenas Vara MA, Conde del Campo A, De Damborenea González JJ, Matykina E, Esteban Moreno J, Gómez Barrena E, Pérez-Jorge Peremarch C, Pérez Tanoira R, inventors; CSIC, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, assignees.** Titanium materials anodised with fluorine. P201030720, PCT/ES2011/070342; 2010 May 14
- **Gomez Barrena E, Cordero García-Galán E, Rico Nieto A, Pozo JJ, Esteban Moreno J, Sarnago H, Lucía Gil O, Acero Acero J, Burdío JM.** Portable desinfection system based on induction heating; September 2022.

3.6.5 Translational Research in Maxillofacial Surgery and Head and Neck Cancer

Publications: 17 | **Q1:** 6

COMPOSITION

José Luis Cebrián Carretero.
Jefe de Servicio de Cirugía Oral y Maxilofacial. Hospital Universitario La Paz
Ana Sastre Perona.
Investigadora senior. FIBHULP

- **Lucía Acero Riaguas.** *Investigadora Predoctoral. FIBHULP*
- **Estefanía Alonso Rodríguez.** *Facultativo Especialista de Área en Cirugía Oral y Maxilofacial. Hospital Universitario La Paz*
- **Íñigo Aragón Niño.** *Médico Interno Residente de Cirugía Oral y Maxilofacial. Hospital Universitario La Paz*
- **Sara María Fernández Díaz.** *Técnico de Grado Superior. FIBHULP*
- **Javier González Martín-Moro.** *Facultativo Especialista de Área en Cirugía Oral y Maxilofacial. Hospital Universitario La Paz*
- **Ana Belén Griso Acevedo.** *Investigadora Predoctoral. FIBHULP*
- **José Luis del Castillo Pardo de Vera.** *Facultativo Especialista de Área en Cirugía Oral y Maxilofacial. Hospital Universitario La Paz*
- **Pedro Manuel Losa Muñoz.** *Facultativo Especialista de Área en Cirugía Oral y Maxilofacial. Hospital Universitario La Paz*
- **Marta Mascarque Checa.** *Investigadora Postdoctoral. Contrato Sara Borrel. FIBHULP*
- **María José Morán Soto.** *Facultativo Especialista de Área en Cirugía Oral y Maxilofacial. Hospital Universitario La Paz*
- **Marta María Pampín Martínez.** *Facultativo Especialista de Área en Cirgía Oral y Maxilofacila. Hospital Universitario La Paz*
- **César Pérez-Pérez Brotons.** *Bioinformático. FIBHULP*
- **Elena Ruiz Bravo-Bruguillos.** *Facultativo Especialista de Área en Anatomía Patológica. Hospital Universitario La Paz*
- **Alejandro San Lorenzo Vaquero.** *Investigadora Predoctoral. FIBHULP*
- **Rocío Sánchez Siles.** *Investigadora Predoctoral. FIBHULP*
- **Blanca Tapia Salinas.** *Facultativo especialista de Área de Anestesiología y Reanimación. Hospital Universitario La Paz*



STRATEGIC OBJETIVES

- To improve the diagnosis and surgical treatment of patients with Oral Cancer using the latest technologies applied to the field of Head and Neck Oncology planning and treatment. Our goal is to establish a workflow in which technological and technical advances are included as part of the treatment protocol for patients with oral cavity cancer.
- The identification of biomarkers of cancer progression and therapy response in head and neck cancers (HNC). HNC are low frequent tumors with poor outcome and limited treatment options. This is due to a poor understanding on the initial steps in tumor initiation and progression, and the implication of the tumor microenvironment in these processes. Using mouse models and novel patient derived organoid models, we are defining the mechanism driving the most aggressive HNC and developing this knowledge into translational tools to guide patient management. In addition, we are applying novel functional genomics to identify genes involved in driving resistance to chemo and targeted therapies, to uncover biomarkers of treatment response and new therapeutic targets. Overall, our goal is to improve patient survival and to increase patient life quality.

RESEARCH LINES

1. Epigenetic characterization of oral tumors and their association with resistance to chemotherapies and immunotherapies, identification of new biomarkers that predict response: Oral squamous cell carcinomas are an aggressive type of HNC with 370.000 cases per year and 50% 5-year survival rate. This is due to the lack of understanding of the biology of the disease and, in consequence, sufficiently efficient therapies. In this line, we are carrying out an epigenetic characterization of these tumors, analyzing characteristics such as their transcriptome and enhancer landscape using novel massive sequencing techniques on patient samples. Through bioinformatics analysis and monitoring the evolution of patients, we uncovered a population of cancer cells that associates with the most aggressive cancers and predicts patients with worse outcomes. Currently we are evaluating the translational impact of these findings. This research line is funded by CP19/00063 and PI20/00329 (ISCIII) and a Luis Álvarez PI5102 grant (FIBHULP).
2. Search for vulnerabilities in oral carcinoma cells using functional genomics. To define the vulnerabilities of tumor cells, our group has established CRISPR/Cas9 screens to evaluate the function of genes involved in the response to different therapies such as chemotherapies or immunotherapies. These screens, which target all protein-coding genes, are allowing us to identify in an unbiased way mechanisms of action that will allow us to understand how cells survive chemotherapy or how they are able to escape the action of the immune system. In this way, we will be able to reuse drugs already approved for these targets or design new ones that will allow us to improve the quality of life of patients with oral tumors. This research line is funded by CP19/00063 and PI20/00329 (ISCIII).
3. The implication of the tumor microenvironment in the acquisition of metastatic capacity of oral tumors. In this research line we are analyzing the connection between tumor microenvironment and the induction cancer progression programs. To this end, we are using novel co-cultures of paired organoids and TME cells from patients and measuring the influence at the level of chromatin remodeling and gene expression. This research is financed by an international competitive grant funded by the Worldwide cancer research and Scientific Foundation of the "Asociación Española Contra el Cáncer" (WWRC-23-0272), and FIBHULP Luis Álvarez grant.

4. Salivary glands malignancies. Salivary gland tumors are rare tumors that account for 5% of head and neck tumors. Their histological diversity and the lack of knowledge of the molecular basis of the disease make their treatment complex. Using NGS techniques we are characterizing the mutations, methylation profiles and tumor heterogeneity of these tumors to identify biomarkers of progression, mutations with targeted therapies and possible targets within the tumor microenvironment. Funding PI22/01512, (ISCIII) and Gilead (GLD22/00166).
5. Study of mechanism of initiation and progression of cutaneous squamous cell carcinoma (cSCC): In this research line, we are exploring the function of several tumor suppressor genes and how their loss of expression affects the composition on the tumor microenvironment and the response to therapy. This project is done in collaboration with L. Sastre, at IIBM Alberto Sols.
6. Application of 3D Medicine in the planning and treatment of head and neck cancer. Virtual design and segmentation of facial structures for generation of biomodels, cutting guides and custom implants. Surgery and personalized medicine. Mutua Madrileña 2022 grant funding.
7. Use of radiotracers and fluorescence with indocyanine green for sentinel node detection in squamous tumors and melanoma of the head and neck.

RESEARCH ACTIVITY

Publications

- **Acero-Riaguas L, Griso-Acevedo AB, SanLorenzo-Vaquero A, Ibáñez-Herrera B, Fernández-Díaz SM, Mascaraque M, Sánchez-Siles R, López-García I, Benitez-Buelga C, Bravo-Burguillos ER, Castelo B, Cebrián-Carretero JL, Perona R, Sastre L, Sastre-Perona A.** DUSP1 and SOX2 expression determine squamous cell carcinoma of the salivary gland progression. Sci Rep-Uk. 2024; 14(1): 15007. Article. IF: 3.9; Q1
- **Álvaro-Martínez M, Cuesta-Urquía C, Ortiz-Peces L, Noguera-Tomas J, González-Otero T, Cebrián-Carretero JL.** Venous malformation differential diagnosis with an odontogenic abscess on a pediatric patient. Case report and review of the literature. J Clin Exp Dent. 2024; 16(3): e387-90. Case Reports. Not Indexed
- **Anguita MB, de Vera JLDP, Khayat S, López AML, Moro JGM, de Frutos GA, Hidalgo RAC, Martínez MP, Larren EG, Cuéllar CN, Carretero JLC, Cuéllar IN.** Mandibular Fractures in Edentulous Patients with Bone Atrophy and Osseointegrated Dental Implants: Therapeutic Management in a Case Series. Med Lith. 2024; 60(11): 1835. Article. IF: 2.4; Q1
- **Aragón-Niño I, Del Castillo-Pardo-de Vera JL, Gutiérrez-Venturini A, Pampin-Martínez MM, López-Martínez C, Cebrián-Carretero JL.** Surface scanned 3D designed customized chinstrap for the treatment of intraoral dehiscence in polytraumatized patient. Technical note. J Clin Exp Dent. 2024; 16(2): e240-2. Article. Not Indexed
- **Aragón-Niño I, Pardo-de Vera JLC, Garrido-Martínez P, Losa-Muñoz PM, Moreiras-Sánchez AD, Cebrián-Carretero JL.** Interdisciplinary innovative approach to an aggressive ossifying fibroma case: Integrating 3D surgery and customized reconstruction in maxillofacial and dental care. J Clin Exp Dent. 2024; 16(5): e661-5. Article. Not Indexed
- **Arranz-Martín B, del-Castillo-Pardo-de-Vera JL, Cebrián-Carretero JL, Rouco-García D, Fernández-Oliva C, Gil-Martínez A.** Quality of life, craniomandibular function, and psychosocial factors related to pain and movement in patients with head and neck cancer. Support Care Cancer. 2024; 32(6): 334. Article. IF: 3; D1
- **Cobos MT, Salinas BT, Venturini AG, Nino IA, de Vera JLDP, Carretero JLC, Orejon RU.** The application of three-dimensional printing in the management of a difficult airway due to Treacher Collins syndrome. Anaesth Rep. 2024; 12(1): e12290. Article. IF: 0.8; Q3
- **de Vera JLDP, Carretero JLC, Niño IA, Martínez MMP, Gómez JTB, Cuéllar IN, López AML, Larren EG, Vila CN, Fernández-Micheltorena PM, Sala AP, Cuéllar CN.** Virtual Surgical Planning for Temporomandibular Joint Reconstruction with Stock TMJ Prostheses: Pilot Study. Med Lith. 2024; 60(2): 339. Article. IF: 2.4; Q1
- **Gil FM, Artal PM, de Llano ACQ, Guerra MM, Ballester DG, Arcas JML, Cedrun JLL, Pérez JLG, Martin-Granizo R, de Vera JLDP, Medina BG, González-García R, Sánchez MM, Rodríguez EV, SanRomán JF, Martos RL, Cagigal BP, Alamillos MR, Mas MM, Gil CS, Medina BR, Ontanon AV, Gridilla JM, Ferrer AD.** Consensus Report and Recommendations on the Management of Late-stage Internal Derangement of the Temporomandibular Joint. J Clin Med. 2024; 13(11): 3319. Article. IF: 2.9; Q1
- **López-Martínez C, Pampín-Martínez MM, García-López-Chicharro A, Aragón-Niño I, Cebrián-Carretero JL.** Application of 3D technology for the design of a guidewire for deep cervicofacial collections percutaneous management.. J Clin Exp Dent. 2024; 16(3): e383-6. Article. Not Indexed
- **Niño IA, Carretero JC.** Robotic surgery: A pending subject in oral and maxillofacial surgery. J Dent Sci. 2024; 19(2): 1282-4. Editorial Material. IF: 3.1; Q1
- **Niño IA, Urquía CC, Chicharro AGL, Martínez CL, Moro JGM, Carretero JLC.** Resident scientific meetings as part of the residency training curriculum: Just a hassle for the resident? J Healthc Qual Res. 2024; 39(3): 199-201. Letter. IF: 1.0; Q4
- **Ortiz-Peces L, Álvaro-Martínez M, de Uribe-Viloria M, Andura-Correas M, Vázquez-Salgueiro E, Cebrian-Carretero JL.** Epithelioid Hemangioendothelioma of Mandibular Gingiva: A Challenging Diagnosis. J Clin Exp Dent. 2024; 16(9): e1151-6. Article. Not Indexed
- **Rodríguez-Molinero J, Pozo-Kreilinger JJ, Ruiz-Roca JA, López-Sánchez AF, Cebrián-Carretero JL.** Clinical and Pathological Features of Osteosarcomas of the Jaws: A Retrospective Study. Clin Pract. 2024; 14(3): 965-79. Article. IF: 2.2; Q2
- **Urquía CC, Martín-Moro JG, Niño IA, de Villota MH, Carretero JLC.** Re: Re: Static retractor made from vessel loop. Brit J Oral Max Surg. 2024; 62(7): 661. Editorial Material. IF: 1.9; Q2
- **Urquía CC, Martin-Moro JG, Niño IA, de Villota MH, Carretero JLC.** Static retractor made from vessel loop. Brit J Oral Max Surg. 2024; 62(3): 304-5. Editorial Material. IF: 1.9; Q2
- **Weng ZC, Salinas BT, Tomas JN, De Vera JLDP, Molina JDD.** Anesthetic Management of a Patient with Madelung's Disease Presenting with a Giant Cervical Lipoma: A Case Report. A A Pract. 2024; 18(4): e01779. Article. IF: 0.6; Q4

Research projects

- **Castrelo Fernández B, Sastre Perona A.** Characterization of cancer-cell plasticity in head and neck cancers: discovery of new therapeutic targets and biomarkers for disease progression and treatment response (PI23/00192). ISCIII. 2024-2026. Managment centre: FIBHULP
- **Cebrián Carretero JL.** Identificación de nuevos biomarcadores de predicción de progresión en pacientes con tumores adenoides císticos y ductales de glándula salivar (PI22/01512). ISCIII. 2023-2025. Managment centre: FIBHULP
- **Cebrián Carretero JL.** Repositorio de biomodelos en traumatología: una biblioteca 3D multidisciplinar y colaborativa (AP180652022). Fundación Mutua Madrileña. 2022-2024. Managment centre: FIBHULP



- **del Castillo Pardo de Vera JL.** Determinación de la relación causal entre el empleo de bifosfonatos y el desarrollo de osteonecrosis en los maxilares. Aplicación de células madre mesenquimales para su tratamiento sobre modelo experimental animal. Varios Financiadores. 2015-Ongoing. Managment centre: FIBHULP
- **del Castillo Pardo de Vera JL.** Expresión de moléculas inmunoreguladoras pd1/ pd-llen el carcinoma oral de células escamosas. Osteoplac Innovations S.L.U. 2021-Ongoing. Managment centre: FIBHULP
- **Mascaraque Checa M.** Contrato Sara Borrel (CD23/00167). ISCIII. 2024-2026. Managment centre: FIBHULP
- **Sastre Perona A.** Contrato garantía juvenil Ayudante de Investigación (PEJ-2023-AI/SAL-GL-27700). CM. 2023-2025. Managment centre: FIBHULP
- **Sastre Perona A.** Contrato garantía juvenil Ayudante de Investigación (PEJ-2023-AI/SAL-GL-27700). CM. 2024-2026. Managment centre: FIBHULP
- **Sastre Perona A.** Contrato garantía juvenil Técnico (PEJ-2021-TL/BMD-21631). CM. 2022-Ongoing. Managment centre: FIBHULP
- **Sastre Perona A.** Contrato PFIS Ana Belén Griso (FI24/00184). ISCIII. 2025-2028. Managment centre: FIBHULP
- **Sastre Perona A.** Defining CAF-induced tumor cell plasticity as a positive switch for tumor progression and therapy resistance. (WWCR-23-0272). Worldwide Cancer Research AECC. 2023-2025. Managment centre: CSIC
- **Sastre Perona A.** Desarrollo de herramientas predictivas y terapeúticas para combatir la resistencia a cisplatino en carcinomas escamosos de cabeza y cuello (PI20/00329). ISCIII. 2021-2024. Managment centre: FIBHULP
- **Sastre Perona A.** Desarrollo de métodos de predicción de la respuesta a inmunoterapia en tumores orales. (PI-5102). FIBHULP. 2022-Ongoing. Managment centre: FIBHULP
- **Sastre Perona A.** Devoloping therapeutic and predictive tools to overcome cisplatin resistance in head and neck squamous cell carcinomas (CP19/00063). ISCIII. 2020-2024. Managment centre: FIBHULP
- **Sastre Perona A.** Dinamización de Ciencia Disruptiva en Predictores de Enfermedades tumorales, infecciosas y hereditarias como base de la Medicina Personalizada (FORT23/00006). ISCIII. 2024-2027. Managment centre: FIBHULP
- **Sastre Perona A.** Integración de las características moleculares, genómicas, morfológicas, y ambientales para mejorar el diagnóstico y tratamiento de precisión en enfermedades pulmonares intersticiales difusas fibrosantes(PRECISION-EPID) (PMP22/00083). ISCIII. 2023-2025. Managment centre: FIBHULP

Clinical trials

- **Cebrián Carretero JL.** ensayo clínico aleatorizado, doble ciego, controlado con placebo y con tratamiento activo, para evaluar la eficacia analgésica y la seguridad de una combinación oral de ibuprofeno (arginina)-tramadol hcl administrada a pacientes con dolor moderado a severo tras someterse a cirugía dental.
  Type/Phase: III
  Sponsored by: Farmalider Sa
  Signature date: 29/05/2024

Patents and trademarks

- **Cuéllar Navarro C, Cebrián JL, Magaña Menéndez J, inventors; Hospital General Universitario Gregorio Marañón and Hospital Universitario La Paz, assignees.** Dispositivo de determinación de avance mandibular para un usuario con apnea. P202430809; 2024 October 8.


3.6.6 Patients Safety and Quality Research

Publications: 21 | **Q1:** 9

COMPOSITION

Elena Ramírez García.
Facultativo Especialista de Área en Farmacología Clínica. Hospital Universitario La Paz

- **Miguel Avenza Jaén.** *Fisioterapeuta. Hospital Universitario La Paz*
- **Nelson Butrago Sánchez.** *Facultativo Especialista de Área en Radiología Pediátrica. Hospital Universitario La Paz*
- **Luis Castro Parga.** *Facultativo Especialista en Anestesiología y Reanimación. Hospital Universitario La Paz*
- **Susana Francisca Chajma Izquierdo.** *Facultativo Especialista en Medicina Fisica y Rehabilitación. Hospital Universitario La Paz*
- **Pilar Durán de la Fuente.** *Facultativo Especialista en Anestesiología y Reanimación. Hospital Universitario La Paz*
- **María Fernández-Velilla Peña.** *Facultativo Especialista en Radiología. Hospital Universitario La Paz*
- **Miguel González Muñoz.** *Facultativo Especialista de Area en Inmunología. Hospital Universitario La Paz*
- **Alberto Martín Vega.** *Facultativo Especialista de Area en Medicina Preventiva y Salud Pública. Hospital Universitario La Paz*
- **Bárbara Martínez de Miguel.** *Facultativo Especialista en Radiofarmacia. Hospital Universitario La Paz*
- **Ana Isabel Martínez Escandell.** *Unidad Hospitalización Quirúrgica. Hospital Universitario La Paz*
- **Covadonga Mendieta Azcona.** *Facultativo Especialista en Cirugía Vascular. Hospital Universitario La Paz*
- **Inés Narrillos Martín.** *Enfermera en Cirugía general y del Aparato Digestivo. Hospital Universitario La Paz*
- **José Jonay Ojeda Feo.** *Facultativo Especialista de Área en Medicina Preventiva y Salud Pública. Hospital Universitario La Paz*
- **Paola Andrea Parra Ramírez.** *Facultativo Especialista de Área en Endocrinología y Nutrición. Hospital Universitario La Paz*
- **Almudena Quintas Viqueira.** *Médico Adjunto en Medicina Preventiva. Hospital Universitario La Paz*
- **Ana Robustillo Rodela.** *Jefe de Servicio de Medicina Preventiva. Hospital Universitario La Paz*
- **Pascual Sanabría Carretero.** *Jefe de Sección Anestesiología Infantil. Hospital Universitario La Paz*
- **Yuri Fabiola Villán Villan.** *Responsable de Seguridad del Paciente. Hospital Universitario La Paz*



STRATEGIC OBJETIVES

- The ocurrence of adverse events due to unsafe care is likely one of the 10 leading causes of death and disability in the world. Research into reducing harm to patients can lead to better health outcomes, as well as significant savings in healthcare costs.
- Patient safety is the health care discipline that arises with the increasing complexity of health care systems and the consequent increase in harm to patients. Its objective is to prevent and reduce the risks, errors and damages suffered by patients during the provision of healthcare. A cornerstone of the discipline is continuous improvement based on learning from mistakes and adverse events.

RESEARCH LINES

- Culture of Patient Safety.
- Incident reporting system for notification and analysis of adverse events associated to Healthcare.
- Zero Infections related to Healthcare.
- Safe Surgery Saves Lives, whose purpose is to reduce the risks associated with surgery.
- Safe Medication, reduce the harm of medications.
- Zero venous thromboembolism, in order to reduce complications attributed to hospitalization.
- Safe Health Worker, Safe patients.
- Safe Transfusions, reduce adverse reactions to transfusion.
- Safe Radiations, to the right patient in the right area.
- Safe Diagnostics, reduce errors that can cause harm.
- Septicemia as a medical emergency.

RESEARCH ACTIVITY



Final Degree Theses

- **Punjabi G.** Adecuación del tratamiento de Fentanilo de liberación inmediata durante urgencias, Hospitalización y al alta[dissertation]. Madrid: Universidad Autónoma de Madrid: 2024(09/06/2024). Director: Ramírez García E

Publications

- **Araujo-Castro M, Fano MP, González-Boillos M, Pascual-Corrales E, Ramírez PP, Rojas-Marcos PM, García-Cano A, Ruiz-Sánchez JG, Vicente A, Gómez-Hoyos E, Casterás A, Puig-Perez A, Sanz IG, Recasens M, San Millan RB, César MJP, Guardiola PD, Perdomo C, Manjón-Miguélez L, Román AR, Lázaro CR, Recio JM, Morales-Ruiz M, Calatayud M, López NJ, Meneses D, Nuñez MS, Ribas EM, Sánchez AS, Diaz CG, Lamas C, Tous MD, Serrano J, Michalopoulou T, Rodrigo ST, Chamorro RR, Aguila FJ, Mateo EMM, Gutiérrez-Medina S, Hanzu FA.** Influence of smoking on cardiometabolic profile and surgical outcomes in patients with primary aldosteronism: a cohort study. Eur J Endocrinol. 2024; 191(6): 579-87. Article. IF: 5.2; Q1
- **Araujo-Castro M, Pascual-Corrales E, Rojas PM, Ramírez PP.** Epidemiology and diagnosis of primary aldosteronism. What have we learned from the SPAIN-ALDO registry? Endocrine. 2024; 83(3): 527-36. Review. IF: 2.9; Q3
- **Araujo-Castro M, Ramírez PP, Hanzu FA.** Executive summary of the Spanish consensus for the diagnosis, management, and follow-up of primary hyperaldosteronism. Endocrinol Diabetes Nutr. 2024; 71(8): 355-64. Article. IF: 1.8; Q3
- **Araujo-Castro M, Ruiz-Sánchez JG, Ramírez PP, Rojas-Marcos PM, Aguilera-Saborido A, Cerezo JFG, Lazareno NL, Quesada MET, Ramos JG, Oriola J, Poch E, Oliveras A, Monter JVM, Muriel IG, Bella-Cueto MR, Cidoncha EM, Runkle I, Hanzu FA.** Screening and diagnosis of primary aldosteronism. Consensus document of all the Spanish Societies involved in the management of primary aldosteronism. Endocrine. 2024; 85(1): 99-121. Review. IF: 2.9; Q3
- **Ballesteros SC, Carretero PS, Barbero FR.** Review of electrical impedance tomography in the pediatric patient. Rev Esp Anestesiol Reanim. 2024; 71(6): 479-85. Article. IF: 0.8; Q3
- **Catalina VS, Pedro NA, Carrillo CA, Paola PR, Carlos PL.** Carotid pseudoaneurysms after endoscopic transsphenoidal surgery for acromegaly. Endocrinol Diabetes Nutr. 2024; 71(1): 35-7. Article. IF: 1.8; Q3
- **Elizalde MU, Eguinoa FJG, de las Huertas AGL, Jiménez-González M, Ramírez E.** Myocarditis and pericarditis risk with mRNA COVID-19 vaccination compared to unvaccinated individuals: A retrospective cohort study in a Spanish Tertiary Hospital. Biomed Pharmacother. 2024; 171: 116181. Article. IF: 7.5; D1
- **Garcés-Visier C, Conejero-González P, Andión-Catalán M, Martín-Vega A, Muñoz-Hernández D, Espinoza-Vega ML, Luis-Huertas AL, Alonso-Calderón JL.** Thyroid abnormalities in patients with Hodgkin lymphoma: The importance of close surveillance. An Pediatr. 2024; 100(5): 325-32. Article. IF: 2.1; Q2
- **Garcés-Visier C, Maruszewski P, Luis-Huertas AL, Borrrego-Jimenez P, Azorín D, Martín-Vega A, Espinoza-Vega M, Herrero-Velasco B, Alonso-Calderón JL.** Non-Wilms renal tumors: Twenty years experience in a referral center. J Pediatr Surg Open. 2024; 8: 100151. Article. IF: 0.3; Q4
- **García JL, Mata EM, Rodríguez CG, Muñoz MG, Albajar MB, Montero AMB, Sánchez LAG.** Drug-Induced Enterocolitis Syndrome due to Acetaminophen in an Adult: A Call for Diagnostic Tools and Accurate Management. J Invest Allerg Clin. 2024; 34(4): 266-7. Editorial Material. IF: 4.8; Q1
- **Lamas C, Araujo-Castro M, Ostermair L, Petersenn E, Ramírez PP, Rebollo-Román A, Stuefchen I, Bruedgam D, Ruiz-Sánchez JG, Michalopoulou T, Perdomo CM, Hanzu FA, Adolf C, Reincke M.** Impact of Cortisol-Cosecretion on Adrenal Venous Sampling Results in Primary Aldosteronism: Study of 225 Cases. Biomedicines. 2024; 12(11): 2430. Article. IF: 3.9; Q2
- **López JG, Armas CE, Diéguez ML, Muñoz IP, Ruiz ED, Rigual R, Fernández-Fournier M, Iglesias GT, Velasco SS, Barranco AT, Rogozina O, Ramírez E, González-Muñoz M, Ballester LL.** Neurological manifestations of immune origin after COVID-19 vaccination: retrospective case study. Front Pharmacol. 2024; 15: 1376474. Article. IF: 4.8; Q1

- **Mir-Ihara P, Vecillas LD, Heredia R, Fiandor A, González-Muñoz M, Zamarrón E, Prados C, Cabañas R.** Protocol for Successful Desensitization to Ivacaftor and Elexacaftor/Tezacaftor/Ivacaftor in a Delayed Hypersensitivity Reaction Confirmed by the Lymphocyte Transformation Test. J Invest Allerg Clin. 2024; 34(3): 211-3. Article. IF: 4.8; Q1
- **Punjabi G, Ramírez E.** Appropriateness of Prescribing Transmucosal Immediate-Release Fentanyl in the Emergency Room, During Hospitalization, and at Discharge: A Retrospective Study. Pharmaceuticals (Basel). 2024; 17(12): 1609. Article. IF: 4.8; Q1
- **Ramírez PP, Rojas-Marcos PM, Fano MP, Boillos MG, Peris BP, Pascual-Corrales E, Cano AMG, Ruiz-Sánchez JG, Delgado AV, Hoyos EG, Ferreira R, Sanz IG, Sala MR, San Millan RB, César MJP, Guardiola PD, Perdomo CM, Manjon-Miguelez L, Centeno RG, Percovich JC, Román AR, Gimeno PG, Lázaro CR, Morales-Ruiz M, Calatayud M, Collao SAF, Meneses D, Núñez MAS, Quesada VE, Ribas EM, Sánchez AS, Diaz CG, Lamas C, Guerrero-Vázquez R, Tous MD, Gotarredona JS, Alevras TM, Mateo EMM, Hanzu FA, Araujo-Castro M.** Is adrenal venous sampling always necessary to differentiate between unilateral and bilateral primary aldosteronism? Lesson from the SPAIN-ALDO register. Endocrine. 2024; 84(2): 683-93. Article. IF: 2.9; Q3
- **Ramírez PP, Rojas-Marcos PM, Fano MP, González-Boillos M, Pascual-Corrales E, Cano AMG, Ruiz-Sánchez JG, Delgado AV, Hoyos EG, Ferreira R, Sanz IG, Sala MR, San Millan RB, César MJP, Guardiola PD, Perdomo CM, Manjón-Miguélez L, Román AR, Lázaro CR, Morales-Ruiz M, Calatayud M, Collao SAF, Meneses D, Sampedro-Núñez MA, Ribas EM, Sánchez AS, Diaz CG, Lamas C, Guerrero-Vazquez R, Tous MD, Gotarredona JS, Alevras TM, Rodrigo ST, Chamorro RR, Aguila FJ, Mateo EMM, Hanzu FA, Araujo-Castro M.** Renin as a Biomarker to Guide Medical Treatment in Primary Aldosteronism Patients. Findings from the SPAIN-ALDO Registry. High Blood Press Cardiovasc Prev. 2024; 31(1): 43-53. Article. IF: 2.9; Q2
- **Rodríguez-Molino P, Sánchez AG, Noguera-Julián A, Soler-García A, Paz PM, Méndez-Echevarría A, Baquero-Artigao F, Muñoz MG, Ruíz-Serrano MJ, Monsonís M, León RS, Saavedra-Lozano J, Santiago-García B, Sainz T.** QuantiFERON-TB reversion in children and adolescents with tuberculosis. Front Immunol. 2024; 15: 1310472. Article. IF: 5.9; Q1
- **Rogozina O, Ruiz-Fernández C, Martín-López S, Akatbach-Bousaid I, González-Muñoz M, Ramírez E.** Organ-specific immune-mediated reactions to polyethylene glycol and polysorbate excipients: three case reports. Front Pharmacol. 2024; 14: 1293294. Article. IF: 4.8; Q1
- **Ros Gómez B Gómez-López J Quintana-Díaz M Calvo Sevilla SV Rodríguez-Fuertes P Tejeda-Jurado F Berrocal-Espinosa P Martínez-Ballester JF Rodríguez-Roca S Rivera Núñez MA Martínez Virto AM Martín-Vega A Fernández-Capitán C Salgueiro-Origlia G Marín-Baselga R Lorenzo Hernández A Sancho Bueso T Puchades Rincón de Arellano R Gutiérrez-Sancerni B Díez-Vidal A Carrasco-Molina S Tung-Chen Y.** Factors Associated with the Evolution of Superficial Vein Thrombosis and Its Impact on the Quality of Life: Results from a Prospective, Unicentric Study. J Vasc Dis. 2024; 3(1): 1-10. Article. Not Indexed
- **Ruiz-García C, Riesco LR, Mateos-Serrano B, Millán RB, Muñoz AJD, Gavilán J, Ramírez PP, Marcos PMR, Catalán AL, Lecumberri B, Álvarez-Escolá C, Castro A.** Disease-free survival and response to therapy of clinically node- negative papillary thyroid cancer treated without central neck dissection: Retrospective study of 321 patients. Acta Otorrinolaringol Esp. 2024; 75(4): 224-30. Article. IF: 1.1; Q3
- **Stewart S, de las Huertas AGL, Jiménez-González M, Carcas AJ, Borobia AM, Ramírez E.** ALDRESS: A Retrospective Pilot Study to Develop a Pharmacological Causality Algorithm for Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). J Clin Med. 2024; 13(9): 2622. Article. IF: 2.9; Q1

Research projects

- **González Muñoz M, Ramírez García E.** Evaluación de la causalidad de las reacciones adversas a medicamentos de carácter grave: utilidad de los algoritmos, test in vitro, toxicologia y farmacogenética (HUL-VIT-2018). FIBHULP. 2019-Ongoing. Managment centre: FIBHULP
- **González Muñoz M.** Evaluación de la causalidad de las reacciones adversas a medicamentos de carácter grave: utilidad de los algoritmos, test in vitro, toxicologia y farmacogenética (HUL-VIT-2018). FIBHULP. 2019-Ongoing. Managment centre: FIBHULP
- **Ramírez Garcia E, Sanabria Carretero P, García García Carla.** Registro de Parada Perioperatoria (HUL-PCP-2017). FIBHULP. 2017-Ongoing. Managment centre: FIBHULP
- **Ramírez Garcia E, Sanabria Carretero P, Peiró Vallejo C.** Registro de parada cardiorespiratoria perioperatoria (HUL-PCP-2017). FIBHULP. 2017-Ongoing. Managment centre: FIHULP
- **Ramírez García E.** Adecuación del tratamiento de Fentanilo de liberación inmediata durante urgencias, Hospitalización y al alta (TFG-HUL-FENTA-2023 (PI-5960)). FIBHULP. 2024-2024. Managment centre: FIBHULP
- **Ramírez García E.** Análisis de desproporcionalidad de meningitis aséptica para las vacunas covid-19 en europa,versión 1.0 del 21/02/2022 (NEUROVAC-19). FIBHULP. 2022-2025. Managment centre: FIHULP
- **Ramírez García E.** Cohorte retrospectiva de miocarditis y pericarditis por vacunas para la covid-19 en el hospital universitario la paz, versión 1.9 del 17/01/2022 (CARDIOVAC-19). FIBHULP. 2022-2024. Managment centre: FIHULP
- **Ramírez García E.** Cohorte Retrospectiva De Registro De Alergias En Atención Primaria Y En HCIS En El Hospital Universitario La Paz (HUL-ALRA-2023). FIBHULP. 2023-2024. Managment centre: FIBHULP
- **Ramírez García E.** Efectividad de la Simulación en la mejora de la cultura de seguridad del paciente (HUL-SIM-2018). FIBHULP. 2018-Ongoing. Managment centre: FIBHULP
- **Ramírez García E.** Estudio de casos y controles anidado en una cohorte para evaluar el efecto de la co-medicación en la evolución de la infección por el coronavirus sars-cov-2. Versión 2 de 24.06.2020 (HULP-COVID19-ACE2-20). FIBHULP. 2021-2022. Managment centre: FIHULP
- **Ramírez García E.** Estudio de incidentes y eventos adersos en el hospital (ESINEA). FIBHULP. 2023-Ongoing. Managment centre: FIHULP
- **Ramírez García E.** Evaluación de la causalidad de las reacciones adversas graves a fármacos: utilidad de los algoritmos de causalidad y ensayos in vitro (PI21/01159). ISCIII. 2022-2024. Managment centre: FIBHULP
- **Sanabria Carretero P.** Mejora de la humanización de la asistencia sanitaria en el bloque quirúrgico infantil del Hospital La Paz. Fundación Icomem Para la Educación y Formación Sanitarias. 2021-Ongoing. Managment centre: FIBHULP
- **Sanabria Carretero P.** Población en riesgo de hipertemia maligna: cohorte ambispectiva (Código HULP:: PI-3528) (HUL-RHM-2019). FIBHULP. 2019-Ongoing. Managment centre: FIBHULP
- **Sanabria Carretero P.** Población en riesgo de hipertemia maligna: cohorte ambispectiva (PI20/01444). ISCIII. 2021-2025. Managment centre: FIBHULP

Patents and trademarks

- **Herrero Ambrosio A, Ramírez García E, Ojeda Feo JJ, Pérez Rodríguez J, Asensio Martín MJ, González Sánchez ML, Moro Agud M, Lorente Romeo M, López Nieto M, Gómez Rioja R, authors; FIBHULP, assignee.** Brand name: SINOIRES. CM 13.080.056; 2014 July 14.

3.6.7 Translational Research and Innovation in General and Digestive Surgery



Publications: 46 | **Q1:** 29

COMPOSITION

Constantino Fondevila Campo.
Jefe de Servicio de Cirugía General y Digestiva. Hospital Universitario La Paz

- **Mario Álvarez Gallego.** *Facultativo Especialista de Área en Cirugía General y de Aparato Digestivo. Hospital Universitario La Paz*
- **Raquel Arranz Jiménez.** *Facultativo Especialista de Área en Endocrinología y Mama. Hospital Universitario La Paz*
- **Ramón Cantero Cid.** *Facultativo Especialista de Área en Cirugía General y de Aparato Digestivo. Hospital Universitario La Paz*
- **Ramón Corripio Sánchez.** *Facultativo Especialista de Área en Cirugía General y de Aparato Digestivo. Hospital Universitario La Paz*
- **Francisca García-Moreno Nisa.** *Jefe de Sección de Cirugía de Urgencias. Hospital Universitario La Paz*
- **Joaquín Gómez Ramírez.** *Coordinador Unidad de Cirugía Endocrina. Hospital Universitario La Paz*
- **Jenny Rosario Guevara Martínez.** *Facultativo Especialista de Área en Cirugía General y de Aparato Digestivo. Hospital Universitario La Paz*
- **Amelia Hessheimer.** *Facultativo Especialista de Área en Cirugía General y de Aparato Digestivo. Hospital Universitario La Paz*
- **Javier Muñoz Luque.** *Técnico de Grado Superior. CIBEREHD*
- **Arnau Paniselló Roselló.** *Investigador Postdoctoral. Institute George Lopez*
- **Isabel Pascual Miguelañez.** *Facultativo Especialista de Área en Cirugía General y de Aparato Digestivo. Hospital Universitario La Paz*
- **Maria Isabel Prieto Nieto.** *Facultativo Especialista de Área en Cirugía General y de Aparato Digestivo. Hospital Universitario La Paz*
- **Inés Rubio Pérez.** *Facultativo Especialista de Área en Cirugía General y de Aparato Digestivo. Hospital Universitario La Paz*
- **Javier Salinas Gómez.** *Facultativo Especialista de Área en Cirugía General y de Aparato Digestivo. Hospital Universitario La Paz*
- **Juan José Segura Sampedro.** *Facultativo Especialista de Área en Cirugía General y de Aparato Digestivo. Hospital Universitario La Paz*
- **Aída Vaquero Rey.** *Investigadora Predoctoral. FIBHULP*
- **Jordi Vengohechea Llorens.** *Investigador Predoctoral. Univerisidad de Barcelona*
- **Elisa York Pineda.** *Facultativo Especialista de Área en Cirugía General y de Aparato Digestivo. Hospital Universitario La Paz*

STRATEGIC OBJETIVES

- **PROBLEM:** Surgery and perioperative care encompass one of the most expensive and resource-intensive areas of clinical medicine. Surgical patients undergo complex interventions, with the goal of curing or at least relieving distressing symptoms from different medical conditions. These same interventions, however, may sometimes result ineffective in achieving this goal. Additionally, they can provoke complications (morbidity) and further affect a patient's physical, mental, and emotional states.
- **APROACH:** The Translational Research & Innovation in General Surgery Group (GITIC) is a multidisciplinary group comprised of surgeons, nurses, and biologists, with various areas of dedication and expertise. The GITIC team works together with the common goal of using surgical innovation and diverse research initiatives to offer the highest level of patient care possible today.
- Given its broad knowledge base and skill set, projects that GITIC currently develops include lines of basic science and experimental research, translational and pre-clinical surgical models, clinical investigation, analysis of post-surgical outcomes, studies involving economic evaluation, the creation of mathematical models, and surgical device design and implementation.
- In order to fulfill its broad research interests and initiatives, GITIC actively collaborates not only with other groups within Hospital Universitario La Paz and IdiPAZ but also other hospitals and public and private research institutions in Spain and abroad. The following is a list of some of GITIC's current collaborations:
  - Donation & Transplantation Institute (DTI), Barcelona, España
  - Guanguong Shunde Innovative Design Institution, Guangdong, China
  - Hospital Virgen de la Salud, Toledo, España
  - Universidad Internacional de Catalunya (UIC), Sant Cugat, España
  - Policlinico Universitario "A. Gemelli", Università Cattolica del Sacro Cuore, Roma, Italia
  - Instituto de Empresa (IE), Madrid, España.
  - Tekniker, Gipuzkoa, España.

RESEARCH LINES

Injury, inflammation, organ failure, & transplantation:

- Assessment and implications of chronic inflammation in obesity
- Experimental models of end-stage liver disease and portal hypertension
- Applicability and results of liver transplantation in the treatment of acute-on-chronic liver failure
- Approaches to transplantation in patients with complex portal vein thrombosis
- Translation and clinical research in ischemia-reperfusion injury
- Novel preservation solutions and techniques of in situ and ex situ organ machine perfusion
- Clinical outcomes and strategies for improvement in donation after circulatory death (DCD) organ transplantation

- Assessment and clinical implications of markers of allograft dysfunction following liver transplantation

Surgical oncology:

- Evaluation of a novel polyfunctional immune liquid biopsy platform to predict and improve responses to cancer immunotherapy using innate immunomodulators
- Evaluation of the utility of cryoablation to provoke immune activation and response to immunotherapy in primary breast tumors
- Evaluation of the diagnostic and therapeutic role of novel immune checkpoints in colon cancer
- Development of three-dimensional in vitro organoid biomodels of colon cancer
- Combination of "omic" and imaging techniques to identify markers associated with response to neoadjuvant therapy in rectal cancer patients
- Effectiveness and safety of hyperthermic intraperitoneal chemotherapy in the prevention of peritoneal recurrence in high-risk colorectal cancer patients
- Immunological and molecular predictors of ovarian cancer arising in the background of endometriosis (Collaboration with H.U. La Paz Gynecology Service)

Surgical technology & innovation:

- Development and pre-clinical evaluation of a novel device for ex situ liver machine perfusion
- Development and clinical trial assessment on the safety and feasibility of a novel rectoscope for rectal cancer surgery
- Development and utility assessment of novel surgical drains
- Evaluation of novel surgical techniques strategies to reduce drainage following axillary lymphadenectomy in breast cancer therapy

Value-based care:

- Patient safety and prevention of perioperative infection
- Evaluation of "best possible outcomes" (benchmarks) in surgical care
- Assessment of perioperative complications, patient quality of life, and postoperative disability following general surgical operations
- Cost-effectiveness and cost-utility of postoperative cancer surveillance strategies
- Economic evaluation of novel surgical approaches and technologies

RESEARCH ACTIVITY

Doctoral Theses

- **del Castillo Díez F.** Abordaje endoscópico peritoneal ascendente suprapúbico para la reparación de hernias anteriores y laterales de la pared abdominal: reparación de hernias anteriores y laterales de la pared abdominal[dissertation]. Madrid: Universidad Autónoma de Madrid: 2024(19/09/2024). Director: Pascual Migueláñez I
- **Ramos Rubio D.** Valor diagnóstico de los niveles séricos de marcadores inflamatorios agudos como indicadores precoces de fugas anastomóticas post-gastrectomía[dissertation]. Madrid: Universidad de Alcalá: 2025(07/05/2024). Director: García-Moreno F

Publications

- **Åberg F, Sallinen V, Tuominen S, Adam R, Karam V, Mirza D, Heneghan MA, Line PD, Bennet W, Ericzon BG, Grat M, Lodge P, Rasmussen A, Schmelzle M, Thorburn D, Fondevila C, Helanterä I, Nordin A.** Cyclosporine vs. tacrolimus after liver transplantation for primary sclerosing cholangitis - a propensity score-matched intention-to-treat analysis. J Hepatol. 2024; 80(1): 99-108. Article. IF: 33.0; D1
- **Badía JM, Amador S, González-Sánchez C, Rubio-Pérez I, Manuel-Vázquez A, Juvany M, Membrilla E, Balibrea JM, Guirao X.** Appropriate Use of Antibiotics in Acute Pancreatitis: A Scoping Review. Antibiotics (Basel). 2024; 13(9): 894. Review. IF: 4.6; Q1
- **Bal P, Cheng JQ, Draman MR, Fadzli AN, Ghauth S, Hung WP, Jamaris S, Koh PS, Krishnasamy S, Lee YS, Liew YT, Lim JZK, Lim RCS, Lim HC, Pauzi SFM, Nah SA, Nair AK, Ng DSW, Yong YJNW, Ramayah K, Roslani AC, Saaid R, Sanmugam A, See MH, Seevalingam KK, Sethi N, Singaravel S, Zaidi SNSJH, Tang CY, Teoh LY, Wong KB, Xavier R, Yahaya AS, Marson FAL, Delibegovic S.** A prognostic model for use before elective surgery to estimate the risk of postoperative pulmonary complications (GSU-Pulmonary Score): a development and validation study in three international cohorts. Lancet Digit Health. 2024; 6(7): e507-19. Article. IF: 24.1; D1
- **Blay L, Larranaga I, Rabadan L, York E.** Endoscopic axillary lymphadenectomy: Tips & tricks. Cir Espan. 2025; 103(4): 220-1. Editorial Material. IF: 1.3; Q3
- **Blay L, Larrañaga I, York E, Rabadán L.** Endoscopic mastectomy in 10 steps. Cir Espan. 2024; 102(2): 103. Editorial Material. IF: 1.3; Q3
- **Bustamante-Madrid P, Barbáchano A, Albandea-Rodríguez D, Rodríguez-Cobos J, Rodríguez-Salas N, Prieto I, Burgos A, de Villarreal JM, Real FX, González-Sancho JM, Larriba MJ, Lafarga M, Muñoz A, Fernández-Barral A.** Vitamin D opposes multilineage cell differentiation induced by Notch inhibition and BMP4 pathway activation in human colon organoids. Cell Death Dis. 2024; 15(4): 301. Article. IF: 9.6; Q1
- **Carbone M, Neuberger J, Rowe I, Polak WG, Forsberg A, Fondevila C, Mantovani L, Nardi A, Colli A, Rockell K, Schick L, Cristoferi L, Oniscu GC, Strazzabosco M, Cillo U.** European Society for Organ Transplantation (ESOT) Consensus Statement on Outcome Measures in Liver Transplantation According to Value-Based Health Care. Transpl Int. 2024; 36: 12190. Article. IF: 3.0; Q1
- **Casas IM, Del Pozo EP, Forssten MP, Munoz-Cruzado VD, Mohseni S, Bass A.** Challenges in managing acute appendicitis differ across Europe: patient and system-level insights from observational cohort study data comparing two European countries. Curr Prob Surg. 2024; 61(11): 101597. Article. IF: 1.9; Q2
- **Cimino MM, Biloslavo A, Kurihara H, Bellio G, Porta M, Fattori S, Bass GA.** Practice patterns and clinical outcomes in acute appendicitis differ in the elderly patient. Eur J Trauma Emerg S. 2024; 50(5): 2155-64. Article. IF: 2.2; Q2
- **Cipriani F, Aldrighetti L, Ratti F, Wu AGR, Kabir T, Scatton O, Lim C, Zhang WG, Sijberden J, Aghayan DL, Siow TF, Dokmak S, Coelho FF, Herman P, Marino MV, Mazzaferro V, Chiow AKH, Sucandy I, Ivanecz A, Choi SH, Lee JH, Gastaca M, Vivarelli M, Giuliante F, Ruzzenente A, Yong CC, Yin MQ, Fondevila C, Efanov M, Morise Z, Di Benedetto F, Brustia R, Dalla Valle R, Boggi U, Geller D, Belli A, Memeo R, Gruttadauria S, Mejia A, Park JO, Rotellar F, Choi GH, Robles-Campos R, Wang XY, Sutcliffe RP, Pratschke J, Lai ECH, Chong CCN, D'Hondt M, Monden K, López-Ben S, Kingham TP, Ferrero A, Ettorre GM, Cherqui D, Liang X, Soubrane O, Wakabayashi G, Troisi RI, Cheung TT, Kato Y, Sugioka A, Han HS, Long TCD, Liu Q, Liu R, Edwin B, Fuks D, Chen KH, Abu Hilal M, Goh BKP.** Impact of Liver Cirrhosis, Severity of Cirrhosis, and Portal Hypertension on the Difficulty and Outcomes of Laparoscopic and Robotic Major Liver Resections for Primary Liver Malignancies. Ann Surg Oncol. 2024; 31(1): 97-114. Article. Not Indexed
- **Craus-Miguel A, Munar M, Moyà-Alcover G, Contreras-Nogales AM, González-Hidalgo M, Segura-Sampedro JJ.** Enhancing Surgical Wound Monitoring: A

Paired Cohort Study Evaluating a New AI-Based Application for Automatic Detection of Potential Infections. J Clin Med. 2024; 13(24): 7863. Article. IF: 2.9; Q1

- **del Castillo-Díez F, Pascual-Migueláñez I, Leivar-Tamayo A, Téllez LGS, Díaz-Domínguez J.** Fully endoscopic preperitoneal ascending suprapubic approach for minimally invasive repair of anterior and lateral abdominal wall hernias. Hernia. 2024; 28(5): 1755-68. Article. IF: 2.4; Q1
- **Fahy M, Kelly ME, Abecasis N, Akhtar SN, Akiyoshi T, Álvarez-Gallego M, Andric MD, Arteaga-Asensio P, Assi H, Austin KK, Ayub B, Aytac E, Bacalbasa N, Balescu , Baransi S, Baseckas G, Bedford MR, Berg P, Berle M, Bloemen JG, Borda-Arrizabalaga N, Bouyer B, Brannigan A, Brecelj E, Brown K, Brunner M, Buchwald PL, Burger JWA, Burgess A, Burns EM, Byrne C, Carvalhal S, Cho J, Chong P, Connolly S, Coscia M, Cosimelli M, Coyne PE, Croner RS, Dattani M, Denost Q, Desouza AL, Drozdov ES, Edhemovic , Enriquez-Navascues JM, Espin-Basany E, Etxart A, Evans MD, Frizelle FA, García-Sabrido JL, Galbraith N, Gentilini L, Gill DR, Ginther DN, Glyn T, Gould L, Gronchi A, Grützmann R, Harris DA, Heriot AG, Hohenberger W, Ito M, Jenkins JT, Kanemitsu Y, Kazi MK, Keller JS, Ketelaers SHJ, Koh CE, Kokelaar R, Kontovounisios C, Carré MK, Kye BH, Lampe B, Larkin JO, Lasso JM, Lee PJM, Lee YS, Limbert M, Lydrup ML, Maciel J, Manfredelli S, Marques CFS, McArthur D, McCormick JJ, McCormick PH, Mehigan BJ, Merkel S, Mikalauskas S, Mulsow J, Nason G, Nieuwenhuijzen GAP, Nordkamp S, Ozer L, Quinn M, Paarnio K, Pascual-Migueláñez , Pellino G, Pezzuto P, Pfeffer F, Pinson J, Poggioli G, Proud D, Qiu S, Rasheed S, Rausa E, Regenbogen SE, Rintala JM, Robert G, Rogers AC, Románo A, Rothbarth J, Rottoli M, Roxburgh CS, Rutegard M, Rutten HJ, Saklani AP, Sammour T, Sayyed RH, Shaban MM, Smart P, Solomon MJ, Sorrentino L, Steele CW, Steffens D, Takala H, Tekkis P, Tsukada Y, Tsukamoto S, Tuech JJ, van Rees JM, Vásquez-Jiménez W, Vather R, Verhoef C, Vierimaa M, Wakeman CJ, Warrier SK, Waters P, Weber K, Williams A, Xavier B, Yildiz , Yoo RN, Winter DC.** Contemporary results from the PelvEx collaborative: improvements in surgical outcomes for locally advanced and recurrent rectal cancer. Colorectal Dis. 2024; 26(5): 926-31. Article. IF: 2.7; Q1
- **Finotti M, Wall A, D'Alessandro A, Schwartz G, Sonnenday C, Goldberg D, Shah AS, Friend P, Orlowski JP, Mckenna G, Newton S, Adams B, Chapman WC, Mathur A, Abouljoud M, Pruett T, Hessheimer A, Trotter JF, Asrani SK, Testa G.** The Dallas Donation after Circulatory Death Transplantation Summit: expanding donation after circulatory death procedures through process improvement, broader utilization, and innovation. Hepatobiliary Surg Nutr. 2024; 13(5): 824-36. Review. IF: 7.8; D1
- **Gallego MA, de las Casas SG, Serrano ED, Migueláñez IP.** Safety and feaseability of a new rectoscope in rectal cancer surgery. First clinical trial. Cir Espan. 2024; 102(10): 548-51. Article. IF: 1.3; Q3
- **Giglio MC, Dolce P, Yílmaz S, Tokat Y, Acarli K, Kilic M, Zeytunlu M, Unek T, Karam V, Adam R, Polak WG, Fondevila C, Nadalin S, Troisi RI.** Development of a model to predict the risk of early graft failure after adult-to-adult living donor liver transplantation: An ELTR study. Liver Transplant. 2024; 30(8): 835-47. Article. IF: 3.9; Q1
- **Gómez-Ramírez J, Jiménez RA.** Surgical tactics of parathyroidectomy: Should we abandon the use of ioPTH?. Am J Surg. 2024; 235: 115709. Editorial Material. IF: 2.7; Q1
- **Guerrero-Ortiz MA, Sánchez-Velázquez P, Burdío F, Gimeno M, Podda M, Pellino G, Toledano M, Nunez J, Bellido J, Acosta-Mérida MA, Vicente E, López-Ben S, Pacheco D, Pando E, Jorba R, Trujillo JPA, Ausania F, Álvarez M, Fernandes N, Castro-Boix S, Gantxegu A, Carre MK, Pinto-Fuentes P, Bueno-Cañones A, Valdes-Hernandez J, Tresierra L, Caruso R, Ferri V, Tio B, Babiloni-Simon S, Lacasa-Martin D, González-Abós C, Guevara-Martínez J, Gutierrez-Iscar E, Sánchez-Santos R, Cano-Valderrama O, Nogueira-Sixto M, Álvarez-Garrido N, Martínez-Cortijo S, Lasaia MA, Linacero S, Morante AP, Rotellar F, Arredondo J, Marti P, Sabatella L, Zozaya G, Ielpo B.** Cost-effectiveness of robotic vs laparoscopic distal pancreatectomy. Results from the national prospective trial ROBOCOSTES. Surg Endosc. 2024; 38(11): 6270-81. Article. IF: 2.7; Q1
- **Hessheimer AJ, Flores E, Fondevila C.** No Evidence of Progressive Proinflammatory Cytokine Storm in Brain Dead Organ Donors: Should We Avoid the Rush to Flush?. Transplantation. 2024; 108(4): 839-40. Editorial Material. IF: 5.0; Q1
- **Hessheimer AJ, Flores E, Vengohechea J, Fondevila C.** Better liver transplant outcomes by donor interventions? Curr Opin Organ Tran. 2024; 29(4): 219-27. Review. IF: 1.9; Q3
- **Hoogteijling TJ, Abu Hilal M, Zimmitti G, Aghayan DL, Wu AGR, Cipriani F, Gruttadauria S, Scatton O, Long TCD, Herman P, Marino MV, Mazzaferro V, Chiow AKH, Sucandy I, Ivanecz A, Choi SH, Lee JH, Gastaca M, Vivarelli M, Giuliante F, Ruzzenente A, Yong CC, Yin MQ, Fondevila C, Efanov M, Morise Z, Di Benedetto F, Brustia R, Dalla Valle R, Boggi U, Geller D, Belli A, Memeo R, Mejia A, Park JO, Rotellar F, Choi GH, Robles-Campos R, Wang XY, Sutcliffe RP, Pratschke J, Tang CN, Chong CCN, Hondt M, Monden K, López-Ben S, Kingham TP, Ferrero A, Ettorre GM, Cherqui D, Liang X, Soubrane O, Wakabayashi G, Troisi RI, Han HS, Cheung TT, Sugioka A, Dokmak S, Chen KH, Liu R, Fuks D, Zhang WG, Aldrighetti L, Edwin B, Goh BKP.** Impact of neoadjuvant chemotherapy on short-term outcomes after simple and complex minimally invasive minor hepatectomy for colorectal liver metastases: A propensity-score matched and coarsened exact matched study. Ejso-Eur J Surg Onc. 2024; 50(6): 108309. Article. IF: 2.9; Q1
- **Kamarajah SK, Fleres F, Cucinotta E, Biondo SA, Viscosi F, Catarsini N, Mazzeo C, Iannello M, Karatas , Gok AFK, Simsek E, Altunay Z, Koç E, Iscan Y, Sormaz IC.** Association between multimorbidity and postoperative mortality in patients undergoing major surgery: a prospective study in 29 countries across Europe. Anaesthesia. 2024; 79(9): 945-56. Article. IF: 6.9; D1
- **Krenzien F, Schmelzle M, Pratschke J, Feldbrügge L, Liu R, Liu Q, Zhang WG, Zhao JJ, Tan HL, Cipriani F, Hoogteijling TJ, Aghayan DL, Fretland ÅA, Siow TF, Lim C, Scatton O, Herman P, Coelho FF, Marino MV, Mazzaferro V, Chiow AKH, Sucandy I, Ivanecz A, Choi SH, Lee JH, Gastaca M, Vivarelli M, Giuliante F, Dalla Valle B, Ruzzenente A, Yong CC, Chen ZW, Yin MQ, Fondevila C, Efanov M, Morise Z, Di Benedetto F, Brustia R, Dalla Valle R, Boggi U, Geller D, Belli A, Memeo R, Gruttadauria S, Mejia A, Park JO, Rotellar F, Choi GH, Robles-Campos R, Wang XY, Sutcliffe RP, Hasegawa K, Tang CN, Chong CCN, Lee KF, Meurs J, D'Hondt M, Monden K, López-Ben S, Kingham TP, Ferrero A, Ettorre GM, Pascual F, Cherqui D, Zheng JH, Liang X, Soubrane O, Wakabayashi G, Troisi RI, Cheung TT, Kato Y, Sugioka A, Dokmak S, D'Silva M, Han HS, Nghia PP, Long TCD, Abu Hilal M, Chen KH, Fuks D, Aldrighetti L, Edwin B, Goh BKP.** Propensity Score-Matching Analysis Comparing Robotic Versus Laparoscopic Limited Liver Resections of the Posterosuperior Segments An International Multicenter Study. Ann Surg. 2024; 279(2): 297-305. Article. IF: 6.4; D1
- **Li E, Bengueddach A, Tidjane A, Tabeti B, Behilil C, Boudjenan-Serradj N, Bensafir S, Meharzi SE, Aissat A, Ghouali AK, Larabi K, Riffi O, Kacimi SEO, Mesli SN, Rezoug W, Mitidieri A, José A, Pablo C, Rodríguez CA, Panettiere MF, Barbalace N, Juan T, Lucena J, Houdin A, Fernandez E, Lococo J, Pedro L, Loban M, Vecchio P, Grinblat A, Carrie A, Veracierto F, Santillan M, Napolitano M, Avellaneda N, La Rosa S, González CM, Ferro E, Muñoz JP, Ventorutti T, Cabrera C, Carrizo C, Mospane C, Leiro F, Espino J, Trama M, Bianchi R, Potolicchio A, Dindri F, Buey L, Lucas N,**

Catalano P, Astilleta R, Quiroga Y, Chwat C, Valli D, Alexandre F, Martres G, Rosato G, Lemme G, Romero , Doniquian AM, Pachajoa DAP, Llahi F, Fiorenza JM, Parodi M, Ocaña N, Gallardo A, Valenzuela A, Perriello J, Nador R, Fermani C, Garay L, Blanco P, Villalobos S, Posner F, Vieyra N, Fiorito P, Ciabattari P, de Kort C, Daryanani D, Smit J, Gosselink MP, Janssen N, Feiss A, Lee CHA, Taylor D, Edington J, Chen N, Ong WM, Aigner F, Moitzi G, Gemes G, Braumille M, Mitteregger M, Gerald S, Uranitsch S, Belarmino A, Waha J, Kahn J, Treiber M, Schemmer P, Mikalauskas S, Ibrahimli A, Samadov E, Orujova E, Namazov , Alikhanli J, Asgarov M, Kutkut A, Almahmeed E, Aljawder H, Juma , Johnston K, Saeed MF, Khairi S, Matovic E, Omerasevic M, Delibegovic S, Hodzic S, Rudell AG, Fuzari J, Farah JF, Nadal LRM, Dos Santos MBA, Lupinacci RA, Pereira TS, Sete AD, Filho AL, Pires BLD, de Queiroz FL, Amaral HAT, Dos Santos MAM, Silvestre SCD, Hanan B, Reis C, Cassia G, da Luz M, Delgado M, Campanati R, Silva R, Bomfa-Barbosa A, Alves BC, Costa BXM, Cortes BGW, Lemos FHT, Arreguy-Borges K, Silva TB, Assis A, Freitas AH, Rezende D, Silva H, Alvarenga , Cascais R, Silva T, Santos G, Pinto H, Silva , Leite L, Massahud M, Meyer M, Tibúrcio R, Martínez CAR, Espinha DR, Marson FAL, Góes IAD, Artioli LMD, Boschiero MN, Takahashi CY, de Oliveira FG, Junior HFL, de Oliveira JCC, Dos Santos JM, Gerber MT, Erdmann TR, Barbosa A, Fernandes A, Júnior AN, Júnior HM, Moreira J, Ribeiro M, Moreira P, Carvalho A, Santos B, Fidelis F, Cruz , Codes L, Aibe R, Boudoux S, Favacho BC, Pinto F, Gava G, Pivati IR, Vilain LF, Kim N, Nunes RL, Dimitrov D, Peneva K, Karamanliev M, Dimitrova S, Ivanov T, Atanasov B, Dzharov G, Shtereva M, Slavchev M, Belev N, Krastev P, Arabadzhiev A, Tonova D, Tzoneva D, Sokolov M, Gribnev P, Maslyankov S, Pavlov , Bakmaz B, Dijan E, Coza , Mihanovic J, Kucic J, Sulen N, Katusic Z, Hudácek K, Farkasová M, Marková M, Grolich T, Kala Z, Pazdírek F, Hoch J, Filipová L, Kocián P, Prikryl P, Hogn A, Moller B, Slot DK, Bælum JK, La Cour K, Ellebæk MB, Eriksen ND, Mahmoud A, Abdellatif A, Nafea A, Ewedah M, Soliman M, Yakout N, Argawy O, Sallam , Kamel , Sherif M, Ashmawy S, Ali A, Saad M, Ahmed M, Mohamed M, Mohamed N, Mahmoud S, Rashed AM, Abd-Errazik MA, Ammar MA, Mohammed R, Ebrahem A, El Aal AA, Abdou K, Wagdy M, Qassem M, Taha M, El-Wafa YA, Shehta A, El Metwally A, Hamed H, Ali MA, Elrefai M, El Sorogy M, Abdelkhalek M, Ragab A, Refky B, Metwally IH, Kamal M, Zuhdy M, Shetiwy M, Sakr A, Elfallal A, Elfeki H, Eldakroury , Elbahrawy K, Mostafa M, Emile S, Tessema A, Tasew A, Gezahegn H, Bekele K, Belay M, Gudisa Z, Teferu Z, Väyrynen A, Kechagias A, Turunen A, Katunin J, Parhiala M, Pengerma P, Lahti P, Carpelan A, Vihervaara H, Huhtinen H, Pasonen J, Heino R, Pakarinen S, Falenius , Pinard B, Nobile C, Duchalais E, Drissi F, Meurette G, Podevin J, Lepenndu M, Hoetzel A, Jud A, Jauch D, Stefan FF, Neeff H, Holzner P, Nguyen P, Ryl A, Kehl F, Pullig F, Baral J, Münch S, Fütterer C, Reissfelder C, Sandra-Petrescu F, Herrle F, Hardt J, Lamm L, Seyfried S, Gharbi A, Aydin F, Stavrou G, Sperber J, de Deken J, Schwarzkopf K, Widyaningsih R, Polidorou A, Mpakas A, Tokidis E, Loun L, Petropoulou T, Balalis D, Korkolis D, Manatakis D, Assimakopoulou E, Bourazani M, Gklavas A, Kalamara E, Papaconstantinou , Theodoraki K, Chardalias L, Konstadoulakis M, Theodosopoulos T, Soulioti E, Kavezou F, Filippou J, Papadoliopoulou M, Michalopoulos N, Vassiliu P, Sidiropoulos T, Charakopoulou A, Panagiotou A, Bouchagier K, Kokkinakis K, Lambridi E, Psarologos M, Sotiropoulou M, Giannaraki S, Kapiris S, Triantafyllou A, Theodoropoulos C, Matthaiou G, Westzaan N, Etelka S, Triantafyllou T, Theodoropoulos G, Schizas D, Mpaili E, Karydakis L, Mpoura M, Danassi D, Karavokyros , Dimitriou N, Livanou X, Kikira A, Tsourouflis G, Tomara NK, Nikiteas N, Dorovinis P, Garoufalia Z, Tsiotos G, Stamou K, Kocka N, Ballian N, Kalakonas S, Athanasakis E, Chrysos E, Xynos E, Tsiaoussis J, Papadaki K, Xenaki S, Nyktari , Sarakatsianou C, Bompou E, Arnaoutoglou E, Tzovaras G, Baloyiannis , Mamaloudis , Perivoliotis K, Apostolidi E, Mulita F, Karpetas G, Maroulis , Vailas M, Petra A, Kontis E, Kaouras E, Katsaros , Katsiaras L, Manikis P, Papadopoulou T, Papadopoulos A, Manioti E, Zeringa G, Katsinelis , Mouzakis O, Kouki P, Nikolaou , Marinis A, Alexopoulou K, Papadaki M, Vederaki SA, Samara A, Giakoustidis D, Christodoulidis G, Bareka M, Chatzikomnitsa P, Tsigara S, Papadopoulos , Zarzava E, Anestiadou E, Lydia L, Apostolakidou M, Ioannidis O, Simeonidis S, Mpitsianis S, Futaba K, Tam PTH, Ng SSM, Lau VNM, Tse WK, Bánky B, Dolhai E, Golub J, Marton J, Lakatos L, Suszták N, Maurya AP, Kumawat H, Saxena P, Lather R, Waindeskar , Khanduri A, Goyal L, Gupta R, Singh S, Saksena AR, Rayani BK, Kasula J, Raju K, Shah MM, Thammineedi SR, Patnaik SC, Rathod D, Poonia DR, Vishnoi JR, Sharma N, Byshetty R, Yadav RK, Misra S, Dhali A, Dhali GK, Biswas J, Ray S, Ghose T, Pipara A, Singh HM, Roy MK, Desai N, Thambudorai R, Ishwarappagol , Chaturvedi A, Verma D, Akhtar N, Gupta S, Rajan S, Tiwari T, Kumar , Mahajan A, Jain D, Liddle D, Jyoti J, Haque PD, Jain R, Veetil SK, Prem W, Lakshminarayana B, Veerabhadrappa SB, Poojary PH, Bhat RRK, Mathew S, Gupta L, Bains LH, Bains L, Kumar M, Singh N, Lal P, Sharma A, Kumar A, Garg L, Aggarwal M, Jakhar R, Bose B, Huda F, Thakur N, Dhar P, Seenivasagam RK, Prakash S, Chaudhari A, Shukla A, Mahakalkar C, Saxena G, Mahuli K, Kaple M, Kshirsagar S, Mehraj A, Parray F, Aziz G, Chowdri N, Wani RF, Gurcoo S, Shah Z, Polamreddy BM, Madhavan S, Subbarayan S, Vino S, Aravindan U, George G, Harikumar CK, Yadev IP, Chisthi M, Revathy PS, Sreekumar RC, Vijayan V, Theodore B, Victor C, Jesudason MR, Arulappan N, Philip R, Mittal R, Durai S, Creavin B, Cullinane C, Davis C, Flynn C, Liam D, Cooke F, Earley H, Mccullough P, Neary P, Hamilton , Di Trani A, Conversano , Cianci P, Petta R, Picciariello A, Altomare DF, Martines G, Grasso S, Moffa S, Papagni , Zanoni A, Belvedere A, Gori A, Románo A, Cuicchi D, Di Croce G, Tanzanu M, Rottoli M, Cardelli S, Lauro A, Sartarelli L, Binetti M, Cervellera M, Tonini , Sanna B, Pusceddu E, Runfola M, Manunza R, Pisanu A, Cois A, Frongia F, Esposito G, Podda M, Mura P, Marzella A, Scotto B, Cuneo D, Ascari F, Giulino G, Varoli M, Laquatra N, Fortunato C, Marino F, Perrone F, Pace M, Convertini O, Cutellè C, Ammerata G, Sena G, Pignataro M, Scozzafava M, Mazza M, Bruni A, Curro G, Hila J, Ammendola M, Curcio S, Signorelli , Marano A, Sasia D, Borghi F, Giuffrida MC, Bonardello M, Palmisano S, Testa , Porta A, Scaltrini F, Iacob G, Gaspa , Guatteri L, Coladonato M, Zapparoli A, Pesce A, Feo C, Pindozzi F, Bigoni , Torchiaro M, Fabbri N, Cianchi F, Staderini F, Elena F, Coratti F, Barbato G, Fortuna L, Romagnoli S, Bergamini C, Villa G, Cecchini , Martellucci J, Izzo M, Trafeli M, Scheiterle M, Manoocheehri F, Cagnazzo F, Spampinato MG, Adam N, Depalma N, D'Ugo S, Garritano S, Mazzeo C, Cucinotta E, Melita F, Viscosi F, Fleres F, Biondo SA, Tripodi VF, Spinelli A, Foppa C, Greco M, Sacchi M, Carvello M, Deac , Laurenti , Frontali A, Zappone A, Cammarata F, Colombo F, Ferrario L, Currà MC, Danelli P, Vignali A, Umberto C, Mastriale F, Riccardo R, Turi S, Elmore U, Galimberti A, Ceretti AP, Vespo D, Opocher E, Longhi M, Mariani NM, Flandoli C, Ciulli C, Vaira G, Ripamonti L, Cigagna L, Oldani M, Tamini N, Palumbo A, Castaldi A, Antropoli C, Rupealta N, Palmiero N, Donatiello , Novi A, Cappiello A, Bianco F, de Luca M, Incollingo P, Esposito R, Gili S, Aprea G, de Simone G, Palomba G, Capuano M, Basile R, D'Angelo S, Tropeano FP, Luglio G, Pagano G, de Palma GD, Cricrì M, Milone M, Manigrasso ME, Anoldo P, Boccia G, Raiano G,

Di Nuzzo MM, Calabria M, Peltrini R, Castiglioni S, Bracale U, Cervone C, Rega D, Caliendo D, Benetti E, Delrio P, Guarino R, de Franciscis S, Coppolino F, Románo FM, Selvaggi F, Pellino G, Sciaudone G, Selvaggi L, de Stefano M, Resendiz A, Carosso F, Degiuli M, Salusso P, Reddavid R, Benetti S, Callari C, Di Miceli D, Pardo D, Sabatino G, Licari L, Lirosi MC, Sorce , Peri A, Mori A, Pugliese L, Filardo M, Nuccio P, Dominioni T, Ciciliot M, Giuseppina F, Angelo F, Raffaele G, Michele M, Roberto P, Mondini A, Muratore A, Valentino C, Calabrò M, Danna R, Cremonini C, Sbarbaro C, Tartaglia D, Coccolini F, Chiarugi M, Musetti S, Pagani S, Neri CM, Leoni C, Rossi E, Randisi E, Puccini M, Buccianti P, Balestri R, Vasale AO, Crescentini G, Ranieri G, Sinibaldi G, Biondi A, Sanesi AP, Vacca C, Lorenzon L, Sollazzi L, Persiani R, Pezzuto R, Ferroni AF, Stipa F, Volturo L, Moretti M, Tierno SM, Marina S, Mingoli A, Fiori E, Pugliese F, Brachini G, Carta G, Sapienza P, Lapolla P, Mazzotta E, Carannante F, Capolupo GT, Masciana G, Sica , Caricato M, Antonelli S, Fiume D, Spoletini D, Lisi G, Carlini M, Menduni , Arturi A, Proietto B, de Lucia C, Baldi C, Passantino DG, Romeo G, Di Paola M, Sensi B, Sica G, Siragusa L, Dauri M, Franceschill M, Campanelli M, Bellato , Porcu A, Garau AGG, Masala ML, Oggianu S, Tedde T, Perra T, Pazzola , Venezia DF, Roviello F, Giacomini G, Carbone L, Marano L, Verre L, Marano M, Ciccarese AA, Bagnardi F, Shahu J, Siciliano W, Iacomino A, Armellin C, Marson F, Zanus G, Santoro GA, de Paoli M, Grossi U, Sekimoto M, Kobayashi T, Horiguchi A, Koike D, Yonekura H, Kato H, Yoshino K, Arakawa S, Asano Y, Alawneh F, Rajab , Ramadan M, Al Masri M, Al Qaisi M, Alsamneh M, Mubaidin O, Al-Jarrah A, Ababneh H, Khdair K, Tawarh T, Sabri W, Arida ZA, Dzhumabekov B, Klyshbayeva D, Fakhradiyev , Ispbayeva K, Nadyrov M, Tanabayeva S, Saliev T, Jumanov A, Aitbaeva A, Arynov A, Kulimbet M, Maulenov N, Dushimova Z, Park EJ, Kim H, Kang J, Baik SH, Song Y, Kwak HD, Kim J, Son JH, Chung JS, Lee H, Baek JH, Nam KH, Lee WS, Jeon Y, Kim CW, Park SE, Lee SH, Son GM, Ahn HM, Lee IY, Kim TK, Pcolkins A, Sivins A, Lobovs D, Ancans G, Kreice , Budnikova , Jelovskis , Emhareb A, Abaidalla A, Hammed A, Khairallah M, Jibreel SS, Mohmmad WAS, Hasan W, Venskutonis D, Daugela E, Dainius E, Juocas J, Kutkevicius J, Vaitkute K, Bradulskis S, Macas A, Pauzas H, Jokubauskas M, Lizdenis P, Budrikiene R, Svagzdys S, Saladzinskas Z, Dulskas A, Volkoviene G, Makauskiene J, Kuliavas J, Bernotaite , Danys D, Kontrimaviciute E, Poskus E, Kryzauskas M, Jakubauskas M, Poskus T, Jotautas , Zakaria AD, Kai MWP, Zainy RHM, Tan SS, Zain WZW, Zakaria Z, Yusoff ZM, Raduan F, Sagap , Razali NYF, Rahman NA, Kanthan SBC, Nie YC, Azman ZAM, Ang CW, Tang CY, Poh KS, Ng K, Hashim NM, Xavier R, Khong TL, Amir AS, Ali CSC, Yew CK, Henry F, Muniandy J, Baharom S, Eng SCR, Hu FSM, Amin-Tai H, Jabar MF, Satar MHSA, Fathi NQ, Rao PS, Podesta AMC, Cini C, Psaila J, Debono M, Sammut M, Spiteri N, Andrejevic P, Muro AG, Leon BP, Perez JAV, Quiñonez JRA, Vera MTR, Gutierrez VMM, Bobadilla BJ, Martínez CM, Rendón JLD, Hererro JAV, Cuichan MVY, Baez NF, Prevost PG, Hoyos-Torres A, Ruiz-Muñoz EA, Alvarez-Bautista FE, Ortíz-Méndez G, Zamudio-Bautista JL, Salgado-Nesme N, Vergara-Fernández O, Sanchez-Valdivieso E, Martínez G, Navarrete-Aleman J, Perez-Arellano J, Maldonado-Barron R, Hernandez-Krauss R, Ousadden A, Benjelloun EB, Bzikha , Ibnmajdoub K, Mazaz K, Marghich O, Touzani S, Benkabbou A, Souadka A, Ahmadi BE, Zaari F, Laamri , Majbar MA, Mohsine R, Van CB, Seuren D, Gillissen F, Aarts F, Konsten J, Van MH, Schlooz S, Naiqiso A, Merrie A, Varghese C, Pugh F, Bissett , Wilson K, Mitchell S, Dawson C, Hill C, Wright D, Hubley S, Lin A, Jones D, Siggins L, Fagan P, Wu S, Ekwesianya A, Nwoye C, Agara D, Ejiofor G, Sundaynweke N, Kwentoh N, Ewah R, Aremu A, Ballah A, Ningi A, Ohia E, Mienda , Aliyu M, Oloko N, Okunlola A, Abiyere H, Bolanle OE, Babatunde O, Fatudimu S, Orewole T, Mba EL, Felix MS, Abdulfatah M, Ibrahim N, Masoro U, Fakoya A, Irabor D, Anyadike F, Ulasi , Orji M, Afuwape O, Ayandipo O, Adeyeye A, Aremu , Adegboye K, Gbadegesin P, Aminu B, Aghadi IK, Makama JG, Joshua S, Kache SA, Sheshe AA, Bala AM, Garzali IU, Abdullahi MMM, Muhammad N, Umar NA, Muhammad S, Okoye A, Emegoakor C, Nwosu C, Egwuonwu OA, Ekwunife O, Amadigwe R, Ojiakor S, Akere A, Okereke C, Olaleye O, Ige O, Olubayo O, Olatiilu T, Idris M, Shehu A, Oluyori D, Nwabuoku E, Ukwubile L, Bashir M, Daniyan M, Rauf H, Ali M, Zakaria M, Hameed M, Amanullah N, Chawla T, Waqar U, Jamal A, Butt A, Kerawala A, Samson S, Dodhy AA, Gill AJ, Malik A, Ali D, Mohsin H, Afzal MF, Batool S, Suleman A, Khalid J, Zafar M, Dilawar M, Janjua MH, Sarwar MZ, Naqi SA, Akbar A, Afzal A, Anwar J, Gondal KM, Shaukat M, Waheed M, Sohail M, Mukhtiar N, Ammar AS, Hussain A, Khan AN, Sarwar A, Khan , Khattak S, Oqaili B, Saada B, Zatari D, Jubran F, Hamdan F, Emar M, Alawi R, Jacome G, Insturain I, Arauz J, Hurtado M, Beron R, Castaño R, Cao VHB, Kwiatkowski A, Dobkowski G, Bartosiak K, Waledziak M, Mozanski M, Zadrozna M, Kowalewski P, Fiedziuk A, Watroba A, Los A, Sitarska M, Rzaca M, Zawadzki M, Czarnecki R, Tavares C, Santos F, Borges F, Real JC, Lima MJ, Carlos S, Pereira , Pacheco A, Gomes G, Pimenta J, Elisiario L, Jervis M, Gonçalves , Pedro , Jordao D, Neves FR, Conceiçao L, Angelo MD, Marques P, Saraiva RP, Caroço TV, Windels A, Machado A, Ribeiro C, Velez C, Oliveira J, Melo MR, Lima R, Pires A, Lareiro C, Martins R, Revez T, Martins A, Cardoso D, Alegre , Estevao P, Andrade D, Gomes DC, Duarte MJ, Custódio P, Nemésio RA, Rodrigues S, Correia A, Domingos H, Herrando , Azevedo J, Fernandez L, Azevedo P, Vieira P, Torre A, Amado A, Paiva M, Saraiva R, Costa S, Mendes T, Queirós T, Silva A, Faustino A, Freitas A, Mendes J, Amaral L, Quintanilha R, Coelho AM, Ribeiro A, Pinto C, Ribeiro N, Reis R, Fernandes , Sanches A, Amorim E, Miguel , Rachadell J, Sanches M, Oliveira S, Baptista , Roxo A, Devesa H, Teslyak O, Barradas R, Marques S, Martins S, Pepino S, Deus AC, Ferreira A, Marinho D, Sousa D, Martins MJ, Matias N, Pinto A, Correia D, Amado F, Cordeiro L, Morales M, Lamas M, Marçal S, Rodrigues A, Santos A, Marçal A, Oliveira A, Gomes C, Ferreira C, Marques R, Chitul A, Alexandrescu C, Bezede C, Cristian D, Mandi D, Grama F, Ungureanu R, Stoica B, Diaconescu C, Ciubotaru C, Tanase , Grintescu , Negoi , Negoita VM, Calin C, Simeanu C, Ciotarla DC, Caltea M, Mirica RM, Luca A, Pasca A, Vlad C, Bonci EA, Stefanescu , Achimas-Cadariu PA, Gata VA, Capusan A, Petrisor C, Dindelegan G, Seicean R, Scurtu R, Bintintan , Fagarasan , Ionescu C, Crisan D, Zanc L, Ene-Cocis M, Muresan MS, Mihalcea SM, Dudric , Musina AM, Ristescu A, Roata CE, Moglan M, Dimofte MG, Lunca S, Iacob S, Dychko A, Litvin A, Kapustina A, Provozina A, Anokhin E, Zabiyaka M, Shin A, Djumabayev K, Kuznetsova M, Gordeyev S, Kochkina S, Mamedli Z, Markaryan D, Galliamov E, Semina E, Agapov M, Malahov P, Garmanova T, Kakotkin , Zaycev A, Sumbaev A, Bedzhanyan A, Orman E, Petrenko K, Bredikhin M, Frolova Y, Tulina , Bashilkina O, Tsarkov P, Rodimov S, Stamov , Balaban , Alexnder A, Yanishev A, Rogozhev D, Yakunina N, Chubukova N, Nugmanov R, Karachun A, Petrov A, Domanskiy A, Panaiotti L, Smolina M, Sapronova T, Pelipas Y, Zagaynov E, Khrykov G, Davidovskaja L, Burlov N, Mankevich N, Tverdohlebova T, Bogatikov A, Lodygin A, Krasnoselsky C, Vasiukova ES, Kopteyev NR, Ovchinnikov T, Kashchenko VA, Novikova A, Terentyeva E, Kuleshov O, Pavlov R, Koshel A, Kostromitsky D, Drozdov E, Klokov S, Camacho A, Khan FN, Al Bandar M, Shamim R,

Chowdhury S, Kovacevic B, Krdzic , Zdravkovic M, Kenic M, Milentijevic M, Petkovic N, Radulovic R, Ngu J, Teo NZ, Singh PA, Ong SY, Li S, Siew BE, Chee C, Koh JJM, Lee KY, Tan KK, Wong SC, Loh W, Pujol AF, Rubio JC, Farrés LP, Vendrell LL, Del Olmo MIU, Pedregosa AB, Galmes C, Luckute D, Casanova D, Artigot M, Guedes X, Olivella Y, Sarda MS, Toscano MJ, Damieta MP, Pera M, Gonçalvez SA, Galvez ST, Ruiz SS, Espin-Basany E, Marinello F, Villarino-Villa L, Heras MVL, Martin-Sanchez R, Mata RM, Blanco-Colino R, Otero A, de Lacy AM, Sanahuja JM, Bravo R, Ferraz T, Gonzabay , González F, Menendez P, Del Castillo VCG, Lopez-Pelaez VM, Lillo-García C, Tauler EM, Sánchez-Guillén L, Manresa MCE, Pérez SL, Llopis SQ, Rubio A, Castillo ER, Miramón FJJ, Rodríguez JLR, Rizo-Lamberti LA, Garrido PG, Carneros VJ, Alfonso BA, Sierra BG, Amador CG, Gomendio MDP, Palomino MVR, Llamas RD, Cafranga EG, Ramos JLE, Estudillo MC, Pérez RE, Pernas RM, Fernández SD, Bautista WMS, Llamazares AL, Valbuena AL, Moran LA, Alvarez LJ, Raposo LG, Ceron SF, González TE, Calvo AC, Valcárcel CR, Peña JP, Gómez LMJ, Díez MC, Lindenbaum PD, Mata SK, Ruiz-De-La-Hermosa A, Abad-Motos A, Toribio-Combarro B, Ripollés-Melchor J, Fuenmayor-Valera ML, Ortega-Domene P, Loscos A, Del Pueblo CS, Dziakova J, Mugüerza JM, Carlin PS, Anula R, Mouvet Y, Forero-Torres A, San Andrés BD, Marcos CM, Rubio , Pascual , Yague J, Alcolea NG, Alonso A, Diéguez B, Ibañez I, Pérez JL, Losada M, García-Conde M, Hernández M, Blazquez-Martin A, Vera-Mansilla C, Mendoza-Moreno F, Hernandez-Salvan J, Diez-Alonso M, Hernandez-Juara P, Barrena-Blazquez S, Minaya-Bravo AM, Galván-Pérez A, Miguel-Méndez CS, González-González E, Alvarez-Díez M, García-Ureña MA, Llorente-Moreno M, Ruiz-Lozano C, Colás-Ruiz E, Pérez-Calvo J, Gomila-Sanso JA, Alvarez-Llano L, Serrano-Fuentes SC, Soto-Montesinos C, Dedeu-Bastardas , Perez-Reche , Labró-Ciurans M, Pardo-López S, Pérez EG, Fernández IO, Canals LO, Espino PC, Ruano PG, Ricardo , Ros EP, Manuel EM, Buleje JAB, Prats MMC, Baños PAP, González PM, Celdrán RG, Pellicer-Franco EM, Valero-Navarro G, Vicente-Villena JP, Martínez-Mercader MM, Baeza-Murcia M, Mengual-Ballester M, Soria-Aledo , Fernández-Martínez D, Varela-Rodríguez L, Garcia-Flórez LJ, Fernández-Hevia M, González-Diaz MJ, Fernández-Arias S, Puertas CP, Carvajal EDP, Cebolla ES, Brainsa E, Bayo JMM, Castro MC, Blanco RR, Gutierrez E, Pinto FL, Alegre JM, Flores N, O'Sullivan SN, Fernández BF, Alonso JE, Conde JGA, Ropero NM, Bayón RA, Dominguez SH, Ramirez S, de Pablos AM, Perez-Sanchez A, Cano-Matias A, Del-Rio-Lafuente FJ, Caballero-Delgado J, Valdes-Hernandez J, Gomez-Rosado JC, Martínez C, Cholewa H, Sancho-Muriel J, Alberola MJ, Navasquillo M, Primo , Moreno , Espí-Macías A, Moro-Valdezate D, Carrascosa-Morales , Martín-Arévalo J, Soro-Domingo M, García-Botello S, Pla-Marti , Abellán AM, Pérez CM, Cortés GFV, Blasco LF, Chornet MR, Martín RS, Romero-De Diego A, Vázquez-Fernández A, Pascual A, De Andrés-Asenjo B, de Heredia JB, Ruiz-Soriano M, Rodríguez-Jiménez R, Iribarren EM, Rodríguez EVF, García MDCC, García-Señoráns MP, Rodríguez PF, Santos RS, Currás RP, Vigorita V, Roche CG, Delgado E, Lafuente F, Gascon , Mallen MVD, Saudi S, Fraj , Gómez ME, Santos EG, Mena EA, Mantecón J, García SS, Fernández-Camuñas A, Wickramasinghe D, de Zoysa , Samarasekera N, Wickramarathne R, Dassanayake , Balathayalan Y, de Silva D, Perera M, Pulleperuma S, Jayasekara S, Wijenayake W, Gunetilleke B, Abeysinghe N, Chandrasinghe P, Kumarage S, Abdalradiy AG, Widatalla ABH, Ahmed AY, Mohamed HA, Hamid HKS, Ali MH, Eldin SJ, Agger E, Jutesten H, Lindgren J, Lepsenyi M, Azhar N, Buchwald P, Hansdotter P, Ekepil A, Brandström G, Smedberg J, Schiffer E, Ris F, Longchamp G, Meyer J, Dupret L, Buchs N, Galetti K, Regusci L, Grischott M, Malugani M, Mouhandes AEF, Danial AK, Khayat M, Sbahi MHE, Marawy MK, Abdullah MA, Douba Z, Mansour A, Niazi A, Hamza A, Mohamad AH, Awead M, Mohammad S, Salloum S, Al Jabar A, Zazo A, Shebli B, Ayoub K, Younes L, Bannoud MH, Zazo R, Saad A, Hamdan A, Wakkaf H, Adra L, Souliman M, Anton M, Hannouf S, Wang JY, Li KL, Cheng K, Ji SJ, Hsieh YC, Parlak EA, Demir M, Kara U, Peker YS, Yigit D, Unal N, Iflazoglu N, Yalkin Ö, Topal S, Gulcu B, Ozturk E, Gümbelek G, Terkanloglu S, Koklucan A, Ince G, Sen M, Isik O, Kural S, Akesen S, Yilmazlar T, Sungurtekin H, Sungurtekin U, Vural U, Ozgen U, Isik A, Onk D, Kurnaz E, Ozker TS, Ipek A, Ferlengez A, Erturk C, Tatar C, Sevik H, Akay O, Sensoy O, Hayirlioglu MB, Aktas S, Ozben , Aliyeva Z, Mutlu AU, Gökay B, Saraçoglu C, Aytaç E, Gülmez M, Isík MU, Hacim A, Akbas A, Soyhan F, Turgut MA, Demirgan S, Meric S, Altinel Y, Baris B, Akova E, Kahraman E, Kucuk HF, Saracoglu KT, Kaya S, Lel S, Gurbulak EK, Caz E, Kostek M, Mihmanli M, Yazici P, Oba S, Kirkan EF, Ulgur HS, Kalin M, Dinkci MD, Ozkan OF, Duzgun O, Ozturk S, Zengin AK, Askar A, Sanli AN, Erginöz E, Özçelik MF, Ergün S, Uludag SS, Kara D, Yilmaz G, Sarici IS, Kara Y, Incesu A, Arican C, Atici SD, Kaya T, Gezer T, Kirmizi Y, Kamer E, Aydin G, Namdaroglu O, Adakaya S, Canda AE, Ozzeybek D, Coskun N, Sokmen S, Ozkardesler S, Bisgin T, Miftari A, Caliskan C, Akgun E, Avseren G, Deniz N, Bozbiyik O, Yoldas T, Güresin A, Zayakov G, Pösteki G, Utkan NZ, Tatar OC, Güler SA, Mantoglu B, Demirel E, Akin E, Gonullu E, Altintoprak F, Palabiyik O, Bayhan Z, Ciftci AB, Colak E, Aybar E, Celik HK, Eraslan H, Yemez K, Ozbilgin SS, Senol S, Gultekin FA, Piskin O, Guler O, Karadere Y, Kakeeto A, Oguttu B, Sikakulya FK, Lule H, Rybachuk A, Shudrak A, Beznosenko A, Lisnyy , Rozhkova , Zvirych , Alawlaqi D, Jamali FE, Al Balooshi , Albers M, Al Ali N, Church R, Dudas G, Wells J, Pavlova M, Sebastiani S, Paterson C, Kaushal M, Patel P, Panchal S, Handa S, Tezas S, Zaidi SN, Raj G, Wright J, Hallam S, Karandikar S, Gates Z, Marshall A, Thompson A, Tennakoon A, Rao M, Callan R, Tufail S, Rajendran G, Polisetty K, Husain N, Clarke N, Naranayanasamy S, Hallett A, Lorejo E, Ward N, Antakia R, Xanthis A, Simillis C, Tweedle E, Panagiotopoulou , Grimes L, Mounstephen L, Bocancia R, Carden C, Lynch J, Noveros MS, Shaalan R, Khalil T, Marshall W, Hodge K, Balfour J, Mcintosh K, Buijs L, Potter MA, Yule M, Vaughan-Shaw PG, Smith S, Anderson T, Mcdermott FD, Daniels IR, Tapp J, Smart N, Rajaretnam N, Bethune R, Clark T, Delimpalta C, Liao C, Banham G, Induruwage L, Velchuru V, Lawrence A, Rahman A, Bennett J, Badawi M, Harshen R, Bhargava A, Gorrela K, Jumah M, Venn M, Hanson M, Arya S, Atendido T, Shrestha A, Cook E, Rakhimov , Collins J, Alamin N, Vigneswaran N, Basnyat P, Shamardal A, Chacko A, Wanshantha D, Bisheet G, Ebdewi H, Abdellatif M, Adu-Poku P, Tore A, Adams F, Allen K, Ahmed K, Kulkarni N, Chitnis A, Patel H, Magsino J, Sarodaya , Minicozzi A, Dempsy C, Ahmed H, Jayasinghe JD, Okail MH, Thaha M, Hallworth S, Parmar C, Chua L, Pizanias M, Samin R, Young T, Sagar J, Yorkmui L, Cirocchi N, Ahmed S, Barreda SC, Kudchadkar S, Baker A, Jayasankar B, Balasubramaniam D, Jackson J, Abdelsaid K, Hassan M, Shetty S, Coldwell C, Davies E, Nader H, Raistrick M, Ryska O, Hawkin P, Raymond T, Witjes C, Van de Steen K, Crabtree N, Boyce S, Somera W, Woodward A, Ryan K, Kassai M, Aleem M, Keogh-Bootland S, Ghosh A, Rixson D, Lewis E, Lynch N, Shovelton C, Zywicka E, Guest F, Barton J, Purnell R, Bamford R, Teare T, Adams B, Chmielewski G, Smith , Smith L, Connolly L, Niblett R, Singh A, Halliwell G, Paraoan M, Doree N, Asaad P, Kilbride C, Carpenter H, Wilson J, Fletcher J, Vijayagopal KA, Abbakar M, Zaimis T, Walsh A, Kubisz-Pudelko AA, Nono J, Pippard L, Chowdhary M, Dalton R,

Moussa T, Dominguez F, Solla G, Curbelo J, Laurini M, Viola M, Brito N, Al-Alnsi A, Al-Naggar H, Saryah L, Al-Shehari M, Alsayadi R, Al-Hutheifi R, Shream S. Evaluation of a quality improvement intervention to reduce anastomotic leak following right colectomy (EAGLE): pragmatic, batched stepped-wedge, cluster-randomized trial in 64 countries. Brit J Surg. 2024; 111(1): znad370. Article. IF: 8.7; D1

- **Montero-Macías R, Segura-Sampedro JJ, Rigolet P, Lecuru F, Craus-Miguel A, Castillo-Tuñón JM.** The Role of Systematic Lymphadenectomy in Low-Grade Serous Ovarian Cancer: A Systematic Review and Meta-Analysis. Cancers (Basel). 2024; 16(5): 955. Review. IF: 4.4; Q2
- **Moreno VP, Caballero-Bermejo AF, Caselles MA, González JS, Arriaga XR, Alcolea NG, Azcona AE, García EI, de la Poza JLL, Movilla AS, Ruiz-Antorán B.** Efficacy of amoxicillin/clavulanic acid after surgical drainage of perianal abscess in the prevention of the development of anal fistula (PERIQxA study): study protocol for a multicenter randomized, double-blind clinical trial. Trials. 2024; 25(1): 122. Article. IF: 2.0; Q3
- **Ocanto A, Teja M, Amorelli F, Couñago F, Palacios AG, Alcaraz D, Cantero R.** Landscape of Biomarkers and Pathologic Response in Rectal Cancer: Where We Stand? Cancers (Basel). 2024; 16(23): 4047. Review. IF: 4.4; Q2
- **Padillo-Ruiz J, Fresno C, Suárez G, Blanco G, Muñoz-Bellvis L, Justo I, García-Domingo M, Ausania F, Muñoz-Forner E, Serrablo A, Martin E, Díez L, Cepeda C, Marin L, Alamo J, Bernal C, Pereira S, Calero F, Tinoco J, Paterna S, Cugat E, Fondevila C, Diego-Alonso E, López-Guerra D, Gomez M, Denninghoff V, Sabater L.** Effects of the superior mesenteric artery approach versus the no-touch approach during pancreatoduodenectomy on the mobilization of circulating tumour cells and clusters in pancreatic cancer (CETUPANC): randomized clinical trial. BJS Open. 2024; 8(6): zrae123. Article. IF: 4.5; D1
- **Padillo-Ruiz J, García C, Suárez G, Blanco G, Muñoz-Bellvis L, Justo I, García-Domingo MI, Ausania F, Muñoz-Forner E, Serrablo A, Martin E, Díez L, Cepeda C, Marin L, Alamo J, Bernal C, Pereira S, Calero F, Laga I, Paterna S, Cugat E, Fondevila C, López-Guerra D, Gallego-Jiménez I, Borrero-Martín JJ, Gomez-Bravo MA, Tinoco J, Sabater L.** Intraoperative liquid biopsy as a tool for detecting R1 resection during pancreatoduodenectomy in patients with pancreatic carcinoma: the CETUPANC trial (part II). Int J Surg. 2024; 110(12): 7798-805. Article. IF: 10.1; D1
- **Pastor-Morate D, Amigo-Morán L, Garranzo-Asensio M, Rejas-González R, Carnicero P, Rodríguez N, Pérez-Robledo JP, Barderas R, Prieto-Nieto I, Domínguez G.** ΔNp73 and its effector targets promote colorectal peritoneal carcinosis and predict survival. J Pathol. 2024; 263(3): 328-37. Article. IF: 5.2; D1
- **Perelló-Trias MT, Serrano-Muñoz AJ, Rodríguez-Fernández AR, Segura-Sampedro JJ, Ramis JM, Monjo M.** Intraperitoneal drug delivery systems for peritoneal carcinomatosis: Bridging the gap between research and clinical implementation. J Control Release. 2024; 373: 70-92. Review. IF: 11.5; D1
- **Podda M, Di Martino M, Pata F, Nigri G, Pisanu A, Di Saverio S, Pellino G, Ielpo B.** Global disparities in surgeons' workloads, academic engagement and rest periods: the on-calL shIft fOr geNEral SurgeonS (LIONESS) study. Updates Surg. 2024; 76(5): 1615-33. Article. IF: 2.2; Q2
- **Raffaelli M, Voloudakis N, Barczynski M, Brauckhoff K, Durante C, Gomez-Ramírez J, Koutelidakis I, Lorenz K, Makay O, Materazzi G, Pandev R, Randolph GW, Tolley N, Vriens M, Musholt T.** European Society of Endocrine Surgeons (ESES) consensus statement on advanced thyroid cancer: definitions and management. Brit J Surg. 2024; 111(8): znae199. Review. IF: 8.7; D1
- **Ramírez-Martín R, Ladrero CM, Martínez JAG, Déniz-González V, Maestre IM, Corral-Sastre L, Villajos-Guijarro M, Menéndez-Colino R, Miguelañez IP, González-Montalvo JI.** Prehabilitation in Frail Octogenarian and Nonagenarian Patients in Colorectal Cancer Surgery: Short- and Medium-Term Outcomes. J Clin Med. 2024; 13(20): 6114. Article. IF: 2.9; Q1
- **Raptis DA, Fusai GK, Kabuli HA, Matyja M.** Pancreatic surgery outcomes: multicentre prospective snapshot study in 67 countries. Brit J Surg. 2024; 111(1): znad330. Article. IF: 8.7; D1
- **Rojas-Holguín A, Fondevila-Campo C, Sanjuanbenito A, Fabregat-Prous J, Secanella-Medayo L, Rotellar-Sastre F, Pardo-Sánchez F, Prieto-Calvo M, Marín-Ortega H, Sánchez-Cabús S, Diez-Valladares L, Alonso-Casado O, González-Serrano C, Rodríguez-Sanjuan JC, García-Plaza G, Jaén-Torrejimeno I, Suárez-Muñoz MA, Becerra-Massare A, Rio PSD, Pando E, López-Andújar R, Muñoz-Forner E, Rodríguez-López M, Pereira F, Serrablo-Requejo A, Turrión VS, Garrido MJ, Burdío F, Martín-Pérez E, Estevan-Estevan R, López-Guerra D, Castell-Gómez J, Salinas-Gómez J, López-Baena JA, López-Ben S, Solar-García L, Perez-Alonso AJ, Martínez-Insfran LA, Blas JL, Cornejo M, Gutierrez-Calvo A, Pozo CDD, Ochando-Cerdan F, Muñoz-Bellvís L, Rebollar-Saenz J, Sánchez B, Jover JM, Gómez-Bravo MA, Ramia JM, Blanco-Fernández G.** Repeated pancreatic resection for pancreatic metastases from renal cell Carcinoma: A Spanish multicenter study (PANMEKID). Surg Oncol. 2024; 52: 102039. Article. IF: 2.4; Q1
- **Saleh M, Pascual F, Ghallab M, Wu AGR, Chin KM, Ratti F, Giglio MC, Garatti M, Nghia PP, Kato Y, Lim C, Herman P, Coelho FF, Schmelzle M, Pratschke J, Aghayan DL, Liu Q, Marino MV, Belli A, Chiow AKH, Sucandy I, Ivanecz A, Di Benedetto F, Choi SH, Lee JH, Park JO, Prieto M, Guzmán Y, Fondevila C, Efanov M, Rotellar F, Choi GH, Robles-Campos R, Kadam P, Sutcliffe RP, Troisi RI, Tang CN, Chong CC, D'Hondt M, Dalla Valle B, Ruzzenente A, Kingham TP, Scatton O, Liu R, Mejia A, Mishima K, Wakabayashi G, López-Ben S, Wang XY, Ferrero A, Ettorre GM, Vivarelli M, Mazzaferro V, Giuliante F, Yong CC, Yin MQ, Monden K, Geller D, Chen KH, Sugioka A, Edwin B, Cheung TT, Long TCD, Abu Hilal M, Aldrighetti L, Soubrane O, Fuks D, Han HS, Cherqui D, Goh BKP.** Factors Associated with and Impact of Open Conversion in Laparoscopic and Robotic Minor Liver Resections: An International Multicenter Study of 10,541 Patients. Ann Surg Oncol. 2024; 31(9): 5615-30. Article. Not Indexed
- **Samuel R, Knight SR, Adams R, Das P, Dorth J, Finch D, Guren MG, Hawkins MA, Moug S, Rajdev L, Sebag-Montefiore D, Renehan AG, Fish R.** International consensus to define outcomes for trials of chemoradiotherapy for anal cancer (CORMAC-2): defining the outcomes from the CORMAC core outcome set. Eclinicalmedicine. 2024; 78: 102939. Review. IF: 10.0; D1
- **Sánchez-Guillén L, Lillo-García C, Barber X, González-Mora C, Álvarez-Gallego M, Ioannidis A, Clermonts S, Frontali A, Saldaña R, Mayol J, Pellino G.** Patients' perception of using telehealth for consultation: insights after pandemic and development of an online calculator platform to predict acceptance of remote consultation: the TELEMED international study. Updates Surg. 2024; 76(5): 2031-41. Article. IF: 2.2; Q2
- **Segura-Sampedro JJ, Cascales-Campos P.** Standardizing Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer Treatment: Navigating Complexities and Charting the Path Forward. Cancers (Basel). 2024; 16(2): 400. Editorial Material. IF: 4.4; Q2
- **Shalaby M, Elsheik A, Hamed H.** Burnout among surgeons before and during the SARS-CoV-2 pandemic: an international survey. Bmc Psychol. 2024; 12(1): 48. Article. IF: 3.0; Q1
- **Tabanera JAV, Ramírez JG, Brabyn P, Barranquero AG, Vicente AP, Porrero B, Luengo P, Cebrián JMF.** Dynamics of PTH levels in the development of post-operative hypoparathyroidism. Acta Chir Belg. 2024; 124(2): 99-106. Article. IF: 0.8; Q3
- **Tong C, Jamous N, Schmitz ND, Szwarcensztein K, Battersby N, Pinkney TD, Bhangu A, Blackwell S, Buchs N, Chaudhri S, Dardanov D, Dulskas A, El-Hussuna A, Frasson M, Gallo G, Glasbey J, Keatley J, Kelly M, Knowles C, Li YE,**

McCourt , Minaya-Bravo A, Neary P, Negoi , Nepogodiev D, Pata F, Pellino G, Poskus T, SánchezGuillen L, Singh B, Sivrikoz, van Ramshorst G, Zmora O, Perry R, Morton DG, Magill EL, Ahmed SE, Abdalkoddus M, Abelevich A, Abraham S, Abraham-Nordling M, Achkasov S, Adamina M, Agalar C, Agalar F, Agarwal T, Agcaoglu O, Agresta F, Ahmad G, Ainkov A, Aiupov R, Aledo VS, Aleksic A, Aleotti F, Alias D, Allison AS, Alonso A, Alonso S, Alós R, Altinel Y, Álvarez-Gallego M, Amorim E, Anania G, Andreev PS, Andrejevic P, Andriola , Antonacci N, Antos F, Anwer M, Aonzo P, Arenal JJ, Arencibia B, Argeny S, Arnold SJ, Arolfo S, Artioukh DY, Ashraf MA, Aslam M, Asteria CR, Atif M, Avital S, Bacchion M, Bach SM, Balestri R, Balfour A, Balik E, Baloyiannis , Banipal GS, Baral JEM, Barisic B, Bartella , Barugola G, Bass GA, Bedford MR, Bedzhanyan A, Belli A, de Heredia JB, Bemelman WA, Bencurik , Benevento A, Bergkvist DJ, Bernal-Sprekelsen JC, Besznyák , Bettencourt , Beveridge AJ, Bhan C, Bilali S, Bilali , Binboga E, Bintintan , Birindelli A, Birsan T, Blanco-Antona F, Blom RLGM, Boerma EG, Bogdan M, Boland MZ, Bondeven P, Bondurri A, Broadhurst J, Brown SA, Buccianti P, Buchs NC, Buchwald P, Bugra D, Bursics A, Burton HLE, Buskens CJ, Recuenco CB, Fernandez CC, Calero-Lillo A, Calu , Camps , Canda AE, Canning L, Cantafio S, Carpelan A, López MJC, Carvas JM, Carvello M, Castellvi J, Castillo J, Castillo-Diego J, Cavenaile , Paniagua LC, Ceccotti AA, Cervera-Aldama J, Chabok A, Chandrasinghe PC, Chandratreya N, Chaudhri SS, Chaudhry ZU, Chirletti P, Ngu JCY, Chouliaras C, Chowdhary M, Chowdri NA, Christiano AB, Christiansen P, Citores MA, Ciubotaru C, Ciuce C, Clemente N, Clerc D, Codina-Cazador A, Colak E, García LC, Coletta D, Colombo F, Connelly TM, Cornaglia S, Real JC, Pereira JC, Costa S, Cotte E, Courtney ED, Coveney AP, Crapa P, Cristian DA, Cuadrado M, Cuinas K, Cuk M, Cuk VV, Cunha MF, Curinga R, Curtis N, Dainius, Dalton RSJ, Daniels IR, D'Alessandro A, Dauser B, Davydova O, De Andres-Asenjo, De Graaf EJR, De la Portilla F, de Lacy F, De Laspra ECD, Defoort B, Dehli T, Del Prete L, Delrio P, Demirbas S, Demirkiran A, Den Boer FC, Di Saverio S, Diego A, Dieguez B, Diez-Alonso M, Dimitrijevic , Dimitrios B, Dimitriou N, Dindelegan G, Dindyal S, Domingos H, Doornebosch PG, Dorot S, Draga M, Drami , Zakaria AD, Echazarreta-Gallego E, Edden Y, Egenvall M, Eismontas , El Nakeeb A, El Sorogy M, Elfike H, Elgeidie A, Guedea ME, Ellul S, El-Masry S, Elmore U, Emile SH, Enciu O, Enriquez-Navascues JM, Epstein JC, Ripoll DE, Espina B, Espin-Basany E, Diz AME, Evans MD, Farina PA, Fatayer, Feliu F, Feo C, Feo C, Fernando J, Feroci F, Ferreira L, Feryn T, Flor-Lorente B, Forero-Torres A, Francis N, Freund MR, Borges MF, Frontali A, Gallardo AB, Galleano R, García D, Flórez LJG, Marín JAG, Septiem JG, García-Cabrera AM, García-González JM, García-Granero E, Garipov M, Gefen R, Gennadiy P, Gerkis S, Germain A, Germanos S, Gianotti L, Santos MG, Gingert C, Glehen O, Golda T, Ruiz MG, Gonçalves D, González, Grainger J, Grama F, Grant C, Griniatsos J, Grolich T, Grosek J, Guevara-Martínez J, Gulcu B, Gupta, Gurjar S, Haapaniemi S, Hamad Y, Hamid M, Hardt J, Harries RL, Harris GJC, Harsanyi L, Hayes J, Hendriks ER, Herbst F, Hermann N, Heuberger A, Hompes R, Hrora A, Hübner M, Huhtinen H, Hunt L, Hyöty M, Ibañez N, Ignjatovic D, Ilkanich A, Inama M, Infantino MS, Iqbal MR, Isik A, Isik O, Ismaiel M, Ivanovich SO, Jadhav , Jajtner D, Carneros VJ, Jimenez-Rodríguez RM, Jotautas , Jukka K, Juloski J, Jung B, Kara Y, Karabacak U, Karachun A, Karagul S, Kassai M, Sergei EK, Katsaounis D, Katsoulis IE, Kelly ME, Kenjic B, Keogh-Bootland S, Khasan D, Khazov A, Kho SH, Khrykov GN, Kivelä AJ, Kjaer MD, Knight JS, Kocián P, Koëter T, Konsten JLM, Korcek J, Korkolis D, Korsgen S, Kostic IS, Krarup PM, Krastev P, Krdzic , Moreno EK, Krivokapic Z, Krones CJ, Krsul D, Kaul NK, La Torre F, Lahodzich N, Lai CW, Laina JLB, Lakkis Z, Lamas S, Lange CP, Lauretta A, Lee KA, Lefèvre J, Lehtonen T, Leo CA, Leong KJ, Lepistö A, Licari L, Lizdenis P, Loftås P, Longhi M, López-Dominguez J, LópezFernández J, Lovén H, Trujillo RL, Lunin R, Luzzi AP, Lydrup ML, Lykke J, Maderuelo-García VM, Madsboell T, Madsen AH, Maffioli A, Majbar MA, Makhmudov A, Makhmudov D, Malik K, Malik SS, Mamedli ZZ, Manatakis DK, Mankotia R, Maria J, Mariani NM, Marimuthu K, Marinello F, Marino F, Marom G, Maroni N, Maroulis , Marsanic P, Marsman HA, Martí-Gallostra M, Martin ST, Alegre JM, Manzano AM, Martins R, Maslyankov S, McArdle K, McArthur DR, McFaul C, McWhirter D, Mege D, Mehraj A, Metwally MZ, Metwally IH, Millan M, Miller AS, Mingoli A, Ruiz GM, Minusa C, Mirshekar-Syahkal B, Mistrangelo M, Mogoanta SS, Mohamed , Möller PH, Möller T, Molteni M, Mompart S, Monami B, Mondragon-Pritchard M, Pedro MP, Cabrera DM, Morais M, Moran BJ, Moretto G, Morino M, Moscovici A, Muench S, Mukhtar H, Muller P, Muñoz-Duyos A, Muratore A, Muriel P, Myrelid P, Nachtergaele M, Nadav H, Nastos K, Navarro-Sánchez A, Nesbakken A, Nestler G, Nicholls J, Nicol D, Nikberg M, Nobre JMS, Nonner J, Norcic G, Norderval S, Norwood MGA, Nygren J, O'Brien JW, O'Connell PR, O'Kelly J, Okkabaz N, Oliveira-Cunha M, Omar GEE, Onody P, Opocher E, Orhalmi J, Orts-Micó FJ, Ozbalci GS, Ozgen U, Ozkan BB, Ozturk E, Pace K, Padín MH, Pandey SB, Pando JA, Papaconstantinou , Papadopoulos A, Papadopoulos G, Papp G, Paraskakis S, Parc Y, Baños PP, Parray FQ, Parvuletu R, Pascariello A, Migueláñez IP, Patel H, Patel PK, Paterson HM, Uriburu JCP, Pattacini GC, Pavlov , Pcolkins A, Pellicer-Franco EM, Ros EP, Pérez HD, Petkov P, Picarella P, Pikarsky AJ, Ceretti AP, Platt E, Pletinckx P, Podda M, Popov D, Poskus E, Prats MC, Pravosudov , Primo-Romaguera , Prochazka , Ribas IP, Proud D, Psaila J, Pullig F, Jinnah MSQ, Montero JR, Radovanovic D, Radovanovic Z, Rahman MM, Rainho R, Rama N, Ramos D, Ramsanahie A, Rantala A, Rasulov A, Rautio T, Raymond T, Raza A, Reddy A, Refky B, Regusci L, Reissman P, Rems M, Reyes-Diaz ML, Riccardo R, Richiteanu G, Richter F, Rios A, Ris F, Rodríguez FL, García PR, López JAR, Romániszyn M, Románo GM, Romero AS, Romero-Simó M, Lal AR, Rossi B, Poblador AR, Rubbini M, Rubio-Perez , Ruiz H, Rullier E, Ryska O, Sabia D, Sacchi M, Saffaf N, Sakr A, Saladzinskas Z, Sales , Salomon M, Salvans S, Samalavicius NE, Sammarco G, Sampietro GM, Samsonov D, Sánchez-García JL, Sánchez-Guillén L, Sanchiz E, Santak G, Torres JS, Saraceno F, Sarici IS, Sarmah PB, Savino G, Scabini S, Schafmayer C, Schiltz B, Schofield A, Scurtu R, Segalini E, Segelman J, Sampedro JJS, Seicean R, Sekulic A, Selwyn D, Paz PS, Shabbir J, Shaikh IA, Shalaby M, Sharma A, Shukla A, Shussman N, Siddiqui ZA, Siironen P, Sileri P, Silva-Vaz P, Simoes JF, Sinan H, Sivins A, Skroubis G, Skrovina M, Skull AJ, Slavchev M, Slavin M, Slesser AAP, Smart CJ, Smart NJ, Smedh K, Smolarek S, Sokolov M, Sotona O, Spacca D, Spinelli A, Stanojevic G, Stearns A, Stefan S, Stift A, Stijns J, Stoyanov , Straarup D, Strouhal R, Stubbs BM, Rodríguez CS, Sungurtekin U, Svagzdys S, Svastics , Syk , Tabares MJM, Tamelis A, Tamhane RG, Tamini N, Tamosiunas A, Tan SA, Tanis PJ, Tate SJ, Junior VT, Terzi C, Testa , Thaha MA, Tham JC, Thavanesan N, Theodore JE, Tinoco C, Todorovic M, Tomazic A, Tomulescu , Tonini , Toorenvliet BR, Torkington J, Torrance A, Toscano MJ, Tóth , Trampus S, Travaglio E, Trostchanky , Truan N, Tulchinsky H, Turrado-Rodríguez , Tutino R, Tzivanakis A, Tzovaras GA, Unger LW, Vaccari S, Vaizey CJ, Valero-Navarro G, Nuñez IV, Van Belle K, Van Belle K, van den Berg , van Geloven AA, Van Loon Y, van Steensel L, Varcada M, Vardanyan AV, Varpe P, Velchuru VR, Vencius J,



Venskutonis D, Vermaas M, Vertruyen M, Vicente-Ruiz M, Vignali A, Vigorita V, Tura MV, Vimalachandran D, Vincenti L, Viso L, Visschers RGJ, Voronin YS, Walega P, Zainira WZW, Wang JH, Wang X, Wani R, Warusavitarne J, Warwick A, Wasserberg N, Weiss DJ, Westerduin E, Wheat JR, White , Williams G, Williams GL, Wilson TR, Wilson JM, Winter D, Wolthuis AM, Wong MPK, Worsoe J, Xynos E, Yahia S, Yamamoto T, Yanishev A, Zaidi Z, Azwan MAZ, Zaman S, Zaránd A, Zarco A, Zawadzki M, Zeromskas P, Zelic M, Zilvetti M. Anastomotic leak after manual circular stapled left-sided bowel surgery: analysis of technology-, disease-, and patient-related factors. BJS Open. 2024; 8(5): zrae089. Article. IF: 4.5; D1

- **Trincado MT, Bellido-Luque J, Gallego MA.** Robotic surgery as a driver of surgical digitalization. Cir Espan. 2024; 102: S16-22. Article. IF: 1.3; Q3
- **Trincado MT, Morales-Conde S, Bellido-Luque J, Gallego MA.** Digital surgery. Cir Espan. 2024; 102: s1-2. Editorial Material. IF: 1.3; Q3
- **Zheng JH, Liang X, Wu AGR, Kabir T, Scatton O, Lim C, Hasegawa K, Sijberden JP, Aghayan DL, Siow TF, Dokmak S, Herman P, Marino MV, Mazzaferro V, Chiow AKH, Sucandy I, Ivanecz A, Choi SH, Lee JH, Prieto M, Vivarelli M, Giuliante F, Ruzzenente A, Yong CC, Yin MQ, Chen ZW, Fondevila C, Efanov M, Morise Z, Di Benedetto F, Brustia R, Dalla Valle R, Boggi U, Geller D, Belli A, Memeo R, Gruttadauria S, Mejia A, Park JO, Rotellar F, Choi GH, Robles-Campos R, Wang XY, Sutcliffe RP, Pratschke J, Lai ECH, Chong CCN, D'Hondt M, Monden K, López-Ben S, Kingham TP, Ferrero A, Ettorre GM, Cherqui D, Cipriani F, Soubrane O, Zhang WG, Wakabayashi G, Troisi RI, Cheung TT, Kato Y, Sugioka A, Long TCD, Liu R, Edwin B, Fuks D, Abu Hilal M, Chen KH, Aldrighetti L, Han HS, Goh BKP.** Impact of liver cirrhosis, severity of cirrhosis and portal hypertension on the difficulty of laparoscopic and robotic minor liver resections for primary liver malignancies in the anterolateral segments. EJSO-Eur J Surg Onc. 2024; 50(1): 107252. Article. IF: 2.9; Q1

Research projects

- **Cantero Cid R.** Desarrollo de biomodelos de organoides en 3D in vitro de cáncer de colon. FIBHULP. 2022-Ongoing. Managment centre: FIBHULP
- **Cantero Cid R.** Generación de microtejidos de colon tridimensionales automatizada para evaluación de farmacos antitumorales. Roche Farma S.A. 2017-Ongoing. Managment centre: FIBHULP
- **Fondevila Campo C.** Estudio para la validación clínica de un nuevo biomarcador para determinar la predisposición a infecciones en pacientes sometidos a cirugía mayor abdominal programada (BIOMAS-001/ PI-5419). Crazy Science & Business S.L. 2022-2024. Managment centre: FIBHULP
- **Fondevila Campo C.** Precondicionamiento portal en injertos hepáticos pequeños mediante perfusión normotérmica ex situ en un model porcino (PI18/00894). ISCIII. 2019-2023. Managment centre: FIBHULP
- **Fondevila Campo C.** Prolonged perfusions of porcine livers on Ips device followed by transplantation. Guangdong Shunde Innovative Design Institute. 2021-Ongoing. Managment centre: FIBHULP
- **Fondevila Campo C.** Proyecto ORGALIVE. FIBHULP. 2022-Ongoing. Managment centre: FIBHULP
- **Fondevila Campo C.** Puesta en marcha del ensayo clínico: liver transplantation in patients with cirrhosis and severe acute-on-chronic liver failure (aclf): indications and outmes study. European Foundation for the Study of Chronic Liver Failure. 2021-Ongoing. Managment centre: FIBHULP
- **Hessheimer AJ.** Estudio piloto sobre la implementacion de resultados reportados por el paciente en la cirugía general mayor (PI22/00847). ISCIII. 2023-2025. Managment centre: FIBHULP
- **Rubio Pérez I.** Estudio piloto prospectivo titulado: sutura continua subcuticular versus grapas cutáneas en pacientes de cirugía colorrectal ¿existen diferencias en la incidencia de infección quirúrgica según la técnica de cierre empleada? Surgical Infection Society-Europe. 2013-Ongoing. Managment centre: FIBHULP
- **Fondevila Campo C.** Reproducción de la homeostasis y de los estímulos metabólicos durante la perfusión normotérmica prolongada en el hígado aislado (PI23/00364). ISCIII. 2024-2026. Managment centre: FIBHULP
- **Fondevila Campo C.** Reproducción de la homeostasis y de los estímulos metabólicos durante la perfusión normotérmica prolongada en el hígado aislado (SET2023 FONDEVILA). Sociedad Española de Trasplantes. 2024-2025. Managment centre: FIBHULP

Cibers and Retics

- **Fondevila Campo C.** CIBER de Enfermedades Hepáticas y Digestivas (CIBERehd)(31/12/2025). ISCIII. FIBHULP

Patents and trademarks

- **Álvarez Gallego M, Castejón Sisamón C, García Prada JC, Meneses Alonso J, inventors; FIBHULP, UC3M, assignees.** Rectoscope. P201630551, PCT/ES2017/070249, EP17788865.8, US20190200853; 2016 April 29.
- **Álvarez Gallego M, inventor; FIBHULP, assignee.** Device for the extraction of surgical specimens by insufflation and suction. P201031490, PCT/ES2011/002357; 2010 October 07.
- **Salinas Gómez J, García Sanz M; inventors; FIBHULP and DISTRIBUCIONES CLINICAS S.**A. (DICLISA), assignees. Two-way probe for flushing and/or draining. U202100070; 2021 February 19.

3.6.8 Anesthesia-Resuscitation Maternity



COMPOSITION

Isabel Valbuena Gómez.
Facultativo Especialista de Área de Anestesia y Reanimación Maternidad. Hospital Universitario La Paz

- **Carla Rebeca García García .** *Facultativo Especialista de Área de Anestesia y Reanimación en Maternidad. Hospital Universitario La Paz*

STRATEGIC OBJETIVES

- To increase our visibility as a research group, increasing the number and quality of projects. To enhance close collaboration with the European Society of Anaesthesia and Intensive Care (ESAIC) and the World Federation of Societies of Anaesthesiologists (WFSA), having also collaborative projects at national level working together within the framework of the Spanish Society of Anaesthesia and Resuscitation (SEDAR).
- To strengthen our collaboration with other research groups led by our senior colleagues, obstetricians, paediatricians, other surgeons and research groups of nurses and midwives. Encourage young researchers to initiate PhD projects in an established research area.

RESEARCH LINES

- Anaesthetic Strategies for Managing Placenta Accreta Spectrum with REBOA. An international collaborative project
- Evaluation of Point of care devices in severe Postpartum Haemorrhage
- Cesarean section practice in Europe. ACCESS project
- Labour analgesia initiation with epidural, DPE or CSE
- Labour epidural analgesia maintenance with low vs ultra-low solutions. Any difference in outcomes and satisfaction?
- Anesthetic and perioperative management of severe preeclamptic patients. An international (Israel and Spain) collaborative project
- Multicentre Spanish study on the prevention of maternal hypotension in caesarean sections

3.6.9 Advanced Medical Informatics Laboratory (LIMA)*

COMPOSITION

Fernando Martín Sanchez.
Deputy Managing Director. La Paz University Hospital

- **Angel Abad Revilla.** *Physician Assistant to the Management. La Paz University Hospital*
- **Lubna Dani Ben Abdellah.** *Medical Coordinator Home Hospitalization Unit. La Paz University Hospital*
- **Mariana Díaz Almirón.** *Associate Data Scientist. La Paz University Hospital*
- **Jorge Díaz-Garzón Marco.** *Specialist in Clinical Analysis. La Paz University Hospital*
- **Carlos María Elvira Martínez.** *Head of Admissions Service. La Paz University Hospital*
- **Susana Kalko Witruk.** *Senior Researcher. FIBHULP*
- **Jesus Morente Lopez.** *Nurse R&D+i Quality. La Paz University Hospital*
- **Oscar Ocampo Perez.** *Information Systems and Technology Management Technician. La Paz University Hospital*
- **Rosario María Torres Santos-Olmo.** *Specialist in Family and Community Medicine. La Paz University Hospital*
- **Rodrigo Torres García.** *Data Engineer. La Paz University Hospital*

STRATEGIC OBJETIVES

- Transforming data into useful knowledge to Improve health research, clinical decision-making, and the Quality of Life our Patients
- Advanced healthcare data processing: development of algorithms and techniques to handle large volumes of clinical and genomic data.
- Annotation and normalization: Use of standardized vocabularies to improve interoperability and data quality.
- Decision support and visualization: Intuitive tools that enable more accurate clinical decisions.
- 360° Patient Data Management: comprehensive management of genomic, phenotypic, and other risk factor data (environmental, social, and digital determinants of health).

RESEARCH LINES

- Digital Health
- Developing a patient-centered, open-source digital platform to improve accessibility to clinical trials for underserved and underrepresented populations (US/UR)
- Co-create and validate methodological approaches, tools, and solutions for the digital transformation of healthcare.
- Design specific training programs for all stakeholders and promote professionalism in this area
- Current projects
- READI - READI Landing Page (ihi-readi.org)
- Data Spaces and AI
- Provide high-quality and secure data already aggregated in the SERMAS data lake (Cloudera), as well as facilitate future ingestion and extraction that may arise.
- Through the Data Office, we aim to promote the value, knowledge, security, privacy, and excellent data quality so that we can encourage its use (secondary use).
- Create clinical data transformation pipelines, ensuring their persistence and compatibility with the most widely used international standards (OMOP, OpenEHR, i2b2, etc.)
- Current projects:




*Group recently created, december 2024

3.6.10 AI Health*

COMPOSITION

Juan José Beunza Nuin.
Principal Investigator Professor at the University of Medicine. European University of Madrid

- **Enrique Puertas Sanz.** *Assistant Professor Doctor. European University of Madrid*
- **Eva Avilés Álvarez.** *Associate Professor. European University of Madrid*
- **José Luis Lafuente Carrasco.** *Assistant Professor Doctor. European University of Madrid*
- **Samuel González López.** *Associate Professor. European University of Madrid. Specialist in Intensive Care Medicine - HLA Moncloa University Hospital*



STRATEGIC OBJETIVES

- The strategic objective of the IASalud group is practical research to implement artificial intelligence tools in clinical practice, primarily focused on intensive care for patients admitted to ICUs.

RESEARCH LINES

- Development of a smart urinometer for automated measurement of diuresis, colorimetry, and spectrometry in critically ill catheterized patients.
- Braga for reducing the pain of dysmenorrhea through TENS electrostimulation.
- Automated capillary refills for peripheral arterial function assessment.
- Thermal camera for automated analysis of body temperature and estimation of internal perfusion.
- Automated detection of respiratory failure in HIV-infected children in sub-Saharan Africa using breath sound analysis.
- Cardiovascular risk prediction using machine learning.
- Automated glucose monitoring in critically ill patients (ICU).
- Automatic monitoring of handwashing in the ICU.
- Noninvasive lactate measurement in critically ill patients.
- Early detection of pre-eclampsia in pregnant women using remote monitoring and analysis of the efficacy of aspirin as preventive therapy.
- Fingerprinting and venous pattern of hands for the identification of newborn children.

**Group recently created, december 2024*

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

3.7. Maternal Infant Child and Youth Research



Documents: 248 | **Originals:** 218 | **D1:** 32 | **Q1:** 114

Cristina Calvo Rey; Antonio Pérez Martínez
coordinadormaterno@idipaz.es

RESEARCH GROUPS

3.7.1 Neonatology
Adelina Pellicer Martínez

3.7.2 Molecular Hepatology
Paloma Jara Vega/Loreto Hierro Llanillo

3.7.3 Maternal and Fetal Medicine
José Luis Bartha Rasero

3.7.4 Pediatric Respiratory, Systemic and Neurological Infections & Host Immune Response
Cristina Calvo Rey

3.7.5 Pediatric Systemic Infections; HIV, Tuberculosis, Imported and Emergent Diseases
Talía Sainz Costa

3.7.6 Translational Research in Pediatric Oncology, Hematopoietic Transplantation and Cell Therapy
Antonio Pérez Martínez

3.7.7 Congenital Malformations and Transplantation
Francisco Hernández Oliveros

3.7.8 Research in Endometriosis
Alicia Hernández Gutiérrez

3.7.9 Research on Comprehensive Care for Transplanted Children and Adolescents
María Jesús Pascau González-Garzón/Luz Yadira Bravo Gallego

3.7.10 Food Oxidative Stress and Cardiovascular Health
Silvia M. Arribas Rodríguez

Strategic Objectives	Development forecast for the coming years:	Actions
The mission of the Maternal, Child and Adolescent Health Area (MIA) is to contribute to the improvement of the health of society by reducing the negative impact of diseases in the pediatric population from birth to adolescence, as well as the mother-child binomial. This recently created area is made up of research groups that cover the entire spectrum of ages from women, through newborns, children and young people. It includes very varied areas of research and proposes to achieve a full development of the adults of the future. To achieve this, we promote and lead cooperative research of excellence, promoting innovation, a multidisciplinary approach, and the translation of scientific results into clinical practice.	Create a stable structure to promote research that encompasses all areas of perinatal medicine, child and adolescent medicine, and women with childbearing potential. Promote collaboration between groups in the area and provide a common space and shared infrastructure and resources that allow joint progress.	Create a portfolio of shared group resources, services and projects for the MIA area that facilitates common work. Hold work meetings to propose shared studies and strategic lines.
	Promote the search for both public and private funding for cooperative research within the MIA area. Promote participation in international projects.	Facilitate the application request for European projects through the IdiPAZ Internalization Platform.
	Promote the incorporation of new technologies in research to advance personalized and precision medicine and the transfer of research results to the scientific community and society: biomedical industry, health administration, general population and any other interlocutor and disseminate the main advances produced as a result of the research.	Promote at international level the different research groups of the area, identifying possible synergies between groups and centers, new partners and funding sources, as well as to forge strategic alliances.

HIGH IMPACT PUBLICATIONS

Fernández-García MD, García-Ibañez N, Camacho J, Gutierrez A, García LS, Calvo C, Moreno-Docón A, Menasalvas AI, Medina A, Pérez-Ruiz M, Toboso MCN, Munoz-Almagro C, Launes C, Berengua C, **Cabrerizo M**. Enhanced echovirus 11 genomic surveillance in neonatal infections in Spain following a European alert reveals new recombinant forms linked to severe cases, 2019 to 2023. Euro Surveill. 2024; 29(44): 2400221. Article. IF: 7,8; D1

Rodríguez-Molino P, Tebruegge M, Noguera-Julian A, Neth O, Fidler K, Brinkmann F, Sainz T, Ivaskeviciene I, Ritz N, Brito MJ, Silva TM, Chechenieva V, Serdiuk M, Lancella L, Russo C, Soler-García A, Navarro ML, Krueger R, Feiterna-Sperling C, Starshinova A, Hiteva A, Hoffmann A, Kalibatas P, Lo Vecchio A, Scarano SM, Bustillo M, Gamero DB, Espiau M, Buonsenso D, Falcón L, Turnbull L, Colino E, Rueda S, Buxbaum C, Carazo B, Álvarez C, Dapena M, Piqueras A, Velizarova S, Ozere I, Götzinger F, Pareja M, Llanos MIG, Soto B, Martín SR, Korta JJ, Pérez-Gorricho B, Herranz M, Hernández-Bartolomé A, Díaz-Almirón M, Vasconcelos MK, Ferreras-Antolín L, Santiago-García B. Tuberculosis Disease in Immunocompromised Children and Adolescents: A Pediatric Tuberculosis Network European Trials Group Multicenter Case-control Study. Clin Infect Dis. 2024; 79(1): 215-22. Article. IF: 7,3; D1

Martínez-Sánchez N, Álvarez-Troncoso J, Robles-Marhuenda A, Fernández-Miranda MD, Hernando MLM, **Bartha JL**. Safety of biologic immunosuppressants in pregnant women with immune-mediated inflammatory diseases. J Autoimmun. 2024; 148: 103301. Article. IF: 7; Q1.

Moreno-Parro I, **Díaz-Garzon J (CA)**, Aarsand AK, Sandberg S, Aikin R, Equey T, Ríos-Blanco JJ, Soto AB, **Fernández-Calle P**. Biological Variation Data in Triathletes for Metabolism and Growth-Related Biomarkers Included in the Athlete Biological Passport. Clin Chem. 2024; 70(7): 987-96. Article. IF: 6,3; D1

Martín-Antonio B, Blanco B, González-Murillo A, Hidalgo L, **Minguillón J,** Pérez-Chacon G. Newer generations of multi-target CAR and STAb-T immunotherapeutics: NEXT CART Consortium as a cooperative effort to overcome current limitations. Front Immunol. 2024; 15: 1386856. Article. IF: 5,9; Q1

Scientific Events by Maternal Infant Child and Youth Research

- **27/02/2024.** Curso teórico-práctico con simulación en ECMO neonatal
- **06/03/2024.** Mujeres en movimiento contra el cáncer. Sesiones Formativas Dirigidas a Pacientes y Profesionales
- **06/03/2024.** II Course on Pediatric controlled DCD
- **12/03/2024.** Actuación en situación de crisis en neonatología
- **04/04/2024.** Curso de asistencia inicial al trauma pediátrico
- **22/05/2024.** 16º Taller de Simulación de Administración Menos Invasiva de Surfactante
- **12/06/2024.** Actuación en situación de crisis en neonatología
- **04/09/2024.** Curso Europeo Soporte Vital Avanzado Pediátrico y Neonatal
- **17/09/2024.** 13º Taller de simulación de administración menos invasiva del surfactante
- **23/09/2024.** Curso de microcirugía en modelos experimentales de trasplante
- **30/09/2024.** Curso Teórico-Práctico con Simulación en ECMO-Neonatal
- **04/10/2024.** Curso Europeo Soporte Vital Avanzado Pediátrico y Neonatal
- **08/10/2024.** Actuación en Situación de Crisis en Neonatología
- **24/10/2024.** Curso de Asistencia inicial al Trauma Pediátrico
- **19/11/2024.** 16º Taller de Simulación de Administración Menos Invasiva del Surfactante
- **10/12/2024.** EPALS-Curso Europeo de Soporte Vital Avanzado Pediátrico y Neonatal 8ª Edición.

3.7.1 Neonatology

Publications: 37 | **Q1:** 21

COMPOSITION

Adelina Pellicer Martínez.
Jefe de Sección de Neonatología. Hospital Universitario La Paz

- **Susana Ares Segura.** *Facultativo Especialista de Área en Neonatología. Hospital Universitario La Paz*
- **Maria Carmen Bravo Laguna.** *Facultativo Especialista de Área en Neonatología. Hospital Universitario La Paz*
- **Antonio Buño Soto.** *Jefe de Servicio de Laboratorio de Urgencias. Hospital Universitario La Paz*
- **Fernando Cabañas González.** *Jefe de Serviciode Pediatría y Neonatología. Hospital Universitario Quironsalud Pozuelo; FIBHULP*
- **Marta Cabrera Lafuente.** *Facultativo Especialista de Área en Neonatología. Hospital Universitario La Paz*
- **María Dolores Elorza Fernández.** *Jefe de Sección de Neonatología Hospital Universitario La Paz*
- **Esperanza Escribano Palomino.** *Médico Adjunto en Neonatología. Hospital Universitario La Paz*
- **Blanca Fabré Estremera.** *Facultativo Especialista en el Área de Análisis Clínicos. Hospital Universitario La Paz*
- **Paloma López Ortego.** *Médico Adjunto en Neonatología. Hospital Universitario La Paz*
- **Miriam Martínez Biarge.** *Facultativo Especialista de Área en Neonatología. Hospital Hammer Smith Londres*
- **María Teresa Montes Bueno.** *Enfermera. Hospital Universitario La Paz*
- **Isabel Moreno Parro.** *Facultativo Especialista en el Área de Análisis Clínicos. Hospital Universitario La Paz*
- **María Jesús del Olmo Barros.** *Profesora Contratada Doctora. Dptp. De Música Facultad de Educación UAM*
- **Laura Sánchez García.** *Médico Adjunto en Neonatología. Hospital Universitario La Paz*
- **Miguel Sáenz de Pipaón Marcos.** *Facultativo Especialista de Área en Neonatología. Hospital Universitario La Paz. Profesor Titular. Universidad Autónoma de Madrid*
- **Belén Sáenz-Rico de Santiago.** *Profesor Titular. Universidad Complutense de Madrid*
- **Eva Valverde Núñez.** *Facultativo Especialista de Área en Neonatología. Hospital Universitario La Paz. Profesor Asociado. Universidad Autónoma de Madrid*
- **Carlos Zozaya Nieto.** *Médico Adjunto en Neonatología. Hospital Universitario La Paz*



STRATEGIC OBJETIVES

- Prevent structural and functional damage to organs and systems in the high risk newborn.
- Reduce the impact of the processes that occurred in the peri-neonatal stage in later life.

RESEARCH LINES

- Macro- and microcirculation: non-invasive monitoring, signal processing and machine learning. Lead: María Carmen Bravo/Adelina Pellicer
- Developmental Neurobiology. Lead: Fernando Cabañas/Eva Valverde
- Nutrition, mycrobiota and Milkbank. Lead: Miguel Saenz-Pipaón/Marta Cabrera
- Perinatal and neonatal infectology. Inmunology and vaccines. Lead: Laura Sanchez Garcia
- Quality improvement. Lead: Adelina Pellicer/Paloma López-Ortego

RESEARCH ACTIVITY

Doctoral Theses

- **Zozaya Nieto C.** Necrotizing enterocolitis in preterm infants: magnitude of the problem and potential novel therapies [dissertation]. Madrid: Universidad Autónoma de Madrid: (04/07/2024). Director: Sáenz de Pipaón Marcos M

Publications

- **Albillos A, Carballo F, Crespo J.** Strategic analysis and recommendations of the Sociedad Española de Patología Digestiva (SEPD) regarding population-based screening programs for colorectal cancer in Spain. Rev Esp Enferm Dig. 2024; 116(6): 319-29. Article. IF: 4.0; Q1
- **Alferink MT, Moreno-Sanz B, Cabrera-Lafuente M, Ergenekon E, de Haan TR, van Kempen AAMW, Lakhwani J, Rabe H, Zaharie GC, Pellicer A.** RISEinFAMILY project: the integration of families at neonatal intensive care units (NICUs) to empower them as primary caregivers: study protocol for a stepped wedge cluster controlled trial. Trials. 2024; 25(1): 248. Article. IF: 2.0; Q3
- **Ayres-de-Campos D, Simon A, Modi N, Tudose M, Saliba E, Wielgos M, Reyns M, Athanasiadis A, Stenback P, Verlohren S, Nikolova G, Lopriore E, Yurtsal B, Pellicer A, Ramenghi L, Jacobsson B.** European Association Of Perinatal Medicine (EAPM) European Midwives Association (EMA) Joint position statement: Caesarean delivery rates at a country level should be in the 15-20 % range. Eur J Obstet Gyn R B. 2024; 294: 76-8. Article. IF: 1.9; Q2
- **Bravo MC, Jiménez R, Parrado-Hernández E, Fernández JJ, Pellicer A.** Predicting the effectiveness of drugs used for treating cardiovascular conditions in newborn infants. Pediatr Res. 2024; 95(4): 1124-31. Article. IF: 3.1; Q1
- **Bravo MC, Lubian S, Horsch S, Cabañas F, de Vries LS.** Neonatal ventriculomegaly: Pathophysiology and management guided with cranial ultrasonography. Dev Med Child Neurol. 2024; 66(11): 1419-31. Review. IF: 4.3; D1
- **Bueno MTM, Muñoz C, Rodríguez S, Sola A.** End-of-life care in neonatal intensive care units in Iberoamerica: A look from the nursing perspective. An Pediatr. 2024; 100(2): 97-103. Article. IF: 2.1; Q2
- **Castro AW, Zozaya C, Ruvira S, Arribas SM, López-Giménez MR, Ramiro-Cortijo D.** Online pilot intervention to improve nutritional and lifestyle in Spanish breastfeeding women. Nutr Hosp. 2024; 41(3): 619-67. Article. IF: 1.1; Q4
- **Farah M, Hickey A, Hoare S, Bravo M C.** Meconium peritonitis and pseudocyst in a preterm infant with trisomy 21. Ir Med J. 2024; 117(5): 963. Article. Not Indexed
- **Feliciano LS, Moro M, Figueras J, Tamayo TS, Zozaya C, Rodrigo FGM, Vento M.** The Spanish Neonatal Network SEN1500: updated information. Pediatr Med. 2024; 7: 10. Review. IF: 0.9; Q3
- **Fewtrell M, Baumann U, Bronsky J, Haiden N, Hill S, Kivelä L, de Koenig B, Köglmeier J, Luque V, Moltu SJ, Norsa L, Savino F, Verduci E, Lanigan J, Banci E, Mustapha M, Asseiceira I, Segerstad EMHA, Strózyk A, Schoeler N, Niseteo T, Koletzko B, da Dalt L, Karara N, De Guchtenaere A, Dembinski L, Grossman Z, Hadjipanayis A, Stordal K, de Boode WP, de Pipaon MS, Meyer R, Arasi S, Marina O, Vázquez-Fria R, Ladino-Meléndez L, Ochoa-Ortiz E, Spolidoro J, D'Agostino D, El-Guindi M, Zekri MA, Mouane N, El Awad M, Rawashdeh M, Sabir O, Koleilat A, Hidra A, Fang SB, Arai K, Treepongkaruna S, Kim KM, Goday PS, Duro D, Lightdale JR, Martin B, Morais-Almeida M, Wong GWK, Ebisawa M, Ansotegui I, Fiocchi A.** World Health Organization (WHO) guideline on the complementary feeding of infants and young children aged 6-23 months 2023: A multisociety response. J Pediatr Gastr Nutr. 2024; 79(1): 181-8. Article. IF: 2.6; Q1
- **Gallego MAM, Sánchez MGC, Olmedo MGS, Soto AB, Casasempere SA, Nozal P, Martínez-Ojinaga E, Arias MM, Losantos-García I, Molero-Luis M.** Trends in Faecal Zonulin Concentrations in Paediatric Patients with Celiac Disease at Baseline and on a Gluten-Free Diet: Exploring Correlations with Other Faecal Biomarkers. Nutrients. 2024; 16(5): 684. Article. IF: 5; Q1
- **García-Lara NR, Escuder-Vieco D, Cabrera-Lafuente M, Keller K, De Diego-Poncela C, Jiménez-González C, Núñez-Ramos R, Flores-Antón B, Escribano-Palomino E, Alonso-Díaz C, Vázquez-Román S, Ureta-Velasco N, Cruz-Bértolo JD, Pallás-Alonso CR.** Clinical Impact of Supplementation with Pasteurized Donor Human Milk by High-Temperature Short-Time Method versus Holder Method in Extremely Low Birth Weight Infants: A Multicentre Randomized Controlled Trial. Nutrients. 2024; 16(7): 1090. Article. IF: 5; Q1
- **Ghanem M, Zozaya C, Ibrahim J, Lee S, Mohsen N, Nasef N, Mohamed A.** Correlation between early postnatal body weight changes and lung ultrasound scores as predictors of bronchopulmonary dysplasia in preterm infants: A secondary analysis of a prospective study. Eur J Pediatr. 2024; 183(5): 2141-53. Article. IF: 2.6; Q1
- **Haiden N, Savino F, Hill S, Kivelae L, De Koning B, Köglmeier J, Luque V, Moltu SJ, Norsa L, De Pipaon MS, Verduci E, Bronsky J.** Infant formulas for the treatment of functional gastrointestinal disorders: A position paper of the ESPGHAN Nutrition Committee. J Pediatr Gastr Nutr. 2024; 79(1): 168-80. Article. IF: 2.6; Q1
- **Hellström A, Kermorvant-Duchemin E, Johnson M, de Pipaón MS, Smith LE, Hård AL.** Nutritional interventions to prevent retinopathy of prematurity. Pediatr Res. 2024; 96(4): 905-11. Review. IF: 3.1; Q1
- **Horsch S, Schwarz S, Arnaez J, Steggerda S, Arena R, Govaert P.** Cerebral Doppler imaging in neonates: A guide for clinical application and diagnosis. Dev Med Child Neurol. 2024; 66(12): 1570-89. Review. IF: 4.3; D1
- **Jánez-Álvarez M, Moreno-Llanos I, Santacatalina-Pulido C, De León-Barrios YJ, García-Laredo E, Del Olmo-Barros MJ, Rodríguez-Garrido C.** Analysis of triadic interaction between parents, their preterm infants, and a sonorous object. Psychol Music. 2024; 52(6): 628-48. Article. IF: 1.6; Q3
- **Jara J, Alba C, Del Campo R, Fernández L, de Pipaón MS, Rodríguez JM, Orgaz B.** Linking preterm infant gut microbiota to nasograstric enteral feeding tubes: exploring potential interactions and microbial strain transmission. Front Pediatr. 2024; 12: 1397398. Article. IF: 2.0; Q2
- **Kooi EMW, Mintzer JP, Rhee CJ, Ergenekon E, Schwarz CE, Pichler G, de Boode WP.** Neonatal somatic oxygenation and perfusion assessment using near-infrared spectroscopy Part of the series on near-infrared spectroscopy by the European Society of Paediatric Research Special Interest Group Near-Infrared Spectroscopy. Pediatr Res. 2024; 96(5): 1180-94. Review. IF: 3.1; Q1
- **León-González R, Ortolá R, Carballo-Casla A, Sotos-Prieto M, Buño-Soto A, Rodríguez-Sánchez I, Pastor-Barriuso R, Rodríguez-Artalejo F, García-Esquinas E.** Growth Differentiation Factor 15 as a Biomarker of Cardiovascular Risk in Chronic Musculoskeletal Pain. J Gerontol A-Biol. 2024; 79(8): glae163. Article. IF: 3.8; Q1
- **Macchiaverni P, Lloyd M, Masters L, Divakara N, Panta K, Imrie A, Sánchez-García L, Pellicer A, Rodríguez JM, Verhasselt V.** Specific IgA, But Not IgG, in Human Milk From COVID-19-Infected Mothers Neutralizes SARS-CoV-2. Pediatr Infect Dis J. 2024; 43(6): 532-5. Article. IF: 2.2; Q2
- **Maroto-García J, Moreno-Álvarez A, Sanz**



de Pedro MP, Buño-Soto A, González A. Biomarcadores sericos para la evaluacion de la fibrosis hepatica. Adv Lab Med. 2024; 5(2): 131-47-. Article. IF: 0.9; Q4

- **Martínez-Campelo L, Blanco-Verea A, López-Fernández T, Martínez-Monzonis A, Buño A, Mazón P, Zamora P, Norton N, Reddy JS, Velasco-Ruiz A, González-Neira A, Vulsteke C, Alonso-Gordoa T, Cruz R, Diz-de Almeida S, Carracedo A, González-Juanatey J, López-Sendón J, Brion M.** Meta-analysis of genome-wide association studies for cancer therapy-related cardiovascular dysfunction and functional mapping highlight an intergenic region close to TP63. Sci Rep-Uk. 2024; 14(1): 18413. Article. IF: 3.9; Q1
- **Moreno-Parro I, Díaz-Garzón J, Aarsand AK, Sandberg S, Aikin R, Equey T, Ríos-Blanco JJ, Soto AB, Fernández-Calle P.** Biological Variation Data in Triathletes for Metabolism and Growth-Related Biomarkers Included in the Athlete Biological Passport. Clin Chem. 2024; 70(7): 987-96. Article. IF: 6.3; D1
- **Moreno-Sanz B, Lázaro-Perona F, Escribano E, Lafuente MC, Montes MT, Amoros R, Arboleya S, Gueimonde M, Mingorance J, de Pipaon MS.** Assessment trial of the effect of enteral insulin on the preterm infant intestinal microbiota. Pediatr Res. 2024; 95(4): 1117-23. Article. IF: 3.1; Q1
- **Plomgaard AM, Stevenson N, Roberts JA, Petersen TH, Vanhatalo S, Greisen G.** Early EEG-burst sharpness and 2-year disability in extremely preterm infants. Pediatr Res. 2024; 95(1): 193-9. Article. IF: 3.1; Q1
- **Rasmussen MIS, Hansen ML, Peters C, Greisen G.** Web-based training and certification of clinical staff during the randomised clinical trial SafeBoosC-III. Trials. 2024; 25(1): 711. Article. IF: 2.0; Q3
- **Rivero-Santana B, Saldaña-García J, Caro-Codón J, Zamora P, Moliner P, Monzonis AM, Zatarain E, Álvarez-Ortega C, Gómez-Prieto P, Pernas S, Rodríguez I, Soto AB, Cadenas R, Ozores PP, Ramírez SP, Salvador MM, Valbuena S, Gasso LF, Juárez V, Severo A, Terol B, Álvarez TD, Rodríguez O, Brion M, González-Costello J, Albendea MC, González-Juanatey JR, Moreno R, López-Sendón J, López-Fernández T.** Anthracycline-induced cardiovascular toxicity: validation of the Heart Failure Association and International Cardio-Oncology Society risk score. Eur Heart J. 2024; 46(3): 273-84. Article. IF: 35.6; D1
- **Rodríguez-Molino P, Alarcón A, Martínez-Biarge M, Cabrera-Lafuente M, Aldecoa V, Fernández-Sánchez A, Fernández-Jiménez E, Baquero-Artigao F, García-Alix A.** Behavioral Problems and Family Impact in Congenital Cytomegalovirus Infection. Pediatr Infect Dis J. 2024; 43(6): 556-8. Article. IF: 2.2; Q2
- **Rostami N, Fabre-Estremera B, Buño-Soto A, Banegas JR, Rodríguez-Artalejo F, Ortolá R.** Growth differentiation factor 15 and malnutrition in older adults. J Nutr Health Aging. 2024; 28(6): 100230. Article. IF: 4.0; Q2
- **Sánchez-Holgado M, Bravo MC, Álvarez-García P, López-Ortego P, Camargo SC, Pellicer A.** Severe pulmonary hypertension and circulatory failure associated with Congenital syphilis. Case report. J Neonatal Perinatal Med. 2024; 17(2): 255-260. Article. IF: 0.9; Q3
- **Sánchez-Holgado M, de Pipaón MS, Jimenez MC, Sánchez GC, Molero-Luis M, Montes MT, Segovia C, Losantos-García I, Jimenez-Gonzalez M, Escribano E, Cabrera-Lafuente M.** Adjusted versus Targeted Fortification in Extremely Low Birth Weight Preterm Infants: Fortin Study-A Randomized Clinical Trial. Nutrients. 2024; 16(17): 2904. Article. IF: 5; Q1
- **Senterre T, van den Akker CHP, Domellof M, de Pipaon MS, Arnell H, Tabbers M, Valla FV, Tomlin S, Paulsson M, Wackernagel D, Haiden N, Luukkainen P, Orfeo L, Carnielli VP, Rigo J.** Safe and ef fi cient practice of parenteral nutrition in neonates and children aged 0-18 years- The role of licensed multi-chamber bags. Clin Nutr. 2024; 43(7): 1696-705. Review. IF: 7.4; D1
- **Terroba-Seara S, Oulego-Erroz I, Palanca-Arias D, Galve-Pradel Z, Delgado-Nicolás S, Pérez-Psérez A, Rodríguez-Ozcoidi J, Lavilla-Oiz A, Bravo MC, La Banda-Montalvo L, Mendez-Abad P, Zafra-Rodríguez P, Rodeno-Fernández L, Montero-Gato J, Bustamante-Hervas C, Vega-Del-Val C, Rodríguez-Fanjul J, Mayordomo-Colunga J, Alegría-Echauri I, Pérez-Álvarez A.** Association between early echocardiography screening of low systemic blood flow and intraventricular hemorrhage in preterm infants: a multicenter cohort study. J Perinatol. 2024; 44(10): 1496-503. Article. IF: 2.4; Q1
- **Tintu AN, Soto AB, Van Hoof V, Bench S, Malpass A, Schilling UM, Rooney K, Sáez PO, Relker L, Luppa P.** The influence of undetected

hemolysis on POCT potassium results in the emergency department. Clin Chem Lab Med. 2024; 62(11): 2169-76. Article. IF: 3.7; Q1

- **Valero-Pérez M, Marcos MSD, Martínez MM, García MEG, Calso M, Gallo D, Merino I, Morais AA, Cabrero DS, Castellanos LA, Milla SP.** Dietitian-nutritionist incorporation in a university hospital: position statement of the Commission on Nutrition, Hospital Universitario La Paz. Nutr Hosp. 2024; 41(1): 244-8. Article. IF: 1.1; Q4
- **Vestager ML, Hansen ML, Greisen G.** Alternative consent methods used in the multinational, pragmatic, randomised clinical trial SafeBoosC-III. Trials. 2024; 25(1): 236. Article. IF: 2.0; Q3

Research projects

- **Bravo Laguna MC, Pellicer Martínez A.** Predicción de la eficacia de los fármacos cardiovasculares en recién nacidos (PI22/00567). ISCIII. 2023-2025. Managment centre: FIBHULP
- **Bravo Laguna MC.** Valoración cuantitativa de la repercusión hemodinámica del ductus arterioso persistente y su tratamiento en el recién nacido de bajo peso. Neonatcare S. L. 2008-Ongoing. Managment centre: FIBHULP
- **Buño Soto A.** Actualización y renovación de la actividad investigadora en el servicio de análisis clínicos del Hospital Universitario La Paz. Various Funders. 2012-Ongoing. Managment centre: FIBHULP
- **Buño Soto A.** Covid-19 severity score predictive model-technological feasibiity, clinical acceptance, and potential impact upon patien management. Siemens Heatlhcare S.L. 2021-Ongoing. Managment centre: FIBHULP
- **Buño Soto A.** Determinación de la variación biologica de magnitudes hematologicas y bioquimicas y de la metabolomica en deportistas de alto rendimiento. Int`L Marketing de Snibe Co. Ltd, Shenzhen New Industries Biomedical Engineering Co. 2022-Ongoing. Managment centre: FIBHULP
- **Buño Soto A.** Estudio en población cognitivamente sana (sin demencia) para la determinacion de valores de referencia de una nueva técnica diagnóstica basada en espectroscopia Raman. Raman Health Technologies S. L. 2016-Ongoing. Managment centre: FIBHULP
- **Buño Soto A.** Recogida de muestras en deportistas de alto rendimiento para la evaluación de su variación biológica. Fundación para la Investigación Biomédica Hospital Universitario La Paz. 2016-Ongoing. Managment centre: FIBHULP
- **Buño Soto A.** Validación de un nuevo método para la detección de anticuerpos IGG e IGM anti Sars-Cov-2 en el analizador atellica solution. Siemens Heatlhcare S. L. 2020-Ongoing. Managment centre: FIBHULP
- **Cabrera Lafuente M.** Proteccion, promoción y apoyo a la lactancia materna en recien nacidos prematuros, pequeños y enfermos (Neo-IHAN). IHAN-Ministerio de Sanidad-UNICEF. 2020-Ongoing. Managment centre: IHAN
- **Escribano Palomino E.** Ensayo clínico aleatorio controlado: Intervención dietética-nutricional basada en al dieta mediterránea durante el embarazo y los dos primeros años, mil primeros días, para la mejora del desarrollo neurológico (PI24/0035). ISCIII. 2025-2028. Managment centre: FIBHULP
- **Pellicer Martínez A.** Alliance for Family Integrated Care (FICare) Implementation in Neonatal Intensive Care Units (RISEinFAMILY). UE. 2020-2025. Managment centre: FIBHULP
- **Pellicer Martínez A.** Dose-finding for dobutamine during transitional circulation in the very preterm infant (ICI23/00072). ISCIII. 2024-2025. Managment centre: FIBHULP
- **Pellicer Martínez A.** ENSEMBLE: European Newborn Study: Early Markers for a Better LifE. Fondation de Paralysee Francaise. 2023-Ongoing. Managment centre: FIBHULP
- **Pellicer Martínez A.** Estudio aleatorizado, doble ciego, de tres brazos controlado con placebo, sobre el tratamiento con dobutamina de la insuficiencia hemodinámica en el periodo postnatal inmediato (PI18/01551). ISCIII. 2019-2023. Managment centre: FIBHULP
- **Pellicer Martínez A.** Estudio retrospectivo de pacientes con sospecha de meningitis para identificar meningitis que requieran o no tratamiento mediante un moelo de IA. Neos New Born Solutions S. L. 2020-Ongoing. Managment centre: FIBHULP
- **Pellicer Martínez A.** Online cerebral pressure autoregulation continuous monitorin as a neurobiomarker to guide assessment and intervention to prevent or minimise brain injury in the high-risk preterm infant. Chiesi Foundation Onlus. 2017-Ongoing. Managment centre: FIBHULP
- **Pellicer Martínez A.** Salvaguardando el cerebro de nuestros niños más pequeños–ensayo clínico por iniciativa del investigador, pragmático, abierto, multinacional, aleatorizado fase III que evalúa el tratamiento basado en la monitorización con espectrometría cercana al infrarrojo versus tratamiento estándar en el niño prematuro. Fundación Mutua Madrileña. 2019-2024. Managment centre: FIBHULP
- **Sáenz de Pipaón Marcos M, Sánchez García L.** Colonización de gestantes por bacterias multirresistentes y transmision perinatal en <32 semanas: prevalencia y morbilidad. Fundación de la Sociedad Española de Neonatología. 2019-Ongoing. Managment centre: FIBHULP
- **Sáenz de Pipaón Marcos M.** Desarrollo de fórmulas nutricionales biodisponibles (PID2020-119084RB-C21). Agencia estatal de Investigacion. 2021-2024. Managment centre: FUAM
- **Sáenz de Pipaón Marcos M.** Efecto de la suplementacion precoz con ácido araquidónico y acido docosahexanoico en la evolución de las concentraciones plasmáticas y eritrocitarias de DHA en recién nacidos prematuros: ensayo controlado aleatorizado (). Nestle España S. A.. 2016-Ongoing. Managment centre: FIBHULP
- **Sáenz de Pipaón Marcos M.** Efecto de la suplementación temprana con ácido docosahexanoico y ácido araquidónico sobre la incidencia de displasia broncopulmonar en niños extremadamente prematuros. European Society For Paediatric Gastroenterology, Hepatology and Nutrition. 2020-Ongoing. Managment centre: FIBHULP
- **Sáenz de Pipaón Marcos M.** Fórmulas nutricionales para el control del déficit de ácido docosahexaenoico dha y ácido araquinódico aa en niños extremadamente prematuros. Fundacion Ramón Areces. 2021-Ongoing. Managment centre: FIBHULP

Cibers and Retics

- **Cabañas González F.** Primary Care Interventions to Prevent Maternal and Child Chronic Diseases of Perinatal and Developmental Origin (SAMID). ISCIII. (31/12/2024). FIBHULP

Clinical trials

- **Pellicer Martínez A; Cabañas González F.** detección y monitorización no invasiva de la meningitis infantil (united meningitis - ultrasound non-invasive technology for early diagnosis of meningitis).
  Type/Phase: PRODUCTO SANITARIO
  Sponsored by: Fundación Privada Instituto Salud Global Barcelona
  Signature date: 31/01/2024
- **Pellicer Martínez A.** dose-finding for dobutamine during transitional circulation in the very preterm infant.
  Type/Phase: I
  Sponsored by: FIBHULP;Instituto De Salud Carlos III
  Signature date: 20/02/2024
- **Sánchez García L.** intervención basada en la evidencia para la reducción de las neumonías asociadas a la ventilación mecánica en unidades neonatales (inbernav-neo).
  Type/Phase: OTROS
  Sponsored by: Instituto Investigación Sanitaria Biocruces
  Signature date: 10/04/2024

Patents and trademarks

- **Segovia Iñigo C, Montes Bueno MT, inventors; Segovia Iñigo C, assignee.** Positioning device for neonates (Utility model). U201330102; 2013 January 31.

3.7.2 Molecular Hepatology

Publications: 7 | **Q1:** 5


COMPOSITION

Paloma Jara Vega.
Emérita Asistencial. Hospital Universitario La Paz
Loreto Hierro Llanillo.
Jefe de Servicio Hepatología Pediátrica. Hospital Universitario La Paz

- **Carmen Camarena Grande.** *Médico Adjunto de Hepatología Pediátrica. Hospital Universitario La Paz*
- **Ángela de la Vega Bueno.** *Médico Adjunto de Hepatología Pediátrica. Hospital Universitario La Paz*
- **Lorena Fernández Tomé.** *Facultativo Especialista en Hepatología y Trasplante Hepática. Hospital Universitario La Paz*
- **Esteban Frauca Remacha.** *Jefe de Sección de Hepatología Pediátrica. Hospital Universitario La Paz*
- **Maria Dolores Lledín Barbancho.** *Facultativo Especialista en Hepatología y Trasplante Hepática. Hospital Universitario La Paz*
- **Gema Muñoz Bartolo.** *Médico Adjunto de Hepatología Pediátrica. Hospital Universitario La Paz*
- **María Ángeles Pajares Tarancón.** *Investigadora Científica. CSIC*
- **Luiz Stark Aroeira.** *Investigador Postdoctoral. Hospital Universitario La Paz*
- **David Vicent López.** *Investigador Senior (Contrato Miguel Servet - I2). Hospital Universitario La Paz*

STRATEGIC OBJETIVES

- Our research interest is focused on the study of the molecular mechanisms underlying the most severe paediatric liver disorders, namely cholestasis, which results from the impaired secretion of bile from the liver to the intestine.
- As such, it represents a clinical and biochemical syndrome that is produced by a wide variety of disease processes that affect the liver. Individuals with cholestasis manifest jaundice, severe itching, malabsorption of fats and lipidsoluble vitamins and, in many cases, progressive liver damage. These clinical manifestations are due to the accumulation in blood and tissues of substances normally secreted in the bile, such as bilirubin, bile acids, and cholesterol and to the absence of bile from the intestine.
- When manifested in early infancy, cholestasis is often life threatening and usually requires liver transplantation. Extrahepatic biliary atresia (EHBA), Alagille syndrome and progressive familial intrahepatic cholestasis (PFIC) constitute the main paediatric cholestatic disorders. EHBA is an enigmatic disease of unknown aetiology, characterised by a precocious and accelerated obstruction of the biliary tree. Alagille syndrome is associated with mutations in the Jag1 gene and is characterised by a paucity or absence of intrahepatic bile ducts. PFIC encompasses a heterogeneous group of autosomal recessive diseases that exhibit similar clinical features. These diseases are caused by mutations in proteins located in the canalicular membrane of the hepatocyte and in proteins involved in bile secretion, such as the bile salt export pump (BSEP; ABCB11), the phospholipid transport protein MDR3 (ABCB4) and the aminophospholipid translocase FIC1 (ATP8B1). These cholestatic disorders constitute the most common indication for liver transplantation in childhood.



RESEARCH LINES

- Molecular basis of paediatric liver diseases
- Liver Pathobiology
- Biomarker identification

RESEARCH ACTIVITY

Publications

- **Chichelnitskiy E, Goldschmidt I, Ruhl L, Rübsamen N, Jaeger VK, Karch A, Beushausen K, Keil J, Götz JK, D'Antiga L, Debray D, Hierro L, Kelly D, Mclin V, Pawlowska J, Mikolajczyk RT, Bravi M, Klaudel-Dreszler M, Demir Z, Lloyd C, Korff S, Baumann U, Falk CS.** Plasma immune signatures can predict rejection-free survival in the first year after pediatric liver transplantation. J Hepatol. 2024; 81(5): 862-71. Article. IF: 33.0; D1
- **de la Cámara RCM, Torices-Pajares A, Miguel-Berenguel L, Reche-Yebra K, Frauca-Remacha E, Hierro-Llanillo L, Muñoz-Bartolo G, Lledín-Barbacho MD, Gutiérrez-Arroyo A, Martínez-Feito A, López-Granados E, Sánchez-Zapardiel E.** Epstein-Barr virus-specific T-cell response

in pediatric liver transplant recipients: a cross-sectional study by multiparametric flow cytometry. Front Immunol. 2024; 15: 1479472. Article. IF: 5.9; Q1

- **García-Boyano M, Díez MA, Tomé LF, Escosa-García L, Ramos FM, Schuffelmann-Gutiérrez C, Bueno EC, Calvo C, Baquero-Artigao F, Remacha EF.** Ceftazidime-Avibactam Use in a Case Series of Difficult-to-Treat or Recurrent Infections in Pediatric Patients with Complex Chronic Conditions: Effectiveness and Absence of Resistance Development. Antibiotics (Basel). 2024; 13(7): 598. Article. IF: 4.6; Q1
- **Guerrero L, Carmona-Rodríguez L, Santos FM, Ciordia S, Stark L, Hierro L, Pérez-Montero P, Vicent D, Corrales FJ.** Molecular basis of progressive familial intrahepatic cholestasis 3. A proteomics study. Biofactors. 2024; 50(4): 794-809. Article. IF: 5.0; Q1
- **Guerrero L, Vindel-Alfageme J, Hierro L, Stark L, Vicent D, Sorzano COS, Corrales FJ.** Discrimination of Etiologically Different Cholestasis by Modeling Proteomics Datasets. Int J Mol Sci. 2024; 25(7): 3684. Article. IF: 4.9; Q1
- **Li WH, van der Doef HPJ, Wildhaber BE, Marra P, Bravi M, Pinelli D, Minetto J, Dip M, Sierre S, de Santibañes M, Ardiles V, Uno JW, Hardikar W, Bates S, Goh L, Aldrian D, Seisenbacher J, Vogel GF, Neto JS, da Fonseca EA, Costa CM, Ferreira CT, Nader LS, Farina MA, Dajani KZ, Parente A, Bigam DL, Liang TB, Bai XL, Zhang W, Gonsorcíková L, Fronek J, Bohus S, Franchi-Abella S, Gonzales E, Guérin F, Junge N, Baumann U, Richter N, Hartleif S, Sturm E, Rajakannu M, Palaniappan K, Rela M, Pawaria A, Rajakrishnan H, Surendran S, Kumar M, Agarwal S, Gupta S, Asthana S, Bandewar V, Raichurkar K, Spada M, Monti L, Alterio T, Yanagi Y, Uchida H, Komine R, Evans H, Carr-Boyd P, Duncan D, Stefanowicz M, Latka-Grot J, Kolesnik A, Broering DC, Raptis DA, Marquez KAH, Mali V, Aw M, Beretta M, Van der Schyff F, Quintero-Bernabeu J, Mercadal-Hally M, Larrarte K M, Andres AM,**



Hernández-Oliveros F, Frauca E, Casswall T, Jorns C, Delle M, Gupte G, Sharif K, McGuirk S, Superina R, Caicedo JC, Jaramillo C, Bitterfeld L, Kastenberg Z, Shah AA, Domenick B, Acord MR, Mazariegos GV, Soltys K, DiNorcia J, Antala S, Florman SS, Buchholz BM, Herden U, Fischer L, Dierckx RAJO, Hartog H, Bokkers RPH. Incidence, management and outcomes in hepatic artery complications after paediatric liver transplantation: protocol of the retrospective, international, multicentre HEPATIC Registry. BMJ Open. 2024; 14(6): e081933. Article. IF: 2.3; Q2

- **Salinero-Fort M, Mostaza-Prieto JM, Lahoz-Rallo C, Cárdenas-Valladolid J, Iriarte-Campo V, Estirado-Decabo E, García-Iglesias F, Gonzalez-Alegre T, Fernández-Puntero B, Rio VM, Sánchez-Arroyo V, Sabín-Rodríguez C, López-López S, Gómez-Campelo P, Taulero-Escalera B, Rodríguez-Artalejo F, Andrés-Rebollo FJS, De Burgos-Lunar C.** External validation of three diabetes prediction scores in a Spanish cohort: does adding high risk for depression improve the validation of the FINDRISC score (FINDRISC-MOOD)?. BMJ Open. 2024; 14(6): e083121. Article. IF: 2.3; Q2

Research projects

- **Hierro Llanillo L.** Desarrollo de métodos de diagnóstico molecular de enfermedades hepáticas infantiles de carácter hereditario. Fundación ACS. 2005-Ongoing. Managment centre: FIBHULP
- **Hierro Llanillo L.** Diagnóstico molecular de enfermedades hepáticas infantiles de carácter hereditario (PI-426). Fundación ACS. 2012-Ongoing. Managment centre: FIBHULP
- **Hierro Llanillo L.** Estableciendo una base de datos como parte de la red europea de referencia en enfermedades rara hepáticas. R-liver. UE. 2019-Ongoing. Managment centre: FIBHULP
- **Hierro Llanillo L.** Validación de marcadores genéticos y moleculares para el diagnostico de atresia biliar (PI20/01496). ISCIII. 2021-2024. Managment centre: FIBHULP
- **Jara Vega P.** Estudio epidemiológico, observacional sobre el riesgo de desarrollo de síndrome linfoproliferativo en pacientes pediátricos trasplantados hepáticos, en el HULP. Roche Farma S. A. 2008-Ongoing. Managment centre: FIBHULP
- **Romero M, Hierro Llanillo L.** Optimization of spleen VCTE examinations with FibroScan. Echosens. 2022-Ongoing. Managment centre: FIBHULP
- **Ruiz de Valbuena R, Hierro Llanillo L.** A prospective and retrospective cohort study to refine and expand the knowledge on patients with chronic forms of Acid Sphingomyelinase Deficiency (ASMD) (Estudio PIR16183). Sanofi . 2021-. Managment centre:
- **Vicent López D.** Caracterización clínica del nuevo factor de riesgo cardiovascular trimetilamina-D-óxido en pacientes diabéticos obesos. Sección de Endocrinología y Nutrición Severo Ochoa. 2015-Ongoing. Managment centre: FIBHULP
- **Vicent López D.** Contrato Miguel Servet Categoria C (CES06/007). ISCIII. 2008-2025. Managment centre: FIBHULP

Cibers and Retics

- **Hierro Llanillo L.** ERN on Hepatological diseases (RARE-LIVER). EU. (31/12/2024). FIBHULP
- **Jara Vega P.** ERN on Transplantation in children (TransplantChild). EU. (31/12/2024). FIBHULP

Clinical trials

- **Frauca Remacha E.** estudio de fase iii, aleatorizado, doble ciego, controlado con placebo, para evaluar la eficacia y la seguridad de maralixibat en el tratamiento de participantes con prurito colestásico.
  Type/Phase: III
  Sponsored by: Mirum Pharaceutical Inc
  Signature date: 23/10/2024

3.7.3 Maternal and Fetal Medicine

Publications: 26 | **Q1:** 7

COMPOSITION

José Luis Bartha Rasero.
Jefe de Servicio de Obstetricia y Ginecología. Hospital Universitario La Paz. Catedrático de Obstetricia y Ginecología. Universidad Autónoma de Madrid

- **Irene Bartha de las Peñas.** *Investigador Clínico en Alergia Pediátrica. King's College de Londres and Guy's and St Thomas NHS Foundation Trust*
- **Alejandra Abascal Saiz.** *Facultativo Especialista de Área en Ginecología y Obstetricia. Hospital Universitario La Paz*
- **Eugenia Antolín Alvarado.** *Jefe de Sección de Obstetricia y Ginecología. Hospital Universitario La Paz. Profesor asociado. Universidad Autónoma de Madrid*
- **Marta Cortés León.** *Médico Especialista en Ginecología y Obstetricia. Hospital Universitario La Paz*
- **Marcos Javier Cuerva González.** *Facultativo Especialista de Área en Ginecología y Obstetricia. Hospital Universitario La Paz*
- **María Amparo Gimeno Sanmartín.** *Médico Especialista en Ginecología y Obstetricia. Hospital Universitario La Paz*
- **María del Mar González Arlazón.** *Facultativo Especialista de Área en Ginecología y Obstetricia. Hospital Universitario La Paz*
- **María de la Calle Fernández-Miranda.** *Jefa de Sección de Tocología de Alto Riesgo y Obstetricia Médica. Hospital Universitario La Paz. Profesora asociada. Universidad Autónoma de Madrid*
- **María de la Cruz González Álvarez.** *Facultativo Especialista de Área en Ginecología y Obstetricia. Hospital Universitario La Paz*
- **Beatriz Herrero Ruiz.** *Médico Adjunto de la Sección de Ecografía y Medicina Fetal. Hospital Universitario La Paz*
- **Sara López Magallón.** *Facultativo Especialista de Área en Ginecología y Obstetricia. Hospital Universitario La Paz*
- **Francisco López Sánchez.** *Jefe de Sección de Obstetricia y Ginecología. Hospital Universitario La Paz*
- **Fernando Magdaleno Dans.** *Jefe de Sección de Obstetricia y Ginecología. Hospital Universitario La Paz. Profesor asociado. Universidad Autónoma de Madrid*
- **María Elena Martín Boado.** *Facultativo Especialista de Área en Ginecología y Obstetricia. Hospital Universitario La Paz*
- **Nuria Martínez Sánchez.** *Facultativo Especialista de Área en Ginecología y Obstetricia. Hospital Universitario La Paz*
- **Marta Luisa Muner Hernando.** *Facultativo Especialista de Área en Ginecología y Obstetricia. Hospital Universitario La Paz*
- **Inmaculada Orensanz Fernández.** *Facultativo Especialista de Área en Ginecología y Obstetricia. Hospital Universitario La Paz*
- **Roberto Rodríguez González.** *Facultativo Especialista de Área en Ginecología y Obstetricia. Hospital Universitario La Paz*
- **Sara Ruiz Martínez.** *Investigadora Juan Rodés. Hospital Universitario La Paz*
- **Laura Sotillo Mallo.** *Facultativo Especialista de Área en Ginecología y Obstetricia. Hospital Universitario La Paz*
- **Inmaculada Duyos Mateo.** *Facultativo Especialista de Área en Ginecología y Obstetricia. Hospital Universitario La Paz*

STRATEGIC OBJETIVES

1. To evaluate the implication of placental energy metabolism in obstetric conditions
2. Finding new biomarkers in gestational diabetes mellitus and macrosomia
3. Find new biomarkers of fetal and perinatal neurological damage and establish new prevention strategies
4. New biomarkers in poor placentation
5. Pathophysiology and new lines of treatment of fetal heart damage in Anti-Ro positive women
6. Fetal therapy
7. Infectious diseases. Microbiota

RESEARCH LINES

1. Diabetes mellitus, obesity and metabolic syndrome in pregnancy. Energy metabolism in pregnancy
2. Poor placentation
3. Fetal Neurodevelopment
4. Inflammation, autoimmunity and pregnancy
5. Fetal Therapy
6. Infectious diseases. Microbiota



RESEARCH ACTIVITY

Doctoral Theses

- **Abascal Saiz A.** Relación de la lipidómica placentaria con la clínica y patogénesis de la preeclampsia[dissertation]. Madrid: Universidad Autónoma de Madrid: 2024(02/07/2024). Director: Bartha Rasero JL, Antolín Alvarado ME
- **Bartha de las Peñas I.** The influence of respiratory allergy, obesity and environment on obstetrics and perinatal outcomes[dissertation]. Madrid: Universidad Autónoma de Madrid: 2024(14/02/2024). Director: Bartha Rasero JL

Publications

- **Abulí A, Antolín E, Borrell A, García-Hoyos M, Santiago FG, Manján IG, Maíz N, González CG, Rodríguez-Revenga L, Palafoll IV, Suela J.** Guidelines for NGS procedures applied to prenatal diagnosis by the Spanish Society of Gynecology and Obstetrics and the Spanish Association of Prenatal Diagnosis. J Med Genet. 2024; 61(8): 727-33. Article. IF: 3.7; Q2
- **Aldeán JA, García FJA, Fernández-Miranda MD, Falcón TF, de Arce AI, Rojano ML, Calle IR, Franch AS.** Vaccination in pregnancy. Consensus document of the CAV-AEP and the SEGO. An Pediatr. 2024; 100(4): 268-74. Article. IF: 2.1; Q2
- **Campillo-Ajenjo M, Pena-Burgos EM, Ruiz BH, Albero GE, Aparicio PR, Pajares MP, Zurita MB, Regojo-Zapata RM, Rasero JLB, Alvarado EA.** Congenital metastatic neuroblastoma with placental involvement as a rare cause of non-immune fetal hydrops. J Obstet Gynaecol Re. 2024; 50(8): 1402-7. Article. IF: 1.5; Q3
- **Cuerva MJ, Canilhas B, Aleixo V, Cruset M, Cortes M, López F, Bartha JL.** Rotational Forceps: Which technique is superior for blade insertion? A simulation study comparing direct, first posterior, and wandering maneuvers. Eur J Obstet Gyn R B. 2024; 301: 181-5. Article. IF: 1.9; Q2
- **Cuerva MJ, Villasante P, Cruset M, Pintado C, De Aguado MP, Cortes M, López F, Bartha JL.** Which type of forceps is better for nonrotational operative births? A simulation study comparing Thierry spatulas and Simpson-Braun and Kielland forceps. Int J Gynecol Obstet. 2024; 167(2): 641-7. Article. IF: 2.4; Q2
- **de la Moral AL, Cuerva MJ, Bartha JL.** Severe malaria in a pregnant woman with severe thrombocytopenia and placental involvement: Management in a non-endemic area. Case report. Clin Invest Ginecol Obstet. 2024; 51(4): 100969. Article. IF: 0.1; Q4
- **de Lucas LMS, Álvarez PO, Marzo LD, Molina TI, Herrero B, Bartha JL, Antolín E.** Prenatal Management and Perinatal Outcome in a Large Series of Hydrops Fetalis. Fetal Diagn Ther. 2024; 51(4): 335-42. Article. IF: 1.6; Q3
- **de Winter DP, Lopriore E, Thorup E, Petersen OB, Dziegiel MH, Sundberg K, Devlieger R, de Catte L, Lewi L, Debeer A, Houfflin-Debarge V, Ghesquiere L, Garabedian C, Le Duc K, Antolin E, Mendez N, Castleman J, Tse WT, Jouannic JM, Maurice P, Currie J, Mullen E, Geerts L, Rademan K, Khalil A, Poljak B, Prasad S, Tiblad E, Bohlin K, Geipel A, Rath J, Malone F, Mackin D, Yinon Y, Cohen S, Ryan G, Vlachodimitropoulou E, Gloning KP, Verlohren S, Mayer B, Lanna M, Faiola S, Srsen TP, Cerar LK, Snowise S, Sun LM, Otaño L, Meller CH, Connors NK, Saxonhouse M, Wolter A, Bedei I, Klaritsch P, Jauch S, Ribeiro ETDS, Peixoto FM, Martínez-Portilla RJ, Matias A, Abad OA, Roca JP, Grisi AGA, Navarro EJJC, van der Bom JG, de Haas M, Verweij EJT.** Variations in antenatal management and outcomes in haemolytic disease of the fetus and newborn: an international, retrospective, observational cohort study. Lancet Haematol. 2024; 11(12): E927-37. Article. IF: 17.7; D1
- **Delavary M, Mesic A, Krebs E, Sesonga P, Uwase-Gakwaya B, Nzeyimana I, Vanlaar W.** Assessing the effect of automated speed enforcement and comprehensive measures on road safety in Rwanda. Traffic Inj Prev. 2024; 25(7): 947-55. Article. IF: 1.9; Q3
- **Donepudi R, Jouannic JM, Maisonneuve E, Sananes N, Muller C, Sánchez-Durán M, Molina F, Carretero P, Antolin E, Duyos I, Fabietti I, Khalil A, Coutinho CM, Sangi-Haghpeykar H, Cortes MS.** Fetal anemia: Determinants and perinatal outcomes according to the method of intrauterine blood transfusion. Fetal Diagn Ther. 2024; 51(1): 76-84. Article. IF: 1.6; Q3
- **Fidalgo AM, Miguel R, Fernández-Buhigas I, Aguado A, Cuerva MJ, Corrales E, Rolle V, Santacruz B, Gil MM, Poon LC.** Level of agreement between midwives and obstetricians performing ultrasound examination during labor. Int J Gynecol Obstet. 2024; 164(1): 131-9. Article. IF: 2.4; Q2
- **Gálvez A, Teran EDD, Espinosa JA, Pérez-Pedregosa J, Bartha-Rasero JL, del Valle JG, Cuerva MJ, Jimenezs E, Badiola C.** Ligilactobacillus salivarius V4II-90 eradicates Group B Streptococcus colonisation during pregnancy: a randomised, double-blind, placebo-controlled trial. Benef Microbes. 2024; 15(4): 387-96. Article. IF: 3.1; Q2
- **Lee NMW, Lau SL, Yeung YK, Chiu CPH, Liu F, Lau YY, Fidalgo AM, Cuerva MJ, Aquise A, Nguyen-Hoang L, Gil MM, Poon LC.** Implementation of sonopartogram: multicenter feasibility study. Ultrasound Obst Gyn. 2024; 64(2): 214-21. Article. IF: 6.3; D1
- **López-Mendizábal L, Varea C, Berlanga A, Patricio MA, Molina JM, Bartha JL.** Non-elective caesarean section risk assessment using Machine Learning techniques. Clin Invest Ginecol Obstet. 2024; 51(3): 100949. Article. IF: 0.1; Q4
- **Martínez-Sánchez N, Álvarez-Troncoso J, Robles-Marhuenda A, Fernández-Miranda MD, Hernando MLM, Bartha JL.** Safety of biologic immunosuppressants in pregnant women with immune-mediated inflammatory diseases. J Autoimmun. 2024; 148: 103301. Article. IF: 7.0; Q1
- **Martín-Palumbo G, Alcorta MD, de Aguado MP, Antolín E, Bartha JL.** Urinary sFlt-1 and PlGF as preeclampsia predictors: sFlt-1/creatinine ratio improves the prediction value. Eur J Obstet Gyn R B. 2024; 298: 53-60. Article. IF: 1.9; Q2
- **Moreno MD, González-Rovira M, Martínez-Pancorbo C, Martín-Cameán M, Nájar-Moyano AM, Romero M, de la Hoz E, López-Beltran C, Mellado E, Bartha JL, Brodin P, Rodríguez-Herrera A, Sainz-Bueno JA, Sousa C.** Foetal gluten immunogenic peptides during pregnancy: a new determinant on the coeliac exposome. BMC Med. 2024; 22(1): 295. Article. IF: 8.3; D1
- **Pena-Burgos EM, Álvarez-Arenas MS, Quirós-González V, Bartha JL, De La Calle M.** Utility of cervical pessary in the prevention of preterm birth in triplet pregnancies: A single-center observational retrospective study of 165 triplet pregnancies. Eur J Obstet Gyn R B. 2024; 295: 48-52. Article. IF: 1.9; Q2
- **Peña-Burgos EM, Duyos-Mateo I, Pozo-Kreilinger JJ, Regojo-Zapata RM, Quirós-González V, de la Calle M.** Comparison of maternal, fetal, obstetric and neonatal outcomes for 234 triplet pregnancies conceived in vivo versus IVF and ICSI conceptions. Reprod Biomed Online. 2024; 48(2): 103419. Article. IF: 3.5; Q1
- **Rol MJ, Cuerva MJ, Palomares MD, Vallecillo C, Franke S, Bartha JL.** Impact of Peripartum Depression and Anxiety Symptoms on Unplanned Cesarean or Operative Vaginal Births: A Prospective Observational Study. Clin Exp Obstet Gyn. 2024; 51(1): 26. Article. IF: 0.6; Q4
- **Sánchez O, Ribera I, Ruiz A, Eixarch E, Antolín E, Cruz-Lemini M, Domínguez C, Arévalo S, Ferrer Q, Rodríguez-Sureda V, Crispi F, Llurba**



E. Angiogenic imbalance in maternal and cord blood is associated with neonatal birth weight and head circumference in pregnancies with major fetal congenital heart defect. Ultrasound Obst Gyn. 2024; 63(2): 214-21. Article. IF: 6.3; D1

- **Silva-Fernández CS, de la Calle M, Camacho PA, Arribas SM, Garrosa E, Ramiro-Cortijo D.** Psychometric Reliability to Assess the Perception of Women's Fulfillment of Maternity Rights. Eur J Investig Health Psychol Educ. 2024; 14(8): 2248-61. Article. IF: 2.6; Q2
- **Silva-Fernández CS, de la Calle M, Suta MA, Arribas SM, Garrosa E, Ramiro-Cortijo D.** Psychometric Evaluation of Women's Knowledge of Healthcare Rights and Perception of Resource Scarcity during Maternity. Healthcare (Basel). 2024; 12(20): 2045. Article. IF: 2.7; Q2
- **Surbek D, Blatny J, Wielgos M, Acs N, Edwards H, Erez O, Bartha JL, Madar H, Mercier FJ, Schlembach D, Di Renzo GC.** Role of recombinant factor VIIa in the clinical management of severe postpartum hemorrhage: consensus among European experts. J Matern-Fetal Neo M. 2024; 37(1): 2332794. Article. IF: 1.6; Q3
- **Tenorio-Castano J, Aparicio EM, Santiago FAG, Klotz CM, Regojo RM, Anguita E, Ryan E, Juusola J, Herrero B, Arias P, Parra A, Pascual P, Gallego N, Cazalla M, Rodríguez-González R, Antolín E, Nevado J, Ruiz-Pérez VL, Lapunzina P.** Non-immune hydrops fetalis is associated with bi-allelic pathogenic variants in the MYB Binding Protein 1a (MYBBP1A) gene. Clin Genet. 2024; 106(6): 713-20. Article. IF: 2.3; Q3
- **Villacampa A, Alfaro E, Morales C, Díaz-García E, López-Fernández C, Bartha JL, López-Sánchez F, Lorenzo O, Moncada S, Sánchez-Ferrer CF, García-Río F, Cubillos-Zapata C, Peiró C.** SARS-CoV-2 S protein activates NLRP3 inflammasome and deregulates coagulation factors in endothelial and immune cells. Cell Commun Signal. 2024; 22(1): 38. Article. IF: 8.9; Q1

Research projects

- **Antolín Alvarado E.** Modelos predictivos de daño neurológico y riesgo cardiovascular mediante la integración de técnicas de imagen y biomarcadores en la gestación monocorial. Biologia de sistemas (PI19/00904). ISCIII. 2020-2024. Managment centre: FIBHULP
- **Bartha Rasero JL.** Biologia de sistemas para la búsqueda de marcadores precoces de placentacion deficiente (PI19/00915). ISCIII. 2020-2024. Managment centre: FIBHULP
- **Bartha Rasero JL.** Implicación de la oxidación mitocondrial de ácidos grasos placentaria en la patogenesis y clínica de la preeclampsia. Laboratorios Farmaceúticos Rovi S. A. 2016-Ongoing. Managment centre: FIBHULP
- **Bartha Rasero JL.** Diagnóstico intraparto de la infección materna por estreptococo del grupo B. Cepheid Iberia S.L.U. 2023-Ongoing. Managment centre: FIBHULP
- **Bartha Rasero JL.** Validación de Nuevos Biomarcadores en Diabetes Gestacional de Inicio Tardío (PI23/01837). ISCIII. 2024-2026. Managment centre: FIBHULP

Clinical trials

- **Bartha Rasero JL.** SAPPHIRE-O - Spanish analysis on postpartum hemorrhage incidence and real evidence -organon.
  Type/Phase: EPA-OD
  Sponsored by: Organon Salud S.L.
  Signature date: 02/01/2024
- **Bartha Rasero JL.** Unidad salud integral materno-infantil. programa de los 1000 días. influencia de una intervención dietética-nutricional durante el embarazo y dos primeros años de vida para la mejora de los resultados perinatales y del desarrollo neurológico. ensayo clínico aleatorizado controlado (estudio conmed)
  Sponsored by: Bartha Rasero Jose Luis; Instituto de Salud Carlos III
  Signature date: 09/10/2024

3.7.4 Pediatric Respiratory, Systemic and Neurological Infections & Host Immune Response

Publications: 51 | **Q1:** 24

COMPOSITION

Cristina Calvo Rey.
Jefe de Sección del Servicio de Pediatría Hospitalaria, Enfermedades Infecciosas y Tropicales. Hospital Universitario La Paz

- **Rosa María Alcobendas Rueda.** *Médica Adjuna en Reunmatología Pediátrica. Hospital Universitario La Paz*
- **Sonia Alcolea Ruiz.** *Investigadora Predoctoral. Hospital Universitario La Paz*
- **María Mercedes Bueno Campaña.** *Facultativo Especialista de Área en Pediatría. Hospital Fundación de Alcorclón*
- **María Cabrerizo Sanz.** *Cientifico titular de OPIs. Instituto de Salud Carlos III*
- **Sara Camarero Serrano.** *Ayudante de Investigación I+D+I. Instituto de Salud Carlos III*
- **Inmaculada Casas Flecha.** *Investigador Cientifico de OPIs. Instituto de Salud Carlos III*
- **María de Ceano-Vivas la Calle.** *Jefa de Sección de Pediatría. Hospital Universitario La Paz*
- **Teresa del Rosal Rabes.** *Médico Adjunto de Pediatría Hospitalaria y Enfermedades Infecciosas y Tropicales. Hospital Universitario La Paz*
- **María Luz García García.** *Jefe de Servicio de Pediatría. Hospital Universitario Severo Ochoa*
- **Paula García Sánchez.** *Médico Adjunto en Servicio de Urgencias Pediátricas. Hospital Universitario La Paz*
- **Isabel González Bertolín.** *Médico Adjunto Urgencias Pediátricas, Pediatría Hospitalaria y Enfermedades Infecciosas. Hospital Universitario La Paz*
- **Carlos Grasa Lozano.** *Contrato Juan Rodés. Hospital Universitario La Paz*
- **Jara Hurtado Gallego.** *Investigadora Postdoctoral. CIBER*
- **María de la Montaña Iglesias Caballero.** *Técnica Superior Especializada de OPIs. Centro Nacional de Microbiología. Instituto de Salud Carlos III*
- **Ana María Méndez Echevarría.** *Facultativo Especialista de Área en Pediatría General. Hospital Universitario La Paz*
- **Mar Molinero Calamita.** *Colaboradora I+D+I. Centro Nacional de Microbiología. Instituto de Salud Carlos III*
- **Juan Francisco Pozo Sánchez.** *Cientifico Titular de OPIs. Unidad de Virus Respiratorios y Gripe. Instituto de Salud Carlos III*
- **Alba Tamargo García.** *Investigadora Postdoctoral. Contrato Sara Borrel. FIBHULP*
- **Clara Udaondo Gascón.** *Facultativo Especialista en Reumatologa Pediátrica. Hospital Universitario La Paz*



STRATEGIC OBJETIVES

- Infectious diseases are the most frequent pathology in childhood. Our group is focused in the study of paediatric infections with special attention to those associated to viruses.
- The acute respiratory infections (ARIs) of lower respiratory tract are the most frequent infectious diseases in humans and these suppose at least 4 million of deaths yearly in the world. A high proportion of these infections are related with viral aetiology and particularly in children. In our country, the viral ARIs are one of the most frequent causes of hospitalization in children less than 2 years old. Using the metagenomics and applying an adapted method designed and developed for ARIs study, we will have achieve an increased knowledge of viral infections in hospitalized children of all ages, as well as in outpatients. Metagenomics could allow recognizing new viruses and also permits a deeper knowledge of traditional respiratory virus groups. Any new technological tool and its application to respiratory infection will mean an improvement in the diagnosis and monitoring of these types of infections and their immediate use is specified for resolving alerts in public health associated with respiratory viral infections is like the case of MERS-CoV, avian flu, or other influenza pandemics. The pandemic caused by SARS-CoV-2 and the COVID-19 disease in childhood has occupied a large part of the research of our group since its appearance. We are also interested in the study of the immunological response of the infants to the viral infections, and the mechanisms that allow develop recurrent wheezing, or asthma (the most frequent chronic disease in children).
- Emerging viral infections have also an important role in the pathology in childhood. Recently picornaviruses, mainly human parechovirus and enterovirus are causing outbreaks and several neurological infections, morbidity and mortality. They were associated with a wide range of pathologies, from febrile syndrome to respiratory, neurological or systemic diseases. In newborns, these infections can be severe, even fatal. Surveillance of these polio-like diseases is a public health concern and it is one of our group objectives.
- Finally, to study viral infections in high risk group of children (newborn, chronic lung diseases, immunodefiencies, oncologic patients, rheumatic deseases…) is also a priority in our group. Emerging areas of research in our group are zoonosis an invasive fungal infections in high risk children.

RESEARCH LINES

- Respiratory viral infections in healthy and high risk children (newborn, chronic lung diseases, immunodeficiencies, oncologic patients…). Torquteno virus in immunocompromised children.. Viral metagenomic methods applied to the severe infections of the lower respiratory tract. SARS-CoV-2 infections in children. Applying of new technologies as echography to value risk conditions in viral infections.
- Immune response of the children and interleukins profile in infants with respiratory viral infections and correlation with the development of recurrent wheezing in the first years of life. Role of microbiome.
- Detection and characterization of enterovirus (EV) and parechovirus (PeV) systemic and neurological infections in children. Neurological development in children with EV and PeV infections.
- Infections related with locomotor system. Osteoarticular infections. Infections in children with rheumatic diseases. Kawasaki disease.
- Emerging infections in high risk children: zoonosis and invasive fungal infections.
- Fetal Therapy
- Infectious diseases. Microbiota

RESEARCH ACTIVITY

Master Theses

- **Bedoya P.** Respuesta ala vacuna nonavelente frente a VPH en niños y adolescentes inmunodeprimidos[dissertation]. Madrid: UCM: 2024(01/10/2024). Director: Méndez Echevarría A.

Final Degree Theses

- **Grima J.** Desarrollo psicomotor en niños con infección grave por virus respiratorio sincitial [dissertation]. Madrid: UAM: 2024(01/06/2024). Director: Calvo Rey C.
- **Simón Montero M.** Pet ownership and mental health in pediatric transplant recipients [dissertation]. Madrid: UAM: 2024(01/06/2024). Director: Méndez Echevarría A.

Publications

- **Ahmed A, Munoz FM, Muller WJ, Agwu A, Kimberlin DW, Galli L, Deville JG, Sue PK, Méndez-Echevarría A, Humeniuk R, Guo SS, Rodríguez L, Han D, Hedskog C, Maxwell H, Palaparthy R, Kersey K, Rojo P.** Remdesivir for COVID-19 in Hospitalized Children: A Phase 2/3 Study. Pediatrics. 2024; 153(3): e2023063775. Article. IF: 6.4; D1
- **Ascunce M, Coccolo A, Mozo Y, Baquero-Artigao F, Rodríguez-Molino P, Toro-Rueda C, García-Clemente P, Sánchez-Zapardiel E, López-Granados E, Corral-Sánchez D, Bueno D, Sisinni L, Pérez-Martínez A, Calvo C, del Rosal T.** Severe Impairment of T-cell Immunity and Pulmonary GvHD Are Major Risk Factors for Nontuberculous Mycobacterial Infection After Pediatric Allogeneic Hematopoietic Stem Cell Transplantation. Pediatr Infect Dis J. 2024; 43(9): 885-8. Article. IF: 2.2; Q2
- **Broberg EK, Svartstroem O, Riess M, Kraus A, Vukovikj M, Melidou A.** Co-circulation of seasonal influenza A(H1N1)pdm09, A(H3N2) and B/Victoria lineage viruses with further genetic diversification, EU/EEA, 2022/23 influenza season. Euro Surveill. 2024; 29(39): 240002. Article. IF: 7.8; D1
- **Bubba L, Broberg EK, Fischer TK, Simmonds P, Harvala H.** Parechovirus A Circulation and Testing Capacities in Europe, 2015-2021. Emerg Infect Dis. 2024; 30(2): 234-44. Article. IF: 6.6; D1
- **Cabrera-Rubio R, Calvo C, Alcolea S, Bergia M, Atucha J, Pozo F, Casas I, Arroyas M, Collado MC, García-García ML.** Gut and respiratory tract microbiota in children younger than 12 months hospitalized for bronchiolitis compared with healthy children: can we predict the severity and medium-term respiratory outcome? Microbiol Spectr. 2024; 12(7): e0255623. Article. IF: 3.8; Q1
- **Calvo C, Lozano JS.** Current epidemiological situation of Streptococcus pyogenes infections. An Pediatr. 2024; 100(3): 161-3. Editorial Material. IF: 2.1; Q2
- **Carriquí-Arenas S, Mosquera JM, Quesada-Masachs E, López M, Clemente D, Boteanu A, Udaondo C, de Inocencio J, Nieto JC, Riancho L, Núñez E, Sánchez-Manubens J, Lirola MJ, Roldán R, Camacho M, Martínez M, Medrano M, Alcañiz P, Antón J, Iglesias E.** Clinical characteristics and prognostic factor in juvenile dermatomyositis: data of the Spanish registry. Pediatr Rheumatol. 2024; 22(1): 66. Article. IF: 2.3; Q2
- **Chorafa E, Iosifidis E, Oletto A, Warris A, Castagnola E, Bruggemann R, Groll AH, Lehrnbecher T, Antolin LF, Mesini A, Agakidou E, Controzzi T, De Luca M, Dimitriou G, Emonts M, Esposito S, Fernàndez-Polo A, Ghimenton-Walters E, Gkentzi D, Grasa C, Hatzidaki E, Jogi P, Kildonaviciute K, Kontou A, Leibold-Aguinarte A, Manzanares A, Mendoza-Palomar N, Metsvaht T, Noni M, Paulus S, Perrone S, Rincón-López E, Romani L, Sánchez L, Cetin BS, Spoulou V, Strenger V, Vergadi E, Villaverde S, Vuerich M, Zamora-Flores E, Roilides E.** Antifungal Drug Usage in European Neonatal Units: A Multicenter Weekly Point Prevalence Study. Pediatr Infect Dis J. 2024; 43(11): 1047-8. Article. IF: 2.2; Q2
- **Cobo-Vázquez E, Aguilera-Alonso D, Rello-Saltor V, Gamell A, Mellado-Sola I, Oltra-Benavent M, Martín-Pedraz L, Manzanares-Casteleiro A, Carrasco-Colom J, Cervantes E, Sanz-Santaeufemia F, Colino-Gil E, Jiménez-Montero B, Soto B, Calvo C, Saavedra-Lozano J.** Central Nervous System Infection by Group a Streptococcus in Children in Spain (2019-2023). Pediatr Infect Dis J. 2024; 43(10): e368-74. Article. IF: 2.2; Q2
- **Couderé K, Benschop KSM, Koen G, van Eijk H, Harvala H, Bailly JL, Bessaud M, Kamau E, Simon I, Joffret ML, Nikolaeva-Glomb L, Georgieva I, Stoyanova A, Diedrich S, Böttcher S, Cabrerizo M, Tabain I, Hruskar Z, Stevanovic V, Susi P, Hietanen E, Palminha P, Rainetova P, Baicus A, Kristensen M, Pajkrt D, Murk JL, Wolthers KC.** Assessment of twelve echovirus virus-neutralisation assays in Europe: recommendations for harmonisation of non-polio enterovirus sero-surveillance studies. J Gen Virol. 2024; 105(9): 1986. Article. IF: 4.3; Q1
- **de Arellano ER, Saavedra-Lozano J, Villalón P, Jové-Blanco A, Grandioso D, Sotelo J, Gamell A, González-López JJ, Cervantes E, Gónzalez MJ, Rello-Saltor V, Esteva C, Sanz-Santaeufemia F, Yagüe G, Manzanares A, Brañas P, de Gopegui ER, Carrasco-Colom J, García F, Cercenado E, Mellado I, del Castillo E, Pérez-Vazquez M, Oteo-Iglesias J, Calvo C.** Clinical, microbiological, and molecular characterization of pediatric invasive infections by Streptococcus pyogenes in Spain in a context of global outbreak. Msphere. 2024; 9(3): e0072923. Article. IF: 3.1; Q2
- **de Ceano-Vivas M, Gutiérrez MAM, López R, Calvo C.** Streptococcus pyogenes infections in Spanish children before and after the COVID pandemic. Coming back to the previous incidence. Enferm Infec Micr Cl. 2024; 42(2): 114-5. Letter. IF: 2.5; Q2
- **de Ceano-Vivas M, Gutiérrez MAM, Mellado-Sola I, Sánchez PG, Grandioso D, Calvo C.** Streptococcus pyogenes infections in Spanish children before and after the COVID pandemic. Coming back to the previous incidence. Enferm Infec Micr Cl. 2024; 42(2): 88-92. Article. IF: 2.5; Q2
- **de la Cámara RCM, Morato MBG, Cámara-Hijón C, Magallares L, Martínez-Ojinaga**



E, González-Torbay A, Miguel-Berenguel L, del Rosal T, Sarría-Osés J, Rodríguez-Pena R. Novel hypomorphic CYBB variant causing chronic granulomatous disease with incomplete penetrance. Pediat Allerg Imm-Uk. 2024; 35(10): e14259. Article. IF: 4.5; Q2

- **Del Buey JFB, Martínez JI, Rodríguez MAG, García MA, Sánchez-Gómez A, Carbajo MDL, Bueno SJ, Vasallo MDE, Zambrano MAL, Rey CC, Luna MS, Olivas MM, Arnáez MAA.** The effectiveness of nirsevimab in reducing the burden of disease due to respiratory syncytial virus (RSV) infection over time in the Madrid region (Spain): a prospective population-based cohort study. Front Public Health. 2024; 12: 1441786. Article. IF: 3.4; Q1
- **del Rosal T, Bote-Gascón P, Falces-Romero I, Sainz T, Baquero-Artigao F, Rodríguez-Molino P, Méndez-Echevarría A, Bravo-Queipo-de-Llano B, Alonso LA, Calvo C.** Multiplex PCR and Antibiotic Use in Children with Community-Acquired Pneumonia. Children (Basel). 2024; 11(2): 245. Article. IF: 2.1; Q2
- **Delaunay CL, Mazagatos C, Martínez-Baz I, Túri G, Goerlitz L, Domegan L, Meijer A, Rodrigues AP, Sève N, Ilic M, Latorre-Margalef N, Lazar M, Maurel M, Melo A, Ivorra BA, Casado I, Horvath JK, Buda S, Bennett C, de Lange M, Guiomar R, Enouf V, Mlinaric I, Hagey TS, Dinu S, Rumayor M, Castilla J, Oroszi B, Dürrwald R, O'Donnell J, Hooiveld M, Gomez V, Falchi A, Filipovic SK, Dillner L, Popescu R, Bacci S, Kaczmarek M, Kissling E.** COVID-19 Vaccine Effectiveness in Autumn and Winter 2022 to 2023 Among Older Europeans. JAMA Netw Open. 2024; 7(7): e2419258. Article. IF: 9.7; D1
- **Fernández-García MD, García-Ibañez N, Camacho J, Gutierrez A, García LS, Calvo C, Moreno-Docón A, Menasalvas AI, Medina A, Pérez-Ruiz M, Toboso MCN, Munoz-Almagro C, Launes C, Berengua C, Cabrerizo M.** Enhanced echovirus 11 genomic surveillance in neonatal infections in Spain following a European alert reveals new recombinant forms linked to severe cases, 2019 to 2023. Euro Surveill. 2024; 29(44): 2400221. Article. IF: 7.8; D1
- **Ferrero F, Lin CY, Liese J, Luz K, Stoeva T, Nemeth A, Gijón M, Calvo C, Natalini S, Toh TH, Deleu S, Chen BH, Rusch S, Sánchez BL, Leipoldt I, Vijgen L, Huntjens D, Baguet T, Bertzos K, Gamil M, Stevens M.** CROCuS, a Phase II Study Evaluating the Antiviral Activity, Clinical Outcomes, and Safety of Rilematovir in Children Aged ≥ 28 Days and ≤ 3 Years with Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus. Pediatr Drugs. 2024; 26(4): 411-27. Article. IF: 3.3; Q1
- **García-Boyano M, Alcalá FJC, Alonso AR, de Villalta MGF, Alonso OZ, Retolaza IR, Melero IQ, Calvo C, García LE.** Antibiotic Choice and Outcomes for Respiratory Infections in Children With Tracheostomies. Hosp Pediatr. 2024; 15(1): 17-27. Article. IF: 2.1; Q2
- **García-Boyano M, Alcala FJC, Alonso AR, de Villalta MGF, Alonso OZ, Retolaza IR, Melero IQ, Calvo C, García LE.** Pneumonia in Children With Complex Chronic Conditions With Tracheostomy: An Emerging Challenge. Pediatr Infect Dis J. 2024; 43(10): 919-23. Article. IF: 2.2; Q2
- **García-Boyano M, Díez MA, Tomé LF, Escosa-García L, Ramos FM, Schuffelmann-Gutiérrez C, Bueno EC, Calvo C, Baquero-Artigao F, Remacha EF.** Ceftazidime-Avibactam Use in a Case Series of Difficult-to-Treat or Recurrent Infections in Pediatric Patients with Complex Chronic Conditions: Effectiveness and Absence of Resistance Development. Antibiotics (Basel). 2024; 13(7): 598. Article. IF: 4.6; Q1
- **García-Sánchez P, Rodríguez BP, López RL, Gutiérrez MAM, Barriocanal MB, la Calle MDV.** Retrospective study of acute mastoiditis in children in Spain attended in a Pediatric Emergency department. Enferm Infec Micr Cl. 2024; 42(5): 263-6. Article. IF: 2.5; Q2
- **García-Sánchez P, Romero-Trancón D, Falces-Romero I, Carrera PN, Ruiz-Carrascoso G, Carmena D, Jiménez MC, Rivero-Juárez A, Moya L, Rodón J, Esperón F, Pérez-Hernando B, Sánchez-León R, Hurtado-Gallego J, Alcolea S, Sainz T, Calvo C, Méndez-Echevarría A.** Zoonosis screening in Spanish immunocompromised children and their pets. Front Vet Sci. 2024; 11: 1425870. Article. IF: 2.9; Q1
- **Gómez-Anca S, Jorge PF, Cabrerizo M, La Calle MDV, Calvo C.** Analytical data as a predictor of duration of hospital admission in human parechovirus infections. An Pediatr. 2024; 100(2): 141-3. Editorial Material. IF: 2.1; Q2
- **González-Bertolín I, Bernardos GB, Santoveña AZ, Suárez LG, López RL, Gallardo MP, Cáceres CD, Calvo C.** NUM-score: A clinical-analytical model for personalised imaging after urinary tract infections. Acta Paediatr. 2024; 113(6): 1426-34. Article. IF: 2.1; Q2
- **Grasa C.** Conference Old pathogens, new behaviors. Bol Pediatr. 2024; 64(269): 164-6. Editorial Material. IF: 0.1; Q4
- **Guillén-Calvo L, Negredo A, Sánchez-Mora P, Molero P, Vazquez A, Cabrerizo M, Orviz E, Ledesma J, Estrada V, Tarragó D, Sánchez-Seco MP.** Mpox, herpes, and enteroviruses: Differential diagnosis. J Med Virol. 2024; 96(1): e29371. Letter. IF: 4.6; Q1
- **Gutiérrez MAM, Lavisier BD, Domínguez JAR, de Oteyza MG, Molina VMV, Arroyo AG, de Ceano-Vivas M.** Impact of nirsevimab immunization on RSV infections attended in the pediatric emergency department: First results in a tertiary hospital in Madrid. Enferm Infec Micr Cl.

2024; 42(7): 367-72. Article. IF: 2.5; Q2

- **Hallmann E, Masny A, Poznanska A, Pozo F, Casas I, Brydak LB.** Molecular Determinants of Drug Resistance and Mutation Patterns in Influenza Viruses Circulating in Poland Across Multiple Epidemic Seasons: Implications for Vaccination Strategies. Med Sci Monitor. 2024; 30: e942125. Article. IF: 2.1; Q3
- **Iglesias-Caballero M, Mas V, Vázquez-Morón S, Vázquez M, Camarero-Serrano S, Cano O, Palomo C, Ruano MJ, Cano-Gómez C, Infantes-Lorenzo JA, Campoy A, Agüero M, Pozo F, Casas I.** Genomic Context of SARS-CoV-2 Outbreaks in Farmed Mink in Spain during Pandemic: Unveiling Host Adaptation Mechanisms. Int J Mol Sci. 2024; 25(10): 5499. Article. IF: 4.9; Q1
- **Launes C, Camacho J, Pons-Espinal M, López-Labrador FX, Esteva C, Cabrerizo M, Fernández-García MD, Fogeda M, Masa-Calles J, López-Perea N, Echevarría JE, Muñoz-Almagro C, Tarragó D.** Hybrid capture shotgun sequencing detected unexpected viruses in the cerebrospinal fluid of children with acute meningitis and encephalitis. Eur J Clin Microbiol. 2024; 43(5): 863-73. Article. IF: 3.0; Q2
- **Lavisier BD, Gutiérrez MAM, Torrejón RCP, Herrero MAG, Mesa MDR, García MF, López RL, Barriocanal MB, Sánchez PG, Domínguez JAR, Lacalle MDV.** Seizures in Children With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Pediatr Neurol. 2024; 157: 151-6. Article. IF: 2.1; Q1
- **Lovell DJ, Tzaribachev N, Henrickson M, Simonini G, Griffin TA, Alexeeva E, Bohnsack JF, Zeft A, Horneff G, Vehe RK, Stanevica V, Tarvin S, Trachana M, del Río AQ, Huber AM, Kietz D, Orbán I, Dare J, Foeldvari I, Quartier P, Dominique A, Simon TA, Martini A, Brunner HI, Ruperto N.** Safety and effectiveness of abatacept in juvenile idiopathic arthritis: results from the PRINTO/PRCSG registry. Rheumatology. 2024; 63(SI2): SI195-206. Article. IF: 4.4; Q1
- **Maldonado-Barrueco A, Gutiérrez-Arroyo A, Bloise I, de Ceano-Vivas M, Rivera-Nuñez A, Santos-Olmos RT, Vega DM, García-Rodríguez J.** Evaluation of CLINITEST® Rapid Covid-19+Influenza antigen test in a cohort of symptomatic patients in an emergency department. Eur J Clin Microbiol. 2024; 43(5): 853-61. Article. IF: 3.0; Q2
- **Martín-Delgado MC, Ramos PD, García-Botella A, Cantón R, García-Lledó A, Hernández-Sampelayo T, Gómez-Pavón J, del Castillo JG, Sánchez FJM, Martínez-Sellés M, García JMM, Guillén SM, Rodríguez-Artalejo F, Ruiz-Galiana J, Burillo A, Muñoz P, Rey CC, Catalán-González M, Cendejas-Bueno E, Halperin-Benito AV, Recio R, Vinuela-Benitez C, Bouza E.** Invasive group A Streptococcus infection (Streptococcus pyogenes): Current situation in Spain. Rev Esp Quim. 2024; 37(6): 454-71. Article. IF: 2.2; Q3
- **Méndez-Echevarría A, Calle-Miguel L, Miralbés S, Barreiro-Pérez S, Afonso-Rodríguez O, Soler-Simón JA, Espeleta-Fox A, Jiménez-Jiménez AB, Méndez-Sánchez A, Rementeria-Radigales JI, Guerrero-Del-Cueto F, Laveglia V, Ortiz-Valentin I, Gomez-Mera E, Fernández-Puentes V, Rodríguez-Noriega-Bejar L, Bustillo M, Retuerta A, Fernàndez-Cantalejo J, Sanz-Rueda L, Ibáñez MM, Berzosa A, Fernández-Ledesma B, Alvaro A, Santamaria-Barrena T, Carazo-Gallego B, Moraleda C, Calvo C.** Increased Severity of Mycoplasma pneumoniae Infections in Spanish Children. Pediatr Infect Dis J. 2024; 43(12): 1113-9. Article. IF: 2.2; Q2
- **Muruzábal C, Vicente L, Taravillo LE, de Llano BBQ, Calvo C, Hortelano MGL.** Off-Label Yellow Fever and Hepatitis A Vaccination in Traveling Children. Children (Basel). 2024; 11(3): 374. Article. IF: 2.1; Q2
- **Pedraz LM, Cuadros EN, Hernández MB, Rueda RMA, Saavedra-Lozano J, Rey CC.** Diagnostic and therapeutic approach to spondylodiscitis in Spanish children through the RIOPed Network: Evaluation before and after the publication of the national consensus document. An Pediatr. 2024; 101(2): 75-83. Article. IF: 2.1; Q2
- **Pérez-Gimeno G, Mazagatos C, Lorusso N, Basile L, Martínez-Pino I, Burgos FC, Rebolla NB, Zarzuelo MBR, Ivorra BA, Duran JG, Castrillejo D, Cañete G, Huerta MH, Becerril MG, Marín VR, Casas I, Pozo F, Monge S.** Effectiveness of influenza vaccines in children aged 6 to 59 months: a test-negative case-control study at primary care and hospital level, Spain 2023/24Effectiveness of influenza vaccines in children aged 6 to 59 months: a test-negative case-control study at primary care and hospital level, Spain 2023/24. Euro Surveill. 2024; 29(40): 2400618. Article. IF: 7.8; D1
- **Pérez-Jurado LA, Cáceres A, Balagué-Dobón L, Esko T, de Heredia ML, Quintela I, Cruz R, Lapunzina P, Carracedo A, Abellán J, Acosta-Isaac R, Aguado JM, Aguilar C, Aguilera-Albesa S, Sabbagh AA, Alba J, Albu S, Alcalá-Gallardo KAM, Alcoba-Florez J, Batres SA, Algarin-Lara HR, Almadana V, Medeiros KA, Almeida J, Almoguera B, Alonso MR, Álvarez N, Walther RAS, Álvarez-Benítez Y, Álvarez-Navia F, dos Santos KA, Andreu-Bernabeu A, Antonijoan MR, Martínez-Aquino E, Arana-Arri E, Aranda C, Arango C, Araque C, Araujo NK, Arcanjo AC, Arnaiz A, Fernández FA, Arranz MJ, López JRA, Artiga MJ, Avello-Malaver Y, Ayuso C, Martín BB, Baptista-Rosas RC, Baldion AM, Barranco-Díaz A, Barreda-Sánchez M, Barrera-Penagos V, Belhassen-García M, Bernal-Bello D, Bernal E, Bezerra JF, Bezerra MAC, Blanca-López N, Blancas R, Boix-Palop L, Borobia A, Bravo E, Brion M, Brochado-Kith O, Brugada R, Bustos M, Cabello A, Cáceres A, Cáceres-Agra JJ, Calbo E, Calderón EJ, Camacho S, Ceballos FC, Cañadas Y, Carbonell C, Cardona-Huerta S, Abad MSC, Segura CC, Carrillo-Avila JA, Campos MC, Casasnovas C, Castaño L, Castaño CF, Castelao JE, Candalija AC, Castillo MA, Chaves-Santiago WG, Chiquillo-Gómez S, Cid-López MA, Cienfuegos-Jiménez O, Conde-Vicente R, Cunha GCR, Cordero-Lorenzana ML, Corella D, Corrales A, Cortés-Sánchez JL, Corton M, Souza KSC, Silva FTC, Cruz R, Cuesta L, Tavares NAC, Carvalho MCC, Dalmau D, Dantas-Komatsu RCS, Darnaude MT, de Andrés R, de Juan C, Troca JJD, de la Horra C, de la Hoz AB, De Martino-Rodríguez A, Cruz MS, Neri JLDA, del Campo-Pérez V, Delgado-Cuesta J, de Bustamante AD, Díaz-Pérez A, Dietl B, Diz-de Almeida S, Alves MD, Domínguez-Garrido E, Rosa LS, Luchessi AD, Echave-Sustaeta J, Eiros R, Enciso-Olivera CO, Escudero G, España PP, Sanabria GE, Fariñas MC, Fernández R, Fernández-Caballero L, Fernández-Cruz A, Fernández-Ferrero S, Martínez YF, Fernández-Nestosa MJ, Fernández-Robelo U, Fernández-Rodríguez A, Fernández-Sampedro M, Fernández R, Fernández-Villa T, Fernández-Capitán C, Carioca AAF, Flores-Pérez P, Fuenmayor-Hernández L, Fuertes-Núñez M, Fumadó V, Gadea I, Gagliardi L, Gago-Domínguez M, Gallego N, Galoppo C, García-Soidán A, García-Cerrada C, García-de-Vicuña A, García-García J, García-García I, García-Ibarbia C, García-Montero AC, García L, García M, Torrejón MCG, García I, García-Vázquez E, Garza-Frias E, Gentile A, Gil-Fournier B, de Araújo JNG, Gómez-Duque M, Gómez-Arrue J, Carrera LG, García MG, Sacristán AG, González JR, González-Neira A, Álvarez BG, de Quirós FGB, González-Montelongo R, González-Peñas J, Gonzalez-Sagrado M, Gonzalo-Benito H, Gorgojo-Galindo O, Górgolas M, Guaragna F, Chaux JG, Guillén-Navarro E, Guillén-Guío B, Guisado-Vasco P, Gutiérrez-Castañeda LD, Gutiérrez-Bautista JF, Heili-Frades S, Jacomo RH, Hernández E, Hernández-Moro C, Hernández-Ortega LD, Hernández-Pérez G, Hernández-Vaquero R, Herráez B, Herranz MT, Herrera M, Herrero MJ, Herrero-González A, Horcajada JP, Imaz-Ayo N, Intxausti-Urrutibeaskoa M, Iñigo-Campos A, Iñiguez M, Jara R, Jiménez A, Jiménez-Alfaro I, Jiménez P, Jiménez-Sousa MA, Jordan I, Laguna-Goya R, Laorden D, Lasa-Lázaro M, Lattig MC, Lauriente A, Borja AL, Llanos L, López-Bernus A, de Heredia ML, López-García E, López-Granados E, López-Rodríguez R, López-Ruz MA, Lorente L, Lorenzo-Salazar J, Lozano JE, Lozano-Espinosa M, Mahillo I, Mancebo E, Mar C, Calvo CM, Marcos-Delgado A, Marcos M, Marín-Candón A, Mariscal-Aguilar P, Martin-Pedraza L, Martin-Fernández M, Martín-López C, Martín-Oterino JA, Martín MD, Martín V, Martín MM, Martín-Vicente M, Martínez A, Martínez-González O, Martínez R, Martínez-Paz P, Díaz-Caneja CM, Martínez-Nieto O, Martínez-López I, Martínez-Reséndez**

MF, Martínez S, Martínez JJ, Martínez-Pérez A, Martínez-Ramas A, Martínez-Robles V, Marzal L, Mazzeu JF, Medrano FJ, Meijome XM, Mejuto-Montero N, Mendes I, Duarte AL, Méndez-Echevarría A, Charris HM, Macías EM, Mercadillo F, Mercado-Sesma AR, Mínguez P, Molina-Roldán E, Molina AJ, Montoya JJ, Pinho SMT, Moreira-Escriche P, Morelos-Arnedo X, Moreno R, Cuerda VM, Moreno-Docón A, Moreno-Escalante J, Fernández AM, García PM, Neira P, Nevado J, Nieto-Gañán I, Silbiger VN, Nuñez-Torres R, Obrador-Hevia A, Ocejo-Vinyals JG, Virginia O, Oliveira SF, Ondo L, Orfao A, Ortega-Paino E, Ortega L, Ortiz-López R, Ortiz-Flores F, Oteo JA, Pacheco M, Pacheco-Miranda FJ, Padilla-Conejo I, Panadero-Fajardo S, Parellada M, Pariente-Rodríguez R, Friaza V, Paz-Artal E, Peces-Barba G, Kus MSP, Perales C, Santos NPC, Guegel GP, Pérez MJ, Pérez A, Pérez-Matute P, Pérez C, Pérez-de-Nanclares G, Pérez-García F, Pérez P, Pérez-Jurado LA, Pérez-Tomás ME, Perucho T, Pichardo LA, Ribeiro AP, Pinsach-Abuin ML, Pinzón LA, Medeiros JFP, Pita G, Pla-Juncà F, Planas-Serra L, Pompa-Mera EN, Porras-Hurtado GL, Pujol A, Quevedo-Chávez ME, Quijada MA, Quintela I, Ramiro-León S, Sedes PR, Nunes JFR, Recalde D, Recio-Fernández E, Resino S, Sousa RR, Rivadeneira-Chamorro CS, Roa-Agudelo D, Pardo MR, Fernandes MR, Rodríguez-Hernández MA, Rodríguez-Palmero A, Rodríguez-Ruiz E, Rodríguez MJ, Rodríguez-Artalejo F, Rodríguez-Ferrer M, Rodríguez-Gallego C, Rodríguez-García JA, Maya BR, Rodríguez-Nicolas A, Rodríguez-Novoa GE, Rodríguez-Urrego PA, Rojo F, Romero-Coronado A, Morilla R, Rondón-García F, Rosales-Castillo A, Rubio C, Olivera MR, Ruiz-Cabello F, Ruiz-Casares E, Ruiz-Cubillan JJ, Ruiz-Hornillos J, Ruiz M, Ryan P, Salamanca HD, Salazar-García L, Salgueiro-Origlia GG, Sangil A, Sánchez-Pernaute O, Sánchez PL, López AJS, Sánchez-Pablo C, Sánchez-Prados MC, Sánchez-Real J, Sánchez-Redondo J, Sancho-Sainz C, Sande E, Santos A, Schlüter A, Segovia S, Serra-Llovich A, Sevil-Puras F, Sevilla-Porras M, Sicolo MA, Silván-Fuentes C, Moraes VMS, Souza VS, Solé-Violán J, Soria JM, Sorlí JV, Silva NS, Souto JC, Sprockel JJ, Suárez-Rama JJ, Suárez-Zamora DA, Taboada-Fraga X, Tamayo E, Tamayo-Velasco A, Taracido-Fernández JC, Vasconcelos RHT, Tellería C, Carratto TMT, Tenorio-Castano JA, Teper A, Araujo IMT, Torres-Macho J, Torres-Tobar L, Torres-Gutiérrez RP, Troya J, Urioste M, Valencia-Ramos J, Valido A, Vargas-Gallo JP, Varón B, Vega T, Velasco-Quirce S, Vélez-Santamaría V, Víctor V, Vidán-Estévez J, Silva GV, Vieitez-Santiago M, Vilches C, Villalobos L, Villar F, Villar-García J, Villaverde C, Villosladas-Blanco P, Virseda-Berdices A, Costa TX, Yáñez Z, Zapatero-Gaviria A, Zarate R, Zazo S, Flores C, Riancho JA, Rojas-Martínez A, Lapunzina P, Carracedo A, González JR.** Clonal chromosomal mosaicism and loss of chromosome Y in elderly men increase vulnerability for SARS-CoV-2. Commun Biol. 2024; 7(1): 202. Article. IF: 5.1; D1

- **Presser LD, van den Akker WMR, Meijer A.** Respiratory Syncytial Virus European Laboratory Network 2022 Survey: Need for Harmonization and Enhanced Molecular Surveillance. J Infect Dis. 2024; 229: S34-9. Article. IF: 4.5; Q1
- **Rodríguez NEG, Aguilera-Alonso D, Escosa L, Gomez-Gil MR, Manzanares A, Ascaso MG, Bermejo-Gomez A, Abad MJG, Ramos AM, Nunez AS, Orellana MA, Cercenado E, Lozano JS, Calvo C, Baquero-Artigao F.** Pseudomonas aeruginosa bloodstream infections in children and adolescents: risk factors associated with carbapenem resistance and mortality. J Hosp Infect. 2024; 149: 56-64. Article. IF: 3.1; Q1
- **Rodríguez-Molino P, Martínez SG, Amador JB, Mellado-Sola I, Martín LM, Falces-Romero I, López-Hortelano MG, Hurtado-Gallego J, Mellado MJ, Grasa C, Sainz T.** Schistosomiasis in migrant children and adolescents in a paediatric tropical referral unit in Spain: diagnosis and long-term management challenges. Eur J Pediatr. 2024; 183(10): 4457-65. Article. IF: 2.6; Q1
- **Rodríguez-Molino P, Sánchez AG, Noguera-Julián A, Soler-García A, Paz PM, Méndez-Echevarría A, Baquero-Artigao F, Muñoz MG, Ruíz-Serrano MJ, Monsonís M, León RS, Saavedra-Lozano J, Santiago-García B, Sainz T.** QuantiFERON-TB reversion in children and adolescents with tuberculosis. Front Immunol. 2024; 15: 1310472. Article. IF: 5.9; Q1
- **Saavedra-Lozano J, Slocker-Barrio M, Fresán-Ruiz E, Grasa C, Pedraz LM, Ruiz AM, Sebastian MS.** Consensus document of the Spanish Society of Paediatric Infectious Diseases (SEIP) and the Spanish Society of Paediatric Intensive Care (SECIP) for the diagnosis and treatment of central venous catheter-related infections in paediatric care. An Pediatr. 2024; 100(6): 448-64. Article. IF: 2.1; Q2
- **Simoes MP, Hodcroft EB, Simmonds P, Albert J, Alidjinou EK, Ambert-Balay K, Andrés C, Antón A, Auvray C, Bailly JL, Baldanti F, Bastings C, Beard S, Berengua C, Berginc N, Bloemen M, Blomqvist S, Bosma F, Böttcher S, Bubba L, Buderus S, Cabrerizo M, Calvo C, Celma C, Ceriotti F, Clark G, Costa I, Coste-Burel M, Couderé K, Cremer J, Casas MD, Daehne T, de Beer J, de Ceano-Vivas M, De Gascun C, de Rougemont A, Dean J, Dembinski JL, Diedrich S, Diez-Domingo J, Dillner L, Dorenberg DH, Ducancelle A, Dudman S, Dyrdak R, Eis-Huebinger AM, Falces-Romero I, Farkas A, Feeney S, Fernández-García MD, Flipse J, Franck KT, Galli C, Garrigue I, Geeraedts F, Georgieva I, Giardina F, Guiomar R, Hauzenberger E, Heikens E, Henquell C, Hober D, Hönemann M, Howson-Wells H, Hruskar Z, Ikonen N, Imbert B, Jansz AR, Jeannoël M, Jirincová H, Josset L, Keeren K, Kramer-Lindhout N, Krokstad S, Lazrek M, Le Guillou-Guillemette H, Lefeuvre C, Lind A, Lunar MM, Maier M, Marque-Juillet S, McClure CP, McKenna J, Meijer A, Menasalvas Ruiz A, Mengual-Chuliá B, Midgley S, Mirand A, Molenkamp R, Montes M, Moreno-Docón A, Morley U, Murk JL, Navascués-Ortega A, Nijhuis R, Nikolaeva-Glomb L, Nordbo SA, Numanovic S, Oggioni M, Vergara EO, Pacaud J, Pacreau ML, Panning M, Pariani E, Pekova L, Pellegrinelli L, Petrovec M, Pietsch C, Pilorge L, Piñeiro L, Piralla A, Poljak M, Prochazka B, Rabella N, Rahamat-Langendoen JC, Rainetova P, Reynders M, Riezebos-Brilman A, Roorda L, Savolainen-Kopra C, Schuffenecker I, Smeets LC, Stoyanova A, Stefic K, Swanink C, Tabain I, Tjhie J, Thouault L, Tumiotto C, Renteria SU, Ursic T, Vallet S, Van Ranst M, Van Wunnik P, Verweij JJ, Vila J, Wintermans B, Wollants E, Wolthers KC, López-Labrador FX, Fischer TK, Harvala H, Benschop KSM.** Epidemiological and Clinical Insights into the Enterovirus D68 Upsurge in Europe 2021-2022 and Emergence of Novel B3-Derived Lineages, ENPEN Multicentre Study. J Infect Dis. 2024; 230(4): E917-28. Article. IF: 4.5; Q1
- **Soriano-Ramos M, Pedrero-Tomé R, Giménez-Quiles E, Albert E, Baquero-Artigao F, Rodríguez-Molino P, del Rosal T, Noguera-Julian A, Fortuny C, Ríos-Barnés M, Saavedra-Lozano J, Dueñas E, Sánchez-Mateos M, Castells L, de la Serna M, Frick MA, de Vergas J, Núñez-Enamorado N, Moral-Pumarega MT, Folgueira MD, Navarro D, Blázquez-Gamero D.** T-Cell Immune Responses in Newborns and Long-Term Sequelae in Congenital Cytomegalovirus Infection (CYTRIC Study). J Pediatr-Us. 2024; 272: 114084. Article. IF: 3.5; D1
- **Tarancón-Diez L, Carrasco I, Montes L, Falces-Romero I, Vázquez-Alejo E, de Ory SJ, Dapena M, Iribarren JA, Díez C, Ramos-Ruperto L, Colino E, Calvo C, Muñoz-Fernández MA, Navarro ML, Sainz T.** Torque teno virus: a potential marker of immune reconstitution in youths with vertically acquired HIV. Sci Rep-Uk. 2024; 14(1): 24691. Article. IF: 3.9; Q1
- **Udaondo C, Rueda RMA, Diaz-Delgado B, Remesal A, Quiles-Melero I, Calvo C.** Clinical Utility of a Multiplex PCR Panel (BioFire Joint Infection®) in the Adjustment of Empiric Antimicrobial Therapy: Experience in Pediatric Osteoarticular Infections. Children (Basel). 2024; 11(10): 1236. Article. IF: 2.1; Q2
- **Vicente Elcano L, Muruzabal Pino C, Calvo C, García López Hortelano M.** Tolerance of Atovacuona/proguanil in off-label indication in children.. Enferm Infecc Microbiol Clin (Engl Ed). 2024; 42(10): 605-6. Article. Not Indexed

Research projects

- **Bueno Campaña M.** Aplicación de la inteligencia artificial en ecografía torácica clínica para el manejo de infecciones respiratorias con sibilancias en menores de 2 años. Fundación Hosptial Alcorcón. 2022-2024. Managment centre: HUFA
- **Cabrerizo Sanz M.** Investigación de las infecciones por enterovirus que causan enfermedades neurológicas y respiratorias graves en niños. Vigilancia molecular y serológica de los tipos emergentes (PI22CIII/00035). ISCIII. 2023-2026. Managment centre: Centro Nacional de Microbiología
- **Calvo Rey C.** Causative Link between respirAtory syncytial viRus and chronic lung diseases: Identifying Targets for therapY (2023.366). UE. 2024-2026. Managment centre: FIBHULP
- **Calvo Rey C.** Colonización por staphylococcus aureus resistente a meticilina en niños sanos de la comunidad: estudio Cosaco. Estudio multicentrico de ambito nacional. Fundación SEIP. 2018-Ongoing. Managment centre: FIBHULP
- **Calvo Rey C.** Highly efficient technology for clean and safe air: development of advanced air purifiers to inactivate pathogens in aerosols. INIA. 2022-Ongoing. Managment centre: FIBHULP
- **Calvo Rey C.** Impacto de la pandemia COVID-19 en las infecciones respiratorias virales, respuesta inmune y microbiota en el primer año de vida incluyendo recien nacidos prematuros (PI21/00377). ISCIII. 2022-Ongoing. Managment centre: FIBHULP
- **Calvo Rey C.** Impacto del covid-19 materno en la respuesta inmune de los niños. Fundación de la Asociación Española de Pediatría. 2021-Ongoing. Managment centre: FIBHULP
- **Calvo Rey C.** Infecciones invasoras por Strpetococcus pyogenes en niños y adultos: evolución y factores de riesgo microbiológicos, clínicos, genéticos y respuesta inmune (IM23/INFEC/3). CIBERINFEC. 2023-Ongoing. Managment centre: CIBERINFEC
- **Calvo Rey C.** Infecciones osteoarticulares en pediatría. Estudio prospectivo multicéntrico. Fundación de la Asociación Española de Pediatría. 2017-Ongoing. Managment centre: FIBHULP
- **Calvo Rey C.** Infecciones respiratorias virales en recién nacidos de muy bajo peso. Fundación Neumomadrid. 2017-Ongoing. Managment centre: FIBHULP
- **Casas Flecha I.** Causative Link between respirAtory syncytial viRus and chronic lung diseases: Identifying Targets for therapy. (CLARITY). EU. 2024-2028. Managment centre: ISCIII
- **Casas Flecha I.** Infección respiratoria aguda en niños tras 2 años de pandemia de SARS-CoV-2: virus y respuesta inmune (PI21CIII/00019). AECI-ISCIII. 2022-2024. Managment centre: Centro Nacional de Microbiología
- **Casas Flecha I.** Integración de la información genómica de SARS-CoV-2 y estudio del comportamiento antigénico de las nuevas variantes y linajes. (COVIDSEQ-UNESPA). Unión Española de Entidades Aseguradoras y Reaseguradoras. 2022-2024. Managment centre: Centro Nacional de Microbiología
- **del Rosal Rabés T.** Infecciones por virus respiratorios y células NK en vías respiratorias en niños receptores de trasplante de progenitores hematopoyéticos. Estudio prospectivo. European Society of Pediatric Infectious Diseases. 2017-Ongoing. Managment centre: FIBHULP
- **del Rosal Rabés T.** Streptococcus pneumoniae colonization in immunocompromised Spanish children and adolescents: a multicenter study. Merck Sharp and Dohme de España S.A. 2023-Ongoing. Managment centre: FIBHULP
- **del Rosal Rabés T.** Torque teno virus (ttv) como potencial marcador de reconstitución inmune y complicaciones en niños sometidos a trasplante alogénico de progenitores hematopoyéticos. FIBHULP. 2022-Ongoing. Managment centre: FIBHULP
- **García-García ML.** The impact of preventing RSV infections on severe respiratory infections caused by other respiratory viruses in children under one year of age. (MISP #102677). Merck Sharp and Dohme de España S.A. 2024-2027. Managment centre: Fundación Puerta de Hierro
- **Gianquinto C, Calvo Rey C.** SARS-coV2 variants Evaluation in pRegnancy and paeDIatrics cohorts. Project acronym: VERDI. Call: HORIZON-HLTH-2021-CORONA-01. (Project 101045989). EU Horizon . 2022-2025. Managment centre: PENTA /FIBHULP
- **Grasa Lozano CD.** A multicenter study of carbapenem-resistant or carbapenemase-producing gram-netative bacteremia in pediatrics. European Society for Paediatric Infectious Diseases. 2022-Ongoing. Managment centre: FIBHULP
- **Grasa Lozano CD.** Estudio de infecciones por bacterias resistentes a carbapenémicos en pediatría - carba-ped. Fundación SEIP. 2022-Ongoing. Managment centre: FIBHULP
- **Grasa Lozano CD.** Optimización del uso de Beta-D-Glucano por Wako en el diagnóstico de la candidiasis invasiva en pediatría. (). Fundación de Investigación Hospital Universitario La Paz (IdiPAZ). 2024-ongoing. Managment centre: FIBHULP
- **Grasa Lozano CD.** Perfect. estudio de infección fúngica invasiva en pediatría. Gilead Science S.L. 2021-Ongoing. Managment centre: FIBHULP
- **Méndez Echecarría AM.** Balance riesgo beneficio de la convivencia con mascotas en niños inmunodeprimidos (PI23/00917). ISCIII. 2024-2026. Managment centre: FIBHULP
- **Oteo J, Calvo Rey C.** La medicina de precisión contra la resistencia a antimicrobianos: Proyecto MePRAM (PMP22/00092). ISCIII. 2023-Ongoing. Managment centre: CIBERINFEC
- **Udaondo Gascón C.** Banco de imagenes de capilaroscopias en población pediátrica. Sociedad Española de Reumatología Pediatrica. 2019-Ongoing. Managment centre: FIBHULP

Cibers and Retics

- **Calvo Rey C.** Centro de Investigación Biomédica en Res en Enfermedades Infecciosas (CIBERINFEC). ISCIII. (31/12/2024). FIBHLP
- **Casas Flecha I.** Red de Laboratorios Españoles de secuenciación Genómica de SA%RS-CoV-2. (RELECOV). EU. (31/12/2024). ISCIII

Clinical trials

- **Alcobendas Rueda RM.** estudio de fase 3, multicéntrico, en el que se evalúan la seguridad y la eficacia a largo plazo de baricitinib en pacientes de entre 1 y menos de 18 años con artritis idiopática juvenil (aij).
  Type/Phase: III
  Sponsored by: Lilly S.A.
  Signature date: 17/07/2024
- **"Calvo Rey C.** estudio abierto, de un solo brazo para evaluar la farmacocinética, seguridad y tolerabilidad, y para explorar los resultados clínicos del tratamiento con dosis única o múltiple de zanamivir iv en neonatos e infantes menores de 6 meses con infección por gripe confirmada complicada.
  Type/Phase: II
  Sponsored by: Glaxosmithkline S.A.
  Signature date: 30/04/2024"
- **"Calvo Rey C.** estudio de fase 1, aleatorizado, con observador-ciego, controlado con placebo, desescalado por edad sobre la seguridad, la tolerabilidad y la inmunogenicidad de mrna-1345 y mrna-1365 en participantes de 5 meses a < 24 meses. A phase 1, randomized, observer-blind, placebo-controlled, age de-escalation study of the safety, tolerability, and immunogenicity of mrna-1345 and mrna-1365 in participants aged 5 months to <24 months.
  Type/Phase: I
  Sponsored by: Modernatx Inc.
  Signature date: 15/01/2024"
- **Calvo Rey C.** estudio de fase ii, aleatorizado, doble ciego, controlado con placebo y de 2 partes, para evaluar pautas de tratamiento de edp-938 en pacientes de 28 días a 24 meses de edad con infección por el virus respiratorio sincitial (vrs).
  Type/Phase: II
  Sponsored by: Enanta Pharmaceuticals Inc.
  Signature date: 07/02/2024
- **de Ceano-Vivas la Calle M.** open-label, prospective study to assess the safety, tolerability, analgesic effect and feasibility of in suf/ket in pediatric patients with moderate or severe pain, in an acute care setting.
  Type/Phase: III
  Sponsored by: Cessatech A/S
  Signature date: 21/03/2024

3.7.5 Pediatric Systemic Infections; HIV, Tuberculosis, Imported and Emergent Diseases

Publications: 26 | **Q1:** 11

COMPOSITION

Talía Sainz Costa.
Facultativo Especialista de Área en Pediatría. Hospital Universitario La Paz. Profesora Asociada. Universidad Autonoma de Madrid

- **Jorge Atucha Margolles.** *Técnico de Laboratorio. FIBHULP*
- **Fernando Baquero Artigao.** *Facultativo Especialista de Área de Pediatría. Hospital Universitario La Paz. Profesor Colaborador. Universidad Complutense de Madrid*
- **Blanca Bravo Queipo de Llano.** *Facultativo Especialista de Área de Pediatría. Contrato Rio Hortega. Hospital Universitario La Paz*
- **Jorge Bustamante Amador.** *Investigador Postdoctoral. Hospital Universitario La Paz*
- **Francisco José Climent Alcalá.** *Facultativo Especialista de Área de Pediatría. Unidad de Patología Compleja. Hospital Universitario La Paz. Colaborador docente. Univesidad Autónoma de Madrid*
- **Roberto del Amparo Temporao.** *Investigador Postdoctoral. FIBHULP*
- **Lucía Escolano Taravillo.** *Investigador Predoctoral. Hospital Universitario La Paz*
- **Luis Escosa García.** *Facultativo Especialista de Área en Pediatría. Hospital Universitario La Paz*
- **Jaime Delgado Pérez.** *Investigador Predoctoral. Hospital Universitario La Paz*
- **Miguel García Boyano.** *Investigador Predoctoral. Hospital Universitario La Paz*
- **Marta García Fernández de Villalta.** *Facultativo Especialista de Área de Pediatría. Hospital Universitario La Paz. Colaborador Clínico Docente. Univesidad Autónoma de Madrid*
- **María Milagros García López de Hortelano.** *Médico Adjunto de Pediatría Hospitalaria y Enfermedades Infecciosas y Tropicales. Hospital Universitario La Paz. Colaborador Clínico Docente. Universidad Autónoma de Madrid*
- **Isabel Mellado Sola.** *Médica Adjunta en Pediatría. Investigador predoctoral. Hospital Universitario La Paz*
- **María Pérez Pascual.** *Médica Adjunta en Pediatría. Investigador predoctoral. Hospital Universitario La Paz*
- **Roi Piñeiro Pérez.** *Jefe Asociado del Servicio de Pediatría. Hospital General de Villalba*
- **Melisa Pucci Molineris.** *Investigadora Postdoctoral. FIBHULP*
- **Paula Rodríguez Molino.** *Contrato Rio Hortega. Hospital Universitario La Paz*
- **María Teresa Sánchez Aparicio.** *Investigadora Marie Sklodwoska-Curie - CIBERInfect*
- **Germán Vallejo Palma.** *Investigador Predoctoral. FIBHULP*
- **Patricia Vizuete Cano.** *Técnico de Laboratorio. FIBHULP*



STRATEGIC OBJETIVES

1. Vertically acquired HIV infection in children: Comorbidities, biomarkers, HIV reservoir, new therapeutic approaches.
2. Epidemiology of Paediatric Tuberculosis is Spain: molecular epidemiology of drug resistant strains, new diagnostic tools and new drugs for TB: Pharmacodynamics in children and TB-drugs Off-label use in paediatrics.
3. Congenital infections: burden of disease, prompt diagnosis and in-utero and postnatal management, host immune response.
4. Epidemiology of imported and emergent diseases in children: Identification and management of emergent outbreaks. Immuno-pathogenesis, preventive measures and management. Covid-19 in children
5. Immunization strategies in children: immune response in high risk patient's vaccine effectiveness and barriers.
6. Social Determinants of Health in Pediatrics
7. Infection and immunity: microbiome ate the corssroad of immunity and allergy
8. Health-care associated Infections. Resistant bacteria and antimicrobial stewardship / Infecciones asociadas con la assitencia sanitaria. Resistencias a antimicrobioanos y programas de optimización de antimicrobianos

RESEARCH LINES

Vertically acquired HIV infection in children

- Immuno-pathogenesis: Immune-activation, inflammation and biomarkers
- Epidemiology, immuno-virological factors
- Comorbidities, long term follow-up, cardioascular risk, bone disorders, metabolic abnormalities, neurocognitive impairment, renal dysfunction.
- Antiretroviral treatment: new drugs, resistances, dosage, toxicity in children, simplification strategies.
- HIV eradication: barriers, HIV reservoir, new antiretroviral drugs and other strategies to achieve HIV replication control.
- Gut Microbiota and bacterial traslocation intestinal as modulating factors for inflammation and Immune-activation in HIV-infected children.
- Transition to adult care: barriers, strategies to maintain adherence to care.
- Epidemiology of paediatric Tuberculosis (TB).
- Epidemiology of paediatric TB. paediatric cases as as a sentinel for burden of diseases.
- Molecular Epidemiology of paediatric TB: resistant strains.
- Immuno-pathogenesis: New diagnostic tools in special Populations: HIV-infected, ID patients
- Management of critical situations. Neonatal TB, multidrug resistant and extra-pulmonary TB.
- Omics for the diagnostis of pediatric TB
- New fixed-dosed combinations. Off label drugs in children. Pharmacodinamic and pharmacokinetic.

Congenital infectious diseases

- Congenital Citomegalovirus and Toxoplasma infections: diagnostic barriers, prognostic factors, new therapeutic approaches.
- CHAGAS disease and congenital TB: diagnostic barriers, prognostic factors, pharmacokinetics in newborns and new drugs.

Epidemiology of imported and emergent diseases in children

- Paediatric International Outbreaks: Epidemiology and public health impact: Zika. Rabies. Dengue. Chikungunya. Haemorragic fevers, Mers-co.
- Imported diseases in Spain: epidemiology and special populations: adopted, migrant, refugees, travelers and ID children. Tropical and parasitic infections in children.
- COVID-19 disease in children: epidemiology , diagnostic markers, treatment.
- Immunization strategies in children, including high risk patients
- Immunization and vaccine response in special populations: immunocompromised children, transplant recipients, chronic patients, HIV-infected, migrants.
- Vaccine immunogenicity: barriers in paediatric populations.
- New challengies in vaccinology

Microbiome in pediatric infectious diseases

- Microbiome-related biomarkers in food allergy and intolerances
- Microbiome-related biomarkers in childhood TB and other respiratory infections
- Social Determinants of Health in Pediatrics
- The burden of chronic disease in childhood
- Health-care associated Infections.
- The burden of antimicrobial resistance
- Antimicrobial stewardship in pediatrics

RESEARCH ACTIVITY

Doctoral Theses

- **Monroy Tapiador MA.** Estudio de la microbiota en niños diagnosticados de Síndrome de Phelan-Mcdermid[dissertation]. Madrid: Universida Autónoma de Madrid: 2024(31/06/2024). Director: Sainz Costa T
- **Rodriguez Molino P.** Limitaciones en el diagnóstico de la tuberculosis en niños y adolescentes en un contexto de baja endemia[dissertation]. Madrid: Universida Autónoma de Madrid: 2024(03/06/2024). Director: Sainz Costa T

Master Theses

- **Díaz Rodriguez KG.** Seguimiento de pacientes adolescentes VIH de un hospital pediátrico al de adulto[dissertation]. Madrid: Uiversidad Rey Juan Carlos: 2024(01/06/2024). Director: Sainz Costa T
- **Vidal Prado T.** Características clínicas y epidemiológicas en relación con el VIH en menores de 17 años[dissertation]. Madrid: Uiversidad Rey Juan Carlos: 2024(45444). Director: Sainz Costa T. NO
- **Bedoya P.** Inmunogenicidad de la vacuna contra VPH 9 Valente en niños y adolescentes inmunocomprometidos [dissertation]. Madrid: Universidad Complutense de Madrid: 2024(01/10/2024). Director: Sainz Costa T. IISP61381

Publications

- **Ascunce M, Coccolo A, Mozo Y, Baquero-Artigao F, Rodríguez-Molino P, Toro-Rueda C, García-Clemente P, Sánchez-Zapardiel E, López-Granados E, Corral-Sánchez D, Bueno D, Sisinni L, Pérez-Martínez A, Calvo C, del Rosal T.** Severe Impairment of T-cell Immunity and Pulmonary GvHD Are Major Risk Factors for Nontuberculous Mycobacterial Infection After Pediatric Allogeneic Hematopoietic Stem Cell Transplantation. Pediatr Infect Dis J. 2024; 43(9): 885-8. Article. IF: 2.2; Q2
- **Baquero F, Pérez-Cobas AE, Aracil-Gisbert S, Coque TM, Zamora J.** Selection versus transmission: Quantitative and organismic biology in antibiotic resistance. Infect Genet Evol. 2024; 121: 105606. Article. IF: 2.6; Q2
- **Berzosa A, Guillen S, Epalza C, Escosa L, Navarro ML, Prieto LM, Sainz T, de Ory SJ, Montes M, Abad R, Vázquez JA, García IS, Ramos-Amador JT.** Immunogenicity of the Conjugate Meningococcal ACWY-TT Vaccine in Children and Adolescents Living with HIV. Microorganisms. 2024; 12(1): 30. Article. IF: 4.2; Q2
- **Cobo-Vázquez E, Aguilera-Alonso D, Rello-Saltor V, Gamell A, Mellado-Sola I, Oltra-**

Benavent M, Martín-Pedraz L, Manzanares-Casteleiro A, Carrasco-Colom J, Cervantes E, Sanz-Santaeufemia F, Colino-Gil E, Jiménez-Montero B, Soto B, Calvo C, Saavedra-Lozano J. Central Nervous System Infection by Group a Streptococcus in Children in Spain (2019-2023). Pediatr Infect Dis J. 2024; 43(10): e368-74. Article. IF: 2.2; Q2

- **de Ceano-Vivas M, Gutiérrez MAM, Mellado-Sola I, Sánchez PG, Grandioso D, Calvo C.** Streptococcus pyogenes infections in Spanish children before and after the COVID pandemic. Coming back to the previous incidence. Enferm Infec Micr Cl. 2024; 42(2): 88-92. Article. IF: 2.5; Q2
- **del Rosal T, Bote-Gascón P, Falces-Romero I, Sainz T, Baquero-Artigao F, Rodríguez-Molino P, Méndez-Echevarría A, Bravo-Queipo-de-Llano B, Alonso LA, Calvo C.** Multiplex PCR and Antibiotic Use in Children with Community-Acquired Pneumonia. Children (Basel). 2024; 11(2): 245. Article. IF: 2.1; Q2
- **García-Boyano M, Alcala FJC, Alonso AR, de Villalta MGF, Alonso OZ, Retolaza IR, Melero IQ, Calvo C, García LE.** Pneumonia in Children With Complex Chronic Conditions With Tracheostomy: An Emerging Challenge. Pediatr Infect Dis J. 2024; 43(10): 919-23. Article. IF: 2.2; Q2
- **García-Boyano M, Díez MA, Tomé LF, Escosa-García L, Ramos FM, Schuffelmann-Gutiérrez C, Bueno EC, Calvo C, Baquero-Artigao F, Remacha EF.** Ceftazidime-Avibactam Use in a Case Series of Difficult-to-Treat or Recurrent Infections in Pediatric Patients with Complex Chronic Conditions: Effectiveness and Absence of Resistance Development. Antibiotics (Basel). 2024; 13(7): 598. Article. IF: 4.6; Q1
- **García-Sánchez P, Romero-Trancón D, Falces-Romero I, Carrera PN, Ruiz-Carrascoso G, Carmena D, Jiménez MC, Rivero-Juárez A, Moya L, Rodón J, Esperón F, Pérez-Hernando B, Sánchez-León R, Hurtado-Gallego J, Alcolea S, Sainz T, Calvo C, Méndez-Echevarría A.** Zoonosis screening in Spanish immunocompromised children and their pets. Front Vet Sci. 2024; 11: 1425870. Article. IF: 2.9; Q1
- **Guarch-Ibáñez B, Carreras-Abad C, Frick MA, Blázquez-Gamero D, Baquero-Artigao F, Fuentes I, Soler-Palacin P.** REIV-TOXO Project: Results from a Spanish cohort of congenital toxoplasmosis (2015-2022). The beneficial effects of prenatal treatment on clinical outcomes of infected newborns. Plos Neglect Trop D. 2024; 18(10): e0012619. Article. IF: 3.4; D1
- **Guarch-Ibáñez B, Carreras-Abad C, Frick MA, Blázquez-Gamero D, Baquero-Artigao F, Fuentes-Corripio I, Soler-Palacin P.** Results of the REIV-TOXO national survey on prenatal screening for toxoplasmosis in Spain. Enferm Infec Micr Cl. 2024; 42(9): 478-83. Article. IF: 2.5; Q2
- **Ligero-López J, Escosa-García L, Schüffelmann-Gutiérrez C, Laplaza-González M, Quiles-Melero MI, Moreno-Ramos F, Baquero-Artigao F, Cacho-Calvo J, Cendejas-Bueno E.** Is it in their eyes? Correlation between microorganisms isolated from bronchial aspirates and conjunctival swabs in a Pediatric Intensive Care Unit. Rev Esp Quim. 2024; 37(2): 176-9. Article. IF: 2.2; Q3
- **Llano BBQD, Sainz T, Sáez CD, Miras EB, Barriocanal MB, Olmo JAC, Martori AF, Baranda AG.** Violence as a health problem. An Pediatr. 2024; 100(3): 202-11. Article. IF: 2.1; Q2
- **Muruzábal C, Vicente L, Taravillo LE, de Llano BBQ, Calvo C, Hortelano MGL.** Off-Label Yellow Fever and Hepatitis A Vaccination in Traveling Children. Children (Basel). 2024; 11(3): 374. Article. IF: 2.1; Q2
- **Ríos-Barnés M, Velasco-Arnaiz E, Fortuny C, Benavides M, Baquero-Artigao F, Muga O, Del Valle R, Frick MA, Bringue X, Herrero S, Vilas J, Alonso-Ojembarrena A, Castells-Vilella L, Rojo P, Blázquez-Gamero D, Esteva C, Sánchez E, Alarcón A, Noguera-Julian A.** Renal Function Impairment in Children With Congenital Cytomegalovirus Infection: A Cross-sectional Study. Pediatr Infect Dis J. 2024; 43(3): 257-62. Article. IF: 2.2; Q2
- **Rodríguez NEG, Aguilera-Alonso D, Escosa L, Gomez-Gil MR, Manzanares A, Ascaso MG, Bermejo-Gómez A, Abad MJG, Ramos AM, Nunez AS, Orellana MA, Cercenado E, Lozano JS, Calvo C, Baquero-Artigao F.** Pseudomonas aeruginosa bloodstream infections in children and adolescents: risk factors associated with carbapenem resistance and mortality. J Hosp Infect. 2024; 149: 56-64. Article. IF: 3.1; Q1
- **Rodríguez-Molino P, Alarcón A, Martínez-Biarge M, Cabrera-Lafuente M, Aldecoa V, Fernández-Sánchez A, Fernández-Jiménez E, Baquero-Artigao F, García-Alix A.** Behavioral Problems and Family Impact in Congenital Cytomegalovirus Infection. Pediatr Infect Dis J. 2024; 43(6): 556-8. Article. IF: 2.2; Q2
- **Rodríguez-Molino P, Martínez SG, Amador JB, Mellado-Sola I, Martín LM, Falces-Romero I, López-Hortelano MG, Hurtado-Gallego J, Mellado MJ, Grasa C, Sainz T.** Schistosomiasis in migrant children and adolescents in a paediatric tropical referral unit in Spain: diagnosis and long-term management challenges. Eur J Pediatr. 2024; 183(10): 4457-65. Article. IF: 2.6; Q1
- **Rodríguez-Molino P, Sánchez AG, Noguera-Julián A, Soler-García A, Paz PM, Méndez-Echevarría A, Baquero-Artigao F, Muñoz MG, Ruíz-Serrano MJ, Monsonís M, León RS, Saavedra-Lozano J, Santiago-García B, Sainz T.** QuantiFERON-TB reversion in children and adolescents with tuberculosis. Front Immunol. 2024; 15: 1310472. Article. IF: 5.9; Q1
- **Rodríguez-Molino P, Tebruegge M, Noguera-Julian A, Neth O, Fidler K, Brinkmann F, Sainz T, Ivaskeviciene I, Ritz N, Brito MJ, Silva TM, Chechenieva V, Serdiuk M, Lancella L, Russo C, Soler-García A, Navarro ML, Krueger R, Feiterna-Sperling C, Starshinova A, Hiteva A, Hoffmann A, Kalibatas P, Lo Vecchio A, Scarano SM, Bustillo M, Gamero DB, Espiau M, Buonsenso D, Falcón L, Turnbull L, Colino E, Rueda S, Buxbaum C, Carazo B, Álvarez C, Dapena M, Piqueras A, Velizarova S, Ozere I, Götzinger F, Pareja M, Llanos MIG, Soto B, Martín SR, Korta JJ, Pérez-Gorricho B, Herranz M, Hernández-Bartolomé A, Díaz-Almirón M, Vasconcelos MK, Ferreras-Antolín L, Santiago-García B.** Tuberculosis Disease in Immunocompromised Children and Adolescents: A Pediatric Tuberculosis Network European Trials Group Multicenter Case-control Study. Clin Infect Dis. 2024; 79(1): 215-22. Article. IF: 7.3; D1
- **Ron R, Martínez-Sanz J, Herrera S, Ramos-Ruperto L, Díez A, Sainz T, álvarez-Díaz N, Correa-Pérez A, Muriel A, López-Alcalde J, Pérez-Molina JA, Moreno S, Serrano-Villar S.** CD4/CD8 ratio and CD8+T-cell count as prognostic markers for non-AIDS mortality in people living with HIV. A systematic review and meta-analysis. Front Immunol. 2024; 15: 1343124. Review. IF: 5.9; Q1
- **Sainz T, Aldrovandi G.** Pediatric perspective: the microbiome in vertical HIV-infection: unravelling gaps, challenges, and therapeutic potential. Curr Opin Hiv Aids. 2024; 19(5): 253-60. Article. IF: 4.0; Q1
- **Sánchez-Merino V, Martín-Serrano M, Beltrán M, Lazaro-Martin B, Cervantes E, Oltra M, Sainz T, García F, Navarro ML, Yuste E.** The Association of HIV-1 Neutralization in Aviremic Children and Adults with Time to ART Initiation and CD4+/CD8+ Ratios. Vaccines (Basel). 2024; 12(1): 8. Article. IF: 3.4; Q2
- **Soriano-Ramos M, Pedrero-Tomé R, Giménez-Quiles E, Albert E, Baquero-Artigao F, Rodríguez-Molino P, del Rosal T, Noguera-Julian A, Fortuny C, Ríos-Barnés M, Saavedra-Lozano J, Dueñas E, Sánchez-Mateos M, Castells L, de la Serna M, Frick MA, de Vergas J, Núñez-Enamorado N, Moral-Pumarega MT, Folgueira MD, Navarro D, Blázquez-Gamero D.** T-Cell Immune Responses in Newborns and Long-Term Sequelae in Congenital Cytomegalovirus Infection (CYTRIC Study). J Pediatr-Us. 2024; 272: 114084. Article. IF: 3.5; D1
- **Tarancón-Díez L, Carrasco I, Montes L, Falces-Romero I, Vázquez-Alejo E, de Ory SJ, Dapena M, Iribarren JA, Díez C, Ramos-Ruperto L, Colino E, Calvo C, Muñoz-Fernández MA, Navarro ML, Sainz T.** Torque teno virus: a

potential marker of immune reconstitution in youths with vertically acquired HIV. Sci Rep-Uk. 2024; 14(1): 24691. Article. IF: 3.9; Q1

- **Villar-Hernández R, Latorre I, Noguera-Julián A, Martínez-Planas A, Minguell L, Vallmanya T, Méndez M, Soriano-Arandes A, Baquero-Artigao F, Rodríguez-Molino P, Guillén-Martín S, Toro-Rueda C, De Souza-Galvao ML, Jiménez-Fuentes MA, Stojanovic Z, Sabriá J, Santos JR, Puig J, Domínguez-Álvarez M, Millet JP, Altet N, Galea Y, Muriel-Moreno B, García-García E, Bach-Griera M, Prat-Aymerich C, Julián E, Torrelles JB, Rodrigo C, Domínguez J.** Development and Evaluation of an NTM-IGRA to Guide Pediatric Lymphadenitis Diagnosis. Pediatr Infect Dis J. 2024; 43(3): 278-85. Article. IF: 2.2; Q2

Research projects

- **Bravo Queipo de Llano B, Sainz Costa T.** Rio Hortega (CM23/00057). ISCIII. 2024-2026. Managment centre: FIBHULP
- **Bravo Queipo de Llano B.** Colonización por bacterias resistentes a los antibióticos en menores recién llegados a españa y su evolución tras un año de estancia en nuestro país (2023684). Fundación SEIP. 2024-Ongoing. Managment centre: FIBHULP
- **Escosa Garcia L.** CARBAPED-1. Bacteriemias por gramnegativos resistentes a carbapenémicos en pediatría: prevalencia, clonalidad y estrategias para la mejora de la supervivencia en España (PI23/00391). ISCIII. 2024-2026. Managment centre: FIBHULP
- **Escosa Garcia L.** Estudio de infecciones por bacterias resistentes a carbapenémicos en pediatría Carba-Ped. Fundación SEIP. 2022-Ongoing. Managment centre: FIBHULP
- **Rodríguez Molino P, Sainz Costa T.** Contrato Río Hortega (CM21/00174). ISCIII. 2022-2024. Managment centre: FIBHLP
- **Rodríguez Molino P.** Estudio de la respuesta vacunal en muestras de sangre seca en población pediátrica (DRIVE study (PI4888)). European Society of Pediatric Infectious Diseases. 2021-ongoing. Managment centre: FIBHLP
- **Rodríguez Molino P.** Impacto del covid-19 materno en la respuesta inmune de los niños. Fundación de la Asociación Española de Pediatría. 2021-Ongoing. Managment centre: FIBHULP
- **Sainz Costa T, Sanchez Aparicio MT.** Contrato postdoctoral Marie Curie (MSCA-Aristos). UE. 2024-2026. Managment centre: CIBERINFEC
- **Sainz Costa T.** Aplicación de técnicas ómicas para el diagnóstico de tuberculosis en niños y adolescentes: CHILD-TB OMICS (PI20/01490). ISCIII. 2021-2024. Managment centre: FIBHULP
- **Sainz Costa T.** Capacitacion de personal sanitario en VIH y ETS en adolescentes (GLD17/0135). Gilead SA. 2017-ongoing. Managment centre: SEIMC-Gesida
- **Sainz Costa T.** Ensayo clínico fase II, randomizado, de quinacina frente a metronidazol en giardiasis resistente en niños: QUIN4kids (ICI22/00065). ISCIII. 2023-2026. Managment centre: FIBHULP
- **Sainz Costa T.** Envejecimiento acelerado en niños que viven con el vih y niños expuestos intraútero al vih/tar: proyecto epikids (PI23/01493). ISCIII. 2024-2026. Managment centre: FIBHULP
- **Sainz Costa T.** Inmunogenicidad de la vacuna 9 valente frente a VPH en niños inmunocomprometidos (IISP61381). MSD. 2023-2026. Managment centre: SEIMC-Gesida
- **Sainz Costa T.** Nuevos algoritmos diagnósticos en TB (IMF/17/22). ISCIII- CIBER. 2022-2025. Managment centre: CIBERINFEC
- **Sainz Costa T.** Proyecto EPIKIDS: envejecimiento epigenético en niños que viven con el VIH y niños expuestos intraútero al VIH/TAR (GLD23/00074 TALIA SAINZ). Gilead Sciences S.L. 2023-2025. Managment centre: FIBHULP
- **Sainz Costa T.** Torquetenovirus como marcador inmunológico en niños con infección por el vih (GLD/00090). Gilead Sciences S.L. 2022-Ongoing. Managment centre: FIBHULP
- **Sainz Costa T.** Utilidad de la ecografía torácica en la indicación de ventilación no invasiva en la bronquiolitis aguda del lactante hospitalizado. Estudio de cohorte (PI2525). European Society of Pediatric Infectious Diseases. 2017-Ongoing. Managment centre: FIBHULP



Clinical trials

- **Baquero Artigao F.** estudio fase ii, aleatorizado y parcialmente ciego, para evaluar la seguridad, reactogenicidad e inmunogenicidad de la vacuna antimeningocócica combinada abcwy tras su administración a lactantes sanos.
  Type/Phase: II
  Sponsored by: Glaxosmithkline S.A.
  Signature date: 29/01/2024
- **Baquero Artigao F.** estudio en fase iia, multicéntrico, aleatorizado, con enmascaramiento para el observador, de 2 grupos para investigar la farmacocinética, la seguridad, la tolerabilidad y la eficacia de aztreonam-avibactam por vía intravenosa ± metronidazol en comparación con el mejor tratamiento disponible (mtd) en participantes pediátricos de entre 9 meses y 18 años de edad con infecciones graves por bacterias gramnegativas incluidas infecciones intrabdominales complicadas.
  Type/Phase: IIa
  Sponsored by: Pfizer Inc.
  Signature date: 08/03/2024
- **Sainz Costa T.** un estudio sin enmascaramiento de fase 2/3 para evaluar la farmacocinética, la seguridad y la actividad antiviral de bictegravir/lenacapavir en niños y adolescentes con vih-1.
  Type/Phase: IIb
  Sponsored by: Gilead Sciences Inc.
  Signature date: 10/09/2024

Patents and trademarks

- **Mellado MJ, Piñeiro R, authors; Asociación Española de Pediatría (AEPED), assignee.** Brand name: PEDIAMÉCUM; ESM 3079824; 2013 June13.

PEDIAMÉCUM

3.7.6 Translational Research in Pediatric Oncology, Hematopoietic Transplantation and Cell Therapy

Publications: 26 | **Q1:** 15

COMPOSITION

Antonio Pérez Martínez.
Facultativo Especialista de Área en Pediatría, Oncología y Hematología. Hospital Universitario La Paz

- **Cristina Aguirre Pórtoles.** *Investigadora Predoctoral. Project Manager. FIBHULP*
- **Alfonso Alba Bernal.** *Investigador Postdoctoral. FIBHULP*
- **Estefanía Ayala Jiménez.** *Investigador Predoctoral. FIBHULP*
- **Saturnino Barrena Delfa.** *Facultativo Especialista de Cirugía Pediátrica. Hospital Universitario La Paz*
- **Halin Bareke.** *Investigadora Postdoctoral. FIBHULP*
- **David Bueno Sánchez.** *Facultativo Especialista de Área en Pediatría, Oncología y Hematología. Hospital Universitario La Paz*
- **Adela Escudero López.** *Facultativo Especialista de Área en Genética. Hospital Universitario La Paz*
- **Mikel Fernández Artacoz.** *Médico Interno Residente en Hematología y Hemoterapia. Hospital Universitario La Paz*
- **Berta González Martínez.** *Facultativo Especialista de Área en Pediatría. Hospital Universitario La Paz*
- **Pilar Guerra García.** *Facultativo Especialista de Área en Pediatría, Oncología y Hematología. Hospital Universitario La Paz*
- **Elisa Izquierdo Delgado.** *Investigadora Postdoctoral. FIBHULP*
- **Manuel Izquierdo Pastor.** *Investigador Científico CSIC. Instituto de Investigaciones Biomédicas Sols-Morreale*
- **Adriana Mañas Núñez.** *Investigador Posdoctoral. FIBHULP*
- **Laura Martín Fernández.** *Asistente Ejecutiva. FIBHULP*
- **Isabel Martínez Romera.** *Facultativo Especialista de Área en Pediatría. Hospital Universitario La Paz*
- **Carmen Mestre Durán.** *Investigadora Predoctoral. FIBHULP*
- **Antonio Jesús Muñoz Serrano.** *Facultativo Especialista de Área en Cirugía Pediátrica. Hospital Universitario La Paz*
- **Gema Pérez Chacón.** *Investigadora Senior. Instituto de Investigaciones Biomédicas Sols-Morreale*
- **Natalia Riestra Ramos.** *Técnico de Grado Superior. FIBHULP*
- **Pedro María Rubio Aparicio.** *Facultativo Especialista de Área en Pediatría, Oncología y Hematología. Hospital Universitario La Paz*
- **Beatriz Ruz Caracuel.** *Investigadora Bioinformática. Hospital Universitario La Paz*
- **Javier Ruiz Navarro.** *Investigador Predoctoral. Instituto de Investigaciones Biomédicas Sols-Morreale*
- **Sonsoles San Román Pacheco.** *Facultativo Especialista de Área en Pediatría, Oncología y Hematología. Hospital Universitario La Paz*
- **Maria Octavia de Santisteban Tara.** *Ayudante de Investigación. Hospital Universitario La Paz*
- **Clara María Venegas Mascaró.** *Investigadora Predoctoral. FIBHULP*
- **Juan Manuel Zapata Hernández.** *Científico Titular. Instituto de Investigaciones Biomédicas Sols-Morreale*

STRATEGIC OBJETIVES

- Our research program focuses on the molecular and immunological characterization of childhood cancer; the development of cell therapies, primarily through the susceptibility of tumor cells to Natural Killer cells; and the optimization of hematopoietic stem cells transplantation.



RESEARCH LINES

- Analysis of solid/hematological tumors samples to determine their susceptibility to cell therapy, at functional, protein expression and genetic level.
- Cell therapy with activated NK cells in childhood cancer.
- Hematopoietic progenitor transplantation as a platform for cell therapy.
- Cell therapy with memory T lymphocytes as adoptive immunotherapy in transplantation of haematopoietic progenitors.
- Optimization of cell therapy by the generation of an NKG2D antigenic chimeric receptor (NKG2DCAR). Evaluation of its specificity, persistence and activity (in vitro and in vivo) for the treatment of childhood cancer.
- Optimization of CAR T cell therapy using nanotechnology and epigenetic regulators
- Induction of immunological tolerance in solid organ transplantation through the induction of hematopoietic mixed chimerism by cell therapy.
- Development of academic clinical trials and collaborations with the pharmaceutical industry as a strategy for the development of new therapies more effective and with fewer side effects in childhood cancer.
- Cell therapy with citokine induced-memory like NK cells for pediatric solid tumors.
- Cell therapy with memory T lymphocytes from COVID-19 convalescent donors as an innovative therapy for COVID-19.

RESEARCH ACTIVITY

Doctoral Theses

- **Galán Gómez V.** Caracterización genética de la leucemia linfoblástica aguda en pediatría para su optimización diagnóstica, pronóstica y terapéutica[dissertation]. Madrid: Universidad Autónoma de Madrid: 2024(24/05/2024). Director: Pérez Martínez A, Escudero López A.
- **Navarro Zapata A.** Evaluation of the Combined Treatment of NKG2D-CAR T Cells and Epigenetic Drugs for Neuroblastoma Therapy[dissertation]. Madrid: Universidad Autónoma de Madrid: 2024(02/12/2025). Director: Pérez Martínez A, Fernández Casanova L.

Publications

- **Ascunce M, Coccolo A, Mozo Y, Baquero-Artigao F, Rodriguez-Molino P, Toro-Rueda C, Garcia-Clemente P, Sánchez-Zapardiel E, López-Granados E, Corral-Sánchez D, Bueno D, Sisinni L, Pérez-Martínez A, Calvo C, del Rosal T.** Severe Impairment of T-cell Immunity and Pulmonary GvHD Are Major Risk Factors for Nontuberculous Mycobacterial Infection After Pediatric Allogeneic Hematopoietic Stem Cell Transplantation. Pediatr Infect Dis J. 2024; 43(9): 885-8. Article. IF: 2.2; Q2
- **Badía X, Calleja MA, Escudero-Vilaplana V, Pérez-Martínez A, Piñana JL, Poveda JL, Vallés JA.** The value of the reflective discussion in decision-making using multi-criteria decision analysis (MCDA): an example of determining the value contribution of tabelecleucel for the treatment of the Epstein Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD). Orphanet J Rare Dis. 2024; 19(1): 308. Article. IF: 3.5; Q2
- **Bailén R, Iacoboni G, Delgado J, López-Corral L, Hernani-Morales R, Ortiz-Maldonado V, Guerreiro M, Caballero AC, Guerra-Domínguez ML, Sánchez-Pina JM, Peña M, Torrent A, Pérez-Martínez A, Bastos-Oreiro M, Reguera-Ortega JL, Martín A, Hernandez-Boluda JC, Martínez-Cibrián N, Sanz J, Briones J, Henriquez HL, Calbacho M, Mussetti A, Sancho JM, Barba P, Kwon M.** Anti-CD19 CAR-T Cell Therapy in Elderly Patients: Multicentric Real-World Experience from GETH-TC/GELTAMO. Transplant Cell Ther. 2024; 30(10): 988. Article. IF: 4.4; Q1
- **Campillo-Ajenjo M, Peña-Burgos EM, Ruiz BH, Albero GE, Aparicio PR, Pajares MP, Zurita MB, Regojo-Zapata RM, Rasero JLB, Alvarado EA.** Congenital metastatic neuroblastoma with placental involvement as a rare cause of non-immune fetal hydrops. J Obstet Gynaecol Re. 2024; 50(8): 1402-7. Article. IF: 1.5; Q3
- **Carabante MIB, Bueno D, García LA, Torija IL, Marsal J, Navarro JMF, Oficialdegui MLU, Panesso M, Molina B, Bieler CB, Palomo P, Martinez AP, Diaz-de-Heredia C.** Use of Eculizumab in Pediatric Patients with High-Risk Transplantation-Associated Thrombotic Microangiopathy: Outcomes and Risk Factors Associated with Response and Survival. A Retrospective Study on Behalf of the Spanish Group for Hematopoietic Transplantation and Cellular Therapy (GETH-TC). Transplant Cell Ther. 2024; 30(6): 601. Article. IF: 4.4; Q1
- **de la Rosa JV, Tabraue C, Huang ZQ, Orizaola MC, Martín-Rodríguez P, Steffensen KR, Zapata JM, Boscá L, Tontonoz P, Alemany S, Treuter E, Castrillo A.** Reprogramming of the LXRα Transcriptome Sustains Macrophage Secondary Inflammatory Responses. Adv Sci (Weinh). 2024; 11(20): e2307201. Article. IF: 14.1; D1
- **Echecopar C, Abad I, Galán-Gómez V, del Castillo YM, Sisinni L, Bueno D, Ruz B, Pérez-Martínez A.** An artificial intelligence-driven predictive model for pediatric allogeneic hematopoietic stem cell transplantation using clinical variables. Eur J Haematol. 2024; 112(6): 910-6. Article. IF: 2.3; Q2
- **Echecopar C, Rey ID, Galán-Gámez V, González-Perez C, del Castillo YM, Martínez BG, Pérez-Martínez A.** The paradigm of total body irradiation in acute lymphoblastic leukemia: Therapeutic effectiveness against the challenges of toxicity. An Pediatr. 2024; 100(4): 259-67. Article. IF: 2.1; Q2
- **Felgueres MJ, Esteso G, García-Jiménez AF, Dopazo A, Aguiló N, Mestre-Durán C, Martínez-Piñeiro L, Pérez-Martínez A, Reyburn HT, Valés-Gómez M.** BCG priming followed by a novel interleukin combination activates Natural Killer cells to selectively proliferate and become anti-tumour long-lived effectors. Sci Rep-Uk. 2024; 14(1): 13133. Article. IF: 3.9; Q1
- **Ferreras C, Hernández-Blanco C, Martín-Quirós A, Al-Akioui-Sanz K, Mora-Rillo M, Ibáñez F, Díaz-Almirón M, Cano-Ochando J, Lozano-Ojalvo D, Jiménez-González M, Goterris R, Sánchez-Zapardiel E, de Paz R, Guerra-García P, Queiruga-Parada J, Molina P, Briones ML, Ruz-Caracuel B, Borobia AM, Carcas AJ, Planelles D, Vicario JL, Moreno MA, Balas A, Llano M, Llorente A, del Balzo A, Cañada C, García MA, Calvín ME, Arenas I, de Diego RP, Eguizábal C, Soria B, Solano C, Pérez-Martínez A.** Results of phase 2 randomized multi-center study to evaluate the safety and efficacy of infusion of memory T cells as adoptive therapy in severe. Cytotherapy. 2024; 26(1): 25-35. Article. IF: 3.2; Q2
- **García LA, Sánchez DB, Navarro JMF, García AR, Blanquer MB, Carabante MIB, del Castillo YM, Soler JLF, Oficialdegui MLU, Sisinni L, Martinez AP, Rubio CDD.** Hematopoietic stem cell transplantation in children with chronic granulomatous disease: the Spanish experience. Front Immunol. 2024; 15: 1307932. Article. IF: 5.9; Q1
- **Garrido-Boltón J, Alcami-Pertejo M, de la Vega R, Hernández-Oliveros F, Pérez-Martínez A, Bravo-Ortiz MF, Fernández-Jiménez E.** Neuropsychological and biopsychosocial evolution, therapeutic adherence and unmet care needs during paediatric transplantation: study protocol of a mixed-methods design (observational cohort study and focus groups) - the TransplantKIDS mental health project. Front Psychol. 2024; 15: 1308418. Article. IF: 2.9; Q1
- **Gruenewald TGP, Postel-Vinay S, Nakayama RT, Berlow NE, Bolzicco A, Cerullo V, Dermawan JK, Frezza AM, Italiano A, Jin JX, Le Loarer F, Martín-Broto J, Pecora A, Pérez-Martínez A, Tam YB, Tirode F, Trama A, Pasquali S, Vescia M, Wortmann L, Wortmann M, Yoshida A, Webb K, Huang PH, Keller C, Antonescu CR.** Translational Aspects of Epithelioid Sarcoma: Current Consensus. Clin Cancer Res. 2024; 30(6): 1079-92. Review. IF: 10.2; D1
- **Guerra-García P, Bomken S, Ling RBC, Lazareva A, Gupte G, Amrolia P, Andres M, Díez-Sebastián J, Taj MM.** Management of paediatric monomorphic post-transplant lymphoproliferative disorders with low-intensity treatment: A multicentre international experience. Pediatr Blood Cancer. 2024; 71(8): e31053. Article. IF: 2.3; Q2
- **Kabat MG, Li Y, Galán V, Mozo Y, Sisinni L, Bueno-Sánchez D, Corral D, Naik S, Echecopar C, Aguirre-Portolés C, Al-Akioui-Sanz K, De Paz R, Marcos A, Romero AB, Talleur A, Yuste VJ, Triplett B, Pérez-Martínez A.** Safety and Efficacy of High-Dose Memory CD45RO+Donor Lymphocyte Infusion in Pediatric Recipients after Hematopoietic Stem Cell Transplantation. Cytotherapy. 2024; 26(12): 1458-64. Article. IF: 3.2; Q2
- **Martín-Antonio B, Blanco B, González-Murillo A, Hidalgo L, Minguillón J, Pérez-Chacón G.** Newer generations of multi-target CAR and STAb-T immunotherapeutics: NEXT CART Consortium as a cooperative effort to overcome current limitations. Front Immunol. 2024; 15: 1386856. Article. IF: 5.9; Q1
- **Mendiola M, Heredia-Soto V, Ruz-Caracuel I, Baillo A, Ramón-Patiño JL, Berjón A, Escudero EJ, Peláez-García A, Hernández A, Feliú J, Hardisson D, Redondo A.** Performance of the Idylla microsatellite instability test in endometrial cancer. Mol Cell Probe. 2024; 77(): 101976. Article. IF: 3.0; Q2
- **Mingot-Castellano ME, Reguera-Ortega JL, Torres DZ, Hernani R, López-Godino O, Guerreiro M, Herrero B, López-Corral L, Luna A, González-Pinedo L, Chinea-Rodríguez A, Africa-Martín A, Bailen R, Martinez-Cibrian N, Balsalobre P, Filaferro S, Alonso-Saladrigues A, Barba P, Pérez-Martínez A, Calbacho M, Pérez-Simón JA, Sánchez-Pina JM.** Use of Eltrombopag to Improve Thrombocytopenia and Tranfusion Requirement in Anti-CD19 CAR-T Cell-Treated Patients. J Clin Med. 2024; 13(17): 5117. Article. IF: 2.9; Q1

- **Molinos-Quintana A, Alonso-Saladrigues A, Herrero B, Caballero-Velázquez T, Galán-Gómez V, Panesso M, Torrebadell M, Delgado-Serrano J, de Soto CP, Faura A, González-Martínez B, Castillo-Robleda A, Díaz-de-Heredia C, Pérez-Martínez A, Pérez-Hurtado JM, Rives S, Pérez-Simón JA.** Impact of disease burden and late loss of B cell aplasia on the risk of relapse after CD19 chimeric antigen receptor T Cell (Tisagenlecleucel) infusion in pediatric and young adult patients with relapse/refractory acute lymphoblastic leukemia: role of B-cell monitoring. Front Immunol. 2024; 14: 1280580. Article. IF: 5.9; Q1
- **Onida F, Gras L, Ge JR, Koster L, Hamladji RM, Byrne J, Avenoso D, Aljurf M, Robin M, Halaburda K, Passweg J, Salmenniemi U, Sengeloev H, Apperley J, Clark A, Remenyi P, Morozova E, Kinsella F, Lenhoff S, Ganser A, Wu KL, Pérez-Martínez A, Hayden PJ, Raj K, Drozd-Sokolowska J, Orti G, de Lavallade H, Yakoub-Agha I, McLornan DP, Chalandon Y.** Mismatched related donor allogeneic haematopoietic cell transplantation compared to other donor types for Ph plus chronic myeloid leukaemia: A retrospective analysis from the Chronic Malignancies Working Party of the EBMT. Brit J Haematol. 2024; 204(6): 2365-77. Article. IF: 3.8; Q1
- **París-Muñoz A, León-Triana O, Pérez-Martínez A, Barber DF.** Helios as a Potential Biomarker in Systemic Lupus Erythematosus and New Therapies Based on Immunosuppressive Cells. Int J Mol Sci. 2024; 25(1): 452. Review. IF: 4.9; Q1
- **Pérez-Chacón G, Vincent-Fabert C, Zapata JM.** Editorial: Community series in mouse models of B cell malignancies, volume II. Front Immunol. 2024; 15: 1488601. Editorial Material. IF: 5.9; Q1
- **Ruiz-Navarro J, Fernández-Hermira S, Sanz-Fernández I, Barbeito P, Navarro-Zapata A, Pérez-Martínez A, García-Gonzalo FR, Calvo V, Pastor MI.** Formin-like 1β phosphorylation at S1086 is necessary for secretory polarized traffic of exosomes at the immune synapse in Jurkat T lymphocytes. Elife. 2024; 13: RP96942. Article. Not Indexed
- **Shephard JLV, Pérez EM, Bujalance SG, Aguilar IM, Martínez BG, Martínez AP, Granados EL, Feito AM, Zapardiel ES.** The challenge of standardizing CAR-T cell monitoring: A comparison of two flow-cytometry methods and correlation with qPCR technique. Cytom Part A. 2024; 105(5): 368-75. Article. IF: 2.1; Q3
- **Sisinni L, Monserrate GXA, Hurtado JMP, Panesso M, Molina B, Fuentes C, Fuster JL, Verdú-Amoros J, Regueiro A, Palomo P, Beléndez C, Pascual A, Badell I, Mozo Y, Bueno D, Pérez-Martínez A, Fernández JM, Vicent MG, de Heredia CD.** Haploidentical versus Cord Blood Transplantation in Pediatric AML. A Retrospective Outcome Analysis on Behalf of the Pediatric Subcommittee of GETH (Grupo Espanol de Trasplante Hematopoyetico). Transplant Cell Ther. 2024; 30(10): 10150. Article. IF: 4.4; Q1
- **Wachowiak J, Galimard JE, Dalissier A, Rihani R, Alsaedi H, Wynn RF, Dalle JH, de Latour RP, Sedlacek P, Balduzzi A, Schroeder T, Bodova I, Vicent MG, Gruhn B, Hamladji RM, Krivan G, Patrick K, Sobkowiak-Sobierajska A, Stepensky P, Unal A, Amrolia P, Martínez AP, Rialland F, Aljurf M, Isgro A, Toren A, Bierings M, Corbacioglu S, Kalwak K.** Outcomes of allogeneic haematopoietic cell transplantation for myelofibrosis in children and adolescents: the retrospective study of the EBMT Paediatric Diseases WP. Bone Marrow Transpl. 2024; 59(8): 1057-69. Article. IF: 5.2; Q1

Research projects

- **Izquierdo Delgado EP.** Utilidad clínica de la biopsia líquida en tumores cerebrales pediátricos, para mejorar el diagnóstico, la estratificación y el seguimiento de los pacientes (PI21/00376). ISCIII. 2022-2024. Managment centre: FIBHULP
- **Mañas Núñez A.** IronKiller_Joining the forces of Natural Killer Cells and Ferroptosis to treat Refractory Neuroblastoma. UE. 2023-2025. Managment centre: FIBHULP
- **Minguillon Pedreño J.** Desarrollo de una terapia car-t específica para la enfermedad rara: leucemia mielomonocítica juvenil. Fundación Leucemia y Linfoma. 2022-Ongoing. Managment centre: FIBHULP
- **Minguillon Pedreño J.** Preclinical and Clinical Validation of a CAR-T CD7 Therapy For Pediatric Leukemias (7CAR4KIDS) (PI23/0029). Comunidad de Madrid. 2024-2026. Managment centre: FIBHULP
- **Pérez Martínez A.** Academic approach using CAR-T in hematological malignancies with unmet medical needs in children and AYA: feasibility, safety and efficacy study (ReALL_CAR-T) (PI22/01226). ISCIII. 2023-2025. Managment centre: FIBHULP
- **Pérez Martínez A.** Analisis genetico, trasnscriptomico y proteomico para identificar antigenos diana de terapia car t en leucemia mielomonocitica juvenil. Fundación Cris Contra el Cáncer. 2021-Ongoing. Managment centre: FIBHULP
- **Pérez Martínez A.** Aproximación académica mediante car-t en hemopatías malignas con necesidad médicas no cubiertas en niños y aya: estudio de viavilidad, seguridad y eficacia (REALL_CAR-T) (PI22/01226). ISCIII. 2023-2025. Managment centre: FIBHULP
- **Pérez Martínez A.** Braintruck: turning car t therapy into iil18 truck as treatment for pediatric central nervous system tumors. Fundación Cris Contra el Cáncer. 2022-Ongoing. Managment centre: FIBHULP
- **Pérez Martínez A.** Consorcio Estatal en Red para el desarrollo de Medicamentos de Terapias Avanzadas (CERT22/00065). ISCIII. 2024-2026. Managment centre: FIBHULP
- **Pérez Martínez A.** Diseño del receptor antigenico quimerico NKG2D (CAR-NKG2D) como terapia celular en los sarcomas infantiles. Ong Otromundoesposible. 2019-Ongoing. Managment centre: FIBHULP
- **Pérez Martínez A.** Ensayo clinico en fase t memoria expresando un receptor chimerico antigenico con especificidad nkg2d en niños, adolescentes y adjultos jovenes con sarcoma avanzado. A phase I trial of memory t cells expressing an anti-nkg2d chimeric antigen receptor in children, adolescents and young adults with advanced sarcoma. Fundación Asociación Española Contra el Cáncer. 2019-Ongoing. Managment centre: FIBHULP
- **Pérez Martínez A.** Ensayo clinico en fase t memoria expresando un receptor chimerico antigenico con especificidad NKG2D en niños, adolescentes y adjultos jovenes con sarcoma avanzado. A phase I trial of memory t cells expressing an anti-NKG2D chimeric antigen receptor. Fundación Asociación Española contra el Cáncer. 2019-2023. Managment centre: FIBHULP
- **Pérez Martínez A.** Ensayo clinico fase I/II, multicentrico abierto, de infusión de celulas nk activadas para el tratamiento de niños, adolescentes y adultos jovenes con sarcomas. estudio sankoma. Fundación la Sonrisa de Alex. 2017-Ongoing. Managment centre: FIBHULP
- **Pérez Martínez A.** Ensayo clínico fase II de infusión intratumoral/intraventricular de células CART-NKG2D o NKIL15 en niños, adolescentes y adultos jóvenes con tumores de alto grado recurrentes/refractarios del sistema nervioso central (CINK-CAR) (ICI19/00052). ISCIII. 2020-2025. Managment centre: FIBHULP
- **Pérez Martínez A.** Entrenamiento cognitivo a través del juego tecnologico para mejorar los efectos cognitivos relacionados con el tratamiento del cáncer infantil(winners o super-vivientes). Fundación Juegaterapia. 2022-Ongoing. Managment centre: FIBHULP
- **Pérez Martínez A.** Estudio mediante tecnologia de alto rendimiento de la predisposición hereditaria al cancer infantil. Fundación Cris Contra el Cáncer. 2017-Ongoing. Managment centre: FIBHULP
- **Pérez Martínez A.** Genetic, transcriptomic and proteomic analysis for the identification of target antigen for CAR T therapy in juvenile myelomonocytic leukemia (CART-JMML). Fundación Cris Contra el Cáncer. 2022-Ongoing. Managment centre: FIBHULP
- **Pérez Martínez A.** Implementación de una escala pediátrica de valoración de alerta temprana en pacientes pediátricos hospitalizados con patología hemato-oncológica y trasplante de progenitores hematopoyéticos como plan de mejora de la calidad y seguridad asistencial. Fundación Aladina. 2020-Ongoing. Managment centre: FIBHULP
- **Pérez Martínez A.** Implementing magnetic targeting of nano-guided immune cells (IMAGINE).

Fight Kids Cancer-European Cancer Foundation. 2021-Ongoing. Managment centre: FIBHULP

- **Pérez Martínez A.** Inmunoterapia en neusoblastomas pediátricos: tratamiento dirigido a las celulas tumorales iniciadoras de la metástasis. Fundación Cris Contra el Cáncer. 2019-Ongoing. Managment centre: FIBHULP
- **Pérez Martínez A.** Inmunoterapia en sarcomas: combinación del anticuerpo anticxcr4 y la terapia celular NK. Fundación la Sonrisa de Alex. 2016-Ongoing. Managment centre: FIBHULP
- **Pérez Martínez A.** Inmunovacter-CM. Regulation of the inflammatory response and dynamics of immunity in COVID-19 and immunocompromised patients from different risk populations. New therapeutic approaches. Fondo Europeo de Desarrollo Regional. 2022-Ongoing. Managment centre: FIBHULP
- **Pérez Martínez A.** Memory-like NK cells: a new therapy for ewing sarcoma (MEMO4ewing). Fundación Cris Contra el Cáncer. 2022-Ongoing. Managment centre: FIBHULP
- **Pérez Martínez A.** Nueva Generación de Inmunoterapias STAb y CART Multidianas (Next Generation CART MAD) (S2022/BMD-7225). CM. 2023-2026. Managment centre: FIBHULP
- **Pérez Martínez A.** Optimización diagnóstica y terapéutica del cáncer infantil mediante su caracterización genética avanzada utilizando tecnología de alto rendimiento. suproyecto: caractaerizacion molecular avanzada de la leucemia linfoblástica aguda en pediatria. Fundación Asociación Española contra el Cáncer. 2022-Ongoing. Managment centre: FIBHULP
- **Pérez Martínez A.** Receptor antigénico quimérico nkg2d para el tratamiento de pacientes pediatricos con leucemia aguda y leucemia mielomonocítica juvenil: validación escala clinica y primer estudio de seguridad en pacientes. Fundación Cris Contra el Cáncer. 2019-Ongoing. Managment centre: FIBHULP
- **Pérez Martínez A.** Sehop-Pencil Study Personalised Medicine for Cancer in Children in Spain (PMP21/00073). ISCIII. 2022-2025. Managment centre: FIBHULP
- **Pérez Martínez A.** Unidad de investigación y de terapias avanzadas en hematooncologia infantil. Fundación Cris Contra el Cáncer. 2016-Ongoing. Managment centre: FIBHULP
- **Rubio Aparicio PM.** Actualización y renovación de la actividad en el servicio de oncología pediátrica del Hospital Universitario La Paz. Varios. 2012-Ongoing. Managment centre: FIBHULP

Cibers and Retics

- **Pérez Martínez A.** RICORS - Terapias avanzadas (RD21/0017/0025). ISCIII. (01/01/2024). FIBHULP

Clinical trials

- **Pérez Martínez A.** sacha: acceso seguro a medicamentos innovadores para niños, adolescentes y adultos jóvenes con cáncer.
  Type/Phase: EOm prospectivo
  Sponsored by: Fundación De La Sociedad Española De Hemetologia Y Oncologia Pediatricas
  Signature date: 06/02/2024
- **Pérez Martínez A.** on-trk: estudio prospectivo no intervencionista en pacientes con cáncer de fusión trk localmente avanzado o metastásico tratados con larotrectinib.
  Type/Phase: EOm prospectivo
  Sponsored by: Bayer Hispania S.L.
  Signature date: 10/04/2024
- **Pérez Martínez A.** estudio en fase 1, multicéntrico y sin enmascaramiento para evaluar la farmacocinética, seguridad y tolerabilidad de una dosis única intravenosa de acetato de rezafungin en sujetos pediátricos desde su nacimiento hasta <18 años de edad que estén recibiendo antifúngicos sistémicos como profilaxis para infección fúngica invasiva o para tratar una posible o confirmada infección fúngica.
  Type/Phase: I
  Sponsored by: Mundipharma Research GMBH & Co Kg
  Signature date: 13/03/2024
- **Pérez Martínez A.** estudio en fase 1/2 de determinación de la dosis y ampliación de la dosis de cobolimab en combinación con dostarlimab en participantes pediátricos y adultos jóvenes con tumores recién diagnosticados y recidivantes/ resistentes al tratamiento (popstar)".
  Type/Phase: II
  Sponsored by: Glaxosmithkline Research And Development Limited
  Signature date: 09/08/2024
- **Rubio Aparicio PM.** estudio de fase 1, multicéntrico, abierto, con intensificación de dosis y expansión de cohorte con niraparib y dostarlimab en pacientes pediátricos con tumores sólidos recurrentes o refractarios.
  Type/Phase: I
  Sponsored by: Glaxosmithkline Research And Development Limited;Glaxosmithkline Research And Development Limited
  Signature date: 22/05/2024
- **Rubio Aparicio PM.** far-rms - un estudio global para niños y adultos con rabdomiosarcoma recién diagnosticado y recidivante.
  Type/Phase: IV
  Sponsored by: University Of Birmingham
  Signature date: 10/06/2024
- **González Martínez B.** inteligencia artificial y radiómica en linfoma pediátrico: interés en la enfermedad residual en la evaluación de respuesta temprana (airly).
  Type/Phase: No EPA
  Sponsored by: Fundación Para La Investigación Delhospital Clínico De La Comunidad Valenciana (Instituto Deinvestigación Sanitaria Inc.liva
  Signature date: 17/10/2024
- **González Martínez B.** protocolo piloto de estudio de tratamiento del consorcio alltogether para niños y adultos jóvenes (0-45 años) con diagnóstico reciente de leucemia linfoblástica (lla).
  Type/Phase: EOm prospectivo
  Sponsored by: Karolinska Universitetssjukhuset
  Signature date: 08/11/2024
- **Pérez Martínez A.** estudio multicéntrico de fase 1/2, de aumento escalonado de la dosis, para evaluar la seguridad, la farmacocinética, la farmacodinámica y la eficacia de quizartinib, en combinación con quimioterapia de reinducción y como tratamiento de mantenimiento con un solo agente, en pacientes pediátricos con mla refractaria o en recaída de entre 1 mes y 18 años (y adultos jóvenes de hasta 21 años) con mutaciones de flt3-itd".
  Type/Phase: I
  Sponsored by: Fortrea Inc. (Labcorp Drug Development Inc.)
  Signature date: 05/12/2024

Patents and trademarks

- **Vela Cuenca M, González Navarro P, Valentín Quiroga J, Escudero López A, Pérez Martínez A, Fernández Casanova L, inventors; FIBHULP, CNIO, assignees.**Anti-CXCR4 antibody combined with activated and expanded natural killer cells for cancer immunotherapy. 62/642,313 US Provisional Application, IB2019/052042; 2018 March 13
- **Pérez Martínez A, Ferreras Puente C,B, inventors; UAM, FIBHULP, Universidad Miguel Hernández de Elche (UMH), Fundación de la Comunitat Valenciana para la gestión del Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL), assignees.** Memory T cells as adoptive cell therapy for viral infections. EP20382850.4 (EP3974029), PCT/ EP2021/076516; 2020 September 25.
- **Mayán Santos M, Acea Nebril B, Varela Eirín M, Rodríguez-Candela Mateos M, Díaz Carballa CC, Fonseca Capdevila E, Barrio LC, Escudero López A, inventors; Fundación Profesor Novoa Santos- Instituto de Investigación Biomédica de A Coruña (INIBIC), assignees.** Composición para el tratamiento de los efectos secundarios de la radioterapia y/o quimioterapia. PCT/ ES2020/070269: 2020 April 27

3.7.7 Congenital Malformations and Transplantation

Publications: 17 | **Q1:** 7

COMPOSITION

Francisco Hernández Oliveros.
Facultativo Especialista de Área en Cirugía Pediátrica. Hospital Universitario La Paz

- **Maria Virginia Amesty Morello.** *Médico Adjunto en Cirugía Pediátrica. Hospital Universitario La Paz*
- **Ane Miren Andrés Moreno.** *Facultativo Especialista de Área en Cirugía Pediátrica. Hospital Universitario La Paz. Pediátrica Profesor Asociado. Universidad Autónoma de Madrid*
- **Sara Cabezuelo Ballestero.** *Facultativo Especialista de Área en Anestesiología. Hospital Universitario La Paz*
- **Carlos de la Torre Ramos.** *Médico Adjunto en Cirugía Pediátrica. Hospital Universitario La Paz*
- **Carlos Delgado Miguel.** *Facultativo Especialista de Área en Cirugía Pediátrica. FIBHULP*
- **José Luis Encinas Hernández.** *Facultativo Especialista de Área en Cirugía Pediátrica. Hospital Universitario Infantil La Paz*
- **Álvaro González Rocafort.** *Facultativo Especialista de Cirugía Cardiovascular. Hospital Universitario Infantil La Paz*
- **Juan Carlos López Gutiérrez.** *Jefe de Servicio de Cirugía Pediátrica . Hospital Universitario Infantil La Paz*
- **María Nieves Moreno.** *Facultativo Especialista de Área en Oftalmología. Hospital Universitario La Paz*
- **Susana Noval Martín.** *Facultativo Especialista de Área en Oftalmología. Hospital Universitario La Paz*
- **Jesús Peralta Calvo.** *Facultativo Especialista de Área en Oftalmología Infantil. Hospital Universitario La Paz*
- **Esther Ramos Boluda.** *Jefe de Sección. Unidad de Rehabilitación y Trasplante Intestinal. Hospital Universitario La Paz*
- **Fernando Reinoso Barbero.** *Jefe de Servicio de Anestesiología y Reanimación Infantil. Hospital Universitario La Paz*
- **Alba Sánchez Galán.** *Facultativo Especialista de Cirugía Pediátrica. Hospital Universitario La Paz*
- **Javier Serradilla Rodríguez.** *Facultativo Especialista en Cirugía Pediátrica. Hospital Universitario La Paz*
- **Paloma Triana Junco.** *Facultativo Especialista de Área en Cirugía Pediátrica. Hospital Universitario La Paz*
- **María Teresa Vallejo Cremades.** *Jefe de Laboratorio Inmunohisto-química (Contrato de Estabilización de Técnicos de Apoyo). FIBHULP*
- **Leandro Vecchio Dezillio.** *Investigador Postdoctoral. FIBHULP*
- **Alejandra Vilanova Sánchez.** *Facultativo Especialista en Cirugía Pediátrica. Hospital Universitario La Paz*

STRATEGIC OBJETIVES

- Paediatric surgical specialities are extremely complex due to the wide spectrum of diseases included in their scope. Many of the problems are related to rare diseases and their treatment frequently requires complex procedures.
- Clinical care of paediatric surgical patients is a long-term task that requires a wide knowledge of the pathology and multidisciplinary committees. Surgical corrections usually consist of multi-step procedures, some of them in the neonatal period while others might be required in young adults.
- This line is therefore characterized by an unusually large spectrum since it encompasses the study of the cellular and molecular mechanisms leading to malformations, the biology of the malformed fetus and embryo, the prenatal chances for intervention on the malformations, and the postnatal operative and perioperative surgical and anesthesic management, including complex procedures as transplantation.

RESEARCH LINES

- Anesthesia, pain management and perioperative intensive care: To develop new procedures for improving safety and efficacy in anesthesic procedures, and to investigate the multiple problems of pain management and anaesthesia support.
- Vascular anomalies: To investigate genetic and molecular mechanisms involved in the pathogenesis of vascular anomalies, and to evaluate new targeted therapies
- Cardiovascular surgery: To assess different organ perfusion devices and to develop new strategies for graft perfusion.
- Congenital malformations: To gain knowledge on the cellular and molecular mechanisms of malformations using animal models, organ and cell cultures and eventually genetically engineered animals.
- Oftalmologic pathology: To investigate genetic and molecular mechanisms involved in the pathogenesis of ocular malformations and ocular rare diseases.
- Transplantation: To investigate new strategies for graft tolerance/avoidance of rejection and to analyze the impact of donation after circulatory death with normothermic reperfusion in pediatric transplantation. Additionally, the management of the conditions leading to organ failure would be included in our topics, like intestinal rehabilitation (intestinal transplantation), liver tumours (liver transplantation) and severe uropathies (renal transplantation).

RESEARCH ACTIVITY

Publications

- **Bilbao I, Lladó L, Cachero A, Campos-Varela I, Colmenero J, del Hoyo J, García EF, Pajares FG, Diéguez LG, Grande RG, Sánchez AG, Oliveros FH, Santos JIH, Lorente S, Mateos RM, López MJM, Alvarez JLM, Codoceo CM, Ferreiro AO, Nieto EO, Soler MR, Cristóbal MR, Oliver LS, Labiano MS, Martín JMS, Trapero-Marugán M, Varo E, de la Rosa G, Rodríguez-Perálvarez ML.** First consensus document of waiting list prioritization for liver transplantation by the Spanish Society of Liver Transplantation (SETH). Rev Esp Enferm Dig. 2024; 116(12): 680-9. Article. IF: 4.0; Q1
- **Delgado-Miguel C, Aguado P, Fuentes E, Diez R.** Neonatal Paratesticular Abscess as the Greatest Mimicker of Testicular Torsion. Urol Int. 2024; 108(2): 172-4. Article. IF: 1.3; Q3
- **Delgado-Miguel C, Amarnath RP, Camps JI.** Robotic-assisted vs. Laparoscopic Heller's Myotomy for Achalasia in Children. J Pediatr Surg. 2024; 59(6): 1072-6. Article. IF: 2.5; Q1
- **Delgado-Miguel C, Arredondo-Montero J, Moreno-Alfonso JC, San Basilio M, Pérez RP, Carrera N, Aguado P, Fuentes E, Díez R, Hernández-Oliveros F.** The Role of Neutrophyl-to-Lymphocyte Ratio as a Predictor of Ovarian Torsion in Children: Results of a Multicentric Study. Life (Basel). 2024; 14(7): 889. Article. IF: 3.4; Q1
- **Delgado-Miguel C, Camps JI.** Robotic-assisted versus laparoscopic splenectomy in children: a costeffectiveness study. J Robot Surg. 2024; 18(1): 51. Article. IF: 3.0; Q1
- **Delgado-Miguel C, Díez R.** Isolated Severe Congenital Penile Torsion of 180 Degrees. Indian Pediatr. 2024; 61(4): 398. Article. IF: 1.5; Q3
- **Delgado-Miguel C, Morán AG, Gómez LF,**

Díaz M, Miguel-Ferrero M, López-Gutiérrez JC. Comparison of the effectiveness of three different skin substitutes for the treatment of pediatric burns. Eur J Pediatr. 2024; 184(1): 80. Article. IF: 2.6; Q1

- **Delgado-Miguel C, Muñoz-Serrano AJ, Aguado P, Fuentes E, Díez R.** Ureteroinguinal Herniation with Consecutive Ureteral Stricture in a 2-Month-Old Infant: Case Report. European J Pediatr Surg Rep. 2024; 12(1): e16-9. Article. IF: 0.7; Q4
- **Delgado-Miguel C, Reparaz L, Clarkson W, Desai K, Camps JI.** Colorectal Robotic-Assisted Surgery in Children. Long-Term Outcomes and Pitfalls. Int J Med Robot Comp. 2024; 20(6): e70032. Article. IF: 2.1; Q2
- **Delgado-Miguel C, Vincent S, Miguel-Ferrero M, López-Gutiérrez JC.** Neonatal Severe Staphylococcal Scalded Skin Syndrome: Management with Autoadhesive Skin Substitute Dressing (Suprathel®). Indian J Pediatr. 2024; 91(9): 984. Letter. IF: 2.0; Q2
- **Garrido-Bolton J, Alcami-Pertejo M, de la Vega R, Hernández-Oliveros F, Pérez-Martínez A, Bravo-Ortiz MF, Fernández-Jiménez E.** Neuropsychological and biopsychosocial evolution, therapeutic adherence and unmet care needs during paediatric transplantation: study protocol of a mixed-methods design (observational cohort study and focus groups) - the TransplantKIDS mental health project. Front Psychol. 2024; 15: 1308418. Article. IF: 2.9; Q1
- **Ivars M, Frieden IJ, Provini L, Wassef M, Weibel L, Theiler M, Lanoel A, Martinez-Glez V, Rodriguez-Laguna L, van der Vleuten C, Guibaud L, Puttgen K, Azaña-Defez JM, Chamlin S, Drolet B, Torres N, Wyrzykowsky D, Colmenero I, López-Gutiérrez JC.** Segmental congenital vascular anomaly with atrophy, ulceration, and scarring (SeCVAUS): Case series and review of literature. Pediatr Dermatol. 2024; 41(6): 1063-76. Article. IF: 1.2; Q3
- **Li WH, van der Doef HPJ, Wildhaber BE, Marra P, Bravi M, Pinelli D, Minetto J, Dip M, Sierre S, de Santibañes M, Ardiles V, Uno JW, Hardikar W, Bates S, Goh L, Aldrian D, Seisenbacher J, Vogel GF, Neto JS, da Fonseca EA, Costa CM, Ferreira CT, Nader LS, Farina MA, Dajani KZ, Parente A, Bigam DL, Liang TB, Bai XL, Zhang W, Gonsorcíková L, Fronek J, Bohus S, Franchi-Abella S, Gonzales E, Guérin F, Junge N, Baumann U, Richter N, Hartleif S, Sturm E, Rajakannu M, Palaniappan K, Rela M, Pawaria A, Rajakrishnan H, Surendran S, Kumar M, Agarwal S, Gupta S, Asthana S, Bandewar V, Raichurkar K, Spada M, Monti L, Alterio T, Yanagi Y, Uchida H, Komine R, Evans H, Carr-Boyd P, Duncan D, Stefanowicz M, Latka-Grot J, Kolesnik A, Broering DC, Raptis DA, Marquez KAH, Mali V, Aw M, Beretta M, Van der Schyff F, Quintero-Bernabeu J, Mercadal-Hally M, Larrarte K M, Andrés AM, Hernandez-Oliveros F, Frauca E, Casswall T, Jorns C, Delle M, Gupte G, Sharif K, McGuirk S, Superina R, Caicedo JC, Jaramillo C, Bitterfeld L, Kastenberg Z, Shah AA, Domenick B, Acord MR, Mazariegos GV, Soltys K, DiNorcia J, Antala S, Florman SS, Buchholz BM, Herden U, Fischer L, Dierckx RAJO, Hartog H, Bokkers RPH.** Incidence, management and outcomes in hepatic artery complications after paediatric liver transplantation: protocol of the retrospective, international, multicentre HEPATIC Registry. BMJ Open. 2024; 14(6): e081933. Article. IF: 2.3; Q2
- **Medio P, Matesanz S, Margareto M, Ostos P, Palomo C, Oliveros FH, Moreno AA.** Outcomes of Pediatric Hepatocellular Carcinoma: A Single-Center Experience With Resection Versus Transplantation. Pediatr Transplant. 2024; 28(8): e14882. Article. IF: 1.4; Q3
- **Montero J, Rico-Jiménez M, Riveros BP, Atuan R, Pakkasjärvi N, Krishnan N, Delgado-Miguel C, Anand S.** Role of type I hypersensitivity reaction in the development of overall and uncomplicated acute appendicitis: a systematic review and meta-analysis. Curr Prob Surg. 2024; 61(9): 101551. Review. IF: 1.9; Q2
- **Moreno-Alfonso JC, Triana P, Ferrero MM, González MD, Gutiérrez JCL.** Risk factors for sequelae after surgery for lymphatic malformations in children. J Vasc Surg Venous Lymphat Disord. 2024; 12(2): 101730. Article. IF: 3.0; Q1
- **Ramírez-Amoros C, Carvalho C, Basilio MS, Martinez L, Encinas JL, Vilanova-Sanchez A.** Classic divided sigmoidostomy vs loop sigmoidostomy in anorectal malformations: time for change?. Pediatr Surg Int. 2024; 40(1): -252. Article. IF: 1.6; Q2

Research projects

- **Andrés Moreno AM.** Influencia del higado en el injerto intestinal. Estudio de su papel protector de rechazo. Sociedad Madrileña de Trasplantes. 2023-Ongoing. Managment centre: FIBHULP
- **Delgado Miguel C.** Trasplante capilar de unidades foliculares en ratas sprague dawley con alopecia cicatricial secundaria a quemaduras . FIBHULP. 2022-Ongoing. Managment centre: FIBHULP
- **Hernández Oliveros F.** Papel protector del hígado frente al rechazo en el trasplante multivisceral. FIBHULP. 2022-Ongoing. Managment centre: FIBHULP
- **Hernández Oliveros F.** Prevención del rechazo mediante transferencia adoptiva de linfocitos T regulatorios en un modelo experimental de trasplante intestinal (PI21/01332). ISCIII. 2022-2026. Managment centre: FIBHULP
- **Hernández Oliveros F.** Trasplantapp: la primera red de comunicación para niños y adolescentes trasplantados. Fundación Mapfre. 2020-Ongoing. Managment centre: FIBHULP
- **Nieves Moreno M.** Estrategia para el diagnóstico integral del nistagmus: estudio de función visual, pronostico y genetico. En busca de biomarcadores. Varios Financiadores. 2023-Ongoing. Managment centre: FIBHULP
- **Andrés Moreno AM.** Desarrollo y aplicación terapéutica de un sistema de perfusión normotérmica extracorpórea en trasplante intestinal: el final de la edad de hielo (PI23/01189). ISCIII. 2024-2026. Managment centre: FIBHULP
- **Hernández Oliveros F.** ERN TransplantChild. EU. 2023-2027. Managment centre: FIBHULP
- **Hernández Oliveros F.** Estudio clínico y experimental de inducción de tolerancia operacional mediante la combinación de traplante de progenitores hematopoyéticos y trasplante de órgano solido (AP-16022/2024). Fundación Mutua Madrileña. 2024-2027. Managment centre: FIBHULP
- **López Gutiérrez JC.** Trasplante de unidades foliculares en niños con alopecia cicatricial. Proyecto experimental con traslación clínica. (PI23/01464). ISCIII. 2024-2026. Managment centre: FIBHULP
- **Triana Junco P.** Estudio genético y funcional en pacientes con enfermedades de Gorham-Stout y anomalías linfáticas generalizadas. The Lymphatic Malformation Institute. 2018-Ongoing. Managment centre: FIBHULP

Clinical trials

- **"López Gutiérrez JC.** EPIK-P2 Estudio de fase II doble ciego con un periodo inicial aleatorizado, controlado con placebo y de 16 semanas de duración para evaluar la eficacia, la seguridad y la farmacocinética de alpelisib (byl719) en pacientes pediátricos y adultos con síndrome de sobrecrecimiento asociado a pik3ca.
  Type/Phase: II
  Sponsored by: Novartis Farmaceutica S.A.
  Signature date: 08/07/2024

Patents and trademarks

- **Hernández Oliveros F, Nana Gómez Mayoral N, Raya González L, Guijarro Fernández E, authors; FIBHULP, HePA, U-TAD, Guijarro Fernández E, assignees.** Trademark name:VTR Virtual Transplant Reality; CM18.000.131;2018 December 14.

3.7.8 Research in Endometriosis

Publications: 16 | **Q1:** 4

COMPOSITION

Alicia Hernández Gutiérrez.
Facultativo Especialista de Área en Ginecología y Obstetricia. Unidad de Ginecología Oncológica. Hospital Universitario La Paz. Profesor Asociado. Universidad Autónoma de Madrid

- **Pedro N. Barri Soldevilla.** *Director del Departamento de Obstetricia, Ginecología y Reproducción Humana. Fundación Dexeus Mujer*
- **Covadonga Álvarez López.** *Facultativo Especialista de Área en Ginecología y Obstetricia. Hospital Universitario La Paz*
- **Mario Álvarez Maestro.** *Facultativo Especialista de Área en Urología. Hospital Universitario La Paz*
- **Martina Aida Angelés Fité.** *Ginecóloga especialista en Oncología. Institut Universitaire Du Cancer De Toulouse*
- **Ónica María Armijo Suárez.** *Facultativo Especialista de Área en Ginecología y Obstetricia. Unidad de Reproducción Asistida. Hospital Universitario La Paz*
- **Myriam García Segovia.** *Médico Adjunto en Ginecología. Hospital Universitario La Paz*
- **Juan Antonio García Velasco.** *Director Médico. IVI - RMA*
- **Silvia Iniesta Pérez.** *Ginecóloga especialista en Reproducción. Hospital Ruber Internacional*
- **Ana López Carrasco.** *Facultativo Especialista de Área en Ginecología y Obstetricia. Hospital Universitario La Paz*
- **Alejandra Martinez Rodriguez-Marin.** *Subdirector del Departamento de Oncología Quirúrgica. Institut Universitaire Du Cancer De Toulouse*
- **Blanca Martínez Serrano.** *Facultativo Especialista de Área en Anestesiología. Hospital Universitario La Paz*
- **Cristina Redondo Guisasola.** *Facultativo Especialista de Área en Ginecología y Obstetricia. Hospital Universitario La Paz*
- **Violeta Romero Camacho.** *Facultativo Especialista de Área en Ginecología y Obstetricia. Hospital Universitario La Paz*
- **Patricia Isabel Salas Bolivar.** *Facultativo Especialista de Área en Ginecología y Obstetricia. Hospital Universitario La Paz*
- **Emanuela Spagnolo.** *Facultativo Especialista de Área en Ginecología y Obstetricia. Hospital Universitario La Paz*

STRATEGIC OBJETIVES

- Endometriosis is a debilitating gynaecological disease, responsible of pain and infertility with consequent worsening of women's quality of life. The prevalence is estimated on 10% of the fertile age women, with an impact on quality of life and reproductive health. Despite its high prevalence and the great scientific activity generated around this disease, we are facing a problem whose etiology remains unknown. Although it is a chronic illness, which begins to cause symptoms very early in a large number of cases, there is still no predictive marker of the disease, no method of early diagnosis, or any way to modify its clinical course, which is highly variable, producing great uncertainty in affected women. Despite of great advances have been made in the treatment of the disease from a global perspective that included women's fertility and pain control, there is still no etiological treatment or any form of cure.
- The endometriosis research group is committed to the following objectives in the next 5 years: to develop a scientific project for FIS 2023, to encourage young researchers, to organize a Master's Degree in Laparoscopy and Endometriosis, to increase the number of final degree projects and final master's projects, to improve the training of gynecological specialty trainee and promote internships abroad, to write publications of the results of our ongoing projects (mainly FIS 2020), to design a website for the HULP- Endometriosis group and to announce monthly workshops of patients with doctors and professionals from the Endometriosis Unit. We also set ourselves the challenge of recognizing the Endometriosis Unit-CSUR (National reference Unit) and promoting gender equality in research and innovation.
- The strategies proposed to achieve these objectives are as follows: Participation in the FIBHULP "Mentor Program", to promote collaboration between senior researcher and junior researcher to carry out research projects, congresses communication, to enable specialist trainee and junior gynecologists to perform the "Winner Project", (an educational program for Endoscopic Gynecological Surgery with 3 levels of progression), to encourage collaboration with providers in the endoscopic sector such as Storz, Olympus and Striker. In addition, we have support from IdiPaz Biostatistics and IdiPAZ Biobank (PT20 / 00004) integrated into the National Network of Biobanks of Spain, technical assistance from the HULP Computer and Bioengineering Service, as well as active collaboration with national associations of patients and announcement of events in "La Paz Informa".
- The Endometriosis Unit of Hospital La Paz has numerous strategic alliances, at the national level (Hospital Clínic of Barcelona, Hospital General of Valencia, Clínica Dexeus Barcelona) and also internationally (Oncopole -Oncology Institute of Toulouse (France), University Hospital of Bologna (Italy), University Hospital of Liège (Belgium), University Hospital of Siena (Italy), University Hospital of Malmo (Stockolm)).

RESEARCH LINES

- Investigation of immunological and molecular factors involved in the pathogenesis of endometriosis.
- Investigation of biomarkers to predict the risk of endometriosis malignant transformation. Our objective is to identify a panel of immune system markers and specific genetic mutations to predict endometriosis patients at increased risk of developing ovarian cancer and to identify factors that allow the use of immunotherapy in this type of cancer. In both pathologies (endometriosis and ovarian cancer), the dysfunction of the immune system favours the progression of the disease. In February 2021, the Endometriosis Group received a Health Research Fund by Health Research Institut Carlos III for the project: "Molecular and immunological factors with predictive value in endometriosis associated ovarian cancer".
- Research of new non-hormonal drugs to control symptoms and disease progression.
- Clinical research and new technologies: the advantages of Fluorescence Guided Surgery (FGS). In our operating rooms (Hospital Maternal, HULP) we use modern technology that allows real-time visualization of certain anatomical structures and helps the surgeon to reduce intraoperative stress and improve performance. Recently, the intraoperative use of indocyanine green (ICG) has shown advantages in intestinal surgery for endometriosis. ICG is a dye that is injected intravenously and rapidly reaches the blood vessels of the abdominal organs and allows the emission of fluorescence in the spectral range of the infrared ray. In this way, the vascularization of the colorectal anastomosis can be assessed after bowel resection in patients with endometriosis. We are currently investigating the use of a macromolecule linked to ICG that allows the dye to remain longer in vascularized tissues (rectum), and with a single injection at the start of surgery. This technique is also useful for delimiting endometriotic nodules before removing them.
- Clinical research focusing on the early diagnosis of endometriosis in adolescent patients (European Multicentre Project: Erasmus Project).

RESEARCH ACTIVITY

Doctoral These

- **García Pineda V.** Implicaciones clínicas de la implementación de la biopsia selectiva del ganglio centinela en el manejo quirúrgico del cáncer de endometrio[dissertation]. Madrid: Universidad Autónoma de Madrid: (13/06/2024). Director: Hernández Gutiérrez MA, Zapardiel Gutiérrez I.
- **Alonso Espías M.** Estudio de los factores asociados al manejo integral del cáncer de cuello uterino precoz y su influencia en los resultados oncológicos[dissertation]. Madrid: Universidad Autónoma de Madrid: (10/11/2024). Director: Zapardiel Gutiérrez I, Hernández Gutiérrez MA.
- **Cristóbal Quevedo I.** Estudio comparativo de la tasa de bilateralidad en cuanto a la técnica del ganglio centinela en el cáncer de endometrio: verde de indocianina como trazador único versus verde de indocianina junto a radiotrazador [dissertation]. Madrid: Universidad Autónoma de Madrid: (05/04/2024). Director: Zapardiel Gutiérrez I, Hernández Gutiérrez MA.

Final Degree Theses

- **Comanescu RT.** Factores predictores de éxito reproductivo en pacientes diagnosticadas de endometriosis sometidas a ciclos de fecundacion en vitro o de preservación fertilidad[dissertation]. Madrid: Universidad Autónoma de Madrid: (26/06/2024). Director: Hernández Gutiérrez MA, Iniesta S.
- **Díaz Alonso G.** Análisis de calidad de vida y disfunción sexual en mujeres premenopáusicas tratadas de cáncer de ovario[dissertation]. Madrid: Universidad Autónoma de Madrid: (26/06/2024). Director: Diestro Tejada MD, Spagnolo E.
- **Gala D.** Factores moleculares implicados en la transformación maligna de la endometriosis ovárica[dissertation]. Madrid: Universidad Autónoma de Madrid: (16/05/2024). Director: Spagnolo E, Tenorio J.
- **Iglesias Martin J.** Incidencia de adenomiosis en pacientes histerectomizadas por patologia benigna en el Hospital Universitario La Paz. Correlación con hallazgos clinicos[dissertation]. Madrid: Universidad Autónoma de Madrid: (26/06/2024). Director: Hernández Gutiérrez MA, Lopez A.

Publications

- **Alonso-Espías M, Gorostidi M, García-Pineda V, Gracia M, Diestro MD, Siegrist J, Zapardiel I, Hernández A.** Survival Impact of Sentinel Lymph Node Biopsy in Patients with Early-Stage Cervical Cancer. Reprod Sci. 2024; 31(10): 3066-73. Article. IF: 2.5; Q2
- **Bazán AA, Yebes A, Álvarez-Maestro M, Díez J, Samblás M, Piñeiro LM.** Conservative management of high-grade renal trauma. Actas Urol Esp. 2024; 48(7): 521-5. Article. IF: 1.2; Q3
- **Cameán MM, Marin IJ, Mendez JIS, Álvarez CM, Alegre FB, Boado EM, Spagnolo E, Zapardiel I, Gutiérrez AH.** Survival in pregnancy-associated breast cancer patients compared to non-pregnant controls. Reprod Biol Endocrin. 2024; 22(1): 34. Article. IF: 4.7; Q1
- **Carrión DM, Baekelandt L, Socarras MR, Brinkman WM, de Oliveira TR, Pini G, de Vriesh AH, Bujoreanu CE, Silvestri T, Skolarikos A, Petrutl B, Veneziano D, Greco F, Álvarez-Maestro M, Sánchez-Salas R, Tourinho-Barbosa RR, Liatsikos E, Somanis B, Rivas JG, Zondervan PJ.** Development of the European Laparoscopic Intermediate UrologicalSkills LUSs2 Curriculum: A Delphi Consensus from the EuropeanSchool of Urology. Eur Urol Open Sci. 2024; 69: 22-50. Article. IF: 4.5; Q1
- **Chico-Sordo L, Ruiz-Martínez T, Toribio M, González-Martín R, Spagnolo E, Domínguez F, Hernández A, García-Velasco JA.** Identification of miR-30c-5p microRNA in Serum as a Candidate Biomarker to Diagnose Endometriosis. Int J Mol Sci. 2024; 25(3): 1853. Article. IF: 4.9; Q1
- **Del Forno S, Raspollini A, Doglioli M, Andreotti A, Spagnolo E, Lenzi J, Borghese G, Raimondo D, Arena A, Rodríguez E, Hernández A, Govoni F, Seracchioli R.** Painful sexual intercourse, quality of life and sexual function in patients with endometriosis: not just deep dyspareunia. Arch Gynecol Obstet. 2024; 310(4): 2091-100. Article. IF: 2.5; Q2
- **Guerrero-Ramos F, Álvarez-Maestro M, Marín AP, Escrig JLD, Faba OR.** Multidisciplinary consensus document on the current treatment of bacille Calmette-Guérin-unresponsive non-muscle invasive bladder tumor. Actas Urol Esp. 2024; 48(4): 262-72. Article. IF: 1.2; Q3
- **Kallidonis P, Spinos T, Zondervan P, Nyirády P, Backhaus MR, Micali S, Hruby S, Álvarez-Maestro M, Tatanis V, Liatsikos E, Gözen AS.** Predictive Value of the Mayo Adhesive Probability (MAP) Score in Laparoscopic Partial Nephrectomies: A Systematic Review from the EAU Section of Uro-Technology (ESUT). Cancers (Basel). 2024; 16(8): 1455. Review. IF: 4.4; Q2
- **Maldonado-Barrueco A, Almazán-Garate E, Armijo-Suárez O, Iniesta-Pérez S, Sanz-González C, Falces-Romero I, Álvarez-López C, Cacho-Calvo J, Quiles-Melero I.** Utility of culture and molecular methods using Allplex™ Bacterial Vaginosis Plus Assay (Seegene®) as a tool for endometriosis, infertility and recurrent pregnancy loss diagnosis. Diagn Micr Infec Dis. 2024; 110(3): 116437. Article. IF: 1.8; Q2
- **Mendiola M, Heredia-Soto V, Ruz-Caracuel I, Baillo A, Ramon-Patino JL, Berjon A, Escudero FJ, Pelaez-García A, Hernández A, Feliu J, Hardisson D, Redondo A.** Performance of the Idylla microsatellite instability test in endometrial cancer. Mol Cell Probe. 2024; 77:

101976. Article. IF: 3.0; Q2

- **Rodríguez Faba O, Fernández Gomez J M, Guerrero-Ramos F, Álvarez-Maestro M, Ledo Cepero M J, Unda Urzaiz M, Martínez-Pineiro L, Cozar Olmo J M, Redorta J Palou, Álvarez-Ossorio J L.** Consensus document on the implications of standardization of BCG supply in the management of patients with non-muscle-invasive bladder cancer. Actas Urol Esp (Engl Ed). 2024; 48(10): 718-31. Article. Not Indexed
- **Segovia MG, Quevedo IC, Gutiérrez IZ, Gutiérrez AH.** Growing teratoma syndrome: diagnostic challenges and outcomes. Arch Gynecol Obstet. 2024; 310(3): 1729-32. Article. IF: 2.5; Q2
- **Sierra A, Etcheverry B, Álvarez-Maestro M, López JM, Fiol M, Torrecilla C, Vigués F, Martínez C, Carbonell E, Martínez-Pérez S, Alcaraz A, Luque MP, Musquera M.** Management of deceased and living kidney donor with lithiasis: a multicenter retrospective study on behalf of the renal transplant group of the Spanish urological association. J Nephrol. 2024; 37(6): 1621-30. Article. IF: 2.6; Q2
- **Subiela JD, Krajewski W, González-Padilla DA, Laszkiewicz J, Taborda J, Aumatell J, Encinas MS, Basile G, Moschini M, Caño-Velascof J, Pérez EL, Duran PD, Galliolig A, Tukiendorf A, D'Andreaj D, Teoh JYC, Céspedes AS, Pichler R, Afferi L, Del Giudice F, Rivas JG, Albisinni S, Soria F, Ploussard G, Mertens LS, Rajwa P, Laukhtinaj E, Praderej B, Tully K, Guerrero-Ramos F, Rodríguez-Faba O, Álvarez-Maestro M, Domínguez-Escrig JL, Szydelko T, Dos Santos VG, Cidre MAJ, Revilla FJB.** Unlocking the Potential of Adequate Bacillus Calmette-Guérin Immunotherapy in Very-high-risk Non-muscle-invasive Bladder Carcinoma: A Multicenter Analysis of Oncological Outcomes and Risk Dynamics. Eur Urol Oncol. 2024; 7(6): 1367-75. Article. IF: 9.3; D1
- **Valcárcel ML, Los Arcos MB, Molina MF, Belmonte IC, Santana VD, Borau PG, Ibiza JF, Maestro MA, Sargos P, Campos FL, Couñago F.** Is trimodal therapy the current standard for muscle-invasive bladder cancer?. Actas Urol Esp. 2024; 48(5): 345-55. Article. IF: 1.2; Q3
- **Wong CHM, Ko ICH, Leung DKW, Liu K, Zhao HD, Álvarez-Maestro M, Pes MDL, de la Rosette J, Teoh JYC.** Impact of Pre-Operative Ureteroscopy on Bladder Recurrence Following Nephroureterectomy for UTUC. Cancers (Basel). 2024; 16(15): 2683. Article. IF: 4.4; Q2

Research projects

- **Hernández Gutiérrez A, Spagnolo E.** Estudio para la implementación de la tecnología ómica en la identificación de marcadores asociados a transformación maligna de la endometriosis ovárica (PI23/00752). ISCIII. 2024-2026. Managment centre: FIBHULP
- **Hernández Gutiérrez A, Spagnolo E.** Monalisa smile. European Erasmus Project (KA220-VET-A25CC5B7). EU. 2022-2024. Managment centre: UAM
- **Hernández Gutiérrez A, Spagnolo E.** Proyecto de Innovación Docente INNOVA 2024/2025. Uso formativo de tecnología 3D e inteligencia artificial en pacientes con endometriosis con afectación intestinal. 2024-2025. Managment centre: UAM
- **Hernández Gutiérrez A.** Dinamización de Ciencia Disruptiva en Predictores de Enfermedades Tumorales Infecciosas y Hereditarias como base de la Medicina Personalizada (FORT23/00006). ISCIII. 2022-2024. Managment centre: FIBHULP
- **Hernández Gutiérrez A.** Factores inmunologicos en la transformación maligna de la endometriosis. FIBHULP. 2018-Ongoing. Managment centre: FIBHULP
- **Hernández Gutiérrez A.** Identificación de factores inmunológicos y moleculares con valor pronóstico en cáncer de ovario asociado a endometriosis e implicados en el potencial de malignización de la endometriosis (PI20/01368). FIBHULP. 2021-2023. Managment centre: FIBHULP
- **Hernández Gutiérrez A.** Implementación de técnicas basadas en "deep learning" para medir la intensidad del verde de indocianina en la cirugía de la endometriosis con resección intestinal. FIBHULP. 2022-Ongoing. Managment centre: FIBHULP
- **Spagnolo E.** Contratos de intensificación (INT24/00022). ISCIII. 2024-2026. Managment centre: FIBHULP

Clinical trials

- **Álvarez Maestro M.** Estudio clínico de fase 2b para evaluar la eficacia y seguridad de tar-200 en combinación con cetrelimab, tar-200 solo o cetrelimab solo en participantes con cáncer de vejiga no músculo-invasivo (cvnmi) de alto riesgo que no responde a la terapia del baci.
  Type/Phase: IIb
  Sponsored by: Janssen Cilag International Nv
  Signature date: 17/01/2024
- **Álvarez Maestro M.** Estudio fase 3, abierto, multicéntrico, aleatorizado para evaluar la eficacia y seguridad de tar-200 en combinación con cetrelimab frente al bacilo de Calmette y Guérin (bcg) intravesical en pacientes con cáncer de vejiga no músculo-invasivo de alto riesgo (hr-nmibc) sin tratamiento previo con el bcg.
  Type/Phase: III
  Sponsored by: Janssen Cilag International Nv; Janssen Inc.
  Signature date: 09/02/2024
- **Álvarez Maestro M.** microbioma y perfil inmune del tumor y de orina como indicadores de la respuesta al tratamiento del cáncer de vejiga no-músculo infiltrante de alto riesgo: modelo de predicción de resistencia al bacilo de calmette-guérin (bcg).
  Type/Phase: OTROS
  Sponsored by: Guard C Onsortium
  Signature date: 22/03/2024
- **Álvarez Maestro M.** A phase 3, single-arm, multicenter study to evaluate the efficacy and safety of ugn-103, a novel formulation of ugn-102, for the treatment of patients with low grade (lg) nonmuscle invasive bladder cancer (nmibc) at intermediate risk (ir) of recurrence.
  Type/Phase: III
  Sponsored by: Urogen Pharma
  Signature date: 04/06/2024
- **Álvarez Maestro M.** Blarwe an observational, multicentre retrospective cohort study to describe the epidemiology, clinical characteristics, treatment patterns and clinical outcomes of bladder cancer patients in spain - blarwe study.
  Type/Phase: EOm no prospectivo
  Sponsored by: Astrazeneca Farmaceutica Spain S.A.
  Signature date: 16/05/2024
- **Álvarez Maestro M.** A phase 3, single-arm, multicenter study to evaluate the efficacy and safety of ugn-103, a novel formulation of ugn-102, for the treatment of patients with low grade (lg) nonmuscle invasive bladder cancer (nmibc) at intermediate risk (ir) of recurrence.
  Type/Phase: III
  Sponsored by: Urogen Pharma
  Signature date: 06/11/2024
- **Hernández Gutiérrez A.** Carga de la incontinencia fecal en mujeres tras el parto vaginal: una encuesta epidemiológica prospectiva y no intervencionista.
  Type/Phase: OTROS
  Sponsored by: Oasis Diagnostics S.A
  Signature date: 15/11/2024

Patents and trademarks

- **Hernández A, López A, Spagnolo E, authors; FIBHULP, assignees; Brand name: EndoPaz: 018876162.** 2023 May 17, 2023 September 27



3.7.9 Research on Comprehensive Care for Transplanted Children and Adolescents

Publications: 1 | **Q1:** 1



COMPOSITION

María Jesús Pascau González-Garzón.
Nursing supervisor. Hospital Universitario La Paz
Luz Yadira Bravo Gallego.
Medical Advisor. FIBHULP


- **María Teresa Álvarez Gómez.** *Supervisora de Enfermería de Servicio de Hemato-oncología pediátrica y Trasplante de Progenitores Hematopoyéticos (TPH). Hospital Universitario La Paz*
- **Almudena Alonso Márquez.** *Supervisora de Enfermería Unidad de Pediatría Compleja y Rehabilitación intestinal. Hospital Universitario La Paz*
- **Mercedes Hermosilla Mínguez.** *Supervisora de Enfermería Unidad de Trasplante Pediátrico de Órgano Sólido. Hospital Universitario La Paz*
- **Carlos Martín Saborido.** *Vocal Asesor. Ministerio de Sanidad y Consumo*
- **Paloma Martínez Campos.** *Enfermera pediátrica en Consulta de Seguimiento y Transición de niño y adolescente trasplantado. Hospital Universitario La Paz*
- **Miriam Muñoz Berges.** *Enfermera Especialista en Pediatría. Hospital Universitario Infanta Sofía*
- **Antonia Polo Lucero.** *Enfermera Especialista en Pediatría. Hospital Universitario La Paz*
- **Guillermo Manuel Sibón Sancho.** *Enfermero pediátrico en Unidad de Enfermedades Minoritarias Infantiles (UMI). Hospital Universitario La Paz*

STRATEGIC OBJETIVES

- Paediatric Solid Organ Transplantation (SOT) and Haematopoietic Stem Cell Transplantation (HSCT) have dramatically changed the life expectancy of many children by providing treatment to them, who would otherwise have not survived. Worldwide, nearly 150,000 SOT1 and 80,000 HSCT are performed annually. Paediatric transplantation constitutes about 10% of the total for SOT and 20% of the total for HSCT. Between 2012 and 2016, 7,741 SOT and 14,717 HSCT were performed on children in the European Union (EU), and the number of PTs performed worldwide continues to increase.
- Paediatric SOT & HSCT replaces end-stage disease with a more sustainable chronic disease state, which enables youth to reach adulthood.3 However, although transplantation can improve personal health outcomes, it can also be associated with long-term side effects that require continuous monitoring and care. Post-transplant follow-up care aims to prevent rejection and transplant-related complications, so that each person can achieve a life expectancy and quality of life (QoL) similar to healthy peers.
- The "Research on comprehensive care for transplanted children and adolescents" group arises from the need to cover gaps in knowledge about the comprehensive care of children and adolescents who receive transplants in the paediatric age.
- The group will be focus on the research of three specific topics:
  1. Transition and transfer of adolescents and young adults (AYAs) living with a transplant to adult clinics: clinical and psychosocial impact. Transition is a gradual, multifaceted, active, and purposeful process involving many important steps and key checkpoints. The process comprises three phases: (1) transition planning and preparation, (2) transfer of care, and (3) integration into adult health care. Each of these phases has unique barriers to success and opportunities for improvement.
  2. Quality of life (QoL) in paediatric transplant setting: patient reported outcomes and experience measures (PROMs and PREMs).
  3. Innovation in health education of transplanted children and adolescents and their parents/caregivers/family: evaluation of programs and validation of tools and questionnaires.

RESEARCH LINES

- Transition and transfer of adolescent and young adult paediatric transplant recipients to adult care: clinical and psychosocial impact.
- Quality of life in paediatric transplantation: outcome measures and patient/family reported experiences (PROMs and PREMs).
- Innovation in health education for transplanted children and adolescents and their parents/caregivers/family: evaluation of programmes and validation of tools and questionnaires.



RESEARCH ACTIVITY

Final Degree Theses

- **Xuanlan Tinoco Francés V.** Percepción actual de los hermanos sanos de pacientes oncológicos pediátricos sobre el impacto de la enfermedad en su vida[dissertation]. Madrid: Universidad Antonio de Nebrija: 2024(26/06/2024). Director: Martínez Campos P
- **Sanz Ontiveros A.** Escala predictora del tiempo de fallecimiento para donación en asistolia controlada en pediatría[dissertation]. Madrid: Universidad Antonio de Nebrija: 2024(26/06/2024). Director: Sibón Sancho GM
- **Fernandez Moya LC.** Adherencia terapéutica farmacológica en adolescentes de 13 a 18 años trasplantados de órgano sólido[dissertation]. Madrid: Universidad Antonio de Nebrija: 2024(26/06/2024). Director: Pascau González-Garzón MJ

Publications

- **Calvo-Apalategi A, Nevado ML, Bravo-Gallego LY, González-Granado LI, Allende LM, Pena RR, López-Granados E, Reyburn HT.** The lack of either IRF9, or STAT2, has surprisingly little effect on human natural killer cell development and function. Immunology. 2024; 172(3): 440-50. Article. IF: 5.0; Q1

Research projects

- **Pascau González-Garzón MJ.** Programa educativo de refuerzo educativo para la transición en trasplante de órgano sólido. Chiesi. 2024-Ongoing. Managment centre: FIBHULP
- **Martínez Campos P.** Escape room educativo: promoviendo la salud y el bienestar en adolescentes con trasplante de órgano sólido. Colegio Oficial de Enfermeria de Madrid (CODEM). 2024-Ongoing. Managment centre: CODEM

3.7.10 Food Oxidative Stress and Cardiovascular Health

Publications: 11 | **Q1:** 7

COMPOSITION

Silvia M. Arribas Rodríguez.
Catedrática de Fisiología Cardiovascular. Universidad Autónoma de Madrid

- **Yolanda Aguilera Gutiérrez.** *Profesora Titular. Universidad Autónoma de Madrid*
- **Alicia Gil Ramírez.** *Profesora Ayudante Doctor. Universidad Autónoma de Madrid*
- **Álvaro Llorente Berzal.** *Profesor Ayudante Doctor. Universidad Autónoma de Madrid*
- **María Ángeles Martín Cabrejas.** *Catedrática en Química Agrícola y Bromatología. Universidad Autónoma de Madrid*
- **María Martín Trueba.** *Investigadora Predoctoral. Universidad Autónoma de Madrid*
- **David Ramiro Cortijo.** *Profesor Ayudante Doctor. Universidad Autónoma de Madrid*
- **Pilar Rodríguez Rodríguez.** *Técnico de Laboratorio. Universidad Autónoma de Madrid*
- **Santiago Ruvira Hernando.** *Investigadora Predoctoral. Universidad Autónoma de Madrid*

STRATEGIC OBJETIVES

- To evaluate the impact of low birth weight and prematurity on cardiometabolic health with a follow-up strategy, analyzing the modulatory effect of lifestyle.
- To study the physiological mechanisms implicated in the association between risk factors and cardiometabolic programming, using animal models of prematurity and intrauterine growth restriction and dietary interventions.
- To assess the influence of sociocultural factors on women health during pregnancy and lactation, and the modulation of biological variables by lifestyle.
- Promotion of healthy habits during pregnancy and lactation.
- To extract and characterize healthy bioactive components from food by-products and to design ingredients and supplements to improve cardiometabolic health.
- To carry out intervention trials in healthy subjects with the designed ingredients, evaluating its anti-inflammatory and antioxidants properties and health effect.

RESEARCH LINES

- Relationship between nutrition and fetal and postnatal programming of cardiometabolic disease. Involvement of oxidative stress and inflammation
- Impact of prematurity on cardiometabolic health.
- Development of new functional ingredients from food by-products focused on cardiometabolic health.
- Study of food ingredient bioactivity, bioavailability and impact on cardiometabolic health.
- Analysis of breastmilk bioactive components and its relationship with maternal and infant health.

RESEARCH ACTIVITY


Doctoral Theses

- **Arribas Rodríguez SM, Ramiro Cortijo D.** Vascular effects of cocoa shell extract supplementation in a rat model of fetal programming of hypertension[dissertation]. Madrid: Universidad Autónoma de Madrid: 2024(21/11/2024). Director: Ruvira Hernando SA.

Publications

- **Burgos-Santamaría A, Rodríguez-Rodríguez P, Arnalich-Montiel A, Arribas SM, Fernández-Riveira C, Barrio-Pérez IM, Río J, Ligero J, Quintana-Villamandos B.** OXY-SCORE and Volatile Anesthetics: A New Perspective of Oxidative Stress in EndoVascular Aneurysm Repair-A Randomized Clinical Trial. Int J Mol Sci. 2024; 25(19): 10770. Article. IF: 4.9; Q1
- **Castro AW, Zozaya C, Ruvira S, Arribas SM, López-Giménez MR, Ramiro-Cortijo D.** Online pilot intervention to improve nutritional and lifestyle in Spanish breastfeeding women. Nutr Hosp. 2024; 41(3): 619-27. Article. IF: 1.1; Q4
- **Cobeta IM, Bris RG, Rodríguez-Rodríguez P, Sáez A, Quintana-Villamandos B, Granado JMG, Arribas SM.** Fetal programming and lactation: modulating gene expression in response to undernutrition during intrauterine life. Pediatr Res. 2024; 95(7): 1764-74. Article. IF: 3.1; Q1
- **Gil-Ramírez A, Cañas S, Cobeta IM, Rebollo-Hernanz M, Rodríguez-Rodríguez P, Benítez V, Arribas SM, Martín-Cabrejas MA, Aguilera Y.** Uncovering cocoa shell as a safe bioactive food ingredient: Nutritional and toxicological breakthroughs. Future Foods. 2024; 10: 100461. Article. IF: 8.2; D1
- **Gil-Ramírez A, Rebollo-Hernanz M, Cañas S, Cobeta IM, Rodríguez-Rodríguez P, Gila-Díaz A, Benítez V, Arribas SM, Aguilera Y, Martín-Cabrejas MA.** Unveiling the Nutritional Profile and Safety of Coffee Pulp as a First Step in Its Valorization Strategy. Foods. 2024; 13(18): 3006. Article. IF: 5.1; Q1
- **Herrero-Fernández B, Ortega-Zapero M, Gómez-Bris R, Sáez A, Iborra S, Zorita V, Quintas A, Vázquez E, Dopazo A, Sánchez-Madrid F, Arribas SM, González-Granado JM.** Role of lamin A/C on dendritic cell function in antiviral immunity. Cell Mol Life Sci. 2024; 81(1): 400. Article. IF: 6.2; Q1
- **Jantape T, Kongwattanakul K, Arribas SM, Rodríguez-Rodríguez P, Iampanichakul M, Settheetham-Ishida W, Phuthong S.** Maternal Obesity Alters Placental and Umbilical Cord Plasma Oxidative Stress, a Cross-Sectional Study. Int J Mol Sci. 2024; 25(19): 10866. Article. IF: 4.9; Q1
- **Ribeiro-Oliveira R, Rodríguez-Rodríguez P, Sousa JB, Ferreira IMPLVO, Arribas SM, Diniz C.** Managing hypertension using brewing bioactive peptides as angiotensin-converting enzyme inhibitors: Impact on vascular tone through ex vivo assays. Pharmanutrition. 2024; 28:100389. Article. IF: 2.4; Q3
- **Ruvira S, Rodríguez-Rodríguez P, Abderrahim F, Morales D, Cañas S, Valdivieso A, Ramiro-Cortijo D, Arribas SM.** Resistance artery vasodilator pathways involved in the antihypertensive effects of cocoa shell extract in rats exposed to fetal undernutrition. J Physiol-London. 2024; 602(22): 6065-85. Article. IF: 4.4; Q1
- **Silva-Fernández CS, de la Calle M, Camacho PA, Arribas SM, Garrosa E, Ramiro-Cortijo D.** Psychometric Reliability to Assess the Perception of Women's Fulfillment of Maternity Rights. Eur J Investig Health Psychol Educ. 2024; 14(8): 2248-61. Article. IF: 2.6; Q2
- **Silva-Fernández CS, de la Calle M, Suta MA, Arribas SM, Garrosa E, Ramiro-Cortijo D.** Psychometric Evaluation of Women's Knowledge of Healthcare Rights and Perception of Resource Scarcity during Maternity. Healthcare (Basel). 2024; 12(20): 2045. Article. IF: 2.7; Q2

3.8. Multidisciplinar Research In Healthy Aging



Documents: 61 | **Originals:** 47 | **D1:** 8 | **Q1:** 22

Rocío Menéndez Colino
coordinadorenvejecimiento@idipaz.es

RESEARCH GROUPS

3.8.1 Aging and Fragility in the Elderly
Rocío Menéndez Colino

3.8.2 Frailty and Healthy Aging
Leocadio Rodríguez Mañas

3.8.3 Frailty, Multimorbidity Patterns and Mortality in the Elderly Population Residing in the Community
Miguel Ángel Salinero Fort

Strategic Objectives	Development forecast for the coming years:	Actions
The Multidisciplinary Research in Healrhy Aging is a recently created area and is made up of three groups. Its main initial mission is to identify synergies between IdiPAZ research groups with professionals or research groups in the field of primary care and health care with the aim of establishing joint interdisciplinary and competitive projects. It also aims to promote the development of training activities aimed at primary care and health care professionals	Increase the quality of the Area's group publications	Promoting quality and impact publishing
	Ensure generational change in the leadership of projects and groups in the area.	Include junior profiles in the groups and consider transition projects
	Improving the success rate in competitive calls for proposals	Increasing the submission rate to competitive calls for proposals and Increase the use of the Institution's resources and platforms for project applications (Mentor Programme, PAIN Platform, Innovation Support Unit, etc.).
	Implementing gender-sensitive analysis of results	Define studies that consider the gender dimension of pathologies in both patients and models.

HIGH IMPACT PUBLICATIONS

Sinclair AJ, Laosa O, Carnicero JA, Rodríguez-Mañas L, **Álvarez-Bustos A**. Disability and Quality of Life Measures in older frail and prefrail people with type 2 diabetes. The MIDFRAIL-Study. Diabetes Res Clin Pr. 2024; 214: 111797. Article. IF: 7,4; D1

Iriarte-Campo V, de Burgos-Lunar C, Mostaza J, Lahoz C, Cárdenas-Valladolid J, Gómez-Campelo P, Taulero-Escalera B, San-Andrés-Rebollo FJ, Rodríguez-Artalejoi F, **Salinero-Fort MA**. Incidence of T2DM and the role of baseline glycaemic status as a determinant in a metropolitan population in northern Madrid (Spain). Diabetes Res Clin Pr. 2024; 209: 111119. Article. IF: 7,4; D1

Reinoso-Párraga PP, González-Montalvo JI, Menéndez-Colino R, Perkisas S, Rivera-Deras I, Garmendia-Prieto B, Arain SJ, Tung-Chen Y, Vilches-Moraga A. Usefulness of point of care ultrasound in older adults: a multicentre study across different geriatric care settings in Spain and the United Kingdom. Age Ageing. 2024; 53(7): afae165. Article. IF: 7,1; D1

Sierra TP, Torrez FLH, Hernández MCP, Velasco RL, Gómez RO, Díaz MDC, Sánchez AIH, Ramírez BP, Fernández JM, Mola SJ, Piñera MAR, Alvarado PYC, Juan CS, Clemente JIR, Martín SV, Manzano IR, Harmand MGC, Robles MC, Aguilar AM, **López PS.** A Prospective, Observational Study of the Effect of a High-Calorie, High-Protein Oral Nutritional Supplement with HMB in an Old and Malnourished or at-Risk-of-Malnutrition Population with Hip Fractures: A FracNut Study. Nutrients. 2024; 16(8): 1223. Article. IF: 5; Q1

Molina-Baena B, Álvarez-Bustos A, Carnicero JA, García-García FJ, **Rodríguez-Mañas L**. The Performance and Associated Risks of the Criteria for Sarcopenic Obesity Proposed by the European Association for the Study of Obesity in a Geriatric Population. Nutrients. 2024; 16(19): 3315. Article. IF: 5; Q1

Scientific Events by Multidisciplinary Research in Healthy Aging

- 08/02/2024. WGS para el estudio de resistencias en Helicobacter pylori
- 29/04/2024. Acercando la investigación de Atención Primaria a IdiPAZ: Evidencias Epidemiológicas sobre Multimorbilidad y Mortalidad en la población anciana
- 09/10/2024. PROA Session: PROA en Atención Primaria.Oportunidades y mejoras

3.8.1 Aging and Fragility in the Elderly

Publications: 13 | **Q1:** 4

COMPOSITION

Rocío Menéndez Colino.
Jefa Servicio de Geriatría en funciones. Hospital Universitario La Paz. Profesora Asociada. Universidad Autónoma de Madrid

- **Francesca Argentina.** *Facultativo Especialista en Geriatría. Hospital Universitario La Paz*
- **Patricia Ysabel Condorhuamán Alvarado.** *Facultativo Especialista de Área en Geriatría. Hospital Universitario La Paz*
- **Victoria María Déniz González.** *Enfermera Especialista en Geriatría. Hospital Universitario La Paz*
- **Javier Gómez Pavón.** *Jefe de Servicio de Geriatría y de Cuidados Paliativos. Hospital Central Cruz Roja San José y Santa Adela*
- **Silvia Martín Martín.** *Enfermera Especialista en Familiar y Comunitaria. FIBHULP*
- **Ana Merello de Miguel.** *Facultativo Especialista de Área en Geriatría. Hospital Universitario La Paz*
- **Raquel Ramírez Martín.** *Facultativo Especialista de Área en Geriatría. Hospital Universitario La Paz*
- **Paola Pastora Reinoso Párraga.** *Facultativo Especialista de Área en Geriatría. Hospital Universitario La Paz*
- **Peggy Paola Ríos Germán.** *ultativo Especialista de Área en Geriatría. Centro de Prevención del Deterioro Cognitivo. Madrid Salud*
- **María del Pilar Sáez López.** *Facultativo Especialista de Área en Geriatría. Fundación Hospital Alcorcón*



STRATEGIC OBJETIVES

- To promote and improve the quality of hospital geriatric care
- Progress in the cross-speciality geriatrics
- Point of care ultrasonography in the management of diseases in the older patient

RESEARCH LINES

- Coordination of the National Registry of Hip Fractures: a multicenter observational study including patients from 75 Spanish hospitals with an acute fragility hip fracture. The registry collects data from the acute hospital phase and a one-month follow-up from abouy 80 Spanish hospitals.
- Study of the influence of frailty in the implantation of transcateter aortic valve. Multicenter project that includes data fron five Spanis hospitals
- Cross-specility Geriatrics: Co-management of old patients diagnosed of cancer in colaboration con the General Surgery, Medical and Radioterapic Oncology, Urology and Vacular Surgery Departments of the La Paz Hospital.
- Observational study of the evolution of old patients affected of a traumatic intracranial hemorage, in colaboration with the Neurosurgery Department of the La Paz Hospital.
- Point of care ultrasound sonography

RESEARCH ACTIVITY

Doctoral Theses

- **Ríos Germán PP.** Diferencias entre los pacientes que ingresan por una fractura de cadera, que viven en residencia o en domicilio y la evolución al mes y al año en ambas poblaciones. Estudios de una cohorte hospitalaria y una cohorte multicéntrica a nivel nacional[dissertation]. Madrid: Universidad Autónoma de Madrid: 2024(29/10/2024). Director: González Montalvo JI, Gutiérrez Misis A.
- **Hormigo Sánchez AI.** Aplicación terapéutica de un protocolo sistemático de valoración oncohematogeriátrica individualizada e integral en pacientes mayores con linfoma de reciente diagnóstico [dissertation]. Madrid: Universidad Autónoma de Madrid: 2024(27/11/2024). Director: González Montalvo JI, Córdoba Mascuñano R.

Publications

- **Boixareu CB, Ojeda-Thies C, Valtueña AG, Veloz BAC, Lázaro MG, Castellanos LN, Matas RQ, Campelo PG, Vicente AR, González-Montalv JI, Sáez-López P.** Beware of Hip Fractures in the Elderly [Response to Letter]. Clin Interv Aging. 2024; 19: 1895-6. Letter. IF: 3.7; Q2
- **Cantón R, Ramos PD, García-Botella A, García-Lledó A, Hernández-Sampelayo T, Gómez-Pavón J, del Castillo JG, Martín-Delgado MC, Sánchez FJM, Martínez-Sellés M, García JMM, Guillén SM, Rodríguez-Artalejo F, Reigadas E, del Campo R, Serrano S, Ruiz-Galiana J, Bouza E.** Human intestinal microbiome: Role in health and disease. Rev Esp Quim. 2024; 37(6): 438-53. Review. IF: 2.2; Q3
- **de Asteasu MLS, Martínez-Velilla N, Zambom-Ferraresi F, Galbete A, Ramírez-Vélez R, Cadore EL, Abizanda P, Gómez-Pavón J, Izquierdo M.** Dose-Response Relationship Between Exercise Duration and Enhanced Function and Cognition in Acutely Hospitalized Older Adults: A Secondary Analysis of a Randomized Clinical Trial. Innov Aging. 2024; 8(6): igae053. Article. IF: 4.3; D1
- **Jiménez EL, Álvarez MN, Colino RM, López MC, Jiménez CG, Rodríguez PP, Brolen BV, Muñana EA, Martín RR, Bouzón CA, Andrés MSA, Boixareu CB, Brañas F, Ibáñez MA, Córcoles RA, Zamora EBC, Jiménez EG, Rizos LR, Céspedes AA, Socorro CRH, Abizanda P.** Muscle mass loss measured with portable ultrasound in hospitalized older adults: The ECOSARC study. J Nutr Health Aging. 2024; 28(1): 100010. Article. IF: 4.0; Q2
- **Martín-Delgado MC, Ramos PD, García-Botella A, Cantón R, García-Lledó A, Hernández-Sampelayo T, Gómez-Pavon J, del Castillo JG, Sánchez FJM, Martínez-Sellés M, Garcia JMM, Guillén SM, Rodríguez-Artalejo F, Ruiz-Galiana J, Burillo A, Muñoz P, Rey CC, Catalán-González M, Cendejas-Bueno E, Halperin-Benito AV, Recio R, Vinuela-Benítez C, Bouza E.** Invasive group A Streptococcus infection (Streptococcus pyogenes): Current situation in Spain. Rev Esp Quim. 2024; 37(6): 454-71. Article. IF: 2.2; Q3
- **Moraga-Llop F, Andradas E, Blesa-Baviera LC, Cantón R, del Castillo JG, Martinó-Torres F, Moya E, Trilla A, Vázquez J, Villena RJ, Ruiz-Galiana J, Ramos PD, García-Botella A, Garcia-Lledó A, Hernández-Sampelayo T, Gómez-Pavón J, Martín-Delgado MC, Sánchez FJM, Martínez-Sellés M, García JMM, Guillén SM, Rodríguez-Artalejo F, Bouza E.** Meningococcal meningitis in Spain in the Horizon 2030: A position paper. Rev Esp Quim. 2024; 37(4): 285-98. Article. IF: 2.2; Q3
- **Ramírez-Martín R, Ladrero CM, Martínez JAG, Déniz-González V, Maestre IM, Corral-Sastre L, Villajos-Guijarro M, Menéndez-Colino R, Miguelañez IP, González-Montalvo JI.** Prehabilitation in Frail Octogenarian and Nonagenarian Patients in Colorectal Cancer Surgery: Short- and Medium-Term Outcomes. J Clin Med. 2024; 13(20): 6114. Article. IF: 2.9; Q1
- **Reinoso-Párraga PP, González-Montalvo JI, Menéndez-Colino R, Perkisas S, Rivera-Deras I, Garmendia-Prieto B, Arain SJ, Tung-Chen Y, Vilches-Moraga A.** Usefulness of point of care ultrasound in older adults: a multicentre study across different geriatric care settings in Spain and the United Kingdom. Age Ageing. 2024; 53(7): afae165. Article. IF: 7.1; Q1
- **Rodríguez-Artalejo F, Ruiz-Galiana J, Cantón R, Ramos PD, García-Botella A, García-Lledó A, Hernández-Sampelayo T, Gómez-Pavón J, del Castillo JG, Martín-Delgado MC, Sánchez FJM, Martínez-Sellés M, García JMM, Guillén SM, de Viedma DG, Bouza E.** COVID-19: On the threshold of the fifth year. The situation in Spain. Rev Esp Quim. 2024; 37(1): 17-28. Review. IF: 2.2; Q3
- **Romero Pisonero E, Mora-Fernández J, Queipo Matas R, González Montalvo JI, Neira Álvarez M, Ojeda Thies C, Saez López P, Malafarina V.** Demographic, functional and clinical characteristics in hip fracture patients according to mental status of the Spanish National Hip Fracture Registry. Rev Esp Geriatr Gerontol. 2024; 59(3): 101450. Article. Not Indexed
- **Ruiz-Galiana J, Cantón R, Ramos PD, García-Botella A, García-Lledó A, Hernández-Sampelayo T, Gómez-Pavón J, del Castillo JG, Martín-Delgado MC, Sánchez FJM, Martínez-Sellés M, García JMM, Guillén SM, Rodríguez-Artalejo F, Fernandez RR, Kestler M, Bouza E.** Respiratory syncytial virus: A new era. Rev Esp Quim. 2024; 37(2): 134-48. Review. IF: 2.2; Q3
- **Sanz-Reig J, Martínez J, Ogea C, González-Montalvo JI, Saez-López P, Roman CM, Ojeda-Thies C.** Time to surgery and 30-day mortality after hip fracture: An observational study of 29,695 patients reported to the Spanish National Hip Fracture Registry (SNHFR). Injury. 2024; 55: 111653. Article. IF: 2.0; Q2
- **Sierra TP, Torrez FLH, Hernández MCP, Velasco RL, Gómez RO, Díaz MDC, Sánchez AIH, Ramírez BP, Fernández JM, Mola SJ, Piñera MAR, Alvarado PYC, Juan CS, Clemente JIR, Martín SV, Manzano IR, Harmand MGC, Robles MC, Aguilar AM, López PS.** A Prospective, Observational Study of the Effect of a High-Calorie, High-Protein Oral Nutritional Supplement with HMB in an Old and Malnourished or at-Risk-of-Malnutrition Population with Hip Fractures: A FracNut Study. Nutrients. 2024; 16(8): 1223. Article. IF: 5; Q1

Research projects

- **Menéndez Colino R.** Impacto de una intervención multidisciplinaria en el pronóstico de pacientes frágiles con estenosis aórtica severa sintomática: ensayo randomizado (PI19/01010). ISCIII. 2020-2024. Managment centre: FIBHULP
- **Martínez Martín R.** Geriatría transversal: detección y manejo de la fragilidad en pacientes adultos mayores con patología quirúrgica. Varios. 2019-Ongoing. Managment centre: FIBHULP
- **Ccondorhuamán Alvarado PY.** Proyecto del registro nacional de fracturas de cadera por fragilidad en el anciano. Amgen S. A. 2017-Ongoing. Managment centre: FIBHULP
- **González Montalvo JI.** Registro nacional de fracturas de cadera estudio RNFC. Fundación Mutua Madrileña. 2018-Ongoing. Managment centre: FIBHULP
- **Menéndez Colino R.** Ensayo clínico randomizado de intervención multidisciplinaria en pacientes frágiles sarcopénicos con estenosis aórtica severa sintomática. IdiPAZ. 2023-Ongoing. Managment centre: FIBHULP
- **Reinoso Párraga P.** Evaluación de los cambios ecográficos que ocurren en la masa muscular tras una intervención multicomponente con suplementación nutricional y un programa estandarizado de ejercicios en pacientes en adultos mayores portadores de sarcopenia evaluados en consultas externas de Geriatría. Abbott S.A. 2024-Ongoing. Managment centre: FIBHULP

Clinical trials

- **Gómez Pavón J.** ensayo clínico multicéntrico, aleatorizado, ciego y controlado para evaluar la eficacia y seguridad de colecalciferol en la corrección del déficit de 25(oh)d de sujetos con deficiencia severa de vitamina d, en comparación a calcifediol. estudio dtreat.
  Type/Phase: IV
  Sponsored by: Itf Research Pharma S.L.U.
  Signature date: 15/10/2024
- **Menéndez Colino R.** ensayo clínico randomizado de intervención multidisciplinaria en pacientes frágiles sarcopénicos con estenosis aórtica severa sintomática
  Sponsored by: Menéndez Colino Rocío
  Signature date: 05/06/2024

3.8.2 Frailty and Healthy Aging

Publications: 21 | **Q1:** 10

COMPOSITION

Leocadio Rodríguez Mañas.
Jefe Servicio de Geriatría. Hospital Universitario de Getafed

- **David Bernal López.** *Gestor de proyectos europeos de investigación. Fundación de investigación Biomédica del Hospital Universitario de Getafe*
- **José Antonio Carnicero Carreño.** *Data Manager. Investigador Senior. Fundación de investigación Biomédica del Hospital Universitario de Getafe*
- **Betty Davies Urizar.** *Médico Adjunto en Geriatría. Hospital Universitario de Getafe*
- **Mariam El Assar de la Fuente.** *Investigadora Senior. Fundación de investigación Biomédica del Hospital Universitario de Getafe*
- **Olga Laosa Zafra.** *Investigador Senior. Fundación de investigación Biomédica del Hospital Universitario de Getafe*
- **Laura Pedraza Sepúlveda.** *Framacóloga Clínica. Fundación de investigación Biomédica del Hospital Universitario de Getafe*
- **Laura Rivero Álvarez.** *Gestora de Proyectos Europeos de Investigación. Hospital Universitario de Getafe*



STRATEGIC OBJETIVES

- This research area, has been developed along the last 25 years by our group, with outstanding contributions to several aspects of the field, ranging from basic science (endothelial function, role of lab and image biomarkers, magnetoelectroencephalography, musculoskeletal function…) to clinical and epidemiological research, raising data that have allowed to promote technological devices (platform to detect, treat and monitor functional decline in an non-obtrusive way) and leading to the creation of a technological SME (MG Biomed)

RESEARCH LINES

- Endothelial dysfunction associated with aging, diabetes and obesity.
- Clinical aspects of frailty.
- New Technologies Applied to Frailty, functional decline and Healthy Aging.
- Models of care in frailty and functional decline in older people
- Role of muscle dysfunction in the promotion of functional decline and frailty Point of care ultrasound sonography


RESEARCH ACTIVITY

Doctoral Theses

- **Oviedo Briones MR.** Instrumentos de detección de fragilidad en distintos medios asistenciales[dissertation]. Madrid: Universidad Autónoma de Madrid: 2024(02/10/2024). Director: Checa López M, Rodríguez Mañas L

Publications

- **Álvarez-Bustos A, Carnicero JA, Coelho-Junior HJ, Calvani R, García-García FJ, Marzetti E, Landi F, Rodríguez-Mañas L.** Diagnostic and prognostic value of calf circumference for sarcopenia in community-dwelling older adults. J Nutr Health Aging. 2024; 28(8): 100290. Article. IF: 4.0; Q2
- **Álvarez-Bustos A, Carnicero JA, Rueda R, Pereira SL, Santos-Fandila A, López-Pedros JM, Molina-Baena B, García-García FJ, Rodríguez-Mañas L.** Relationship of endogenous plasma concentrations of (3-hydroxy (3-methyl butyrate (HMB) with frailty in community dwelling older adults with type-2 diabetes mellitus. J Nutr Health Aging. 2024; 28(6): 100229. Article. IF: 4.0; Q2
- **Álvarez-Bustos A, Laosa O, Marzetti E, Carnicero JA, Castro-Rodríguez M, Landi F, Sinclair AJ, Rodríguez-Mañas L.** Response rates and associated factors after a multicomponent intervention in frail older adults with diabetes. Age Ageing. 2024; 53(1): afad253. Article. IF: 7.1; D1
- **Bareiro FAQ, Carnicero JA, Acha AA, Artalejo CR, Jiménez MCG, Mañas LR, García FJG.** Carotid-femoral pulse wave velocity score, an estimator of cognitive performance in the elderly: results from the Toledo Study for Healthy Aging. Geroscience. 2024; 46(6): 5711-23. Article. IF: 5.4; Q1
- **Butcher L, Carnicero JA, Pérès K, Bandinelli**



S, García-García FJ, Rodríguez-Artalejo F, Rodríguez-Mañas L, Erusalimsky JD. Frailty Influences the Relationship between the Soluble Receptor for Advanced Glycation-End Products and Mortality in Older Adults with Diabetes Mellitus. Gerontology. 2024; 70(6): 585-94. Article. IF: 3.0; Q3

- **Coelho HJ Jr, Aguiar SD, Gonçalves ID, Álvarez-Bustos A, Rodríguez-Mañas L, Uchida MC, Marzetti E.** Agreement and Associations between Countermovement Jump, 5-Time Sit-To-Stand, Lower-Limb Muscle Power Equations, and Physical Performance Tests in Community-Dwelling Older Adults. J Clin Med. 2024; 13(12): 3380. Article. IF: 2.9; Q1
- **Coelho HJ Jr, Álvarez-Bustos A, Picca A, Calvani R, Rodríguez-Mañas L, Landi F, Marzetti E.** Dietary Intake of Polyunsaturated Fatty Acids Is Associated with Blood Glucose and Diabetes in Community-Dwelling Older Adults. Nutrients. 2024; 16(23): 4087. Article. IF: 5; Q1
- **Coelho HJ Jr, Álvarez-Bustos A, Rodríguez-Mañas L, Gonçalves ID, Calvani R, Picca A, Uchida MC, Aguiar SD, Marzetti E.** Five-Time Sit-To-Stand Lower Limb Muscle Power in Older Women: An Explorative, Descriptive and Comparative Analysis. J Frailty Aging. 2024; 13(4): 397-404. Article. IF: 3.3; Q2
- **El Assar M, Angulo J, Carnicero JA, Molina-Baena B, García-García FJ, Sosa P, Rodríguez-Mañas L.** Gender-specific capacity of insulin resistance proxies to predict functional decline in older adults. J Nutr Health Aging. 2024; 28(11): 100376. Article. IF: 4.0; Q2
- **El Assar M, Carnicero JA, Angulo J, Cámara-Hernández V, García-García FJ, Rodríguez-Mañas L.** Fat Mass Accounts for Insulin Resistance Impact on Functional Decline and Mortality in Nondiabetic Older Adults. J Am Med Dir Assoc. 2024; 25(3): 448-53. Article. IF: 3.8; Q2
- **El Assar M, La Fuente JM, Sosa P, Fernández A, Pepe-Cardoso AJ, Martínez-Salamanca JI, Rodríguez-Mañas L, Angulo J.** PKC Inhibition Improves Human Penile Vascular Function and the NO/cGMP Pathway in Diabetic Erectile Dysfunction: The Role of NADPH Oxidase. Int J Mol Sci. 2024; 25(6): 3111. Article. IF: 4.9; Q1
- **El Assar M, Rodríguez-Sánchez I, Álvarez-Bustos A, Rodríguez-Mañas L.** Biomarkers of frailty. Mol Aspects Med. 2024; 97: 101271. Review. IF: 10.3; D1
- **Molina-Baena B, Álvarez-Bustos A, Carnicero JA, García-García FJ, Rodríguez-Mañas L.** The Performance and Associated Risks of the Criteria for Sarcopenic Obesity Proposed by the European Association for the Study of Obesity in a Geriatric Population. Nutrients. 2024; 16(19): 3315. Article. IF: 5; Q1
- **Rodríguez Mañas L, Cano Gutierrez CA.** In memoriam of Dr. Juan Jose Solano Jaurrieta. Rev Esp Geriatr Gerontol. 2024; 59(4): 101510. Article. Not Indexed
- **Rodríguez-Mañas L, Moreno-Villares JM, Hernández JA, Secín AAR, Díaz-Ufano MLL, González FS, Costa-Grille A, López-Miranda J, Fernández-Garcia JM.** Awareness and Self-Reported Knowledge and Training on Nutrition in Older People among Primary Care Practitioners. J Frailty Aging. 2024; 13(2): 157-62. Article. IF: 3.3; Q2
- **Rodríguez-Sánchez I, Rodríguez-Mañas L.** Nutrition and frailty: additional evidence supporting their relationships. J Nutr Health Aging. 2024; 28(4): 100218. Editorial Material. IF: 4.0; Q2
- **Sánchez IR, Mañas LR.** Healthy aging, what does demography point out? Med Clin-Barcelona. 2024; 162(12): 588-90. Editorial Material. IF: 2.1; Q2
- **Sepúlveda M, Palomo I, Montecino-Garrido H, Wehinger S, Rodríguez-Mañasb L, Trostchansky A, Fuentes E.** Physiological changes associated with aging: Identification of novel biomarkers for frailty syndrome in women. Free Radical Bio Med. 2024; 223: 160-71. Article. IF: 8.2; D1
- **Sinclair AJ, Laosa O, Carnicero JA, Rodríguez-Mañas L, Álvarez-Bustos A.** Disability and Quality of Life Measures in older frail and prefrail people with type 2 diabetes. The MIDFRAIL-Study. Diabetes Res Clin Pr. 2024; 214: 111797. Article. IF: 7.4; D1
- **Valdés-Aragonés M, Pérez-Rodrígue R, Carnicero JA, Moreno-Sánchez PA, Oviedo-Briones M, Villalba-Mora E, Abizanda-Soler P, Rodríguez-Mañas L.** Effects of Monitoring Frailty Through a Mobile/Web-BasedApplication and a Sensor Kit to Prevent Functional Decline in Frailand Prefrail Older Adults:FACET (Frailty Care and Well Function)Pilot Randomized Controlled Trial. J Med Internet Res. 2024; 26: e58312. Article. IF: 6.0; D1
- **Virto N, Río X, Angulo-Garay G, Molina RG, Céspedes AA, Zamora EBC, Jiménez EG, Córcoles RA, Mañas LR, Costa-Grille A, Matheu A, Marcos-Pérez D, Lazcano U, Vergara I, Arjona L, Saeteros M, López-de-Ipiña D, Coca A, Soler PA, Sanabria SJ.** Development of Continuous Assessment of Muscle Quality and Frailty in Older Patients Using Multiparametric Combinations of Ultrasound and Blood Biomarkers: Protocol for the ECOFRAIL Study. Jmir Res Protoc. 2024; 13: e50325. Article. IF: 1.5; Q3

Research projects

- **Rodríguez Mañas L.** Dual effects of insulin resistance on frailty status, disability and death: proof of concept and risk models building project (PI20/00977). ISCIII. 2021-2024. Managment centre: FIBHUG
- **Rodríguez Mañas L.** Papel de nuevos biomarcadores pronósticos de recuperación funcional tras deterioro catastrófico y no catastrófico en personas mayores vulnerables: Biomarc-RF (PI23/00877). ISCIII. 2024-2026. Managment centre: FIBHULP
- **Laosa Zafra O.** Ecosistema computacional con apoyo motivacional y evaluación funcional para un programa autónomo de ejercicio para un envejecimiento saludable. MOTIVA (PID2022-140214OA-C22). Agencia Estatal de Investigación. 2023-2026. Managment centre: FIBHUG/UPM
- **Rodríguez Mañas L .** DIABFRAIL-LATAM: Adaptación de un programa de intervención ya contrastado en personas mayores con diabetes y fragilidad en América Latina (278803-2). EU. 2019-2024. Managment centre: CIBER-FIBHUG
- **Rodríguez Mañas L.** Gestión predictiva, personalizada, preventiva y participativa (4P) de la fragilidad y la multimorbilidad para la transición digital de la economía de los cuidados- MIRATAR (TED2021-132149B-C41). Agencia Estatal De Investigación. Proyectos de Transición Ecológica y Transición Digital. 2023-2024. Managment centre: FIBHUG/Universidad Castilla la Mancha/ Universidad Carlos III

Cibers and Retics

- **Rodríguez Mañas L.** Centro de Investigación Biomédica en Red en Fragilidad y Envejecimiento Saludable (CIBERFES). ISCIII. (31/12/2024). FIBHUG

3.8.3 Frailty, Multimorbidity Patterns and Mortality in the Elderly Population Residing in the Community

Publications: 15 | **Q1:** 7

COMPOSITION

Miguel Ángel Salinero Fort.
Responsable Gestión Conocimiento. Consejería Sanidad

- **Beatriz Álvarez Embarba.** *Enfermera. Escuela Universitaria de Enfermería Cruz Roja Española*
- **Navid Behzadi Koochani.** *Facultativo Especialista de Área en Medicina Familiar y Comunitaria. Atención Primaria*
- **Juan Cárdenas Valladolid.** *Enfermero. Atención Primaria*
- **María Victoria Castell Alcalá.** *Facultativo Especialista de Área en Medicina Familiar y Comunitaria. Atención Primaria*
- **Teresa Gijón Conde.** *Profesora Honoraria. Universidad Autónoma de Madrid*
- **Paloma Gómez Campelo.** *Subdirectora Ténica de IdiPAZ. Investigadora Postdoctoral. FIBHULP*
- **Alicia Gutiérrez Misis.** *Profesora Contratada Doctora. Vicedecana de Innovación Docente y Simulación. Universidad Autónoma de Madrid*
- **Víctor Iriarte Campo.** *Investigador predoctoral. Atención Primaria*
- **Paula Regueiro Toribio.** *Facultativo Especialista de Área en Medicina Familiar y Comunitaria. Atención Primaria*
- **Antonio Ruiz García.** *Director de Centro de Atención Primaria. Atención Primaria*
- **Francisco Javier San Andrés Rebollo.** *Facultativo Especialista de Área en Medicina Familiar y Comunitaria. Atención Primaria*
- **Belén Taulero Escalera.** *Investigadora Predoctoral. Atención Primaria*
- **Pilar Vich Pérez.** *Facultativo Especialista de Área en Medicina Familiar y Comunitaria. Atención Primaria*



STRATEGIC OBJETIVES

- The group's research focuses on the morbidity and mortality risks of elderly patients in the community setting, with particular attention to the study of modifiable factors such as nutrition, alcohol consumption, smoking, inappropriate use of drugs, lack of therapeutic adherence, sedentary lifestyle, and vulnerability to climate change. In addition, classic factors such as hypertension, diabetes, obesity/overweight, hypercholesterolemia, multimorbidity, and suboptimal control of blood pressure, glucose, and LDL cholesterol. Furthermore, the study of the factors that delay urgent/emergent attention of time-dependent pathologies (*). All with a perspective of gender and vulnerability across the life course.

(*) Those emergency diseases in which the diagnostic or therapeutic delay negatively influences the process's evolution and prognosis since its morbidity and mortality are directly related to the delay in starting treatment.

RESEARCH LINES

- Effect of Glycemic Variability on morbidity and mortality
- Effect of Arterial Hypertension Variability on morbidity and mortality
- Predictive model of morbidity and mortality in elderly patients residing in the community
- Predictive model of morbidity and mortality in patients with type 2 diabetes mellitus
- Effect of product of fasting glucose and triglyceride (TyG index), on incident Type 2 Diabetes Mellitus.
- Sex differences in preventive medicine.
- Incidence of mortality in adult patients diagnosed with epilepsy in the community of Madrid: EPILEPSIE- Madrid retrospective cohort.
- Mortality Rates and causes of death in patients with Type 2 Diabetes: An Analysis of MADIABETES Cohort (Spain)
- Metabolomics, genomics and nutrition for personalized medicine of cardiovascular disease (OMIC-CARD)
- LADA-type diabetes: development and validation of a high-risk score for use in Primary Care.

RESEARCH ACTIVITY

Doctoral Theses

- **Moreno Caballero B.** Prevención cardiovascular en atención primaria durante la pandemia por Sars-Cov-2 [dissertation]. Madrid: Universidad Autónoma de Madrid: 2024(11/10/2024). Director: Castell Alcalá MV, Gutiérrez Misis A.
- **Gómez-Morán Quintana M.** Reducción de la mortalidad intrahospitalaria con el uso precoz de la ventilación no invasiva prehospitalaria en el edema agudo de pulmón y la enfermedad pulmonar obstructiva crónica agudizada. Estudio

ventilamadrid[dissertation]. Madrid: Universidad Autónoma de Madrid: 2024(12/01/2024). Director: Gutiérrez Misis A, Horrillo García CL.

Master Theses

- **Egido Rodríguez I.** Eficacia de una intervención de refuerzo de enfermería sobre la presión arterial y el control de lípidos, frente a una intervención convencional en pacientes dados de alta recientemente por un ictus[dissertation]. Madrid: UAX: 2024(16/06/2024). Director: Salinero Fort MA.
- **Muñoz Martínez M.** Revisión sistemática. Presencia de los familiares en la reanimación cardiopulmonar en pacientes adultos, para una mejora de las complicaciones psicológicas y afrontamiento de la situación.[dissertation]. Madrid: UAX: 2024(16/06/2024). Director: Salinero Fort MA.

Final Degree Theses

- **Vergara Ortega S.** Microbiota y envejecimiento saludable: análisis de datos de encuestas sobre conocimiento de microbiota, suplementos alimenticios e interés en productos de salud intestinal[dissertation]. Madrid: Universidad Complutense de Madrid : 2024(24/07/2024). Director: Carrillo de Santa Pau E.

Publications

- **Armario P, Vinyoles E, Gijón-Conde T, Arranz C, Galceran JM.** Hypertension and Vascular Risk already has an impact factor. Now a new challenge begins. Hipertens Riesgo Vasc. 2024; 41(2): 73. Editorial Material. IF: 1.3; Q3
- **Banegas JR, Sánchez-Martínez M, Gijón-Conde T, López-García E, Graciani A, Guallar-Castillón P, García-Puig J, Rodríguez-Artalejoa F.** Numerical values and impact of hypertension in Spain. Rev Esp Cardiol (Engl Ed). 2024; 77(9): 767-78. Article. IF: 4.9; Q1
- **Boixareu CB, Ojeda-Thies C, Valtueña AG, Veloz BAC, Lázaro MG, Castellanos LN, Matas RQ, Campelo PG, Vicente AR, González-Montalv JI, Sáez-López P.** Beware of Hip Fractures in the Elderly [Response to Letter]. Clin Interv Aging. 2024; 19: 1895-96. Letter. IF: 3.7; Q2
- **Caballero BM, Alcalá MVC, Misis AG.** Cardiovascular prevention in primary care in crisis situations: multicenter comparative study before, during and after the SARS-COVID-19 pandemic. Aten Prim. 2024; 56(1): 102778. Article. IF: 1.6; Q2
- **Gijón-Conde T, Sánchez CF, Delgado II, Jiménez BR, Banegas JR.** Clinical profile of severe hypercholesterolemia in 156,000 adults in primary care. Clin Investig Arterioscler. 2024; 36(1): 1-11. Article. IF: 1.9; Q3
- **González ER, Arroyo AMH, Benasach FG, Conde TG.** Hypertensive states of pregnancy. Hipertens Riesgo Vasc. 2024; 41(2): 118-31. Review. IF: 1.3; Q3
- **Iriarte-Campo V, de Burgos-Lunar C, Mostaza J, Lahoz C, Cárdenas-Valladolid J, Gómez-Campelo P, Taulero-Escalera B, San-Andrés-Rebollo FJ, Rodríguez-Artalejoi F, Salinero-Fort MA.** Incidence of T2DM and the role of baseline glycaemic status as a determinant in a metropolitan population in northern Madrid (Spain). Diabetes Res Clin Pr. 2024; 209: 111119. Article. IF: 7.4; D1
- **Koochani NB, Romo RM, Palencia IH, Bernal SL, Curto CM, Rodríguez JC, Reguillo AC.** Minimum data set harmonization in the management of cross-border Multi Casualty Incidents. Modified Delphi (VALKYRIES-H2020 project). Plos One. 2024; 19(7): e0305699. Article. IF: 2.6; Q2
- **Ruiz-García A, Serrano-Cumplido A, Arranz-Martínez E, Escobar-Cervantes C, Pallarés-Carratalá V.** Hyperuricaemia Prevalence Rates According to Their Physiochemical and Epidemiological Diagnostic Criteria and Their Associations with Cardio-Renal-Metabolic Factors: SIMETAP-HU Study. J Clin Med. 2024; 13(16): 4884. Article. IF: 2.9; Q1
- **Ruiz-García A, Serrano-Cumplido A, Escobar-Cervantes C, Arranz-Martínez E, Pallarés-Carratalá V.** Prevalence Rates of Abdominal Obesity, High Waist-to-Height Ratio and Excess Adiposity, and Their Associated Cardio-Kidney-Metabolic Factors: SIMETAP-AO Study. Nutrients. 2024; 16(22): 3948. Article. IF: 5; Q1
- **Ruiz-García A, Serrano-Cumplido A, Escobar-Cervantes C, Arranz-Martínez E, Pallarés-Carratalá V.** Atrial Fibrillation Prevalence Rates and Its Association with Cardiovascular-Kidney-Metabolic Factors: SIMETAP-AF Study. Med Lith. 2024; 60(8): 1309. Article. IF: 2.4; Q1
- **Salinero-Fort M, Mostaza-Prieto JM, Lahoz-Rallo C, Cárdenas-Valladolid J, Iriarte-Campo V, Estirado-Decabo E, Garcia-Iglesias F, González-Alegre T, Fernandez-Puntero B, Rio VM, Sánchez-Arroyo V, Sabín-Rodríguez C, López-López S, Gómez-Campelo P, Taulero-Escalera B, Rodríguez-Artalejo F, Andrés-Rebollo FJS, De Burgos-Lunar C.** External validation of three diabetes prediction scores in a Spanish cohort: does adding high risk for depression improve the validation of the FINDRISC score (FINDRISC-MOOD)?. BMJ Open. 2024; 14(6): e083121. Article. IF: 2.3; Q2
- **Salinero-Fort MA, San Andrés-Rebollo FJ, Cardenas-Valladolid J, Mostaza J, Lahoz C, Rodríguez-Artalejo F, Gómez-Campelo P, Vich-Pérez P, Jiménez-García R, de-Miguel-Yanes JM, Maroto-Rodríguez J, Taulero-Escalera B, Campo VI.** Effect of glucose variability on the mortality of adults aged 75 years and over during the first year of the COVID-19 pandemic. BMC Geriatr. 2024; 24(1): 533. Article. IF: 3.8; Q1
- **Serrano-Cumplido A, Ruíz-García A, del Rio-Herrero A, Antón-Eguía PB, Micó-Pérez RM, Calderón-Montero A, Romero-Rodríguez E, Segura-Fragoso A, Martín-Sánchez V.** Effect of the Omicron variant on cumulative incidence of infection and lethality during the sixth wave of the COVID-19 epidemic in Spain. Semergen. 2024; 50(2): 102073. Article. IF: 0.9; Q4
- **Vázquez-Fernández A, Lana A, Struijk EA, Vega-Cabello V, Cardenas-Valladolid J, Salinero-Fort MA, Rodríguez-Artalejo F, López-Garcia E, Caballero FF.** Cross-sectional Association Between Plasma Biomarkers and Multimorbidity Patterns in Older Adults. J Gerontol A-Biol. 2024; 79(1): glad249. Article. IF: 3.8; Q1

Research projects

- **Behzadi Koochani N.** Harmonizationanndpre-standarization of equipment, training and tactical coordinated procedures for first aid vehicles deployment on European multi victim disasters (H2020-101020676). EU. 2021-2023. Managment centre: Indra Sistemas
- **Salinero-Fort MA.** Metabolómica, genómica y nutrición para la medicina personalizada de la enfermedad cardiovascular (OMIC-CARD) (PMP21/00093). ISCIII. 2021-2024. Managment centre: UAM
- **San Andrés-Rebollo FJ.** Efecto de la Variabilidad Glucémica sobre la incidencia de eventos cardiovasculares, mortalidad cardiovascular, por todas las causas y por COVID en las cohortes de DM2 y pre-DM de Madrid (PI22/01499). ISCIII. 2023-2025. Managment centre: FIIBAP
- **Carrillo de Santa Pau E.** Inteligencia Artificial para la Prevención de Enfermedades Crónicas a través de una Nutrición Personalizada. Comunidad de Madrid. Comunidad de Madrid. 2021-2024. Managment centre: IMDEA Alimentación
- **Carrillo de Santa Pau E.** NUTRIclock: a tool based on microbiome and artificial intelligence for implementing precision nutrition. MSCA Postdoctoral Fellowships 2022 (101105645). EU. 2023-2025. Managment centre: IMDEA Alimentación
- **Carrillo de Santa Pau E.** Gut-Finder, an AI-based technology to Promote Healthy Aging. Fundación Ramón Areces. -. Managment centre:
- **Gutierrez-Misis A.** Implantación de la simulación con paciente estandarizado en la asignatura Medicina de Familia para mejorar las competencias en comunicación asistencial. Proyecto SIPE-2. Universidad Autónoma de Madrid. 2024-2025. Managment centre: UAM

Cibers and Retics

- **Salinero-Fort MA.** Red de Investigación en Cronicidad, Atención Primaria y Promoción de la Salud. (RICAPPS). ISCIII. (31/12/2025). FIIBAP
- **Castell Alcalá V.** Red de Investigación en Cronicidad, Atención Primaria y Promoción de la Salud. (RICAPPS). ISCIII. (31/12/2025). FIIBAP
- **Gómez Campelo P.** Plataforma de biobanco y biomodelos (organoides) del Instituto de Investigación Sanitaria del Hospital Universitario La Paz (PT20/00004). ISCIII. (31/12/2024). FIBHULP

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

4 Associated clinicians



4.1 Endocrinology and Nutrition Group

4.2 Ophtalmology Group

4.3 Pediatric Nephrology Group

4.4 Urology Group

4.1 Endocrinology and Nutrition Group

Publications: 29 | **Q1:**15

COMPOSITION

Cristina Álvarez Escolá

- Beatriz Barquiel Alcalá
- Beatriz Lecumberri Santamaría
- Patricia Martín Rojas-Marcos
- Laura Mola Reyes
- Rosa María García Moreno
- Elena García Pérez de Sevilla
- Noemí González Pérez de Villar
- Natalia Hillman Gadea
- Arturo Lisbona Catalán
- Óscar Moreno Domínguez
- Miriam Zapatero Larrauri
- Gonzalo Miñón Sánchez
- Mary Gaby Llaró Casas
- Maíra Cristina Montes Castillo
- Elvira Maíra Melián Pérez



RESEARCH AREAS

- Surgery, transplantation and health technology

RESEARCH ACTIVITY

Publications

- **Araujo-Castro M, Biagetti B, Torre EM, Novoa-Testa I, Cordido F, Pascual-Corrales E, Berrocal VR, Guerrero-Pérez F, Vicente A, Hualpa JCP, García-Centeno R, González-Fernández L, García MDO, Echarri AI, Rodríguez MDM, Novo-Rodríguez C, Calatayud M, Villar-Taibo R, Bernabéu I, Álvarez-Escola C, Valderrama PB, Tenorio-Jiménez C, Galiana PA, Venegas E, González-Molero I, Iglesias P, Blanco-Carrera C, De Lara FVO, Novoa PD, Mezquita EL, Hanzu FA, Aldecoa I, Aznar S, Lamas C, Aulinas A, Asla Q, Gimeno PG, Recio-Córdova JM, Avilés-Pérez MD, Asensio-Wandosell D, Sampedro-Núñez M, Cámara R, Fano MP, Ruz-Caracuel I, Fajardo C, Marazuela M, Puig-Domingo M.** Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs. Endocr-Relat Cancer. 2024; 31(7): e240043. Article. IF: 4.6; Q1
- **Araujo-Castro M, Fano MP, González-Boillos M, Pascual-Corrales E, Ramírez PP, Rojas-Marcos PM, García-Cano A, Ruiz-Sánchez JG, Vicente A, Gómez-Hoyos E, Casterás A, Puig-Pérez A, Sanz IG, Recasens M, San Millan RB, César MJP, Guardiola PD, Perdomo C, Manjón-Miguélez L, Román AR, Lázaro CR, Recio JM, Morales-Ruiz M, Calatayud M, López NJ, Meneses D, Nuñez MS, Ribas EM, Sánchez AS, Diaz CG, Lamas C, Tous MD, Serrano J, Michalopoulou T, Rodrigo ST, Chamorro RR, Aguila FJ, Mateo EMM, Gutiérrez-Medina S, Hanzu FA.** Influence of smoking on cardiometabolic profile and surgical outcomes in patients with primary aldosteronism: a cohort study. Eur J Endocrinol. 2024; 191(6): 579-87. Article. IF: 5.2; Q1
- **Araujo-Castro M, Pascual-Corrales E, Rojas PM, Ramírez PP.** Epidemiology and diagnosis of primary aldosteronism. What have we learned from the SPAIN-ALDO registry? Endocrine. 2024; 83(3): 527-36. Review. IF: 2.9; Q3
- **Araujo-Castro M, Ramírez PP, Hanzu FA.** Executive summary of the Spanish consensus for the diagnosis, management, and follow-up of primary hyperaldosteronism. Endocrinol Diabetes Nutr. 2024; 71(8): 355-64. Article. IF: 1.8; Q3
- **Araujo-Castro M, Ruiz-Sánchez JG, Ramírez PP, Rojas-Marcos PM, Aguilera-Saborido A, Cerezo JFG, Lazareno NL, Quesada MET, Ramos JG, Oriola J, Poch E, Oliveras A, Monter JVM, Muriel IG, Bella-Cueto MR, Cidoncha EM, Runkle I, Hanzu FA.** Screening and diagnosis of primary aldosteronism. Consensus document of all the Spanish Societies involved in the management of primary aldosteronism. Endocrine. 2024; 85(1): 99-121. Review. IF: 2.9; Q3
- **Araujo-Castro M, García Sanz I, Mínguez Ojeda C, Hanzu F, Mora M, Vicente A, Blanco Carrera C, Miguel Novoa P, López García MC, Lamas C, Manjón-Miguélez L, Del Castillo Tous M, Rodríguez de Vera P, Barahona San Millan R, Recasens M, Fernández-Ladreda M, Valdes N, Gracia Gimeno P, Robles Lazaro C, Michalopoulou T, Álvarez Escola C, García**

Centeno R, Calatayud M. Risk factors for intraoperative hypertensive crisis in patients with pheochromocytomas and sympathetic paragangliomas. J Hypertens. 2024; 42(2): 252-9. Article. IF: 4.1; Q1

- **Biagetti B, Araujo-Castro M, Torre EM, Novoa-Testa I, Cordido F, Corrales EP, Berrocal VR, Guerrero-Pérez F, Vicente A, Percovich JC, Centeno RG, González L, García MDO, Echarri AI, Rodríguez MDM, Novo-Rodríguez C, Calatayud M, Villar-Taibo R, Bernabeu I, Álvarez-Escola C, Valderrama PB, Tenorio-Jiménez C, Galiana PA, Moreno EV, Molero IG, Iglesias P, Blanco C, De Lara FVO, de Miguel P, Mezquita EL, Hanzu F, Aldecoa I, Aznar S, Lamas C, Aulinas A, Roca QA, Gracia P, Córdova JMR, Avilés M, Asensio-Wandosel D, Sampedro M, Cámara R, Paja M, Ruz-Caracuel I, Fajardo-Montanana C, Asanza EC, Martínez-Sáez E, Marazuela M, Puig-Domingo M.** Effectiveness of combined first-line medical treatment in acromegaly with prolactin cosecretion. Eur J Endocrinol. 2024; 190(6): 458-66. Article. IF: 5.2; Q1
- **Campos Del Portillo R, Palma Milla S, Matia Martin P, Loria-Kohen V, Martínez Olmos MA, Mories Alvarez MT, Castro Alija MJ, Martin Palmero MA, Carrillo Lozano E, Valero-Pérez M, Campos Del Portillo I, Sirvent Segovia AE, Plaza Blazquez P, de la Cruz López DM, Pita Gutierrez F.** A consensus report by the Working Group on Eating Disorders of Sociedad Espanola de Nutricion Clinica y Metabolismo (GTTCA-SENPE). Evaluation, medical and nutritional management of anorexia nervosa. Update 2023. Nutr Hosp. 2024; 41(Spec No1): 21916. Article. IF: 1.1; Q4
- **Catalina VS, Pedro NA, Carrillo CA, Paola PR, Carlos PL.** Carotid pseudoaneurysms after endoscopic transsphenoidal surgery for acromegaly. Endocrinol Diabetes Nutr. 2024; 71(1): 35-7. Article. IF: 1.8; Q3
- **Chu-Montiel D, Palma-Milla S, López-Plaza B, Valero-Pérez M, Gómez-Candela C, Bermejo LM.** Effects of a functional yogurt enriched with soluble dietary fiber or vegetable proteins on appetite profile. An acute randomized controlled clinical trial. Nutr Hosp. 2024; 41(5): 994-1002. Article. IF: 1.1; Q4
- **García IA, Moreno RMG, Plaza BL, Alcalá BB, Pérez PV, Bonis ACB, de Lucas EZ, Milla SP, Sánchez MCP, de Villar NGP.** Impact of triple transmembrane regulator therapy on glucose metabolism in cystic fibrosis related diabetes during clinical practice. Diabetes Res Clin Pr. 2024; 216: 111839. Article. IF: 7.4; D1
- **García-Feijoo P, López CP, Paredes I, Cancela AA, Álvarez-Escola C, Calatayud M, Lagares A, Librizzi MS, Berrocal VR, Araujo-Castro M.** Exploring risk factors of severe pituitary apoplexy: Insights from a multicenter study of 71 cases. Endocrine. 2024; 86(1): 333-41. Article. IF: 2.9; Q3
- **García-Moreno RM, Reyes LM, López-Plaza B, Milla SP.** C-Reactive Protein-to-Prealbumin and C-Reactive Protein-to-Albumin Ratios as Nutritional and Prognostic Markers in Hospitalized Patients-An Observational Study. Nutrients. 2024; 16(16): 2610. Article. IF: 5; Q1
- **Lamas C, Araujo-Castro M, Ostermair L, Petersenn E, Ramírez PP, Rebollo-Román A, Stuefchen I, Bruedgam D, Ruiz-Sánchez JG, Michalopoulou T, Perdomo CM, Hanzu FA, Adolf C, Reincke M.** Impact of Cortisol-Cosecretion on Adrenal Venous Sampling Results in Primary Aldosteronism: Study of 225 Cases. Biomedicines. 2024; 12(11): 2430. Article. IF: 3.9; Q2
- **López-Plaza B, Álvarez-Mercado AI, Arcos-Castellanos L, Plaza-Díaz J, Ruiz-Ojeda FJ, Brandimonte-Hernández M, Feliú-Batlle J, Hummel T, Gil A, Palma-Milla S.** Efficacy and Safety of Habitual Consumption of a Food Supplement Containing Miraculin in Malnourished Cancer Patients: The CLINMIR Pilot Study. Nutrients. 2024; 16(12): 1905. Article. IF: 5; Q1
- **Marqués-Pamies M, Gil J, Sampedro-Núñez M, Valassi E, Biagetti B, Giménez-Palop O, Hernández M, Martínez S, Carrato C, Villar-Taibo R, Araujo-Castro M, Blanco C, Simón-Muela I, Simó-Servat A, Xifra G, Vázquez F, Pavón I, Rosado JA, García-Centeno R, Zavala R, Hanzu FA, Mora M, Aulinas A, Vilarrasa N, Librizzi S, Calatayud M, de Miguel P, Álvarez-Escola C, Picó A, Salinas I, Fajardo-Montañana C, Cámara R, Bernabéu I, Jordà M, Webb SM, Marazuela M, Puig-Domingo M.** Personalized Medicine in Acromegaly: The ACROFAST Study. J Clin Endocr Metab. 2024; 110(1): 30-40. Article. IF: 5.1; Q1
- **Milla SP, Luna PPG, Casariego AV, González FV, Folgueras TM, Jáuregui OI, Rey SG, Fernández AC, Plaza BL, Quintana TC, Román DAD.** Adherence and impact of an oral nutritional supplement enriched in leucine, EVOO, EPA and DHA, and beta-glucans on the coverage of energy and protein requirements in patients with cancer and malnutrition: Alisenoc study. Nutrition. 2024; 120: 112355. Article. IF: 3.0; Q2
- **Monteagudo M, Calsina B, Salazar-Hidalgo ME, Martínez-Montes AM, Piñeiro-Yáñez E, Caleiras E, Martín MC, Rodríguez-Perales S, Letón R, Gil E, Buffet A, Burnichón N, Fernández-Sanromán A, Díaz-Talavera A, Mellid S, Arroba E, Reglero C, Martínez-Puente N, Roncador G, del Olmo MI, Corrales PJP, Oliveira CL, Alvarez-Escolá C, Gutiérrez MC, López-Fernández A, García NP, Regojo RM, Díaz LR, Laorden NR, Guadarrama OS, Bechmann N, Beuschlein F, Canu L, Eisenhofer G, Fassnacht M, Nölting S, Quinkler M, Rapizzi E, Remde H, Timmers HJ, Favier J, Gimenez-Roqueplo AP, Rodríguez-Antona C, Currás-Freixes M, Al-Shahrour F, Cascón A, Leandro-García LJ, Montero-Conde C, Robledo M.** MAML3-fusions modulate vascular and immune tumour microenvironment and confer high metastatic risk in pheochromocytoma and paraganglioma. Best Pract Res Cl En. 2024; 38(6): 101931. Article. IF: 6.1; Q1
- **Paredes I, Rodríguez-Berrocal V, Pérez-López C, García-Feijoo P, Álvarez-Escola C, Cancela AA, Araujo-Castro M, Calatayud M, Librizzi MS, Lagares A.** Influence of surgical timing on the visual prognosis of patients suffering from a pituitary apoplexy with visual impairment. Neurosurg Rev. 2024; 47(1):-852. Article. IF: 2.5; Q1
- **Pascual-Corrales E, Biagetti B, Marazuela M, Asensio-Wandosel D, Berrocal VR, Echarri AI, Novo-Rodríguez C, Calatayud M, Bernabéu I, Álvarez-Escola C, Tenorio-Jiménez C, Molero IG, Iglesias P, Blanco C, de Miguel P, Mezquita EL, Lamas C, Aulinas A, Gracia P, Recio-Córdova JM, Sampedro-Nuñez M, Paja M, Rodríguez MDM, Fajardo-Montañana C, Cordido F, Torre EM, Percovich JC, García-Centeno R, Cámara R, Hanzu FA, Delgado AV, Fernández LG, Guerrero-Pérez F, García-Agulló MDO, Novoa-Testa I, Villar-Taibo R, Valderrama PB, Galiana PA, Moreno EV, De Lara FVO, Enseñat J, Aznar S, Asla Q, Aviles-Pérez MD, Puig-Domingo M, Araujo-Castro M.** Glucose metabolism outcomes after pituitary surgery in patients with acromegaly. Pituitary. 2024; 27(5): 497-506. Article. IF: 3.4; Q2
- **Plaza-Díaz J, Ruiz-Ojeda FJ, López-Plaza B, Brandimonte-Hernández M, Álvarez-Mercado AI, Arcos-Castellanos L, Feliú-Batlle J, Hummel T, Palma-Milla S, Gil A.** Effect of a Novel Food Rich in Miraculin on the Oral Microbiome of Malnourished Oncologic Patients with Dysgeusia. Cancers (Basel). 2024; 16(19): 3414. Article. IF: 4.4; Q2
- **Quirós C, Arranz MTH, Amigó J, Wägner AM, Beato-Vibora PI, Azriel-Mira S, Climent E, Soldevila B, Barquiel B, Colomo N, Durán-Martínez M, Corcoy R, Codina M, Díaz-Soto G, Pardo RM, Martínez-Brocca MA, Román AR, López-Gallardo G, Cuesta M, Fernández JG, Goya M, Guedes BV, Mathison LCM, Perea V.** Real-World Evidence of Off-Label Use of Commercially Automated Insulin Delivery Systems Compared to Multiple Daily Insulin Injections in Pregnancies Complicated by Type 1 Diabetes. Diabetes Technol The. 2024; 26(8):



596-606. Article. IF: 6.3; Q1

- **Ramírez PP, Rojas-Marcos PM, Fano MP, Boillos MG, Peris BP, Pascual-Corrales E, Cano AMG, Ruiz-Sánchez JG, Delgado AV, Hoyos EG, Ferreira R, Sanz IG, Sala MR, San Millan RB, Cesar MJP, Guardiola PD, Perdomo CM, Manjón-Miguélez L, Centeno RG, Percovich JC, Román AR, Gimeno PG, Lázaro CR, Morales-Ruiz M, Calatayud M, Collao SAF, Meneses D, Nunez MAS, Quesada VE, Ribas EM, Sánchez AS, Diaz CG, Lamas C, Guerrero-Vázquez R, Tous MD, Gotarredona JS, Alevras TM, Mateo EMM, Hanzu FA, Araujo-Castro M.** Is adrenal venous sampling always necessary to differentiate between unilateral and bilateral primary aldosteronism? Lesson from the SPAIN-ALDO register. Endocrine. 2024; 84(2): 683-93. Article. IF: 2.9; Q3
- **Ramírez PP, Rojas-Marcos PM, Fano MP, González-Boillos M, Pascual-Corrales E, Cano AMG, Ruiz-Sánchez JG, Delgado AV, Hoyos EG, Ferreira R, Sanz IG, Sala MR, San Millán RB, Cesar MJP, Guardiola PD, Perdomo CM, Manjón-Miguélez L, Román AR, Lázaro CR, Morales-Ruiz M, Calatayud M, Collao SAF, Meneses D, Sampedro-Núñez MA, Ribas EM, Sánchez AS, Díaz CG, Lamas C, Guerrero-Vázquez R, Tous MD, Gotarredona JS, Alevras TM, Rodrigo ST, Chamorro RR, Aguila FJ, Mateo EMM, Hanzu FA, Araujo-Castro M.** Renin as a Biomarker to Guide Medical Treatment in Primary Aldosteronism Patients. Findings from the SPAIN-ALDO Registry. High Blood Press Cardiovasc Prev. 2024; 31(1): 43-53. Article. IF: 2.9; Q2
- **Reyes LM, García-Moreno RM, López-Plaza B, Milla SP.** Prevalence, Risk Factors, and Clinical Management of Disease-Related Malnutrition in Hospitalized Patients: A Descriptive Analysis Using GLIM and SGA Criteria. Nutrients. 2024; 16(23): 4099. Article. IF: 5; Q1
- **Román DD, Almeida JMG, Guerrero DB, Rolo GG, Martín A, Martín DP, García-Delgado Y, Guirado-Peláez P, Palmas F, Pérez CT, Olivares MG, Jiménez MM, Lesmes IB, Teomiro CMA, Baena JMG, Romero LAC, Prior-Sánchez I, García-Luna PP, Pacheco MG, Martínez-Olmos MA, Alabadí B, Alcántara-Aragon V, Milla SP, Folgueras TM, García AM, Molina-Baena B, Barragán HR, Gómez PRD, Fernández MR, Portilla AJ, López-Gómez JJ, Martín NP, Madrid NM, Eguinoa AZ, Fernández CP, Guerrero MJT, Aguado MR, Gimeno CV, Martínez ADH, Rodríguez MN, Hernández NCI, Medina MD, Navarro IG, López FJV, Fernández-Pombo A, Olveira G.** Ultrasound Cut-Off Values for Rectus Femoris for Detecting Sarcopenia in Patients with Nutritional Risk. Nutrients. 2024; 16(11): 1552. Article. IF: 5; Q1
- **Ruiz-García C, Riesco LR, Mateos-Serrano B, Millán RB, Muñoz AJD, Gavilán J, Ramírez PP, Marcos PMR, Catalán AL, Lecumberri B, Alvarez-Escolá C, Castro A.** Disease-free survival and response to therapy of clinically node-negative papillary thyroid cancer treated without central neck dissection: Retrospective study of 321 patients. Acta Otorrinolaringol Esp. 2024; 75(4): 224-30. Article. IF: 1.1; Q3
- **Sampedro-Núñez M, Herrera-Martínez AD, Ibáñez-Costa A, Rivero-Cortés E, Venegas E, Robledo M, Martínez-Hernández R, García-Martínez A, Gil J, Jordà M, López-Fernández J, Gavilán I, Maraver S, Marqués-Pamies M, Cámara R, Fajardo-Montañana C, Valassi E, Dios E, Aulinas A, Biagetti B, Escola CA, Araujo-Castro M, Blanco C, Paz D, Villar-Taibo R, Álvarez C, Gaztambide S, Webb SM, Castaño L, Bernabéu I, Picó A, Gálvez MA, Soto-Moreno A, Puig-Domingo M, Castaño JP, Marazuela M, Luque RM, REMAH Investigators.** Integrative clinical, hormonal, and molecular data associate with invasiveness in acromegaly: REMAH study. Eur J Endocrinol. 2024; 190(6): 421-33. Article. IF: 5.2; Q1
- **Valdés N, Romero A, Diego E, Calatayud M, Lamas C, Araujo-Castro M, Álvarez-Escolá C, Díaz JA, Alcázar V, Sastre J, Martínez R, Oriola J, Paja M, Sánchez-Sobrino P, Salinas I, Recio-Córdova JM, Navarro E, Chiara MD, Castaño L, Casterás A.** Long term outcomes of pituitary adenomas in Multiple Endocrine Neoplasia type 1: a nationwide study. Front Endocrinol (Lausanne). 2024; 15: 1427821. Article. IF: 4.6; Q1

Research projects

- **Martín Rojas-Marcos P.** Evaluación del valor predictivo de la prueba copeptina para el diagnóstico de deficiencia de arginina-vasopresina en pacientes en postoperatorio temprano de cirugía hipofisaria y del área selar. Sociedad de Endocrinología, Nutrición y Diabetes de la Comunidad De Madrid. 2024-2025. Managment centre: FIBHULP

Clinical trials

- **Zapatero Larrauri M.** A phase III, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with bi 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (cvd) or chronic kidney disease, or at least two risk factors for cvd.
  Type/Phase: III
  Sponsored by: Boehringer Ingelheim España S.A
  Signature date: 30/01/2024
- **Lisbona Catalán A.** Ensayo clínico multicéntrico, aleatorizado, ciego y controlado para evaluar la eficacia y seguridad de colecalciferol en la corrección del déficit de 25(oh)d de sujetos con deficiencia severa de vitamina d, en comparación a calcifediol. Estudio Dtreat.
  Type/Phase: IV
  Sponsored by: Itf Research Pharma S.L.U.
  Signature date: 17/09/2024

4.2 Ophtalmology Group

Publications: 33 | **Q1:**24

COMPOSITION

Félix Armada Maresca

- Ester Carreño Salas
- M. Ventura Hidalgo Barrero
- M. Pino Cidad Betegón
- Ana M. Boto de los Bueis
- Jesús Peralta Calvo
- Ana Isabel Ramos Castrillo
- Paola Cristina Vázquez Colomo
- Julia Esther Murillo Doria
- Álvaro Arbizu Duralde
- Mónica Asencio Durán
- María Capote Díez
- Oriana D'Anna
- María Granados Fernández
- Irene Canal Foncuberta
- Lilian C. Martínez Godoy
- Ricardo Romero Martín
- Jesús Fraile Maya
- José Vicente Dabad Moreno
- Beatriz Manzano Muñoz
- María Begoña Pastor Nieto
- Margarita Sánchez Orgaz
- Silvana Lubisco Portella
- Irene Rosa Pérez
- Javier F. Coca Robinot
- Rosa María Cordero Ros
- Gloria Amorena Santisteban
- Sofía Katina de Manuel Triantafilo
- Ana María Martín Ucero
- Diego Asensio Celdrán Vivancos
- Natalia Arruti Vázquez
- Almudena del Hierro Zarzuelo

RESEARCH AREAS

- Large system pathology



RESEARCH ACTIVITY

Doctoral Theses

- **Marcos Lorenzo D.** Salud de la columna en la descarga axial provocada durante los vuelos espaciales y la recarga mediante ejercicio[dissertation]. : Universidad Autónoma de Madrid: 2024(12/04/2024). Director: Gil Martínez A, Green DA
- **Díaz Saéz MC.** La lengua como órgano clave en el abordaje de los trastornos temporomandibulares[dissertation]. : Universidad Autónoma de Madrid: 2024(23/05/2024). Director: Gil Martínez A, Beltrán Alacreu H
- **Sanjuán Riera L.** Resultados funcionales del tratamiento con Bevacizumab Intravítreo en retinopatía del prematuro[dissertation]. Madrid: Universidad Autónoma de Madrid: 2024(07/11/2024). Director: Peralta Calvo J

Publications

- **Alforja S, Hunt A, Nguyen V, O'Toole L, Gabrielle PH, Invernizzi A, Mehta H, Ponsioen TL, Squirrell D, Casaroli-Marano RP, Barthelmes D, Gillies MC, Zarranz-Ventura J.** Three-Year Outcomes of VEGF Inhibitors in Naive Branch Retinal Vein OcclusionFight Retinal Blindness!. Ophthalmol Retina. 2024; 8(10): 962-70. Article. IF: 5.7; D1
- **Asencio-Durán M, Fernández-Gutiérrez E, Larranaga-Cores M, Klein-Burgos C, Dabad-Moreno J V, Capote-Díez M.** Ocular side effects of oncological therapies: Review. Arch Soc Esp Oftalmol (Engl Ed). 2024; 99(3): 109-32. Review.Not Indexed
- **Carreño E, Hernanz I, Collado B, Pichi F.** Description of Macrophage-Like Cells in Active Ocular Toxoplasmosis. Ocul Immunol Inflamm. 2024; 32(8): 1893-6. Letter. IF: 2; Q2
- **Cores ML, García LD, Vásquez NE, Burgos CK, de los Bueis AB, Zarzuelo AD.** Corneal Crystals in Patients With Tyrosinemia Types I and II. Cornea. 2024; 43(3): e4-5. Letter. IF: 2.1; Q2
- **de la Fuente J, Llorente-González S, Fernández-Robredo P, Hernández M, García-Layana A, Ochoa I, Recalde S.** Suitability of machine learning for atrophy and fibrosis development in neovascular age-related macular degeneration. Acta Ophthalmol. 2024; 102(5): e831-41. Article. IF: 2.8; Q1
- **de los Bueis AB, Arranz CV, Del Hierro-Zarzuelo A, Valle DD, Fernández RM, Hermosilla MIG, del Castillo JMB, García-Arranz M.** Long-Term Effects of Adipose-Derived Stem Cells for the Treatment of Bilateral Limbal Stem Cell Deficiency. Curr Eye Res. 2024; 49(4): 345-53. Article. IF: 2.0; Q2
- **Farrall AL, Radford MHB, Smith JR.** Presentation, Diagnostic Testing and Initial Treatment of Vitreoretinal Lymphoma. Ophthalmol Retina. 2024; 8(1): 72-80. Article. IF: 5.7; D1
- **Fernández-Caballero L, Martín-Merida I, Blanco-Kelly F, Ávila-Fernandez A, Carreño E, Jose PFS, Irigoyen C, Jimenez-Rolando B, López-Grondona F, Mahillo I, Martin-Gutierrez MP, Minguez P, Perea-Romero I, Del Pozo-Valero M, Riveiro-Alvarez R, Rodilla C, Rodríguez-Peña L, Sánchez-Barbero AI, Swafiri ST, Trujillo-Tiebas MJ, Zurita O, García-Sandoval B, Corton M, Ayuso C.** PRPH2-Related Retinal Dystrophies: Mutational Spectrum in 103 Families from a Spanish Cohort. Int J Mol Sci. 2024; 25(5): 2913. Article. IF: 4.9; Q1
- **Fonollosa A, Carreño E, Vitale A, Jindal AK, Ramanan AV, Pelegrín L, Santos-Zorrozua B,**



Gómez-Caverzaschi V, Cantarini L, Fabiani C, Hernández-Rodríguez J. Update on ocular manifestations of the main monogenic and polygenic autoinflammatory diseases. Front Ophthalmol (Lausanne). 2024; 4: 1337329. Review. IF: 0.9; Q4

- **Gaggiano C, Gupta V, Agrawal R, De Smet MD, Frediani B, Tosi GM, Paroli MP, Sridharan S, Pavesio CE, Pleyer U, Denisova EV, Babu K, de-la-Torre A, Yang PZ, Davis JL, Cunningham ET, Carreño E, Goldstein D, Fonollosa A, Cantarini L, Sobrin L, Fabiani C.** Knowledge and Current Practices in Monogenic Uveitis: An International Survey by IUSG and AIDA Network. Ophthalmol Ther. 2024; 13(1): 127-47. Article. IF: 3.2; Q1
- **García AG, del Arco C, Fernández DL, Frías-Vargas M, Guillán M, Méndez-Bailón M, Grinspan MR, Aguado-Castaño AC, Maya JF, González GL, Castañeda S.** Executive summary on the optimization of the multidisciplinary and integrated approach to polymyalgia rheumatica and giant cell arteritis in Madrid region. Rev Clin Esp. 2024; 224(1): 48-56. Article. IF: 1.7; Q2
- **García L, Gutiérrez-Arroyo A, Miguel-Buckley R, Ucero A, Cantizani J, Boto-de-los-Bueis A.** Persistent and Severe Mpox Keratitis Despite Systemic and Topical Treatment. Cornea. 2024; 43(6): 777-83. Article. IF: 2.1; Q2
- **García-Sánchez A, Villalaín-Rodes I, Jaureguizar A, Zamarrón E, Martínez-Cerón E, Casitas R, Galera R, Cubillos-Zapata C, García J, Asencio M, García-Río F.** Continuous Positive Airway Pressure Effect on Progression of Retinal Disease in Patients with Sleep Apnea and Nonproliferative Diabetic Retinopathy A Randomized Clinical Trial. Ann Am Thorac Soc. 2024; 21(1): 102-13. Article. IF: 5.4; Q1
- **González-Martin-Moro J, Maya JF, Martínez LC.** Leber Hereditary Optic Neuropathy 3 Weeks After COVID-19 Vaccination. J Neuro-Ophthalmol. 2024; 44(1): e207. Letter. IF: 2.0; Q2
- **Izquierdo-Serra J, Martín-Pinardel R, Moll-Udina A, Bernal-Morales C, Garay-Aramburu G, Sánchez-Monroy J, Arruabarrena C, Fernandez-Hortelano A, Figueroa MS, Abraldes M, de los Mozos FJL, Zapata MA, Ruiz-Moreno JM, Broc-Iturralde L, González-Guijarro J, Escobar-Barranco JJ, Gallego-Pinazo R, Parrado-Carrillo A, Dotti-Boada M, Alforja S, Figueras-Roca M, Barthelmes D, Gillies MC, Casaroli-Marano RP, Zarranz-Ventura J.** Macular Neovascularization Type In fl uence on Anti-VEGF Intravitreal Therapy Outcomes in Age-Related Macular Degeneration. Ophthalmol Retina. 2024; 8(4): 350-9. Article. IF: 5.7; D1
- **Klein-Burgos C, Sanjuan-Riera L, Larranaga-Cores M, Fernández-Gutiérrez E, Boto-de Los Bueis A.** Thermokeratoplasty and amniotic membrane transplantation for refractory corneal hydrops in a patient with pellucid marginal degeneration. Arch Soc Esp Oftalmol (Engl Ed). 2024; 99(12): 566. Article. Not Indexed
- **Mehta H, Gabrielle PH, Hashimoto Y, Kibret GD, Arnold J, Guillaumie T, Kheir WJ, Kok G, Vujosevic S, O'Toole L, Mangelschots E, Jaross N, Ceklic L, Daien V, Viola F, Squirrell D, Lavid FJ, Creuzot-Garcher C, Barthelmes D, Gillies M.** One-Year Anti-VEGF Therapy Outcomes in Diabetic Macular Edema Based on Treatment Intensity Data from the Fight Retinal Blindness! Registry. Ophthalmol Retina. 2024; 8(9): 872-9. Article. IF: 5.7; D1
- **Mesa-del-Castillo P, Ugarte IY, Bolarín JM, Martínez D, Montesinos BL, González HB, Penadés IC, Pérez LL, Clemente D, Robledillo JC, Ferrán IV, Mancheño BB, Plats MR, Pedraz LM, Linero CA, Sevilla-Pérez B, García-Serrano JL, Mir-Perelló MC, Druetta N, Souto A, López-López F, Zarallo-Reales C, Fidalgo MJ, Fajardo JS, Fontana NP, Pablo RD, Pinedo MC, Fonollosa A, Casano VJ, García JJM, Brandy A, López AG, Esteban-Ortega M, Reinoso T, Calzada-Hernández J, Cardeñosa AL, Martín CG, Verdú EM, Vidal MPM, Martí NQ, Alvarado MC, De Inocencio J, Alonso-Martín B, Recuero-Diaz S, Carreño E, González**

JCN, Ibares L, de Salazar JRG, Sevila JL. Childhood-Onset Non-Infectious Uveitis in the Biologic Era. Results From Spanish Multicenter Multidisciplinary Real-World Clinical Settings. Ocul Immunol Inflamm. 2024; 32(9): 2159-69. Article. IF: 2; Q2

- **Pichi F, Neri P, Aljeneibi S, Hay S, Chaudhry H, Saturno MC, Carreno E.** In Vivo Visualization of Macrophage-Like Cells in Patients with Uveitis by Use of En Face Swept Source Optical Coherence Tomography. Ocul Immunol Inflamm. 2024; 32(8): 1532-8. Article. IF: 2; Q2
- **Pichi F, Neri P, Aljneibi S, Hay S, Chaudhry H, Carreno E.** Vitreoretinal Interface Cells Correlate In Vivo With Uveitis Activity and Decrease With Anti-Inflammatory Treatment. Transl Vis Sci Technol. 2024; 13(5): 15. Article. IF: 2.6; Q2
- **Pichi F, Neri P, Moreno-Rodríguez L, Carreño E.** Dancing in the eye: dynamic optical coherence tomography to distinguish different retinal microglia populations. Int Ophthalmol. 2024; 44(1): 165. Editorial Material. IF: 1.4; Q3
- **Pichi F, Smith SD, Goldstein DA, Baddar D, Gerges TKA, Janetos TM, Ruiz-Cruz M, Concha-del-Río LE, Maruyama K, ten Berge JC, Rombach SM, Cimino L, Bolletta E, Miserocchi E, Scandale P, Serafino M, Camicione P, Androudi S, González-López JJ, Lim LL, Singh N, Gupta V, Gupta N, Amer R, Dodds EM, Inchauspe S, Munk MR, Donicova E, Carreno E, Takeuchi M, Chee SP, Chew MC, Agarwal A, Schlaen A, Gomez RA, Couto CA, Khairallah M, Neri P.** The Humira in Ocular Inflammations Taper (HOT) Study. Am J Ophthalmol. 2024; 258: 87-98. Article. IF: 4.2; Q1
- **Roca-Cabau MA, Kumaran N, Asencio-Durán M, Pita-Ortiz I, Moreno VD.** Pseudomelanoma diagnosis in a tertiary ophthalmologic centre in Spain. Can J Ophthalmol. 2024; 59(6): e763-7. Article. IF: 2.8; Q1
- **Sabapathypillai S, Miller VJ, Shakoor A, Palestine AG, Thorne JE, Goldstein DA, Gaudio PA, Goldberg N, Vitale A, Schlaen A, Thomas A, Merrill PT, Raiji V, Lin P, Oliver AL, Moorthy RS, Chandra G, Carreno E, Smith WM, Van Stavern G, Hassman LM.** Optic Disc Edema Is an Under-Recognized Feature of Birdshot Chorioretinitis. J Neuro-Ophthalmol. 2024; 44(4): 545-51. Article. IF: 2.0; Q2
- **Tarsia M, Vitale A, Gaggiano C, Sota J, Maselli A, Bellantonio C, Guerriero S, Dammacco R, La Torre F, Ragab G, Hegazy MT, Fonollosa A, Paroli MP, Del Giudice E, Maggio MC, Cattalini M, Fotis L, Conti G, Mauro A, Civino A, Diomeda F, de-la-Torre A, Cifuentes-González C, Tharwat S, Hernández-Rodríguez J, Gómez-Caverzaschi V, Pelegrín L, Babu K, Gupta V, Minoia F, Ruscitti P, Costi S, Breda L, La Bella S, Conforti A, Mazzei MA, Carreno E, Amin RH, Grosso S, Frediani B, Tosi GM, Balistreri A, Cantarini L, Fabiani C.** Effectiveness and Safety of Biosimilars in Pediatric Non-infectious Uveitis: Real-Life Data from the International AIDA Network Uveitis Registry. Ophthalmol Ther. 2024; 13(3): 761-74. Article. IF: 3.2; Q1
- **Testa F, Carreño E, van den Born LI, Melillo P, Perea-Romero I, Di Iorio V, Risca G, Iodice CM, Pennings RJE, Karali M, Banfi S, Auricchio A, Galimberti S, Ayuso C, Simonelli F.** Multicentric Longitudinal Prospective Study in a European Cohort of MYO7A Patients: Disease Course and Implications for Gene Therapy. Invest Ophth Vis Sci. 2024; 65(6): 25. Article. IF: 4.7; D1
- **Thng ZX, Putera I, Testi I, Chan K, Westcott M, Chee SP, Dick AD, Kempen JH, Bodaghi B, Thorne JE, Barisani-Asenbauer T, de Smet MD, Smith JR, McCluskey P, Nora RL, Jabs DA, de Boer JH, Sen HN, Goldstein DA, Khairallah M, Davis JL, Rosenbaum JT, Jones NP, Nguyen QD, Pavesio C, Agrawal R, Gupta V.** The Infectious Uveitis Treatment Algorithm Network (TITAN) Report 1-global current practice patterns for the management of Herpes Simplex Virus and Varicella Zoster Virus anterior uveitis. Eye. 2024; 38(1): 61-7. Article. IF: 3.2; Q1
- **Thng ZX, Putera I, Testi I, Chan K, Westcott M, Chee SP, Dick AD, Kempen JH, Bodaghi B, Thorne JE, Barisani-Asenbauer T, de Smet MD, Smith JR, McCluskey P, Nora RL, Jabs DA, de Boer JH, Sen HN, Goldstein DA, Khairallah M, Davis JL, Rosenbaum JT, Jones NP, Nguyen QD, Pavesio C, Agrawal R, Gupta V.** The Infectious Uveitis Treatment Algorithm Network (TITAN) Report 2-global current practice patterns for the management of Cytomegalovirus anterior uveitis. Eye. 2024; 38(1): 68-75. Article. IF: 3.2; Q1
- **Vidal C, Robles I, Carreno E.** Tubulointerstitial Nephritis and Uveitis Syndrome (TINU) after Intake of Dietary Supplement. Ocul Immunol Inflamm. 2024; 32(2): 242-3. Letter. IF: 2; Q2
- **Vidal C, Robles I, Escamilla N, Losada D, Serrano C, Miranda C, Pastor AI, Carreño E.** Hypopyon Uveitis as a Manifestation of Primary Choroidal Lymphoma. Ocul Immunol Inflamm. 2024; 32(7): 1462-4. Letter. IF: 2; Q2
- **Vitale A, Caggiano V, Martín-Nares E, Di Meglio N, Sica C, Hinojosa-Azaola A, Perfetti MO, Pagliara A, Guidetti G, Fonollosa A, López R, Sbalchiero J, Sota J, Carreño E, Kawakami-Campos PA, Gentileschi S, de-la-Torre A, Tosi GM, Mazzei MA, Balistreri A, Frediani B, Cantarini L, Fabiani C.** Dry eye disease and spondyloarthritis: expanding the spectrum of systemic inflammatory disorders associated with ocular surface disease. Data from the international AIDA Network Spondyloarthritis Registry. Front Med (Lausanne). 2024; 11(): -1422307. Article. IF: 3; Q1
- **Vitale A, Palacios-Olid J, Caggiano V, Ragab G, Hernández-Rodríguez J, Pelegrín L, Mejía-Salgado G, Zarate-Pinzón L, Gentileschi S, Sota J, Fonollosa A, Carreño E, Gaggiano C, Amin RH, Balistreri A, Narváez J, Tosi GM, Frediani B, Cantarini L, de-la-Torre A, Fabiani C.** Efficacy and safety of Janus kinase inhibitors in non-infectious inflammatory ocular diseases: a prospective cohort study from the international AIDA network registries. Front Med (Lausanne). 2024; 11: 1439338. Article. IF: 3; Q1
- **Zhang LD, Rojas-Carabali W, Choo SS, Thng ZX, Lim YH, Lee BR, Jun SW, Patnaik G, Biswas J, Agarwal A, Testi I, Mahajan S, Kempen JH, Smith JR, Mccluskey P, Kon OM, Nguyen QD, Pavesio C, Gupta V, Agrawal R.** Validation of the Online Collaborative Ocular Tuberculosis Study Calculator for Tubercular Uveitis. Jama Ophthalmol. 2024; 142(12): 1140-8. Article. IF: 9.2; D1

Research projects

- **Asencio Durán M.** Actividades de creación de un material didáctico impreso de difusión de la experiencia investigadora del servicio de oftalmología en patología de retina. Bayer Hispania S.L. 2021-2024. Managment centre: FIBHULP
- **Asencio Durán M.** Actividades de creación de un material didáctico impreso de difusión de la experiencia investigadora del servicio de oftalmología en patología de retina. Alcon Healthcare S.A. 2021-Ongoing. Managment centre: FIBHULP
- **Rodriguez L, Carreño Salas E.** Eficacia, seguridad y coste-efectividad del metotrexato, adalimumab, o su combinación en uveítis no anterior no infecciosa: un estudio multicéntrico, aleatorizado, paralelo de 3 brazos, con control activo, de fase 3, abierto, con evaluador cegado (ICI19/00020). ISCIII. 2020-2025. Managment centre: HCSC
- **Arruti Vazquez N.** Caracterización clínica del síndrome alcohólico-fetal: repercusión sobre la función visual y la visión funcional. ONCE. 2024-2025. Managment centre: FIBHULP

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

4.3 Pediatric Nephrology Group



Publications: 2 | **Q1:** 1

COMPOSITION

Alejandro Zarauzo Santoveña

- **Juan Bravo Feíto**
- **Carlota Fernández Camblor**
- **Diego Morante Martínez**
- **Sara Rodríguez López**
- **Laura García Espinosa**

RESEARCH AREAS

- Maternal Infant Child and youth research

RESEARCH ACTIVITY

Publications

- **Espinosa LG, Santoveña AZ, Feito JB, Hijosa MM, Camblor CF, Melgar AA, Roman LE.** 40 Years experience in Bartter's syndrome. Nefrologia. 2024; 44(5): 766-8. Editorial Material. IF: 2.6; Q2
- **González-Bertolín I, Bernardos GB, Santoveña AZ, Suarez LG, López RL, Gallardo MP, Cáceres CD, Calvo C.** NUM-score: A clinical-analytical model for personalised imaging after urinary tract infections. Acta Paediatr. 2024; 113(6): 1426-34. Article. IF: 2.1; Q2

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

4.4 Urology Group

Publications: 8 | **Q1:**4

COMPOSITION

Luis Martínez-Piñeiro

- **Alfredo Aguilera Bazan**
- **Jose Maria Alonso Dorrego**
- **Ramon Cansino Alcaide**
- **Cristina De Castro Guerin**
- **Esau Fernandez Pascual**
- **Maria Jesús Garcia-Matres Cortes**
- **Asier Leivar Tamayo**
- **Estefania Linares Espinos**
- **Jose Antonio Moreno Valle**
- **Miriam Serrano Liesa**
- **Héctor Ricardo Ayllón Blanco**


RESEARCH AREAS

- Large system pathology

RESEARCH ACTIVITY

Publications

- **Felgueres MJ, Esteso G, García-Jiménez AF, Dopazo A, Aguiló N, Mestre-Durán C, Martínez-Piñeiro L, Pérez-Martínez A, Reyburn HT, Valés-Gómez M.** BCG priming followed by a novel interleukin combination activates Natural Killer cells to selectively proliferate and become anti-tumour long-lived effectors. Sci Rep-Uk. 2024; 14(1): 13133. Article. IF: 3.9; Q1
- **Manfredi C, Boeri L, Sokolakis I, Schifano N, Pyrgidis N, Fernández-Pascual E, Sansone A, García-Gómez B, Albersen M, Corona G, Romero-Otero J, Fode M.** Cell therapy for male sexual dysfunctions: systematic review and position statements from the European Society for Sexual Medicine. Sex Med. 2024; 12(1): qfad071. Article. IF: 2.0; Q2
- **Paciotti M, Diana P, Gallioli A, De Groote R, Farinha R, Ficarra V, Gaston R, Gontero P, Hurle R, Martínez-Piñeiro L, Minervini A, Pansadoro V, Van Cleynenbreugel B, Wiklund P, Casale P, Lughezzani G, Uleri A, Mottrie A, Palou J, Gallagher AG, Breda A, Buffi N.** International consensus panel for transurethral resection of bladder tumours metrics: assessment of face and content validity. BJU Int. 2024; 134(6): 932-8. Article. IF: 4.4; Q1
- **Rodríguez Faba O, Fernández Gómez J M, Guerrero-Ramos F, Álvarez-Maestro M, Ledo Cepero M J, Unda Urzaiz M, Martínez-Piñeiro L, Cózar Olmo J M, Redorta J Palou, Álvarez-Ossorio J L.** Consensus document on the implications of standardization of BCG supply in the management of patients with non-muscle-invasive bladder cancer. Actas Urol Esp (Engl Ed). 2024; 48(10): 718-31. Article. Not Indexed
- **Sierra A, Etcheverry B, Álvarez-Maestro M, López JM, Fiol M, Torrecilla C, Vigués F, Martínez C, Carbonell E, Martínez-Perez S, Alcaraz A, Luque MP, Musquera M.** Management of deceased and living kidney donor with lithiasis: a multicenter retrospective study on behalf of the renal transplant group of the Spanish urological association. J Nephrol. 2024; 37(6): 1621-30. Article. IF: 2.6; Q2
- **Toribio-Vázquez C, Rivas JG, Amigo F, Carrión DM, Yebes A, Alonso-Bartolomé M, Ayllón H, Aguilera A, Martínez-Piñeiro L, Antón-Juanilla M, Crespo-Atín V, Otaola-Arca H, Herranz-Yagüe JA, Rivero MVM, MacKenzie KR, Shah TT, Gao C, Zimmermann E, Jefferies M, Nambiar A, Gallagher KM, Khadhouri S, Kasivisvanathan V.** Prevalence of urinary tract



cancer in the Spanish cohort of the IDENTIFY study. Actas Urol Esp. 2024; 48(3): 228-37. Article. IF: 1.2; Q3
- **Toribio-Vázqueza C, Martínez-Pitheiro L.** Re: Pembrolizumab Versus Placebo as Post-nephrectomy Adjuvant Therapy for Clear Cell Renal Cell Carcinoma (KEYNOTE-564): 30-month Follow-up Analysis of a Multicentre, Randomised, Double-blind, Placebocontrolled, Phase 3 Trial. Eur Urol. 2024; 85(3): 306. Editorial Material. IF: 25.2; D1
- **Yebes A, Martínez-Pineiro L.** Re: Grade V Renal Trauma Management: Results from the Multi-institutional Genito-urinary Trauma Study. Eur Urol. 2024; 85(3): 305. Editorial Material. IF: 25.2; D1

Clinical trials

- **Abad López P.** Estudio prospectivo, multicéntrico, para evaluar la seguridad y efectividad de sulky® gel lubricante hidrosoluble en instrumentaciones y exploraciones ginecológicas, urológicas y gastroenterológicas.
  Type/Phase: OTROS
  Sponsored by: Laboratorios Bohm S.A.
  Signature date: 23/07/2024
- **Fernández Pascual E.** Estudio observacional multicéntrico para comparar las recomendaciones de médicos y las decisiones de auto-medicación de pacientes en el uso de tadalafilo para el tratamiento de la disfunción eréctil.
  Type/Phase: EOm prospectivo
  Sponsored by: Laboratorios Cinfa Sa Laboratorios Cinfa S.A.
  Signature date: 29/08/2024
- **Fernández Pascual E.** Fibronie: estudio piloto sobre eficacia y seguridad de fibrorestil® como tratamiento intralesional coadyuvante en pacientes con enfermedad de peyronie con tratamiento estándar.
  Type/Phase:
  Sponsored by: Martinez Salamanca Juan Ignacio
  Signature date: 30/10/202
- **Linares Espinós EE.** Ensayo clínico de fase ii, multicéntrico, abierto y aleatorizado para evaluar la eficacia de talazoparib más enzalutamida como tratamiento de primera línea para pacientes con cáncer de próstata metastásico resistente a la castración después de la progresión con abiraterona.
  Type/Phase: II
  Sponsored by: Fundación Oncosur
  Signature date: 05/07/2024
- **Ríos González E.** Estudio fase III, aleatorizado, doble ciego y controlado con placebo sobre el uso de apalutamida en pacientes con cáncer de próstata de alto riesgo, localizado o localmente avanzado candidatos a una prostatectomía radical. Type/Phase: III; Sponsored by: Janssen-Cilag España S.A.; Signature date: 18/04/2024

IdiPAZ
Instituto de Investigación
Hospital Universitario La Paz

SCIENTIFIC REPORT 2024

IdiPAZ Sostenible

Hospital Universitario La Paz
Hospital Carlos III
Hospital Cantoblanco
SaludMadrid

Hospital Universitario La Paz
Fundación para la Investigación Biomédica
SaludMadrid
Comunidad de Madrid

Hospital Universitario de Getafe
SaludMadrid

UAM
Universidad Autónoma de Madrid

Universidad Europea